P01  Developmental Anomalies, Department of Medical Reproductive Genetics/Prenatal Genetics Genetics, Dijon University Hospital, Dijon, France, 7APHM, Department of pediatric neurology, La Timone 
P01 .01A hospital, Marseille, France, 8Department of clinical Prenatal whole exome sequencing in agenesis of the genetics, CHU d’Angers, Angers, France, 9Department of corpus callosum clinical genetics, CHU de Reims, Reims, France, 10APHP, Department of cytogenetics, Trousseau hospital, Paris, S. Heide1, B. Keren1, M. Moutard2, T. Billette de France,11HCL,Departmentofpediatricneurology,HFME, Villeumeur2, M. Spentchian1, C. Garel3, C. Mignot1, Bron, France, 12HCL, Department of radiology, HFME, J. Buratti1, V. Layet4, V. Tsatsaris5, S. Moutton6, Bron, France, 1314. APHP, Fetal Medicine Department, M. Milh7, M. Gorce8, M. Spodenkiewicz9, G. Quenum Trousseau Hospital, Sorbonne Medicine University, Paris, Miraillet10, S. Chantot-Bastaraud10, d. Vincent11, France L. Guibaud12, J. Jouannic13, S. Valence2, D. Heron1 Agenesis of the corpus callosum (ACC) is usually 1APHP, Department of Genetics, Armand-Trousseau and diagnosed by prenatal ultrasound examination. In case of Pitié Salpêtrière hospital, Reference Center for Intellectual isolated ACC (iACC), neurodevelopment is within normal disability of Rare Causes, Paris, France, 2APHP, range in 80 % of cases whereas 20 % of children present Department of pediatric neurology, Armand Trousseau mild to severe intellectual disability (ID). Among genetic hospital,Paris,France,34.APHP,Departmentofpediatric etiologies, only chromosomal causes are investigated radiology, Armand Trousseau hospital, Paris, France, (karyotyping and microarray) during prenatal period while 4Department of genetics, Le Havre hospital, Le Havre, ACCwithIDisduetoasinglegenemutationinmostcases.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1175 Thus,parentsmakethedecisiontocontinueorterminatethe 8361 fetuses was carried out in Department of Medical pregnancy on statistics. Biology from the samples of amniotic fluids which were Our study aims to evaluate the feasibility of prenatal sent from Department of Obstetrics and Gynecology of testing of all known ACC genes using whole exome Balcali Hospital. A standard nomenclature has been sequencing (WES). developed to describe each of types of abnormality found Eighteen fetuses with ACC were included (ongoing in human chromosomes. inclusions): 14 iACC and 4 cases of ACC associated to Results: A total of 8361 amniocentesis specimens were otheranomalies(aACC).TrioWESwereperformedonfetal processedduringthestudyperiod.601fetuses(7.18%)had DNA extracted from amniotic fluid sampling. Only patho- various chromosomal abnormalities. 54.4% of abnormal genic variants in known ACC genes were considered. karyotypes (329 cases) were numerical and 43.09% (259 Variants of unknown significance (VUS) and secondary cases) were structural. Both numerical and structural chro- findings were not reported. WES results were available mosomal aberrations were observed in 13 cases (2.16%). within an average of 21 days. Thirteen WES (72%) were The ratios were as: trisomy 21 (48.93%), trisomy 18 normal (11 iACC, 2 aACC). A pathogenic variant in an (17.93%), monosomy X (9.72%), trisomy 13 (6.99%), ACC with ID gene was identified in two cases (11%): Triploidy (4.86%),Klinefelter Syndrome (3.34%),Trisomy BRAT1(aACC)andPP
P2 R1A(iACC).Apathogenic6q27 X (1.21%), XYY Syndrome (0.91%), and the others in all deletionwasidentifiedinonecase(aACC).Weidentifieda numerical abnormalities. The frequent structural abnormal- VUS in 2 cases. ities were as: 46,XX/XY, inv(9) (p11;q12)/(p11;q13) Our preliminary results suggest feasibility of prenatal (29.34%), 46,XX/XY, 1qh(+)(11.58%), 46,XY, Yqh(-) WES in fetuses with prenatal diagnosis of ACC. In case of (7.33%), 46,XX/XY, 16qh(+)(7.33%), 46,XX/XY, 9qh(+) etiological diagnosis, WES helps the parents to make a (4.63%) and 46,XY, Yqh(+)(4.24%). Balanced and unba- decision for the pregnancy. However, WES in the prenatal lanced translocations, deletions and duplications were also period arises ethical questions. found in less ratio. S. Heide: None. B. Keren: None. M. Moutard: None. Conclusions: According to the literature and our results, T. Billette de Villeumeur: None. M. Spentchian: None. advanced maternal age is the main cause of fetal chromo- C. Garel: None. C. Mignot: None. J. Buratti: None. V. somal abnormalities. Fetal chromosomal abnormality ratio Layet: None. V. Tsatsaris: None. S. Moutton: None. M. that we found was 7.18%. This ratio emphasizes the Milh: None. M. Gorce: None. M. Spodenkiewicz: None. importance of prenatal diagnosis. G. Quenum Miraillet: None. S. Chantot-Bastaraud: A. Pazarbasi: None. D. Alptekin: None. I.N. Uslu: None.D.Vincent:None.L.Guibaud:None.J.Jouannic: None.N.S.Ilgaz:None.L.Ozpak:None.G.Comertpay: None. S. Valence: None. D. Heron: None. None. G. Ay: None. N. Cetinel: None. E. Akbal-Isık: None. G. Evyapan: None. S. Kocaturk-Sel: None. 
P01 .02B U. Luleyap: None. M.B. Yilmaz: None. S. Buyukkurt: Results of karyotype analysis of 8361 pregnancies in None. prenatalyidentifiedcaseswithamniocentesisfromsouth of Turkey 
P01 .03C BiallelicvariantsinAMPD2genecauseprenatalisolated A. Pazarbasi1, D. Alptekin1, I. N. Uslu1, N. S. Ilgaz1, agenesis of corpus callosum L. Ozpak1, G. Comertpay1, G. Ay1, N. Cetinel1, E. Akbal- Isık1, G. Evyapan1, S. Kocaturk-Sel1, U. Luleyap1, L. Mouthon1, S. Heide1, C. Depienne2, C. Nava3, M. B. Yilmaz1, S. Buyukkurt2 A. Rastetter4, D. Lacombe5, T. Attie Bitach6, D. Héron1 1University of Çukurova, Faculty of Medicine, Dept of 1UF Génétique Médicale, APHP Hôpital Pitié Salpêtrière, Medical Biology, Adana, Turkey, 2University of Çukurova, Paris, France, 2Institüt für Humangenetik, Faculty of Medicine, Dept of Obstetrics and Gynecology, Universitätsklinikum, Essen, Germany, 3UF de Génomique Adana, Turkey du Développement, APHP Hôpital Pitié Salpêtrière, Paris, France,4InstitutduCerveauetdelaMoelleépinière,Paris, Objectives: Amniocentesis is a very crucial diagnostic France, 5Service de Génétique Clinique Médicale, CHU procedure for preventing the birth of genetically defective Bordeaux, Bordeaux, France, 6Département de Génétique, fetuses in order to decrease the prevalence of genetic Hôpital Necker -Enfants Malades, Paris, France diseasesinpopulations.Methods:Aretrospectivereviewof our amniocentesis database for the period from January Introduction: Recessive mutations in AMPD2 gene cause 2000toFebruary2019wascarriedout.Thekaryotypingof Pontocerebellar Hypoplasia (PCH) type 9. This severe1176 neurodevelopmental disease is characterized by intellectual aneuploidies and large CNV is possible it is not disability associated with epilepsy and spasticity. Brain recommended in Obstetricians and Gynecologists guide- imaging shows the association of pontocerebellar anoma- lines. Majority of NIPS providers do not report this lies,agenesisofcorpus callosum(ACC)andmicrocephaly. information. The 2 fetuses already reported with mutations in this gene Materials and Methods: NIPS was carried on Ion had HPC associated with ACC on prenatal ultrasound or 
S5  sequencer with in-house developed data analysis pipe- MRI. We report two cases of AMPD2 mutations in sibling line. 1300 samples collected at 11-20 weeks of gestation fetuses with prenatal diagnosis of isolated ACC (iACC). were analyzed. NIPS results were confirmed with kar- Cases: Male fetus 1 : prenatal iACC at 32 gestational yotyping of invasively obtained samples or blood cells weeks (GW) ; termination of pregnancy (top) at 37GW, obtained postnatally. Four biopsies of placental tissue were normal CGH array; postnatal iACC (neuropathological performed to assess placental karyotype. examination). Male fetus 2:prenataliACC ;top at31 GW; Results: High aneuploidy risk was detected in 39 cases. normal CGH array; postnatal iACC (neuropathological 14 - trisomy 21, 3 - trisomy 13, 15 sex chromosome examination). abnormalities (4 due to maternal mosaicism) and 7 rare Method: Whole exome sequencing (2 fetuses and 2 autosomalabnormalities(trisomies7,8,10,largeCNV).In parents). one case large CNV was confirmed in the fetus. In two Results: Identification of two compound heterozygous cases of rare trisomies, placental tissue was available, in AMPD2 mutations (c.751C>T, p.Arg251Trp; c.1648G>A, both cases, mosaic trisomy was confirmed in the placenta. p.Glu550Lys) in the 2 fetuses. Conclusions: High risk of rare autosomal abnormality Discussion: We report here an unusual prenatal pre- could be associated with miscarriage, confined placental sentationofPCH9in2siblingfetuses,limitedtoaprenatal mosaicism, true fetal mosaicism, and uniparental disomies. andpostnataliACC.ACC isone ofthemost frequentbrain Whole genomeanalysismay identify pregnanciesatriskof malformations, usually detected by prenatal ultrasound. miscarriageandothercomplications.Thestudyissupported Prognosis is variable and correlates with the presence or by the Ministry of Healthcare of Russian Federation absence of other malformations. When isolated, the neuro- J. Shubina: None. I.Y. Barkov: None. O.K. Stupko: development is within a normal range in 80 % of cases None. L.V. Kim: None. T.O. Kochetkova: None. A.Y. whereas 20 % have mild to severe intellectual disability. Goltsov: None. I.S. Mukosey: None. M.V. Kuznetsova: Establishing an etiological diagnosis of a prenatal appar- None.N.A.Karetnikova:None.N.K.Tetruashvili:None. ently iACC is essential to assess neurodevelopmental V.A. Bakharev: None. D.Y. Trofimov: None. prognosis. AMPD2 should be considered as a gene responsible for isolated prenatal ACC. 
P01 .05A L. Mouthon: None. S. Heide: None. C. Depienne: Array CGH and next-generations sequencing in None. C. Nava: None. A. Rastetter: None. D. Lacombe: diagnostics of fetal skeletal dysplasia None. T. Attie Bitach: None. D. Héron: None. I. Dimova1, V. Peycheva1, P. Chaveeva2, R. Bozhilova1, 
P01 .04D K. Mihova1, K. Kamenarova1, A. Kanev3, A. Todorova1, Rare autosomal abnormalities detected using V. Dimitrova4, R. Kaneva1 noninvasive prenatal screening 1Medical University Sofia, Sofia, Bulgaria, 2SAGBAL "Dr J. Shubina, I. Y. Barkov, O. K. Stupko, L. V. Kim, Shterev", Sofia, Bulgaria, 3Military Medical Academy, T. O. Kochetkova, A. Y. Goltsov, I. S. Mukosey, Sofia, Sofia, Bulgaria, 4SBALAG "Maichin dom", Sofia, M. V. Kuznetsova, N. A. Karetnikova, N. K. Tetruashvili, Sofia, Bulgaria V. A. Bakharev, D. Y. Trofimov Background: Array CGH is routinely used in prenatal Nationalmedicalresearchcenterforobstetrics,gynecology diagnostics of structural fetal defects where the possibility and perinatology named after academician, Moscow, to find genomic aberrations is high. This technique is Russian Federation especiallysuitableinahistoryofrepeatedpregnancyfailure together with structural defects. Introduction:NoninvasiveprenatalDNAscreening(NIPS) MaterialsandMethods:Wereportheretheresultsfrom is believed to be highly sensitive to common aneuploidy genomic analysis in fetal skeletal dysplasia (SD) - we per- detection.SincesomeNIPStechnologiesusewholegenome formedarrayCGHincaseswithrepeatedabortionsandfetal sequencing, aneuploidies and large CNV of any chromo- skeletalanomaliesandnext-generationsequencing(NGS)- some could be detected. Although detection of rareAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1177 in cases with lack of diagnosis after aCGH or phenotypes, and 6-8% of sperm showed chromosomal abnormalities. strongly suggestive for monogenic disorder. This percentage significantly increases with advancing age Results:ThefindingsfromarrayCGHandNGSanalyses in women and in cases of abnormalities of sperm in men. are presented in the Table below. We present the results of oligonucleotide array applica- tion in a cohort of 31 cases of mothers with adverse preg- nancy histories. DNA was extracted from trophoblast and Clinicalmanifestation Genomic/geneaberration umbilical cord. Array CGH was performed using 4x180K Limbsanomaliesand3 7q21.3(94,214,445-95,257,297)x1 microarrays from Oxford Gene Technology (CytoSure previousabortions (1.04Mb)Splithand/footmalformation ISCA, v3). 3rdpregnancywith 1q21.1(145425395-146507577)x1 The detection rate in our cohort was 61,3% (19/31). The phocomelyandlimbs (1.08Mbp)TARsyndrome most commonly found (73,7%) were aneuploidies: trisomy aplasia of chromosomes 14, 16, 18, 21, 22, Turner syndrome and Skeletaldysplasiaand2 17q21.33(48,264,999-48,277,988)x3 previousabortions (12.99Кbp,includingCO
L1 A1gene) triploidy. Other chromosomal abnormalities included 2ndpregnancywith Xq28(154,974,667-155,208,354)x0 structuralaberrations:deletion7p22.3p12.3andduplication arthrogryposis (234Kbp)VOUS:c.357T>G,p. 9p24.3p13.2 inherited from normal father, deletion Ile119Met(NM_017946.3)in 3q13.31q22.2, deletion 3q22.3q23, duplication 17p12 FKB
P14 gene inherited from father with foot malformations, deletion 1stpregnancywithdwarfism Possiblydamagingvariants: 17p13.1inheritedfromnormalmother,deletion5q14.3and c.6117C>G(p.Ile2038Met)inHSPG2 de novo deletion 1q21.1q21.2. gene;c.7223C>G(p.Ala2408Gly)in PCNTgene Our research shows that microarray is the only method permitting the identification of all unbalanced aberrations (number and structure) with a much higher resolution than Conclusion:GeneticdiagnosisofSDsisstronglyneeded karyotype. because there are so many diseases with complex pheno- The work was supported by project 2016/23/N/NZ2/ types and identification of the responsible gene(s) is 02364 from the National Science Centre, Poland. important to understand the diseases themselves. We K. Sobecka: B. Research Grant (principal investigator, demonstrated here the diagnostic utility of aCGH, which collaborator or consultant and pending grants as well as couldbethefirst-linetestinprenatalsettings.NGSisavery grants already received); Significant; National Science powerfultechniqueindiagnosticsofveryrare diseases,but Centre,Poland.M.Smyk:None.M.Chojnacka:None.B. needsmuchlongertimeforanalysisandadditionalstepsfor Wiśniowiecka-Kowalnik: None. E. Michalak: None. T. elucidations of the found variants. Klepacka: None. B. Nowakowska: None. I. Dimova: None. V. Peycheva: None. P. Chaveeva: None. R. Bozhilova: None. K. Mihova: None. K. Kame- 
P01 .08D narova: None. A. Kanev: None. A. Todorova: None. V. Screening by Multiple ligation-dependent probe Dimitrova: None. R. Kaneva: None. amplification assay of AZF a, b, c regions in primary infertile men with azoospermia 
P01 .06B Applicationofarraycomparativegenomichybridization K. Haziyeva1, O. Cilingir1, B. Durak Aras1, I. Ure2, (aCGH) for identification of lethal chromosomal E. Erzurumluoglu1, E. Tosumoglu1, S. Artan1 aberrations in spontaneous abortion 1Eskisehir Osmangazi University, Faculty of Medicine, K. Sobecka, M. Smyk, M. Chojnacka, B. Wiśniowiecka- Department of Medical Genetics, Eskısehır, Turkey, Kowalnik, E. Michalak, T. Klepacka, B. Nowakowska 2Eskisehir Osmangazi University, Faculty of Medicine, Department of Urology, Eskısehır, Turkey Institute of Mother and Child, Warsaw, Poland Y chromosome microdeletions are the most common cause Spontaneous abortions occur in 8-20% cases of recognized of azoospermia and occur in 5-15% of infertile men with pregnancies. Most often, the miscarriage take place in the azoospermia. Microdeletions/partial deletions of the azoos- first trimester (7-11 weeks). There are many causes of permia factor(AZF) regions on the Y chromosome are a pregnancy loss, but the most important (~75%) is the well-known genetic cause of male infertility, resulting in presenceofchromosomalaberrations.Ahighpercentageof impairmentofspermatogenesis.Wesoughttodeterminethe chromosomal aberration is caused by the abnormal genetic frequency and the character of AZF region microdeletions/ materialofgermcells.Researchshowedthat20-30%ofova partialdeletionsininfertilemenwithazoospermiabyusing1178 Multiplex Ligation-Related Probe Amplification (MLPA). digital images, which may enable accurate diagnosis of In total, 50 azoospermic infertile men without gene and complexmultisystemsyndromes,inparticularinsmallearly chromosome mutations, were screened for Y chromosome gestation fetuses. microdeletions in AZF regions and 50 fertile men assigned We describe the case of a 33 year old primigravida, who 12+5 to control group. The total frequency of the microdeletions attended for antenatal sonography at weeks gestation. was 16%. Most deletions (10%) were seen in the AZFc Anincreasednuchaltranslucencyandhypoplasticleftheart followed by the AZFb (4%). The partial BPY2 gene were observed; multicystic kidneys suspected. Array-CGH deletions, located at AZFc region were detected in five wasnormal.Thecoupleoptedtoterminatethepregnancyat 15+6 patients while partial EIF1AY gene deletions, located in weeks. AZFblocuswereseenintwopatients.ThecombinedAZFb Due to small foetal size, whole-body micro-CT was andAZFclocideletionwasrevealedinapatient.NoAZFa performed. Image analysis revealed an atrioventricular regiondeletionwasdetectedamong theazoospermiccases. septal defect, mitral valve stenosis, left ventricular hypo- In the literature, it has been shown that BPY2 gene is plasia, aortic atresia and ascending and aortic arch hypo- effective in male germ cell development and loss of plasia. Multiple renal cortical cysts and bilateral upper and EIF1AY gene function can result in azoospermia sporadi- lower limb post-axial polydactyly were observed. Renal cally. The present findings suggest that MLPA is more histology confirmed extensive cystic dilatation of the renal appropriate compared to mPCR because it investigates tubules. partial and complete deletions of AZF regions for male Genetic testing identified compound heterozygous muta- sterility compared to previous methods. Our study shows tionsinBB
S7 [c.187G>A;p.(Gly63Arg)matandc.973G>T; that microdeletion and partial deletions, which are men- p.(Glu325Ter)pat],consistentwithBardet-BiedlSyndrome. tionedintheliteratureasthereasonofazoospermia,canbe Given a recurrence risk for future pregnancies at 25%, the detected by MLPA method at the same time. couple received counselling regarding future preimplanta- K.Haziyeva:None.O.Cilingir:None.B.DurakAras: tion genetic testing. None. I. Ure: None. E. Erzurumluoglu: None. E. Tosu- Inconclusion,micro-CTisanon-invasivehighlydetailed moglu: None. S. Artan: None. method for assessing early gestation foetal anatomy, and provides an adjunctive or alternative tool to the standard 
P01 .09A foetal autopsy technique. Characterisation of Bardet Biedl Syndrome in a foetus A.Beleza-Meireles:None.S.C.Shelmerdine:None.M. by post-mortem microfocus computed tomography Singh: None. I. Simcock: None. A.D. Calder: None. M. Ashworth:None.N.J.Sebire:None.O.J.Arthurs:None. A. Beleza-Meireles1,2, S. C. Shelmerdine3,4, M. Singh3, I.Simcock3,4,A.D.Calder3,M.Ashworth5,N.J.Sebire5,4, 
P01 .11C O. J. Arthurs3,4 Preconception expanded carrier screening in a developing country: where does science exactly meet 1Guy’s Hospital, London, United Kingdom, 2Centre for bioethics? Craniofacial & Regenerative Biology, King’s College London,London,Austria,3DepartmentofRadiology,Great S. Klumsathian1, B. Panthan1, N. Iemwimangsa1, Ormond Street Hospital for Children NHS Foundation I. Sensorn1, A. Charoenyingwattana1, Trust,London,UK,London,UnitedKingdom,4UCLGreat T. Chareonsirisuthigul2, Y. Worakijthamrongchai3, Ormond Street Institute of Child Health, London, United M. Sukpraserrt3, W. Chantratita1, O. Trachoo4,1 Kingdom, 5Department of Histopathology, Great Ormond Street Hospital for Children NHS Foundation Trust, 1Center for Medical Genomics, Faculty of Medicine London, United Kingdom Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 2Department of Pathology, Faculty of Medicine Confirmation of antenatally detected foetal anomalies is Ramathibodi Hospital, Mahidol University, Bangkok, vital following termination of pregnancy due to congenital Thailand, 3Department of Obstetrics-Gynecology, Faculty anomalies. Phenotypic information is essential for genetic of Medicine Ramathibodi Hospital, Mahidol University, testingandcounselling.Howeverantenatalultrasonography Bangkok, Thailand, 4Department of Medicine, Faculty of identifiesonlyupto68%ofautopsyfindings,whicharenot Medicine Ramathibodi Hospital, Mahidol University, always available. Bangkok, Thailand Post-mortem imaging using microfocus computed tomo- graphy (micro-CT) provides an alternative, or com- Introduction: Expanded carrier screening (ECS) was plementarytool,toautopsy.Itprovideshigh-resolution,3D recently introduced to Thailand and other developingAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1179 countries in Asia by a large number of international reproductive healthcare depends largely on prospective laboratories. Several incidences were reported concerning parents’ interest in ECS. In this systematic review, we negative psychosocial impact, i.e., anxiety and difficulty in synthesized evidence from empirical studies exploring making decision on reproductive option. interest in ECS among individuals and couples in the Material and Methods: Forty healthy Thai couples generalpopulation.Studiesincludedinthisreviewreported visiting preconception clinic were enrolled. ECS was per- prospective parents’ intentions to undergo a (hypothetical) formed using 630-disease panel covering most autosomal ECS test, uptake of an actual ECS offer, or both. Four recessive and X-linked disorders. Thereafter, attitudes on databases (Pubmed, Web of Science, CINAHL, Cochrane ECSandclinicalapplicationwereinterviewed.Geneticdata Library) were systematically searched for relevant publica- were then combined with previous in-house database, tions and 12 empirical studies were included in the review. pooling up to 355 unrelated individuals. Carrier identifica- Owing to the novelty of ECS, all the included studies were tionwereinterpretedusingourdevelopedbioinformaticand relatively recent, having been published during 2015-2019. clinical criteria suitable for legal and ethical issues. In the included studies, 33%-66% of respondents were Results: The most common carrier frequency in our interested in a (hypothetical) ECS test, while uptake rates cohort belonged to beta thalassemia (1/5) which was con- for actual ECS offers were reported at 10%-50%. The sistent with national statistics. Interestingly, primary highest uptake was observed in a study where ECS was hemochromatosisH63D,whichhaveneverbeenrecognised offeredtopregnantwomen.Bycontrast,studiesfocusingon in Southeast Asian populations, became the second com- the preconception population reported lower uptake rates, mon (1/16). Other carriers detected as common in Thais even though some of these preconceptional ECS tests were included alpha thalassemia, Gilbert syndrome, 21- providedfreeofcharge.Ourfindingssuggestthattheremay hydroxylase-deficient congenital adrenal hyperplasia and be discrepancies between prospective parents’ self-reported spinalmuscularatrophy.Morethan95%ofthesubjectshad intentions to undergo ECS and their actual test-taking a positive attitude to ECS. They accepted preimplantation behavior, particularly during the preconception period. genetic diagnosis as their reproductive option if they were D. Chokoshvili: None. E. Van Steijvoort: None. P. identifiedascouplesatrisk,eithermildorseverecondition. Borry: None. Conclusions: ECS would be useful if the selection cri- teria were clear and consistent with national regulation and 
P01 .14B ethics. Pre-test genetic counseling was necessarily required Prenatal clubfoot increases the risk for clinically for the couples to understand further outcome. significant chromosomal microarray (CMA) results - Grants: Faculty of Medicine Ramathibodi Hospital and analysis of 269 singleton pregnancies Center of Excellence on Medical Biotechnology, Mahidol University. A. Singer1, I. Maya2, B. Ehud3, H. Baris4, C. Vinkler5, S. Klumsathian: None. B. Panthan: None. N. Iemwi- C. Vinkler5, S. Ben-Shachar6, A. Bar-Shira6, L. Sagi- mangsa: None. I. Sensorn: None. A. Char- Dain7 oenyingwattana:None.T.Chareonsirisuthigul:None.Y. Worakijthamrongchai:None.M.Sukpraserrt:None.W. 1Community Genetics, Public Health Services, Ministry of Chantratita: None. O. Trachoo: None. Health, Jerusalem, Israel, 2Recanati Genetics Institute, Beilinson Hospital, Rabin Medical Center, Petach Tikva, 
P01 .12D Israel,3GeneticInstituteKaplanMedCntr,Rehovot,Israel, Interest in expanded carrier screening among 4 The Genetics Institute, Rambam the Technion, Haifa, prospective parents: systematic review of the literature Israel, 5Genetic Institute Wolfson Med Cntr, Holon, Israel, 6Genetic Institute Tel Aviv Sourasky Medical Center, Tel D. Chokoshvili, E. Van Steijvoort, P. Borry Aviv,Israel,7GeneticInstituteCarmelmedicalCntr,Haifa, Israel University of Leuven, Leuven, Belgium Clubfoot, also known as talipes equinovarus, is a well- Expanded carrier screening (ECS) is a reproductive genetic recognized congenital foot deformity. It is diagnosed in test aimed at identifying prospective healthy parents who about 1:1000 pregnancies. Clubfoot can present as an are at risk of conceiving a child affected with a recessive isolated defect or as non-isolated, also called "complex" or disorder. ECS tests screen for large numbers of recessive "syndromic", clubfoot, associated with additional disorders and are currently available through various anomalies. genetic testing laboratories. However, the extent to which Objective: This work was done in order to examine the ECS can be successfully implemented in the context of detection rate of clinically significant chromosomal1180 microarrayanalysis(CMA)resultsinsingletonpregnancies without CMA, irrespective of the result of the CMA, we with clubfoot. found significant fewer terminations of pregnancies in the Methods: Data from all CMA tests performed due to group with CMA, even if the severity of malformations of sonographic abnormal findings between January 2013 and the fetuses were comparable. September 2017 were retrospectively obtained from Min- Conclusions: In summary the decision on termination of istry of Health computerized database. All singleton preg- pregnancy is individual and there are many influencing nancies with sonographic diagnosis of clubfoot (talipes factors to consider. However our data suggests that the equinovarus) and documentation of CMA result were result of additional CMA can be a crucial factor in the included. decision on termination of pregnancy. Results: Of the 5750 CMA tests, a total of 269 (4.7%) T. Reischer: None. J. Brandstetter: None. R. Dra- were performed due to demonstration of fetal clubfoot. Of honsky: None. C. Fast-Hirsch: None. B. Streubel: None. the229caseswithisolateddeformity,nine(3.9%)clinically significantCMAresultsweredetected.Thisdetectionrateis 
P01 .16D significantly increased compared CMA results in normal Congenital anomalies in children born after assisted pregnancies as previously reported. In 40 pregnancies with reproduction in the Czech Republic: Population based syndromic clubfoot, seven (17.5%) clinically significant study CMAresultsweredetected,asignificantlyhigherfrequency compared to isolated clubfoot cases. A. Sipek Jr1,2, V. Gregor2,3, A. Sipek Sr2,3,4,5, Conclusion: Sonographic diagnosis of clubfoot, whether J. Klaschka6,7, M. Maly6,8, J. Jirova9 isolated or associated with additional sonographic anoma- lies,seemstoincreasetheriskforabnormalCMAfindings. 1InstituteofBiologyandMedicalGenetics,FirstFacultyof Thus, CMA analysis, in conjunction with thorough sono- Medicine, Charles University, Prague, Czech Republic, graphic anatomic survey, should be recommended in such 2Department of Medical Genetics, Thomayer Hospital, pregnancies. Prague,CzechRepublic,3DepartmentofMedicalGenetics, A. Singer: None. I. Maya: None. B. Ehud: None. H. PronatalSanatorium,Prague,CzechRepublic,4Instituteof Baris:None.C.Vinkler:None.C.Vinkler:None.S.Ben- Medical Genetics, 3rd Faculty of Medicine, Charles Shachar:None.A.Bar-Shira:None.L.Sagi-Dain:None. University, Prague, Czech Republic, 5GENNET, Prague, CzechRepublic,6InstituteofComputerScienceoftheCzech 
P01 .15C AcademyofSciences,Prague,CzechRepublic,7Instituteof The influence of prenatal chromosomal microarray Biophysics and Informatics, First Faculty of Medicine, analysis on the decision on termination of pregnancy Charles University, Prague, Czech Republic, 8National Institute of Public Health, Prague, Czech Republic, T. Reischer, J. Brandstetter, R. Drahonsky, C. Fast- 9Institute for Health Information and Statistics, Prague, Hirsch, B. Streubel Czech Republic Medical University of Vienna, Vienna, Austria Introduction: Assisted reproduction (AR) is nowadays commonly-used method for treating various fertility Introduction: Chromosomal microarray analysis (CMA) problems. However, several studies have shown a higher was introduced to prenatal genetic diagnosis a couple of incidence of selected types of congenital anomalies among years ago. There have been many publications before AR-conceived children. Our goal was to study this demonstrating the benefit of CMA in detecting micro- association on a large population cohorts (over 3 millions duplicationsandmicrodeletionsintheprenatalsetting.Aim of live-births) using data from our population based ofthisstudyistoevaluatetheassociationbetween prenatal registries. CMA and the decision on termination of pregnancy. Methods: Our retrospective epidemiological study is Materials and Methods:This isa retrospective study of based on the official data from the National Registry of a single prenatal center in Austria between 2011 and 2017, Congenital Anomalies and National Registry of assisted includingallfetusesthathadprenataldiagnosiswithCMA. Reproduction(runbytheInstituteoftheHealthInformation Results: In general highest rates of pathogenic CNVs and Statistics of the Czech Republic). The registration were found if the indication for prenatal diagnosis was processispopulation-wideandcompulsorybynationallaw. congenital heart disease or brain malformations. There was We evaluated the incidence of congenital anomalies (ICD- astatisticalsignificantassociationbetweenpathogenicCNV 10 diagnoses Q00-Q99) in AR-conceived children and andthedecisiononterminationofpregnancy(p<0,05).But compared it to the incidence of congenital anomalies in comparing pregnancy outcomes with prenatal CMA and naturally-conceived children. Time period: 2013-2015.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1181 Results: The overall incidence of congenital anomalies frequency data. Therefore, we conduct a study to gather was slightly higher in the AR-children group however, the the frequency of pathogenic variants in the associated difference was not statistically significant. The congenital diseases by offering ECS to a Thai couple who plan to anomalies were more common in twins (p<0.005). The conceive. incidence of congenital anomalies in AR-twins was sig- Methods: DNA samples of 40 non-consanguineous Thai nificantlyhigherthantheincidenceofcongenitalanomalies couples were underwent sequencing by NGS in 540 genes in non-AR-twins (p<0.005) while the difference of con- associated with AR and XLR diseases. We classified the genital anomalies incidence in AR and non-AR singletons variantsdetectedbyNGSusingpopulationdatabases(1000 was not significant. Genomes Project, gnomAD, and our in-house Thai exome Discussion: We have found that the incidence of con- database) and diseases databases (Clinvar and HGMD genital anomalies was higher especially in twins born after professional) to determine their pathogenicity. assistedreproductionwhileinsingletonsthedifferencewas Results: 76 variants with strong evidence for pathogeni- not significant. We will further analyze this finding during city are identified. Deafness is the most common AR dis- the next phases of our population study. eases with six individuals carry deafness-related variants in Acknowledgments: The study is supported by the RVO these genes: SL
C26 A4, USH2A, OTOF, and MYO3A fol- project: “Thomayerova nemocnice - TN, 00064190”. lowed by five carriers of vision-loss variants in GRM6, A. Sipek Jr: B. Research Grant (principal investigator, USH2A, EYS, and ABCA4 gene. One couple shared a dif- collaborator or consultant and pending grants as well as ferent pathogenic mutation in the ABCA4 gene. grants already received); Significant; Thomayer Hospital - Conclusions: Though deafness and vision-loss are the Research grant TN, 00064190. V. Gregor: B. Research twomostcommonARcarrierfoundintheThaipopulation, Grant (principal investigator,collaboratororconsultantand considerationneedtobetakeniftheywereintheECSpanel pendinggrantsaswell asgrantsalreadyreceived); Modest; because these phenotypes are not severe enough for a pre- Thomayer Hospital - Research grant TN, 00064190. A. natal diagnosis. Sipek Sr: B. Research Grant (principal investigator, colla- Grant: The study is supported by the Faculty of Medi- borator or consultant and pending grants as well as grants cine Ramathibodi Hospital, Mahidol University and Center already received); Modest; Thomayer Hospital - Research of Excellence on Medical Biotechnology (CEMB). grant TN, 00064190. J. Klaschka: None. M. Maly: None. S. Klumsathian: None. W. Lorlipiwong: None. K. J. Jirova: None. Sararat: None. N. Poolthong: None. N. Iemwimangsa: None. I. Sensorn: None. B. Panthan: None. A. Char- 
P01 .17A oenyingwattana:None.T.Chareonsirisuthigul:None.O. Carriers for deafness and vision loss are identified as Trachoo: None. W. Chantratita: None. common autosomal recessive conditions in 40 healthy Thai couples obtaining expanded carrier screening 
P01 .18B High risk - what’s next? Decisional conflict, regret and S. Klumsathian1, W. Lorlipiwong1, K. Sararat1, satisfaction among pregnant women making choices N. Poolthong1, N. Iemwimangsa1, I. Sensorn1, about further prenatal testing after a high probability B. Panthan1, A. Charoenyingwattana1, result from the combined test T. Chareonsirisuthigul1,2, O. Trachoo1,3, W. Chantratita1 C. Ingvoldstad Malmgren1,2,3, T. Schlaikjær Hartwig4, 1Center for Medical Genomics, Faculty of Medicine C. Borregaard Miltoft5, A. Tabor5, F. Stener Jørgensen6 Ramathibodi Hospital Mahidol University, Bangkok, Thailand, 2Department of Pathology, Faculty of Medicine 1Dept of Clinical Science, Intervention and Technology, Ramathibodi Hospital Mahidol University, Bangkok, Division of Obstetrics and Gynaecology, Stockholm, Thailand, 3Department of Medicine, Faculty of Medicine Sweden,2DepartmentofPublicHealthandCaringScience, Ramathibodi Hospital Mahidol University, Bangkok, Uppsala University,, Uppsala, Sweden, 3Department of Thailand Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, 4Fetal Medicine Unit, Department of Introduction: One of the applications for next-generation Obstetrics and Gynecology, Copenhagen University sequencing (NGS) is expanded carrier screening (ECS) Hospital Hvidovre, Denmark, Copenhagen, Denmark, which offer prospective parents to learn their carrier status 5Fetal Medicine Center, Department of Obstetrics, of many autosomal recessive (AR) and x-linked recessive Copenhagen University Hospital Rigshospitalet, (XLR) diseases at once. However, designing an ECS panel Copenhagen, Denmark, 6Fetal Medicine Unit, Department for Thais can be difficult due to insufficient variant1182 of Obstetrics and Gynecology, Copenhagen University of Medical Sciences, Tehran, Iran, Islamic Republic of, Hospital Hvidovre, Copenhagen, Denmark 4Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran, Introduction: The aim was to investigate decision-making Islamic Republic of among Danish high-risk pregnant women when choosing between non-invasive prenatal testing (NIPT), invasive Introduction: Duchenne (DMD) and Becker muscular testing or no further testing. Women with a high-risk result dystrophy (BMD) are one of the most common genetic from the combined first trimester screening were invited to muscular dystrophies. Prenatal diagnosis (PND) or Pre- fill in two online questionnaires at GA 12-14(Q1) and GA implantation Genetic Diagnosis (PGD) could be attractive 24(Q2). The scales used were Decisional Conflict and options to prevent the birth of new affected cases. Regret Scales, Satisfaction with genetic Counselling Scale Aneuploidiesarethecauseofover50%ofallmiscarriages. and Health-Relevant Personality Inventory. Early aneuploidy screening in conjunction with PND or Results: In total, 339 women were included, and the PGD can decrease the subsequent complication of preg- response rates were 76 % on Q1 and 88% on Q2, respec- nancy termination. tively.Oftheparticipants,75.4%choseaninvasivetestand Methods: This study aimed to develop a novel panel to 23.8% chose NIPT. The median DCS score among all confirm detection of DMD/BMD and aneuploidy screening participants was within the level associated with imple- simultaneously. The panel functions on the principle of menting decisions, whereas 13.3% had a high level of hemizygosity mapping ofthe6novels STR(Short Tandem decisional conflict. Choosing NIPT was associated with a Repeat) markers linked to dystrophin gene. Additionally, high decisional conflict; receiving genetic counselling the thisincludesautosomalSTRmarkersforthecriticalregions samedaywasassociatedwithahighdecisionalconflict;and ofChromosomes21,18,13,XandY.Thesemarkers were a high satisfaction with the genetic counselling was asso- amplifiedinatime-savingandcost-effectivemultiplexPCR ciated with low decisional conflict. Furthermore, ‘alex- reaction. ithymia’,thepersonalitysub-traitthatdescribesadisinterest Results: Allele frequency and heterozygosity assessment or inability in identifying and understanding feelings, was of STR markers were studied in 250 unrelated healthy associated with low decisional conflict. High decisional individuals. Totally, 85 alleles were detected. Hetero- regret was associated with high decisional conflict and low zygosity of markers was 75.7%-89.8%. Genotype fre- satisfaction with genetic counselling. quenciesofmarkerswerefoundtobeinagreementwiththe Conclusion: The results from this study show that satis- Hardy–Weinberg equilibrium (P ≥ 0.1899). For further faction with, and timing of counselling are essential factors confirmation direct mutation analysis was also performed. to limit decisional conflict. Also, the results indicate that The results were compatible. The panel was used for more women choosing NIPT have more decisional conflict than150PNDcasesand15PGDcandidatesandtheresults comparedtowomenchoosinginvasivetesting.Therewasa were successful. significant association between high decisional conflict and Conclusion: This panel increases the accuracy and sen- later decisional regret. sitivity of diagnosis. It can be easily applied for PGD/PND C. Ingvoldstad Malmgren: None. T. Schlaikjær ofDMD,aneuploidyscreeningandsexdetermination.Also Hartwig:None.C.BorregaardMiltoft:None.A.Tabor: provides extra advantages like ruling out maternal cell None. F. Stener Jørgensen: None. contamination, paternity testing and avoidance of sample cross-contamination. 
P01 .19C Z. Sharifi: None. F. Golnabi: None. F. Rahiminejad: A novel diagnostic panel of 15 STR markers used to None. S. Amini: None. H. Farahzadi: None. S. confirm the detection of Duchene Muscular Dystrophy, Zeinali: None. aneuploidy screening, and sample authenticity testing 
P01 .20D Z. Sharifi1,2, F. Golnabi1,2, F. Rahiminejad1, S. Amini1, Relativetelomerelengthinwomenwithearlypregnancy H. Farahzadi3, S. Zeinali1,4 losses 1Dr. Zeinali’s Medical Genetics Laboratory, Kawsar N. Huleyuk1, D. Zastavna1,2, M. Tyrka2, I. Tkach1 Human Genetics Research Center, Tehran, Iran, Islamic Republicof,2DepartmentofGenetics,FacultyofAdvanced 1Institute of Hereditary Pathology NAMS of Ukraine, Lviv, ScienceandTechnology,Tehran MedicalSciences, Islamic Ukraine, 2Rzeszów University of Technology, Department Azad University, Tehran, Iran, Islamic Republic of, of Biochemistry and Biotechnology, Rzeszów, Poland 3Proteomics Research Center, Shahid Beheshti UniversityAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1183 Introduction: Early pregnancy loss (EPL), a spontaneous InstituteofMolecularandCellBiology,UniversityofTartu, abortion before 14 weeks of gestation, occurs in ~ 15% of Tartu, Estonia, 7Lifesequencing SL, Valencia, Spain, clinically-recognized pregnancies and is the most common 8Igenomix Foundation/INCLIVA, Valencia, Spain, complication of pregnancy. Recurrent early pregnancy loss 9Research Department, Igenomix SL, Valencia, Spain, (REPL) affects 1-2% of couples and has a complex 10Department of Pediatrics, Obstetrics and Gynecology, etiology. Approximately half of miscarriages from EPL Valencia University, Valencia, Spain, 11Department of cases are caused by chromosomal abnormalities in the Obstetrics and Gynecology, University of Helsinki and embryo. Spontaneously lost pregnancies are characterized Helsinki University Hospital, Helsinki, Finland by shortened telomeres, especially in embryos with aneuploidies. Thus, short telomere length may be more Introduction: The proportions of epithelial and stromal frequent in women with REPL. cells vary in endometrial tissue during the menstrual cycle. Material and Methods: Relative telomere length (RTL) Each cell type has its unique gene expression profile, that was measured in DNA isolated from the blood samples compose whole-tissue expression pattern. using areal-timepolymerasechain reactionapproach.RTL Materials and Methods: Using cell-type specific tran- was examined in three groups of women with EPL scriptome data and computational deconvolution approach, (N=171): (i) patients with single EPL (EP
L1 ) (N=52), (ii) we estimated the epithelial and stromal cell proportions in patients with two EPL (EP
L2 ) (N=68), (iii) patients with whole-tissuebiopsiestakenduringearlysecretory(ES)and REPL (N=49); and control group (C) - women who had mid-secretory(MS)phases.Theestimatedproportionswere healthy pregnancies with no history of infertility or mis- used as covariates in whole-tissue differential gene carriage (N=113). expression (DGE) analysis. For RNA sequencing we used Results: The EPL group had significantly lower RTL paired ES and MS endometrial biopsies, obtained from 35 than control (EPL: 1.39±0.06 versus C: 2.23±0.01, healthy,fertilevolunteers(23-36years).DGEanalysiswas P=0.0000001). Average RTL were similar in EP
L2  and performed using two approaches - with and without REPL groups (1.36 ±0.04 in EP
L2  and 1.31±0.07 in RPL) deconvolution step, and results compared with each other. and were significantly lower compared to control (EP
L2 : Results: The estimated average proportions of stromal 1.36 ±0.04 vs C: 2.23±0.01, P=0.000001 and REPL: 1.31 and epithelial cells in ES phase were 65% and 35%, and ±0.07 vs C: 2.23±0.01, P=0.000001). during MS phase 46% and 54%, that correlated with his- Conclusions: Women experiencing two or more EPL tological evaluation (r=0.88, p=1.1×10-6). Endometrial have shorter telomeres. We assume that short telomeres in DGE analysis showed 26% differentially expressed tran- women are involved in complex factors that provoke early scripts (n=946) in receptive endometrium in both cell-type pregnancy loss. unadjusted and adjusted analyses. However, the other 74% N. Huleyuk: None. D. Zastavna: None. M. Tyrka: (n=2,645) become statistically non-significant after cell- None. I. Tkach: None. type adjustment, underlining the impact of tissue hetero- geneity on DGE analysis. The results suggest new 
P01 .21A mechanisms involved in endometrial maturation involving Endometrial receptivity revisited: endometrial genes like LIN
C01320 , SL
C8 A1 and GGTA1P, described transcriptome adjusted for tissue cellular heterogeneity for the first time in endometrial receptivity context. Conclusion: The better understanding of molecular pro- M. Suhorutshenko1,2, V. Kukushkina3, A. Velthut- cesses during transition from pre-receptive to receptive Meikas2, S. Altmäe2,4, M. Peters2,1, R. Mägi3, endometriumservestoimprovetheeffectivenessofassisted K. Krjutškov2,5, M. Koel2,6, F. M. Codoñer7, J. Martinez- reproduction protocols. Biopsy cellular composition should Blanch7, F. Vilella8, C. Simón8,9,10, A. Salumets2,1,11, betakenintoaccountinfutureendometrial‘omics’studies. T. Laisk2,1,3 M. Suhorutshenko: None. V. Kukushkina: None. A. Velthut-Meikas: None. S. Altmäe: None. M. Peters: 1Department of Obstetrics and Gynecology, Institute of None. R. Mägi: None. K. Krjutškov: None. M. Koel: Clinical Medicine, University of Tartu, Tartu, Estonia, None. F.M. Codoñer: None. J. Martinez-Blanch: None. 2Competence Centre on Health Technologies, Tartu, F. Vilella: None.C.Simón: None. A.Salumets: None. T. Estonia, 3Estonian Genome Center, Institute of Genomics, Laisk: None. University of Tartu, Tartu, Estonia, 4Department of Chemistry and Biotechnology, Tallinn University of 
P01 .22B Technology, Tallinn, Estonia, 5Research Program of A prospective evaluation of exome sequencing in 51 Molecular Neurology,Research ProgramsUnit, University fetuses with multiple congenital anomalies and lessons ofHelsinki,Helsinki,Finland,6DepartmentofCellBiology, for future prenatal implementation1184 A. Yeung1,2,3, F. Chan4,3, A. Vasudevan5, J. Collett4,3, M. A. de Koning1, M. C. Haak2, P. N. Adama van S. Prystupa6, Y. Chan6, G. McGillivray1,5,3 Scheltema2,C.M.P.C.Peeters-Scholte3,T.T.Koopman1, E. A. R. Nibbeling1, E. Aten1, N. S. den Hollander1, 1Victorian Clinical Genetics Services, Murdoch Children’s C.A.L.Ruivenkamp1,M.J.V.Hoffer1,G.W.E.Santen1 Research Institute, Parkville, Australia, 2Monash Genetics, Monash Health, Melbourne, Australia, 3Melbourne 1Dept. of Clinical Genetics, Leiden University Medical Genomics Health Alliance, Melbourne, Australia, Center, Leiden, Netherlands, 2Dept. of Obstetrics, Leiden 4Department of Anatomical Pathology, Royal Women’s University Medical Center, Leiden, Netherlands, 3Dept. of Hospital, Parkville, Australia, 5Department of Clinical Neurology, Leiden University Medical Center, Leiden, Genetics, Royal Women’s Hospital, Parkville, Australia, Netherlands 6Department of Anatomical Pathology, Monash Health, Melbourne, Australia Introduction:Exomesequencing(ES)isanefficienttoolto diagnosegeneticdisorderspostnatally.Recentstudiesshow Introduction: Exome sequencing (ES) is a powerful that it may have a considerable diagnostic yield in fetuses adjunct to post-mortem examination for investigating with structural anomalies on ultrasound. We report on the fetuses with congenital anomalies. However, with the clinical impact of the implementation of prenatal ES (pES) implementation of rapid “in-utero” sequencing becoming for ongoing pregnancies in routine care. eminentlyfeasible,fetalphenotypingmay,infuture,relyon MaterialandMethods:Weretrospectivelyanalyzedthe antenatal imaging alone. impact of pES on pregnancy outcome and pre- or perinatal Aim:Todeterminewhether thediagnosticyieldofESin management in the first 22, consecutively referred patients fetuses with congenital anomalies following autopsy is toourdepartmentforpESbecauseofoneormorestructural comparable to the yield of ES implemented at the time of anomalies on fetal ultrasound. antenatal ultrasound detection. Results: In two cases, a diagnosis was made by chro- Method: ES was prospectively performed on 51 fetal mosomal microarray analysis after ES counselling. The probandsfollowingautopsyaspartofthePerinatalAutopsy remaining20casesweredividedinthreegroups;(1)pESto Flagship of the Melbourne Genomics Health Alliance aid parental decision making (n = 12), (2) pES in the Demonstration Project. Candidate variants concordant with context of late pregnancy termination requests (n = 5) and phenotypic findings from fetal autopsy were classified by (3)pEStoguideprenatalorperinatalmanagement(n=3). multidisciplinary review using ACMG guidelines. Inde- pES had a clinical impact in 75% (9/12), 40% (2/5) and pendently, a phenotype-driven virtual gene panel for each 100%(3/3)respectively,showinganoverallclinicalimpact proband was derived from antenatal imaging reports by of pES of 70% (14/20). clinicians blinded to autopsy findings. Where a pathogenic Conclusion: We show that clinical implementation of variantfellwithinthis“pre-autopsy”virtualgenepanel,this pES is feasible and affects parental decision making or was viewed as a diagnosis that would have been made by prenatal and perinatal management supporting further combining WES with antenatal imaging alone. implementation of ES in the routine prenatal setting. Results: The diagnostic rate in this cohort was 17/51 M.A. de Koning: None. M.C. Haak: None. P.N. (33%)with4furthervariantsawaitingfunctionalvalidation. AdamavanScheltema:None.C.M.P.C.Peeters-Scholte: Phenotypes with the highest diagnostic yield included None.T.T.Koopman:None.E.A.R.Nibbeling:None.E. skeletal dysplasias (100%); multiple malformations (33%) Aten: None. N.S. den Hollander: None. C.A.L. Rui- and hydrops fetalis (33%). 14/17 of diagnoses would have venkamp: None. M.J.V. Hoffer: None. G.W.E. beenmadeonantenatalfindingsalonewhile3/17additional Santen: None. diagnoses were made with findings only apparent on autopsy. 
P01 .24D Conclusion: ES in pregnancy following the detection of Diagnosis of fetal structural abnormalities using whole structural anomalies on ultrasound is feasible and returns exome sequencing: a single centre study comparablediagnosticyieldstoEScombinedwithautopsy. A.Yeung:None.F.Chan:None.A.Vasudevan:None. S. Drury1, L. Reed1, V. Ramachandran1, Y. Patel1, J. Collett: None. S. Prystupa: None. Y. Chan: None. G. A. Haworth1, J. Rizvi1, R. Dubis1, J. Anton1, J. Short2, McGillivray: None. E. Dempsy2, S. Mansour2, T. Homfray2 
P01 .23C 1Congenica Ltd, Hinxton, United Kingdom, 2South West Fromdiagnosticyieldtoclinicalimpact:implementation Thames Regional Genetics Service, St George’s University of prenatal exome sequencing in routine car Hospitals NHS FoundationTrus, London, United KingdomAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1185 
P01 .25A Introduction: Fetal abnormality detected on ultrasound Chorionic villi sampling and QF-PCR + SNP-array occursinupto5%offetuses.Intheabsenceofaneuploidy routinely offered in early pregnancy losses or cytogenetic causes, single gene disorders can be responsible; a recent review of 31 prenatal exome A. Borrell1, M. Pauta2, M. Grande3, V. Borobio1, sequencing studies by Best et al., (2018) showed a C. Illanes1, L. Rodriguez-Revenga4, A. Soler4, diagnostic rate of 6.2% to 80%. We have undertaken C. Badenas4 exome sequencing at a single centre for cases of unexplained fetal anomaly in both ongoing and retro- 1BCNatal. Hospital Clinic Barcelona, Barcelona, spective pregnancies. Catalonia, Spain, 2BCNatal. IDIBAPS. Hospital Clinic Materials and Methods: Patients with a fetal abnorm- Barcelona, Barcelona, Catalonia, Spain, 3IDIBAPS. ality detected on ultrasound were referred to clinical Hospital Clinic Barcelona, Barcelona, Catalonia, Spain, genetics at St George’s Hospital, London. Fetal DNA was 4Biomedical DiagnosticCenter.HospitalClinicBarcelona, from CVS, amniotic fluid, fetal blood or tissue. Maternal Barcelona, Catalonia, Spain cell exclusion was performed where relevant. DNA was enriched using the Agilent SureSelect CREv2 and Background:Geneticinvestigationisnotroutinelyoffered sequenced using Illumina NextSeq 500. Variant analysis in early pregnancy loss due to its high failure and maternal performedusingSapienita™.Genepanelsandvariantfilter cell contamination rates. settings including Exomiser prioritisation were pre- Objective: To identify the genetic causes of early preg- configured to expedite analysis. nancy losses, with the use of QF-PCR and SNP-array in Results:Inthefirstyear(2018),42familieswerereferred chorionic villi samples obtained previously to evacuation. for exome sequencing due to fetal anomaly. A diagnosis Methods:Womenwithapregnancylossbefore13weeks was made in 15 cases (36%); 9/17 singletons (BICD2, were offered transcervical chorionic villi sampling prior to FGFR2, LZTR1, NIPBL, PTPN11, RAF1, RMRP, surgical or medical uterine evacuation. During a 3-year SL
C26 A2, TS
C1 ), 1/1 duo (UB
E2 A), 4/23 trios (CHD7, study period (September 2015-October 2018) 584 women PIEZO1, POMGNT1, SL
C6 A9, TUBA1A) and 0/1 quad. consented. A first round of QF-PCR including chromo- Updated figures will be presented. somes 21, 18, 13, X, Y and a second round with chromo- Conclusions: The diagnostic rate for this selected group somes 15, 16, and 22 were assessed. Concurrent is consistent with the literature and is higher than recent karyotyping was also performed and SNP-array when the unselected cohort studies (Petrovski et al 2019, Lord et al chromosomes were normal. 2019). Inseveralcases themolecular diagnosiswas notthe Results: Fifty-five (9%) samples were excluded after primary suspected clinical diagnosis emphasising the con- microscopic inspection because only maternal decidua tinued importance of expanding and publishing prenatal could be retrieved. Among the 529 samples suitable for genotype-phenotype associations. analysis, a chromosomal anomaly was found in 159 (30%) S.Drury:A.Employment(fullorpart-time);Significant; cases at the first QF-PCR round, and 128 (24%) at the Congenica Ltd. L. Reed: A. Employment (full or part- second round. The karyotype revealed 66 (12%) anomalies time); Significant; Congenica Ltd. V. Ramachandran: A. undetected by QF-PCR. Among the 176 remaining early Employment(fullorpart-time);Significant;CongenicaLtd. losses with a normal karyotype, SNP-array was performed Y. Patel: A. Employment (full or part-time); Significant; in 90 cases with sufficient DNA ad 6 (2.4%) submicro- Congenica Ltd. A. Haworth: A. Employment (full or part- scopic anomalies were found. time);Significant;CongenicaLtd.J.Rizvi:A.Employment Conclusions: QF-PCR and SNP-array in chorionic villi (fullorpart-time);Significant;CongenicaLtd.R.Dubis:A. samples are able to provide a result in 91% of early preg- Employment(fullorpart-time);Significant;CongenicaLtd. nancy losses. Two rounds of QF-PCR detected a chromo- J. Anton: A. Employment (full or part-time); Significant; somal anomaly in 54% of the cases. If karyotyping is Congenica Ltd. J. Short: A. Employment (full or part- replaced by SNP-array in QF-PCR normal cases, further time); Significant; St George’s University Hospitals NHS 12% chromosomal anomalies, 2.4% submicroscopic FoundationTrust.E.Dempsy:A.Employment(fullorpart- anomalies and molar pregnancies will be revealed. time); Significant; St George’s University Hospitals NHS A. Borrell: B. Research Grant (principal investigator, Foundation Trust. S. Mansour: A. Employment (full or collaborator or consultant and pending grants as well as part-time); Significant; St George’s University Hospitals grants already received); Modest; Illumina. M. Pauta: NHS Foundation Trust. T. Homfray: A. Employment (full None. M. Grande: None. V. Borobio: None. C. Illanes: or part-time); Significant; St George’s University Hospitals None. L. Rodriguez-Revenga: None. A. Soler: None. C. NHS Foundation Trust. Badenas: None.1186 
P01 .26B 1Departement for Clinical Genetics, Aarhus University NGS based multigene panel analysis in cases of fetal Hospital, Aarhus, Denmark, 2Department for Obstetrics brain malformations and Gynecology, Aarhus University Hospital, Aarhus N, Denmark,3CenterforFetalDiagnostics,AarhusUniversity D. Liebrecht, C. Daumer-Haas, C. Bagowski, Hospital, Aarhus, Denmark, 4Biomedicine, Aarhus N. Hirschberger, S. Minderer, T. Schramm, University, Denmark, Denmark K. P. Gloning, M. Shoukier Introduction: Whole Exome Sequencing (WES) is cur- Praenatal-Medizin München, Munich, Germany rently enteringprenatalgenetic diagnosisforunsolvedfetal malformations. Diagnosticratesvarysignificantly,butwith Introduction: Identifying the genetic cause of fetal brain low diagnostic rates in isolated increased nuchal translu- malformations is a diagnostic challenge due to the genetic cency (NT) or cystic hygroma [Best et al 2018]. heterogeneity. We present here the results of multigene MaterialsandMethods:G5
P2 withseverehydropsin2 panel analysis (MGPA) of 65 fetuses with congenital brain malefetuses(missedabortionweek19and20)andhealthy malformations. children. Both hydrope fetuses presented with normal first Materials and Methods: From January to December trimesterscans.Cytomegalovirus(CMV)wasthepresumed 2018, 65 prenatal cases with fetal brain malformations (10 cause for the first case of hydrops, as the mother ser- with minor extracerebral anomalies) were investigated by oconverted just after the pregnancy. However, PCR for targetedNextGeneration Sequencingofthecodingregions CMV was negative in tissue from the aborted fetuses. of 262 genes. Genes were selected from the developmental Array-CGH was carried out on DNA obtained from brain disorders database (DBDB) and results reported amnioticfluidfrombothpregnancies,butleavingbothcases within two weeks. Familial co-segregation analysis for unresolved. WES was performed as trio on DNA extracted variant pathogenicity assessment was carried out, when from amniotic fluid from the second pregnancy, and both necessary. Karyotypes and array-CGH results of fetuses parents. Results were validated by Sanger sequencing. were normal. Results: A novel variant in FOX
P3  was identified in Results: Pathogenic variants were identified in 10 (15%) hemizygous state in the second pregnancy, inherited from out of the 65 cases. Mutations were found in a total of 8 themother,andsubsequentlyconfirmedincellculturefrom genes: TUBA1A and ASPM (2 cases respectively) as well the first pregnancy. This variant is currently under further asinGPSM2,FKRP,KAT6B,OFD1,TSEN54andTUBB validation. (1 case each). In addition variants of unclear significance Conclusions:GermlineFOX
P3 mutationscauseimmune were detected in 4 cases (6%). No mutation was identified dysregulation, polyendocrinopathy and enteropathy, X- in a total of 51 fetuses (79%). Our findings show a strong linked (IPEX) syndrome. This syndrome is well character- correlation between the detection rate of causative muta- izedinpatientspostnatally.Prenatally,mutationshavebeen tions and complexity of the fetal phenotype. Additionally, reportedtocausethelossofmalefetusesasaresultoffetal Trio-based whole exome sequencing should be considered hydrops[Reichertetal.2015].Thiscaseaddstothebodyof incaseswithnegativeMGPAresultstofurtherimprovethe knowledge suggesting that WES can improve our under- detection rate. standing of prenatal presentation of not only fetal mal- Conclusions: MGPA facilitates the identification of formations but also isolated hydrops. genetic causes with a good diagnostic yield and should be S. Ringsted: None. L. Andreassen: None. C. Kamper: used for routine molecular genetic diagnosis of fetal brain None. N. Becher: None. I. Vogel: None. malformations. D. Liebrecht: None. C. Daumer-Haas: None. C. 
P01 .28D Bagowski: None. N. Hirschberger: None. S. Minderer: Absence of AGG interruptions is a risk factor for a full None. T. Schramm: None. K.P. Gloning: None. M. mutation expansion among ethnically diverse FMR1 Shoukier: None. premutation carriers 
P01 .27C N. Domniz1, L. Ries-Levavi1, Y. Cohen1, L. Marom A caseoffetal hydropsand FOX
P3  -another argument Haham1, M. Berkenstadt1, E. Pras1, A. Glicksman2, for using exomes in pregnancy for isolated hydrops N. Tortora2, G. J. Latham3, A. G. Hadd3, S. L. Nolin2, S. Elizur1 S. Ringsted1, L. Andreassen1, C. Kamper2, N. Becher1,3, I. Vogel1,3,4 1Sheba MedicalCenter, TelHashomer, Ramat Gan, Israel, 2New York State Institute for Basic Research inAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1187 Developmental Disabilities, New York, NY, United States, Introduction:Wereportonacaseofanonconsanguineous 3Asuragen, Austin, TX, United States couple with one healthy child and two spontaneous abortions (one at 22 and one at 36 weeks of gestation). Introduction:GeneticcounselinggiventoFMR1premuta- Test results of the couple’s chromosome analysis were tion carriers is currently based upon the number of CGG normal, and there was no evidence of genetically relevant repeats. However, recent studies revealed that AGG diseasesintheirfamilies.Frozenskincellsofthefirstabort interruptions may decrease the risk of intergenerational had an insufficient quality to perform gene panel analysis. expansion. Materials and Methods: Clinical exome sequencing MaterialsandMethods:AllFMR1premutationcarriers (CES) was performed on the parents’ DNA followed by who underwent chorionic villus sampling (CVS) or screening for carrier status in 34 relevant genes for intrau- amniocentesis (AC) at Sheba Medical Center during the terine fetal death. period of 2011-2017 were included in this study. To Results: In the maternal DNA sample, we identified a increase the accuracy of our results, we combined results heterozygous novel mutation c.2423-1G>T in the FRA
S1  fromIsraelwiththosefromtheNewYorkStateInstitutefor gene affecting a highly conserved donor splice site and BasicResearchinDevelopmentalDisabilities(IBR).FMR1 leading most probably to aberrant splicing. Various splice PCR and Asuragen Kit were used to determine the number sitemutationsintheFRA
S1 havebeendescribedbefore.In of CGG repeats and AGG interruptions in all women and the paternal DNA sample, copy number variation (CNV) fetuses. analysis based on next-generation sequencing data showed Results:Thecombineddataincluded1471transmissions a novel heterozygous deletion of thelast three exonsof the of maternal premutation alleles: 369 (25.1%) stable and FRA
S1  gene. Junction fragment PCR confirmed this dele- 1,102 (74.9%) unstable transmissions. Full mutation tion and sequencing of the PCR products revealed the expansions were identified in 20.6% (303/1471) of trans- breakpoints (c.11092+658_*12039+6368del). Although missions.Atotalof97.4%(388/397)oftransmissionsfrom the material of the first abort had poor quality, Sanger alleles with no AGGs were unstable, compared to 79.6% sequencingandjunctionfragmentPCRonfrozenskincells (513/644) in alleles with 1 AGG and 46.7% (201/430) in wereabletoidentifythesetwonovelvariantsascompound alleleswith2ormoreAGGs.40%(159/397)ofalleleswith heterozygous. no AGGs expanded to a full mutation, compared to 20.2% Conclusion: Therefore, clinical exome sequencing in (130/644)foralleleswith1AGGandonly3.2%(14/430)in combination with CNV analysis on a couple’s DNA is an alleles with 2 AGGs or more. appropriate method to detect possible causes of multiple Conclusions: Based on this ethnically diverse data we stillbirths, especially when no fetal DNA is available. recommend that the risk estimates for a full mutation M.Kuhn:None.M.Burkert:None.S.Tschürtz:None. expansion for FMR1 premutation carriers will include the K. Mehnert: None. D. Gläser: None. number of AGG interruptions as well as CGG repeat size. Study funding/competing interest(s) - Azrieli foundation, 
P01 .30B Canada-Israel Identification of compound heterozygous FTO- N. Domniz: None. L. Ries-Levavi: None. Y. Cohen: mutations in a severe malformation syndrome None. L. Marom Haham: None. M. Berkenstadt: None. E. Pras: None. A. Glicksman: None. N. Tortora: None. U. Siebers-Renelt, Y. Stratis, J. Seggewiß, S. Ledig, G.J.Latham:None.A.G.Hadd:None.S.L.Nolin:None. J. Horvath, P. Wieacker S. Elizur: None. Institut für Humangenetik, Muenster, Germany 
P01 .29A Targeted next-generation sequencing and CNV analysis We report on a non-consanguineous couple who presented identifies two novel mutations in the FRA
S1  gene in the 19th week of their 6th pregnancy with ultrasound abnormalitiesofthefetus(broadneckwithincreasednuchal M. Kuhn1, M. Burkert1, S. Tschürtz2, K. Mehnert1, translucency, multicystic dysplasia of the kidney, short D. Gläser1 femur, fetal clubfoot). The couple has got just one healthy child. Two spontaneous abortions occurred and one 1genetikum - Center for Human Genetics, Neu-Ulm, pregnancy with trisomy 21 was terminated. Another child Germany, 2Medical Office for Prenatal Medicine, Munich, also exhibited a broad neck and additional omphalocele Germany early in pregnancy. Hydrocephaly was first visible in the 32nd week. After delivery in the 35th week, she required artificial respiration. MRI showed a complex brain1188 malformation.Thatchilddeceasedattheageofonemonth. Results: Main contributors to moderate/severe PE Chromosome analysis and microarray were normal in both development: pre-existing vascular complications (nephro- malformed children. After termination of pregnancy we pathy[χ2=10,05,p=0,004,OR=11,2395%CI2,13-59,26], performed a clinical trio-exome (Agilent SureSelect Inher- lower extremities angiopathy [χ2=7,39, p=0,007, ited Disease Panel). We identified two loss-of-function OR=16,00 95%CI 1,86-137,61], retinopathy [χ2=4,27, mutationsincompoundheterozygosityintheFTOgenenot p=0,039, OR=6,50 95%CI 1,25-33,91]) and their combi- yetdescribed(ACMGclass4).Thedeceasedsiblingcarried nations (nephropathy + retinopathy; nephropathy + lower both mutations and the healthy sister none. Homozygous extremities angiopathy) and ACE DD-genotype. In FTO loss-of-function mutations have been associated with PON1_108CT carriers clinical parameters exerted modify- multiple malformations including short broad neck, differ- ing effect: when combined with nephropathy, or T1DM ent brain malformations, severe developmental delay, duration < 8,5 years, or BMI < 23,8 kg/m2, mild PE failure to thrive and high risk of death in early childhood develops; moderate/severe PE develops when diabetes (Boissel 2009, Daoud 2016). In summary, the FTO- duration is > 13,5 years or BMI is > 25,17 kg/m2. Combi- mutations are very likely to be causative for the disease nation ACE_II/PON1_CC was protective against PE because of the type of mutation, the phenotype and the development, while ACE_ID/PON1_CT is associated with segregation data. Nevertheless, prenatal molecular analysis mild PE. Conclusion: Genetic markers are helpful in should be accompanied by a detailed ultrasound work-up. identification of women at high risk for severe PE. Moreover,thecouplehastobeawarethattheabsenceofthe T. Avramenko: None. A. Hrybanov: None. FTO-mutations does not completely exclude the disease. U.Siebers-Renelt:None.Y.Stratis:None.J.Seggewiß: 
P01 .32D None. S. Ledig: None. J. Horvath: None. P. Case of 8p and 18p genetic imbalance in a subfertile Wieacker: None. female patient without pronounced physical and mental abnormalities 
P01 .31C Early prediction of preeclampsia (PE) severity in Y. V. Shilenkova, A. A. Pendina, O. A. Efimova, pregnant women with preexisting type 1 diabetes A. V. Tikhonov, O. G. Chiryaeva, V. S. Dudkina, mellitus (T1DM): new implements for genetic markers L. I. Petrova, I. D. Mekina, O. V. Malysheva, E. S. Shabanova, T. E. Ivashchenko, A. M. Gzgzyan, T. Avramenko1, A. Hrybanov1,2,3 I. Y. Kogan 1State Institution "Institute of pediatrics, obstetrics and D.O. Ott Research Institute of Obstetrics, Gynecology and gynecologybytheNationalAcademyofMedicalSciencesof Reproductology, Saint Petersburg, Russian Federation Ukraine",Kyiv,Ukraine,2MaternityHospital#2,Mykolaiv, Ukraine, 3Public Health Board by Mykolaiv Region State Introduction: We report an unusual case of unbalanced Administration, Mykolaiv, Ukraine karyotype female carrier with no physical and mental abnormalities and her reproductive history. Background: Severe PE strongly correlates with persistent Materials and Methods: Conventional karyotyping disability, long-term cardiovascular complications in (GTG and QFH/AcD-banding techniques) was performed mothers and prematurity, IUGR or BPD in neonates. The on the chorionic villi from aborted material and on PHA- study objective was to establish reliable clinical, genetic stimulated lymphocytes of the patient, her husband and markers associated with PE severity in T1DM women. patient’s parents. FISH and aCGH (CGXv1.1 8x60K,Per- MaterialsandMethods:Group1includedpatientswith kinElmer) were performed on thepatient’sPHA-stimulated mild(n=15),moderate(n=11),severe(n=4)PE;Group2- lymphocytes and whole blood sample, respectively. Stan- 30 patients, in whom pregnancy was not complicated with dard IVF was performed with an embryo biopsy on day 3 PE. Polymorphisms in eNOS (4b/4a, G894T), ACE (I/D), (6-8-cell stage) for PGT-SR by FISH. AT2R1 (A1166C), MGP (Thr83Ala, T138C) and PON1 Results: The patient - 28-years old women - sought (
C108 T) genes were detected using PCR-RFLP. Data was genetic counseling after loss of two naturally conceived analyzed with SPS
S17 .0 using paired sample t-test, Pear- pregnancies. The first miscarriage was not karyotyped. The son’s chi-squared test with 95%CI calculation for OR. second had karyotype 45,ХХ,der(8)t(8;18)(p23;p11.3),- Binary logistic regression was used to generate statistical 18mat. The patient appeared to have the same karyotype: models and evaluate their prognostic value. ROC curve 45,ХХ,der(8)t(8;18)(p23;p11.3),-18dn. aCGH revealed analysiswasperformedinordertoestablishtheinfluenceof terminal deletions combined with microduplication: del(8) polymorphic variants of genes on PE severity. (p23.1p23.3) (6.718Mb), dup(8)(p22p22) (4.937Mb), delAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1189 (18)(p11.31p11.32) (3.693Mb), dup(18)(q23q23) association study (GWAS) for GDM, in 1,399 affected (0.060Mb). The patient’s husband and parents had normal Koreanwomen,revealedassociationsattwoloci:MNTR1B karyotypes. The patient had only slight dysmorphic face and CDKA
L1 . We conducted trans-ethnic meta-analysis of features and no pronounced physical and mental abnorm- 21 GWAS in 5,374 cases and 346,506 controls of diverse alities.Subsequently,thepatientunderwentfourIVFcycles ancestry (62.0% European, 16.5% East Asian, 3.2% with a total of 25 oocytes obtained. Only 13 of them Mexican-American and 18.3% Afro-Caribbean), each reached MII (52% versus expected 75-90%). Only one out imputed up to reference panels from the 1000 Genomes of 10 embryos was cytogenetically balanced. The embryo Project or Haplotype Reference Consortium. The trans- was transferred, but the pregnancy was not registered. ethnic meta-analysis, performed with MR-MEGA to allow Conclusions: The present case demonstrates a genotype- for heterogeneity in allelic effects between ancestries, phenotype disparity in the carrier of unbalanced chromo- included 13,980,490 variants, after excluding those with somal rearrangement. Considering an unpredictable effect minor allele count <5 and imputation quality <0.4 in each of the genetic imbalance on the offspring phenotype, a GWAS. We replicated both known GDM associations at personalizedapproachtothepatient’sgeneticcounselingis genome-wide significance (P<5x10-8): MTNR1B requiredinordertoachievepregnancywithcytogenetically (rs10830963, P=2.3×10-49) and CDKA
L1  (rs9348441, balanced embryo. P=9.7×10-15). We also identified three additional novel Y.V. Shilenkova: None. A.A. Pendina: None. O.A. loci: TCF7
L2  (rs7903146, P=1×10-14), CDKN2A/B Efimova: None. A.V. Tikhonov: None. O.G. Chiryaeva: (rs10811660, P=1.9×10-9) and LO
C105369513  None. V.S. Dudkina: None. L.I. Petrova: None. I.D. (rs143421658, P=4.1×10-8). Allelic effects of GDM Mekina: None. O.V. Malysheva: None. E.S. Shabanova: associationsignalsweremostlyhomogeneousacrossethnic None. T.E. Ivashchenko: None. A.M. Gzgzyan: None. I. groups. The exception was at the CDKA
L1  locus Y. Kogan: None. (P =3.68×10-9), where the signal was driven by East het Asian ancestry GWAS (OR =1.67(1.46-1.89); East-asian 
P01 .33A OR =1.06(1.01-1.12)). Four of the loci (MTNR1B, Europeans Trans-ethnic meta-analysis meta-analysis of gestational CDKA
L1 , TCF7
L2 , and CDKN2A/B) have also been diabetes reveals shared genetic background with type 2 robustlyassociatedwithT2D,andleadvariantsareidentical diabetes to those we have identified for GDM, supporting a shared underlying genetic contribution to both diseases. N. Pervjakova1,2, J. P. Cook3, A. P. Morris3,4, N. Pervjakova: A. Employment (full or part-time); T. Ferreira5,6, R. Mägi1 Modest; AnteGenes OÜ. J.P. Cook: None. A.P. Morris: None. T. Ferreira: None. R. Mägi: None. 1Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia, Tartu, Estonia, 
P01 .34B 2Genomics of Common Disease, Division of Diabetes, Genome-wide analysis of losses and gains a better Endocrinology and Metabolism, Department of Medicine, understanding of idiopathic male infertility Imperial College London, UK, London, United Kingdom, 3Department of Biostatistics, University of Liverpool, A.Hodžić1,N.Trošt1,B.Zorn2,D.Plaseska-Karanfilska3, Liverpool, UK, Liverpool, United Kingdom, 4Estonian P.Noveski3,T.Kunej4,K.Urh4,L.Lovrečić1,B.Peterlin1 GenomeCenter,InstituteofGenomics,UniversityofTartu, Tartu, Estonia, 5Big Data Institute, Li Ka Shing Center for 1Clinical Institute of Medical Genetics, University Medical Health for Health Information and Discovery, Oxford Centre Ljubljana, Ljubljana, Slovenia, 2Andrology Unit, University, Oxford, UK, Oxford, United Kingdom, 66. Reproductive Unit, Department of Obstetrics and Wellcome Centre for Human Genetics, University of Gynecology, University Medical Centre Ljubljana, Oxford, Roosevelt Drive, Oxford OX3 7BN, UK, Oxford, Ljubljana, Slovenia, 3Research Centre for Genetic United Kingdom Engineering and Biotechnology "Georgi D. Efremov" Macedonian Academy of Sciences and Arts, Skopje, Gestational diabetes mellitus (GDM), defined as glucose Macedonia, The Former Yugoslav Republic of, intolerance first recognized in pregnancy, has important 4Department of Animal Science, Biotechnical Faculty, implications for both mother and child. Offspring of University of Ljubljana, Ljubljana, Slovenia mothers with GDM have an increased risk of birth complications associated with higher risk for developing Introduction: Diagnosting workup of infertile man, which metabolic syndrome, type 2 diabetes (T2D) and cardiovas- include screening for chromosomal aberrations and Y cular disease in later life. To date, the only genome-wide chromosomal azoospermia factor deletions, have not been1190 changed for years and still the etiology of most of the 6Genomics Core Facility, Newcastle University, Newcastle infertile cases remains unknown. Aiming to achieve upon Tyne, United Kingdom progress in elucidating genetic causes of male infertility and to examine suitability of novel genetic testing methods Introduction: Approximately 7% of all men are infertile in clinical routine of infertile man, we investigated man andgeneticsisknowntoplayanimportantroleinthemost with unexplained infertility with Array Comparative severeformsofinfertilitysuchasazoospermiaandextreme Genomic Hybridisation method. oligozoospermia. However, most patients remain undiag- Materials and Methods: We enrolled 90 patients with nosed. In this study, we explored the role of de novo copy- severe male factor infertility, defined as idiopathic azoos- number variations (CNVs) in whole-exome sequencing permia or oligoasthenoteratozoospermia, and analyzed (WES) data from a unique cohort of 108 infertile men and DNA using SurePrint G3 Unrestricted CGH 4x180K their parents. microarrays. We have selected candidate Copy Number Material and Methods: Three different software, CoN- Variants (CNVs) according 2 criterias: 1st criteria was that IFER, XHMM and an optimized GATK4 pipeline were identified CNVs are not present in currently available used to detect rare de novo CNVs. XHMM and GATK4 databases of genomic variants, and 2nd criteria was that reducedtheinherentnoiseintheexomecoveragedatabest, identified CNVs are not present in our control data set of resulting in the most accurate CNVs detection. Addition- men with proven fertility. ally, the GATK4 pipeline allowed to integrate allele fre- Results: We identified 5 CNVs which included genes quency analysis, confirming the loss of heterozygosity previously related to male infertility (CLCA4, USF1, (LOH) in deletions. FCER1G, FNTA, HOTAIR). We have also identified 7 Results: Application of these tools revealed two rare de CNVs not presented in currently available databases of novo deletions in two different patients. One deletion genomic variants or in our control data set. The identified occurred on chromosome 11 and partially overlapped a CNVs spanning genes with noticed expression in testis, deletionpreviouslyreportedinaninfertileman.Thesecond, however, their possible functional impact on infertility are affected NXT2 on chromosome X, a gene evolutionary currently not known. conserved and highly expressed in testis. Both CNVs were Conclusion: We provide a several candidate CNVs, validated by microarrays and/or Q-PCR. possibly implicated in male infertility. Taken together with Conclusions: These first data indicates that de novo previousresearch,thesefindingsareonemorestepforward CNVsmayplayanimportantroleinseveremaleinfertility. to implementation of new testing methods into routine However, replication and functional studies are required to clinical practice of infertile man. further validate the impact of our findings. By further A. Hodžić: None. N. Trošt: None. B. Zorn: None. D. improving CNV detection from WES data we may be also Plaseska-Karanfilska: None. P. Noveski: None. T. able to identify additional de novo CNVs that are currently Kunej: None. K. Urh: None. L. Lovrečić: None. B. missed,aswellasmaternallyinheritedCNVsthatmayplay Peterlin: None. a role in male infertility. F.K. Mastrorosa: None. M.J. Xavier: None. A. Miku- 
P01 .35C lasova: None. M.S. Oud: None. R.M. Smits: None. G. Detection of de novo copy-number variations from Astuti: None. B. Alobaidi: None. S.J. Cockell: None. J. exome sequencing of 108 infertile patient-parents trios Coxhead:None.C.Gilissen:None.L.Ramos:None.J.A. Veltman: None. F. K. Mastrorosa1, M. J. Xavier1, A. Mikulasova2, M. S. Oud3, R. M. Smits4, G. Astuti3, B. Alobaidi1, 
P01 .36D S. J. Cockell5, J. Coxhead6, C. Gilissen3, L. Ramos4, Identification of a Novel Genetic Cause of Familial J. A. Veltman1,3 Nonobstructive Azospermia 1Institute of Genetic Medicine, Newcastle University, S. G. TEME
L1 , B. Turkgenç2, K. Teralı3, M. Ergören4, Newcastle upon Tyne, United Kingdom, 2Institute of M. Cetinkaya5, M. Başar6, S. Kahraman5 Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 3Department of Human Genetics, 1UNIVERSITY OF ULUDAG, FACULTY OF MEDICINE, Donders Institute for Brain, Cognition and Behaviour, DEPARTMENT OF MEDICAL GENETICS, BURSA, Radboudumc, Nijmegen, Netherlands, 4Department of Turkey, 2Acibadem Genetic Diagnostic Genetic Center, Obstetrics and Gynaecology, Radboudumc, Nijmegen, labgen,ISTANBUL,Turkey,3NearEastUniversity,Faculty Netherlands, 5Bioinformatics Support Unit, Newcastle ofMedicine, Department ofBiochemistry, Nicosia,Cyprus, University, Newcastle upon Tyne, United Kingdom, 4University of Near East, Faculty of Medicine, DepartmentAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1191 of Medical Biology, NICOSIA, Cyprus, 5Assisted Male infertility is a clinically and genetically highly Reproductive Technologies and Reproductive Genetics heterogeneous disease, mostly characterised by spermato- Centre, Istanbul Memorial Hospital, Istanbul, Turkey, genetic failure, clinically noted as oligo- or azoospermia. 6Department of Urology & Andrology, Memorial Sisli The most common form of the latter phenotype is non- Hospital, Istanbul, Turkey obstructive azoospermia (NOA), which can be caused by various genetic defects such as chromosomal aberrations, Infertility is a global reproductive health problem, and in Y-chromosomalAZFmicrodeletionsormonogenicdefects. males it is usually because of the reduced number or the Inthis study, we systematicallyanalysed24genes reported completeabsenceofspermcellsinsemen(oligozoospermia tobeassociatedwithNOAintheOMIMdatabase.Variants and azoospermia, respectively). Nonobstructive azoosper- in these genes were detected in whole exome sequencing mia (NOA) is the most severe form of male infertility data from 484 well-phenotyped infertile patients (azoos- affecting ~0.6% of men from the general population and permia, N=94; cryptozoospermia, N=52; mixed atrophy, ~10% of infertile men. Its etiology remains largely N=93;Sertoli-Cell-Onlysyndrome,N=179;meioticarrest, unknown. To identify the genetic cause of NOA in four N=43; other arrest, N=23). Other clinical causes for their affected members from a consanguineous family, we infertility such as previous chemo-/radiotherapy, as well as performedwhole-exomesequencing(WES).WESrevealed karyotype aberrations and AZF deletions had been a homozygous c.1166C>T (p.Pro389Leu) variation in the excluded. Exclusively novel or rare coding variants were M1AP gene. The segregation of the M1AP variant with assessedconcerningtheirpotentialpathogenicity.Outofthe NOA in this family was confirmed by Sanger sequencing. 24 genes listed in OMIM, TEX14, TEX11, NR5A1 and The 3D structure of the mutant protein was predicted DMRT1 were validated as clinically relevant genes causing computationally. Sequence- and structure-based in silico NOAwithstrongevidence.Specifically,weidentifiedeight studies andsubsequent preliminarygeneexpression studies patientscarryingTEX11variants.Tenpatientsdemonstrated imply that the M1AP variant has severe implications for compound heterozygous or homozygous TEX14 variants. protein structure and function. Further functional studies to Five patients carried NR5A1 and five others DMRT1 corroborate our findings are ongoing. Overall, M1AP is a variants. This is the first report of concise exome novel candidate gene for male infertility and, to the best of sequencing in a large group of infertile males. Our results ourknowledge,thisisthefirstreportidentifyingM1APasa clearly demonstrate that the TEX14, TEX11, NR5A1 and cause for human familial NOA. And our pedigree analysis DMRT1geneshavereachedasufficientlevelofevidenceto suggests an autosomal recessive mode of inheritance for be prioritised for clinical analyses. This work was carried NOA due to M1AP in the present family. out within the frame of the DFG Clinical Research Unit S.G. Temel: None. B. Turkgenç: None. K. Teralı: “Male Germ Cells: from Genes to Function” (CRU 326). None. M. Ergören: None. M. Cetinkaya: None. M. A. Röpke: None. N. Köckerling: None. M.J. Wyrwoll: Başar: None. S. Kahraman: None. None. J. Emich: None. M. Wöste: None. M. Dugas: None. A. Pilatz: None. H. Schuppe: None. T. Diemer: 
P01 .39C None. D. Fietz: None. C. Krallmann: None. S. Kliesch: Geneticanalysisof24candidategenesvalidatesTEX14, None. C. Friedrich: None. F. Tüttelmann: None. TEX11, NR5A1 and DMRT1 as clinically relevant for non-obstructive azoospermia 
P01 .40D Maternal copy number variations in the DMD gene as A. Röpke1, N. Köckerling1, M. J. Wyrwoll1, J. Emich1, incidental findings in non-invasive prenatal testing M. Wöste2, M. Dugas2, A. Pilatz3, H. Schuppe3, T. Diemer3, D. Fietz4, C. Krallmann5, S. Kliesch5, N. Brison1, J. Storms1, K. Claeys2, L. Dehaspe1, C. Friedrich1, F. Tüttelmann1 E. Dimitriadou1, C. Melotte1, T. de Ravel1, L. De Waele3, N. Goemans4, E. Legius1, H. Peeters1, H. Van Esch1, 1InstitutfürHumangenetik,Münster,Germany,2Institutfür V. Race1, J. Vermeesch1, K. Devriendt1, K. Van Den Medizinische Informatik, Münster, Germany, 3Klinik und Bogaert1 Poliklinik für Urologie, Kinderurologie und Andrologie, Gießen, Germany, 4Institute of Veterinary Anatomy, 1Department of Human Genetics, Leuven, Belgium, Histology and Embryology, Gießen, Germany, 5Centre of 2Department of Neurology, Leuven, Belgium, 3Department Reproductive Medicine and Andrology, Department of of Pediatric Neurology, Leuven, Belgium, 4Department of Clinical and Surgical Andrology, Münster, Germany Neurosciences, Leuven, Belgium1192 Noninvasive prenatal testing (NIPT) using shallow whole- (group B, n=110). Associated maternal buffy coats were genome sequencing also reveals maternal copy number blindedandsenttoCHOPforcytogeneticanalysisusingthe variations (CNV’s). Some of those variants are clinically Global Screening Array (GSA, Illumina). actionable or could be harmful for the fetus. CNV’s in the Results:Of107groupAsamples,101wereconfirmedby DMD gene, potentially causing dystrophinopathies, are GSA to have maternal X CA (PPV: 94.4%; 97.5% con- amongstthemostcommonlyobservedmaternalCNV’s.We fidence interval (CI), 88.2-100%); in the remaining 6 sam- analyzed the data of maternal CNV’s detected in the DMD ples, 3 were discordant (GSA unable to detect suspected gene by NIPT. Out of 26.123 NIPT analyses, 16 maternal maternalCA),andintheother3samples,maternalCAwas CNV’s in the DMD gene were detected (1/1.632 pregnant suspected, but too ambiguous to call as present. In 67.3% women). Variant classification regarding pathogenicity and (68/101)cases, NIPS vs.GSAinterpretationsmatched; and phenotypic severity was based on public databases, 32.7% (33/101) showed similar but varied interpretations segregation analysis in the family and a prediction of the duetoambiguitiesarisingfrommosaicismand/orspecificX effect on the reading frame. Ten CNV’s were classified as abnormality. No maternal X CA were found in group B by pathogenic, 4 as benign whereas 2 remained unclassified. GSA (NPV: 100%; 97.5% CI, 96.7-100%). We present our experience with the detection of maternal Conclusions: The study supports the reporting of CNV's in the DMD gene and propose a scheme for the maternal X CA suspected by SNP-based NIPS, which was interpretationandthereturningoftheseCNV’sdetectedby confirmed in 94.4% of suspected cases. No maternal NIPT. We show that genome-wide NIPT leverages CNV abnormalities were identified when a fetal abnormality was screeninginthegeneralpopulationofpregnantwomenand suspected. thatinterrogatingthematernalCNVlandscapecanimprove V. Kantor: A. Employment (full or part-time); Sig- overall pregnancy management. nificant; Full-time Employee, Natera, Inc.. E. Ownership N.Brison:None.J.Storms:None.K.Claeys:None.L. Interest (stock, stock options, patent or other intellectual Dehaspe:None.E.Dimitriadou:None.C.Melotte:None. property); Significant; Stock, Natera, Inc. R. Dhamankar: T. de Ravel: None. L. De Waele: None. N. Goemans: A. Employment (full or part-time); Significant; Full-time None. E. Legius: None. H. Peeters: None. H. Van Esch: Employee,Natera,Inc..E.OwnershipInterest(stock,stock None.V.Race:None.J.Vermeesch:None.K.Devriendt: options, patent or other intellectual property); Significant; None. K. Van Den Bogaert: None. Stock,Natera,Inc.E.Valenti:A.Employment(fullorpart- time); Significant; Full-time Employee, Natera, Inc.. E. 
P01 .41A Ownership Interest (stock, stock options, patent or other ValidationofSNP-basednoninvasiveprenatalscreening intellectual property); Significant; Stock, Natera, Inc.. D. test to detect maternal X chromosome abnormalities Lyons:None.M.T.Trefogli:A.Employment(fullorpart- time); Significant; Full-time Employee, Natera, Inc.. E. V. Kantor1, R. Dhamankar1, E. Valenti1, D. Lyons1, Ownership Interest (stock, stock options, patent or other M.T.Trefogli1,I.Balosbalos1,C.Kao2,H.Hakonarson2, intellectual property); Significant; Stock, Natera, Inc. I. K. A. Martin1 Balosbalos:A.Employment(fullorpart-time);Significant; Full-time, Natera, Inc.. E. Ownership Interest (stock, stock 1Natera, Inc., San Carlos, CA, United States, 2Center for options, patent or other intellectual property); Significant; Applied Genomics, Children’s Hospital of Philadelphia, Stock,Natera,Inc..C.Kao:None.H.Hakonarson:None. Philadelphia, PA, United States K.A. Martin: None. Introduction: Maternal chromosome abnormalities (CA) 
P01 .42B are known incidental findings with non-invasive prenatal Geneticsignalsforuseofhormonereplacementtherapy screening (NIPS), contributing to false positives with in post-menopausal women suggest potential drug quantitative methodologies. SNP-based NIPS can distin- targets and reflect changes in health practice guish the maternal and fetal SNP allele distributions. This study validates the performance of SNP-based NIPS to K. S. Ruth, R. N. Beaumont, J. Tyrrell, A. R. Wood, detect maternal CA on chromosome X. S. E. Jones, M. N. Weedon, T. M. Frayling, A. Murray Methods: Plasma samples from singleton pregnancies were obtained (April-December 2018) and analyzed by University of Exeter Medical School, Exeter, United SNP-based NIPS. Samples were included in the analysis if Kingdom the algorithm could not return a result (below threshold for reporting) for suspected CA. These samples were stratified Introduction: Hormone replacement therapy (HRT) is an into suspected maternal (group A, n=107) and fetal origin effective treatment for vasomotor symptoms aroundAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1193 menopause, but in the UK HRT usage dropped following advanced maternal age, previous pregnancy with aneu- the publication of health risks in 2002. ploidy, positive biochemical or NIPT, anxiety etc. Materials and Methods: To understand the biology of Molecularkaryotypeshowsanincreaseddiagnosticyield HRT use, we carried out genome-wide analyses of self- compared to conventional karyotype varying from 1,4% to reported HRT phenotypes (ever taken, age started, age 3,4% depending on the referral reason with the highest stopped and time taken) in up to 153,152 white European addedvalueinfetuseswithabnormalU/Sfindings.Among women aged 40-70 years from the UK Biobank. all abnormal CGH samples with normal karyotype, 72,5% Results: We identified 15 independent signals. A signal of clinically significant imbalances would have escaped (AF=95%) in TACR3, the receptor for neurokinin B, was detection from NIPT since they concern rare syndromes associated with raised odds of using HRT (1.18 per allele; (25%), susceptibility to-loci (60%) and backbone abnorm- P=1×10-26) and with vasomotor symptoms in a previous alities (15%) related to the referral reason. genome-wideanalysis(Crandalletal2017).Additionally,a Conclusion:Sincemorethan70%oftheabnormalCGH putative signal (AF=0.1%) near ALDH8A1 (gene involved cases would not be detected neither by conventional kar- in tryptophan catabolism) was associated with taking HRT yotypenorbyNIPT,wesuggestthateverypregnantwoman for longer (0.5 SD per allele; P=4×10-8). Tryptophan is a ofanyageshouldbeofferedtheinformedchoicetoundergo precursor of serotonin, which has been implicated in hot molecular karyotype prenatal testing. flushes, as has neurokinin B. F. Sachinidi: None. E. Panou: None. D. Mpouzarelou: Of the signals, 13/15 were associated with starting HRT None. C. Billi: None. L. Florentin: None. younger at P<5×10-8 and 11 with earlier menopause. A genetically-predicted one year earlier menopause raised the 
P01 .44D odds of HRT use in women starting treatment before 2002 Prenatally diagnosed megalencephaly-polymicrogyria- (OR=1.12, 95% CI=1.10,1.13) but not after 2002 polydactyly-hydrocephalus syndrome (OR=1.02, 95% CI=0.95,1.00). In contrast, the signals near TACR3 and ALDH8A1 were not associated with K. Tael1, K. Ridnõi2,3, E. Kurvinen1, P. Ilves2,4, menopause timing. L. Makarenkova3, S. Pajusalu1,2,5, M. H. Wojcik6,7, Conclusions: Genetic associations for HRT are largely K. Õunap1,2,7, T. Reimand1,2 drivenbymenopausetimingandareaffectedbychangesin healthpractice.Weidentifiedtwogeneticsignals,whichare 1Department of Clinical Genetics, United Laboratories, not affected by health practice, near plausible candidate Tartu University Hospital, Tartu, Estonia, 2Institute of genes for vasomotor symptoms. Clinical Medicine, University of Tartu, Tartu, Estonia, K.S. Ruth: None. R.N. Beaumont: None. J. Tyrrell: 3East-Tallinn Central Hospital, Tallinn, Estonia, 4Clinic of None. A.R. Wood: None. S.E. Jones: None. M.N. Wee- Radiology,TartuUniversityHospital,Tartu,Estonia,5Yale don: None. T.M. Frayling: None. A. Murray: None. University School of Medicine, Department of Genetics, New Haven, CT, United States, 6Division of Genetics and 
P01 .43C Genomics, Department of Medicine, Boston Children’s Prenatal diagnostics: the utility of molecular Hospital, Harvard Medical School, Boston, MA, United karyotyping States, 7Broad Institute of MIT and Harvard, Cambridge, MA, United States F. Sachinidi, E. Panou, D. Mpouzarelou, C. Billi, L. Florentin Introduction: Megalencephaly-polymicrogyria-polydactyly- hydrocephalus (MPPH) syndrome is characterized by Alfalab, Genetics and Genomics Center, Athens, Greece megalencephaly, polymicrogyria and a variant in one of three genes: CCND2, AKT3 or PIK3R2. To the best of our Introduction:theaimofthisstudyistohighlighttheuseof knowledge, there is only one prenatally reported MPPH molecular karyotyping in the context of prenatal diagnostic case. We present a new case of MPPH with a variant in testing. CCND2 that was diagnosed prenatally. Materials and Methods: Molecular karyotype was Casereport:Chorionicbiopsywasperformedduringthe appliedon4012prenatalsamples(CVS,amnioticfluids)as 1st trimester of the pregnancy due to increased NT value thefirstlinediagnostictool.Specimenshavebeenanalyzed (3.39 cm) to a 29-years-old patient. The karyotype of the using Agilent SurePrint G3 8x60K ISCA design and fetuswas 46,XY. Ultrasonographyandmagneticresonance Cytogenomics software. imaging of the fetus showed extensive bilateral cortical Results: women who underwent prenatal molecular kar- dysplasia of the supratentorial cerebral parenchyma with a yotypewerereferredforultrasoundfindings,increasedNT, suspected focal acute lesion in the right parietotemporal1194 region. Dysgenesis of the corpus callosum as well as polymorphic microsatellite markers. Bidirectional TP-PCR asymmetry of the hemispheres of cerebellum were also and dodecaplex marker PCR assays were optimized and visualized. The radiological changes were nonspecific but validated on whole-genome amplified single lymphoblasts indicated either intrauterine infection or genetic brain mal- isolated from DM1 reference cell lines, and tested on a formation.Thepregnancywasultimatelyterminated,andan simulated PGT-M case comprising a parent-offspring trio autopsy revealed multiple congenital cerebral anomalies: and three simulated embryos. DMPK TP-PCR reliably abnormal cranial occlusion, abnormal additional clefts on detects repeat expansions regardless of allele size, and right in the occipital and parasagital regions, dysgenesis of employing TP-PCR in both directions ensures successful the corpus callosum, and a collapsed and hypoplastic sep- expansion detection even when non-CTG interruptions tum pellucidum. There were no polydactyly and signs of occur at either the 5’ or 3’ end of the expanded allele. inflammation in the placental and fetal tissues. To investi- Misdiagnoses and diagnostic ambiguity due to allele gate the underlying etiology of this phenotype, trio exome dropout or exogenous DNA contamination can be easily sequencing (ES) analysis was done. detected through the use of tightly linked microsatellite Result: ES revealed a pathogenic de novo missense var- markers,minimizingtheexclusionofpotentiallyunaffected iant: NM_001759.3(CCND2):c.839C>A p.(Thr280Asn) embryosforuterinetransfer.Thehighlypolymorphicmulti- rs587777620, confirmed by Sanger sequencing. marker panel also maximizes the likelihood of marker Conclusions: MPPH syndrome should be considered informativenessinat-riskcouples,thusminimizingtheneed when prenatally cerebral dysgenesis is visualized on US for couple-specific assay customization. and/or MRI. M. Lian: None. C.G. Lee: None. S.S. Chong: None. Funding:EstonianResearchCouncilgrantsPRG471and PUTJD827. 
P01 .47C K.Tael:None.K.Ridnõi:None.E.Kurvinen:None.P. Nicotine and resveratrol alter sox2 and sox4 genes Ilves: None. L. Makarenkova: None. S. Pajusalu: None. expression levels in human amniotic cell culture M.H. Wojcik: None. K. Õunap: None. T. Reimand: None. G. Cömertpay, Ü. H. Lüleyap, B. M. Yılmaz, P. Pazarcı 
P01 .46B Cukurova University, Medical Faculty, ADANA, Turkey Robust strategy for preimplantation genetic testing of myotonic dystrophy type 1 by bidirectional triplet- Introduction: The aim ofthis researchistoinvestigate the primed PCR combined with multi-microsatellite effectsofnicotineonexpressionlevelsofSOX2andSOX4 haplotyping following whole genome amplification mastergenesinhumanamnioticcellculturestoindicatethe risksofsmokinginpregnancy.Theeffectsofresveratrolon M. Lian1,2, C. G. Lee3,4,5, S. S. Chong3,1,2 expression levels of these genes in human amniotic cell cultures, which are treated by nicotine were also examined 1National University Health System, Singapore, Singapore, in this study. 2National University Hospital, Singapore, Singapore, Materials and Methods: Twenty patients were included 3National University of Singapore, Singapore, Singapore, in our study and for each patient; control, nicotine treated 4Duke-NUS Graduate Medical School, Singapore, and nicotine + resveratrol treated cell culture groups are Singapore,5NationalCancerCenter,Singapore,Singapore formed. The expression levels of SOX2 and SOX4 genes are examined in each group by using real time RT-PCR. Myotonicdystrophytype1(DM1)iscausedbymoderateto Results: According to the results of our study, change in very large expansions of the DMPK CTG trinucleotide expression levels of SOX2 and SOX4 genes in nicotine repeat. Disease transmission to offspring can be avoided treatedgroupwerefoundtobestatisticallysignificant.Also, through prenatal diagnosis or preimplantation genetic when groups treated with nicotine and nicotine + resvera- testing for monogenic disorders (PGT-M). We describe a trol were compared the difference was found to be statisti- robust PGT-M strategy that can be applied to virtually any cally significant. coupleatriskforDM1,includingcarriersoflargeexpanded Conclusion: In conclusion, nicotine increased the alleleswithnon-CTGinterruptionsateitherthe5’or3’end expression levels of SOX2 and SOX4 genes by 60% in of the repeat. This strategy utilizes whole-genome ampli- human amniotic cell cultures and resveratrol was found to fication by multiple displacement amplification, followed be an important antioxidant that reduces the increased by bidirectional triplet-primed PCR (TP-PCR) sizing of the expression levels of SOX2 and SOX4 genes caused by DMPK CTGrepeat,inparallelwithsingle-tubegenotyping nicotine treatment. and haplotype phasing of 12 closely linked and highlyAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1195 This study was supported by the Scientific Research J. Domaradzka: None. M. Deperas: None. E. Obersz- Project Unit of the Çukurova University tyn: None. A. Kucińska-Chahwan: None. N. Brison: G. Cömertpay: None. Ü.H. Lüleyap: None. B.M. None.K.VanDenBogaert:None.T.Roszkowski:None. Yılmaz: None. P. Pazarcı: None. M. Kędzior: None. M. Bartnik-Głaska: None. A. Łuszczek: None. K. Jakubów-Durska: None. J. Ver- 
P01 .48D meesch: None. B. Nowakowska: None. A placental trisomy 2 detected by NIPT evolved in a fetal small Supernumerary Marker Chromosome 
P01 .49A (sSMC) Non-Invasive Prenatal Testing pitfalls: exceptional report of multiple discrepancies between noninvasive J. Domaradzka1, M. Deperas1, E. Obersztyn1, screening for fetal trisomy 21, karyotype, array CGH A. Kucińska-Chahwan2, N. Brison3, K. Van Den and fetal ultrasound Bogaert3, T. Roszkowski2, M. Kędzior1, M. Bartnik- Głaska1, A. Łuszczek1, K. Jakubów-Durska1, F. Kundul1, K. Cassinari1, G. Joly-Hélas1, N. Le Meur1, J. Vermeesch3, B. Nowakowska1 J. Coursimault1, M. Castelain1, A. Diguet2, E. Verspyck2, S. Torre3, B. Macé1, T. Frebourg1, P. Chambon1 1MedicalGeneticsDepartment,TheInstituteofMotherand Child, Warsaw, Poland, Warsaw, Poland, 2Department of 1Normandie Univ, UNIROUEN, Inserm U1245 and Rouen Obstetrics and Gynecology, Witold Orlowski Public University Hospital, Department of Genetics, F76000, Teaching Hospital, Warsaw, Poland, Warsaw, Poland, NormandyCentreforGenomicandPersonalizedMedicine, 3CentreforHumanGenetics,KULeuven,Leuven,Belgium, Rouen,France,2DepartmentofGynecologyandObstetrics, Leuven, Belgium RouenUniversityHospital-CharlesNicolle,Rouen,France, 3Department of Neonatal Pediatrics, Intensive Care and Objective: Here we report a prenatally detected mosaicism Neuropediatrics,RouenUniversityHospital,Rouen,France of a small supernumerary marker chromosome (sSMC) derived from chromosome 2. The 38-year-old woman Introduction: Pitfalls of noninvasive prenatal test (NIPT) underwent amniocentesis because of a high risk of trisomy for fetal trisomy 21 on circulating cell-free DNA are 2 revealed by the Non-Invasive Prenatal Test (NIPT). currently well known and are linked to confined placental Methods and results: A genome-wide NIPT detected a mosaicism,maternalorfetalmosaicism,maternalneoplasia, trisomy of chromosome 2. The amniocentesis was per- evanescent twin, or low fetal DNA fraction. Unbalanced formed to verify the NIPT result. Array comparative chromosomalrearrangementsmayalsointerferewithNIPT. genomichybridization(aCGH)fromunculturedamniocytes We report here a rare anomaly identified through NIPT. revealed a duplication of 14,83 Mb on chromosome Case: A NIPT was performed on a 39-year-old woman 2q11.1q13. Interphase fluorescence in situ hybridization with abnormal first trimester serum markers. This NIPT (FISH)revealedthreesignalsofcentromere2in30%ofthe (Clarigo,MultiplicomAgilent)didnotshowanytrisomy21 cells. GTG-banded metaphases confirmed the abnormal but was evocative of trisomy 18. An amniocentesis was karyotype (47,XX,+mar[21]/46,XX[19]), indicating 52% performed at the 22th week of gestation (WG) and FISH mosaicism of the cell line with the sSMC. The ultrasound analyses(Aneucyte, Cytocell) onnativeamnioticfluidwere examination did not reveal abnormalities. The pregnancy compatible with a trisomy 18 in a female fetus. Unexpect- has been terminated. Cytogenetic analyses (FISH, aCGH edly, concomitant ultrasound control didn’t detect any and conventional karyotype) on fetal skin biopsies were morphological abnormality on a male fetus. Then, fetal performed and confirmed the genomic gain of the cen- karyotype and array-CGH confirmed the female chromo- tromericregionofchromosome2.Intheplacenta,threecell somalsexandrevealedaverypartialtrisomy18,linkedtoa lines were detected: a normal cell line, a cell line with small supernumerary marker chromosome, in mosaic, trisomy2andathirdonewithonlythesSCMderivedfrom which was derivative from a chromosome 18. In addition, chromosome 2. Conclusion: Whole-genome NIPT allows SRY locus was found on the short arm of one X chromo- not only the identification of common fetal trisomies (13, some. Genetic counseling being less alarming in this con- 18, 21) but also diagnosis of rare chromosomal abnormal- text than with a complete trisomy 18, this patient pursued ities. Especially in such cases, it is extremely important to her pregnancy and delivered a boy at 36 WG with normal performnotonly NIPT verificationonasampleofmaterial neonatal examination. A regular monitoring of his psy- other than trophoblast, but also to apply appropriate chomotor development is under way. research methods. Such conduct allows detailed analysisof Discussion: This observation underlines the necessary the detected aberration, thus appropriate clinical validity. precautions while interpreting NIPT and the necessity of a1196 strong cytogenetic confirmation. This case also illustrates 
P01 .51C that incidental findings are to be expected with NIPT. Unexpected finding of uniparental disomy mosaicism in F. Kundul: None. K. Cassinari: None. G. Joly-Hélas: term placentas: Is it a common feature in trisomic None. N. Le Meur: None. J. Coursimault: None. M. placentas? Castelain:None.A.Diguet:None.E.Verspyck:None.S. Torre: None. B. Macé: None. T. Frebourg: None. P. D.Van Opstal1, K. E.M. Diderich1, M.Joosten1,L.C. P. Chambon: None. Govaerts1, J. Polak1, M.Boter1, J. J. Saris1, W. Cheung1, S. van Veen1, R. M. van der Helm1, A. T. J. I. Go1, 
P01 .50B M.F.C.M.Knapen1,D.N.M.Papatsonis2,A.Dijkman3, Pilot study of locally performed noninvasive prenatal F. A. T. de Vries1, R. H. Galjaard1, L. H. Hoefsloot1, testing NIPT in Bulgaria M. I. Srebniak1 R. RAYNOVA, S. Bichev, S. Andonova, N. Yaneva, 1Erasmus MC, Rotterdam, Netherlands, 2Amphia Hospital, C. Kercheva, I. Bradinova, A. Savov Breda, Netherlands, 3Reinier de Graaf Hospital, Delft, Netherlands National Genetic Laboratory, University Hospital of Obstetrics and Gynecology, Medical University, Sofia, Objective: Non‐invasive prenatal testing (NIPT) detects Bulgaria placental chromosome aberrations. When amniocentesis reveals a normal karyotype, confined placental mosaicism Introduction: With the introduction of noninvasive (CPM) may be assumed. In order to confirm this, placental prenatal testing (NIPT), the prenatal screening for chromo- cytogenetic studies were performed. somal aneuploidies has been expanded beyond ultrasound Method: NIPT was conducted in the course of the examinationandcombinedfirst-trimesterscreening(cFTS). DutchTRIDENT study. Placentas of 10 cases with NIPT NIPT using cell-free DNA (cfDNA) circulating inmaternal results indicating an autosomal trisomy and showing a blood presents as an early, accurate, and safe prenatal normal (N = 9) or low mosaic karyotype (N = 1) in testing. Since August 2018 NIPT for chromosomes 21, 18, amniotic fluid (AF) were investigated. The cytotrophoblast 13 and sex determination was introduced in-situ in the as well as the mesenchymal core of two to four placental UniversityHospitalofObstetricsandGynecology”Maichin chorionicvilli biopsies were studied with single nucleotide dom”, Sofia. The analysis was discussed with pregnant polymorphism (SNP) array. Clinical outcome data were women after performing cFTS. collected. MaterialsandMethods:Atotalof134pregnantwomen Results: In 10/10 cases, CPM was proven. In 3/10 cases were screened for chromosomal aneuploidies by NIPT trisomy/uniparental disomy (UPD)/biparental disomy using ion semiconductor sequencing platform (Ion Pro- (BPD)mosaicismwasdiscovered.In2/3cases,allthreecell ton™, Thermo Fisher Scientific) and IONA® test (Pre- lineswerepresentintheplacenta, whereasBPDwasfound maithaHealthplc,Manchester,UK).Thepatientswereata in AF. In 1/3 cases trisomy 22/UPD22 was present in AF mean age of 34.5 years. Plasma samples were collected while trisomy 22/BPD22 mosaicism was found in the pla- between 10+5 and 24+5 g.w. centa. Five of 10 pregnancies were affected with pre‐ Results: Due to an intermediate risk (1/100 to 1/1000) eclampsia, low birth weight, preterm delivery, and/or con- NIPT was performed on 68 (47.76%) pregnant women. genital malformations. Othersweretestedbecauseofmaternalanxietyoradvanced Conclusion: The presence of trisomy/UPD/BPD mosai- age. An average of 10.6% (from 3 to 24%) fetal fraction cismin3/10casesthatweinvestigatedprovesthattrisomic (FF) was achieved. One report was unsuccessful due to a zygote rescue may involve multiple rescue events during low fetal fraction inpatientwithBMI=43.03. We obtained early embryogenesis. UPD mosaicism, when present in 132“lowrisk”reportsandone“highrisk”-fortrisomy21, crucialfetaltissues,mayexplaintheabnormalphenotypein confirmed by amniocentesis followed by QF-PCR. undiagnosed cases. Conclusions: This is the first introduction of locally D. Van Opstal: None. K.E.M. Diderich: None. M. performed NIPT in Bulgaria. With the accumulation of Joosten: None. L.C.P. Govaerts: None. J. Polak: None. moresamplesanddataapossiblecorrelationbetweencFTS M. Boter: None. J.J. Saris: None. W. Cheung: None. S. results and NIPT; FF or/and gestational week and NIPT vanVeen:None.R.M.vanderHelm:None.A.T.J.I.Go: results could be established. None. M.F.C.M. Knapen: None. D.N.M. Papatsonis: R. Raynova: None. S. Bichev: None. S. Andonova: None. A. Dijkman: None. F.A.T. de Vries: None. R.H. None. N. Yaneva: None. C. Kercheva: None. I. Bradi- Galjaard: None. L.H. Hoefsloot: None. M.I. nova: None. A. Savov: None. Srebniak: None.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1197 
P01 .53A (86.2,100.0) (99.95,100.0) Non-Invasive Prenatal Testing: Laboratory Clinical Sexchromosome 80 14 0 100 99.93 aneuploidies Experience: 20000 Clinical Samples (95.42,100.0) (99.88,99.96) G. Savarese, L. De Falco, P. Savarese, R. Ruggiero, All 299 25 0 100 99.87 L. D’Amore, T. Suero, L. Circelli, R. D’Angelo, (98.73,100.0) (99.81,99.91) C. Ramiro, I. Pisano, A. Di Carlo, E. Evangelista, Multiplegestation TP FP FN Sensitivity(% Specificity(% n=441 (95%Cl)) (95%Cl)) G. Furino, M. Bruno, C. Vicedomini, A. Fico T21 5 0 0 100 100 AMES Genetic Lab, Polidiagnostic Instrumental Centre, (56.55,100.0) (99.13,100.0) Casalnuovo di Napoli, Italy T13 0 1 0 99.77 (99.13,100.0) Introduction:Whole-genomesequencing(WGS)ofmater- ARTpregnancies TP FP FN Sensitivity(% Specificity(% n=984 (95%Cl)) (95%Cl)) nalplasmacell-freeDNA(cfDNA)canpotentiallyevaluate T21 2 0 0 100 100 all 24 chromosomes to identify abnormalities of the placenta, fetus, or pregnant woman. The objective of this (34.24,100.0) (99.61,100.0) studyistogiveacompleteandrobustclinicalpictureofthe T18 2 0 0 100 100 currentperformanceofNIPTfortrisomy13,18,and21and (34.24,100.0) (99.61,100.0) sex chromosomes aneuploidies as well as for the other T13 0 1 0 99.77 chromosomes. (99.13,100.0) Materials and Methods: All data were generated in our Sexchromosome 7 3 0 100 99.69 AMES accredited laboratory from January 2017 to January aneuploidies 2019 in 20000 samples. The pipeline included automated (64.57,100.0) (99.10,99.69) library preparation (VeriSeq NIPT Microlab STAR, Illu- mina) and WGS sequencing on a Next550 (Illumina). VeriSeq NIPT Assay Software (www.illumina.com/ G. Savarese: None. L. De Falco: None. P. Savarese: NIPTsoftware) was used for data analysis of aneuploidy None. R. Ruggiero: None. L. D’Amore: None. T. Suero: status of 13, 18, 21, X and Y chromosomes and fetal None. L. Circelli: None. R. D’Angelo: None. C. Ramiro: fraction of cffDNA. An in house algorithm was optimized None. I. Pisano: None. A. Di Carlo: None. E. Evange- to analyze other aneuploidies and subchromosomal lista: None. G. Furino: None. M. Bruno: None. C. aberrations. Vicedomini: None. A. Fico: None. Results: The main results were showed in Table 1. We also reported 19 rare autosomal trisomies (RATs) and 
P01 .54B 6 structural abnormalities identified in 10500 samples, HightotalDNAcontributestolowfetalfractioninNIPT mainly trisomy 15 (n = 5), followed by trisomy 8 (n = 4) and tends to resolve on redraw and trisomies 16 and 22 (n=2). Conclusions: The performance characteristics were A. Ryan, S. Krinshpun established in samples in which we analysed all 24 chro- mosomes with a minimum fetal fraction of 4%, and has Natera, San Carlos, CA, United States been confirmed by our extensive clinical experience in the same clinical population. Introduction:Lowfetalfraction(FF)isacommoncauseof testfailuresinNIPTandiscorrelatedwithmaternalweight, Table 1: Clinical performance based on clinical gestational age,and aneuploidy[1,2].We show that low FF Experience can also be associated with high DNA concentration (DC) which frequently reverts toward average after redraw. Overall TP FP FN Sensitivity(% Specificity(% performance (95%Cl)) (95%Cl)) Materials and Methods: Sample DC was estimated by n=20000 comparing to a reference sequence added before amplifi- cation. 99,936 eligible samples were collected between T21 151 1 0 100 100 2012and2014.Additionally,1,374received aredraw after (97.52,100.0) (99.97,100.0) test failure and changes in DC and FF between the two T18 44 6 0 100 99.97 draws were observed. (91.97,100.0) (99.93,100.0) Results: Samples with low DC (below 10th percentile) T13 24 4 0 100 99.98 have average FF 12.4% and samples with high DC (above1198 90th percentile) have average FF 8.6%. The average FF is Results: Fifty CMA analyses were performed due to 10.1%. Samples with test failure were twice as likely to oligohydramnios. Of these, in 21 tests it constituted an havehighDC.Afterredraw,caseswithhighinitialDChad isolated anomaly, 13 cases were associated with anatomic 38 times larger median reduction in DC compared to defects, and the remaining 16 pregnancies were diagnosed overall.The10%ofcaseswithgreatestreductioninDChad with intra-uterine growth restriction (IUGR) as well. All median FF increase 1.2%, compared to FF increase 0.4% CMA tests were normal, except for one pathogenic finding for cases without significant change in DC. Change in DC in the IUGR group - a 16p11.2 duplication sized 722Kb. wasasignificantparameter(p<10-5)inalogisticregression Literature search yielded 394 titles, of which two relevant model for redraw success. articles were found. One of these, published at 1998, yiel- Conclusions:Sampleswith high DCareoverrepresented ded 31 (20.1%) abnormal karyotypes in 154 pregnancies in test failures and have lower average FF. High DC tends with oligohydramnios (11 of these as an isolated findings), to reduce after redraw, producing larger FF increase. This while another (1995) did not find any aberrations in 28 supports the option for repeat NIPT after a failure due to pregnancies with isolated oligohydramnios. low FF. Discussion: Current evidence does not support invasive [1] Pergament et al. Obstet Gynecol. 2014 Aug;124(2 Pt prenatal testing in pregnancies with isolated 1):210-8. oligohydramnios. [2] McKanna et al. Ultrasound Obstet Gynecol. 2019 S. Sagi: None. L. Sagi-Dain: None. I. Maya: None. S. Jan;53(1):73-79. Ben-Shachar: None. A. Singer: None. A.Ryan: A.Employment (full orpart-time); Significant; Natera. S. Krinshpun: A. Employment (full or part-time); 
P01 .57A Significant; Natera. Early experiences with screening for aneuploidy in preimplantation genetic testing for inherited disorders 
P01 .55C Microarray findings in pregnancies with T. Diemer1, C. L. F. Toft2, C. Hnida3, B. Degn2, oligohydramnios - a retrospective cohort study and H. Okkels2, A. Ernst2, H. J. Ingerslev3, I. S. Pedersen2 literature review 1Department of Clinical Genetics, Aalborg University S. Sagi1, L. Sagi-Dain2, I. Maya3, S. Ben-Shachar4, Hospital, Aalborg, Denmark, 2Department of Molecular A. Singer5 Diagnostics, Aalborg University Hospital, Aalborg, Denmark, 3Fertility Unit, Aalborg University Hospital, 1BnaiZionMedicalCenter,Haifa,Israel,2CarmelMedical Aalborg, Denmark Center, Haifa, Israel, 3Rabin Medical Center, Petah Tikva, Israel,4SouraskiMedicalCenter,TelAviv,Israel,5Ministry Preimplantation genetic testing (PGT) is divided into three of Health, Jerusalem, Israel categories based on the indication: PGT-M (Monogenic), PGT-SR (Structural rearrangements) and PGT-A (Aneu- Introduction: This study was performed following a ploidy). A large study of more than 15000 trophectoderm statement in national position paper defining the advised biopsies found the lowest rate of aneuploidy to be 25% in management of pregnancies with abnormal amniotic fluid young women increasing with maternal age to more than volume. The proposed statement recommended to refer all 90%. Thus at least 1 in 4 embryos are expected to be pregnancies with oligohydramnios to genetic counseling, aneuploid, possibly leading to implantation failure, mis- except for proven rupture of membranes, evidence of carriage or an abnormal fetus. Hence, selection of euploid placental insufficiency or oligohydramnios diagnosed after embryos should in theory increase pregnancy rates and 37 weeks of gestational age. Thus, the objective of this decrease miscarriage rates, but this is still a subject of study was to explore the risk for abnormal chromosomal intenseinternationaldiscussion.Inourcenterwedon’toffer microarray analysis (CMA) findings in pregnancies with PGT-A, but as our PGT-SR setup is based on Shallow oligohydramnios. Whole Genome Sequencing, the ploidy status is revealed, Methods:DatafromallCMAanalysesperformeddueto and thus used for prioritizing embryos. Our PGT-M setup oligohydramnios between January 2013 and September includes fragment analysis of short tandem repeats, and 2017 were retrospectively obtained from the Ministry of SNaPshot analysis of the specific mutation when relevant. Health database. In addition, a search was conducted Since PGT-M setup does not detect aneuploidy, we would through the Pubmed database from inception to February expectahigherrateofimplantationwhenperformingPGT- 2018 for English articles exploring the issue. SR. Mean maternal age is similar in the two groups (30.96 in the PGT-M and 32.56 in the PGT-SR group). WeAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1199 examinedtherateofpositivehCGandongoingpregnancies reassuranceandguideappropriatemedicalmanagementand (OPR) per transfer (SET) on embryos (159 PGT-M and 27 counseling about cause and recurrence risk. PGT-SR) transferred between 01-01-2017 and 01-12-2018. K.L. Howard: A. Employment (full or part-time); Sig- Surprisingly,wefoundnosignificantdifferenceinoutcome nificant; Full Time Employee, Natera, Inc.. E. Ownership inthetwogroupsintermsofpositivehCG(49.7vs.48.1,P Interest (stock, stock options, patent or other intellectual =0.881)orOPR(34.6vs.37.0,P=0.805),butthenumber property); Significant; Stock, Natera, Inc. M.K. Mai- of cases is still rather low. senbacher: A. Employment (full or part-time); Significant; T. Diemer: None. C.L.F. Toft: None. C. Hnida: None. Iamfulltimeemployee,Natera,Inc..E.OwnershipInterest B. Degn: None. H. Okkels: None. A. Ernst: None. H.J. (stock, stock options, patent or other intellectual property); Ingerslev: None. I.S. Pedersen: None. Significant; Stock, Natera, Inc. K. Merrion: A. Employ- ment (full or part-time); Significant; Full Time Employee, 
P01 .58B Natera, Inc.. E. Ownership Interest (stock, stock options, Counseling conundrum: sex discordance identification patent or other intellectual property); Significant; Stock, followingpreimplantationgenetictestingornoninvasive Natera, Inc. S. Leaonard: A. Employment (full or part- prenatal testing using SNP-based methodologies time); Significant; Full Time Employee, Natera, Inc. W. DiNonno: A. Employment (full or part-time); Significant; K. L. Howard, M. K. Maisenbacher, K. Merrion, Full Time Employee, Natera, Inc.. F. Consultant/Advisory S. Leaonard, W. DiNonno Board; Significant; Stock Options, Natera, Inc.. Natera, Inc., San Carlos, CA, United States 
P01 .59C Preimplantation genetic testing of monogenic disease: Introduction: Preimplantation genetic testing (PGT) and experience in Russia noninvasiveprenataltesting(NIPT)candeterminefetalsex with high accuracy prior to/during pregnancy. However, S. O. Zhikrivetskaya, Y. L. Volkova, E. V. Musatova, additional prenatal screening or clinical presentation may Y. V. Sofronova, N. A. Shirokova, E. A. Pomerantseva indicatesexdiscrepancyrequiringmedicalfollow-upforan infant’s health. CenterofGeneticsandReproductiveMedicineGENETICO Methods:CasesofpossiblesexdiscrepancyafterPGTor LLC, Moscow, Russian Federation NIPT at a single lab were retrospectively reviewed. For PGT, genotyping was performed using Illumina Cyto12 Introduction: Preimplantation genetic testing of mono- SNP-basedmicroarraywithinformatics.ForNIPT,cell-free genic disease (PGT-M) is an alternative to prenatal testing DNA was isolated and amplified by massively-multiplexed for couples with high risk of having offspring with single- PCRtargeting13,392SNPscoveringchromosomes13,18, gene disorder. PGT-M is technically challenging, because 21,XandY.Onlycaseswithtestingtoidentifyacausefor of extremely small amount of biomaterial. We report here discrepancy were included. our experience of PGT-M in “Genetico” center in Russia. Results: Four of 23,297 (0.02%) PGT and 49 of Material and Methods: A retrospective analysis of all 1,081,541 (0.005%) NIPT cases had discrepant sex by requests and cycles of PGT-M referred to our center was prenatal screening or postnatal exam. For PGT, child con- performed. Personalized PGT-M assays combine direct cordance with parental samples and remaining embryos diagnosisofthepathogenicvariantsandlinkageanalysisof revealed 2 (50%) resulted from incorrect embryo transfers highly heterozygous STRs. PGT-A by NGS or aCGH was and 2 (50%) resulted from natural conception around the performed for unaffected embryos upon patient’s request. time of embryo transfer. For NIPT, phlebotomy labeling Results:Of109couplesreferredtoourcenterforPGT-M, errors comprised 6 (12.2%); confined placental mosaicism, 92 completed preliminary test for PGT-M for 42 genetic 10(20.4%);ultrasounderrors,13(26.6%);anddisordersof condition: 24 autosomal-dominant, 54 autosomal-recessive, sexual development (DSD), 20 (40.8%). No discrepancies 13X-linkedrequests.Themostfrequentindicationwasspinal were due to lab error for PGT/NIPT cases. muscularatrophy(17).Weperformed85PGT-Mcycleswith Conclusions: Causes of discordant sex after PGT or 413 embryos. The whole genome amplification failed in 16 NIPT can include sample swap, ultrasound errors, PGT/ cases(3,9%).Mediannumberofmarkersintest-systemswas NIPT result errors, natural conception around the time of 12 and for embryo analysis it was 10. These highly infor- embryo transfer, vanished twin on non-SNP-based NIPT, mative test systems contributed to low number of incon- embryo mosaicism, confined placental mosaicism and var- clusiveresults - only for7 samples (1,8%). For 156 (58,6%) ious DSDs. A thorough investigation can provide unaffected embryos PGT-A was performed and 91 (34,1%) were suitable for transfer. At the moment we have1200 information about43transfers, 19 pregnanciesand 7 healthy R. Inno: None. S. Sõber: None. M. Laan: None. births and no affected pregnancy or birth. Conclusions: Highly informative test system and accu- 
P01 .62B rate analysis of results can lead to both - high accuracy of Whole exome-based preconception carrier test (PCT) obtained results and decreased number of embryos, that for consanguineous couples: first results from clinical were rejected because of inconclusive results. practice S.O. Zhikrivetskaya: None. Y.L. Volkova: None. E.V. Musatova: None. Y.V. Sofronova: None. N.A. Shir- S. C. E. H. Sallevelt1, B. de Koning1, C. E. M. de Die- okova: None. E.A. Pomerantseva: None. Smulders1, C. Gilissen2, A. P. A. Stegmann1, H. G. Brunner1,2, A. D. C. Paulussen1 
P01 .60D Identifying eQTL influence on gene expression through 1Maastricht University Medical Centre+, Maastricht, microRNAs Netherlands, 2Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands R. Inno, S. Sõber, M. Laan Introduction:consanguineouspartnersareatincreasedrisk InstitueofBiomedicineandTranslationalMeidicine,Tartu, of both being carrier of the same autosomal recessive (AR) Estonia disorder, with 25% risk of affected offspring as a consequence. Until recently, no comprehensive preconcep- Introduction: microRNAs drive coordinated expressional tion carrier test was available to identify the very rare changes of their target genes and trigger functional shift in disease-causing mutations these couples may carry. We cells. Placental microRNAs are specifically involved in developed such a test for consanguineous couples and trophoblast differentiation and function. Single nucleotide implemented this in our clinical practice. variants(SNVs)associatedwiththeexpressionlevelofgenes Materials and Methods: both individuals of a couple aredefined asexpressionquantitative trait loci (eQTLs).The undergowholeexomesequencing(WES).Firstthecouple’s aim of my PhD project is to identify placental eQTLs sequencedataaremerged:onlyvariantspresentinthesame modulating the expression of microRNAs and to understand geneinbothofthemandwithapopulationfrequency<5%, their downstream effect on the placental transcriptome. remain in the dataset. Subsequently, this dataset is filtered Materials and Methods: Placental miRSeq (unpubl. against a gene panel, consisting of >1900 genes associated data) and genotyping (Kasak et al 2015) datasets were with known AR diseases (OMIM-based). Only combina- subjected togenetic associationtestingfor eQTL discovery tionsoflikelypathogenicorpathogenicmutations(classIV (n = 40), implicated in PLINK v1.07 (Purcell et al 2007). or V variants) in both partners are reported. Carriership in microRNAs and their eQTLs were cross-referenced with only one individual is not detected. newbors growth parameters. Additionally association test- Results:thusfar22consanguineouscoupleswereincluded. ing between identified miRNA eQTLs and placental For7(32%),‘unexpected’pathogenicvariantswerereported expression levels of predicted target genes were analyzed. conferring risk of severely affected offspring, allowing these Correlations between the expression profile of placental couples to opt for prenatal or preconception diagnostic choi- miRNAs (miRSeq dataset) and transcripts (RNA-Seq ces. Disease examples are: sulfite oxidase deficiency, AR dataset; Sõber et al 2015) were analyzed using DESeq2 epidermolysis bullosa dystrophica, restrictive dermatopathy, platform (Love et al 2014). eQTL and newborn growth infantile epileptic encephalopathy. None of the disease asso- parameter association was validated in combined REPRO- ciations were linked to any known disease in the family, META and Happy Pregnancy cohort (n = 2100) demonstrating the innovative value of this approach. Results: In total, 11 placental microRNAs were detected Conclusions: our WES-based preconception carrier test that were expressionally modulated by eQTLs. Four of (PCT)providesapowerfuldiagnostictoolforidentification these microRNAs and their eQTLs show assosiation with of serious disease carrier status in consanguineous couples. newbornsgrowthparametes.Severalnoveltargetgenesand Outcomes provide significant reproductive choices that no biological pathways were identified for these microRNAs. other test currently offers. Conclusions: miRNA eQTLs may represent additional S.C.E.H. Sallevelt: None. B. de Koning: None. C.E.M. modulators of the placental transcriptome, placental func- de Die-Smulders: None. C. Gilissen: None. A.P.A. Steg- tion and pregnancy course. mann: None. H.G. Brunner: None. A.D.C. Funding:EuropeanUnionthroughtheEuropeanRegional Paulussen: None. Development Fund (project Happy Pregnancy, 3.2.0701.12- 0047) and Estonian Research Council (IUT34-12).Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1201 
P01 .63C or part-time); Significant; Gennet. M. Koudova: A. CarrierTest - the expanded preconception carrier Employment (full or part-time); Significant; Gennet. D. screening Stejskal: A. Employment (full or part-time); Significant; Gennet. F. Lhota, F. Zembol, L. Dohnalova, Z. Vilimova, M. Bittoova, I. Soldatova, B. Honysova, M. Famfulikova, 
P01 .64D M. Koudova, D. Stejskal The prevalence of genetic and anatomic fetal defects: data from Happy Pregnancy Study Gennet, Clinic of genetics and reproductive medicine, Prague, Czech Republic K. Rull1,2,3, E. Hanson1,2, M. Laan3 We have developed a NGS panel which screens (i) 889 1Women’s Clinic of Tartu University Hospital, Tartu, mutations causing 68 severe genetic disorders that can Estonia, 2Department of Obstetrics and Gynecology, affect progeny ofhealthyindividuals(genetic compatibility University of Tartu, Tartu, Estonia, 3Institute of test), (ii) mutations associated with blood hypercoagul- Biomedicine and Translational Medicine, University of ability influencing infertility treatment and pregnancy, (iii) Tartu, Tartu, Estonia inherited ovarian response to gonadotrophin stimulation. The test is designated for patients undergoing an IVF Introduction: The study aimed to assess the prevalence of program and for gamete donors. genetic and anatomic abnormalities among the participants CarrierTest is a custom NGS panel with locally assem- of the prospective Happy Pregnancy study (“Development bledbioinformaticpipelineandvariantdatabase.Toreplace of novel non-invasive biomarkers for fertility and healthy MLPAandfragmentationanalysisweimplementedspecific pregnancy"). design adjustments and sequencing data analysis allowing Methods: The pregnancy course and outcome including detectionoflargedeletionsofSMN1,CFTRgenesandalso the first trimester serum test and ultrasound scans at 11-14 microdeletions on chromosome Y (AZF region) within one and 19-21 weeks were documented in the cohort of 2320 laboratory test.The report containscomparative analysis of women visiting the Women’s Clinic of Tartu University detected variants for evaluation of residual risk and pre- Hospital, Estonia in 2013-2015. Targeted FISH, karyotyp- conception compatibility of couple for consideration of ing and SNP-based array was applied in cases of abnormal preimplantation (PGT-M) or prenatal diagnostics. findings after 12 gestational weeks. So far 8258 samples were analyzed. These include: 3196 Results: In 63 cases (2.7%), the pregnancy resulted with couples before conception, 1388 gamete donors and 478 early (<12 weeks) /late (>12 weeks) loss (n=42 /8) or ter- patients with reproduction impairment without compat- minationofpregnancy(TOP)before22weeks(n=13).The ibilitytesting.Frequentoccurrenceofcarrierswasobserved genetic disorders were detected in 16 cases (0.7%), the inthecommonlyscreenedgenes(SMN12,4%,CFTR3,7%, anatomic defects occurred in 53 cases (2.3%). Serious GJB2 6,2%) but also in other genes previously not tested anatomicdefects,resultedwithTOP,fetaldeathorpostnatal (e.g. ABCA4 4,2%, DHCR7 2,7%, SERPINA1 2,7%, PAH surgical intervention during the first year after birth occur- 2,5%, ACADM 1,5%, AT
P7 B 1,2%, AR 1,1%). We identi- red in 14 cases (0.6%); anomalies two were not antenatally fied 79 pairs (2,4%) with a reproduction risk, which is diagnosed: univentricular heart and cleft lip. twofold increase detection rate in comparison with only CFTR/SMN1/GJB2 testing. Defect Antenataldiagnosis Diagnosisafterbirth CarrierTest facilitates informed decision about reproduc- tion. Screening of couples and gamete donors allows to elu- Genetic 9(7)* 7(1trisomy18) cidatehighernumberofcarriersofseveredisordersinorderto Hand/foot 1 7 offer appropriate preconception and prenatal care. Cleftlip/palate 1(1)* 1 F.Lhota:A.Employment(fullorpart-time);Significant; Cardiacmild/severe 1/4(1)* 7/1 Gennet. F. Zembol: A. Employment (full or part-time); Urogenital 12 5 Significant;Gennet.L.Dohnalova:A.Employment(fullor Gastrointestinal 4(1)* 1 part-time); Significant; Gennet. Z. Vilimova: A. Employ- Cerebral 4(1)* 0 ment (full or part-time); Significant; Gennet. M. Bittoova: Minor 1 3 A. Employment (full or part-time); Significant; Gennet. I. Total 37(11)* 32 Soldatova: A. Employment (full or part-time); Significant; Gennet. B. Honysova: A. Employment (full or part-time); *termination of pregnancy Significant;Gennet.M.Famfulikova:A.Employment(full1202 Summary: The overall prevalence of the serious genetic Freireich: None. R. Segel: None. T. Eldar Geva: None. and/or anatomic among unselected pregnant women in G. Altarescu: None. Happy Pregnancy cohort was 0.97%. Funding: The European Regional Development Fund 
P01 .67C (3.2.0701.12-0047), Estonian Research Council (grants Preimplantation genetic test in couples with history of IUT34-12). infertility and pregnancy loss K. Rull: None. E. Hanson: None. M. Laan: None. S. Y. Yaneva Staykova1, G. Stamenov2, R. Staneva1,2, 
P01 .65A M. Pancheva2, M. Serafimova2, K. Nikolova2, Selecting fetuses in ambiguous setting: Preimplantation O. Antonova1, D. Toncheva1, S. Hadjidekova1,2 Genetic Diagnosis (PGD) for variants of unknown significant (VUS) 1Medical University of Sofia, Medical Faculty, Department of Medical Genetics, Sofia, Bulgaria, 2Nadezhda Hospital, S. Zuckerman1, K. Rotshenker Olshinka2, O. Weiss1, Sofia, Bulgaria N.Srebnik2,S.Shaviv1,O.Freireich1,R.Segel1,T.Eldar Geva2, G. Altarescu1 Introduction: Preimplantation genetic test (PGT) is a cutting-edge technology of early genetic disease detection 1MedicalGeneticsInstitute,ShaareZedekMedicalCenter,, in embryos prior to their implantation in the uterus. The Jerusalem, Israel, 2IVF Unit, Division of Obstetrics and purposeofourstudyistoshowthevalueofPGTincouples Gynecology, Shaare Zedek Medical Center, Jerusalem, with infertility; its ability to reduce the risk of birth of Israel chromosomally unbalanced offspring and pregnancy loss; to increase the chance of successful pregnancy and birth of The introduction of new technologies of chromosomal an unaffected child. microarrays(CMA)andwholeexomesequencingisleading MaterialsandMethods:Wedescribe185coupleswitha to wider awareness of people to their genetic background historyofinfertilityandpregnancyloss,whoafterextensive andinfluenceonoffspring.ThedecisiontoperformPGDto genetic counseling opted for in vitro fertilization procedure select an embryo with no inherited VUS, considering the with PGT. Trophectoderm biopsy was carried out on 497 inherent ambiguity of VUS which is not unequivocally blastocyst stage embryos originating from 231 oocyte linked to a disorder, may give false hope and lead to retrievalcycles.DNAwasextractedandsubjectedtowhole frustration if an affected child is born. In order to evaluate genome amplification. Array-based comparative genomic Israeli VUS carriers’ intentions regarding PGD for VUS hybridizationwithmicroarrayplatforms24surev3/24sure+ findings, we have analyzed database from a large PGD and next-generation sequencing with VeriSeqPGS Librar- center. Twenty three couples required PGD for VUS yPrep protocol were performed. Results were analyzed by detected, in at least one spouse, by CMA analysis. Five BlueFuse Multi version 4.3 software. couples had two VUS detected. Eight couples (35%) had Results: 196 embryos had a balanced profile (39.44%), previous pregnancy termination (TOP) solely due to the 292embryosshowedanunbalancedprofile(58.75%)and9 detectionofVUSinanembryo.Thirteencouples(57%)had embryoscould notbe interpreted(1.81%).Embryo transfer no other indication for PGD. The interpretation of VUS in was conducted in 109 cases (58.92%) and chemical preg- the time of counseling was ‘likely-pathogenic’ in 10 cases nancy was detected in 33.03% of the women. Pregnancy (36%), ‘VUS’ in 9 cases (32%) and ‘likely-benign’ in 9 lossoccurredin3.67%ofcases.Livebirthratewas29.36%. cases (32%). PGD was performed in 14 couples (61%): 9/ Conclusions:PGTreducesthenumberoffailedtransfers 10 likely-pathogenic, 5/9 VUS and 1/9 likely-benign VUS. andeliminatesthetrauma ofterminating desired pregnancy Although most couples performed PGD for a likely- and possible medical complications. In couples with pathogenic VUS, some couples regard likely-benign VUS reproductivefailures,PGTcanberecommendedinorderto asanindicationforTOPandPGD.Futuredemandforsuch considerably increase the chance of conceiving with a controversial PGD applications will be growing and chromosomallybalancedembryoandlivebirthofahealthy challenge the medical milieu also considering continuous offspring. re-interpretation of VUS. Setting guidelines for VUS’ S.Y. Yaneva Staykova: None. G. Stamenov: None. R. interpretations, proper counselling regarding VUS’ mean- Staneva: None. M. Pancheva: None. M. Serafimova: ingsanddefiningthejustifiedapplicationsofPGDusesare None. K. Nikolova: None. O. Antonova: None. D. crucial steps in practicing PGD for VUS findings. Toncheva: None. S. Hadjidekova: None. S. Zuckerman: None. K. Rotshenker Olshinka: None. O. Weiss: None. N. Srebnik: None. S. Shaviv: None. O.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1203 
P01 .68D were detected in fetuses with skeletal dysplasias (n=11, Rapid whole exome sequencing to identify the 65%), multiple congenital anomalies (n=4, 23%) or underlying genetic cause in fetuses with sonographic intracerebral structural anomalies (n=2, 12%). anomalies These results suggest that rWES is likely to improve prenatal diagnosis of fetuses with ultrasonic abnormalities. I. Feenstra1, A. C. Deden2, M. I. Nelen1, K. Neveling1, I. Feenstra: None. A.C. Deden: None. M.I. Nelen: S.Castelein3,C.F.Gilissen3,R.P.Pfundt4,M.W.Elting5, None. K. Neveling: None. S. Castelein: None. C.F. T.K.Rinne4,K.E.Diderich6,S.C.Sallevelt7,N.Corsten- Gilissen: None. R.P. Pfundt: None. M.W. Elting: None. Janssen8, K. D. Lichtenbelt9, T. Gardeitchik4, L. Vissers4, T.K. Rinne: None. K.E. Diderich: None. S.C. Sallevelt: H. G. Yntema4, W. A. van Zelst-Stams1 None. N. Corsten-Janssen: None. K.D. Lichtenbelt: None. T. Gardeitchik: None. L. Vissers: None. H.G. 1Department of Human Genetics, Radboud University Yntema: None. W.A. van Zelst-Stams: None. Medical Center, Radboud Institute for Health Sciences, Nijmegen, Netherlands, 2Department of Human Genetics, 
P01 .69A Radboud University Medical Center, Nijmegen, Half decade experience: karyotyping, aCGH or NIPT - Netherlands, 3Department of Human Genetics, Radboud changes in prenatal testing strategy UniversityMedicalCenter,RadboudInstituteforMolecular Life Sciences, Nijmegen, Netherlands, 4Department of E.Kuznetsova,V.Gnetetskaya,M.Ermakova,M.Kurtser, Human Genetics, Donders Institute for Brain, Cognition, Y. Tarasova and Behaviour, Radboud University Medical Center, Nijmegen, Netherlands, 5Department of Genetics, Mother and Child, Moscow, Russian Federation Amsterdam Medical University, Amsterdam, Netherlands, 6Department of Genetics, Erasmus University Medical Over 5 years the strategy of genetic counseling signifi- Centre, Rotterdam, Netherlands, 7Department of Clinical cantly has changed after introduction of new prenatal Genetics, Maastricht University Medical Center, diagnostic methods of detection chromosomal abnormal- Maastricht, Netherlands, 8Department of Genetics, ities. In 2013 our laboratory had possibility to use cell- University Medical Centre Groningen, Groningen, based FISH and karyotyping for pregnancies at risk Netherlands, 9Department of Genetics, University Medical (maternal serum screening, advanced age, ultrasound Centre Utrecht, Utrecht, Netherlands examination (US), family history, patient’s anxiety). Since 2014 patients in first trimester with NT>=2,5 mm Rapid whole exome sequencing (rWES) in critically ill or/and US abnormalities were recommended chorionic newborns with a presumed genetic disorder has shown to villus sampling followed by karyotyping and DNA increase diagnostic yield earlier in life, which leads to extraction which allowed to perform aCGH (array-based improved patient care. Due to this impact, rWES has comparative genomic hybridization) in case of normal become a routine genetic test in this group of patients. We fetus karyotype. In second trimester after the amniocent- hypothesize that rWES could have the same effect even esis mostly aCGH/FISH analysis were recommended due before birth. Therefore we studied the use of rWES in to time limit with compare to cell cultivation of amniotic fetuses with a wide range of sonographic anomalies fluid for standard karyotyping. Chromosome imbalances representing the clinical practice. byaCGHlet us revealabout20 familieswhere one ofthe Weperformedaretrospectiveanalysisofthefirst54cases parents had a balanced rearrangement invisible by referred to our laboratory for prenatal rWES following the standard karyotyping. For these aims subtelomeric FISH detection of fetal sonographic anomalies. Parental and fetal analysis have been performed. When a noninvasive DNAs were sequenced simultaneously in 53 of the cases prenatal testing (NIPT) appeared in 2016 the whole and as singleton analysis in one case due to a deceased amount of invasive procedures decreased up to 50%. parent.Themostcommonidentifiedsonographicanomalies NIPT should be recommended to women without US were(multiple)congenitalanomalies,skeletaldysplasiaand abnormalities and family history (Table). Otherwise only intracerebral structural anomalies. invasive prenatal testing is acceptable due to limits of We were able to identify a causative pathogenic mole- NIPT. Since 2013 more than 12000 prenatal analyses cular variant in 12 of the 54 cases (22%) and a likely were done. aCGH increased the detection of pathogenic causative pathogenic molecular variant in another five chromosomal aberrations on 12%. Prenatal counseling is cases(9%),bringingthemoleculardiagnosticyieldinthis the most important tool for clarifying the appropriate cohort to 31%. Pathogenic and likely pathogenic variants strategy in each case.1204 Table. Comparison of NIPT results. case with monosomy X. In 118 cases we made prenatal NIPTtest Result Confirmed False False Refused diagnosis for other reason (usually for chromosomal positive negative invasive pathology in antecedents) and we found only two cases Lowrisks Highrisk procedure with trisomy 21 [1.69%]. In conclusion, prenatal diagnosis Panorama 3381 191 91(61%) 58(38%) 1(0,6%) 41 of chromosomal disorders is very useful in cases with (Natera, since2016) congenital anomalies and positive NIPD. Harmony 1939 79 57(80%) 14(20%) 0 8 V. Martiniuc: None. M. Gramescu: None. S. Popa: (Ariosa Diagnostics, None.R.Popescu:None.A.Paduret:None.I.Resmerita: since2016) None. L. Caba: None. L. Butnariu: None. M. Panzaru: VERASITY 1583 33 31(100%) 0 0 2 (NIPD None. C. Rusu: None. E. Gorduza: None. genetics, since2017) Total 6903 303 179 72 1 51 
P01 .71C Applicational of the array comparative genomic hybridization (aCGH) in the prenatal diagnostics of E. Kuznetsova: None. V. Gnetetskaya: None. M. fetuses with increased risk of aneuploidy Ermakova:None.M.Kurtser:None.Y.Tarasova:None. M. Chojnacka1, K. Sobecka1, M. Bartnik-Głaska1, 
P01 .70B M. Smyk1, I. Plaskota1, B. Wiśniowiecka-Kowalnik1, Correlation between reason to apply a prenatal M. Kędzior1, J. Bernaciak1, K. Jakubów-Durska1, diagnosis for aneuploidy and the results of test - A E. Obersztyn1, T. Roszkowski2, A. Kucińska-Chahwan2, retrospectivestudyon2,881foetusinvestigatedinlast15 P. Kretowicz3, B. Nowakowska1 years by FISH method in “Cuza Voda” Maternity, Iasi, Romania 1Institute of Mother and Child, Warsaw, Poland, 2Clinic of Obstetrics and Gynecology, Professor Witold Orłowski V. Martiniuc1, M. Gramescu2, S. Popa2, R. Popescu2, Independent Public Clinical Hospital - Postgraduate A. Paduret1, I. Resmerita2, L. Caba2, L. Butnariu2, Medical Education Centre, Warsaw, Poland, 3II M. Panzaru2, C. Rusu2, E. GORDUZA1,2 Department of Obstetrics and Gynecology, Medical Center of Postgraduate Education (CMKP), Warsaw, Poland 1"Cuza Voda" Obstetrics and Gynecology Hospital, Iasi, Romania, 2"Grigore T. Popa" University of Medicine and Theoccurrenceofaneuploidyisestimatedat5-11%ofall Pharmacy, Iasi, Romania fetuses. The most common are trisomies of chromosomes 13, 18, 21 and monosomy of the chromosome X. We analysed retrospectively 2,881 cases investigated by Noninvasive prenatal screening tests allow the risk calcula- prenatal diagnosis, using FISH method in the last 15 years tion of the aneuploidies based on the patients age (above inIasi,Romania.Weusedprobesforchromosomes13,18, 35), biochemical markers (free β-hCG) and ultrasono- 21, X and Y and we found 215 foetus with aneuploidy graphic markers (nuchal translucency parameter). The (7.46%). In 642 cases with abnormal double test we results suggesting a high risk of aneuploidy give strong identified 17 chromosomal anomalies [2.64%] (12 cases indications for further invasive diagnostics. with trisomy 21 and 1 case with trisomy 18, trisomy 13, The aim of this project was to evaluate the frequency of trisomy XXY and trisomy XYY). In 577 cases with chromosome aberrations other than aneuploidies in the abnormaltripletestweidentified8chromosomalanomalies groupof204patientswithhighriskoftrisomybasedonthe [1.38%] (4 cases with trisomy 21 and 4 cases with trisomy screening tests, where the ultrasound test did not show any 18).In42caseswithabnormaldoubleandtripletestwedid abnormalities. To perform the array diagnostic evaluation not identified chromosomal anomalies. In 759 cases with DNA from uncultured amniotic fluid, trophoblast or cul- congenital anomalies identified by ultrasonography we tured amniocytes was used. found 162 chromosomal anomalies [21.34%] (78 cases Aneuploidy was identified in 34/204 fetuses (17%). with trisomy 21, 52 cases with trisomy 18, 13 cases with Trisomy 21 was the most frequent abnormality (66%). The trisomy 13, 10 cases with monosomy X and 9 cases with trisomy 13 and 18 were detected in 3% and 11%, respec- triploidy). In 732 cases with advanced maternal age (> 35 tively, followed by X monosomy (11%), X mosaic years) we identified 16 chromosomal anomalies [2.18%] monosomy (3%) and sex chromosomes disomy (11%). In (14 cases with trisomy 21 and 1 case with trisomy 13, and 10/204cases(5%)structuralaberrationsof115kbto41Mb triploidy). We applied FISH test in 11 cases with positive were identified. Two of them were classified as potentially NIPD and we confirmed 9 cases with trisomy 21 and one pathogenic and 8 as pathogenic, where 4 were localized inAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1205 the regions of known microdeletion and microduplication Results: We identified a novel homozygous missense syndromes. mutation (NM_006731.2, c.898G>A, p.Gly300Arg) in Therefore,wepostulatethatCGHisthemostreliableand Fukutin gene (FKTN), which is associated to Muscular thefastestmethodforidentificationofgenomicimbalances, Dystrophy-Dystroglycanopathies. Fetal MRI supported even in the cohort of patients with normal results of ultra- molecular findings. Structural modeling analyses indicated sound examination. a potential pathogenetic mechanism of the variant, through M. Chojnacka: None. K. Sobecka: None. M. Bartnik- a reduced activation of the sugar moieties, which in turn Głaska: None. M. Smyk: None. I. Plaskota: None. B. impairs transfer to α-dystroglycan and thus its glycosyla- Wiśniowiecka-Kowalnik: None. M. Kędzior: None. J. tion. These findings pointed to a redefinition of the ultra- Bernaciak: None. K. Jakubów-Durska: None. E. sonographic suspicion of DWM recurrence to a Muscular Obersztyn: None. T. Roszkowski: None. A. Kucińska- Dystrophy-Dystroglycanopathy type A. Chahwan: None. P. Kretowicz: None. B. Conclusions: The present case confirmed WES as a Nowakowska: None. reliabletoolforprenatalidentificationofmolecularbasesof Central Nervous System phenotypes. Moreover, it high- 
P01 .72D lights the importance of considering Muscular Dystrophy- Prenatal whole exome sequencing detects a novel Dystroglycanopathies when a posterior fossa anomaly is Fukutin (FKTN) mutation in a fetus with a suspected early prenatally described. recurrence of Dandy-Walker malformation Grant: Italian Ministry of Health, R
C1801 G
C11  A. Traversa: None. E. Marchionni: None. A. Gio- A. Traversa1, E. Marchionni2, A. Giovannetti2, vannetti: None. M. Genovesi: None. S. Bernardo: None. M. Genovesi2, S. Bernardo2, D. Guadagnolo2, D. Guadagnolo: None. N. Panzironi: None. G. Napoli: N. Panzironi2, G. Napoli2, B. Torres3, A. Paiardini4, None. B. Torres: None. A. Paiardini: None. L. Bernar- L. Bernardini3, T. Mazza5, M. Carella1, V. Caputo2, dini: None. T. Mazza: None. M. Carella: None. V. A. Pizzuti2,1 Caputo: None. A. Pizzuti: None. 1LaboratoryofMedicalGenetics,FondazioneIRCCSCasa 
P01 .73A Sollievo della Sofferenza, San Giovanni Rotondo (FG), The advantage of comparative genomic hybridization Italy, 2Department of Experimental Medicine, Sapienza (aCGH) over quantitative fluorescence PCR (QF-PCR) University of Rome, Rome, Italy, 3Laboratory of in genetic testing of chorions after miscarriage Cytogenetics, Fondazione IRCCS Casa Sollievo della Sofferenza,SanGiovanniRotondo(FG),Italy,4Department K. Matuszewska1,2, M. Piechota1, B. Wieckowska3, of Biochemical Sciences "A. Rossi Fanelli", Sapienza K. Milanowska1, N. Kochalska1, A. Stachowiak1, University of Rome, Rome, Italy, 5Laboratory of K. Lacna1, P. Puacz4, T. Olejniczak5, A. Latos- Bioinformatics, Fondazione IRCCS Casa Sollievo della Bielenska1,2 Sofferenza, San Giovanni Rotondo (FG), Italy 1Centers for Medical Genetics GENESIS, Poznan, Poland, Introduction:Posteriorfossamalformationsareamongthe 2Department of Medical Genetics, Poznan University of mostfrequentCentralNervousSystemanomaliesprenatally MedicalSciences,Poland,Poznan,Poland,3Departmentof detected. We report on a 17 weeks male fetus with an Medical Statistics and Information Technologies, Poznan ultrasonographic suspicion of Dandy-Walker Malformation University of Medical Sciences, Poland, Poznan, Poland, (DWM) recurrence. The previous pregnancy of the couple 4Department of Mother and Child Health, Poznan had been interrupted at 22 gestational weeks following a University of Medical Sciences, Poland, Poznan, Poland, diagnosisofDWM.Weidentifiedthemolecularcauseusing 5Division of Perinatology and Women’s Diseases, Poznan Next Generation Sequencing in prenatal diagnosis. University of Medical Sciences, Poland, Poznan, Poland Materials and Methods: Whole exome sequencing (WES) has been performed on fetal genomic DNA. After Atleast60%ofspontaneousabortionsoccurduetogenetic reads pre-processing, mapping, variant calling and annota- disease(mostoftenchromosomalaberration)intheembryo tion,afilteringstrategybasedonallelicfrequency,recessive and fetus. Genetic testing of miscarriage material is very inheritance and phenotypic ontologies has been applied. A important in order to determine the etiology of miscarriage fetal MRI at 18 gestational weeks has been performed. In and to identify couples at risk. silicoanalysisofapotentialcausativevariantintheFukutin In our laboratory two methods QF-PCR (for chromo- protein has been carried out through a structural modeling somes: 13, 15, 16, 18, 21, 22, X, Y) - 827 chorions and approach.1206 aCGH (with resolution 12x135k or 8x60k) - 417 chorions finding – increased nuchal translucency, hygroma coli, were used. cardiac abnormalities, excess amniotic fluid, etc. Most fre- Chromosomal aberrations (numerical or structural) were quently causative variants were found in PTPN11 gene (4/ found in 56,5% of chorions analyzed by aCGH and in 10). Surprisingly, in two cases (2/10) we have detected 52,5%testedbyQF-PCR.Amongchromosomeaberrations variant in RIT1, one of the recently reported gene for mostfrequentweretrisomies(65,7%;mostfrequenttrisomy Noonan syndrome. Especially in prenatal diagnostic var- 16;trisomy14with thesamefrequencyastrisomy18),45, iants of uncertain significance (VOUS) pose a significant X (14%) and triploidy (13,1%). The higher number of problem. There is not enough information to sort them out miscarriages identified in an individual case, the smaller into classificatory categories, so they complicate con- percentage of abnormal results were observed. secutive genetic consultation. In our group VOUS was StructuralchromosomalaberrationsincludingCNVswere identified in 14 samples (14/104; 13,5 %). However, seg- identifiedin13,6%ofnoneuploidmiscarriagesexaminedby regation analysis of the variants in family members helped aCGH.SomeCNVswererepeatedandcontainedgenesthat to clarify their significance in eight of them. could be candidate genes critical for maintaining healthy Conclusions: The aim of this study was to evaluate pregnancy. The most common micro-aberration (6 none- clinical benefits of massive parallel sequencing in prenatal uploid chorions analyzed by aCGH) concerned the locus diagnosticsofcasessuspectedforRASopathy(i.e.detection 3p21.31, and involved the DAG1 gene. The DAG1 is rate) and compare them to the fraction of detected VOUS. expressed in the placenta during pregnancy. Literature data In general, our results establish this approach as effective correlate deficiency of alpha dystroglycan encoded by but with non-negligible number of uncertain findings. DAG1 gene with embryonic lethality. E. Svobodová: None. M. Matyášová: None. J. Kadle- Introduction of aCGH to the diagnostics of miscarriages, cová: None. D.N. Grochová: None. P. Vlašín: None. enabled the dynamic development of research on genetic causes of recurrent pregnancy losses including other than 
P01 .75C chromosomal aberrations. 1 out of 4 healthy individuals are carriers of a severe K. Matuszewska: None. M. Piechota: None. B. recessive or X-linked disease after using a panel of 15 Wieckowska: None. K. Milanowska: None. N. genes Kochalska:None.A.Stachowiak:None.K.Lacna:None. P. Puacz: None. T. Olejniczak: None. A. Latos- M. Sánchez-Soler1,2, A. Urbano1,2,3,4, E. Montoya1,2,3,4, Bielenska: None. I. Ochando1,2,3,4, R. Vázquez1,2, J. Rueda1,2,3,4 
P01 .74B 1Unidad de Genética, Hospital HLA Vistahermosa, Two years’ experience with molecular diagnostics of Alicante, Spain, 2Cátedra de Biomedicina Reproductiva RASopathies in prenatal cases Vistahermosa, UMH, Alicante, Spain, 3Departamento Histología, Facultad de Medicina, UMH, Alicante, Spain, E. Svobodová1, M. Matyášová1, J. Kadlecová1, 4E-GENETICARE, UMH, Parque Científico, Elche, Spain D. N. Grochová1, P. Vlašín2 Preconceptional tests use Next Generation Sequencing 1Cytogenetická laboratoř Brno, s.r.o., Brno, Czech (NGS) to identify carriers of recessive and X-linked Republic, 2Centrum prenatální diagnostiky, s.r.o., Brno, diseases, with the aim of reducing the risk of offspring Czech Republic bornwiththese alterations. Thegoal ofthepresentstudyis to show the results of the implementation of a reduced Introduction: RASopathies are a group of diseases with carrier screening test analyzed by NGS in a population of similar symptoms caused by disruption of RAS/MAPK 1097 healthy individuals who attend a reproduction center. pathway function. The most abundant diseases are Noonan This test includes 15 genes associated with the 16 most syndrome and neurofibromatosis type 1. prevalent autosomal recessive and X‐linked diseases in Materials and Methods: Resequencing of 20 selected Caucasian population, following the current recommenda- genes was performed by massive parallel sequencing tions of scientific societies (high prevalence, severe, early approach on samples with normal karyotype originated onsetandwithcleargenotype-phenotyperelationdiseases). from amniotic fluid or chorionic villi tissue. Amongthetotalofindividuals,809(73.7%)arewomenand Results: Samples were indicated on the basis of ultra- 288 (26.3%) are men. 25.4% are carriers of at least 1 sound findings. From a total of 104 prenatal samples cau- pathogenicorprobablypathogenicalteration(22.5%havea sative variant was found in 10 of them (detection rate 9,6 single mutation and 2.9% have two). Diseases with highest %). All those positive samples had severe ultrasound probability of being a carrier are: cystic fibrosis andAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1207 congenital bilateral aplasia of vas deferens (1/13), GJB2- 1qh+ and 9qh+ (0.4%), 5 structural Y-chromosome aber- related DFNB 1 non-syndromic hearing loss and deafness rations (0.4%), 2 deletions of Xqter and 1 ring21 chromo- (1/16),familialMediterraneanfever(1/42),spinalmuscular some. In cases of fetal anomalies array CGH revealed atrophy (1/50) and phenylketonuria (1/52). Out of the 809 17р13.3 microdeletion (Miller-Dieker syndrome), 1p36 women, 2.1% are carriers of a premutation (45-200 CGG microdeletion, 22q11.21 microdeletion (Di George syn- repeats) in the FMR1 gene, causative of X-fragile drome), 22q11.1 microduplication (Cat-eye syndrome), syndrome. In conclusion, 1 out 4 patients without other 10q26.3 microdeletion (2 cases), 22q11.21 microduplica- diseases who attend a reproduction center is a carrier of a tion (2 cases), 15q11.2 microdeletion (3 cases), 17p11.2 pathogenicalterationinoneofthescreenedgenes.Thistest microdeletion (Smith-Magenis syndrome). identifies the most frequent alterations that are at risk of Conclusions: In 6.5% of couples with reproductive fail- beingtransmittedtotheoffspringtopromotetheautonomy ure chromosomal alterations were detected. There is a high of patients to make reproductive decisions. probability (about 30%) to reveal microstructural genomic M. Sánchez-Soler: None. A. Urbano: None. E. Mon- aberrations by array CGH in cases of recurrent fetal toya: None. I. Ochando: None. R. Vázquez: None. J. anomalies. Rueda: None. K. Belemezova: None. M. Rizov: None. R. Kaneva: None.V.Peicheva: None.A.Kanev: None.M.Hristova- 
P01 .77A Savova: None. T. Milachich: None. A. Shterev: None. I. Genomic analyses in cases with reduced fertility and Dimova: None. recurrent fetal anomalies 
P01 .79C K. Belemezova1,2,3, M. Rizov1, R. Kaneva4, V. Peicheva4, Using Preimplantation Genetic Diagnosis (PGD) for A. Kanev5, M. Hristova-Savova1, T. Milachich1, retinoblastoma survivors: cost-effectiveness and quality A. Shterev1, I. Dimova1,4 of life improvements 1Medical complex „Dr Shterev“, Sofia, Bulgaria, M. Zeppel1, D. Schofield1, S. Staffieri2, R. Shrestha1, 2University Hospital “St. Ivan Rilski”, Department of D. Jelovic3, R. Jamieson4 Clinical Laboratory and Clinical Immunology, Medical University of Sofia, Sofia, Bulgaria, 3Tissue Bank BulGen, 1GenIMPACT, North Ryde, Australia, 2Dept of Sofia, Bulgaria, 4Center of Molecular medicine, Medical Ophthalmology, Royal Children’s Hospital, Parkville, University of Sofia, Sofia, Bulgaria, 5Military Medical Australia, 3Eye Genetics Research Unit, Children’s Academy, Sofia, Bulgaria Hospital at Westmead, Children’s Medical Research Institute,SaveSightInstitute,UniversityofSydney,Sydney, Objective:Genomicaberrationsareusuallyassociatedwith NSW, Australia, 4Eye Genetics Research Unit, Children’s reduced fertility, recurrent abortions or fetal anomalies. Hospital at Westmead, Children’s Medical Research Establishment of the exact genetic diagnosis in such cases Institute,SaveSightInstitute,UniversityofSydney,Sydney, has a great impact on the determination of the reproductive Australia risk and making a decision for reproductive options. Design:Inourstudywehavecollectedpatientsamplesin Background: Retinoblastoma (Rb) is a paediatric cancer, the following clinical cases of disturbed reproduction: leadingtolossofvision,eye(s)orlife.Approximately40% infertility or repeated abortions, structural fetal anomalies ofpatientshaveaheritableformofthedisease,causedbya and intrauterine death. mutationinRB1.Offspringoftheseindividualsareata50% Materials and Methods: We performed cytogenetic risk of inheriting the disease. Aggressive and invasive analysisonlymphocytesfromcouplesinallthelistedabove treatments in the first five years of life under general cases (1425 samples) and array CGH analysis of abortion anaesthetic, followed by regular monitoring until age 18, samples in cases of disturbed fetal development impact the patient, family, hospital resources. Preimplanta- (40 samples). tiongeneticdiagnosis(PGD)offersalternativereproductive Results: Chromosomal alterations were established by choices for individuals with a heritable mutation. Costs of cytogenetic analysis in 93 patients (6.5%), distributed as genomic sequencing are rapidly declining, with increasing follows - 19 chromosomal translocations (1.3%), 7 numer- availability of reproductive technologies. ical X/Y aberrations (0.5%), 10 cases of X/Y mosaicism Methods and Materials: We undertook a cost- (0.7%), 2 cases of mosaic marker (0.1%), 25 cases of chr9 effectiveness study of access to PGD for survivors with inversion (1.75%), 20 cases of acrocentric satellite poly- heritable retinoblastoma. We modelled the cost of repro- morphisms (1.4%), 5 cases of pericentric heteromorphism ductive technology, number of affected/unaffected births,1208 and quality of life gains, for parental uptake rates of PGD genotypewasalmostthesameinthestudygroups(18.75% from0-100%.Weincludedthecostsofhospitalvisitsfrom and 12.12%, p>0.05), and the absence of such CD- 0-18years,andcostsofIVFandPGDusingthreecycles(1 predisposing alleles was significantly lower in women fresh, 2 frozen). with RPL compared to control (25% and 78.79%, p Results:Inacohortofretinoblastomasurvivors,usingin- <0.0001). vitrofertilization(IVF)andPGDalwaysledtocost-savings, Conclusions:Thestudyofapossiblecorrelationbetween and quality of life improvements, even at low uptake rates. HLA-DQ2/DQ8 haplotype and RPL might suggest new Cost-savings were $156,538 and 20.58 Quality Adjusted diagnostic and therapeutical approaches for RPL women. Lifeyearsweregainedfortencoupleswith50%usingPGD K. Sosnina: None. O. Terpyliak: None. D. compared to the natural pregnancy pathway. Zastavna: None. Conclusions: IVF and PGD were always less expensive, withhigherquality-of-lifecomparedwithtakingthenatural 
P01 .81A pregnancy approach. Affordable and accessible PGD will Expanding our non-invasive prenatal diagnosis (NIPD) lead to savings for families and health systems for families service using droplet digital PCR with heritable retinoblastoma. M. Zeppel: None. D. Schofield: None. S. Staffieri: J. Shaw, S. Sheppard, N. Chandler, H. Ahlfors, L. Chitty None. R. Shrestha: None. D. Jelovic: None. R. Jamieson: None. North East Thames Regional Genetics Service, London, United Kingdom 
P01 .80D Celiac disease predisposition and Recurrent pregnancy Introduction:NIPDwherethemothercarriesamutationis loss: HLA- genotyping hindered by the maternal mutant background in cell-free DNA (cfDNA). Relative haplotype dosage analysis is used K. Sosnina1, O. Terpyliak1, D. Zastavna1,2 in clinical laboratories for NIPD of recessive and X-linked disorders, however this technique requires DNA from both 1InstituteofHereditaryPathology,NAMSofUkraine,Lviv, parentsandaproband.Droplet digital PCR (ddPCR)offers Ukraine, 2Department of Biotechnology and high sensitivity for quantification of cfDNA and has Bioinformatics, Faculty of Chemistry, Rzeszow University potential for use in carrier mothers via relative mutation of Technology, Rzeszow, Poland dosage usingonlyamaternal sample.Wehaveappliedthis technologytosicklecelldiseaseand8X-linkeddisordersto In recent years, has been discussed a relationship between determine clinical utility. RPL and celiac disease (CD), one of the most common Methods: ddPCR assays were designed and validated intestinaldisordersinthesmallintestineaffectingupto1% using gDNA for the pathogenic variant. Testing was per- of individuals in Western populations. It is known that formed on cfDNA from maternal plasma samples for susceptibility to CD is linked to certain human leukocyte 22 sickle cell risk pregnancies and 10 X-linked mutations. antigen (HLA) class II alleles, especially in the HLA-DQ Fetalfractionwasdeterminedusingthreedifferentmethods. region. In this context, the aim of this study was to Fetal genotype predictions were generated using sequential investigatetheprevalenceoftheCD-predisposingallelesin probability ratio test, with results confirmed by invasive women with RPL. sampling. Results: The presence of appropriate HLA alleles in 32 Results: For sickle cell disease, correct predictions of women with RPL and 33 women of control group was fetal HBB genotype were generated for 11 samples, with 2 determined. High CD predisposition was considered in incorrect predictions and 9 inconclusive results. Incorrect individuals with HLA alleles DQA1*0501, DQB1*0201- andinconclusivepredictionsresultedfromlowfetalfraction 0203 (encoding HLA-DQ2) and DQB1*0302 (encoding and threshold positioning during analysis. For X-linked HLA-DQ8), the presence of only the alleles DQA1*0501, conditions, assay design has been successful and develop- DQB1*0201-0203 was considered as medium-high predis- ment of the analysis pipeline initiated. position CD and a low risk CD are related allele Conclusions: ddPCR has the potential to be used for DQB1*0302. A significantly higher frequency HLA-DQ2/ NIPD for maternal mutation carriers using only a maternal DQ8 haplotype in women with RPL compared to control sample. We will report testing of over 50 additional ongo- was established (21.88% vs. 3.03%, p<0.025). The geno- ing cases to refine and validate the analysis pipeline to type HLA-DQ2 is established with a significantly higher further extend the scope of our NIPD clinical service. frequencyinwomenwithRPLcomparedtocontrol(34.8% J. Shaw: None. S. Sheppard: None. N. Chandler: vs. 6.06%, p <0.005). The frequency of the HLA-DQ8 None. H. Ahlfors: None. L. Chitty: None.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1209 
P01 .82B 
P01 .83C Comprehensive chromosome screening of human first What is the actual risk of couples carriers for the polar bodies and oocytes using four different whole mutation DHCR7:c.964-1G>C? genome amplification methods and single-cell next- generation sequencing H. Daum1, V. Meiner1, R. Michaelson-Cohen2, R. Sukenik-Halevy3,4, M. Levy-Zalzberg5, A. Bar-Ziv6, A. Sarosiak1,2, I. Minota1, K. Koziol3, M. Oldak1 A. Weiden7, S. Scher8, M. Shohat4,9,10, J. Zlotogora1 1Department of Genetics, Institute of Physiology and 1Department of Genetics and Metabolic Diseases, Pathology of Hearing, Warsaw, Poland, 2Postgraduate Hadassah-Hebrew University Medical Center, Jerusalem, School of Molecular Medicine, Medical University of Israel, 2Medical Genetics Institute, Dept. of Obstetrics & Warsaw, Warsaw, Poland, 3Novum Fertility Clinic, Gynecology, Shaare Zedek Medical Center, Hebrew Warsaw, Poland University of Jerusalem, Jerusalem, Israel, 3Recanati Genetic Institute, Rabin Medical Center, Petah Tikva, Background: Aneuploidy is the most frequent type of Israel,4SacklerSchoolofMedicine,TelAvivUniversity,Tel chromosome aberration and the most significant clinically. aviv, Israel, 5Genetic Institute, Soroka, Beer sheva, Israel, Itoccursasaresultofmeioticchromosomalmalsegregation 6The Danek Gertner Institute of Human Genetics, Sheba during formation of a haploid oocyte by subsequent Medical Center, Tel hashomer, Israel, 7Dor Yeshorim, extrusion of two polar bodies: polar body first (PB1) and Committee for Prevention of Jewish Genetic Diseases, second (PB2). Based on meiosis mechanism, genome of a Jerusalem, Israel, 8Dor Yeshorim, Committee for single oocyte can be deduced by analyzing its siblingpolar Prevention of Jewish Genetic Diseases, Brooklyn, NY, bodies. United States, 9Bio-informatics department, Cancer center, Material and Methods: Next-generation sequencing Sheba Medical center, Tel hashomer, Israel, 10Institute of technology for comprehensive chromosome screening was Medical Genetics, Maccabi HMO, Rehovot, Israel used to assess ploidy status of the oocytes and their sibling PB1. A total of 120 single cells (60 PB1 and 60 oocytes) Introduction:Smith-Lemli-Opitzisanautosomalrecessive were subjected for whole genome amplification (WGA) disorder characterized by variable expression including using four different commercially available WGA kits and multiple congenital malformations, dysmorphic features, analyzed using VeriSeq PGS kit on the MiSeq sequencer metabolic derangement and intellectual disability. The (Illumina). Random samples were validated using genomic founder mutation DHCR7:c.964-1G>C was introduced into arrays (aCGH). Aneuploidy detection with the tested kits theIsraelipreconceptionscreeningtestsforAshkenaziJews was evaluated. in2017sincethecarrierfrequencyofthemutationishighin Results: Aneuploidy status was determined for 112 of this population (1.2%). Despite the high carrier rate, the 120 (93,3%) samples. In the group of well-amplified PB1- diseaseitselfisnotknowntobefrequentinthispopulation. oocyte pairs (33/60) a 97% concordance between the Discrepancy between the carrier and disease frequency chromosomal status of PB1 and the corresponding oocyte raises the question of the actual risks for affected offspring was observed. Differences in WGA kits performance for couples detected by the screening program. including amplification uniformity and aneuploidy calling Methods: We performed a literature review of all pub- potential were evaluated and the most optimal kit for PB1 lications available with detailed information regarding genomeWGAwasselected.ResultsfromaCGHvalidation homozygous DHCR7:c.964-1G>C fetuses/patients were of the randomly selected samples showed full consistency included. We also collected clinical data about the couples with the NGS results. identified in the national screening program, such as Conclusions: NGS-based method used for PB1 genome reproductive history. analysis showed a high predictive potential of PB1 in Results:Outof31homozygousfetuses,sixdiedin-utero deducingploidystatusofthecorrespondingoocyteandisa (IUFD),tenpregnancieswereterminatedduringthesecond promising method for genetic preconception testing of trimester and 15 children were born. All 15 died between oocytes. day one till three months of age. Reproductive history of Supported by: POIR.02.03.02-14- 0092/17 Smith-Lemli-Opitz at-risk couples showed that out of 61 A. Sarosiak: None. I. Minota: None. K. Koziol: None. pregnancies, 32 spontaneous miscarriages were M. Oldak: None. reported (52%). Discussion: Our observations support the previous knowledge that homozygosity for c.964-1G>C in DHCR7 leads to a severe phenotype or early spontaneous abortion.1210 An unexpected observation was the excess of early spon- B. Panthan: B. Research Grant (principal investigator, taneousabortions.Thereasonforthisisnotclearandawaits collaborator or consultant and pending grants as well as further studies. grants already received); Modest; Leader Medical Genetics H. Daum: None. V. Meiner: None. R. Michaelson- and Genomics, Co., Ltd.. S. Klumsathian: None. A. Cohen: None. R. Sukenik-Halevy: None. M. Levy-Zalz- Charoenyingwattana: None. W. Chantratita: None. O. berg: None. A. Bar-Ziv: None. A. Weiden: None. S. Trachoo: B. Research Grant (principal investigator, colla- Scher: None. M. Shohat: None. J. Zlotogora: None. borator or consultant and pending grants as well as grants already received); Modest; Leader Medical Genetics and 
P01 .85A Genomics, Co., Ltd.. Developing quantitative real-time PCR for preconception spinal muscular atrophy carrier 
P01 .86B screening in Thai population Detection and validation of subchromosomal aberrations detected as part of routine noninvasive P. Chit ayanan1, B. Panthan2, S. Klumsathian2, prenatal testing A. Charoenyingwattana2, W. Chantratita2, O. Trachoo3,2 M.Sekelská1,A.Izsáková1,K.Kubošová1,P.Tilandyová1, 1Panthupark Genetics Clinic, Bangkok, Thailand, 2Center E. Csekes1, Ž. Kúchová1, R. Lukáčková2, D. Landlová2, for Medical Genomics, Faculty of Medicine Ramathibodi M. Hýblová2, M. Haršányová3, J. Budiš3, T. Szemes3, Hospital, Mahidol University, Bangkok, Thailand, P. Križan2, G. Minárik2 3DepartmentofMedicine,FacultyofMedicineRamathibodi Hospital, Mahidol University, Bangkok, Thailand 1Trisomy test Ltd., Bratislava, Slovakia, 2Medirex Inc., Bratislava, Slovakia, 3Geneton Ltd., Bratislava, Slovakia Introduction: Spinal muscular atrophy (SMA) is a severe neuromuscular disease and one of the most common Introduction: Noninvasive prenatal testing is based on autosomal recessive diseases in children, caused by analysis of circulating DNA from blood of pregnant homozygous absence of the survival motor neuron gene women. Low coverage whole genome sequencing is able (SMN1).Heterozygousexon7deletionofSMN1isdefined to detect not only most commonly screened chromosomal as a carrier with the reported frequency of 1/40 to 1/50 aneuploidiesbutalsodifferentsubchromosomalaberrations. worldwide.Clinicalpracticeinmanycountriesrecommends Aim:Aimoftheworkwasprospectivestudyofdetection SMA carrier screening for most couples at the and validation of subchromosomal aberrations of fetal ori- preconception stage. ginidentifiedaspartofroutinenoninvasiveprenataltesting. Materials and Methods: We developed a quantitative MaterialsandMethods:FromApril2016tillDecember real-time PCR protocol to detect SMN1 exon 7 deletion 2018, more than 8000 samples of pregnant women using (SMADX7™) as a cost-effective method, aiming to per- Illumina NextSeq 500 platform were analysed. Low cov- form carrier screening in 430 Thai individuals visiting erage whole genome sequencing was used in combination preconceptionclinic. Validationofthemethodwasdonein with optimized CNV detection algorithm. 100 positive and negative controls compared to standard Results: In tested cohort of patients different suchromo- DHPLC method. somal aberrations were detected in 32 samples. Half of Results: The result of control testing was 100% con- patients (16) refused confirmatory testing or we were not sistent between real-time PCR and DHPLC. Further popu- abletogetsampleorfeedbackfromthefurthermanagement lation screening revealed the SMA carrier frequency of 1/ of the patient. In second half of samples (16) DNA from 72. amniocenteses were available for confirmatory testing. Of Conclusion: Developing of SMADX7™ is an out- thesecases5findingswereconfirmedand11werenegative standing strategy for SMA carrier screening in Thai popu- after verification analyses. In samples with detected aber- lation due to good cost-benefit and rapid turnaround time rationsfetalfractionvariedbetween10,3and18,26%.The within 24 hours. Carrier frequency in our cohort seemed to smallest reported aberration was 1 Mb and the largest one be lower than global frequency; however, additional sub- approx. 80 Mb long. jects are required to be enrolled, aiming to obtain the Conclusions: In this prospective study the possibility of national data that can represent overall carrier frequency. utilization of low coverage genomic sequencing for detec- Grants: Leader Medical Genetics and Genomics, tionofsubchromosomalaberrationsoverthewholegenome Co., Ltd. was confirmed. For proper estimations of sensitivity, spe- P. Chitayanan: A. Employment (full or part-time); cificity, NPV and PPV larger studies are necessary as Modest; Leader Medical Genetics and Genomics, Co., Ltd.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1211 samples significantly differ in crucial factors that are fetal 
P01 .88D fraction, position and size of detected aberration. A molecular strategy increases the PGD accuracy for M. Sekelská: None. A. Izsáková: None. K. Kubošová: Taiwan b-thalassemia population None. P. Tilandyová: None. E. Csekes: None. Ž. Kúchová: None. R. Lukáčková: None. D. Landlová: Y. C. Li1,2,3, Y. C. Chen1, H. H. Shih1, E. H. Cheng1, None. M. Hýblová: None. M. Haršányová: None. J. Y. P. Lin1, Y. P. Pai1, M. S. Lee1,3,4 Budiš: None. T. Szemes: None. P. Križan: None. G. Minárik: None. 1LeeWomen’sHospital,Taichung,Taiwan,2ChinaMedical University, Taichung, Taiwan, 3Chung-Shan Medical 
P01 .87C University, Taichung, Taiwan, 4Chung-Shan Medical The risk of spontaneous abortion in subfertile couples University Hospital, Taichung, Taiwan G.C.COZARU1,2,M.Aschie1,2,A.Mitroi1,2,C.Brinzan1,2 β-thalassemia carries over 1.1% prevalent rate in Taiwan and has polymorphism variants coordinated with geogra- 1CEDMOG - “Ovidius” University of Constanta, phy. Both β-thalassemia carrier couple would transmit 1/4 Constanta, Romania, 2“Sf Apostol Andrei” Emergency risk of thalassemia major to their offspring in every Clinical County Hospital of Constanta, Constanta, pregnancy. Thalassemia major patients require lifelong Romania transfusions, iron-chelation therapy and, an expensive support system. These bring a great socioeconomic burden Our research has gone from the observation that women to the suffered family. PGD (preimplantation genetic with a history of subfertility have been shown to have diagnosis) for β-thalassemia is conducted in IVF (in vitro increased rates of subclinical early pregnancy loss, as fertilization) to transfer an embryo without thalassemia detected via human chorionic gonadotropin, relative to major to the uterus. The problem of allele dropout (ADO) women without a history of impaired fertility. andpreferentialamplificationhighlyexistinPGDinvolving Objectives: The purpose of this study was to assess the WGA (whole genomeamplification) ofblastocystbiopsies. association between subfertility and spontaneous abortion. It had been reported that a combination of Sanger Methods: A total of 122 women in Constanta reported sequencing and QF-PCR of STR markers increased the 384 pregnancies between 2014 and 2018 and were able to detection rate of the mutated β-globin gene in PGD. provide an estimate of the waiting time to conception for However,theuninformativeSTRsandADOofthemutated 276 (71.87% of the 384 eligible pregnancies). We noted gene usually limited the validation of PGD. Moreover, the retrospective data, including sociodemographic character- heterozygosity rate of STRs is highly population different. istics, obstetric and medical history, genetic risk factors, In this study, we verified several STRs for providing cigarette smoking, caffeine and alcohol consumption, and enoughinformativeSTRsforTaiwanβ-thalassemiapopula- occupational information. Rates of spontaneous abortion tion. Our results showed that six linked STRs (D11
S4146 , were determined among women with and without sub- D11
S1760 , D11
S1243 , D11
S4891 , D11
S2352 , and fertility,andadjustedoddsratios(ORs)and95%confidence D11
S1871 ) with highly heterozygous polymorphism and intervals (CIs) were estimated via multiple logistic low recombination rate in Taiwan population and would regression. achieve up to 99% diagnostic validation in PGD for Results: Multivariate logistic regression analyses with β-thalassemia. Furthermore, the multifluorescent PCR of generalizedestimatingequationsindicatedthatspontaneous STRs conductedin a single tube for the linkage analysisof abortion rates were 28.0% in pregnancies preceded by the mutated β-globin gene provided a simple method for subfertility and 17.0% in pregnancies without impaired performingthePGDofβ-thalassemiamajor.Thisstudywas fertility (adjusted OR=1.68, 95% CI=1.36, 2.84). supported from MOST of Taiwan (107-2314-B-040-019), The attributable risk of spontaneous abortion associated CSMU (104-OM-A-102), and CSMU-CCH (CSMUCCH- with subfertility was 6.9%. 102-06). Conclusions: Subfertile women evidence an increased Y.C. Li: A. Employment (full or part-time); Significant; number of spontaneous abortions. Lee Women’s Hospital. B. Research Grant (principal Research supported by CEDMOG, Ovidius University of investigator, collaborator or consultant and pending grants Constanta, POS CCE 2.21. Project, (ID 1844, SMIS aswellasgrantsalreadyreceived);Significant;Chung-Shan 48750). Medical University. Y.C. Chen: A. Employment (full or G.C.Cozaru:None.M.Aschie:None.A.Mitroi:None. part-time); Significant; Lee Women’s Hospital. H.H. Shih: C. Brinzan: None. A. Employment (full or part-time); Significant; Lee Women’s Hospital. E.H. Cheng: A. Employment (full or1212 part-time); Significant; Lee Women’s Hospital. Y.P. Lin: Table. Distribution of genes variants A. Employment (full or part-time); Modest; Lee Women’s Gene Genotypes Basicgroup, Comparison Hospital. Y.P. Pai: A. Employment (full or part-time); (polymorphic n/% group,n/% Significant;LeeWomen’sHospital.M.S.Lee:B.Research variants) (n=412) (n=70) Grant (principal investigator,collaboratororconsultantand Protrombin GG 393/95,39 69/98,57 pending grants as well as grants already received); Sig- (G20210A) GA 19/4,61 1/1,43 nificant; Chung-Shan Medical University. AA 0/0,00 0/0,00 FactorV GG 394/95,63 69/98,57 
P01 .89A (G1691A) GA 17/4,13 1/1,43 Maternal and paternal genotypes analysis of AA 1/0,24 0/0,00 thrombophilic gene variants in the risk of reproductive disorders in married couples FGB CC 209/50,73 39/55,71 (
C148 T) CT 180/43,69 28/40,00 Z. I. Rossokha1,2, O. F. Popova1, N. L. Medvedieva1, TT 23/5,58 3/4,29 L. P. Sheiko2, N. G. Gorovenko2 FGB GG 226/54,85 40/57,14 (-455G/A) GA 165/40,05 28/40,00 1State Institution “Reference-centre for molecular AA 21/5,10 2/2,86 diagnostic of Public Health Ministry of Ukraine”, Kyiv, PAI-I 5G/5G 82/19,90 23/32,86 Ukraine, 2State Institution «Genetic and Regenerative (-6755G/4G) 5G/4G 203/49,27 29/41,43 Medicine of the National Academy of Medical Sciences of 4G/4G 127/30,83 18/25,71 Ukraine», Kyiv, Ukraine Introduction: Inherited thrombophilia is well defined. Z.I. Rossokha: None. O.F. Popova: None. N.L. Med- Factor V Leiden mutation and prothrombin G20210A vedieva: None. L.P. Sheiko: None. N.G. genetic variants are classic thrombophilic determinants for Gorovenko: None. clinical manifestation of reproductive disorders. But new geneticvariantsarediscussednow.Theaimofthestudyto 
P01 .90B evaluatetheinfluenceofclassicandnewgeneticvariantson Droplet digital PCR multiplexing for fetal aneuploidy reproductive disorders in married couples. detection Materials and Methods: The genetic variants of Factor V(G1691A,rs6025),prothrombin(G20210A,rs1799963), I. Zednikova1, M. Korabecna1, E. Pazourkova1, PAI-I (675 5G/4G, rs 1799889), FGB (
C148 T, G-455A, rs S. Santorova1, P. Calda2, M. Brestak2,3, A. Horinek1 1800787 and rs 1800790) were analyzed in 206 couples with reproductive disorders (69 with unspecified infertility/ 1InstituteofBiologyandMedicalGenetics,FirstFacultyof 137 with recurrent pregnancy loss) and 35 couples of Medicine, Charles University and General University comparison group (who gave birth to one or two healthy Hospital in Prague, Prague 2, Czech Republic, children). Frequency genotypes analysis was carried out 2DepartmentofObstetricsandGynecology,FirstFacultyof withouttakingintoaccounttheorigin(maternalorpaternal) Medicine, Charles University and General University of genotypes. SNP Stats program were used for statistical Hospital in Prague, Prague 2, Czech Republic, 3Screening analysis. Center ProfiG2, Prague, Czech Republic Results: There were found no significant differences for prothrombin, Factor V and FGB genes variants among Background: Nowadays, cell-free fetal DNA (cffDNA) in investigated groups. 5G/5G genotypes were significantly maternal plasma is routinely applied for non-invasive decreased among couples with reproductive disorders prenatal testing (NIPT). Detection of the most common (Table). We identified significant dominant inheritance fetal aneuploidies is ordinarily performed using NGS models for PAI-I (5G/4G) gene (χ²=5,16; p=0,023; technology. Low concentration of cffDNA in maternal OR=0,51, 95%CI: 0,29-0,88) for reproductive failure in circulation prevents the utilization of cheaper and simpler couples. technology - droplet digital PCR (ddPCR). The aim of our Conclusions: We suppose that PAI gene has a beneficial studywastoovercomethisproblembytargetmultiplexing. effect on reproductive function due to improved antic- Methods: Three genes on chromosome 21 and chromo- oagulant properties of blood when genotype 5G/5G in some 18 were absolutely quantified in one ddPCR reaction married couples present or for embryos this genotype are (hexaplex). Targets on different chromosomes were dis- predicted. tinguished using different labelling (FAM/HEX). ExpectedAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1213 FAM/HEX ratio for DNA with normal karyotype is 1. In malformation in a fetus with a sib with similar phenotype, case of fetal trisomy of 21 or 18, the ratio will be deflected without known genetic cause. We performed trio WES accordingly. Artificial mixtures of euploid and trisomic analysis using a custom virtual gene-panel (~3,800 OMIM DNA were used for pilot study. genes, excluding late-onset disease genes). Results:DNAwithnormalkaryotypewassystematically Results:WeestablishedanadditionalgeneticWES-based mixed with DNA with trisomy of 21 (0%; 5%; 10%; 20%; diagnosis in nine fetuses, being: syndromes of MIRAGE 40%);chromosome18wasusedasareferencechromosome (SAMD9), Zellweger (PEX1), Walker Warburg in this case. Eight replicates for each mixture were per- (POMGNT1), Noonan (PTN
P11 ), Kabuki (KMT2D), formed.DetectedFAM/HEXratiosalwayscorrespondedto CHARGE (CHD7); two cases of Osteogenesis Imperfecta theexpectedratiosforrespectivemixtures.Eventhelowest type 2 (CO
L1 A1), and one potential diagnosis in a fetus representation of aneuploid DNA (5%) was correctly with hydrops (MYH7). In six out of 25 cases the WES detected. diagnosis aided in perinatal management. The mean turn- Conclusion: After promising results of the initial phase around time was 10 (range 6-15) working days. with the artificial mixtures, the optimized workflow will Conclusion: Our prospective study shows that imple- now be applied for the analysis of plasma of pregnant menting WES as a routine test in the prenatal setting is women. This method could be applicable for detection of challenging, but technically feasible and has a promising trisomy 21 or 18 in the same reaction, as both trisomies diagnostic yield and significant clinical relevance. together have never been observed. Supported by the N.Corsten-Janssen: None. J.C.D. Diphoorn: None.K. MinistryofHealthoftheCzechRepublicRVOVFN64165 Bouman: None. J. El Mecky: None. J.B.G.M. Verheij: I. Zednikova: None. M. Korabecna: None. E. None. W.S. Kerstjens: None. A. Scheper: None. R. Pazourkova:None.S.Santorova:None.P.Calda:None. Kinds: None. I.M. van Langen: None. R.J. Sinke: None. M. Brestak: None. A. Horinek: None. R.H. Sijmons: None. B. Sikkema-Raddatz: None. H. Westers: None. C.C. van Diemen: None. 
P01 .91C Clinical implementation of diagnostic whole exome 
P01 .92D sequencing for fetal multiple congenital anomalies on CNVs with unknown significance on chromosome 15 in ultrasound prenatal samples N.Corsten-Janssen,J.C.D.Diphoorn,K.Bouman,J.El K. Markova, R. Mansfeldova, V. Becvarova, H. Pekova, Mecky, J. B. G. M. Verheij, W. S. Kerstjens, A. Scheper, T. Marie, M. Spacirova, B. Laposova, J. Starkova, R. Kinds, I. M. van Langen, R. J. Sinke, R. H. Sijmons, V.Sucha,P.Sidova,J.Horacek,M.Koudova,D.Stejskal B. Sikkema-Raddatz, H. Westers, C. C. van Diemen Gennet, Prague, Czech Republic, Prague, Czech Republic Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands, Groningen, Introduction:Chromosomalmicroarrayanalysis(CMA)is Netherlands increasingly used in prenatal diagnostics. It provides better resolution than conventional karyotyping, nevertheless, Introduction:Identifyingthecauseoffetalanomaliesseen CNVswithvariableexpressivityandlowpenetrancerequire on ultrasound provides important information for perinatal a proper interpretation attitude. management, but we can diagnose only ~40% of fetuses Materials and Methods: More than 2200 prenatal sam- using conventional genetic tests (QF-PCR and microarray). ples (AMC, CVS) were examined at our clinic within the Whole Exome Sequencing (WES) may improve diagnostic lasttwoyears.In9.8%samplesananeuploidywasdetected yield, but is challenging due to uncertainties around fetal byQFPCR.TheremainingsampleswereanalyzedbyCMA phenotyping, variant interpretation, ethical/counseling as a first-tier test: samples were assessed by array CGH (or issues of incidental findings and variants of unknown SNP-array) and analyzed with AgilentCytoGenomics soft- clinical significance, and the requirement of short turn- ware. Parental samples were analyzed using CMA to spe- around times. In this study, we implemented WES in cify the origin of the identified aberrations. prenatal care to increase our diagnostic yield. Results: 72 CMA analyzed samples were considered to Materials and Methods: We conducted a prospective be pathogenic (out of them 56 below karyotype resolution) study of rapid trio WES analysis next to conventional while additional 112 cases as variants of unknown sig- genetic tests for twenty-five fetuses with ultrasound nificance: class 2, 3 and 4 (likely benign, uncertain clinical abnormalities.Inclusioncriteriawereatleasttwocongenital relevance, likely pathogenic) or without subclassification. malformations on ultrasound or one congenital Most frequent VOUS were identified on chromosomes 151214 (19), 16 (8) and X (13). Prominent CNVs were del/dup were VOUS. The proportion of matings who were PV/ 15q11.2 (B
P1 B
P2 ) and del/dup 15q13.2q13.3 encompass- LPV*PV/LPV was 2.7-3.8% (depending on the panel), ing significant genes NIPA1 and CHRNA7, respectively. similar to previous reports. The proportion of PV/ These CNVs are associated with neurodevelopmental dis- LPV*VOUS matings was 17-20%. Considering only exo- orders, autism and behavioral problems. Penetrance is nic, non-UTR VOUS resulted in a decreased proportion of incomplete and expressivity varies greatly. Databases, lit- PV/LPV*VOUS matings to ≈7%. Most (65-70%) PV/ eraturesearchandfamilialgenealogydidnotprovedefinite LPV*VOUS matings were at risk for severe/profoundly- pathogenicity. The most of these CNVs was inherited and severe diseases, while only 6-7% were at risk for mild alltraceablepregnancieswithnormalultrasoundcontinued. diseases. Conclusion: All fetuses with VOUS on chromosome 15 Conclusions: Non-reporting of VOUS in ECS may miss except one had normal ultrasound. CNVs identified on at-risk couples for severe diseases. Reporting PV/ chromosome 15 except deletion of CHRNA7, were LPV*VOUS couples would triple the proportion of at-risk described as likely benign with respect to prevailing par- couples,evenifconsideringonlyexonic,non-UTRVOUS. ental origin and normal ultrasound. Even if only 10% of VOUS are ultimately reclassified as K. Markova: None. R. Mansfeldova: None. V. Bec- PV/LPV, reporting PV/LPV*VOUS would increase the varova: None. H. Pekova: None. T. Marie: None. M. yield of ECS by ≈25%. Spacirova:None.B.Laposova:None.J.Starkova:None. H. Fridman: None. D. Behar: A. Employment (full or V. Sucha: None. P. Sidova: None. J. Horacek: None. M. part-time); Significant; Igentify. E. Ownership Interest Koudova: None. D. Stejskal: None. (stock, stock options, patent or other intellectual property); Significant; Igentify. S. Carmi: None. E. Levy- 
P01 .93A Lahad: None. Preconception carrier screening: effect of reporting variantsofunknownsignificanceinpartners ofcarriers 
P01 .94B with clinically significant variants Incidence of Y chromosome microdeletion in different world populations: systematic review H. Fridman1,2,3, D. Behar4, S. Carmi2, E. Levy-Lahad1,3 A. Kurtovic-Kozaric1,2, H. Komic2,3, L. Mehinovic2, 1Medical Genetics Institute, Shaare Zedek Medical Center, M. Kozaric4, I. Eminovic2, Z. Halilovic5 Jerusalem, Israel, 2Braun School of Public Health and CommunityMedicine,TheHebrewUniversityofJerusalem, 1Laboratory of Human Genetics, Department of Clinical Jerusalem, Israel, 3Faculty of Medicine, The Hebrew Pathology, Cytology and Human Genetics, Clinical Center University of Jerusalem, Jerusalem, Israel, 4Igentify, Tirat of the University of Sarajevo,, Sarajevo, Bosnia and Hacarmel, Israel Herzegovina, 2Department of Genetics, Biology Section, Faculty of Science, University of Sarajevo, Sarajevo, Background: Expanded preconception carrier screening Bosnia and Herzegovina, 3TIMM Laboratory at (ECS) panels can identify at-risk couples for multiple Sahlgrenska Cancer Center, University of Gothenburg, diseases. ECS reports are currently limited to pathogenic/ Gothenburg, Sweden, 4Clinic of Gynecology and likely-pathogenic variants (PV/LPV). Variants of unknown Obstetrics, Clinical Center of the University of Sarajevo, significance (VOUS) are not reported, even though Sarajevo, Bosnia and Herzegovina, 5Laboratory of Human reporting VOUS is routine in genomic and chromosomal Genetics, Department of Clinical Pathology, Cytology and array testing in both postnatal and prenatal settings. This Human Genetics, Clinical Center of the University of policy misses pairings of PV/LPV carriers with VOUS Sarajevo, Sarajevo, Bosnia and Herzegovina carriers(PV/LPV*VOUS),whomaybeat-risk.Toevaluate theimportanceofthisomission,weexaminedtheratesand Introduction: Y chromosome microdeletions in azoosper- characteristics of PV/LPV*VOUS virtual matings in an miafactor(AZF)sub-regionsofitslongarmarethesecond Ashkenazi-Jewish (AJ) cohort, a population with well- most frequent genetic cause of male infertility. The aim of established preconception screening. Methods: We ana- this study was to analyze data on Y chromosome lyzed 672 AJ genomes (225,456 virtual couples) for microdeletion world-wide. variants in different gene-panels (exons ±10bp): AJ (55 Materials and Methods: A recall search yielded 924 genes), pan-ethnic (168 genes) and combined (180 genes), papers, 73 papers met the inclusion criteria. Risk of bias using an ACMG classifier. was the size of tested population (>100 men) and its Results: Across 180 genes, we identified 4671 variants, applicationexcluded31studies,yielding42papersforfinal among them 144 (3.1%) were PV/LPV and 1963 (42%) analysis.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1215 Results: The mean Y microdeletion frequency for all 4.45% and 3.97%, respectively. The highest frequencies included studies was 8.35% (n=32996), and 6.4% were detected in South Korean (38%) and Syrian (28%) (n=31552) for the studies that passed risk of bias criteria. populations.The lowest frequencies wereinDanish (0.7%) The mean Y microdeletion frequencies per continent and Croatian (0.9%) populations. The frequencies among (Asian,American,EuropeanandAfrican)were9%,6.83%, AZF sub-regions showed the same pattern in almost all ThefrequenciesofdifferentAZFsub-regionmicrodeletionsindifferentworldpopulations Continent Country AZFa AZFb AZFc AZFa+b AZFa+c AZFb+c AZFa+b+c Ref. EUROPE Denmark 0% 1.54% 92.30% 0% 0% 3.08% 3.08% Olesenetal.2017 0% 0% 66.67% 0% 0% 33.33% 0% Boretal.2002 Slovakia 25% 0% 50% 0% 0% 12.5% 12.5% Behulovaetal.2011 Netherlands 0% 0% 100% 0% 0% 0% 0% Dohleetal.2002; 0% 0% 100% 0% 0% 0% 0% Paracchinietal.2000 Slovenia 10% 0% 50% 0% 0% 20% 20% Peterlinetal.2002 Italy 11.11% 8.08% 65.66% 0% 0% 13.13% 2.02% Ferlinetal.2007 Germany 5.26% 10.53% 78.95% 0% 0% 5.26% 0 Maureretal.2001 Croatia 100% 0% 0% 0% 0% 0% 0% Medicaetal.2005 Turkey 3.81% 3.81% 49.52% 0% 0% 26.67% 16.19% Kumtepeetal.2009 21% 25% 42% 0% 4% 8% 0% Cavkaytaretal.2012 Latvia 0% 0% 60% 0% 0% 0% 40% Puzukaetal.2011 UK 0% 38.46% 38.46% 0% 0% 15.38% 7.70% Mascarenhasetal.2016 Czech 0% 0% 62.50% 0% 0% 37.50% 0% Machatkovaetal,.2002 Sweden 0% 0% 0% 0% 0% 100% 0% Österlundetal.2000 Macedonia 0% 0% 88.89% 0% 0% 11.11% 0% Plaseskietal.2006 ASIA Japan 0% 30% 60% 0% 0% 10% 0% Nakashimaetal.2002 China 4.7% 4% 73.30% 0% 0% 11.30% 6.7% Zhuetal.2016 2.22% 13% 75% 0% 0% 9.62% 0% Elfatehetal.2014 2.01% 4.7% 75.18% 0% 1.34% 14.09% 2.68% Zhangetal.2013 India 16.67% 33.33% 33.33% 0% 0% 16.67% 0% Abidetal.2008 22.22% 11.11% 33.33% 0% 0% 33.33% 0% Mitraetel.2008 0% 12.5% 37.5% 37.5% 0% 12.5% 0% Dadaetal.2006 Thailand 0% 33.33% 50% 0% 0% 16.67% 0% Vutyavanichetal.2007 SouthKorea 0% 0% 73.64% 0% 0% 26.36% 0% Choietal.2013 4.95% 7.92% 54.46% 0% 0% 23.76% 8.91% Kimetal.2012 SriLanka 0% 0% 100% 0% 0% 0% 0% Wettasingheetal.2012 Jordan 0% 0% 66.7% 0% 0% 33.3% 0% Khabouretal.2014 Kuwait 0% 0% 28.57% 0% 0% 71.43% 0% Mohammedetal.2007 11.1% 0% 55.6% 0% 0% 33.30% 0% Alkhalaf&Al-Shoumer,2010 Iran 0% 0% 50% 0% 0% 50% 0% Saliminejadetal.2012 Pakistan 0% 0% 100% 0% 0% 0% 0% Siddiquietal.2013 Palestine 0% 0% 100% 0% 0% 0% 0% Shaqalaihetal.2009 SaudiArabia 0% 12.5% 75% 0% 12.5% 0% 0% Hellanietal.2006 Israel 0% 12.5% 87.5% 0% 0% 0% 0% Kleimanetal.1999 MiddleEast 9.09% 42.43% 30.30% 0% 0% 18.18% 0% Alhalabietal.2013 AFRICA Tunisia 0% 10% 30% 0% 0% 30% 30% Rajebetal.2008 0% 0% 100% 0% 0% 0% 0% Hammamietal.2014 Morocco 0% 0% 50% 0% 0% 50% 0% Imkenetal.2007 AMERICA Brazil 8.33% 0% 58.33% 0% 0% 25% 8.33% Pina-Netoetal.2006 US 2.68% 11.41% 52.35% 0% 0% 21.48% 12.08% Stahletal.2010 5% 5% 64% 0% 0% 17% 9% Hofherretal.20111216 studies, with AZFc being most frequent (90.5%), followed Conclusions: We would like to suggest that PAX6 gene by AZFb+c. variants c.991C>T (p.Arg331Ter) and c.392_393delTA (p. Conclusion: Isolated AZFc microdeletion was the most Ile131Thrfs*15) are cause of aniridia for our patients. frequent,exceptforCroatian,Swedish,KuwaitiandMiddle R. Traberg: None. V. Asmoniene: None. D. Cereske- East populations. These results can serve as a basis for vicius: None. M. Sukys: None. creating future guidelines for genetic diagnostics of male infertility. 
P02 .02D A. Kurtovic-Kozaric: None. H. Komic: None. L. The role of next-generation sequencing in the Mehinovic:None.M.Kozaric:None.I.Eminovic:None. differential diagnosis of congenital iris anomalies Z. Halilovic: None. F.Blanco-Kelly,M.Tarilonte,C.Villaverde,S.T.Swafiri, A. Arteche, A. Avila-Fernandez, J. Moya, I. Lorda, 
P02  M. Trujillo-Tiebas, C. Ayuso, M. Corton Sensory disorders (eye, ear, pain) Genetics Department, IIS-Fundación Jiménez Díaz- 
P02 .01C CIBERER, UAM, Madrid, Spain PAX6 gene analysis for aniridia patients: single Lithuanian centre experience in 2017-2018 years period Abnormal development of the iris is a feature of several congenital ocular malformations. Classical aniridia, the R. Traberg, V. Asmoniene, D. Cereskevicius, M. Sukys mostcommonform,isapanoculardiseasecharacterizedby iris and foveal hypoplasia, keratopathy, cataracts and HospitalofLithuanianUniversityofHealthSciencesKauno glaucoma, caused by PAX6 haploinsufficiency. The pre- klinikos, Kaunas, Lithuania sence of variable expressivity and phenotypic overlapping with other types of anterior segment dysgenesis (ASD) Introduction: Aniridia is a very rare congenital panocular hindersthegeneticcharacterizationofatypicalpresentations disorder characterized by complete or partial iris hypopla- of aniridia. Here, we evaluate the usefulness of NGS to sia. PAX6 gene mutations occur in around 90% of aniridia improve the clinical diagnosis of these pathologies. A cases. Two-thirds of aniridia cases are inherited in an cohort of 106 families was studied, including cases with autosomal dominant pattern and 1/3 are sporadic cases. classical aniridia or atypical forms (iris hypoplasia, atrophy Materials and Methods: PAX6 gene analysis was per- or coloboma). The entire PAX6 gene and other 260 genes formed for patients who were diagnosed with isolated and associated with ocular malformations were analyzed using syndromic aniridia. Their first line and/or affected family custom targeted NGS and aCGH approaches, as well as members also was analysed. The PAX6 gene was analysed clinical or whole exome and/or Sanger sequencing. About by Sanger sequencing (2-13 exones). If no point mutations 82% of the cases presented likely pathogenic variants or were found, analysis was extended to deletion/ duplication CNVsin5differentgenes.DefectsinPAX6explain75%of search with multiplex ligation-dependent probe amplifica- cases, including not only all characterized cases with tion (MLPA) kit (MRC-Holland SALSA MLPA 
P219  PAX6 classical aniridia, but also 30% of patients with more kit). atypical presentations, in whom LOF or atypical missense Results: 5 families and 3 single cases were tested for andnon-codingvariantswereidentified,respectively.Other PAX6 gene mutations in 2 years period (2017 - 2018) (20 aniridia-likepatientspresentedpathogenicvariantsinASD- analyses altogether). Six different mutations were found in related genes or variants of uncertain significance in 15(75%)cases:1missensemutation,1intragenicdeletion, candidate genes. Molecular analysis of iris malformations 4 nonsense mutations. The 2 truncating mutations presents high diagnostic yield not only in cases with (c.991C>T (p.Arg331Ter) and c.392_393delTA (p. classical aniridia (95%) but also in patients with aniridia- Ile131Thrfs*15)) were newly described. De novo PAX6 like phenotypes (>50%). Our work evidences the clinical gene variant c.991C>T (p.Arg331Ter) was found for utility of differential genetic studies based on NGS in patient, who diagnosed with aniridia and doubled kidney. patients with congenital iris anomalies. PAX6 gene variant c.392_393delTA (p.Ile131Thrfs*15) Grants: ISCIII (PI17_01164, CPII17_00006), FEDER was found for family members with isolated aniridia. and Conchita Rabago Foundation. Members of one family with various clinical presentation F. Blanco-Kelly: None. M. Tarilonte: None. C. Villa- (unilateral aniridia and Peters anomaly, cataracts, optic verde: None. S.T. Swafiri: None. A. Arteche: None. A. nerve hypoplasia) shared missense variant of unknown Avila-Fernandez: None. J. Moya: None. I.Lorda:None. significance c.422T>C (p.Leu141Pro).Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1217 M. Trujillo-Tiebas: None. C. Ayuso: None. M. T.A. Vasilyeva: None. V.V. Kadyshev: None. A.A. Corton: None. Voskresenskaya: None. N.V. Petrova: None. A.V. Mar- akhonov: None. R.A. Zinchenko: None. 
P02 .03A Genotype-phenotype correlations in congenital PAX6- 
P02 .04B associated aniridia Congenital aniridia caused by new PAX6 variants involving exonic cryptic-splicing sites T.A.Vasilyeva1,V.V.Kadyshev1,A.A.Voskresenskaya2, N. V. Petrova1, A. V. Marakhonov1,3, R. A. Zinchenko1,4 M. Tarilonte, P. Ramos, J. Moya, C. Villaverde, G. Sanz, S. T. Swafiri, B. Gener, F. Blanco-Kelly, C. Ayuso, 1Research Centre for Medical Genetics, Moscow, Russian M. Corton Federation, 2Cheboksary branch of S. Fyodorov Eye Microsurgery Federal State Institution, Cheboksary, IIS-UniversityHospitalFundaciónJiménezDíaz,Madrid, Russian Federation, 3Far Eastern Federal University, Spain Vladivostok, Russian Federation, 4Pirogov Russian National Research Medical University, Moscow, Russian Congenitalaniridiaisapanoculardisease,withaworldwide Federation incidence of 1:50.000-100.000 births, characterized by iris and foveal hypoplasia and additional anomalies in the Objectives: Aniridia is an autosomal dominant severe cornea, anterior segment and lens, leading to low visual panocular disorder caused by pathogenic variants in the acuity. Up to 90% of the aniridia cases carried monoallelic PAX6 gene or large chromosomal aberrations affecting loss-of-function variants causing haploinsufficiency of 11p13 region. Aniridia phenotype varies greatly. Based on PAX6, a highly-conserved transcriptional regulator that is the occurrence of several aniridia characteristics in groups critical for normal ocular development. Here, we aimed to of patients with the same type ofPAX6mutation, genotype assess functionally the implication on splicing of different —phenotype correlations were analyzed. exonic and intronic variants of uncertain significance Methods: 155 patients from 129 unrelated families were (VUS), mainly located in the PAX6 homeodomain. First, examined in the course of the earlier study, 118 patients novel VUS including synonymous, missense and non- werefound tohaveintragenicpathogenic variantswhile37 canonical splicing variants were identified in our cohort of others have large chromosomal deletions. Patients were 87 Spanish families with aniridia after classical genotyping allocated into 6 groups according to the type of PAX6 and/or targeted next generation sequencing (NGS) of the mutation: missense, nonsense, frame shifting, splicing, 3′- entire PAX6 locus. No additional pathogenic variants were cis-regulatory region deletions, and all other 11p13 chro- found in other 250 eye developmental genes. Functional mosomedeletions.Dataonsixfrequentlyobservedaniridic splicing assays were performed using in silico predictors, eye anomalies were collected: complete or partial aniridia, in vitro minigenes and, when available, patients-derived cataract, glaucoma, kerathopathy, fovea hypoplasia, and lymphocytes cell lines. We described new spliceogenic nystagmus. Fisher’s exact test with Benjamini—Hochberg mechanisms for PAX6 variants through activating different correction for multiple testing was applied for 2×2 con- exonic cryptic donors as the most plausible cause for tingency tables created to compare occurrence of each congenital aniridia in several families. These included an ocular sign in the group of patients with one type of additional case of parental PAX6 mosaicism, as confirmed mutationsversusthecorrespondingoccurrenceinthegroup by digital-droplet PCR, for a synonymous variant in an with all other mutations. asymptomatic mother with two affected siblings. In Results: Only patients with 3′-cis-regulatory region conclusion, clinical interpretation of silent and non- deletions significantly more often develop a distinct and canonical splicing variants represents a real challenge for milder aniridia phenotype without kerathopathy, fovea the genetic counseling. Our study revealed the importance hypoplasiaandnystagmus.Identifiedmissenseandsplicing of functional studies to elucidate the role of non-coding mutations were associated with severe aniridia phenotype PAX6 variants underlying ocular development. and in their consequences could not be distinguished from Grants: ISCIII (PI17_01164, CPII17_00006), FEDER the loss-of-function mutations. and Conchita Rabago Foundation Conclusions: Revealed genotype-phenotype correlations M. Tarilonte: None. P. Ramos: None. J. Moya: None. in PAX6-associated aniridia suggests common disease C. Villaverde: None. G. Sanz: None. S.T. Swafiri: None. mechanism for all mutations except for 3′-cis-regulatory B.Gener:None.F.Blanco-Kelly:None.C.Ayuso:None. region deletions. M. Corton: None. Supported by grant RSF №17-15-01051.1218 
P02 .05C M.Brumat:None.A.Morgan:None.M.Cocca:None. Preliminary results from a new GWAS meta-analysis M. Mezzavilla: None. G. Van Camp: None. E. Fransen: point at new loci for age-related hearing loss (ARHL) None. G. Biino: None. U.Ambrosetti: None. D. Toniolo: None. S. Ghiselli: None. P. Gasparini: None. G. M. Brumat1, A. Morgan1, M. Cocca2, M. Mezzavilla2, Girotto: None. G. Van Camp3, E. Fransen4, G. Biino5, U. Ambrosetti6, D. Toniolo7, S. Ghiselli2, P. Gasparini1,2, G. Girotto1,2 
P02 .06D Multi-level evidence of an allelic hierarchy of USH2A 1Department of Medicine, Surgery and Health Sciences, variants; hearing loss, auditory processing and speech/ University of Trieste, Trieste, Italy, 2Institute for Maternal language outcomes and Child Health - IRCCS Burlo Garofolo, Trieste, Italy, 3Center of Medical Genetics, University of Antwerp and P. A. Perrino1, L. Nedevska2, R. Reader3,4, A. Hill5, Antwerp University Hospital, Antwerp, Belgium, WG
S500  Consortium, A. R. Rendall1, H. S. Mountford2, 4Department of Biomedical Sciences, University of A. N. Buscarello1, N. Lahiri6, A. Saggar6, R. H. Fitch1, Antwerp, Antwerp, Belgium, 5Institute of Molecular D. F. Newbury2 Genetics, National Research Council of Italy, Pavia, Italy, 6Audiologia, Fondazione IRCCS Ca’ Granda Ospedale 1Department of Psychological Science/Behavioral Maggiore Policlinico, University of Milan, Milan, Italy, Neuroscience,UniversityofConnecticut,Storrs,CT,United 7Center for Translational Genomics and Bioinformatics, States, 2Faculty of Health and Life Sciences, Oxford S. Raffaele Scientific Institute, Milan, Italy Brookes University, Oxford, United Kingdom, 3Wellcome Trust Centre for Human Genetics, Oxford, United Introduction: With the progressive ageing of world Kingdom, 4School of Veterinary Medicine and Science, population,thereisaneedtofurtherinvestigatethegenetic University of Nottingham, Sutton Bonington, United baseoflate-onsetdisorderssuchasARHL.Withthisstudy, Kingdom, 5Centre for Child & Adolescent Health, we aim to increase our knowledge of this complex disease. University of Bristol, Bristol, United Kingdom, 6Institute of Materials and Methods: We performed a case-control MolecularandClinicalSciences,UniversityofLondon&St GWAS analysis on 2663 subjects (aged >=50) coming George’s University Hospitals NHS Foundation Trust, from Italy, Northern Europe and Caucasus clinically char- London, United Kingdom acterized including the audiometric phenotype. Cases and controls were classified as previously described Introduction: Hearing and auditory processing are funda- (DOI:10.3109/21695717.2014.911472). Genotype data mental to language development. Genetic mechanisms that were imputed using 1000Gph3 reference panel. Results alter these processes may therefore have secondary effects were pooled together with METAL. Replication of results on emergentlanguage. Inthis work,we considervariations was performed with UK-Biobank data (ie. speech-in-noise acrosstheUSH2Ageneandcharacteriseanallelichierarchy phenotype). Analyses on natural selection in European associatedwithalternateanddistinctclinicalmanifestations populationswereperformedandintegratedhaplotypescores including Auditory Processing Disorder (APD), Develop- (iHS) on significant GWAS results were collected. mental Language Disorder (DLD) and Usher syndrome. Results: Meta-analysis identified some strongly sig- Materials and Methods: This investigation combines nificant loci. To prioritize these genes, signals of selection wholegenomesequencingdatafromafamilyaffectedbya were checked to evaluate the presence of genetic variants severe form of APD and speech dysarthria with genetic that could have some evolutionary role and a stronger characterisation of two large population cohorts; the Avon effect. A significant hit on chr5 was detected in a gene/ LongitudinalStudyofParentsandChildren(ALSPAC)and protein (|iHS|score>2) catalysing the conversion of homo- UK10K. To compliment human findings, a mouse model cysteine to other amino-acids. Signal of selection was pre- with a genetic knockout of the rodent homolog Ush2a was sent in North European populations, but absent in South assessed for auditory processing and vocalizations. European ones. Interestingly, literature showed a relation- Results: Combined human and mouse results show: (1) ship between hyperhomocysteinemia induced by folate heterozygous USH2A disruptions lead to impaired low- deficiency and premature hearing loss, prompting further frequency sound perception; (2) low-level hearing impair- investigation and discussion on these results. ments caused by heterozygous disruption of Ush2a Conclusions: As the association signal is mainly driven associate with persistent higher-order acoustic processing byNorthernItalianandEuropeanpopulations,apopulation- deficits and altered vocalizations in mice; and (3) risk var- specific haplotype involved in folate metabolism should iants of USH2A combined with altered low-frequency also implicated directly or indirectly in ARHL.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1219 hearing thresholds lead to significantly worse language PTC-freeCE
P290 isoforms from themutantallelecarrying outcomes in humans. the c.6869dup in the fibroblasts from 
P3 .1 and 
P3 .2. Conclusions: We identify a complex, interactive genetic However, we detected some correctly spliced CE
P290  mechanism under which variants in USH2A contribute to mRNAs transcribed from the second allele carrying the low-frequency hearing loss and alter higher-order auditory c.1824+3A>G mutation and small amounts of the protein processing increasing the risk of language disorder. Since by Western blot analysis. these variants are found in 0.85% of the population, we Conclusion: Here, we report that CE
P290  pleiotropy recommend comprehensive genetic screening to enable the involves splicing regulation through different mechanisms early identification of carrier individuals alongside specific that can act individually or in combination and include assessment of low-frequency hearing in individuals at risk. NAS, BES and hypomorphic consensus splice site P.A. Perrino: None. L. Nedevska: None. R. Reader: mutations. None. A. Hill: None. A.R. Rendall: None. H.S. Mount- I.Barny:None.I.Perrault:None.S.Thomas:None.T. ford: None. A.N. Buscarello: None. N. Lahiri: None. A. Attié-Bitach: None. M. Rio: None. C. Hamel: None. H. Saggar: None. R.H. Fitch: None. D.F. Newbury: None. Dollfus:None.S.Defoort-Dhellemmes:None.J.Kaplan: None. J. Rozet: None. X. Gerard: None. 
P02 .07A Expanding the mechanisms underlying CE
P290  
P02 .08B pleiotropy: about 4 cases The role of HCN1 variation in circadian chronotypes I. Barny1, I. Perrault1, S. Thomas1, T. Attié-Bitach1, S. Smieszek1, C. P. S. Polymeropoulos2, M.Rio2,C.Hamel3,H.Dollfus4,S.Defoort-Dhellemmes5, M. Polymeropoulos2 J. Kaplan1, J. Rozet1, X. Gerard1 1Vanda Pharmaceuticals, WASHINGTON, DC, United 1Institut Imagine, Paris, France, 2IHU Necker Enfants States, 2Vanda Pharmaceuticals, DC, OH, United States Malades, Paris, France, 3Institut des Neurosciences de Montpellier, Montpellier, France, 4Centre de référence To ascertain the genetic risk factors for morningness/ pour les affections génétiques ophtalmologiques CARGO, eveningness phenotypes we conducted a genome-wide Strasbourg, France, 5CHRU de Lille, Lille, France association analysis using 316 whole genome sequencing samples. We have directly tested the association between Introduction: CE
P290  is pivotal for the assembly/main- SNPs and MEQ (morning-evening questionnaire). We tenanceofprimaryandmotileciliainawiderangeofcells. computed association test results by linear regression Consistently, CE
P290  mutations cause a spectrum of assuming additive allelic effects (covariates: age, gender, ciliopathies ranging from Leber congenital amaurosis andthe3PCs).Wedetectalargeregiononchromosome5 (LCA10) to embryo-lethal Meckel syndrome (MKS). (more than ~400 adjacent SNPs in LD, spanning ~2mb) LCA10 manifests invariably as a congenital and dramati- centered within HCN1, Brain Cyclic Nucleotide-Gated cally severe cone-dominant disease with visual function Channel 1. Regional enrichment yields a p-value of < 10- reduced to light perception. Here, we report 4 individuals 99. It is highly expressed in the brain and potentially with some preserved vision despite biallelism for presum- modulates excitability in the brain and responding to ably severe CE
P290  mutations and functional analysis in regulation by cyclic nucleotides, playing a critical role in fibroblastsweperformedtobetterunderstandthemolecular shaping the autonomous activity of single neurons and the bases of CE
P290  pleiotropy. periodicity of network oscillations. It has been shown in a Materials and Methods: in silico, mRNA, protein and double-mutant mouse model that lack of HN
C1  mediated ciliation analyses were performed in 
P1  (p.Ile556Phefs*17, feedback in rod photoreceptor cells prolongs rod responses homozygous), 
P2  (p.Lys170*/p.Glu1364*), 
P3 .1 and 
P3 .2 and saturates the downstream retinal network during bright (c.1824+3A>G/ p.Asn2290Lysfs*6) and controls. light stimulation. The risk allele is effectively correlated Results: mRNA analysis of 
P1  and 
P2  mRNA revealed withlowerMEQscorehenceeveningphenotype.Thelocus spontaneousskippingofexonsencompassingthepremature has been shown to be a significant (1.6e-09) eQTL for stop codons by mechanisms involving basal exon-skipping HCN1 in GTEX. HCN1 channel is responsible for the (BES) and nonsense-associated altered splicing (NAS) feedback on the rods regulating the dynamic range of light individually or in combination. Protein analysis detected reactivity under dim or intermediate light conditions. We small amounts of a CE
P290  protein and unaltered ciliation hypothesizethatifthisfeedbackisnotfunctioningproperly ability compared to controls. In contrast, we detected no an individual may get saturated with even dim light BES or NAS which could have enabled the production of resulting in misperception of the light conditions resulting1220 in a circadian delay. This would suggest that HCN1 prevented additional unnecessary testing and provided the variations may directly impact the ME phenotype. opportunityforanticipatoryguidanceinasubsetofpatients S. Smieszek: None. C.P.S. Polymeropoulos: A. that could be precisely defined. Employment (full or part-time); Modest; Vanda Pharma- E. Lenassi: None. S. Ramsden: None. J. Clayton- ceuticals. M. Polymeropoulos: A. Employment (full or Smith: None. S. Douzgou: None. G. Hall: None. V. part-time); Modest; Vanda Pharmaceuticals. Sharma: None. I. Lloyd: None. J.L. Ashworth: None. S. Biswas: None. G.C. Black: None. P. Sergouniotis: None. 
P02 .09C Clinical utility of panel-based genetic testing in infants 
P02 .11A and young children with inherited eye disease Founder haplotype bearing mutation c.1621C>T (p. Gln541*) in the FYCO1 gene causing of autosomal E. Lenassi1, S. Ramsden2, J. Clayton-Smith2, recessive cataract (CTRCT18) in the Sakha Republic of S. Douzgou2, G. Hall2, V. Sharma3, I. Lloyd4, Russia J.L.Ashworth3,S.Biswas3,G.C.Black1,P.Sergouniotis1 N. A. Barashkov1,2, L. S. Vychuzhina1, A. V. Solovyev1,2, 1University of Manchester, Manchester, United Kingdom, F. M. Teryutin1, V. G. Pshennikova1,2, T. E. Burtseva1,2, 2Manchester Centre for Genomic Medicine, St Mary’s M. I. Tomsky1, F. A. Platonov2, G. P. Romanov2, Hospital,Manchester,UnitedKingdom,3ManchesterRoyal N.N.Gotovtsev1,E.K.Khusnutdinova3,4,O.L.Posukh5,6, Eye Hospital, Manchester, United Kingdom, 4Great S. A. Fedororva1,2 Ormond Street Hospital for Children, London, United Kingdom 1Yakut Scientific Centre of Complex Medical Problems, Siberian Branch of the Russian Academy of Medical Introduction: Advances in ocular genetics have trans- Sciences, Yakutsk, Russian Federation, 2M.K. Ammosov formed our understanding of inherited eye diseases (IEDs) North-Eastern Federal University, Yakutsk, Russian and have led to the development of powerful diagnostic Federation, 3Ufa Federal Research Center of Russian tests. However, integration of these tests into routine Academy Sciences, Institute of Biochemistry and Genetics, healthcare is frequently ineffective. Providing robust Ufa, Russian Federation, 4Bashkir State University, Ufa, evidence of benefit can accelerate implementation; for Russian Federation, 5Federal Research Center Institute of example,theadoption ofagenetictestismuch morelikely Cytology and Genetics, Novosibirsk, Russian Federation, when its clinical utility (i.e. its ability to influence 6Novosibirsk State University, Novosibirsk, Russian management and health outcomes) has been clearly Federation demonstrated. Here we assess the current clinical utility of genetic testing in paediatric IED. Novel nonsense mutation c.1621C>T (p.Gln541*) in the Materials and Methods: Unrelated children (0-5 years FYCO1 gene was previously revealed by whole exome old) with IED were retrospectively ascertained through the sequencing as the main genetic cause of congenital database of the UK North West Genomic Laboratory Hub. autosomal recessive cataract (CTRCT18) in patients from The cohort was consecutively collected and included indi- the Sakha Republic (Eastern Siberia). In this report we vidualspresentingbetween09/2011and08/2018.Allstudy present the results of the c.1621C>T (p.Gln541*) carrier participantswereexaminedintertiarypaediatricophthalmic frequency analysis in 424 adult individuals without of genetic clinics and underwent panel-based genetic testing. visual impairments from 7 populations of Eastern Siberia Results: 229 children were evaluated including 33 with (Russians,Yakuts,Evenks,Evens,Dolgans,Yukaghirsand albinism, 83 with bilateral paediatric cataracts, 19 with Chukchi). The highest carrier frequency of this mutation congenital glaucoma, 7 with ectopia lentis and 57 with was found in Yakut population (7.9%), the lowest in inheritedretinaldisorders.Thediagnosticyieldwashighest Evenks (1.7%) and Evens (2.0%), and c.1621C>T (p. for albinism and ectopia lentis and lowest for congenital Gln541*) was absent in Russians, Yukaghirs, Dolgans and glaucoma. Genetic testing altered management (e.g. pre- Chukchi. Common haplotypes for c.1621C>T (p.Gln541*) ventedadditionalinvestigationsorledtotheintroductionof were reconstructed as a result of genotyping of 6 STR personalisedsurveillancemeasuresordeterminedeligibility markers flanking the FYCO1 gene in 25 patients homo- for treatment trials) in significant subsets of children with zygous for c.1621C>T (p.Gln541*) and in 114 patients ectopia lentis, albinism, bilateral cataracts and inherited without this mutation. Common haplotypes bearing retinal disorders. c.1621C>T (p.Gln541*) indicate the role of founder effect Conclusions: Genetic testing helped identify an aetiolo- in the spread of this mutation in the Sakha Republic. The gical diagnosis in the majority of children with IED. This highestdiversityofthec.1621C>T-haplotypeswasrevealedAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1221 in the Central Yakuts ethno-territorial group. The mutant Conclusion: CES of related subjects from an isolated haplotypes of the Vilyui and Northern Yakuts groups are family with Congenital Cataract identified a causal NHS probably derived from the c.1621C>T-haplotypes found in mutation and confirmed the mode of inheritance in the theCentralYakutsgroup.Ourresultssuggestthatmutation family as X-linked recessive. This finding will aid drama- c.1621C>T (p.Gln541*) in the FYCO1 gene causing tically the clinical management of this whole family. CTRCT18 arose about 260±65 years ago (in the middle E. Louizou: None. S. Rapti: None. A. Vasiageorgi: of the XVIII century) and spread among Yakut population None. G. Kapetsis: None. E. Tsitsopoulos: None. C. as a result of founder effect. This study was supported by Yfanti: None. the Ministry of Education and Science of the Russia (#6.1766.2017) and the RFBR (18-05-600035_Arctica). 
P02 .13C N.A. Barashkov: None. L.S. Vychuzhina: None. A.V. A heterozygous likely pathogenic variant in MAF Solovyev: None. F.M. Teryutin: None. V.G. Pshenni- transactivationdomainasacauseofbilateralcongenital kova:None.T.E.Burtseva:None.M.I.Tomsky:None.F. cataract without intellectual disability or seizures A. Platonov: None. G.P. Romanov: None. N.N. Gotovt- sev: None. E.K. Khusnutdinova: None. O.L. Posukh: L. Lovrecic, A. Maver, I. Vrečar, B. Peterlin None. S.A. Fedororva: None. University Medical Center Ljubljana, Clinical Institute of 
P02 .12B Medical Genetics, Ljubljana, Slovenia ClinicalExomeSequencingrevealsthegeneticcauseina family with congenital cataract Introduction: Congenital cataract is a developmental disorderofthelensresultinginlenscloudinessoropacities. E. Louizou, S. Rapti, A. Vasiageorgi, G. Kapetsis, The hereditary congenital cataracts are genetically hetero- E. Tsitsopoulos, C. Yfanti geneous and can be transmitted under an autosomal dominant, recessive or X-linked inheritance model. The Molecular Genetics Department, Bioiatriki S.A., Athens, MAF gene (OMIM*177075) pathogenic sequence variants Greece inthec-terminalDNAbindingdomainhavebeenshownto cause autosomal dominant isolated congenital cataract Introduction: Cataracts are the principal cause of treatable phenotype. On the other hand, MAF N-terminal transacti- blindnessworldwide.Inheritedcongenitalcataractshowsall vation domain genetic variants are associated with Ayme- types of inheritance patterns in a syndromic and non- Gripp syndrome (OMIM#601088), in which the eye syndromic form. Congenital Cataract is an opacification of anomalies are accompanied by intellectual disability, the lens, usually diagnosed at birth and without proper sensorineural hearing loss, seizures, distinctive facial treatment,thevisionneverdevelopsnormally.Inthisstudy appearance, reduced growth and skeletal anomalies. we present a family from Central Greece with six affected Materials and Methods: A female patient, law graduate membersbornwithCongenitalCataract,fivemalesandone by profession, was referred to genetic consultation in her female, all of which had bilateral nuclear cataracts as first pregnancy for her history of bilateral congenital cat- newborns. Despite efforts to medically improve their aract. Other medical history was unremarkable, except for condition, many members had a gradual deterioration of milddelayinachievingdevelopmentalmilestonesandmild their vision which led to blindness, before the age of thirty unilateral sensorineural hearing loss. She never needed years old. hearing aid. General examination at 30 years showed nor- Materials and Methods: Clinical Exome Sequencing mal height and distinctive flat facial appearance. Clinical (CES)wasperformedwiththeSophiaGeneticsProtocolon exomesequencingwasusedtotestforcausativevariantsin aMiSeqIlluminaplatform,inoneoftheaffectedprobands. 110 known genes associated with isolated and syndromic Inordertoconfirmourfindingandtoinvestigatethecarrier cataract. status of most family members, Sanger sequencing was Results: A heterozygous likely pathogenic de novo performed for the region of interest. missense variant c.188C>G (Pro63Arg) in the N-terminal Results: The analysis revealed a possibly pathologic transactivation domain of the MAF gene was identified. mutation -c.3808C>T(p.Gln1270*) -on the NHS gene, Conclusions:Thisisthefirstreportofpathogenicvariant which is located on the X chromosome. The mutation has in the N-terminal transactivation domain of the MAF gene not been previously recorded in any database but the NHS in an individual without intellectual disability/learning dif- gene is known to be the cause of X-linked Congenital ficulties, seizures or significant hearing loss. Cataract - Nans Hooran Syndrome. L. Lovrecic: None. A. Maver: None. I. Vrečar: None. B. Peterlin: None.1222 
P02 .15A S. Morovvati1, M. Ajallooeian2, N. Ayoubzadeh3 Important contribution of STRC copy number variations to the development of mild-to-moderate 1Human Genetic Research Center, Baqiyatallah University hearing loss of Medical Sciences, Tehran, Iran, Islamic Republic of, 2BaqiyatallahUniversityofMedicalSciences,Tehran,Iran, B. Harasimowicz1, D. Ozieblo1,2, H. Skarzynski3, Islamic Republic of, 3Faculty of Biological Sciences, M. Oldak1 TarbiatModaresUniversity,Tehran,Iran,IslamicRepublic of 1Department of Genetics, Institute of Physiology and Pathology of Hearing, Warsaw, Poland, 2Postgraduate Introduction: Hearing loss (HL) is one of the most School of Molecular Medicine, Medical University of commoncongenitalimpairmentswhichoccursoneinevery Warsaw, Warsaw, Poland, 3Oto-Rhino-Laryngology thousandchildren.Morethanhalfofthesecasesarecaused Surgery Clinic, Institute of Physiology and Pathology of bygeneticfactors.Atthepresenttime,morethan150genes Hearing, Warsaw/Kajetany, Poland have been identified to be associated with hearing loss. MaterialsandMethods:Inthisstudy,formorethan600 Background: Copy number variations (CNVs) are com- patientsaffectedbydeafness,geneticcounseling was done. mon cause of genetically determined hearing loss (HL). 320patientsselectedforgeneticanalysis.Infirststep,forall CNVs are frequently found in the STRC gene which is selected patients, analysis of GJB2 gene was done. Then, relatedtoautosomalrecessiveHL.DuetopresenceofSTRC for patients who had normal result for GJB2 gene, hearing pseudogene and technological limitation of CNVs detec- loss genetic panel (including 127 genes involved in deaf- tion, large deletions and duplications encompassing STRC ness) was performed using NGS method. Finally, for are still an underestimated contributor to HL development. patients for whom no pathogenic mutation was detected in Material and Methods: A group of 50 patients with their genetic panel, Whole Exome Sequencing (WES) was mild-to-moderate HL diagnosed before the age of 10 and done by NGS method. withnoDFNB1pathogenicwasrecruitedforthestudy.All Results: 19 different pathogenic mutations were found patients were tested for CNVs in STRC gene using quanti- GJB2 gene in 92 out of 320 patients (28.75%). Deafness tativecomparativefluorescentPCR(QF-PCR)withprimers genetic panel and WES were performed for 65 and 57 specific to the STRC gene and its pseudogene followed by patientswithnormalGJB2testrespectively.Pathogenicand multiplex-ligation probe amplification (MLPA). likely pathogenic mutations were detected in 75 subjects Results: Genetic prescreen with QF-PCR revealed a including 25 novel mutations. complete deletion of the STRC tested regions in 24% (24/ Discussion: Due to the prevalence of consanguine mar- 100) and partial deletion in 5% of the studied alleles (5/ riages in Iran, autosomal recessive hearing loss is common 100).Thismethodallowedusalsotoidentifytwocomplete in our country. Genetic analysis, especially WES can be and two partial deletion of tested regions in the STRC very helpful in preventing the birth of deaf children. pseudogene. Complete deletions of the STRC gene regions S. Morovvati: None. M. Ajallooeian: None. N. were fully confirmed by MLPA. One additional STRC Ayoubzadeh: None. partial deletion and one duplication were also detected. Considering the genotypes, in 26% (13/50) of HL patients 
P02 .17C homozygous or compound heterozygous CNVs were Gene-wise burden analysis on painful diabetic detected. In 10% (5/50) of patients only simple hetero- neuropathy zygous CNVs was found. Conclusions:ThisstudyshowsthatCNVsinSTRCarea E. Salvi1, M. Marchi1, M. Gerrits2, R. Almomani2, frequent cause of mild-to-moderate hearing loss in Polish I. D’Amato1, R. A. Malik3,4, D. Ziegler5,6, G. J. Bönhof6, patients.ThereisastrongneedtoincludeCNVsanalysisof I. S. J. Merkies2,7, C. G. Faber2, G. Lauria Pinter1,8, STRC gene in the standard HL diagnostic workflow. PROPANE study group B. Harasimowicz: None. D. Ozieblo: None. H. Skar- zynski: None. M. Oldak: None. 1Neuroalgology Unit - Fondazione IRCCS Istituto Neurologico “Carlo Besta, Milano, Italy, 2Clinical 
P02 .16B Genetics and Department of Neurology, Maastricht Genetic analysis of 320 Iranian patients affected by University Medical Center, Maastricht, Netherlands, deafness using Sanger sequencing and Next Generation 3Institute of Human Development, Centre for Sequencing (NGS) methods EndocrinologyandDiabetes,UniversityofManchesterand Central Manchester NHS Foundation Trust, ManchesterAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1223 Academic Health Science Center, Manchester, United A. erjavec skerget, B. zagradisnik, D. krgović, A. golub, Kingdom, 4Department of Medicine, Weill Cornell J. rebol, A. kravos, N. kokalj vokač Medicine,Doha,Qatar, 5InstituteforClinicalDiabetology, German Diabetes Center, Leibniz Center for Diabetes university Medical Centre Maribor, maribor, Slovenia Research, Heinrich Heine University, Düsseldorf, Germany,6Department ofEndocrinology andDiabetology, Introduction: Mutations in the gene encoding protein Medical Faculty, Heinrich Heine University, Düsseldorf, connexin 26 (GJB2) have been shown as a major Germany, 7Department of Neurology, St. Elisabeth contributor to prelingual, sensorineural, nonsyndromic, Hospital,Willemstad,Curaçao,8DepartmentofBiomedical recessive deafness. One specific mutation, 35delG, has and Clinical Sciences "Luigi Sacco", University of Milan, accounted for the majority of the mutations detected in the Milano, Italy GJB2 gene in Caucasian populations. The purpose of our study was to evaluate the characterisation and the Introduction:Neuropathicpainisoneofthemostcommon prevalence of all, GJB2, GJB6 and other known mutations complication of diabetic patients. It is a complex trait among affected individuals from North Eastern Slovenia. influenced by multiple genes and environmental factors. A Materials and Methods: There were 33 individuals debated hypothesis is that many rare variants might diagnosed with hereditary deafness (DF) enrolled in the contribute to the missing heritability unexplained by study. The allele specific PCR, MLPA technique and the common variants. Since frequencies of rare variants are Sanger sequencing was used to screen the GJB2 coding very low, even with high penetrance, it is challenging to region.NGSsequencingwithOto-GeneSGKit®wasusedin detect association. Burden tests collapse the rare variants 10 probands with bilateral, pre-lingual non syndromic DF within the gene as a single genetic variable. This study withanegativemedicalhistoryrelatedtopotentialcausesof proposes a gene-wise burden test to look for genes with an acquired DF. overrepresentation of variations in painful (PDN) versus Results: The overall diagnostic yield of the DF cohort painless (PLDN) diabetic neuropathy patients. was8/33(24.2%).Thehomozygousmutationc.35delGwas Material and Methods: 107 candidate genes were identifiedinfouroutof33patients(12.1%).Byfivepatients sequenced by single molecule Molecular Probes-Next mono-allelic mutation c.35delG was detected (15.15%; 5/ Generation Sequencing (MIP-NGS) in 61 PDN and 125 33). Three among them were compound heterozygotes: PLDNpatients.Totestdifferencesinthemutationalburden c.35delG variant compounded with variants: c.109G>A; between PDN and PLDN, we applied SKAT-O test as WTIVS 1+1: G>A; and c.235delC. NGS detected one implemented in EPACTS on all non-synonymous variants homozygous disease-causing variant c.2464C>T in OTOF with a maximum minor allele frequency of 5%. gene in one patient (10%), which is also heterozygote for Results: Comparing the excess of rare variants in PDN the c.35delG. respecttoPLDN,
P2 RX7andSCN11Ashowedthelowestp- Conclusion: The relative low ratio of individuals homo- values (p=0.01 and p=0.03, respectively) even if they did zygous (12.1%) and heterozygous (15.15%) for the not reach the significant Bonferroni threshold. c.35delG mutation suggest that there are other genes Conclusions:Theburdenapproachprovidedbiologically responsiblefornonsyndromicdeafnessintheNorth-Eastern plausible signals that would have remained indistinguish- Slovenianpopulation.Inoneoutof10testedprobandswith able from random noise with the traditional single-variant NGS this was confirmed. analysis, because of high allelic heterogeneity. Our results A. erjavec skerget: None. B. zagradisnik: None. D. could leave the possibility that a combination of protein- krgović: None. A. golub: None. J. rebol: None. A. kra- altering variants in 
P2 RX7 and SCN11A contribute to the vos: None. N. kokalj vokač: None. risk of PDN. The work has been supported by F
P7  PRO- PANE (602273) and the H2020-MSCA PAIN-Net 
P02 .19A (721841) Grants. Investigating the genetic architecture of fuchs E.Salvi:None.M.Marchi:None.M.Gerrits:None.R. endothelial corneal dystrophy (FECD) in a genetically Almomani: None. I. D’Amato: None. R.A. Malik: None. refined cohort of patients D. Ziegler: None. G.J. Bönhof: None. I.S.J. Merkies: None. C.G. Faber: None. G. Lauria Pinter: None. A. N. Sadan1, N. J. Hafford-Tear1, K. Muthusamy1,2, L. Dudakova3, P. Skalicka3,4, P. Liskova3,4, 
P02 .18D A. J. Hardcastle1, S. J. Tuft1,2, N. Pontikos1, Genetic causes of non-syndromic bilateral deafness in A. E. Davidson1 North-Eastern Slovenia1224 1UCL Institute of Ophthalmology, London, United M. Fjellberg Moldenæs1, N. Dahl Rendtorff2, Kingdom, 2Moorfields Eye Hospital, London, United L. Sandbjerg Hindbæk2, Ø. Nilssen1,3, L. Tranebjærg2,4 Kingdom, 3Department of Ophthalmology, First Faculty of Medicine, Charles University and General University 1Department of Clinical Medicine, University of Tromsø, Hospital in Prague, Prague, Czech Republic, 4Research Tromsø, Norway, 2The Kennedy Centre, Department of Unit for RareDiseases; First Faculty ofMedicine, Charles Clinical Genetics, Copenhagen University hospital, University and General University Hospital in Prague, Copenhagen, Denmark, 3Department of Medical Genetics, Prague, Czech Republic University Hospital of North-Norway, Tromsø, Norway, 4Institute of Clinical Medicine, University of Copenhagen, Introduction:Fuchsendothelialcornealdystrophy(FECD) Copenhagen, Denmark is a degenerative condition affecting up to 4.5% of the population over the age of 50 years. Symptoms conse- Introduction:Waardenburg-andCHARGEsyndromesare quently result in a reduction in vision. An intronic CTG associated with overlapping clinical manifestations such as triplet-repeatexpansion(termedCTG18.1)situatedinTCF4 hearing impairment and malformations of the semicircular has been significantly associated with disease. canals.Thesyndromesareheterogeneous,bothwithrespect Material and methods: DNA samples were obtained to the genes involved and the clinical abnormalities found. from British and Czech FECD patients (n=679). Samples Materials and Methods: Eleven patients from eight were genotyped for CTG18.1 using a short tandem repeat families were shown to have bilateral profound hearing (STR) assay and triplet-primed-PCR. Individuals harbour- impairment with variable additional clinical features. ing bi-allelic non-expanded CTG18.1 alleles (<50 repeats) Completeorpartialagenesisofthesemicircularcanalsgave were analysed by whole exome sequencing (WES) and suspicion of either CHARGE or Waardenburg syndrome. when possible followed up for familial history and deep Results: Genetic testing was carried out which included phenotyping. WES data was interrogated for rare deleter- genes involved in these two syndromes. Here we present ious variants (minor allele frequency [MAF] <0.5% and eight families harboring SOX10 pathogenic variants. The CADD>20) in genes previously associated with corneal patients demonstrated a spectrum of SOX10 mutations of disease and genes with a defined functional role within the which six were novel, six occurred de novo and two were cornea. Samples without an identifiable rare causal variant, found to be dominantly inherited. Both familial cases pre- are currently being analysed by a gene burden analysis sented with novel SOX10 mutations. using an internal WES dataset as the control group. Conclusions: The results presented here add six novel Results: 20% (138/679) of the FECD patients had non- pathogenic variants, one missense and four frameshift var- expanded copies of CTG18.1. Interrogation of WES data iants, to the spectrum of SOX10 mutations and associated identified several candidate disease-associated variants, clinical features involved in Waardenburg syndrome are including CO
L8 A2 and ZEB1 variants in atypical early- described. Grant references: University of Tromsø - The onsetcases.Resultsofthegeneburdenanalysispresenteda Arctic University of Norway. numberofpotentiallynovelgeneswithintherefinedpatient M. Fjellberg Moldenæs: None. N. Dahl Rendtorff: cohort. None. L. Sandbjerg Hindbæk: None. Ø. Nilssen: None. Conclusion: This study reveals the incidence of non L. Tranebjærg: None. CTG18.1-mediatedFECDinourcohortandaimstoprovide insight into the genetic causes of disease within this 
P02 .21C genetically refined patient group. This project is funded by Targeted Next-Generation Sequencing (NGS) gene the National Eye Research Centre and Rosetrees Trust. panel testing in 200 Danish individuals with primary A.N. Sadan: None. N.J. Hafford-Tear: None. K. non-syndromic hearing impairment Muthusamy: None. L. Dudakova: None. P. Skalicka: None. P. Liskova: None. A.J. Hardcastle: None. S.J. N. D. Rendtorff1, H. G. Karstensen1, L. S. Hindbæk1, Tuft: None. N. Pontikos: None. A.E. Davidson: None. L. Tranebjærg1,2 
P02 .20B 1The Kennedy Centre, Copenhagen, Denmark, 2Institute of Clinical manifestations and novel SOX10 pathogenic Clinical Medicine, Copenhagen, Denmark variants in Danish probands with profound hearing impairment and malformations of the semicircular Introduction: Hearing impairment is the most common canals sensory impairment and is genetically heterogeneous. Identification of the causative variants underlying hearing impairment is challenging, since >100 different genes forAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1225 non-syndromic hearing impairment have so far been and one Italian family is homozygous for the c.466G>T, p. reported. (Glu156*) mutation. Materials and Methods: In this study, 200 index Materials and Methods: We report an eight-year-old patients, mostly of Danish origin, with hearing impairment boy of non-consanguineous Danish Caucasian parents with underwent targeted Next-Generation Sequencing (NGS) prelingual bilateral moderate sensorineural non-syndromic using hearing impairment gene panels for Illumina plat- hearing loss. Both parents had adult onset non-syndromic forms. Causative variants were confirmed by Sanger hearing loss and several members of the mother’s family sequencing and segregation analysis was performed when also had early-onset hearing loss. Diagnostic whole-exome relevant samples were available. Prior to NGS sequencing, sequencing was performed using DNA from the index on DFNB1 and SL
C26 A4-related hearing impairment had the NextSeq 500 (Illumina Inc., San Diego, CA) using been excluded by Sanger sequencing in most patients. SureSelect CRE Exome Kit v2 (Agilent Technologies Inc., Result: Of the 200 patients sequenced, we were able to Santa Clara, CA). Data analysis was performed by an in- detectcausativevariantsin73cases(37%).Furthermore,in house pipeline limited to 123 known hearing loss genes an additional 12 cases (6%) only one pathogenic variant using VarSeq version 2.0.2 (Golden Helix Inc., Bozeman, was identified so far. The study emphasizes the genetic MT). The mutation was verified by direct sequencing. heterogeneity of hearing impairment since causative var- Results: NM_016366.2:c.637+1G>T was found in a iantswerefoundin41differentgenes.Intotal,113different homozygous state in the index. No other causative variants likely pathogenic or pathogenic variants were detected. were identified. Forty-four variants (38%) were novel (absent from the Conclusion: To our knowledge, this is the first time the literature). NM_016366.2:c.637+1G>T mutation is identified in a Conclusions: Targeted Next-Generation Sequencing patient of Caucasian descend and the first time CAB
P2 - allowedustodetectcausativevariantsin73oftestedcases. related non-syndromic hearing loss is reported in a patient In this cohort, the diagnostic yield was slightly higher in of Northern European descend. Grants: None cases with presumed autosomal recessive hearing impair- A.T. Højland:B. Research Grant (principalinvestigator, ment and in patients with an early onset of hearing collaborator or consultant and pending grants as well as impairment. Copy number variation detection studies are grants already received); Modest; The Foundation for Pro- ongoing. Regarding the non-solved cases, selected families motion of Medical Science, The Hede Nielsen Family will be analyzed by whole exome sequencing. Foundation. B. Research Grant (principal investigator, col- N.D. Rendtorff: None. H.G. Karstensen: None. L.S. laboratororconsultantandpendinggrantsaswellasgrants Hindbæk: None. L. Tranebjærg: None. already received); Significant; The Obel Family Founda- tion, Jacob Madsen & wife Olga Madsen’s Foundation, 
P02 .22D Doctor Sofus Carl Emil Friis & wife Olga Doris Friis’s First reported Northern European with CAB
P2 -related Foundation, Aase & Ejnar Danielsen’s Foundation, Axel non-syndromic hearing loss Muusfeldt’s Foundation, L. F. Foght’s Foundation, The Augustinus Foundation.H.Okkels:None.M.B. Petersen: A. T. Højland1,2,3, H. Okkels1,4, M. B. Petersen1,3,2 B. Research Grant (principal investigator, collaborator or consultant and pending grants as well as grants already 1Research and Knowledge Center in Sensory Genetics, received);Significant;JacobMadsen&wifeOlgaMadsen’s Aalborg University Hospital, Aalborg, Denmark, Foundation,TheAugustinusFoundation,DoctorSofusCarl 2Department of Clinical Medicine, Aalborg University, Emil Friis & wife Olga Doris Friis’s Foundation, Axel Aalborg, Denmark, 3Department of Clinical Genetics, Muusfeldt’s Foundation, L.F. Foght’s Foundation. Aalborg University Hospital, Aalborg, Denmark, 4Section of Molecular Diagnostics, Department of Clinical 
P02 .23A Biochemistry, Aalborg University Hospital, Aalborg, Presumed, unknown second mutation in GJB2 Denmark monoallelicpatientsisnotaCNVintheDFNB1(GJB2/ GJB6) region, but it must exist Introduction: Autosomal Recessive Deafness 93 is caused by homozygous mutations in the CAB
P2  gene located at D. Safka Brozkova, P. Lassuthova, A. Uhrova 11q13.2. Five families with CAB
P2 -related Autosomal Meszarosova, P. Seeman Recessive Deafness 93 have been reported in PubMed. Four families (three Iranian and one Pakistani) are DNA laboratory, Department of Pediatric Neurology, 2nd homozygous for the NM_016366.2:c.637+1G>T mutation Medical School and University Hospital Motol, Prague, Czech Republic, Prague 5, Czech Republic1226 There is a phenotypic variability observed in patients with Introduction: In almost 40% of patients with autosomal different type and localization of KCNQ4 pathogenic recessivehearingloss,biallelicpathogenicmutations inthe variants. To date, only three frameshift mutations were GJB2 gene are detected. For 6% patients with only one describedintheN-terminalcytoplasmicdomainofKCNQ4 pathogenic GJB2 mutation (monoallelic) the second is in ADHL families with late-onset and pure high unknown. Moreover, there is a significant excess of frequency HL. monoallelic among hearing loss population (6%) compared MaterialsandMethods:DNAwascollectedfromafive- to the normal hearing population (3%). Therefore we generation family with progressive high frequency ADHL. assumethesecondcausalmutation,yetunknown,inpartof High throughput sequencing on proband’s DNA was per- monallelichearinglosspatientswhichexplaintheirhearing formed. In family members (n=15) segregation analysis of loss. Because of the character of GJB2 mutations, we theidentifiedvariantswithHLwasconductedusingSanger expected to find the CNV, most likely one deletion within sequencing. Deep genotype-phenotype correlation analysis the critical region. was performed using cross-sectional linear regression test- Materials and Methods: The CNV analysis was per- ing of pure tone audiometry results. formed with SureSelect custom panel covering continuous Results: Genetic testing revealed a novel, probably chr13:20.735.021-21.102.144. Altogether 33 monoallelic pathogenic c.274G>A (p.Glu92Lys) variant in KCNQ4, patients were examined with use of three biallelic GJB2 which fully segregated with HL in the studied family. patientsascontrols.TheCNVanalysiswasperformedwith Detected variant has not been reported in population data- NextGene sw. bases and was classified as pathogenic. The p.Glu92Lys is Results: The shared 1.6kb large deletion was found in the first missense variant identified in the N-terminal cyto- four monoallelic. Nevertheless, the deletion was not possi- plasmic region of KCNQ4. HL observed in the analyzed ble to confirm with use of another independent method as family was more severe at mid frequencies as compared to SangersequencingorPCR.Eventhehaplotypeanalysisdid the previously published families with truncating variants not reveal any common haplotype in monoallelic. More- located in this domain. over, the NGS of a gene panel of 71 recessive hearing loss Conclusions: Identification of KCNQ4 p.Glu92Lys in a genesdidnotrevealcausalmutationinothergeneingroup ADHL family confirms the association between missense of 15 monoallelic. KCNQ4 pathogenic variants and a high frequency HL with Conclusion: Therefore we believe the second unknown similarannualprogressionatmidandhighfrequencies.The and undiscovered mutation which contribute and cause data suggest that the type of KCNQ4 detected variants hearing loss in the substantial part of GJB2 monoallelic provides a better prognostic factor than their topological patients exist, but is probably not the CNV in the critical localization. DFNB1 region. Supportedby:NCNResearchGrantno.2016/22/E/NZ5/ Supported by: Ministry of Health of the CZ - nr 16- 00470 SONATA BI
S6 . 31921A M. Oldak: None. A. Madejska: None. D. Ozieblo: D. Safka Brozkova: None. P. Lassuthova: None. A. None. M. Leja: None. H. Skarzynski: None. Uhrova Meszarosova: None. P. Seeman: None. 
P02 .25C 
P02 .24B Genetic basis of autosomal dominant hearing loss in First missense variant in N-terminal cytoplasmic region pediatric patients of KCNQ4: analysis of the genotype-phenotype correlation D. Ozieblo1,2, M. Leja1,2, H. Skarzynski3, M. Oldak1 M. Oldak1, A. Madejska1, D. Ozieblo1,2, M. Leja1,2, 1Department of Genetics, Institute of Physiology and H. Skarzynski3 Pathology of Hearing, Warsaw/Kajetany, Poland, 2Postgraduate School of Molecular Medicine, Medical 1Department of Genetics, Institute of Physiology and University of Warsaw, Warsaw, Poland, 3Oto-Rhino- Pathology of Hearing, Warsaw, Poland, 2Postgraduate Laryngology Surgery Clinic, Institute of Physiology and School of Molecular Medicine, Medical University of Pathology of Hearing, Warsaw/Kajetany, Poland Warsaw, Warsaw, Poland, 3Institute of Physiology and Pathology of Hearing, Warsaw, Poland Introduction:AutosomalDominantHearingLoss(ADHL) is the second most common form of inherited hearing loss Introduction: Pathogenic variants in KCNQ4 are a well- with an onset after the second decade of life. Current known cause of autosomal dominant hearing loss (ADHL). knowledge on the genetic aspects of ADHL in PolishAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1227 patientsislimited,whichsignificantlyaffectsthediagnosis, MaterialsandMethods:Multigenerationalfamilieswith genetic counselling and prevents prediction of disease ADHL were recruited in the study (n=19). Genomic DNA progression. was isolated from whole blood and buccal swabs samples. Materials and Methods: Thirteen families with ADHL In probands’ DNA samples a multigene high throughput diagnosedbefore18yearsofagewereenrolledinthestudy. sequencing was performed. Family segregation analysis of DNA was isolated from peripheral blood or oral cavity the identified variants was conducted using Sanger swab samples from probands and family members. High- sequencing. All detected variants were analyzed in the throughput genetic analysis using the TruSight One panel context of population databases and literature. Pathogeni- (IlluminaInc.)andtheMiSeqsequencerwascarriedoutfor city of identified variants was predicted by different com- the probands. To confirm the presence of identified genetic putational approaches. variants and their segregation with ADHL in individual Results: Genetic testing revealed probably pathogenic families Sanger’s sequencing was performed. variants in almost 63% (12/19) of the analyzed families. Results: Genetic cause of ADHL was identified in The majority of identified variants were novel, previously approximately 60% (8/13) of the families. The identified not reported and hitherto not linked to the disease (7/12). variants were located in ACTG1, COCH, DIAPH1, EYA4, Novel variants were missense changes and all of them KCNQ4, PTPRQ, TB
C1 D24 and TM
C1 . Among the iden- (except for two genetic changes located in MYO6) were tified variants approximately 60% (6/8) were novel. In the found in different genes. remaining families the selected variants did not segregate Conclusions: Our study revealed a high involvement of with ADHL. novel probably pathogenic variants in the development of Conclusions:Ourresultsshowhighgeneticheterogeneity ADHL andconfirmed a high heterogeneity of the identified of ADHL in Polish pediatric patients. Considering frequent geneticchanges.HighthroughputsequencinginHLpatients identification of new genetic variants, it is necessary to generates large amount of data that should be interpreted perform thorough clinical examination and segregation carefully and confirmed by family studies. There is also a analysis of the selected variants with ADHL in the largest needforfunctionalvalidationofthedetectednovelvariants. possible number of family members. In patients with no Supportedby:NCNResearchGrantno.2016/22/E/NZ5/ genetic cause identified, the study area should be extended 00470 SONATA BI
S6 . and include all protein coding regions or whole genome. D.Ozieblo:None.M.L.Leja:None.A.Sarosiak:None. Supported by: NCN SonataBI
S6  grant no. 2016/22/E/ H. Skarzynski: None. M. Oldak: None. NZ5/00470 D. Ozieblo: None. M. Leja: None. H. Skarzynski: 
P02 .28B None. M. Oldak: None. CochlearimplantationoutcomeinpatientswithDFNB1 locus pathogenic variants - implications for precision 
P02 .27A medicine Novelvariantsinknowngenes-resultsofgenetictesting in families with autosomal dominant hearing loss D. Ozieblo1,2, A. Obrycka3, A. Lorens3, H. Skarzynski4, M. Oldak1 D.Ozieblo1,2,M.L.Leja1,2,A.Sarosiak1,2,H.Skarzynski3, M. Oldak1 1Department of Genetics, Institute of Physiology and Pathology of Hearing, Warsaw, Poland, 2Postgraduate 1Department of Genetics, Institute of Physiology and School of Molecular Medicine, Medical University of Pathology of Hearing, Warsaw, Poland, 2Postgraduate Warsaw, Warsaw, Poland, 3Department of Implants and School of Molecular Medicine, Medical University of Auditory Perception, Institute ofPhysiology and Pathology Warsaw, Warsaw, Poland, 3Oto-Rhino-Laryngology of Hearing, Warsaw, Poland, 4Oto-Rhino-Laryngology Surgery Clinic, Institute of Physiology and Pathology of Surgery Clinic, Institute of Physiology and Pathology of Hearing, Warsaw/Kajetany, Poland Hearing, Warsaw, Poland Introduction: Hearing loss (HL) is the most common Introduction: Almost 80% of children with profound disability of human senses and genetic factors play an prelingual hearing loss (HL) have a genetic cause of importantroleinitsdevelopment.AutosomaldominantHL deafness; most often two GJB2/GJB6 (DFNB1 locus) (ADHL)isusuallycharacterizedbypostlingualageofonset recessive pathogenic variants. Cochlear implantation (CI) and progression. To date 63 loci with 45 different genes is a treatment of choice in profound HL patients but only were causally involved in the pathogenesis of ADHL. few studies combine the etiology of HL with CI outcome.1228 Materials and Methods: Patients with profound pre- Introduction: High myopia (HM) is an eye disorder lingual HL who received CI before the age of 2 years and characterized by refractive error (RE) greater than -6.0 had a completed DFNB1 genetic testing were enrolled in diopters (D) with both environmental and genetic factors the study (n=159). LittlEARS questionnaire and relative involved. Although a number of loci, candidate genes, and auditory development delay (RADD) at 6th month after CI sequence variants have been identified in HM, the general activation were used to assess auditory development. genetic factor explaining the causes of HM has not been Results: Statistically significant differences were specified. The aim of this study was to unravel the role of observed in RADD between patients implanted early epigenetic changes in HM which could explain the relation (before 12 months of age) vs. late (after 12 months of age) between HM and environmental factors. and between patients with a short (≤6 months) vs. long (≥ Materials and Methods: In order to verify if the dysre- 6 months) hearing aids (HAs) experience. Interestingly, in gulated methylation of genes could contribute to the HM the most genetically homogenous patient group with two development, using a genome-wide DNA methylation GJB2 c.35delG pathogenic variants there was no statisti- array, we studied 18 Polish cases (aged 4-12 years, RE cally significant difference in RADD between patients between -6.0 and -15.0 D) and 18 matched controls. CpGs implanted early and late and between patients with a short withthehighestfoldchangeorthehighestdifferenceinthe and long HAs experience. methylation level between cases and controls were ana- Conclusions: In children with homozygous GJB2 lyzed. Pathway overrepresentation analyses among hyper- c.35delGpathogenicvariants,applicationofCIbefore12or methylatedgeneswereperformedusingConsensusPathDB. 24 months ofage brings similar outcome.Childrenwithan Results: In total, 1,541 CpGs, representing 1,745 genes, unknown genetic cause of HL should be implanted before were hypermethylated (≥2.0-fold change, FDR p≤0.05, 12 months of age to achieve better results in auditory ROC-AUC ≥0.75) in HM subjects compared to controls. development. Further studies in the non-DFNB1 group are The most hypermethylated CpGs with more than 20% dif- planned to determine the link between genetic background ferenceinthemethylationlevelbetween casesandcontrols of HL and the CI outcome. were located in TIMM50, RAB3C, MICA
L3 , RWDD4A, Supported by: NCN Grant 2017/27/N/NZ5/02369 XRC
C2 , and FAR
P2 . Enrichment analysis of hypermethy- D.Ozieblo:None.A.Obrycka:None.A.Lorens:None. lated myopia-related genes set (>5 genes shared, p≤0.01) H. Skarzynski: None. M. Oldak: None. revealed overrepresentation of genes from several path- ways, including signal transduction, transcription, and sig- 
P02 .31A naling pathways as receptor tyrosine kinases, JAK-STAT, HypermethylatedgenesandpathwaysinPolishchildren TGF-beta, EGF-EGFR. with high myopia Conclusions: Methylation of genes and disruption of identified pathways could contribute to HM phenotype. M. Gajecka1,2, S. Vishweswaraiah3, J. A. Karolak2,1, M. Gajecka: None. S. Vishweswaraiah: None. J.A. M. Mrugacz4, U. Ratnamala5, N. K. Mishra6, C. Guda6, Karolak: None. M. Mrugacz: None. U. Ratnamala: S. S. Chettiar7, K. R. Johar7, U. Radhakrishna3, None.N.K.Mishra:None.C.Guda:None.S.S.Chettiar: J. Swierkowska1 None. K.R. Johar: None. U. Radhakrishna: None. J. Swierkowska: None. 1Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland, 2Department of Genetics and 
P02 .32B Pharmaceutical Microbiology, Poznan University of Diagnostic yield of whole exome sequencing-based Medical Sciences, Poznan, Poland, 3Department of genetic testing for patients with inherited eye diseases Obstetrics and Gynecology, Oakland University William Beaumont School of Medicine, Royal Oak, MI, United K. Wells, K. Kämpjärvi, E. Mårtensson, M. Mehine, States, 4Department of Ophthalmology and Eye J. Känsäkoski, L. Sarantaus, H. Västinsalo, J. Schleit, Rehabilitation, Medical University of Bialystok, Bialystok, I. Saarinen, M. Muona, S. Myllykangas, T. Alastalo, Poland, 5Department of Pharmacology, Creighton J. W. Koskenvuo, S. Tuupanen University, Omaha, NE, United States, 6Department of Genetics, Cell Biology & Anatomy College of Medicine, Blueprint Genetics, Helsinki, Finland University of Nebraska Medical Center, Omaha, NE, UnitedStates,7DepartmentofZoology,SchoolofSciences, Genetictestingisessentialinthediagnosisandmanagement Gujarat University, Ahmedabad, India ofinheritedeyediseases(IEDs).However,IEDdiagnostics can be compromised by poorly validated and curated tests. We aimed to develop and validate a high quality wholeAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1229 exome sequencing (WES) based platform and to assess 
P02 .33C diagnostic yield in a large IED cohort. Performance of the New insights into the phenotypic spectrum of PROM1- WES assay with bespoke clinical content, was tested associated retinopathy through next generation sequencing (NGS) of reference samples using the Illumina NovaSeq platform. The assay M. del Pozo-Valero1, I. Martín-Mérida1,2, B. Jiménez- was designed to cover clinically-relevant intronic and Rolando3, A. Arteche1, A. Ávila-Fernández1,2, F. Blanco- difficult-to-sequence regions, and detect copy number Kelly1, R. Riveiro-Álvarez1, C. Van Cauwenbergh4, E. De variants (CNVs). Based on this assay, 23 ophthalmology Baere4, C. Rivolta5, B. García-Sandoval3, M. Cortón1,2, gene panels were curated. The assay showed high average C. Ayuso1,2 sequencing depth (183x) and coverage (99.7% regions covered >20x), and uniform coverage over difficult-to- 1Department of Genetics, Instituto de Investigación sequence regions, including RPGR ORF15. Detection Sanitaria–Fundación Jiménez Díaz University Hospital sensitivity was high for SNVs (0.998), INDELs (0.97), 1- (IIS-FJD-UAM), Madrid, Spain, 2Center for Biomedical exon CNVs (0.93) and 5-exon CNVs (0.99). The Usher Network Research on Rare Diseases (CIBERER), ISCIII, Syndrome Panel gave the highest diagnostic yield (>80%). Madrid,Spain,3DepartmentofOphthalmology,Institutode The most frequently ordered 266-gene Retinal Dystrophy Investigación Sanitaria–Fundación Jiménez Díaz Panel yielded a diagnosis in 58% (of 1587) cases. University Hospital (IIS-FJD-UAM), Madrid, Spain, Diagnoses were made in a total of 111 genes, the most 4Center for Medical Genetics Ghent, Ghent University and common genes being ABCA4, USH2A, RPGR, RHO and GhentUniversityHospital,Ghent,Belgium,5Departmentof PRPH2, as well as in newly implicated IEDs genes, and in Computational Biology, Unit of Medical Genetics, custom targeted deep intronic regions. Approximately 3% University of Lausanne, Laussane, Switzerland of patients had a diagnostic CNV. A WES assay with boosted clinical content provides high diagnostic yields for Purpose:Inheritedretinaldystrophy(IRD)referstoagroup IED patients. The genetic variability of diagnoses in our of progressive and degenerative diseases that affect the cohort supports the use of comprehensive NGS panels in photoreceptor cells and lead to visual impairment. One of IED diagnostics, to optimize diagnostic yield and the genes associated with IRD is PROM1. Disease-causing clinical care. PROM1 variants have been associated with different K.Wells:A.Employment(fullorpart-time);Significant; phenotypes. The aim was to provide a detailed analysis of Blueprintgenetics.K.Kämpjärvi:A.Employment(fullor the genetic and phenotypic characteristics of the PROM1- part-time); Significant; Blueprint genetics. E. Mårtensson: associated retinopathy in a large cohort of patients. A. Employment (full or part-time); Significant; Blueprint Methods: PROM1 screening was performed using clas- genetics. M. Mehine: A. Employment (full or part-time); sicalmoleculartechniquesand/ortargetedNext-Generation- Significant; Blueprint genetics. J. Känsäkoski: A. Sequencinginacohortof2216IRDfamilies.Copynumber Employment (full or part-time); Significant; Blueprint variation analysis was carried out in unsolved monoallelic genetics.L.Sarantaus:A.Employment(fullorpart-time); cases. Detailed ophthalmic evaluation was performed in 25 Significant; Blueprint genetics. H. Västinsalo: A. patients. Employment (full or part-time); Significant; Blueprint Results: Thirty-two families presented PROM1 variants, genetics. J. Schleit: A. Employment (full or part-time); including likely pathogenic and unknown significance var- Significant; Blueprint genetics. I. Saarinen: A. Employ- iants, 10 of which are novel. Causative variants were ment (full or part-time); Significant; Blueprint genetics. M. identified in 21 families segregating in autosomal recessive Muona: A. Employment (full or part-time); Significant; (17)ordominant(4)pattern,3ofthemwithfoundereffect. Blueprint genetics. S. Myllykangas: E. Ownership Interest Phenotypic analysis in 25 patients carrying disease-causing (stock, stock options, patent or other intellectual property); PROM1 variants revealed clinical heterogeneity regardless Significant; Blueprint genetics. T. Alastalo: E. Ownership of genotype. Most of the patients suffered from cone-rod Interest (stock, stock options, patent or other intellectual dystrophy and some patients presented with macular dys- property); Significant; Blueprint genetics. J.W. Kosken- trophy or retinitis pigmentosa, all presenting macular vuo: E. Ownership Interest (stock, stock options, patent or damage. other intellectual property); Significant; Blueprint genetics. Conclusions: Our study reports the largest and compre- S. Tuupanen: A. Employment (full or part-time); Sig- hensive description of genetic and clinical findings in nificant; Blueprint genetics. PROM1-retinopathy. The prevalence of PROM1 variants that seems to reliably explain the IRD phenotype in our cohort is about 1%. This study also highlights the great heterogeneity of PROM1-associated phenotypes.1230 Regardless of the initial diagnosis of primary cone or rod Grants: This study was supported by Fundació Privada loss, all patients developed a common macular involve- Cellex(Fi-201501)andFundaciódeRecercadel’Institutde ment, a characteristic phenotypic finding of PROM1. Microcirurgia Ocular (Fi-201401). M.delPozo-Valero:None.I.Martín-Mérida:None.B. V. Abad-Morales: None. S. Ruiz-Nogales: None. R. Jiménez-Rolando: None. A. Arteche: None. A. Ávila- Navarro: None. P. Méndez: None. M. Riera: None. A. Fernández: None. F. Blanco-Kelly: None. R. Riveiro- Burés-Jelstrup: None. B. Corcóstegui: None. E. Álvarez: None. C. Van Cauwenbergh: None. E. De Pomares: None. Baere: None. C. Rivolta: None. B. García-Sandoval: None. M. Cortón: None. C. Ayuso: None. 
P02 .36B Next generation sequencing in patients with bilateral 
P02 .35A optic atrophy: Leber hereditary optic neuropathy and Contribution of DRAM2 gene in inherited retinal beyond dystrophies with early macular involvement M. Volk1, A. Maver1, A. Fakin2, N. Teran1, M. Jarc V. Abad-Morales1,2, S. Ruiz-Nogales1,2, R. Navarro1,3, Vidmar2, S. Petrović2, M. Hawlina2, B. Peterlin1 P. Méndez1,2, M. Riera1,2, A. Burés-Jelstrup1,3, B. Corcóstegui1,3, E. Pomares1,2 1Clinical institute of medical genetics, UMC Ljubljana, Ljubljana, Slovenia, 2Eye hospital, UMC Ljubljana, 1Fundació de Recerca de l’Institut de Microcirurgia Ljubljana, Slovenia Ocular,Barcelona,Spain,2DepartmentofGenetics,Institut de Microcirurgia Ocular (IMO), Barcelona, Spain, Leber hereditary optic neuropathy (LHON) is caused by 3Department of Retina, Institut de Microcirurgia Ocular missense mutations in the mitochondrial genes (mtDNA) (IMO), Barcelona, Spain encoding complex I subunits of the respiratory chain. However, mutations affecting genes in the nuclear genome Introduction: Macular Dystrophies (MD) are a group of maystrikinglyresembletheclinicalpresentationofLHON. Inherited Retinal Dystrophies (IRD) characterized by the We conducted a study to define best testing strategy using degeneration of the central retina or macula, principally next generation sequencing in bilateral optic atrophy and formed by cone photoreceptors. Although there are more inconclusivefamilyhistory.Herewereporton30unrelated than55MDgenes,aconsiderablepercentageofthesecases individuals referred to our institution for genetic testing remain unsolved. because of the optic nerve atrophy and clinically suspected Methods: Whole exome sequencing of a cohort of IRD LHON. None of the patients had lesions suggestive for families was performed, analyzing a panel of 300 IRD multiplesclerosisonbrain MRI. Genetic analysis consisted genes in order to determine the genetic pathogenic cause. of mtDNA sequencing followed by clinical exome sequen- Forsomenewmutations,functionalanalyzeswereruledout cing. In two unrelated patients mtDNA sequencing from patients blood samples. identified typical LHON pathogenic variants Results:ThreenewDRAM2homozygousmutationswere (m.11778G>A, m.3700G>A). Exome sequencing in three identified in three independent families: one frameshift and unrelated patients revealed OPA1 mutation (c.2489G>A, two splicing variants. All patients shared a singular phe- likely pathogenic variant), compound heterozygous muta- notype, with an early macular involvement followed by a tions in ACO2 (c.2253dupC, VUS and c.719G>C, patho- peripheral degeneration. However, the age of onset and the genic variant) and a de novo mutation in WF
S1  evolutionofthepathologyweredifferentineachcase.Ata (c.2480C>T, likely pathogenic variant). Upon genetically molecular level, functional studies revealed alterations in guided clinical review,thelast patient was found toexhibit gene expression differing between patients. signs on macular OCT, typical for Wolfram syndrome. We Conclusions: DRAM2 was firstly associated to IRD in found possible causative variants in 5 of 30 patients with 2015, and only scanty cases and 10 different pathogenic bilateral optic atrophy and clinically suspected LHON. In mutations have been reported to date. Thus, its function in addition to typical LHON mitochondrial variants we found the retina and the associated phenotypes are still much causative variants associated with autosomal dominant, unknown. In this context, the results obtained significantly autosomal recessive and syndromic forms of optic neuro- contribute to the comprehension of the role of this gene in pathy and reclassified clinical diagnoses. Our results themolecularbasesofIRD,increasingthenumberandtype provide evidence that a combined approach with mtDNA of reported pathogenic variants and their functional effects, and clinical exome sequencing is recommended in cases of and strengthening the DRAM2 genotype-phenotype corre- clinically suspected LHON and negative family history. lations in the retina.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1231 M. Volk: None. A. Maver: None. A. Fakin: None. N. K. Kamenarova: None. S. Cherninkova: None. K. Teran:None. M.JarcVidmar: None. S. Petrović:None. Mihova: None. F. Shakola: None. V. Mitev: None. I. M. Hawlina: None. B. Peterlin: None. Tournev: None. R. Kaneva: None. 
P02 .37C 
P02 .38D Targeted next generation sequencing reveals Burden of missense variants in hearing loss genes in homozygous PD
E6 C mutation in a pedigree with sporadic Meniere disease macular aplasia A. Gallego-Martinez1, T. Requena1, P. Román-Naranjo1, K. Kamenarova1, S. Cherninkova2, K. Mihova1, J. Lopez-Escamez1,2 F. Shakola1, V. Mitev1, I. Tournev2, R. Kaneva1 1Centro Pfizer-Universidad de Granada-Junta de 1Molecular Medicine Centre, Medical University – Sofia, Andalucía de Genómica e Investigación Oncológica Sofia, Bulgaria, 2Department of Neurology, University (GENYO), Granada, Spain, 2Department of Hospital Alexandrovska, Medical University – Sofia, Sofia, Otolaryngology,InstitutodeInvestigaciónBiosanitariaIbs. Bulgaria GRANADA, Hospital Universitario Virgen de las Nieves, Granada, Spain Introduction: Macular, or foveal aplasia refers to the lack of foveal depression with continuity of all neurosensory Introduction: Meniere disease (MD) is a rare inner ear layers in the presumed location of the fovea. It has been disorder defined by episodes of vertigo, sensorineural reported in cases of aniridia, albinism, microphthalmia and hearing loss (SNHL) and tinnitus. MD has been described achromatopsia. Inherited retinal dystrophies (IRD), among mostly in sporadic cases, being familial cases around 10% whichmacular aplasia(MA), constituteagroupofdiseases of total observed cases. Between 20-45% of the cases have characterizedbyclinicalvariabilityandpronouncedgenetic bilateralhearingloss.Theaimofthisstudyistoinvestigate heterogeneity.ByusingIRD-panelnext-generationsequen- the burden of rare variants in SNHL genes in sporadic cing,weaimedtoidentifythedisease-causingmutationina cases of MD. large Bulgarian pedigree with MA inherited in autosomal- Methods: We designed a targeted-sequencing panel recessive pattern. including SNHL genes in supporting cells and sequenced Materials and Methods: A large pedigree with MA, 890 Spanish MD patients. The frequency of rare variants mostlikelyachromatopsia,accompaniedbynystagmusand (with a MAF inferior to 0.1) in the gene panel was com- decreased visual acuity presented from birth was recruited pared with three independent datasets as controls for the and DNA from the proband was sequenced using the Illu- gene burden analysis. Interaction model between rare and ® mina platformandTruSightOnesequencingpanel.Protein common variants is proposed for most relevant genes in coding and splice-site variants were filtered in a panel with MD cases. 341 genes related to retinal dystrophies. Results: Patients with sporadic MD showed a significant Results: Genetic analysis identified a homozygous mis- enrichment of missense variants in SNHL genes that was sense variant c.2141T>A (p.Ile714Asn) in a conserved not found in the controls. The list of genes includes GJB2, aminoacidwithinthegeneencodingthecatalyticsubunitof USH1G, SL
C26 A4, ESRRB and CLDN14. A rare synon- the cone photoreceptor phosphodiesterase, PD
E6 C. The ymous variant with unknown significance was found inthe commonly used prediction tools classified the PD
E6 C- MARVELD2 gene in several unrelated patients with MD. c.2141T>A variant to be putatively damaging/deleterious. Conclusions:Thereisaburdenofrarevariationincertain ThereisonlyonePD
E6 C-c.2141AallelefoundintheNon- SNHL genes in sporadic MD. Furthermore, the interaction Finnish European population suggesting an extremely low ofcommonandrarevariantsinSNHLgenesmayhaveand frequencyforthischange. Segregation studyisinprogress. additive effect on MD phenotype. Conclusions: We have identified a family affected by Funding: FPS-PI0496-2014, Spain; EF-0247-2017 grant autosomal-recessive dystrophy of the central photoreceptor from Consejeria de Salud, Spain; Luxembourg National system and found homozygous possibly pathogenic variant Research Fund (INTER/Mobility 17/11772209), Lux- in PD
E6 C, mutations in which have been previously embourg, and 2016-MeniereSociety Grant, UK. reported in patients with autosomal-recessive inherited A. Gallego-Martinez: None. T. Requena: None. P. achromatopsia and early-onset cone photoreceptor dys- Román-Naranjo: None. J. Lopez-Escamez: None. function. Grant references: DUNK01/2/2009 and Grant-D- 109/03.05.20018.1232 
P02 .39A E. Tavares1, C. Tang1, A. Paterson1, S. Li1, M. Liang1, Burden of rare variants in OTOF gene in familial M. Wilson1, E. Campos1, A. Vincent1,2, E. Héon1,2 Meniere disease 1TheHospitalforSickChildrenResearchInstitute,Toronto, P.Roman-Naranjo1,C.A.Jimenez-Ruiz1,M.C.Moleon2, ON, Canada, 2Department of Ophthalmology and Vision A. Gallego-Martinez1, J. A. Lopez-Escamez1,2 Sciences, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada 1CentreforGenomicsandOncologicalResearch(GENYO), Granada, Spain, 2Department of Otolaryngology, Instituto Introduction:NorthCarolinaMacularDystrophy(NCMD) de Investigación Biosanitaria ibs.GRANADA, Hospital is a high penetrance autosomal dominant inherited disease. Universitario Virgen de las Nieves, Granada, Spain Thenon-codingSNPsinthelinkageregiononchromosome 6 fall within a DNase I hypersensitive site upstream of Introduction: Meniere disease (MD) is a rare inner ear PRDM13 and which regulates PRDM13 expression during disordercharacterizedbyvertigo,sensorineuralhearingloss development.Thisstudyaimedtounderstandthemolecular (SNHL) and tinnitus. Familial aggregation isfound in 10% basis of NCMD through differential expression analysis. of MD cases with autosomal dominant inheritance and Methods:PSSMscanningwasusedtopredictchangesin several genes already described, such as DTNA, FAM136A bindingofknowntranscriptionfactorsinretinaforthenon- andSEMA3Dgenes.Thus,thegoalofthisstudyistodefine coding variants on chromosome 6. RNA-seq from skin- new candidate genes for familial MD (FMD). derived RNA for three sibling pairs (affected/unaffected Materials & Methods: We recruited 62 FMD cases to each) within a family was done for differential gene perform whole-exome sequencing. Variant calling was expression analysis. performed with GATK. Candidate genes were prioritized Results: These variants introduce a gain of binding sites based on pathogenicity using PhenIX. Single rare variant for two important retinal transcription factors (PAX6 and analysis (SRVA) focused on SNHL genes was performed OTX2)upstreamofPRDM13.Thiscanpotentiallyalterthe using MAF<0.001. Likewise, a gene burden analysis PRDM13regulationinretinaltissue.RNA-seqrevealed~50 (GBA) with MAF<0.05 was performed to analyze the differently expressed genes between the affected and unaf- interaction of common and rare variants. We studied the fected. Although we did not find a direct association of relationship between rare and common variants which these genes to the known genes involved in macular dys- modulate gene expression. trophies, GO enrichment analysis showed ~30 statistically Results:Forty-percentofFMDcasescarriedonenovelor significant processes with lipid metabolism being most ultrarare likely pathogenic (CADD>15) variant in SNHL significant and it was previously linked to age-related genes. Ninety-four rare variants were selected from SRVA. macular dystrophy. A total of 222 rare variants were retrieved with GBA Conclusions: The introduction of PAX6 and OTX2 resulting in a high enrichment of variants in OTOF gene binding sites upstream of PRDM13 can potentially cause (correctedp-value:3x10-4).Fourrarevariantsinourcohort PRDM13 overexpression and may interfere with lipid showed a significant association with three common var- metabolism and oxidative stress by increasing the amount iants regulating the expression of OTOF gene. of lipids in the retina. Conclusions:ThereisaburdenofrarevariantsinSNHL Funding: Mira Godard, FFB, McLaughlin Centre. genes. Particularly, the interaction of rare and common E. Tavares: None. C. Tang: None. A. Paterson: None. variantsinOTOFgenemayplayanimportantroleinFMD. S. Li: None. M. Liang: None. M. Wilson: None. E. Funding: Supported by the Luxembourg National Campos: None. A. Vincent: None. E. Héon: None. Research Fund INTER/Mobility/17/11772209 and EF- 0247-2017 from Andalusian Health Government to JALE. 
P02 .43A P. Roman-Naranjo: None. C.A. Jimenez-Ruiz: None. The most common forms of non-GJB2-related M.C. Moleon: None. A. Gallego-Martinez: None. J.A. nonsyndromic (NSHL) and disguised syndromic (SHL) Lopez-Escamez: None. hearing impartment in Russian patients 
P02 .41C O. L. Mironovich1, E. A. Bliznetz1, T. G. Markova2, Differential expression analysis suggests lipid M. R. Latayants2, T. V. Markova1, L. A. Bessonova1, metabolism plays a role in North Carolina Macular M. S. Petukhova1, O. N. Makienko1, D. M. Guseva1, Dystrophy I. V. Anisimova1, O. P. Ryzhkova1, A. V. Polyakov1Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1233 1Federal State Budgetary Institution «Research Centre for 1Research Centre for Medical Genetics, Moscow, Russian Medical Genetics», Moscow, Russian Federation, 2Federal Federation, 2Far Eastern Federal University, Vladivostok, State Budgetary Institution «National Research Center for Russian Federation, 3S. Fyodorov Eye Microsurgery Audiology and Hearing Rehabilitation», Moscow, Russian Federal State Institution, Moscow, Russian Federation, Federation 4Pirogov Russian National Research Medical University, Moscow, Russian Federation, 5Moscow Regional Research Introduction: Hearing loss is a common disorder, and and Clinical Institute, Moscow, Russian Federation according to the audiological screening in Russia, con- genital hearing impairment affects nearly 3 in every 1000 Objectives: Hereditary ophthalmic pathology is a geneti- livebirths.ApartfromtheGJB2gene,morethan100genes callyheterogeneousgroupofdiseasesthatoccureitherasan responsible for NSHL and more than 400 genes associated isolated eye disorder or as a symptom of hereditary with SHL are known. Currently, massive parallel sequen- syndromes (chromosomal and monogenic). That is why cing(MPS)istheoptimaldiagnosticmethodfornon-GJB2- diagnostic search in some cases of ophthalmic pathology related forms of hearing impairment. could be time- and cost-consuming. The most challenging Materials and Methods: DNA samples of 205 Russian situation could arise when prenatal diagnosis is needed patients with NSHL (without mutations in GJB2 gene) and during ongoing pregnancy. 10 patients with the incoming diagnosis of Pendred, Bran- Materials and Methods: A family is referred to the chiootorenal, Usher and Alstrom syndromes were tested by RCMGforaffectedchildbirthriskprognosisat7-8weekof using custom targeted MPS panel which includes 33 genes gestationbecause theprevious child,six-years-old boy,has of NSHL and SHL. 25 DNA samples were searched for congenital aniridia, glaucoma, retinal detachment, severe abnormal copy numbers with MLPA. psychomotor delay, lack of speech, several ophthalmic Results:Among205patientswithNSHL,pathogenicand surgeries. The affected child had been previously tested for probably pathogenic variants have been identified in 41 PAX6 mutations and 11p13 copy number variation which cases (20%) in following genes: STRC (10), USH2A (6), revealed no changes. SL
C26 A4(4),MYO7A(4),OTOF(4),POU3F4(2),TECTA Results: Considering ongoing pregnancy, lack of patho- (2), TMPRS
S3  (2), PTPRQ (1), ADGRV1 (1), TM
C1  (1), genic changes and precise diagnosis in an affected boy, LOXHD1 (1), ACTG1 (1), MYO15A (1), OTOA (1). Diag- NGSsequencingofclinicallyrelevantgeneswasperformed nostic efficiency in patients with SHL was 80% (8/10). In which revealed a novel hemizygous substitution patients with NSHL, syndromic forms have been identified NM_000266.3(NDP_v001):c.385G>T, p.(Glu129*), in in 9% of total cases (18/205). The majority of causative NDPgeneassociatedwithNorriedisease(OMIM#310600). mutations in STRC and OTOA were large CNVs (80% and Subsequent Sanger validation of the affected boy and his 50%). Mutations c.11864G>A, c.2171_2174delTTTG, mother confirmed identified substitution inherited in X- c.107A>C in USH2A, STRC, SL
C26 A4 genes are assumed linked recessive mode. Amniotic fluid testing revealed the to be frequent in Russian patients. fetus is hemizygous for the variant. Complications were Conclusions:Theproportionofdetectedgeneticformsof developed during subsequent interruption of pregnancy hearing loss in Russia is about 12% of all non-syndromic driven by medical necessity. hearing loss. Conclusions: Clinical polymorphism of hereditary oph- O.L. Mironovich: None. E.A. Bliznetz: None. T.G. thalmic pathology could severely complicate the establish- Markova: None. M.R. Latayants: None. T.V. Markova: ment of exact diagnosis and make it time- and cost- None. L.A. Bessonova: None. M.S. Petukhova: None. O. consuming. NGS appears to be the method-of-choice in N. Makienko: None. D.M. Guseva: None. I.V. Anisi- complicated cases which could substantially hasten the mova: None. O.P. Ryzhkova: None. A.V. establishment of diagnosis and genetic risk estimation. Polyakov: None. Supported by RFBR grant № 19-015-00122. A.V. Marakhonov: None. S.A. Repina: None. I.A. 
P02 .44B Akimova:None.M.V.Shurygina:None.T.A.Vasilyeva: Prenatal diagnosis of Norrie disease after exome None. S.I. Kutsev: None. V.V. Kadyshev: None. R.A. sequencing of affected proband during ongoing Zinchenko: None. pregnancy 
P02 .45C A. V. Marakhonov1,2, S. A. Repina1, I. A. Akimova1, Screening TYR gene variations in Turkish M. V. Shurygina3, T. A. Vasilyeva1, S. I. Kutsev1,4, oculocutaneuse albinism patients V. V. Kadyshev1, R. A. Zinchenko1,51234 O. HATIRNAZ NG1, E. Yılmaz1, Z. Parlakgüneş2, p. Tyr149Ser K. Yararbaş3, S. Ziylan2, Y. Alanay3, U. Ozbek3 TYR NM_000372.4 p. frameshift 0,0263 CM90077 c.919_925delTCCAGAA Leu140fs* TYR NM_000372.4c.616G>A p. missense 0,0263 rs28940880 1Acibadem Mehmet Ali Aydınlar University, School of Ala206Thr TYR NM_000372.4c.140G>A p. missense 0,0263 rs61753180 Medicine, Department of Medical Biology, ISTANBUL, Gly47asp Turkey, 2YeditepeUniversity, Medical Faculty, Department TYR NM_000372.4c.61C>T p.Pro21Ser missense 0,0263 rs61753178 TYR NM_000372.4c.661G>T p.Glu221* stopgain 0,0263 novel of Eye Diseases, ISTANBUL, Turkey, 3Acibadem Mehmet TYR NM_000372.4c.1058G>A p. missense 0,0132 rs1415792453 AliAydınlarUniversity,SchoolofMedicine,Departmentof Gly353Glu TYR NM_000372.4c.225T>A p.Tyr85* stopgain 0,0132 rs746208814 Medical Genetics, ISTANBUL, Turkey TYR NM_000372.4c.139G>T p. missense 0,0132 rs796051878 Gly47Cys TYR NM_000372.4c.1430G>A p.Trp477* stopgain 0,0132 rs748052034 Introduction: Oculocutaneous albinism (OCA) is charac- TYR NM_000372.4c.763C>T p.Gln255* stopgain 0,0132 CM91283 terised by a generalized reduction in pigmentation of hair, TYR NM_000372.4c.715C>T p. missense 0,0132 rs774670098 Arg239Trp skin and eyes and variable ocular findings including TYR NM_000372.4c.1193A>G p.Glu398G missense 0,0132 CM41866 nystagmus, reduced visual acuity and photophobia. The TYR NM_000372.4c.1255_1256insTTG insertion 0,0132 novel most common mutated gene in OCA is TYROSINASE TYR NM_000372.4c.1036- splicesite 0,0132 novel 9_1041delTAATGAACAGGATTT (TYR). Currently, no data available on the frequency or TYR NM_000372.4c.1036+3A>C splicesite 0,0132 novel molecular background of Albinism in Turkey. TYR NM_000372.4c.308G>C p. missense 0,0132 novel Cyc103Ser Materials and Methods: Forty OCA patients (23 male and 17 female, 3 pairs of siblings) with a median age 19.2 years (min: 6mo-max 70.1 years) were enrolled. Following O. Hatirnaz ng: None. E. Yılmaz: None. Z. Par- DNA isolation, the coding regions of TYR genes were lakgüneş:None.K.Yararbaş:None.S.Ziylan:None.Y. analysed by PCR and direct sequencing. Alanay: None. U. Ozbek: None. Results:Wehavedetected28differentTYRvariationsin 31(77.5%,17homozygous,16compoundheterozygousand 
P02 .46D 1 heterozygous) of the OCA patients (Table1). The most Copy number analysis of the OPN1LW and OPN1MW frequent variants were c.815G>A, p.Trp272* and genes by MLPA c.741C>A, p.Cyc247* with an allele frequency of 0.06. Among28variationsfiveofthemwerenovel(Table1).The A. S. Hoekstra1, L. Haer-Wigman2, M. Tjon-Pon-Fong2, allele frequencies of two common TYR polymorphisms M. Zegers1, M. Ketema1, R. Vijzelaar1 
S192 Y and R402Q were 34% and 14.6% respectfully. Conclusion: TYR gene is commonly mutated in OCA 1MRC-Holland, Amsterdam, Netherlands, 2Radboud patientsinTurkey.ThepatientwithonlyheterozygousTYR University Medical Center, Nijmegen, Netherlands variant,additiontoother8patientswithnovariationshould be evaluated for other related genes. Further studies with Introduction: X-linkedcone dysfunction disorders suchas new patients and investigation of other melanin related BlueConeMonochromacyandConeDystrophyarecaused genes in TYR negative patients are ongoing. bypathogenicvariantsandrearrangementsinOPN1LWand OPN1MWwhichsharemorethan98%sequencesimilarity. Table 1: TYR variations and their allele frequencies Located in tandem, they are susceptible to meiotic detected in our patients. mispairing, unequal homologous and nonhomologous recombination. This might lead to different copy numbers Gene cNomen pNomen codingeffect allefreq Known/Novel of OPN1LW and/or OPN1MW or the formation of hybrid TYR NM_000372.4c.815G>A p.Trp272* stopgain 0,0658 rs779454147 opsin genes. Because of the frequent exchange, X TYR NM_000372.4c.741C>A p.Cyc247* stopgain 0,0658 rs1185485047 TYR NM_000372.4c.996G>A p. missense 0,0526 CM91273 chromosomes have around one to five OPN1MW copies, Met332Ile whereas they rarely have more than one OPN1LW copy. TYR NM_000372.4c.1217C>T p. missense 0,0526 CM910385 Pro406Leu Using the current diagnostic tests, it remains difficult to TYR NM_000372.4c.1204C>T p.Arg402* stopgain 0,0395 CM942074 determine the copy number and presence of gene TYR NM_000372.4c.1A>G p.Met1Val missense 0,0395 CM941342 TYR NM_000372.4c.573delA p.Gly191* stopgain 0,0395 rs1364823765 rearrangements in OPN1LW and OPN1MW. TYR NM_000372.4c.613C>A p. missense 0,0395 rs61754362 Methods: A novel multiplex ligation-dependent probe Pro205Thr TYR NM_000372.4c.230G>A p. missense 0,0263 rs61753185 amplification (MLPA) assay was developed and tested on Arg77Gln 14 patient samples with a known copy number status of TYR NM_000372.4c.1118C>A p. missense 0,0263 rs617543388 Thr373Lys OPN1LWandOPN1MW.Copynumberandrearrangements TYR NM_000372.4c.816G>C p. missense 0,0263 11116710 inOPN1LWandOPN1MWwereanalysedinmorethan100 Trp272Cys TYR NM_000372.4c.446A>C missense 0,0263 rs797046082 DNA samples.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1235 Results: The copy number of OPN1LW and OPN1MW from family B were diagnosed with optic atrophy in early was confirmed in the 14 patients and could be easily childhood. A missense variant (p.
S36 L) in the TMEM126A determined in 75 male and female DNA samples and in 45 genewasidentifiedinagenepanel-baseddiagnosticsetting clinical samples consisting of affected individuals and car- in both siblings. This missense variant is ultra rare in the riers. Ten patients with hybrid opsin genes were identified, general population, affects a highly evolutionarily con- including one patient with two hybrid genes. served amino acid and segregates with the disease within Conclusion: The newly developed MLPA assay enables the family. The three probands reported in this study had a determination of the copy number status and identification relatively mild clinical course without any evidence of a of gene rearrangements in OPN1LW and OPN1MW. The syndromic (e.g. neurological) comorbidity, which is in line addition of MLPA to routine sequencing of OPN1LW and with previous studies. OPN1MW will improve detection of the cause of X-linked We provide additional evidence for the implication of cone dysfunction disorders. biallelic TMEM126A mutations in arOA. Our findings A.S. Hoekstra: A. Employment (full or part-time); Sig- extend both the mutational spectrum and geographic pre- nificant; MRC-Holland. L. Haer-Wigman: None. M. sence of TMEM126A in arOA. Tjon-Pon-Fong:None.M.Zegers:A.Employment(fullor N. Weisschuh: None. M. Synofzik: None. C. Kern- part-time); Significant; MRC-Holland. M. Ketema: A. stock: None. S. Schimpf-Linzenbold: None. F. Schuet- Employment(fullorpart-time); Significant;MRC-Holland. tauf: None. A. Neu: None. K. Kloth: None. R. Vijzelaar: A. Employment (full or part-time); Sig- nificant; MRC-Holland. 
P02 .48B A familial optic atrophy associated with mild 
P02 .47A neurodevelopmental disorder caused by SOX5 Novel mutations in TMEM126A causing non-syndromic haploinsufficiency autosomal recessive optic atrophy A. Gouronc1, Y. Perdomo2, L. Maurin2, A. Schalk1, S. El N.Weisschuh1,M.Synofzik2,3,C.Kernstock1,S.Schimpf- Chehadeh3, E. Schaefer3, H. Dollfus2,3, S. Scheidecker1 Linzenbold4, F. Schuettauf5, A. Neu6, K. Kloth7 1Laboratoires de Diagnostic Génétique, Hôpitaux 1Institute for Ophthalmic Research, Tuebingen, Germany, Universitaires de Strasbourg, Strasbourg, France, 2Centre 2Hertie Institute for Clinical Brain Research, Tuebingen, de Référence pour les Affections Rares en Génétique Germany, 3German Center for Neurodegenerative Ophtalmologique (CARGO), Hôpitaux Universitaires de Diseases,Tuebingen,Germany,4CeGaTGmbHandPraxis Strasbourg, Strasbourg, France, 3Service de Génétique für Humangenetik, Tuebingen, Germany, 5Department of Médicale, Hôpitaux Universitaires de Strasbourg, Ophthalmology, University Medical Center Hamburg- Strasbourg, France Eppendorf,Hamburg,Germany,6DepartmentofPediatrics, UniversityMedicalCenterHamburg-Eppendorf,Hamburg, Introduction: Inherited optic neuropathies (ION) are a Germany,7InstituteofHumanGenetics,UniversityMedical clinically and genetically heterogeneous group of disorders Center Hamburg-Eppendorf, Hamburg, Germany caused by nuclear or mitochondrial DNA variants. Isolated andsyndromicformsaredescribed.ThemostfrequentION Reports on autosomal recessive optic atrophy (arOA) are are autosomal dominant optic atrophy (ADOA), due to sparse and so far, only one gene has been specifically OPA1 variant, and Leber hereditary optic neuropathy associated with non-syndromic arOA, namely TMEM126A. (LHON), caused by mitochondrial DNA variant. To date, all reports of TMEM126A mutations are from Materials and Methods: Herein we report on three patients of Maghrebian origin, who all carry an identical patients from a family suffering from bilateral optic neu- nonsense mutation. We report two novel variants in the ropathyandsuggestinganautosomaldominantinheritance. TMEM126A gene from two non-Maghreb patients/families, Twoofthemshowadditionalfeaturessuchasspeechdelay, both resulting in an arOA phenotype. mild learning disabilities and behavior disorders. The The proband of family A was diagnosed with visual loss sequencing of a panel of ION’s genes including the OPA1 inearlychildhoodbutadiagnosisofopticatrophywasonly gene is normal. The SNP array analysis reveals an 82 kb madeat14years.Adiagnosticgenepanelrevealedasplice intragenic heterozygous deletion of the SOX5 gene that donor variant (c.86+2T>C) in the TMEM126A gene. Ana- segregates with the disease. lysis of this variant based on RNA from whole blood Discussion:TheSOX5haploinsufficiencyleadstoLamb- revealed a single aberrant transcript lacking exon 2, pre- Shaffer syndrome classically associating global develop- sumably representing a functional null allele. Two siblings mentaldelay,withpredominantspeechimpairment,mildto1236 severe intellectual disability and mild dysmorphic features. mRNA degradation by NMD mechanism. Besides, five 5ʹ- Some patients have additional features such as brain UTRvariantswerefoundtoleadtoasignificantdecreasein abnormalities or musculoskeletal anomalies. Optic atrophy the translation efficiency, including three of them, which is described in only two patients carrying SOX5 hetero- alsoleadtoaberrantsplicing.Ourfurtheranalysisallowsus zygous de novo variants: a 53 kb intragenic deletion and a tosuggestthemechanismof5ʹ-UTR variantspathogenicity pointvariantresultinginaprematurestopcodon.Thesetwo through disruption of upstream ORF which possibly exists patientsdisplayedamoderatetosevereneurodevelopmental in PAX6 5ʹ-UTR. disorder. Conclusions: Using functional analysis we have con- Conclusion: Here we report on the first family of firmed the pathogenicity of 12 PAX6 noncoding mutations. inherited autosomal dominant optic atrophy due to SOX5 Moreover, ourresultssuggestthe exact mechanism of their heterozygous deletion associated with mild neurodevelop- pathogenic action. mentalfeatures.ThisobservationsuggeststhataSOX5gene A. Filatova: None. T. Vasilyeva: None. A. Mar- analysis could be performed in patients presenting with akhonov:None.R.Zinchenko:None.M.Skoblov:None. optic atrophy associated with developmental disorder even mild. 
P02 .50D A. Gouronc: None. Y. Perdomo: None. L. Maurin: Mutations in PL
S1 , encoding fimbrin, cause autosomal None. A. Schalk: None. S. El Chehadeh: None. E. dominant non-syndromic hearing loss (ADNSHL) Schaefer:None.H.Dollfus:None.S.Scheidecker: None. A. Morgan1, D. Koboldt2,3, E. Barrie2, E. Crist2,3,4, 
P02 .49C M. Mezzavilla5, F. Faletra5, T. Mosher2,3,4, R. Wilson2,3, PAX6 non-coding sequence variants cause congenital K. Manickam3,4, P. Gasparini1,5, D. Dell’Orco6, aniridia G. Girotto1,5 A. Filatova1, T. Vasilyeva1, A. Marakhonov1,2, 1University of Trieste, Trieste, Italy, 2Institute for Genomic R. Zinchenko1,3, M. Skoblov1,2 Medicine at Nationwide Children’s Hospital, Columbus, OH, United States, 3Department of Pediatrics at The Ohio 1Research Centre for Medical Genetics, Moscow, Russian StateUniversity,Columbus,OH,UnitedStates,4Divisionof Federation, 2School of Biomedicine, Far Eastern Federal Genetic and Genomic Medicine at Nationwide Children’s University, Vladivostok, Russian Federation, 3Pirogov Hospita, Columbus, OH, United States, 5IRCCS Burlo Russian National Research Medical University, Moscow, Garofolo, Trieste, Italy, 6Department of Neurosciences, Russian Federation Biomedicine and Movement Sciences, Section of Biological Chemistry, University of Verona, Verona, Italy Introduction:Congenitalaniridia(AN)isarareautosomal dominant panocular disorder caused by mutations in the Introduction: NSHL is a common sensory disorder PAX6 gene. A previously conducted molecular genetic characterized by high genetic heterogeneity. Despite huge studyofalargecohortofRussianpatientswithANrevealed effortsingenesdiscovery,almosthalfofpatientsstillfailto several groups of PAX6 nucleotide variants which patho- receive a molecular diagnosis. genicity is not obvious, including variants out of canonical Methods:TwounrelatedADNSHL-familiesofEuropean splicing site dinucleotides, possibly affecting splicing, and ancestry negative for mutations in known deafness-genes 5ʹ-UTR variants. These variants were classified as VUS or underwent next-generation sequencing. Data were filtered likely pathogenic according to the ACMG recommenda- according to frequency, pathogenicity and pattern of tions. Thus, to validate the pathogenicity of such variants inheritance. To prioritize genes a population-based analysis functional studies are required. was performed (including statistics on natural selection in Materials and Methods: To determine the effect of Europeans and gene constrains from gnomAD database) PAX6 variants on splicing we used a minigene assay. To followed by in silico protein modelling. study 5ʹ-UTR variants we generated luciferase constructs Results: Among the genes found mutated in the two with full-length PAX6 5ʹ-UTR (wt and mutants). The analysedfamilies,interestingly,PL
S1 showedsignatures of translationefficiencywasmeasuredbyluciferaseassay,and natural selection and low observed/expected ratio of both the RNA expression level was evaluated by qPCR. missense and loss of function mutations. Thus, these find- Results: Using a minigene assay, seven out of eight ings suggested a level of conservation and allowed to investigated probably affecting slicing variants (six deep prioritize PL
S1  in which two novel likely-pathogenic mis- intronic and two exonic) were showed to disrupt normal sensevariantswereidentified.PL
S1 encodesfimbrin,oneof splicing patterns and result in frame shifting followed by themostabundantactin-bundlingproteinsofthestereocilia.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1237 Recently, it was demonstrated that Pls1-/- mice show a toperformcomprehensivephenotypingincombinationwith moderate/progressive form of HL across all frequencies appropriategeneticdiagnostictestingtoachieveanaccurate (PMID: 25124451). In silico protein modelling displayed diagnosis. This work was supported by GACR 17-12355S. that both variants affect the actin-binding domain-1, and P. Liskova: None. L. Dudakova: None. P. Skalicka: suggestedanoveralldestabilizationoftheproteinstructure, None. A.E. Davidson: None. reducing the protein’s ability to bind F-actin. Conclusion: Present results (genomic data of two inde- 
P02 .52B pendent ADNSHL-families, literature updates, evidence of Molecular genetic study of primary congenital evolutionary constrains and protein modelling results) pro- glaucoma: the mutational analysis of CY
P1 B1and vide evidence that PL
S1  isrequiredfor normal hearing and LTB
P2  genes once mutated might cause ADNSHL. The identification of PL
S1  as a new ADNSHL-gene provides a new possible V. Szabó1, K. Knézy1, M. Csidey1, A. Szigeti1, E. Maka1, target for the development of therapeutic approaches. M. Bausz1, K. Sényi1, Z. Nagy1, G. Holló1, P. Kövy2, A.Morgan:None.D.Koboldt:None.E.Barrie:None. T. Krähling2, A. Tordai3, H. Andrikovics2, A. Bors2 E. Crist: None. M. Mezzavilla: None. F. Faletra: None. T.Mosher:None.R.Wilson:None.K.Manickam:None. 1Semmelweis University, Dept. of Ophthalmology, P. Gasparini: None. D. Dell’Orco: None. G. Budapest, Hungary, 2Central Hospital of Southern Pest - Girotto: None. National Institute of Hematology and Infectious Diseases, Budapest, Hungary, 3Semmelweis University, Dept. of 
P02 .51A Pathophysiology, Budapest, Hungary Coincidental occurrence of Schnyder corneal dystrophy and posterior polymorphous corneal dystrophy type 3 Introduction: Purpose of our study was to examine the mutationsofCY
P1 B1andLTB
P2 genesinpatientsandtheir P.Liskova1,L.Dudakova1,P.Skalicka1,2,A.E.Davidson3 relatives with primary congenital glaucoma, (PCG) and to evaluate genotype-phenotype correlations. 1First Faculty of Medicine, Charles University, Prague, PatientsandMethods:molecularanalysisof26children Czech Republic, 2General University Hospital in Prague, of21familieswithPCGwasperformed.Firstweexamined Prague,CzechRepublic,3UCLInstituteofOphthalmology, the common mutation p.Glu387Lys of CY
P1 B1 gene using London, United Kingdom RFLP technique. In cases where wild-type or heterozygous p.Glu387Lys variant was detected, Sanger-sequencing of Purpose:Toreportthesimultaneousoccurrenceoftworare CY
P1 B1 was performed. Common p.Arg299Ter corneal dystrophies. (c.895C>T) mutation in LTB
P2  gene was also genotyped. Methods:Casereportofa30-year-oldmalewithafamily Wecarriedoutaretrospectiveevaluation,usingclinicaldata historyofposteriorpolymorphouscornealdystrophytype3 as follows: age at diagnosis, ophthalmological status, pre- (PPCD3) was invited for ophthalmic examination. Sanger andpostoperativevisualacuityandintraocularpressureand sequencing of the coding regions and intron/exon bound- pedigree. aries of disease-associated genes, ZEB1 and UBIAD1 was Results: we identified two mutations in 20 patients performed. (76,92%)inourstudygroup.Thep.Arg299Ter(c.895C>T) Results: The clinical findings suggested co-occurrence of mutation in LTB
P2  gene was found in one family in PPCD3 and Schnyder corneal dystrophy (SCD) in the pro- homozygous form. We identified the homozygous p. band.Thisdualdiagnosiswassupportedbygeneticfindings. Glu387Lys mutation of CY
P1 B1 gene in 12 members of 8 Hewasidentifiedtocarryapreviouslyreportedheterozygous families, in two siblings of one family we found two nonsense mutation in ZEB1; c.2157C>G, p.(Tyr719*), and a deletions causing frameshift (p.Arg355Hisfs*69/p. novel heterozygous missense mutation in UBIAD1; His401Leufs*24), compound heterozygous mutations c.569T>C; p.(Ile190Thr). The mother of the proband only describedintheliteraturebeforewereidentifiedinfurther5 carried the c.2157C>G ZEB1 variant and slit-lamp examina- families. No causative mutation was detected in 6 families tion of her corneas showed endothelial lesions characteristic (28,57%)neitherinCY
P1 B1gene,norinexaminedposition ofPPCD3.Thesisteroftheprobandcarriedthec.569T>Cin of LTB
P2  gene. UBIAD1 and had corneal crystal deposition in her anterior Conclusion: No genotype-phenotype correlations were stroma consistent with the diagnosis of SCD. foundinourstudygroupwithPCG,onecouldnotconclude Conclusion: This case illustrates the coincidental occur- onthegroundsofgenotypeofclinicalcourseandprognosis. rence of two rare and genetically distinct corneal dystro- This is the first study investigating the mutations of phiesinasinglepatient.Furthermore,ithighlightstheneed1238 CY
P1 B1 gene and the p.Arg299Ter (c.895C>T) in LTB
P2  family and the previously reported families, CPAMD8- gene of PCG in Hungary. associated ASD should be taken into consideration as a V.Szabó:None.K.Knézy:None.M.Csidey:None.A. differential diagnosis for PCG. Szigeti: None. E. Maka: None. M. Bausz: None. K. H. Verdin: None. I. Balikova: None. J. Van De Velde: Sényi: None. Z. Nagy: None. G. Holló: None. P. Kövy: None. P.G. Kestelyn: None. B.P. Leroy: None. E. De None. T. Krähling: None. A. Tordai: None. H. Andri- Baere: None. kovics: None. A. Bors: None. 
P02 .54D 
P02 .53C Whole exome sequencing and linkage analysis of Expanding the CPAMD8-associated eye disease extended pedigrees to identify glaucoma susceptibility spectrum to primary congenital glaucoma: lessons genes learned from a large consanguineous family with pseudodominance P.Graham1,J.Peralta1,2,N.Blackburn1,2,J.Blangero1,2, M. Wirtz3, A. Hewitt1, D. Mackey4, K. Burdon1, H. Verdin1, I. Balikova1,2,3, J. Van De Velde1, J. Charlesworth1 P. G. Kestelyn2, B. P. Leroy1,2, E. De Baere1 1MenziesInstituteforMedicalResearch,Hobart,Australia, 1Center for Medical Genetics, Ghent University, Ghent, 2South Texas Diabetes and Obesity Institute, Brownsville, Belgium,2Department ofOphthalmology, GhentUniversity TX, United States, 3Casey Eye Institute, Portland, OR, and Ghent University Hospital, Ghent, Belgium, United States, 4Lions Eye Institute, Perth, Australia 3Department of Ophthalmology, Children Hospital Queen Fabiola, Brussels, Belgium The use of next generation sequencing in extended pedigreeshassignificantpotentialforidentifyingfunctional Primary congenital glaucoma (PCG) is defined as an variants linked with complex disease. We are using whole isolated trabeculodysgenesis that occurs in the first three exome sequencing (WES) of five large, complex families yearsoflifeandismostoftencausedbybiallelicmutations from Tasmania (Australia) and Oregon (USA) to identify in CY
P1 B1. Other early-onset, developmental glaucomas susceptibility genes for primary open-angle glaucoma mayarisesecondarytodevelopmentalmalformationsofthe (POAG), the leading cause of irreversible blindness world- anteriorsegmentoftheeye,andoccuraspartofananterior wide. Extended pedigrees, enriched for POAG, provide a segment dysgenesis (ASD) disorder. Consequently, these powerfultooltosearch forrareandprivategenetic variants overlapping phenotypes may challenge the diagnosis influencing the disease, where enrichment of rare variants of PCG. occurs as a function of segregation from the founders. The Here we studied a highly consanguineous Jordanian families in this study range in size from 48 to 201 pedigree with over 17 affected individuals in three gen- individuals (28 to 91 sequenced) and span 5 to 7 erations,displayingaclinicaldiagnosisofPCG.Inaddition generations. These families are being used to locate to PCG, the proband also presented with iris atrophy, quantitative trait loci (QTLs) for intraocular pressure ectropion uveae and corectopia. Moreover, the familial (IOP), an important glaucoma endophenotype. Variance historyrevealedthepresenceofotherocularmanifestations components linkage analysis of IOP was conducted on the in the family including cataracts, lens luxation and iris WESdata from249individuals andwe identifiedQTLson abnormalities. Using homozygosity-based filtering of chromosomes 2,3,6,7 and 15. The chromosome 2 locus exome data, we identified a homozygous frameshift variant (2q22.2-24.3)spans a20millionbase pair region.Threeof inCPAMD8:c.785_788del,p.Tyr262Serfs*17.Thisvariant the five families independently contribute linkage informa- is not present in population databases and segregates with tion to this peak, which is a novel locus for both IOP and the phenotype in the family. Recently, CPAMD8 was POAG. Further analysis is being undertaken to identify reportedasthecauseforauniqueautosomalrecessiveASD genes with family specific, potentially deleterious variants; that is characterized by bilateral iris hypoplasia, ectopia whichwillbevalidatedinlargePOAGcase/controlcohorts. lentis, corectopia, ectropion uveae, and cataracts, clinical Finding genes involved with POAG susceptibility will features also observed here. Interestingly, two affected increase our understanding of the biological pathways siblings who were initially diagnosed with PCG received a involved with the disease process and from that, diagnostic clinical diagnosis of megalocornea in retrospect. In con- tools and more effective treatments can be developed. clusion, we identified the molecular cause underlying a P. Graham: None. J. Peralta: None. N. Blackburn: PCG phenotype in a large consanguineous family using None. J. Blangero: None. M. Wirtz: None. A. Hewitt: combined homozygosity-mapping and WES. Based on thisAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1239 None. D. Mackey: None. K. Burdon: None. J. chromosome and encodes phosphoribosyl pyrophosphate Charlesworth: None. synthetase 1 (PRS-1). We illustrate the clinical variability associated with decreased PRS-1 activity, ranging from 
P02 .55A mildisolatedhearinglosstosevereencephalopathy.Oneof PRP
S1 loss-of-function variants, from isolated hearing the variants we identified has already been reported with a loss to severe congenital encephalopathy phenotype similar to our patient’s, whereas the other three were unknown. The clinical and biochemical information S. marlin1,2, O. Mercati1, M. Abi Warde3, G. Lina- weprovidewillhopefullycontributetogaininsightintothe Granade4, M. Rio5, S. Heide6, P. de Lonlay7, I. Ceballos- correlation between genotype and phenotype in this rare Picot8, M. Robert9, V. Couloigner10, J. Beltrand11, condition, in females as well as in males. Moreover, our N. Boddaert12, D. Rodriguez13, A. Rötig14, H. Prokisch15, observation of a new family in which hemizygous males S. Lyonnet2, N. Loundon10, J. Kaplan16, J. Bonnefont17, display hearing loss without any neurological or ophthal- A. Munnich18, C. Besmond18, L. Jonard1,17 mological symptoms prompts us to suggest analysing PRP
S1 in cases of isolated hearing loss. 1Centre de Référence des Surdités Génétiques, Institut S. marlin: None. O. Mercati: None. M. Abi Warde: Imagine, Hôpital Necker-Enfants Malades, APHP, Paris, None. G. Lina-Granade: None. M. Rio: None. S. Heide: France, 2Laboratoire d’Embryologie et de Génétique des None. P. de Lonlay: None. I. Ceballos-Picot: None. M. Malformations Congénitales, INSERM UMR 1163, Institut Robert: None. V. Couloigner: None. J. Beltrand: None. Imagine, Université Paris Descartes, Paris, France, N.Boddaert:None.D.Rodriguez:None.A.Rötig:None. 3Département de NeuroPédiatrie, CHU, Strasbourg, H. Prokisch: None. S. Lyonnet: None. N. Loundon: France, 4Service d’Otorhinolaryngologie et chirurgie None. J. Kaplan: None. J. Bonnefont: None. A. Mun- cervico-faciale Pédiatrique, CHU, Lyon, France, nich: None. C. Besmond: None. L. Jonard: None. 5Département de Génétique, Hôpital Necker-Enfants Malades, APHP, Paris, France, 6Département de 
P02 .56B Génétique, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, BiallelicsequenceandstructuralvariantsinRAX2area Paris,France,7CentreRéférencedesMaladieshéréditaires novel cause for autosomal recessive inherited rod- du Métabolisme, Hôpital Necker-Enfants Malades, AP-HP, dominated retinal disease Paris, France, 8Laboratoire de Biochimie Métabolomique et Protéomique, Hôpital Necker-Enfants Malades, AP-HP, S.VandeSompele1,C.Smith2,M.Karali3,4,M.Corton5,6, Paris, France, 9Service d’Ophtalmologie pédiatrique, K. Van Schil1, F. Peelman7, T. Cherry8, T. Rosseel1, Hôpital Necker-Enfants Malades, AP-HP, Paris, France, H. Verdin1, J. Derolez1, T. Van Laethem1, K. N. Khan9, 10Service d’Otorhinolaryngologie et chirurgie cervico- M. McKibbin9, C. Toomes2, M. Ali2, A. Torella3, faciale Pédiatrique, Hôpital Necker-Enfants Malades, AP- F. Testa10, B. Jimenez11, F. Simonelli10, J. De Zaeytijd12, HP, Paris, France, 11Service Endocrinologie, Gynécologie J. Van den Ende13, B. P. Leroy1,12,14, F. Coppieters1, et Diabétologie Pédiatrique, Hôpital Necker-Enfants C. Ayuso5,6, C. F. Inglehearn2, S. Banfi3,4, E. De Baere1 Malades, AP-HP, Paris, France, 12Département de Radiologie pédiatrique, Hôpital Necker-Enfants-Malades, 1Center for Medical Genetics, Ghent University and Ghent AP-HP; UMR 1163, Institut Imagine, Université Paris University Hospital, Ghent, Belgium, 2Section of Descartes, Paris, France, 13Service de NeuroPédiatrie, Ophthalmology and Neuroscience, School of Medicine, Hôpital Trousseau, AP-HP, Paris, France, 14Laboratoire University of Leeds, St James’s University Hospital, Leeds, de Génétique des maladies Mitochondriales, INSERM United Kingdom, 3Medical Genetics, Department of UMR1163, Institute Imagine, Université Paris Descartes, PrecisionMedicine, Università degli Studi della Campania Paris, France, 15Institute of Human Genetics, Helmholtz “Luigi Vanvitelli”, Naples, Italy, 4Telethon Institute of Zentrum München, Neuherberg, Germany, 16Laboratoire Genetics and Medicine, Pozzuoli, Italy, 5Genetics de Génétique Ophtalmologique INSERM UMR1163, Department,InstitutodeInvestigaciónSanitaria-Fundación Institute Imagine, Université Paris Descartes, Paris, Jimenez Diaz University Hospital, Madrid, Spain, 6Center France, 17Laboratoire de Génétique Moléculaire, Hôpital of Biomedical Network Research on Rare Diseases, Necker-Enfants Malades, AP-HP, Paris, France, Madrid,Spain,7FlandersInstituteforBiotechnology(VIB), 18Université Paris Descartes, Institut Imagine, Paris, Department of Medical Protein Research, Faculty of France Medicine and Health Sciences, Ghent University, Ghent, Belgium, 8Center for Developmental Biology and Wedescribetwosporadicandtwofamilial cases with loss- Regenerative Medicine, Seattle Children’s Research of-function variations in PRP
S1 , which is located on the X Institute, Seattle, WA, United States, 9Department of1240 Ophthalmology, St. James’s University Hospital, Leeds, Coppieters: None. C. Ayuso: None. C.F. Inglehearn: United Kingdom, 10Eye Clinic, Multidisciplinary None. S. Banfi: None. E. De Baere: None. Department of Medical, Surgical and Dental Sciences, Università degli Studi della Campania “Luigi Vanvitelli”, 
P02 .57C Naples, Italy, 11Department of Ophthalmology, Fundación Investigation of the role of a homozygous mutation in Jimenez Diaz University Hospital, Madrid, Spain, BB
S10  in non syndromic retinal degeneration 12Department of Ophthalmology, Ghent University and Ghent University Hospital, Ghent, Belgium, 13Center for A. V. Vig1,2, E. Tavares2, O. Kehelwathugoda1,2, Medical Genetics, Antwerp University Hospital, Antwerp, A. Mollica1,2, J. Maynes2,1, A. Vincent2,1, E. Heon2,1 Belgium, 14Division of Ophthalmology, The Children’s Hospital of Philadelphia, Philadelphia, PA, United States 1University of Toronto, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada RAX2 encodes a homeobox-containing transcription factor, in which four monoallelic pathogenic variants have been Introduction: Bardet-Biedl syndrome (BBS) is rare auto- previously described in autosomal dominant cone- somalrecessivedisorder,characterized byretinaldegenera- dominated retinal disease. Here, exome sequencing in a tion, obesity, digital anomalies, genito-urinary defects, and European cohort with inherited retinal disease (IRD) variable cognitive impairment. It is part of a broader (n=2086) revealed biallelic RAX2 sequence and structural pleotropic class of diseases called ciliopathies. Ciliopathies variants in five unrelated European index cases, displaying are caused by mutations in genes that play important roles non-syndromic autosomal recessive retinitis pigmentosa in the function of cellular signaling organelles called cilia. (ARRP)withanageofonsetrangingfromchildhoodtothe BB
S10  encodes a chaperonin–like protein that mediates mid 40s (average mid 30s). Protein structure modeling of assemblyoftheBBSome,whichtransportsvesiclestocilia. the novel recessive missense variants points to loss-of- BB
S10  is one of the most frequently mutated BBS genes, function while a dominant-negative effect is predicted for accounting for approximately 16% of cases. the previously reported dominant RAX2 alleles. Structural Methods:A29yofemalefromaconsanguineousfamily variants were fine-mapped to disentangle their underlying had non-syndromic cone-rod dystrophy (CRD) and did not mechanisms and haplotyping of c.335dup in two cases have any mutation identified using standard of care clinical suggests a common Belgian ancestry. One additional genetic testing. Whole exome sequencing was performed. unrelated Belgian ARRP patient carried the same Candidate variants were assessed based on family segre- c.335dup allele in the absence of a second RAX2 coding gation, predicted effect on protein structure and function, or structural variant, suggesting a role for non-coding amino acid conservation, and population frequency. variantsinRAX2associatedARRP.Toconclude,wefound Results: Whole genome sequencing revealed a novel biallelic pathogenic variants in RAX2 to be associated with homozygous mutation in BB
S10 . The variant is rare and ARRP, revealing RAX2 as a novel gene for recessively segregated in the family. It occurs at a residue which is inherited rod-dominated retinal diseases. The identification highly conserved among chaperonins. Based on modelling of RAX2 biallelic pathogenic variants in five families of ofBB
S10 secondarystructure,itispredictedthatthevariant Europeanoriginindicatesthatthisgenemayunderlieanon- could 1) affect multimer assembly or 2) alter how ATP negligiblefraction ofARRPcasesofother populationsthat hydrolysis induces the protein conformation changes that still lack a molecular diagnosis. The RAX2 mutational are vital to chaperone function. spectrum was broadened from sequence to structural Conclusions: We have identified a rare homozygous variants (SVs). Finally, the identification of pathogenic variant we presume significant in BB
S10  in a patient with structural variants in RAX2 stresses the importance of SV non-syndromic CRD. We are exploring the functional assessment in WES and WGS data in IRD. consequences of thevariant through phenotyping a patient- Funding: BOF15/GOA/011; BOF/01D04716; FWO/ derived fibroblast cell line. 1145719N; FWO/1802215N; Italian Telethon Foundation Funding: FFB, Mira Godard, McLaughlin Centre, ORF S.Van deSompele: None.C.Smith:None.M.Karali: A.V. Vig: None. E. Tavares: None. O. Kehelwathu- None. M. Corton: None. K. Van Schil: None. F. Peel- goda: None. A. Mollica: None. J. Maynes: None. A. man: None. T. Cherry: None. T. Rosseel: None. H. Vincent: None. E. Heon: None. Verdin:None.J.Derolez:None.T.VanLaethem:None. K.N. Khan: None. M. McKibbin: None. C. Toomes: 
P02 .58D None.M.Ali:None.A.Torella:None.F.Testa:None.B. Clinical utility of a custom NGS panel in routine Jimenez:None.F.Simonelli:None.J.DeZaeytijd:None. evaluation of retinal dystrophies J. Van den Ende: None. B.P. Leroy: None. F.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1241 I. Hernan, E. Borràs, M. Gamundi, B. Mañé, V. García- Prompt, comprehensive genetic diagnosis of RD can assist Prieto, B. Delàs, M. Carballo in risk assessment, symptom management and selection of theappropriatetargetedtreatment.Thegenetictestingneeds Hospital de Terrassa (CST), Terrassa, Spain to take into account sequence alterations and copy number variants(CNVs).Weevaluatedtheratesandcharacteristics Introduction: Retinal dystrophies (RD) are a broad group of CNVs in 2754 patients tested using a comprehensive of clinically and genetically heterogeneous disorders RD panel. affecting the retina. The non-syndromic forms of RD can DNA from patients was sequenced by targeted OS-Seq be attributed to mutations in more than 100 genes. using the Illumina NextSeq500 sequencing platform or the Consequently, next generation sequencing (NGS) technol- IDT xGEN Exome Research Panel using the Illumina ogies are among themost promising approaches toidentify NovaSeqplatform. CNVs weredetectedbyCNVkitandan mutations in RD patients. in-house developed deletion caller. Materials and Methods: A cohort of patients including CNVsin47genesmatchingthepatient’sphenotypewere independent cases with various forms of RD, especially reported in 4.6% of the cases. Of the CNVs, 71.1% were Retinitis Pigmentosa and Stargardt disease were analysed. partial gene deletions, 13.3% whole gene deletions, 3.1% To identify the RD causative gene, a custom SureSelect oneexondeletions,and0.8%partialexondeletions.11.7% capturepanel(Agilent) targeting 104genesassociated with of the identified CNVs were duplications (partial or whole non-syndromic retinal disease was developed. NGS librar- gene). 88.3% of CNVs were likely pathogenic or patho- ies were run on Illumina MiSeq or HiSeq Sequencer. genic,11.7%werevariantsofuncertainsignificance.Ofthe Analyses, annotation, filtration and variant curation were likely pathogenic and pathogenic CNVs, 73.4% were done using GeneSystems software (Sistemas Genómicos). diagnostic. USH2A and PRPF31 were enriched in CNVs Whenitwaspossible,segregationanalysisofthecandidate compared to other genes. Notably, CNVs were identified variant was performed in additional family members by also in genes in which CNVs are not commonly reported, Sanger sequencing. e.g. ABCA4 and RP
E65 . Results: A pathogenic variant was identified in 25 RD These results highlight the importance of comprehensive patients (58%), including novel mutations in ABCA4, genetic testing for the diagnosis of retinal dystrophies. We CACNA1F,EYSandPRCDgene.In7patients,avariantof identified CNVs ranging from one exon to whole gene unknownsignificancewasdetected;afunctionaltestwould deletions in multiple genes. In addition, we detected a be necessary to assess their clinical significance. relative high percentage of copy number duplications that Conclusions: Five novel variants have been identified as warrant further investigation. acausativemutationforRDusingthecustomcapturepanel. L. Guidugli: A. Employment (full or part-time); Sig- ThedesignedNGSassayachievesadetectionrateofalmost nificant;BlueprintGenetics.S.Tuupanen:A.Employment 60% and provides an adequate routine assay for genetic (full or part-time); Significant; Blueprint Genetics. M. analysis of patients with retinal disease. Mehine: A. Employment (full or part-time); Significant; I.Hernan:None.E.Borràs:None.M.Gamundi:None. BlueprintGenetics.K.Kämpjärvi:A.Employment(fullor B.Mañé:None.V.García-Prieto:None.B.Delàs:None. part-time);Significant;BlueprintGenetics.L.Koskinen:A. M. Carballo: None. Employment (full or part-time); Significant; Blueprint Genetics. K. Wells: A. Employment (full or part-time); 
P02 .59A Significant; Blueprint Genetics. J. Känsäkoski: A. Copy number variants (CNVs) identified by Employment (full or part-time); Significant; Blueprint comprehensive genetic testing of inherited retinal Genetics. M. Valori: A. Employment (full or part-time); dystrophies Significant; Blueprint Genetics. I. Saarinen: A. Employ- ment(fullorpart-time);Significant;BlueprintGenetics.M. L. Guidugli1, S. Tuupanen1, M. Mehine1, K. Kämpjärvi1, Muona: A. Employment (full or part-time); Significant; L. Koskinen1, K. Wells1, J. Känsäkoski1, M. Valori1, Blueprint Genetics. E. Sankila: A. Employment (full or I. Saarinen1, M. Muona1, E. Sankila2, S. Myllykangas1, part-time); Modest; Blueprint Genetics. S. Myllykangas: J. W. Koskenvuo1, T. Alastalo1 A. Employment (full or part-time); Significant; Blueprint Genetics.E.OwnershipInterest(stock,stockoptions,patent 1BlueprintGenetics,Helsinki,Finland,2HelsinkiUniversity or other intellectual property); Significant; Blueprint Eye Hospital, Helsinki, Finland Genetics. J.W. Koskenvuo: A. Employment (full or part- time); Significant; Blueprint Genetics. E. Ownership Inter- Retinal dystrophies (RD) are disorders that damage the est (stock, stock options, patent or other intellectual prop- photoreceptors in the retina and cause visual impairment. erty); Significant; Blueprint Genetics. T. Alastalo: A.1242 Employment (full or part-time); Significant; Blueprint Employment (full or part-time); Significant; Blueprint Genetics.E.OwnershipInterest(stock,stockoptions,patent Genetics. J. Känsäkoski: A. Employment (full or part- or other intellectual property); Significant; Blueprint time); Significant; Blueprint Genetics. K. Wells: A. Genetics. Employment (full or part-time); Significant; Blueprint Genetics. J. Schleit: A. Employment (full or part-time); 
P02 .60B Significant;BlueprintGenetics.M.Valori:A.Employment Prevalence and characteristics of RPGR ORF15 (full or part-time); Significant; Blueprint Genetics. P. Sal- variants in patients with inherited retinal dystrophies menperä: A. Employment (full or part-time); Significant; Blueprint Genetics. E. Ownership Interest (stock, stock J. Sistonen1, S. Tuupanen1, K. Kämpjärvi1, P. Siivonen1, options, patent or other intellectual property); Significant; M. Mehine1, J. Känsäkoski1, K. Wells1, J. Schleit1, Blueprint Genetics. E. Sankila: A. Employment (full or M. Valori1, P. Salmenperä1, E. Sankila2, E. Salminen1, part-time); Modest; Blueprint Genetics. E. Salminen: A. T. Alastalo1, J. Koskenvuo1, S. Myllykangas1 Employment (full or part-time); Significant; Blueprint Genetics. T. Alastalo: A. Employment (full or part-time); 1BlueprintGenetics,Helsinki,Finland,2HelsinkiUniversity Significant; Blueprint Genetics. E. Ownership Interest Eye Hospital, Helsinki, Finland (stock, stock options, patent or other intellectual property); Significant; Blueprint Genetics. J. Koskenvuo: A. Introduction: The exon ORF15 in RPGR is a mutational Employment (full or part-time); Significant; Blueprint hotspot for X-linked retinitis pigmentosa (XLRP). How- Genetics.E.OwnershipInterest(stock,stockoptions,patent ever, it generally performs poorly in standard sequencing- or other intellectual property); Significant; Blueprint basedassaysduetoahighlyrepetitivepurine-richsequence. Genetics. S. Myllykangas: A. Employment (full or part- ToaddresstheclinicalimportanceofRPGRORF15andthe time); Significant; Blueprint Genetics. E. Ownership Inter- lack of high-quality next generation sequencing (NGS) est (stock, stock options, patent or other intellectual prop- -based diagnostics, we aimed to develop a comprehensive erty); Significant; Blueprint Genetics. clinical test for inherited retinal dystrophies. Materials and Methods: We optimized a whole exome 
P02 .61C sequencing workflow with the Illumina NovaSeq 6000 Prevalence and genetic characteristics of RP
E65 - platform to cover 266 retinal dystrophy-associated genes, associated retinal disease includingthedifficult-to-sequenceregioninRPGRORF15. WeevaluatedtheperformanceofRPGRsequencingin1587 J. Tommiska1, T. Alastalo2, K. Kämpjärvi1, L. Guidugli2, unselected patient samples. J. Känsäkoski1, K. Wells1, H. Västinsalo1, M. Kaare1, Results: In our clinical cohort, the overall diagnostic L. Sarantaus1, P. Salmenperä1, M. Gentile1, S. Bruce1, yield was 58%. A molecular diagnosis in RPGR was E. Sankila3, J. W. Koskenvuo1, S. Myllykangas1, identified in 5.7% (90/1587) of the patients. The 90 S. Tuupanen1 pathogenic/likely pathogenic variants consisted of 63 fra- meshift (70.0%), 21 nonsense (23.3%), three missense 1BlueprintGenetics,Helsinki,Finland,2BlueprintGenetics, (3.3%), and two consensus splice site (2.2%) variants, and SanFrancisco,CA,UnitedStates,3HelsinkiUniversityEye one gross deletion (1.1%). Seventy-one out of 90 (79%) Hospital, Helsinki, Finland pathogenic/likely pathogenic variants were detected in the ORF15,ofwhich28(39%)wereinthedifficult-to-sequence RP
E65  variants are associated with severe retinal diseases central region between residues p.824 and p.1077. Female including Leber congenital amaurosis (LCA) and retinitis patients accounted for 24% of the diagnostic cases. pigmentosa (RP). Recent advancements in targeted therapy Conclusions: Our results highlight the importance of have incentivised genetic diagnostics and increased the RPGRORF15sequencinginretinaldystrophypatients.The efforts to identify RP
E65  patients eligible for therapy. We high-quality NGS-based assay enables rapid and reliable evaluated the prevalence of RP
E65  variants in 2240 retinal molecular diagnostics of RPGR ORF15, and enhances the dystrophy patients by using next-generation identification of patients for ongoing gene therapy trials. sequencing (NGS). J. Sistonen: A. Employment (full or part-time); Sig- Methods:PatientswithLCA,RP,rod-conedystrophy,or nificant;BlueprintGenetics.S.Tuupanen:A.Employment earlyonsetretinaldystrophyweretestedataCLIAcertified (full or part-time); Significant; Blueprint Genetics. K. laboratory 2016 - 2018. Analysis was done using in-house Kämpjärvi:A.Employment(fullorpart-time);Significant; developed and validated NGS, bioinformatics and clinical Blueprint Genetics. P. Siivonen: A. Employment (full or interpretation. part-time); Significant; Blueprint Genetics. M. Mehine: A.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1243 Results: Of 18 patients (0.8%) with RP
E65 -related dis- Employment (full or part-time); Significant; Blueprint ease, 7 (38.8%) had LCA, 4 (22.2%) had RP, 6 (33.3%) Genetics. wereaffectedwithsevereearlyonsetretinaldystrophy,and one (5.5%) had congenital stationary night blindness 
P02 .62D (CSNB). The median age at molecular diagnosis was 13 Identification of pathogenic mutations in genes involved years (range 1 - 60 years). Of the 35 disease-associated in non syndromic hearing loss and Usher syndrome RP
E65  variants 18 (51%) were missense, 10 (29%) protein truncating, 5 (13%) splice site variants, and 2 (5.7%) copy F. Cesca1,2, E. Bettella1,2, R. Polli1,2, E. Leonardi1,2, number variants (CNVs). Two (11.1%) patients carried a M. C. Aspromonte1,2, M. Bellini1,2, A. Sensi3, S. Bigoni4, CNV: a single exon deletion and a deletion of the whole P. Scimemi5,6, R. Santarelli5,6, A. Murgia1,2 RP
E65  gene, respectively. Twelve (67%) patients had at least one loss-of-function variant. One patient had the 1Laboratory of Molecular Genetics of Neurodevelopment, c.1430A>G, p.(Asp477Gly) variant associated with auto- Department of Women’s and Children’s Health, University somal dominant disease and displayed an atypical of Padua, Padua, Italy, 2Fondazione Istituto di Ricerca form of RP. Pediatrica (IRP), Città della Speranza, Padua, Italy, 3U.O. Conclusions:RP
E65 hasasignificantroleinLCAandis Medical Genetics Romagna, M. Bufalini Hospital, Cesena, important in differential diagnostics of retinal dystrophies. Italy,4Medical GeneticsUnit,FerraraUniversityHospital, Our results also highlight the importance of high-quality Ferrara, Italy, 5Audiology and Phoniatric Service, genetic diagnostics covering both sequence variants and DepartmentofNeurosciences,UniversityofPadua,Padua, CNVs for optimized diagnosis and clinical care. Italy, 6Santi Giovanni e Paolo Hospital, ULS
S3  J. Tommiska: A. Employment (full or part-time); Sig- Serenissima, Venice, Italy nificant; Blueprint Genetics. T. Alastalo: A. Employment (full or part-time); Significant; Blueprint Genetics. E. Non-syndromic hearing loss is characterized by a vast Ownership Interest (stock, stock options, patent or other geneticheterogeneity;somesyndromicformshaveonsetas intellectual property); Significant; Blueprint Genetics. K. isolated deafness and then evolve later in life, as Usher Kämpjärvi:A.Employment(fullorpart-time);Significant; syndrome.WedevelopedanNGStargetedgene-panelof59 Blueprint Genetics. L. Guidugli: A. Employment (full or genes using the Ion Torrent PGMTM platform combined part-time); Significant; Blueprint Genetics. J. Känsäkoski: withacustomizedbioinformaticpipelinefortheanalysisof A. Employment (full or part-time); Significant; Blueprint DNA samples from clinically highly selected subjects with Genetics. K. Wells: A. Employment (full or part-time); sensorineural hearing loss, negative for GJB2 mutations/ Significant; Blueprint Genetics. H. Västinsalo: A. GJB6 deletions. Among the 158 subjects tested, 64 were Employment (full or part-time); Significant; Blueprint found to carry pathogenic variants (41%) that in 18 cases Genetics. M. Kaare: A. Employment (full or part-time); (28%) altered genes involved both in NSHL and Usher Significant; Blueprint Genetics. L. Sarantaus: A. syndrome(ADGRV1,CDH23, MYO7A, PCDH15,USH1C, Employment (full or part-time); Significant; Blueprint USH2A); 13 of these subjects were under 15 years of age Genetics. P. Salmenperä: A. Employment (full or part- and were largely referred for NSHL. 7/18 positive-subjects time); Significant; Blueprint Genetics. E. Ownership Inter- carried mutation in CDH23, the most frequently mutated est (stock, stock options, patent or other intellectual prop- gene in our cohort. We achieved a diagnosis of Usher erty); Significant; Blueprint Genetics. M. Gentile: A. syndrome type I in three subjects (3 y.o.; 6 y.o.; 16 y.o.) Employment (full or part-time); Significant; Blueprint with congenital profound hearing loss, retinal anomalies/ Genetics.E.OwnershipInterest(stock,stockoptions,patent retinitis pigmentosa and/or history of motor delay, who or other intellectual property); Significant; Blueprint carried mutations in CDH23, MYO7A and PCDH15. Usher Genetics. S. Bruce: A. Employment (full or part-time); syndrome type II was diagnosed in a 12 y.o. boy referred Significant; Blueprint Genetics. E. Sankila: A. Employ- for congenital bilateral mild hearing loss and subsequently ment (full or part-time); Modest; Blueprint Genetics. J.W. found to have early signs of retinal alteration. 13 novel Koskenvuo:A.Employment(fullorpart-time);Significant; likelypathogenicmutationswereidentifiedinNSHL/Usher Blueprint Genetics. E. Ownership Interest (stock, stock genes; 1 splice-site mutation has been further characterized options, patent or other intellectual property); Significant; at the RNA level. We demonstrate the importance and Blueprint Genetics. S. Myllykangas: A. Employment (full efficacyofintegratingthepowerfulNGStechnologywitha orpart-time);Significant;BlueprintGenetics.E.Ownership comprehensive careful clinical evaluation, to reach an Interest (stock, stock options, patent or other intellectual earlier diagnosis and provide important prognostic and property);Significant;BlueprintGenetics.S.Tuupanen:A. follow-up information.1244 F. Cesca: None. E. Bettella: None. R. Polli: None. E. Conclusions: We identified a novel heterozygous dele- Leonardi: None. M.C. Aspromonte: None. M. Bellini: tion of ACTG2 explaining the patient’s phenotype. Muta- None. A. Sensi: None. S. Bigoni: None. P. Scimemi: tions in ACTG2 cause visceral myopathy. The None. R. Santarelli: None. A. Murgia: None. microdeletion also included DGUOK. Mutations in DGUOK lead to autosomal recessive deoxyguanosine kinase deficiency causing neurological symptoms and liver 
P03  dysfunction.Nootherpathogenicmutationswereidentified Internal organs & endocrinology (lung, kidney, liver, in DGUOK. To the authors’ knowledge, no deletions in gastrointestinal) ACTG2 have previously been reported causing visceral myopathy. 
P03 .01A M.Kraatari:None.H.Kokkonen:None.M.Mäkinen: VisceralmyopathyduetoanoveldeletionoftheACTG2 C. Other Research Support (supplies, equipment, receipt of gene: a case report drugs or other in-kind support); Modest; Amgen. S. Tur- unen: D. Speakers Bureau/Honoraria (speakers bureau, M. Kraatari1,2,3, H. Kokkonen2,4, M. Mäkinen2,5, symposia, and expert witness); Modest; Abbvie. J. Moila- S. Turunen6, J. Moilanen1,2,3, O. Kuismin1,2,3 nen: None. O. Kuismin: None. 1Department of Clinical Genetics, Oulu University 
P03 .02B Hospital, Oulu, Finland, 2Medical Research Center, Oulu Thegeneticbackgroundinagroupof56Polishpatients University Hospital, University of Oulu, Oulu, Finland, with suspected Alport syndrome 3PEDEGO Research Unit, University of Oulu, Oulu, Finland, 4Northern Finland Laboratory Centre NordLab, P.Halat-Wolska1,E.Ciara1,L.Obrycki2,J.Antoniewicz2, Oulu, Finland, 5Cancer and Translational Medicine K. Gadomska-Prokop2, J. Kosińska3, M. Rydzanicz3, Research Unit, Department of Pathology, University of D. Siestrzykowska1, P. Stawiński3,4, B. Chałupczyńska1, Oulu, Oulu, Finland, 6Department of Children and D. Jurkiewicz1, P. Kowalski1, M. Pelc1, D. Piekutowska- Adolescents, Oulu University Hospital, Oulu, Finland Abramczuk1, K. Iwanicka-Pronicka1,5, P. Iwanowski1, J. Lesiak2, A. Łuba2, A. Niemirska2, A. Rogowska6, Introduction: ACTG2-related disorders are a part of D. Wicher1, M. Krajewska-Walasek1, R. Grenda2, visceral myopathy, a rare hereditary myopathic degenera- K. Chrzanowska1, R. Płoski3, M. Litwin2 tion of gastrointestinal and urinary tracts causing chronic intestinal pseudo-obstruction. Visceral myopathy is char- 1DepartmentofMedicalGenetics,TheChildren’sMemorial acterized by impaired intestinal function and motility Health Institute, Warsaw, Poland, 2Department of resulting in severe abdominal pain, malnutrition and even Nephrology, The Children’s Memorial Health Institute, death. Inter- and intrafamilial variability is present. Warsaw, Poland, 3Department of Medical Genetics, Diagnostic criteria include absence of mechanical obstruc- WarsawMedicalUniversity,Warsaw,Poland,4Department tion and histological examination of intestinal biopsies. of Genetics, Institute of Physiology and Pathology of Materials and Methods: We report a 10-year-old boy Hearing, Warsaw, Poland, 5Department of Audiology and referred to Oulu university hospital in March 2016 due to Phoniatrics, The Children’s Memorial Health Institute, pseudo-obstruction of the small intestine. Previously, per- Warsaw, Poland, 6Department of Ophthalmology, The sistent ductus arteriosus was closed operatively and diag- Children’s Memorial Health Institute, Warsaw, Poland nosisoffunctionalgrowthhormonedisturbancewasplaced. He had suffered from periodic abdominal pain, vomiting Introduction: Alport syndrome (AS) is a clinically and andslowweightgainfrominfancy.Hisclinicalpicturewas genetically heterogeneous nephropathy caused by patho- severe and he was completely dependent on parental genic variantsinCO
L4 A3-CO
L4 A5.Whilemost(80%) AS nutrition. Clinical suspicion of visceral myopathy was cases are X-linked, approximately 15% and 5% are aroused. autosomal recessive or difficult to differentiate from thin Results: Deletion/duplication analysis of ACTG2 identi- basement membrane nephropathy (TBMN) dominant fied a heterozygous likely pathogenic deletion encompass- forms. Digenic inheritance among CO
L4 A3-CO
L4 A5 or ing the entire ACTG2. Chromosomal microarray showed a their concomitance with other glomerulopathy or chronic heterozygous microdeletion 2p13.1 of 84 kb including the kidney disease (CKD) related genes, has been recently exons2-9ofACTG2andentireDGUOK.Thedeletionwas proposedtoexplainthevariablephenotypicexpressionand not identified in the parents and thus, was considered de incomplete penetrance frequently observed in AS patients. novo.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1245 Materials and Methods: NGS analysis of 55 glomer- in CO
L4 A3 and CO
L4 A4. All affected individuals develop ulopathy and CKD related geneswas performed in a group renal failure, usually as young adults. of 56 unrelated Polish patients with suspected AS. Carriers of a single autosomal mutation develop Thin Results: In all patients clinical diagnosis was confirmed Basement Membrane Nephropathy (TBMN) associated at the molecular level. Overall, 17 known and 32 novel, with ‘benign familial haematuria’. We analysed a cohort of likely pathogenic alterations in CO
L4 A3-CO
L4 A5 were 119 individuals (29 probands and 85 relatives identified by identified. The inheritance was X-linked in 73% of cases, cascadetesting)withheterozygousmutationsinCO
L4 A3or remaining9%autosomalrecessiveand18%weredominant CO
L4 A4 identified by Next Generation Sequencing and AS/TBMN. Changes were randomly distributed across all assessed genotype/phenotype correlations. 70% had hae- CO
L4 A3-CO
L4 A5 coding regions, however we revealed a maturia, 38% developed proteinuria, 21% had chronic recurrent CO
L4 A5 variant c.1871G>A in twelve patients. kidney disease and 10% reached end stage renal disease. Additionally, four patients with this alteration had likely 36% of our cohort had a single mutation in CO
L4 A4 pathogenic variant in CO
L4 A3, HNF1B or MYH9, which c.2906C>G p.(Ser969Ter), representing 18% of cases of may modify disease’s severity. proteinuria. 50% of these patients developed proteinuria Conclusions: The results of this study broaden the gen- compared with 31% of patients with other mutations. The otypic spectrum ofAS,whichwillfacilitate futureresearch riskofeGFRfallingbelow60ml/minincreasedfrom6%to on the genotype-phenotype correlations. Multiple-gene 8% in patients with the CO
L4 A4c.2906C>G p.(Ser969Ter) sequencing is an effective approach to obtain genetic mutation. Single CO
L4 A3/4 mutations are recognised sus- information in AS, particularly about the mode of inheri- ceptibility factors for developing proteinuria, hypertension tance which is important for counselling and may help to and renal disease in later life, but these risks have pre- predicttheclinicalcourse,especiallyforthosepatientswith viously not been quantified. It is recommended that all mild, non-specific or atypical phenotype. patients with a single CO
L4 A3/4 mutation should have Partially supported: CMHI-M29/18 annual checks of blood pressure and urine, with a low P. Halat-Wolska: None. E. Ciara: None. L. Obrycki: threshold for prescribing an ACE inhibitor, and this is None. J. Antoniewicz: None. K. Gadomska-Prokop: important for those with the high-risk genotype. None. J. Kosińska: None. M. Rydzanicz: None. D. In conclusion, this is the largest study ever performed of Siestrzykowska: None. P. Stawiński: None. B. Chałupc- the implications of carrying a single autosomal CO
L4 A3/4 zyńska: None. D. Jurkiewicz: None. P. Kowalski: None. mutationandourfindingsclarifytheriskofrenaldiseasein M. Pelc: None. D. Piekutowska-Abramczuk: None. K. this population. Iwanicka-Pronicka: None. P. Iwanowski: None. J. A.Cianflone:None.H.Storey:None.F.Flinter:None. Lesiak: None. A. Łuba: None. A. Niemirska: None. A. F. Forzano: None. Rogowska: None. D. Wicher: None. M. Krajewska- Walasek: None. R. Grenda: None. K. Chrzanowska: 
P03 .04D None. R. Płoski: None. M. Litwin: None. Molecular genetic analysis in patients with clinically suspected autosomal recessive polycystic kidney disease 
P03 .03C Genotype/phenotype correlations in carriers of a single L. Obeidova1, V. Elisakova1, T. Seeman2, J. Reiterova3, autosomal CO
L44 A3 and CO
L4 A4 mutation J. Vcelak4, J. Stekrova1 A. Cianflone1,2,3, H. Storey4, F. Flinter1, F. Forzano1 1InstituteofBiologyandMedicalGenetics,FirstFacultyof Medicine, Charles University and General University 1Clinical Genetics department, Guy’s & St Thomas’ NHS Hospital in Prague, Prague, Czech Republic, 2Department Foundation Trust, London, United Kingdom, 2Department ofPaediatrics,2ndFacultyofMedicine,CharlesUniversity of Neurosciences, Rehabilitation, Ophthalmology, Genetic in Prague and Motol University Hospital in Prague, and Maternal and Infantile Sciences (DINOGMI), Prague,CzechRepublic,3DepartmentofNephrology,First University of Genova, Genova,Italy,3Ospedale Policlinico Faculty of Medicine, Charles University in Prague and San Martino IRCCS-Medical Genetic Unit, Largo R. Benzi General University Hospital in Prague, Prague, Czech 10, Genova, Italy, 4Molecular Genetics, Viapath, Guy’s Republic, 4Institute of Endocrinology, Prague, Czech Hospital, London, United Kingdom Republic Alport’s syndrome is complex: 85% cases show X linked Introduction: Autosomal recessive polycystic kidney inheritancewithpathogenicmutationsinCO
L4 A5and15% disease (ARPKD) is a severe form of chronic kidney autosomal recessive inheritance with pathogenic mutations disease, frequently diagnosed prenatally or in an early age.1246 ARPKD is primaly caused by mutations in the PKHD1 disability. But feeding difficulties, constipation, and other gene, nevertheless, phenotype of polycystic kidneys GI problems were also reported. Whether these symptoms clinically resembling ARPKD can be caused by mutations are due to primary impairment or a secondary effect of in number of other genes, such as HNF1β, PKD1, PKD2, alteredbehaviourorsideeffectsofpsychotropicmedication NPHPetc.Thus,themoleculargeneticanalysiscanbevery remains unclear. useful in differential diagnosis of ARPKD in patient. The We investigated the GI tract of patient-relevant Foxp1 resultsofmoleculargeneticanalysisinelevenpatientswith +/-mice. These mice have a lower body weight than wild clinically suspected ARPKD, who did harbor mutations in type animals and show altered feeding behaviour. Foxp1 other genes than PKHD1, are presented. was expressedin all GI sections and was reduced in Foxp1 Materials and Methods: The molecular analysis was +/-mice compared with WT. A pronounced atrophy of the carried out using next-generation sequencing method with tunica muscularis was detected in the oesophagus and enrichment capture-based and amplicon-based library pre- colon, caused by reduced muscle cell proliferation. Nitric paration. The panel of approximately 80 genes associated oxide-inducedrelaxationoftheloweroesophagussphincter with the formation of polycystic kidneys was analyzed. was impaired and achalasia confirmed in vivo by mano- Results:Themostfrequentmutationsfoundinourgroup metry. Several Foxp1 targets previously identified by ofpatientswerevariantsintheTMEM67gene(5patients). microarray analysis in the brain were significantly deregu- In three patients, mutation in PKD1 was detected (in one lated in the oesophagus of Foxp1+/- mice. The total gut patientincombinationwithPKHD1mutationintrans).Two transit was significantly prolonged. Spatiotemporal maps patients harbored combination of two mutations: (1) muta- depicting the colonic contraction patterns revealed strongly tion in PKHD1 and TMEM237, (2) PKHD1 mutation and disturbed contractility and peristalsis. Overall, our findings deletion of 3 exons in the NPH
P3  gene. In one patient, provide the first evidence that GI disturbances in patients deletion of whole HNF1β gene was identified. with FOX
P1  autism spectrum disorder may be caused by Conclusions: Because of an etiologic heterogeneity of impaired gut motility and achalasia, driven by FOX
P1 - polycystic kidney disease phenotype, the complex muta- dependent deregulation of genes. Furthermore, this is the tional analysis, encompassing analysis in other genes first report of achalasia being caused by a heterozygous (especially TMEM67), should be used for reliable differ- gene deletion. ential diagnosis. Supported by the grant projects GAUK H. Fröhlich: None. M. Kollmeyer: None. M. Stuhlin- 1015, PROGRES- Q25/LF1 and RVO VFN64165 ger:None.V.Linz:None.D.Groneberg:None.A.Reigl: L. Obeidova: None. V. Elisakova: None. T. Seeman: None.E.Zizer:None.A.Friebe:None.B.Niesler:None. None. J. Reiterova: None. J. Vcelak: None. J. G. Rappold: None. Stekrova: None. 
P03 .06B 
P03 .05A HLA and non-HLA susceptibility genes to childhood Gastrointestinal dysfunction in autism spectrum steroid-sensitive nephrotic syndrome in the Japanese disorder: New insights from the Foxp1+/-mouse with population altered gut motility and achalasia X. Jia1, T. Horinouchi2, Y. Hitomi1, Y. Kawai1, K. Nozu2, H. Fröhlich1, M. Kollmeyer1, M. Stuhlinger1, V. Linz1, C.Nagano2,T.Yamamura2,M.Nagasaki3,K.Tokunaga1, D. Groneberg2, A. Reigl2, E. Zizer3, A. Friebe2, K. Iijima2 B. Niesler1, G. Rappold1 1Dept Human Genetics, Grad Sch Medicine, Univ Tokyo, 1Department of Human Molecular Genetics, Institute of Tokyo, Japan, 2Dept Pediatrics, Grad Sch Medicine, Kobe Human Genetics, University of Heidelberg, Heidelberg, Univ, Kobe, Japan, 3Dept Integrative Genomics, Tohoku Germany, 2Institute ofPhysiology, University ofWürzburg, Medical Megabank, Tohoku Univ, Sendai, Japan Würzburg, Germany, 3Department of Internal Medicine I, University of Ulm, Ulm, Germany Idiopathic nephrotic syndrome (INS) is the most common cause of kidney disease in children, about 80% of pediatric Gastrointestinal (GI) dysfunction is common in individuals patients respond to steroid treatment and are classified as with autism spectrum disorder (ASD), but these symptoms steroid-sensitive NS (SSNS). Previous genome-wide asso- are often overlooked and it is still not clear how GI ciation studies (GWASs) have identified HLA-DR/DQ as dysfunction relates to the core features of ASD. thepredominantriskfactorsofchildhoodSSNS.Ourgroup FOX
P1  syndrome is characterized by autistic traits, such reported the first GWAS for childhood SSNS in Japanese. as social deficits, language impairment, and intellectual Genome-wide significant associations were identified inAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1247 HLA-DR/DQregionanddisease-associatedHLAallelesand #227810) linked to GLUT2 deficiency. Two boys are haplotypeswerefurtherclarified(JAmSocNephrol,2018). affected by both Cockaine and GLUT2 deficiency. To identify other loci contributing to susceptibility to Fanconi-Bickels syndrome is related to SL
C2 A2 muta- childhood SSNS, especially in non-HLA regions, we tions (3q26) and glucose transporter protein-2 (GLUT2) performed an extended GWAS with a larger number of defect. The typical clinical picture is characterized by samples. Discovery stage including 897 patients with hepatorenalglycogenaccumulationresultinginhepato-and childhood-onset SSNS and 2,807 adult healthy controls nephromegaly. In this family the patients with SL
C2 A2 wascarriedoutintheJapanesepopulation,genotypedusing mutationshowgrowthretardation,majorhepatomegalyand Affymetrix ‘Japonica Array’. Whole-genome imputation renalfailure.Thehomozygousmutation isintronic:lV
S9 -1 was conducted using a phased reference panel of 2,049 g>a /IV
S9 -1g>a. healthy Japanese individuals (2KJPN panel). Quality In Cockaine syndrome, 2 genes are affected ERC
C6  and control was performed to exclude the samples with low ERC
C8 . Here a new homozygous pathogenic variation has calling rate (<97%) and the variants with low genotyping been identified in ERC
C8  (5q12.1): c.730C>T (exon 9) rate (<97%), minor allele frequency (MAF) <0.5% and (Calmel N et al. Orphanet J Rare Dis. 2016). ERC
C8  Handy-Weinberg equilibrium (HWE) test p-value <1×10-5. encodes the CSA protein involved in DNA repair. The Association analysis was conducted using logistic regres- patients aging 15 to 28 years in the family show neonatal sion with the adjustment of gender and principal compo- photosensibility, growth retardation, dysmorphic features, nents. In this discovery GWAS, the most significant lypoatrophy,intellectualdeficiency,lateonsetdeafnessand association was detected in HLA-DR/DQ region as we tremor. The RRS test (Recovery RNAsynthesis afterDNA reported before (P=2.98×10-32, odds ratio (OR)=0.34). damage) was altered and UDS test (unscheduled DNA Furthermore,tworegionsonchromosome19and18showed synthesis) was normal. ERC
C8  is involved in Cockaine genome-wide significant associations (p=3.28×10-18, Syndrome and UV-Sensitive syndrome, both very rare in OR=1.95; p=5.38×10-9, OR=1.65). Replication studies Europe (1/200000 and 1/1000000 respectively). were successfully performed in other Asian sample sets. The occurrence of several genetic pathology in the same X. Jia: None. T. Horinouchi: None. Y. Hitomi: None. familyisnowmorefrequentlypresented.Wereportherethe Y. Kawai: None. K. Nozu: None. C. Nagano: None. T. association of two very rare syndromes affecting most Yamamura: None. M. Nagasaki: None. K. Tokunaga: children in a unique family. None. K. Iijima: None. M. Doco-Fenzy: None. N. Calmels: None. H. Thorn: None. C. Poirsier: None. M. Spodenkiewiscz: None. E. 
P03 .07C Gouy: None. L. Le Collen: None. R. Santer: None. B. Two genetic disease in one family: Cockaine Syndrome Digeon: None. A. Doe: None. A. Lebre: None. A. Leh- (ERC
C8 ) and Fanconi Bickels (SL
C2 A2) mann: None. C. Obringer: None. V. Laugel: None. G. Thiefin: None. M. Doco-Fenzy1, N. Calmels2, H. Thorn1, C. Poirsier1, M. Spodenkiewiscz1, E. Gouy1, L. Le Collen1, R. Santer3, 
P03 .08D B. Digeon4, A. Doe5, A. Lebre1, A. Lehmann6, Apparently isolated congenital hyperinsulinism due to C. Obringer7, V. Laugel7, G. Thiefin8 KDM6A mosaic pathogenic variant 1Service de Génétique, CHU-Reims, Reims, France, M. Yacobi Bach1, E. Elkon Tamir2, S. Ben Shachar1, 2Service de génétique, strasbourg, France, 3genetic, O. Eyal3 Hambourg, Germany, 4Service de Pédiatrie, CHU-Reims, Reims, France, 5Service de Neurologie, CHU-Reims, 1Genetics institute, Tel Aviv, Israel, 2Pediatric Reims, France, 6Genome center Sussex university, Endocrinology institute, Tel Aviv, Israel, 3Pediatric Cambridge,UnitedKingdom,7ServicedeGénétique,CHU- Endocrinology institute, Tel Aviv, Israel Strasbourg, strasbourg, France, 8Service de Gastroentérologie, CHU-Reims, Reims, France Introduction: Kabuki Syndrome- KS is a syndrome with multiple congenital anomalies. It is characterized by We report a rare consanguinous family suffering from 2 dysmorphic facial features, craniofacial and skeletal congenitalautosomicrecessivegeneticdisease.Theparents anomalies, dermatoglyphic abnormalities, mild to moderate are cousins and have 7 children. 3 boys and 1 girl show cognitive decline, and postnatal growth deficiency. Con- Cockainesyndrome(OMIM#216400)and3children(1girl genitalhyperinsulinismasthepresentingfeatureofKS,was and 2 boys) show Fanconi-Bickels symptoms (OMIM described in 10 affected individuals. The gene KDM6A is responsible for KS in approximately 5% of patients.1248 KDM6A mosaicism was reported in at least one patient candidate genes was done to specify the functional effects with typical KS manifestations. of the mutations. The variants found in potential candidate Case report: A 20-month-old girl diagnosed with iso- genes were validated and segregated by re-sequencing. lated,persistentcongenitalhyperinsulinismresponsiveonly After prioritisation of the best candidate gene, re- to Diazoxide treatment. She has no dysmorphic features, sequencing of this candidate gene in a cohort of 30 spora- normal development, and no structural anomalies. Mole- dic cases is warranted. cular Analysis of the coding regions and exon/intron Results: The filtering of WES-data identified four rare boundaries of 16 genes responsible for congenital hyper- homozygous variants in ZNF512 (p.His90Arg), SM
C6  (p. insulinism was performed on a clinical basis by targeted Thr679Met),BRE(p.Ser11Cys)andGCKR(p.Arg149Lys). nextgenerationsequencing.Amosaicpathogenicvariantin Conclusions: We suggest novel recessive candidate thegeneKDM6Ac.514C>Tp.Arg172Terwasdetectedinat genes for congenital chylothoraces. Re-sequencing in a least 20%. of the cells. No other variants were identified. cohort of 30 sporadic cases with congenital chylothoraces Discussion: It has been suggested previously that female and functional studies in zebrafish of the most promising patients with KDM6A mutations have milder phenotypes candidate genes is pending. than males. This is the first report of KDM6A pathogenic S. Schneider: None. A.C. Hilger: None. H. Thiele: variant causing isolated congenital hyperinsulinism in an None. J. Altmüller: None. A. Müller: None. H. apparentlyhealthygirl.Itislikelythatthecombinationofa Reutter: None. mosaic state of variant and female gender resulted in con- genital hyperinsulinism. We suggest the gene KDM6A will 
P03 .11C be included in the molecular studies of isolated congenital A novel homozygous nonsense mutation (p.R516X) in hyperinsulinism. the SL
C5 A5 gene causing congenital hypothyroidism M.YacobiBach:None.E.ElkonTamir:None.S.Ben Shachar: None. O. Eyal: None. F.B.Isik1,M.D.Sozuguzel1,B.K.Aydin2,C.Parlayan1, M. Yildiz2, H. Cangul1 
P03 .10B Genetic Drivers of Congenital Chylothoraces 1Istanbul Medipol University, istanbul, Turkey, 2Kanuni SultanSüleymanTrainingandResearchHospital,istanbul, S. Schneider1,2, A. C. Hilger1,2, H. Thiele3, J. Altmüller3, Turkey A. Müller2, H. Reutter1,2 Congenital hypothyroidism (CH) is the most common 1Institute of Human Genetics, University of Bonn, Bonn, neonatal endocrine disorder with an incidence of 1 in 3500 Germany, 2Department of Pediatrics, Children’s Hospital, livebirthsand2%ofCHcaseshavefamilialorigin.Unless University of Bonn, Bonn, Germany, 3Cologne Center for a timely treatment is introduced, CH causes mental Genomics, University of Cologne, Cologne, Germany retardationandgrowthdelay.Morethan10causativegenes havebeendescribedforthepathogenesisofinheritedCHto Introduction: Congenital chylothoraces (CCT) are rare date.InthisstudyweinvestigatedaMendeliancauseofCH fetal conditions, occurring in 1/10,000 pregnancies. Its in a consanguineous family with 2 affected children. Both clinical course varies from small thoracic effusions to life‐ casesshowedshortstature,mentalretardationandboneage threatening thoracic compression and secondary hydrops retardation. Next generation sequencing analysis of 16 fetalis. Primary CCT result from malformations of the candidate CH genes identified a homozygous nonsense thoracic lymphoid system, secondary CCT result from change (p.R516*, c.1546C>T) in the SL
C5 A5 gene cardiacanomaliesorinflammatorydisease.Previousstudies (NM_000453.2) in both cases. We confirmed the presence suggest underlying genetic causes and found several genes of this variant by Sanger sequencing and both parents and to be mutated in some patients with lymphatic disorders. the unaffected sibling carried this variant at heterozygous The aim of this study is to investigate new genetic drivers state, underlying the co-segregation of the variant with the for primary CCT. disease status in the family. Moreover, this variant was not Methods: We applied whole-exome sequencing (WES) present in 400 ethnically matched control chromosomes. p. in two affected sibling pairs and their healthy parents. To R516*variantintheSL
C5 A5geneisnotcurrentlylistedas identify disease causing variants we applied standardized a mutation in clinical databases. Since (i) it introduces a filtering of WES-data. First, we filtered for autosomal- prematurestopcodoninthegene;(ii)co-segregateswiththe recessive and autosomal-dominant novel variants. Second, disease status in the family and (iii) is not present in 400 the predicted deleteriousness and the conservation of the ethnically matched control chromosomes, here we report it mutations was controlled. Third, further research on the as a novel mutation causing congenital hypothyroidism.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1249 F.B. Isik: None. M.D. Sozuguzel: None. B.K. Aydin: 
P03 .13A None. C. Parlayan: None. M. Yildiz: None. H. Application of next-generation sequencing in the search Cangul: None. ofgeneticcausesforTaiwanesepatientswithsyndromic disorders of sex development 
P03 .12D Molecular analysis of CY
P21 A2 gene in 100 patients M. Tsai with Congenital Adrenal Hyperplasia (CAH) due to 21- hydroxylase deficiency DepartmentofPediatrics,NationalChengKungUniversity Hospital, Tainan, Taiwan E. Fylaktou1, A. Sertedaki1, E. Charmandari1,2 Objective: This study aimed primarily to establish a rapid 1Division of Endocrinology, Metabolism and Diabetes, andhigh-throughputgenetictestforsyndromicdisordersof First Department of Pediatrics, National and Kapodistrian sex development (DSD). Meanwhile, the applicability and University of Athens, Medical School, ‘Aghia Sophia’ effectiveness of next-generationsequencing wereevaluated Children’s Hospital, Athens, Greece, 2Division of in searching for the remaining unknown causative genes of Endocrinology and Metabolism, Biomedical Research this inherited disease. Foundation of the Academy of Athens, Athens, Greece Methods: Patients with clinically diagnosis of DSD with additional dysmorphic features were recruited. We applied Introduction: Congenital adrenal hyperplasia (CAH) due the filter-based hybridization method as the main strategy to 21-hydroxylase deficiency is an autosomal recessive for whole exome sequence (WES) enrichment. The ampli- condition in which mutations of the cytochrome 
P450  21- fiedexomeswerehybridizedagainsttheDNAlibrariesand hydroxylase gene (CY
P21 A2) result in decreased synthesis sequenced subsequently. We finally used the integrated of glucocorticoids and often mineralocorticoids. The computing programs to call the genetic variants for DSD. clinical spectrum of the disease ranges from most severe, Results: We enrolled a total of 10 syndromic DSD to mild forms depending on the degree of 21-hydroxylase patients.Targetedampliconsweresmoothlygeneratedwith activity. adequate capture efficiency (coverage 98% of exons and Materials and Methods: Seventy-one cases (69 referred 100% >30 read depths). Among them, we found 2 patients forCAHand2forprenataldiagnosis),aswellas29siblings compatiblewithCHARGEsyndrome(oneisc.1480C>T,p. of carriers/patients with CAH, were tested for CY
P21 A2 Arg494X and the other is c.6571G>A, p.Glu2191Lys in gene mutations. Long range PCR was employed to selec- CHD7 gene), one with Robinow syndrome tively amplify the CY
P21 A2 gene against its pseudogene, (c.1571delCGGGTGGGGCAGCGfs in DV
L1  gene), one followed by Sanger sequencing. MLPA analysis was with OPHN1 syndrome (c.1171T>A, p.Arg391Trp in undertaken for samples with an indication of duplication/ OPHN1 gene), and one with FG syndrome (c.1864C>T, p. deletion of the gene. Glu622Lys in FLNA gene). Results: Thirty patients with CAH were compound het- Conclusion: We identified a number of genetic variants erozygotesorhomozygotes,whilefortywereheterozygotes accounting for syndromic DSD in Taiwanese population. forCY
P21 A2genemutations.Oneoftheprenatalcaseswas Withidentificationofthesecausativegenes,itextendedour compound heterozygote, while the other was simple het- current understanding of sex development and related erozygoteforCY
P21 A2genemutations.Themostcommon congenitaldisorders.Furtherfunctionalverificationofthese mutations detected were as follows: p.V281L (25%), p. variants may be needed on the cell line models. 
P30 L(14%),I2SpliceSite(10%),p.I172N(4%),p.Q318X Funding: This research was funded by the research (2%), p.
P482 S (3%), p.
P453 S (13%) and *13G>A 3' UTR grants awarded by the National Cheng Kung University (7%).Fourparentswithnoclinicalsymptomswerefoundto Hospital (NCKUH-10702001 and NCKUH-10307006). be compound heterozygotes for the non-classic form of M. Tsai: None. CAH. Eight samples harbored genomic rearrangements in one or both alleles of the gene. 
P03 .14B Conclusion: Molecular analysis of the CY
P21 A2 gene is Splice site mutation in GRHPR gene in Iranian family essential for proper management of patients with CAH due with ESRD and nephrocalcinosis to 21-hydroxylase deficiency, as well as for genetic coun- seling and prenatal diagnosis. R. Miri Moosavi1, S. Saber1, A. Ebrahimi1, E. Fylaktou: None. A. Sertedaki: None. E. T. Malakoutian2 Charmandari: None.1250 1Jordan medical and genetic laboratory, Tehran, Iran, fasting hyperglycemia which is often discovered inciden- Islamic Republic of, 2Department of Nephrology, tally during routine medical screening. Hasheminejad Kidney Center, Iran University of Medical Materials and Methods: After clinical examination, 56 Sciences, Tehran, Iran, Islamic Republic of patients with stable hyperglycemia, small 2 hour increment in OGTT, positive family history of type 2 or gestational Introduction:End-stagerenaldisease(ESRD)occurswhen diabetes and negative pancreatic antibodies were tested for your kidneys clearly begin to shut down. Both genetic and GCK-MODY. The promoter, whole coding region and epigenetic increase risk of ESRD. A three-to nine-fold flankingintronicregionsoftheGCKgenewereanalyzedby greater risk of ESRD is observed in individuals with a Sanger sequencing. Pathogenicity of identified mutations family history of ESRD, so role of genetic study is was verified in reference databases for mutations related important nowadays. with GCK-MODY. Materialand Method:A 43-year-old, Iranian man were Results:17 different mutationsinGCK genewerefound detected ESRD with nephrocalcinosis (multiple stones). in 32 patients. Most of the mutations were in exon 7 (six According to nephrologist decision, primary hyperoxaluria mutationsin16patients)andinexon9(fivemutationsin5 was considered so that was candidate for kidney and liver patients). The most common mutation was p.Thr228Met in transplant. So, genetic analysis was requested to approve exon 7 found in 8 patients from 4 different famillies. One mentioned diagnosis. Whole exome sequencing (WES) test patient was apparently homozygous for mutation p. was performed to find variants responsible for renal Gly170Asp,butitstruehomozygosityisnotyetconfirmed, disorder. it can be a result of an allele dropout due to SNP in the His parents had consanguineous marriage. His father and primer region. In one patient we detected a novel variant two sisters suffered from nephrocalcinosis. According to c.806T>G, p.Phe269Cys in exon 7. results of WES test and analysis all genes responsible to Conclusions:GCK-MODYisfrequentlyunderdiagnosed renal disorder, one likely pathogenic/pathogenic variant and inadequately treated. Treatment is rarely necessary if (c.735-1G>A) in splice site region was found in GRHPR the mild hyperglycemia remains stable. gene. This gene is responsible for primary hyperoxaluria A. Merkler: None. A. Špehar Uroić: None. N. Krnić: type 2 with an autosomal recessive inheritance pattern. None. H. Ljubić: None. D. Caban: None. A. Acman Clinical manifestations in patients were same as Men- Barišić: None. D. Kaštelan: None. J. Sertić: None. tioned disease, after examining of clinical data. Familial segregation was done and his father and two sisters are 
P03 .16D carrier of this variant. Liver transplant might be considered Novel variants in DHH gene identified with 46,XY within kidney transplant in this case. gonadal dysgenesis Conclusion: Genetic analysis should be considered in renal failure to do the best management in therapy. A. Aghayev1, G. Toksoy1, S. Poyrazoglu2, B. Karaman1, R. Miri Moosavi: None. S. Saber: None. A. Ebrahimi: S. Avcı1, Z. Yavas Abalı2, U. Altunoglu1, F. Bas2, None. T. Malakoutian: None. F. Darendeliler2, S. Basaran1, Z. Uyguner1 
P03 .15C 1Dept. Med. Genet., Istanbul Med. Faculty, Istanbul GCK mutations in Croatian MODY patients University, Istanbul, Turkey, 2Dept. Ped. Endocrinology, IstanbulMed.Faculty,IstanbulUniversity,Istanbul,Turkey A. Merkler1, A. Špehar Uroić1, N. Krnić1, H. Ljubić1, D. Caban1, A. Acman Barišić1, D. Kaštelan1,2, J. Sertić1,2 Introduction: Desert Hedgehog (DHH) a member of the hedgehog family, is located in 12q13.1 and acts on early 1University Hospital Centre Zagreb, Zagreb, Croatia, testicular development, testis cord formation and differ- 2University of Zagreb School of Medicine, Zagreb, Croatia entiation of fetal Leydig cells. To date, six homozygous mutations have been described in DHH in 46,XY patients Introduction: Maturity onset diabetes of the young conferring phenotypes ranging from partial to complete (MODY) is clinically and genetically heterogeneous group gonadal dysgenesis, associated with of without of diabetes inherited in autosomal dominant manner. It polyneuropathy. usually occurs in adolescence or young adulthood and Materials and Methods: We investigated three patients accounts for at least 1-3% of all diabetes. GCK-MODY is from two families with 46,XY gonadal dysgenesis, for one of four most common type of MODY with estimated pathogenicsequencealterationsin31associatedgenes,with prevalence of 1:1000. It is characterized by mild, stable in-house-designed next generation sequencing (NGS) tar- getedgenepanel,usinganIonTorrentplatform.UltrasoundAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1251 and histopathological examination of the gonads with an 
E3  ubiquitin ligase, EDD1 in the cell. By utilizing electrophysiological examination of peripheral nerves were various cell culture models, we demonstrate that HBx and performed. Protein modeling was done to predict the effect TI
P60  form a complex with EDD1. Interestingly, this of the missense mutations. hackingofTI
P60 protein,enablesincreasedproliferationof Results: We have identified three different homozygous hepatocytes, as confirmed by various growth assays and mutations, one in two siblings, c.[1146G>A];[1146G>A], mechanistically by increased expression of TERT and (p.[Trp382*];[Trp382*]), and two in singleton case, decreased levels of TI
P60  protein. Additionally, tissue c. [71G>C;1063C>T];[71G>C;1063C>T], (p.[Gly24Ala; microarray analysis(TMA)of HBV-positive malignant Arg355Cys];[Gly24Ala;Arg355Cys]). One of the siblings tumor samples demonstrate a strong correlation between presented with penoscrotal hypospadias, bilateral inguinal TI
P60  and EDD1 levels,furthersupporting our hypothesis. testes,Mullerianstructureevidentonbiopsy,noresponseto WethereforeproposeTI
P60 asoneofthecellulartargetsin HCG at one-year and raised as female initially. Second HBx mediated viral infection and to utilize small molecule sibling presented micropenis, bilateral inguinal testes, no inhibitors against the identified ubiquitin-ligase in HBx- Mullerian structure, response was normal to HCG at age mediatedHBV-carcinogenesis.Inconclusion,ourstudyhas 14 days and raised as male. In addition, both patients suf- identifiedarelativelyunknownroleofHBx,itsdestabiliza- fered from polyneuropathy. Third patient presented at age tion of an epigenetic writer and the mechanism involved in 19 days with penoscrotal hypospadias, bilateral inguinal thisphenomenon.ThisworkwassupportedbyMOEgrants testes,noMullerianstructure,lowAMHandraisedasmale. (MOE AcRF Tier 1 T1-2012 Oct-04 and T1-2016 Apr-01) Conclusions: DHH mutation should be analyzed in and CSI(R-713-006-014-271). SH is supported by NUS- patients with 46,XY gonadal dysgenesis for diagnosis and Research Scholarship awarded by NUS Yong Loo Lin the presence of potential neuropathy and gonadal tumors. School of Medicine. A. Aghayev: None. G. Toksoy: None. S. Poyrazoglu: S. Hora: None. N. Kumari: None. D. Rajagopalan: None.B.Karaman:None.S.Avcı:None.Z.YavasAbalı: None. L. Hooi: None. T.B. Toh: None. K.K. Lee: None. None.U.Altunoglu:None.F.Bas:None.F.Darendeliler: W.S. Teo: None. T. Tan: None. P.L. Chen: None. E.K. None. S. Basaran: None. Z. Uyguner: None. Chow: None. H.P. Koeffler: None. S. Jha: None. 
P03 .17A 
P03 .18B HBx destabilizes TI
P60  in HBV-induced hepatocellular Next generation sequencing approach for determining carcinoma the molecular basis of familial hematuria S. Hora1,2, N. Kumari1, D. Rajagopalan1, L. Hooi1, O. Beltcheva1, K. Kamenarova1, K. Mihova1, A. Boueva2, T. B. Toh1, K. K. Lee1, W. S. Teo1, T. Tan2, P. L. Chen1, D. Roussinov3, G. Zlatanova3, V. Lazarov4, P. Miteva3, E. K. Chow1, H. P. Koeffler1, S. Jha1,3 M. Gaydarova3, B. Deliyska4, V. Mitev1, R. Kaneva1 1Cancer Science Institute of Singapore, Singapore, 1Molecular Medicine Center, Dept. of Medical Chemistry Singapore, 2Department of Biochemistry, National and Biochemistry, Medical University-Sofia, Sofia, University of Singapore, Singapore, Singapore, Bulgaria,2NephrologyandDialysisClinics,SBALDB“Dr. 3Department of Biochemistry, National University of Lisichkova”, Varna, Bulgaria, 3SBAL Pediatric Diseases, Singapore, Sinagpore, Singapore Nephrology and Hemodialysis Clinic, Department of Pediatrics, Medical University -Sofia, Sofia, Bulgaria, TI
P60 (TAT-interactive protein of 60 kDa),is a lysine 4Nephrology Clinic, University Hospital “Queen acetyltransferase (KAT5) and acts as a haplo-insufficient Giovanna”, Medical University - Sofia, Sofia, Bulgaria tumor suppressor in multiple cancer-types. TI
P60  isknown to be destabilized by different onco-viruses and this Introduction: Hematuria is a non-specific symptom of intrigued us to inspect its role in another onco-virus kidneyorurinarytract pathology. Thepresenceofbloodin pathogenesis, hepatitis B virus (HBV). HBV, the leading the urine could be due to trauma, infections, systemic cause of hepatocellular carcinoma (HCC) is the 6th most disease, disorders of the coagulation or genetic mutations common cancer in the world. Among the four overlapping affecting the development and function of particular cell open reading frames of HBV, the HBV X gene (HBx) is andtissuetypes.Thepresenceoffamilyhistoryisindicative consideredthecausativeagentformalignanttransformation of a hereditary condition such as disorders of the basement associated with HBV infection. In this conference I am membrane, complement or podocytes. Differential diag- going to discuss data that show TI
P60  being targeted by nosis of hematuria is crucial for successful treatment of the HBx,aproto-oncogeneofHBVproteasomally,byutilizing underlying condition.1252 Materials and Methods: Illumina TruSight One Materials and Methods: A 57-year-old patient with Sequencing Panel was used for mutation screening in 8 congenitaloculocutaneousalbinism, thrombocytopathy and families with multiple members with hematuria. The index lateonsetacceleratedpulmonaryfibrosiswasreferredtoour patients were referred with initial diagnoses of glomerulo- clinic.Negativefamilyhistoryofthesesymptomssuggested pathy, thin basement membrane nephropathy, uric acid autosomal-recessive mode of inheritance. We performed nephropathy, focal segmental glomerulosclerosis, tubu- NGS analysis of proband-parents trio. Whole-exome lointerstitial nephritis and/or chronic kidney disease. libraries were prepared according to the Nimblegen Seq- Results: Using next generation screening we determined CapEZExomev3protocol andsequencingwas performed the genetic cause of hematuria in Bulgarian families. onNextSeq500forallofthem.Furthermore,weperformed Pathogenic variants were found in the type IV collagen in silico analysis of a virtual gene panel, including HP
S1 , (autosomalrecessiveanddominantvariantsinCO
L4 A4,X- A
P3 B1, HP
S3 , HP
S4 , HP
S5 , HP
S6 , DTNB
P1 , BLO
C1 S3
, linked in CO L4
A5) and complement genes. Both missense and PLDN. and splice mutations, known pathogenic and novel variants Results: Whole-exome sequencing identified a com- were found. A potential role of heterozygous  C1
QC muta- poundheterozygousgenotypeinHP S1
geneintheproband. tions in the pathogenesis of G3 glomerulopathy was We identified a pathogenic frameshift variant c.1189delC observed. (p.Gln397Serfs*2), resulting in a premature stop codon, Conclusion:Clinicaldiagnosisofhereditaryhematuriais associated with HPS. Furthermore, we identified a rare, oftenhinderedbyphenotypevariability,lackofinformation previously undescribed nonsense variant, c.1507C>T (p. fordiseaseprogressioninolderfamilymembers,difficulties Gln503*), resulting in a premature stop and mRNA in obtaining biopsy samples, etc. Addition of massive par- degradation. Presence of both variants was verified by allel sequencing of large gene to the diagnostic procedure Sanger sequencing. The following molecular-genetic ana- would allow timely and precise determination of the lysis of parents confirmed their heterozygous carrier status. molecular cause of the disease. Conclusions: Compound heterozygous mutations in Grant references: D-73/2018; DUNK 01/2/2009 HP S1
 in the proband lead to disruption of HP S1
 gene and O. Beltcheva: None. K. Kamenarova: None. K. clinicalmanifestationofHermansky-Pudlaksyndromewith Mihova:None.A.Boueva:None.D.Roussinov:None.G. severe pulmonary fibrosis leading to respiratory failure and Zlatanova: None. V. Lazarov: None. P. Miteva: None. death. This study was supported by Czech Ministry of M. Gaydarova: None. B. Deliyska: None. V. Mitev: Health (grant AZV 16-29447A) and Masaryk University None. R. Kaneva: None. (grant MUNI/A/1105/2018). J. Trizuljak: None. M. Doubková: None. A. Hraz-  P03
.19C dírová:None.Z.Vrzalová:None.I.Blaháková:None.L. A rare diagnosis: Hermansky-Pudlak syndrome in a Radová: None. Š. Pospíšilová: None. M. Doubek: None. patient with pulmonary fibrosis, oculocutaneous albinism and thrombocytopathy  P03
.20D Genetic testing for hereditary hemorrhagic J. Trizuljak1,2, M. Doubková3, A. Hrazdírová3, telangiectasia diagnosis: identification of new ENG and Z.Vrzalová2,I.Blaháková2,L.Radová2,Š.Pospíšilová1,2, ACVR L1
 mutations in Italian families M. Doubek1,2 F. Cro’1, C. Lapucci1, E. Buscarini2 1Department of Internal Medicine, Hematology and Oncology, University Hospital and Faculty of Medicine, 1Synlab Italia - Laboratory of Medical Genetics, Brno, Czech Republic, 2Central European Institute of Castenedolo,Italy,2Hospital"Maggiore"ASST-European Technology, Brno, Czech Republic, 3Department of Reference Network (ERN) HHT, Crema, Italy Pulmonary Diseases and Tuberculosis, University Hospital and Faculty of Medicine, Brno, Czech Republic Introduction: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease characterized by Introduction: Hermansky-Pudlak Syndrome (HPS) is an mucocutaneous telangiectasias, epistaxis and visceral arter- autosomal recessive disorder associated with oculocuta- iovenousmalformations(AVMs).HHT-type-1iscausedby neous albinism, bleeding diathesis, granulomatous colitis, ENG gene mutations and it is characterized by a high and highly penetrant pulmonary fibrosis in some subtypes, incidence of pulmonary and cerebral AVMs. Type-2 is Homozygous or compound heterozygous mutations in caused by ACVR L1
 gene mutations and it is associated HP S1
,HP S3
,HP S4
andseveralothergenesleadtoclinical with hepatic AVMs. Mutations in SMAD4 gene cause manifestation of the disease. Juvenile Polyposis/HHT syndrome. Here we report twoAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1253 cases with suspected HHT-1 and HHT-2 in which new Hirschsprung disease (HSCR) is characterized by absence ENG and ACVR L1
 mutations where found. of enteric ganglia, primarily in the distal colon. Approxi- MaterialsandMethods:DNAwasextractedfromblood mately 18% of patients have additional anatomical samples of patients with suspected HHT. ENG, ACVR L1
 malformations or associated neurodevelopmental disorders, and SMAD4 genes were analyzed by Next Generation including autism and intellectual disability. A subset of Sequencing and results were confirmed by Sanger these patients have a known genetic syndrome in which Sequencing. HSCR has a variable expression or penetrance. In others, Results: Case-1: mutation c.780_781insCCTACG (p. the genetic etiology is unknown and we hypothesize that Ser260_Trp261insProTh) on ENG gene was identified in a rare Copy Number Variation (CNV) impacts their disease 16-year-old boy with epistaxis, PAVM and HHT-1 family development. Indeed, rare Copy Number (CN) losses were history. This mutation hasn’t been reported yet. Genetic significantlyenrichedinpatientswithHSCRandadditional testing was also performed in patient’s three brothers and anomalieswithoutaknowncausalvariant(n=23,p=3.64E- twocousins.Themutationwasidentifiedinonebrother(4- 7),andnotinisolatedHSCR(n=20,p=0.700)orinHSCR years-old,experiencingbleedingepisodes)andbothcousins patients with a known RET or other causal variant (n=15, (9 and 7 years-old). Two brothers (15 and 9 years-old, p=0.705). Of the HSCR patients with additional anomalies without any HHT symptoms) resulted negative. Case-2: tested, at least five (three males and two females) had a mutationc.1327T>G(p.Cys443Gly)onACVR L1
genewas largedenovoCNVandonemaleinheritedanX-linkedCN identifiedina45-years-oldwomanwithsevereliverAVMs loss. Patients with a known causal variant had a significant and enlisted for transplantation, rare epistaxis and no HHT lower burden of the known HSCR predisposing risk family history. The mutation, consistent with clinical sus- haplotypes (P=0.0232), and isolated HSCR patients a pect of HHT-2, hasn’t been described yet. higherburden(P=0.0277)comparedtopatientswithHSCR Conclusions: Here we report new ENG and ACVR L1
 and additional anomalies without a known causal variant. mutationsthoughttobecausativeofhereditaryhemorrhagic The rare CN losses identified are enriched for dosage telangiectasia.Furtherclinicalevaluationoncarrierandnot- sensitive genes, expressed in the developing mouse enteric carrier relatives will be performed. nervous system (ENS; p=1.760E-10): SL C8
A1, DDR1, F. Cro’: A. Employment (full or part-time); Significant; GN L1
, GABBR1, MAPK8, UFD1L, FHIT, AKT3, TUBB, Synlab Italia. C. Lapucci: A. Employment (full or part- TBX2,BCA S3
andUS P32
.Additionally,thelatterfour,had time); Significant; Synlab Italia. E. Buscarini: None. rare putative deleterious variants in HSCR patients without a deleterious CNV, confirming our hypothesis that rare  P03
.21A CNV contributes to syndromic HSCR with unknown Enrichment for large deletions encompassing genes genetic etiology. expressedintheentericnervoussysteminHirschsprung K.C. MacKenzie: None. C.S. Tang: None. J.D. Wind- disease patients with additional associated anomalies ster: None. T. Le: None. B.M. de Graaf: None. R. van der Helm: None. Y. van Bever: None. C.E.J. Sloots: K.C.MacKenzie1,C.S.Tang2,J.D.Windster1,3,T.Le4,5, None. C. Meeussen: None. D. Tibboel: None. A. de B.M.deGraaf1,R.vanderHelm1,Y.vanBever1,C.E.J. Klein: None. R.M.H. Wijnen: None. S. Lyonnet: None. Sloots3,C.Meeussen3,D.Tibboel3,A.deKlein1,R.M.H. M.Garcia-Barcelo:None.P.K.H.Tam:None.M.Alves: Wijnen3, S. Lyonnet4,6,5, M. Garcia-Barcelo2, P. K. H. None. A. Brooks: None. R.M.W. Hofstra: None. E. Tam2, M. Alves1, A. Brooks1, R. M. W. Hofstra1, Brosens: None. E. Brosens1  P03
.22B 1Clinical Genetics, Erasmus Medical Centre – Sophia The impact ofNRG1expressions and methylation on Children’s Hospital, Rotterdam, Netherlands, 2Department multifactorial Hirschsprung disease in Indonesia of Surgery, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China, 3Paediatric Surgery, Gunadi1, A. Kalim2, N. Budi2, N. Arfian2, E. Purnomo3, Erasmus Medical Centre – Sophia Children’s Hospital, K. Iskandar3 Rotterdam,Netherlands,4ParisDescartes-SorbonneParis Cité University, Imagine Institute, Paris, France, 1Faculty of Medicine, Public Health and Nursing, 5Laboratory of embryology and genetics of congenital Universitas Gadjah Mada/Dr. Sardjito Hospital, malformations, INSERM UMR1163, Paris, France, Yogyakarta,Indonesia,2FacultyofMedicine,PublicHealth 6Service de Génétique, Necker Enfants Malades University and Nursing, Universitas Gadjah Mada, Yogyakarta, Hospital,, Paris, France Indonesia, 3Faculty of Medicine, Public Health and1254 Nursing, Universitas Gadjah Mada/UGM Academic Hospital, Yogyakarta, Indonesia Background and aims: Lipid metabolism is under circadian control and long-term disturbance can lead to Background: Hirschsprung disease (HSCR) is a complex metabolic syndrome. Herein we test the hypothesis that genetic disorder characterized by absence of ganglion cells variants rs738409 (p.I148M) in PNPLA3 and rs58542926 inthegastrointestinaltract.Ourpreviousstudyrevealedthat (p. E167
K) in TM6SF2 associated with pathogenesis of NRG1 rare variant frequency in Indonesian HSCR patients Non-Alcoholic Fatty Liver Disease also represent novel is <1%. Therefore, we wished to investigate NRG1 hypercholesterolemia-associated variants. We propose that expression and methylation effect on HSCR pathogenesis bothnon-synonymousvariantsassociatewiththechangeof in Indonesia. circadian behavior in hepatic cells and contribute to the Methods: NRG1 type I (HRGα, HRGβ1, HRGβ2, development of the hypercholesterolemia. HRGβ3, HRGγ and NDF43 isoforms), type II and type III MaterialsandMethods:DNAsamplesfromaSlovenian expressions in both ganglionic and aganglionic colon of general screening programme of preschool children, age of HSCR patients and control colons were analysed by real- 5, with known total cholesterol and LDL-cholesterol diag- timepolymerasechainreaction(RT-PCR).Next,wetreated nosed with FH were obtained (N=121). The frequency of the extracted gDNA from HSCR patients’ and control variants rs738409 and rs58542926 were compared to Eur- colons with sodium bisulfate and analyzed the methylation opean individuals from 1000 Genomes and Exome variant pattern of NRG1 exon 1 with methylation-specific PCR. server databases. With CRISPR/Cas9 technology we gen- Results: NRG1 expressions were up-regulated in HSCR eratedHepG2 cellswithdifferent PNPLA3and/or TM6SF2 patients colon compared with control (type I: 13.81±1.79 genotypes and assessed the metabolic, expression and pro- vs.15.22±1.22 vs. 17.78±1.27; type II: 13.93±1.52 vs. liferation aspects. 15.67±1.52 vs. 16.57±1.02; type III: 11.98±2.86 vs.16.24 Results: An association between the PNPLA3 rs738409 ±2.28 vs. 17.51±1.48, respectively), with p-value of 0.02, and TM6SF2 rs58542926 minor allele with hypercholes- 0.03 and 0.01, respectively. Furthermore, HRGβ1/HRGβ2 terolemia has been identified if compared to European expressionsalmostreachedasignificantdifferencebetween males from 1000 Genomes (OR=1.451, 95%CI=1.093- ganglionic and control colons (13.07±1.32 vs. 14.75±1.26, 1.926, p<0.01; OR=0.3583, 95%CI=0.1536-0.8358, p=0.09). Most HSCR patients (80%) and controls (75%) p<0,05) and European Americans from EVS database revealed partially methylated NRG1. NRG1 methylation (OR=1.491, 95%CI=1.075-2.097, p<0.05; OR=0.3621, levels were lower in the ganglionic and aganglionic than 95%CI=0.1603- 0.8181, p<0,01). HepG2 cells were found control colons, however did not reach a significant level homozygous for rs738409 minor allele and rs58542926 (p=0.31 and 0.13, respectively). majorallele.Wecurrentlyevaluatethecircadianexpression Conclusions:WeshowstheaberrantNRG1expressionin of both genes and the effect of cholesterol on genotypes of Indonesian HSCR patients and might not be due to DNA genetically modified cell lines. methylation. Moreover, our study provides further insights Conclusions: We propose both polymorphisms as a into the contribution of aberrant NRG1 expression in the novel hypercholesterolemia-associated genetic variant that HSCR pathogenesis. disrupts the circadian rhythm and contribute to elevated Gunadi: None. A. Kalim: None. N. Budi: None. N. plasma lipids. Arfian: None. E. Purnomo: None. K. Iskandar: None. Acknowledgement: Slovenian Research Agency pro- gram grant  P1
-0390 and graduate fellowship.  P03
.23C U.Kovac:None.J.Kovac:None.E.Malicev:None.E. The circadian aspect of PNPLA3 p.I148M and TM6SF2 A. Jasper: None. K. Trebušak Podkrajšek: None. T. p. E167
K in hypercholesterolemia Battelino: None. K.K. Ryckman: None. D. Rozman: None. U. Kovac1, J. Kovac2, E. Malicev3, E. A. Jasper4, K. Trebušak Podkrajšek1,2, T. Battelino2,1,  P03
.24D K. K. Ryckman4, D. Rozman1 Large deletions are an underappreciated cause of hyperinsulinism 1University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, 2University Medical Centre Ljubljana, University T. W. Laver1, M. N. Wakeling1, R. Caswell1, B. Bunce2, Children´s Hospital, Ljubljana, Slovenia, 3University of J. A. L. Houghton2, K. A. Patel1, K. Hussain3, S. Ellard1, Ljubljana, Blood Transfusion Centre of Slovenia, S. Flanagan1 Ljubljana, Slovenia, 4University of Iowa, Department of Epidemiology, Iowa, IA, United StatesAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1255 1Institute of Biomedical and Clinical Science, Exeter, UniversityHospital,Madrid,Spain,3HospitalUniversitario United Kingdom,2Royal Devon & Exeter NHS Foundation 12 de Octubre, Madrid, Spain Trust, Exeter, United Kingdom, 3Sidra Medicine, Doha, Qatar In the last decade, the number of Idiopathic Central Precocious Puberty (ICPP) cases has decreased thanks to Introduction: Hyperinsulinism is a disorder where dysre- the discovery of mutations in different genes. The gulated insulin secretion leads to hypoglycaemia. 50% of identification of loss of function of the maternal imprinted patients do not have a mutation in a known gene. Large gene MKRN3 is the principal genetic cause of ICP P1
-12. contiguous gene deletions have been reported as an More recently DLK1 has also been discovered as another extremely rare cause of hyperinsulinism but are not imprinted gene implicated in the pathogenesis of ICP P13
. routinely screened thus these may be an underappreciated Aims of the study: 1) To analyze the presence of cause of the disorder. pathogenic variants in 13 genes related to GnRH pathway; We aimed to assess the contribution of large deletions to 2) To evaluate the diagnostic yield of the coding region the aetiology of hyperinsulinism. analysis of MKRN3; 3) To determine the presence of copy Materials and Methods: Using off-target CNV (copy numbervariation(CNV)ofDLK1andMKRN3genes;4)To number variant) calling from targeted next generation exclude uniparental disomy (UPD) of chromosome14. sequencing data we screened 865 patients with hyper- PatientsandMethods:patientswithICPPweregathered insulinism for large deletions (>1Mb). from 2015 to 2018. In 20 patients we analyzed the clinical Results: We identified causative contiguous gene dele- exome filtered by 13 genes that included MKRN3. Addi- tions in 16/865 patients in our cohort. 13 were previously tionally,inanother11patientsweanalyzedMKRN3coding reportedtocausehyperinsulinism:Xchromosomedeletions regionbySangersequencing.Inallpatientsweanalyzed:a) (Turner syndrome) (n=3), 9p deletions (n=9) and a 16p DLK1 coding region by Sange sequencing; b) CNVs of deletion (n=1). We also identified 3 patients with over- MKRN3 and DLK1 by MLPA technique; c) UPD of chro- lapping de novo deletions on chromosome 20. These were mosome 14 using STRs markers. the only novel large (>1Mb) de novo deletions within the Results: from the 31 patients recruited we found two cohort. They are a new cause of hyperinsulinism. likely pathogenic variants in MKRN3 in one sporadic case Conclusions: 2% of patients in our cohort had causative and in one familial case. large contiguous gene deletions. This is likely to be an Conclusion: MKRN3 gene is the most frequent genetic underestimate of the prevalence of large deletions in cause both sporadic and familial ICPP so we propose it as hyperinsulinismassome patientswillhavehadcytogenetic the first one to be screened in the genetic approach of testing prior to referral for hyperinsulinism genetic testing. patients with ICPP. Large deletions are a rare but significant cause of hyper- N.V. Ortiz Cabrera: None. R. Riveiro Álvarez: None. insulinism and should be screened for as part of genetic M.A. López Martínez: None. J. Cruz Rojo: None. L. panel tests for the disease. We also highlight a novel cause GarzónLorenzo:None.T.GavelaPérez:None.P.Pérez of hyperinsulinism: 20p11.2 deletions. Segura: None. I. Aragón Gómez: None. L. Soriano Funding: Wellcome Trust and the Royal Society Guillén: None. M.J. Trujillo Tiebas: None. (105636/Z/14/Z and WT098395/Z/12/Z). T.W.Laver:None.M.N.Wakeling:None.R.Caswell:  P03
.26B None. B. Bunce: None. J.A.L. Houghton: None. K.A. Complex indel variant calling in a repetitive genomic Patel: None. K. Hussain: None. S. Ellard: None. S. region Flanagan: None. S. L. Wilkinson1, M. Edwards1, S. John1, F. Honti1,  P03
.25A J. Mackintosh2, D. J. Morris-Rosendahl1,3 Searching for genes related to idiopathic central precocious puberty (ICPP) in a Spanish cohort 1Clinical Genetics and Genomics Laboratory, Royal Brompton and Harefield NHS Foundation Trust, London, N. V. Ortiz Cabrera1,2, R. Riveiro Álvarez2, M. A. López United Kingdom, 2Respiratory Medicine, Royal Brompton Martínez2, J. Cruz Rojo3, L. Garzón Lorenzo3, T. Gavela and Harefield NHS Foundation Trust, London, United Pérez2, P. Pérez Segura2, I. Aragón Gómez2, L. Soriano Kingdom, 3Genomic Medicine, National Heart and Lung Guillén2, M. J. Trujillo Tiebas2 Institute, Imperial College London, London, United Kingdom 1Hospital InfantilUniversitario NiñoJesús, Madrid,Spain, 2Health Research Institute-Jiménez Díaz Foundation1256 Introduction: Interstitial Lung Disease (ILD) represents a 4Faculty of Sport, University of Ljubljana, Ljubljana, collection of many different pulmonary disorders that Slovenia, 5Research Unit for Comparative Microbiome interfere with the tissue and space surrounding the alveoli, Analysis, Helmholtz Zentrum München - German Research causing irreversible damage. We performed genetic testing Center for Environmental Health, Neuherberg, Germany, on a patient diagnosed with idiopathic pulmonary fibrosis 6Laboratory for Machine Inteligence, Faculty of Electrical who also had telomere lengths in the 1st centile. Engineering, University of Ljubljana, Ljubljana, Slovenia, Materials and Methods: Next-Generation sequencing 7Slovenian NMR Centre, National Institute of Chemistry, was performed on patient DNA using our in-house Respi- Ljubljana, Slovenia, 8Department of Environmental gene™ panel of 172 genes. An in-house bioinformatics Physiology, Swedish Aerospace Physiology Centre, Royal pipeline, configured to interpret genes associated with rare Institute of Technology, Stockholm, Sweden, 9Group for respiratory conditions, was used to classify SNVs Genetics, Animal Biotechnology and Immunology, and CNVs. Department of Animal Science, Biotechnical Faculty, Results: Initial analysis did not detect any potentially University of Ljubljana, Ljubljana, Slovenia, 10Faculty of pathogenic variants in genes associated with ILD in the Civil and Geodetic Engineering, University of Ljubljana, patient.AnotherlaboratoryreportedaRTE L1
splicevariant: Ljubljana,Slovenia,11CenterforClinicalNeurophysiology, c.1266+3A>G.Furtherinvestigationusingdifferentvariant Faculty of Medicine, University of Ljubljana, Ljubljana, callers detected a 78bp deletion at the RTE L1
 exon 15/ Slovenia intron 15 boundary. Sanger sequencing and Tapestation analysis confirmed the patient to be heterozygous for the Introduction: We explored pathophysiological conse- 78bp deletion. This deletion is classified as a VUS, but we quences of inactivity and hypoxia on human physiology consider it more likely pathogenic than benign. The c.1266 and intestinal microbiota in healthy males during the +3A>Gvariantshowedanallelicbalanceoflessthan40%, randomized crossover design of run-in (5 day) and and our results suggest it is an artefact caused by bioin- experimental phases [21-day normoxic bedrest (NBR), formatic misalignment of the complex repeat region. hypoxic bedrest (HBR) and hypoxic ambulation (HAmb) Conclusion: Complex and repetitive genomic regions (hypoxic ~4000 m simulated altitude)] in a strictly still prove challenging for routinely-used variant calling controlled laboratory environment, with balanced fluid softwareandSangersequencing.Theerrorinvariantcalling and dietary intakes and 24/7 medical surveillance. may have resulted in a missed genetic diagnosis in this Materials and Methods: Incorporating system medicine patient. Increasing intronic flanking regions for bioinfor- approach, intestinal transit spanning constipation, matic analysis when performing targeted sequencing and eosinophil-derivedneurotoxin,bile acids,dietcomposition, ‘training’ of bespoke bioinformatic pipelines will improve intestinal electrical conductivity, indole etc., along with detectionofcomplexvariantsintheexon/intronboundaries NMRmetabolomics,wereassessed.Furthermore,structure, and beyond. diversity and function of intestinal microbiota using shot- S.L. Wilkinson: None. M. Edwards: None. S. John: gun metagenomics were investigated. Finally, all observa- None.F.Honti:None.J.Mackintosh:None.D.J.Morris- tionswereintegratedandanalyzedincorrelationtonegative Rosendahl: None. physiological symptoms, related to obesity and metabolic syndrome in same participants.  P03
.27C Results: Inactivity negatively affected fecal consistency Changesinhumanphysiologyinresponsetothree-week and in combination with hypoxia aggravated the state of gut inactivity or how your training trains your microbiome inflammation. On the other hand, many of the microbial parameters were shown to lag behind the changes in human R. Šket1,2, T. Debevec3,4, S. Kublik5, M. Schloter5, physiology and intestinal environment, since significant N. Treichel5, B. Murovec6, D. Makuc7, K. Pečnik7, changesinbacterialcommunityweredelayeduntilweekfour J. Plavec7, I. Mekjavić3, O. Eiken8, J. Kovač1, in HBR only, where members of the genus Bacteroides and Z. Prevoršek9, B. Stres2,10,11 proteins involved in iron acquisition and metabolism, cell wall,capsule,virulenceandmucindegradationwereenriched. 1University Medical Centre Ljubljana Slovenia,Divisionof Conclusions: Our multi-omics approach suggest a time- Paediatrics, Unit of Special Laboratory Diagnostics, dependent and complex interplay between the host physiol- Ljubljana, Slovenia, 2Group for Microbiology and ogy (including apparent constipation), immunity (inflamma- Microbial Biotechnology, Department of Animal Science, tion), controlled diet, intestinal environment variables and Biotechnical Faculty, University of Ljubljana, Ljubljana, microbiome physiology during the acute cessation of exer- Slovenia, 3Department of Automation, Biocybernetics and cise. Funding: PlanHab project (Grant no. 284438) and Robotics, Jozef Stefan Institute, Ljubljana, Slovenia, Young Research Fellowship to RŠ (SRA#37426).Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1257 R.Šket:None.T.Debevec:None.S.Kublik:None.M. thenuclearfamily. WBandIHCstudies revealed markedly Schloter:None.N.Treichel:None.B.Murovec:None.D. reduced CARMI L2
 expression in patient cells compared to Makuc: None. K. Pečnik: None. J. Plavec: None. I. controls. Comprehensive in vitro immunological analyses Mekjavić: None. O. Eiken: None. J. Kovač: None. Z. demonstratedseverelyreducedregulatoryT-cells(T )with reg Prevoršek: None. B. Stres: None. impaired CD4+ T cell proliferation and T generation. reg CyTOFanalysisrevealedsignificantshiftsintheinnateand  P03
.28D adaptiveimmunecellsofthepatientcomparedtoulcerative A novel homozygous CARMI L2
 variant leads to colitis patients and healthy controls. infantile-onset colitis and gastrointestinal eosinophilic Conclusions: Pathogenic bi-allelic CARMI L2
 variants disease without recurrent infections cause an immunodeficiency syndrome characterized by recurrent infections and skin lesions, occasionally with A. Kurolap1,2, O. Eshach Adiv1,2,3, L. Konnikova4,5,6, concurrent diarrhea. This study expands our knowledge on L. Werner7, C. Gonzaga-Jauregui8, M. Steinberg2, the immune landscape alterations caused by CARMI L2
 V. Mitsialis5,6, A. Mory2, M. Y. Nunberg7, S. Wall5, defectsandunderscorestheroleofCARMI L2
asacandidate R.Shaoul1,3,J.D.Overton8,A.R.Shuldiner8,Y.Zohar1,9, gene for early-onset inflammatory and eosinophilic GI T. Paperna2, S. B. Snapper5,6,10, D. S. Shouval7, H. Baris disease. The predominant GI manifestations in the patient Feldman1,2 warrant further study of CARMI L2
 function in the gut. A. Kurolap: None. O. Eshach Adiv: None. L. Konni- 1The Bruce and Ruth Rappaport School of Medicine, kova:None.L.Werner:None.C.Gonzaga-Jauregui:A. Technion, Haifa, Israel, 2The Genetics Institute, Rambam Employment (full or part-time); Significant; Regeneron Health Care Campus, Haifa, Israel, 3Pediatric Pharmaceuticals Inc.. M. Steinberg: None. V. Mitsialis: Gastroenterology, Rambam Health Care Campus, Haifa, None. A. Mory: None. M.Y. Nunberg: None. S. Wall: Israel, 4Devision of Newborn Medicine, Department of None. R. Shaoul: None. J.D. Overton: A. Employment Pediatrics, Children’s Hospital of Pittsburgh of UPMC, (full or part-time); Significant; Regeneron Pharmaceuticals Pittsburgh, PA, United States, 5Division of Inc. A.R. Shuldiner: A. Employment (full or part-time); Gastroenterology, Hepatology and Nutrition, Boston Significant; Regeneron Pharmaceuticals Inc.. Y. Zohar: Children’s Hospital, Boston, MA, United States, 6Harvard None. T. Paperna: None. S.B. Snapper: B. Research Medical School, Boston, MA, United States, 7Pediatric Grant (principal investigator,collaboratororconsultantand Gastroenterology Unit, Edmond and Lily Safra Children’s pending grants as well as grants already received); Sig- Hospital, Sheba Medical Center, Ramat Gan, Israel, nificant; NIH grants H L59561
, DK034854, and AI50950; 8RegeneronGeneticsCenter,Tarrytown,NY,UnitedStates, the Helmsley Charitable Trust; and the Wolpow Family 9Institute of Pathology, Rambam Health Care Campus, Chair in IBD Treatment and Research. D.S. Shouval: B. Haifa, Israel, 10Division of Gastroenterology, Hepatology Research Grant (principal investigator, collaborator or and Endoscopy, Brigham and Women’s Hospital, Boston, consultant and pending grants as well as grants already MA, United States received); Significant; The Israel Science Foundation and Jefferey Modell Foundation grants. H. Baris Introduction: Infantile-onset colitis refers to inflammatory Feldman: None. gastrointestinal (GI) disorders manifesting before the two years of age. Nearly 100 genes have been implicated in  P03
.29A syndromespresenting withearly-onsetcolitis.Weaimedto Clinicalutilityofgenepanelsequencingfordiagnosisof decipher the genetic basis of severe infantile colitis and early-onset chronic kidney disease eosinophilicGIdiseasewithoutrecurrentinfectionsina10- years-old boy, and subsequently characterize his GI and A. Domingo Gallego1, M. Pybus1, G. Bullich1, P. Ruiz1, immunological phenotypes. L. Lorente-Grandoso1, M. Furlano1, G. Fraga2, Materials and Methods: We used trio whole exome G. Ariceta3, M. Borregán3, J. Piñero-Fernández4, sequencing(WES)forpathogenicvariantdiscovery.Protein L. Rodríguez-Peña4, I. Llano-Rivas5, R. Sáez6, expression was studied using western blot (WB) analysis L. Guirado1, R. Torra1, E. Ars1 and immunohistochemical (IHC) staining. Immunological workupincludedinvitroT-cellstudies,flowcytometryand 1Fundació Puigvert, Barcelona, Spain, 2Hospital de la CyTOF analyses. Santa Creu i Sant Pau, Barcelona, Spain, 3Hospital Vall Results: WES revealed a rare homozygous variant in d’Hebron, Barcelona, Spain, 4Hospital Universitario CARMI L2
: c.1590C>A; p.Asn530Lys. The variant was Virgen de la Arrixaca, Murcia, Spain, 5Hospital predicted pathogenic and co-segregated with the disease in1258 Universitario Cruces, Bizkaia, Spain, 6Hospital Donostia, Introduction: Rare variants in telomere metabolism San Sebastián, Spain associated genes have recently been shown to be important contributors to idiopathic pulmonary fibrosis (IPF), regard- Introduction: Inherited kidney diseases (IKD) are the lessofthefamilyhistory.Weaimedtovalidatetheresultin leading cause of chronic kidney disease (CKD) in the first an independent cohort of IPF patients. three decades of life and encompass a broad range of Methods:Wecalculatedthatinordertohave80%power nephropathies. to detect at least one IPF patient with a causative mutation Methods:Targetednextgenerationsequencingwithhigh inatelomere metabolism associatedgene,iftheprevalence sequencingdepthofalargeIKD-genepanelwasperformed of mutations is the same as in the above referenced study in426patientswithearly-onsetCKD(<30years),including (13.2%),wehadtosequence11patientsforthepresenceof patientswith:1)congenitalabnormalitiesofthekidneyand mutations in those genes. To get a random sample we urinary tract (CAKUT) (n=89) (with bilateral anomalies included 11 consecutive IPF patients, regardless of their and/or extrarenal defects and/or familial CAKUT), 2) renal familyhistoryofIPF,attheircontrolvisitatourUniversity cystic ciliopathies (n=180), 3) suspected inherited glo- Clinic. All patients had IPF diagnosis according to ATS/ merular disease (n=129) and 4) renal tubulopathies/ ERS/JRS/ALAT guidelines. Sequencing of telomere meta- nephrolithiasis/nephrocalcinosis (n=28). bolism associated genes was performed on the Illumina Results: Causative mutations were found in 64% (271/ platform. 426)ofpatients:42%(37/89)withCAKUT,76%(137/180) Results: Demographic statistics of our sample were with renal cystic ciliopathies, 60% (77/129) with suspected comparable to other IPF demographics with regard to age inherited glomerular disease and 71% (20/28) with renal (mean age = 71.2 years), IPF family history (1/11 (9.1%)) tubulopathy/nephrolithiasis/nephrocalcinosis. Copy number and sample male predominance (8/11 (72.7%)). In 2 out of variants were detected in 11% of all genetically diagnosed 11 (18.2%) patients, none of which had a family history of patients (29/271). Pathogenic variants were identified in 57 IPF and were therefore classified assporadic IPF cases, the different genes,10ofwhich(CO L4
A3,CO L4
A4,CO L4
A5, causative variant was found (NM_001283009(RTE L1
): HNF1B,NPH P3
,PAX2,PKD1,PKD2,PKHD1andTS C2
) c.326_329del (p.I109fs); NM_001193376(TERT): explained 75% (203/271) of patients. c.1374delC(p.W459fs)).Despitesufficientcoverage(mean Conclusion: Our IKD-gene panel allowed a precise coverage = 121X) we didn’t confirm the causative variant molecular diagnosis in nearly two-thirds of patients with in the only patient with a family history of IPF in our early-onsetCKD.Thehighdiagnosisyieldofourapproach cohort. can be explained by 1) the efficient detection of copy Conclusions: Causative variants in telomere metabolism number variants and variants in complex genomic regions, associatedgenesplayasignificantrolealsoinsporadicIPF. such as PKD1 gene, due to the high sequencing depth and J. Šelb: None. M. Rijavec: None.K. Osolnik: None. P. 2)thestrictclinicalinclusioncriteriatofavorgenetictesting Korošec: None. in patients with likely monogenic cause of nephropathy. Funding:InstitutodeSaludCarlosIII/FEDER(PI16/01998,  P03
.31C PI18/00362). A new form of hereditary iron overload unlinked to A. Domingo Gallego: None. M. Pybus: None. G. Bul- known hereditary hemochromatosis genes lich: None. P. Ruiz: None. L. Lorente-Grandoso: None. M.Furlano:None.G.Fraga:None.G.Ariceta:None.M. D. Wallace, N. Subramaniam Borregán: None. J. Piñero-Fernández: None. L. Rodrí- guez-Peña: None. I. Llano-Rivas: None. R. Sáez: None. IHBI, School of Biomedical Sciences, Queensland L. Guirado: None. R. Torra: None. E. Ars: None. University of Technology, Brisbane, Australia  P03
.30B Hereditary hemochromatosis (HH) is normally caused by Large effect of rare variants with large effect sizes in homozygosity for pathogenic mutations in the HFE (sporadic) IPF (homeostatic iron regulator) gene. Other autosomal reces- sive forms of HH are associated with mutations in genes J. Šelb, M. Rijavec, K. Osolnik, P. Korošec involvedin iron homeostasisincluding hemojuvelin (HJV), hepcidin (HAMP) and transferrin receptor 2 (TFR2). University Clinic of Respiratory and Allergic Diseases Autosomal dominant forms of iron overload are associated Golnik, Golnik, Slovenia with mutations in the cellular iron exporter ferroportin (SL C40
A1), with a single case linked to a mutation in the 5’UTRoftheH-ferritingene(FTH1).WedescribeafamilyAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1259 with apparent autosomal dominant iron overload with remaining healthy tissues. Several surgical techniques have characteristics similar to the classical form of ferroportin been developed for such purpose, including partial disease. The condition is characterised by elevated serum hepatectomy (PH), intraoperative portal vein ligation ferritin levels with normal or mildly elevated transferrin (PVL),andassociatedliverpartitionandportalveinligation saturation. Perls’ Prussian blue staining of liver biopsy for staged hepatectomy (ALPPS). Indeed, while clinical sections in two affected individuals show prominent iron outcomes are somewhat comparable, different procedures deposition in both Kupffer cells and hepatocytes. Sequen- show clinically distinct recovery patterns. The observable cing of the coding sequences and splice sites of genes clinicaldifferenceslikelymirrorsomeunderlyingvariations known to cause HH revealed no mutations in the proband. in the patterns of gene activation and regeneration Whole genome SNP genotyping was performed on 15 pathways. members of the pedigree. Linkage analysis showed Materials and Methods: We provided a comprehensive haplotypes on regions of chromosomes 1, 3, 12, 18 and comparative analysis of the gene regulation in regenerating 19 that were shared among the four most clearly affected rat livers temporally spaced at 24h and 96h after PH, PVL, members of the pedigree but not present in the three most and ALPPS using the next-generation RNA sequencing clearly unaffected members. These regions encompass a transcriptomics analysis. total of 93 megabases, approximately 3% of the human Results: The time-dependent factors appear to be the genome and contain over 1500 canonical genes. Impor- most important determinant of post-injury alterations of tantly,thesegenomicintervalsdonotcontaintheSL C40
A1 gene expression in liver regeneration. Early transcriptomic geneindicatingthataffectedmembers ofthisfamilydonot changes that were found in all three procedures included have a variant form of ferroportin disease. cellcycleassociatedgenesandimmune-responseactivation D. Wallace: None. N. Subramaniam: None. genes as well as transcription factors, DNA replication regulators, G1/S-transition regulators, and cytokinesis.  P03
.32D Conclusions: The functional pathway and gene network Transcriptome profiling in regenerating rat liver after analyses revealed both unique and overlapping molecular partialhepatectomy,portalveinligation,andassociated mechanisms and pathways for each surgical procedure. liver partition and portal vein ligation for staged Identificationofmolecularsignatures,suchasgene-to-gene hepatectomy interactions, regenerative signaling pathways, specific to each surgical procedures further our understanding of key D. Colak1, O. Al-Harazi1, I. H. Kaya2,3, O. M. Mustafa1, regulators of liver regeneration as well as patient popula- F. Meng4,5, A. M. Assiri5,6,2, D. K. Dhar4,5,7, tions that are likely to benefit from each procedure. Fund- D. C. Broering4,2 ing: This study is funded by KFSHRC Research Grants (2110006 and 2180030 to DC). 1Biostatistics, Epidemiology, and Scientific Computing D.Colak:None.O.Al-Harazi:None.I.H.Kaya:None. Department, King Faisal Specialist Hospital and Research O.M.Mustafa:None.F.Meng:None.A.M.Assiri:None. Center, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, D.K. Dhar: None. D.C. Broering: None. 2College of Medicine, AlFaisal University, Riyadh, Saudi Arabia, 3Biostatistics, Epidemiology, and Scientific  P03
.33A Computing Department, King Faisal Specialist Hospital Biallelic LZTR1 mutation in a patient with non-classical and Research Center, Riyadh, Saudi Arabia, 4Department Noonan phenotype ofSurgeryandOrganTransplantationCenter,KingFaisal Specialist Hospital and Research Center, Riyadh, Saudi L. Tiberi1, A. La Barbera2, A. Provenzano2, P. Reho2, Arabia, 5Comparative Medicine Department, King Faisal E. Bosi2, M. Bozzola3, S. Giglio2,4 Specialist Hospital and Research Center, Riyadh, Saudi Arabia, 6Institute for Research and Medical Consultations, 1medical genetics unit Department of Experimental and ImamAbdulrahmanBinFaisalUniversity,Dammam,Saudi Clinical Biomedical Sciences "Mario Serio" University of Arabia, 7Institute for Liver and Digestive Health, Florence, Florence, Italy, 2medical genetics unit Regenerative Medicine & Fibrosis Group University Department of Experimental and Clinical Biomedical College London, Royal Free Hospital, London, United Sciences, Florence, Italy, 3Pediatrics Unit University of Kingdom Pavia, Pavia, Italy, 4Medical Genetics Unit Meyer Children's Hospital, Florence, Italy Introduction:Liverhasphenomenalcapacitytoregenerate, which has been shown clinically where diseased liver parts Noonan syndrome (NS) is an autosomal dominant, multi- are removed to preserve and stimulate the growth of the systemic disorder caused by dysregulation of the RAS/1260 mitogenactivatedproteinkinase(MAPK)pathway.Hetero- typical clinical inclusion criteria. Patients in the database zygous variants in 11 known genes account for approxi- who provided all answers to the MODY calculator ques- mately 80% of cases. Whole exome sequencing (WES) tionnaire --106 GCK-MODY and 92 HNF1A-MODY-- studies recently identified the existence of a recessive form were included. The control group was established with 85 ofNoonansyndromecausedbybiallelicpathogenicLZTR1 T1DM individuals and it does not include any T2DM variants,howeverinformation onthephenotypesofLZTR1 patients due to insufficient number of sub-35-year-old patients and functional properties of the mutations are T2DM cases in our outpatient clinic --as required in the limited. We report a 15-year-old boy with typical facial calculator model. features of NS in the absence of congenital heart defects, Results: The mean predictive value using the calculator cardiomyopathy, skin anomalies and intellectual disability. was 63.1% for GCK-MODY and 44.92% for HNF1A- The patient had been treated with growth hormone (GH) MODYpatients.Thisisincontrastwiththemeancalculator betweenages11and15withoutanyeffectongrowth.WES predictive value of 4.82% for T1DM patients. Only two revealed compound heterozygosity for a missense LZTR1 T1DM patients out of 85 obtained a calculator predictive variantc.2102C>G;p.Pro701Arginheritedfromhishealthy valuehigherthan25%--theminimumsuggestedcriteriafor father and a missense variant c.2062C>G: p.Arg688Gly genetic testing referral. Only 11 GCK-MODY patients and NM_006767 inherited from his mother. We identified the 33 HNF1A-MODY patients received a sub-25% score. variant inherited from his mother by exome reanalyses Sensitivity and specificity for both types of MODY were modifying pipelines parameters. Both variants were in the 77.78% and 97.65% respectively. GCK-MODY when BTB domain of LTZR1. Mutations in LZTR1, already compared to HNF1A-MODY obtained better sensitivity. known to be causal in familial schwannomatosis type 2, Conclusion: The model based on the Hattersley's group have been recently involved in some patients with calculator reliably indicated genetic testing for GCK- autosomal dominant and recessive Noonan syndrome in MODY patients among our sub-population of Polish which clinical manifestations include cardiomyopathy and patients. The obtained results for HNF1A-MODY patients intellectual disability. This is the first case in which only were also satisfactory. facialfeatures,shortstatureandnoresponsetoGHtherapy M. Szopa: None. D. Ucieklak: None. I. Solecka: None. are reported. Recently LZTR1 was associated to sporadic I. Solecka: None. S. Mrozinska: None. J. Hohendorff: cerebral tumors so it is necessary a careful clinical None. M. Sani: None. M. Malecki: None. observation in order to consider GH treatment in patients carrying LZTR1 variants.  P03
.35C L.Tiberi:None.A.LaBarbera:None.A.Provenzano: AssessmentofgenesknowntobeassociatedwithMODY None. P. Reho: None. E. Bosi: None. M. Bozzola: None. by next-generation sequencing S. Giglio: None. O. Cilingir1, B. Durak Aras1, E. Simsek2, D. Cınar1,  P03
.34B M. A. Temena1, S. Arslan1, H. Bas1, E. Erzurumluoglu1, UtilityofMODYprobabilitycalculatoramongHNF1A- S. Artan1 and GCK-MODY Polish patients (a retrospective analysis) 1Eskisehir Osmangazi University, Faculty of Medicine, Department of Medical Genetics, Eskısehır, Turkey, M. Szopa, D. Ucieklak, I. Solecka, I. Solecka, 2Eskisehir Osmangazi University, Faculty of Medicine, S. Mrozinska, J. Hohendorff, M. Sani, M. Malecki Department of Pediatric Endocrinology, Eskısehır, Turkey JUMC, Krakow, Poland MODY (Maturity Onset Diabetes of the Young) is a autosomal dominant heterogeneous form of diabetes Introduction: The most common form of monogenic mellitus which mainly affects children and young adults. diabetes is MODY. An easy-to-use MODY prediction The defect in beta cell function is the cause of MODY. model for identifying genetic-test indicated patient cases There are several known subtypes of MODY and each was developed in 2012: www.diabetesgenes.org/content/ subtype occurs by pathogenic variants of different genes. mody-probability-calculator. The aim of this study was to Approximately 80% of MODY occurs by GCK and validate the utility of this tool with MODY patients in the HNF1A pathogenic variants in European population, but Polish population. different ethnics may have different rates of subtypes. This Materials and Methods: Our MODY patient database study aimed to explain the genetic architecture of MODY- was established 18 years ago at the Department of Meta- suspected 132 Turkish patients. In this study, genes known bolic Diseases, JUMC, Krakow, Poland and was based on to be associated with MODY (SL C161
,KLF11,G6P C2
,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1261 Genes Mutations Genotype Classification n Frequencies(%) GCK p.Arg191Trp(c.571C>T) Heterozygous Pathogenic 2 1,51 p.Gln38Pro(c.113A>C) Heterozygous Pathogenic 1 0,75 p.Arg191Gln(c.572G>A) Heterozygous Pathogenic 2 1,51 p.Thr228Met(c.683C>T) Heterozygous Pathogenic 2 1,51 p.Asp364Glyfs) Heterozygous VUS 1 0,75 (c.1090_1091insGCTGCGACCCTCGACCACCG)Novel p.Ala380Thr(c.1138G>A) Heterozygous VUS 2 1,51 p.Arg37Trp(c.109C>T) Heterozygous Pathogenic 2 1,51 p.Val227Met(c.679G>A) Heterozygous Pathogenic 1 0,75 BLK p.Ala71Thr(c.211G>A) Heterozygous VUS 6 4,54 p.Asp166fs(c.497delA) Heterozygous VUS 1 0,75 PDX1 p.Pro33Ala(c.97C>G) Heterozygous Pathogenic 2 1,51 RFX6 p.Glu75Gln(c.223G>C) Heterozygous VUS 1 0,75 c.2393+8T>C Heterozygous VUS 1 0,75 G6P C2
 p.Tyr207Ser(c.620A>C) Heterozygous DAP 2 1,51 HADH p.Phe92Cys(c.275T>G) Heterozygous VUS 5 3,78 HNF1A p.Ala15Thr(c.43G>A) Heterozygous VUS 1 0,75 HNF1B p.His336Asp(c.1006C>G) Heterozygous Pathogenic 1 0,75 PDX1 p.Pro33Thr(c.97C>A) Compound PathogenicVUS 1 0,75 HADH p.Gly34Ser(c.100G>A) Heterozygous RFX6 p.Glu75Gln(c.223G>C) Compound VUS 1 0,75 HNF4A p.Gln10Terp(c.28C>T) Heterozygous VUS G6P C2
 p.Tyr207Ser(c.620A>C) Compound DAP 1 0,75 HNF4A p.Gln10Terp(c.28C>T) Heterozygous VUS G6P C2
 p.Tyr207Ser(c.620A>C) Compound DAP 1 0,75 INSR p.Val1012Met(c.3034G>A) Heterozygous VUS SL C16
A1 p.Tyr359Ser(c.1076A>C) Compound VUS 1 0,75 GCK p.Thr229Met(c.686C>T) Heterozygous Pathogenic PAX4HNF4A c.539-5C>T Compound VUS 1 0,75 p.Ile463Val(c.1387A>G) Heterozygous VUS WILDTYPE 93 70,45 TOTAL 132 100 HADH,MOG,ZF P57
,RFX6,GCK,PAX4,BLK,GLI S3
,NEUR O. Cilingir: None. B. Durak Aras: None. E. Simsek: OG3,GLUD1,INS,KCNJ11,ABC C8
, HNF1A,PDX1,HNF1B, None. D. Cınar: None. M.A. Temena: None. S. Arslan: INSR,NKX2-2,HNF4A,FOX P3
) were sequenced by using None. H. Bas: None. E. Erzurumluoglu: None. S. IonTorrent  S5
 and runs were then analyzed with bioinfor- Artan: None. maticspipeline.Of132patients,pathogencic,VUS(variant- unknown-significance), and DAP(disease-associated poly-  P03
.36D morphism) were detected in 39 patients. Additionally, a Molecular characterization of a cohort of MODY new variant identified in GCK is classified as pathogenic patients from the North of Portugal according to ACGM criteria and this variant was deter- mined as de novo with the segragation analysis. The most F. E. D. R. Laranjeira1, I. Ribeiro1,2, A. Amado3, common pathogenic variants were seen in GCK and the E. Pinto1, J. Vilaverde3, A. R. Soares4, S. Rocha1, resultsareshownonthetable.Thenovelvariantdetectedin A. Carvalho3, S. Teixeira3, J. Dores3,2, C. Amaral3, GCKresultsinprematurestopcodonbecauseofframeshift I.Palma3,C.Reis4,M.T.Pereira3,C.Freitas3,C.Soares4, mutation. The pathogenic variants detected in different M. J. Oliveira3, R. Almeida3, G. Soares4, A. Fortuna4,2, genes revealed that NGS method is suitable to test genetic D. Quelhas1,2, H. Cardoso3,2 ethiology of multigenic diseases like MODY. Table: Mutations and frequencies (%) in 39 patients.1262 1Unidade de Bioquímica Genética, Centro de Genética (HNF1A), 4 Alpha (HNF4A) and 1 Beta (HNF1B) in Médica Doutor Jacinto Magalhães, Centro Hospitalar Maturity-Onset Diabetes of the Young in Croatia Universitário do Porto, Porto, Portugal, 2Unidade Multidisciplinar de Investigação Biomédica (UMIB), D. Caban1,2, A. Merkler1, H. Ljubić1, A. Špehar Uroić1, Instituto de Ciências Biomédicas Abel Salazar, N. Krnić1, M. Čavlović Naglić3, L. Smirčić-Duvnjak3, Universidade do Porto, Porto, Portugal, 3Serviço de D. Kaštelan1, J. Sertić1,4 Endocrinologia,CentroHospitalarUniversitário doPorto, Porto, Portugal, 4Serviço de Genética Médica, Centro de 1University Hospital Centre Zagreb, Zagreb, Croatia, GenéticaMédicaJacintodeMagalhães,CentroHospitalar 2University of Applied Health Sciences, Zagreb, Croatia, Universitário do Porto, Porto, Portugal 3Merkur University Hospital, Zagreb, Croatia, 4University of Zagreb School of Medicine, Zagreb, Croatia Introduction: Maturity-onset diabetes of the young (MODY) is a group of monogenic disorders of autosomal Introduction: Maturity-onset diabetes of the young dominant transmission resulting from a primary defect in (MODY) is a monogenic form of diabetes that is insulin secretion, associatedwithpancreatic β-cell dysfunc- characterized by an early onset (usually before 25 years), tion. It is the cause in approximately 2% of diabetic autosomal dominant mode of inheritance and a primary patients, butit isfrequently misdiagnosed astype 1 ortype defect in pancreatic β-cell function. MODY is a common 2 diabetes. Although fourteen different genes have been form of monogenic diabetes and it may account for 1% to implicated, mutations in the glucokinase gene, GCK, and 2% of all diabetes cases in Europe. Many people with genes coding for hepatocyte nuclear factor 1α, 1β and 4α MODY are misdiagnosed with type 1 or type 2 diabetes. (HNF1A, HNF1B and HNF4A, respectively), are the most MaterialsandMethods:Alladultsubjectswithdiabetes common causes of MODY, accounting for up to 70% of onset under age of 45 years and currently older than 18 mutated alleles. years. Other inclusion criteria are: evidence of endogenous Methodology: 112 patients with criteria for MODY type insulin secretion (fasting or random C-peptide ≥ 0.2 nmol/ diabetes, from adults Endocrinology or Genetics consulta- L) and negative glutamic acid decarboxylase antibodies tion, underwent molecular genetics testing at UBG. Mole- (GADA), islet cell autoantibodies (ICA) and islet tyrosine culargeneticsstudieswereperformedbySangersequencing phosphatase 2 (IA2). We analysed 44 patients for HNF1A- ofoneormoreofthefollowinggenes,accordingtoclinical MODY, 14 patients for HNF4A-MODY and 8 patients for suspicion: HNF1A, GCK, HNF4A and HNF1B. HNF1B-MODY. For identification of mutations in the Results: We presentthe molecular characterization of 24 codingandpromoterregionofanalyzedgenes,weusedthe patients where a definite or probable causing mutation was Sanger sequencing method. identified, thus 21%. Fourteen (58%) are HNF1A-MODY, Results: We identified six different mutations in nine eight (33%) are GCK-MODY and two (8%) are HNF1B- patients for subtype HNF1A-MODY. These mutations are MODY.Eighteendifferentmutationswereidentified-10in located in exons 2, 3, 4 and 6, but the greatest number are HNF1A, 6 on GCK and 2 on HNF1B - including 3 novel found in exon 4, p.Gly292Argfs*25. For subtype HNF1B- mutations: c.1146_1156del and c.1422_1424delGCCin- MODYweidentifiedonemutation,p.Val458Glyinexon7. sCAG in HNF1A and c.863T>C on GCK. No HNF4A-MODY gene mutations were identified in any Conclusions: The prevalence of HNF1A-MODY and of patients analyzed. GCK-MODY in our cohort is much lower than the values Conclusions:CorrectlyidentifyingMODYhasimportant described. The MODY spectrum in Portugal is expected to implications for treatment, surveillance of complications be different from the one reported in other populations and andassociated extra-pancreatic disorders, andidentification willberevealedafterthestudyofremainderMODYgenes. of affected and at-risk family members. F.E.D.R. Laranjeira: None. I. Ribeiro: None. A. D. Caban: None. A. Merkler: None. H. Ljubić: None. Amado: None. E. Pinto: None. J. Vilaverde: None. A.R. A. Špehar Uroić: None. N. Krnić: None. M. Čavlović Soares: None. S. Rocha: None. A. Carvalho: None. S. Naglić: None. L. Smirčić-Duvnjak: None. D. Kaštelan: Teixeira: None. J. Dores: None. C. Amaral: None. I. None. J. Sertić: None. Palma: None. C. Reis: None. M.T. Pereira: None. C. Freitas: None. C. Soares: None. M.J. Oliveira: None. R.  P03
.38B Almeida: None. G. Soares: None. A. Fortuna: None. D. MODY genes HNF1A, GCK and HNF4A pathogenic Quelhas: None. H. Cardoso: None. variant spectrum in pediatric patients  P03
.37A M. Šukys, V. Ašmonienė, R. Traberg, D. Čereškevičius Mutations in the Hepatocyte Nuclear Factor 1 AlphaAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1263 Hospital of Lithuanian University of Health Sciences, and Chemical Engineering, Western Norway University of Kauno klinikos, Kaunas, Lithuania Applied Sciences, Bergen, Norway Introduction: Maturity onset diabetes of the young Introduction: Variants in the hepatocyte nuclear factor- (MODY) is a rare form of diabetes which is caused by 1alphagene(HNF1A)cancauseMaturity-OnsetDiabetesof pathogenicvariantinoneofthethirteenknownresponsible the Young (MODY3). MODY3 patients, who are often genes, but mostly in 3 genes: HNF1A, GCK, HNF4A. misdiagnosed as type1/type2 diabetes, are important to Correct diagnosis might allow change treatment, especially identify, since they can benefit from sulfonylurea treatment when it is mistaken for type 1 diabetes. Here we analyzed ratherthaninsulin.Theaimofthisstudywastofunctionally genetic variants in Lithuanian pediatric patients with investigate possible pathogenic effects of 11 HNF1A suspected monogenic diabetes. variants from the Norwegian MODY registry, in order to Materials and Methods: We performed GCK, HNF1A, provide a precise diagnosis and treatment. HNF4A genes Sanger sequencing for pediatric patients (0- Materials and Methods: The Norwegian MODY reg- 18 years old) for whom there was mild hyperglycemia or istry includes 2125 individuals with suspected MODY. were diagnosed type 1 diabetes with negative antibody HNF1A variants (Sanger identified) were investigated by markers (glutamic acid decarboxylase, insulin and transactivation (luciferase assay), protein expression insulinoma-associated-2 antibodies) in the year 2017-2018. (immunoblotting), DNA binding (electrophoretic mobility Results:32patientswereanalyzedforall3genes,orone shift assay) and nuclear localization assays. ofthemdependingonclinicalsituation.50%ofthemhadat Results:AllHNF1Avariantsinvestigatedwereclassified least second degree relative with anamnesis of diabetes or as variants of uncertain significance. Variants p. hyperglycemia. For 8 of the patients we found GCK non- (Ala116Thr),p.(Lys222del)andp.(Asn266Ser)showedlow synonymous heterozygous variants which were previously transcriptional activity (15-36%). p.(Ala116Thr) and p. reportedaspathogenic.2patientshadheterozygousvariants (Lys222del) demonstrated low DNA binding (23% and in HNF1A: one with frameshift variant c.872dupC and 17%), and impaired nuclear localization. Moreover, p. another nonsynonymous variant c.809A>C which was not (Lys222del) exhibited low protein expression (26%). Car- reported earlier. This variant changes amino acid in DNA riersoffunctionallyimpairedvariantsmanifestedwithearly binding region (p.Asn270Thr), cosegregates in patients diabetes-onset (<25 years). The autoantibody status was family as patients father and grandmother (father‘s line) negative or not tested. Carriers of p.(Ala116Thr) and p. were diagnosed with diabetes. Also, as multiple in silico (Lys222del) had a family history of diabetes. The p. predictors showed as pathogenic variant, we ascertained (Ala116Thr)-carrier had earlier been treated with sulfony- variant as likely pathogenic. lurea with no optimal effect. Her sister (also carrier), is Conclusion: In our study, only 1/3 of patients were treated successfully with sulfonylurea. The p.(Lys222del) provenforcarryingadiseasecausingalleleofallsuspected and p.(Asn266Ser) patients are currently treated with insu- MODY patients. One patient had novel variant with no lin/metformin, and should be considered shifted to sulfo- previous report. nylurea. The remaining variants were either functionally M. Šukys: None. V. Ašmonienė: None. R. Traberg: normal or moderately impaired. None. D. Čereškevičius: None. Conclusions: Functional investigation of HNF1A var- iants should support precision medicine in MODY3  P03
.39C patients. Functional characterization of HNF1A variants Grants: Helse Vest, Norwegian Diabetes Association, identifiedintheNorwegianMODYdiabetesregistrycan foundation of K.G. Jebsen implement precision medicine in diabetes clinics I.Aukrust:None.A.Kaci:None.P.Svalastoga:None. J. Molnes: None. L. Bjørkhaug: None. P.R. I. Aukrust1,2, A. Kaci2,3, P. Svalastoga2, J. Molnes1,2, Njølstad: None. L. Bjørkhaug4, P. R. Njølstad2,3  P03
.40D 1Department of Medical Genetics, Haukeland University New generation sequencing as an effective method of Hospital, Bergen, Norway, 2Center for Diabetes Research, diagnosing patients with various form of monogenic Department of Clinical Science, University of Bergen, diabetes Bergen, Norway, 3Department of Pediatrics and Adolescents, Haukeland University Hospital, Bergen, M. Borowiec1, K. Antosik1, P. Mludzik1, A. Zmyslowska2 Norway, 4Department of Biomedical Laboratory Sciences1264 1Department of Clinical Genetics, Medical University of Objectives: Nephronophthisis is an autosomal recessive Lodz, Lodz, Poland, 2Department of Pediatrics, disease genetically very heterogenous. Currently is Diabetology, Endocrinology and Nephrology, Medical described25genesresponsibleforupto70%ofthedisease University of Lodz, Lodz, Poland from which 30-40% is caused by NPH P1
 gene deletion. The main symptoms are kidney degeneration and fibrotic Introduction:Monogenicformsofdiabetesrepresent5-7% tissueformation,leadinginrenalfailureofteninchildhood. of all diabetes types. They are a heterogeneous group of Other less common symptoms include growth retardation, disorders caused by mutations in single genes, most of anemiaandmetabolicchanges.Thediseaseiscausedbythe which regulate the pancreatic β cells function. The aim of presenceoftwocausalmutationsfromparents,formationof the study was to determine the genetic background in disease de novo is rare. We describe three families their patients referred to the Outpatient Genetics Clinic of the children have a defined clinical diagnosis of Centre for Monogenic Diabetes in Lodz, Poland. nephronophtisis. Materials and Methods: The study group consisted of Methods:WetestedDNAisolatedfromperipheralblood 379 patients with suspected monogenic diabetes aged from and the molecular analysis of genes associated with 3 months to 38 years diagnosed from February 2017 to nephronophthisis was performed by MLPA and custom January 2019. They were referred based on the age of designed NGS. Found causal mutations were verified by diagnosis, family history, autoantibodies status, preserved Sanger sequencing. insulin secretion, different clinical course of diabetes or Results: By the analysis of 3 patients with clinical coexistence of other symptoms. The next generation diagnosis of nephronophtisis we found homozygous causal sequencing(NGS)methodwasperformedusingadesigned mutations in two of them and two different heterozygous panel of 35 genes (SureSelect, Agilent) and the following causal mutations (compound heterozygote) in one of them. platforms and programs: Variant Studio (Illumina®), Phe- Conclusion: Molecular genetic testing confirmed a clin- nIX (Charité Universitätsmedizin Berlin) and IGV (Broad ical diagnosis of nephronophtisis in all three patients. Institute). Follow-up segregation of causal variants in the patients’ Results: Various forms of monogenic diabetes were families identified healthy carriers of these variants and in confirmed in 75/379 (19.8%) of patients. 40 pathogenic one family we confirmed the diagnosis in affected siblings. variants of the GCK gene (MODY2), 8 variants of the The knowledge of causal mutations is important not only HNF1A gene (MODY3), 7 variants of the HNF4A gene for confirmation of the diagnosis, but also for healthy car- (MODY1), 7 variants of the BLK gene (MODY11), 7 var- riers in case of pregnancy planning and possible prenatal iants of the KCNJ11 gene (PNDM - permanent neonatal testing. diabetes mellitus), 5 variants of the HNF1B gene (RCAD - J. Indrakova: None. N. Havranova: None. M. Dvor- renal cysts and diabetes syndrome) and 1 variant of the akova:None.I.Uhliarikova:None.J.Rydlova:None.M. ABC C8
 gene (PNDM) were identified. Zelinova: None. R. Kremlikova Pourova: None. J. Las- Conclusions: The NGS method seems to be effective tuvkova: None. A. Boday: None. diagnostic tool for patients with monogenic diabetes. Sup- ported by the grants No 2015/19/B/NZ5/02243, 502-03/2-  P03
.43C 159-02/502-24-307 and 502-03/2-159-02/502-24-306. PEMT, PCYT1 A and B polymorphisms in children M. Borowiec: None. K. Antosik: None. P. Mludzik: with obesity None. A. Zmyslowska: None. P. Tutac1, N. Andreescu1, A. Mihailescu1, D. Tiugan1,  P03
.41A V. Serafim1, C. Zimbru1, C. Paul2, I. Velea2, Analysis of genes associated with the development of M. Niculescu1, M. Puiu1 nephronophthisis 1University of Medicine and Pharmacy Victor Babes, J. Indrakova1, N. Havranova1, M. Dvorakova1, Center of Genomic Medicine, Timisoara, Romania, I.Uhliarikova1,J. Rydlova1,M.Zelinova2, R. Kremlikova 2University of Medicine and Pharmacy Victor Babes, Pourova2, J. Lastuvkova3, A. Boday1 Pediatrics Discipline, Timisoara, Romania 1AGELLaboratories,NovyJicin,CzechRepublic,2Charles Introduction:VariationsinPCTY1AandBgenesassociate univerzity2ndFacultyofMedicineandUniversityHospital with alterations of PCTY1 expression and of phosphati- Motol, Prague, Czech Republic, 3Masaryk's Hospital in dylcholine (PC) synthesis. PC, the major glyceropho- Usti nad Labem, Usti nad Labem, Czech Republic spholipid in eukaryotic cells, can be synthesized by three pathways: the de-novo pathway, also known as KennedyAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1265 pathway,theLandscycleandthephosphatidylethanolamine Introduction: Circulating cell-free DNA (ccfDNA) analy- methyl transferase (PEMT) pathway. PC biosynthesis is sis has been lately used as a minimally invasive method in required for normal very low-density lipoprotein secretion cancer diagnostics. Currently, there is a scarce amount of from hepatocytes and generation of arachidonic acid information on adenoma derived ccfDNA. We examined (ARA); its inhibition may lead to excess storage of lipids the possibility to detect pituitary adenoma (PA) derived within liver, contributing to the development of obesity- ccfDNA, by performing targeted NGS on ccfDNA using associated hepatosteatosis. semiconductor sequencing. Aim: Whether PCTY1A, PCTY1A B and PEMT gene Materials and Methods: Blood samples used were polymorphisms in obese children associate with obesity- obtained from five NFPA patients before PA surgery. Six- related somatometric and biochemical parameters. teen tumor specific mutations each in unique gene (dis- Materialand Method: 200 obese children, aged 7to 18 covered in exome sequencing) were targeted in ccfDNA. yearsold;BMI>+2SD;abdominalcircumferenceabovethe Results: Sequencing coverage was 6191X on average 90th percentile; +/- HTA and dyslipidemia or insulin (range444-13026).Intwomutationsites(twopatients)the resistance. PCTY1A (rs 1580820) and PCTY1B (rs alternate allele was in less than in 10% of reads: RYR1 (G/ 4898190), PEMT(rs1109859, rs12103822, rs16961845, A,2.27%),MPRIP(C/T,3.65%).Fivemutations(fromtwo rs4244593, rs4479310, rs7214988, rs7946, rs8068641, patients) had the alternate allele close to 50% of reads: rs936108, rs13342397, rs6502603) were analysed using VP S13
D (C/T, 48%), LDLRAD2 (C/T, 47%), SPEN (A/G, next generation sequencing. 49%), GPATCH4 (C/T, 58%), G6P C2
 (C/G, 46%). The Results: PCTY1A, PCTY1B and PEMT rs1109859 var- alternate allele was in less than in 0.1% of reads in nine iations were positively correlated with glycemia, choles- mutations, however, the estimated background alternate terol, HDLc, total LA, ARA, BMI, cardiac frequency, and allele rate in non-mutation sites also was below 0.1%. arterialandsystolicbloodpressure.PCTY1AandPCTY1B Conclusions: Results indicate that while it is possible to polymorphisms were correlated with plasma choline, and detect somatic mutations found in adenoma in ccfDNA possiblywithplasmabetaineand5-methyltetrahydrofolate. using semiconductor sequencing the source of mutated Conclusion: Genetic variations involved in choline ccfDNA molecules should be further researched. Mutation metabolism were associated with alterations in choline, rate in 50% of reads could be due to somatic mosaicism or folate, and cholesterol metabolism in obese children, and due to increased tumor cell apoptosis/necrosis in these could play important roles in the severity of associated patients. metabolic alterations. Acknowledgement: This work was Research was supported by the European Regional performed at The Center of Genomic Medicine, POSCCE Development Fund project no.1.1.1.1/16/A/066: “Mole- Project, SMIS:48749, and funded by POC Project Nutri- cular markers of pituitary tumor development, progression Gen, SMIS:104852. and therapy response”. P. Tutac: None. N. Andreescu: None. A. Mihailescu: H. Niedra: None. K. Megnis: None. R. Peculis: None. None. D. Tiugan: None. V. Serafim: None. C. Zimbru: V. Rovite: None. I. Balcere: None. I. Konrade: None. J. None.C.Paul:None.I.Velea:None.M.Niculescu:None. Stukens: None. V. Pirags: None. J. Klovins: None. M. Puiu: None.  P03
.45A  P03
.44D Exome sequencing of non-functioning pituitary Detection of adenoma derived circulating cell-free DNA adenomas reveal tumors with high amount of somatic of human pituitary adenoma using semiconductor mutations and previously reported genes sequencing R. Pečulis1, V. Rovīte1, H. Niedra1, I. Balcere2, H. Niedra1, K. Megnis1, R. Peculis1, V. Rovite1, J. Nazarovs3, J. Stuķēns3, I. Konrāde2, V. Pīrāgs1,3,4, I. Balcere2, I. Konrade2, J. Stukens3, V. Pirags1,3,4, J. Kloviņš1 J. Klovins1 1Latvian Biomedical Research and Study Centre, Riga, 1Latvian Biomedical Research and Study Centre, Riga, Latvia, 2Riga East Clinical University Hospital, Riga, Latvia, 2Riga East Clinical University Hospital, Riga, Latvia, 3Pauls Stradiņš Clinical University Hospital, Riga, Latvia, 3Pauls Stradins Clinical University Hospital, Riga, Latvia, 4University of Latvia, Faculty of Medicine, Riga, Latvia, 4University of Latvia Faculty of Medicine, Riga, Latvia Latvia Introduction: The most commontype ofpituitary diseases is pituitary adenomas (PA). Although not undergoing1266 metastasis, PAs are responsible for increased mortality and mesenchymal stromal cells (MSC). We studied genetic morbidity. Genetic causes of PAs are known in a minority relationshipbetweenpatients’germlineDNA,tumourtissue of cases: several genes are implicated in familial PA. somaticDNA,DNAofPS andMSC obtained from culture Somatic mutations in GNAS and US P8
 are cause in to trace origin of each type of cultured cells. subgroups of sporadic GH and ACTH secreting PA, Materials and Methods: PA patients were enrolled to respectively. Exome and genome sequencing is used to nationalbiobank-GenomeDatabaseofLatvianPopulation study PA genetics nowadays, but is hampered by hetero- from Pauls Stradins Clinical University Hospital where geneity of PAs. transsphenoidal surgery of PA was performed for all MaterialsandMethods:Exomes(TruSeqRapidExome patients. Exomes (Illumina TruSeq_Rapid_Ex- TargetedRegions v1.2) of normal - tumor DNA pairs of ome_TargetedRegions_v1.2) of germline, tumour somatic, seven non-functioning PA patients were sequenced using PS and MSC were sequenced using Illumina NextSeq with Illumina NextSeq. Data were analysed using Isaac-Starling 75bppairedendreads.Sequencingdatawereanalyzedwith pipeline. Somatic mutations were reviewed with IGV2.2.4. Illumina Basespace Enrichment App (v3.0.0) aligning to Sangersequencingvalidationwasperformedforasubsetof human HG19 reference genome using Isaac Genome mutations covering all PA patients. AlignmentSoftware,variantscalledwithStarlingalgorithm Results: Various somatic mutation rate was observed in and variants annotated with Illumina Annotation Engine. the exomes of sequenced tumors. Two PAs were hyper- Filtered variants were reviewed using IGV 2.3.14. mutatedwith272and671somaticmutations.OtherfivePA Results: PAs contain low amount of tissue specific hadalowsomaticmutationratebetweenoneto12somatic mutations(median4,range2-6).Somaticmutationsofthe mutation per exome. VP S13
D in hypermutated tumor and primarytumourcanbedetectedintherespectivePS,butnot RYR1 had somatic mutations and had been reported con- in the respective MSC. Genetic alterations of MSCs corre- taining somatic mutation previously in GH secreting ade- sponded to mutations in PA patients’ germline DNA. nomas. Somatic mutations in G6PC and SMARCAD1 Conclusions: Using exome comparison we were able to previously have been detected in adenomas of different trace origin of PS and MSC cell cultures, showing that location. genome of PS represents genome of PA while MSC most Conclusions: Some PAs contain a significantly higher likely represent normal cells of pituitary or surrounding amount of somatic mutations than expected from non- tissues. metastasizing tumor. Somatic mutations in genes reported V.Rovite:None.R.Peculis:None.I.Mandrika:None. previously in connection with PA provide research targets R. Petrovska: None. K. Megnis: None. I. Balcere: None. for upcoming studies. The study was supported by ERDF J.Stukens:None.I.Konrade:None.A.Breiksa:None.J. grant 1.1.1.1/16/A/066. Nazarovs: None. V. Pirags: None. J. Klovins: None. R.Pečulis:None.V.Rovīte:None.H.Niedra:None.I. Balcere: None. J. Nazarovs: None. J. Stuķēns: None. I.  P03
.47C Konrāde: None. V. Pīrāgs: None. J. Kloviņš: None. Improved mapping quality and coverage in highly homologous PKD1 gene enable high diagnostic yield in  P03
.46B ADPKD Tracingoriginofculturedpituitaryadenomacellsusing “omics" analysis S.Valo1,J.Tallila1,M.Kaare1,H.Jalanko2,J.Sistonen1, A. Korppoo1, K. Gall3, M. Muona1, P. Salmenperä1, V. Rovite1, R. Peculis1, I. Mandrika1, R. Petrovska1, M.Gentile1, S.Myllykangas1,T.Alastalo3,J.Koskenvuo1 K. Megnis1, I. Balcere2, J. Stukens3, I. Konrade2, A. Breiksa3, J. Nazarovs3, V. Pirags1,3,4, J. Klovins1 1BlueprintGenetics,Helsinki,Finland,2HelsinkiUniversity Central Hospital, Helsinki, Finland, 3Blueprint Genetics, 1Latvian Biomedical Research and Study centre, Riga, San Francisco, CA, United States Latvia, 2Riga Eastern Clinical University Hospital, Riga, Latvia, 3Pauls Stradins Clinical University Hospital, Riga, Introduction: Autosomal dominant polycystic kidney Latvia, 4University of Latvia Faculty of Medicine, Rigs, disease (ADPKD) is an adult-onset multisystem disorder Latvia characterized by cysts in the kidneys and liver. It is estimated that PKD1 explains 85% and PKD2 15% of Introduction:Pituitaryadenomas(PA)arebenigntumours ADPKD cases. Genetic testing has become an important of the anterior pituitary that cause increased mortality and factorinthemanagementofADPKD.However,analysisof morbidity. Cell cultures derived from PA tissue can form PKD1 is technically challenging due to its large size, high freefloatingaggregatescalledpituispheres(PS)oradherent GC-contentandduplicationofthefirst33exonswithahighAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1267 degree of homology to pseudogenes (PKD1 P1
- P6
). We  P03
.48D evaluated the diagnostic yield and performance of our In- Detection of DZI P1
L mutations by whole exome house panels for cystic kidney disease. sequencing in two consanguineous families with Materials and Methods: Next-generation sequencing polycystic kidney disease (NGS) was performed using the IDT xGEN Exome Research Panel with addedcustomprobes and theIllumina J. M. Hertz1, P. Svenningsen2, H. Dimke3, NovaSeq 6000 platform. This assay provides improved M. B. Engelund1, H. Norgaard4, A. Hansen5, mapping quality and coverage of PKD1 compared to other N. Marcussen6, H. C. Thiesson7, B. L. Jensen3, NGS methods assessed in our laboratory. M. J. Larsen1 Results:PKD1providedbothhighmeancoverage(199x) and excellent mapping quality with 99.5% of the target 1Department of Clinical Genetics, Odense University nucleotidescovered atleast20x.Inthestudycohortof131 Hospital, Odense C, Denmark, 2Department of index patients, a genetic diagnosis was established in 52% CardiovascularandRenalResearch,InstituteofMolecular ofcaseswithdiseasecausingvariantsdetectedin7different Medicine, University of Southern Denmark, Odense C, genes. In 63% of the diagnostic cases the disease causing Denmark, 3Department of Cardiovascular and Renal variant was identified in PKD1. Interestingly, 84% (n=36) Research, Institute of Molecular Medicine, University of of the variants were located in the duplicated region of Southern Denmark, Odense C, Denmark, Odense C, PKD1. Denmark, 4Department of Pediatrics, Rigshospitalet, Conclusions: Our results demonstrate that our in-house Copenhagen, Denmark, 5Vestergade 21, Koge, Denmark, NGS platform is well-suited for clinical diagnostics with 6Department of Clinical Pathology, Odense University comprehensive coverage in difficult-to-sequence regions of Hospital,OdenseC,Denmark,7DepartmentofNephrology, PKD1.Themethodprovidesacost-effectivediagnostictool Odense University Hospital, Odense C, Denmark to simultaneously diagnose various types of mutations. S. Valo: A. Employment (full or part-time); Significant; Autosomalrecessivepolycystickidneydisease(ARPKD)is BlueprintGenetics.J.Tallila:A.Employment(fullorpart- an early onset cystic renal disease with an incidence of time); Significant; Blueprint Genetics. M. Kaare: A. about 1 per 20,000 live births. It is most frequently caused Employment (full or part-time); Significant; Blueprint bymutationsinthePKHD1gene,encodingfibrocystin,but Genetics. H. Jalanko: A. Employment (full or part-time); mutationsinothercilia-relateddiseasegenesmaymimicthe Modest; Blueprint Genetics. J. Sistonen: A. Employment phenotype. In 2017, Lu et al. reported homozygous (full or part-time); Significant; Blueprint Genetics. A. mutations in DZI P1
L located at 3q22.1, encoding the basal Korppoo: A. Employment (full or part-time); Significant; body protein DAZ interacting protein 1-like protein Blueprint Genetics. K. Gall: A. Employment (full or part- (DZI P1
L) in seven children with ARPKD from four time); Significant; Blueprint Genetics. M. Muona: A. unrelated and consanguineous families. DZI P1
L is located Employment (full or part-time); Significant; Blueprint at the basal body of the primary cilium, and impaired Genetics. P. Salmenperä: A. Employment (full or part- functionofDZI P1
Lisassociatedwithadefectintheciliary time); Significant; Blueprint Genetics. E. Ownership Inter- traffickingofpolycystin-1andpolycystin-2.Sofar,noother est (stock, stock options, patent or other intellectual prop- DZI P1
Lmutationshavebeenreported,andARPKDcaused erty); Significant; Blueprint Genetics. M. Gentile: A. by DZI P1
L mutations is a rare form of polycystic kidney Employment (full or part-time); Significant; Blueprint disease.We performed whole exome sequencing in two Genetics.E.OwnershipInterest(stock,stockoptions,patent consanguineousfamilieswiththreechildrenwithpolycystic or other intellectual property); Significant; Blueprint kidney disease, and identified two different and not Genetics. S. Myllykangas: A. Employment (full or part- previously reported DZI P1
L mutations in homozygous time); Significant; Blueprint Genetics. E. Ownership Inter- form: c.193T>C; p.(Cys65Arg), and c.216C>G; p. est (stock, stock options, patent or other intellectual prop- (Cys72Trp). All three children are phenotypically charac- erty); Significant; Blueprint Genetics. T. Alastalo: A. terized by enlarged echogenic kidneys with poor cortico- Employment (full or part-time); Significant; Blueprint medullary differentiation. No liver cysts were detected. Genetics.E.OwnershipInterest(stock,stockoptions,patent Liver stiffness were evaluated in two of the children by or other intellectual property); Significant; Blueprint transient elastography, and with normal result. Functional Genetics. J. Koskenvuo: A. Employment (full or part- analyses of the p.Cys72Trp mutation indicate that this time); Significant; Blueprint Genetics. E. Ownership Inter- variant causes a disruption of a localization signaling or est (stock, stock options, patent or other intellectual prop- interaction domain of DZI P1
L. erty); Significant; Blueprint Genetics. J.M. Hertz: None. P. Svenningsen: None. H. Dimke: None. M.B. Engelund: None. H. Norgaard: None. A.1268 Hansen: None. N. Marcussen: None. H.C. Thiesson:  P03
.50B None. B.L. Jensen: None. M.J. Larsen: None. Preparing for genomics: a retrospective audit of a metropolitan renal genetics clinic  P03
.49A Genetic analysis in pulmonary arterial hypertension E. I. Krzesinski1,2, Y. B. Prawer1,2, M. J. P. Regan1, Sicilian patients: preliminary results A. Yeung1,2,3, M. F. Hunter1,2 I. Loddo, F. Barbera, M. Beretta, A. Callari, L. Martino, 1Monash Genetics, Monash Health, Melbourne, Australia, D. Di Carlo, P. Conaldi, P. Vitulo 2Department of Paediatrics, Monash University, Melbourne,Australia,3VictorianClinicalGeneticsService, ISMETT Mediterranean Institute for Transplantation and Melbourne, Australia Advanced Specialized Therapies (ISMETT), Palermo, Italy Introduction: Hereditary kidney conditions are rare but Background: Pulmonary arterial hypertension (PAH) is a account for a significant burden on hospitals in both adults progressive and fatal disorder associated with high and children. Monash Health is a KidGen/ Australian pulmonary artery pressure. Most heritable PAH (75%) is Genomics Health Alliance/Melbourne Genomics Health caused by a pathogenic variant in BMPR2, pathogenic Alliance flagship recruitment site, aiming to assess the variants in other genes are considerably less common (1- impact of multidisciplinary renal-genetic clinics on patient 3%). care while providing access to whole exome Genetic testing enables early diagnosis and offers an sequencing (WES). opportunity for family screening. Materials and Method: This three year audit (2015- Materials and Methods: We designed a target sequen- 2017) of renal patients referred to the Monash Health cing custom panel that includes 15 genes of interest. genetics service provides a picture of the renal genetics Genetic counselling was offered to every patients. landscape at the outset of renal flagship WES testing. The To identify genetic mutations and help make a precise electronic medical record was searched using renal key- diagnosis and family screening, we performed genetic words; each file was manually assessed for inclusion and testing by NGS in six patients with PAH. exclusion criteria. Data collection included referrer speci- Results:Inthreepatientsweidentifiedvariantsclassified alty,condition,familyhistory,inheritancepattern,typeand according to ACMG Guidelines. cost of genetic testing and impact of genetic testing on In a 47 years old female affected by familial PAH, we management and reproductive options. identified a heterozygous nonsense variant (c.2617C>T) p. Results: Through keyword matching 676 patients were Arg873* in BMPR2 gene, classified as pathogenic. identified, 86 met inclusion criteria; 59 (69%) were pro- Ina31yearsoldfemaleaffectedbyPAHwithPulmonary bands with a primary renal condition and 35 (40.1%) were Capillary Hemangiomatosis, we identified a homozygous referred by a nephrologist. Cystic renal disease was the frameshift pathogenic variant (c.2666_2667insAATC) p. commonestreasonforreferral.Genetictestingwasarranged Lys891Aspfs* in EIF2AK4 gene, classified as pathogenic for 50 patients of whom 21 (42%) had informative results. and never described before. Diagnosis rate improved from 2015 to 2017; cost per In a 55 years old male affected by Pulmonary Arterial informative patient diagnosis was $2499. Hypertension, we identified a heterozygous missense var- Conclusion: Audit provides a snapshot of the utility of iant (c.1151T>A) p.Val384Asp in SMAD9 gene, classified clinical genetics input in a renal genetics context at the as likely pathogenic and never described before. All var- outset of improved WES access. Fourteen referred patients iants were confirmed by Sanger sequencing. were unaffected providing them with reproductive reassur- Genetic counselling and molecular analysis was offered ance. Diagnosis rate improved from 2015 to 2017 as more to high-risk relatives. molecular diagnoses were obtained, thus improving patient Conclusions: Our study confirm that NGS Target rese- management. quencingrepresents avaluabletool inPAHgenetictesting. E.I. Krzesinski: None. Y.B. Prawer: None. M.J.P. Analyses of PAH casual genes have a great help to clinical Regan: None. A. Yeung: None. M.F. Hunter: None. diagnosis and deep implications in patients management and disease treatment.  P03
.51C I. Loddo: None. F. Barbera: None. M. Beretta: None. Molecular genetic analysis of Steroid Resistant A. Callari: None. L. Martino: None. D. Di Carlo: None. Nephrotic Syndrome: Detection of a novel mutation P. Conaldi: None. P. Vitulo: None. A. Shojaei1, N. Serajpour1, B. Karimi2, P. Khosravi2Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1269 1Department of Medical Genetics and Molecular Biology, phenotypes of IBD in terms of disease extension, disease Faculty of Medicine, Iran University of Medical Sciences, severity and extraintestinal manifestations (EIM). EIM in Tehran, Iran, Islamic Republic of, 2Medical Genetic IBDarefrequentandmaysignificantlyimpactthequalityof laboratory, Shahid Akbarabad hospital, Iran University of patients life. Our aim was to investigate two TNF-alpha Medical science, Tehran, Iran, Islamic Republic of gene SNPs for association with clinical manifestations in IBD patients. Background: Nephrotic syndrome is one of the most Materials and Methods: The study included 142 IBD common kidney diseases in childhood. About 20% of patients (78 CD, 43M/35F and 64 UC, 40M/24F), all of children are steroid-resistant NS (SRNS) which progress to Romanian origin. EIM were documented in 34 patients (20 end-stage renal disease (ESRD). More than 53 genes are CD, 14 UC). The two SNPs of TNF-alpha gene rs361525 associated with SRNS which represent the genetic hetero- (-238G/A) and rs1800629 (-308G/A) were genotyped by geneity of SRNS. This study was aimed to screen disease TaqMan Allelic Discrimination Assay (7300 Real-Time causing mutations within NPH S1
 and NPH S2
 and evaluate PCR System, Applied Biosystems by Thermo Fisher Sci- new potential variants in other genes. entific, USA). Association tests for each polymorphism Method: In first phase of study, 25 patients with SRNS wereperformedwith DeFinettionlinesoftware(http://ihg2. were analyzed for NPH S1
 (exon 2, 26) and all exons of helmholtzmuenchen.de/cgi-bin/hw/hwa1.pl) and p values NPH S2
 genes by Sanger sequencing. In the second phase, ≤0.05 were considered significant. Results. We found a whole exome sequencing was performed on 10 patients significant association between -308A variant and the pre- with no mutations in NPH S1
 and NPH S2
. senceofEIMinbothulcerativecolitis(p=0.0002,OR8.51) Result:WESanalysisrevealedanovelmutationinFAT1 and Crohn’s disease (p=0.002, OR 5.19). For UC, -238A (c.10570C>A; Q3524K). We identified 4 pathogenic allele and the GA genotype were more frequent in patients mutations, located in exon 4 and 5 of NPH S2
 gene in 20% with EIMthan inpatientswithoutEIM(p=0.01,OR27.03 of patients (V180M,  P118
L, R168C and Leu156Phe). Also and p=0.0009, OR 30.13 respectively). No other associa- our study has contributed to the descriptions of previously tions with clinical phenotype were observed. known pathogenic mutations across WT1 (R205C) and Conclusion: TNF-α polymorphisms influence clinical SMARCA L1
 (R764Q) and a novel polymorphism manifestations of IBD in Romanian patients. These results in CRB2. should be confirmed on larger patients cohorts. Grant sup- Conclusion: Our study concludes that mutations of exon port: IDEI 311/2007. 4and5NPH S2
genearecommoninIranianandsomeother O.M. Popa: None. C. Tieranu: None. M. Bojinca: ethnic groups. We suggest conducting WES after None. I. Tieranu: None. M. Diculescu: None. NPH S2
 screening and further comprehensive studies to identify the most common genes in the development of SRNS,whichmighthelpinClinicalimpactonmanagement  P04
 in patients with SRNS. Skeletal, connective tissue, ectodermal and skin A. Shojaei: None. N. Serajpour: None. B. Karimi: disorders None. P. Khosravi: None.  P04
.01A  P03
.52D Comprehensive re-assessment of causality of ABC C6
 TNF-alpha gene polymorphisms influence disease missense variants associated with pseudoxanthoma phenotype in inflammatory bowel disease elasticum O. M. Popa1, C. Tieranu2, M. Bojinca1, I. Tieranu1, S. Verschuere1,2, P. Coucke1,2, O. M. Vanakker1,2 M. Diculescu1 1Center for Medical Genetics Ghent, Ghent University 1University of Medicine and Pharmacy 'Carol Davila', Hospital, Ghent, Belgium, 2Department of Biomolecular Bucharest, Romania, 2Elias University Emergency Medicine, Ghent University, Ghent, Belgium Hospital, Bucharest, Romania Introduction: Pseudoxanthoma elasticum (PXE) is an Introduction: Tumor necrosis factor (TNF) alpha is a autosomal recessive ectopic mineralization disorder caused major proinflammatory cytokine involved in the immune by ABC C6
 mutations. Inconsistencies in variant interpreta- response in inflammatory bowel disease (IBD). IBD is tion raised the question whether all variants reported in composed of two main subtypes, namely Crohn’s disease literature or variant databases are truly disease-causing. (CD) and Ulcerative Colitis (UC). There are multiple Especially for missense substitutions it is challenging to1270 predict the impact on protein function. We therefore re- heart disease, skeletal malformations, and characteristic evaluated pathogenicity of all ABC C6
 missense variants. facies. Materials and Methods: The score-based variant clas- Materials and Methods: Patients with de novo hetero- sification system Sherloc was used to analyze 234 variants zygous missense variants in AB L1
 were identified via trio from literature, ClinVar and in-house patient screenings. WESthroughtheDDDStudywithSangerconfirmationvia Clinical and functional evidence were scored according to UK regional genetics laboratories. Clinical assessments of the rules and guidelines of Nykamp et al. (2017). patients were carried out via regional clinical genetics ser- Results: Comprehensive classification revealed 74% vices. To investigate AB L1
 kinase activity in vitro, variants of uncertain significance (VUS), 12% likely HEK293T cells were transfected with plasmid constructs pathogenic, 10% pathogenic, 3% benign and 1% likely encoding wild-type or mutant AB L1
 cDNA. Phosphoryla- benign variants. VUS classification was further refined into tion of AB L1
-specific substrates was measured by immu- truly uncertain variants (69% of VUS) and those leaning noblotting and potential for reversal investigated by towards likely benign (1% of VUS) or likely pathogenic treatment with imatinib. Bio-informatic analysis of gene- (30% of VUS). Taking the latter into account, 44% of wide conservation and germline/somatic variation was ABC C6
variantsis(likely) pathogenicwhenconsideringall performed. available population, clinical, experimental and in silico Results: We identified three unrelated patients with de data. This is significantly different from ClinVar, where novo pathogenic missense variants in AB L1
, including two 87% of ABC C6
 missense variants are allegedly pathogenic novel variants. All variants cluster in the myristoyl-binding and only 11% VUS. pocket of AB L1
 – a region critical for auto-inhibitory reg- Conclusions: Our results underline that variant classifi- ulation of the kinase domain, which is subject to high cationshouldbedonesystematicallyandwithcaution,asit missense constraint and evolutionary conservation. All has important consequences for patients and heterozygous patients recapitulate the phenotype of the AB L1
 develop- carriers. The high number of VUS confirms the need for mentalsyndrome.FunctionalstudiesofmutantAB L1
kinase functional testing to prove or refute their causality before activity are ongoing and will be presented. returning them to patients. Conclusions: We describe three new cases with patho- S. Verschuere: None. P. Coucke: None. O.M. genic AB L1
 missense variants causing skeletal malforma- Vanakker: None. tionsandcongenitalheartdisease.Mutationsclusteraround themyristoylbinding-pocketofAB L1
,suggestingagain-of-  P04
.02B function mechanism due to loss of auto-inhibition. De novo pathogenic AB L1
 variants cluster in a A.J.M. Blakes: None. E. Gaul: None. W. Lam: None. myristoyl-binding pocket N. Shannon: None. A. Chase: None. A.G.L. Douglas: None. A. J. M. Blakes1, E. Gaul2, W. Lam3, N. Shannon4, A. Chase2, DDD Study, A. G. L. Douglas1,2  P04
.03C Rare loss-of-function variants in the Epidermal 1Wessex Clinical Genetics Service, University Hospital Differentiation Complex predispose individuals to Southampton NHS Foundation Trust, Southampton, Atopic Dermatitis Southampton, United Kingdom, 2Human Development and Health, Faculty of Medicine, University of Southampton, S. P. Smieszek, C. Polymeropoulos, G. Birznieks, Southampton, UK, Southampton, United Kingdom, 3South M. Polymeropoulos East of Scotland Clinical Genetics Service, Western General Hospital, Crewe Road, Edinburgh, UK, Vanda Pharmaceuticals, Washington, DC, United States Edinburgh, United Kingdom, 4Clinical Genetics Service, Nottingham University Hospitals NHS Trust, Hucknall Theepidermaldifferentiationcomplex(EDC)includesover Road, Nottingham, UK, Nottingham, United Kingdom fifty genes encoding proteins involved in keratinocyte development. Of these genes, filaggrin (FLG) located on Introduction: AB L1
 is a proto-oncogene encoding a chromosome 1 q21, is the most studied in the context of nonreceptortyrosinekinase.Itisbestknowninthesomatic skinbarrierdysfunction.Weinvestigatedthefrequencyand BCR-ABL fusion gene associated with chronic myeloid effectofrareloss-of-function(LOF)variantsinpatientsofa leukaemia. Recently, Wang et al. described two germline clinical study, VP-VLY-686-2102 (randomized, double- missense variants in AB L1
 causing an autosomal dominant blind, placebo-controlled, in patients with chronic pruritus developmental syndrome (OMIM 617602) with congenital associated with AD) with 117 whole genome sequencing (WGS) samples. We have shown that 45/117 AD patientsAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1271 carry significantly more, rare loss-of-function (LOF) inheritance pattern and variable expressivity. We applied mutations in the SFTP family of genes as compared to large-insertjumpinglibrariestolocalizethebreakpointsand 55/316 in a control population (p-value = 0.000004). This confirmed these results with Sanger sequencing to char- group of EDC LOF (stopgain, frameshift) rare variants acterize breakpoints of a t(2;7)(p21;p15), followed by gene (EDC-LR) consists of 20 variants observed in the 45 AD expression studies to explore the functional impact of the patients resulting in a calculated Odds Ratio of 2.96 and a rearrangement. Sequencing revealed five breakpoints, dis- Relative Risk of 2.38. Among the detected LOF variants, rupting two genes, HDA C9
 and MAC C1
. We discovered there are 25 cases of FLG LOF mutations as defined by altered expression of TWIST1 located downstream of R501X(rs61816761),2282del4(rs558269137),otherLOFs HDA C9
. Our results suggest that an inversion in the inFLGaswellasLOFsinFLG2,HRNR,LC E4
A,LC E5
A, HDA C9
-TWIST region in 7p21.1 affects regulation of TCHH, TCHH L1
 and other members of the EDC. We TWIST, thereby producing a skeletal dysplasia with examine the regional accumulation of rare LOF variants in intrafamilial variable expressivity. These analyses suggest FLG region. For the entire EDC, we obtained a p-value of that the mechanism of this rearrangement might involve 4.7e-20, much lower than for FLG alone p-value of 4.5e-6, alterationofregulatorysequenceslocatedatadistanceincis indicative of an even greater effect when analyzed jointly that dysregulate TWIST and insinuate HDA C9
 as a new (entire family vs. FLG alone) in the AD context. The disease locus producing craniosynostosis. identified LOF variants within the region can serve as B. Turkgenc: None. R.P. Aguilar: None. B. Curral: biomarkers as well as help delineate the genetic profile in None. C. Lowther: None. E. Schields Wilch: None. M. AD patients. Talkowski: None. C. Morton: None. S.G. Temel: None. S.P. Smieszek: A. Employment (full or part-time); Modest; Vanda Pharmaceuticals. C. Polymeropoulos: A.  P04
.05A Employment (full or part-time); Modest; Vanda Pharma- Novel variant in PRKAR1A associated with ceuticals.G.Birznieks:A.Employment(fullorpart-time); brachydactyly type E without hormone resistance Modest; Vanda Pharmaceuticals. M. Polymeropoulos: A. Employment (full or part-time); Modest; Vanda A. Pereda1, K. Heath2,3,4, J. Wu5, I. Valenzuela-Palafoll6, Pharmaceuticals. S. S. Taylor5,7, G. Perez de Nanclares1  P04
.04D 1Molecular (Epi)Genetics Laboratory, BioAraba National A balanced translocation t(2;7)(p21;p15) in three Research Institute, Vitoria-Gasteiz, Spain, 2Institute of generations: Genome sequencing offers an opportunity Medical and Molecular Genetics (INGEMM), Hospital to understand molecular etiology of Saethre-Chotzen/ Universitario La Paz, Universidad Autonóma de Madrid, Robinow-Sarouf syndromes IdiPAZ, Madrid, Spain, 3Skeletal dysplasia Multidisciplinary Unit (UMDE), Hospital Universitario La B.Turkgenc1,R.P.Aguilar2,3,B.Curral3,4,C.Lowther3,4, Paz, Madrid, Spain, 4CIBERER, ISCIII, Madrid, Spain, E. Schields Wilch3, M. Talkowski3,4,5, C. Morton2,3,5,6, 5Department of Pharmacology, University of California at S. G. Temel7 San Diego, San Diego, CA, United States, 6Area de Genètica Clínica i Malalties Minoritàries. Hospital Vall 1Acibadem Diagnostic Center, Istanbul, Turkey, 2Brigham d'Hebron,Barcelona,Spain,7DepartmentofChemistryand and Women's Hospital, Boston, MA, United States, Biochemistry, University of California at San Diego, San 3Harvard Medical School, Boston, MA, United States, Diego, CA, United States 4Massachusetts General Hospital, Boston, MA, United States, 5Broad Institute of MIT and Harvard, Cambridge, Introduction: Protein kinase A (PKA) is a tetramer MA,UnitedStates,6UniversityofManchester, Manchester, containing a regulatory (R) subunit dimer locking 2 UnitedKingdom,7UniversityofBursa,FacultyofMedicine, catalytic (C) subunits. The most abundantly expressed R- Department of Medical Genetics, Bursa, Turkey subunitisPRKAR1A,composedofadimerizationdomain, an inhibitory site, and 2 cAMP-binding domains (CNB:A; Recent developments in genomic analyses have facilitated CNB:B), each containing a phosphate binding cassette theprecisemapping oftranslocation breakpointsassociated (PBC). Inactivating mutations in PRKAR1A cause acrody- withMendeliandisorderstodecipheriftherearrangementis sostosis with hormonal resistance (ACRDY S1
). likely to contribute to the observed phenotype. We Patients and Methods: We present a case of a 15 year- evaluated the phenotypic consequences of an apparently old girl with clinical suspicion of pseudopseudohypopar- balanced translocation in a family affected by craniosynos- athyroidism based on brachydactyly type E, severe sco- tosis and limb malformations presenting with a dominant liosis, and short stature without hormone resistance. Her1272 mother presented a similar phenotype. After discarding ofanaffectedfetusrevealedanabnormalproliferativezone alterations in GNAS, PTHLH, IHH and GDF5 (Sanger and a broad hypertrophic zone. To confirm the role of sequencing, MS-MLPA/MLPA), a skeletal dysplasia NGS Kiaa0753 in skeletal ciliopathies, we used the zebrafish panel was performed. model.Phenotypingofzebrafishlarvaecarryinganonsense Results: A heterozygous novel variant in PRKAR1A mutation in homozygosity showed that mutant larvae pre- [NM_002734.4:c.592G>C; p.(Gly198Arg)], bioinformati- sentedwithcurvedbody,atypicalciliopathyphenotype,as callypredictedaslikelypathogenic,wasidentified.Familial well as abnormal cartilage patterning. kiaa0753-null zeb- studies confirmed cosegregation (mother harbored; healthy rafishdonotsurvivebeyondthefirstweekofdevelopment, grandparents did not harbor). Gly198 precedes the PBC of suggesting that loss-of-function (LoF) mutations in CNB:A and its substitution to Arg is predicted to affect kiaa0753 are embryonic lethal. Interestingly, these functionbecause:(1)itmightaffectcAMPbindingtoCNB: kiaa0753-null larvae show loss of cilia and abnormal cell A, as the long side-chain of arginine will crash with its rearrangements, helping us understand how LoF mutations neighboring residues (inactivating mutation); (2) the intro- in kiaa0753 affect cell organisation and embryonic devel- duction of the longer side-chain into the tight PBC space opment. In aggregate, our results show that Kiaa0753 is couldchangeitsconformationleadingtoanalteredbinding importantfortheearlyembryodevelopmentinzebrafish,in between the C and the R (activating/inactivating mutation). accordance with the phenotypes seen in patients. Future Conclusions: PRKAR1A variants can lead to phenotypes plans involve using this disease model to develop treat- milder than ACRDY S1
 depending on the affected protein ments for patients with KIAA0753 mutations. domain. Incomplete or partial PKA inactivation could lead R.Vaz:None.A.Hammarsjö:None.F.Taylan:None. to an isolated non-severe brachydactyly without hormone D. Chitayat: None. G. Grigelioniene: None. A. resistance. Lindstrand: None. Funding: Instituto de Salud Carlos III (PI16/00073); Basque Department of Health (GV2016/111105).  P04
.07C A. Pereda: None. K. Heath: None. J. Wu: None. I. p63 establishes epithelial enhancers at craniofacial Valenzuela-Palafoll: None. S.S. Taylor: None. G. Perez development genes involved in orofacial clefting de Nanclares: None. E. Lin-Shiao1,2, J. Welzenbach3, Y. Lan1,2,  P04
.06B K.A.Alexander1,2,Z.Zhang1,2,M.Knapp4,E.Mangold3, KIAA0753 mutations in skeletal ciliopathies: unveiling M. Sammons1,2, S. L. Berger1,2, K. U. Ludwig3 disease mechanisms 1DepartmentofCellandDevelopmentalBiology,University R. Vaz1, A. Hammarsjö2, F. Taylan1, D. Chitayat3, of Pennsylvania, Philadelphia, PA, United States, G. Grigelioniene2, A. Lindstrand2 2Epigenetics Institute, University of Pennsylvania, Philadelphia, PA, United States, 3Insitute of Human 1Department of Molecular Medicine and Surgery, Center Genetics, School of Medicine, University of Bonn, Bonn, for Molecular Medicine, Karolinska Institutet, Stockholm, Germany, 4Insitute of Medical Biometry, Informatics and Sweden, 2Department of Molecular Medicine and Surgery, Epidemiology, School of Medicine, University of Bonn, Center for Molecular Medicine, Karolinska Institutet; Bonn, Germany Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden, 3Division of Clinical and Metabolic Transcription factor p63 is a key mediator of epidermal Genetics, Department of Pediatrics, The Hospital for Sick commitment, development, and differentiation. In humans, Children, University of Toronto, Toronto, ON, Canada point mutations in the p63 coding region lead to develop- mental defects, including syndromic orofacial clefting. Skeletalciliopathiesareaheterogeneousgroupofdisorders Notably, common risk variants located intronically in p63 caused by mutations in more than 25 genes, such as contribute also to the risk of nonsyndromic cleft lip with/ KIAA0753. Mutations in KIAA0753 have been associated without cleft palate (nsCL/P), the most frequent isolated with Joubert syndrome, orofaciodigital syndrome, and formoforofacialclefting.Todate,ourknowledgeislimited moderate to fetal lethal skeletal dysplasia with narrow about the role of p63 in human craniofacial development, thorax and abnormal metaphyses. due in part to a lack of tractable models. Here we We have previously reported patients with biallelic fra- investigated the role of p63 in human craniofacial meshift and nonsense mutations in this gene. We have also development, and in the pathogenesis of nsCL/P. Using shown that KIAA0753 is expressed in normal fetal human an inducible trans-differentiation model and systematic growthplateandimmunohistochemistryofthegrowthplate epigenomicsequencing(includingATAC-seqtogetherwithAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1273 ChIP-seq of p63 and H3K27ac) we show that p63 radiological and genetics data, phosphocalcic balance, establishes enhancers at craniofacial development genes to markers of bone remodeling and bone densitometry data modulatetheirtranscription.Specificsubstitutionmutations of45CCDpatientsaged9monthsto60.8years(median= in the DNA binding or SAM protein interaction domain of 15.4 years). 7% of patients evaluated had at least one p63 respectively eliminate or reduce establishment of these fracture without trauma (3/45). 32% (13/41) patients have enhancers. Furthermore, using large-scale GWAS data we secondaryhyperparathyroidism,arecognizedriskfactorfor showthatenhancersestablishedbyp63arehighlyenriched osteopenia due to increased bone resorption induced by for SNPs associated with nsCL/P. These orthogonal parathyroid hormone and 20% (8/41) patients have vitamin approaches indicate a strong molecular link between p63 Ddeficiency(25-OHD<20ng/mL).TheanalysisofBMD enhancer function and nsCL/P, illuminating molecular shows that the Z-score at the lumbar level of 38.7% of mechanisms underlying this developmental defect and patients(12/31)islessthan-2DS.Theseresultsindicatethe revealing vital regulatory elements and new candidate need for active prevention of osteoporosis and fractures in causative genes. patients with CCD, ensuring at an early age of sufficient E. Lin-Shiao: None. J. Welzenbach: None. Y. Lan: intakes calcium and vitamin D, but also regular physical None. K.A. Alexander: None. Z. Zhang: None. M. activitytoallowoptimal/maximalbonemassacquisitionin Knapp:None.E.Mangold:None.M.Sammons:None.S. adulthood. L. Berger: None. K.U. Ludwig: None. A. Lavillaureix: None. C. Michot: None. G. Baujat: None. G. Maruani: None. M. Polak: None. M. De la  P04
.08D Dure-Molla: None. J. Souberbielle: None. E. Koumakis: Cleidocranial dysplasia: natural history of bone None. V. Cormier-Daire: None. manifestations  P04
.09A A. LAVILLAUREIX1,2, C. Michot2, G. Baujat2, A novel mutation in CO L2
A1 leading to G. Maruani3, M. Polak4, M. De la Dure-Molla5, spondyloepiphyseal dysplasia congenita J. Souberbielle6, E. Koumakis7, V. Cormier-Daire2 Y. Kendir Demirkol1, Ö. Akgün Doğan1, M. Say2, 1Service de Génétique Clinique, Centre de référence T. Kızılboğa Akgün3,4, L. Doğanay4 "Maladies Rares" CLAD-Ouest, CHU Rennes - Université Rennes1,Rennes, France, 2Service deGénétiqueClinique, 1Department of Pediatric Genetics, Health Sciences Centre deRéférence Maladies Osseuses Constitutionnelles, University, Umraniye Education and Research Hospital, APHP-HôpitalNecker-EnfantsMalades-InstitutImagine İstanbul, Turkey, 2Bioinformatic Team, Gen-Era - INSERM UMR 1163 - Université Paris Descartes Diagnostic, İstanbul, Turkey, 3Department of Molecular SorbonneParisCité,Paris,France,3Serviced'explorations Biology and Genetics, İstanbul Technical University, fonctionnelles, AP-HP - Hôpital européen Georges- İstanbul, Turkey, 4GLAB (Genomic Laboratory) Health Pompidou, Paris, France, 4Service d'endocrinologie, Sciences University, Umraniye Education and Research gynécologie et diabétologie pédiatrique, APHP - Hôpital Hospital, İstanbul, Turkey Necker-Enfants Malades, Paris, France, 5Service d'Odontologie,AP-HP-HôpitalRothschild,Paris,France, Introduction: Spondyloepiphyseal dysplasia congenita 6Laboratoired'explorationsfonctionnelles,APHP-Hôpital (SEDC, OMIM# 183900) is a rare autosomal dominant Necker-Enfants Malades, Paris, France, 7Service de inherited chondrodysplasia. SEDC is characterised by Rhumatologie, APHP, Hôpital Cochin, Paris, France dwarfism and skeletal abnormalities caused by mutations oftheCO L2
A1gene,whichpreventbonegrowth.Themost Cleidocranialdysplasia(CCD)isarareautosomaldominant common features of SEDC are skeletal deformities such as skeletal dysplasia whose most characteristic signs are the short-trunk dwarfism, odontoid hypoplasia, cervical spine delayed closure of cranial sutures with wide fontanelle at subluxation,scoliosis,kyphosis,lumbarlordosis,coxavara, birth, hypoplastic or aplastic clavicles, a short height and genu valgum, clubfoot, pes planus and metaphyseal multiple dental anomalies. The natural history of CCD is changes. Cervical cord compression is the most hazardous poorly known. Isolated cases of patients with multiple skeletal deformity in patients with SEDC which requires fractures or osteoporosis have been described, without special attention and management. Here, we present a evaluating the other risk factors for bone fragility. The mother and a son with SEDC due to a novel heterozygous purposeofthisstudyistoevaluatebonemineralizationand mutation in SEDC. the occurrence of fractures inpatients with CCD, children Material andMethods:Thepatientwasthefirstchildof and adults. In an observational study, we collected clinico- non consanguineous parents, born at 33 gestation week a1274 birth length of 39 cm (3-10th centile). Postnatal he was to ACMG/AMP classification. As glycine substitutions are hospitalized in intensive care unit due to respiratory insuf- typical for SEMD-S patients, it is highly probable that the ficiency. Physical examination revealed facial dysmorphic identified variant is causative of the SEMD-S phenotype. features and short neck. The mother has disproportionate Conclusion: To our knowledge, this missense variant in short stature, facial dysmorphic features and operation scar CO L2
A1 has not been reported before. It extends the due to hip dislocation. Her X ray showed platyspondyly, mutational spectrum allowing for better genotype/pheno- kyphosis, scoliosis, coxa vara and flattened epiphyses. type correlation in patients with SEMD-S. Molecular Results: Next-generation sequencing was performed on genetic analysis is helpful for the diagnosis of skeletal Illumina MiSeq (v1.9) platform using the virtual panel for dysplasias with overlapping phenotypes. skeletal dysplasia consisting of 130 genes. The novel het- M.Kero:None.A.Meašić:None.A.Bobinec:None.I. erozygous variant in CO L2
A1 (c.2006G>C) was detected Sansović: None. I. Barišić: None. bothsonandmother.Segregationwithinthemothersfamily showed the mutation was denova.  P04
.12D Conclusions:SEDCisarareskeletaldysplasia.Targeted Defining the clinical features associated with variants in exomeanalysishasgreatimportanceinthefastandaccurate CO L4
A2: case report and review of the literature setting in the diagnosis and avoid serious neurological deficits and or mortality. A.Hanson-Kahn1,K.Vlessis1,E.J.Smith2,M.Manning1 Y. Kendir Demirkol: None. Ö. Akgün Doğan: None. M. Say: None. T. Kızılboğa Akgün: None. L. 1Stanford University, Stanford, CA, United States, Doğanay: None. 2Stanford Children's Health, Palo Alto, CA, United States  P04
.10B CO L4
A2 encodes the α2 chain of type IV collagen, which Novel variant in CO L2
A1 gene causing assemblesintoheterotrimerswithCO L4
A1chainstoforma spondyloepimetaphyseal dysplasia Strudwick type component of the basal membrane. Heterozygous variants (SEMD-S) inCO L4
A2havebeendescribedinfewerthan20familiesin association with familial cerebrovascular disease manifest- M. Kero, A. Meašić, A. Bobinec, I. Sansović, I. Barišić ingasporencephalyandintracerebralhemorrhage.Seizures, cortical malformations, lens opacities, hematuria and Children´s Hospital Zagreb, Zagreb, Croatia elevated creatine kinase have been reported. We present a 4-1/2 year old male with ischemic stroke and deep vein Introduction: Collagenopathies type IIare rare autosomal- thrombosis, intracranial hemorrhage, systemic arterial dominant conditions characterized by skeletal dysplasia, involvement (tapering of the abdominal aorta, occlusion short stature and sensorial defects. More than 400 of the left common iliac artery, small right iliac artery and heterozygous mutations in type II collagen gene CO L2
A1 collateralsoftheupperextremities)andmildlydilatedaortic have been identified, but only 5 of them are found in root and ascending aorta. Whole exome sequencing patients with spondyloepimetaphyseal dysplasia Strudwick reported a maternally inherited variant in CO L4
A2 type (SEMD-S), a rare phenotype of intermediate severity. (c.1396G>A, p.G466S). This variant is not reported in WepresentafemalepatientwithSEMD-Sphenotypeanda ClinVarbutisreportedingnomADwithanallelefrequency novel mutation in the CO L2
A1 gene. of 5.0x10-5. In silico models predict this variant to be Patients and Methods: The patient presented at birth damaging. The patient’s mother is asymptomatic; brain with severe short trunk-short limb dwarfism, short chest, MRI,echocardiogramandophthalmologyexaminationsare coxa vara, clubfoot, cleft palate, conductive hearing loss being coordinated. While intracranial hemorrhage has also andmildexternalhydrocephalus.Metaphysealirregularities beenseeninotherpatientswithCO L4
A2variants,systemic permittedclinicaldifferentiationfromSEDcongenita.Now, arteriopathy and mild enlargement of the aortic root have attheageof7years,herstatureissignificantlyreducedand notbeenpreviouslydescribed.Wereviewtheliteratureand a waddling gait, genu valgum and lumbar lordosis devel- further define the clinical features associated with variants oped. Hands and feet are normal. The genomic DNA from in CO L4
A2 to include arteriopathy and aortic root blood leukocytes of the patient was isolated and Next dilatation. Generation Sequencing (NGS) analysis was done focusing A. Hanson-Kahn: None. K. Vlessis: None. E.J. Smith: on about 200 genes associated with skeletal dysplasias. None. M. Manning: None. Results: NGS revealed a novel heterozygous missense variant (c.2177G>A, p.Gly726Asp) in exon 33 of the CO L2
A1 gene, categorised as likely pathogenic accordingAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1275  P04
.13A  P04
.14B Next generation sequencing in neonates presenting with I L11
RA and pansynostosis collodion baby syndrome A. Topa1,2, A. Rohlin2, L. Lovmar2, G. Stenman1, A.Bobinec1,A.Meašić1,M.Kero1,I.Sansović1,S.Ožanić L. Kölby3 Bulić2, N. Pustišek2, S. Murat-Sušić3, I. Barišić1,2 1Department of Pathology and Genetics, University of 1DepartmentofMedicalGeneticsandReproductiveHealth, Gothenburg, The Sahlgrenska Academy, Gothenburg, Children's Hospital Zagreb, Scientific Centre of Excellence Sweden, 2Department of Clinical Genetics, Sahlgrenska for Reproductive and Regenerative Medicine (CERRM), University Hospital, Gothenburg, Sweden, 3Department of University of Zagreb School of Medicine, Zagreb, Croatia, Plastic Surgery, University of Gothenburg, The 2Division of Dermatology, Children's Hospital Zagreb, Sahlgrenska Academy, Gothenburg, Sweden University of Zagreb School of Medicine, Zagreb, Croatia, 3Department of Dermatology and Venerology, University Thegeneticbackgroundofcraniosynostosisiscomplexand Hospital Centre Zagreb, University of Zagreb School of implicates multiple signaling pathways. The role of Medicine, Zagreb, Croatia interleukin 11 receptor, alpha (I L11
RA), a cell-derived cytokine, has been evidenced in the pathogenesis of Introduction: Collodion baby (CB) is a rare condition multiple synostosis with autosomal recessive inheritance characterized by the presence of parchment or-cellophane- pattern (Craniosynostosis and dental anomalies, like collodion membrane encompassing the whole body. OMIM#614188).ACrouzon-likeappearancewithdifferent CB is a genetically heterogeneous disorder that usually typesofcraniosynostosishasbeenobserved.Severalcausal presents with lamellar ichthyosis (LI) or congenital missense and truncating variants have been reported. We ichthyosiform erythroderma (CIE). Other less common present three additional cases with homozygous novel disorders as self-improving collodion ichthyosis, Netherton pathogenic and likely pathogenic variants in I L11
RA syndrome, Gaucher disease type 2, Chanarin-Dorfman (NM_001142784.2: c.598C>A, p.Pro200Thr; c.696C>A, syndrome, ectodermal dysplasia or Sjögren Larsson syn- p.Tyr232*; c.866A>G, p.His289Arg). All three patients drome may also be responsible for this phenotype. presented with high intracranial pressure, a Crouzon-like Materials and Methods: Clinical exome sequencing phenotype and early closure of all cranial sutures (pansy- (CES)wasperformedin4patientswithreferraldiagnosisof nostosis). Our cases, together with previous reports of CB using Illumina TruSight One Kit. I L11
RA-related pansynostosis, suggest a key regulator role Results: CES analysis revealed mutations in ALOX12B, for I L11
RA in the morphogenesis and maintenance of SPINK5, NIPA L4
 and TGM1 genes. In patient 1 ( P1
), we patency of all cranial sutures. found a homozygous mutation in the ALOX12B gene, A.Topa:None.A.Rohlin:None.L.Lovmar:None.G. known to cause self-improving collodion ichthyosis. This Stenman: None. L. Kölby: None. was consistent with a rapid resolution of almost all skin lesions.  P2
 and  P3
 developed Netherton syndrome. In  P2
  P04
.15C compound heterozygous mutations in the SPINK5 gene Diagnosticvalue oftargetednext-generation sequencing confirmed the diagnosis. In  P3
 no causative genetic varia- in craniosynostosis tionswerefound.In P4
,presentingwithCBevolvingtoLI, wedetectedtwoheterozygousvariants,oneinNIPA L4
gene E. M. Olech1, A. Sowińska-Seidler1, D. Popiel2, (likely pathogenic) and other in TGM1 (uncertain G. Koczyk2,3, M. Socha1, J. Walczak-Sztulpa1, significance). A. Materna-Kiryluk1,2, A. Latos-Bieleńska1,2, R. Posmyk4, Conclusion:ClinicalevolutionofCBishardtopredictas R. Śmigiel5, A. Dawidziuk1, A. Jamsheer1 clinical presentation and severity may vary from mild to life-threatening. CES provided a timely and precise diag- 1Department of Medical Genetics, Poznan University of nosis in most of our patients which is important for treat- Medical Sciences, Poznan, Poland, 2Centers for Medical mentplanning,diseaseprognosisandgeneticcounsellingof Genetics GENESIS, Poznan, Poland, 3Institute of Plant affected families. Genetics (PAS), Department of Biometry and A.Bobinec:None.A.Meašić:None.M.Kero:None.I. Bioinformatics, Poznan, Poland, 4Podlaskie Center of Sansović: None. S. Ožanić Bulić: None. N. Pustišek: Clinical Genetics, Bialystok, Poland, 5Department of None. S. Murat-Sušić: None. I. Barišić: None. Pediatric Propedeutics and Rare Diseases, Wroclaw Medical University, Wroclaw, Poland1276 Background: Craniosynostosis (CS), the premature fusion 1Genometrics Section, Computational and Statistical of one or more cranial sutures, occurs either as an isolated Genomics Branch, Division of Intramural Research, malformation or in a syndromic form, representing a NHGRI, NIH, Baltimore, MD, United States, 2Department genetically heterogeneous and clinically variable group of of Pediatrics, University of California Davis, Sacramento, disorders. Routine diagnostic screening of common CA, United States, 3Department of Pediatrics, Seattle craniosynostosis-associated genes enables to establish Children's Craniofacial Center, University of Washington, genetic aetiology in 21% to 62% depending on the size of Seattle, WA, United States, 4MRC Weatherall Institute of the study, ethnicity of the population, and range of the Molecular Medicine, University of Oxford, John Radcliffe molecular analysis. Hospital, Oxford, United Kingdom, 5Clinical Genetics Materials and Methods: We performed targeted next- Service, Oxford Centre for Genomic Medicine, Oxford generationsequencinginagroupof60patientsmanifesting University Hospitals NHS Foundation Trust, Oxford, CS with negative results of molecular screening. We have United Kingdom, 6West Midlands Regional Clinical designedacustomhybridisation-basedpanel,encompassing Genetics Service and Birmingham Health Partners, 61 genes and 11 SNPs chosen based on current knowledge Birmingham Women’s and Children’s Hospitals NHS about variants involved in craniofacial development using Foundation Trust, Birmingham, United Kingdom, online databases. We sequenced captured and indexed 7Department ofClinical Genetics, Liverpool Women's NHS libraries on Ion Torrent  S5
 sequencing system. Foundation Trust,, Liverpool, United Kingdom, 8Clinical Results: This approach revealed pathogenic variants or Genetics Service, Great Ormond Street Hospital, London, probably pathogenic variants among patients presenting United Kingdom, 9National Institute of Pediatrics, Sofia with different forms of CS. We found pathogenic and Medical University, Sofia, Bulgaria, 10Molecular Medicine probably pathogenic variants or variants of unknown sig- Center, Department of Medical Chemistry and nificance within the ALX4, BM P4
, CY P26
B1, EDN3, Biochemistry,MedicalFaculty,MedicalUniversityofSofia, EFNB1, EFTUD2, FGFR1, FGFR2, FGFR3, IFT122, Sofia, Bulgaria, 11National Genetic Laboratory, University IFT140, IHH, MEGF8, RECQ L4
, RUNX2, SKI, Hospital of Obstetrics and Gynecology “Maichin Dom”, TCF12 genes. Medical University of Sofia, Sofia, Bulgaria, 12Department Conclusion: We present an NGS targeted gene panel of Neurosurgery, University Hospital 'St. Ivan Rilski', approachasavaluablediagnostictoolinthegenetictesting Medical University of Sofia, Sofia, Bulgaria, 13Department of patients presenting with craniosynostosis. of Otolaryngology, Head and Neck Surgery, University of This work was supported by the grants from the Poznan California Davis,, Sacramento, CA, United States, University of Medical Sciences, Poland 502-14-11261860- 14Department of Neurosurgery, University of California 41259 and the Polish National Science Centre, Poland Davis, Sacramento, CA, United States, 15Neuroscience UMO-2016/23/N/NZ5/02577 to Ewelina M. Olech, and Research Australia, University of New South Wales, UMO-2016/22/E/NZ5/00270 to Aleksander Jamsheer Sydney, Australia, 16Institute of Anatomy and Cell Biology, E.M. Olech: None. A. Sowińska-Seidler: None. D. The Catholic University Sacred Heart, Rome, Italy, Popiel: None. G. Koczyk: None. M. Socha: None. J. 17Department of Epidemiology, College of Public Health, Walczak-Sztulpa: None. A. Materna-Kiryluk: None. A. The University of Iowa, Iowa City, IA, United States, Latos-Bieleńska: None. R. Posmyk: None. R. Śmigiel: 18Department of Pediatrics, Stead Family Children’s None. A. Dawidziuk: None. A. Jamsheer: None. Hospital, The University of Iowa, Iowa City, IA, United States, 19Gene and Environment Interaction Section,  P04
.16D NHGRI, NIH, Bethesda, MD, United States, A genome-wide association study implicates BM P7
 as a 20Epidemiology Branch, Eunice Kennedy Shriver NICHD, risk factor for nonsyndromic metopic craniosynostosis NIH, Bethesda, MD, United States, 21Division of Genetics, WadsworthCenter,NYSDepartmentofHealth,Albany,NY, C. M. Justice1, A. Cuellar2, K. Bala2, J. A. Sabourin1, United States, 22Department of Nutritional Sciences, M. L. Cunningham3, A. O. M. Wilkie4, J. M. Phipps4, University of Texas at Austin, Austin, TX, United States Y. Zhou4, K. Crawford4, D. Cilliers5, J. E. V. Morton6, A. Weber7, L. C. Wilson8, E. Simeonov9, R. Kaneva10, Craniosynostosis(CS)arisesfromprematureclosureofone N. Yaneva11, K. Georgiev12, A. Busarski12, C. Senders13, ormorecranialsutures.Previously,weobservedthatBM P2
 M. Zwienenberg14, T. Roscioli15, M. Barba16, (rs1884302) and BB S9
 (rs10262453) were independently W. Lattanzi16, K. Conway17, V. Sheffield18, L. Brody19, associated with sagittal nonsyndromic CS (sNCS). In this J. Mills20, D. Kay21, R. Sicko21, R. Tittle22, A. F. Wilson1, study, we conducted a genome-wide association study P. A. Romitti17, S. A. Boyadjiev2, the National Birth (GWAS) for metopic NCS (mNCS). In an international Defects Prevention Study sample of 228 non-Hispanic white case-parent trios, threeAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1277 variants were genome-wide significant: rs781712 1MRC Weatherall Institute of Molecular Medicine, (P=4.788x10-9;oddsratio(OR)=2.407)intronictoSPRY3; University of Oxford, Oxford, United Kingdom, rs6127972 (P=5.611x10-9; OR=2.257) intronic to BM P7
; 2Department of Pediatrics, University of California Davis, and rs62590971 (P=4.046x10-8; OR=0.380) located ~155 Sacramento,CA,UnitedStates,3DepartmentsofPathology kbupstreamfromTGIF2LX.Theassociationforrs6127972 and Bioinformatics, Erasmus MC, University Medical was replicated in an independent sample (194 unrelated Center Rotterdam, Rotterdam, Netherlands, 4Sheffield mNCS cases, 333 controls, P=0.0042, OR=1.45) and in a Clinical Genetics Service, Sheffield Children's NHS meta-analysis,P=3.11x10-9(OR=1.45).Rs1884302and Foundation Trust, Sheffield, United Kingdom, 5West rs10262453, identified as risk factors from our previous Midlands Regional Clinical Genetics Service and sNCS GWAS, were also genotyped in our mNCS samples. Birmingham Health Partners, Birmingham Women’s and Rs10262453 was borderline significant in the mNCS Children’s Hospitals NHS Foundation Trust, Birmingham, discovery and replications cohorts (P=9.216x10-5, United Kingdom, 6Department of Clinical Genetics, OR=1.716), (P=0.0003, OR=1.62) respectively, and had Liverpool Women's NHS Foundation Trust, Liverpool, a meta-analysis P=1.330x10-7(OR=1.62). Notably, the C UnitedKingdom,7ClinicalGeneticsService,GreatOrmond allele for this variant was over-transmitted in mNCS Street Hospital, London, United Kingdom, 8Craniofacial probands, whereas the A allele was over-transmitted in Unit, Oxford University Hospitals NHS Trust, John sNCS probands. Functional assessment of rs6127972 using Radcliffe Hospital, Oxford, United Kingdom, 9Department western blot and ELISA showed no difference in BM P7
 of Plastic and Reconstructive Surgery, Erasmus MC, expression or protein levels in synostotic metopic versus University Medical Center Rotterdam, Rotterdam, opensutures.Datafromluciferasestudiessuggestedthatthe Netherlands, 10National Institute of Pediatrics, Sofia locus may act as a repressor element with the risk allele Medical University, Sofia, Bulgaria, 11Institute of Anatomy exerting stronger repression. Zebrafish transgenic analysis and Cell Biology, The Catholic University Sacred Heart, produced inconclusive results. Our findings implicate the Rome, Italy, 12Genomics England, London, United BMP/TGFβsignalingpathwayinmidlineNCSandsupport Kingdom, 13William Harvey Research Institute, Queen the role of BB S9
 locus in the etiology of metopic Mary University of London, London, United Kingdom craniosynostosis. [Grants NIH X01HG008936 and R01D E016886
] Incompletepenetranceisacomplicatingfactorindiagnosis C.M. Justice: None. A. Cuellar: None. K. Bala: None. and makes genetic counselling very challenging. Usually J.A. Sabourin: None. M.L. Cunningham: None. A.O.M. the mechanisms explaining the non-penetrance are not Wilkie: None. J.M. Phipps: None. Y. Zhou: None. K. understood, with few epistatically-interacting genetic fac- Crawford: None. D. Cilliers: None. J.E.V. Morton: tors described in humans. One recent example of such a None.A.Weber:None.L.C.Wilson:None.E.Simeonov: “two-locus” model is the proposal by Timberlake et al None.R.Kaneva: None. N.Yaneva:None.K. Georgiev: (eLife,2016)ofaninteractionofSMAD6variantsinmidline None. A. Busarski: None. C. Senders: None. M. Zwie- craniosynostosis (premature fusion of the metopic and/or nenberg: None. T. Roscioli: None. M. Barba: None. W. sagittal cranial sutures of the skull) with a common Lattanzi:None.K.Conway:None.V.Sheffield:None.L. polymorphism near BM P2
, to explain frequent non- Brody: None. J. Mills: None. D. Kay: None. R. Sicko: penetrance in the parent transmitting the SMAD6 variant. None. R. Tittle: None. A.F. Wilson: None. P.A. Romitti: We aimed (i) to validate the findings in an independent, None. S.A. Boyadjiev: None. largercohort, and (ii) to delineate the phenotype associated withSMAD6variants.WeperformedNGS-basedresequen-  P04
.17A cing of multiplexed PCR products of SMAD6 in 800 BM P2
 or not BM P2
? A SMAD6-related question in unsolved patients with any type of craniosynostosis, and craniosynostosis genotypedthers1884302BM P2
polymorphisminSMAD6- positive individuals. We identified 18 different rare E. Calpena1, A. Cuellar2, K. Bala2, S. M. A. damaging SMAD6 variants (2.25% overall), with the Swagemakers3, N. Koelling1, S. J. McGowan1, highest prevalence in metopic synostosis (~6%) and a M. Balasubramanian4, J. E. V. Morton5, A. Weber6, ~23-fold enrichment of loss-of-function variants compared L. C. Wilson7, D. Johnson8, S. A. Wall8, S. R. F. Twigg1, to gnomAD data (P<0.00001). This confirms that SMAD6 I. M. J. Mathijssen9, E. Simeonov10, W. Lattanzi11, variants increase the risk of craniosynostosis (especially F. Boardman-Pretty12,13, S. A. Boyadjiev2, A. O. M. metopic). Combining these data with a further 6 indepen- Wilkie1,8 dently identified variants, 17/24 were transmitted from an unaffected parent but the BM P2
 genotype did not correlate with presence/absence of craniosynostosis. Hence further1278 work is needed to identify the factors accounting for classification due to clinical variability. Furthermore, genes reduced penetrance of SMAD6 variants - both in craniosy- which reside in or are disrupted by rare CNVs represent nostosis,andinthepanoplyofotherphenotypes(including candidate genes for craniosynostosis. congenital heart disease, thoracic aortic aneurysm and In addition to sequencing approaches CNV screening intellectual disability), with which SMAD6 variants have methods like aCGH should be included in the genetic been associated. testing algorithm for craniosynostosis patients. This will E.Calpena:None.A.Cuellar:None.K.Bala:None.S. enable diagnosis in a significant portion of yet unsolved M.A. Swagemakers: None. N. Koelling: None. S.J. syndromic as well as non-syndromic cases. McGowan: None. M. Balasubramanian: None. J.E.V. E. König: None. E. Kunstmann: None. A. Quattlän- Morton: None. A. Weber: None. L.C. Wilson: None. D. der: None. T. Schweitzer: None. E. Klopocki: None. Johnson:None. S.A. Wall:None. S.R.F.Twigg: None. I. M.J. Mathijssen: None. E. Simeonov: None. W. Lat-  P04
.19C tanzi:None.F.Boardman-Pretty:None.S.A.Boyadjiev: Biallelic loss of function mutations in CSGALNACT1 None. A.O.M. Wilkie: None. cause a mild skeletal dysplasia with joint laxity  P04
.18B R. Meyer1, M. Begemann1, A. Schulze2, A. Kochs3, Chromosomal rearrangements and CNVs identified in I. Kurth1, M. Elbracht1 craniosynostosis cases 1Institute of Human Genetics, RWTH Aachen University, E. König1, E. Kunstmann2, A. Quattländer3, Aachen, Germany, 2Department of Orthopedic Surgery, T. Schweitzer4, E. Klopocki1 RWTH Aachen University, Aachen, Germany, 3Praxis für Orthopädie und Unfallchirurgie, Aachen, Germany 1InstituteofHumanGenetics,Würzburg,Germany,2Praxis für Humangenetik, Würzburg, Germany, 3Kinderarztpraxis Biallelic loss of function mutations in CSGALNACT1 were Volkach,Volkach,Germany,4DepartmentofNeurosurgery, recently proposed to cause a prenatal onset mild skeletal Section of Pediatric Neurosurgery, University Hospital of dysplasia with joint laxity in a single 3.5 years old female Würzburg, Würzburg, Germany patient. The phenotype in this patient reflects the skeletal dysplasia of Csgalnact1-/- mice and resembles the clinical Craniosynostosis,theprematurefusionofcranialsutures,is andradiographicpictureofamilderspectrumofDesbuquois acommonbirthdefect(~1:2500newborns)occurringeither dysplasia (Vodopiutz et al., 2017). CSGALNACT1 encodes asanisolatedorsyndromicform.Singlenucleotidevariants chondroitin sulfate N-acetylgalactosaminyltransferase-1 (SNVs) in known craniosynostosis genes i.e. FGFR2, (CSGalNAcT-1, ChGn-1) which has a critical role in the FGFR3 and TWIST1 account for only 20% of cases. biosynthesis of chondroitin sulfate and dermatan sulfate. Besides these SNVs, a significant subgroup (15%) of Here we report on a 12 years old boy born from patients with syndromic craniosynostosis show chromoso- consanguineous parents with a mild skeletal dysplasia, mal rearrangements. Due to the small number of patients short stature (-3SD), and joint laxity. Psychomotor devel- with identical chromosomal aberrations reported in the opment was normal. Whole exome sequencing revealed a literature,itisoftendifficulttodeterminethecriticalregion/ homozygous 1bp-deletion in CSGALNACT1 (c.372del, p. gene which contributes to the phenotype and perform a (His125Thrfs*9)). Segregation analysis confirmed both specific diagnostic analysis. Thus, aCGH was chosen as parents as heterozygous carriers. The identified variant is genome-wideCNVscreeningapproachforidentificationof neither reported in gnomAD and dbSNP nor in the CNVs in a cohort of 33 craniosynostosis patients. literature.Itleads toaframeshift andprematurestop codon In total we detected likely pathogenic CNVs in 18% of and, thus, with high probability to loss of function of the our cohort. These CNVs encompass known craniosynos- corresponding protein. This is the second report of a tosis genes like MSX2 and TCF12 and novel craniosynos- patient with biallelic loss of function mutations in tosis candidate genes, respectively. Three patients carried CSGALNACT1 which underlines its role in mild skeletal unbalanced translocations and in additional three cases we dysplasia, short stature, and joint laxity without obvious detected interstitial gains and losses. Clinically these additional organ manifestations and normal psychomotor patientspresentedwithisolatedaswellassyndromicforms development. of craniosynostosis. R. Meyer: None. M. Begemann: None. A. Schulze: Our results emphasize the importance of chromosomal None. A. Kochs: None. I. Kurth: None. M. rearrangements and CNVs as a genetic cause of craniosy- Elbracht: None. nostosis, particularly in case of unclear syndromeAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1279  P04
.20D  P04
.21A Prenatal diagnosis of Desbuquois dysplasia by whole Vascular ehlers-danlos syndrome exome sequencing before the occurrence of specific ultrasound signs N. Agaoglu1, Y. Kendir Demirkol2, O. Akgun Dogan2, M. Say3, T. Kizilboga Akgun1, H. Doganay1 C. Houdayer1, F. Boussion2, A. Ziegler1, S. Blesson3, C. Bris1, A. Toutain3, F. Biquard2, A. Guichet1, 1GLAB (Genomic Laboratory) Health Sciences University, D. Bonneau1,4, E. Colin1,4 Umraniye Education and Research Hospital, Istanbul, Turkey,2DepartmentofPediatricGenetics,HealthSciences 1Department of Biochemistry and Genetics, Angers University, Umraniye Education and Research Hospital, University Hospital, ANGERS, France, 2Department of Istanbul, Turkey, 3Bioinformatic Team, Gen-Era Obstetrics and Gynecology, Angers University Hospital, Diagnostic, Istanbul, Turkey ANGERS, France, 3Department of Genetics, Tours UniversityHospital,TOURS,France,4MitovascLab,Team, Introduction: Vascular Ehlers-Danlos syndrome is an Institut MitoVasc, UMR CNRS 6015, INSERM U1083, autosomal dominant connective tissue disorder caused by Angers University, Angers, France mutations in CO L3
A1 and CO L1
A1. It is considered as the mostsevere form ofEhlers-Danlos syndrome (EDS) dueto Osteochondrodysplasiaisagroupofhereditarydisordersof the high mortality rate associated with the fragility of theconnectivetissue,bonesorcartilagethatimpairskeletal arteries and internal organs. Common symptoms include developmentwithaprevalenceofabout2per10000births. thin, translucent skin; easy bruising; characteristic facial The genetic and phenotypic heterogeneity of this group of appearance; and fragile arteries, muscles and internal disordersistremendousinvolvingmorethan300genesthat organs. Treatment and management options are limited are responsible for more than 450 distinct conditions. One and focused on preventing serious complications. Here we of them, Desbuquois syndrome dysplasia (DBQD) is a rare presenta5yearsoldfemalewithvasculartypeEDSdueto skeletal osteochondrodysplasia characterized by severe a novel heterozygous mutation CO L3
A1. micromelic dwarfism, joint laxity with multiple joint Materials and Methods: The patient was the first child dislocations, specific radiographic findings features and ofnon-consanguineoushealthyparents,bornattermwitha facial dysmorphism. DBQD is a very severe and often birthweightof2600gr(3-10thcentile).Easlybruisingeven sometime lethal form of micromelic dwarfism. We report with small traumas have been noticed from the infancy here a case for which whole exome sequencing allowed to period. She also had difficulty in wound healing. Physical performanearlyprenataldiagnosisbeforetheoccurrenceof examination revealed wide forehead, deep-set eyes, thin characteristic ultrasound signs. Indeed, at 21 WG, the translucent skin with multiple bruising and atrophic scars, ultrasound scan confirmed that the fetus was very likely joint laxity, and profound superficial veins. affected with an osteochondrodysplasia because all bio- Results: Next-generation sequencing was performed on metric parameters were below -4 SD associated with Illumina MiSeq(v1.9) platform using the virtual panel for bilateral vertical talus. However, it was impossible, at that collagenopathy consisting of 51 genes. The heterozygous time, to pinpoint the exact diagnosis. Using exome variant in CO L3
A1(c.3563G>A) was detected. Segregation sequencing,weevidencedtwovariantsinCANT1,thegene within the family showed that the variant is de-novo. responsible for DBDQ. The parents were informed that the Conclusions: Although vascular type EDS is a rare fetus was very likely affected with DBQD at a gestational genetic disease, it should be kept in mind in patients with ageof24weeks.Thepresentcase,istoourknowledge,the easy bruisable skin and atrophic scar. Accurate and early first oneinwhoma molecular prenataldiagnosis ofDBQD diagnosis have great importance in preventing serious life is performed in the absence of relevant family history and threating complications. before the appearance of evocative sonographic features. It N. Agaoglu: None. Y. Kendir demirkol: None. O. highlights the utility of prenatal exome sequencing in Akgundogan:None.M.Say:None.T.Kizilbogaakgun: performing a precocious diagnosis for severe fetal None. H. Doganay: None. conditions. C. Houdayer: None. F. Boussion: None. A. Ziegler:  P04
.23C None.S.Blesson:None.C.Bris:None.A.Toutain:None. Homozygous mutations of EGFR gene as a cause of F.Biquard:None.A.Guichet:None.D.Bonneau:None. lethal syndrome with progeroid features in two Roma E. Colin: None. families1280 J. Laštuvková1, P. Hitka2, S. Mazurová3, M. Magner3, 1Department of Clinical Genetics, Odense University M. Tesařová3, V. Stránecký3, V. Čejnová1 Hospital, Odense C, Denmark, 2H C Andersen Childrens Hospital,OdenseUniversityHospital,OdenseC,Denmark, 1DepartmentofMedicalGenetics,MasarykHospitalinUsti 3Center for Rare Diseases, Aarhus University Hospital, nadLabem,Krajskazdravotni,a.s.,UstinadLabem,Czech Aarhus C, Denmark Republic, 2Clinic of Neonatology Faculty of Health Care Studies Jan Evangelista Purkyně University in Usti nad The parents of a girl born with Tessier no. 4 facial clefting Labem and Krajska zdravotni, a.s., Masaryk Hospital in soughtgeneticcounsellingconcerningrecurrenceriskinthe Usti nad Labem, Usti nad Labem, Czech Republic, next pregnancy. The pattern of the facial clefting and a 3Department of Paediatrics and Adolescent Medicine First constriction ring on the right leg raised the suspicion of MedicalFaculty,CharlesUniversityinPragueandGeneral amniotic band to be the cause. Trio exome analysis was University Hospital in Prague, Czech Republic, Prague, performed to best possible rule out other causes. A Czech Republic maternally inherited substitution of glycin to serin in the triple helix domaine (CO L3
A1:c.2689G>A;p.Gly897Ser) EGFR gene encodes an epidermal growth factor receptor wasidentifiedintheCO L3
A1-gene,raisingthesuspicionof which is important in cell proliferation and differentiation. vascular Ehlers-Danlos syndrome. The family history was Sofar,onlyrarereportsofgermlinemutationsintheEGFR without vascular catastrophes, but one affected had severe gene as a cause of monogenic disease in children are bleedingafteragynecologicalsurgery.Somecarriersofthe available. Our patient was a young pregnant woman of variant had easy bruising, whereas others did not. It is well Roma origin. Her previous pregnancy was complicated by knownthatsubstitutionsofglycintoserininthetriplehelix polyhydramnios and IUGR and her daughter was born in domaine lead to a better prognosis and a milder phenotype the 31st week of pregnancy, birth weight 660g. Child had than other glycin substitutions in vascular Ehlers-Danlos no organ malformation but very fragile skin and died after Syndrome, which most likely explains the mild vascular 46 days because of multiorgan failure. The current phenotype in this family. This case reminds us that some pregnancywasalsocomplicatedbyseverepolyhydramnios, collagendiseasesincrease therisk of amniotic banding,the there were hyperechogenic kidneys and bowels and IUGR. risk being estimated to approximately 1 %. The other way The boy was born in the 30th week with birth weight of round, the risk of a collagen disease in case of amniotic 760g. The boy had progeroid features with lack of banding is to the best of our knowledge unknown. We subcutaneous fat and very thin and fragile skin. He died suggest that genetic analysis for selected collagen diseases in 34 days because of metabolic dysbalance. Whole exome should be done in case of amniotic banding. sequencing revealed presence of homozygous mutation C.R. Fagerberg: None. R.M. Schmidt: None. S. Far- c.1283G>A (p.Gly428Asp) in the EGFR gene in both holt: None. K.P. Sørensen: None. deceased siblings, both parents are heterozygous carriers. Thirteen years ago, we examined Roma family in which 3  P04
.26B children died in early infancy with very similar clinical Natural exon skipping reveals that antisense features. The diagnosis of Netherton syndrome was oligonucleotide-mediated exon skipping should be considered,butwasn'tconfirmed.Withournewexperience directed at the recessive type of dystrophic we tested mutation of EGFR gene in one ofthese deceased epidermolysis bullosa children.Homozygousmutationc.1283G>Awasconfirmed by Sanger sequencing. Mutations of EGFR gene should be J. Bremer1, E. H. van der Heijden1, D. S. Eichhorn2, consideredinadifferentialdiagnosisofprogeroidsyndrome R. Meijer3, H. H. Lemmink1, H. Scheffer3, R. S. Sinke1, especially in Roma families. Our report describes features M. F. Jonkman2, A. M. G. Pasmooij2, P. C. Van den of these children. Dedication: RVO-VFN 64165/2012 Akker1 J. Laštuvková: None. P. Hitka: None. S. Mazurová: None. M. Magner: None. M. Tesařová: None. V. Strá- 1University of Groningen, University Medical Center necký: None. V. Čejnová: None. Groningen, Department of Genetics, Groningen, Netherlands, 2University of Groningen, University Medical  P04
.24D Center Groningen, Department of Dermatology, Tessier no. 4 facial cleft leading to the diagnosis of Groningen, Netherlands, 3Department of Human Genetics, familial vascular Ehlers-Danlos syndrome Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands C. R. Fagerberg1, R. M. Schmidt2, S. Farholt3, K. P. Sørensen1Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1281 Introduction:Dystrophicepidermolysisbullosa(DEB)isa Genetics (PAS), Department of Biometry and devastating genetic blistering disease affecting skin and Bioinformatics, Poznan, Poland mucous membranes. DEB is caused by pathogenic variants intheCO L7
A1geneencodingtypeVIIcollagen,andcanbe Background: Facial dysostoses (FD) encompass rare and inherited dominantly or recessively. The structure of heterogeneouscongenitalcraniofacialanomaliessubdivided CO L7
A1 makes it an attractive candidate for exon- into mandibulofacial dysostoses (MFDs) and acrofacial skipping therapy. Recently, we demonstrated promising dysostoses (AFDs). Both MFDs and AFDs result from proof-of-principle for antisense oligonucleotide (AON)- impaired migration of neural crest cells to the pharyngeal mediatedexon-skipping as a systemic therapeutic approach arches and the face during embryogenesis. The main forDEB.However,itisunclearwhatphenotypiceffectmay clinical featuresobservedinaffectedpatientsaremaxillary, be expected from exon-skipping and which patient groups malar and mandibular hypoplasia, cleft palate, and/or ear may benefit the most. defects. In AFDs, limb defects are present as an additional Patients and Methods: To answer these questions, we feature. studied new clinical and molecular data on seven patients Materials and Methods: To determine the molecular from the Dutch EB registry and reviewed the literature on aetiology of FD, we performed a custom amplification- pathogenic CO L7
A1 variants inducing ‘natural exon- basedpanelof37genes(145.5kb,761amplicons)bynext- skipping’. generation sequencing on Ion Torrent  S5
 sequencing sys- Results: We found that the natural skipping of certain tem. We analysed a group of 25 patients affected by vari- exons led to disease in a heterozygous state, while the able forms of FD and validated clinically relevant variants skippingofotherexonsonlyledtodiseaseifcombinedwith byconventionalsequencinginbothaffectedindividualsand a pathogenic variant on the other CO L7
A1 allele. The their parents. dominant DEB phenotypes associated with heterozygous Results:Testingwithtargetednext-generationgenepanel exon-skipping could not be distinguished from dominant revealed pathogenic or probably pathogenic variants in 14 phenotypes caused by heterozygous CO L7
A1 variants not out of 25 patients presenting with different forms of FDs. inducing exon-skipping. Phenotypes associated with reces- We found either novel or known variants within the sive exon-skipping mutations were, however, on average ALDH1A1, ALX1, DHODH, EFNB1, EFTUD2, FGFR1, relatively mild in the spectrum of recessive DEB. SF3B4, SRCAP, TCOF1, and ZSWIM6 genes. Conclusions: For dominant DEB, AON-mediated exon- Conclusion:Weprovedtheefficiencyandclinical utility skipping is unlikely to make a clinical difference. In con- ofthe designed gene panel. The targeted strategy presented trast, we anticipate that exon-skipping has the potential to here is a suitable and helpful approach in the genetic induce a clinicallyrelevant improvementof the devastating diagnostics of variable forms of FD. recessive DEB phenotype, especially the types caused by This work was supported by the grant from the Poznan bi-allelic null variants. University of Medical Sciences, Poland 502-14-11261860- Grants and Fellowships: Clinical Fellowship ZonMW 41259 to Ewelina M. Olech. and grant from the Polish (90715614, PvdA) National Science Centre, Poland UMO-2016/22/E/NZ5/ J. Bremer: None. E.H. van der Heijden: None. D.S. 00270 to Aleksander Jamsheer Eichhorn:None.R.Meijer:None.H.H.Lemmink:None. E.M. Olech: None. D. Popiel: None. G. Koczyk: None. H. Scheffer: None. R.S. Sinke: None. M.F. Jonkman: A. Materna-Kiryluk: None. M. Badura-Stronka: None. None. A.M.G. Pasmooij: None. P.C. Van den M. Wiśniewska: None. A. Latos-Bieleńska: None. A. Akker: None. Jamsheer: None.  P04
.27C  P04
.29A Targetednext-generation sequencing in the diagnosisof Novel mutations in autosomal dominant inherited facial dysostoses syndromes with cutaneous manifestations E. M. Olech1, D. Popiel2, G. Koczyk1,3, A. Materna- E. Borràs, I. Hernan, M. A. Pol, F. Corella, Kiryluk1,2, M. Badura-Stronka1,2, M. Wiśniewska1,2, M. J. Gamundi, B. Mañé, M. Carballo A. Latos-Bieleńska1,2, A. Jamsheer1,2 Hospital de Terrassa (CST), Terrassa, Spain 1Department of Medical Genetics, Poznan University of Medical Sciences, Poznan, Poland, 2Centers for Medical Introduction: Molecular diagnosis provides useful infor- Genetics GENESIS, Poznan, Poland, 3Institute of Plant mation for disease prognosis and genetic counseling, especially when cutaneous changes are result from an1282 underlying hereditary tumor syndrome. We present four Materials and Methods: We have observed clinical and solved cases of autosomal dominant hereditary disorders genealogical examination of two patients (14 month-old displaying skin manifestations. boy and 11 month-old girl) with unusual phenotypes: the Materials and Methods: The cases consist on a 28 yo evaluation confirmed following symptoms: generalized woman with multiple trichoepitheliomas (Brooke-Spiegler muscle hypotonia, progressive kyphoscoliosis, and joint syndrome); a 10 yo girl with connective tissue nevi and hypermobility. Echocardiogram and hearing was normal. osteopoikilosis (Buschke-Ollendorff syndrome); and two Boy’s ultrasound scan showed expansion of the axillary patients with multiple cutaneous leiomyomas (Reed syn- vein and girl’s one showed ectasia of the internal jugular drome),a31yowomanwithcutaneous/uterineleiomyomas vein.Patientsunderwentgenetictestingviahigh-throughput and renal cancer and a 38 yo man with cutaneous leio- sequencing followed by capillary Sanger sequencing. myomas whose mother and sister had uterine lesions. All Results: In 2 patients from 2 unrelated Russian families had a family history of the condition compatible with an identified homozygosity for a 1-bp insertion within a 5C- autosomal dominant inheritance pattern. Disease-associated nucleotide repeat in exon 3 (c.362dupC, NM_017946.2) of genes were analysed using PCR and direct sequencing and theFKB P14
gene,causingaframeshiftpredictedtoresultin deletions/duplications were detected by MLPA. a premature termination codon (Glu122ArgfsTer7). Their Results: Pathogenic mutations were identified in all unaffected parents were heterozygous of the mutation. cases, three of them being novel. Patients with Brooke- Conclusion:Cliniciansshouldgivemoreconsiderationto Spiegler and Buschke-Ollendorff syndrome had non-sense rare genetic syndromes, especially inthe case of symptoms mutationsinrespectivelyCYLD(p.Gly282Ter)andLEMD3 from different clinical areas. Genotype/phenotype associa- (p.Trp581Ter), while Reed syndrome patients carried tion studies will be necessary to elucidate further the cause completeorpartialFHdeletions.Thisnovelpartialdeletion of the variability of the disease severity. As it has early extends1.9kbanditsbreakpointsarelocatedwithinexon2 clinical manifestations, FKB P14
-related EDS is still a and intron 2, disrupting the FH gene. Genetic counseling challenge and the key issue for its effective follow-up that was performed and relatives at risk were offered direct includescardiovascularmonitoringthatiscerebral,thoracic, molecular testing. Positive cases were further examined by abdominal MRA, and cervical dynamic radiograph. The imaging techniques to assess the presence of other lesions 362dupC mutation was linked to the same haplotype in all or malignancies. individuals despite their geographically diverse origins, Conclusions: Molecular testing confirmed the hereditary suggesting a possible founder event syndromes initially diagnosed and allowed to adopt ade- V. Rumyantseva: None. I. Girba: None. N. Scherba- quate prevention and treatment measures in those positive kova: None. N. Samoilova: None. E. cases with an increased risk of internal cancer. Zaklyazminskaya: None. E. Borràs: None. I.Hernan:None. M.A.Pol: None. F. Corella:None.M.J.Gamundi:None.B.Mañé:None.M.  P04
.31C Carballo: None. Bi-allelic mutations in LSS, encoding lanosterol synthase, cause autosomal-recessive hypotrichosis  P04
.30B simplex TwocasesEhlers-Danlossyndrome,kyphoscoliotictype, 2 caused by FKB P14
 mutation M. Romano1, A. Tafazzoli1, M. Mattern1, S. Sivalingam1, S. Wolf1, A. Rupp2, H. Thiele3, J. Altmüller4, V. Rumyantseva1, I. Girba1, N. Scherbakova1, P. Nürnberg4, J. Ellwanger5, R. Gambon6, A. Baumer7, N. Samoilova1, E. Zaklyazminskaya1,2 N. Kohlschmidt8, D. Metze9, S. Holdenrieder2, R. Paus10, D. Lütjohann11, J. Frank12, M. Geyer13, M. Bertolini14, 1Petrovsky Russian Research Centre of Surgery, Moscow, P. Kokordelis1, R. C. Betz1 Russian Federation, 2Pirogov Russian Research Medical University, Moscow, Russian Federation 1Institute of Human Genetics, Bonn, Germany, 2Institute of Laboratory Medicine, Technical University Munich, Introduction: FKB P14
-related Ehlers-Danlos syndrome Munich, Germany, 3Cologne Center for Genomics, (EDS) is an extremely rare recessive connective tissue University of Cologne, Cologne, Germany, 4Center for disorder. The poor prognosis is anticipated due to typical Molecular Medicine Cologne, University of Cologne, features of the syndrome and possible potentially life- Cologne, Germany, 5Dermatological Practice, Munich, threatening vascular complication in childhood and atlan- Germany, 6Pediatric Practice Feldstrasse, Thusis, toaxial instability. Switzerland, 7Institute for Genetic Medicine, University of Zürich, Zürich, Switzerland, 8Institute of Clinical Genetics,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1283 Bonn, Germany, 9Department of Dermatology, University None. M. Geyer: None. M. Bertolini: None. P. Kokor- of Münster, Münster, Germany, 10Centre for Dermatology delis: None. R.C. Betz: None. Research, University of ManchesterInstitute of Human Genetics, ManchesterInstitute, United Kingdom, 11Institute  P04
.32D for Clinical Chemistry and Clinical Pharmacology, Phenotypic presentations of Hajdu-Cheney syndrome University of Bonn, Bonn, Germany, 12Department of according to age - 5 distinct clinical presentations Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany, 13Institute L. Graversen1, M. Handrup2, M. Irving3, H. Hove4, of Innate Immunity, Department of Structural Immunology, B. Diness5, L. Risom5, D. Svaneby6, M. Aagaard6, University of Bonn, Bonn, Germany, 14Monasterium I. Vogel1, H. Gjørup7, M. Davidsen8, M. Hellfritzsch9, Laboratory - Skin and Hair Research Solutions GmbH, P. Gregersen1 Münster, Germany 1Department of clinical genetics, Aarhus University Hypotrichosis simplex (HS) is a rare form of hereditary Hospital, Aarhus, Denmark, 2Pediatrics and Adolescent alopecia characterized by childhood-onset of diffuse and Medicine, Centre for Rare Diseases, Aarhus University progressivescalpandbodyhairloss.Althoughresearchhas Hospital, Aarhus, Denmark, 3Guy’s and St Thomas NHS identified a number of causal genes, genetic etiology in Trust,London,UnitedKingdom,4CentreforRareDiseases, about 50% of HS cases remains unknown. The present Copenhagen University Hospital, Copenhagen, Denmark, report describes the identification via whole exome 5Department of clinical genetics, Copenhagen University sequencing of five different mutations in the gene LSS in Hospital, Copenhagen, Denmark, 6Department of clinical three unrelated families with unexplained, potentially genetics, Hospital Lillebaelt, Vejle, Denmark, 7Center for autosomal recessive HS. Affected individuals showed OralHealthinRareDiseases,DepartmentofMaxillofacial sparse to absent, lanugo-like scalp hair, sparse and brittle Surgery, Aarhus University Hospital, Aarhus, Denmark, eyebrows, sparse eyelashes and body hair. The LSS gene 8Department of Orthopaedic Surgery, Aarhus University encodes lanosterol synthase (LSS), which is a key enzyme Hospital, Aarhus, Denmark, 9Department of Radiology, inthecholesterolbiosyntheticpathway.Thispathwayplays Aarhus University Hospital, Aarhus, Denmark an important role in hair follicle biology. After localizing LSSproteinexpressioninthehairshaftandbulbofthehair We present five Danish individuals with Hajdu-Cheney follicle, the impact of the mutations on keratinocytes was syndrome (HJCYS) (OMIM #102500), a rare multisystem analyzed using immunoblotting and immunofluorescence. skeletal disorder with distinctive facies, generalised osteo- Interestingly, wild-type LSS was localized in the endoplas- porosisandprogressivefocalbonedestruction.Infourcases mic reticulum (ER), whereas mutant LSS proteins were positive genetic screening of exon 34 of NOTCH2 localizedinpartoutsideoftheER.Aplausiblehypothesisis supported the clinical diagnosis; in one of these cases, that this mislocalization has potential deleterious implica- mosaicismwasdemonstrated,which,toourknowledge,has tions for hair follicle cells. Immunoblotting revealed no notpreviouslybeenreported.Inonecasenogenetictesting differences in the overall level of wild-type and mutant was performed since the phenotype was definite, and the protein. Analyses of blood cholesterol levels revealed no diagnosisinthemotherwasgeneticallyconfirmed.Theage decrease in cholesterol or cholesterol intermediates, thus of the patients differs widely from seven to 56 years, supporting the previously proposed hypothesis of an allowing a natural history description of the phenotype alternative cholesterol pathway. The identification of LSS associated with this ultra-rare condition. The evolution of as causal gene for autosomal recessive HS highlights the the condition is most apparent in the incremental bone loss importance of the cholesterol pathway in hair follicle leading to osteoporosis and the acro-osteolysis, both of biology,andmayfacilitatenoveltherapeuticapproachesfor which contribute significantly to disease burden. hair loss disorders in general. L. Graversen: None. M. Handrup: None. M. Irving: M. Romano: None. A. Tafazzoli: None. M. Mattern: None. H. Hove: None. B. Diness: None. L. Risom: None. None. S. Sivalingam: None. S. Wolf: None. A. Rupp: D.Svaneby:None.M.Aagaard:None.I.Vogel:None.H. None.H.Thiele:None.J.Altmüller:None.P.Nürnberg: Gjørup: None. M. Davidsen: None. M. Hellfritzsch: E. Ownership Interest (stock, stock options, patent or other None. P. Gregersen: None. intellectual property); Modest; ATLAS Biolabs GmbH. J. Ellwanger: None. R. Gambon: None. A. Baumer: None.  P04
.33A N.Kohlschmidt:None.D.Metze:None.S.Holdenrieder: Design of a candidate smMIPS sequencing study in None. R. Paus: None. D. Lütjohann: None. J. Frank: patients with hereditary angioedema of unknown cause (U-HAE)1284 C. Mathey1, C. Stieber1,2, K. U. Ludwig1, A. Maaser1, Maladies Rares: Génétique et Métabolisme, Université de S. Heilmann-Heimbach1, M. M. Nöthen1,2 Bordeaux, Bordeaux, France, 5INSERM U1127, CNRS UMR 7225, UPMC Université Paris 06 UMR  S1127
, 1Institute ofHuman Genetics,University of Bonn School of Sorbonne Université Institut du Cerveau et de la Moelle Medicine & University Hospital Bonn, Bonn, Germany, épinière, ICM F-75013, PARIS, France, 6Université de 2CenterforRareDiseasesBonn,UniversityofBonn,Bonn, Lorraine, Inserm, DCAC, Vascular Medicine Division and Germany Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Centre Hospitalier Hereditary angioedema (HAE) is a rare, potentially life- RegionalUniversitairedeNancy,Nancy,France,7INSERM threatening disease with an estimated prevalence of U970 Paris Cardiovascular Research Centre, Paris, 1:50,000 characterized by recurrent episodes of subcuta- France, 8Service de Génétique Médicale, CHU de neous or submucosal swellings. Transmitted as an auto- Bordeaux et Laboratoire MRGM, INSERM U1211, somal dominant trait, there are five types of HAE with Université de Bordeaux, Centre de Référence known genetic defects. While HAE with decreased  C1
- Neurogénétique, Service de Génétique Médicale, CHU de InhibitorcanbeexplainedbymutationsinSERPING1,only Bordeaux, France, Bordeaux, France about 20-25% of the cases of HAE with normal  C1
- Inhibitor can be explained by mutations in FXII. But two Background: Pseudoxanthoma elasticum (PXE) is an recently discovered mutations in ANGPT1 and PLG have autosomal recessive disorder characterized by ectopic been linked to two further forms of HAE with normal  C1
- mineralization and fragmentation of the elastic fibers of Inhibitor. Despite these successes in identifying causes of connective tissues. ABC C6
 has been the only identified HAE, there still remains a significant fraction of patients gene, but up to 18% of cases remain genetically unsolved with the diagnosis of so called HAE with unknown cause withoneornopathogenicvariantinABC C6
(Legrandetal, (U-HAE).Aimingtoidentifypotentialnewdisease-causing 2017).The correspondingnegativeFrench PXEcases were genes that may play a role in the development or clinical genetically explored for new PXE gene(s). heterogeneity of HAE, we performed multiplex targeted Methods: Exome sequencing was performed in one sequencing using the single-molecule molecular inversion ABC C6
 negative PXE family with additional features, to probes (smMIPs). Our smMIPs panel comprises 29 genes search for pathogenic variants. We identified a candidate that were prioritized by systematic literature research and gene (CG) in a congruent metabolic pathway, and pathway analysis and are mainly related to known disease- sequenced 46 additional ABC C6
 negative PXE index cases causing genes and pathways in HAE. The panel was (IC). An in vitro biochemical assay was carried out to established on a MiSeq platform where we achieved a determine the pathogenicity of identified missense variants coverage ≥100x for 95% of all exons in 27 out of andaclinicaldescriptionofpositivecaseswasperformedto 29 selected genes. Sequencing in our patient cohort of refine their phenotypic spectrum. 125 HAE patients with U-HAE is currently ongoing on a Results: Out of 47 PXE IC, 3 harbored 2 pathogenic IlluminaHiSeqplatformandresultswillbepresentedatthe variants in our CG. Histologically-confirmed skin lesions, upcoming conference. and diminished visual acuity due to maculopathy evoked C. Mathey: None. C. Stieber: None. K.U. Ludwig: the diagnosis of PXE. The association with neurological None. A. Maaser: None. S. Heilmann-Heimbach: None. symptoms was strikingly present in the 3 cases, evoking a M.M. Nöthen: None. phenotype of PXE “plus” neurological symptoms. Bio- chemical analyses confirmed loss of activity of the corre-  P04
.34B sponding mutated enzyme. ExpandingthephenotypeofPseudoxanthomaelasticum Conclusion:OurCGismutatedin6.4%ofourunsolved with hereditary spastic paraplegia PXE cases and should be systematically sequenced in sus- pected PXE cases with neurological findings: spastic para- A. LEGRAND1,2, A. Mesnil3, C. Durand4, C. Tesson5, plegia, dystonia, cognitive impairment, peripheral S. Zuily6, X. Jeunemaitre3,7,2, C. Goizet8, J. Albuisson3,7,2 neuropathy and brain MRI abnormalities. The mechanism leading to overlapping phenotypes for these 2 genes 1INSERM U970 Paris Cardiovascular Research Centre, remains to be explored to explain their role and link in PARIS, France, 2Université Paris Descartes, Sorbonne mineralization. Paris Cité,facultédeMédecine,Paris,France, 3Assistance A.Legrand:None.A.Mesnil:None.C.Durand:None. Publique-Hôpitaux de Paris, Hôpital Européen Georges C. Tesson: None. S. Zuily: None. X. Jeunemaitre: None. Pompidou, Centre de Référence des Maladies Vasculaires C. Goizet: None. J. Albuisson: None. Rares, PARIS, France, 4INSERM U1211, LaboratoireAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1285  P04
.35C cortical dysplasia; only few presented with linear depig- Post-zygotic MTOR mutations and Ito hypomelanosis: mentation. Here, we report clinical manifestations in phenotypic spectrum and ultrastructural 12 sporadic cases with Ito hypomelanosis and post- characterization zygotic mutation of MTOR. We performed exome analysis or ultra-deep targeted V. Carmignac1,2, A. Sorlin3,2, V. E. R. Parker4, sequencing of MTOR gene on hypopigmented skin biopsy, E. Blanchard-Laumonnier5,6, C. Mignot7,8, M. Aubriot- and performed precise clinical reappraisal. In two patients, Lorton9, J. Courcet2, Y. Duffourd2, P. Kuentz10, we analyzed the phenotype histologically and D. Rodriguez11, R. G. Knox12, A. Boland13, R. Olaso13, ultrastructurally. V. Darmency14, C. Quelin15, S. Odent15, D. Amram16, We identified 9 MTOR post-zygotic mutations including M. Chevarin2, c. Vincent-Delorme17, B. Catteau18, six novel. Two were recurrent. Clinically, patients had L. Guibaud19, A. Arzimanoglou20, D. Bessis21, blaschkolinear hypopigmentation (11/12), epilepsy (9/12), D. Geneviève22, J. Deleuze13, R. Semple23, C. Philippe2,24, macrocephaly (8/12), hemi-hypertrophy (7/12), and severe L. Faivre2, J. Rivière25, P. Vabres1 intellectualdisability(7/12),2haveiriaheterochromia, and one nephromegaly. Primary fibroblasts (p.Glu2419Lys) 1MAGEC-Mosaique Dijon, CHU Dijon-Bourgogne, Dijon, showed activation of PIK3K-AKT pathway. Skin biopsies France, 2INSERM UMR1231-GAD team, Dijon, France, showed a decreased number of melanocytes melanosome 3Genetic Department - CHU Dijon-Bourgogne, Dijon, immaturity in melanocytes and a decreased number of France, 4University of Cambridge Metabolic Research melanosomes in keratinocytes in hypopigmented areas. Laboratories, Cambridge, United Kingdom, 5Service Although somatic MTOR mutations have already been d’Anatomie et Cytologie Pathologiques, UF de Biologie reported in Ito's hypomelanosis, this is the first clinical- Cellulaire et Microscopie Electronique, Tours, France, genetic characterization of this association. Neurologically, 6INSERMU1259«MorphogenèseetAntigénicitéduVIHet there are analogies with SKS and hemimegalencephaly. des virus des hépatites », Tours, France, 7Service de Reduction of intrakeratinocyte melanosomes had already neuropédiatrie et pathologie du développement, Hôpital been reported in Ito's hypomelanosis, but without genetic Trousseau,, Paris, France, 8Département de Génétique et study results as well as in hypochromic spots of tuberous Centre de Référence Déficiences Intellectuelles de Causes sclerosis (TS), which is due to mutations of mTOR Rares,GroupeHospitalierPitié-Salpêtrière,Paris,France, repressor TS C1
/2. We found that tuberous sclerosis and 9Service de Pathologie, CHU Dijon, Dijon, France, MTOR-related hypomelanosis shared common pathophy- 10GeneticDepartment-CHUBesançon,Besançon,France, siologyprocess,withalackofmaturationofmelanosomes. 11Service de neuropédiatrie et pathologie du Importantly, no renal involvement known in TS has been développement, Hôpital Trousseau, Paris, France, identified in cases with MTOR mutations. Therapeutic use 12University of Cambridge Metabolic Research of rapamycin, a MTOR inhibitor, is therefore possible. Laboratories, Institute of Metabolic Science, Cambridge, V. carmignac: None. A. Sorlin: None. V.E.R. Parker: France, 13Centre National de Génotypage, Institut de None. E. Blanchard-Laumonnier: None. C. Mignot: Génomique, CEA, Evry, France, 14Pediatric and medical None. M. Aubriot-Lorton: None. J. Courcet: None. Y. genetics, Dijon, France, 15clinical genetics, CHU Rennes, Duffourd: None. P. Kuentz: None. D. Rodriguez: None. Rennes, France, 16clinical genetics, CH Créteil, Créteil, R.G. Knox: None. A. Boland: None. R. Olaso: None. V. France, 17Medical genetics- CHU Lille, Lille, France, Darmency: None. C. Quelin: None. S. Odent: None. D. 18Dermatology departement-CHU Lille, Lille, France, Amram:None.M.Chevarin:None.C.Vincent-Delorme: 19pediatricandfoetalimagerydepartment,HCLlyon,Lyon, None. B. Catteau: None. L. Guibaud: None. A. Arzi- France, 20ESEFNP, HCL Lyon, Lyon, France, manoglou:None.D.Bessis:None.D.Geneviève:None.J. 21Dermatology departement-CHU Montpellier, Deleuze: None. R. Semple: None. C. Philippe: None. L. Montpellier, France, 22Medical genetics department, CHU Faivre: None. J. Rivière: None. P. Vabres: None. Montpellier, Montpellier, France, 23University of Cambridge Metabolic Research Laboratories, Institute of  P04
.36D Metabolic Science, Cambridge, United Kingdom, Molecular analysis of ALPL gene in Russian cohort of 24UF6254-CHU Dijon, Dijon, France, 25Mc Gill patients with suspected hypophosphatasia University, Montréal, QC, Canada M. Fedyakov1, Y. Eismont1, T. Ivaschenko2, I. Sosnina3, Germline MTOR mutations are associated with Smith- E. Snegova3, A. Sarana1,4, S. Scherbak1,4, O. Glotov1,2 Kingsmore syndrome (SKS), whereas somatic mutations are reported in patients with hemimegalencephaly/focal1286 1City Hospital 40, Saint-Petersburg, Russian Federation, Department of Paediatrics, University of Melbourne, 2D.O.Ott Research Institute of Obstetrics, Gynecology and Parkville, Australia, 4Department of Medicine, Austin Reproductology, Saint-Petersburg, Russian Federation, Hospital, University of Melbourne, Heidelberg, Australia, 3Consultative and diagnostic center for children, Saint- 5Florey Institute of Neuroscience and Mental Health, Petersburg, Russian Federation, 4Saint-Petersburg State Heidelberg, Australia, 6Department of Medical Imaging, University, Saint-Petersburg, Russian Federation Royal Children's Hospital, Parkville, Australia, 7Florey Institute of Neuroscience and Mental Health, Parkville, Introduction: Hypophosphatasia (HPP) is a rare heritable Australia metabolic disorder characterized by defective mineraliza- tionofboneand/orteethinthepresenceofreducedactivity Background:MaffucciSyndromeisarare,highlyvariable, of unfractionated serum alkaline phosphatase (ALP). The somaticmosaic condition,causedbyrecurrentmutationsin overallprevalenceofsevereHPPisrangefrom1/100000to eitherIDH1orIDH2.Featuresincludebenignenchondroma 1/300 000. Mild forms of HPP are more frequent than andspindle cellhaemangioma,witharecognizedincreased severe forms - expected prevalence can reach 1/6000 in risk of various malignancies. Fewer than 200 cases have Westernpopulations.Russianprevalenceofmildandsevere been reported, therefore accurate estimates of malignancy HPP is still unknown. Genetic analysis provides determin- risk are difficult to quantify and recommended surveillance ing of diagnosis in cases with suspected HPP. guidelines are not available. IDH1 and IDH2 mutations are Materials and Methods: We analyzed genomic DNA also implicated in a variety of other benign and malignant samples from 112 unrelated individuals with signs of HPP tumours. Recently, the FDA approved specific IDH1 and (low and/or recurrent low levels of ALP, low growth, IDH2 inhibitors for use in individuals with relapsed acute recurrent fractures and others). Primers’ system for Sanger myeloid leukaemia. sequencing was designed and validated for 2-12 exons of Methods: An adult male was assessed via the Austin ALPL gene. First exon of this gene was excluded because Health Clinical Genetics Unit, after he presented with soft it’s non-coding and GC-rich region. palpable lesions on the left upper limb. Imaging and his- Results:Studiedgroupincluded66malesand46females topathology raised the possibility of Maffucci syndrome. (mean age 9yo, range from 1 month to 66yo). Low ALP DNAwasextractedfromperipheralbloodlymphocytesand (age- and sex-dependent reference range) was founded in from surgically resected tissue. Sanger sequencing and 79% (89/112). We detected 15 pathogenic mutations (13% Droplet-digital PCR analysis of the IDH1 gene was detection rate): 13 in heterozygous and 2 in compound- performed. heterozygous. 3 novel missense variants were founded. Results: Imaging and histopathology results were vir- Most frequent variant was p. E191
K in exon 6. The pre- tuallypathognomonicofMaffuccisyndrome.Weidentified valence of this mutation was 6,25% (7/112) in our study a recurrent, somatic mosaic c.394C>T (p.R132C) mutation whereas gnomAD prevalence is 0,25%. in exon 5 of IDH1, in DNA derived from haemangioma Conclusions: We presented the data of prevalence mild tissue (~ 17% mutant allele frequency) that was absent in HPP in Russian cohort of patients with suspected HPP. DNA derived from blood. This mutation is a well- Mild HPP was founded in 87% positive cases (13/15). established cause of Maffucci syndrome. Variant p. E191
K in ALPL is common for Russian Conclusion: We present an instructive case of a rare population. condition,andexplorethepotentialtherapeuticbenefitsand M.Fedyakov:None.Y.Eismont:None.T.Ivaschenko: risks of IDH1 and IDH2 inhibitors in this disorder. None. I. Sosnina: None. E. Snegova: None. A. Sarana: Funding: NHMRC Program Grant (1091593):I.E.S., None. S. Scherbak: None. O. Glotov: None. Project Grant (1079058):M.S.H., Practitioner Fellowship (1006110):I.E.S., R.D Wright Career Development Fel-  P04
.37A lowship (1063799):M.S.H. Recurrent somatic IDH1 mutation in an adult with N.J. Brown: None. Z. Ye: None. C. Stutterd: None. A. Maffucci syndrome Schneider: None. S. Mullen: None. S. Mandelstam: None. I.E. Scheffer: None. M.S. Hildebrand: None. N. J. Brown1,2,3, Z. Ye4, C. Stutterd2,3, A. Schneider4, S. Mullen4,5, S. Mandelstam3,5,6, I. E. Scheffer3,4,7,  P04
.38B M. S. Hildebrand4 FBN1 gene mutations in 26 Hungarian patients with suspected Marfan syndrome or related fibrillinopathies 1Victorian Clinical Genetics Services, MCRI, Parkville, Australia,2DepartmentofClinicalGenetics,AustinHealth, Heidelberg, Australia, 3Royal Children’s HospitalAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1287 L. Madar1, K. Szakszon2, G. Pfliegler3, G. P. Szabó2,  P04
.39C B. Brúgós3, N. Ronen1, J. Papp4, K. Zahuczky4, Identification of a novel two-exon deletion of FBN1gene E. Szakos4, G. Fekete5, É. Oláh2, K. Koczok1, I. Balogh1 inapatientwithMarfan syndromeandhomocystinuria 1Division of Clinical Genetics, Department of Laboratory G. Buki1,2, K. Hadzsiev1,2, L. Pinter1,2, B. Melegh1,2, Medicine, Faculty of Medicine, University of Debrecen, J. Bene1,2 Debrecen, Hungary, 2Department of Pediatrics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, 1University of Pecs, Medical School, Clinical Center, 3Division of Rare Diseases, Department of Internal Department of Medical Genetics, Pecs, Hungary, Medicine, Faculty of Medicine, University of Debrecen, 2Szentagothai Research Center, University of Pecs, Pecs, Debrecen, Hungary, 4Department of Pediatrics, Borsod- Hungary Abaúj-Zemplén County University Hospital, Miskolc, Hungary, 52nd Department of Pediatrics, Semmelweis Introduction: Marfan syndrome (MFS) is an autosomal University, Budapest, Hungary dominant multi-system disorder of connective tissue with high clinical heterogeneity. Some characteristic features of Introduction: Marfan syndrome (MFS) is an autosomal thesyndrome,suchasectopialentis,long-boneovergrowth, dominant connective tissue disorder with cardiovascular, a high arched palate, a crowded dentition, scoliosis, ocular and musculo-skeletal system involvement. FBN1 kyphosis and arachnodactyly overlap with those seen in genemutationsleadtoMFSandrelatedfibrillinopathies.In homocystinuria. Co-occurrence of these disorders can be this work we describe clinical and molecular data of 26 observedinanumberofpatients.MFSismainlycausedby unrelated individuals with suspected MFS who were mutations in the fibrillin-1 gene (FBN1), mapped to referredtoourlaboratoryforFBN1genemutationanalysis. chromosome 15q21.1. Majority of classic MFS patients Materials and Methods: Genomic DNA samples and in bear small alterations, however, a smaller number of onecaseRNAsampleisolatedfromdermalfibroblastswere patientshavelargergenomicrearrangementsinFBN1gene. analyzed by next generation sequencing (NGS) and Sanger Materials and Methods: After negative results of sys- sequencing methods. tematicsequencingofFBN1,TGFBR1andTGFBR2genes, Results: We identified 23 causative or potentially cau- an MLPA ( P065
- P066
 MRC-Holland) analysis was per- sative (including variants of uncertain significance) FBN1 formed in a 21 years old female patient suffering from variants, seven of them was novel (~30%). About 30% of Marfan syndrome based on Ghent criteria and the cases were sporadic. Missense mutations were detected homocystinuria. in 69.6% (16/23), the majority of them were located in one Results: In contrast to the generally detected large dele- of the cbEGF motifs and ~70% of them substituted con- tions, a novel two-exon deletion (exon 46-47) has been served cystein residues. Small deletions/duplications observed in our patient. This results in the loss of 31-32nd accounted for 13% of the cases (3/23), while splice site calcium binding EGF-like domain which is responsible for variants were identified in 17.4% (4/23). In three unrelated the development of classic Marfan phenotype. patients a low frequency (<1%) recurrent silent variant Conclusions: Less than 10% of the disease causing (c.3294C>T (p.Asp1098=) was identified. FBN1 mRNA mutations are copy number alterations, in which single or analysisshowed thatthemutation doesnotlead toaberrant multipleexondeletionscanbedetectedbyMLPAinacost- splicing, based on available data the variant was classified effective manner even in the NGS era. Our case points out as benign. the importance of testing the MFS patients for homo- Conclusions:FBN1mutationswereassociatedwithMFS cystinuria, since an elevated level of homocysteine is inthemajorityofthepatients,intwocaseswithsevereand associated with the risk of severe cardiovascular manifes- early onset manifestation of the syndrome. tations,thoughatpresentonlyafewguidelinesrecommend Funding: this study was supported by the Ministry of testing for homocystinuria. National Economy, Hungary, Grant/Award Number: G.Buki:None.K.Hadzsiev:None.L.Pinter:None.B. GINOP‐2.3.2‐15‐2016‐00039. Melegh: None. J. Bene: None. L. Madar: None. K. Szakszon: None. G. Pfliegler: None. G.P. Szabó: None. B. Brúgós: None. N. Ronen:  P04
.40D None. J. Papp: None. K. Zahuczky: None. E. Szakos: A fibrillinopathy the marfanoid-progeroid- None.G.Fekete:None.É.Oláh:None.K.Koczok:None. lipodystrophy syndrome - in mother and daughter I. Balogh: None. A. Kutkowska-Kaźmierczak, M. Gos, E. Obersztyn1288 DepartmentofMedicalGenetic,InstituteoftheMotherand 1InstituteofHumanGenetics,UniversityofBonn,Schoolof Child, Warsaw, Poland Medicine & University Hospital Bonn, Bonn, Germany, 2Center for Molecular Medicine Cologne (CMMC), Introduction: Marfanoid-progeroid-lipodystrophy syn- University of Cologne, Cologne, Germany, 3Institute of drome (MPLS) is a very rare genetic disorder with clinical Human Genetics, University of Cologne, Cologne, featuresoverlappingthoseofcongenitalMarfansyndrome- Germany, 4Institute of Anatomy, University of Bonn, Bonn, ocular, cardiovascular and skeletal manifestations, proger- Germany,5InstituteofHumanGenetics,PhilippsUniversity oidsyndromes-progeroidappearanceofthefaceandbody Marburg,Marburg,Germany,6CologneExcellenceCluster not associated with other manifestation of early aging and forCellularStressResponsesinAging-AssociatedDiseases lipodystrophy with the extreme congenital lack of sub- (CECAD), University of Cologne, Cologne, Germany cutaneous fat tissues not associated with metabolic disturbances. To our knowledge only seven patients with Introduction: Nonsyndromic cleft lip with/without cleft this syndromewere reportedso far. In allpatients mutation palate (nsCL/P) is a common facial malformation with in exon 64 of the FBN1 gene was detected. multifactorial etiology. The majority of genetic risk loci PatientsandMethods:Wepresentclinicalevaluationof map to non-coding regions of the genome, suggesting that mother and daughter in whom the same mutation the underlying pathomechanisms act through regulatory Trp2756Ter in exon 64 of the FBN1 gene was detected effectsongeneexpression.Onepotentialmechanismmight using next generation sequencing method (NimbleGen be posttranscriptional gene regulation by micro RNAs SeqCap Target Enrichment Roche) with panel of genes (miRNA). FornsCL/P,asuitable cellular modelarehuman associated with craniosynostosis genes (developed in the neuralcrestcells(hNCCs),themesenchymalprecursorcells Department of Medical Genetics of the Institute of the that give rise to the majority of cranial cartilage and bones. Mother and Child in Warsaw, Poland). Methods and Results: We combined array-based Results: Both patients have marfanoid habitus with miRNA profiling in hNCC with in-house GWAS data to overgrowth, myopia, archnodactyly, pectus excavatum, identify candidate miRNAs for nsCL/P. This analysis hyperextensible joints, scoliosis, dysmorphic features with revealed miR-149-3p as strong candidate for nsCL/P progeroid facial appearance associated with congenital involvement, based on consistent hNCC-expression across lipodystrophy. Scaphocephalic head’s shape observed replicatesandthepresenceofassociatedriskvariantswithin especially in daughter was probably a result of wide fon- its genomic region. Next, we aimed at characterizing the tanelles and disturbances in cranial sutures fusion in molecular mechanisms of miR-149-3p in the context of childhood. Mental and motor development in both were craniofacialdevelopment.Invitro,wemodifiedmiRNA149 within normal limits. abundance levels in cultured hNCC by overexpression and Conclusions: This is the second report presenting the inhibition assays and monitored the migration behavior of patient with MPLS and cranial suture development dis- hNCC using scratch assays. We found that inhibition of turbances. This syndrome should be included in the dif- miR-149-3p significantly increases cellular migration of ferential diagnosis of Marfan syndrome and progeroid- hNCC compared to untreated hNCCs. RNA-Seq data at lipodystrophy syndromes coexisting with disturbances in different time points revealed differential expression of cranial suture development. GP C1
 and BM P7
. To follow up these findings, in vivo Supported from IM&Ch intramural grant no. OPK-510- analyses are currently performed in the zebrafish. 18-48 Conclusion: Through integration of large-scale genetic A. Kutkowska-Kaźmierczak: None. M. Gos: None. E. data and expression patterns in relevant cell types we here Obersztyn: None. identified a novel regulatory mechanism that is involved in craniofacial development and might be related to the etiol-  P04
.41A ogy of nsCL/P. Identification and characterization of microRNA-149, a R. Hollstein: None. L.G. Stüssel: None. M. Laugsch: candidate for orofacial clefting None. F. Haeberlein: None. L.M. Hochfeld: None. J. Welzenbach:None.J.Schröder:None.F.Thieme:None. R. Hollstein1, L. G. Stüssel1, M. Laugsch2,3, A. Heimbach: None. T. Hess: None. J. Gehlen: None. S. F. Haeberlein4, L. M. Hochfeld1, J. Welzenbach1, Heilmann-Heimbach: None. E. Mangold: None. A. J. Schröder1, F. Thieme1, A. Heimbach1, T. Hess1,5, Rada-Iglesias: None. B. Odermatt: None. K.U. J. Gehlen1,5, S. Heilmann-Heimbach1, E. Mangold1, Ludwig: None. A. Rada-Iglesias2,6, B. Odermatt4, K. U. Ludwig1  P04
.43C Detection of a new AluY insertion in the NF1 geneAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1289 C. Schmidt1, W. Brechan1, K. Tveten2, T. I. Nordtveit3, J. Fazaal1, J. Welzenbach1, A. Heimbach1, C. Maj4, R. Østern1, O. Bojovic3 J. Hausen3,4,5, R. Raff1, A. Hoischen6,7,8, M. Dixon9, A. Rada-Iglesias10,11, M. Bartusel10,11, A. Rojas- 1Department of Medical Genetics, St. Olavs Hospital, Martinez12, K. Aldhorae13, B. Braumann14, T. Kruse14, Trondheim, Norway, 2Department of Medical Genetics, C. Kirschneck15, H. Reutter16,1, S. Nowak1, L. Gölz17,18, Telemark Hospital Trust, Skien, Norway, 3Department of M. Knapp5, P. Krawitz4, M. M. Nöthen1, M. Nothnagel2, Medical Genetics, Haukeland University Hospital, Bergen, T. Becker19, K. U. Ludwig1, E. Mangold1 Norway 1InstituteofHumanGenetics,UniversityofBonn,Schoolof Introduction: Neurofibromatosis type I (OMIM# 162200) Medicine & University Hospital Bonn, Bonn, Germany, is a common autosomal dominant disorder associated with 2Cologne Center for Genomics, Cologne, Germany, 3Core variants in the NF1 gene. The spectrum of pathogenic UnitforBioinformaticsAnalysis,UniversityofBonn,Bonn, variants is large, up to 30% affect splicing. Our diagnostic Germany, 4Institute for Genomic Statistics and procedure combines analysis of genomic DNA and cDNA. Bioinformatics, University of Bonn, School of Medicine & By cDNA analysis we were able to detect a previously University Hospital Bonn, Bonn, Germany, 5Institute of undescribed Alu insertion that was not detected by next Medical Biometry, Informatics and Epidemiology, generation sequencing (NGS). University of Bonn, Bonn, Germany, 6Department of Patient and Methods: A 44-year-old patient presented Human Genetics, Radboud University Medical Center, with café-au-lait spots, multiple subcutaneous nodules, Nijmegen, Netherlands, 7Department of Internal Medicine, vertebral neurofibroma, multiple iris hamartoma and chor- Radboud University Medical Center, Nijmegen, oidal nevi. DNA was first analyzed by a targeted capture- Netherlands, 8Radboud Institute for Molecular Life based NGS-panel (NF1, NF2 and SPRED1) and MLPA Sciences, Radboud University Medical Center, Nijmegen, analysis(NF1andNF2)withnormalresults.Heparinblood Netherlands, 9Manchester Academic Health Sciences was used for cDNA analysis. Genetic analysis was per- Centre, University of Manchester, Manchester, United formed on RNA extracted from short term lymphocyte Kingdom, 10Center for Molecular Medicine Cologne culture; puromycine was used to prevent mRNA decay. (CMMC), University of Cologne, Cologne, Germany, Result:cDNAsequencingrevealedadeletionofexon26 11CologneExcellenceClusterforCellularStressResponses (r.3315_3496del, p.(Tyr1106Leufs*28); in Aging‐Associated Diseases (CECAD), University of NM_001042492.2). Extended DNA-analysis of exon 26 Cologne, Cologne, Germany, 12Tecnologico de Monterrey, and flanking regions by Sanger sequencing showed inser- School of Medicine, and Universidad Autonoma de Nuevo tion of a truncated AluY transposable element in exon 26: Leon, Centro de Investigación y Desarrollo en Ciencias de c.3337_3338insAluY,3327_3337dupATTTATGAACC. la Salud, Monterrey, Mexico, 13Orthodontic Department, The insertion leads to disruption of the 3’ acceptor splice College of Dentistry, Thamar University, Thamar, Yemen, siteinexon26,deletionofexon26resultsinreadingframe 14Department of Orthodontics, University of Cologne, shift and premature stop codon. Retrospective analysis of Cologne, Germany, 15Department of Orthodontics, NGS data indicated a loss of coverage in this specific University of Regensburg, Regensburg, Germany, region. 16Department of Neonatology, Children's Hospital, Conclusion: While NGS is a powerful method it has University of Bonn, Bonn, Germany, 17Department of limitationsindetectionofmoreuncommonvariants.InNF1 Orthodontics, University of Erlangen, Erlangen, Germany, genetic diagnostics, cDNA sequencing remains the gold 18Department of Orthodontics, University of Bonn, Bonn, standard for mutation detection, specifically for variants Germany, 19Institute for Community Medicine, University affecting splicing. of Greifswald, Greifswald, Germany C. Schmidt: None. W. Brechan: None. K. Tveten: None. T.I. Nordtveit: None. R. Østern: None. O. Non-syndromiccleft lip with or without cleft palate (nsCL/ Bojovic: None. P) is a common congenital malformation and has a multifactorialetiology.Todate,40genome-widesignificant  P04
.46B risk loci for nsCL/P have been identified, but these explain Whole-exome sequencing and large-scale re-sequencing less than 40% of the genetic liability. Epidemiological in nonsyndromic cleft lip with/without cleft palate observations suggest that a fraction of the unidentified identify novel susceptibility genes heritability might be explained by rare dominant de novo mutations (DNMs) in genes involved in craniofacial N. Ishorst1, L. Henschel1, F. Thieme1, D. Drichel2, development. If highly penetrant, such DNMs may be of S. Sivalingam3,4,5, S. L. Mehrem1, A. C. Fechtner1, relevanceinadiagnosticsettingandforgeneticcounselling.1290 We performed whole-exome sequencing in 50 trios Introduction: Osteoarthritis (OA) is the most common (discovery cohort) and identified 33 rare protein-altering joint disease worldwide. OA is a highly heterogeneous DNMs in 33 “candidate genes”, two of them previously condition, with a wide range age of onset. Non-syndromic found associated with nsCL/P (CDH1, TRMO). Of note, early-onset OA (EO-OA) is very rare and mainly familial. this is the first study in nsCL/P trios using DNMs for can- Strict inclusion criteria for EO-OA are based on: XRays didate gene identification. evidence,bodymassindex(BMI)≤30,ageofonset≤40y, The “candidate genes” were subjected to resequencing ≥ 1 joint site involved and positive familial history. with single molecule molecular inversion probes in 1,010 Although multifactorial mode of inheritance is common in nsCL/P patients from European, Arabian, and Mexican OA, EO-OA are mainly monogenic conditions. Based on ancestryand1,574population-matchedcontrols(replication thesedata,weaimedtostudythemonogeniccausesofnon- cohort). Of the total callset of 2,956 variants, 373 were syndromic EO-OA in French patients. absent from controls and showed CADD≥15 and Materials and Methods: From 2013 to 2018, clinician MAF≤0.1% in public reference datasets. As a first step, we experts in the field of skeletal dysplasia referred EO-OA performed segregation analysis in the European cohort. patients to our Montpellier competence center, which Here, we could identify further DNMs in four of the genes assessed the diagnostic and excluded chondrodysplasia, (CSMD1, MDN1, ANK1, PAXI P1
). In those genes we also basedonclinicalandradiologicaldata.Forgeneticanalysis, found co-segregating variants (MDN1, CSMD1) and one we usedeitherSanger sequencingoranNGScustompanel compound heterozygous index (MDN1). RNA sequencing approach. datasets confirmed expression of MDN1, ANK1 and Results: We recruited 40 EO-OA patients, with a mean PAXI P1
 in relevant embryonic mouse tissues and human ageofonsetofarticular painat23years,rangingfrom7to neuralcrestcells,makingthosegenespromisingcandidates 60 years. Pathogenic or a likely pathogenic heterozygous for functional follow-up. mutations were identified in 14/40 cases (35%), with 11/14 N.Ishorst:None.L.Henschel:None.F.Thieme:None. CO L2
A1 mutation (78.6%). We also observed a genetic D. Drichel: None. S. Sivalingam: None. S.L. Mehrem: heterogeneity involving CO L11
A2, CO L9
A3, and surpris- None. A.C. Fechtner: None. J. Fazaal: None. J. Wel- ingly a homozygous pathogenic variation in SL C26
A2. zenbach: None. A. Heimbach: None. C. Maj: None. J. Familial segregation of CO L2
A1 pathogenic variants was Hausen: None. R. Raff: None. A. Hoischen: None. M. observed for 6 cases. Dixon:None.A.Rada-Iglesias:None.M.Bartusel:None. Conclusions: We confirmed that CO L2
A1 is the most A. Rojas-Martinez: None. K. Aldhorae: None. B. Brau- common genetic cause of familial EO-OA. However, at mann: None. T. Kruse: None. C. Kirschneck: None. H. leastthreeothergenesareinvolveinEO-OA.Therefore,we Reutter: None. S. Nowak: None. L. Gölz: None. M. recommendtoscreengenesinvolvedincartilagematrixand Knapp: None. P. Krawitz: None. M.M. Nöthen: None. homeostasis. M. Nothnagel: None. T. Becker: None. K.U. Ludwig: V. Ruault: None. D. Genevieve: None. F. Blotman: None. E. Mangold: None. None. P. Blanchet: None. A. Fabre: None. M. Fradin: None.B.Isidor:None.C.Jorgensen:None.D.Lacombe:  P04
.47C None.M.LeMerrer:None.S.Moutton:None.S.Odent: Genetic distribution of early onset osteoarthritis in a None. G. Plessis: None. E. Sanchez: None. S. Sigaudy: series of 40 patients None. F. Tran Mau Them: None. M. Willems: None. I. Touitou: None. M. Barat-Houari: None. V. Ruault1, D. Genevieve1, F. Blotman1, P. Blanchet1, A. Fabre1, M. Fradin2, B. Isidor3, C. Jorgensen1,  P04
.48D D. Lacombe4, M. Le Merrer5, S. Moutton6, S. Odent2, Mutations in osteoarthritis susceptibility genes cause G. Plessis7, E. Sanchez1, S. Sigaudy8, F. Tran Mau joint shape variation detectable during ontogeny in Them6, M. Willems1, I. Touitou1, M. Barat-Houari1 zebrafish 1CHU, Montpellier, MONTPELLIER, France, 2CHU, E. Kague1, F. Turci2, Y. Yang2, S. Cross3, E. Lawrence1, Rennes, RENNES, France, 3CHU, Nantes, NANTES, L. McGowan1, J. Moss1, P. Royal2, C. L. Hammond1 France, 4CHU, Bordeaux-GH Pellegrin, BORDEAUX, France, 5CHU Paris - Hôpital Necker-Enfants Malades, 1University of Bristol, The School of Physiology, PARIS, France, 6CHU, Dijon, DIJON, France, 7CHU, Pharmacology and Neuroscience, Biomedical Sciences, Caen, CAEN, France, 8CHU, Marseille, MARSEILLE, Bristol, United Kingdom, 2University of Bristol, School of France Physics, Bristol, United Kingdom, 3University of Bristol,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1291 Wolfson Bioimaging Facility, Biomedical Sciences, Bristol, fractures, blue sclera, tooth abnormalities, short stature and United Kingdom skeletal deformity. The diversity of clinical features and its severity varies between patients, even within a single Osteoarthritis (OA) is a joint degenerative disease and family, ranging from severe perinatal lethal to a mild form. leading cause of pain and disability worldwide. Joint shape The aim of this project was to determine genetic hetero- is commonly used to predict OA. GWAs have rapidly geneity versus clinical variability observed in patients increased the number of OA associated genes. Despite few affected by OI. geneswerelinkedtoshapevariation,evidenceforcausality MaterialsandMethods: NGSusingcustompanelof34 and functionality or their effect on joint shape are still genes with confirmed and probable significance in OI lacking.Therefore, there isan unmet need todeveloprapid pathogenesis was performed. The study included 118 and alternative screening platforms to test OA genes. We patients, aged 1-44 years, presenting a broad spectrum of use the zebrafish jaw joint (JJ) to investigate the impact of clinical manifestation. Based on bioinformatic analysis, OA genes and ageing on joint shape variation. 3D selected variants were verified with Sanger sequencing in a morphometrics showed shape abnormalities in aged JJ, group of 77 patients. accompanied by OA histopathological signs. Interestingly, Results: We have identified CO L1
A1 mutations in 47 such modifications were prematurely found in OA mutants patients, CO L1
A2 in 24 patients and mutations in 3 non- (chsy1, col9a1, col11a2, and wnt16). We investigated if collagenousgenesin6patients.Atotalof41differentpoint shape changes would be detected during JJ ontogeny by mutations in CO L1
A1 and 20 in CO L1
A2 were found. testing a broader list of OA mutants (chsy1, col9a1, Respectively15and11havenotbeenreportedindedicated col11a2,gdf5,barx1,mcf2l,dot1l,wnt16andncoa3)using Osteogenesis Imperfecta Variant Database. We also repor- confocalimagingoflarvaeimmunostainedforcollagentype ted patient with a deletion spanning 25 exons in CO L1
A1 2 followed by 2D and 3D analysis. Distinct classes of OA gene. Thus far expected lethality of particular domains in proteins leaded to significant shape variation in larvae, collagen type I genes revealed to be dubious, as we iden- mostly explained by abnormal cell behaviour and collagen tified 11 patients aged 1,5 to 38 years with pathogenic distribution. Dramatic shape variation caused joint move- mutations situated in these regions. ment impairment. We tested whether the use of mosaics, Conclusions: Inter- and intrafamilial phenotype varia- CRISPR G0s, could be sufficient to detect shape and cell bility in OI makes genetic counseling based on clinical changes. Surprisingly, wnt16 mosaics and wnt16-/- dis- symptoms challenging and proves panel targeted rese- played similar cellular and shape changes in larvae and quencing is a powerful and useful diagnostic tool. Young adults. By developing computational tools to facilitate 3D Scientist Grant 2016/IV/57-MN analysis we delivered a powerful and rapid screening K. Sałacińska: None. L. Rutkowska: None. I. Pinkier: platform to test OA genes. Versus Arthritis (grants None. D. Salachna: None. A. Rusińska: None. E. Jaku- 19497, 21161) bowska-Pietkiewicz: None. A. Jamsheer: None. L. E. Kague: None. F. Turci: None. Y. Yang: None. S. Jakubowski: None. A. Gach: None. Cross:None.E.Lawrence:None.L.McGowan:None.J. Moss: None. P. Royal: None. C.L. Hammond: None.  P04
.50B Genotype and phenotype in 201 Portuguese patients  P04
.49A withosteogenesisimperfecta-unusualmolecularresults Genetic heterogeneity in Polish patients with challenge genetic counseling Osteogenesis Imperfecta A. M. Travessa1, P. Dias1, M. Aza-Carmona2, K. Sałacińska1, L. Rutkowska1, I. Pinkier1, D. Salachna1, J. Rosmaninho-Salgado3, T. Saraiva4, A. Grangeia5, A. Rusińska2, E. Jakubowska-Pietkiewicz2, A. Jamsheer3, M. Amorim6, M. Gonçalves-Rocha7, G. Araújo8, L. Jakubowski1, A. Gach1 H. Santos1, M. Rodrigues1, A. Medeira1, I. Cordeiro1, J. Dupont1, O. Moldovan1, A. Beleza3, J. Sá3, 1Polish Mother's Memorial Hospital Research Institute, J. M. Saraiva3, L. Ramos3, M. Venâncio3, S. Maia3, Łódź,Poland,2DepartmentofPropaedeuticsofPaediatrics S. Fernandes3, G. Soares4, J. P. Freixo6, F. Díaz2, and Metabolic Diseases, University Teaching Hospital, C. Barreiros9, C. de la Torre2, A. Bandeira10, Łódź,Poland,3DepartmentofMedicalGenetics,University J. Campagnolo11, F. Godinho9, M. Cassiano-Neves12, of Medical Science, Poznań, Poland V. Tavares13, F. Teixeira8, T. Kay6, R. Oliveira5, A. Fortuna4, S. B. Sousa3, K. E. Heath2, A. B. Sousa1 Introduction: Osteogenesis Imperfecta is a rare genetic disorder of connective tissue characterized by numerous1292 1Serviço de Genética Médica, Departamento de Pediatria, and FKB P10
-related cases had recognizable phenotypes. Hospital de Santa Maria, Centro Hospitalar Universitário TheidentificationofahomozygousvariantinCO L1
A2and Lisboa Norte, Centro Académico de Medicina de Lisboa, heterozygous variants in autosomal recessive genes com- Lisbon, Portugal, 2Institute of Medical & Molecular plicate genetic counselling. No variant was identified in Genetics (INGEMM) and Skeletal dysplasia 6.5% of probands. Multidisciplinary Unit, IdiPAZ, Hospital Universitario La A.M. Travessa: None. P. Dias: None. M. Aza-Car- Paz, UAM, & CIBERER, ISCIII, Madrid, Spain, 3Medical mona:None.J.Rosmaninho-Salgado:None.T.Saraiva: Genetics Unit, Hospital Pediátrico, Centro Hospitalar e None. A. Grangeia: None. M. Amorim: None. M. Gon- Universitário de Coimbra, Coimbra, Portugal, 4Centro de çalves-Rocha: None. G. Araújo: None. H. Santos: None. Genética Médica Doutor Jacinto Magalhães, Centro M. Rodrigues: None. A. Medeira: None. I. Cordeiro: Hospitalar Universitário do Porto, Oporto, Portugal, None. J. Dupont: None. O. Moldovan: None. A. Beleza: 5Serviço de Genética Médica, Centro Hospitalar de São None.J.Sá:None.J.M.Saraiva:None.L.Ramos:None. João, Oporto, Portugal, 6Unidade de Genética Médica, M.Venâncio:None.S.Maia:None.S.Fernandes:None. HospitalDonaEstefânia,CentoHospitalarLisboaCentral, G. Soares: None. J.P. Freixo: None. F. Díaz: None. C. Lisbon, Portugal, 7Unidade de Genética Médica, Hospital Barreiros: None. C. de la Torre: None. A. Bandeira: deBraga,Braga,Portugal,8ServiçodePediatria,Hospital None. J. Campagnolo: None. F. Godinho: None. M. Dr. Nélio Mendonça, Funchal, Portugal, 9Associação Cassiano-Neves: None. V. Tavares: None. F. Teixeira: PortuguesadeOsteogéneseImperfeita,Sacavém,Portugal, None. T. Kay: None. R. Oliveira: None. A. Fortuna: 10Serviço de Pediatria and Centro de Referência para None. S.B. Sousa: None. K.E. Heath: None. A.B. Doenças Metabólicas, Centro Hospitalar Universitário do Sousa: None. Porto, Oporto, Portugal, 11Serviço de Ortopedia Infantil, HospitalDonaEstefânia,CentoHospitalarLisboaCentral,  P04
.51C Lisbon, Portugal, 12Serviço de Ortopedia Infantil, Hospital Nextgenerationsequencingperformanceinosteogenesis CUF, Lisbon, Portugal, 13Serviço de Reumatologia, imperfecta Hospital Garcia de Orta, Almada, Portugal S. Monnot1,2, G. Baujat1,2, C. Michot1,2, J. Litzler1, Introduction: Osteogenesis imperfecta (OI) is a rare A. Tourre1, J. Bonnefont1,2, J. Steffann1,2, V. Cormier- genetic bone fragility disorder. Although mutations in Daire1,2 CO L1
A1/2 account for 90% of cases, up to 17 different geneswereassociatedwithOI.Ouraimwastocharacterize 1Department of genetics, Necker Hospital, Paris, France, the clinical and mutational spectrum of OI in Portugal and 2INSERM UMR1163, Paris Descartes University, Imagine to correlate genotype and phenotype. Institute, Paris, France Materials and Methods: Clinical data of 201 OI indi- viduals (135 adults, 58 children, and 8 fetuses) from 157 Osteogenesisimperfecta(OI)isaconnectivetissuedisorder families were collected through clinical evaluation and/or characterized by bone fragility. An important clinical medical records analysis. Sanger and/or different NGS heterogeneity exists ranging from severe antenatal letal based strategies and MLPA (CO L1
A1/2) were used for form to mild postnatal affection. For now, 19 genes are molecular analysis. known to be responsible for OI: 3 dominant autosomal Results: One hundred thirty-seven individuals had mild, forms (CO L1
A1, CO L1
A2 and IFITM5), 14 recessive 31 moderate, 24 severe, and 9extremely severe OI. Atotal autosomal forms and 2 X-linked forms (PL S3
, MBTP S2
). of123differentvariants(65novel)wereidentified.Variants Importance of a proper molecular diagnosis for genetic in CO L1
A1 (n=91, including one multi-exonic deletion) counselingledustodesignapaneloftargetedresequencing and CO L1
A2 (n=29, including one homozygous case) of the 19 gene coding regions, substituting for the former accountfor85.1%ofallmolecularlydiagnosedfamilies(66 Sanger analyses. Some genes implicated in differential withquantitativeand48withqualitativevariants),followed diagnoseslikehypophosphatasiaoroverlappingphenotypes by SERPINF1 (n=4), LR P5
 (n=4), IFITM5 (n=3), wereadded,increasingto39thetotalnumberofgenes.All FKB P10
 (n=3), WNT1 (n=2), CRTAP (n=1), TMEM38B requests were submitted to the Reference Center for (n=1),  P3
H1 (n=1), PPIB (n=1), and BM P1
 (n=1). Constitutional Bone Diseases with clinical and radiological Interestingly, heterozygous variants in severe autosomal details. Libraries were prepared using capture technology recessive OI genes were found in 3 patients with mild OI. (SureSelectXT Custom - Agilent) and medium throughput Conclusions: This is the first large-scale study on OI in sequencingonaNextSEqsequencer(Illumina).Since2015, Portugal.Inaccordancewithotherpopulations,quantitative 368mutationswereidentifiedin517patients(71%):187in variantspredominateinmildCO L1
A1/2cases,andIFITM5 the CO L1
A1 gene (50%), 98 in the CO L1
A2 gene (26%),Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1293 15inIFITM5(4%),48inrecessivegenesresponsibleforOI Netherlands, 14Dept. of Endocrinology, Erasmus Medical (13%), 3 in X-linked gene. All these mutations were Center, Rotterdam, Netherlands confirmed by Sanger sequencing. The results are discussed during a feedback meeting with clinicians and biologists. Introduction: Our Genomediagnostics laboratory in This panel allows efficient screening for all OI genes, Amsterdam UMC offers targeted NGS analysis of genes leading to time and cost-savings. Using a panel strategy involved in Osteogenesis imperfecta (OI) and other avoid incidental findings. The main limit is the occasional connective tissue disorders. OI is characterized by bone difficulty to determine the pathogenicity of the identified fragility and fractures, bone deformities, short stature, variant.Wholeexomesequencinganalysiscanbeproposed dentinogenesis imperfecta, hearing loss, and blue sclerae. for patient without mutation. The phenotype is highly variable, from mild to perinatal S. Monnot: None. G. Baujat: None. C. Michot: None. lethal. Osteoporosis is a common, multifactorial disorder, J.Litzler:None.A.Tourre:None.J.Bonnefont:None.J. characterized by reduced bone-mass and fractures. A few Steffann: None. V. Cormier-Daire: None. genes have been associated with (early-onset) monogenetic non-syndromic osteoporosis (OP). Here we present the  P04
.52D results ofthe analysis of a panel of 19OI/OP-related genes Diagnostic yield of NGS analysis of a panel of in 550 patients referred with OI, OP or a related disorder. Osteogenesis imperfecta-related genes in 550 patients MaterialandMethods:Asolution-basedenrichmentkit with Osteogenesis imperfecta, (early-onset) was designed tocapture exons and splice sites of the target nonsyndromic osteoporosis and related disorders genes. Data were analysed using an in-house pipeline and Cartagenia, and an NGS-based CNV analysis tool. 68% of A. Maugeri1, E. Voorhoeve1, N. M. Appelman-Dijkstra2, the patients (mean age 37y) had osteoporosis and/or frac- A. T. H. van Dijk3, F. S. van Dijk4, E. M. W. Eekhoff5, tures; no additional OI-related features were reported (OP- M. W. Elting1, A. van Haeringen6, A. Harsevoort7, cohort).23%ofthepatients(meanage22y)hadatleastone M. Isrie1, G. J. M. Janus7, R. T. de Jongh5, J. M. van de other OI-related symptom reported (OI-cohort). Results Kamp1, M. C. van Maarle8, C. L. M. Marcelis9, M. E. H. Diagnosiswasmolecularlyconfirmedin67%ofthepatients Simon10, S. Simsek11, C. T. R. M. Stumpel12, in the OI-cohort, versus 6% in the OP-cohort. In the OP- P. A. Terhal10, H. E. Veenstra-Knol13, M. C. Zillikens14, cohort, a suspicious VUS was identified in 12% of the E. J. Meijers-Heijboer1,8, E. A. Sistermans1, patients. Variant distribution among genes was different M. M. Weiss1,8, G. Pals1, D. Micha1 between OI- and OP-cohorts. Conclusions: As expected, the yield of genetic testing 1Dept. of Clinical Genetics, Amsterdam UMC, Vrije was significantly higher in the OI-cohort versus the OP- Universiteit Amsterdam, Amsterdam, Netherlands, cohort. However, the proportion of patients with a (poten- 2Department of Endocrinology, Leiden Universitary tial)geneticcauseintheOP-cohortisrelevantandwarrants MedicalCenter,Leiden,Netherlands,3Dept.ofPaediatrics, further investigation of these patients. University Medical Center Utrecht, Utrecht, Netherlands, A. Maugeri: None. E. Voorhoeve: None. N.M. Appel- 4London North West Thames Regional Genetics Service, man-Dijkstra: None. A.T.H. van Dijk: None. F.S. van London North West Healthcare NHS Trust, Harrow, Dijk: None.E.M.W.Eekhoff:None.M.W. Elting: None. London,UnitedKingdom,5Dept.ofInternalMedicine,sect. A.vanHaeringen:None.A.Harsevoort:None.M.Isrie: Endocrinology, Amsterdam UMC, Vrije Universiteit None. G.J.M. Janus: None. R.T. de Jongh: None. J.M. Amsterdam, Amsterdam, Netherlands, 6Dept. of Clinical van de Kamp: None. M.C. van Maarle: None. C.L.M. Genetics, Leiden Universitary Medical Center, Leiden, Marcelis: None. M.E.H. Simon: None. S. Simsek: None. Netherlands, 7Dept. of Orthopaedics, Isala Clinics Zwolle, C.T.R.M. Stumpel: None. P.A. Terhal: None. H.E. Zwolle, Netherlands, 8Dept. of Clinical Genetics, Veenstra-Knol: None. M.C. Zillikens: None. E.J. Mei- Amsterdam UMC, University of Amsterdam, Amsterdam, jers-Heijboer: None. E.A. Sistermans: None. M.M. Netherlands, 9Dept. of Human Genetics, Radboud Weiss: None. G. Pals: None. D. Micha: None. University Medical Center, Nijmegen, Netherlands, 10Dept. of Genetics, University Medical Center Utrecht, Utrecht,  P04
.53A Netherlands, 11Dept. of Internal Medicine, Noordwest Between LSD and skeletal dysplasia - a rare case of Ziekenhuisgroep,Alkmaar,Netherlands,12Dept.ofClinical Touraine-Solente-Golé syndrome caused by new Genetics and GROW-School for Oncology and mutation Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands, 13Dept. of Genetics, H. M. Kathom1, D. Avdjieva-Tzavella1, T. Todorov2, University Medical Center Groningen, Groningen, A. Todorova21294 1Department of Clinical Genetics, University Pediatrics CathepsinCgene.Patientsmainlysufferfrompalmoplantar Hospital, Medical University Sofia, Sofia, Bulgaria, keratosis, periodontitis, and early loss of teeth. The present 2Genetic Medico-Diagnostic Laboratory "Genica", Sofia, study is concerned with the dental management of PLS Bulgaria patients through periodontal and prosthetic intervention. Materials and Methods: Nine PLS patients were inclu- Introduction: Primary hypertrophic osteoarthropathy ded in this study. The patients were referred to our Oro- (PHO), also known as pachydermoperiostosis (PDP) or dental Genetics Clinic complaining of early loss of the Touraine-Solente-Golé syndrome, is a rare genetic osteo- deciduous dentition and were in different stages of perma- arthro-dermopathic syndrome with familial and idiopathic nent teeth eruption. Our management protocol included; forms differentiating it from secondary (pulmonary) conventional scaling and root planning every 3 month, hypertrophic osteoarthropathy. Though the diagnosis can diode laser curettage and pocket sterilization monthly ses- bemadeonthebasisoftheclassicclinicalandradiological sions and construction of a removable prosthesis to restore findings, it is often missed due to variable presentations the lost teeth. Pocket depth, bleeding index and mobility PHO is characterized by digital clubbing, periostosis, was assessed every 6 month during the 2-year period of acroosteolysis, painful joint enlargement, and skin mani- the study. festations that include thickened facial skin, a thickened Results: All patients showed good response to the laser scalp,andcoarsefacialfeatures.Thedisorderhasestimated treatment. Gingival inflammation was controlled with less prevalenceof0.16%,andusuallymanifestsinadolescence, bleeding,decreasedmobilityofteethandnoteethwerelost occurring almost exclusively in males, with a M: F ratio over 2 years. However, panoramic radiographs showed of 7:1. bone loss in the pocket areas. MaterialsandMethods:Wepresenta15yearsoldboy, Conclusion: Laser pocket disinfection was effective in from Afghanistan, born to consanguine parents who pre- reducing gingival tissue inflammation, yet the progressive sented for the first time in our department with painful bone loss was a concerning outcome that needs further swelling of hands, feet, and face, coarse facial features, investigations. hypertrichosis,shortandbroadpalms,andsoles.Hereports Y.M. Khalil: None. M.R. Abouzeid: None. M.A. Abd on elder brother with similar swelling, and alopecia. Radi- Elkader: None. P.M. Abdelmassieh: None. ological examinations show wide and thick metacarpals, short distal phalanges, square-like vertebras.  P04
.55C Results:Manytestswereperformedtoruleoutlysosomal Abnormalactivationofmutatedcomplement1subunits storage disorders, and skeletal dysplasia. After performing  C1
r/ C1
s in periodontal Ehlers-Danlos syndrome an NGS-analysis (clinical exome sequencing), the patient was found to carry, in homozygous state, a new mutation R. Gröbner1, E. Brunner1, R. Redolfi1, A. Amberger1, (c.290G>A) in SLCO2A1 gene causing PHO type 2. H. Stoiber1, N. Thielens2, C. Gaboriaud2, I. Kapferer- Conclusions: PDP type 2 has diverse radiological and Seebacher1, J. Zschocke1 clinical features. It may remain undiagnosed for long time and progress until there are significant facial, joint, and 1Medical University, Innsbruck, Austria, 2Institut de digitaldeformitiesthatfinallymakethepatientseekmedical Biologie Structurale, Grenoble, France attention. H.M. Kathom: None. D. Avdjieva-Tzavella: None. T. Introduction: Periodontal Ehlers–Danlos syndrome Todorov: None. A. Todorova: None. (pEDS) is a connective-tissue disorder characterized by early severe periodontitis and various joint and skin  P04
.54B manifestations. Most EDS types are caused by mutations Dental Management Experience for Patients Suffering in collagens or protein-modifying enzymes. In contrast, from Papillon-Lefévre Syndrome periodontal type is caused by heterozygous missense or in- frame insertion/deletion mutations in  C1
R or  C1
S, indicat- Y. M. Khalil1, M. R. Abouzeid1, M. A. Abd Elkader1,2, ing a previously unknown connection between the inflam- P. M. Abdelmassieh1 matory complement pathway and connective tissue homeostasis. pEDS is autosomal dominant and involves 1national research center, giza, Egypt, 2Misr International gain-of-function effects; loss-of-function variants in  C1
R/ University, Cairo, Egypt  C1
S are asymptomatic when heterozygous and can cause a lupus-like phenotype when homozygous. Introduction: Papillon–Lefévre syndrome (PLS) is a rare Methods and Results: In-vitro overexpression in autosomal recessive disorder caused by mutation of the HEK293T cells demonstrated that all pathogenic  C1
RAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1295 variants except a mutant in the  C1
q binding motif cause Mutation analysis was performed using NGS panel, abnormal intracellular processing and secretion of enzy- homozygosity mapping, then candidate gene approach. matically active serine protease. Unlike  C1
r wild type, Results: the first family included a 15 years male who mutations in the CUB1 and CC P1
 domains of  C1
r show presented with repeated fractures around 10 times/year, intracellularretentionoftheN-terminalfragment.Mutations deformities and severe kyphoscoliosis (clinical severity in the CUB2 domain cause secretion of aggregated N- score; CSS 17). The second family had a 9 years old girl terminal fragments, whereas CC P2
 domain mutations milder in severity with 1-2 fractures/year (CSS 14). Both induce a new cleavage site. Importantly, the C-terminal patientshadnojointcontractures.Theywereshortandhad catalytic fragment from all  C1
r mutants was secreted and Wormian bones in their skull x-rays and osteoporosis con- enzymatically active in the supernatant. Western blot ana- firmed by DEXA. Molecular testing for both patients lysis of patient-derived skin and gingival fibroblasts con- revealedhomozygousdonor splicesitemutationinPLOD2 firmed aberrant activation and secretion of mutated  C1
r in intron 12(c.1358+5G>A). The mutation was hetero- eveninthepresenceof C1
sand C1
inhibitor. C1
sactivation zygous in the parents. was confirmed by in-vitro complement activation assays. Conclusion: This study and previous reports from other Conclusion: pEDS is caused by gain-of-function muta- centers identified different PLOD2 mutations with repeated tions that cause abnormal activation of complement 1 fractures and variable severity but without contractures and independent of microbial triggers. We hypothesize that thisexpandsthephenotypicspectrumofPLOD2associated secreted catalytic fragments cleave extracellular matrix mutations. Accordingly, it’s important to reconsider the proteins with adverse consequences on connective tissue current classification to include BS as a variant of OI sub- homeostasis. types rather than being a separate syndrome. Funded by FWF I-2909-B30. G.A. Otaify: None. V. Ruiz-Perez: None. P. Lapun- R. Gröbner: None. E. Brunner: None. R. Redolfi: zina: None. S. Temtamy: None. M.S. Aglan: None. None. A. Amberger: None. H. Stoiber: None. N. Thie- lens:None.C.Gaboriaud:None.I.Kapferer-Seebacher:  P04
.58B None. J. Zschocke: None. Clinical and molecular characteristics of GNAS inactivation disorders observed in 18 Korean patients  P04
.57A Genotype of Bruck syndrome with phenotype of J. Ko, S. Han, Y. Lee, C. Shin, S. Yang, B. Lim, T. Cho Osteogenesis Imperfecta, separate syndromes or expansion of the spectrum SeoulNationalUniversityHospital,Seoul,Korea,Republic of G. A. Otaify1, V. Ruiz-Perez2, P. Lapunzina2, S. Temtamy1, M. S. Aglan1 The GNAS gene on chromosome 20q13.3 is a complex, imprintedlocusregulatedinatissue-specificmanner.GNAS 1Clinical Genetics Department, Human Genetics and inactivation disorders are a heterogeneous group of rare Genome Research Division, National Research Centre, disorders caused by mutations and methylation defects. Cairo, Egypt, 2Instituto de Investigaciones Biomedicas, These are divided into pseudohypoparathyroidism (PHP) Consejo Superior de Investigaciones Cientificas, types 1a and 1b, pseudo-pseudohypoparathyroidism Universidad Autonoma de Madrid, Madrid, Spain (PPHP), and progressive osseous heteroplasia (POH), depending on the presence or absence of hormone Introduction: Osteogenesis Imperfecta (OI) is heteroge- resistance, Albright’s hereditary osteodystrophy (AHO), nousgroupofdisorderswithincreasedbonefragility.Bruck and ectopic ossification. This study analyzed the clinical Syndrome (BS) is a rare autosomal recessive syndrome characteristics and molecular genetic backgrounds of 18 characterized by OI with congenital contractures due to Korean patients from 16 families with a genetically mutations in FKPB10 and PLOD2 genes (B S1
 and B S2
 confirmed GNAS defect. Auxological parameters, AHO respectively). FKPB10 mutations were found to cause phenotypes, types of hormonal resistance, family history, moderately severe OI type XI and PLOD2 was reported and molecular genetic disturbances were reviewed retro- before to cause fractures without contractures. Herein we spectively. Nine (90%) patients with PH P1
a showed present two patients from two Egyptian families with resistance to parathyroid hormone (PTH) and all patients recurrent fractures but without joint contractures having showed elevated thyroid-stimulating hormone (TSH) levels PLOD2 mutations. at diagnosis. Eight (80%) patients were managed with Materials and Methods: two unrelated Egyptian con- levothyroxine supplementation. Three of six patients with sanguineous families with repeated fractures were studied. PH P1
bhadelevatedTSHlevels,butnoneofwhomneeded1296 levothyroxine medication. AHO features were absent in abdominalmineralizationregardlessofgenotype,indicating PH P1
b. Patients with PPHP and POH did not show any putative toxicity. hormone resistance. Among the 11 families with PH P1
a, Conclusions: We confirmed the Cmg52-/- mineralization PPHP, and POH, eight different (three novel) mutations in phenotype to be a good read-out for compound screening. theGNASgenewereidentified.Amongthesixpatientswith Our data suggests a role for VK1 in PXE pathogenesis PH P1
b, two were sporadic cases and four were familial though further validation is required. The STS data under- cases. This, the largest single-center series study of GNAS scorestheimportanceofpropercontrolsandthatcompound inactivation disorders in Korea, summarizes the detailed screening data need to be interpreted cautiously. clinical and molecular genetic characteristics of these M. Van Gils: None. A. Willaert: None. P.J. Coucke: diseases. Identification of molecular genetic backgrounds, None. O.M. Vanakker: None. along with clinical phenotypes, enables appropriate man- agement and proper genetic counseling.  P04
.61A J. Ko: None. S. Han: None. Y. Lee: None. C. Shin: Retinoic acid catabolism defects affecting skeletogenesis None. S. Yang: None. B. Lim: None. T. Cho: None. and resembling craniosynostosis syndromes  P04
.59C I. Chacon Fonseca1, R. Babul-Hirji1, E. Campos2, Compound screening for PXE using zebrafish abcc6a P. Kannu1 mutant models: a proof-of-concept study 1DivisionofClinicalandMetabolicGenetics,Toronto,ON, M. Van Gils1,2, A. Willaert1,2, P. J. Coucke1,2, Canada,2TheHospitalforSickChildrenResearchInstitute, O. M. Vanakker1,2 Toronto, ON, Canada 1Center for Medical Genetics Ghent, Ghent University Introduction: Homozygous missense mutations in the Hospital, Ghent, Belgium, 2Department of Biomolecular CY P26
B1 gene, have been described in very few indivi- Medicine, Ghent University, Ghent, Belgium duals with phenotypes ranging from a lethal generalised skeletal dysplasia characterised by severe skull defects and Introduction: Pseudoxanthoma elasticum (PXE) is an craniosynostosis, radiohumeral fusions, oligodactyly and ectopic mineralization disease due to biallelic ABC C6
 narrow thorax to a milder presentation described in one mutations. As no curative therapy is available, we adult affected by multiple craniosynostosis, characteristic characterized a zebrafish abcc6a CRISPR/Cas9 knockout facies, radiohumeral joint limitation, hearing loss and model (Cmg52) for drug screening purposes, identifying intellectual disability. The enzyme coded by CY P26
B1 is spinal hypermineralization as an early, quantifiable pheno- involvedinretinoicacidcatabolismandregulatesitsprecise type. As a proof-of-concept we tested our screening temporo-spatial gradient during embryogenesis. Case pre- workflow on two compounds (80μM Vitamin K1 [VK1] sentation: We describe a healthy non-consanguineous and 30μM Sodium Thiosulfate [STS]), both implicated couple with 2childrenwith distinctivecraniofacialfeatures in PXE. including turribrachycephaly, shallow orbits, malar hypo- Cmg52+/- Materials and Methods: Following incross, plasia,low-setandprotrudingears,smallmouth,highpalate Cmg52+/+ , Cmg52+/-and Cmg52-/- embryoswere collected. with crowding teeth and pointy chin. Both siblings have At 3 days post-fertilization (dpf), embryos are distributed bilateral conductive hearing loss, arachnodactyly, reduced per 20 in baskets. From 3-10dpf, 60 embryos are treated movement of the radio-ulnar joints and mild to moderate with 8ml compound in 1x  E3
-medium and refreshed daily. learning disability. Their phenotype resembles that of the Followingeuthanasiaat10dpf,embryosarefixed,bleached reported adult. andstainedformineralization.Photosaretakenofembryos Results: Whole exome sequencing revealed both sibs under identical conditions and via ImageJ mineralization is inherited two missense mutations in trans affecting quantified. DNA is extracted from embryos and miner- CY P26
B1. Variant c.353C>T (p. P118
L) was paternally alization values are linked to respective genotypes for sta- inherited, not previously described and not seen in large tistical analysis. population cohorts, and variant c.701G>A (p.R234Q),with Results: VK1 significantly reduced spinal mineralization frequency of 0.06% in large databases, was maternally inCmg52-/-([Mean±SD]Controls:19.371±12.794;VK1: inherited.Bothvariantswerepredictedtohaveadeleterious 10.322 ± 5.519; P<0.05). STS-treated larvae had no spinal impact on the protein structure. mineralization or higher mortality compared to controls. Conclusion: Our patients add to the wide phenotypic However, 33% of STS-treated animals had spotty constellation seen with CY P26
B1 pathogenic variants. We infer that higher retained enzyme activity is non-lethal andAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1297 mostly associated with skeletal and neurological features D.Cocciadiferro:None.E.Agolini:None.L.Sinibaldi: including characteristic craniofacial features resembling None. M.C. Digilio: None. A. Dotta: None. M. Castori: craniosynostosis, hearing loss and intellectual disability. None. A. Novelli: None. Funding source: Rare disease Foundation microgrant. Year 2018 #2803.  P04
.63C I. Chacon Fonseca: B. Research Grant (principal Chipping away the challenges of diagnostic genomics investigator, collaborator or consultant and pending grants applications for short stature as well as grants already received); Modest; Rare disease Foundation. R. Babul-Hirji: None. E. Campos: None. P. D. N. Azmanov1,2, G. M. Arscott1, M. B. Abraham3,4, Kannu: None. J. Miller2, C. Connell2, G. Pathak5, S. Townshend5, B. Kamien5, A. Siafarikas3,4, G. Baynam4,5,6, J. Beilby1,  P04
.62B C. S. Choong2,3,4 The splicing variant c.1815G>A in KIAA0586 is associated with a phenotype overlapping short rib 1DepartmentofDiagnosticGenomics,PathWest,Nedlands, polydactyly and oral facial digital syndrome Australia, 2Faculty of Health and Medical Sciences, University of Western Australia, Crawley, Australia, D. Cocciadiferro1, E. Agolini1, L. Sinibaldi2, 3Department of Endocrinology and Diabetes, Perth M. C. Digilio2, A. Dotta3, M. Castori4, A. Novelli1 Children’s Hospital, Nedlands, Australia, 4Division of Paediatrics, Medical School, University of Western 1LaboratoryofMedicalGenetics,BambinoGesùChildren's Australia,Crawley,Australia,5GeneticServicesofWestern Hospital, Rome, Italy, 2Medical Genetics Unit, Bambino Australia, King Edward Memorial Hospital, Subiaco, Gesù Children's Hospital, Rome, Italy, 3Department of Australia, 6Western Australian Register of Developmental Neonatal Surgery, Bambino Gesù Children's Hospital, Anomalies, King Edward Memorial Hospital, Subiaco, Rome, Italy, 4Division of Medical Genetics, Fondazione Australia IRCSS Casa Sollievo della Sofferenza, San Giovanni Rotondo (Foggia), Italy Introduction: As for many common complex disorders, diagnosticgenomicsapplications for shortstature (SS)face Ciliopathies are a group of hereditary disorders caused by many challenges. In the absence of consensus international abnormal structure/function of primary cilia, which are guidelinesongenetictestingforSS,variousclinicalcriteria ubiquitouslyexpressedorganellescharacterizedbyamother areusedtoinformappropriatetesting.Theextentofgenetic centriole-derivedbasalbody,amicrotubule-basedaxoneme heterogeneity and complexity of SS are still being andaspecializedmembraneharboringproteinsrequiredfor elucidated, challenging diagnostic approaches. signal detection and amplification. Causative variants in Materials and Methods: We employed a retrospective KIAA0586,thehuman orthologofchickentalpid3 essential analysis of diagnostic genomics yield for SS patients for primary ciliogenesis and hedgehog signaling, were first receiving growth hormone therapy on the Western Aus- associated with Joubert syndrome, a multisystem disorder tralian Paediatric Endocrine Database. In addition, a pro- displaying pathognomonic hindbrain malformation as well spective systematic study using chromosomal microarray as variable skeletal, renal and ocular defects. KIAA0586 is and a clinical exome panel on cases with unknown genetic alsoassociatedwithotherciliopathiessuchastheshortrib- aetiology was initiated in 2018. polydactyly, a lethal bone dysplasia with severely hypo- Results: A major genetic aetiology was identified in plastic thorax. Here we describe two Roma Gypsy siblings ~31% of cases prior to the systematic application of con- affected by a neonatal lethal short rib-thoracic dysplasia, temporarygenomictechnologies(35outof114participants harboring the KIAA0586 homozygous variant c.1815G>A born since 2005 and receiving growth hormone for >2 (p.Gln605Gln), identified by targeted resequencing analy- years). Presence of composite genomic findings in some sis. Clinical features of this family are not limited to the patients challenged interpretation. Referral to a local inter- typical short rib-polydactyly syndrome but also include disciplinary undiagnosed disease program helped in resol- tongue/oral hamartomas, multiple frenulae and cleft palate. ving the diagnostic odyssey for complex patients. The same combination of intraoral findings have been Conclusions: Diagnostic genomics applications for SS already identified in patients with the esonic splice site are still evolving and some of the challenges can be over- variant p.Gln605Gln; suggesting continuity between short- come by pre-test clinical selection, detailed phenotyping rib-polydactyly and oral-facial-digital syndromes in the and contribution of an inter-disciplinary team input. The context of KIAA0586 clinical spectrum. current efforts focus on the detection of high penetrance genetic causes, and the remaining challenge is to interpret1298 moderate to low penetrance genetic risk factors for SS. A.Fanelli:None.D.Babu:None.S.Mellone:None.F. Acknowledgements: Merck Serono Australia, grant Prodam: None. S. Bellone: None. G. Genoni: None. S. 201603.4701.POT; DNA is supported by a Raine clinical Vannelli: None. M. Giordano: None. researchfellowship(CRF018,project“Diagnosticgenomics applications for short stature”).  P04
.66B D.N. Azmanov: None. G.M. Arscott: None. M.B. Report of a novel variant causing a schneckenbecken- Abraham: None. J. Miller: None. C. Connell: None. G. like dysplasia Pathak: None. S. Townshend: None. B. Kamien: None. A.Siafarikas: None. G.Baynam: None. J. Beilby: None. O.W.Quarrell1,C.Rautengarten2,K.Stals3,R.Caswell4, C.S. Choong: None. E. De Franco5, E. Baple6, N. Burgess7, R. Jokhi8, J. L. Hazelwood9, A. C. Offiah10, B. Ebert2, S. Ellard6  P04
.64D Identifications of novel variants affecting SHOX 1Dept Clinical Genetics Sheffield Children's Hospital, expression in Short Stature patients Sheffield  S10
 2TH, United Kingdom, 2School of BioSciences, The University of Melbourne, Victoria 3010, A. Fanelli1, D. Babu1, S. Mellone1, F. Prodam1, Australia, 3Royal Devon & Exeter NHS Foundation Trust, S. Bellone1, G. Genoni1, S. Vannelli2, M. Giordano1 Exteter EX2 5DW, United Kingdom, 4College of Medicine and Health, University of Exeter, Exeter EX2 5DW, United 1Dipartimento di Scienze della Salute, Novara, Italy, Kingdom, 5Royal Devon & Exeter NHS Foundation Trust, 2Ospedale Regina Margherita, Divisione di Pediatria, ExeterEX25DW,UnitedKingdom,6RoyalDevon&Exeter Torino, Italy NHS Foundation Trust and College of Medicine and Health, University of Exeter, Exeter EX2 5DW, United Haploinsufficiency of the pseudoautosomal SHOX gene Kingdom, 7Dept Histology, Sheffield Children’s Hospital causes70-90%ofLéri-Weilldyschondrosteosis(LWD)and NHS Foundation Trust., Sheffield  S10
 2TH, United 2-10%ofidiopathicshortstature(ISS).Deletionsremoving Kingdom, 8Dept. of Obstetrics and Gynaecology, Sheffield the gene or enhancers and nonsense/frameshift mutations teaching Hospitals, Sheffield  S10
 2SF, United Kingdom, represent a well-established cause of disease. Otherwise, 9School of BioSciences, The University of Melbourne,, rearrangements not encompassing any described enhancer Victoria 3010, Australia, 10University of Sheffield, and5’UTRvariationsarealsoidentifiedinpatientsbuttheir Academic Unit of Child Health, Sheffield Children's pathogenic role remains unclear. During diagnostic screen- Hospital, Sheffield  S10
 2SF, United Kingdom ingperformedon934patientsbystandardmethods(MLPA and sequencing) we identified SHOX alterations in 82 Introduction: A homozygous pathogenic variant in patients (8.8%). Among these, 65 (78%) carried deletions SL C35
D1, an endoplasmic reticulum nucleotide sugar while 17 (22%) point mutations. Besides these pathogenic transporter, was identified as a cause of schneckenbecken mutations we also identified small deletions not encom- dysplasia in 2007. We report a case of a skeletal dysplasia passing any already described enhancer (n=11) and withinconclusivepathologicalandradiologicalfeaturesand variations within 5’UTR (n=5) in 24 LWD/ISS patients a missense change in SL C35
D1. whosepathogenicrolewaslessclearthatwereclassifiedas Material and Methods: A consanguineous family had 4 VOUS. The aim of this work was to investigate through pregnancies affected by a skeletal dysplasia. Insufficient functionalstudiesthepathogenicroleofthesevariations.To DNA from the 4 pregnancies meant that exome couple better characterize the deletions not encompassing the analysiswasundertakenontheparentsfollowedbyinsilico enhancers we used a fine-tiling custom aCGH and protein modelling using Phyre2 web and I-TASSER ser- performed in vitro functional assays to assess the potential vers. Functional effects of variants were assessed using a enhanceractivityofconservedsequenceswithinthedeleted proteo-liposome assay (Rautengarten et al., 2014 PNAS areas. The variants within the 5’UTR were tested for their 111: 11563-11568). abilitytointerferewithcorrectgeneexpression.Ourresults Results: Both parents were heterozygous for a missense showed that some of the VOUS might be responsible of change in SL C35
D1 c.398C>T p.(Pro133Leu). Reappraisal SHOX deficiency either by removing putative regulatory of the radiographs was consistent with schneckenbecken- elements or affecting the proximal promoter activity. In like dysplasia. Testing of one of the fetuses and 2 healthy conclusion, the present study allowed us to reclassify as unaffectedsiblingswasconsistentwithautosomalrecessive likely pathogenic some of the novel variants of uncertain inheritance but not sufficient to confirm pathogenicity. In significance, that we detected in the diagnostic screening, silico protein modelling showed that p.Pro133 lies directly thus reducing them of at least 10%. opposite p.Thr65, the site of the only previously reportedAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1299 pathogenic missense variant, at the mouth of the solute disease histories with severe growth retardation of prenatal channel, implying pathogenicity. The prote-liposome assay onset, characteristic facial features and respiratory difficul- demonstrated 2-4% in transport activity compared to wild- ties, the latter being most prominent in the index patient; type but also showed SCLD231 is a general UDP-sugar which confirmed the diagnosis of SOFT syndrome. transporter with clear activity towards UDP-Xylose, sug- Conclusion: The finding i) considerably increases the gesting a mechanism by which the Golgi synthesized sub- number of reported SOFT syndrome patients allowing for strate can be imported into the endoplasmic reticulum for furtherclinicaldelineationofthisraredisorder,andii)adda essential xylosylation reactions. novelPO C1
Amissensevariantinexon2,allowingtorefine Conclusion: An agnostic approach to molecular testing the relevance of the functional domain affected by this together with protein modelling and a functional assay change and expand the genotype- phenotype correlation in demonstrated pathogenicity of an SL C35
D1 variant and PO C1
A-related disorders. increased the protein's biochemical characterization. N. Grüning: A. Employment (full or part-time); Sig- O.W. Quarrell: None. C. Rautengarten: None. K. nificant; Centogene AG. M. Al-Shehhi: None. A. Wes- Stals: None. R. Caswell: None. E. De Franco: None. E. tenberger: F. Consultant/Advisory Board; Significant; Baple: None. N. Burgess: None. R. Jokhi: None. J.L. Centogene AG. P. Scott: None. O. Brandau: A. Hazelwood:None.A.C.Offiah:None.B.Ebert:None.S. Employment(fullorpart-time);Significant;CentogeneAG. Ellard: None. L. Abbasi-Moheb: A. Employment (full or part-time); Significant; Centogene AG. Z. Yüksel: A. Employment  P04
.67C (fullorpart-time);Significant;CentogeneAG.C.Beetz:A. AnovelPO C1
Avariantinexon2causesclassicalSOFT Employment(fullorpart-time);Significant;CentogeneAG. syndrome: Clinical presentations of seven patients P. Bauer: A. Employment (full or part-time); Significant; Centogene AG. A. Rolfs: A. Employment (full or part- N.Grüning1,M.Al-Shehhi2,A.Westenberger1,3,P.Scott4, time); Significant; Centogene AG. E. Ownership Interest O. Brandau1, L. Abbasi-Moheb1, Z. Yüksel1, C. Beetz1, (stock, stock options, patent or other intellectual property); P. Bauer1, A. Rolfs1, A. Al-Kindy4 Significant; Centogene AG. A. Al-Kindy: None. 1Centogene AG, Rostock, Germany, 2Royal Hospital,  P04
.69A Muscat, Oman, 3University of Lübeck, Lübneck, Germany, Phenotypic overlap between spondyloepimetaphyseal 4Sultan Qaboos University, Muscat, Oman dysplasiawithjointlaxitytype2andMorquiosyndrome type A: case report Introduction: Biallelic pathogenic variants in PO C1
A (centriolar protein A) cause either SOFT (Short-stature- M. Mijovic1, A. Miletic1, H. Janeski1, B. Dimitrijevic1, Onychodysplasia-Facial-dysmorphism-and-hypoTrichosis) J. Ruml Stojanovic1, M. Lukic1, G. Cuturilo1,2 syndrome or a milder and only partially overlapping phenotype, i.e., variant PO C1
A-related syndrome – with 1University Children's Hospital, Department of Medical this pleiotropic effect depending on the respective exon Genetics, Belgrade, Serbia, 2Faculty of Medicine, affected by mutation. Pathogenic changes in a total of only University of Belgrade, Belgrade, Serbia 22 patients had been described underlining the disease rareness. Two large consanguineous families of Omani Introduction:Wepresentfifteen-year-oldboypatient,with origin presentedto the clinic with7 individuals affected by complexskeletal phenotypehighlysusceptible tomucoply- primordial dwarfism resembling SOFT syndrome, but of saccharidosistypeIVA(Morquiosyndrome).Hehassevere unknown genetic cause and diagnosis. skeletal dysplasia including disproportionate short stature Materials and Methods: Detailed clinical work-up to with short trunk, kyphoscoliosis with gibbus, joint hyper- define the symptoms and whole-exome sequencing (WES) mobility, bilateral congenital hip dislocations, knock-knee were performed in one of the index patients and two rela- and ulnar deviation of the wrists. The patient is immobile tives, as well as subsequent Sanger sequencing for further since his sixth year. He doesn’t have hepatosplenomegaly, segregation studies. respiratory complications, cardiac valve abnormalities and Result: WES yielded the variant PO C1
A dental abnormalities. No pathological ophthalmology find- (NM_015426.4): c.64G>T p.(Val22Phe) which showed ings, neither hearing loss. segregation within the tested individuals and further family Materials and Methods: We performed enzymes blood members. Thisvariantaffects the alternative exon2, thatis testing for several types of mucopolysaccharidosis in first present only in two of three PO C1
A transcripts. Never- line testing, and exome sequencing which targeted genes theless, all of the investigated patients had comparable1300 related to observed clinical presentation in second line c.268C>T;p.(Arg90*)andc.1739dup;p.(Gly581Trpfs*20). testing. Bi-allelic CO L9
A1 [MIM 120210] and CO L9
A2 [MIM Results: Unexpectedly, enzyme level of N-acet- 120260] mutations are already known to cause autosomal- ylgalatosamine-6-sulfate-sulphatease showed normal result recessive inherited Stickler syndrome [MIM 614134; and excluded Morquio syndrome. Subsequently, exome 614284]. However, as far as we know, only one family sequencing showed presence of heterozygous pathogenic with bi-allelic occurrence of a CO L9
A3 nonsense mutation missense variant in KIF22 gene (c.443C>T, p.Pro148Leu). and Stickler syndrome is published until now. As in our Pathogenic variants in KIF22 gene represent an established patient, in this family the affected individuals showed a causeofspondyloepimetaphysealdysplasiawithjointlaxity comparatively mild phenotype with no vitreoretinal invol- type2(OMIM:603546).TheclinicalpresentationofKIF22- vement or cataracts so far and no cleft palate/Pierre-Robin associated conditions includes skeletal abnormalities, joint sequence.Thus,thefindings inourcasefurthersupportthe laxity, joint dislocations, spinal deformities and short sta- assumption that bi-allelic CO L9
A3 mutations are very ture, which is compatible with the clinical presentation in likely sufficient to cause Stickler syndrome as well. our patient. A. Bohring: None. J. Horvath: None. P. Conclusion: Between Morquio syndrome and spondy- Wieacker: None. loepimetaphyseal dysplasia may exist completely over- lapping skeletal phenotype, which is confirmed literature  P04
.71C data (ref. Biswas SN et al., 2017). The distinction between Stüve-Wiedemann syndrome: a rare clinical entity these diseases is very important because of available enzymereplacementtherapyforMorquiosyndrometypeA O. Akgün Dogan1, Y. Kendir Demirkol1, M. Say2, and completely different pattern of inheritance and recur- T. Kizilboga Akgün3,4, L. Doğanay4 rencerisk.Exomesequencingshouldbefirstgenetictestin patient with severe skeletal dysplasia with overlapping 1Department of Pediatric Genetics, Health Sciences phenotype. University, Umraniye Education and Research Hospital, M.Mijovic:None.A.Miletic:None.H.Janeski:None. İstanbul, Turkey, 2Bioinformatic Team, Gen-Era B. Dimitrijevic: None. J. Ruml Stojanovic: None. M. Diagnostic, İstanbul, Turkey, 3Department of Molecular Lukic: None. G. Cuturilo: None. Biology and Genetics, Istanbul Technical University, İstanbul, Turkey, 4GLAB (Genomic Laboratory), Health  P04
.70B Sciences University, Umraniye Education and Research Further evidence for CO L9
A3 associated autosomal Hospital, İstanbul, Turkey recessive Stickler syndrome Introduction:Stüve-Wiedemannsyndrome(SWS)(MIM601559) A. Bohring, J. Horvath, P. Wieacker is an autosomal recessive skeletal dysplasia characterized by bowing of extremities, severe osteoporosis, joint contractures, Institut für Humangenetik, Münster, Germany dysautonomia, frequent respiratory infections, and feeding difficulty. Mutations in LIFR are responsible for the syndrome. Heterozygous CO L9
A3 [MIM 120270] mutations were Althoughthemajorityofpatientsarelostduetocomplicationsin reported to cause multiple epiphyseal dysplasia-3 [MIM infancy,patientswhoreachadolescentperiodarereportedrarely. 600969] which is mainly characterized by stiffness and/or Here, we present a 9 years-old male with SWS with severe pain in the knees, due to flattened, irregular epiphyses, and skeletalfindingsduetoanovelhomozygousmutationinLIFR. varus or valgus deformity, waddling gait, and mild short Materials and Methods: The patient was the third child stature insomepatients.Herewereport onthesecond case of healthy, consanguineous parents, born at term with a with bi-allelic CO L9
A3 nonsense mutations. The boy was birth weight of 3600g(50-75th centile). Bowing in lower born with club feet and moderate hearing loss to healthy extremities was remarkable at birth, and progressed gradu- parents. Radiographs revealed flat lumbar vertebrae, coxa ally with age. He was hospitalized many times for respira- retrotorta,andbroadfemoralmetaphyses.Atexaminationat torydistress,feedingdifficulties,andrecurrentfever.Motor age 2,5 years we saw a triangular face, bilaterally mild developmental milestones were delayed however, mental epicanthus, a high arched palate, and short fingers. In development was normal. Physical examination revealed addition, myopia was diagnosed recently. Height was 92 facial dysmorphic features, bending of the extremities, cm, weight 15 kg (50. and 75. centile, respectively). laxity of the metacarpophalangeal joints, scoliosis, promi- Because of the phenotype, the provisional diagnosis of nent heels, and pes planus. X-ray of extremities showed Stickler syndrome was made and molecular analyses bowing of the limbs, bilateral valgus deformity, and revealed compound-heterozygosity for CO L9
A3 mutations widening of the femoral and tibial metaphysis.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1301 Results: Next-generation sequencing was performed on contributes to genotype-phenotype associations of this rare Illumina MiSeq(v1.9) platform using the virtual panel for disorder. skeletal dysplasia consisting of 130 genes. The novel S. Alter: None. A. Hotz: None. A. Jahn: None. N. Di homozygous variant in LIFR(c.274C>T) was detected. Donato: None. E. Schröck: None. M. Smitka: None. M. Segregation within the family showed that parents were von der Hagen: None. J. Schallner: None. M. Menschi- heterozygous carriers. kowski: None. C. Gillitzer: None. M.W. Laass: None. J. Conclusions: Although SWS is a rare genetic disease, it Fischer: None. A. Tzschach: None. should be kept in mind in patients with congenital bowing in extremities. Targeted exome analysis has great impor-  P04
.74B tance in the fast and accurate setting in the diagnosis of Analysis of a French cohort of patients with Werner heterogeneous groups of syndromes such as bent bone syndrome; clinical and molecular features dysplasias. O. Akgün Dogan: None. Y. Kendir Demirkol: None. B. Dauriat1, N. Uhrhammer2,3, H. Adamski4, C. Colson5, M. Say: None. T. Kizilboga Akgün: None. L. P. D’Anella6, F. Demurger7, H. Dollfus8, V. Drouin- Doğanay: None. Garraud9, C. Francannet10, M. Gerard5, F. Giuliano11, B. Isidor12, H. Journel7, P. Lacroix13, H. Levesque14,  P04
.73A L. Mary8, C. Moraine1, X. Piguel15, M. Pistorius16, Novel VP S33
B mutation in a patient with autosomal G. Plessis5, I. Reingeard17, M. Rio18, M. Ruivard19, recessive keratoderma-ichthyosis-deafness (ARKID) G. Vera9, C. Vigouroux20, M. Vincent12, J. Bignon2,3, syndrome C. Yardin1,21 S.Alter1,A.Hotz1,A.Jahn2,N.DiDonato2,E.Schröck2, 1Department of Cytogenetics and Medical Genetics, M. Smitka3, M. von der Hagen3, J. Schallner3, Dupuytren University Hospital, Limoges, France, M. Menschikowski4, C. Gillitzer3, M. W. Laass3, 2Department of Oncogenetics, Centre Jean Perrin, J. Fischer1, A. Tzschach1,2 Clermont-Ferrand University Hospital, Clermont-Ferrand, France, 3INSERM U1240, Imagerie Moléculaire et 1InstituteofHumanGenetics,Freiburg,Germany,2Institute Stratégies Théranostiques, Clermont-Ferrand, France, of Clinical Genetics, Technische Universität Dresden, 4Department of Dermatology, Rennes University Hospital, Dresden, Germany, 3Children´s hospital, Medical Faculty Rennes, France, 5Department of Genetics, Caen University Carl Gustav Carus, Technische Universität Dresden, Hospital, Caen, France, 6Department of Endocrinology, Dresden, Germany, 4Institute of Clinical Chemistry and Avignon Hospital, Avignon, France, 7Department of Laboratory Medicine, Medical Faculty CarlGustav Carus, Clinical Genetics, Rennes University Hospital, Rennes, Technische Universität Dresden, Dresden, Germany France, 8Department of Genetics, Strasbourg University Hospital, Strasbourg, France, 9Department of Genetics, Autosomal recessive keratoderma-ichthyosis-deafness Rouen University Hospital, Rouen, France, 10Department (ARKID) syndrome is a rare multisystem disorder caused of Genetics, Estaing University Hospital, Clermont- by biallelic mutations in VP S33
B; only three patients have Ferrand, France, 11Department of Genetics, Nice been reported to date. ARKID syndrome is allelic to University Hospital, Nice, France, 12Department of arthrogryposis-renal dysfunction-cholestasis (ARC) syn- Genetics, Nantes University Hospital, Nantes, France, drome (MIM #208085), a severe disorder with early 13Department of Thoracic and Vascular Surgery-Vascular lethality whose phenotypic characteristics also include Medicine,DupuytrenUniversityHospital,Limoges,France, ichthyosis, hearing loss, severe failure to thrive, platelet 14Department of Internal Medicine, University of Rouen, dysfunction and osteopenia. We report on an 11-year-old Institute for Research and Innovation in Biomedicine, male patient with ARKID syndrome and compound Rouen, France, 15Department of Endocrinology, Poitiers heterozygous VP S33
B mutations, one of which University Hospital, Poitiers, France, 16Department of [c.1440delG; p.(Arg481Glyfs*11)] was novel. Clinical Internal Medicine, Nantes University Hospital, Nantes, features of this patient included ichthyosis, palmoplantar France, 17Department of Endocrinology, Montpellier keratosis, hearing loss, intellectual disability, unilateral hip University Hospital, Montpellier, France, 18Department of dislocation, microcephaly and short stature. He also had Pediatrics, Neurology and Genetics, Hôpital Necker- copper hepatopathy and exocrine pancreatic insufficiency, Enfants-Malades, Paris, France, 19Department of Internal features that have not been associated with neither ARKID Medicine, Estaing University Hospital, Clermont-Ferrand, norARCsyndromesofar.Thepatientbroadenstheclinical France, 20AP-HP Saint-Antoine Hospital, Molecular and molecular spectrum of ARKID syndrome and Biology and Genetics Laboratory, Endocrinology1302 Department, National Reference Center for Insulin 1de Duve Institute, Brussels, Belgium, 2Cliniques Secretion and Insulin Sensitivity Rare Diseases, Paris, Universitaires St. Luc, Brussels, Belgium, 3Cliniques France, 21Limoges University, CNRS, XLIM, UMR 7252, Universitaires St Luc & Institute of Experimental and Limoges, France Clinical Research, UCLouvain, Brussels, Belgium, 4Ghent University Hospital, Ghent, Belgium Introduction: Werner syndrome (WS) belongs to adult onset progeroid diseases, leading to a premature ageing of Systemic sclerosis (SSc) is a multi-system disease of mesenchymal and epithelial tissues, affecting one person unknown cause, characterized by vascular and immune per a million in the world. Its cardinal signs are short dysregulation that results in progressive fibrosis of the skin stature, lipodystrophy and atrophic skin, premature cataract and other organs. While rare, it can be lethal, and there are and greying of hair; age-associated complications may currently no treatments. SSc is typically sporadic; familial occur in WS such as osteoporosis, chronic skin ulcers or forms are extremely rare. By applying genome-wide Next diabetes mellitus, and patients usually die around 53 years Generation Sequencing (NGS) to such families, we aim to of age from cardiovascular or neoplastic causes. This identify genetic “drivers”, i.e., disease-causative or recessive genetic affection is linked to loss-of-function strongly-predisposing alleles. We hypothesize that these mutations of WRN gene, coding for a helicase involved in genes may also contribute to sporadic disease, when they multiple DNA pathways. No recent clinical nor molecular carry strong de novo mutations, weak inherited variants description were available for French WS patients. (that cause disease only in combination with other genetic Methods: Data from French laboratories found 36 andenvironmentalfactors),orsomaticmutationsinaffected genetically confirmed WS cases, whose 34 for which tissues. We performed whole exome sequencing (WES) on molecular and clinical data were collected. blood-DNA from two affected first-degree relatives each Results:31mutationsincluding14newlydescribedones from five families, and filtered for genes with missense or wereidentified,withsomeassociatedwithaspecificFrench nonsense variants that (i) co-segregate with disease, (ii) are region. The mean age for diagnosis was 40.5 years, the rare in public sequence databases and an in-house WES cardinal signs were found in all the patients, and under- database, and (iii) predicted to affect protein function in estimated features (deafness, hepatic, thyroid, valvular, silico. Between 18 and 40 such genes were identified per hypertensive or capillary impairments) were commonly family. Candidate gene prioritization was performed using diagnosed.Deathoccurredat53.6yearsofage,mostlyfrom literature and database-mining, as well as intersection with cancerous etiologies. Despite the homogeneity of the main RNASeqdata from sporadicSSc cutaneoustissue biopsies. signs, it seems that phenotypes with less severe evolution Variants in the two highest-ranked candidates (one a pro- may exist, without associated predictive or causal factors. fibrotic growth factor, the other a cytokine receptor with Conclusion: This cohort gives an exhaustive description pro-fibrotic, pro-inflammatory effects) are currently being of French patients presenting genetically confirmed WS testedfortheireffectsonproteinfunction.Proofofaneffect since the beginning of WRN testing. It defines accurate onproteinfunctionwillbefollowedbytestingforaroleina frequencies for all the numerous symptoms and gives the bleomycin-induced mouse model of SSc. opportunity for prospective investigations. N. Limaye: None. M. Vanthuyne: None. F. Houssiau: B.Dauriat:None.N.Uhrhammer:None.H.Adamski: None. V. Smith: None. B. Lauwerys: None. None.C.Colson:None.P.D’Anella:None.F.Demurger: None. H. Dollfus: None. V. Drouin-Garraud: None. C.  P04
.76D Francannet:None.M.Gerard:None.F.Giuliano:None. WNT10A mutations: refining genotype, phenotype, B. Isidor: None. H. Journel: None. P. Lacroix: None. H. penetrance, clinical variability and inheritance manner Levesque: None. L. Mary: None. C. Moraine: None. X. Piguel: None. M. Pistorius: None. G. Plessis: None. I. O. Patat1, I. Bailleul-Forestier2, J. Plaisancie1, Reingeard: None. M. Rio: None. M. Ruivard: None. G. D. Bonneau3, E. Colin3, C. Colson4, M. Cordier5, Vera: None. C. Vigouroux: None. M. Vincent: None. J. C. Coubes6, F. Demurger7, A. Dieux-Coeslier8, Bignon: None. C. Yardin: None. M. Fradin7, M. Gerard4, A. Goldenberg9, B. Isidor10, H. Journel10, D. Lacombe11, M. Lebrun12, D. Martin-  P04
.75C Coignard13, M. Nizon10, S. Odent7, F. Petit8, N. Philip14, Genetic predisposition to systemic sclerosis J. Piard15, J. Piard15, G. Plessis4, A. Putoux5, C. Quelin7, J. Thevenon16, A. Toutain17, C. Vanleberghe8, N. Limaye1, M. Vanthuyne2, F. Houssiau3, V. Smith4, A.Verloes18,C.Vincent-Delorme8,Y.Capri18,F.Vaysse2, B. Lauwerys3 P. Calvas1, N. Chassaing1Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1303 1CHU Toulouse, Toulouse, France, 2Faculté de Chirurgie delorme: None. Y. Capri: None. F. Vaysse: None. P. Dentaire, Toulouse, France, 3CHU Angers, Angers, Calvas: None. N. Chassaing: None. France, 4CHU Caen, Caen, France, 5CHU Lyon HCL, Lyon, France, 6CHRU Montpellier, Montpellier, France, 7CHURennes,Rennes,France,8CHRULille,Lille,France,  P05
 9CHU Rouen, Rouen, France, 10CHU Nantes-Hôtel dieu, Cardiovascular disorders Nantes, France, 11CHU Bordeaux, Bordeaux, France, 12CHU Saint-Etienne, Saint-Etienne, France, 13CHU Le  P05
.01A Mans, Le Mans, France, 14CHU Marseille, Marseille, European Reference Network For RareVascular France, 15CHRU Besançon, Besançon, France, 16CHU Diseases (VASCERN) consensus statement for the Grenoble, Grenoble, France, 17CHRU Tours, Tours, screening and management of patients with pathogenic France, 18CHUParisHôpital Robert Debré,Paris, France ACTA2 variants Introduction: The agenesis of several teeth is a prevalent I. van de Laar1, E. Arbustini2, B. Loeys3,4, E. Björck5, malformation in human. Hypodontia is defined by the M. Groenink6, M. Kempers4, J. Timmermans4, J. Roos- agenesis of six teeth or less, whereas oligodontia refers to Hesselink1,K.Benke7,G.Pepe8,B.Mulder6,Z.Szabolcs7, the agenesis of more than six teeth, excluding the third G. Teixidó-Turà9, L. Robert10, Y. Emmanuel10, molars. Hypodontia and oligodontia can be associated with A. Evangelista11, A. Pini12, Y. von Kodolitsch13, defects in the development of other ectodermal structures G. Jondeau14, J. De Backer15 suchashairs,sweatglandsandnails,definingthespectrum ofectodermaldysplasias.MutationsinWNT10Aareknown 1Erasmus MC, University Medical Center Rotterdam, as a major cause of oligodontia with or without associated Rotterdam, Netherlands, 2IRCCS foundatoin Policlinico ectodermal dysplasia signs. San Matteo, Pavia, Italy, 3University Hospital of Antwerp Patients and Methods: Based on the analysis of a large University of Antwerp, Antwerp, Belgium, 4Radboud seriesof413probandswithhypooroligodontiaand190of University Medical Center, Nijmegen, Netherlands, theirrelatives,wereport395subjectswithmutationsinthe 5Karolinska University Hospital, Stockholm, Sweden, gene WNT10A. 6Academic Medical Center, Amsterdam, Netherlands, Results: We found a mutation in WNT10A in 227 of the 7Semmelweis University, Heart and Vascular Center, 413 probands, among which two recurrent mutations the Budapest, Hungary, 8Careggi Hospital, University of c.682T>A (p.Phe228Ile) and c.321C>A (p.Cys107Ter) are Florence, Florence, Italy, 9hospital universitari Vall respectivelyinvolvedin178and33unrelatedprobandsand D'Hebron, CIBER-CV, Barcelona, Spain, 10South East families. We show a pattern of tooth agenesis in patients Thames Regional Genetic Service, London, United withWNT10Amutationsandabroadphenotypicvariability Kingdom, 11hospital universitari Vall D'Hebron, despite a correlation between the number of mutations, the Barcelona, Spain, 12Centro Malattie Rare Cardilogiche, number of tooth agenesis and the presence of ectodermal Milan, Italy, 13University Heart Center Hamburg, signs. We confirm the incomplete penetrance of WNT10A UniversityMedicalCenterHamburg-Eppendorf,Hamburg, mutation with an estimate of the penetrance and report Germany,14HopitalBichat-ClaudeBernard,Paris,France, several asymptomatic cases with biallelic mutations. 15Ghent University Hospital, Ghent, Belgium Discussion: Despite some degree of genotype-phenotype correlation, we highlight the incomplete penetrance and The ACTA2 gene encodes for smooth muscle specific α- broad clinical variability associated with WNT10A actin,acriticalcomponentofthecontractileapparatusofthe mutations. vascular smooth muscle cell. Pathogenic variants in the O. Patat: None. I. Bailleul-forestier: None. J. Plai- ACTA2 gene are the most frequently encountered genetic sancie: None. D. Bonneau: None. E. Colin: None. C. cause of familial thoracic aortic aneurysm/dissection Colson: None. M. Cordier: None. C. Coubes: None. F. (FTAAD). Although TAAD is the main clinical manifesta- Demurger: None. A. Dieux-coeslier: None. M. Fradin: tion, a variety of occlusive vascular disease and extra- None.M.Gerard:None.A.Goldenberg:None.B.Isidor: vascular manifestations occur in ACTA2 related None.H.Journel:None.D.Lacombe:None.M.Lebrun: vasculopathy. Current data suggest possible mutation- None. D. Martin-coignard: None. M. Nizon: None. S. specific manifestations of vascular and extra-aortic traits. Odent: None. F. Petit: None. N. Philip: None. J. Piard: Despite its relatively high prevalence, comprehensive None.J.Piard:None.G.Plessis:None.A.Putoux:None. recommendations on the care of patients and families with C. Quelin: None. J. Thevenon: None. A. Toutain: None. pathogenic variants in ACTA2 have not yet been estab- C. Vanleberghe: None. A. Verloes: None. C. Vincent- lished. We aimed to develop a consensus document to1304 provide medical guidance for all health care professionals vEDS. We evaluated the impact of celiprolol and losartan involved in the recognition, diagnosis and treatment of on the biomechanical integrity of the vEDS thoracic aorta. patients and relatives with pathogenic variants in ACTA2. Methods:We(re-)characterisedamurinevEDSmodelat The hereditary thoracic aortic disease (HTAD) Working molecular level using WGS and developed an objective Group of the European Reference Network for Rare approach to measure the maximum tensile force at rupture VascularDiseases(VASCERN)convenedtoreviewcurrent of uniaxially-stretched murine thoracic aortic rings. To literature and discuss expert opinions on clinical manage- assesstreatmenteffect,heterozygousmiceat4weeksofage ment of ACTA2 related vasculopathy. This consensus underwenta4-weektreatmentwithceliprolol,losartan,and, statement summarizes our recommendations on diagnosis, asaproof-of-conceptdrug,theMMP-inhibitordoxycycline. monitoring, treatment, genetic counselling and testing in Results: Heterozygous mice showed a significant reduc- patients with ACTA2 related vasculopathy. However, there tion in the rupture force compared to wild-type mice. isaclearneedforadditionalprospectivemulticenterstudies Compared to age- and sex-matched untreated heterozygous to further define proper guidelines. mice, treatment with doxycycline or celiprolol resulted in a I. van de Laar: None. E. Arbustini: None. B. Loeys: significant increase of rupture force, whereas no significant None. E. Björck: None. M. Groenink: None. M. Kem- change was detected upon losartan treatment. pers: None. J. Timmermans: None. J. Roos-Hesselink: Conclusions: Our novel read-out system is suitable for None.K.Benke:None.G.Pepe:None.B.Mulder:None. the assessment of the biomechanical effect of candidate Z. Szabolcs: None. G. Teixidó-Turà: None. L. Robert: drugs. In a vEDS model, celiprolol or doxycycline, but not None. Y. Emmanuel: None. A. Evangelista: None. A. losartan, can improve the biomechanical integrity of the Pini:None.Y.vonKodolitsch:None.G.Jondeau:None. aortic wall. As doxycycline is a broad-spectrum antibiotic J. De Backer: None. with considerable side effects, celiprolol may be more sui- table for a long-term therapy and thus rather indicated for  P05
.02B themedicationofpatientswithvEDS.Thisisthefirststudy Novel approach reveals celiprolol but not losartan as demonstrating that celiprolol improves the rupture force of medical therapy for vascular Ehlers-Danlos syndrome the thoracic aorta. N. Dubacher: None. J. Münger: None. M.C. Gor- N. Dubacher1, J. Münger1, M. C. Gorosabel1, J. Crabb2, osabel:None.J.Crabb:None.A.A.Ksiazek:None.S.M. A. A. Ksiazek3,4, S. M. Caspar1, E. N. T. P. Bakker5, Caspar: None. E.N.T.P. Bakker: None. E. van Bavel: E. van Bavel5, U. Ziegler6, T. Carrel7, B. Steinmann8, None. U. Ziegler: None. T. Carrel: None. B. Steinmann: S. Zeisberger3, J. Meienberg1, G. Matyas1 None. S. Zeisberger: None. J. Meienberg: None. G. Matyas: None. 1Center for Cardiovascular Genetics and Gene Diagnostics, Foundation for People with Rare Diseases,  P05
.03C Schlieren-Zurich, Switzerland, 2Institute of Mechanical Next Generation Sequencing identifies novel variants in Systems, Swiss Federal Institute of Technology Zurich, TJ P1
, T P63
 and PP P1
R13L genes in Arrhythmogenic Zurich, Switzerland, 3Institute for Regenerative Medicine, Cardiomyopathy patients UniversityofZurich,Zurich,Switzerland,4ClinicforSmall Animal Internal Medicine, University of Zurich, Zurich, M. Calore1,2, G. Poloni2, A. V. Postma3, A. Lorenzon2, Switzerland, 5Department of Biomedical Engineering and G. Minervini4, G. Vazza2, I. E. A. Li Mura5, A. Telatin5, Physics, Academic Medical Center, University of I. Zara5, B. Simionati5, J. Ponti2, G. Occhi2, L. Vitiello2, Amsterdam, Amsterdam, Netherlands, 6Center for B. Bauce6, S. C. E. Tosatto4, P. J. van Tintelen3, Microscopy and Image Analysis, University of Zurich, A. Rampazzo2, M. De Bortoli2,7 Zurich, Switzerland, 7Department of Cardiovascular Surgery,UniversityHospital,Berne,Switzerland,8Division 1Department of Cardiology, Faculty of Health, Medicine of Metabolism, University Children's Hospital, Zurich, andLifeSciences,Maastricht,Netherlands,2Departmentof Switzerland Biology, Padova University, Padova, Italy, 3Department of Medical Biology and Department of Clinical Genetics, Aims: Antihypertensive drugs are included in the medical Academic Medical Center, Amsterdam, Netherlands, therapy of vascular Ehlers-Danlos syndrome (vEDS). The 4Department of Biomedical Sciences, Padova University, β-blocker celiprolol has been suggested to prevent arterial Padova,Italy,5BMRGenomics,Padova,Italy,6Department damage in vEDS, but the underlying mechanism remains of Biology Cardiac, Thoracic, and Vascular Sciences, unclear. It is also unknown whether the widely-used Padova University, Padova, Italy, 7Institute for AGTR1-antagonist losartan has a therapeutic effect inAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1305 Biomedicine, Eurac Research, Bolzano, Italy, Affiliated L. Zahavich1,2, A. Ali3, R. Mendoza-Londono4, Institute of the University of Lübeck, Lübeck, Germany N. Tehrani3, L. Grosse-Wortmann1, R. K. Jobling4,5 Among the most common inherited cardiomyopathies, 1Division of Cardiology Labatt Family Heart Centre and arrhythmogenic cardiomyopathy (ACM) is characterized DepartmentofPaediatrics,TheHospitalforSickChildren, by progressive myocardial fibro-fatty replacement, arrhyth- University of Toronto, Toronto, ON, Canada, 2Department miasandriskofsuddendeath.Mutationsingenesencoding of Genetic Counseling, The Hospital for Sick Children, proteinsofcardiacintercalateddiscsaccountforabout60% University of Toronto, Toronto, ON, Canada, 3Department of ACM cases, but the remaining 40% is still genetically of Ophthalmology and Vision Sciences, The Hospital for elusive. Sick Children, University of Toronto, Toronto, ON, Aim: We aim at identifying novel ACM genes by next Canada,4DivisionofClinicalandMetabolicGenetics,The generation sequencing. HospitalforSick Children,UniversityofToronto,Toronto, Methods and Results: The DNA of 40 ACM patients ON, Canada, 5Ted Rogers Centre for Heart Research, was analyzed using a targeted gene panel consisting of 15 Cardiac Genome Clinic, The Hospital for Sick Children, known Toronto, ON, Canada ACM genes and 53 candidate genes. We found two novel variants in T P63
 (c.796C>T, p.R266*) and PP P1
R13L Traboulsi syndrome (OMIM 601552) is a rare autosomal (c.1858G>C, p.A620P) candidate genes, encoding for the recessive disorder caused by mutations in ASPH (OMIM proteins p63 and iASPP, respectively. The T P63
 variant is 600582). It is characterized by ectopia lentis, spontaneous scoredaslikelypathogenicandthePP P1
R13Lvariantasof filtering blebs, other anterior segment anomalies and uncertain significance and involves a conserved functional craniofacial dysmorphism. Thirteen patients have been domain. reported, and aortic dilatation has not been noted, though Importantly, the mutant T P63
 allele leads to nonsense- details regarding aortic measurements have not been mediated-mRNA decay, causing consistently provided. We report three paediatric patients haploinsufficiency. from two families affected with Traboulsi syndrome Also,novelvariantsinTJ P1
geneweredetectedbywhole presenting with mild-moderate aortic dilatation in addition exome sequencing in additional 4 ACM Italian and Dutch/ to the ocular phenotype. The two affected individuals in German probands. Out of the 4 variants, p.Y669C in the Family 1 have dilation of the aortic root (Patient 1-I aortic encoded protein ZO-1 promotes structural rearrangements sinus30.2Boston z-score 2.2,Patient 1-IIaortic sinus 28.2 of the GUK domain, whereas the p.R265W, p. S329
L, and mm,Bostonz-score4.1,andsinotubularjunction23.7mm, p.D360V are predicted to impair the function of the Boston z-score 4.7). In addition Patient 1-I has a involved the disordered region between PDZ2 and PDZ3 myxomatous mitral valve with regurgitation, and Patient domains. Furthermore, rare variants in TJ P1
 are sig- 1-II has a bicuspid aortic valve. Both patients harbor a nificantly enriched in patients with ACM relative to homozygous variant in ASPH (NM_004318.3 c.2204 G>A controls. (ep.Arg735Gln)). The substitution of tryptophan for Conclusions:WeprovidethefirstevidencelinkingT P63
 arginine at this residue has been reported previously in and TJ P1
 variants to ACM, while the functional involve- Traboulsi syndrome. The ocular findings in Family 1 ment of PP P1
R13L remains to be determined. included both microspherophakia and ectopia lentis. The Grants: TRANSAC CPDA133979/13; Target Projects affectedpatientinFamily2(Patient2-I)hasadilatedaortic 331/12, RP 2014-00000394; (PRAT) CPDA133979; root (aortic sinus 27.4 mm, Boston z-score of 4.1 and CVON2012-10 PREDICT;CVON2015-12 eDETECT sinotubular junction at 20.9 mm, Boston z-score 3.2). M.Calore:None.G.Poloni:None.A.V.Postma:None. Patient 2-I has a homozygous nonsense variant A. Lorenzon: None. G. Minervini: None. G. Vazza: c.2181_2183dupATG (p.W728X) in ASPH discovered on None. I.E.A. Li Mura: None. A. Telatin: None. I. Zara: whole exome sequencing. Comprehensive testing of FBN1 None. B. Simionati: None. J. Ponti: None. G. Occhi: was negative in both families. The phenotype of this None.L.Vitiello:None.B.Bauce:None.S.C.E.Tosatto: extremely rare disorder is continues to evolve and affected None. P.J. van Tintelen: None. A. Rampazzo: None. M. patients require a thorough cardiac assessment. De Bortoli: None. L. Zahavich: None. A. Ali: None. R. Mendoza-Lon- dono: None. N. Tehrani: None. L. Grosse-Wortmann:  P05
.04D None. R.K. Jobling: None. Aortic dilatation in patients with Traboulsi syndrome1306  P05
.06B Ben-Gurion University, Beer-Sheva, Israel Metagenomic search for the protozoa in atherosclerotic plaques Introduction: Three generations of a kindred presented with autosomal dominant early-onset paroxysmal atrial A. Zarubin1, A. Markov1, D. Sharysh2, V. Puzyrev1,2, fibrillation (pAF), with recurrent nocturnal self-terminating M. Nazarenko1 palpitations. Methods: Whole exome sequencing, linkage analysis, 1Research Institute of Medical Genetics, Tomsk National electrophysiological assays in Xenopus oocytes. Research Medical Center, Tomsk, Russian Federation, Results:Through geneticstudies weidentifiedadisease- 2Siberian State Medical University, Tomsk, Russian causing p. S447
R mutation in KCND2, encoding the pore- Federation forming (α) subunit of the Kv4.2 cardiac potassium chan- nel. Kv4.2, with Kv4.3, contributes to the cardiac fast Background: Several reports have shown the relevance of transient outward K+ current, I . I underlies the early to to infection in development of atherosclerosis. However, the repolarization phase in the cardiac action potential, setting bacterial DNA of atherosclerotic plaques mainly was the initial potential of the plateau phase and governing its investigated by metagenomic approaches. Objective: To duration and amplitude. In Xenopus oocytes, the p. S447
R search for the protozoa by using genome-wide sequencing mutationincreasedinactivationtimeconstantofthechannel data of human atherosclerotic plaques (AP). andaffecteditsregulation:themutationresidesinaprotein- Material and Methods: We used the results of whole kinase C (PKC) phosphorylation site, which normally genome sequencing of DNA isolated from 12 athero- attenuates Kv4.2 membrane expression. Mutant Kv4.2 sclerotic plaques (SRA149235) and 2 blood samples from exhibitedimpairedresponsetoPKC,resultinginaugmented 1000 Genomes Project (HG00096, HG00099). Sequence Kv4.2 membrane expression and enhanced potassium cur- reads were aligned to the human reference genome (hg19) rents. Moreover, in a hybrid channel composed of Kv4.3 using Bowtie2. The taxonomic classification of the reads and Kv4.2, simulating the mature endogenous hetero- was performed with Kraken2 using a curated microbial tetrameric channel underlying I , the Kv4.2 mutation to genome database containing archaea, bacteria, fungi, pro- exerted gain-of-function effect on Kv4.3. Thus, the muta- tozoa, viruses reference genome sequence. Results and tion exerts gain-of-function effect on both Kv4.2 homo- discussion:Pre-alignmentonthehumangenome,evenwith tetramers and Kv4.2-Kv4.3 hetero-tetramers. “very-sensitive” option of Bowtie2, cannot completely Conclusions: Gain-of-function mutation in Kv4.2 causes clean up human gene sequences. Kraken2 determined 13% nocturnal pAF. Interestingly, Kv4.2 expression was pre- to92%ofthehumangenesequencesinunmatchedreadsof viouslyshowntodemonstratecircadianvariation,withpeak different AP samples. We found sequences of Toxoplasma expression at daytime in murine hearts (human nighttime), gondiigenomein8samples(about1678readspersample). with possible relevance to the nocturnal onset of parox- These sequences were shown to be mapped to contigs ysmal AF symptoms in our patients. The atrial-specific (NW_017384310.1, NW_017384809.1). These contigs phenotype suggests that targeting Kv4.2 might be effective were also found in samples from 1000 Genomes Project. in the treatment of nocturnal paroxysmal AF, avoiding Conclusions: There were no protozoa in genome-wide adverse ventricular effects. sequencing data of human atherosclerotic plaques. The M.Drabkin:None.N.Zilberberg:None.S.Menahem: reads that mapped to the Toxoplasma genome are false None. W. Mulla: None. D. Halperin: None. Y. Yogev: positive. Some microbial reference genomes probably to None. O. Wormser: None. Y. Perez: None. R. Kadir: containhumanDNAsequencesnotpresentedinthehuman None. Y. Etzion: None. A. Katz: None. O. Birk: None. reference genome assembly. A. Zarubin: None. A. Markov: None. D. Sharysh:  P05
.08D None. V. Puzyrev: None. M. Nazarenko: None. Novel ABC C9
 missense mutation in a Chinese infant with Cantu syndrome without skeletal manifestations  P05
.07C Gain of function mutation in the cardiac Kv4.2 R. Guo1,2,3,4, C. Hao1,2,3,4, S. Qian1, W. Li1,2,3,4 potassium channel underlies paroxysmal atrial fibrillation 1Beijing Children's Hospital, Capital Medical University, Beijing, China, 2Beijing Key Laboratory for Genetics of M. Drabkin, N. Zilberberg, S. Menahem, W. Mulla, Birth Defects, Beijing Pediatric Research Institute,Beijing, D. Halperin, Y. Yogev, O. Wormser, Y. Perez, R. Kadir, China, 3Genetics and Birth Defects Control Center, Y. Etzion, A. Katz, O. Birk National Center for Children's Health, Beijing, China,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1307 4MOE Key Laboratory of Major Diseases in Children, Liverpool, Australia, 5Service de Génétique, Centre Beijing, China hospitalier universitaire de Caen – Hôpital Clémenceau,, Caen, France, 6Paediatric dermatology, Our Lady’s Background: Cantu syndrome (CS) is a congenital rare Children’sHospitalCrumlin,NationalChildren’sResearch disorder characterized by congenital hypertrichosis, neona- Centre and Trinity College, Dublin, Ireland, 7Centre for tal macrosomia, a distinct osteochondrodysplasia, and VascularAnomalies,DivisionofPlasticSurgery,Cliniques cardiomegaly. It is a dominant condition caused by universitaires Saint-Luc, Université catholique de Louvain, heterozygous variants in ABC C9
 or KCNJ8. Here, we Brussels, Belgium report a baby boy patient who was referred to Cantu syndrome without skeletal manifestations. Background: Capillary malformation-arteriovenous mal- Methods:Bloodsamplesandclinicaldatawerecollected formation is an autosomal dominant disorder, characterised after informed consent. Trio whole exome sequencing was by capillary malformations and increased risk of fast-flow performed inthispatientandhis parents.Public population vascular malformations, caused by loss-of-function muta- SNP databases (dbSN P147
, gnomAD, ExAC and 1000 tions in the RASA1 or EPHB4 genes. Around 25% of the Genomes project) and in silico predictive algorithms were patients do not seem to carry germline mutation in either used to identify the pathogenic variants. one of these two genes. While some of those 25% of Results: We detected a novel de novo heterozygous patients may have mutations in as-yet-unidentified genes, missense,likelypathogenicvariant(c.3203T>C)inABC C9
 mutationsinRASA1orEPHB4thatescapedetectionbyless gene. This mutation was located in transmembrane cyto- sensitivetechniques,suchaspost-zygoticmosaicmutations, plasmic domain 2 (TMD2) which may be gain-of-function are also possible explanations. and increase K channel activity. Methods: DNA was extracted from peripheral blood ATP Conclusion: This is the first report of a Chinese baby lymphocytes,salivaorvascularmalformationtissuesfrom4 patient with pathogenic mutation in ABC C9
. Our descrip- patients. RASA1 and EPHB4 coding regions and exon/ tion of the patient’s phenotype would be a part of a spec- intron boundaries were analysed by targeted custom gene trum of features associated with Cantu syndrome. The panel sequencing. A second panel and/or Sanger sequen- unreported mutation extends the genetic spectra of ABC C9
 cing were used to confirm the mutations identified. and emphasizes the usefulness of WES for genetic diag- Results: Four distinct mosaic RASA1 mutations, with an nosis in clinical context. Keywords: Cantu syndrome, allelefrequencyrangingfrom3%to25%,wereidentifiedin ABC C9
 gene, whole exome sequencing, cardiovascular the 4 index patients with classical capillary malformation - abnormalities. arteriovenous malformation phenotype. Three mutations Grant references: This work was partially supported by were known, one was novel. In one patient, a somatic the Ministry of Science and Technology of China second-hit was also identified. One index case had three (2016YF C1000306
), and the Beijing Municipal Commis- affected children, illustrating germline mosaicism. sion of Health and Family Planning Foundation Conclusion: This study shows that RASA1 mosaic (PXM2017_026274_000001). mutations can cause capillary malformation - arteriovenous R. Guo: None. C. Hao: None. S. Qian: None. W. malformation.Thus,highlysensitivesequencingtechniques Li: None. should be considered as diagnostic tools, especially for patients with no family history. Even low-level mosaicism  P05
.09A can cause the classical phenotype and increased risk for RASA1 mosaic mutations in patients with capillary offspring. In addition, our study further supports the malformation - arteriovenous malformation second-hit pathophysiological mechanism to explain the multifocality of vascular lesions in this disorder. N. Revencu1, E. Fastre1, M. Ravoet1, R. Helaers2, N. Revencu: None. E. Fastre: None. M. Ravoet: None. P. Brouillard2, A. Bisdorff-Breson3, C. W. Chung4, R. Helaers: None. P. Brouillard: None. A. Bisdorff-bre- M. Gerard5, V. Dvoravoka6, A. D. Irvine6, L. Boon7, son: None. C.W. Chung: None. M. Gerard: None. V. M. Vikkula2 Dvoravoka:None.A.D.Irvine:None.L.Boon:None.M. Vikkula: None. 1CenterforHumanGenetics,CliniquesuniversitairesSaint- Luc, Université catholique de Louvain, Brussels, Belgium,  P05
.10B 2Human Molecular Genetics, de Duve Institute, Université Unique cardiogenetic clinic- our experience from 300 catholique de Louvain, Brussels, Belgium, 3Service de patients from Israeli diverse ethnic population Neuroradiologie, Hopital Lariboisière, Paris, France, 4Department of Clinical Genetics, Liverpool Hospital,1308 N. Ruhrman Shahar1, A. Oz1, D. Monakier2, I. Maya1, M. J. Gamundi, B. Mañé, A. I. Jaber, D. López, L. Salzer Sheelo1, L. Basel - Salmon1,3, Y. Goldberg1, M. D. Martínez, J. Martínez, C. Moure, A. Sánchez, L. Bazak1 A. Vancells, J. M. Viguer, I. Hernan, E. Borràs, M. Carballo 1Recanati Genetic Institute, Rabin Medical Center, Petah Tikva, Israel, 2Cardiology Dept. Beilinson Hospital, Rabin Hospital de Terrassa (CST), Terrassa, Spain Medical Center, Petah Tikva, Israel, 3Sackler Faculty of Medicine, Tel Aviv Universit, Tel Aviv, Israel Introduction: Inherited cardiomyopathies (CMs) are a major cause of heart disease. They can be classified in Introduction: Genetic heart diseases are a major public hypertrophic cardiomyopathy (HCM), dilated cardiomyo- healthproblemworldwide.Cardio-geneticsisemergingasa pathy (DCM), arrhythmogenic right ventricular cardiomyo- main discipline for deciphering multiple cardiac patholo- pathy (ARVC), restrictive cardiomyopathy (RCM) and left gies, with immediate clinical effects on diagnosis, treat- ventricular non-compaction (LVNC). Due to their clinical ment,preventionandprognosisforpatientsandtheirfamily and genetic heterogeneity, targeted-gene Next-Generation- members. Sequencing (NGS) can be a helpful tool in their diagnosis Methods: We have established the first designated and to early detect them in pre-symptomatic carriers. cardio-genetics clinic in Israel as part of a tertiary hospital Materials and Methods: 39 DNA samples of patients twoyearsago.Weretrospectivelyreviewedallourpatient's affectedwithdifferentCMswereanalyzedbytargeted-NGS files from the last 2 years. using Cardio-GeneSGKit® (n=238 genes) or Cardio-Gen- Results:Threehundredpatientsfrom200familiesvisited eSGKit® MCP (n=90 genes). Results were filtered and our clinic and they represent variant population from all analyzed with GeneSystems® platform and informed to over Israel both from Jewish and non Jewish origins. The patients.Co-segregationanalysisand/orcarriertestingwere patients were referred from both pediatric and adults car- performed when possible. diologists, cardiovascular surgeons and primary care Results: 7 pathogenic/probably pathogenic variants were physicians. detected in 5 HCM patients and 2 DCM patients. In HCM Most visits (90%) in our clinic were as outpatients and patients, mutations were found in MYBP C3
 (p.Arg495Gln, only 10% were acutely hospitalized. p.Gly532Alafs*23andp.Arg597Gln),CAV3(p.Thr78Met), The patients were referred due to: congenital heart dis- TNN C1
 (p.Ala8Val) and TNNI3 (p.Arg145Gln). In DCM easesin10%,hypertrophiccardiomyopathyin52%,dilated patients, mutations were detected in DSP (p.Leu1773- cardiomyopathy in 14%, arrhythmogenic right ventricle Tyrfs*8) and TTN (p.Pro28946Leufs*6). Also, 17 variants dysplasia in 8%, left ventricular non- compaction in 4%, of unknown significance (VOUS) were detected in 14 channelopathies in 10% and 2% due to aborted patients affected with HCM (n=10), DCM (n=3) and sudden death. ARVC (n=1). These VOUS were mainly detected in Thepatientsunderwentageneticinvestigationindifferent MYBP C3
 (n=7) but also in other genes as DS C2
 (n=1), methods according to the clinical presentation: Sanger FH L1
 (n=1), FLNC (n=1), LDB3 (n=1), LMNA (n=1), sequencing for known familial/founder mutation, single MYH7 (n=2), PK P4
 (n=1), SCN5A (n=1) and gene sequencing, NGS based gene panel sequencing, TNNT2 (n=2). Whole Exome Sequencing and chromosomal microarray. Conclusions: 19 of the 39 analyzed patients (48.7%) We have identified the underlying genetic cause in presentedaclinicallysignificantvariantinoneortwogenes approximately 40% of the families - the percentage varies associated with CMs. Detection of pathogenic/probably between the different cardiac pathologies. pathogenic variants in probands can help to improve the Summary:Cardio-geneticsclinicisausefultoolbothfor diagnostic, prognostic and treatment in them and in pre- the patient, families and the primary care physician in symptomatic carriers. various Genetic heart disease. M.J. Gamundi: None. B. Mañé: None. A.I. Jaber: N. Ruhrman Shahar: None. A. Oz: None. D. Mon- None. D. López: None. M.D. Martínez: None. J. Martí- akier: None. I. Maya: None. L. Salzer Sheelo: None. L. nez: None. C. Moure: None. A. Sánchez: None. A. Basel - Salmon: None. Y. Goldberg: None. L. Vancells: None. J.M. Viguer: None. I. Hernan: None. E. Bazak: None. Borràs: None. M. Carballo: None.  P05
.11C  P05
.12D Molecular diagnostic testing of inherited Something old, something new: two syndromes cardiomyopathies by targeted Next-Generation associated with pediatric-onset cardiomyopathy Sequencing in a public hospitalAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1309 J. C. Herkert, A. J. van Essen, I. M. van Langen Cardiomyopathyisadiseaseoftheheartmuscleassociated with a disorder of its function. This is a heterogeneous University of Groningen, University Medical Center group of diseases with various clinical signs that can Groningen, Groningen, Netherlands ultimately lead to heart failure. A significant proportion of cardiomyopathies is genetically determined. In this group Introduction: Hypertrophic and dilated cardiomyopathies can be found congenital heart defects, muscular dystrophy (HCM/DCM)areinheritedheartmuscledisorders.Theyare and congenital myopathy, hereditary disorders of metabo- isolated in the majority of patients, but are often lism and genetic syndromes, (rasopathies). The use of the accompanied by extracardiac features in children. Distin- whole exome sequencing is currently one of the most guishing children with one syndromic disorder from those effective tools for elucidating the genotype of individual withtwoinheritedconditionsisimportantbecausethismay patients. We have successfully used this method for affectmanagementoptions,cardiacsurveillanceinrelatives studying of genetic architecture of dilated cardiomyopathy and reproductive decision-making. cohortwhereinabout80%ofthe460examinedpatientswe Methods and Results: We present two patients with have found probably causal variant. Most frequently intellectual disability (ID) and cardiomyopathy. Patient 1 affected genes were TTN (18%), FLNC (4%), MYBP C3
 presented with paroxysmal ventricular tachycardia at age (4%), MYH7 (4%), DSP (4%), RBM20 (3%), TNNT2(3%), 3 months. At age 5 she showed severe HCM, prolonged DES (2%), LMNA (1%). We have also found CNV QTc, severe ID, epilepsy and cerebral vision impairment. variations in DMD, LAM P2
, FLNC, LMNA and MYH7 Exome sequencing(ES)revealedadamagingc.247C>T,p. genes, which were predicted to cause major structural and (Arg83Cys) variant in NAA10, which encodes a ribosomal functional abnormalities of the affected genes. We are also proteininvolvedinN-terminalacetylation.SeveralX-linked focusing on paediatric forms of cardiomyopathy which are NAA10 variants have been associated with genetic dis- more complex and the clarification is below 50%. orders,butcardiomyopathyhadnotdescribeduntilrecently. Successful molecular biology diagnostic helps to identify Patient2wasdiagnosedwithsevereDCMatage4months, the risk of occurrence of the disease in the family and to mild ID, microcephaly (-6.2SDS), failure to thrive and provideprenataldiagnosis.Inselectedcases,thephenotype clinodactyly. ES revealed compound heterozygous variants can also be studied in cell models, which contribute to the in CE P135
. Biallelic variants in CE P135
 have also been understanding of the molecular mechanism of the disease reported in two families with microcephaly. Interestingly, andallowamoreaccurateinterpretationofextremeclinical most of Patient 2’s clinical features overlap with those of or laboratory findings. LM201509 NCLG, AZV 15- five previously reported unrelated patients with autosomal 27682A, AZV 15-28208A, SVV-260367 recessive inherited microcephaly-cardiomyopathy syn- L. Piherova: None. K. Hodanova: None. H. Hart- drome with unknown genetic etiology. Genematcher iden- mannova: None. D. Musalkova: None. M. Kubanek: tifiedanother patient withneonatalcardiomyopathy, failure None. A. Krebsova: None. S. Kmoch: None. to thrive, microcephaly and biallelic variants in CE P135
. CE P135
 may thus have a role in cardiomyopathy.  P05
.14B Conclusions: These two cases illustrate that ES is a 11 years of the Queensland Cardiac Genetics Service valuablediagnostictoolforpediatric-onsetcardiomyopathy thatcanidentifynovelfeaturesinwell-knownsyndromesor R. Jonathan1, J. McGaughran1, J. Atherton2,3 novel genes associated with pediatric cardiomyopathy. J.C. Herkert: None. A.J. van Essen: None. I.M. van 1Genetic Health Queensland, Brisbane, Australia, 2Royal Langen: None. Brisbane and Women's Hospital, Brisbane, Australia, 3University of Queensland, Brisbane, Australia  P05
.13A Cardiomyopathy: genomic-diagnostic approach Introduction: A dedicated conjoint cardiac genetics clinic (CGC)wasestablishedthroughGeneticHealthQueensland L. Piherova1, K. Hodanova1, H. Hartmannova1, and the Cardiology Department at the Royal Brisbane and D. Musalkova1, M. Kubanek2, A. Krebsova2, S. Kmoch1 Women’s Hospital in 2007. The aim of this study was to characterizethepatientcohortseenandassesstheuptakeof 1RURD, Prague 2, Czech Republic, 2Institute for Clinical genetic testing and diagnostic rates achieved. and Experimental Medicine (IKEM), Department of Methods: We explored the local databases and patient Cardiology, Prague, Czech Republic charts to characterise the age, sex, referral phenotype and incidence of genetic testing for all patients who had atten- dedtheCGC.Theoutcomesofgenetictesting,andnumber1310 of at risk relatives screened were also calculated. Unsolved cardiomyocytes and a human myoblast cell line and cases who would benefit from further testing with Whole observed dramatic changes in cell size and morphology. Genome Sequencing were identified. Patient-derived iPSC-cardiomyocytes were hypertrophic, Preliminary Results: Over 1400 individuals were seen displayed sarcomeric structural disarray and had slower for the first time during the 11-year period and over 900 contractile velocity compared to control iPSC- have been characterized to date. 488 were probands, the cardiomyocytes. Using Co-Immunoprecipitation for majority (265) of whom were referred for a cardiomyo- ACTN2, followed by mass-spectrometry, we identified pathy. 141 were referred for an arrhythmia syndrome, and missing protein-protein interactions in the patient with the 72 had had a cardiac arrest or were the relative of an indi- truncated ACTN2. vidual with a sudden cardiac death. 385 probands were Conclusions: Here, we provide evidence that two struc- tested, with a genetic diagnosis being achieved in 164 turalgeneticvariantsinACTN2areassociatedtocontractile (43%).Thehighestdiagnosticratewasachievedinpatients dysfunction and lead to cardiac abnormalities, including with cardiomyopathies (47%). Predictive testing was per- hypertrophy and arrhythmia. formed in a further 415 patients. No specific grant funded this study. Conclusions: We have reviewed the characteristics of a M.E.Lindholm:None.H.Zhu:None.Y.Huang:None. large cohort of cardiac genetics patients and compared our E.A. Ashley: E. Ownership Interest (stock, stock options, diagnosticratestothoseintheliterature.Wehaveidentified patent or other intellectual property); Significant; Persona- unsolvedfamilieswhowillbenefitfromfurthertestingwith lis, DeepCell. F. Consultant/Advisory Board; Modest; contemporary technologies. SequenceBio, Genome Medical. M. Wheeler: None. R. Jonathan: None. J. McGaughran: None. J. Atherton: None.  P05
.16D Genetic cardiomyopathies revisited: reevaluating  P05
.15C current gene panel testing Structural variants in Alpha-actinin 2 are associated with cardiomyopathy and hypertrophy in human D.Dooijes,M.A.Siemelink,J.J.vanderSmagt,R.L.E. cardiac tissue and iPSC-derived cardiomyocytes van Loon, J. G. Post, J. F. van der Heijden, F. W. Asselbergs, A. F. Baas, J. P. van Tintelen M. E. Lindholm, H. Zhu, Y. Huang, E. A. Ashley, M. Wheeler UMC Utrecht, The Netherlands, Utrecht, Netherlands Stanford Cardiovascular Institute, School of Medicine, Introduction:Thereisanongoingdebateonthegenesthat Stanford University, Stanford, CA, United States shouldbeexaminedduringgenetic evaluationofidiopathic cardiomyopathy patients. Although several genes have Background:Instriatedmuscle,alpha-actinin2isacritical sufficient evidence to be cardiomyopathy-related, for other cytoskeletal protein that anchors actin filaments within the genesthisremainsunclear.Thesegenesmayhowevercause sarcomere. Rare mutations in ACTN2 have been associated asignificantburdenonvariantevaluation.Inordertomake with cardiac abnormalities, including arrhythmias and an evidence-based estimation of the value of genes cardiomyopathy. However, the mechanisms behind how examined, we assessed results of cardiomyopathy gene dysfunctional ACTN2 causes cardiac malfunction is not panels after reevaluation and reclassification of variants known. The aim of the present study was to investigate the according to current criteria. effects of two novel ACTN2 variants on human cardiac Materials and Methods: All results of a 64-gene NGS- tissue and patient-specific iPSC-derived cardiomyocytes. cardiomyopathypanelperformedbetween2014and2018in Methods and Results: We identified patients in the the UMC Utrecht, the Netherlands were retrieved. The Stanford Center for Inherited Cardiovascular Disease data- pathogenicityofallgenevariantswasreevaluatedaccording base with novel ACTN2 variants using a custom mutation to current criteria by an experienced clinical laboratory pipeline optimizedfor rare variantdiscovery. We identified specialistincardiogenetics.Benignorlikelybenignvariants one patient homozygous for a stop-gain mutation (p. were excluded from analysis. Summary results were deter- Q860X)inACTN2andafamilywithanexon8-10deletion. mined for all individual genes. In heart transplant tissue of the homozygous patient, we Results:1264cardiomyopathy panelsperformedshowed observed mild hypertrophy and interstitial fibrosis. There 848 variants (657 unique) in 638 patients (overall yield wasnoevidenceofvariationinACTN2proteinexpression, 50.5%). Of the 848 variants, 124 variants were reclassified indicating absence of nonsense mediated decay. We used (15%), of which 117 were downgraded (94%). Reclassifi- siRNA to knock down ACTN2 in neonatal rat ventricular cation was mostly due to a high frequency in controlAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1311 populations or based on in-house clinical data (e.g. non- myocardialinfarctionandT2DMincomparisontocontrols, segregation). 28 genes were determined to be of limited with a p-value of 1.42x10-4 and odds ratio equal to 7.37 value in regular pan-cardiomyopathy gene panel testing (95% CI: 4.15 to 13.08). Other SNPs in ARNTL, CLOCK, because of the absence of relevant variants, published lit- and PER2 genes were notsignificant additional risk factors erature (including ClinGen gene adjudication). for myocardial infarction in T2DM patients. We provide Conclusions: Cardiomyopathy NGS-gene panels per- evidencethatgeneticvariationinARNTLgenemightbean formed on 1264 patients, identified 28 genes of limited additional risk factor for myocardial infarction in T2DM value in regular genetic testing for cardiomyopathy. In patients. addition, state-of-art reevaluation of variants resulted in a I. Škrlec: None. J. Milić: None. I. Cilenšek: None. D. notable downgrading of previously identified variants. Petrovič: None. B. Peterlin: None. D. Dooijes: None. M.A. Siemelink: None. J.J. van der Smagt: None. R.L.E. van Loon: None. J.G. Post: None.  P05
.18B J.F.vanderHeijden:None.F.W.Asselbergs:None.A.F. Clinical Utility of Next Generation Sequencing (NGS) Baas: None. J.P. van Tintelen: None. Panel Testing in Patients with a Clinical Suspicion of Catecholaminergic Polymorphic Ventricular  P05
.17A Tachycardia (CPVT) Circadian clock genes and myocardial infarction in patients with type 2 diabetes mellitus E. H. Seppälä, I. Saarinen, J. Tallila, J. Hathaway, S.Tuupanen,H.Turpeinen,T.Kangas-Kontio,J.Schleit, I.Škrlec1,J.Milić2,I.Cilenšek3,D.Petrovič3,B.Peterlin4 J. Tommiska, E. Salminen, P. Salmenperä, J. Sistonen, M. Gentile, S. Myllykangas, J. Paananen, T. Alastalo, 1Department of Biology and Chemistry, Faculty of Dental J. Koskenvuo Medicine and Health, J. J. Strossmayer University of Osijek, Osijek, Croatia, 2Faculty of Medicine, Blueprint Genetics, Helsinki, Finland J. J. Strossmayer University of Osijek, Osijek, Croatia, 3Institute of Histology and Embryology, Faculty of Catecholaminergic Polymorphic Ventricular Tachycardia Medicine, University Ljubljana, Ljubljana, Slovenia, (CPVT) is a rare, but potentially fatal channelopathy. 4Clinical Institute of Medical Genetics, University Medical Genetic testing may be used to confirm a diagnosis in Center Ljubljana, Ljubljana, Slovenia unclearcasesandtherefore,isincreasinglybeingperformed in a heterogeneous patient population. This is a retro- Disruption of circadian clock may trigger the onset of spective review of 134 patients with clinical suspicion of diabetesmellitusandmyocardialinfarction.Type2diabetes CPVTreferredforgenetictestingatBlueprintGeneticsover mellitus (T2DM) is well-known risk factors for cardiovas- a 5-year period (2013-2018). Genetic test results were cular diseases and myocardial infarction. Several physiolo- compiled. A sub-analysis of diagnostic RYR2 variants gical factors can stimulate the emergence of T2DM and (location, segregation) was performed. A pathogenic (P) myocardialinfarction,andsomeofthesefactorsareknown or likely pathogenic (LP) variant was identified in 27 to oscillate with circadian rhythms. This study aimed to patients(20.1%).Twentypatients(14.9%)hadadiagnostic explore a possible association of the genetic variability in finding in a CPVT-associated gene: 62.9% in RYR2, 7.4 % thecircadian clock genes ARNTL,CLOCK,andPER2with in CALM1, and 3.7% in CASQ2 (biallelic). Four patients myocardial infarction in patients with type 2 diabetes (14.8%) had a P or LP variant in KCNQ1, KCNJ2 or mellitus as an additional risk factor for myocardial SCN5A and three (11.1%) had a P or LP variant in a infarction. The study group consisted of 231 patients with cardiomyopathy-associated gene (DSG2, DSP or PLN). All myocardialinfarctionandT2DMandacontrolgroupof426 P/LP RYR2 variants were missense, except a deletion T2DM patients. Altogether, 8 SNPs were tested, three in encompassingexon3.Parentaltestingwasperformedin11/ ARNTL gene (rs3789327, rs4757144 and rs12363415), 17 cases where P/LP RYR2 variants were found; 8 (72.7%) threeinCLOCK(rs11932595,rs6811520andrs13124436), variantsweredenovo.EnrichmentofP/LPRYR2variantsin and two in PER2 (rs35333999 and rs934945). The the four described hotspots (OR 50, 95% CI 29-85, significance of association for individual SNP was calcu- P<0.0001) was observed. In conclusion, 37% of patients lated to compare the allelic frequency and genotype with a diagnostic test result had a clinically significant distribution in patients and control participants using the variant in a gene other than RYR2. Interestingly, 26% of Chi-Square test. After using Bonferroni correction signifi- thesepatientshadgeneticdiagnosisofacardiomyopathyor cant difference in the distribution of ARNTL rs12363415 a channelopathy other than CPVT. This study supports the polymorphism genotypes were found in patients with1312 utilization of broad NGS panels for patients with a clinical geneisresponsibleforthevariousclinicalsyndromes.Upon suspicion of CPVT. sequencing45suchpatients,weidentifiedsevenpathogenic E.H. Seppälä: A. Employment (full or part-time); Sig- variantsinfivegenesencodingcomponentsofRAS/MAPK nificant; Blueprint Genetics. I. Saarinen: A. Employment signaling (BRAF, KRAS, SO S1
, RASA1, and PTPN11) in (full or part-time); Significant; Blueprint Genetics. J. Tal- seven unrelated patients. Additionally, we identified a lila: A. Employment (full or part-time); Significant; Blue- recurrent somatic missense mutation in a candidate gene, print Genetics.J. Hathaway: A.Employment (full or part- ARAF (c.640T>C:p. S214
P), as the basis for CCLA in two time); Significant; Blueprint Genetics. S. Tuupanen: A. unrelated patients. ARAF encodes for serine/threonine- Employment (full or part-time); Significant; Blueprint protein kinase A-Raf. Little is known about ARAF apart Genetics. H. Turpeinen: A. Employment (full or part- fromtheenzymebeinginvolvedinMAPKpathwaywithno time); Significant; Blueprint Genetics. T. Kangas-Kontio: previous involvement in lymphatic disease report. Primary A. Employment (full or part-time); Significant; Blueprint endothelial cell studies showed the mutation altered actin Genetics. J. Schleit: A. Employment (full or part-time); skeleton and VE-cadherin organization, which were fully Significant; Blueprint Genetics. J. Tommiska: A. reversed by inhibition of MEK signaling. Functional Employment (full or part-time); Significant; Blueprint relevance of the mutation was also validated by recreating Genetics. E. Salminen: A. Employment (full or part-time); a lymphatic phenotype in a zebrafishmodel, with rescue of Significant; Blueprint Genetics. P. Salmenperä: A. the anomalous phenotype using a MEK inhibitor. Sub- Employment (full or part-time); Significant; Blueprint sequent therapy of the lead proband with a MEK inhibitor Genetics.E.OwnershipInterest(stock,stockoptions,patent led to dramatic clinical improvement, with remodeling of or other intellectual property); Significant; Blueprint the patient’s lymphatic system with resolution of the Genetics. J. Sistonen: A. Employment (full or part-time); lymphatic edema, marked improvement in his pulmonary Significant; Blueprint Genetics. M. Gentile: A. Employ- function tests, cessation of supplemental oxygen require- ment (full or part-time); Significant; Blueprint Genetics. E. ments, and near normalization of daily activities. Taken Ownership Interest (stock, stock options, patent or other together,ourworkdemonstratestherealizationofprecision intellectual property); Significant; Blueprint Genetics. S. medicine approach enabled through a novel genetic Myllykangas: A. Employment (full or part-time); Sig- discovery in a patient with lymphatic anomaly of a nificant; Blueprint Genetics. E. Ownership Interest (stock, previously unknown etiology. stock options, patent or other intellectual property); Sig- D. Li: None. nificant; Blueprint Genetics. J. Paananen: A. Employment (full or part-time); Significant; Blueprint Genetics. T.  P05
.21A Alastalo: A. Employment (full or part-time); Significant; Copy number variants detection by microarray and Blueprint Genetics. E. Ownership Interest (stock, stock multiplex ligation-dependent probe amplification in options, patent or other intellectual property); Significant; congenital heart diseases BlueprintGenetics.J.Koskenvuo:A.Employment(fullor part-time); Significant; Blueprint Genetics. E. Ownership O. Nagy1, K. Szakszon2, D. Nagy3, G. Mogyorósy2, Interest (stock, stock options, patent or other intellectual B. Biro4, B. Nagy5, I. Balogh1, A. Ujfalusi1 property); Significant; Blueprint Genetics. 1Division of Clinical Genetics, Department of Laboratory  P05
.19C Medicine, Faculty of Medicine, University of Debrecen, Mutations in genes involved in MAPK pathway cause Debrecen, Hungary, 2Department of Pediatrics, Faculty of lymphatic anomalies Medicine, University of Debrecen, Debrecen, Hungary, 3Department of Medical Genetics, Faculty of Medicine, D. Li University of Szeged, Szeged, Hungary, 4First Department of Obstetrics and Gynecology, Semmelweis University, Center for Applied Genomics, Philadelphia, PA, United Budapest, Hungary, 5Department of Human Genetics, States Faculty of Medicine, University of Debrecen, Debrecen, Hungary Complex lymphatic anomalies include a variety of diag- noses: lymphangiectasia, central conducting lymphatic Congenital heart diseases (CHDs) are the most common anomaly (CCLA), generalized lymphatic anomaly, kaposi- birthdefectsamonglifebirths,whichcouldbepresentedas form lymphangiomatosis, and Gorham Stout disease. The isolated or syndromic with other congenital malformations. overlapping of diagnostic criteria for these disorders The etiology of CHD largely unknown, genetic and suggests that a common pathway rather than a common environmental factors contribute to the disease. RecurrentAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1313 copy number variants (CNVs) have been reported in the disease. Gene expression signature was determined by RT- pathogenesisofCHD.Theaimofthisstudywastoevaluate qPCR with hydrolysis probes. the clinical utility of multiplex ligation-dependent probe Results: We found that DP P4
 and APLN mRNA amplification (MLPA) and microarray analyses on isolated expression was significantly (P<0.05) increased only in and syndromic CHD cases and to explore the relationship adipocytesisolatedfromepicardialadiposetissuecompared between identified CNVs and CHD. tothesubcutaneousfat.TheITLN1genewasoverexpressed Materials and Methods: Cytoscan 750K array (Affy- in epicardial adipose tissue compared to both subcutaneous metrix) and MLPA SALSA  P250
 and  P311
 kits (MRC- and perivascular tissues and expression of ADIPOQ gene Holland)wereusedinthestudy.TheidentifiedCNVswere was reduced both in EAT and PVAT compared to SCAT. confirmed by fluorescence in situ hybridization. Results. Moreover, APLN mRNA expression was positively corre- Eighteen prenatal samples, 16 isolated and 33 syndromic lated with total and LDL cholesterol plasma level, and patients with mild to severe CHD phenotype were studied. DP P4
 mRNA expression - with VLDL cholesterol con- Prenatal and isolated CHD cases did not show pathogenic centration. We found no significant changes in LCN2 and CNVs. Clinically significant CNVs were detected in 7/33 NAMPT mRNA level between studied adipose depots. (21%)syndromicCHDpatients:del22q11.2(n=2),8p23.1 Conclusions: Adipocytes isolated from different adipose duplication (n=2), deletion 5p (n=1), deletion 6q21-q22 depots are characterized by differential gene expression of (n=1), unbalanced translocation causing partial deletion of adipokines.EATisofparticularinterestinthecontextofits 4q34.3 and duplication of 6q25.1 (n=1). function, molecular and genetic mechanisms of regulation Conclusion: The identified genomic imbalances contain of the cardiovascular system and as a therapeutic target for genes that has been associated with human CHD before. correction of adipose tissue-induced effects on health. This The present study demonstrates that using microarray and work was supported by RSF grant No. 17-75-20026. MLPAanalysisincreasesthedetectionrateofcausalCNVs M. Sinitsky: None. Y. Dyleva: None. E. Uchasova: in individuals with syndromic CHD. This study was sup- None. E. Belik: None. O. Gruzdeva: None. A. ported by the Ministry of National Economy, Hungary Ponasenko: None. (GINOP-2.3.2-15-2016-00039). O.Nagy:None.K.Szakszon:None.D.Nagy:None.G.  P05
.26B Mogyorósy: None. B. Biro: None. B. Nagy: None. I. Cardiac arrhythmias at baseline predict a clinically Balogh: None. A. Ujfalusi: None. relevant genetic yield in idiopathic non familial DCM affecting long term outcome  P05
.24D Adipokine profile of adipocytes isolated from different J. Verdonschot1, M. T. H. M. Henkens1, A. G. Raafs1, fat depots of coronary artery disease patients P.Wang1,J.J.Merken1,G.R.F.Claes1,I.P.C.Krapels1, E. K. Vanhoutte1, A. van den Wijngaard1, M. Sinitsky1,2, Y. Dyleva1, E. Uchasova1, E. Belik1, H. G. Brunner1,2, M. R. Hazebroek1, S. R. B. Heymans1 O. Gruzdeva1,3, A. Ponasenko1 1Maastricht University Medical Center, Maastricht, 1Research Institute for Complex Issues of Cardiovascular Netherlands, 2Radboud University Medical Center, Diseases, Kemerovo, Russian Federation, 2Federal Nijmegen, Netherlands Research Center of Coal and Coal Chemistry of SB RAS, Kemerovo, Russian Federation, 3Kemerovo State Medical Background: Current guidelines recommend genetic Academy, Kemerovo, Russian Federation analysis only in familial dilated cardiomyopathy (DCM) patients without acquired disease. The genetic yield in so- Introduction:Adiposetissueisinterestinginthecontextof called acquired and/or non-familial DCM remains largely its role in pathogenesis of cardiovascular diseases. Human unknown. adipokinome consists of hundreds of molecules many of Methods:Thisstudyincluded689DCMpatientswhoall which have not yet been well characterized and have underwent genetic evaluation using a 47 cardiomyopathy- variable expression in different adipose depots. associated gene panel and had complete cardiac diagnostic Materials and Methods: We compared DP P4
, LCN2, work-up including echocardiography, cardiac MRI, endo- NAMPT, ITLN1, APLN and ADIPOQ mRNA levels in myocardial biopsies and holter monitoring. Environmental adipocytes isolated from the biopsies of subcutaneous triggers were predefined as viral, inflammatory, toxic, (SCAT),epicardial(EAT)andperivascular(PVAT)adipose electrical and systemic auto-immune disease. tissue obtained from 25 patients with coronary artery Results: At least one etiology (genetic and/or environ- mental) was found in 530 patients (77%) after complete1314 diagnostic workup, of which 159 (23%) had a genetic mutations in dilated cardiomyopathy (DCM) regarding mutation.OneinfiveoftheDCMpatients(n=90;20%)had (endo)phenotype, penetrance, and management. a combination of a genetic and acquired (environmental) Materials and Methods: A family with DCM and SCD trigger. All of the acquired triggers had a genetic yield was referred to our cardiogenetics outpatient clinic. Accu- around 20%. Although familial DCM had a significant rate genetic and cardiologic assessments were performed. higher yield of genetic mutations compared to non-familial DNA sequencing was initiated in the proband using NGS DCM (43% versus 16%, p<0.001), pathogenic mutations (cardiopanel). were still present in 1 of 6. In non-familial DCM patients Results: A novel variant in DSP c.4639dupC was iden- with arrhythmias atbaselinewithout environmental trigger, tified, absent in gnomAD, locus-specific databases and thegeneticyieldwas even 39%,comparable totheyieldin predicted as deleterious by dedicated software, affecting familial DCM (43%; p=0,17). Also, genetic DCM has a cardiac-specific isoform and leading to frameshift p. worse prognosis compared to non-genetic DCM (Log- (Gln1547ProfsTer80). The 60-year-old proband and her Rank=0.008), irrespective of familial history (Log- three nieces (aged 32-45) were diagnosed with DCM and Rank=0.29). ICD implanted. Five siblings (aged 25-61) had SCD. Seg- Conclusions:OneinfiveDCMpatientswithanacquired regation analysis in asymptomatic relatives identified two trigger and/orabsence offamilialhistory hasan underlying mutated siblings (31 and 47 years): one presented an epi- genetic mutation. Non-familial DCM patients with sode of acute myocarditis. Despite detailed cardiologic arrhythmias and no clear etiology have a comparable evaluation, they did not meet current diagnostic guidelines genetic yield compared to familial DCM. for AC/DCM. J.Verdonschot:None.M.T.H.M.Henkens:None.A.G. Conclusions: Loss-of-function DSP mutations cause Raafs:None.P.Wang:None.J.J.Merken:None.G.R.F. different phenotypesincludingACandDCM. Adiagnostic Claes: None. I.P.C. Krapels: None. E.K. Vanhoutte: grey zone between left-dominant AC and arrhythmogenic None. A. van den Wijngaard: None. H.G. Brunner: DCM exists, indicating the need for updating current clas- None. M.R. Hazebroek: None. S.R.B. Heymans: None. sification.Moreover,genotype-baseddefinitioniswarranted to develop personalized management in patients/asympto-  P05
.27C matic-mutated subjects. Intrafamilial phenotypic variability A novel truncating mutation in DSP (Desmoplakin) and lack of penetrance demand modifier variants in addi- causes autosomal dominant dilated cardiomyopathy tional, yet unknown, genes or epigenetic factors. with variable penetrance Funding: Fondi Ricerca Premiale from University of L’Aquila, Italy L. Camerota1, V. Ferradini2, R. Petroni3,4, R. Monetta4,1, L. Camerota: None. V. Ferradini: None. R. Petroni: S. Romano3, G. Ussia5, F. Sangiuolo6, F. Brancati1,4 None. R. Monetta: None. S. Romano: None. G. Ussia: None. F. Sangiuolo: None. F. Brancati: None. 1MedicalGeneticsDivision,DepartmentofLife,Healthand Environmental Sciences, University of L'Aquila, L'Aquila,  P05
.28D Italy, 2Department of Biomedicine and Prevention, Double heterozygosity in a group of patients with rare University of Rome Tor Vergata, Rome, Italy, 3Department cardiovascular diseases of Cardiology, University of L'Aquila, L'Aquila, Italy, 4Laboratory of Molecular and Cell Biology, Istituto S. Josifovska1,2, R. Vazharova3, L. Balabanski2, Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy, M. Malinov2, A. Kaneva4, S. Panov1, M. Ganev5, 5Facoltà Dipartimentale di Medicina e Chirurgia, D. Toncheva5 University Campus Bio-Medico, Rome, Italy, 6Department of Biomedicine and Prevention, University of Rome Tor 1Laboratory of Molecular Biology, Faculty of Natural Vergata, L'Aquila, Italy Sciences and Mathematics, Ss. Cyril and Methodius University, Skopje, Macedonia, The Former Yugoslav Background: Arrhythmogenic Cardiomyopathy (AC) is Republic of, 2Genome Centre, GARH Malinov, Sofia, mainly determined by mutations in desmosomal genes. Bulgaria, 3Department of Biology, Medical Genetics and Approximately 75% of AC patients show bi-ventricular Microbiology, Faculty of Medicine, Sofia University St. involvement and left-dominant forms are not uncommon. KlimentOhridski,Sofia,Bulgaria,4DepartmentofPediatric Loss-of-function mutations in Desmoplakin (DSP) cause a Cardiology, National Heart Hospital, Sofia, Bulgaria, form of AC often manifesting with severe arrhythmias and 5Department of Medical Genetics, Medical University of sudden cardiac death (SCD). Less is known about DSP Sofia, Sofia, BulgariaAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1315 Introduction: Rare cardiovascular diseases (CVD) are Background: Cardiovascular disease (CVD) is ranked as heterogeneous and this complicates their diagnosis. The thesecondleadingcausesofdeathinTaiwan.Dyslipidemia more complex forms of rare CVD tend to result from the is one of the risk factors for CVD. The LPL and APOE integrated effect of multiple genetic variants that create a geneswerefoundtobeinvolvedinlipidmetabolism.Many backgroundofsusceptibilityrequiringsometimesadditional studiesuncoveredtheassociationbetweendyslipidemiaand factors for the disease to manifest. Whole exome, whole CVD, however, conventional epidemiological studies may genome and target sequencing offer new possibilities to sufferfromun-measuredconfoundersandreversecausality. discoverthecomplex etiologyofsuchdiseases. Theaimof We aimed to elucidate the causal relationship between this study was to identify genetic variants associated with dyslipidemia and CVD using Mendelian randomization the rare CVD using next generation sequencing (NGS). design. Materials and Methods: NGS with TruSight panels Methods: A total of 1951 Chinese adults were recruited (Illumina) was used to analyze DNA samples from 24 from the Matsu community-based integrated health patients with rare CVD: Long QT Syndrome, Tetralogy of screeningprojectduring2015-2017.TwoSNPs(LPLrs328 Fallot, Familial Hypercholesterolemia, suspected Marfan and APOE rs157580) were selected as the instrumental Syndrome, Pathology of great vessels, Cardiomyopathies variables. Both logistic regression and two-stage least- and other. squareinstrumentalvariable(IV)regressionwereappliedto Results: In 14 (58%) of the 24 patients, at least one estimate the relationship between the lipid profiles pathogenic or likely pathogenic variant was found. Of and CVD. those, in 8 patients we detected only one variant, in 3 Results: We found rs328 was significantly associated patients there was a combination of two or more only withdecreasedtriglyceridelevels(β=-9.105,p=0.012)and pathogenic/likely pathogenic variants, and in 3 patients the increased HDL-C levels (β=1.317, p=0.037), but not with combinationwasofpathogenic/likelypathogenicandVUS. LDL-C levels. The rs157580 was marginally associated Oftheremaining10patients,in5(21%)patients,onlyVUS with increased LDL-C levels. We further found a sig- weredetected(3withtwoVUSand2withoneVUS)andin nificantly protective effect of LDL-C levels on cardiovas- 5 (21%) patients, we did not detect significant mutations. cular disease (OR=0.987, 95% CI=0.980-0.994), but not Overall, in 9 (47%) of the patients with detected variants, with triglycerides, HDL-C and CVD. The IV analysis more than one variant was found indicating multiple het- revealed an increasing risk of LDL-C levels on cardiovas- erozygosity. In conclusion, NGS has a potential to detect cular disease by using rs157580 and allele score as the IVs multiple heterozygosity in complex rare cardiovascular (rs157580: OR=1.028, 95% CI=1.018-1.038; allele score: diseases. OR=1.028, 95% CI=1.019-1.038). Triglyceride and HDL- S. Josifovska: None. R. Vazharova: None. L. Bala- C were also associated with cardiovascular disease. banski: None. M. Malinov: None. A. Kaneva: None. S. Conclusion: We identified the causal relationships Panov: None. M. Ganev: None. D. Toncheva: None. between dyslipidemia and cardiovascular disease by using APOE rs157580 and allele score as the instrumental vari-  P05
.29A ables. Grant No: MOST 106-2314-B-010-020-MY3 The causal relationship between dyslipidemia and E. Wan: None. T. Wu: None. W. Wu: None. S. Chen: cardiovascular disease using Mendelian randomization None.A.Yen:None.Y.Lee:None.C.Tse:None.T.Liu: None. H. Chen: None. M. Lin: None. E. Wan1, T. Wu2, W. Wu1, S. Chen3, A. Yen3, Y. Lee4, C. Tse5, T. Liu6, H. Chen7, M. Lin1  P05
.30B Common atrium,atrioventricularcanal defect/postaxial 1InstituteofPublicHealth,NationalYang-MingUniversity, polydactyly:amildclinicalsubtypeofEllis-vanCreveld Taipei,Taiwan,2DepartmentofPublicHealth,Chung-Shan syndrome caused by compound heterozygosity for loss Medical University, Taichung, Taiwan, 3School of Oral of function and hypomorphic EVC mutations Hygiene, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan, 4Department of Internal F. Piceci Sparascio1, M. C. Digilio2, A. Palencia- Medicine, National Taiwan University Hospital, Taipei, Campos3,4,I.Torrente1,V.Guida1,J.Rosati5,A.D'Anzi5, Taiwan, 5Bureau of Health and Welfare, Lienchiang S. Briuglia6, P. Versacci7, B. Dallapiccola8, V. Ruiz- County Government, Matsu, Taiwan, 6Lienchiang County Perez3,4, B. Marino7, A. De Luca1 Government, Matsu, Taiwan, 7Institute of Epidemiology and Preventative Medicine, College of Public Health, 1Molecular Genetics Unit, Ospedale Casa Sollievo della National Taiwan University, Taipei, Taiwan Sofferenza, IRCCS, San Giovanni Rotondo, Italy, 2Medical Genetics, Department of Pediatrics, Ospedale Pediatrico1316 Bambino Gesù, IRCCS, Rome, Italy, 3CIBER de  P05
.31C enfermedadesRaras(CIBERER),InsititutodeSaludCarlos Heritability and family-based GWAS analyses of the III,Madrid,Spain,4InstitutodeInvestigacionesBiomédicas circulating ceramide, endocannabinoid, and N-acyl de Madrid, Consejo Superior de Investigaciones ethanolamide lipidome Científicas-Universidad Autónoma de Madrid, Madrid, Spain, 5Cellular Reprogramming Unit, Ospedale Casa K. McGurk, A. Nicolaou, B. Keavney Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy, 6Department of Human Pathology of Adult and University of Manchester, Manchester, United Kingdom Childhood "Gaetano Barresi", Unit of Emergency Pediatrics, University of Messina, Messina, Italy, Introduction: Lipids of the endocannabinoid (EC), N-acyl 7Department of Pediatrics, Università Sapienza, Rome, ethanolamine (NAEA), and ceramide (CER) classes are Italy, 8Genetics and Rare Diseases Research Division, potential novel biomarkers of coronary artery disease and Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy type-2 diabetes. Major-gene effects have been discovered for certain lipid species, notably lipoprotein(a). We sought ClinicalexpressionofEllisvanCreveldsyndrome(EvCS) toestablishtheheritabilityofEC,NAEA,andCERspecies, is variable with a classic form associated with homo- and identify DNA variants influencing their concentrations zygous/compound heterozygous mutations in EVC and in plasma. EV C2
genes,andthemilderWeyersacrodentaldysostosis Materials and Methods: We undertook heritability linked to specific heterozygous mutations in the last (QTDT, GCTA) and GWAS analyses (FaST-LMM) of 11 coding exon of EV C2
. Additional transitional phenotypes ECs and NAEAs, and 37 CERs in 1,016 plasma samples have been described, including patients with prevalently from 196 British Caucasian families ascertained through a cardiac and limb involvement, presenting with atrioven- hypertensive proband, using targeted mass spectrometry tricular canal defect with common atrium (AVCD-CA) and Illumina 660W-Quad genotyping. and postaxial polydactyly. We report on the results of Results:NAEAsaremoreheritablethanwell-studiedEC molecular analysis of a family with vertical transmission anandamide(AEA) (h2AEA =32-35%;P<5.80x10-11).24- in father and daughter of AVCD-CA and postaxial 46% of the variation in potential biomarker CER is due to polydactyly. The father was compound heterozygous for genetic factors (P<1.00x10-7). GWAS identified associa- the known recessive p.Arg622* nonsense variant and the tions with eQTLs of proteins in their metabolism (e.g. novelp.Arg663PromissensechangeintheEVCgene.His FAAH; P DHEA <6.33x10-12, SPTL C3
; P N(24)S NAEA CER affected daughter was compound heterozygous for the (18) <8.99x10-19) and novel loci implicated in cancer risk same nonsense variant and the novel splice-site c.1316- and non-alcoholic fatty liver disease (e.g. FBXO28; P N CER 7A>Gvariant.Twoadditionalunaffectedsisterswerealso (24)S(19)ratio <1.95x10-8, SULT1 C4
; P N(24)S(19) CER examined.Onewasheterozygouscarrierofthep.Arg622* <8.99x10-19). Two-sample Mendelian randomisation sug- variant, while the other was compound heterozygous for gests that a variant in FAAH (rs324420) influencing the both the p.Arg663Pro change and the c.1316-7A>G level of plasma NAEAs (beta DHEA = 0.39; NAEA variant. mRNA sequencing in the affected daughter’s P<6.33x10-12) is causally associated with both obesity and fibroblast showed that c.1316-7A>G resulted in the in- drug addiction. frameinsertion of6nucleotidesbetweenEVC exon9 and Conclusions:Wedemonstrate forthefirsttimeestimates 10, and that the expression of the p.Arg622* correspond- of heritability for this extended array of bioactive lipids, ing allele was greatly decreased. Consistently, western identify GWAS-significant SNPs associating with their blotanalysisshowedaresidualamountofEVCproteinin levels in circulation, and implicate the lipid species studied the father's and daughter's fibroblasts. Present results here in cardiovascular disease, cancer, and drug addition. suggest that p.Arg663Pro and c.1316-7A>G are hypo- K.M. is supported by a MRC Doctoral Award (MR/ morphicEVCallelesthatactasgeneticmodifierstogether K501311/1) and Travel Grant from The Company of with a loss of function mutation to cause a milder clinical Biologists. subtype of EvCS characterized by AVCD-CA and K. McGurk: None. A. Nicolaou: None. B. postaxial polydactyly. Keavney: None. F. Piceci Sparascio: None. M.C. Digilio: None. A. Palencia-Campos: None. I. Torrente: None. V. Guida:  P05
.32D None. J. Rosati: None. A. D'Anzi: None. S. Briuglia: A new zebrafish model for in vivo optical mapping of None.P.Versacci:None.B.Dallapiccola:None.V.Ruiz- cardiac action potentials Perez: None. B. Marino: None. A. De Luca: None.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1317 D. Schepers1, E. Sieliwonczyk1, A. Schlaeppi2, Objective:Diagnostic yieldinaheterogeneous cohortof B. Vandendriessche1, E. Simons1, M. Alaerts1, patients with a suspicion of HCM D. Knapen3, J. Huisken2, B. Loeys1 Methods: A retrospective review of patients with a sus- pected clinical diagnosis of HCM referred for genetic test- 1Center of Medical Genetics, University of Antwerp and ing at Blueprint Genetics between 2013 and 2018 was Antwerp University Hospital, Antwerp, Belgium, undertaken. Variants classified as pathogenic (P) or likely 2Morgridge Institute for Research, Madison, WI, United pathogenic (LP) at the time of reporting were considered States, 3Zebrafishlab, Veterinary Physiology and diagnostic. Biochemistry, University of Antwerp, Antwerp, Belgium Results: Diagnostic yield was 26.2% (361/1,376). In total, 373 P/LP variants were identified including 363 var- Genetically encoded voltage indicators (GEVI) allow iants diagnostic for HCM whereas only 10 were diagnostic opticalmappingofvoltagechangesandofferanalternative for another type of cardiomyopathy based on clinical and method for measuring alterations in cell membrane genetic interpretation (DES, DSP, LMNA, TTN). Approxi- potentials. Initially driven by the neuroscience field, the mately 86% (n=320) of diagnostic variants (23.3% of all development of GEVIs has now found applications in the tests) involved genes encoding the sarcomere. Seventeen P cardiovascular sciences as well. Thanks to these GEVIs, it orLPvariants(4.6%ofvariantsand1.2%ofalltests)were has become possible to image cardiac voltage dynamics at inRASopathygenesandthirteenPorLPvariants(3.5%of the cellular level in vivo in translucent organisms such as 0.9% of all tests) were in metabolic/infiltrative disease zebrafish. Unfortunately, up to now, the fluorescent signal genes. In addition, three patients with non-diagnostic find- of the cardiac voltage sensors used in zebrafish has been ings for cardiomyopathy had P or LP variants in genes very dim. For this reason, we developed a new stable linked to a channelopathy (RYR2, SCN5A) or neurofi- transgenic zebrafish model, expressing Ace2N-mNeon, a bromatosis (NF1). next generation voltage sensor with brighter fluorescence, Conclusions: The diagnostic yield of genetic testing in a underthecontrolofthemyocardialspecificpromotermyl7. heterogeneouscohortofpatientswithasuspecteddiagnosis UsingSelectivePlanellluminationMicroscopy(SPIM),the of HCM analyzed is lower than what has been reported in conduction of individual action potentials in the heart of 3 well characterized patient cohorts. Importantly, 8% of all dpf zebrafish larvae can be visualized in vivo, allowing the diagnosticfindingswereinmetabolicandRASopathygenes measurements of action potential duration and conduction which have significant systemic medical management speed. Next, we will apply this new transgenic zebrafish implications. model to evaluate the pathogenicity of genetic variants of J. Koskenvuo: None. J. Hathaway: None. I. Saarinen: unknown significance identified in arrhythmia genes of None. J. Tallila: None. E.H. Seppälä: None. S. Tuupa- patients with inherited primary electrical diseases. nen: None. H. Turpeinen: None. T. Kangas-Kontio: D. Schepers: None. E. Sieliwonczyk: None. A. None.J.Schleit:None.J.Tommiska:None.E.Salminen: Schlaeppi: None. B. Vandendriessche: None. E. Simons: None. P. Salmenperä: None. J. Sistonen: None. M. None. M. Alaerts: None. D. Knapen: None. J. Huisken: Muona: None. M. Gentile: None. V. Kytölä: None. S. None. B. Loeys: None. Myllykangas: None. J. Paananen: None. T. Alastalo: None.  P05
.33A Diagnostic Yield of Genetic Testing in an Unselected  P05
.34B Cohort of 1,376 HCM Patients Psycho-social impact of predictive genetic testing in hereditary heart diseases (PREDICT Study) J. Koskenvuo, J. Hathaway, I. Saarinen, J. Tallila, E. H. Seppälä, S. Tuupanen, H. Turpeinen, T. Kangas- C. Bordet1, S. Brice2, C. Maupain1, E. Gandjbakhch1,3, Kontio, J. Schleit, J. Tommiska, E. Salminen, B. Isidor4, A. Palmyre5, A. Moerman6, A. Toutain7, P. Salmenperä, J. Sistonen, M. Muona, M. Gentile, S. Odent8, A. Brehin9, L. Olivier Faivre10, C. Rooryck V. Kytölä, S. Myllykangas, J. Paananen, T. Alastalo Thambo11, E. Schaefer12, K. Nguyen13, D. Dupin Deguine14, C. Rouzier15, P. Jouk16, M. Port Lys17, Blueprint Genetics, Helsinki, Finland I. Denjoy18, S. Staraci1, R. Mansouri1, M. Hebert1, A. Bekhechi1, I. Raji1, V. Fressart19, F. Ader19, Introduction: Genetic testing in Hypertrophic Cardiomyo- P.Richard19,S.TezenasduMontcel20,21,M.Gargiulo22,23, pathy (HCM) is recommended by published guidelines. P. Charron1,24 Genetic testing by NGS panels offers practical differential diagnostic solution.1318 1Referral Center for hereditary heart disease, Department psychological and socio-professional impact of predictive of Genetics, Pitié Salpêtrière University Hospital,, Paris, genetic testing in hereditary heart diseases. France, 2INSERM, Sorbonne Université, Institut Pierre Patients and Methods: This multicentric French study Louis d’Epidémiologie et de Santé Publique, F75013, involved 20 expert centers in hereditary heart diseases. We Paris, France, 3Sorbonne Universités, UPMC Université included 517 adult relatives (42.3±16.7 years, 60.6% Paris 6, AssistancePublique-Hôpitaux de Paris, Hôpital females) who performed predictive genetic testing (pro- Pitié-Salpêtrière, ICAN, Département de Cardiologie,, spective study: N=264, retrospective study: N=253). The Parsi, France, 4Department of Genetics, Nantes University opinion and experience were collected via auto-ques- Hospital,, Nantes, France, 5Department of Genetics, tionnaires, at various moments in the prospective study, Ambroise Paré University Hospital,, Paris, France, with different items and validated scales (STAI and IES). 6Department of Genetics, Lille University Hospital, Jeanne Results: In the prospective study, the main motivations de Flandre Hospital,, Lille, France, 7Department of for performing the test were: “to remove doubt” (65.3%), Medical Genetics, Tours University Hospital, Tours, “for children” (64.0%), “to benefit from medical super- France, 8Department of Medical Genetics, Rennes vision” (34.9%). A mutation was present in 39.4% of University Hospital, Rennes, France, 9Department of relatives. No regret was expressed after testing (only 2.3% Genetics, Normandy Centre for Genomic and Personalized regrets). The result did not lead to a socio-professional Medicine, Rouen University Hospital, Rouen, France, change or family relationship change in 60.7%. Among 10Medical Genetics Unit, Dijon University Hospital, Dijon, thosewhohadachange,itwasperceivedasunfavorablefor France, 11Department of Medical Genetics, Bordeaux only3%.Thelevelofanxiety(STAIscale)increasesbefore University Hospital, Bordeaux, France, 12Department of the test result and decreased to return to baseline. Subjects Genetics, Strasbourg University Hospital, Hautepierre withdepressionhistoryweremorelikelytodevelopanxiety Hospital, Strasbourg, France, 13Department of Medical at long term (p=0.004). Genetics, APHM, GMGF, Timone Hospital, Aix Marseille Conclusions: Our results show no or marginal adverse University,, Marseille, France, 14Department of Medical psychological and socio-professional impact of genetic Genetics, Toulouse University Hospital, Toulouse, France, testing when performed by a team expert in predictive 15Department of Medical Genetics, Université Côte d'Azur, testing. CHU, Inserm, CNRS, IRCAN, Nice, France, 16Department C.Bordet:None.S.Brice:None.C.Maupain:None.E. of Medical Genetics, Centre Hospitalo-Universitaire Gandjbakhch:None.B.Isidor:None.A.Palmyre:None. Grenoble Alpes, Grenoble, France, 17Clinical Genetics A. Moerman: None. A. Toutain: None. S. Odent: None. Unit, University Hospital, Pointe-à-Pitre University A. Brehin: None. L. Olivier Faivre: None. C. Rooryck Hospital, Guadalupe Island,, Pointe à Pitre Guadeloupe, Thambo:None.E.Schaefer:None.K.Nguyen:None.D. France, 18Department of cardiology, Referral Center for DupinDeguine:None.C.Rouzier:None.P.Jouk:None. hereditary heart disease, Bichat Hospital, Paris, France, M.PortLys:None.I.Denjoy:None.S.Staraci:None.R. 19UF cardiogenetics, Pitié Salpêtrière University Hospital, Mansouri:None.M.Hebert:None.A.Bekhechi:None.I. Paris, France, 20Sorbonne Université, INSERM, Institut Raji: None. V. Fressart: None. F. Ader: None. P. PierreLouisd’EpidémiologieetdeSantéPublique,AP-HP, Richard: None. S. Tezenas du Montcel: None. M. Gar- Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, giulo: None. P. Charron: None. Département de Santé Publique, F75013,, Paris, France, 21INSERM UMR-1136, Paris, France, 22Institut of  P05
.35C Myologie, Pitié Salpêtrière University Hospital,, Paris, Development of a fast and cost effective genetic France, 23Sorbonne Université, INSERM, Institut Pierre diagnostic method for familial hypercholesterolemia in Louis de Santé Publique, Medical Information Unit, Pitié Sweden SalpêtrièreUniversityHospital,,Paris,France,24Sorbonne Université, INSERM, UMR_S 1166 and ICAN Institute for K. Duvefelt1, E. Hagström2, E. Bachus3, V. Hamrefors3, Cardiometabolism and Nutrition,, Paris, France M. Rehnberg4, S. Romeo5, M. Linde1, P. Kiviluoma1, B. Angelin1, P. Benedek1, J. Kere1, M. Eriksson1 Introduction: Hereditary heart diseases are most often characterized by autosomal dominant inheritance and 1Karolinska University hospital, Stockholm, Sweden, delayed cardiac expression. Predictive genetic testing is 2Uppsala University, Uppsala, Sweden, 3Skånes University offeredtoasymptomaticrelatives to allow targetedmedical hospital, Malmö, Sweden, 4Linköping University, care with early therapeutics in order to reduce the risk of Linköping, Sweden, 5Gothenburg University, Gothenburg, complications. The aim of this study was to evaluate the SwedenAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1319 Familial hypercholesterolemia (FH) is an autosomal cardiomyopathy (MIM616117). No TNNI3K mutations dominant disease causing elevated levels of low-density have been found to cause hypertrophic cardiomyopathy in lipoprotein cholesterol, carrying a high risk of premature (HCM: MIM192600). We performed a 178 gene-panel coronary heart disease such as myocardial infarction. The enrichedand next-generationsequencingin8 Thaifamilies prevalence of FH is approximately 1/250. There is an withHCM.8pathogenic(P)/likelypathogenic(LP)variants obviousneedforimprovingearlydetectionandtreatmentof were found in 7 families (MHY7(4), TPM1(2),TNNI2(1), FH, which is currently an underdiagnosed condition. TTR(1)). One family harbored two variants in MYH7 and We aimed to characterize the disease-causing mutation TPM1. The remaining family without identified P/LP spectrum in Sweden, and to develop a cost-effective diag- variants was sent for whole-exome sequencing. We nostics.Thiswasdonethroughiterativeimprovementofthe identified a rare spliced TNNI3K (c.1178-2A>G) variant analytical strategy, consisting of (i) targeted mutation ana- in the 41-year-old male with severe eccentric HCM who lysis using a panel based on Agena mass spectrometry- presented with syncope from ventricular arrhythmia. His based genotyping; (ii) sequencing of samples failing to asymptomatic 60-year-old father with apical HCM also show mutations; and (iii) redesign of the panel to include harboredthisvariant.The variantwas observedonceinthe new, recurrently found mutations. ExAC database and once in our in-house Thai-exome To date, we have included 1,143 patients from 14 hos- database (>2,000 cases). RNA analysis revealed an altered pitals across Sweden in a nationwide collaboration using a splicing mRNA predicted to create a protein with only N- panel of 113 pathogenic/likely pathogenic mutations in the terminal Ankyrin repeats without the kinase and the C- LDLR, PCSK9 and APOB genes. terminal serine-rich domain. Since the C-terminal serine Dutch Lipid Clinical Network (DLCN) score was avail- richdomainisaninhibitorydomain,theidentifiedmutation able for 482 patients in whom mutations were detected in may represent a gain-of-function variant by diminishing 27%. If restricted to patients with probable or definite FH inhibitory signal of the kinase domain. A previous study (score ≥6; n=309) pathogenic mutations were detected in expressing wild-type human TNNI3K in transgenic-mice 35%. The two most prevalent mutations were found that the mice had cardiac hypertrophy. TNNI3K NM_000384.2(APOB):c.10580G>A(p.Arg3527Gln) and inhibitor which has undergone preclinical testing can serve NM_000527.4(LDLR):c.259T>G(p.Trp87Gly). In total, 38 as a potential therapy for patients with HCM. In summary, different mutations were detected by the panel. 142 panel we report a family with a probably gain-of-function negativesamplesweresequencedwiththeSEQPPRO-LIPO mutation in TNNI3K, suggesting that TNNI3K is a new method, yielding 15 additional mutations in 16 patients. disease gene for HCM. In conclusion, our FH-panel detected mutations in P. Phowthongkum: None. S. Tongkobpetch: None. K. approximately one fourth of Swedish patients with sus- Suphapeetiporn: None. V. Shotelersuk: None. pected FH. The number was increased if analyses were restricted to patients with high DLCN score.  P05
.37A Vinnova 2016-02972 Circulating miRNAs profiling in diabetic patients with K. Duvefelt: None. E. Hagström: None. E. Bachus: ischemic heart disease None. V. Hamrefors: None. M. Rehnberg: None. S. Romeo: None. M. Linde: None. P. Kiviluoma: None. B. A. Bielska1, M. Niemira1, A. Szalkowska1, Angelin: None. P. Benedek: None. J. Kere: None. M. J. Raczkowska1, D. Ostrowski1, W. Bauer1, Eriksson: None. P. Prokopczuk2, S. Dobrzycki2, A. Kretowski1,3  P05
.36D 1ClinicalResearchCentre,MedicalUniversityofBialystok, A novel candidate gene of familial hypertrophic Białystok, Poland, 2Department of Invasive Cardiology, cardiomyopathy with therapeutic potential Medical University of Bialystok, Białystok, Poland, 3Department of Endocrinology, Diabetology and Internal P. Phowthongkum, S. Tongkobpetch, K. Suphapeetiporn, Medicine, Medical University of Bialystok, Bialystok, V. Shotelersuk Poland Faculty of Medicine, Bangkok, Thailand Introduction: Due to a global increase of morbidity and mortality with ischemic heart disease (IHD) in type 2 TNNI3K encodes cardiac troponin I-interacting kinase diabeticpatients,thereisanurgentneedtoidentifyofearly (TNNI3K), forming homo-dimers or homo-oligomers and biomarkers, which would help to predict an individual risk involving in the cardiac contractility regulation. Loss-of- of development of IHD. MiRNAs are small noncoding function mutations in TNNI3K can lead to dilated RNAs which regulate gene expression and the last few1320 years appear as a key tool for understanding the Patients and Methods: The study included 81 patients pathophysiologyofIHD.Here,wepostulatethatcirculating with chroniccerebralischemia(withoutahistoryofstroke) serum-derived miRNA may serve as potential biomarkers and 69 patients with ischemic stroke (IS). Genotyping was for early IHD diagnosis and help to identify diabetic performed using microarray to determine 21 SNPs in the individuals with a predisposition to develop ischemic heart АСЕ, SERPIN E1
, FGB, F5, F7, F12, G P1
BA, GPIIIa, disease. MTHFR,CY P11
B2,PON1,PON2,NO S2
,NO S3
,PD E4
D, Materials and Methods: We obtained serum samples HIFla, LTA, ALOX5AP genes. Stroke subtypes were from 39 T2DM patients (22 with IHD and 17 free of defined according to TOAST criteria. complications). The levels of 798 miRNAs were analysed Results: In patients with chronic cerebral ischemia, the using NanoString nCounter Technology Platform. The TT genotype of the PD E4
D (rs966221, SN P83
C>T) was miRNA regulatory network analysis was performed using associated with rapidly progressive arterial hypertension the Ingenuity Pathway Analysis software. (OR=6.22; 95%CI=1.9-20.8; p=0.0036). In patients with Results: Our data showed that 28 miRNAs (including IS the D allele of the ACE gene (rs1799752, I>D) and the miR-615-3p, miR-1303, miRR-122-5p, miR-217) were DD genotype were associated with cardioembolic subtype significantly upregulated and 1 miRNA (miR-451a) was of stroke (OR=2.67, 95%CI=1.23-5.8, p=0.02 and downregulated in T2DM IHD patients compared to T2DM OR=7.14,95%CI=1.7-29.7,p=0.0057).InpatientswithIS patientswithoutIHD(adjp<0.05).Basedontheaboveall the C allele of the G P1
BA gene (rs2243093, -5T>C) and miRNAs were classified into four interactive signalling TC genotype were associated with large-artery athero- networks. Targeted genes by the identified miRNAs were sclerosis subtype of stroke (brachiocephalic artery stenosis enriched in pathways associated with metabolic and cardi- >75% and large-artery occlusion) (OR=3.39, 95%CI=1.1- ovascular diseases, cardiac dysfunction and cardiovascular 10.2, p=0.03 and OR=4.44, 95% CI=1.3-15.5, p=0.023). system development. Conclusions: Detailed genetic analysis in the context of Conclusions: Taken together, our findings suggest that clinical features of cerebrovascular disease will allow the circulating miRNAs might have a crucial role in the identification of significant associations. developmentofIHDindiabeticpatientsandmaybeusedas A.Ikonnikova:None.A.Gunchenko:None.S.Galkin: a potential for early diagnosis. None. A. Anisimova: None. T. Nasedkina: None. A. Bielska: None. M. Niemira: None. A. Szalkowska: None. J. Raczkowska: None. D. Ostrowski: None. W.  P05
.39C Bauer:None.P.Prokopczuk:None.S.Dobrzycki:None. ApolipoproteinEe4associatestoageofischemic stroke A. Kretowski: None. onset but not to stroke outcome  P05
.38B C. Lagging1,2, E. Lorentzen3, A. Pedersen1,2, Association of polymorphisms in PD E4
D, ACE and T. M. Stanne1, M. Söderholm4,5, J. M. Maguire6,7, G P1
BA genes with clinical characteristics in patients A. Lindgren4,5, C. Jern1,2 with ischemic stroke and chronic cerebral ischemia 1Department of Laboratory Medicine, Institute of A. Ikonnikova1, A. Gunchenko2, S. Galkin2, Biomedicine, the Sahlgrenska Academy, University of A. Anisimova2, T. Nasedkina1 Gothenburg,Gothenburg,Sweden,2DepartmentofClinical Genetics and Genomics, Sahlgrenska University Hospital, 1Engelhardt Institute of Molecular Biology RAS, Moscow, Gothenburg, Sweden, 3Bioinformatics Core Facility, Russian Federation, 2N.I. Pirogov Russian National University of Gothenburg, Gothenburg, Sweden, Research Medical University, Ministry of Health of the 4Department of Clinical Sciences Lund, Neurology, Lund Russian Federation, Moscow, Russian Federation University, Lund, Sweden, 5Department of Neurology and Rehabilitation Medicine, Skåne University Hospital, Lund, Introduction:Alargedatahasbeenaccumulatedaboutthe Sweden, 6Faculty of Health, University of Technology role of genetic factors in the development of cerebrovas- Sydney, Sydney, Australia, 7Hunter Medical Research cular diseases, but the identified associations are often not Centre, Newcastle, Australia reproducible in replication studies and meta-analyses. This may be due to the multifactorial nature of this group of Introduction: APOE genotype is a candidate predictor for diseases, the heterogeneity of pathogenic mechanisms, and stroke outcomes. We evaluated whether common APOE theethnicityofpatients.Theworkwasaimedtoinvestigate allelesassociatewithischemicstrokeoutcome,severityand the association of genetic polymorphisms with patient’s age at onset, within the large multicenter Genetics of characteristics in well-defined clinical groups. Ischaemic Stroke Functional Outcome (GISCOME) study.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1321 Methods: This study comprises 6,165 ischemic stroke Enfermedades Raras (CIBERE, Madrid, Spain, cases with genotype data from SNP arrays. Baseline stroke 3Department of Internal Medicine, Hospital Clínico San severity was scored according to the NIH Stroke Scale Carlos, Madrid, Spain., Madrid, Spain, 4Hospital (NIHSS). Functional outcome at 3 months was scored UniversitarioFundacionAlcorcon,Madrid,Spain,Madrid, accordingtothemodifiedRankinScale(mRS).Wederived Spain, 5Unidad de Genética del Hospital Universitario de common APOE allele status (ε2,ε3,ε4) by combining Getafe, (Madrid), Spain, Madrid, Spain, 6Department of information from SNPs rs7412 and rs429358. Effects of Internal Medicine, Hospital Carlos III, Madrid, Spain, minor allele count (ε4,ε2) on age at stroke, stroke severity Madrid, Spain, 7Department of Genetics, Hospital de La andoutcomewereestimatedseparatelyincomparisontothe Princesa, Madrid, Spain, Madrid, Spain, 8Lipid and most common ε3/ε3 genotype. VascularUnit,HospitalCarlosIII,Madrid,Spain,Madrid, Results:Wefoundnoevidenceofadirecteffectofε4on Spain outcome. There was, however, an inverse association between ε4 allele count and age at stroke (β-1.8, Introduction: About 70% of human plasma cholesterol P=0.00017).Thisassociationwassignificantinbothsexes. circulates as a component of low-density-lipoproteins The ε2 allele was independently associated with poor (LDL). Most LDL is cleared from the circulation through functional outcome (mRS>2) in men (odds ratio[OR]1.47, the hepatic LDL-receptor(1). Reduction in activity or P=0.008), but not in women (OR 0.87, P=0.44). number of LDLR gives rise to Familial hypercholester- Conclusion: This is the largest meta-analysis on APOE olemia(FH;MIM#143890).Earlydetectionofpatientswith genotype and ischemic stroke outcome to our knowledge. FH allows initiation of treatment, thus reducing the risk of We found a lower age at stroke onset in ε4 carriers and a coronary heart disease. In this study we performed in vitro worse functional outcome in male ε2 carriers. Even larger characterization of new LDLR variants found in FH studies are warranted to further investigate the effects of patients. APOE alleles on ischemic stroke outcome in different age MaterialsandMethods:DNAsamplesfromFHpatients and sex strata. wereanalyzedbyNextGenerationSequencing(NGS)using Studyfunding:TheSwedishResearchCouncil,Swedish a customized panel of 198 genes. The LDLR missense Heart and Lung Foundation, Swedish State; ALF- variants were generate into the expression vector agreement. LDLR_NM_000527-Human-cDNA-GFPSpark®-tagbysite- C. Lagging: None. E. Lorentzen: None. A. Pedersen: directed-mutagenesisandtransfectedinLDLR-deficientcell None. T.M. Stanne: None. M. Söderholm: None. J.M. line CHO-ldlA7(2,3). Activity and expression of cell surface Maguire: None. A. Lindgren: D. Speakers Bureau/Hon- LDLRweremeasuredbyflowcytometry.LDLRexpression oraria (speakers bureau, symposia, and expert witness); was detected by Western Blot and immunofluorescence. In Modest;Bayer,BMSPfizer.F.Consultant/AdvisoryBoard; order to characterize the LDLR intronic variant, the RNA Modest; Bayer, Astra Zeneca, Boehringer Ingelheim, BMS extractedfrompatient´speripheral-blood-mononuclear-cells Pfizer, Reneuron. C. Jern: None. was analyzed by RT-PCR followed by Long-Range-PCR. All transcripts were validated by Sanger sequencing.  P05
.40D Results: Seven new variants at LDLR were character- Functional characterization of new missense and ized. The missense variants c.776A>G;p.(Tyr259Cys), intronic variants in LDLR c.851G>A;p.(Cys284Tyr), c.1072T>G;p.(Cys358Gly) showed significant differences in activity and expression C. Rodríguez-Jiménez1, N. Agra2, L. Reinares-garcía3, of LDLR regarding to the wildtype(WT). The variants C. Guijarro4, A. Carazo-Álvarez1, B. Gil Fournier5, c.2279C>T;p.(Thr760Ile) and c.2579C>A;p.(Ala860Glu) F. García-Iglesias6, C. Alonso-Cerezo7, J. Mostaza8, did not showed any differences. The intronic variant S. Rodríguez-Nóvoa1 c.2389+4A>G revealed impact on splicing of LDLR resulting as pathogenic. 1DepartmentofGeneticsofmetabolicsdiseases.Instituteof Conclusions: The functional in vitro characterization of Medical & Molecular Genetics (INGEMM), Hospital rare variants at the LDLR allow us to confirm the genetic Universitario La Paz, Universidad Autónoma de Madrid, diagnosis of FH, avoiding the classification as “uncertain IdiPAZ,Madrid,Spain;CentrodeInvestigaciónBiomédica significant variants”, and therefore, to allow for cascade en Red de Enfermedades Raras (CIBERE, Madrid, Spain, family screening. 2Vascular Malformations Section. Institute of Medical & C. Rodríguez-Jiménez: None. N. Agra: None. L. Molecular Genetics (INGEMM), Hospital Universitario La Reinares-garcía: None. C. Guijarro: None. A. Carazo- Paz, Universidad Autónoma de Madrid, IdiPAZ, Madrid, Álvarez: None. B. Gil Fournier: None. F. García- Spain; Centro de Investigación Biomédica en Red de1322 Iglesias: None. C. Alonso-Cerezo: None. J. Mostaza: M. Polyak1, A. A. Bukaeva1, A. G. Shestak1, None. S. Rodríguez-Nóvoa: None. O. V. Blagova2, L. B. Mitrofanova3, E. A. Mershina4, Y. V. Frolova1, S. L. Dzemeshkevich1,  P05
.41A E. V. Zaklyazminskaya1,5 Divergent degradation pathways for corresponding LDLR and VLDLR disease-causing mutants 1Petrovsky Russian Research Center of Surgery, Moscow, RussianFederation,2SechenovFirstMoscowStateMedical P. Kizhakkedath, A. John, L. Al-Gazali, B. R. Ali University,Moscow,RussianFederation,3FederalAlmazov North-West Medical Research Centre, Saint Petersburg, United Arab Emirates University, Al-Ain, United Arab Russian Federation, 4Medical Scientific and Educational Emirates Center of Lomonosov Moscow State University, Moscow, Russian Federation, 5Pirogov Russian National Research Introduction: Misfolded proteins in the early secretory Medical University, Moscow, Russian Federation pathway are mainly degraded by the ubiquitin-proteasome systems known as ER associated degradation (ERAD) Introduction:Leftventricularnoncompaction(LVNC)isa whichhasbeenimplicatedinthepathogenesisofnumerous cardiomyopathywithcausativegeneticvariantsidentifiedin congenital disorders. Therefore, ERAD has been a promis- more than 20 genes. It's often accompanied by other types ing target for therapy of such diseases. In this study we of myocardium remodeling. Several guidelines recommend compare and contrast the degradation behavior of equiva- DNA-diagnostics for LVNC patients but strategy remains lent disease-causing mutations in LDLR and VLDLR, two unclear. The aim of our study is to evaluate efficiency of LDLR family receptors. DNA-diagnostic in LVNC patients using gene panel (13 Materials and Methods: HRD1-SE L1
L knockout (KO) candidate genes). HEK293 cell lines have been generated using CRISPR/ Materials and Methods: We observed 67 probands Cas9. The missense mutants were generated by Quik- diagnosed with LVNC. Deep phenotyping was performed Change site-directed mutagenesis. The expressed proteins including evaluation of cardiac remodeling (dilatation, were analyzed biochemically and by microscopy. hypertrophy or isolated noncompaction). Genetic screening Results: We found that the disequilibrium syndrome- by NGS (Ion Torrent) sequencing of 13 genes was per- causingVLDLRmissensemutants(p.D487Y,p.D521Hand formed for all patients. Sanger sequencing of additional p. C706
F)areretainedintheERwhereasonlyp.D482Hand genesandwholeexomesequencing(WES)wereperformed p. C667
F of the LDLR corresponding mutants are retained. if needed. Pathogenecity of genetic variants was analyzed Two of the ER-retained VLDLR mutants were found to be according to ACMG Recommendations (2015). Results. aggregation-prone leading to ER stress as measured by Overall 33 genetic variants in 30 probands (45% of cases) spliced-XBP mRNA levels. However, there was no differ- were ascribed to III-V classes of pathogenicity: 12 variants ences betweenLDLR wild type andmutants with regard to were classifiedas likely pathogenic/pathogenic, and 21-as their aggregation status or ER stress. Treatment with inhi- variants of unknown significance. Efficiency of DNA bitors of autophagy seemed to stabilize the degradation of diagnostic was 22.4% in whole cohort but it varied sig- wild type receptors. In addition, p. C706
F VLDLR mutant nificantly depending on cardiac remodeling. The highest stabilized during early phase of both proteasomal and rate of V-IV class variants was found in “LVNC+cardiac autophagy inhibition. Cycloheximide chase analysis in hypertrophy” subgroup (53%). In subgroup “LVNC+car- SE L1
L-KO cells revealed that the HRD1-SE L1
L complex diac dilation” variants of V-IV class were detected in 14% could be involved in the clearance of ER-retained VLDLR of probands. We detected no mutations in isolated mutants. LVNC cases. Conclusions:ThedownstreamdegradationandERstress Conclusion: Phenotype-driven strategy might be useful induction behavior of ER-retained corresponding LDLR for decision-making in LVNC patients. Screening of 13 and VLDLR mutants are divergent suggesting different genes might be cost-effective in “LVNC+cardiac hyper- clearance mechanisms despite their structural similarities. trophy” subgroup. In patients with isolated LVNC/LVNC P. Kizhakkedath: None. A. John: None. L. Al-Gazali: and dilatation WES might be preferred. This work was None. B.R. Ali: None. supported by RSF grant № 16-15-10421 M. Polyak: None. A.A. Bukaeva: None. A.G. Shestak:  P05
.42B None. O.V. Blagova: None. L.B. Mitrofanova: None. E. Phenotype-driven strategy of DNA diagnostics in A. Mershina: None. Y.V. Frolova: None. S.L. Dze- patients with LVNC and different types of myocardium meshkevich: None. E.V. Zaklyazminskaya: None. remodelingAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1323  P05
.43C Andršová: None. A. Floriánová: None. P. Vít: None. R. Molecular analysis confirmed common ancestor of 10 Navrátil: None. CzechfamilieswithlongQTsyndromecarrying C926
T- KCNQ1 variant  P05
.44D Novel LOX mutations in five probands with thoracic I. Synková1,2, I. Valášková1,2, R. Gaillyová1,2, aortic/arterial aneurysm and dissection with variable T. Novotný3,2, M. Bébarová4, I. Andršová3,2, connective tissue findings A. Floriánová3, P. Vít5,2, R. Navrátil6 M. Perik1, I. Van Gucht1, A. Krebsova2, B. Diness3, 1Department of Medical Genetics, University Hospital, R. Zhurayev4, D. Adlam5, M. Kempers6, I. Luyckx7, Brno, Czech Republic, 2Faculty of Medicine, Masaryk N. Peeters1, L. Van Laer1, A. Verstraeten1, B. Loeys1,6 University, Brno, Czech Republic, 3Department of Internal MedicineandCardiology,UniversityHospital,Brno,Czech 1Center of Medical Genetics, Faculty of Medicine and Republic, 4Department of Physiology, Faculty of Medicine, HealthSciences,UniversityofAntwerp,AntwerpUniversity MasarykUniversity,Brno,CzechRepublic,5Departmentof Hospital, Antwerp, Belgium, 2Department of Cardiology, Pediatrics, University Hospital, Brno, Czech Republic, IKEM, Prague, Czech Republic, 3Department of Clinical 6Repromeda, Biology Park, Brno, Czech Republic Genetics, Copenhagen University Hospital, Copenhagen, Denmark, 4Department of Clinical Pathology, Lviv Introduction: Long QT syndrome (LQTS) is a hereditary National Medical University after Danylo Halytsky, Lviv, arrhythmic syndrome characterized by abnormal prolonga- Ukraine, 5Acute and interventional Cardiology, University tion of QT interval, increased risk of ventricular arrhyth- of Leicester, Leicester, United Kingdom, 6Department of mias, and sudden death. It is the most often diagnosed Human Genetics, Radboud University Medical Center, hereditaryarrhythmicdisorderwithprevalence1:2000.The Nijmegen, Netherlands, 7Center of Medical Genetics, KCNQ1geneisoneofthe3majorgenes(KCNQ1,KCNH2 Faculty of Medicine and Health Sciences, University of and SCN5A) which account for 75 % of the genetically Antwerp, Anwerp University Hospital, Antwerp, Belgium identified LQTS cases. The same KCNQ1 mutation c.926C>T (p.T309I) was identified in 10 putatively Loss-of-function variants in LOX, encoding lysyl oxidase, unrelated families. werereportedtocausefamilialthoracicaorticaneurysmand Materials and Methods: 11 highly polymorphic short dissection (TAAD). Using gene panel and exome sequen- tandem repeats (STR) markers were chosen for haplotype cing, we identified five additional probands carrying likely analysis in 10 families. Multiplex PCR and fragment ana- pathogenicLOXvariants,includingthreemissensevariants, lysis were performed to identify variant linked to the affecting highly conserved amino acids and absent from mutation across families. Single nucleotide polymorphism gnomAD. The two stopcodons, (c.(351delC)) and p. (SNP) analysis was performed with HumanKaryomap-12 (Gly149*), were identified in males with type A dissection DNA Analysis Kit (Illumina) in one member of each at19and51yearswithoutfamilyhistory.Thefirstproband family. 6219 SNPs on p arm of chromosome 11 were also suffered from splenic rupture, pneumothorax and analysed. varicose veins whereas the second presented with flat feet Results:Thesamehaplotypewasidentifiedinthenearest and inguinal hernia surgery. A p.(Thr99Ala) missense regionofthemutationspotineveryfamilybySTRanalysis variant was found in a Marfan syndrome-like male with and then confirmed by SNP analysis, which also identified TAA. The second missense variant, p.(Met298Arg), was possible crossing-overs. The maximum size of the area discoveredin46yearoldfemalepresentingwithleftcarotid shared by all families is 658407 bp and contains the whole and prior coronary artery dissection. Interestingly, the sequence of KCNQ1 gene. The maximum size of the area identicalLOXvariantpreviouslysegregatedinfiveaffected shared by two families is 12633501 bp. members of a TAAD family. The woman presented skin Conclusion: Allelic frequencies of identified alleles in hyperelasticity with recurrent shoulder dislocations. Her STRmarkersincontrolpopulationsuggestthatthereisonly motherisknownwithberryaneurysm,butnotavailablefor onecommonancestorwithmutationc.926C>Tinthegroup genetic testing. The last missense variant, p.(Leu306Pro), of families investigated in this study. was found in a tall male with dilatation of the aorta sinus SupportedbygrantoftheMinistryofhealthoftheCzech and ascendens with elective surgery at age 15. Family Republic: NV16-30571A. history issignificant for aorticdissectionatpaternalside of I. Synková: None. I. Valášková: None. R. Gaillyová: the family. Segregation studies revealed the absence of p. None. T. Novotný: None. M. Bébarová: None. I. (Leu306Pro) in unaffected mother. The latter two missense variants are both located within the LOX catalytic domain.1324 Our data demonstrate that loss-of-function LOX variants anomaly with autosomal dominant inheritance and variable cause a wide spectrum of aortic and arterial aneurysmal penetrance. disease (including coronary artery dissection), combined NGS target resequencing represents a valuable tool in with connective tissue findings. cardiomyopathy genetic testing. M. Perik: None. I. Van Gucht: None. A. Krebsova: I. Loddo: None. F. Barbera: None. G. Di Gesaro: None. B. Diness: None. R. Zhurayev: None. D. Adlam: None. D. Bellavia: None. E. La Franca: None. G. None. M. Kempers: None. I. Luyckx: None. N. Peeters: Mamone: None. G. Gentile: None. F. Clemenza: None. None. L. Van Laer: None. A. Verstraeten: None. B. D. Di Carlo: None. Loeys: None.  P05
.47C  P05
.46B Genetic screening of cardiovascular genes in a heart Left ventricular non-compaction and Ebstein anomaly transplantation cohort inapatientwithavariantinthesarcomeregeneMYH7 E. Cuesta-Llavona1, J. Gómez1, B. Díaz-Molina1, I. Loddo, F. Barbera, G. Di Gesaro, D. Bellavia, E. La J.Lambert1,B.Alonso1,R. Lorca2,J.Reguero1,E.Coto1 Franca, G. Mamone, G. Gentile, F. Clemenza, D. Di Carlo 1HospitalUniversitarioCentraldeAsturias,Oviedo,Spain, 2Hospital General Universitario Gregorio Marañón, IRCCS Mediterranean Institute for Transplantation and Madrid, Spain Advanced Specialized Therapies (ISMETT), Palermo, Italy Heart failure is considered one of the main causes of death Introduction: Left ventricular non-compaction (LVNC) is in developed countries. Moreover, it is a disease that is a rare hereditary cardiomyopathy, resulting from abnormal influenced by multiple genetic risk factors and the only embryonic myocardial development. effective treatment when there are no medical or surgical ThemostprevalentCongenitalHeartDiseaseinLVNCis alternativeswouldbehearttransplant.Theaimofthisstudy Ebsteinanomaly(EA),characterizedbyapicaldisplacement istogeneticallycharacterizedpatientswhoseundergoheart and partial fusion of the septal and posterior leaflet of the transplantation.Wesequenced65transplantedpatientsfora tricuspid valve with the ventricular septum. comprehensive cardiovascular gene panel of 209 genes, MaterialsandMethods:Wepresentthecaseof46years using Ion semiconductor chips technology in a Ion old male affected by EA and LVNC. GeneStudio  S5
 Sequencer. We identified 29 patients with MR imaging shows an Ebstein anomaly, in which the rare variants (either not described or gnomAD frequency ≤ origin of the septal leaflet is displaced downward into the 0.0001). Twenty-two of them were single carriers (75.9%), right ventricle, dividing it into a proximal atrialized and six harbor two variants (20.6%), and in one case we distal ventricularized (true or functional ventricle) cham- identified three variants (3.5%). Regarding to its patho- bers.Thesefeatures,inadditiontoannulardilatation,result genicity, eight patients were carriers of at least a variant in valve regurgitation and right chambers dilatation. MR classifiedaspathogenicbyClinVardatabase,sixasvariants imaging shows the coexistence of left ventricle hyper- of unknown significance, and the others have no classifica- trabeculation with spongy appearance of the myocardium tion.Thereasonfortransplantationofthesecarrierswasdue consistent with left ventricular non-compaction. to ischemic heart disease in 48% of cases, 29% to dilated Genetic counselling was offered. He reported that his cardiomyopathy,4%valvular,4%hypertrophicand15%to nephewwasaffectedbyEAandshediedatthreemonthsof another type of heart disease. In conclusion, we have age.MolecularanalysisbyNGStargetpanelwasperformed identified a significant percentage of new or rare genetic to our patient. variants in genes that would be associated with heart Results: We identified a heterozygous missense variant diseasesinahearttransplantedcohort.Therefore,detection (c.728G>A) p.Arg243His in MYH7 gene, classified as of these variants might be helpful to achieve an early pathogenic according to ACMG Guidelines. diagnosis of these diseases. Further co-segregation and Thisvariantwasoriginallyreportedinanindividualwith functional studies have to be performed in order to hypertrophic cardiomyopathy, has subsequently been accomplish an accurate variant classification. reported in multiple individuals with LVNC and in an E. Cuesta-Llavona: None. J. Gómez: None. B. Díaz- individual with isolated EA. Molina: None. J. Lambert: None. B. Alonso: None. R. Conclusions: The association between EA, LVNC and Lorca: None. J. Reguero: None. E. Coto: None. mutationsinMYH7,seemstorepresentasubtypeofEbsteinAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1325  P05
.48D Biomédica en Red de enfermedades Raras (CIBERER), Analysis of endothelin-1 (EDN-1) UTR regions Madrid, Spain, 6Hospital 12 de Octubre, Madrid, Spain, 7Fundación Jiménez Díaz, Madrid, Spain, 8Centro de C.Solarat1,M.Lago-Docampo1,A.Baloira2,D.Valverde1 Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain, 9Centro de 1University of Vigo, Vigo, Spain, 2Servicio de Neumología, Investigación Biomédica en Red de Enfermedades Complexo Hospitalario Universitario de Pontevedra, Vigo, Cardiovasculares (CIBERCV), Madrid, Spain, Madrid, Spain Spain, 10Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain Pulmonary Arterial Hypertension (PAH) is a disease characterized by an increase of secretion and deregulation Introduction:PulmonaryArterialHypertension(PAH)isa of Endothelin-1 (ET-1). This peptide is secreted by the rare and fatal disease consisting in the obliteration of the endothelium of blood vessels and promotes vasoconstric- pulmonary precapillary arteries, leading to right heart tion.WecarriedoutthecharacterizationoftheUTRregions failure and death. of endothelin-1gene (EDN-1), in order to determine Methods: We used targeted panel sequencing with a common variations that may modulate disease outcome. custom panel (HAP v1.2) including 21 genes in 318 PAH The analysis was carried out in 60 patients with different patientsfromtheSpanishregistry(REHAP).Afterdetecting classes of PAH, testing a fragment of 2 kb for both UTR several changes in ABC C8
 we carried out a functional region. An in silico analysis was performed to evaluate analysis by minigene assay to evaluate possible splicing binding transcription factors. Luciferase assay was done to variants (8/10). Lastly, we used protein modeling by evaluateinvitrotheSNPinfluenceingeneexpression.Data homology (Phyre2) to evaluate the pathogenicity of the revealed the presence of a deletion in the promoter region changes at protein level assessing its stability with (rs397751713), while a transversion in the 3’ UTR region MODELLER. was found (rs2859338). The distribution of the genotype Results:Aftervalidation,weidentifiedtenvariantsinthe frequenciesinourPAHpatientswere:forrs397751713: A/ ABC C8
 gene that had never been related to PAH: A:0.08;A/-:0.27;-/-:0.66;forrs2859338:A/A:0.15;A/G: c.298G>A:p.(Glu100Lys), c.2176G>A p.(Ala726Thr) and 0.60; G/G: 0.25. Variations are located in a KLF4 binding c.3238G>A:p.(Val1080Ile) were classified as neutral. sequence and a vitamin D receptor binding sequence c.2422C>A:p.(Gln808Lys) and c.3976G>A:p.(Glu1326- respectively. Both transcription factors are related to PAH Lys) were classified as likely pathogenic. c.1429G>A:p. development.Inconclusion,theseSNPsintheUTRregions (Val477Met), c.1643C>T:p.(Thr548Met), c.2694+1G>A, of EDN1 are related with gene expression levels, as we c.3288_3289del:p.(His1097ProfsTer16) and c.3394G>A:p. measuredhigherexpressionratesforpatientswithA/Aand (Asp1132Asn) were classified as pathogenic. Minigenes G/G genotype. Moreover, we hypothesized that this over- confirmed the pathogenicity of c.3394G>A:p. expression is due to the inability of KLF4 and vitamin D (Asp1132Asn) inducing an exon skipping, and the correct receptor to attach the target sequence and to regulate the processing of c.298G>A:p.(Glu100Lys) and c.1643C>T:p. expressionofEDN1,asKLF4isprobetoavoidPAHwhen (Thr548Met). But they were inconclusive for 5 variants, present and vitamin D is an anti-hypertrophic factor. noneoftheencodedexonstranscribedcorrectlyeveninthe C. Solarat: None. M. Lago-Docampo: None. A. wild type. Protein modeling of the possible outcomes Baloira: None. D. Valverde: None. revealed that amino acid changes would not alter protein stability. The skipping of exons 20, 27 and 32 would yield  P05
.49A unstable proteins, while skipping of exon 22 would barely Rare ABC C8
 variants identified in Spanish pulmonary affect stability. arterial hypertension patients Conclusions: We identified ten variants in ABC C8
, confirmed experimentally the pathogenicity of c.3394G>A: M. Lago Docampo1,2,3, J. Tenorio4,5, C. Pérez Olivares6, p.(Asp1132Asn) and bioinformatically c.3288_3289del:p. I. González Hernández7,8, P. Escribano Subías6,9, (His1097ProfsTer16). Protein stability analysis allowed us G.Pousada2,A.Baloira10,M.Arenas1,2,3,P.Lapunzina4,5, topredictthepossibleoutcomesoftheunconfirmedsplicing D. Valverde1,2,3 variants. M. Lago Docampo: None. J. Tenorio: None. C. Pérez 1University of Vigo, Vigo, Spain, 2IIS Galicia Sur, Vigo, Olivares: None. I. González Hernández: None. P. Spain, 3Centro de Investigaciones Biomédicas (CINBIO), Escribano Subías: None. G. Pousada: None. A. Baloira: Vigo, Spain, 4Instituto de Genética Médica y Molecular None. M. Arenas: None. P. Lapunzina: None. D. (INGEMM), Madrid, Spain, 5Centro de Investigación Valverde: None.1326  P05
.51C Conclusions: The functional characterization of variants Familial hypercholesterolemia: functional in PCSK9 has allowed us to classify the variants avoiding characterization of new variants in PCSK9 the“uncertainsignificance”variantsandthustoconfirmthe genetic diagnosis of hypercholesterolemia. The results S.Rodríguez-Nóvoa1,C.Rodríguez-Jiménez1,E.Sánchez- suggest that the variant c.1978G>A;p.(Asp660Asn) could Nieves1, A. Carazo-Álvarez1, F. Arrieta2, L. Reinares- explaintheraisedlevelofLDL-cinthepatientbeinganew García3, P. Martínez-Hernández4, R. Cañas5, J. Mostaza6 case of FH3 due to gain-of-function variant in PCSK9. S. Rodríguez-Nóvoa: None. C. Rodríguez-Jiménez: 1DepartmentofGeneticsofmetabolicsdiseases.Instituteof None. E. Sánchez-Nieves: None. A. Carazo-Álvarez: Medical & Molecular Genetics (INGEMM), Hospital None. F. Arrieta: None. L. Reinares-García: None. P. Universitario La Paz, Universidad Autónoma de Madrid, Martínez-Hernández: None. R. Cañas: None. J. IdiPAZ,Madrid,Spain;CentrodeInvestigaciónBiomédica Mostaza: None. en Red de Enfermedades Raras (CIBERE, Madrid, Spain, 2DepartmentofEndocrinologyandNutrition.UnitHospital  P05
.52D Ramón y Cajal. Hospital Universitario Ramón y Cajal, Polygenicriskinformationforcoronaryarterydisease- Instituto Ramón y Cajal de Investigación Sanitaria  P5
.fi FinHealth (IRyCIS), E-28034. CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid, Spain, M. M. Marttila1, T. Paajanen1, H. Marjonen1, N. Kallio1, 3Department of Internal Medicine, Hospital Clínico San A. Haukkala2, H. Kääriäinen1, K. Kristiansson1, Carlos, Madrid, Spain., Madrid, Spain, 4Department of M. Perola1,3 Internal Medicine, Hospital Universitario la Paz, Madrid, Spain., Madrid, Spain, 5Department of Internal Medicine, 11 National Institute for Health and Welfare, Helsinki, Fundación Jiménez Díaz, Madrid, Spain, Madrid, Spain, Finland, 22 Faculty of Social Sciences, University of 6Lipid and Vascular Unit, Hospital Carlos III, Madrid, Helsinki, Finland, Helsinki, Finland, 33 Research Program Spain, Madrid, Spain for Clinical and Molecular Metabolism, Faculty of Medicine,UniversityofHelsinki,Finland,Helsinki,Finland Introduction:Proproteinconvertasesubtilisin/kexintype9 (PCSK9) is a post-transcriptional regulator of the Low- Introduction: We have tested how polygenic risk scores density-lipoprotein receptor(LDLR). “Lost_of_function_- (PRS) for coronary artery disease (CAD), type 2 diabetes variants” at PCSK9 has been related with lower LDL- and venous thromboembolism affect the risk of disease cholesterol while the “gain_of_function_variants” result in within the following ten years in participants from a autosomal dominant hypercholesterolemia-3 (FH3, population-based study FINRISK. We will also utilize OMIN#603776) whose prevalence is 0,1-2%(1,2). NMR metabolomic risk information in disease prevention. Materials and Methods: The DNA samples from Materials and Methods: Based on follow-up data from patientsclinicallyclassifiedashavingprobableordefinitive national health care registries we modelled PRS in whole familial hypercholesterolemia(FH), were analysed by NGS genomegenotypedpopulationbasedFINRISKcohortswith using a customized panel of 198 genes. The new variants multiple registry follow-up for incident cases (N=21726) found in PCSK9 were generated into the expression vector using Cox regression models. We modelled the impact of PCSK9_NM_174936.3-Human-cDNA-GFPSpark®-tag by genetic and traditional risk factors on a risk of disease site directed mutagenesis. The constructs were transfected within the next 10 years. inHepG2cells.Wemeasurebothactivityandexpressionof Results: We compared the CAD classification of Cox LDLR by flow cytometry in order to determine the impact regressionmodelwithtraditionalriskfactorsandpolygenic of PCSK9 variants. additive model with 6,6M variants. From basic model risk Results: In silico study showed six variants in PCSK9: class 10-20% PRS reclassified 205 participants to highest c.289C>T;p.(Arg97Cys), c.1130C>G;p.(Thr377Ser), >20%riskclass.InFINRISKparticipantsriskforCADwas c.1495C>T;p.(Arg499Cys), c.1633A>G;p.(Ser545Gly), higher for men and smoking adds to risk of disease in all c.1978G>A;p.(Asp660Asn), c.1987A>G;p.(Thr663Ala) PRS classes. Risk for disease increases with BMI being with potential effect in PCSK9. The variant c.1978G>A;p. highest in BMI class 30-35. (Asp660Asn) had a 15% decreased level of internalization Conclusions: The validation showed that adding PRS to of LDL and 20% decreased level of LDLR expression the traditional risk factors significantly changed the risk regardingWT-PCSK9.Therestofvariantshadthesameor enabling reclassification of as many as 17% of the partici- incremented level ofLDL internalization and expression of pants. PRS and metabolic risk information are returned to LDLR regarding WT-PCSK9. volunteering participants through an internet portal.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1327 Changes in life style are followed up using questionnaires digenic inheritance or genetic synergism, associated with through the portal and the morbidity will be collected changes in RYR2 and KCNH2, has been postulated. through health registers.  P5
 study is a pilot for  P6
 which Conclusions: PVT-related channelopathies remain a will recruit 200 000 participants and study 10-20 diseases. diagnosticandtherapeuticchallenge.Phenotypicexpression M.M. Marttila: None. T. Paajanen: None. H. Marjo- and/or variable penetration observed in the disease may nen: None. N. Kallio: None. A. Haukkala: None. H. result from the confluence of defects in different genes Kääriäinen:None.K.Kristiansson:E.OwnershipInterest encoding or modulating ion channels’ function. NGS (stock, stock options, patent or other intellectual property); technology provides foundation to better understanding of Significant; Negen oy. M. Perola: None. the genetic profile, phenotype-genotype correlations and etiopathological mechanisms of PVT. Improved detection  P05
.53A of risk factors will influence genetic counseling and ther- Aheterogeneous molecularbackground of polymorphic apeutic decision-making, preventing severe consequences, ventricular tachycardia in pediatric patients with like sudden cardiac death. channelopathy and normal heart Partially supported: CMHI-M31/18. M. Pelc: None. P. Kowalski: None. A. Madej-Pilarc- M. Pelc1, P. Kowalski1, A. Madej-Pilarczyk1, zyk: None. D. Jurkiewicz: None. J. Kosińska: None. M. D. Jurkiewicz1, J. Kosińska2, M. Rydzanicz2, Rydzanicz:None.M.Posadowska:None.K.Pręgowska: M. Posadowska3, K. Pręgowska3, P. Stawiński2,4, None. P. Stawiński: None. M. Brzezińska: None. E. M. Brzezińska3, E. Ciara1, D. Piekutowska-Abramczuk1, Ciara: None. D. Piekutowska-Abramczuk: None. P. P. Halat-Wolska1, D. Siestrzykowska1, R. Płoski2, Halat-Wolska: None. D. Siestrzykowska: None. R. K. Chrzanowska1, K. Bieganowska3 Płoski: None. K. Chrzanowska: None. K. Bieganowska: None. 1DepartmentofMedicalGenetics,TheChildren’sMemorial Health Institute, Warsaw, Poland, 2Department of Medical  P05
.54B Genetics, Warsaw Medical University, Warsaw, Poland, RNF213 is a causative gene for pulmonary arterial 3Department of Cardiology, The Children’s Memorial hypertension and is associated with poor clinical HealthInstitute,Warsaw,Poland,4DepartmentofGenetics, outcomes InstituteofPhysiologyandPathologyofHearing,Warsaw, Poland H. Suzuki1, M. Kataoka1, T. Hiraide1, M. Yamada1, T. Uehara1, T. Takenouchi1, N. Hirose1, S. Gamou2, Introduction: Polymorphic ventricular tachycardia (PVT) K. Fukuda1, K. Kosaki1 isalife-threateningarrhythmiaconcomitantwiththegenetic disorders related to myocyte transmembrane ion channel 1KeioUniversity,Tokyo,Japan,2KyorinUniversity,Tokyo, dysfunction called “channelopathies”. They comprise long Japan and short QT syndromes (LQTS/SQTS), Brugada syn- drome, and catecholaminergic polymorphic ventricular Introduction: Pulmonary arterial hypertension (PAH) is tachycardia (CPVT). Although nearly 30 genes have been characterizedbyastronggeneticcomponent.About30%of associated with arrhythmogenic channelopathies so far, the patients with idiopathic/heritable PAH have variants in mutation detection rate in syndromes other than LQTS is BMPR2.Thecausativegenes, ifany,intheremaining70% relatively low (~15-65%), therefore their molecular profile of patients have yet to be clarified. Since we reported 2 remains largely unknown. unrelated patients with homozygosity for RNF213 p. Patients and Results: A 62-gene panel comprising Arg4810Lys who had Moyamoya disease and severe knownandcandidategeneswasusedforNGSscreeningof pulmonary hypertension in 2016, we suspected RNF213 12 patients with PVT-associated channelopathy. In 8 would be causative gene for PAH. patients we identified 4 known and 6 novel, likely patho- Method: We performed whole-exome sequencing for 76 genic variants in KCNH2, RYR2 and SCN5A. Additionally, patients (19 males, 57 females) with idiopathic PAH who rare variants of unknown significance in AKA P9
, KCNA5, hadbeennegativefor BMPR2 andother knownpathogenic KCNH2, KCNT1, MYH6, SCNN1A, TRDN, TTN were gene mutations. found in 6 cases. Interestingly, in one CPVT patient two Result: We identified RNF213 p.Arg4810Lys in a het- novel RYR2 variants inherited from healthy parents co- erozygous state in 7 (9.2%) of the 76 PAH patients. Since occured, suggesting recessive pattern ofinheritance.In two the minor allele frequency for the p.Arg4810Lys is 0.77% otherpatientsdiagnosedwithPVTandLQTSpossibilityof in the normal Japanese population, individuals who are heterozygousforthep.Arg4810Lysmightbepredisposedto1328 PAH. From a therapeutic standpoint, patients with the congenital heart disease (CHD). In CTD, we have found RNF213 p.Arg4810Lys were low responders to PAH- one pathogenic mutation and four VUS and, and for CHD specific vasodilators. The event-free rate of death or lung two pathogenic variants and 6 VUS. In addition, in a small transplantation was significantly poorer in RNF213 p. proportion of patients (0,93%) digenic mode of inheritance Arg4810Lys variant carriers than in BMPR2 variants car- was detected. riers (5-year event-free rate since the introduction of pros- Conclusions: These results highlight the importance of taglandin I2 infusion, 0% vs. 93%, P<0.001). thegeneticscreeningofPAHandallowtodetectvariantsin Conclusion: We demonstrated that nearly 10% of PAH-associated forms not described previously. Molecular patients with PAH were heterozygous for the RNF213 p. confirmationoftheclinicalsuspiciousismandatoryincases Arg4810Lys. Documentation of an RNF213 p.Arg4810Lys with clinical overlapping and to perform a properly man- might provide clinically relevant information when select- agement and follow up of the patients. Grants FIS-PI15/ ing pharmacologic interventions. 02012 Actelion unrestricted grant FCHP-grant Grant references: This work was supported by J.A. Tenorio: Other; Significant; Actelion. P. Arias: KAKENHI from the MEXT, a grant from the Medical None.I. Hernández:None.N. Ochoa: None. E. Granda: DepartmentCollaborativeProjectofKyorinUniversity,and None. P. Navas: None. G. Gómez-Acebo: None. N. Gal- a grant from AMED (17kk0205002h0002) in Japan. lego: None. P. Lapunzina: None. P. Escribano: C. Other H.Suzuki:None.M.Kataoka:None.T.Hiraide:None. Research Support (supplies, equipment, receipt of drugs or M. Yamada: None. T. Uehara: None. T. Takenouchi: other in-kind support); Significant; Actelion. None. N. Hirose: None. S. Gamou: None. K. Fukuda: None. K. Kosaki: None.  P05
.57A A case report of recessive restrictive cardiomyopathy  P05
.55C caused by a novel mutation in cardiac troponin I Customized massive paralleled sequencing panel for (TNNI3) diagnosis of Pulmonary Arterial Hypertension M. P. Pantou1, P. Gourzi1, A. Gkouziouta2, I. Armenis2, J. A. Tenorio1, P. Arias1, I. Hernández2, N. Ochoa3, C. Zygouri3, P. Constantoulakis3, S. Adamopoulos2, E. Granda1, P. Navas4, G. Gómez-Acebo1, N. Gallego1, D. Degiannis1 PAH Spanish consortium, P. Lapunzina1, P. Escribano3 1Molecular Immunopathology and Histocompatibility Unit, 1INGEMM, Madrid, Spain, 2Hospital Universitario Molecular Genetics Facility, Kallithea-Athens, Greece, Fundación Jiménez Díaz, Madrid, Spain, 3Hospital 2HeartFailure,MCSandTransplantUnit,OnassisCardiac Universitario 12 de Octubre, Madrid, Spain, 4Hospital Surgery Center, Kallithea-Athens, Greece, 3Department of Universitario Gregorio Marañón, Madrid, Spain Molecular Genetics, BioAnalytica-Genotypes S.A., Athens, Greece Introduction: Diagnosis of Pulmonary Arterial Hyperten- sion (PAH) is challenging due to phenotypic overlapping Introduction: Restrictive cardiomyopathy is a rare cardiac and variable expressivity. Current classification based on disease, for which several genes including TNNT2, MYPN, clinical features, does not reflect the underlying molecular FLNC and TNNI3 have been associated with its profilingofthesegroups,andpatientsfromdifferentgroups familial form. canshareclinicalfeaturesthatcouldbeassociatedwiththeir Materials and Methods: The index case and her rela- response.Theadvanceinthemassiveparalleledsequencing tives underwent full cardiological assessment. Genetic technologies has allowed describing several new genes analysis of the index case was performed using Illumina's related to PAH, improving diagnosis ratio and a better Trusight Cardio sequencing panel and Sanger sequencing clinicalcharacterizationThus,ouraimedwastoaddressthe was used to screen members of the family for the presence molecular diagnosis of patients with any form PAH of the reported mutation. Material and Methods: 318 patients were included in Results: Here we describe a female proband with a the analysis. 21 gene NGS custom panel was designed the severely manifested restrictive phenotype leading to heart sequencing was performed with a MiSeq. Custom script transplantationattheageof41whowasfoundhomozygous was developed to annotate and filter the variants. forthenovelTNNI3mutation:NM_000363.4:c.586G>C,p. Results: Pathogenic and likely pathogenic variants were (Asp196His). Her parents were third-degree cousins origi- found in 13% of the patients with a 14% of variants of nating from a small village and although they were found unknown significance. Interesting, we have found variants heterozygous for the same variant they displayed no in patients with connective tissue disease (CTD) and symptoms of the disease. Her older sister who was alsoAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1329 found heterozygous was asymptomatic. Her twin sister and formation, and for each individual three iPSC clones were her brother who were homozygous for the same variant established. For differentiation to iPSC-CMs we followed displayed a restrictive and a hypertrophic phenotype, two published protocols and evaluated the cells using respectively. immunostaining and patch-clamp experiments. Conclusion: These observations point to a recessive Results: Optimization of the methods resulted in robust mode of inheritance reported for the first time for this patient and control iPSC-CM models. The patient cells combination of gene/disease. displayedareducedsodiumcurrentcomparedtothecontrol M.P. Pantou: None. P. Gourzi: None. A. Gkouziouta: iPSC-CMs. None. I. Armenis: None. C. Zygouri: None. P. Con- Conclusion: We established iPSC-CM models for a stantoulakis: None. S. Adamopoulos: None. D. unique Belgian SCN5A founder mutation displaying Degiannis: None. remarkable variable expressivity. Further experiments including transcriptomics, whole-genome sequencing,  P05
.58B electrophysiological and functional investigations will The first Belgian SCN5A founder mutation: enable us to identify genetic modifiers and unravel their establishment of an iPSC-cardiomyocyte model to mechanism of action. This will hopefully stimulate the identify genetic modifiers development of novel drugs for cardiac arrhythmias. M.Alaerts:None.A.Nijak:None.E.Simons:None.E. M. Alaerts1, A. Nijak1, E. Simons1, E. Sieliwonczyk1, Sieliwonczyk: None. D. Schepers: None. B. Vanden- D. Schepers1, B. Vandendriessche1, E. Van driessche: None. E. Van Craenenbroeck: None. J. Sae- Craenenbroeck2, J. Saenen2, A. Labro3, D. Snyders3, nen: None. A. Labro: None. D. Snyders: None. P. P. Ponsaerts4, B. Loeys1,5 Ponsaerts: None. B. Loeys: None. 1Center of Medical Genetics, University of Antwerp and  P05
.59C Antwerp University Hospital, Antwerp (Edegem), Belgium, Clinical and genetic data of 151 individuals from 58 2Department of Cardiology, Antwerp University Hospital, unrelated families with SMAD3 mutations Antwerp, Belgium, 3Laboratory for Molecular Biophysics, Physiology and Pharmacology, Department of Biomedical B. Chesneau1,2, T. Edouard2, Y. Dulac2, H. Colineau3,4, Sciences, University of Antwerp, Antwerp, Belgium, N. Hanna5, N. Chassaing1, S. Julia1, G. Jondeau5, 4Laboratory of Experimental Hematology, Vaccine and J. Albuisson6, P. Khau Van Kien7, J. Plaisancié1,2 Infectious Disease Institute, University of Antwerp, Antwerp, Belgium, 5Department of Human Genetics, 1Service de génétique médicale, Hôpital Purpan, CHU de Radboud University Medical Centre, Nijmegen, Toulouse, Toulouse, France, 2Centre de Référence du Netherlands syndrome de Marfan etdes syndromes apparentés, Hôpital des Enfants, CHU de Toulouse, Toulouse, France, Introduction: The SCN5A gene encodes the α-subunit of 3Department of Epidemiology, Health Economics and the voltage-gated cardiac sodium channel Na 1.5. Muta- Public Health, Toulouse University Hospital, Toulouse, v tions are detected in 20% of the patients with Brugada France, 4LEASP UMR1027, INSERM, Université Toulouse syndrome (BrS), an inherited cardiac arrhythmia that III, Toulouse, France, 5Centre de référence pour le predisposes to sudden cardiac death (SCD). We have syndrome de Marfan et apparentés, Assistance Publique- identified a loss-of-function SCN5A founder mutation Hôpitaux de Paris, Hôpital Bichat, Faculté Paris Diderot, (c.4813+3_4813+6dupGGGT) in 23 different Belgian LVTS INSERM U1148, Paris, France, Paris, France, families.Werecruited89mutationcarriersandtheirclinical 6Service de génétique médicale, Hôpital Purpan, CHU de spectrum ranges from completely asymptomatic to palpita- ToulouseAP-HP, Hôpital Européen Georges Pompidou, tions, syncopes and SCD. This provides us with a unique DépartementdeGénétique,ServicedeMédecineVasculaire patient cohort to study modifiers that play a role in this et Centre de Référence des Maladies Vasculaires Rares, variable expressivity and we decided to create patient- Paris, France, 7Service de génétique médicale, Centre specific induced pluripotent stem cell (iPSC)-derived Hospitalier Régional Universitaire de Nîmes, Nîmes, cardiomyocytes(CM) asa modelfor furtherinvestigations. France Materials and Methods: Dermal fibroblasts from a skin biopsy of two patients with different phenotypic severity PathogenicvariantsinSMAD3aremainly responsiblefor a and two unrelated control individuals were reprogrammed thoracic aortic disease, characterized by aneurysms and using Sendai viral vectors. The resulting iPSCs were vali- dissections,whichhasamajorimpactintermsofmorbidity datedusingimmunostaining,RT-qPCRandembryoidbody and causing early mortality. These vascular damages are1330 associated with multisystemic signs including premature might also play an important role in cases of unexplained osteoarthritis. SMAD3 encodes one of the canonical TGF-β sudden cardiac death (SCD) in young subjects. pathway members whose defect is involved in connective Materials and Methods: We investigated the cohort of tissue disorders such as Loeys-Dietz syndrome and Czech cardiac arrest (CA) survivors/victims by performing represents a rare cause (2%) of familial thoracic aneurysms massively parallel sequencing using a custom-made panel and dissections. Clinical variability and incomplete pene- comprising 229 cardiac conditions-related genes (Nimble- trance are commonly associated with pathogenic SMAD3 Gen/Illumina). Detected variants were validated by Sanger variants. This prompted us to review all the individuals for sequencing, including their familial segregation and classi- which a SMAD3 mutation was identified in our Reference fied according to ACMG. Centre and to compare these with published cases, to Results: We have identified variants in FLNC gene in 3 determine any genotype-phenotype correlation associated cases. In 2/3 cases the rare variant NM_001458.4 (FLNC): with mutations of this gene. Here, we report clinical and c.102G>A p.(Trp34*) was found in non-related Czech genetic data from 20 new cases from 8 families from our subjects (26 years old male CA victim and 16 years old Reference Centre.Afteracompletereviewoftheliterature, femaleCAsurvivor).NM_001458.4(FLNC):c.1732G>Tp. wecollectedatotalof49uniquevariantsofdifferentnature, (Gly578Cys) in CA victim, where this variant was coex- from 151 individuals of 58 unrelated families, including istent with probable causative variant in TTN gene. missense, truncating and splicing variants. This report Conclusion: Both, truncating and missense mutations in confirms the absence of correlation between the mutation the FLNC gene might be associated with SCA and type and the phenotype severity and highlights the demonstrate the clinical utility of genetic testing in at-risk important inter and intra familial clinical variability and family members. The aim of our study is to increase the incomplete penetrance described with SMAD3 mutated usage of genetic analysis in post mortem investigations of patients. Thus, this report brings additional data for the SCD in the young cases in order to improve clinical man- absence of genotype-phenotype correlation of SMAD3 agement of relatives at risk in the Czech Republic. Sup- mutationsandtheneedtoexploreinmoredetailtheeffects ported by I P00064203
/6003; LM2015091; CZ.02.1.01/0.0/ of potential modifying factors that could influence the 0.0/16_013 and AZV - NV18-02-00237. phenotype. P. Votýpka: None. P. Norambuena: None. M. Macek B. Chesneau: None. T. Edouard: None. Y. Dulac: Jr.: None. A. Krebsová: None. None. H. Colineau: None. N. Hanna: None. N. Chassa- ing: None. S. Julia: None. G. Jondeau: None. J. Albuis-  P05
.61A son:None.P.KhauVanKien:None.J.Plaisancié:None. Determination of disease-associated genes and gene-sets in Tetralogy of Fallot  P05
.60D Clinical utility of FLNC variants identified in 3 young R. Manshaei1, M. S. Reuter1,2, B. A. Mojarad3, sudden cardiac arrest victims/survivors for clinical G. Pellecchia2, M. Zarrei2, R. Chaturvedi1,4, management of their at-risk relatives A. S. Bassett5,6,7,8, R. Kim1,9,10, D. Merico2,11 P. Votýpka1, P. Norambuena1, M. Macek Jr.1, 1Ted Rogers Centre for Heart Research, Cardiac Genome A. Krebsová2 Clinic, The Hospital for Sick Children, Toronto, ON, Canada, 2The Centre for Applied Genomics, The Hospital 1DepartmentofBiologyandMedicalGenetics,2ndFaculty for Sick Children, Toronto, ON, Canada, 3Program in of Medicine, Charles University and Motol, Prague 5, Genetics and Genome Biology, The Hospital for Sick Czech Republic, 2Department of Cardiology, Institute for Children, Toronto, ON, Canada, 4Labatt Heart Centre, Clinical and Experimental Medicine (IKEM), Prague, Division of Cardiology, The Hospital for Sick Children, Czech Republic Toronto, ON, Canada, 5Clinical Genetics Research Program, Centre for Addiction and Mental Health, Introduction: Mutations in FLNC gene were initially Toronto, ON, Canada, 6Division of Cardiology, Toronto related to muscular dystrophy and myofibrillar myopathy Congenital Cardiac Centre for Adults at the Peter Munk butmorerecently,variantsinFLNCwerereportedtocause Cardiac Centre, Department of Medicine, University familialcardiomyopathiesintheabsenceofskeletalmuscle Health Network, Toronto, ON, Canada, 7The Dalglish defects. Truncating mutations in FLNC cause an over- Family 22q Clinic for Adults with 22q11.2 Deletion lapping phenotype of dilated cardiomyopathy or arrhyth- Syndrome,DepartmentofPsychiatry,andTorontoGeneral mogenic cardiomyopathy while missense mutations are Research Institute, University Health Network, Toronto, associated with familiar hypertrophic cardiomyopathy and ON, Canada, 8Department of Psychiatry, University ofAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1331 Toronto, Toronto, ON, Canada, 9Division of Clinical and 1Petrovsky Russian Research Center of Surgery, Moscow, Metabolic Genetics, The Hospital for Sick Children, Russian Federation, 2Pirogov Russian National Research Toronto, ON, Canada, 10Fred A. Litwin Family Centre in Medical University, Moscow, Russian Federation, Genetic Medicine, University Health Network, Department 3Bashlyaeva Pediatric City Hospital, Moscow, Russia, of Medicine, University of Toronto, Toronto, ON, Canada, Moscow, Russian Federation, 4Centre of Genetics and 11Deep Genomics Inc., Toronto, ON, Canada Reproductive Medicine “Genetico”, Moscow, Russian Federation Introduction:Genesandpathwaysareanalyzedforexcess of ultra-rare truncating and missense variants in Tetralogy Introduction:Idiopathicdilatedcardiomyopathy(DCM)is ofFallotusingabinomialtestcomparingobservedvariation hastheprevalenceof1:250,andatleastone-thirdofallthe rates to background de-novo mutation rates. This method casesareinherited.Accordingtovariousstudiesfocusedon doesn’t require matched controls. the adult patients, mutations in the TTN gene accounts 10- Materials and Methods: Since original background 30%ofDCMcases.ThemutationrateintheTTNgene,the mutation rates were estimated for de-novo variants, we characteristics of manifestations and their prognostic appliedascalingfactortoobtainnewprobabilitiesP'=k*P; significance in childhood have not been studied. factor k was computed so that the number of predicted and Aim: To determine TTN mutation rate in children with observed ultra-rare variants match. We applied the same DCM and the relevance of including this gene in the DNA method pooling expected probabilities and observed var- diagnostic protocol for pediatric DCM. iants by pathway, to boost power. We addressed the pro- Materials and Methods: Complete clinical and instru- blemofgene-setcorrelationsbyusingagreedy-step-down- mental examination of 36 DCM aggregation approach; and computed a sampling-based patients was conducted in cardiology centres. Genetic FDR only for aggregated gene-sets. We tested gene-sets study had included sequencing based on the IonTorrent ™ derived from Gene Ontology and pathways, and MPO platform of the TTN isoform N2BA (25 isolated cases) and annotation of human orthologs in mouse. wholeexomesequencingtriosontheIlluminaplatform(11 Results: By applying this method to genes predicted family cases). haploinsufficient, we found significant genes: FLT4 (BH- Resultsanddiscussion:Thegroupincluded36probands FDR~0%), NOTCH1 (BH-FDR~0.5%), and etc. For Gene diagnosed with DCM before 18 years (average age: 6.5 Ontology and pathways, we found the VEGF and related years). The sex ratio (M:F) was 23: 8. The only likely pathways (FDR~0%, including FLT4,KDR, ⋯), Cardiac pathogenic truncating variant p.Arg33703*in the TTN gene Vascular Smooth Muscle Cell Differentiation, and related was found in a 16-year-old male proband out of 36 (3%). pathways (FDR~0.08%, including NOTCH1 gene, ⋯). For Apparently, TTN-dependent forms of DCMs manifest later MPO terms, we found abnormal vitelline vascular remo- at a young or more mature age. deling and related pathways (FDR~0%, including FLT4, Conclusion: These results do not support the TTN gene KDR,FOXO1, ⋯), delayed heart looping and related as the first line of DNA diagnostics for DCM in the pathways (FDR~0.05%, including NOTCH1 gene, ⋯). pediatric group. Further research is needed to compare the Conclusions: FLT4,KDR,FOXO1, and NOTCH1 genes representationofmutationsintheTTNgeneindifferentage were in line with manual gene curation findings. Also, groups of DCM patients. pathways results confirm manual curation findings which This study was supported by grant of Russian Research support dysregulated VEGF signaling as a novel mechan- Foundation 16-15-10421 ism contributing to the pathogenesis of TOF. Funded by V. Mikhailov: None. E. Zaklyazminskaya: None. A. Ted-Rogers Centre for Heart Research, and CIHR (MOP- Bukaeva: None. N. Kotlukova: None. I. Povolotskaya: 89066). None. S. Dzemeshkevich: None. R. Manshaei: None. M.S. Reuter: None. B.A. Mojarad: None. G. Pellecchia: None. M. Zarrei: None.  P05
.63C R.Chaturvedi:None.A.S.Bassett:None.R.Kim:None. Large-scale genetic study provides new insights into D. Merico: None. genetics and etiology of varicose veins  P05
.62B A.S.Shadrina1,2,3,S.Z.Sharapov1,2,T.I.Shashkova1,4,5, Pediatric patients with DCM have lower than expected Y. A. Tsepilov1,2 mutation rate in the TTN gene 1Novosibirsk State University, Novosibirsk, Russian V. Mikhailov1, E. Zaklyazminskaya1,2, A. Bukaeva1, Federation, 2Institute of Cytology and Genetics, N. Kotlukova2,3, I. Povolotskaya4, S. Dzemeshkevich1 Novosibirsk, Russian Federation, 3Institute of Chemical1332 Biology and Fundamental Medicine, Novosibirsk, Russian E.Sundberg1,B.Magnusson1,C.R.Ferreira2,C.Grant2, Federation, 4Moscow Institute of Physics and Technology, J. Mitchell3, P. Harmatz4, N. O. Mungan5, F. D. Bulut5, Moscow,RussianFederation,5A.A.KharkevichInstitutefor C. Lampe6, N. Guelbert7, N. Arslan8, B. Makay8, Information Transmission Problems, Moscow, Russian R. D. Puri9, S. Bijarnia-Mahay9, L. Selim10, I. Gamal el Federation Din10,S.Kapoor11,M.DiRocco12,S.Ozen13,E.D.Batu13, G. Gokcay14, M. Torcoletti15, J. Karafilidis16, A. Solyom17 Introduction: Varicose veins are a common pathology of lower extremities. Although heredity is a well-known risk 1Karolinska University Hospital, Stockholm, Sweden, factor for varicose veins, genetic architecture of this 2Children's National Medical Center, Washington, DC, condition is still poorly understood. United States, 3Montreal Children's Hospital, Montreal, Materials and Methods: This study is a genome-wide QC,Canada,4UCSFBenioffChildren'sHospital,Oakland, association study with deep in-silico functional follow-up CA, United States, 5Cukurova University Hospital, Adana, analysis.Summarystatisticsfor408,455European-ancestry Turkey, 6HSK Wiesbaden, Wiesbaden, Germany, individuals were provided by the Gene ATLAS and the 7Children's Hospital of Cordoba, Cordoba, Argentina, Neale Lab projects. 8Dokuz Eylul University Hospital, Izmir, Turkey, 9Sir Results: Seven loci associated with the risk of varicose GangaRamHospital,NewDelhi,India,10CairoUniversity veins were identified that explain 10% of the SNP-based Children's Hospital, Cairo, Egypt, 11Lok Nayak Hospital heritability. In six of them, we prioritized the most likely and Maulana Azad Medical College, New Delhi, India, causalgenesCASZ1,PIEZO1,PP P3
R1,EBF1,STIM2,and 12Istituto Giannina Gaslini, Genoa, Italy, 13Hacettepe HFE.Genesetenrichmentanalysisrevealedgenecategories University, Ankara,Turkey, 14Istanbul University, Istanbul, related to abnormal vasculogenesis. Summary data-based Turkey, 15University of Milan, Milan, Italy, 16Enzyvant, Mendelian Randomization analysis followed by the Het- Cambridge, MA, United States, 17Enzyvant, Basel, erogeneity in Dependent Instruments test showed pleio- Switzerland tropic effects on body mass-, fat-, blood- and blood pressure-related traits. Genetic correlation analysis con- Introduction: Farber disease is a rare lysosomal storage firmed known epidemiological associations between VVs disorder caused by mutations in both alleles of the ASAH1 and deep venous thrombosis, weight, rough labor, and gene.Theresultingdeficiencyofthelysosomalenzymeacid standing job, and found a genetic overlap with multiple ceramidase, and accumulation of the pro-inflammatory novel traits, including height, pain, educational attainment, sphingolipid ceramide, causes a broad spectrum of fluidintelligence,walkingpace,smoking,andgonarthrosis. symptoms and disease severity which may delay diagnosis Mendelianrandomizationanalysisrevealedcausaleffectsof or lead to misdiagnosis. The ongoing study described here plasma levels of MICB and CD209 proteins and anthro- is the first comprehensive, systematic clinical study of the pometric traits such as height, weight, waist and hip natural history of Farber disease. circumference. Methods:TheObservationalandCross-SectionalCohort Conclusions: Our results provide novel insight into the Study of the Natural History and Phenotypic Spectrum of genetic underpinnings of varicose veins and their etiology. Farber Disease (NCT03233841) is designed to collect ret- Prioritized genes and identified proteins can be good can- rospective and prospective data including demographics, didates for future functional studies. The study was sup- clinical presentation, phenotype, and diagnostic history of ported by the Russian Science Foundation [Project No 17- patients diagnosed with Farber disease who have or have 75-20223]. not undergone hematopoietic stem cell transplantation A.S. Shadrina: None. S.Z. Sharapov: None. T.I. (HSCT),alongwithspecificprospectiveclinicalevaluations Shashkova: None. Y.A. Tsepilov: None. in living patients. Results: From November 2017 to December 2018, 42 patients (25 living, 17 deceased) have been enrolled in the  P06
 study. The average age of the living patients is 9 years Metabolic and mitochondrial disorders (range 1 to 28 years). Average time from onset of first symptoms to diagnosis is 2 years (range < 1 to 12 years).  P06
.03B Patient countries of birth include Afghanistan, Argentina, Farber disease (acid ceramidase deficiency): Canada, Egypt, Germany, India, Iraq, Italy, Mexico, Swe- demographic and diagnostic data from the first-ever den, Syria, Turkey, and the USA. natural history study Conclusions: Patients representing the breadth of the phenotypic spectrum of Farber disease, from rapidly pro- gressive (severe), to slowly progressive (attenuated) haveAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1333 been enrolled from 15 centers (9 countries). Demographic  P06
.04C data and numbers of patients enrolled indicate that Farber Lysosomal storage, neurodegeneration, and albinism disease is likely not as rare as previously thought. due to effects of a de novo CLCN7 mutation on E. Sundberg: B. Research Grant (principal investigator, lysosomal acidification collaborator or consultant and pending grants as well as grants already received); Modest; Enzyvant. B. Magnus- E. Nicoli1, M. Weston2, M. Hackbarth1, A. Becerril2, son:B. Research Grant(principal investigator, collaborator A. Larson3, W. M. Zein4, P. R. Baker II3, J. D. Burke5, or consultant and pending grants as well as grants already H. Dorward5, M. Davids1, Y. Huang1, D. R. Adams1,6, received); Modest; Enzyvant. C.R. Ferreira: None. C. P. M. Zerfas7, D. Chen8, T. C. Markello1,6, C. Toro1,6, Grant: None. J. Mitchell: B. Research Grant (principal G. Elliott9, M. Vu10, U. Undiagnosed Disease Network11, investigator, collaborator or consultant and pending grants W. Zheng10, L. Garrett9, C. J. Tifft1,6, W. A. Gahl1,6,5, as well as grants already received); Modest; Enzyvant. P. D. L. Day-Salvatore12, J. A. Mindell2, M. C. V. Harmatz: B. Research Grant (principal investigator, col- Malicdan1,6,5 laboratororconsultantandpendinggrantsaswellasgrants already received); Modest; Enzyvant. N.O. Mungan: B. 1NationalHumanGenomeResearchInstitute,NIHandNIH Research Grant (principal investigator, collaborator or Undiagnosed Diseases Program, Common Fund, Office of consultant and pending grants as well as grants already the Director, NIH, Bethesda, MD, United States, received); Modest; Enzyvant. F.D. Bulut: None. C. 2Membrane Transport Biophysics Section, National Lampe: B. Research Grant (principal investigator, colla- Institute of Neurological Disorders and Stroke, NIH, borator or consultant and pending grants as well as grants Bethesda, MD, United States, 3Department of Pediatrics, already received); Modest; Enzyvant. N. Guelbert: B. Section of Genetics, University of Colorado School of Research Grant (principal investigator, collaborator or Medicine, Aurora, CO, United States, 4Ophthalmic consultant and pending grants as well as grants already Genetics and Visual Function Branch, National Eye received);Modest;Enzyvant.N.Arslan:B.ResearchGrant Institute, NIH, Bethesda, MD, United States, 5Human (principal investigator, collaborator or consultant and Biochemical Genetics Section, National Human Genome pendinggrantsaswell asgrantsalreadyreceived); Modest; Research Institute, NIH, Bethesda, MD, United States, Enzyvant. B. Makay: B. Research Grant (principal inves- 6Office of the Clinical Director, National Human Genome tigator, collaborator or consultant and pending grants as Research Institute, NIH, Bethesda, MD, United States, well as grants already received); Modest; Enzyvant. R.D. 7Diagnostic and Research Services Branch, Office of Puri: B. Research Grant (principal investigator, colla- Research Services, NIH, Bethesda, MD, United States, borator or consultant and pending grants as well as grants 8Division of Hemapathology, Mayo Clinic, Rochester, MN, already received); Modest; Enzyvant. S. Bijarnia-Mahay: United States, 9Embryonic Stem Cell and Transgenic None. L. Selim: B. Research Grant (principal investigator, Mouse Core, National Human Genome Research Institute, collaborator or consultant and pending grants as well as NIH, Bethesda, MD, United States, 10National Center for grants already received); Modest; Enzyvant. I. Gamal el Translational Science, NIH, Bethesda, MD, United States, Din: None. S. Kapoor: B. Research Grant (principal 11NIH, Bethesda, MD, United States, 12Department of investigator, collaborator or consultant and pending grants Medical Genetics and Genomic Medicine, Saint Peter’s as well as grants already received); Modest; Enzyvant. M. University Hospital,, New Brunswick, NJ, United States DiRocco: B. Research Grant (principal investigator, colla- borator or consultant and pending grants as well as grants LysosomesrelyonthemaintenanceofanacidicluminalpH alreadyreceived);Modest;Enzyvant.S.Ozen:B.Research for optimal function. The active accumulation of protons is Grant (principal investigator,collaboratororconsultantand driven primarily by V-ATPase, but luminal acidification pendinggrantsaswell asgrantsalreadyreceived); Modest; also requires a neutralizing ion movement. Chloride has Enzyvant. E.D. Batu: None. G. Gokcay: B. Research been proposed to provide this counterion through the Grant (principal investigator,collaboratororconsultantand transporter ClC-7, encoded by CLCN7. Individuals with pendinggrantsaswell asgrantsalreadyreceived); Modest; loss-of-functionCLCN7mutationsdeveloposteopetrosis;in Enzyvant. M. Torcoletti: B. Research Grant (principal contrast, here we describe two unrelated children with an investigator, collaborator or consultant and pending grants identical pathogenic de novo variant in CLCN7 without as well as grants already received); Modest; Enzyvant. J. osteopetrosis but instead showing a pleotropic syndrome, Karafilidis:A.Employment(fullorpart-time);Significant; including cutaneous albinism, developmental delay, hepa- Enzyvant. A. Solyom: A. Employment (full or part-time); tosplenomegaly, lysosomal storage, cellular accumulation Significant; Enzyvant. of large intracellular vacuoles, and no osteopetrosis. The mutation, c.2144A>G; p.Tyr715Cys, increases ClC-7-1334 mediated chloride flux, decreases lysosomal pH and affected at prenatal testing; pregnancy was ended. Inter- increases the size and number of intracellular vacuoles in estingly, neuroimaging in the first patient showed pro- thepatients’fibroblasts,withasimilarphenotypicspectrum gressive cerebral atrophy but not the typical white matter in mice carrying an equivalent mutation. The cellular abnormalities seen in previously described complex II hyperacidity and cellular phenotype were rescued in vitro deficient patients. This might point towards a distinct fea- by treatment with the alkalinizing agent, chloroquine, ture of complex II deficiency caused by SDHC disruption, emphasizing the role of ClC-7 in regulating lysosomal pH. compared to complex II deficiency caused by disruption of E. Nicoli: None. M. Weston: None. M. Hackbarth: the other SDH-genes and SDHAF1. None. A. Becerril: None. A. Larson: None. W.M. Zein: Conclusion:Herewereportforthefirsttimetwocasesof None. P.R. Baker II: None. J.D. Burke: None. H. Dor- complex II deficiency caused by biallelic disruption of ward: None. M. Davids: None. Y. Huang: None. D.R. SDHC, emphasizing the importance of screening all SDH- Adams: None. P.M. Zerfas: None. D. Chen: None. T.C. genes in patients with (or suspected of) complex II Markello:None.C.Toro:None.G.Elliott:None.M.Vu: deficiency. None. U. Undiagnosed Disease Network: None. W. S.I.M. Alsters: None. S.N. van der Crabben: None. Q. Zheng: None. L. Garrett: None. C.J. Tifft: None. W.A. Waisfisz: None. L.P. van der Heuvel: None. R.J. Gahl: None. D.L. Day-Salvatore: None. J.A. Mindell: Rodenburg: None. M.S. van der Knaap: None. None. M.C.V. Malicdan: None.  P06
.07B  P06
.06A Screening & Diagnosis of Congenital Metabolic Biallelic disruption of SDHC leads to a novel Disorders using Mass Spectrometry in India: 15 Years’ presentation of mitochondrial complex II deficiency Experience with Issues & Challenges S. I. M. Alsters1, S. N. van der Crabben1, Q. Waisfisz1, U. P. Dave L. P. van der Heuvel2, R. J. Rodenburg2, M. S. van der Knaap3 MILS International India & Haffkine Institute, Mumbai, India 1Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Clinical Genetics, Amsterdam, Netherlands, Introduction: Most congenital metabolic disorders cause 2Nijmegen Center for Mitochondrial Disorders (NCMD) at severe pathological sequel, such as mental retardation, the Department of Pediatrics, Radboud University Medical sudden infantile death or other irreversible mental/motor Center, Nijmegen, Netherlands, 3Amsterdam UMC, Vrije disabilities. The dilemma for a clinician is overlapping Universiteit Amsterdam, Department of Child Neurology, symptoms in majority of amino, organic & fatty acid Amsterdam, Netherlands disorders like failure to thrive, seizures, vomiting, poor feeding, metabolic acidosis, lethargy, and developmental Introduction: Succinate dehydrogenase complex (i.e. delay. Hence, a need of metabolic test to cover a large complex II) deficiency is a rare mitochondrial disorder. So spectrum of disorders in one test. far, in three out of the four nuclear encoded proteins MaterialsandMethods:Theurinarymetabolicprofiling composing succinate dehydrogenase (SDHA, SDHB, and to cover more than 140 metabolic abnormalities was SDHD),andinoneofitsassemblyfactorgenes(SDHAF1), developed for screening the 5880 patients. The confirmed biallelic disruption has been shown to cause complex II diagnosis was by gas chromatography /mass-spectrometry deficiency with a leukoencephalopathy as central clinical or mutational analysis. presentation.ForthefourthSDH-genecomposingsuccinate Results: The 48 % (2856 of 5880 cases) were diagnosed dehydrogenase, SDHC, biallelic disruption has not been to have metabolic abnormality. Amino and organic acido- reported, as of yet. pathiesaccountedhighestasamajorcauseofmortalityand Methods and Results: Here we describe the clinical and morbidity. Overall, low birth weight (34%), convulsions molecular analysis of two siblings with biochemically (33%), premature birth (27%), acidosis, refusal to feed confirmed complex II deficiency, caused by compound (13%) and respiratory distress (13%) were recorded, with heterozygous variants in SDHC (c.31C>T; p.(Arg11Cys) consanguinity, history of mental retardation and death of andc.202T>C;p.(Ser68Pro)).Segregationanalysissupports earliersibsasotherhigh-riskgeneticfactors.Thishigh-risk the recessive pattern of inheritance: in none of four healthy screeningindicatedthatwhichmetabolicdisordersaremore siblingstestedbothvariantswerepresent.Onepatienthada frequent in Indian population and a need of strategic plan- severeneurologicalhandicapanddiedofrespiratoryfailure ning for newborn screening at affordable cost. at the age of 11 years. The other sibling was found to beAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1335 Conclusions: The method used for diagnosis covered a  P06
.09D largespectrumofmetabolicdisordersinashortesttimewith D-Bifunctional protein deficiency - diagnosis by whole cost-effective approach & was found significant in a exome sequencing and fibroblast analysis despite resource constraint Indian scenario. Our experience & data normal plasma biochemistry will be demonstrated emphasizing genetic counselling & prenatalmutationaldiagnosisinfewillustrativecasesalong M. McClatchey1, M. D'Alessandro2, A. Ross1, withissues&challengeswhileimplementationofthestudy. S. Ferdinandusse3, DDD Study, J. C. S. Dean1 U.P. Dave: None. 1North of Scotland Regional Genetics Service, Aberdeen,  P06
.08C United Kingdom, 2Unviersity of Aberdeen, Aberdeen, cDNA structure analysis revealed a novel CTNS United Kingdom, 3Laboratory of Genetic Metabolic mutation Diseases, Academic Medical Centre, University of Amsterdam, Amsterdam, United Kingdom V. Serzhanova1, A. Filatova1, S. Papizh2, M. Skoblov1,3 D-Bifunctional protein (DBP) deficiency is an autosomal 1Research Center for Medical Genetics, Moscow, Russian recessive disorder of peroxisomal fatty-acid beta-oxidation, Federation, 2Research Institute of Pediatrics and Pediatric caused by mutations in the HSD17B4 gene. It is Surgery, Moscow, Russian Federation, 3School of characterisedbyearly-onsetneurologicalsymptomsinclud- Biomedicine, Far Eastern Federal University, Vladivostok, ing hypotonia and seizures, developmental delay and Russian Federation eventual neuroregression. Survival beyond 36 months is rare.Diagnosisreliesonthedetectionofaccumulatedlevels Introduction: Cystinosin, encoded by the CTNS gene, is a of VLCFAs in plasma but occasional patients have carrier protein responsible for the export of cystine out of undetectable or near normal plasma levels, sometimes the lysosome. Its deficiency leads to cystinosis, an associated with longer survival. autosomal recessive lysosomal storage disorder. Here, we We report a 9 year old male patient born to non- report a patient with Infantile Nephropathic type of consanguineousnorthernEuropeanparents,presentingwith cystinosis (INC). neonatal seizures and global developmental delay from Materials and Methods: Total RNAs from peripheral early infancy. Developmental progress was made until blood mononuclear cells of participants and primary fibro- around 4 years, after which steady neuro-regression was blasts were extracted by the standard Trizol-based method. seen. Metabolic testing of urine and plasma, including The cDNA structure analysis was performed by electro- VLCFAs, demonstrated normal findings on multiple phoresis (EP) following Reverse Transcription PCR (RT- occasions. PCR) and Sanger sequencing. Trio based whole exome sequencing undertaken through Results:The cDNA structure analysis of all exons ofthe the DDD study identified compound heterozyosity for a CTNS revealed homozygous loss of 4th and 5th exons. On missense and a frameshift variant in HSD17B4, consistent theDNAlevelweconfirmed9kbdeletion,spanningregion with DBP-deficiency. The diagnosis was confirmed by from 3rd to 5th introns. In order to identify the inheritance enzyme analysis in cultured skin fibroblasts which showed pattern we analyzed the pro-band's mother's CTNS gene reduced DBP activity (mildly reduced hydratase activity; both on the cDNA and the DNA levels. Mother was found undetectable dehydrogenase activity) despite a persistent to be heterozygous for the same mutation. normal VLCFA profile, consistent with type III DBP Conclusions:ForINCdiagnosticsweshowedadvantages deficiency. of cDNA sequencing versus DNA sequencing. First of all, ThiscasehighlightstheunreliabilityofplasmaVLCFAin in case of some genes, such as CTNS, it is cheaper to thediagnosisofDBP-deficiency,particularlywhenresidual sequence cDNA fragments rather than all exons separately. enzymaticactivitymaybepresent.Triobasedwholeexome We amplified CTNS cDNA, consisting of 12 exons,as sequencing is an alternative, with confirmation by analysis 3 separate fragments. Secondly, long enough deletions or of enzyme activity in cultured fibroblasts. insertions could be detected by electrophoresis with fol- M. McClatchey: None. M. D'Alessandro: None. A. lowing confirmationbyDNA sequencing.Weestimatethis Ross:None.S.Ferdinandusse:None.J.C.S.Dean:None. novel deletion to be classified as pathogenic according to ACMG criteria because it leads to a truncated CTNS  P06
.10A protein. A case of dihydropyrimidine dehydrogenase deficiency V. Serzhanova: None. A. Filatova: None. S. Papizh: and homozygous mutation DPYD:c.1905+1G>A in None. M. Skoblov: None. Bulgarian patient with severe autistic disorder1336 M. B. Ivanova1,2, V. Jordanova1, T. Todorov3,  P06
.11B A. Todorova3,4, D. Dimitrov1, I. Dimova5, A. Savov1 Electronic nose for diagnosis of metabolic diseases via breath samples 1National Genetic Laboratory, University Hospital of Obstetrics and Gynecology „Maichin dom“, Medical M. Shinawi1, S. Q. Shen1, R. Jeries2, M. Malik1, L. Bai1, University, Sofia, Bulgaria, 2Faculty of Chemistry and A.Osula1,R.Wu1,B.Tomic1,E.Toolan1,D.K.Grange1, Pharmacy, Department of Analytical Chemistry, Sofia H. Haick2 University "St. Kl. Ohridski", Sofia, Bulgaria, 3Genetic Medico-Diagnostic Laboratory “Genica”, Sofia, Bulgaria, 1Washington University School of Medicine, Saint Louis, 4Department of Medical Chemistry and Biochemistry, MO, United States, 2Technion−Israel Institute of Medical University, Sofia, Bulgaria, 5Department of Technology, Haifa, Israel Medicalgenetics,MedicalUniversitySofia,Sofia,Bulgaria Inborn errors of metabolism (IEMs) are individually rare Background: Dihydropyrimidine dehydrogenase (DPD) but often devastating illnesses characterized by the toxic deficiency is an autosomal recessive disorder of the accumulation of metabolites. Early diagnosis, frequent pyrimidine metabolism characterised by thymine-uraciluria monitoring, and dietary intervention starting in early with variable expressivity and different phenotypes. It infancy substantially decrease morbidity and mortality. variesfromasymptomatictosevereneurologicalmanifesta- However,currentdiagnosisandmonitoringmethodsrelyon tions and an increased risk of toxicity from 5-fluorouracil repeated blood draws and costly laboratory tests with treatment. prolongedturnaroundtimes.Thus,anon-invasive,efficient, Materials and Methods: A child with severe autistic and rapid approach is needed. Here, we present a novel behavior, intellectual disability (no speech at 6 years old) approach for monitoring patients with IEMs based on and family history - aunt with mental retardation, was analysis of volatile organic compounds (VOCs) in breath referred for genetic counseling. Metabolic screening was samples using a nanomaterial-based sensor array, the performed in urine sample by dipstick - glucose, ketone, electronicnose(eNose).Exhaledbreathwascollectedfrom pH, and reducing sugars, followed by LC-MS/MS blood 31patientswithIEMsand34healthycontrolsandanalyzed aminoacids and acylcarnitines and GC/MS urine organic using both eNose and gas chromatography mass spectro- acids analysis. Mutations in DPYD gene are reported in metry (GC-MS). IEM patients comprised 21 patients with DPD deficiency patients. The gene was investigated by phenylketonuria (PKU), three patients with ornithine direct Sanger sequencing in proband and his parents. transcarboxylase deficiency, and 7 patients with various Results: Elevated levels of thymine and uracil were other IEMs. Machine learning-based pattern recognition detectedbyGC/MSurinetestwhichwassuggestiveofDPD algorithms were used to identify breath profiles that deficiency. Molecular analysis of DPYD gene showed a distinguished IEM patients from healthy controls with homozygous splice-site mutation c.1905+1G>A in the 78% accuracy, 80-87% sensitivity, and 71-77% specificity. proband, inherited from heterozygous parents. Subse- When restricting the analysis to patients with PKU, these quently, prenatal testing in the family was performed. The patients could be distinguished from healthy controls with fetus was healthy non-carrier. 78% accuracy, 80% sensitivity, and 76% specificity. GC- Conclusion: Here we report the first Bulgarian patient MSshowedthat dodecane,5-butylnonane,andapropanoic withsevereautisticdisordercausedbyDPDdeficiencyand acid-derived compound were significantly elevated in subsequentprenataldiagnosticsperformedinthefamily.As breath samples from PKU patients. Each of these patients with this deficiency could be easily detected by compounds reliably discriminated PKU patients from determinationofthethymine-uraciluria,screeningforthese controls (c-statistic = 0.786-0.815). Together, these results defects are indicative for all patients with any autistic suggest that breath analysis could become a viable non- behavior and intellectual disability. It also could be useful invasive clinical monitoring and screening tool for IEMs for those patients who are going to be treated with 5- and other disorders that affect pediatric populations. fluorouracil to prevent lethal toxicities and personalise M. Shinawi: None. S.Q. Shen: None. R. Jeries: None. treatments. M. Malik: None. L. Bai: None. A. Osula: None. R. Wu: M.B. Ivanova: None. V. Jordanova: None. T. None. B. Tomic: None. E. Toolan: None. D.K. Grange: Todorov:None. A.Todorova: None.D.Dimitrov: None. None. H. Haick: None. I. Dimova: None. A. Savov: None.  P06
.13D Measurement of myocardial native T1 value in Fabry patients with treatmentAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1337 O. MIGITA1, K. Kida2, A. Kotoku3, H. Yamamoto1 FLPbasedongeneticbackground.Themostcommonform is FPL type 2 (Dunnigan disease) caused by mutation in 1Department of Pediatrics, St. Marianna University School LMNA gene. Typical clinical features of patients with FLP of Medicine, Miyamae, Kawasaki, Japan, 2Department of are excessive subcutaneous fat accumulation in the neck Pharmacology, St. Marianna University School of andface,reducedsubcutaneousfatinthearmsandlegsand Medicine, Miyamae, Kawasaki, Japan, 3Department of muscular appearance due to muscular hypertrophy. The Radiology, St. Marianna University School of Medicine, extentofadiposetissuelossusuallydeterminestheseverity Miyamae, Kawasaki, Japan of the associated metabolic complications such as hyper- glycemia, hyperinsulinemia, insulin-resistant diabetes mel- Fabrydiseaseisknownasmostprevalentlysosomalstorage litus, increased serum triglicerydes, hepatic steatosis, disease, and caused by mutations in the GLA gene. pancreatitis, high blood pressure, and premature athero- Complete or partial defected enzyme activity leads to the sclerosis with an increased risk of coronary heart disease. accumulation of enzyme substrate, sphingolipids in cells MaterialsandMethods:Among64patientstestedusing and multiple organ failure. Several reports have been custom NGS panel due to familiar dyslipidemia, 9 showed published that native T1 value from magnetic resonance lipodystrophic features. Similarity of the phenotypic traits imagingmethodsmayreflectsthestorageoforgans.Several and characteristic significant hypertriglyceridemia sug- reports also mentioned that native T1 value reduction was gested the diagnosis of FPL type 2. observed in patients with Fabry disease which prior of Results: The study revealed the presence of R482Q cardial structural or functional changes. alteration in LMNA gene in 4 subjects in two families and ECG, echocardiographic and MRI, including calculation R148K in PPARG gene in two subjects in one family. of native T1 value assessment, were performed with two Conclusions: Recognition of FPL type 2 and type 3 patients with Fabry disease prior to enzyme replacement confirm the molecular heterogeneity of familial partial treatment. In those patients LVH was absent, but native T1 lipodystrophy. Identification of patients with FPL is chal- valueshowedlowervaluethanmeansvalueinothers.After lenging due to variable and often mild phenotype. Severe startingERTtreatment,nochangesincardiacfunctionwere hypertriglyceridemia was consistent and easy to identify observed. But native T1 values were slightly normalized in feature. Thus we recommend all patient with markedly after 6-12 month ERT treatment. elevated TG to undergo molecular testing for FPL, pre- The native T1 value is one of the candidate quantitative ferably with targeted NGS. Financing: Statutory Research assessment for myocardial storage for lysosomal diseases. No.2016/X/9-SZB, PMM Hospital Research Institute Our results show that it may detect early cardiac involve- L. Rutkowska: None. I. Pinkier: None. K. Salacinska: ment and efficacy the treatment of Fabry disease. The None. D. Salachna: None. L. Jakubowski: None. A. reports which mentioned about T1 values in Fabry patients Gach: None. have been limited. Therefore, it is still unclear whether the native T1 value represents myocardial accumurations of  P06
.15B substrate in Fabry patients. Further results needed to L-Ferritin: one gene, five diseases; from hereditary translatethese finding,butnativeT1valuewouldbeuseful hyperferritinemia to hypoferritinemia - Report of new for clinical evaluation of lysosomal diseases. cases O.Migita: None.K. Kida: None.A.Kotoku: None.H. Yamamoto: None. B. Cadenas1,2,3, J. Fita-Torró4, M. Bermúdez-Cortés5, I. Hernandez-Rodriguez6, J. Fuster5, M. Llinares5,  P06
.14A A. Galera5, J. Romero7, S. Pérez-Montero4, Molecularheterogeneityinpatientswithfamilialpartial C. Tornador1,4, M. Sanchez4,8,9 lipodystrophy 1Whole Genix SL., Barcelona, Spain, 2Josep Carreras L. Rutkowska, I. Pinkier, K. Salacinska, D. Salachna, Leukemia Research Institute (IJC), Badalona, Spain, L. Jakubowski, A. Gach 3Universitat de Vic-Universitat Central de Catalunya, Vic, Spain, 4BloodGenetics SL, Esplugues de Llobregat, Spain, Polish Mother's Memorial Hospital Research Institute, 5Clinic University Hospital Virgen de laArrixaca,Instituto Lodz, Poland Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain, 6University Hospital Germans Trias i Pujol Introduction:Familialpartiallipodystrophy(FPL)isarare (HGTiP), Institut Català d’Oncologia (ICO), Badalona, AD transmitted disorder characterized by abnormal dis- Spain, 7University of Texas at Austin, Austin, TX, United tribution of adipose tissue. There are six different types of States, 8Program of Predictive and Personalised Medicine1338 ofCancer (PMPPC),Institutd’InvestigacióGermansTrias 1Department of Medical Genetics, Istanbul Medical iPujol(IGTP),Badalona,Spain,9UniversitatInternacional Faculty, Istanbul University, Istanbul, Turkey, 2Division of de Catalunya (UIC), Barcelona, Spain Pediatric Nutrition and Metabolism, Department of Pediatrics, Istanbul Medical Faculty, Istanbul University, Introduction: Ferritin is a multimeric protein composed of Istanbul, Turkey light (L-ferritin) and heavy (H-ferritin) subunits that binds and stores iron inside the cell. A variety of mutations have Introduction: Classical galactosemia is a disorder of beenreportedintheL-ferritinsubunitgene(FTLgene)that pathogenic GALT variants leading to galactose-1-phos- cause the following five diseases: (1) hereditary hyperferri- phate-uridyl-transferase deficiency. Majority of the patho- tinemiawithcataractsyndrome(HHCS),(2)neuroferritino- genic variants are small sequence alterations, nevertheless pathy, a subtype of neurodegeneration with brain iron grossalterationshavealsobeenreported(1%).Weaimedto accumulation (NBIA), (3) benign hyperferritinemia, (4) L- investigate the frequency and distribution of GALT muta- ferritindeficiencywithautosomaldominantinheritance,and tions in Turkish galactosemia patients with genotype- (5) L-ferritin deficiency with autosomal recessive inheri- phenotype correlation. tance. Defects in the FTL gene lead to abnormally high Material and Methods: Clinically and biochemically levels of serum ferritin (hyperferritinemia) in HHCS and diagnosed 91 patients with galactosemia were included in benign hyperferritinemia, while low levels (hypoferritine- this study. Algorithmic genetic testing strategy for GALT mia) are present in neuroferritinopathy and in autosomal was performed initially with Sanger sequencing (n=91) dominant and recessive L-ferritin deficiency. followed by MLPA (n=19), only for cases with incompa- Methods:WehavesequencedFTLgeneeitherbySanger tible sequence result. sequencing or by next generation sequencing (NGS) in Results: We identified 11 known and four novel patho- three families with abnormal levels of ferritin. Moreover, genic variants (p.R67Pfs*19, p. S236
Rfs*30, p. S156
*, p. we have performed an extensive review of all reported V243I) in 91 patients leading to 95% detection rate. Ret- variants in the FTL gene linked with the previously rospectiveinvestigationofmutationunidentifiedcaseswere described five conditions. tentatively considered galactosemia initially however Results: Here, we identified two novel FTL variants that deviated in follow ups. causedominantL-ferritindeficiencyandHHCS(c.375+2T Conclusions:AsinEuropeancohorts,p.Q188Rinexon6 > A and 36_42delCAACAGT, respectively), and one pre- was the most common (38%) GALT mutations. Second viouslyreportedvariant(Met1Val)thatcausesdominantL- most frequent mutation was p. E340
* (14%) in exon 10, ferritin deficiency. whichisknowntobespecificforpopulationinTurkey.The Conclusions: Globally, genetic changes in the FTL gene third most frequent mutation (8%) was a novel single are responsible for multiple phenotypes and an accurate nucleotide deletion leading to frameshift (p. R67Pfs*19) in diagnosisisusefulforappropriatetreatment.Weincludeda exon2,foundtoaggregateinpatientsfromeasternTurkey. diagnosticalgorithmforthedetectionofdiseasescausedby Algorithmic analysis of exons 6 and 10 would delineate defects in FTL gene. molecular genetic diagnosis for 60% of the patients. Funding: This research was partially supported by grant Absenceofgrossmutationsisattributedtooursmallsample SAF2015-70412-R from Spanish Secretary of Research, size. Nevertheless, MLPA should still be recommended for Development and Innovation (MINECO) Spain to M.S. galactosemia patients with unidentified pathogenic B.Cadenas:None.J.Fita-Torró:None.M.Bermúdez- sequence variants in GALT. Cortés:None.I.Hernandez-Rodriguez:None.J.Fuster: I. Kalay: Other; Modest; Istanbul University Research None. M. Llinares: None. A. Galera: None. J. Romero: Fund (Project No: TTU-2018-31142). M. Balci: None. C. None. S. Pérez-Montero: None. C. Tornador: None. M. gulec: None. G. Gokcay: None. M. Demirkol: None. S. Sanchez: None. Basaran: None. Z.O. Uyguner: None.  P06
.16C  P06
.17D The contribution of molecular genetic methods to the GBA1 mutational spectrum in the Republic of diagnosis of classical galactosemia and investigation of Macedonia and a report of a novel de novo mutation genotype-phenotype correlation H. Ajdarche1, M. Vujovic1, M. Jakimovska1, I.Kalay1,M.Balci2,C.gulec1,G.Gokcay2,M.Demirkol2, Z. Stojanovski2, O. Karanfilski2, K. Martinova3, S. Basaran1, Z. O. Uyguner1 D. Plaseska-Karanfilska1Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1339 1RCGEB “Georgi D. Efremov”, Macedonian Academy of M. F. Broekema1, M. Stahl Madsen2, M. Rønn Madsen2, Sciences and Arts, Skopje, Macedonia, The Former A.Koppen1,M.E.G.Kranendonk1,M.GrootKoerkamp1, Yugoslav Republic of, 2University Clinic for Hematology, N. Hamers1, A. Borgmans1, A. M. J. J. Bonvin3, F. C. P. Medical Faculty, University “Ss Cyril and Methodius”, Holstege1, W. Spiering4, H. Monajemi5, D. Cassiman6, Skopje, Macedonia, The Former Yugoslav Republic of, S. Mandrup2, E. Kalkhoven1 3University Pediatric Clinic, Medical Faculty, University “SsCyrilandMethodius”,Skopje,Macedonia,TheFormer 1CenterforMolecularMedicine,UniversityMedicalCenter Yugoslav Republic of Utrecht, Utrecht, Netherlands, 2Functional Genomics and Metabolism Research Unit, University of Southern Introduction: Gaucher disease (GD) is caused by the Denmark, Odense, Denmark, 3Bijvoet Center for deficient activity of β-glucocerebrosidase due to homo- Biomolecular Research, Utrecht University, Utrecht, zygous or double heterozygous GBA1 mutations. In Netherlands,4DepartmentofVascularMedicine,University addition, heterozygous GBA1 mutations represent the most Medical Center Utrecht, Utrecht, Netherlands, 5Internal common genetic risk factor for Parkinson’s disease. We Medicine,RijnstateHospital,Arnhem,Netherlands,6Center aimed to determine the GBA1 mutational spectrum among for Metabolic Diseases, Leuven University Hospitals, GDpatientsandthefrequencyofcommonGBA1mutations Leuven, Belgium among the general population from R. Macedonia. Material and Methods: Thirty-four individuals belong- Introduction: The nuclear receptor PPARγ, encoded by ing to 10 families with 15 GD Type 1 patients, as well as PPARG, isthe master regulator of adipocyte differentiation 392 individuals from the general population were studied. and function. Mutations in PPARG cause familial partial GD patients were studied using several different methods: lipodystrophysubtype3(FPLD3),characterizedbyadipose directDNAsequencingofGBA1exons,MultiplexLigation tissue redistribution causing type 2 diabetes, and dyslipide- Probe-Dependent Amplification (MLPA), and next- mia. In two non-consanguineous patients we identified generation sequencing on MiSeq using Illumina TruSight PPARγ  E379
K and R212Q. The mutations are situated in Inherited panel. Allele-specific amplification was designed distinctdomainsofthePPARγ.Whereas, E379
Kislocated to screen for five common GBA1 mutations among the in theligandbinding domain (LBD) and contactstheDNA general population. binding domain (DBD) of its binding partner RXRα in the Results: A total of eight pathogenic variants (c.115 PPARγ-RXRα-DNA crystal structure, R212Q is located in +1G>A, c.392A>G, c.882T>G, c.1226A>G, c.1263- the hinge region and interacts with the DNA. Methods and 1317del, c.1312G>A, c.1342G>C and c.1363A>G) were materials: We have used genome-wide sequencing-based detected. The most common mutation was c.1226A>G strategiesinPPARGknockoutmouseembryonicfibroblasts (N370S),representing60%ofGBA1alleles.Thec.882T>G transduced with PPARγ to determine how these PPARG and c.1342G>C were present on one allele (H255Q: mutations-thatdonotinterfereininteractionswithRXRα, D409H). The novel c.392A>G variant was detected in one ligand,andcofactors,butdoimpairtheadipogeniccapacity GD patient as a de novo event. The frequencies of GBA1 - affect the ability of PPARγ to activate PPARG target mutations among the general population were the follow- genes in the context of native chromatin structure. ing: c.1226A>G (3/700, 0.43%), c.882T>G/c.1342G>C (2/ Results: Both PPARG mutations impair the transactiva- 784, 0.26%), c.115+1G>A (1/668, 0.15%), while c.1263- tion potential of PPARγ on an overlapping subset of target 1317del was not detected among the studied individuals. genes. Classical PPARγ target genes such as FAB P4
, Conclusion: The knowledge of GBA1 mutational spec- ANGPT L4
, and LPL are among the genes that are highly truminourcountrywillallowforbettermanagementofGD affected. Genome-wide profiling of PPARγ (WT and patients as well as easier carrier screening among GD mutants)andtheenhanceractivitymarkerH3K27Acshows family members and Parkinson’s patients. that these PPARG mutations impair PPARγ binding on H. Ajdarche: None. M. Vujovic: None. M. Jaki- enhancers that require PPARγ for chromatin remodeling. movska: None. Z. Stojanovski: None. O. Karanfilski: Conclusion: These findings indicate that a subset of None. K. Martinova: None. D. Plaseska- PPARγ target genes are sensitive to PPARG mutations. In Karanfilska: None. addition, relatively subtle molecular defects in PPARγ are sufficient to cause lipodystrophy.  P06
.18A M.F. Broekema: None. M. Stahl Madsen: None. M. FPLD3-associated PPARγ mutants define subclasses of Rønn Madsen: None. A. Koppen: None. M.E.G. Kra- target genes nendonk:None.M.GrootKoerkamp:None.N.Hamers: None. A. Borgmans: None. A.M.J.J. Bonvin: None. F.C. P. Holstege: None. W. Spiering: None. H. Monajemi:1340 None. D. Cassiman: None. S. Mandrup: None. E. A.Rotig:None.N.Boddaert:None.M.Metodiev:None. Kalkhoven: None. B. Ruzzenente: None.  P06
.19B  P06
.20C Ten novel mutations in the mitochondrial elongation Mutations in GLDC and AMT genes in Czech and translation factor EFG1 are associated to neurological Slovak patients with nonketotic hyperglycinemia involvement D. Zahorakova, J. Kucerova, M. Buganova, G. Barcia1,2, M. Rio1,2, Z. Assouline1,2, C. Zangarelli2, A. Puchmajerova, J. Zeman, P. Martasek M. Schiff1,2, M. Barth3, A. Munnich1,2, V. Procaccio3, J. Steffann1,2, A. Rotig2, N. Boddaert1,2, M. Metodiev2, Department of Pediatrics, Charles University and General B. Ruzzenente2 University Hospital, Prague, Czech Republic 1Necker Hospital, Paris, France, 2Imagine Institute, Paris, Introduction: Nonketotic hyperglycinemia (NKH, France, 3CHU Angers, Angers, France MIM#605899) is a rare, life threatening disorder caused by a defect in the mitochondrial enzyme complex - glycine Mutationsinnucleargenesencodingco-factorsorstructural cleavage system (GCS). The defect results in an accumula- subunitsofthemitochondrialtranslationmachineryprevent tionofglycineinthebody.ClassicalformofNKHpresents the synthesis of the 13 mitochondrial DNA encoded in the first days of life with lethargy, hypotonia, seizures, proteins which causes OXPHOS deficiency. Mutations in coma and apnea. Surviving patients have profound devel- the GFM1 gene, encoding the mitochondrial translation opmental delay and severe, usually pharmacoresistant elongation factor EFG1, have been linked to mitochondrial epilepsy. Cerebral spinal fluid (CSF) and plasma glycine diseases with neurologic or hepatic presentations in few levels are elevated as well as CSF:plasma glycine ratio. patients. NKH is an autosomal recessive disorder with causative Here, we further expand the genetic and phenotypic mutations identified in genes encoding the components of spectrum of GFM1-linked disease mutations by reporting GCS - GLDC, AMT and GCSH. We present the results of clinical, biochemical and neuroimaging findings from 9 mutation analysis in seven patients with classical form unrelated pediatric patients harboring homozygous or of NKH. compound heterozygous GFM1 mutations, including 10 Materials and Methods: Analysis of the GLDC and novel pathogenic variants. AMT genes was performed by Sanger sequencing All patients were born at term and without fetal distress. and MLPA. In 8/9 children, the firsts clinical signs were noticed during Results: Mutations in the GLDC gene, including a large the neonatal period. Only 1 child had psychomotor regres- deletion of exons 10 to 25, were detected in four patients. sion and lactic acidosis (8 months) after initial normal Five mutations (c.1420G>A, c.1543A>G, c.1877T>G, development. All patients presented with neurological c.2594del, c.2579G>T) are novel. Mutations in the AMT involvement with axial hypotonia and dystonia being the genewereidentifiedinthreepatients.Analysisofmutations major signs. West syndrome was frequently observed (5/9 in parents was performed to confirm compound hetero- patients). One child had liver failure. Western blot analysis zygosity in all patients. on patient fibroblasts revealed that all mutations result in Conclusions: Identification of molecular defect enabled decreased abundance of the mutant EFG1 protein. Specific genetic counseling and prenatal genetic testing in affected decrease of mtDNA-encoded proteins confirmed that families. We report 5 novel GLDC mutations and our mitochondrialtranslationwasimpairedinpatients,whichin findings expand the spectrum of described variants asso- turn, resulted in an impaired biogenesis of OXPHOS ciated with NKH. complexes I and IV. Supported by grants PROGRES Q26/LF1 and RVO- In conclusion, GFM1 mutations result in OXPHOS VFN 64165. deficiency and constant neurological involvement with D. Zahorakova: None. J. Kucerova: None. M. Buga- hypotonia, dystonia, and epilepsy. Some patients had a nova:None.A.Puchmajerova:None.J.Zeman:None.P. neonatal rapidly progressive disease, but a stable course is Martasek: None. more frequent. Liver failure is not a constant feature of GFM1 related diseases.  P06
.21D G.Barcia:None.M.Rio:None.Z.Assouline:None.C. GeneticanalysisofpatientswithGLUT1DSsuspect:the Zangarelli: None. M. Schiff: None. M. Barth: None. A. importance of diagnostic confirmation Munnich: None. V. Procaccio: None. J. Steffann: None.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1341 O. Sánchez-Lijarcio1,2, D. Yubero3,2, A. I. Vega1,2, À. None. C. Pérez-Cerdá: None. R. Artuch: None. B. García-Cazorla3,2, M. O'Callaghan3,2, L. G. Gutiérrez- Pérez: None. Solana4,2,M.L.Couce5,2,M.delToro6,2,E.López-Laso7,2, M. Ugarte1,2, C. Pérez-Cerdá1,2, R. Artuch3,2, B. Pérez1,2  P06
.22A Targeted next generation sequencing in selected inborn 1Centro de diagnóstico de Enfermedades Moleculares, errors of metabolism Centro de Biología Molecular, UAM, Madrid, Spain, 2CIBERER, Madrid, Spain, 3Hospital Sant Joan de Déu, L. Dvorakova, K. Peskova, M. Reboun, M. Novakova, Barcelona, Spain, 4Hospital Niño Jesús, Madrid, Spain, G. Storkanova, P. Chrastina, T. Honzik 5ComplejoHospitalarioUniversitariodeSantiago,Madrid, Spain, 6Hospital Universitario Vall d’Hebron, Barcelona, Clinic of Pediatrics and Adolescent Medicine, Prague 2, Spain,7HospitalUniversitarioReinaSofía,Córdoba,Spain Czech Republic Introduction: Classic patients with GLUT1DS present Introduction: We implemented a targeted NGS for the hypoglycorrhachia, drug-resistant epilepsy, developmental diagnosisofpatientswithasuspicionforselectedgroupsof delay, a complex movement disorder and, in 50% of the inborn errors of metabolism (IEM). cases, an acquired microcephaly. Furthermore, patients Methods: A total of 195 genes were analyzed using a respond to ketogenic diet. custom-designed oligo capture probe set (Roche Nimble- Methods:Inthisstudy,48suspectedcasesofGLUT1DS Gen)andMiSeqsequencer(Illumina).Positiveresultswere were included. Inclusion criteria were: CSF glucose level confirmed by Sanger sequencing. below 50.5 mg/dL and clinical findings suitable for Results: In total, we identified 74 mutations in genes GLUT1DS.Wehaveperformedtheidentificationofexonic associated with IEM. The found mutations were usually SNV and deletions in SL C2
A1 by Sanger combined with SNVs or small deletions/insertions. In two cases we iden- MLPA or its entire sequence were analysed by next gen- tified gross deletions (PHKA2, NM_000292.2: deletion of eration sequencing (NGS). Patients without pathogenic exon 33, AGL, NM_000642.3: deletion of exons 11-21). ® variants in SL C2
A1 were analysed by TruSight One panel Genes associated with glycogen metabolism were analyzed (Illumina® ). in 46 probands. The diagnosis of GSD was confirmed by Results: We have detected 27 patients with variations in finding of causative mutations in 19 of them: GY S2
 (1x), SL C2
A1. Ten of them were de novo mutations, while five G6PC (1x), AGL (4x), PYGL (2x) and PHKA2 (11x). We others were associated to maternal or paternal inheritance established the diagnosis in 3 out of 6 patients with rhab- (missense variants). The mutational spectrum in SL C2
A1 domyolyses (2x RYR1, 1x PFKM). Four out of 6 patients includes two large deletions, three small deletions, one were diagnosed in the group of peroxisomal disorders (1x small duplication and twenty nucleotide changes (eighteen PEX1, 1x PEX12, 2x HSD17B4). Among 17 patients with likely missense and two splice site mutations). Fifteen hyperhomocysteinemia we identified 1 patient with CblD variants are novel, five loss-of-functions and ten likely deficiency (MMADHC), 2 patients with FTCD deficiency, missense, six with unknown significance following the and 3 patients with the MTHFR deficiency. In two patients ACMG guidelines. In twenty-one cases no pathogenic with biochemical findings leading to urea cycle disorders mutations in SL C2
A1 were detected and were further ana- wediagnosed1patientwithargininosuccinicaciduria(ASL) lysed by TruSight One® panel, allowing the detection of and1patientwithCPSIdeficiency.Thediagnosticyieldfor pathogenic variants in eight different genes related to ion MSUD was 100% (1x BCKDHA, 8x BCKDHB). channels, transcriptional factors or cellular trafficking. Conclusions: The correlation of phenotypic signs, bio- Conclusions: Our results show that a response to keto- chemicalfindingsandNGSresultsiscrucialforcompleting genicdiet,drug-resistantepilepsyand/orhypoglycorrhachia thediagnosisofIEM.Support:MZCR-RVOVFN64165, is not a pathognomonic marker for GLUT1DS. Moreover, SVV No.260367 the results highlight the fact that geneticanalysis should be L. Dvorakova: None. K. Peskova: None. M. Reboun: a must-have for GLUT1DS classification. None. M. Novakova: None. G. Storkanova: None. P. ACCI-CIBERER project: ER18 P2
A C746
 and Chrastina: None. T. Honzik: None. ERTRLEOI1 O. Sánchez-Lijarcio: None. D. Yubero: None. A.I.  P06
.23B Vega:None.À.García-Cazorla:None.M.O'Callaghan: Haemochromatosistype4:structure/functionanalysisof None. L.G. Gutiérrez-Solana: None. M.L. Couce: None. the newly identified p.Ser47Phe missense mutation M. del Toro: None. E. López-Laso: None. M. Ugarte: provides new insights abouttheferroportinbiologyand mechanisms of disease1342 K. Uguen1, M. Le Tertre1, A. Elbahnsi2, C. Ka1, 1Robarts Research Institute, London, ON, Canada, I. Gourlaouen1, C. Ferec1, I. Callebaut2, G. Le Gac1 2Western University, London, ON, Canada 1InsermUMR1078,LaboratoiredeGénétiqueMoléculaire Introduction: Polygenic risk scores (PRSs) are often et Histocompatibilité, CHRU de Brest, Hôpital Morvan, calculated in prospective cohorts representing generally Université Bretagne Loire, Brest, France, 2IMPMC, healthy populations. Given the rarity of phenotypic Sorbonne Universités – UMR CNR S7590
, UPMC Univ extremes, characterizing the polygenic underpinnings of a Paris 06, Muséum d’Histoire Naturelle, IRD UMR206, quantitative trait’s full spectrum can be challenging. In Paris, France patients referred to a specialized lipid clinic, we aimed to establish polygenic profiles for triglyceride (TG), high- Haemochromatosistype4isthesecondmostfrequentcause density lipoprotein cholesterol (HDL-C), and low-density of inherited iron overload after HFE-related haemochroma- lipoprotein cholesterol (LDL-C). tosis. The disease is due to heterozygous mutations in the Materials and Methods: We performed PRS analyses SL C40
A1 gene, which encodes the sole iron export protein usinga16-SNPTGscore(N=1,406),9-SNPHDL-Cscore reportedinmammals;namelyferroportin1(FPN1).Alarge (N=1,298), and 10-SNP LDL-C score (N=1,226). For phenotypicheterogeneityisobservedinadultpatients.This clinical practicality, we utilized smaller PRSs that incor- is partially explained by the existence of two categories of porate SNPs with the largest phenotypic effects. Extreme geneticvariants:loss-of-functionmutations,whichleadtoa scores reflecting an excess of trait-raising SNPs were progressive accumulation of iron in reticuloendothelial definedasscores≥90thpercentile,ascalculatedinthe1000 cells,andgain-of-functionmutations,whichareresponsible Genomes cohort. forapartialtocompleteresistancetohepcidin(thesystemic Results: As TG levels increased, the prevalence of ironmetabolismregulatoryhormone)andaprogressiveiron extreme TG PRSs greatly increased; patients with the deposition in parenchymal cells. The p.Ser47Phe missense highestTGlevelswere5.30-fold(P<0.0001)morelikelyto mutationwasidentifiedin8relatedpatientspresentingwith haveanextremePRScomparedtothosewithnormallevels. anironoverloadphenotypecharacteristicofFPN1dysfunc- As HDL-C levels increased, the prevalence of extreme tion.InvitroevaluationswereperformedinHEK293Tcells. HDL-C PRSs increased slightly; patients with the highest They revealed that the 47Phe mutant was correctly HDL-C levels were 2.37-fold (P=0.003) more likely to expressed at the cell surface, while it significantly reduced haveanextremePRScomparedtothosewithnormallevels. abilityofFPN1toexportiron.Theyalsoevidencedthatthe As LDL-C levels increased, the prevalence of extreme 47Phe mutant was strongly resistant to hepcidin. Using a LDL-CPRSsincreasedslightly;however,theprevalenceof 3D model of human FPN1, built by homology to the extreme PRSs was not different between patients with the experimental structure of a bacterial homolog (BbFpn) in highest LDL-C levels and those with normal levels. the outward-facing state, we observed that Ser47 is located Conclusions: The polygenic profiles of these lipid traits in the vicinity of residues that play a critical role in the were quite distinct. Evaluation of patients at phenotypic transport of iron across the plasma membrane. The region extremesallowsformoreefficientuseofresourcestodefine might also be involved in the docking of hepcidin and clinically relevant genetic determinants. down-regulation of FPN1. We conclude that p.Ser47Phe J.S. Dron: None. J. Wang: None. H. Cao: None. M.A. missense mutation is responsible for ambivalent functional Iacocca:None.A.D.McIntyre:None.M.R.Ban:None.J. effects, with loss-of-function having a predominant con- F. Robinson: None. R.A. Hegele: None. sequence on phenotype. K. Uguen: None. M. Le Tertre: None. A. Elbahnsi:  P06
.25D None. C. Ka: None. I. Gourlaouen: None. C. Ferec: Hyperphenylalaninemia: identification and None. I. Callebaut: None. G. Le Gac: None. characterization of pathogenic variants in DNAJ C12
  P06
.24C D. Gallego1, F. Leal1, M. Castro1, I. Vitoria2, M. Bueno- Polygenicriskscoreprofilingofquantitativelipidtraits: Delgado3, A. Belanger-Quintana4, A. Morais5, lessons from a specialized dyslipidemic cohort C. Pedrón6, I. García7, C. Alcalde8, V. Hamilton9, J. Campistol10, R. Artuch10, M. Ugarte1, A. Gámez1, J. S. Dron1,2, J. Wang1, H. Cao1, M. A. Iacocca1,2, L. R. Desviat1, B. Pérez1 A. D. McIntyre1, M. R. Ban1, J. F. Robinson1, R. A. Hegele1,2 1Centro de diagnóstico de Enfermedades Moleculares, CentrodeBiologíaMolecular,UAM,Madrid,Spain,2H.U. La Fe, Valencia, Spain, 3H. U. Virgen del Rocío, Sevilla,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1343 Spain, 4H. U. Ramón y Cajal, Madrid, Spain, 5H. U. La Ege university Medical Faculty Division of Pediatric Paz, Madrid, Spain, 6H.U.Niño Jesús, Madrid, Spain, 7H. Genetics, Izmir, Turkey U.Miguel Servet,Zaragoza,Spain, 8Hospital RíoHortega, Valladolid, Spain, 9INTA, Santiago de Chile, Chile, 10H. Introduction: Leigh syndrome (LS) associated with Sant Joan de Déu, Barcelona, Spain cytochrome c oxidase (COX) deficiency is an early onset, fatal mitochondrial encephalopathy, leading to multiple Introduction: Hyperphenylalaninemia (HPA) is caused in neurologicalfailureandeventuallydeath,usuallyinthefirst 98% of cases by loss-of-function mutations in the gene decade of life. Mutations in SURF1, a nuclear gene coding for the hepatic protein phenylalanine hydroxylase encoding a mitochondrial protein involved in COX (PAH). The remaining 2% accounts for defects in the assembly, are the most common cause of LS. synthesis or regeneration of tetrahydrobiopterin (BH4), Material-Methods: SURF1 gene was sequenced in 48 cofactor of PAH and tyrosine and tryptophan hydroxylases patients with clinical suspicion of mitochondrial disorder (TH,TPH),bothneurologicallyexpressed.Biallelicvariants (mainly complex IV deficiency and LS) between January in gene DNAJ C12
, cochaperone of these hydroxylases, 2016 and January 2019. Demographical, clinical and were recently described in HPA patients with neurological molecular findings of the patients were obtained from symptoms and early-onset Parkinson. Here, we report the hospital files. genetic analysis of DNAJ C12
 in unsolved Spanish HPA Results: We identified 13 patients with clinical features cases and the functional characterization of variants. of LS who are either homozygous or compound hetero- Patients and Methods: The study included DNAJ C12
 zygous for SURF1 mutations. Of the 26 mutant alleles, 14 sequencing of 15 Spanish HPA cases (120-442 μM) neu- (54%) had null mutations (8 frameshift and 6 nonsense) 12 rologicallyasymptomatic.BH4treatmentwasonlyrequired (46%)hadmissense.Themostcommontwomutationswere under fever episodes. Functional analysis of variants was C.769G>A (6/26) and c.870dupT (6/26) (%23). Although doneusingpatient-derivedfibroblaststransientlytransfected mutations in SURF1 have been mainly associated with with the three hydroxylases. typicalLS,threeofthepatientsinthisreporthadanatypical Results:Fournovelnucleotidechangeswereidentifiedin course of LS. There is no definite genotype-phenotype DNAJ C12
 in 15 HPA cases: two pathogenic variants correlation.Electrontransportchainstudieswereperformed probably affecting splicing (c.298-2A>C, c.502+1G>C) in six patients in whom either muscle or skin fibroblasts and two likely pathogenic variants c.309G>T (p. specimen available. The COX activity in each of these six Trp103Cys) and c.524G>A (p.Trp175Ter). The change p. patients was significantly decreased. Trp175Ter, present in 0.1% of Spanish control population, Conclusions: To date, more than 100 patients of Leigh was detected in 80% of alleles, with 9 homozygous cases. disease with SURF1 mutations have been reported. We DNAJ C12
 mRNA levels were slightly diminished and reportclinicalandmolecularfindingsof13patientsfrom12 immunorreactive protein was undetectable. PAH transfec- families and also the first case series of SURF1 gene defi- tion suggest a pathogenic effect on PAH and TH stability ciency from Turkey. while no effect was found for TPH. M. Kose: None. H. Onay: None. F. Ozkınay: None. Conclusions: DNAJ C12
 sequencing should be incorpo- ratedinroutineHPAgeneticconfirmationofcasesdetected  P06
.27B in newborn screening to apply a tailored therapy. To avoid Progeroid syndrome with focal segmental future neurological complications, our cases should be glomeruloscrelosis due to ZMPST E24
 mutations included in clinical follow-up. Grants: PI16/00573; LCF/PR/PR16/11110018; ERDF M. Matsuo1, N. Iwasaki2,1, T. Kusakabe3, K. Sato4, D. Gallego: None. F. Leal: None. M. Castro: None. I. G. Nishimura5, K. Saito1 Vitoria: None. M. Bueno-Delgado: None. A. Belanger- Quintana: None. A. Morais: None. C. Pedrón: None. I. 1Institute of Medical Genetics, Tokyo Women's Medical García: None. C. Alcalde: None. V. Hamilton: None. J. University, Tokyo, Japan, 2Institute of Geriatrics, Tokyo Campistol:None.R.Artuch:None.M.Ugarte:None.A. Women'sMedicalUniversity,Tokyo,Japan,3Departmentof Gámez: None. L.R. Desviat: None. B. Pérez: None. Endocrinology, Metabolism, and Hypertension Research, ClinicalResearchInstitute,NationalHospitalOrganization  P06
.26A Kyoto Medical Center, Kyoto, Japan, 4Department of Mutations in SURF1 Gene Associated with Leigh Cardiology, Tokyo Women’s Medical University, Tokyo, Syndrome İn Turkey Japan, 5Center for Intractable Diseases, Saitama Medical University Hospital, Saitama, Japan M. Kose, H. Onay, F. Ozkınay1344 Introduction: Biallelic ZMPST E24
 mutations cause man- Isolated methylmalonic acidaemia (iMMA) is a group of dibuloacral dysplasia with type B lipodystrophy (MADB), autosomal recessive disorders caused by impairment of an autosomal recessive progeroid syndrome characterized propionatemetabolism.Theseverityofclinicalpresentation by mandibular hypoplasia, progressive acroosteolysis, and dependsontheunderlyinggeneandcanrangefrommildto lipodystrophy. Two MADB patients with focal segmental life-threatening condition with failure to thrive, hypotonia, glomerulosclerosis (FSGS) were reported previously. metabolic acidosis, developmental delay, encephalopathy, Herein,wepresentanadditionalMADBpatientwithFSGS pancreatitis, and chronic kidney disease. The common sign due to ZMPST E24
 mutations. is increased methylmalonic acid plasma/urine level and Materials and Methods: The patient is 42-year-old hyperamonaemia. iMMA is genetically heterogeneous and Japanese female. Her older sister had succumbed from can be due to defects in genes involved in propionate diabetic nephropathy at age 41 years. Her clinical course pathway or cobalamin metabolism. The most common are was as follows: subcutaneous fat atrophy since childhood; MUT, MMAA, and MMAB. proteinuria in her twenties; proteinuria with hypertension Patients and Methods: Nine children were reported for after delivering her son at age 31 years; diabetes mellitus genetictesting.Fivepatientswereclinicallydiagnosedafter (DM), hyperlipidemia, and fatty liver at 36 years; loss of manifestationbeforeyear2013and4patientswerefoundin visceral fat and renal dysfunction due to FSGS proven on extendedneonatalscreeningfrombloodspotsthathasbeen kidney biopsy at 39 years, and kidney transplantation at 41 undertakeninSlovakiasince2013.GenesMUTandMMAA years.Atage42years,shewasreferredfordiagnosticwork were sequenced using Sanger sequencing. One patient was up. She showed a progeroid appearance with decreased analyzed using whole exome sequencing. subcutaneous fat. Radiographs revealed open cranial suture Results: The diagnosis of iMMA was genetically con- and thin clavicles. The study protocol was approved by the firmed in all tested patients. Six patients had bi-allelic Institutional Review Boards of Tokyo Women’s Medical MMAA mutations (three different known pathogenic var- University. Written informed consent was obtained. iants and one novel variant p.A102T), two patients had bi- Results: Two rare heterozygous variants, p.Q41X and p. allelicMUTmutations(twoknownpathogenicvariantsand R412L in ZMPST E24
, were detected. R412L, a novel var- one novel variant p.R93C) and one patient had a homo- iant conserved over species, was not found in ExAC or zygous known pathogenic MMAB variant. 1000G, and was predicted to be pathogenic on PolyPhen2 Conclusions:Theneonatalscreeningfrombloodspotsisan and Mutation T@ster. She has since received Metreleptin effective way for early pick-up of individuals with iMMA. injections, achieving improvements of DM, liver dysfunc- The most prevalent iMMA underlying gene in Slovakia is tion, and renal dysfunction. MMAAfollowedbyMUTandMMAB,unlikereportedinother Conclusion: We reported a progeroid patient associated countries, where the MUT gene is the most prevalent one. with FSGS caused by ZMPST E24
 mutations. Metreleptin Support: APVV-17-0296, VEGA 2/0083/17, APVV-107-12 was estimated to ameliorate renal function. M. Skopkova: None. K. Brennerova: None. J. Sali- M. Matsuo: None. N. Iwasaki: None. T. Kusakabe: gova:None.L.Potocnakova:None.K.Halova:None.V. None. K. Sato: None. G. Nishimura: None. K. Bzduch: None. J. Stanik: None. D. Gasperikova: None. Saito: None.  P06
.30A  P06
.28C A novel homozygous missense mutation in TUFM leads Isolated methylmalonic acidaemia in Slovakia to a mitochondrial cardiomyopathy syndrome without progressive encephalopathy M. Skopkova1, K. Brennerova2, J. Saligova3, L. Potocnakova3, K. Halova4, V. Bzduch2, J. Stanik1,2, T. Hershkovitz1, A. Kurolap1,2, T. Paperna1, A. Mory1, D. Gasperikova1 C. Gonzaga-Jauregui3, S. E. Wolf3, J. D. Overton3, A. R. Shuldiner3, H. Mandel4, H. Baris Feldman1,2 1Institute of Experimental Endocrinology, Biomedical ResearchCenter,SAS,Bratislava,Slovakia,2Departmentof 1The Genetics Institute, Rambam Health Care Campus, Pediatrics, Medical Faculty of Comenius University and Haifa, Israel, 2The Ruth & Bruce Rappaport Faculty of National Institute of Children's Diseases, Bratislava, Medicine, Technion–Israel Institute of Technology, Haifa, Slovakia, 3Department of Pediatrics, Medical Faculty of Israel,3RegeneronGeneticsCenter,Tarrytown,NY,United PavolJozefSafarikandChildrenFacultyHospital,Kosice, States, 4Institute of Human Genetics and Metabolic Slovakia, 4Pediatric Clinic, Children Faculty Hospital, Disorders, Western Galilee Medical Center, Nahariya, Banska Bystrica, Slovakia IsraelAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1345 Introduction: Mitochondrial dysfunction typically results Sciences, Firenze, Italy, 3Medical Genetics Unit Cardarelli in clinically heterogeneous, often devastating, disorders. University Hospital, Napoli, Italy, 4Pediatric Neurology, Accurate molecular diagnosis can be challenging. We Neurogenetics and Neurobiology Unit and Laboratories, describeaproband,thethirdsonofhealthyconsanguineous Children's Hospital A. Meyer-University of Florence, parentsofMuslimArabdescent.Hepresentedatsixmonths Firenze, Italy, 5Metabolic and Muscular Unit, Meyer with fatal, severe cardiogenic shock, dilated cardiomyo- Children's Hospital, Firenze, Italy, 6Molecular Medicine, pathy,lacticacidosisandmultiplemitochondrialrespiratory IRCCS Fondazione Stella Maris, Pisa, Italy, 7 Medical complex deficiency. GeneticsUnit,DepartmentofBiomedicalExperimentaland Materials and Methods: We performed trio whole- Clinical Sciences, Firenze, Italy exome sequencing (WES) and singelton mitochondrial genome sequencing. Results were filtered for rare, protein- We evaluated a 14-month-old girl with apostural tetrapar- altering variants in genes related to mitochondrial function. esis, growth delay, severe psychomotor retardation, pro- Protein structures were modelled using SWISS-MODEL found sensorineural hearing loss, leopard-like retinopathy, based on the bovine crystal structure of mitochondrial hypogammaglobulinemia, anemia and thrombocytopenia, Elongation Factor Tu/Ts complex (PDB #1XB2), and hepatopathy, esophageal varices and calcifications in the visualized with UCSF Chimera software. hepatic segment VI, startle-type critical manifestations, Results: We identified a novel homozygous missense brain calcifications, progressive cortico-subcortical atrophy variantinTUFM(NM_003321.4):c.344A>C;p.His115Pro, that result in tetraventricular hydrocephalus. Moreover, encoding the mtDNA translation elongating factor Tu reduction of mitochondrial respiratory complex-I-III was (EFTu). Pathogenic variants were not detected in observed.Theseriousconditionsledthepatienttoexitusat mitochondrial DNA. 24 months of age. Several molecular tests (panel genes for Thismissensevariantislocatedindomain1oftheEFTu brain calcification, Aicardi-Goutières syndrome, disorders protein, which is required for GTP/GDP-binding and for ofglycosylation,peroxisomaldisease)andCGH-arraywere complex formation with elongation factor Ts (EFTs). This normal. Whole exome sequencing (WES) identified two highlyconservedHis115(GER P5
.42)ispredictedtobean rare variants in KARS gene. KARS gene encodes the exposed and functional residue; therefore, substitution with mitochondrial and cytoplasmic isoform of the t-RNA a physiochemically different residue may disrupt proper synthase of lysine, essential for a correct protein synthesis. protein folding, and may hamper Tu/Ts complex stability To date, mutations in KARS are associated with autosomal and EFTu reactivation. recessive Charcot-Marie-Tooth, non-syndromic hearing Conclusions: To date, only four patients with bi-allelic loss, clinical features characterized by microcephaly, TUFM mutations have been reported, all with severe early- epilepsy, leukoencephalopathy, peripheral neuropathy, onset lactic acidosis and progressive infantile encephalo- visual impairment, auditory and hepatic failure and others pathy without cardiomyopathy. We present a novel variant with severe cardiomyopathy, psychomotor and mild delay inapatientwithdilatedcardiomyopathyandlacticacidosis myopathy.Functionalstudyonmusclebiopsyofourpatient but without early encephalopathy, thus expanding the phe- revealed an alteration of protein expression. notype of TUFM-related mitochondrial disease. OurcaseshowsonceagainhowWESanalysisisthefirst T. Hershkovitz:None.A.Kurolap:None.T. Paperna: level method in clinical practice in children with multi- None. A. Mory: None. C. Gonzaga-Jauregui: None. S.E. systemic, neurological and/or neuromuscular problems, Wolf: None. J.D. Overton: None. A.R. Shuldiner: None. mostly in case of mitochondrial disorders whose diagnosis H. Mandel: None. H. Baris Feldman: None. is often problematic because of their large phenotypic and genotypic heterogeneity. Finally, the use of WES allowed  P06
.31B us to outline a new phenotype associated with a poorly EfficacyofWESinpatientswith"unsolvedphenotype": characterized gene. expansion of the phenotype spectrum associated with V. Palazzo: None. F. Peluso: None. L. Dosa: None. M. mutations in KARS gene Della Monica: None. F. Mari: None. E. Procopio: None. M.Donati:None.F.Santorelli:None.R.Guerrini:None. V. Palazzo1, F. Peluso2, L. Dosa1, M. Della Monica3, S. Giglio: None. D. Vergani: None. F. Mari4, E. Procopio5, M. Donati5, F. Santorelli6, R. Guerrini4, S. Giglio1,2, D. Vergani7  P06
.32C Muscle involvement in a large cohort of pediatric 1Medical Genetics Unit, Meyer Children's University patients with genetic diagnosis of mitochondrial disease Hospital, Firenze, Italy, 2Medical Genetics Unit, Department of Biomedical Experimental and Clinical1346 C. Jou1, J. D. Ortigoza-Escobar1, M. M. O'Callaghan1, Pesini: None. S. Emperador: None. E. Lopez-Gallardo: A. Nascimento1, A. Darling1, L. Pias-Peleteiro1, B. Perez- None. P. Bayona-Bafaluy: None. R. Montero: None. C. Dueñas1, M. Pineda1, A. Codina1, C. Arjona1, Jimenez-Mallebrera: None. A. Garcia-Cazorla: None. J. J. Armstrong1, F. Palau1, A. Ribes2, L. Gort2, F. Tort2, Montoya: None. D. Yubero: None. R. Artuch: None. P. Navas3, E. Ruiz-Pesini4, S. Emperador4, E. Lopez- Gallardo4,P. Bayona-Bafaluy4,R. Montero1, C. Jimenez-  P06
.33D Mallebrera1, A. Garcia-Cazorla1, J. Montoya4, Multiple mitochondrial DNA deletions due to mtDNA- D. Yubero1, R. Artuch1 maintenance defects are identified by next generation sequencing of the mitochondrial genome through 1Institut de Recerca Sant Joan de Déu, Esplugues de eKLIPse Llobregat, Spain, 2Hospital Clínic, IDIBAPS, CIBERER- ISCIII, Barcelona, Spain, 3Universidad Pablo de Olavide C. Bris1,2, D. Goudenège1,2, S. Bannwarth3, and CIBERER-ISCIII, Sevilla, Spain, 4Instituto de P. Gaignard4,5, B. Rucheton6, C. Jardel6, A. Trimouille7, investigación Sanitaria de Aragón and CIBERER-ISCIII, M. Martin-Négrier7, S. Allouche8, A. Slama4, Zaragoza, Spain V. Desquiret-Dumas1,2, N. Gueguen1,2, D. Bonneau1,2, M.Barth1,G.Lenears2,P.Reynier1,2,P.Amati-Bonneau1, Mitochondrial diseases (MD) are a group of genetic and V. Paquis-Flucklinger3, V. Procaccio1,2 acquired disorders which present significant diagnostic challenges. Here we report the disease characteristics of a 1Département de biochimie et génétique, CHU d'Angers, large cohort of pediatric MD patients (n = 95) with a angers, France, 2MITOVASC – Equipe MITOLAB UMR definitive genetic diagnosis, giving special emphasis on CNRS 6214 - INSERM 1083, Angers, France, 3Université clinical muscle involvement, biochemical and histopatho- Côte d'Azur, CHU de Nice,INSERM, CNRS, IRCAN, Nice, logical features. Of the whole cohort, 51 patients harbored France, 4Biochemistry Laboratory, Bicêtre Hospital, mutations in nuclear DNA (nDNA) genes and 44 patients Assistance Publique-Hôpitaux de Paris, Le Kremlin- had mutations in mitochondrial DNA (mtDNA) genes. The Bicêtre, France, 5U1195 Inserm and University Paris-Sud nDNA patients were more likely to have a reduction in and University Paris-Saclay, Le Kremlin-Bicêtre, France, muscle fiber succinate dehydrogenase (SDH) stains and in 6Biochemistry Department and Genetics Center, APHP, SDH-positive blood vessels, while a higher frequency of GHU Pitié-Salpêtrière, Paris, France, 7CHU Bordeaux, mtDNApatientshadraggedred(RRF)andbluefibers.The ServicedeGénétiqueMédicale,Bordeaux,France,8Service presence of positive histopathological features was asso- de biochimie, Centre Hospitalier et Universitaire de Caen, ciated with ophthalmoplegia, myopathic facies, weakness Caen, France and exercise intolerance. In 17 patients younger than two yearsofage,RRFandbluefiberswereobservedonlyinone Purpose: Diseases caused by nuclear genes affecting case, six cases presented cytochrome c oxidase (COX) mitochondrial DNA (mtDNA) stability are an important reduction/COX-fibers, SDH reduction was observed in five group of mitochondrial disorders and characterized by andallexceptonepresentedSDH-positivebloodvessels.In multiple mtDNA deletions. However, mtDNA deletions conclusion, muscle involvement was a frequent finding in also accumulate during aging, making their interpretation our series of MD patients, especially in those harboring difficult in patients suspected of mitochondrial diseases. mutations in mtDNA genes. The objective of this work was to identify criteria to Grant References: This work was supported by grants distinguish normal aging vs mtDNA maintenance defects. from the Instituto de Salud Carlos III (PI17/00109, PI17/ Methods: MtDNA of patient muscles with known 00021, PI17/01286, PI15/01082, PI16/01048), Fundación pathogenic variants in nuclear genes involved in mtDNA Mutua Madrileña MMA17/01, AEPMI, the FEDER Fund- maintenance (n=34) and muscle from controls without ing Program from the European Union, the Agència de mitochondrial enzyme and assembly defects (n=53) were Gestiód’AjutsUniversitarisideRecerca (AGAUR)(2014: sequenced by next-generation sequencing (NGS). The SGR 393), the CERCA Programme/Generalitat de Catalu- sequencing data were processed through eKLIPse, a nya and CIBERER-ISCIII. bioinformatic tool allowing the detection of mtDNA rear- C. Jou: None. J.D. Ortigoza-Escobar: None. M.M. rangements.Thedeletions’profileswerecomparedbetween O'Callaghan: None. A. Nascimento: None. A. Darling: patients and controls according to age groups. None. L. Pias-Peleteiro: None. B. Perez-Dueñas: None. Results:Intheoverallcohort,selectedparameterssuchas M. Pineda: None. A. Codina: None. C. Arjona: None. J. location or number of deletions and heteroplasmy level Armstrong: None. F. Palau: None. A. Ribes: None. L. were significantly different between patients and controls. Gort: None. F. Tort: None. P. Navas: None. E. Ruiz- However, the criteria for identifying mtDNA maintenanceAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1347 defects was depending on patient age: The number of the RD-Connect PhenoTips instance, and variant filtration deletions appearing to be significantly relevant only in the and prioritisation was undertaken using the RD-Connect elderly, while in young subjects breakpoint repeat lengths Genome-Phenome Analysis Platform. surrounding the deletions were discriminant. InonepatientWESidentifiedararenuclearhomozygous Conclusion: EKLIPse analysis of mtDNA NGS allowed mis-sense variant c.308C>T (rs749249430) in NDUFAF3 to discriminate age-related mtDNA rearrangements from on chromosome 3, three INDELs in NDUF S1
, intronic those related to mtDNA maintenance defects. These char- variants in NDUFA10 on chromosome 2 and a hetero- acteristics are promising criteria in order to guide the zygous intronic variant c.408+6468C>T (rs752756523) in molecular diagnosis towards mtDNA maintenance defects NDUFB9 on chromosome 8. In the other patient, a mito- and also to facilitate the prioritization of novel variants chondrialDNA(mtDNA)mis-sensemutationinMT-AT P6
 identified in nuclear-encoded genes involved in mtDNA c.163A>G at m.8689 and a splice donor variant c.207 stability. +2T>G (rs782792601) and two mis-sense splice region C. Bris: None. D. Goudenège: None. S. Bannwarth: variants: c.206A>G (rs781909386) and c.205A>G None.P.Gaignard:None.B.Rucheton:None.C.Jardel: (rs782503581) in NDUFB11 were identified on the X None.A.Trimouille:None.M.Martin-Négrier:None.S. chromosome. Allouche: None. A. Slama: None. V. Desquiret-Dumas: NDUFAF3isamitochondrialrespiratorychaincomplexI None. N. Gueguen: None. D. Bonneau: None. M. Barth: ( C1
) assembly factor. mtDNA mutation m.8689 is asso- None. G. Lenears: None. P. Reynier: None. P. Amati- ciated with mitochondrial complex V deficiency and Leigh Bonneau: None. V. Paquis-Flucklinger: None. V. syndrome while NDUFB11 is associated with mitochon- Procaccio: None. drial  C1
 deficiency. The pathogenicity of these genes is in the process of being confirmed in patient fibroblasts.  P06
.34A WES followed by functional validation of disease alleles Molecular diagnosis of mitochondrial respiratory chain could identify disease-causative variants in mitochondrial complex deficiencies by whole exome sequencing respiratory chain complexes. J. Vella: None. S. Laurie: None. L. Matalonga: None. J.Vella1,S.Laurie2,L.Matalonga2,J.Borg1,3,D.Soler4, J. Borg: None. D. Soler: None. E. Said: None. A. E. Said5, A. Felice1,5,6 Felice: None. 1The Malta BioBank (BBMRI.mt), Centre of Molecular  P06
.36C Medicine and Biobanking, University of Malta, Msida, Two long-surviving adults with Myopathy Lactic Malta, 2Centro Nacional de Análisis Genómico (CNAG- Acidosis Sideroblastic Anemia 1 (MLASA1) due to CRG), Center for Genomic Regulation; Barcelona Institute previously undescribed mutations in PU S1
 of Science and Technology (BIST); University Pompeu Fabra (UPF), Barcelona, Spain, 3Department of Applied M. F. Smeland1, K. Arntzen2,3,4, M. van Ghelue1,3, G. Å. Biomedical Science, Faculty ofHealth Sciences, University M. Hansen1, H. Hjellnes1, M. I. Olsen5 ofMalta,Msida,Malta,4DepartmentofPaediatrics,Mater Dei Hospital, Msida, Malta, 5Department of Pathology, 1Dpt of Medical Genetics, University Hospital of North Mater Dei Hospital, Msida, Malta, 6Department of Norway, Tromsø, Norway, 2Dpt of Neurology, University Physiology and Biochemistry, Faculty of Medicine and Hospital of North Norway, Tromsø, Norway, 3Department Surgery, University of Malta, Msida, Malta of Clinical Medicine, The Arctic University of Norway, Tromsø, Norway, 4The National Neuromuscular Centre of Mitochondrial disorders are considered to be rare diseases Norway, University Hospital of North Norway, Tromsø, which are genetically heterogenous. The oxidative phos- Norway, 5Dpt of Haematology, University Hospital of phorylation system consists of five multiprotein enzyme North Norway, Tromsø, Norway complexes. We report here two cases of patients suspected to have a mitochondrial disorder whose samples were Introduction: Myopathy, lactic acidosis, and sideroblastic banked at the Malta BioBank (BBMRI.mt). anemia 1 (MLASA 1, MIM#600462) is a rare, autosomal The analysis was part of a collaborative BBMRI-Large recessivemitochondrialdiseasewhichismostoftenfatalby Prospective Cohort (BBMRI-LPC) project focused on adolescence. A few cases of long-surviving patients have mitochondrial disorders. The full mitochondrial genome been reported. Microcephaly, short stature, cognitive sequenicng, whole exome sequencing (WES) and data impairment and cardiomyopathy are variable features. We processing were carried out at Centro Nacional de Análisis present two females aged 26 and 31, further demonstrating Genómico(CNAG-CRG).Phenotypicdatawasrecordedin long survival in MLASA 1.1348 Materials and Methods: Patient 1 presented with myo- of Molecular Medicine, Biotech Research Center, Pasteur pathy,lactacidosisandanemiaatage7,andMLASA1was Institute of Iran,, Tehran, Iran, Islamic Republic of suspected. Patient 2 presented with anemia at age 24. Severe exercise intolerance and myopathy since childhood Maple syrup urine disease (MSUD) is the primary was revealed. In both patients PU S1
 was sequenced by aminoacidopathyaffecting branched-chain amino acid Sanger/Next-Generation Sequencing. Further clinical (BCAA) metabolism. The disease is mainly caused by the investigations and cDNA analysis are ongoing. deficiency of an enzyme named branched-chained α-keto Results: In patient 1, compound heterozygosity for acid dehydrogenase (BCKD), which consist of four NM_025215.5(PU S1
):c.431G>Ap.(Arg144Gln)andc.441 subunits, and encoded by BCKDHA,BCKDHB, DBT, and +1G>A was detected. Patient 2 was shown to be homo- DLDgenerespectively.Consanguinityincreasesthechance zygous for c.441+1G>A. This mutation is predicted to of the presence of pathogenic mutations in a homoallelic disrupt the donor splice site of intron 3, making aberrant state.Bearingthisonourminds,autozygositymappingwas splicing likely. The missense variant c.431G>T p. performed with two sets of multiplex polymorphic STR (Arg144Gln) is located both at a highly conserved nucleo- (Short Tandem Repeat) markers linked to the above- tide and amino acid. Both patients have high S-lactate and mentioned genes. The aim was to indirectly find the chronic acidosis. Ringed sideroblasts were observed only probable mutated gene in the studied families. Then once, in patient 1, but have otherwise not been demon- families who showed a homozygous haplotype for the strable in our patients. STR markers flanking gene/genes were subsequently Conclusions: cDNA analysis might give further insights sequenced. In this study, we also summarized our recent into the consequences of the identified mutations, possibly molecular genetics findings to illustrate the mutation explaining the long survival. Classical sideroblastic anemia spectrum of MSUD in our country with high rate of is not obvious in all MLASA patients, and the expressivity consanguineous marriage (38.4%). Eleven novel mutations and age of presentation of symptoms are variable. Darbe- and some recently reported mutations were identified. We poetin alfa seems effective in controlling the anemia, while foundthatBCKDHBmutationisthemostcommonmutated severe lactacidosis is difficult to treat. gene in our study which is different from other reports in M.F. Smeland: None. K. Arntzen: None. M. van other parts of the world. Additionally, structural modelling Ghelue:None.G.Å.M.Hansen:None.H.Hjellnes:None. of MSUD mutations has been analyzed to predict the M.I. Olsen: None. pathogenicityofthenewlyidentifiedvariants.Identification of these mutations will further expand the spectrum of  P06
.37D known gene mutations and contributes to the genotype- Maple syrup urine disease mutation spectrum in a phenotype correlation and is very important in prenatal cohortof40consanguineouspatients;insilicoanalysisof molecular diagnosis of MSUD at- risk families. novel mutations M. Abiri: None. H. Saei Ahan: None. M. Eghbali: None. R. Karamzadeh: None. T. Shirzadeh: None. Z. M.Abiri1,H.SaeiAhan2,1,M.Eghbali3,R.Karamzadeh4, Sharifi: None. S. Zeinali: None. T. Shirzadeh5, Z. Sharifi6, S. Zeinali7  P06
.38A 1Department of Medical Genetics and Molecular Biology, Identification and characterization of new RNASEH1 Faculty of Medicine, Iran University of Medical Sciences, mutations associated with PEO syndrome and multiple Tehran, Iran, Islamic Republic of, 2Student Research mtDNA deletions committee,FacultyofMedicine,IranUniversityofMedical Sciences,Tehran,Iran,IslamicRepublicof,3Departmentof L. Carreño-Gago1,2, C. Blazquez-Bermejo1,2, J. Díaz- Medical Genetics, Faculty of Medicine, Tehran University Manera3,2, Y. Camara1,2, E. Gallardo3,2, R. Marti1,2, of Medical Sciences, Tehran, Iran, Islamic Republic of, J. Torres-Torronteras1,2, E. Garcia-Arumi4,1,2 44Department of Stem Cells and Developmental Biology at CellScienceResearchCenter,RoyanInstituteforStemCell 1Departament dePatologíaMitocondrial iNeuromuscular, Biology and Technology, ACECR, Tehran, Iran, Islamic Hospital Universitari Vall d'Hebron Institut de Recerca Republicof,5KawsarHumanGeneticsResearchCenter,41 (VHIR), UAB, Barcelona, Spain, 2Centro de Investigación Majlesi St., Vali Asr St, Tehran, Iran, Islamic Republic of, Biomédica en Red de Enfermedades Raras (CIBERER), 6Department of Midwifery, Faculty of Nursing and ISCIII, Barcelona, Spain, 3Servei de Neurologia, Midwifery, Tehran Medical Sciences, Islamic Azad Laboratori de Neurologia Experimental, Hospital de la University, Tehran, Iran, Islamic Republic of, 7Department Santa Creu i Sant Pau i Institut de Recerca de HSCSP, UAB, Barcelona, Spain, 4Àrea de Genètica Clínica iAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1349 Molecular. Hospital Universitari Vall d'Hebron., subunits (MT-ND genes) of complex I diagnosed in our Barcelona, Spain department. Material: In the cohort of 106 unrelated families with Mitochondrial DNA (mtDNA) depletion and deletion mtDNA mutations, mutations in MT-ND genes were found syndrome encompasses a group of disorders caused by in 13 patients from 12 families. mutations in genes involved in mtDNA replication and Results: Among 13 patients, 8 different heteroplasmic maintenance. The clinical phenotype ranges from fatal mtDNAmutationsinMT-ND1(2x),MT-ND3(1x)andMT- infantile hepatocerebral forms to mild adult onset progres- ND5(5x)geneswerefound.Inpatientwithchildhood-onset siveexternalophthalmoplegia(PEO).Wereportthecaseof of migraines followed by stroke-like episodes later in a patient with PEO and multiple mtDNA deletions, with adulthood, novel heteroplasmic mutation m.13091T>C in two new homozygous mutations in RNASEH1. The first MT-ND5 was found. Six patients with heteroplasmy levels mutation (c.487T>C) is located in the same catalytic >60% developed Leigh syndrome and their prognosis was domain as the four previously reported mutations, and the significantly worse compared to five patients with hetero- second(c.258_260del)islocatedintheconnectiondomain, plasmy levels <60%. MELAS syndrome including stroke- where no mutations have been reported. In silico study of like episodes was observed in these five patients. In two the mutations predicted only the first mutation as patho- children, the diseases started with optic neuropathy genic, but functional studies showed that both mutations mimicking LHON syndrome, later it transitioned to multi- cause loss of ribonuclease H1 activity. mtDNA replication system diseases compatible with MELAS syndrome. CI dysfunction was demonstrated in patient fibroblasts, which activities in muscle mitochondria were decreased in most were unable to recover normal mtDNA copy number after patients and mitochondrial energy-generating capacity was ethidium bromide-induced mtDNA depletion. Our results altered in some patients. demonstrate the pathogenicity of two new RNASEH1 Conclusions: Patients with multisystem MD due to variants found in a patient with PEO syndrome, multiple mutations in mtDNA-encoded subunits of complex I deletions,andmildmitochondrialmyopathy.Thisworkwas usuallydevelopLeighorMELASsyndromesandrepresent supported by the Spanish Instituto de Salud Carlos III, 11%offamilieswithmaternallyinheritedMDdiagnosedin FondodeInvestigacionesSanitarias;EGAistherecipientof our centre. Early onset of the disease and higher mtDNA agrantfromtheFISPI15-01428-FEDER.JTwasfundedby mutation heteroplasmy levels are accompanied with Leigh a fellowship granted by the Generalitat de Catalunya phenotype and worse prognosis. (PERIS program, SLT002/16/00370). Supported by AZV17-30965A, RVO VFN 64165, AZV16- L. Carreño-Gago: None. C. Blazquez-Bermejo: None. 32341A, and AZV16-33018A. J. Díaz-Manera: None. Y. Camara: None. E. Gallardo: T. Daňhelovská: None. H. Kolářová: None. K. None. R. Marti: None. J. Torres-Torronteras: None. E. Beránková: None. A. Vondráčková: None. H. Hansí- Garcia-Arumi: None. ková: None. T. Honzík: None. J. Zeman: None. M. Tesařová: None.  P06
.39B Novel mutation m.13091T>C in MT-ND5 gene leads to  P06
.40C MELAS phenotype - retrospective study in Czech The mutation spectrum of NAGLU in patients with mutations in mtDNA-encoded subunits of mucopolysaccharidosis type III B patients complex I F. Ozkinay1, D. A. Emecen1, M. Kose1, E. Isik1, T. Daňhelovská, H. Kolářová, K. Beránková, E. A. Bozaci2, E. Canda2, B. Tuysuz3, T. Atik1, H. Onay4 A. Vondráčková, H. Hansíková, T. Honzík, J. Zeman, M. Tesařová 1Subdivision of Pediatric Genetics, Department of Pediatrics, Faculty of Medicine, Ege University, Izmir, Department of Pediatrics and Adolescent Medicine, First Turkey, 2Subdivision of Pediatric Metabolism, Department Faculty of Medicine, Charles University and General of Pediatrics, Faculty of Medicine, Ege University, Izmir, University Hospital in Prague, Prague, Czech Republic Turkey, 3Subdivision of Pediatric Genetics, Department of Pediatrics, Faculty of Medicine, Cerrahpasa University, Isolated respiratory chain complex I (CI) deficiency, the Istanbul,Turkey,4DepartmentofMedicalGenetics,Faculty mostcommon causeofmitochondrialdisorders(MD),may of Medicine, Ege University, Izmir, Turkey be caused by mutations in nuclear or mitochondrial DNA (mtDNA). We analysed patients with maternally inherited Aim: Mucopolysaccharidosis type III B (MPS IIIB) is an multisystem MD due to mutations in mtDNA-encoded autosomal recessive lysosomal storage disease caused by1350 mutations in the NAGLU gene which codes the lysosomal Results: In 83 cases (40%), we identified likely patho- enzyme alpha-N-acetylglucosaminidase. The major symp- genic or pathogenic variants in genes that have been asso- toms of the disease are cognitive and neurological defects. ciated with mitochondrial diseases (42), other In this study molecular spectrum of 13 MPS IIIB patients neurometabolic diseases (21) or other neurodevelopmental were evaluated. disorders (20). In 58 cases (28%) we identified variants of MateryalandMethods:TwelveMPSIIIBpatientsfrom unknown significance where follow up studies for func- 11 families both clinically and molecularly diagnosed were tionalanalysesarepending.Moreoverwenewlyidentified8 included in this study. NAGLU gene sequencing was per- candidate genes affecting the mitochondrial function or formed using a next generation sequencing platform (Illu- selenoprotein metabolism. However 27% of the cases minaMiSeq).Demographic,clinicalandlaboratoryfindings remain unsolved. Further ongoing investigations of the of the patients were obtained from the hospital records. latterinaresearch settingincludetheadditionalanalysisof Results:Tendifferent mutationsin13MPSIIIBpatients parental DNAs (trio analysis) as well as full genome, were identified. Eight of the all mutations were missense, transcriptome and proteome analysis. one mutation was splice site and one large deletion. Three Conclusions: Although presenting with a wide pheno- mutations (c.509G>T, c.700C>G, and c.1000G>A) were typic spectrum WES facilitated a definite diagnosis in 40% defined for the first time in this study. and a possible diagnosis pending follow up in 28% of Conclucion: Our study expanded the mutation spectrum the cases. of the NAGLU gene, contributing to the improved genetic S.Beck-Woedl:None.L.Laugwitz:None.R.Buchert: counseling of MPSIIIB patients. In accordance with the None. M. Grimmel: None. M. Sturm: None. U. Grassh- literature, missense mutations were also the most common off: None. O. Rieß: None. T. Haack: None. mutations in our study. F. Ozkinay: None. D.A. Emecen: None. M. Kose:  P06
.42A None.E.Isik:None.E.A.Bozaci:None.E.Canda:None. The study of the full spectrum of variants leading to B. Tuysuz: None. T. Atik: None. H. Onay: None. hyperphenylalaninemia have revealed 10 new variants in the PAH gene  P06
.41D Diagnostic exome in neurometabolic disorders I. Kuznetcova, P. Gundorova, O. Ryzhkova, A. Polyakov S. Beck-Woedl1,2, L. Laugwitz1,2,3, R. Buchert1, Federal State Budgetary Institution «Research Centre for M. Grimmel1, M. Sturm1, U. Grasshoff1,2, O. Rieß1,2, Medical Genetics», Moscow, Russian Federation T. Haack1,2 Introduction:Hyperphenylalaninemia(HPA)isagroupof 1Medical Genetics and Applied Genomics, Tuebingen, disease characterized by elevated concentrations of pheny- Germany, 2ZSE, Rare Disease Center, University of lalanine inblood. HPAincludes phenylketonuriaandBH4- Tübingen, Tübingen, Germany, 3Children’s Hospital, deficient forms of hyperphenylalaninemia. Pediatric Neurology and Developmental Medicine, Materials and Methods: 1265 unrelated probands from University of Tübingen, Tübingen, Germany Russia were previously searched for 25 frequent mutations inthePAHgene.DNAsamplesof293probandswithoutor Introduction: Molecular diagnosis of neurometabolic with one frequent mutation were analyzed. The next gen- diseases is challenging due to the large number of eration sequencing (NGS) of PAH, PTS, GCH1, PCBD1, established and candidate disease genes associated with an QDPR, SPR and DNAJ C12
 genes to search for point extreme heterogeneity of clinical presentations at variable mutations and MLPA method to search for gross deletions ages. Especially in infancy-onset of inborn errors of were conducted. metabolism an early diagnosis is crucial to guide down- Results: Among 327 chromosomes without identified stream clinical management and treatment decisions. mutations, mutations in the PAH gene were found on 259 MaterialsandMethods:Weherereportontheresultsof chromosomes, and mutations in the PTS gene were found exome-based diagnostics of 209 index cases with clinically on 10 chromosomes. On 10 chromosomes gross deletions suspected neurometabolic diseases. Coding genomic by the MLPA method were detected. 104 rare variants of regions were enriched with a SureSelect Human All Exon the РАН gene, including 10 variants not previously Kit V6/7 (Agilent technologies) for subsequent sequencing described (p.Pro69Thr, p.Leu83Trpfs*9, p.Gln232Pro, p. on an Illumina HiSeq2500/NovaSeq6000 system. Clinical Cys237Phe, p.Ala300Asp, p.Gly312Ser, p.Thr328Pro, p. variant prioritization included different filtering steps (e.g. Tyr417*, p.Asp435Val, IV S9
-1G>C), and 6 variants of the MAF < 0.1 % in gnomAD, in-house database).Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1351 PTSgenewererevealed.Throughttheuseallthepresented BDNF, LY86, ABCG2 polymorphisms and obesity. The methods,mutationswerefoundon97.3%ofchromosomes. research is part of the EUF P7
 ProMarka and ROMCAN Conclusions: According to the study results, a spectrum studies. Replication studies for confirmation of these of mutations leading to hyperphenylalaninemia in Russia markes are ongoing. was established. The data obtained helped to reveal rare O. Andrei: None. P. Iordache: None. G. Ursu: None. mutations of the PAH gene and establish the percentage of V. Radoi: None. L. Bohiltea: None. R. Ursu: None. tetrahydrobiopterin-dependentHPAformsinRussia-0.4%. I. Kuznetcova: None. P. Gundorova: None. O. Ryzh-  P06
.45D kova: None. A. Polyakov: None. Gene discovery for favourable adiposity using cross- phenotype analysis  P06
.43B Correlation of BDNF, LY86, ABCG2 polymorphisms L. O. Huang1, U. Schick2, N. Yang2, T. O. Kilpeläinen1, and obesity in an Romanian Caucasian male cohort R. J. F. Loos2 O. Andrei1, P. Iordache2, G. Ursu3, V. Radoi4, 1Novo Nordisk Foundation Center for Basic Metabolic L. Bohiltea4, R. Ursu4 Research, Copenhagen N, Denmark, 2The Charles BronfmanInstituteforPersonalizedMedicine,IcahnSchool 1”Carol Davila” University of Medicine and Pharmacy, of Medicine at Mount Sinai, New York, NY, United States Bucharest, Romania, 2”Carol Davila” University of Medicine and Pharmacy, Department of Epidemiology, Obesity has become a global pandemic in the last few Bucharest, Romania, 3”Agrippa Ionescu” Emergency decades. It is often associated with cardiometabolic Military Hospital, Bucharest, Romania, 4”Carol Davila” comorbidities such as cardiovascular disease and type 2 University of Medicine and Pharmacy, Department of diabetes. However, some individuals remain cardiometabo- Medical Genetics, Bucharest, Romania lically healthy despite being obese, also called the metabolically healthy obese (MHO). The biological Introduction: Obesity is one of the most important public mechanisms that underlie MHO are poorly understood. To health problems worldwide. In Romania, the prevalence of identify novel adiposity-increasing variants with protective obesity is increasing and it is more common in male. The cardiometabolic effects, we performed pairwise analyses of aim of this study is to identify the genes involved in the adiposity and cardiometabolic traits using available sum- predispositionandpathogenesisofobesity.3allelicvariants mary statistics from 11 GWAS. These include three of genes related to this condition were analysed: adiposity traits (body fat percentage, body mass index, rs11030104 of BDNF gene, LY86 gene rs2199936 poly- and waist-to-hip ratio) and eight cardiometabolic traits morphism and rs2199936 of ABCG2 gene. (high-density lipoprotein cholesterol, low-density lipopro- Methods: This study consists of 5281 male patients tein cholesterol, triglycerides, fasting glucose and insulin, hospitalized between 2012 and 2017 in multiple clinics in blood pressure, and incident coronary artery disease and Bucharestforvariousmedicalreasons.Allsubjectswereof type 2 diabetes). We identified genome-wide significant self‐reported European descent. No significant difference associations (P<5x10-8) with any of the 24 trait pairs was observed between the average age of the cases (66.9) consisting of one of three adiposity traits and one of the and controls (64.3). DNA was extracted from whole blood eight cardiometabolic traits. This resulted in the discovery at deCODE Genetics (Reykjavik, Iceland) and genotyped, of 62 independent loci residing in gene regions such as using Infinium OmniExpress‐24 bead chips (Illumina). A COBL L1
, PPARG, VEGFB and VEGFA. Results of tissue total of 716 503 SNPs were genotyped for each individual and cell enrichment analyses using DEPICT implicate included in the study. strongestenrichmentinadiposetissue,adrenalcortex,liver, Results: The BDNF rs11030104 polymorphism has and arteries. Gene set enrichment analyses using DEPICT shown statistical correlation for obesity alike with the highlighted several pathways (P<5x10-4), such as “abnor- worldwide rates (p=0.0004642). Another statistical corre- mal muscle cell glucose uptake”, “decreased percent body lation between obesity and the rs1294410 LY86 variant, fat”,and“responsetoinsulinstimulus”.Ourresultsprovide responsible for the waist to hip ratio variation, was identi- insights into biological pathways that may underlie MHO fied (p=0.003984). ABCG2 rs2199936, which is involved and could shed light on future drug development targeting intheserumuricacidadjustment,hasalsoshownstatistical improvement in cardiometabolic profile of unhealthy obese correlation for obesity (p= 0.003733; OR= 0.4707). individuals. Conclusions: The results suggest that in the European Danish Council for Independent Research (DFF6110- male population there is a strong correlation between the 00183), Novo Nordisk Foundation (NNF18C C0034900
)1352 L.O. Huang: None. U. Schick: None. N. Yang: None.  P06
.47B T.O. Kilpeläinen: None. R.J.F. Loos: None. Enrichment of variants affecting mitochondrial metabolism in patients with Parkinson disease  P06
.46A A clinical case of somatic mosaicism in an unaffected G. Bergant, A. Maver, B. Peterlin fatheroffemalepatientwithornithinetranscarbamylase deficiency (OTC) Clinical Institute of Medical Genetics, Ljubljana, Slovenia N. Semenova1, I. Anisimova1, O. Shchagina1, While age-related accumulation of somatic mitochondrial A. Chuchrova1, O. Ryzhkova1, I. Bychkov1, mutationshasbeendemonstratedinParkinsondisease(PD) N. Pechatnikova2 patients, the role of germline mitochondrial variants has never been systematically studied. In the present study, we 1Reseach Center for Medical Genetics, Moscow, Russian aimed to investigate the germline genetic burden in genes Federation, 2Morozov Children’s City Clinical Hospital, affecting mitochondrial function and the role of the Moscow, Russian Federation subsequent genetic variability in PD. For this reason, we compared the genetic variability in 70 patients with early Introduction: Ornithine transcarbamylase deficiency onsetorfamilialPDwithoutadiscoveredmonogeniccause (OTC) is an X-linked inborn error of metabolism of the with that of 253 controls. Mitochondrial genome was urea cycle. OTC deficiency can occur as a severe neonatal- reconstructed from clinical or whole exome sequencing onset disease in males and as a post-neonatal-onset (partial data,whichallowedustoinvestigatebothmitochondrialas deficiency) disease in females. well as nuclear genes, including nuclear genes involved in MaterialsandMethods:Wepresentfamilywith4-years human mitochondrial disorders. For further analysis, old girl who has clinical symptoms of urea cycle disorders. variants were filtered excluding nuclear variants based on Anothermembersoffamilyarehealthy.Proband’sperinatal in-house populational data, those with mean allele period was normal. Since the first year she refused to eat frequency over 5% in public databases and synonymous meat product. At age of 3 years she was detected liver mitochondrial variants. We detected significant differences transaminase elevated (more than 10 norm) with neurolo- in burden of variants in three mitochondrially encoded gical symptoms. Orotic acid concentration in urine was genes. The greatest increase of variant burden between PD normal. A low-protein diet was effective: a liver transami- and controls was observed in MTND5 (38.6% versus nase normalized, neurological symptoms stopped. 26.9%), MTCO2 (10.5% versus 5.5%) and MTND4L (7% Results: Analysis of whole exome sequencing data versus 0.5%), with the first and last being mitochondrial revealed a pathogenic heterozygous variant c.78-1G>A in respiratory complex I components. No significant differ- OTC gene in the proband. This variant was confirmed by ences have been observed in the variant burden of nuclear Sanger sequencing in proband, wasn’t detected in her genes. In conclusion, our findings support the hypothesis motherandherhealthyoldersister,andwasdetectedinher thatgermlinemitochondrialvariantsmightcontributetothe fatherinheterozygousstateinmosaicform.Inherfatherwe pathogenesis of PD. detected only one copy of X -chromosome by different G.Bergant:None.A.Maver: None.B.Peterlin:None. methods, including cytogenetic. We detected mosaicism of variant c.78-1G>A in OTC gene in the different tissues  P06
.48C (buccal epithelium, blood, seminal fluid, urinary sediment) Rapid mitochondrial genome (mtDNA) sequencing: which are having an origin from every germ layer (ecto- facilitating rapid diagnosis of mitochondrial diseases in derm, mesoderm, endoderm). paediatric acute care Conclusions: Our clinical case shows that affected females may inherit the OTC pathogenic variant from her L. S. Akesson1,2,3, S. Eggers1, C. J. Love1, B. Chong1, father who doesn't have clinical symptoms of disease. It is M. F. Hunter3,4, E. I. Krzesinski3,4, N. J. Brown1,2, important for determination of genetic risk and discussion T. Y. Tan1,2, C. M. Richmond1, D. R. Thorburn1,2,5, of the necessary of prenatal testing. J. Christodoulou1,2,5, Z. Stark1,2,5, S. Lunke1,2,5 N. Semenova: None. I. Anisimova: None. O. Shcha- gina:None.A.Chuchrova:None.O.Ryzhkova:None.I. 1Victorian Clinical Genetics Services, Melbourne, Bychkov: None. N. Pechatnikova: None. Australia, 2University of Melbourne, Melbourne, Australia, 3Monash Genetics, Monash Health, Melbourne, Australia, 4Monash University, Melbourne, Australia, 5Australian Genomics Health Alliance, Melbourne, AustraliaAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1353 Phenylketonuria(PKU) is an inborn error of metabolism Introduction: Standard rapid genomic testing techniques involving impaired metabolism of phenylalanine that leads analyse nuclear DNA variants using exome and/or genome to severe mental retardation. In Moldova PKU diagnosis is sequencing (ES/GS). Rapid mtDNA analysis is not based on newborn screening(NBS) from 1989. routinely available, particularly in centres performing ES, Materials and Methods: Diagnosis of 123 Moldavian which does not deliver clinical-grade mtDNA sequencing. PKU/HPA patients was based on Phe level >3mg/dL and WedescribeourexperienceusingrapidmtDNAsequencing genetic analysis by PCR/RFLP method of hot-spot muta- in tandem with an ES-based rapid genomic diagnosis tions (R408W,  P281
L, R158Q, R261Q, R252W, IV S12
 program as part of the Australian Genomics Acute Care +1G>A,  L48
S, R261X, G272X, IV S10
-11G>A) carried out flagship. onEppendorfMasterCyclerProfollowedby“Sanger”DNA Methods: Two infants presenting with persistent lactic sequencing on ABI 3130xl Genetic Analyzer(Switzerland), acidosis and bone marrow failure were recruited for rapid ABI 3500dx Genetic Analyzer(Moldova). genomic testing. With clinical suspicion of mitochondrial The results: During 28 years, 107 PKU patients have disease, both infants underwent rapid ES and mtDNA been identified by NBS and 16 patients - extra screening, sequencing in tandem, the latter using Nextera libraries showing the total PKU incidence of 1:6463 newborns, from a full length mtDNA amplicon. screening rate 92-97% for last 5 years. Most of them(69%) Results: ES was non-diagnostic in both infants. mtDNA have a classical PKU phenotype(Phe levels at diagnosis sequencingidentifiedasinglelargemtDNAdeletioninboth 24,3-52mg/dl), followed by moderate PKU(21%), mild infants, diagnostic of Pearson syndrome (MIM 557000). PKU(7%), and HPA(2%). The 105 PKU patients were Diagnostic reports were issued within 73 hours 55 minutes subjected to genetic analysis of PAH gene being identified and54hours25minutes,respectively.Bothinfantsavoided 32diseasecausingmutations:18missense(56%),8splicing invasive bone marrow biopsies and a range of other (25%), 3 deletion(9%) and 3 nonsense(9%) mutations, that investigations. compound 47 different genotypes in Moldavian PKU Conclusions: Rapid mtDNA sequencing in tandem with patients. The most common mutation was R408W found in ES results in additional diagnoses in seriously ill children 50.5%ofcases.Onenovelmutationc.2T>Cinexon1was withsuspectedmitochondrialpathology,suggestingthatES identified in a patient with constantly Phe level ~13mg/dL, alone may be insufficient in this setting. When designing slight intellectual disability and no other mutations in PAH rapid genomic diagnosis programs, centres should consider gene was detected, that was suggestive for errors in BH4 incorporating mtDNA amplification and analysis in indivi- biosynthesis genes. duals with suspected mitochondrial pathology, by combin- Conclusion: Efficiency of PKU diagnosis in Moldova ing ES and mtDNA sequencing in tandem, or analysing has been increased, due to NBS coverage and mutation mtDNA data from GS, which captures the mitochondrial detection over 90% rate, applying a targeted specialized genome. treatment and prenatal diagnosis. L.S.Akesson:None.S.Eggers:None.C.J.Love:None. K.R. Boiciuc: None. C. Gemperle-Britschgi: None. D. B. Chong: None. M.F. Hunter: None. E.I. Krzesinski: Sato: None. N. Rimann: None. T. Croitori: None. D. None. N.J. Brown: None. T.Y. Tan: None. C.M. Rich- Blanita: None. E. Halabudenco: None. V. Sacara: None. mond: None. D.R. Thorburn: None. J. Christodoulou: B. Thöny: None. N. Usurelu: None. None. Z. Stark: None. S. Lunke: None.  P06
.50A  P06
.49D Whole genome sequencing characterizes precise break Biochemical and molecular genetic diagnosis of points and extent of heterozygous deletion in PAH in a Moldavian PKU patients: A novel missense mutation in patient identified by newborn screening PAH gene E. K. Samuelsson, S. Rajaei, J. Asin Cayuela K. R. Boiciuc1, C. Gemperle-Britschgi2, D. Sato2, N. Rimann2, T. Croitori1, D. Blanita1, E. Halabudenco1, Department of Clinical Chemistry, Göteborg, Sweden V. Sacara1, B. Thöny2, N. Usurelu1 Since 1965, newborn babies in Sweden are screened for 1Institute of Mother and Child, Chisinau, Moldova, Inborn Errors of Metabolism (IEM) by biochemical Republicof,2UniversityChildren'sHospitalZurich,Zürich, analysis. For the past few years, findings are genetically Switzerland characterized in our laboratory by exon panel sequencing and Sanger. Here we complement exon panel sequencing with whole genome sequencing (WGS), which is superior1354 characterizing copy number variations. Exon panel sequen- Results: Celastrol treatment significantly increases cing of a sample positive for phenylketonuria (PKU) on PMM2 proteinlevelsandactivity ofvariousmutants inthe newborn screening detected a heterozygous SNV (single cellular model. Theseresultscorrelate with an increment in nucleotide variant) in a well known CpG hotspot for PKU, the transcriptional and proteomic levels of some HSPs of in PAH. Copy number analysis (CNV) indicated a the proteostasis network. The HS P90
 inhibitor, but not the heterozygous deletion spanning exon 3 PAH, but not exon HS P70
one,interfereswiththeeffectofcelastrolonPMM2. 2 nor 4. Using whole genome sequencing, we were able to The combination of celastrol and CVIII has a mutation- reveal the exact break points andsize ofthe deletion. Exon dependent synergistic effect on PMM2 activity. 3 of PAH is involved in encoding the regulatory domain Conclusions: These results show the positive effect of (located at the N-terminal) of phenylalanine hydroxylase. celastrol on the PMM2 stability and activity through the This domain determines the specificity of the enzyme for HS P90
-drivenmodulationoftheproteostasisnetwork.This the amino acid phenylalanine. The break points as well as isaproof-of-conceptofthepossibletherapeuticuseofPRs theSNV,weresubsequentlyverifiedbySanger sequencing and PCs for PMM2-CDG. and both parents were also analyzed by Sanger sequencing D.Gallego:None.A.Vilas:None.P.Yuste:None.L.R. to confirm their heterozygous genotypes. The proband was Desviat: None. M. Ugarte: None. C. Pérez-Cerdá: None. consequentlyfoundtobecompoundheterozygote,resulting A. Gámez: None. B. Pérez: None. in classical PKU. E.K. Samuelsson: None. S. Rajaei: None. J. Asin  P06
.52C Cayuela: None. Functional consequences of bi-allelic PNPT1 variants associated with multisystemic disease  P06
.51B Proteostasis regulators as a possible mutation-specific R. Rius1,2, L. G. Riley3,4, N. J. Van Bergen1,2, therapeutic approach for PMM2-CDG A. G. Compton1,2, D. J. Amor1,2,5, M. Kava6,7,8, S. Balasubramaniam9,10,11, M. Fanjul-Fernandez5, D. Gallego1, A. Vilas1, P. Yuste2, L. R. Desviat1, M. Cowley12,13,14, M. Fahey15, T. Y. Tan1,2,5, M. Ugarte1, C. Pérez-Cerdá1, A. Gámez1, B. Pérez1 D. R. Thorburn1,2,5, J. Christodoulou1,2,5 1Centro de Diagnóstico de Enfermedades Moleculares 1Murdoch Children’s Research Institute, Melbourne, (CEDEM), Centro de Biología Molecular Severo Ochoa, Australia, 2Department of Paediatrics, University of UniversidadAutónomadeMadrid,CentrodeInvestigación Melbourne, Melbourne, Australia, 3Kids Research, The Biomédica en Red de Enfermedades Raras (CIBERER), Children's Hospital at Westmead, Sydney, Australia, InstitutodeInvestigaciónSanitariaIdiPAZ,Madrid,Spain, 4Discipline of Child & Adolescent Health, Sydney Medical 2Max Planck Institute for Biochemistry, Munich, Germany School, University of Sydney, Syndey, Australia, 5Victorian Clinical Genetics Services, Royal Children’s Hospital, Introduction: PMM2-CDG, the most common glycosyla- Melbourne, Australia, 6Department of Neurology, Perth tiondisorderforwhichthereisnocure,hasbeensuggested Children’s Hospital, Perth, Australia, 7School of to be a conformational disease. The misfolded nature of Paediatrics and Child Health, University of Western most of the disease-causing mutations makes the use of Australia, Perth, Australia, 8Department of Metabolic stabilizingmolecules,pharmacologicalchaperones(PCs)or Medicine and Rheumatology, Perth Childrens’ Hospital, proteostasis regulators (PRs), a promising therapeutic Perth,Australia,9DisciplineofChild&AdolescentHealth, strategy. The aim of this study was to evaluate the effect Sydney Medical School, University of Sydney, Sydney, of PRs on the stability and activity of PMM2 unstable Australia, 10Western Sydney Genetics Program, The mutants and decipher their molecular mechanisms. Children’s Hospital at Westmead, Sydney, Australia, Materials and Methods: Patient-derived fibroblasts 11Discipline of Genetic Medicine, Sydney Medical School, transduced with their own PMM2 folding or oligomeriza- University of Sydney, Sydney, Australia, 12Children's tion mutation were treated with different concentrations of CancerInstitute,Randwick,Australia,13SchoolofWomen's PRs (celastrol and MG-132) or combining celastrol and a and Children's Health, UNSW Sydney, Syndey, Australia, PC (CVIII). Their effect was studied by western blot and 14Cancer Division, Garvan Institute of Medical Research, PMM enzymatic assay. The expression levels of several Sydney, Australia, 15Department of Paediatrics, Monash molecular chaperones (HSPs) were assessed by qRT-PCR University, Melbourne, Australia and western blot. The specificity of the molecular chaper- ones involved was evaluated by using specific HS P70
 or Introduction: PNPT1 encodes the Polyribonucleotide HS P90
 inhibitors. nucleotidyltransferase 1 protein which predominantlyAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1355 localizes to the mitochondria, and is involved in multiple of Torino, Torino, Italy, 3Medical Genetics Unit, Meyer RNAprocessingfunctions.Bi-allelicpathogenicvariantsin Children's University Hospital, Firenze, Italy, 4Pediatric PNPT1 have been identified in patients with a hetero- Clinic, Foundation IRCCS Policlinico "San Matteo", geneous phenotype ranging from non-syndromic deafness University of Pavia, Pavia, Italy to a multisystemic presentation with severe global devel- opmental delay, seizures, dystonia, choreoathetosis, Mitochondrialdiseases(MD)arethemostcommoncauseof ophthalmologicalabnormalitiesanddifferentMRI-findings. inherited metabolic diseases. Combined respiratory chain Materials and Methods: We investigated 5 unrelated (RC) complexes defects are caused by mutations in the patientswithbi-allelicvariantsinPNPT1identifiedthrough mtDNA-encoded RNA products and mutations in nuclear massively parallel sequencing. The patients presented with genes involved in mtDNA translation machinery. PU S1
, a clinical features in common with previously reported mul- nuclear gene, encodes for cytoplasmatic and mitochondrial tisystemic cases. Using patient fibroblasts and peripheral tRNA pseudouridine-synthase-1, that converts uridine into blood samples, we performed functional studies to confirm pseudouridine in several tRNA positions increasing the pathogenicity including cDNA studies, complex I (CI) and efficiency of protein synthesis on both compartments. IV (CIV) enzyme activity assays, immunoblotting, RT- Mutations in PU S1
 cause MLASA syndrome, a rare qPCR analysis for detection of mitochondrial unprocessed autosomal recessive disorder of oxidative phosphorylation transcripts, and expression of targeted interferon and iron metabolism, clinically characterized by Mitochon- signalling genes. drial Myopathy, Lactic Acidosis and Sideroblastic Anemia. Results:Comparedtocontrols,patientfibroblastsshowed We report clinical, biochemical and molecular findings of mildlyreducedCIandCIVproteinactivities,therewasalso unreported patient in which Whole Exome Sequencing a reduction in PNPT1 protein expression and a 2-6 fold (WES) revealed the presence of new biallelic mutations in accumulation of MT-ND5+MT-ND6 and MT-CYTB+MT- PU S1
.Reviewofthe16PU S1
mutantpatientspublishedto ND6mitochondrialRNAunprocessedtranscripts.Inblood, date demonstrates a huge clinical heterogeneity with therewasanincreasedexpressionof6genesinvolvedinthe intellectual disability, microcephaly and anemia as typical interferon I pathway. clinical elements. Given the paucity of the patients Conclusions: The accumulation of mitochondrial described, it is not possible to delineate a complete unprocessed transcripts and increased interferon pathway phenotypic picture and the associated clinical evolution, expression provides furtherevidencefor therole ofPNPT1 and it is not possible to establish an accurate genotype - in mitochondrial RNA processing, and of the possible phenotype correlation that allows us to indicate a proper contribution of an immune response to disease pathogen- prognosis and follow-up. Moreover, our patient had severe esis. It also demonstrates that in order to confirm patho- osteoporosis with multiple fractures that were never genicity, functional analyses of the primarily affected previously reported in the literature and a more early processes are more sensitive than the modest defects evolution of neuro-muscular symptoms than the other detected downstream on the respiratory chain enzyme patients. WES is increasing the diagnostic yield in MD, in activities. particularenhancingtheabilitytoidentify potential nuclear R. Rius: None. L.G. Riley: None. N.J. Van Bergen: gene mutations in patients with biochemically defined None.A.G.Compton:None.D.J.Amor:None.M.Kava: defects affecting multiple mitochondrial RC and complex None. S. Balasubramaniam: None. M. Fanjul-Fernan- phenotype. dez:None.M.Cowley:None.M.Fahey:None.T.Y.Tan: F. Peluso: None. B. Siri: None. V. Palazzo: None. A. None. D.R. Thorburn: None. J. Christodoulou: None. Provenzano:None.R.Artuso:None.A.Pagliazzi:None. G. Forzano: None. G. Contro': None. F. Di giovanni:  P06
.53D None. T. Foiardelli: None. F. Bassanese: None. S. Whole exome sequencing (WES) in suspected Savasta: None. S. Giglio: None. mitochodrialdisease:PU S1
geneandMLASAspectrum  P06
.54A F. Peluso1, B. Siri2, V. Palazzo3, A. Provenzano1, Mitochondrial disease caused by a novel homozygous R. Artuso3,A. Pagliazzi1, G.Forzano1, G.Contro'1, F. Di mutation (Gly106del) in the SCO1 gene Giovanni1, T. Foiardelli4, F. Bassanese4, S. Savasta4, S. Giglio1,3 N. Brix1, J. M. Jensen2, I. S. Pedersen3,4, A. Ernst3, S. Frost2, P. Bogaard5, L. Bender1, M. B. Petersen2,4 1Medical Genetics Unit, Department of Biomedical Experimental and Clinical Sciences, University of Firenze, 1Dept. of Pediatrics, Aalborg, Denmark, 2Dept. of Clinical Firenze,Italy,2DepartmentofPediatrics,OIRM,University Genetics, Aalborg, Denmark, 3Section of Molecular1356 Diagnostic, Aalborg, Denmark, 4Dept. of Clinical France, 2Nice Sophia-Antipolis University, IRCAN, CNRS, Medicine, Aalborg, Denmark, 5Pathological institute, INSERM, UMR 7284 & U1081, 06107 Nice, France Aalborg, Denmark Mitochondrial dysfunction is associated with a variety of Introduction:TheCytochromeCoxidaseassemblyprotein diseases. Each human cell contains several mitochondria SCO1 gene encodes a mitochondrial protein essential for which hold multiple copies of mitochondrial DNA the mammalian energy metabolism. Only three cases of (mtDNA). mtDNA heteroplasmy is the coexisting of wild- SCO1 mutations have thus far been reported. All cases typeandmutantmtDNAmoleculesinacell.Theproportion presented with lactate acidosis and encephalopathy. Two of mutated mtDNA should exceed a threshold to cause hadhepatopathyandhypotonia.Onefurtherpresentedwith biochemical defects. NGS leaded us to identify an intrauterinegrowthretardationandhypertrophiccardiomyo- increasingnumberofpathogenicvariantsbutalsoofvariant pathy leading to cardiac failure. of unknown significance (VUS).Only a tiny sub-group of Here we present a case of a girl of Afghan con- VUS was functionally evaluated with certitude, while the sanguineous parents, born premature with a novel homo- pathogenicity of the great majority was only assessed in- zygous mutation in the SCO1 gene and a different silico.Weinvestigatedsevenpatientswithclinicalfeatures, phenotype than previously reported cases. muscle biopsy and biochemical defects suggesting a Within the first two hours, the girl developed severe mitochondrial dysfunction, including the presence of lactate acidosis and hypoglycemia. Echocardiography, eye cytochrome c oxidase - deficient fibers (COX (-)). mtDNA examination, ultrasound of the brain, kidneys and urinary sequencing found a VUS for each patient. In order to tract were normal. As was the level of ammonium. At four determinethepathogenicityoftheseVUS,wequantifiedthe days old an investigation of suspected metabolic disease level of mtDNA heteroplasmy by semi-quantitative fluor- was initiated including whole exome sequencing. Merely escent PCR in muscle fibres COX (+) and COX (-) single five days later whole exome sequencing revealed a novel cells. We found a statistically significant heteroplasmic homozygous mutation in the SCO1 gene (c.317_319del- difference between individual COX (+) and COX (-) cells GAG)inexon2resultinginanin-framedeletionofGly106. for 6 patients, which supports the pathogenicity of these A muscle biopsy was later performed, showing reduced VUS, allowing us to confirm the diagnosis for these activity of complex IV in accordance with the SCO1 patients. Determining the pathogenicity of the VUS mutation detected by whole exome sequencing. The girl identified by NGS is becoming a major goal to reduce died 1 month old. diagnostic wandering in patients. The single cell hetero- Conclusion: We identified a novel homozygous SCO1 plasmy quantification is a gold-standard method for the mutation (Gly106del) in a patient with a clinical course of mutation-diseasecausallinkassessmentandshouldbeused mitochondrial disease different from previously reported routinely in diagnosis. In this objective, we designed a SCO1 cases. Mitochondrial disease may manifest in neo- fastest and easiest single cell quantification tool. nates, but early diagnosis has so far been difficult. Because E.Zereg:None.S.Bannwarth:None.G.Morel:None. of improved technique as whole exome sequencing early A. Chaussenot: None. S. Ait-El-Mkadem: None. K. diagnosis and consideration of treatment level are now Fragaki: None. B. Chafino: None. M. Berthet: None. V. possible. Paquis-Flucklinger: None. C. Rouzier: None. N.Brix:None.J.M.Jensen:None.I.S.Pedersen:None. A. Ernst: None. S. Frost: None. P. Bogaard: None. L.  P06
.56C Bender: None. M.B. Petersen: None. TANGO2 associated autosomal recessive disease: A novel case  P06
.55B Characterization of seven mitochondrial DNA variants R. Ripszám, K. Hadzsiev, J. Zima, Á. Till, B. Melegh of unknown significance by quantification of single cell heteroplasmy University of Pécs, Medical School, Pécs, Hungary E. Zereg1, S. Bannwarth1,2, G. Morel1, A. Chaussenot1, Introduction: TANGO2-related disorder was first pub- S.Ait-El-Mkadem1,K.Fragaki1,B.Chafino1,M.Berthet1, lished in 2016. Homozygous or compound heterozygous V. Paquis-Flucklinger1,2, C. Rouzier1 mutations of TANGO2 gene lead to the disease Metabolic encephalomyopathiccrises,recurrent,withrhabdomyolysis, 1Departement of Medical Genetics, National Center for cardiac arrhythmias, and neurodegeneration. Symptoms Mitochondrial Diseases, Nice Teaching Hospital, Nice, include recurrent metabolic crises associated with encepha- lopathy, rhabdomyolysis, cardiac arrhythmias andAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1357 laboratory findings such as hypoglycaemia, hyperammone- years and 35 years, respectively. The main clinical mia, lactic acidosis and elevated CK levels. With the symptoms were problems with mild dysarthria, rapid progression of the disease epilepsy, developmental delay, speech, proximal weakness of lower extremities, balance cognitive impairment, global brain atrophy and pyramidal disturbances and/or psychiatric disorders. Cerebellar atro- signs appear. phy in brain MRI was a constant feature. Leukocyte Materials and Methods: We report a 4-year-old child hexosaminidaseA activity was decreased to 1.8 - 4.1% of with developmental delay. From 21 months of age he controls.Allpatientscarriedatleastoneallelewiththemild showed episodes of suddenly onset hypotonia, gait variant p.Gly269Ser; a novel variant p.Arg252Cys was instability, ataxia, and distortion of the head and upper detected in one family. Adult form of TSD seems to be an body. During these paroxysm plasma creatinine kinase and underdiagnosedalthoughanenzymeassayinserum/plasma lactate was elevated. He has seizures from 2-years-of-age: isafast,inexpensiveandreliabletooltodetectpatientswith grand mal and spasms also occurred. He has this form of TSD and genetic confirmation is routine. hypothyreoidism. UNCE 204064; PROGRES Q26/LF1; RVO-VFN 64165 Results: A pathogenic apparently homozygous H. Vlaskova: None. H. Jahnova: None. E. Kostalova: TANGO2:c.385C>Tvariantwasidentifiedinexon4ofthe None. M. Magner: None. J. Jireckova: None. H. Pou- TANGO2 gene by Whole Exome Sequencing. We exam- petova: None. K. Peskova: None. V. Kozich: None. ined the parents for the above mentioned variant, but we could only detect the variant in the mother. Based on that  P06
.58A furtherexaminationswereneededtodistinguishinbetween TRMU-relatedtransientliverfailureofinfancypresents homozygosity versus heterozygosity with a deletion. With with microcephaly and neurodevelopmental delay quantitative PCR assay by using 3 gene-specific amplicons encompassingthecodingexons3,4,5oftheTANGO2gene H. Azaklı1, E. Yücel2, Ç. Arıkan3, A. Armutlu4, a large deletion encompassing exons 3-5 was detected. S. Eraslan2, H. Kayserili1,2 Conclusions: The above mentioned compound hetero- zygous state in our patient confirms the diagnosis of 1Institute of Health Sciences, Koç University School of TANGO2-associated biallelic disorder. The disease might Medicine (KUSoM), İstanbul, Turkey, 2Medical Genetics be very underdiagnosed, whole exome sequencing is still a Department, Koç University School of Medicine (KUSoM), clue to find the alterations in TANGO2 gene. İstanbul, Turkey, 3Gastroenterology Department, Koç R.Ripszám:None.K.Hadzsiev:None.J.Zima:None. University School of Medicine (KUSoM), İstanbul, Turkey, Á. Till: None. B. Melegh: None. 4PathologyDepartment,KoçUniversitySchoolofMedicine (KUSoM), İstanbul, Turkey  P06
.57D Adult form of Tay-Sachs disease: main symptoms, 21 months-old girl presented at genetics outpatient clinics enzyme and genetic diagnostics in Czech patients due to microcephaly, mild neurodevelopmental delay and facial dysmorphism. She was born to healthy non- H. Vlaskova, H. Jahnova, E. Kostalova, M. Magner, consanguineous couple. Prenatal and perinatal history was J. Jireckova, H. Poupetova, K. Peskova, V. Kozich uneventful. She was followed up at metabolism& gastro- enterology clinics for vomiting attacks, elevated liver Department of Pediatrics and Adolescent Medicine, enzymes/ lactate levels during 3-to-12 month-of-age. GeneralUniversityHospitalandFirstFacultyofMedicine, Mitochondrial work-up had not revealed the underlying Charles University in Prague, Prague 2, Czech Republic pathology. SNParray showed 16q23.1 deletion encompass- ing two genes, WWOX and LSM3 P5
, which is associated Tay-Sachs disease (TSD) is a rare neurodegenerative with bilateral cataracts, iris coloboma and autistic beha- disorder caused by lysosomal β-hexosaminidase A defi- viour. Paternal transmission of the microdeletion was ciency due to mutations in the HEXA gene. Phenotypic conclusive for its possibly benign nature. Clinical Exome spectrum of TSD is diverse and differs between infantile Sequencing(CES) revealed homozygous TRMU gene c. andadult form.No effective treatmentfor TSDisavailable G835A(c.V279M) pathogenic change explanatory for the and genetic counselling (DNA analysis) is thus important historyoftransientliverfailureofinfancy.FibroScanat21/2 forprenataldiagnosis.Ourcohortincludes14patientswith yearsrevealedstage2hepatosteatosiswithmildfibrosisand adult form of TSD (surprisingly twice more than infantile liver biopsy was performed for histopathological evalua- form) diagnosed in the Czech Republic between 2002 and tion. TRMU (tRNA 5-methylaminomethyl-2-thiouridylate 2018 yielding an estimated birth prevalence of 1:325,000. methyltransferase) gene mutations were identified as Median age of first symptoms and of diagnosis were 21 responsible from transient liver failure of infancy at 2009.1358 Twenty-two patients have been reported uptill now and earlydiagnosisofthedisease.Acknowledgement:Thiswork clinical variability ranges from early death(6/22) to normal was supported by Biomedical Research Program in WCM- development. Although no systematic follow-up is avail- Q, and by Qatar National Research Funds grants numbers: able,microcephalyandmild neurodevelopmentaldelayhas 09-740-3-192 and 09-741-3-793. been reported. The case we reported herein presented with N.A. Yousri: None. K.A. Fakhro: None. K. Suhre: microcephaly and psychomotor retardation and diagnostic None. R.G. Crystal: None. work-up revealed the etiopathogenesis of transient liver failureininfancy.CESastheleadingdiagnostictechnology  P06
.60C for single gene disorders, enables clinical management, High-throughput metabolomics for early detection of counselling also for TRMU-related hepatic failure which individuals at increased risk for type 2 diabetes has a relatively benign course. TRMU gene sequencing is highly recommended in infants with unexplained liver J. Hällfors, S. Ruosaari, P. Würtz, N. Tertipis failure not only in Yemenite Jewish but in all Middle East populations and Turkey. Nightingale Health Ltd., Helsinki, Finland H. Azaklı: None. E. Yücel: None. Ç. Arıkan: None. A. Armutlu: None. S. Eraslan: None. H. Kayserili: None. Introduction: Advances in metabolomics now allows for profiling of large-scale cohorts. We identified circulating  P06
.59B blood biomarkers predictive of T2D. Also, metabolic Genetics meets Metabolomics in Type 2 Diabetes in a signaturesweregeneratedforriskstratificationandtracking Middle Eastern Population the health of the individuals. Materials and Methods: NMR metabolomics was used N. A. Yousri1, K. A. Fakhro2, K. Suhre1, R. G. Crystal3 to quantify 228 metabolic measures in 11,896 individuals fromfourFinnishcohorts(meanage35years,range24-45). 1Weill Cornell Medical College- Qatar, Doha, Qatar, Results: Associations between baseline metabolites and 2Sidra Medical Research, Doha, Qatar, 3Weill Cornell diabetes onset during the 7-15 years of follow-up (392 Medical College- NY, New York, NY, United States incident cases) were assessed by logistic regression. Alto- gether 113 metabolites were associated with incident dia- T2D and its complications are a major concern for its high betes(P<0.0009;rangeofoddsratios(OR)per1-SD:0.59- prevalence in Qataris, and both genetic risk and lifestyle/ 1.50)afteradjustingforsex,baselineage,glucoseandBMI. environmental factors play a role in T2D. We investigate: Amongthestrongestpredictorsofincreasedriskofdiabetes PolygenicRiskScores(PRS)ofT2DinQataris,genetically were higher concentrations of branched-chained and aro- Determined Metabotypes (GDM) of T2D and gene- matic amino acids (OR: 1.33), triglycerides in very-low- metabolic networks. Polygenic risk scores highlight the density lipoproteins (VLDL; OR 1.50), and lower levels of role of genetics in early diagnosis, compared to other risk omega-6 fatty acids (OR 0.75). A biomarker signature factors. Identifying gene-metabolite associations is impor- comprised of phenylalanine, free cholesterol in large HDL, tant for understanding the genetic factors affecting meta- and the ratio of cholesteryl esters to total lipids in large bolic pathways. 1000 Qatari samples (57% T2D), with VLDLwaspredictiveofincidentdiabetesinanindependent whole exome sequence and genotype array data were used. validation cohort after adjusting for baseline glucose and All samples were profiled for more than 1000 metabolites. BMI (OR 10.1 comparing 5th vs 1st quintile of the bio- We constructed a PRS using those SNPs that replicated marker score). from81publishedloci,inthearraydata,andcomputedthe Conclusions: Individuals at risk for T2D display a dis- accuracyofPRSinindividualswithwholeexomedata.For tinct metabolic signature even years before the disease determining GDMs in T2D, we first identified metabolites develops. Using the signature, both early risk stratification significantlyassociatedwithT2D,andthentheassociations and personalised follow-up of the disease progression is ofthosemetaboliteswith1.6millioncommonvariants.We enabled. High-throughput metabolomics therefore provides found229metabolitesassociatedwithT2D,amongwhich6 apowerfultoolforpopulation-widediabetespreventionand metabolitesaresignificantlyassociatedwithSNPsin5loci. control programs. Metabolomics is already used for health We identified a gene-metabolic network containing 21 tracking in Finland. uniquelociand33uniquemetabolicpathways.Inthisstudy J. Hällfors: A. Employment (full or part-time); Sig- weshowgenesthatcontributetothepolygenicriskscoreof nificant; Nightingale Health Ltd. S. Ruosaari: A. T2D, genetically determined metabotypes and gene- Employment (full or part-time); Significant; Nightingale metabolic networks in T2D. We believe these results will Health Ltd. P. Würtz: A. Employment (full or part-time); helpimprovetheunderstandingofT2Dmechanismsandin Significant; Nightingale Health Ltd. N. Tertipis: None.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1359  P06
.61D pathogens discovered through Multiplex Serology Fromprenatalcystichygromatoraremetabolicdisease- screening in UK Biobank a patient with Zellweger Syndrome A. Y. Chong1, N. Brenner2,3, A. Jimenez Kaufmann4, J. Jovanovic1, A. Maver2, A. Hodzic2, B. Peterlin2, A. Cortes5, R. Almond6, M. Hill7, T. J. Littlejohns8, O. Miljanovic1 J. J. Gilchrist1,9, T. Parks1, C. Watson10, O. Rodriguez10, N. Allen6,8, G. McVean5, T. Waterboer2, A. Moreno 1Centre for MedicalGenetics and Immunology, Podgorica, Estrada4, A. Hill1,11, A. J. Mentzer1,5 Montenegro, 2University Medical Centre, Ljubljana, Slovenia 1Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, 2Infections and Cancer Introduction: Zellweger syndrome (ZS) is a rare, fatal, Epidemiology, German Cancer Research Center, autosomal, recessive inheritable disease that occurs as a Heidelberg, Germany, 3Faculty of Biosciences, Heidelberg consequence of mutations in one of the 14 PEX familial University, Heidelberg, Germany, 4Human Population genes. ZS represents the absence of peroxisomes resulting GenomicsLab,LaboratorioNacionaldeGenómicaparala in damaging metabolic pathways, especially beta oxidation Biodiversidad,Irapuato,Mexico,5BigDataInstitute,LiKa of very long chain fatty acids. ZS is characterized by facial Shing Centre for Health Information and Discovery, dysmorphia, neurological disorders and gradual insuffi- University of Oxford, Oxford, United Kingdom, 6UK ciency of all vital organs. In the second half of pregnancy Biobank, Stockport, United Kingdom, 7MRC-Population the ventriculomegaly appearance is possible and endocra- HealthResearchUnit,UniversityofOxford,Oxford,United nium MRI could detect characteristical ZS changes: Kingdom, 8Nuffield Department of Population Health, abnormal gyral forms, disturbed myelination and cerebral University of Oxford, Oxford, United Kingdom, periventricular pseudocysts. 9Department of Paediatrics, University of Oxford, Oxford, The aim istouse thecase report on a ZSpatient to point United Kingdom, 10Department of Biochemistry and out the possibility of recognising a rare inheritable disease Molecular Genetics, University of Louisville School of expected with a frequency of one in 50,000 live births. Medicine, Louisville, KY, United States, 11The Jenner Results: The infant with dysmorphia, hypotonia, hyper- Institute, University of Oxford, Oxford, United Kingdom bilirubinaemia, and hepatomegaly is presented. In 13th week of gestation the enlarged nuchal region cystic Introduction: Infectious agents contribute significantly to hygroma and the border ventriculomegaly were found by theglobalburdenofdisease,throughbothacutesyndromes ultrasound examination. Pre-natal diagnosis excluded and chronic disease sequelae. Understanding the biological chromosomalaberrationsandpregnancywascontinuedand mechanisms underpinning susceptibility to infection and completed by birth in term. Severe hypotonia and dys- development of chronic disease may inform future pre- morphia were present at birth. In the further course a ventative and therapeutic strategies. jaundice, rise in liver enzymes and lactate dehydrogenase, Materials and Methods: Using a rigorously validated development of hepatic insufficiency, and multiorganic Multiplex Serology platform, we sought to identify human failure have occurred with a lethal outcome in the fifth genetic variation associated with differential response to month of life. A clinical exome sequencing (NGS) identi- infectious agents. We undertook genetic association analy- fiedthehomozygousmutationinthePEX6gene,described sis of antibody responses measured against 45 antigens as pathogenic-causative to ZS. targeting 20 infectious agents implicated in chronic disease Conclusion: Considering the characteristics of ZS, set- pathogenesis (including human herpes and papilloma- ting up a suspicion and conducting prenatal diagnosing for viruses, and Helicobacter pylori) using baseline serum ZS are crucial in preventing this syndrome among samplesfrom9,611individualsselectedatrandomfromthe liveborns. UK Biobank. J.Jovanovic:None.A.Maver:None.A.Hodzic:None. Results:Weidentified2853non-HLAregionsassociated B. Peterlin: None. O. Miljanovic: None. with antibody responses to our selected pathogens (p < 1x10-5), 13 of which contained peaks reaching genome- wide significance (p < 5x10-8). Some of these association  P07
 signals validate candidate mechanisms of infection activity Immunology and hematopoietic system whereas others implicate other plausible yet previously unrecognised molecular pathways. Associations were  P07
.01A observed within the extended MHC region for at least one Shared immunogenetic associations across common antigen from each of the 20 pathogens. Of the non-MH C1360
 associations, we identified three regions associated with distribution between neonates with BPD and without BPD more than one pathogen. These regions span NFKB1 on by dominant model (GG vs. GA/AA) (p=0.001; chromosome 4, the IGH region on chromosome 14, and RR=2.188, 95% CI 1.428-3.348; OR=3.138, 95% CI FUT2 on chromosome 19. 1.539-6.397). After the adjustment for BMW, gestational Conclusions: The findings and approaches used in this age, and sepsis, logistic regression confirmed statistically work and future ambitions to apply the Multiplex Serology significant association between TNF -308G/A genotypes platform to the entire UK Biobank cohort are likely to and development of BPD in premature infants (B=- 0.992, improveourunderstandingofinfection-diseaseassociations p=0.003). TNF -308 A allele is risk factor for BPD and molecular mechanisms facilitating therapeutic dis- (p=0.0007). covery and precision medicine. Conclusions:OurfindingssuggestthatTNF-308Aallele A.Y. Chong: None. N. Brenner: None. A. Jimenez is a risk factor for development of BPD in premature neo- Kaufmann: None. A. Cortes: None. R. Almond: None. nates under the 32 weeks. M. Hill: None. T.J. Littlejohns: None. J.J. Gilchrist: T.M.Damnjanovic:None.T.Varljen:None.O.Rakic: None. T. Parks: None. C. Watson: None. O. Rodriguez: None. B. Jekic: None. J. Liston: None. I. None.N.Allen:None.G.McVean:None.T.Waterboer: Novakovic: None. None. A. Moreno Estrada: None. A. Hill: None. A.J. Mentzer: None.  P07
.04D Hereditaryangioedemadueto C1
-inhibitordeficiencyin  P07
.03C south-eastern Europe: SERPING1 mutations and StudyofTNF,I L1
B,andI L6
genespolymorphismsand genetic factors modifying the clinical phenotype susceptibility to bronchopulmonary dysplasia in premature neonates M. Rijavec1, M. Košnik1,2, M. Zidarn1, S. Andrejević3, L. Karadža-Lapić4, D. Cikojević5, V. Grivčeva-Panovska6, T. M. Damnjanovic1, T. Varljen2, O. Rakic3, B. Jekic1, P. Korošec1 J. Liston4, I. Novakovic1 1University Clinic of Respiratory and Allergic Diseases, 1InstituteofHumanGenetics,Belgrade,Serbia,2Instituteof Golnik, Slovenia, 2Medical Faculty Ljubljana, Ljubljana, Legal Medicine, Belgrade, Serbia, 3Institute of Slovenia, 3Clinic of Allergology and Immunology, Clinical Neonatology, Belgrade, Serbia, 4Escola de Ciencias Da Center of Serbia, Belgrade, Serbia, 4General Hospital Saude, Faculdade de Medicina, ItajaI, Santa Catarina, Šibenik, Šibenik, Croatia, 5University Hospital Split, Split, Brazil Croatia,6DermatologyClinic,SchoolofMedicine,Ss.Cyril andMethodiusUniversity,Skopje,Macedonia,TheFormer Introduction: Bronchopulmonary dysplasia (BPD) is a Yugoslav Republic of commonchroniclungdiseaseassociatedwithpretermbirth. Our objective was to investigate whether the TNF, I L1
B, Introduction: Hereditary angioedema due to  C1
 inhibitor I L6
 genes polymorphisms have influence on BPD deficiency ( C1
-INH-HAE) is a rare genetic disorder susceptibility. characterized by recurrent oedemas and large heterogeneity Materials and Methods: The study included 351 neo- in clinical presentation. Our aim was to determine the nateswith gestationperiodlessthan32weeks.Genotyping spectrum of SERPING1 mutations in  C1
-INH-HAE ofI L1
B-511G/A,I L6
-174G/CandTNF-308G/Avariants patients, including genotype-phenotype relationship and if was performed by Real-time PCR. The statistical differ- functional genetic variants in F12 and KLKB1 affect the ences in genotypes distribution among the groups were disease expression. compared using the chi-square or Fisher exact test. Materials and Methods: Acohort of150 clinicallywell Results: BPD was present in 36 neonates (11.43%). characterised  C1
-INH-HAE patients from 75 unrelated There were no significant differences in the genotypes families from Croatia, Republic of Macedonia, Serbia, and distribution and allele frequencies for the I L1
B and I L6
 Sloveniawasrecruited for genetic analysis,whichincluded genes variants between neonates with and without BPD. sequencing and MLPA analysis of SERPING1, as well as The frequencies of TNF genotypes were GG 55.6%, GA detection of F12 (rs1801020) and KLKB1 (rs3733402) 38.9%andAA5.6%inneonateswithBPDandGG79.7%, variants. GA 19.7% and AA 0.6% in neonates without BPD. TNF Results: We have identified 39 different mutations (14 genotypes frequencies between these groups were statisti- missense, 11 nonsense, 7 frameshift, 1 in-frame deletion, cally significantly different (p=0.001). Also, statistically 2 splicing defects, 1 substitution affecting the promoter, 3 significant difference was observed in TNF genotypes large indels). Thirteen mutations have not been previouslyAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1361 described. When addressing the genotype-phenotype rela- incubatedinconditionedmediumfromeditedHCT116cells tionship we found that patients with nonsense and frame- showedloweractivationandslowerproliferationthanthose shiftmutations,largeindels,splicingdefects,andmutations incubated in medium conditioned by wild-type HT C116
 affecting the  C1
-INH active site (at Arg444) exhibited an cells. Unlike, edited HCT116 cells presented a higher increased clinical severity score, compared with those with proliferationratecomparedtowildtypecells.Inconclusion, missense mutations, excluding mutations at Arg444. disruption of the rs6822844 region provokes alterations in Importantly, the F12 variant was associated with disease intestinalcellsthatseemtoaffectmonocytesandinturnthe onset. No association between KLKB1 variant and disease inflammatory status, suggesting the presence of genomic expression was identified. elements within the region that could contribute to the Conclusions: Our study identified 39 different, among development of celiac disease. Funding: PI16/00258 (JRB) them 13 novel, disease-causing mutations in  C1
-INH-HAE and EJ-2017111082 and ACM (ACR). patients, highlighting the heterogeneity of mutations in the M. Sebastian de la Cruz: None. A. Olazagoitia-Gar- SERPING1 gene. The mutations with a clear effect on  C1
- mendia: None. I. Romero-Garmendia: None. I. Iras- INH function predispose patients to a more severe disease torza: None. A. Castellanos-Rubio: None. J.R. phenotype and the CC F12 variant to earlier disease onset. Bilbao: None. M.Rijavec:None.M.Košnik:None.M.Zidarn:None. S. Andrejević: None. L. Karadža-Lapić: None. D.  P07
.06B Cikojević: None. V. Grivčeva-Panovska: None. P. Immunoregulatoryeffectandtheroleofplasmacell-free Korošec: None. DNA in celiac disease  P07
.05A A. Zinkova1, I. Brynychova1,2, I. Hoffmanova3, Functional study of the rs6822844 SNP associated with M. Korabecna1, P. Dankova2 risk to celiac disease in intestinal cells 1Institute of Biology and Medical Genetics of the First M. Sebastian de la Cruz1, A. Olazagoitia-Garmendia1, Faculty of Medicine, Charles University and General I. Romero-Garmendia1, I. Irastorza2, A. Castellanos- University Hospital, Prague, Czech Republic, 2Faculty of Rubio1,3, J. R. Bilbao1 Science, Charles University, Department of Anthropology and Human Genetics, Prague, Czech Republic, 3Third 1University of the Basque Country (UPV-EHU), BioCruces Faculty of Medicine, Charles University and University HealthResearchInstitute,Leioa,Spain,2CrucesUniversity Hospital Kralovske Vinohrady, Second Department of Hospital (UPV/EHU), Barakaldo, Spain, 3IKERBASQUE, Internal Medicine, Prague, Czech Republic Basque Foundation for Science, Bilbao, Spain Introduction:Immunoregulatoryeffectsofplasmacell-free SNP rs6822844 shows the strongest association with celiac DNA (cfDNA) have been reported but its role in disease (CeD) susceptibility outside the HLA region. The pathogenesis of celiac disease (CD) has not been SNPislocatedbetweenI L2
 andI L21
 genes, which encode studied yet. for immune IL-2 and IL-21 cytokines, respectively, and Materials and Methods: We determined the total havebeenproposedascandidateetiologicalgenesforCeD, cfDNA concentration and relative content of telomeric although functionally confirmation is still pending. Thus, sequencesinplasmacfDNAinrecentceliacdiseasepatients the main aim of this study was to analyze the effect of (rCD, n = 10) and healthy age-matched controls (HC, n = rs6822844inintestinalcells.Forthatpurpose,thegenomic 10) by qPCR. To document that the observed biological region surrounding rs6822844 was mutated in HCT116 effects are caused by cfDNA molecules, we treated the epithelial intestinal cells using CRISPR-Cas9, and mRNA paired plasma samples with DNase. Using paired samples levelsofI L2
,I L21
andFGF2wereanalyzed.TheCRISPR- ofplasma(non-treatedandtreated byDNase),weanalyzed Cas9 edition produced a complex reorganization of the the contribution of cfDNA to the activation of TLR9 and genomic region, and provoked a downregulation of FGF2 TNF-α mRNA expression in TH P1
 monocytic cell line. expression located 240kb downstream of the SNP. On the Results: We found neither significant differences in the contrary, FGF2 expression was upregulated in intestinal quantity of cfDNA nor in the relative amount of telomere biopsies from CeD patients. In addition, U937 monocytes sequences in the non-treated rCD and HC plasma. Stimu- were incubated in edited and non-edited HCT116-condi- lation of TH P1
 cells with non-treated rCD plasma led to tioned media and ILB1 expression was measured to higher mRNA expression level TNF-α (p=0.031) than sti- evaluate their activation. Proliferation assays were also mulation with non-treated HC plasma. The cfDNA in rCD performed in both HCT116 and U937 cells. Monocytes plasmasamplesstimulatedtheproductionofTLR9mRNA.1362 TheTLR9mRNAexpressionwassignificantly(p=0.014) P. Comella: None. N. Beckmann: None. G. Hoffman: lowered after cfDNA removal from rCD plasmas. None. E. Schadt: A. Employment (full or part-time); Sig- Conclusions: We provide the first evidence that cfDNA nificant; Sema4 Genomics. contained in rCD plasma differs in its immunoregulatory capacity from cfDNA in HC plasma.  P07
.08D SupportedbytheMinistryofEducation,YouthandSport Angiogenesis in CML: miRNAs and angiogenic factors oftheCzechRepublic[grantnumbersProgresQ25,Progres in plasma before and after TKI treatment Q43,SVV260436andSVV260373]andbytheMinistry of Health of the Czech Republic [grant number RVO/VFN Z. Litwinska1, K. Łuczkowska1, A. Sobuś1, D. Rogińska1, 64165]. E. Pius-Sadowska1, A. Pietrzyk2, E. Paczkowska1, A. Zinkova: None. I. Brynychova: None. I. Hoffma- M.Gniot3,G.Helbig4,K.Lewandowski3,B.Machaliński1 nova: None. M. Korabecna: None. P. Dankova: None. 1Department of General Pathology, Pomeranian Medical  P07
.07C University, Szczecin, Poland, 2Department of Clinical Machine learning classifiers implicate B cell activation Genetics and Pathology, University of Zielona Góra, in chronic fatigue syndrome Zielona Góra, Poland, 3Department of Hematology and Bone Marrow Transplantation, University of Medical P. Comella, N. Beckmann, G. Hoffman, E. Schadt Sciences,Poznan,Poland,4DepartmentofHematologyand Bone Marrow Transplantation, School of Medicine in Icahn School of Medicine at Mount Sinai, New York, NY, Katowice, Medical University of Silesia, Katowice, Poland United States Introduction: The differences of an angiogenic potential Chronic Fatigue Syndrome (CFS) is a disease resulting in between clinical phases of chronic myeloid leukemia extreme fatigue without any known underlying medical (CML), point at the significance of neovascularisation in condition. CFS often presents in patients following a viral CML pathogenesis. Tyrosine kinase inhibitors (TKI), infectionandpatientsmay appear tohaveslightlyimpaired possessing antiangiogenic properties and microRNAs immunesystems.Withnopositivediagnostic,CFSisoften (miRNAs), implicated in governing angiogenesis, both misunderstoodandmisdiagnosed.Apilotclinicalstudywas seem vital in this process. In this study, we aimed to established to give further insight into the immunological investigate how TKI treatment affects angiogenesis-related role of CFS. This pilot study included 15 CFS patients and miRNAsexpressionandangiogenicfactorsconcentrationin 15 age and sex matched controls undergoing cardiopul- plasma of CML patients. monary exercise testing (CPET). Blood was extracted at Materials and Methods: Peripheral blood plasma sam- four time points - immediately before, 1 day after, 2 days ples were obtained from CML patients at the diagnosis after and 3 days after. Five immune cell types were sorted (n=23) and during TKI treatment (n=12). Quantitative fromwholebloodcollectedfromeachparticipant,andRNA assessment of the expression of miRNA-126-3p, miRNA- was extracted and sequenced for each cell type, as well as 150-5p and miRNA-21-3p was performed with qRT-PCR. whole blood, at each time point. Additionally, each Concentrations of selected angiogenic factors in plasma participant underwent extensive clinical surveys and (Angiogenin, bFGF, Endostatin,aFGF, PDGF-AA, PIGF, questionnaires. Thrombospondin-2, VEGF-D, Angiopoietin-1, VEGF) Our team has employed machine learning approaches to were assessed using multiplex fluorescent bead-based construct classifiers that can accurately distinguish CFS immunoassays (Luminex Corporation). from non-disease states in immune cells using RNA-Seq Results: MiRNA-150-5p and miRNA-21-3p expression data. This technique has generated non-linear gene asso- was evidently higher in the treatment group (p=0,001 and ciations that can be used to understand distinct gene p=0,03, respectively). PDGF-AA concentration in newly expression differences between disease and non-disease diagnosed patients with CML was higher than in already states. We were able to identify B cell classifiers as being treated patients (942,84 pg/ml vs 512,5 pg/ml, p=0,02), the highest performing classifiers in the immune cell similarly to VEGF (262,82 pg/ml vs 27 pg/ml, p=0,03). populations, suggesting B cells contain more interesting Conclusions: TKI treatment affects miRNAs expression disease-statebiology.Genesignaturesfromtheseclassifiers and angiogenic factors concentration in plasma of CML werefurtherfoundtobeenrichedinco-expressionmodules patients. MiRNAs could serve as biomarkers in monitoring associated with B cell maturation. These classifier algo- CML progression and drug response, however, their exact rithms can also be used to predict unseen observations as a role in CML-related angiogenesis remains to be further future diagnostic tool. elucidated.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1363 Funding: This work was supported by Pomeranian S. Jalil: None. Y. Novik: None. R. Maldonado: None. MedicalUniversityYoungInvestigatorGrantMB-173-218/ D. Balboa: None. T. Otonkoski: None. U. Wartiovaara- 17. Kautto: None. K. Wartiovaara: None. Z. Litwinska: None. K. Łuczkowska: None. A. Sobuś: None. D. Rogińska: None. E. Pius-Sadowska: None. A.  P07
.10B Pietrzyk: None. E. Paczkowska: None. M. Gniot: None. Genome-wide association study identifies seven novel G. Helbig: None. K. Lewandowski: None. B. loci associating with circulating cytokines and cell Machaliński: None. adhesion molecules in Finns  P07
.09A E. Sliz1, K. Marita1, A. Ahola-Olli2, O. Raitakari2, Increasing fetal hemoglobin by genetic editing the cells M. Perola3, V. Salomaa3, T. Lehtimäki4, T. Karhu1, of sickle cell disease patients H. Viinamäki5, M. Salmi2, K. Santalahti2, S. Jalkanen2, J. Jokelainen1, S. Keinänen-Kiukaanniemi1, S. Jalil1, Y. Novik1, R. Maldonado1, D. Balboa1, M. Männikkö1, K. Herzig1, M. Järvelin1, S. Sebert1, T. Otonkoski1,U.Wartiovaara-Kautto2,K. Wartiovaara3,1 J. Kettunen1 1StemCellsandMetabolismResearchProgram,University 1University of Oulu, Oulu, Finland, 2University of Turku, of Helsinki, Helsinki, Finland, 2Comprehensive Cancer Turku,Finland,3NationalInstituteforHealthandWelfare, Center, Helsinki University Hospital, Helsinki, Finland, Helsinki,Finland, 4Tampere University, Tampere,Finland, 3Clinical Genetics, Helsinki University Hospital, Helsinki, 5University of Eastern Finland, Kuopio, Finland Finland Introduction: Genetic factors modulate the inflammatory Beta-hemoglobinopathies, such as Sickle Cell Disease load, but the exact mechanisms are incompletely (SCD) and beta-thalassemia are amongstthemostcommon understood. monogenic diseases with tens of millions of patients Methods: We performed a genome-wide association globally.Theyarisefrommutationsinthebeta-globingene study (GWAS) on 16 circulating inflammatory phenotypes HBB and the only curative treatment is an allogenic in Northern Finland Birth Cohort 1966 (NFB C1966
, hematopoieticstemcelltransplant,whichiscomplicatedby N=5,284). A subsequent meta-analysis was completed for limited matching donor availability, severe adverse reac- 10phenotypesavailableinapreviousGWAS[1]addingup tions and excessive costs. Hemoglobinopathy symptoms to 13,577 individuals in the study. Complementary asso- can also be ameliorated with the increase of fetal ciationtestswereperformedtostudytheeffectoftheABO hemoglobin (HbF), but pharmacological treatments are blood types on soluble adhesion molecule levels. sub-optimal.However,naturallyoccurringbeneficialaltera- Results: We identified seven novel and six previously tionscanleadtoelevatedlevelsofHbFinadulthood.When reported genetic associations (p<3.1x10-9). We observed these benign Hereditary Persistence of Fetal Hemoglobin three loci associating with soluble vascular cell adhesion (HPFH) syndrome alterations are coinherited with a beta- molecule-1 (sVCAM-1) level, one of which is the ABO hemoglobinopathy the disease can be much milder or even locus that has been previously associated with soluble E- symptomless. Several HPFH alterations have been identi- selectin (sE-selectin) and intercellular adhesion molecule-1 fied.GenetherapyandgeneeditingtoolssuchasZFNs,and (sICAM-1) levels [2-4]. Our findings further suggest that CRISPR/Cas9 hold much promise for the treatment of thebloodtypeBassociatesprimarilywiththeconcentration genetic diseases and have been studied also for the ofsVCAM-1whiletheA1subtypeshowsarobusteffecton treatment of beta-hemoglobinopathies. The first CRISPR/ sE-selectinandsICAM-1levels.ThegenotypesintheABO Cas9 clinical trials are also underway. Here, we have used locus associating with higher soluble adhesion molecule the CRISPR/Cas9 - based genetic engineering as well as levels tend to associate with lower circulating cholesterol singlebaseeditingtoproducebeneficialHPFHmutationsto levels and lower cardiovascular disease risk. hematopoietic cell lines, control and SCD patient hemato- Conclusions: The present results extend the knowledge poietic CD34+ cells in vitro. After genetic editing and aboutgeneticfactorscontributingtotheinflammatoryload. differentiation to hemoglobin- producing red blood cells, Our findings suggest that two distinct mechanisms con- the cells show up to 35% production of fetal Hb. The tribute to the soluble adhesion molecule levels at the ABO differentiation capacity and the genetic profile of the cells locus and that increased soluble adhesion molecule levels shownosignificantchanges.Funding:AcademyofFinland, by itself may not increase risk for cardiovascular disease. grants 308481, 286773 References: (1) Am J Hum Genet 2017;100:40-50. (2) PLoS Genet 2008;4:e1000118. (3) PLoS One 2012;7:1364 e51441. (4) Arterioscler Thromb Vasc Biol 2009;29:1958- for some particular genes, this possibility should not be 67. underestimated. E. Sliz: None. K. Marita: None. A. Ahola-Olli: None. G. Kök: None. A. Aykut: None. A. Durmaz: None. E. O. Raitakari: None. M. Perola: None. V. Salomaa: D. Pariltay: None. N. Gülez: None. F. Genel: None. M.Ö. Speakers Bureau/Honoraria (speakers bureau, symposia, ÇoĞulu: None. andexpertwitness);Modest;NovoNordisk.Other;Modest; Bayer Ltd. T. Lehtimäki: None. T. Karhu: None. H.  P07
.12D Viinamäki: None. M. Salmi: None. K. Santalahti: None. Geneticvariantrs16944inI L1
Bgeneisariskfactorfor S. Jalkanen: None. J. Jokelainen: None. S. Keinänen- early onset sepsis susceptibility and outcome in preterm Kiukaanniemi: None. M. Männikkö: None. K. Herzig: infants None. M. Järvelin: None. S. Sebert: None. J. Kettunen: None. N. Maksimovic1, T. Varljen2, G. Sekulovic3, T. Damnjanovic1, I. Novakovic1  P07
.11C DOCK8 deficiency; two patients with large deletions 1Institute of Human Genetics, Faculty of Medicine, detected by Next-generation sequencing UniversityofBelgrade,Belgrade,Serbia,2InstituteofLegal Medicine, Faculty of Medicine, University of Belgrade, G. KÖk1, A. Aykut1, A. Durmaz1, E. Pariltay1, N. GÜlez2, Belgrade, Serbia, 3Institute of Neonatology, Belgrade, F. Genel2, M. Ö. ÇoĞulu1 Serbia 1Ege University, Faculty of Medicine, Department of Introduction: Neonatal sepsis is progressive immunologi- MedicalGenetics,İzmir, Turkey, 2Dr Behçet Uz Children’s cal process caused by invasion of microbial pathogens on Hospital,Clinic of Pediatrics, İzmir, Turkey thenormallysteriletissueofinfants.Despitethesignificant improvement of intensive neonatal care it is the most Dedicator ofcytokinesis 8 (DOCK8)gene mutationslead a frequent cause of morbidity and mortality among preterm combined primary immunodeficiency which is first infants. Interleukin-1-beta (I L1
B), is a proinflammatory described as a new entity in the autosomal recessive Hyper mediator that appears very early in response to infection. IgE syndrome (HIES). Just like the HIES, these mutations The polymorphism -511 G/A in I L1
B gene is located cause elevated serum IgE, eosinophilia, frequent staphylo- upstream of the transcriptional start site and influences its coccalinfections.Patientshaveincreasedriskforinfections transcriptional activity. The aim of this study was to as well as autoimmunity and malignancy. DOCK8 gene evaluate the relationships between rs16944 polymorphism spans 48exonsanddeletionsare themostcommontype of inI L1
B(-511G/A)andsusceptibilityandoutcomeofearly mutations. Here, we present 2 primary immune deficiency onset sepsis (EOS) in preterm infants. patientswhoareclinicallydiagnosedasDOCK8deficiency. MaterialandMethods:Ourstudyincluded 471preterm Both of the patients have consanguineous parents and infants, 285 with EOS and 186 healthy premature infants. laboratory results indicating DOCK8 deficiency. Ion For all patients data about gender, gestational age, weight AmpliSeq™ Primary Immune Deficiency Research Panel onbirth(BMW),Apgarscoredeterminedinthe5thminute designed for sequencing 264 primary immune deficiency (A S5
’), type of delivery and multiple pregnancies are col- genes were used for mutation detection. After initial lected.I L1
B-511G/Agenotypesweredetectedwithcustom analysis of 264 genes filtering through minor allele real time genotyping assay. frequency, variant location and variant effect no causative Results: Frequency of AA I L1
B -511G/A genotype is mutation was detected. Immune gene panel rechecked in statistically significantly higher in EOS group (p=0.028). both cases due to the strong clinical findings and large Genotype frequencies between EOS and control groups by deletions were detected in both patients. First patient was recessive (GG+GA/AA) model also show significant dif- foundtohaveahomozygousdeletion(c.(53+1_54-1)_(827 ferences (p=0.012). Logistic regression with weight on +1_828-1)del) extending from 2nd to 7th exons and second birthandgestationalageascovariatesconfirmedsignificant patient have homozygous c.(53+1_54-1)_(3234+1_3235- association between I L1
B -511 G/A genotypes and devel- 1) deletion extending from 2nd to 26th exons. opment of sepsis (B=-0.427, p=0.000). Also, in the EOS We want to underline that large deletions may escape group AA genotype was significant predictor of lethal from routine filtering analysis and the suspected genes outcome (p=0.033). should be checked individually by an integrative genomic Conclusion: I L1
B -511 G/A polymorphism could be viewer. If deletions are the majority types of the mutation associated with early onset sepsis susceptibility and out- come in preterm infants.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1365 N.Maksimovic:None.T.Varljen:None.G.Sekulovic: S. Rüeger: None. C. Hammer: A. Employment (full or None. T. Damnjanovic: None. I. Novakovic: None. part-time); Significant; Genentech. A. Loetscher: None. E. Zdobnov: None. J. Fellay: None.  P07
.13A Genome-to-genome analysis of Epstein-Barr virus  P07
.14B infection Implementationofanewdiagnosticstrategyforfamilial erythrocytosis in Slovenia S. Rüeger1,2, C. Hammer3,4, A. Loetscher5,2, E. Zdobnov5,2, J. Fellay1,2,6 A. Kristan1, J. Gašperšič1, P. Hudler1, D. Germ1, T. Režen2, D. Rozman2, T. Kunej3, T. Pajič4, M. Fink4, 1Global Health Institute, School of Life Sciences, EPFL, S. Anžej Doma4, Š. Žula4, I. Preložnik Zupan4, R. Količ5, Lausanne, Switzerland, 2Swiss Institute of Bioinformatics, T. Marčac Grahek5, M. Moškon6, N. Debeljak1 Lausanne, Switzerland, 3Department of Cancer Immunology, Genentech, South San Francisco, CA, United 1Medical Centre for Molecular Biology, Institute of States, 4Department of Human Genetics, Genentech, South Biochemistry,FacultyofMedicine,UniversityofLjubljana, San Francisco, CA, United States, 5Faculty of Medicine, Ljubljana, Slovenia, 2Centre for Functional Genomics and University of Geneva, Geneva, Switzerland, 6Precision Bio-Chips, Institute of Biochemistry, Faculty of Medicine, Medicine Unit, Lausanne University Hospital, Lausanne, University of Ljubljana, Ljubljana, Slovenia, 3Department Switzerland of Animal Science, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia, 4Clinical department of Epstein-Barr virus (EBV) is one of the most common Haematology, University Medical Centre Ljubljana, viruses latently infecting humans. It is the cause of Ljubljana, Slovenia, 5Kemomed Research and infectious mononucleosis and has oncogenic potential. Development, Kemomed Ltd., Kranj, Slovenia, 6Faculty of Littleisknownaboutthepotentialimpactofhumangenetic Computer and Information Science, University of variation on inter-individual differences in response to Ljubljana, Ljubljana, Slovenia EBV. The challenge of genetic determinant discovery explaining host susceptibility and response to EBV Introduction: Familial erythrocytosis is a rare congenital infection is compounded by pathogen genetic variation. disorder defined by increased red blood cell number, Wehereuseagenome-to-genome(G2G)strategytosearch haemoglobin and haematocrit. Variants in genes involved for genetic associations between paired human and EBV in oxygen sensing pathway (including EGLN1) or genes samples, which could highlight sites of host-pathogen affecting haemoglobin oxygen affinity results in seven genomic conflicts and shed light on pathogenesis. different types of familial erythrocytosis. We obtained and curated human genome-wide genotyp- Materials and Methods: National diagnostic algorithm ingdataandconsensusEBVgenomesequencingdatafrom was developed to identify patients with familial ery- 266 HIV-infected individuals with elevated EBV plasma throcytosis, among patients undergoing polycythemia vera viral load (>2000 copies/ml). We performed a separate testing over five-year period in Slovenia. Libraries were genome-wide association study (GWAS) for each viral prepared according to the protocol for Illumina Nextera variant using generalized linear mixed models, while con- DNAExome,enrichedbasedontheprotocolforIntegrated trolling for human and EBV population structure. DNA Technologies xGen Hybridization Capture of DNA We performed a total of 850 GWASs. No host-pathogen Libraries and sequenced on MiniSeq sequencer. Identified association survived the Bonferroni corrected G2G sig- variants were validated by Sanger sequencing. nificance threshold of 10-11. We observed four signals with Results: National diagnostic algorithm revealed that P<10-8, including an association between variants in the among 1054 polycythemia vera negative patients, only 81 EBV gene BFRF1 and in the human gene RSR C1
, which had increased haemoglobin and haematocrit at least twice functions in spliceosome assembly and participates in over a 2 month period. Further examinations pointed out multiplestepsofmRNAsplicing.BecauseEBVdependson seven families indicative for familial erythrocytosis. Tar- host proteins for viral gene expression, changes in alter- geted exome-sequencing identified heterozygous substitu- nativesplicingduetoRSR C1
variationcouldinfluenceEBV tion rs61750991 in EGLN1 gene in two affected but not in pathogenesisbyselectingspecificBFRF1escapemutations. unaffected members of one family. The described diag- The joint analysis of host and pathogen genetic variation nostic algorithm was also established within the in-house can help uncover novel genetic influences on infectious developed ViDis platform, enabling visualisation and diseases. sharing of medical algorithms (http://vidis.fri.uni-lj.si).1366 Conclusions: We successfully established diagnostic  E148
Q (P=0.004), M694V/ E148
Q (P<0.001) and V726A/ algorithm for familial erythrocytosis in Slovenia and V726A (P=0.001). Of note, 12/354 (3.39%) patients were facilitated its broad accessibility within medical society via found to be homozygous for the M694V mutation. ViDis platform. Implementation into clinical practice iden- Conclusions: Our data suggest that late-onset FMF is tified an EGLN1 variant rs61750991 in one studied family, moreprevalentinwomenandisofgreatergeneticdiversity indicative for familial erythrocytosis type 3. than previously reported. Further studies including late- Supported by Slovenian Research Agency grant no.  L3
- onset FMF patients homozygous for MEFV mutation 9279 and Young Researcher founding. All rights reserved. M694V are ongoing and may lead to the identification of A. Kristan: None. J. Gašperšič: None. P. Hudler: novel disease-modifying mechanisms. None. D. Germ: None. T. Režen: None. D. Rozman: G. Kriegshäuser: None. H. Hayrapetyan: None. S. None.T.Kunej:None.T.Pajič:None.M.Fink:None.S. Atoyan: None. S. Nemeth: None. C. Oberkanins: None. Anžej Doma: None. Š. Žula: None. I. Preložnik Zupan: T. Sarkisian: None. None. R. Količ: None. T. Marčac Grahek: None. M. Moškon: None. N. Debeljak: None.  P07
.16D Rare frameshift mutation in SERPINA3 contributes to  P07
.15C generalized pustular psoriasis Genotypic diversity observed within a large cohort of Armenian patients with late-onset familial U. D. Hüffmeier1, H. Sticht2, J. Wenzel3, D. Wilsmann- Mediterranean fever Theis3, K. Wolff4, S. Löhr1, B. Frey5, M. Hahn6, A. B. Ekici1, S. Uebe1, C. Thiel1, A. Reis1, J. Prinz7, G. Kriegshäuser1,2, H. Hayrapetyan3,4, S. Atoyan3,4, V. Oji8, P. Schulz9, K. Kingo10, S. Kõks11, R. Mössner12, S. Nemeth5, C. Oberkanins5, T. Sarkisian3,4 L. Munoz6, A. E. Kremer4, S. Frey6 1Institute of Clinical Chemistry and Laboratory Medicine, 1Human Genetics, University of Erlangen, Erlangen, General Hospital, Steyr, Austria, 2Clinical Institute of Germany, 2Bioinformatics, Biochemistry, University of Medical and Laboratory Diagnostics, Medical University, Erlangen, Erlangen, Germany, 3Department of Graz, Austria, 3Center of Medical Genetics and Primary Dermatology, University of Bonn, Bonn, Germany, Health Care, Yerevan, Armenia, 4Department of Medical 4Department of Medicine 1, University of Erlangen, Genetics, Yerevan State Medical University, Yerevan, Erlangen, Germany, 5Department of Radiation Oncology; Armenia, 5ViennaLab Diagnostics, Vienna, Austria Universitätsklinikum Erlangen, Erlangen, Germany, 6Department of Internal Medicine 3 - Rheumatology and Introduction: Familial Mediterranean fever (FMF) as an Immunology; Friedrich-Alexander-Universität Erlangen- autoinflammatory disease, results from mutations in the Nürnberg and Universitätsklinikum Erlangen, Erlangen, MEFV gene mainly with an autosomal recessive mode of Germany, 7Department of Dermatology, University of inheritance. The age of onset of FMF varies, with about Munich, Munich, Germany, 8Department of Dermatology, 60% and 90% of patients experiencing their first attack University of Münster, Münster, Germany, 9Department of beforetheageof10and20years,respectively.Hence,FMF Dermatology, Fachklinik Bad Bentheim, Bad Bentheim, with the first attack occurring at the age of ≥ 40 years (i.e. Germany, 10Department of Dermatology, Dermatology late-onset FMF) is rare and only a few small studies have Clinic,UniversityofTartu,Tartu,Estonia,11Departmentof addressed this disease subset. Pathophysiology, University of Tartu, Tartu, Estonia, Objectives: This work aimed at investigating the mole- 12Department of Dermatology, Georg-August-University culargeneticcharacteristicsofArmenianpatientsdiagnosed Göttingen, Göttingen, Germany with late-onset FMF. Methods: Genomic DNA isolated from 354 Armenian Recent research in psoriasis has identified pustular mani- late-onset FMF patients were analysed for the 12 most festationsaseitherMendelianoroligogenictraitsincontrast commonMEFVmutationsplusSAA1isoforms1.1,1.3and to the numerous associated SNPs in common plaque 1.5 using multiplex PCR and reverse-hybridisation. Muta- psoriasis. Autosomal-recessive mutations in I L36
RN have tional spectra and resulting genotypes were then matched been identified in 16-30% of patients with generalized against the clinico-demographic profiles collected for these pustular psoriasis (GPP), a rare, severe pustular psoriasis patients. accompanied by multi-systemic inflammation. These muta- Results:Ofall354patients,194(54.80%)werefemaleand tions increase pro-inflammatory signaling in the IL-36 160 (45.20%) were male. The following genotypes were pathway. In exome sequences of 25 independent patients significantly associated with the late-onset variant: M680I/ negative for I L36
RN, we identified 2 patients with theAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1367 identicalheterozygousframeshiftvariantinSERPINA3.We toidentifyhowIFN-λandTypeIInterferonpathwaygenes nextsequencedthecodingexonsinfurther54GPPand319 are expressed during treatment. palmoplantar PP patients by Sanger without identifying MaterialsandMethods:Weevaluatedtheexpressionof further truncating variants. SERPINA3 is an excellent genes of the type I IFN signaling pathway in 24 CHC functional candidate as it encodes serine protease inhibitor patientstreated with pegylated interferon plus ribavirin and A3 which inhibits cathepsin G, a neutrophil-specific further stratified according to rs12979860 polymorphism. protease known to increase IL-36ß activity >500fold. Samples were evaluated at different time points (time 0, SERPINA3 expression in liver cell lines, fibroblasts and week 1 and week 12 during treatment and week 3 after the epidermal cell line HaCaT could be stimulated by pro- treatment). Allelic discrimination was performed using inflammatory cytokines and dexamethasone. Protein Taqman Genotyping SNP assay (AHBKCW9, Thermo- amounts in sera of the two mutation carriers were in the Fisher). Expression levels for 30 Type I IFN genes was lower normal range. By transfecting HaCaT cells with evaluated using Biomark HD System (Fluidigm). Kruskal- vectors containing the mutant or wildtype cDNA, we Wallis and Dunn´s post tests were used for comparisons. observed evidence for an unstable mRNA and lack of Results:Mostofthegeneshadelevatedexpressionlevels protein in the mutant. Immunohistochemical analyses before treatment, except for IFNA1, IFNAR and IFHI. revealed an increased staining of serpin A3 within upper Overall, they had a decline in week 1 and a significant epidermal layers in GPP, accentuated at the edge of higher expression levels in later time points. In week 1 psoriatic pustules. This close proximity to neutrophils during treatment, CC homozygote patients for rs12979860 suggests an interaction between serpine A3 and the hadlowergeneexpressionlevels,comparedtopatientsthat neutrophilic enzyme cathepsin G. This interaction might carried the risk allele T, this was observed for IFI6, IFI16, be compromised by SERPINA3 variants leading to more IRF9 and RIGI. In contrast, relative mRNA expression for activation of pro-inflammatory IL-36ß. IFH1 and RNASEL were subtle higher in patients with CC Funding: CR C1181
-project A05, BMBF-Metarthros genotype. 01E C1407
A Conclusions: Gene expression levels in Type I IFN sig- U.D. Hüffmeier: None. H. Sticht: None. J. Wenzel: nature genes was different according to time points eval- None. D. Wilsmann-Theis: None. K. Wolff: None. S. uated and also when patients were stratified according to Löhr:None.B.Frey:None.M.Hahn: None.A.B.Ekici: rs12989860 polymorphism. None. S. Uebe: None. C. Thiel: None. A. Reis: None. J. A. Marques Vieira da Silva: None. L.E. Alvarado- Prinz: None. V. Oji: None. P. Schulz: None. K. Kingo: Arnez:None.T.Azamor:None.L.RibeiroBatista-Silva: None. S. Kõks: None. R. Mössner: None. L. Munoz: None. F.S.G. Kehdy: None. T. Leal Calvo: None. M. None. A.E. Kremer: None. S. Frey: None. Ribeiro-Alves: None.C.Bayma:None.A.C.Magalhães: None. M.D.L. Sousa Maia: None. R. Páez Meireles:  P07
.17A None.H.NodarseCuni:None.P.DornellesPicon:None. DifferentialexpressionofTypeIIFNsignalingpathway D.C. de Souza Matos: None. M. Ozório Moraes: None. genes in Hepatitis C patients treated with Pegylated Interferon plus ribavirin  P07
.18B Analysis of the CD40 and CD40LG in Turkish Hyper A. Marques Vieira da Silva1, L. E. Alvarado-Arnez2, IgM Syndrome: Mutation profile and description of six T. Azamor1, L. Ribeiro Batista-Silva1, F. S. G. Kehdy1, novel mutations T. Leal Calvo1, M. Ribeiro-Alves1, C. Bayma1, A. C. Magalhães1, M. D. L. Sousa Maia1, R. Páez E. uzay1, A. Aykut1, A. Durmaz1, N. Karaca2, N. Gülez3, Meireles3, H. Nodarse Cuni3, P. Dornelles Picon4, N. Kütükçüler2, Ö. Çoğulu1 D. C. de Souza Matos1, M. Ozório Moraes1 1Ege university faculty of medicine. department of medical 1FundaçãoOswaldoCruz(Fiocruz),RiodeJaneiro,Brazil, genetics,İzmir,Turkey,2Egeuniversityfacultyofmedicine. 2Universidad Privada Franz Tamayo - UNIFRANZ, department of pediatric immunology, İzmir, Turkey, 3Dr Cochabamba, Bolivia, Plurinational State of, 3Centro de Behçet uz children's hospital. clinicof pediatrics, İzmir, Ingeniería Genética y Biotecnología, Havana, Cuba, Turkey 4HospitaldeClínicasdePortoAlegre,PortoAlegre,Brazil Hyper IgM syndromes (HIGM) is a group of primary Introduction: InChronic Hepatitis C, 20% of patients will immune deficiency disorders characterized by defective develop cirrhosis and may progress to hepatocellular CD40 signaling. Five types of Hyper IgM syndrome have carcinoma. Over the past years, many studies have tried beencharacterized:HyperIgMsyndrometype3(autosomal1368 recessive) (MIM: 606843) is characterized by mutations of The highly-multiplexed targeted re-sequencing technol- theCD40geneandHyper-IgMsyndrometype1(X-linked) ogy Molecular Inversion Probes (MIPs) enabled a genetic (MIM308230),characterizedbymutationsoftheCD40LG screenforthecompletecodingsequenceof48genesofthe gene. Patients with HIGM syndrome are susceptible to I L1
-pathway. Rare Variant Burden Analysis (RVBA) was recurrentandsevereinfectionsandinsometypesofHIGM performed on 520 healthy individuals for whom extensive syndrome opportunistic infections and an increased risk of immunophenotyping measurements are available. cancer as well. The disease is characterized by decreased We identified 221 variants, out of which 166 rare (gno- levels of immunoglobulin G(IgG) in the blood and normal mAD-Exome AF< 1%), in 41 genes. When considering or elevated levels of IgM. The aim of this study was to individuals with 1% most extreme cytokine production, evaluate the spectrum of CD40 and CD40LG gene RVBA showed association with identical genes over dif- mutations in Turkish HIGM patients. We present a ferentstimulations;e.g.inindividualswiththehighestI L6
- molecularanalysisof9TurkishHIGMpatients.Allmutant producing macrophages, I L1
R2 is associated with LPS-, alleleswereidentified,including7CD40LGmutations4of Candida- and MTB-stimulations. When using the con- which were novel and 2 novel CD40 mutations. CD40LG tinuous measurements, associated genes are unique per mutations were c.31C>T (p.Arg11Ter), c.755G>A (p. stimulation. More than 50% of the continuous associations Gly252Asp), were previously reported whereas c.89 T>A become stronger in extreme phenotypes; e.g. I L6
- (p.Val30Asp),c.446G>A(p.Ser149Asn),c.578T>G L193
R production in whole blood stimulated with PHA is asso- (p.Leu193Arg) c.616_619delCTCA ( L206
EfsX35) muta- ciated to NCF4 continuously, in the corresponding 1% of tions were novel. Novel CD40 mutations were individuals with lowest I L6
-production this signal is mag- c.170_172delTAA and one stoploss mutation nified and even extended by associations with NCF2 and c.830_833delAGTG. Herein, we describe on 8 HIGM CYBA (other ROS-production genes). patientsofTurkishoriginandreportfivenovelmutationsin Weshowthatdistinctiverare genetic variation,identified CD40 and CD40LG genes. byMIPs, influencecytokineresponsestovariousstimuliin E. Uzay: None. A. Aykut: None. A. Durmaz: None. N. different cell-types in healthy individuals. We now plan to Karaca:None.N.Gülez:None.N.Kütükçüler:None.Ö. validateinitialassociationsbyfunctionalfollow-upandaim Çoğulu: None. to expand this method to various I L1
-mediated diseases. R.C.vanDeuren:None.P.Arts:None.L.A.B.Joosten:  P07
.19C None. M. Jaeger: None. M. Steehouwer: None. M. van The role of rare genetic variation in the Interleukin-1 der Vorst: None. C. Gilissen: None. C.A. Dinarello: pathway None. M.G. Netea: None. F.L. van de Veerdonk: None. A. Hoischen: None. R. C. van Deuren1,2, P. Arts1,2, L. A. B. Joosten1, M. Jaeger1, M. Steehouwer2, M. van der Vorst2,  P07
.20D C.Gilissen2,C.A.Dinarello1,3,M.G.Netea1,F.L.vande Identification of novel Non-MHC association loci/region Veerdonk1, A. Hoischen1,2 in IgAD patients through MHC risk allele stratification and polygenic risk score analysis 1Department of Internal Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical C. LIM1,2, J. Varadé3, Y. Goh1, T. Behrens4, Center, Nijmegen, Netherlands, 2Department of Human L. Hammarström2,5 Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, 1Singapore General Hospital, Singapore, Singapore, Netherlands, 3Department of Medicine, University of 2Karolinska Institutet, Stockholm, Sweden, 3University of Colorado, Aurora, CO, United States Vigo, Immunology- Biomedical Research Center CINBIO Singular Research Center, Vigo, Spain, 4Genentech, Inc, The interleukin-1 (I L1
)-pathway has a fundamental role in South San Francisco, CA, United States, 5BGI-Shenzhen, infection and inflammation. It comprises both I L1
-agonists Shenzhen, China and -antagonists that together are responsible for maintain- ing a balance in innate immunological response. Common Introduction: Immunoglobulin A deficiency(IgAD) is the variants in underlying genes have previously been asso- most common human primary immunodeficiency disease ciated with infection, inflammation, cardiovascular disease andhasstrongassociationwiththemajorhistocompatibility and cancer, whereas the role of rare variants remains to be complex(MHC),however,itsetiologyremainsunclear.We elucidated. aimedtoidentifynon-MHCregionmarkersassociatedwithAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1369 IgAD by defined genotypic subgroups of IgAD based on hematological assays. In addition, these disorders exhibit MHC susceptibility alleles. a genetic heterogeneity with over 50 genes involved. This Materials and Methods: Total of 10993 individuals study reports the results of an upfront diagnostic strategy were analyzed. Previously published MHC risk haplotypes using whole-exome sequencing (WES) with a targeted were evaluated and the subjects were then stratified based analysisofapanelof145genesinvolvedinthrombosisand on the MHC susceptibility alleles (HLA*B0801- hemostasis(besidesplateletgenesalsoothergenesinvolved DRB1*0301-DQB1*0201/HLA-DRB1*0701-DQB1*0202/ in coagulation and venous thrombosis embolism are HLA-DRB1*01-DQB1*0501). Gene-based association ana- analysed). Sixty-Six patients suspicious for an IPD were lysiswasperformedtoinvestigatethenon-MHCassociation subjected to this WES approach. Fourteen patients (21%) using approximately 540000 SNPs and 24000 genes. harbored (likely) pathogenic variants that explained the Additionally, polygenic risk score (PRS) pathway/gene set clinical spectrum in these patients. Genes affected were analysis was performed using 4760 pathway/genes set to G P9
, MYH9 (2 cases), NBEA L2
,  P2
RY12, RUNX1 (3 infer the pathway involved in the respective subgroup. cases), SLFN14 and VWF (2 cases); all involved in Results: The presence of HLA-DRB1*0301-DQB1*0201 thrombocytopenia or thromobocytopathy. Additionally, 2 (P=0.07) or HLA-DRB1*0701(P=0.72) alone was not patients with a mutation in the THPO gene and 1 patient sufficient to confer susceptibility to IgAD. In the cohort with a mutation in SEPRIN C1
 were observed, both genes carrying at least one MHC risk allele, a protective allele, areknowntobeinvolvedinvenousvenousthromboembolic rs4097492,atSTXB P6
(P=7.63x10−9)wasobserved.CD40 disease thromboembolic diseasethromboembolic diseaseve- (P=6.89x10−5) was observed potentially associated with nousthromboembolicdisease.In4(6%)otherpatientsonly patients homozygous for the HLA-B*0801-DRB1*0301- one heterozygous (likely) pathogenic variant of an auto- DHX38(P=8.60x10−5), DQB1*0201 haplotype whereas a somal recessive gene was observed. In 12 patients (18%) a novel inhibitor of protein phosphatase 4, shows a weak variant of unknown significance (VUS/class 3) was association with patients homozygous for HLA-DRB1*01- observed. Further segregation studies within the family en DQB1*0501. For patients lacking any risk alleles, seven functional studies are requiredtofullysolve these cases. In generegionswereidentified,includingTNFRSF13B(TACI) conclusion, we found that WES is a powerful tool in (P=1.12x10−4), with suggestive evidence of association genetically diagnosing patients with IPD. with IgAD. Pathway PRS analysis shows that cohort car- A. Simons: None. M. Stevens-Kroef: None. W. van rying at least one HLA-B*0801-DRB1*0301-DQB1*0201 Heerde: None. S. Schols: None. P. Brons: None. S. de haplotype have strong association with autoimmune and Munnik: None. immunepathwaywhileHLA-DRB1*01-DQB1*0501cohort having association with asthma pathway and IgA  P07
.22B production. Uncovering the pathogen induced host-response on Conclusions: Our findings suggest that the pathogenesis RNA level to aid genetic diagnosis of primary of IgAD may be different depending on the presence of immunodeficiencies (PIDs) selected MHC susceptibility haplotypes. C. Lim: None. J. Varadé: None. Y. Goh: None. T. S. Kersten1,2, C. Kaffa3, M. G. Netea2, A. Hoischen1,2 Behrens: None. L. Hammarström: None. 1Department of Human Genetics, Radboud Institute for  P07
.21A Molecular Life Science, Radboud University Medical Applicationofwholeexomesequencingforpatientswith Center, Nijmegen, Netherlands, 2Department of inherited platelet disorders Experimental Internal Medicine, Radboud Institute for Molecular Life Science, Radboud University Medical A. Simons, M. Stevens-Kroef, W. van Heerde, S. Schols, Center, Nijmegen, Netherlands, 3Centre for Molecular and P. Brons, S. de Munnik Biomolecular Informatics (CMBI), Radboud University Medical Center, Nijmegen, Netherlands Radboud University Medical Center Nijmegen, Nijmegen, Netherlands Primary immunodeficiencies (PIDs) constitute a group of diseasescharacterizedbyimmunesystemdysfunction,that, Inherited platelet disorders (IPDs) are disorders consisting duetoitsphenotypicalandclinicallyheterogeneousnature, of thrombocytopenia (reduction in number of platelets), remains complex to diagnose. Consequently, leading to thromobocytopathy (defect in function of platelets) or a misdiagnosis and misclassification of patients in a clinical combination of these. Diagnosis is often hampered by the setting. Although whole exome sequencing (WES) has lack of specificity and correct validation of current proven its significance as a diagnostic assay in PIDs, two-1370 thirds of all patients remains diagnosis-negative. As 3 patients we detected a homozygous (likely) pathogenic accurate identification of the underlying genetic defect is variant inthe genes MK L1
, DHFRand PRF1, respectively. paramount to the clinical management of the disease, The exome-wide analysis did not result in additional exploring alternative approaches to improve PID diagnosis diagnoses. For the 3 solved cases the genetic diagnosis is crucial. Given the relative ease of access to the affected had direct impact on the clinical decision making. tissue and ex vivo stimulations, we hypothesize RNA- Medication was adjusted, specific dietary suggestions were sequencingholdsthepotentialtoreducethisdiagnosticgap provided for the DHFR case and the genetic diagnosis was significantly. instrumental in finding potential matching transplantation To gain functional insight into the host-response, donors for the PRF1 and MK L1
 cases. Also the diagnosis 3’mRNA-seq was performed on peripheral blood mono- helped the parents in future family planning. We conclude nuclear cells (PBMCs) isolated from five healthy donors. thatrapidexomesequencingcanbeofgreataddedvaluefor Mimicking bacterial, viral, fungal and a more general thediagnosisandtreatmentchoiceofpatientswithasevere immune response, PBMCs were exposed to specific inborn error of immunity. immune stimulants, i.e. S.Auris, PolyI:C, C.Albicans and W. Koole: None. K. Neveling: None. S. Castelein: LPS, respectively, in vitro for 4 and 24 hours (n=50). None. S.S.V. Henriet: None. J. Schuurs-Hoeijmakers: Differentiallyexpressedgeneswereidentifiedbycorrecting None.T.Rinne:None.M.Nelen:None.A.Simons:None. for baseline expression in non-stimulated PBMCs. In turn, comparison of differential expression between conditions  P07
.24D enabled us to unravel the core host-response, as well as The impact of rare and low-frequency genetic variants pathogen specific responses in both the early and late con- in common variable immunodeficiency (CVID) text. Collectively, these insights not only aid our quest to identify novel PID candidate genes, i.e. genes of unknown A. Bisgin1,2, O. Sonmezler1, I. Boga1, M. Yilmaz3 function or undescribed immune function, it also assists WES-based variant filtering and prioritization. Ultimately, 1CukurovaUniversityAGENTEM(AdanaGeneticDiseases paving way to expand the current host-response series for Diagnosis and Treatment Center), Adana, Turkey, unsolved PID patients. 2CukurovaUniversityFacultyofMedicine,BalcaliHospital S. Kersten: None. C. Kaffa: None. M.G. Netea: None. and Clinics, Department of Medical Genetics, Adana, A. Hoischen: None. Turkey, 3Cukurova University Faculty of Medicine, Balcali Hospital and Clinics, Division of Pediatric Allergy and  P07
.23C Immunology, Adana, Turkey Clinical importance of rapid exome sequencing in patients with inborn errors of immunity Introduction: NGS (Next Generation Sequencing) have uncovered hundreds of common and rare genetic variants W. Koole, K. Neveling, S. Castelein, S. S. V. Henriet, involved in complex and rare diseases such as immune J. Schuurs-Hoeijmakers, T. Rinne, M. Nelen, A. Simons deficiencies. However, these rare variants cannot be classified clinically vice versa those common variants only Radboud University Medical Center, Nijmegen, marginally contributes to disease susceptibility. In this Netherlands study, we evaluated the multi-gene panel results of CVID patients and argued that if rare variants located in different Incaseofasevereinbornerrorofimmunityafastdiagnosis genes could in fact play a more important role in disease is of vital importance and can change clinical decision susceptibility and/or etiology. making. In order to get a diagnosis in critically ill patients Material and Methods: We performed NGS from 103 with a differential diagnosis for an inborn immunity patients’ peripheral blood via a CVID-related 19 genes disorder we make use of our in-house rapid whole-exome panel (CARD11, CD19, CD81, ICOS, CTLA4, CXCR4, sequence workflow with a turnaround time of 1-3 weeks. GATA2,ICOS,IRF2B P2
,MOGS,M S4
A1,NFKB1,NFKB2, Using this workflow we, so far, have analyzed the exomes PLCG2,TNFRSF13B,TNFRSF13C,TNFSF12,TRNT1and of 14 patients using a primary immunodeficiency gene- TT C37
). Detected variants were evaluated and classified panel (currently 386 genes). Depending on the clinical based on their impact, pathogenicity classification and phenotype, another gene panel analysis and/or an analysis population frequency as well as the frequency within our of the entire exome was additionally performed in 8 out of study group. 14 cases. For 10 of the 14 cases trio-sequencing was Results: Next generation sequencing revealed 112 dif- performed to enable de novo analysis. The panel analyses ferent (total of 227) variants with under 10% population resulted in agenetic diagnosis in3 patients (21%). Inthese frequency in 103 patients which 22 (19.6%) were benign,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1371 28 (25%) were likely benign, 5 (4.5%) were likely patho- + EVs may be an inducing factor for Treg cell differ- genicand2(1,8%)werepathogenic.Moreover,55(49.1%) entiation and memory Treg expansion. variants were classified as variant ofuncertainsignificance. GrantsandFellowships:ÚNKP-18-3-IV-SE-14.Árpád- We also observed different variant frequencies when com- FerencKovácsisaKerpel-FroniusÖdönFellow. pared to population frequency databases. Á.F. Kovács: None. N. Fekete: None. L. Kőhidai: Conclusion:Case-controldataisnotsufficientenoughto None. E.I. Buzás: None. É. Pállinger: None. unravel the genetic etiology of immune deficiencies. Thus, it is important to understand the incidence of two or more  P07
.26B rare variants’ coexistence for the possible key role in the Reduced Severity of Collagen-induced Arthritis in pathogenesis of immune deficiencies. Peptidylarginine deiminase knockout mice A. Bisgin: None. O. Sonmezler: None. I. Boga: None. M. Yilmaz: None. A. Suzuki, Y. Kochi, T. Shibuya, K. Yamamoto  P07
.25A RIKEN, Yokohama, Japan Unravelling the role of HSP E1
 in regulatory T cell heterogeneity identified by a single-cell transcriptomic Previously,peptidylargininedeiminasetype4(PADI4)was approach identified as a susceptibility gene for Rheumatoid arthritis (RA) by genome-wide association studies. Peptidyl citrul- Á. F. Kovács, N. Fekete, L. Kőhidai, E. I. Buzás, É. line is a target antigen of anti-citrullinated peptide Pállinger antibodies (ACPAs), and only PADs (translated protein from PADI genes) can provide peptidyl citrulline via Dept. of Genetics, Cell- and Immunobiology, Budapest, modification of protein substrates. Also the distribution of Hungary PADI4andPADI2hasoverlapinimmunecells.Theaimof this study was to investigate the relationship between Introduction: Regulatory T cell (Treg) signature is PADI4geneandPADI2geneintheprogressionofRA.To composed of cell clusters of discrete states dispersed in a clarify the physiological function of PADI4 and PADI2 in continuum gravitating around four different well-definable RA, we used collagen-induced arthritis (CIA), known as a functional poles. The cell number and function of memory RA model mouse. We examined that localization of PAD4 Treg cells is of key question, as these cells promote and PAD2 protein was indicated by immunohistochemistry reproductivefitnessduringhumanpregnancybyreinforcing in CIA mice. We also measured expression of Padi genes immune tolerance against fetal antigens. The aim of our and various inflammatory cytokines in immune cells by study was to examine the role of HSP E1
 in Treg real-time TaqMan assay and ELISA, respectively. We differentiation and its influence on the functional states. generated PADI4−/− and PADI2−/− mice and performed Methods: Single-cell Treg and naïve T cell sequencing experimental arthritis. We demonstrated that the clinical data were obtained from 10x Genomics repository. Python disease score was significantly decreased in PADI4−/− basedScanpytoolkitwasusedfortheanalysisofsingle-cell miceandPADI4expressionwasinducedbyCIIimmuniza- data. Furthermore, qPCR-based gene expression of HSP E1
 tion. In PADI4−/− mice sera, serum anti-type II collagen in circulating PBMCs was evaluated. (CII)IgM,IgG,andinflammatorycytokinelevelswerealso Results:Weidentified7differentcellclustersintheTreg significantly decreased compared with those in wild-type cell population. We defined 4 in-house panels for the Treg mice sera. Interestingly, PADI2 expression was compensa- cell subtype identification. Two clusters of memory Treg tionally induced in CD11b+ cells of PADI4-/- mice. wereidentified.AmongTregcells,HSP E1
showsacluster- Furthermore, we examined that the clinical disease score dependent expression pattern; the memory subtype expres- and expression levels of Padi genes in PADI2−/− CIA sing the highest levels. Furthermore, mass spectrometry mice. It appears that PADI4 and PADI2 enhance collagen- showedthepresenceofHSP E1
inBeWotrophoblasticcell- initiated inflammatory responses. This study was supported derived extracellular vesicles (EVs). BeWo-derived EVs by Grants-in-Aid for Scientific Research (C). bound to CD4+ T cells and induced downregulation of A. Suzuki: None. Y. Kochi: None. T. Shibuya: None. I L6
RA together with an increased IL-10 production. K. Yamamoto: None. Conclusion:Byourinsilicoapproach,wedefined4gene panels which provide a good identification tool for the  P07
.27C different Treg cells subtypes. Single-cell analysis shows a A systems genetics approach to study Candida Treg cell subtype-specific signature of HSP E1
 expression. susceptibility using single-cell RNA-seq Our results raise the possibility that BeWo-derived HSP E11372
 D. H. de Vries, V. Matzaraki, M. G. P. van der Wijst, E. Svenungsson6, S. Rantapää-Dahlqvist4, O. B. Bakker, V. Kumar, L. Franke A. A. Bengtsson5, A. C. Syvänen8, K. Lindblad-Toh9, L. Rönnblom1, The DISSECT Consortium UMCG, Groningen, Netherlands 1Rheumatology, Department of Medical Sciences, Uppsala Candida albicans infection of the blood stream, candidae- University,Uppsala,Sweden,2ScienceforLifeLaboratory, mia, has mortality rates over 30% and is the most common Department of Medical Biochemistry and Microbiology, invasive fungal infection in immunocompromised patients. Uppsala University, Uppsala, Sweden, 3Dept. of Medicine Candidaemia is poorly understood and has poor treatment (Solna), Karolinska Institutet, and Dept. of Endocrinology, available. To better understand candidaemia response, we Metabolism and Diabetes Karolinska University Hospital, usedsingle-cellRNA-seq(scRNA-seq)in24hourCandida Stockholm, Sweden, 4Department of Public Health and stimulated and unstimulated peripheral blood mononuclear Clinical Medicine/Rheumatology, Umeå University, Umeå, cellsofsixdonorstoidentifycell-type-specificresponsesto Sweden, 5Department of Clinical Sciences Lund, Candida stimulation. Rheumatology,LundUniversity,SkåneUniversityHospital, Differential expression (DE) analysis with MAST bulk- Lund, Sweden, 6Department of Medicine, Rheumatology like scRNA-seq, shows high (97.3%) concordance with an unit, Karolinska Institutet, Stockholm, Sweden, independent bulk RNA-seq candida cohort. In addition, 7Department of Clinical and Experimental Medicine, MAST was also run on 7 cell types to identify cell-type- Rheumatology/Neuro and Inflammation Sciences, specific DE effects. While the CD4+ T cells and natural Linköping, Sweden, 8Department of Medical Sciences, killer (NK) cells have most DE genes (1459 and 1313, Molecular Medicine and Science for Life Laboratory, respectively), classical monocytes have the most distinct Uppsala University, Uppsala, Sweden, 9Broad Institute of response. We are now able to show that the previously MIT and Harvard, Boston, USA, and Science for Life identifiedinterferonpathwayupregulationincandidaemiais Laboratory, Department of Medical Biochemistry and consistently present throughout all immune cell types after Microbiology, Uppsala University, Uppsala, Sweden stimulation with Candida albicans. Subsequently,wedideQTLanalysison72stimulatedand Introduction: Childhood onset systemic lupus erythema- 75 unstimulated individuals with bulk RNA-seq data tosus (SLE) is associated with a more aggressive disease available, to identify response-specific eQTLs. However, course and higher mortality risk than adult onset SLE. To we were unable to link specific cell types to these eQTLs identify genetic risk loci in juvenile onset SLE (jSLE) we when we overlapped the eQTL genes with the DE genes, performed DNA sequencing in a Swedish SLE cohort. likely due to small sample sizes in both datasets. In con- Materials and Methods: Coding and regulatory regions clusion, we found no enrichment of stimulation-specific of1853genesweresequencedin958patientswithSLEand eQTLs in cell-type-specific DE genes, but were able iden- in 1030 healthy individuals. 117 of the patients had jSLE tify cell-type-specific responses to Candida albicans expo- (disease onset at age <18 years). Target capturing was sure, revealing NK cells to have a stronger response than performed with a Roche NimbleGen custom liquid capture expected from previous studies. library followed by Illumina HiSeq2500 sequencing. Funding: L.F.: ZonMW-VIDI 917.14.374, ERC Starting Results: Single variant case-control association analysis Grant 637640 revealed that 40 SNVs were associated with jSLE D.H.deVries:None.V.Matzaraki:None.M.G.P.van (FDR<5%). These 40 SNVs were enriched for missense der Wijst: None. O.B. Bakker: None. V. Kumar: None. variants (8% vs 1.8% for all SNVs). Two coding SNVs in L. Franke: None. the NCF2 gene showed the strongest evidence of associa- tion to jSLE (rs17849502 and rs17849501, best P= 1E-10,  P07
.28D OR=3.9, 95% CI[2.6-5.9]). This association exceeded the Targetednext-generationsequencingsuggestsnovelrisk signal from the human leukocyte antigen (HLA) region in loci in juvenile onset systemic lupus erythematosus statistical significance (best HLA SNV was TNXB rs369580, P=6E-08, OR=2.5[1.8-3.5]). In order to further J. K. Sandling1, L. Hultin Rosenberg2, F. H. G. Farias2, isolate the genetic contribution to jSLE, a case-case asso- A. Alexsson1, D. Leonard1, S. Kozyrev2, E. Murén2, Å. ciation analysis comparing juvenile and adult onset SLE Karlsson2, A. Mathioudaki2, P. Pucholt1, D. Eriksson3, cases was also performed. The two top loci from this ana- G. Pielberg2, J. Meadows2, J. Nordin2, J. Dahlqvist2, lysis were I L27
 and LIFR (P<1E-05). Currently replication M. Bianchi2, The ImmunoArray Development ofthesetwolociisongoinginanadditional100jSLEcases. Consortium, C. Bengtsson4, A. Jönsen5, L. Padyukov6, Conclusion: Using targeted sequencing we have identi- M. L. Eloranta1, C. Sjöwall7, I. Gunnarsson6, fied coding SNVs in novel candidate risk loci in jSLE,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1373 highlighting differences in the genetic risk factors for Results: We identified a novel homozygous missense var- childhood and adult onset SLE. iant NM_001024858.3(SPTB):c.6119C>T (p.Thr2040Ile), J.K.Sandling:None.L.HultinRosenberg:None.F.H. located in the spectrin repeat region. Parents were both het- G. Farias: None. A. Alexsson: None. D. Leonard: None. erozygous for this variant. The time from sample receipt to S. Kozyrev: None. E. Murén: None. Å. Karlsson: None. result was 68hrs. Pretransfusion eosin-5-maleimide ( E5
M) A. Mathioudaki: None. P. Pucholt: None. D. Eriksson: stainingintheprobandwasmarkedlyreduced(ratio<0.6)and None. G. Pielberg: None. J. Meadows: None. J. Nordin: blood film showed marked spherocytosis including micro- None. J. Dahlqvist: None. M. Bianchi: None. C. spherocytes and nucleated erythrocytes. Both parents Bengtsson: None. A. Jönsen: None. L. Padyukov: None. demonstrated mildly reduced  E5
M staining, with occasional M.L. Eloranta: None. C. Sjöwall: None. I. Gunnarsson: spherocytesandelliptocytesseeninthematernalandpaternal None. E. Svenungsson: None. S. Rantapää-Dahlqvist: blood films respectively. The proband has life-threatening None. A.A. Bengtsson: None. A.C. Syvänen: None. K. haemolytic anaemia with progressive liver failure, and early Lindblad-Toh: None. L. Rönnblom: B. Research Grant genetic diagnosis has facilitated hypertransfusion to suppress (principal investigator, collaborator or consultant and ineffective erythropoiesis and reverse hepatic dysfunction. pending grants as well as grants already received); Sig- Conclusions: This case of severe prenatal haemolytic nificant; AstraZeneca. anaemiaduetoahomozygousSPTBmutationbroadensthe genotypic and phenotypic spectrum of spectrin deficiency  P07
.29A and highlights the value of rapid early genomic diagnosis. Rapid identification of a bi-allelic SPTB mutation in a C.M.Richmond:None.S.Campbell:None.H.W.Foo: neonate with severe haemolytic anaemia and liver None. S. Lunke: None. Z. Stark: None. E. Bannister: failure None. A. Greenway: None. N.J. Brown: None. C.M.Richmond1,S.Campbell2,H.W.Foo3,S.Lunke1,4,  P07
.30B Z.Stark1,5,6,E.Bannister3,5,A.Greenway2,N.J.Brown1,5 A genome-wide association study of CM-SJS/TEN with SOC in Japanese population based on whole genome 1Victorian Clinical Genetics Services, Murdoch Children's sequencing Research Institute, Melbourne, Australia, 2Department of Haematology, Royal Children’s Hospital, Melbourne, Y. Kawai1, Y. Hitomi1, M. Ueta2, S. Khor1, K. Nakatani1, Australia, 3Department of Gastroenterology, Royal C. Sotozono3, S. Kinoshita2, M. Nagasaki4, K. Tokunaga1 Children’s Hospital, Melbourne, Australia, 4Department of Clinical Pathology, University of Melbourne, Melbourne, 1Department of Human Genetics, Graduate School of Australia, Melbourne, Australia, 5Department of Medicine, The University of Tokyo, Tokyo, Japan, Paediatrics, University of Melbourne, Melbourne, 2Department of Frontier Medical Science and Technology Australia, 6Australian Genomics Health Alliance, for Ophthalmology, Kyoto Prefectural University of Melbourne, Australia Medicine, Kyoto, Japan, 3Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan, Introduction: Erythrocyte membrane defects, caused by 4Department of Integrative Genomics, Tohoku Medical deficienciesinmembraneproteinsankyrinandspectrin,are MegabankOrganization,TohokuUniversity,Sendai,Japan an important cause of neonatal non-immune haemolytic anaemia. Heterozygous mutations in SPTB, encoding Introduction: Stevens-Johnson syndrome and toxic epi- β-spectrin, cause autosomal dominant hereditary spherocy- dermalnecrolysis(SJS/TEN)areimmunologicallymediated tosis. Few cases of bi-allelic mutations have been reported, severe reactions of the skin and mucous membranes. with severe consequences, including hydrops fetalis and Although previous genome-wide association studies identi- fatalornear-fatalanaemia.Rapidgenomictestingfacilitates fied the common SNPs as genetic risk factors of cold early diagnosis and informs management in critically ill medicinerelatedSJS/TENwithsevereocularcomplications patients. We describe rapid genomic diagnosis of a novel (CM-SJS/TEN with SOC), little is known about the homozygous SPTB mutation in a case of severe prenatal- contribution of rare variants and structural variants (SVs) onsethaemolyticanaemiawithtransfusion-dependence,and to development of CM-SJS/TEN with SOC. conjugated hyperbilirubinaemia with hepatosplenomegaly. Materials and Methods: In order to investigate impact Methods: Clinical rapid trio exome testing was per- ofthesevariantsaswellascommonvariants,weconducted formed on DNA extracted from peripheral blood using thewholegenomesequencing(WGS)of133CM-SJS/TEN Agilent Sureselect QXT CREv2 kit, followed by sequen- with SOC patients and 418 healthy control. cing on Illumina NextSeq500.1374 Results:WGSidentifiedmorethan21millionvariants,of Results: A missense variant in Toll-Like receptor 1 which 2.3 million were SVs. Genome-wide association test (TLR1) rs5743618 was a cytokine QTL for IFN-gamma of these variants reproduced the associations of previously responsetotheTLR1/2stimulusPAM3CSK4atage11(p- reported common variants on HLA-A and chromosome value =1x10-4)andage16(p-value =3.42x10-9) FDRcorr FDRcorr 16q12.1 loci. In addition, the novel associations of micro- years. The same variant was a cytokine QTL for IL-13 satellite polymorphism near CDH12 gene and the aggre- response to PAM3CSK4 at age 11 (p-value =1x10-4) FDRcorr gationofrarecodingvariantsonTRPM8andPARD3genes andage16(p-value =3.53x10-3)andIL-2responseto FDRcorr were identified. in silico gene expression analysis revealed LPS at age 11 (p-value =0.031) and age 16 (p- FDRcorr that the disease susceptibility alleles of HLA-A and BRD7 value =3.34x10-2) years. FDRcorr affect gene expression levels at whole blood in GTEx Conclusions: The missense variant rs5743618 in TLR1 database. was identified as the main cytokine QTL for IFN-gamma Conclusion: Majority of variants with significant asso- and IL-13 to TLR1/2 ligand PAM3CSK4 as well as IL-2 ciation with CM-SJS/TEN with SOC were found among responsestoLPS.Thisvarianthasrecentlybeenassociated non-coding region illuminating the regulatory role of with asthma and allergic rhinitis inlarge-scale GWAS.The genetic variations on the development of CM-SJS/TEN mechanisms linking immune responses to allergic disease with SOC. needs to be established. Grants: This study was partially supported by grants in M. Tutino: None. L. Lin: None. J. Hankinson: None. aidfromtheMinistryofEducation,Culture,Sports,Science E. Bakhsoliani: None. J. Curtin: None. M. Edwards: and Technology of the Japanese government (BioBank None. A. Custovic: None. M. Rattray: None. S. John- Japan Project) and the Japan Agency for Medical Research ston: None. A. Simpson: None. and Development (J P17
km0405001). Y. Kawai: None. Y. Hitomi: None. M. Ueta: None. S.  P07
.32D Khor: None. K. Nakatani: None. C. Sotozono: None. S. Rare variants in antiviral response genes drive severe Kinoshita: None. M. Nagasaki: None. K. viral respiratory infections in children Tokunaga: None. D. Lawless1, S. Asgari2, L. Schlapbach3, J. Fellay1  P07
.31C Genetic predictors of immune response to bacterial and 1Global Health Institute, École Polytechnique Fédérale de viral stimuli in children Lausanne, Lausanne, Switzerland, 2Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United M. Tutino1, L. Lin1, J. Hankinson1, E. Bakhsoliani2, States, 3Mater Research Institute, University of J. Curtin1, M. Edwards2, A. Custovic2, M. Rattray1, Queensland, Brisbane, Australia S. Johnston2, A. Simpson1 A robust and self-limiting immune response is required for 1The University of Manchester, Manchester, United clearance of viral respiratory infections. In rare cases, life- Kingdom, 2Imperial College, London, United Kingdom threatening infections may occur in previously healthy children.Touncoverthissusceptibilitytoseverediseasewe Background: Little is known about variability of immune searched for rare genetic variants in 120 children requiring responses to microbial ligands between individuals, and intensivecaresupportuponinfectionbyarespiratoryvirus. over time. Within the setting of a population based birth We used exome sequencing followed by protein network cohort, we investigated genetic predictors of immune analysistocatalograrecoding variantsandcluster themby responses to bacterial and viral stimuli in children. known physical and functional associations. We identified Materials and Methods: We measured cytokine potentially causal variants in 14 genes involved in responses (n=27) to stimuli including live viruses and proinflammatory response and viral nucleic acid detection, bacteria (n=14) in peripheral blood mononuclear cell from including DDX58 and IFIH1, encoding RIG-I and MDA5, children at ages 11 (n=306) and 16 (n=335) years. We respectively. Both proteins share a common mechanism of sequenced exons, promoters and 3’- and 5’-UTRs of 364 RNA recognition and signal repression. In the absence of immune response genes. After QC, 1705 SNPs (LD R2 < viral infection, each is maintained in an autoinhibited state, 0.8 and MAF > 8%) and 328 differentially expressed where the CARD effector domain and the ATP-binding cytokine-stimulus pairs at age 11, and 364 cytokine- helicase domain are masked by the C-terminal repressor stimulus pairs at age 16 were available for cytokine domain(CTD).BindingofviraldsRNAattheCTDrelieves Quantitative Trait Loci (QTL) analysis using linear repression and results in a proinflammatory cascade. Three regression. loss-of-function variants inIFIH1werepreviouslyreportedAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1375 for this cohort. A further four patients had helicase / ATP- by site directed mutagenesis, and tested for its ability to binding domain variants in IFIH1 and one patient with a complement DNA repair defects of a FANCA-KO human rare CTD variant. Rare variants were found in DDX58 cell line generated by TALEN technologies. affecting the RNA binding motif; one patient harboured a Results:usingWESdata,weidentified93.3%ofmutated variant predicted to disrupt the ATP-binding helicase. In alleles including large deletions later confirmed by MLPA total, we identified 10 rare variants in 15 patients. We or SNPs arrays. We demonstrated pathogenicity of 3 present a primary immunodeficiency resulting in extreme FANCAmissensevariantsanddemonstratedthat2FANCA susceptibility to common respiratory RNA viruses, due to variants reported in mutations databases as “affecting geneticvariantsinacommonpathwaythatseverelyimpairs functions” are non pathogenic SNPs. Deep analysis of viral recognition. SNSF Grant P P00
P3157529  sequencing data revealed the actual mutations, highlighting D. Lawless: None. S. Asgari: None. L. Schlapbach: the importance of functional analysis. None. J. Fellay: None. Conclusion:WESandproperbioinformaticsanalysisare sufficient to effectively characterize FA patients regardless 
P07 .33A complementation group, type of mutations, mosaic condi- Whole exome sequencing and functional studies for tion, and DNA source. Fanconi anemia diagnostics M.Bogliolo:None.M.Aza-Carmona:None.N.Muñoz Subirana: None. R. Pujol: None. J. Casado: None. F. M. Bogliolo1, M. Aza-Carmona2, N. Muñoz Subirana1, Garcia: None. T. Paprotka: None. C. Bauser: None. J. R. Pujol1, J. Casado3, F. Garcia4, T. Paprotka5, Dopazo: None. J. Bueren: None. J. Surrallés: None. C. Bauser6, J. Dopazo7, J. Bueren3, J. Surrallés1 1Hospital de Sant Pau and UAB, Barcelona, Spain, 
P08  Intellectual disability 2Institute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz, IdiPAZ, Universidad 
P08 .01B Autónoma de Madrid, Spain; Skeletal Dysplasia CNOT2 as the critical gene for phenotypes of 12q15 Multidisciplinary Unit, Hospital Universitario La Paz, microdeletion syndrome Madrid, Spain., Madrid, Spain, 3Centro de Investigación Biomédica en Enfermedades Raras CIBERER U710: T. Uehara1, H. Suzuki1, M. Yamada1, T. Takenouchi1,2, Hematopoietic Innovative Therapies Division, (CIEMAT). K. Kosaki1 Advanced Therapies Mixed Unit. Instituto de Investigación Sanitaria-Fundación Jiménez Díaz (UAM, IIS-FJD). 1Center for Medical Genetics, Keio University Hospital, Madrid. Spain., Madrid, Spain, 4Centro de Investigación Tokyo, Japan, 2Department of Pediatrics, Keio University Biomédica en Enfermedades Raras (CIBERER) U715: School of Medicine, Tokyo, Japan Departamento de Genómica Computacional, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain, [Background]Chromosome 12q15 microdeletion is charac- Valencia, Spain, 5GATC Biotech AG, Jakob-Stadler-Platz terized by intellectual disability and dysmorphic facial 7,D-78467Konstanz,Germany,Kostanz,Germany,6GATC features. Recently, the smallest region of overlap (SRO) in Biotech AG, Jakob-Stadler-Platz 7,D-78467 Konstanz, 16 previously reported patients was used to define three Germany, Konstanz, Germany, 7Clinical Bioinformatics candidate genes for the 12q15 microdeletion syndrome: Area, Director Fundacion Progreso y Salud CDCA, CNOT2, KCNMB4, and PTPRB. The relative contributions Hospital Virgen del Rocío c/Manuel Siurot s/n, 41013, of these three genes have not yet been delineated. Herein, Sevilla, Spain, Sevilla, Spain we document a patient with a microdeletion of the chromosomal12q15regionandre-definetheSRO.[Clinical Introduction: Fanconi anemia (FA) patients exhibit Report]The patient was a 12-year-old female with intellec- chromosome fragility, bone marrow failure, malformations tual disability and multiple structural abnormalities includ- and cancer susceptibility. FA is caused by point mutations ing cleft lip and palate and 2-3 toe syndactyly. She and large deletions in 22 genes following 3 heritability exhibited dysmorphic facial features such as upslanting patterns, making it diagnostics challenging. andshortpalpebralfissures,micrognathia,low-setears,and Material and Methods: 68 FA patients with a positive hypoplastic antihelix. [Molecular Analysis] A microarray chromosome fragility test were analyzed by WES. Copy analysis showed a de novo 1.32-Mb deletion within 12q15 number variations were evaluated by sequencing data ana- that included CNOT2, a member of the CCR4-NOT lysis with Rstudio. To test FANCA missense variants, complex that regulates gene expression by regulating wtFANCAcDNAwasclonedandvariantswereintroduced transcription and mRNA degradation, and 14 other genes.1376 Results and Discussion: Remapping of the 12q15 dele- 11UMR-Inserm 1231 GAD Team, Génétique des Anomalies tion region in the 16 previously reported patients together du Développement, Université de Bourgogne Franche- with that in the newly identified patient indicated that Comté, Dijon, France, 12Department of Pediatric CNOT2 is the only gene that is commonly deleted. In Neurology and Developmental Medicine, University of conclusion,thesefindingssuggestthatCNOT2istheprime Basel Children's Hospital (UKBB), Basel, Switzerland, candidate for the neurological phenotypes of the 12q15 13CH Auray-Vannes, Hôpital Bretagne Atlantique, Service microdeletion syndrome.[Funding] This study was sup- de Pédiatrie, Vannes, France, 14Ecole Pratique des Hautes ported by Ministry of Health, Labour and Welfare (Grant Etudes, PSL Research University, Paris, France, Number: Research on Rare and Intractable Diseases) and 15PediatricNeurologyUnit,CliniquesUniversitairesSaint- Japan Agency for Medical Research and Development Luc, Université Catholique de Louvain, Brussels, Belgium, (Grant Number: J
P18 ek0109301). 16Center of Autism and Departmentof Genetics, University T.Uehara:None.H.Suzuki:None.M.Yamada:None. Hospital Liège, Liège, Belgium, 17GeneDx, Gaithersburg, T. Takenouchi: None. K. Kosaki: None. MD,UnitedStates,18CentredeGénétique,HôpitalCouple- Enfant, CHU de Grenoble-Alpes, La Tronche, France, 
P08 .02C 19Centre de génétique humaine, Université de Franche- Bi-allelic pathogenic variants in the lanosterol synthase Comté, Besançon, France, 20Integrative and Cognitive gene LSS involved in the cholesterol biosynthesis cause Neurosciences Research Unit EA481, University of alopecia with intellectual disability, a rare recessive Franche-Comté, Besançon, France, 21Department Medical neuroectodermal syndrome GeneticandPathology,UniversityHospitalofBasel(USB), Basel, Switzerland, 22Laboratory of Mass Spectrometry, T. Besnard1,2, N. Sloboda3, A. Goldenberg4, S. Küry1,2, INSERM ERL 1157, CNRS UMR 7203 LBM, Sorbonne B. Cogné1,2, F. Breheret1, E. Trochu1, S. Conrad1, Universités-UPMC, CHU Saint-Antoine, Paris, France M. Vincent1,2, W. Deb1,2, X. Balguerie5, S. Barbarot6, G. Baujat7, T. Ben-Omran8, A. Bursztejn9, Purpose: Lanosterol synthase (LSS) gene was initially V. Carmignac10,11, A. N. Datta12, A. Délignières13, described in families with extensive congenital cataracts. L. Faivre10,11, B. Gardie2,14, J. Guéant3, P. Kuentz10,11, Recently, a study has highlighted LSS associated to M. Lenglet2,14, M. Nassogne15, V. Ramaekers16, hypotrichosis simplex. We expanded the phenotypic R. E. Schnur17, Y. Si17, E. Torti17, J. Thevenon18, spectrum of LSS to a recessive neuroectodermal syndrome P. Vabres10,11, L. Maldergem19,20, D. Wand21, formerly named Alopecia with mental retardation (APMR) A. Wiedemann3, B. Cariou2, R. Redon2, A. Lamazière22, syndrome. It is a rare autosomal recessive condition S. Bézieau1,2, F. Feillet3, B. Isidor1,2 characterized by hypotrichosis and intellectual disability (ID) or developmental delay (DD), frequently associated 1CHU de Nantes, Service de Génétique Médicale, Nantes, withearlyonsetepilepsyandotherdermatologicalfeatures. France, 2L'institut du thorax, INSERM, CNRS, UNIV Methods: Through a multi-center international colla- Nantes, CHU de Nantes, Nantes, France, 3INSERM, UMR borative study, we identified LSS pathogenic variants in 1256 Nutrition-Genetics-Environmental Risk Exposure and APMR individuals either by exome sequencing or LSS Reference Centre of Inborn Metabolism Diseases, Sanger sequencing. Splicing defects were assessed by University of Lorraine and University Hospital Centre of transcripts analysis and minigenes assays. Nancy (CHRU Nancy), Nancy, France, 4Department of Results: We reported 10 APMR individuals from 6 Genetics,RouenUniversityHospital,NormandyCentrefor unrelated families with bi-allelic variants in LSS. We Genomic and Personalized Medicine, Rouen, France, additionally identified one affected individual with a single 5DepartmentofDermatology,UniversityHospitalCenterof rare variant in LSS and an allelic imbalance suggesting a Rouen, Rouen, France, 6CHU de Nantes, Department of second event. Among the identified variants, two were Dermatology, Nantes, France, 7Department of Medical truncating, seven were missense and two were splicing Genetics, INSERM UMR 1163, Paris Descartes-Sorbonne variants.Quantificationofcholesterolanditsprecursorsdid Paris Cité University, IMAGINE Institute, Necker Enfants not reveal noticeable imbalance. Malades Hospital, Paris, France, 8Section of Clinical and Conclusion: In the cholesterol biosynthesis pathway, the Metabolic Genetics, Department of Pediatrics, Hamad lanosterol synthase leads to the cyclization of (S)-2,3-oxi- Medical Corporation, Doha, Qatar, 9Dermatology dosqualeneintolanosterol.OurdatasuggestLSSasamajor department, hôpital Brabois, Vandœuvre-Lès-Nancy, gene causing a rare recessive neuroectodermal syndrome. France, 10Centre de Génétique et Centre de Référence T. Besnard: None. N. Sloboda: None. A. Goldenberg: Anomalies du Développement et Syndromes Malformatifs None. S. Küry: None. B. Cogné: None. F. Breheret: de l'Est, FHU-TRANSLAD, CHU Dijon, Dijon, France, None. E. Trochu: None. S. Conrad: None. M. Vincent:Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1377 None. W. Deb: None. X. Balguerie: None. S. Barbarot: hand,patientscarryingvariantsinSATB2,ASX
L3 ,SPTAN1 None. G. Baujat: None. T. Ben-Omran: None. A. and LA
S1 L genes present some but not all the consistent Bursztejn: None. V. Carmignac: None. A.N. Datta: features attributed to these genes. None. A. Délignières: None. L. Faivre: None. B. Gardie: Conclusion:MolecularheterogeneityinAS-likepatients, None. J. Guéant: None. P. Kuentz: None. M. Lenglet: together with the presence of distinctive clinical features in None. M. Nassogne: None. V. Ramaekers: None. R.E. someofthem,indicatesthatAS-likeismadeupbydifferent Schnur: A. Employment (full or part-time); Significant; clinical entities overlapping phenotypically with AS, mak- GeneDx. Y. Si: A. Employment (full or part-time); Sig- ing them difficult to distinguish. nificant; GeneDx. E. Torti: A. Employment (full or part- We thank ISCIII (PI16/01411), Asociación Síndrome time); Significant; GeneDx. J. Thevenon: None. P. Angelman and Fundació Parc Taulí-I3PT (CIR2016/025) Vabres:None.L.Maldergem:None.D.Wand:None.A. for their financial support. Wiedemann:None.B.Cariou:None.R.Redon:None.A. C.Aguilera:None.A.Ruiz:None.E.Gabau:None.N. Lamazière: None. S. Bézieau: None. F. Feillet: None. B. Baena: None. N. Spataro: None. L. Capel: None. N. Isidor: None. Capdevila: None. A. Ramírez: None. V. Delgadillo: None. S. Ourani: None. C. Brun: None. M. 
P08 .03D Guitart: None. Genotype-phenotype correlation in 11 Angelman-like syndrome patients with new molecular diagnosis 
P08 .04A When high incidence and high genetic heterogeneity C. Aguilera1, A. Ruiz1, E. Gabau2, N. Baena1, lead to different genetic aetiologies within one family: a N. Spataro1, L. Capel1, N. Capdevila2, A. Ramírez2, caseoftwo sibswithneurodevelopmentaldisordersand V. Delgadillo1, S. Ourani2, C. Brun2, M. Guitart1 de novo variants in one known and one candidate gene 1Genetics Laboratory, UDIAT-Centre Diagnòstic. Parc D. Prchalová1, M. Havlovicová1, M. Hančárová1, Š. Taulí Hospital Universitari. Institut d’Investigació i Bendová1, V. Stránecký2, Z. Sedláček1 Innovació Parc Taulí I3PT. Universitat Autònoma de Barcelona, Sabadell, Barcelona, Spain, 2Paediatric Unit. 1Department of Biology and Medical Genetics, Charles Parc Taulí Hospital Universitari. Institut d’Investigació i University2ndFacultyofMedicineandUniversityHospital Innovació Parc Taulí I3PT. Universitat Autònoma de Motol, Prague, Czech Republic, 2Department of Pediatrics Barcelona, Sabadell, Barcelona, Spain and Adolescent Medicine, Diagnostic and Research Unit for Rare Diseases, Charles University 1st Faculty of Introduction: Approximately 10% of patients with a Medicine and General University Hospital, Prague, Czech clinical diagnosis of Angelman syndrome (AS) remain Republic without a molecular diagnosis (AS-like). Whole-exome sequencing in a cohort of 17 AS-like patients led to the Wereportonafamilywithtwoaffectedpatients,a13-year- identification of 11 pathogenic/likely pathogenic de novo oldgirl(
P1 ) with severe intellectualdisability (ID), autism, variants in 10 genes involved in neurodevelopment agenesis of corpus callosum, abnormal EEG findings, disorders, not previously associated with AS. Clinical re- hearing loss, eye defect and short stature, and her brother evaluation was performed in order to establish the (
P2 ) with congenital chylothorax and hydrops who died genotype-phenotype correlation in the molecularly diag- 36 hours after birth. nosed patients. Exome sequencing identified in 
P2  a de novo PTPN11 Materials and Methods: The clinical characteristics of variant NM_002834.4:c.417G>C p.(
E139 D) listed as the 11 patients were reviewed for the presence of the con- pathogenic in ClinVar and causing Noonan syndrome, sistent and frequent AS clinical features. Additional dis- which was consistent with theclinical findings. There were tinctive clinical features were collected and compared with noclear-cutfindingsin
P1 ,withapossibleexceptionofade the clinical phenotypes reported in the literature in patients novo frameshift ARGLU1 variant NM_018011.4: carrying pathogenic variants in the identified genes. c.695delAAGAp.(K232Ffs*6).ARGLU1encodesarginine- Results: Clinical re-evaluation showed that the 11 and glutamate-rich protein 1 which may have a transcrip- patients meet the consistent and almost all of the frequent tional regulatory role. ARGLU1 has not been associated features of AS. The additional clinical findings in patients with ID yet but is among possible candidate genes. The carrying variants in SMARC
E1 , KIF1A, SYNGA
P1  and gene is intolerant to loss-of-function variation (3/20 SL
C6 A1 genes fit with the phenotypes reported in patients observed/expected variants in gnomAD). Several de novo with pathogenic variants in the same genes. On the other ARGLU1 variants (gene deletions and a frameshift) have1378 been identified in a large candidate gene screen, and the epilepticseizuresat5monthsanddiedat6months.Patient samevariantasthatof
P1 wasdenovoinonepatientofthe #2 had a similar disease course, except that he had no DDD cohort. The variant is located in the last exon but epilepsy. He died at 4 months of cardio-respiratory failure. truncates the glutamate-rich domain, which may alter pro- Both patients had null auditory evoked potentials. teinfunction.Phenotypeinformationonpreviouspatientsis Whole-exome sequencing (WES) in patient #2 revealed limited but suggests overlap with 
P1 . the previously reported c.1070_1071del p. Our study supports the notion that due to the high inci- (His357Argfs*15) ATAD1 homozygous variant. We rein- dence of neurodevelopmental disorders and their huge terpreted WES data obtained five years ago for patient #1, genetic heterogeneity affected siblings often have different previously interpreted as normal, which highlighted the genetic aetiologies. Additional patients and analyses are novel c.383G>T p.(Gly128Val) homozygous variant in needed to confirm or exclude ARGLU1 as a new ID gene. ATAD1. Supported by 17-29423A and 00064203. The phenotype of these two patients was close to that of D. Prchalová: None. M. Havlovicová: None. M. published patients, associating neonatal stiffness with Hančárová: None. Š. Bendová: None. V. Stránecký: immobility. We confirm the auditory involvement reported None. Z. Sedláček: None. once. The retrospective diagnosis of our patient #1 illus- trates that ATAD1 mutation is associated with a recogniz- 
P08 .05B able clinical presentation, which is critical for genetic Lethal neonatal stiffness and immobility caused by counseling and potential targeted therapy. biallelic variations in ATAD1 M.Villy:None.R.Bunod: None. S.Whalen: None.K. Maincent:None.D.Doummar:None.N.Dorison:None. M. Villy1, R. Bunod2, S. Whalen2, K. Maincent3, M. Mayer: None. A. Isapof: None. T. Billette: None. A. D. Doummar3, N. Dorison3, M. Mayer3, A. Isapof3, Afenjar: None. P. Léger: None. I. Martin: None. B. T. Billette3, A. Afenjar2, P. Léger4, I. Martin5, B. Keren6, Keren: None. D. Héron: None. C. Mignot: None. D. Héron1,2, C. Mignot1,2,6,7 
P08 .06C 1APHP, Département de génétique, Groupe Hospitalier New candidate genes in autism spectrum disorder PitiéSalpêtrière,Paris,France,2APHP,Unitédegénétique clinique, Hôpital Armand Trousseau, Paris, France, F. Mari1, C. Fallerini1, A. Curró1, D. Lopergolo1, 3APHP, Unité de neuropédiatrie et pathologie du E. Benetti2, A. Giliberti1, M. Cannone1, F. Valentino1, développement,Hôpital Armand Trousseau, Paris, France, F. Ariani1, A. Pinto3, S. Furini2, R. Canitano4, 4APHP, Réanimation néonatale et pédiatrique, Hôpital J. D. Buxbaum5, S. De Rubeis5, A. Renieri1 Armand Trousseau, Paris, France, 5APHP, Soins intensifs de néonatalogie, Hôpital Armand Trousseau, Paris, 1Medical Genetics, University of Siena, Siena, Italy, France, 6Centre deRéférence DéficiencesIntellectuellesde 2Department of Medical Biotechnologies, University of Causes Rares, Paris, France, 7INSERM, U 1127, CNRS Siena,Siena,Italy,3GeneticaMedica,AziendaOspedaliera UMR 7225, Sorbonne Université, UPMC Université Paris Universitaria Senese, Siena, Italy, 4Child Neuropsychiatry, 06 UMR S 1127, Institut du Cerveau et de la Moelle Azienda Ospedaliera Universitaria Senese, Siena, Italy, épinière, ICM, Paris, France 5Department of Psychiatry, Ichan School of Medicine, at Mount Sinai, New York, NY, United States ATAD1 encodes for thorase, a protein which regulates the surface-expressionofAMPAreceptors.Thus,thoraseplays Introduction: Autism spectrum disorder (ASD) is a well- an essential role in neurotransmission. Biallelic loss-of- known highly genetic heterogeneous entity. functionoractivatingATAD1mutationshavebeenrecently Materials and Methods: In the context of an Interna- describedinsixpatientsfromthreedifferentfamilies. They tional project aiming at identifying the genetic causes of presented with severe encephalopathy characterized by ASD (Autism Sequencing Consortium, Mount Sinai), we neonatal stiffness, limited or absent mobility, poor eye performed a whole exome sequencing (WES) analysis in a contact, feeding difficulties and respiratory distress. cohortof100ASDpatients,notharboringCNVs,attending Here,wereportontwonovelinfantswiththiscongenital the Medical Genetics Unit of Siena. immobility and hypertonia syndrome. Patient #1 needed Results: Mutations in already known ASD-related genes intensive cares from birth because of secondary neonatal were detected in 11% of cases, while either de novo or respiratory distress. He had extreme stiffness of limbs and inheritedmutationsinnovelgeneswereidentifiedin21%of axialhypotonia,immobility,absenceofeyecontact,limited cases. The novel identified genes can be pooled in three responsiveness to stimuli and weak sucking. He had categories: i-genes for which causative mutations have notAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1379 beenpreviouslyreported(eightgenes),ii-genesforwhicha Center, Durham, NC, United States, 14Division of likelyassociationwithASDhasbeenpreviouslyreportedin BiochemicalDiseases,DepartmentofPediatrics,University a single case (eg DR
P2  etc) and iii-genes whose mutations of British Columbia, BC Children's Hospital, Vancouver, have been previously associated with intellectual disability BC, Canada, 15Department of Pediatrics, Duke University (ID) in only one (eg BCOR
L1  etc) or a few families (eg Medical Center, Durham, NC, United States, 16Center for BRD4 recently associated with a Cornelia De Lange-like Integrative Brain Research, Seattle Children’s Research phenotype etc). Institute, Seattle, WA, United States, 17Department of Conclusions: Overall, our extensive approach goes Pediatrics, University of Washington, Seattle, WA, United beyond safely confirming the pathogenic role of ASD/ID States candidate-genes and allows establishing the novel role of ID-related genes in ASD. It delineates the impact of new The evolutionarily conserved Notch signaling pathway genes across neurodevelopmental dimensions, providing operates in many different developmental, homeostatic and importantnewinsightsintofunctionalpathwaysinvolvedin disease processes. In vivo and in vitro studies have shown heterogeneous ASD phenotypes. an important role of the Notch ligand DL
L1  in the F.Mari: None.C.Fallerini: None.A.Curró:None.D. development of the nervous system and somites, among Lopergolo: None. E. Benetti: None. A. Giliberti: None. others. M.Cannone:None.F.Valentino:None.F.Ariani:None. We identified 14 individuals from ten unrelated families A.Pinto:None.S.Furini:None.R.Canitano:None.J.D. with heterozygous DL
L1  variants by exome sequencing. Buxbaum: None. S. De Rubeis: None. A. Renieri: None. The most common features in our cohort were intellectual disability, autism spectrum disorder, seizures and variable 
P08 .07D brain malformations. Four patients had scoliosis including Mutations in DL
L1  cause variable neurodevelopmental one with a vertebral segmentation defect. We identified six disorders nonsense variants, two splice site variants, one missense variant affecting a highly conserved cysteine in the DSL B. Fischer-Zirnsak1, L. Segebrecht1,2, P. Charles3, domain, and one 122 kb deletion containing DL
L1 . Ana- C. F. Boerkoel4, K. Brown5, T. Cartwright6, Y. Chen7, lysis of the splice site variant NM_005618.4:c.54+1G>A C. Costin8, S. Fehr9, K. Foss10, T. Ha11, G. Hildebrand1, showed an in-frame insertion of 12 bp near the sequence D. Horn1, S. Liu7, E. J. Marco12, M. McDonald13, coding for the signal peptide, possibly affecting proper K. McWalter7, S. Race14, M. Schubach1,2, Y. C. Si7, localizationofthemutantDL
L1 protein.Thefeaturesinour A. Slavotinek11, S. Stockler14, A. Telegrafi7, E. Torti7, cohortresemblethoseofpatientswithoverlappingterminal A.C.Tsai5,X.Wang7,M.Zafar15,B.Keren3,U.Kornak1, deletions of 6q27 encompassing DL
L1 , supporting the G. Mirzaa16,17, N. Ehmke1 previous hypothesis that haploinsufficiency of DL
L1  is causative of the phenotype in this deletion. 1Charité - Universitätsmedizin Berlin, Berlin, Germany, In conclusion, we identified heterozygous mutations in 2Berlin Institute of Health (BIH), Berlin, Germany, DL
L1  in a cohort with a variable neurodevelopmental 3Department of Genetics, Assistance Publique - Hôpitaux phenotypeandothermulti-systemfeatures.Ourclinicaland de Paris, Hôpital Pitié-Salpêtrière, Paris, France, molecular data support haploinsufficiency as a mechanism 4Department of Medical Genetics, University of British forthepathogenesisofDL
L1 -relateddisordersandillustrate Columbia, Vancouver, BC, Canada, 5Department of the importance of DL
L1  in human brain development. Pediatrics,TheChildren'sHospital,UniversityofColorado Grants: National Institute of Neurological Disorders and School of Medicine, Aurora, CO, United States, Stroke (NINDS), award number K08N
S092898 ; Jordan’s 6Neuroscape Center, Departments of Neurology, Guardian Angels. Pediatrics, Physiology, Radiology, and Psychiatry, B. Fischer-Zirnsak: None. L. Segebrecht: None. P. UniversityofCalifornia,SanFrancisco,CA,UnitedStates, Charles:None.C.F.Boerkoel:None.K.Brown:None.T. 7GeneDx, Gaithersburg, MD, United States, 8Akron Cartwright:None.Y.Chen:A.Employment(fullorpart- Children’s Hospital, Akron, OH, United States, 9Praxis für time); Significant; GeneDx. C. Costin: None. S. Fehr: HumangenetikTübingen,Tübingen,Germany,10Divisionof None.K.Foss:None.T.Ha:None.G.Hildebrand:None. GeneticMedicine, Seattle Children's Hospital,Seattle, WA, D.Horn:None.S.Liu:A.Employment(fullorpart-time); United States, 11Division of Genetics, Dept. Pediatrics, Significant; GeneDx. E.J. Marco: None. M. McDonald: UniversityofCalifornia,SanFrancisco,CA,UnitedStates, None. K. McWalter: A. Employment (full or part-time); 12DepartmentofChildNeurology,CorticaHealthcare,San Significant;GeneDx.S.Race:None.M.Schubach:None. Rafael, CA, United States, 13Department of Pediatrics, Y.C. Si: A. Employment (full or part-time); Significant; Division of Medical Genetics, Duke University Medical GeneDx. A. Slavotinek: None. S. Stockler: None. A.1380 Telegrafi: A. Employment (full or part-time); Significant; like phenotype and propose a loss-of-function effect of GeneDx. E. Torti: A. Employment (full or part-time); BRD4 mutations. The variability of the phenotype might in Significant; GeneDx. A.C. Tsai: None. X. Wang: A. part be explained be different effects on target Employment (full or part-time); Significant; GeneDx. M. effector genes. Zafar: None. B. Keren: None. U. Kornak: None. G. N.N. Hauer: None. C. Vogl: None. B. Popp: None. C. Mirzaa: None. N. Ehmke: None. Büttner: None. S. Uebe: None. H. Sticht: None. A.B. Ekici: None. P. Klinger: None. C. Kraus: None. M. 
P08 .08A Krumbiegel: None. A. Wiesener: None. H. Dörr: None. Exploring the phenotypical spectrum of BRD4 defects A. Reis: None. C.T. Thiel: None. N. N. Hauer1, C. Vogl1, B. Popp1, C. Büttner1, S. Uebe1, 
P08 .09B H. Sticht2, A. B. Ekici1, P. Klinger3, C. Kraus1, Truncating CHD8 variants cause a Sotos-like syndrome M. Krumbiegel1, A. Wiesener1, H. Dörr4, A. Reis1, with autism C. T. Thiel1 S. Douzgou1, H. Liang2, K. Metcalfe1, S. Somarathi1, 1Institute of Human Genetics, Friedrich-Alexander- M. Tischkowitz3, W. Mohamed4, U. Kini4, S. McKee5, Universität Erlangen-Nürnberg FAU, Erlangen, Germany, L. Yates6,7, M. Bertoli6, S. Lynch8, S. Holder9, -. the 2Institute of Biochemistry, Friedrich-Alexander-Universität Deciphering Developmental Disorders study10, S. Banka1 Erlangen-Nürnberg FAU, Erlangen, Germany, 3Department of Orthopaedic Rheumatology, Friedrich- 1Manchester Centre for Genomic Medicine, St Mary’s Alexander-Universität Erlangen-Nürnberg FAU, Erlangen, Hospital, Manchester University Hospitals NHS Germany, 4Department of Pediatrics and Adolescent Foundation Trust, Manchester Academic Health Sciences Medicine, Friedrich-Alexander-Universität Erlangen- Centre, Manchester, United Kingdom, 2Division of Nürnberg FAU, Erlangen, Germany Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, United Bromodomain Protein 4 (BRD4) is a member of the Kingdom, 3Academic Department of Medical Genetics, bromodomain protein family involved in binding to University of Cambridge, Cambridge University Hospitals hyperacetylated genomic regions of promotors and enhan- NHS foundation Trust, Cambridge Biomedical Campus, cers. BRD4 mediates CDK9 activity to influence transcrip- Cambridge, United Kingdom, 4Oxford Centre for Genomic tion elongation by RNA polymerase II and thus regulates Medicine, Oxford University Hospitals NHS Foundation gene expression, cell differentiation and cell cycle. Trust, Oxford, United Kingdom, 55Northern Ireland Recently, frameshift and missense variants were reported Regional Genetics Centre, Belfast Health and Social Care with a Cornelia de Lange-like phenotype. In three Trust, Belfast City Hospital, Belfast, United Kingdom, independent families we identified 2 missense and 1 6West of Scotland Regional Genetics Service, NHS Greater frameshift heterozygous de novo variants in BRD4 Glasgow and Clyde, Institute of Medical Genetics, Yorkhill (c.1856G>T; c.2513A>T; c.2728delC). The individuals Hospital, Glasgow, United Kingdom, 7KwaZulu-Natal with the c.1856G>T and the c.2728delC variants presented Research and Innovation Sequencing Platform (KRISP), withintellectualdisabilityandCorneliadeLange-likefacial University of KwaZulu-Natal, Durban, South Africa, gestalt. Short stature was present in all but the individual 8TempleStreetChildren’sHospital,Dublin,Ireland,9North with the frameshift variant. Protein structure modelling West Thames Regional Genetics Service, Harrow, London, indicates that variant c.1856G>T (p.Ser619Iso) likely United Kingdom, 10Department of Medical Genetics, affects binding of BRD4 to its ligands. Expression analysis Cambridge University Hospitals Foundation Trust, showed that both missense variants, but not the frameshift Cambridge, United Kingdom variant, lead to a reduced expression indicating a loss-of- function effect of all three identified variants. Immuno- Variants in the chromodomain helicase DNA-binding fluorescence analysis from cells with the missense variants protein 8 (CHD8) have been associated with intellectual confirmed a reduced cellular growth and smaller cell size disability (ID), autism spectrum disorders (ASD) and comparedtocontrols.Transcriptionalprofilingtoassessthe overgrowth and CHD8 is one of the causative genes for effect of BRD4 on known effector proteins highlighted a OGID (overgrowth and ID). However, the phenotypic complex dysregulation in patient and CRISPR/Cas9 spectrum of individuals heterozygous for CHD8 truncating meditated BRD4 defect cell lines. We expand the clinical variants has not been clearly defined. We investigated 26 spectrum of mutations in BRD4 from idiopathic short individuals with CHD8 protein truncating variants (PTVs), staturewithoutdistinctfacialgestalttoaCorneliadeLange- including 10 previously unreported patients, and found aAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1381 pattern of common features: macrocephaly (76%), tall University of Arizona, Phoenix, AZ, United States, stature (65%), developmental delay and/or intellectual 13Murdoch Children's Research Institute, Royal Children's disability (DD/ID, 81%), autism spectrum disorders (ASD, Hospital & The University of Melbourne, Parkville, 81%), sleep difficulties (48%), gastrointestinal problems Australia, 14Department of Clinical Genetics, Leiden (42%),anddistinctfacialfeatures.Thegestaltisreminiscent University Medical Center, Leiden, Netherlands, ofSotosandWeaversyndromes.Mostoftheindividualsin 15DepartmentofClinicalGenetics,ErasmusMC,University our cohort had moderate-to-severe intellectual disability, Medical Center, Rotterdam, Netherlands and some had regression of speech (37%), seizures (27%) and hypotonia (27%), and two individuals were also non- Introduction: Pathogenic variants in the CLTC gene have ambulant. Most individuals had ASD (81%), similarly to beenreported in14patientswithintellectualdisability(ID) previous studies, but we found a higher incidence of with or without epilepsy. comorbidneurodevelopmentaldelay/impairment.Ourstudy Methods: We describe 13 novel patients with a likely showsthathaploinsufficiencyofCHD8isassociatedwitha pathogenic de novo CLTC variant, identified by using Sotos-like syndrome with pronounced autistic traits. diagnostic exome sequencing or an ID gene panel. S.Douzgou:None.H.Liang:None.K.Metcalfe:None. Results: All individuals presented with intellectual dis- S. Somarathi: None. M. Tischkowitz: None. W. ability (ID), ranging from mild to moderate/severe, with or Mohamed: None. U. Kini: None. S. McKee: None. L. without additional neurologic, behavioral, craniofacial, Yates: None. M. Bertoli: None. S. Lynch: None. S. ophthalmologic and gastrointestinal features. The severe Holder: None. -. the Deciphering Developmental Dis- end of the clinical spectrum, including severe ID, epilepsy, orders study: None. S. Banka: None. microcephaly and hypoplasia of corpus callosum was more frequently observed in the group of individuals with mis- 
P08 .10C senseandin-framevariantsthaninthosewithnonsenseand Delineation of the clinical phenotype caused by de novo frameshift variants, although this difference was not sig- CLTC variants nificant(Fisher’sExactTest;p-value>0.0125).A3Dmodel of the CH
C1  protein showed that the de novo missense M.J.NabaisSá1,H.Venselaar2,L.Wiel3,A.Trimouille4, CLTC variants do not cluster in 3D dimensionalproximity. E. Lasseaux4, S. Naudion4, D. Lacombe4, A. Piton5, However, these variants may affect the interaction with C.Vincent-Delorme6,C.Zweier7,A.Reis7,R.Trollmann8, otherclathrinheavyandlightchainsasCH
C1 interactswith A. Ruiz9, E. Gabau10, A. Vetro11, R. Guerrini11, three light chains to form clathrin. The nonsense and fra- S. Bakhtiari12, M. Kruer12, K. Crompton12, D. J. Amor13, meshift variants are all predicted to result in nonsense- E. K. Bijlsma14, T. S. Barakat15, M. F. van Dooren15, mediated mRNA decay. R. Pfundt1, C. Gilissen1, B. B. de Vries1, A. P. de Conclusion: Taken together, these results suggest that Brouwer1, D. A. Koolen1 missense and in frame variants exert a dominant negative effect (antimorph), whereas the nonsense and frameshift 1Radboudumc/Donders Institute for Brain, Cognition and variants would result in haploinsufficiency (hypomorph). Behaviour, Nijmegen, Netherlands, 2Center for Molecular Consequently, the wide phenotypic variability observed in and Biomolecular Informatics, RIMLS, Radboudumc, CLTC-related ID seems to be associated with allelic Nijmegen, Netherlands, 3Department of Human Genetics, heterogeneity. RILMS, Nijmegen, Netherlands, 4Hôpital Pellegrin, CHU M.J. Nabais Sá: None. H. Venselaar: None. L. Wiel: Bordeaux, Bordeaux, France, 5Institut de Genetique et de None. A. Trimouille: None. E. Lasseaux: None. S. Nau- BiologieMoleculaireetCellulaire,INSERMU964&CNRS dion: None. D. Lacombe: None. A. Piton: None. C. UMR 7104, Illkirch-Graffenstaden, France, 6Hôpital Vincent-Delorme:None.C.Zweier:None.A.Reis:None. Jeanne de Flandre, Lille, France, 7Institute of Human R.Trollmann:None.A.Ruiz:None.E.Gabau:None.A. Genetics, Friedrich-Alexander-Universität Erlangen- Vetro: None. R. Guerrini: None. S. Bakhtiari: None. M. Nürnberg, Erlangen, Germany, 8Department of Pediatrics, Kruer: None. K. Crompton: None. D.J. Amor: None. E. Division of Neuropediatrics, Friedrich-Alexander K.Bijlsma:None.T.S.Barakat:None.M.F.vanDooren: UniversityErlangen-Nürnberg(FAU),Erlangen,Germany, None.R.Pfundt:None.C.Gilissen:None.B.B.deVries: 9Laboratori de Genètica, UDIAT-Centre Diagnòstic, None. A.P. de Brouwer: None. D.A. Koolen: None. CorporacióSanitàriaParcTaulí,InstitutUniversitariParc Tauli-UAB, Sabadell, Spain, 10Corporació Sanitària Parc 
P08 .11D Taulí, Institut Universitari Parc Tauli-UAB, Sabadell, Four further patients with bi-allelic CNTNA
P2  Spain, 11A. Meyer Children's Hospital, University of aberrations Florence, Florence, Italy, 12Phoenix Children's Hospital/1382 M. Rio1, C. Gitiaux2, M. Hully2, A. Munnich1, 2q14.3deletioninvolvingmultipleexonsofCNTNA
P5 ina N. Boddaert3, K. Poirier4, C. Besmond4, G. Barcia1 child with developmental delay and microcephaly. Materials and Methods: A 9-year-old girl with an 1Department of genetics, Necker Hospital, paris, France, intellectual disability and microcephaly (OFC < 0.4th per- 2Department of neuropediatrics, Necker Hospital, paris, centile) was seen in the genetics clinic. The girl had parti- France, 3Department of radiology, Necker Hospital, paris, cular difficulties with visual-spatial tasks and she had very France, 4Imagine Institut, paris, France low working memory and processing speed. An 850 kb SNP array (Illumina Human CytoSNP-12 Beadchip) was Biallelic defects in CNTNA
P2  gene were previously done which identified the deletion. No other copy number described in an autosomal recessive disorder with severe variations were identified and detailed investigations for an intellectual disability (ID), epilepsy and cortical dysplasia. alternative cause were all normal. Parents were of normal Todate,25affectedindividualshavebeenreported.Mostof intelligence. patients have severe ID with absent or limited expressive Results: An 838kb de novo 2q14.3 deletion was identi- speech and limited verbal comprehension. Only two fied (chr2: 125,204,264-126,042,867; hg19). There are few patients with moderate ID and able to use sentences were reports of deletions involving CNTNA
P5  but all have reported. We described four children from three families involvedmultipleothergenesorcopynumbervariants.This with novel homozygous or compound heterozygous is the first reported case of a de novo deletion disrupting deleteriousCNVsandmutationsinCNTNA
P2 gene.Motor CNTNA
P5  in an individual with intellectual disability and milestones were mildly delayed in all patients, with a microcephalyandnootherCNVsidentified.CNTNA
P5 isa walking age between 22 and 30 months. All patients had member of the neurexin family of multidomain transmem- ID. Two patients had severe ID with complete lack of brane proteins involved in cell adhesion and intercellular speech. Two unrelated patients had mild ID with preserved communication,leadingtoourhypothesisthatmutationsin speech and good verbal comprehension. One of them was CNTNA
P5  result in abnormalities of neurodevelopment. able to write and read, while his brother had severe Conclusion: We hypothesise that CNTNA
P5  is an intellectual disability with no language. Epilepsy occurred important gene in neurodevelopment and disruption of in all patients, with an age at onset between 3 and CNTNA
P5  causes neurodevelopmental disability. 2q14.3 24 months. One patient was seizure free for 4 years. All deletions involving CNTNA
P5  may constitute a new dele- patients, except one, had cortical dysplasia. No specific tion syndrome. facial dysmorphism was noted. Birth parameters and post- E.G. Ludington: None. H. Bae: None. S. Yu: None. C. natal growth were in the normal range. In conclusion, we P. Barnett: None. reported four individuals from three families with biallelic aberrationsinCNTNA
P2 causingIDandadditionalfeatures 
P08 .13B such as epilepsy and cortical dysplasia. In contrast to Linked homozygous CRADD and US
P44  variants in previous reports, we observed moderate ID with preserved intellectual disability speech and verbal comprehension in two children suggest- ing clinical variability even in a same family. M. Koprulu1, G. Nalbant1, Q. Zaman2, R. Muhamamad M. Rio: None. C. Gitiaux: None. M. Hully: None. A. Kamran Shabbir2, S. Malik2, A. Tolun1 Munnich:None.N.Boddaert:None.K.Poirier:None.C. Besmond: None. G. Barcia: None. 1Bogazici University, Istanbul, Turkey, 2Quaid-i-Azam University, Islamabad, Pakistan 
P08 .12A Noveldenovo2q14.3deletiondisruptingCNTNA
P5 ina Background: The global prevalence of intellectual dis- girl with intellectual impairment and microcephaly ability is estimated to be around 1%; however, the molecular basis remains unknown in most cases. We E. G. Ludington1, H. Bae1, S. Yu2, C. P. Barnett1 studied a consanguineous Pakistani kinship with severe intellectualdisability,mildlissencephaly,brainatrophyand 1Women's and Children's Hospital, North Adelaide, progressivedeclineincognitiveskillstoidentifythegenetic Australia, 2SA Pathology at Women's and Children's basis of the disease. Hospital, North Adelaide, Australia Materials and Methods: Homozygosity mapping was performed and exome sequence file of one affected indivi- Introduction: Reports of small 2q14.3 deletions including dual was investigated for candidate variants. CNTNA
P5  are rare and the clinical effect is currently Results: In a 3.9-Mb region of shared homozygosity,we unknown. Here we present a case of an 838kb de novo detected CRADD c.2T>G variant and novel US
P44 Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1383 c.873_884del and c.886delA variants. CRADD variant Manchester, United Kingdom, 6Division of Evolution & alters the initiation codon (AUG◊AGG; p.(M1?) or p. Genomic Sciences, School of Biological Sciences, Faculty (M1A)), anditisextremelyrare(highestMAF=3.28E-05). ofBiology,MedicineandHealth,UniversityofManchester, CRADD variant leads to premature translational Manchester, United Kingdom, 7Department of Pediatrics, termination. Klinikum Nuremberg, Nuremberg, Germany, 8Department Discussion:BiallelicdamagingvariantsinCRADDcause of Neuropediatrics, Klinikum Weiden, Kliniken recessive mental retardation 34 (MRT34) with mild to Nordoberpfalz AG, Weiden, Germany, 9Le Bonheur moderate intellectual disability (ID) and in some cases Children’s Hospital, Memphis, TN, United States, additional lissencephaly and megalencephaly. Only one ID 10Division of Medical Genetics, Department of Pediatrics, familyhasbeenreportedwithanUS
P44 variant,whichisa University of Tennessee Health Science Center, Memphis, deletion similar to ours. Phenotype of our patients, severe TN, United States, 11Department of Neuropediatrics, Lyon intellectual disability and mild lissencephaly but no sei- University Hospital, Lyon, France, 12University of zures,isdifferentfromphenotypesofpatientswithCRADD Oklahoma Health Sciences Center, Oklahoma City, OK, orUS
P44 mutationsaloneandisnotassevereaswouldbe United States, 13HudsonAlpha Institute for Biotechnology, expected of an additive effect. Huntsville, AL, United States, 14Northern Genetics Service, Conclusion: Familial linked homozygous variants are Newcastle upon Tyne Hospitals NHS Foundation Trust, very rare, and we found such variants in CRADD and Newcastle upon Tyne, United Kingdom, 15Institute of US
P44 intwocousinswithsevereintellectualdisabilityand Human Genetics, Friedrich-Alexander-Universität mild lissencephaly. This study also highlights that whole Erlangen-Nürnberg (FAU), Erlangen, Germany, exome sequencingratherthancandidategeneapproachcan 16Department of Medical Genetics, Lyon University uncover a novel molecular basis for a disorder. Hospital, Lyon, France, 17CNRS UMR 5292, INSERM M. Koprulu: None. G. Nalbant: None. Q. Zaman: U1028, Claude Bernard Lyon 1 University, Lyon, France, None. R. Muhamamad Kamran Shabbir: None. S. 18Institute of Human Genetics, Klinikum rechts der Isar, Malik: None. A. Tolun: None. Technical University of Munich, Munich, Germany, 19Children’s National Health System, Washington, DC, 
P08 .14C United States, 20Department of Clinical Genetics, Institute Spatially clustering de novo variants in CYFI
P2 , of Clinical Medicine, University of Tartu, Tartu, Estonia, encoding the cytoplasmic FMRP interacting protein 2, 21Department of Clinical Genetics, United Laboratories, cause intellectual disability and seizures Tartu University Hospital, Tartu, Estonia, 22Division of General Pediatrics, Department of Pediatrics and M. Zweier1, A. Begemann1,2, K. McWalter3, M. T. Cho3, Adolescent Medicine, Medical University Graz, Graz, L. Abela4,2, S. Banka5,6, B. Behring7, A. Berger8, Austria, 23Ambry Genetics, Aliso Viejo, CA, United States, C. W. Brown9,10, M. Carneiro11, J. Chen12, 24Department of Biomedicine, Institute of Biomedicine and G. M. Cooper13, Deciphering Developmental Disorders TranslationalMedicine,UniversityofTartu,Tartu,Estonia, (DDD) Study, C. R. Finnila13, M. J. Guillen Sacoto3, 25Department of Nephrology, Klinikum rechts der Isar, A. Henderson14, U. Hüffmeier15, P. Joset1, B. Kerr5,6, Technical University of Munich, Munich, Germany, G. Lesca16,17, G. S. Leszinski18, J. H. McDermott5, 26Department of Pediatrics, Neurology and M. R. Meltzer19, K. G. Monaghan3, R. Mostafavi9, Neurotherapeutics, University of Texas Southwestern K. Õunap20,21, B. Plecko4,2,22, Z. Powis23, G. Purcarin12, MedicalCenter,Dallas,TX,UnitedStates,27Departmentof T. Reimand20,21,24, K. M. Riedhammer18,25, Clinical Genomics, Mayo Clinic Florida, Jacksonville, FL, J. M. Schreiber19, D. Sirsi26, K. J. Wierenga12,27, United States, 28Broad Institute of MIT and Harvard, M. H. Wojcik28, S. M. Papuc1,29, K. Steindl1, H. Sticht30, Cambridge, MA, United States, 29Victor Babes National A. Rauch1,2 Institute of Pathology, Bucharest, Romania, 30Institute of Biochemistry, Emil-Fischer Center, Friedrich-Alexander- 1InstituteofMedicalGenetics,UniversityofZurich,Zurich- UniversitätErlangen-Nürnberg(FAU),Erlangen,Germany Schlieren, Switzerland, 2Radiz–Rare Disease Initiative Zurich, Clinical Research Priority Program for Rare CYFI
P2 , encoding the evolutionary highly conserved Diseases, University of Zurich, Zurich, Switzerland, cytoplasmic FMRP interacting protein 2, has previously 3GeneDx, Gaithersburg, MD, United States, 4Division of beenproposedasacandidategeneforintellectualdisability Child Neurology, University Children’s Hospital Zurich, and autism because of its important role linking FMRP- Zurich, Switzerland, 5Manchester Centre for Genomic dependenttranscriptionregulationandactinpolymerization Medicine, St Mary’s Hospital, Manchester University NHS via the WAVE regulatory complex (WRC). Recently, de Foundation Trust, Health Innovation Manchester, novo variants affecting the amino acid p.Arg87 of CYFI
P21384  were reported in four individuals with epileptic encephalo- A. Rieß1, K. Schäferhoff1, S. Spranger7, M. Sturm1, pathy. We here report 12 independent patients harboring a A. Weichselbaum2, O. Rieß1, T. B. Haack1 variety of de novo variants in CYFI
P2  broadening the molecular and clinical spectrum of a novel CYFI
P2 -related 1Institute of Medical Genetics and Applied Genomics, neurodevelopmental disorder. Using trio whole-exome or University Tübingen, Tübingen, Germany, 2Department of -genome sequencing, we identified 12 independent patients Neuropediatrics and Neurometabolic Laboratory, carryingatotalofeightdistinctdenovovariantsinCYFI
P2  Children's Hospital of the University of Tübingen, with a shared phenotype of intellectual disability, seizures, Tübingen, Germany, 3Institute of Human Genetics, and muscular hypotonia. We detected seven different University of Duisburg-Essen, Essen, Germany, 4Dept. of missense variants, of which two occurred recurrently (p. Biotechnology and Genetic Engineering, Philadelphia (Arg87Cys) and p.(Ile664Met)), and a splice donor variant University, Amman, Jordan, 5Institute of Human Genetics, inthelastintronforwhichweshowedexonskippinginthe Heidelberg University, Heidelberg, Germany, transcript. The latter is expected to escape nonsense- 6Gemeinschaftspraxis für Humangenetik Homburg/Saar, mediated mRNA decay resulting in a truncated protein. Homburg, Germany, 7Praxis für Humangenetik, Bremen, Despite the large spacing in the primary structure, the Germany variants spatially cluster in the tertiary structure and are all predicted to weaken the interaction with WAV
E1  or WeperformeddiagnosticWholeExomeSequencing(WES) NCKA
P1  of the actin polymerization regulating WRC- in1037caseswithintellectualdisability(ID)andfilteredfor complex.Preliminarygenotype–phenotypecorrelationindi- pathogenic variants as well as pathogenic CNVs in genes cates a profound phenotype in p.Arg87 substitutions and a previouslyreportedinID.In234casesweranTrioanalysis; more variable phenotype in other alterations. This study in another 79 cases we sequenced more than one affected evidenced a variety of de novo variants in CYFI
P2  as a individualperfamily.Withthisapproachwecouldidentify novel cause of mostly severe intellectual disability with pathogenic variants or CNVs in 31% of the cases and seizures and muscular hypotonia. prioritize candidate variants of unclear significance in M. Zweier: None. A. Begemann: None. K. McWalter: another 17.6% of the cases. A. Employment (full or part-time); Significant; GeneDx, About 66% of the pathogenic variants occurred de novo Inc. M.T. Cho: A. Employment (full or part-time); Sig- or were transmitted in an autosomal dominant manner, nificant; GeneDx, Inc.. L. Abela: None. S. Banka: None. while21%ofthevariantswereautosomalrecessive.Onlya B.Behring:None.A.Berger: None.C.W.Brown:None. minority of 11% was X-chromosomal and less than 1% M.Carneiro:None.J.Chen:None.G.M.Cooper:None. occurred in mitochondrial DNA. C.R.Finnila:None.M.J.GuillenSacoto:A.Employment Among these we identified severalcases with pathogenic (full or part-time); Significant; GeneDx, Inc.. A. Hender- variants in HNRNPH2, NBEA, PU
S3 , RHOBTB2, TBCK son:None.U.Hüffmeier:None.P.Joset:None.B.Kerr: and TB
C1 D23, genes that have been associated with ID None. G. Lesca: None. G.S. Leszinski: None. J.H. very recently. Besides identifying pathogenic variants in McDermott: None. M.R. Meltzer: None. K.G. Mon- genes previously associated with ID, we were also able to aghan: A. Employment (full or part-time); Significant; identify22newcandidategenessuchasBC
L11 B,FBXO11 GeneDx, Inc.. R. Mostafavi: None. K. Õunap: None. B. and KMT2E. Plecko: None. Z. Powis: None. G. Purcarin: None. T. Taken these results together we could reveal causative Reimand: None. K.M. Riedhammer: None. J.M. variants in about 31% of cases and identify potentially Schreiber: None. D. Sirsi: None. K.J. Wierenga: None. causative variants in another 17% of cases in a study M.H. Wojcik: None. S.M. Papuc: None. K. Steindl: comprising more than 1000 individuals with intellectual None. H. Sticht: None. A. Rauch: None. disability. R. Buchert: None. M. Grimmel: None. S. Beck-Wödl: 
P08 .15D None. A. Bevot: None. A. Dufke: None. M. Elgizouli: Diagnostic whole exome sequencing identifies new None. T. Froukh: None. D. Gauck: None. U. Grasshoff: causative variants in 1000 cases with intellectual None. N. Kaiser: None. M. Kehrer: None. I. Krägeloh- disability Mann: None. H. Küpper: None. A. Kuechler: None. L. Laugwitz: None. J. Magg: None. U. Moog: None. A. R. Buchert1, M. Grimmel1, S. Beck-Wödl1, A. Bevot2, Müller: None. B. Oehl-Jaschkowitz: None. A. Rieß: A. Dufke1, M. Elgizouli3, T. Froukh4, D. Gauck1, None. K. Schäferhoff: None. S. Spranger: None. M. U. Grasshoff1, N. Kaiser2, M. Kehrer1, I. Krägeloh- Sturm:None.A.Weichselbaum:None.O.Rieß:None.T. Mann2, H. Küpper2, A. Kuechler3, L. Laugwitz1,2, B. Haack: None. J. Magg2, U. Moog5, A. Müller1, B. Oehl-Jaschkowitz6,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1385 
P08 .16A A.A.Qaisar12,E.Falconnet2,V.Zoete8,13,E.Ranza2,14,15, Language impairment with a partial duplication of P. Makrythanasis2,16, F. A. Santoni2,17, J. Ahmed4, DOCK8 N. Katsanis1, C. Walsh6, S. E. Antonarakis2,14,18 A.Benítez-Burraco1,M.Fernández-Urquiza2,S.Jiménez- 1CenterforHumanDiseaseModeling,Durham,NC,United Romero3 States,2DepartmentofGeneticMedicineandDevelopment, University of Geneva, Geneva, Switzerland, 3Human 1Faculty of Philology, Seville, Spain, 2Faculty of Molecular Genetics Laboratory, Health Biotechnology Humanities, Oviedo, Spain, 3Faculty of Psychology, Division, National Institute for Biotechnology and Genetic Córdoba, Spain Engineering (NIBGE), Faisalabad, Pakistan, 4Institute of Basic Medical Sciences, Khyber Medical University, In this talk we will report on a boy with a microdeletion in Peshawar, Pakistan, 5Atlantic Health System, Goryeb 8p23.1 (arr[hg19] 8p23.1 (7169490-7752586) and a micro- Children's Hospital, Morristown, NJ, United States, duplication in 9p24.3 (arr[hg19] 9p24.3 (266045-459076). 6HowardHughesMedicalInstituteandDivisionofGenetics Our proband exhibits a moderate language delay, mostly and Genomics, Children's Hospital Boston, and Neurology affecting the expressive domain, as well as cognitive delay and Pediatrics, Harvard Medical School Center for Life andbehaviouraldeficits,includingattentionalproblemsand Sciences, Boston, MA, United States, 7Medical and aggressiveness. Whereas the microdeletion in chromosome Population Genetics Program and Center for Mendelian 8 is reported as benign, the microduplication in chromo- Genomics, Broad Institute of MIT and Harvard, some9ishypothesizedaspathogenic,affectingthebodyof Cambridge, MA, United States, 8Swiss Institute of the gene DOCK8. We will discuss the role of this gene in Bioinformatics, Molecular Modeling Group, Batiment brain developmentand function, focusingonthefunctional Genopode, Unil Sorge, Lausanne, Switzerland, 9GeneDx, linksoftheDOCK8proteinwithCD
C42 ,inturnassociated Gaithersburg, MD, United States, 10Department of to nearly 30 candidates for language disorders and/or Biosciences, COMSATS University, Islamabad, Pakistan, language evolution, including SLIT1, SLIT2, and ROBO1, 11Department of Medicine, KMU Institute of Medical which play a key role in the externalization of language Sciences, Kohat, Pakistan, 12Radiology Department, Lady (speech). We will also present results of a targeted whole Reading Hospital, Peshawar, Pakistan, 13Department of transcriptome sequencing analysis (RNA-seq) aimed to Fundamental Oncology, Lausanne University, Ludwig determine changes in the expression levels in the blood of Institute for Cancer Research, Epalinges, Switzerland, DOCK8, its functional partners with a known role in 14Service of Genetic Medicine, University Hospitals of language development, impairment, and/or evolution Geneva, Geneva, Switzerland, 15Medigenome, The Swiss (AB
L1 , DCD
C2 , DOCK4, MAPK1, MET, ROBO1, and Institute of Genomic Medicine (current address), Geneva, SLIT2), and several other robust candidate genes for Switzerland, 16Biomedical Research Foundation of the language disorders and/or language evolution (AUT
S2 , Academy of Athens, Athens, Greece, 17Department of BAZ1B, BM
P2 , CMIP, CNTNA
P2 , DLX1, EL
P4 , FLNA, Endocrinology Diabetes and Metabolism, University FOX
P1 , FOX
P2 , GRIN2A, POU3F2, RUNX2, and SOX9). Hospital of Lausanne, Lausanne, Switzerland, 18iG
E3  We will conclude that the phenotype exhibited by our Institute of Genetics and Genomics of Geneva, Geneva, proband might result from a severe deficit in working Switzerland memory (mostly impacting on language structure and use), seemingly resulting from a reduced dosage of DOCK8 and Cargotransportalongthecytoplasmicmicrotubularnetwork the subsequent alteration of a CD
C42 -regulated network isessentialforneuronalfunction,andcytoplasmic dynein-1 important for language development. is an established molecular motor critical for neurogenesis A. Benítez-Burraco: None. M. Fernández-Urquiza: and homeostasis. We performed whole exome sequencing, None. S. Jiménez-Romero: None. homozygosity mapping, and chromosomal microarray studies in five individualsfrom three independent pedigrees 
P08 .17B and identified likely pathogenic variants in DYN
C1 I2 Biallelic variants in DYN
C1 I2 cause syndromic (Dynein Cytoplasmic 1 Intermediate Chain 2), encoding a microcephaly with intellectual disability, global component of the cytoplasmic dynein 1 complex. In a developmental delay and dysmorphic facial features consanguineous Pakistani family with three affected indivi- duals presenting with microcephaly, severe intellectual E. E. Davis1, M. Ansar2, F. Ullah1,3, S. A. Paracha4, disability, cerebral malformations and dysmorphic facial D. J. Adams5, A. Lai6, L. Pais7, J. Iwaszkiewicz8, features, we identified a homozygous splice donor site F. Millan9, M. T. Sarwar4, Z. Agha10, S. F. Shah11, variant (NM_001378.2:c.607+1G>A). We report two1386 additional cases with similar neurodevelopmental deficits Both copy number losses and gains occur within andcraniofacialfeatureswhoharbordeleteriousvariants:an subtelomeric 9q34 region without common breakpoints. individual bearing a p.(Tyr247Cys) change in trans with a The microdeletions cause Kleefstra syndrome (KS), 374 kb deletion encompassing DYN
C1 I2; and an unrelated whose responsible gene is EHMT1 (euchromatin histone case harboring compound heterozygous variants p. methyltransferase 1). A 9q34 duplication syndrome (Gln290*) and p.(Tyr247Cys). F0 zebrafish larvae with (9q34DS) had been reported in literature, but it has never CRISPR/Cas9 gene disruption or transient suppression of been characterized by a molecular point of view. At the dync1i2adisplayedsignificantlyalteredcraniofacialpattern- best of our knowledge, we report on the two patients ing with concomitant reduction in head size. We monitored carrying the smallest 9q34.3 duplications containing cell death and cell cycle progression in dync1i2a zebrafish EHMT1 as the only relevant gene. We compared them models and observed significantly increased apoptosis, to 21 described patients carrying 9q34.3 duplications likelyduetoprolonged mitosiscausedby abnormalspindle encompassing the entire gene and extending within 3 morphology,offeringinitialinsightsintothecellularbasisof Mb~. By surveying the available clinical and molecular microcephaly. Additionally, complementation studies in cytogenetic data, we could find out that similar neurode- zebrafish demonstrate that the p.(Tyr247Cys) attenuates velopmental disorders (NDDs) were shared by patients gene function, consistent with protein structural analysis. carriers of even very different sized duplications. More- Our genetic and functional data indicate that the DYN
C1 I2 over, some facial features of the 9q34DS were more dysfunction likely causes an autosomal recessive micro- represented than those of KS. However, an accurate in cephaly syndrome, and highlightfurther thecritical roles of silico analysisofthe genesmapped in all the duplications the dynein-1 complex in neurodevelopment. allowedustosupportEHMT1asbeingsufficientto cause E.E. Davis: None. M. Ansar: None. F. Ullah: None. S. a NDD phenotype. Wider patient cohorts are needed to A. Paracha: None. D.J. Adams: None. A. Lai: None. L. disentangle whether the rearrangements have full causa- Pais: None. J. Iwaszkiewicz: None. F. Millan: None. M. tive role or simply confer the susceptibility to NDDs and T. Sarwar:None.Z. Agha: None. S.F.Shah:None.A.A. possibly to identify the cognitive and behavioral profile Qaisar: None. E. Falconnet: None. V. Zoete: None. E. associated to the EHMT1 increased dosage. Ranza: None. P. Makrythanasis: None. F.A. Santoni: A. Sironi: None. M.T. Bonati: None. C. Castronovo: None. J. Ahmed: None. N. Katsanis: E. Ownership None.D.Zimbalatti:None.M.Crippa:None.I.Bestetti: Interest (stock, stock options, patent or other intellectual None. J.A. Rosenfeld: None. D.A. Scott: None. P. Stan- property); Significant; Rescindo Therapeutics. C. Walsh: kiewicz: None. A. Novelli: None. S. Loddo: None. J. None. S.E. Antonarakis: None. Taylor: None. F. Devillard: None. L. Larizza: None. P. Finelli: None. 
P08 .18C 9q34.3 microduplications lead to Neurodevelopmental 
P08 .19D Disorders through EHMT1 overexpression Epha7 haploinsufficiency is associated with neurodevelopmental delay A.Sironi1,2,M.T.Bonati3,C.Castronovo2,D.Zimbalatti2, M. Crippa1,2, I. Bestetti1,2, J. A. Rosenfeld4, D. A. Scott4, J. Levy, C. Dupont, H. Nasser, E. Yvon-Chaou, P. Stankiewicz4, A. Novelli5, S. Loddo5, J. Taylor6, M. Rachid, M. Lopez, B. Benzacken, E. Pipiras, F. Devillard7, L. Larizza2, P. Finelli1,2 A. Verloes, A. Tabet 1Department of Medical Biotechnology and Translational AP-HP, Paris, France Medicine, Milan, Italy, 2Lab. of Medical Cytogenetics and Molecular Genetics, IRCCS Istituto Auxologico Italiano, Interstitial6q15-q16.1deletionsarerareandfewcaseshave CusanoMilanino,Milan,Italy,3ClinicofMedicalGenetics, beenreportedintheliterature.Genotype-phenotypecorrela- San Luca Hospital, IRCCS Istituto Auxologico Italiano, tion is complex because of incomplete penetrance and Milan, Italy, 4Dep. of Molecular and Human Genetics, variableexpressivity,varioussizeandbreakpointsofthe6q Baylor College of Medicine, Houston, TX, United States, deletions.Wereport6additionalpatientsfromtwofamilies 5Lab. of Medical Genetics, Bambino Gesù Children's with 6q16.1 deletion encompassing or disrupting EPHA7 Hospital, Rome, Italy, 6Genetic Health Service New gene. All patients presented a neurodeveloppemental Zealand, Auckland, New Zealand, 7Département de disorder. SNP array analysis of family 1 (patient 1 to 5) GénétiqueetProcréation,CHUGrenoble-Alpes,Grenoble, showeda4,5Mbdeletionat6q16.1disruptingexons10-17 France of EPHA7 (OMIM *602190) in all affected children and alsoinheritedfromtheaffectedfather.Forfamily2(patientAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1387 6), SNP array analysis revealed a 3,1 Mb deletion at Case presentation: Here we report on a boy with pro- 6q15q16.1 encompassing only one OMIM gene: EPHA7. found developmental and motor delay, drug-resistant epi- TheephrinreceptorA7(EPHA7,mappedin6q16.1)encode lepsy starting at 7 months and recurrent episodes of status a member of ephrin receptor subfamily of the protein- epilepticus.Trio-exomesequencingrevealedthecompound tyrosinekinasefamily.EPHandEPH-relatedreceptorshave heterozygous variants in SC
L25 A12; c.225del; p.(Glu76- been implicated in mediating developmental events, Serfs*17)andc.1747C>A;p.(=),whichareabsentinpublic particularly in the nervous system. EphA7 play a role in databases. As the phenotype was overlapping and the corticaldomainsformation,determinebrainsizeandshape, synonymous variant was predicted to alter the splicing, we and is involved in development of the central nervous performed mRNA analysis on blood of the patient that system. We provide further evidence for EPHA7 haploin- revealed a loss of full-length cDNA. Western blot on sufficiency role in neurodevelopmental disorder and muscle biopsy of the patient confirmed these results. Brain delineate clinical phenotype. Interestingly, one patient MRI including MR-spectroscopy further supported the (patient 3) had a 6q16.1 deletion encompassing geneticfindingssincecholine/myoinositolwerefoundtobe EPHA7 and a 1,4 Mb 7q11.23 microdeletion associated elevatedinthemedullarylayer,whereasNAAwasreduced. with more severe symptoms than those observed in Conclusion: The clinical presentation as well as char- Williams-Beuren syndrome. EPHA7 deletion could also acteristic MR-spectroscopy pattern combined with the loss contribute to the most severe neurodevelopmental pheno- of mRNA/protein expression in patient´s tissues confirmed type as a second hit. the pathogenicity of both variants. Thus, we could set the J. Levy: None. C. Dupont: None. H. Nasser: None. E. diagnosis of EIE
E39 . However, at our lab and as far as we Yvon-Chaou: None. M. Rachid: None. M. Lopez: None. know at other laboratories, synonymous (and many spli- B.Benzacken:None.E.Pipiras:None.A.Verloes:None. cing) variants are not well characterized. Bioinformatics A. Tabet: None. toolsforsplicingareoftennotwellintegratedandfollowing mRNA analyses is hampered by technical and economical 
P08 .20A obstacles. Hence, improvements are urgently needed to A deleterious synonymous SL
C25 A12 variant in a boy identify causative synonymous and splicing variants. with severe epileptic encephalopathy J. Hentschel: None. F. Distelmaier: None. D. Klee: None.H.Zöllner: None. M.Nastainczyk-Wulf: None. T. J. Hentschel1, F. Distelmaier2, D. Klee3, H. Zöllner3, Bartolomaeus: None. E. Jäger: None. D. Wieczorek: M. Nastainczyk-Wulf1, T. Bartolomaeus1, E. Jäger4, None. S. Redler: None. R. Jamra: None. D. Wieczorek5, S. Redler6, R. Jamra1 
P08 .21B 1InstituteofHumanGenetics,UniversityofLeipzigMedical Somaticinstability ofCGG repeatsintheFMR1geneis Center, Leipzig, Germany, 2Department of General a factor in symptom severity in Fragile X syndrome Pediatrics, Neonatology and Pediatric Cardiology, patients University Hospital, Heinrich-Heine-University, Düsseldorf, Germany, 3Department of Diagnostic and D. V. Yudkin1, I. V. Grishchenko1, A. A. Tulupov2,3, Interventional Radiology, Medical Faculty, Heinrich Heine Y. M. Rymareva2,3, Y. V. Maksimova4,5, A. R. Shorina5 University, Düsseldorf, Germany, 4Rheumatology Unit, Department of Internal Medicine, University of Leipzig, 1FBRI SRC VB “Vector”, Rospotrebnadzor, Koltsovo, Leipzig,Germany,5InstituteofHumanGenetics,University Novosibirsk region, Russian Federation, 2International Clinic Duisburg-Essen, Essen, Germany, 6Heinrich‐Heine‐ Tomography Center Siberian Branch of Russian Academy University, Medical Faculty, Institute of Human Genetics, of Sciences, Novosibirsk, Russian Federation, 3Novosibirsk Düsseldorf, Germany State University, Novosibirsk, Russian Federation, 4Novosibirsk State Medical University, Novosibirsk, Background: SL
C25 A12 encodes a mitochondrial mem- Russian Federation, 5Novosibirsk Clinical City Hospital brane protein ARALAR/AG
C1  that contributes to the No. 1, Novosibirsk, Russian Federation exchange of aspartate/glutamate. Biallelic pathogenic var- iants lead to decreased availability of N-acetyl aspartate in Introduction: Fragile X syndrome is a main cause of thebrain,leadingtoearlyinfantileepilepticencephalopathy inherited intellectual disability in humans. The molecular (OMIM #612949) with global cerebral hypomyelination, basis of the disorder is a CGG-repeat expansion in the developmental regression, apnea, seizures, and muscular FMR1 gene. Normal repeat lengths are fewer than 50 hypotonia. triplets; the full mutation repeat size is more than 200 triplets. It has been shown that carriers of a large allele1388 exhibit repeat size somatic instability. This instability was information about the protein is not a prerequisite to assess suggested to be linked to symptom severity. Here, we the pathogenicity of the variant. This allows us to assess present a study of the relationship between somatic whether variants in protein domains for which the precise instability in patients with changes in their brains and the function is unknown or cannot be assessed biochemically, severity of their psychiatric symptoms. are pathogenic. Moreover, we can test variants in proteins Materials and Methods: Measurements of the repeat for which no biological information is available at all. size were carried out by fragment analysis on an ABI During the presentation an overview will be given on the 3130XL Genetic Analyzer, and the MRIs were performed number of mutations tested until now using the PRiSM onanAchievascannerwithamagneticfieldstrengthof1.5 screeningandtheiroutcomes,discussingamongstothersthe T. Patients were diagnosed by genetic and psychiatric sensitivity and specificity as well as the strengths and the assessments at NCCH No. 1. weaknesses of this screen. Taken together, we have now Results: The efficiency of PCR in repeat sizing does not setup a functional genomics screen which has already allow the calculation of the instability index by the quan- proven its value at the diagnostic as well as the titationofeachallele,ashasbeendonepreviouslyinmouse scientific level. studies. We developed a novel approach for evaluating G.M. van Woerden: None. Y. Elgersma: None. somatic instability in humans based on repeat sizes and the number of alleles. A strong correlation between somatic 
P08 .23D instability and changes in brain-region connectivity was GATAD2B-Associated Neurodevelopmental Disorder found in Fragile X syndrome patients and in some brain (GAND),furtherdelineationofthephenotypeinaseries regions of the patients’ healthy mothers. Additionally, of 10 patients somatic instability significantly influenced the psychiatric and behavioral symptoms of Fragile X syndrome patients. G. Vera1, A. Sorlin2, G. Delplancq2, F. Lecoquierre1, The study is supported by Russian Science Foundation F.Petit3,T.Smol3,A.Ziegler4,D.Bonneau4,S.Mercier5, Grant 18-15-00099. P. Edery6, G. Lesca7, N. Chatron7, B. Duban-Bedu8, D.V. Yudkin: None. I.V. Grishchenko: None. A.A. C. Colson9, B. Gerard10, B. Durand10, Y. Capri11, Tulupov: None. Y.M. Rymareva: None. Y.V. Maksi- T. Frebourg1, A. Lebre12, G. Nicolas1, P. Saugier-Veber1, mova: None. A.R. Shorina: None. A. Guerrot1 
P08 .22C 1Normandie Univ, UNIROUEN, Inserm U1245 and Rouen PRiSM, a functional genomics screen to assess the University Hospital, Department of Genetics, F 76000, pathogenicity of candidate variants of NormandyCenterforGenomicandPersonalizedMedicine, neurodevelopmental disorders Reference Center for Developmental Disorders, Rouen, France, 2Centre de Génétique, CHU Dijon Bourgogne, G. M. van Woerden, Y. Elgersma Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, INSERM 1231, Erasmus MC, Rotterdam, Netherlands Génétique des Anomalies du Développement, Université Bourgogne Franche-Comté, Dijon, France, 3CHU Lille, Nextgenerationsequencing(NGS)hasbecomethemethod Clinique de Génétique, Hopital Jeanne de Flandre, F- of choice to identify the presence of pathogenic mutations 59000andEA7364RADEME,UniversitédeLille,F-59000, in children with a neurodevelopmental disorder. Recent Lille, France, 4Department of Biochemistry and Genetics, studies suggested that a possible pathogenic genetic University Hospital, 49933 Angers Cedex 9 ; UMR CNRS mutation can be identified in the majority of individuals 60154-INSERM 1083 and Mitovasc Institute, University of withintellectualdisability.However,manyoftheidentified Angers, 49933, Angers, France, 5Service de génétique variants are genetic variants of unknown significance médicale, CHU Nantes, Nantes, France, 6Service de (VUS). To establish whether these variants are pathogenic, génétique clinique, Centre de Référence Anomalies du independent confirmation is needed. The PRiSM (Pipeline Développement etSyndromes Malformatifs Sud Est- HCL ; for Rapid in silico/in vitro/in vivo Screening of Mutations) CentredeRechercheenNeurosciencesdeLyon,GENDEV, is developed as a functional genomics screen to test the Inserm U1028, UMR CNRS 5292, UCB
L1 , Lyon, France, pathogenicity of such variants. (see: www.functiona 7Hospices Civils de Lyon, Genetic Department and lgenomics.nl).Althoughwe can make useofmany specific Molecular Biology Laboratory, Centre de Biologie Est, biochemical read-outs to establish the pathogenicity of a Bron,F-69677,France;UniversitéClaudeBernardLyon1, variant (eg, kinase assays, ubiquitin assays) the core assays F-69100, Villeurbanne, Lyon, France, 8Cytogenetics of the PRiSM screen are hypothesis-free: biological Service, Saint Vincent de Paul Catholic HospitalsAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1389 Association of Lille, Free Faculty of Medicine, Lille, 
P08 .24A France, 9Service de Génétique, CHU de Caen - Hôpital Mutations in PIGU, impairing the function of the GPI Clémenceau, Caen, France, 10Laboratoire de Diagnostic transamidase complex cause severe intellectual Génétique, Hôpitaux Universitaires de Strasbourg, disability, epilepsy, and brain anomalies Strasbourg, France, 11Department of Genetics, APHP- Robert DEBRE University Hospital, Denis Diderot School A. Knaus1, F. Kortüm2, T. Kleefstra3, A. Stray-Pedersen4, ofMedicine,ParisUniversity,Paris,France,12Department D. Đukić1, T. Gerstner5, D. Horn6, M. Hempel2, of Genetics, Reims University Hospital, Reims, France P. M. Krawitz1 Introduction: Pathogenic variants in the GATAD2B gene 1Institute for Genomic Statistics and Bioinformatics, have recently been associated with a syndromic neurode- University Hospital Bonn, Bonn, Germany, 2Institute of velopmental disorder (GAND) characterized by severe Human Genetics, University Medical Center Hamburg- intellectual disability (ID), impaired speech, childhood Eppendorf, Hamburg, Germany, 3Department of Human hypotonia, and dysmorphic features. The majority of Genetics, Radboud University Medical Center, Nijmegen, reported patients harbored de novo loss of function (LoF) Netherlands, 4Norwegian National Unit for Newborn variants. To date, the phenotype of only four patients has Screening, Division of Pediatric and Adolescent Medicine, been precisely described in the literature, contrasting with Oslo University Hospital, Oslo, Norway, 5Department of the relative frequency of detection of such LoF GATAD2B Pediatrics, Sørlandet Hospital, Arendal, Norway, 6Institute variants.Here,we describe 10patientswith confirmedLoF of Medical and Human Genetics, Charité- GATAD2B variants and further delineate the clinical Universitätsmedizin Berlin,, Berlin, Germany phenotype. Methods: Patients were included by contacting referent The glycosylphosphatidylinositol (GPI) anchor links over clinicians from several French genetics departments. 150 proteins to the cell surface and is present on every cell Results: Developmental delay was severe with a median type. Many of these proteins play crucial roles in neuronal age of 2.4 years (range [2-5]) for independent walking and developmentandfunction.Mutationsin18ofthe29genes, of 2.75 years (range [1-4]) for first spoken words. They implicatedinthebiosynthesisoftheGPIanchor,havebeen showed very little subsequent progress, one patient identified as the cause of GPI biosynthesis deficiencies remaining non-verbal at age 30 years. ID was mostly (GPIBDs) in humans associated with intellectual disability moderate, with only one severe and one mild case, which and seizures as the cardinal features. PIGU is an essential differs from the original description of severe ID. Most component of the GPI transamidase complex along with common dysmorphic features included broad forehead, PIGK, PIGS, PIGT, and GPAA1 that links GPI anchored deeply set eyes, hypertelorism, downturned mouth and, proteins(GPI-APs)ontotheGPIanchorintheER.Here,we anomalies of the extremities. Conversely, prenatal compli- report two homozygous missense mutations cations, non-cerebral organ malformations, epilepsy and (NM_080476.4:c.209T>A and c.1149C>A) in five indivi- autistic behaviour were very rare. One patient presented duals from three unrelated families. All individuals asthma and recurrent respiratory infections, another one presented with global developmental delay, severe to presented severe feeding difficulties and developed acute profound intellectual disability, muscular hypotonia, sei- lymphoblastic leukemia and IgG deficiency. zures,brainanomalies,scoliosis,andmildfacialdysmorph- Conclusions:NGS-basedapproachesforsequencingwill ism. Using flow cytometry, a characteristic profile for GPI improve the detection of GATAD2B variations. Better transamidase deficiency consisting of reduced cell surface knowledge of the clinical phenotype is essential for a cor- expressionofFLAER,CD16,andCD24,butnotCD55and rect interpretation of the molecular results and for an CD59 on granulocytes and free GPI anchor detected by T5 accurate management of these patients. antibody on B-cells, was determined. Moreover, computer- G. Vera: None. A. Sorlin: None. G. Delplancq: None. assisted facial analysis of different GPIBDs revealed a F. Lecoquierre: None. F. Petit: None. T. Smol: None. A. shared characteristic facial gestalt between individuals with Ziegler: None. D. Bonneau: None. S. Mercier: None. P. mutationsinPIGUandGPAA1.Ourfindingsstrengthenthe Edery: None. G. Lesca: None. N. Chatron: None. B. roleoftheGPItransamidasecomplexinthedevelopmentof Duban-Bedu: None. C. Colson: None. B. Gerard: None. nervous and skeletal systems and expand the clinical B. Durand: None. Y. Capri: None. T. Frebourg: None. spectrum of disorders belonging to the group of inherited A. Lebre: None. G. Nicolas: None. P. Saugier-Veber: GPI anchor deficiencies. None. A. Guerrot: None. A.Knaus:None.F.Kortüm:None.T.Kleefstra:None. A. Stray-Pedersen: None. D. Đukić: None. T. Gerstner:1390 None. D. Horn: None. M. Hempel: None. P.M. Krawitz: 
P08 .26C F. Consultant/Advisory Board; Significant; FDNA Inc.. Exome sequencing of 100 patients with intellectual disability 
P08 .25B Cryptic unbalanced translocations causing intellectual O. Levchenko1, E. Dadali1,2, L. Bessonova1, N. Demina1, disability or congenital malformations can be G. Rudenskaya1, G. Matyushchenko1, T. Markova1, surprisingly large I. Anisimova1, N. Semenova1, O. Schagina1, O.Ryzhkova1, R. Zinchenko1,2, V. Galkina1,V. Voinova3, K. Cremer1, M. Kreiß1, R. C. Betz1, J. Buchholz2, A. Lavrov1,2 E. Mangold1, H. Lüdicke2, J. Maric-Biresev1, E. Engels1, H. Hundertmark1, J. Becker1, H. Engels1 1Research centre for medical genetics, Moscow, Russian Federation, 2Department of Molecular and Cellular 1Institute of Human Genetics, University of Bonn, Bonn, Genetics, Biomedical Faculty, Pirogov Russian National Germany, 2Heinrich-Meng-Institut gGmbH, ResearchMedicalUniversity,Moscow,RussianFederation, Sozialpädiatrisches Zentrum Rhein-Erft-Kreis, Kerpen, 3The Research and Clinical Institute for Pediatrics named Germany after Academician Yuri Veltischev of the Pirogov Russian National Research Medical University, Moscow, Russian Unbalancedreciprocaltranslocationsareafrequentcauseof Federation intellectual disability (ID) and are usually diagnosed by conventional cytogenetic diagnostics. However, some of Introduction: Intellectual disability (ID) is a widespread them are only detectable by e.g. FISH, MLPA or group of diseases with a frequency of 1% to 3%. Next chromosomal microarrays (CMA) and are thus cryptic. generation sequencing (NGS) technologies significantly Here,wepresentthreeunbalancedtranslocationsdetected reduced the time of diagnostics compared to single-gene after cytogenetic analyses with normal results at our insti- sequencing. Optimal method of NGS is a whole (WES) or tuteinthelastyear.InPatient1,a10-yearoldgirlwithi.a. clinical (CES) exome sequencing. ID and dysmorphisms, CMA detected a 5.0Mb terminal MaterialsandMethods:Thestudyincluded100patients gain of 2q and a 3.6Mb terminal loss of 21q. Surprisingly, with various forms of ID. All cases were submitted from theterminalimbalancesinpatients2and3werequitelarge: geneticists. Martin-Bell, Rett syndromes and chromosomal CMAdetectedan11.4Mblossof10pandan8.9Mbgainof pathologywereexcluded,thepatientshadnotraumaticand 13q in Patient 2, a 10-month old boy with i.a. growth infectious brain damage. WES was performed for 69 retardation, VSDs and choanal atresia. In Patient 3, a 15- patients.CES(panelof6500HGMDgenes)wasperformed year old boy with i.a. ID, short stature, microcephaly, sei- for 31 patients. Founded gene variants were confirmed by zures and renal agenesis, CMA detected a 10.4Mb loss of Sanger sequencing in trios. 9p and an 11.4Mb gain of 12p. FISH demonstrated unba- Results: We diagnosed syndromes (Kabuki, Cohen, lanced translocations in all patients and balanced maternal Cowden, Nicolaides-baraitser, ZTTK, Smith-Magenis, translocations for patients 1 and 2. For Patient 3, parental Helsmoortel van der Aa, Cornelia de Lange-like, multiple material was unavailable. congenital anomalies-hypotonia-seizures syndrome 1), Especially patients 2 and 3 are instructive examples with metabolic diseases (MPS III type), early epilepsy ence- imbalancesgreaterthan10Mbwhichtheoreticallyshouldbe phalopathy (type 4 and 7), mental retardation autosomal detectable by GTG-banding. However, the affected regions dominant (7, 8, 35, 36, 49 types, ID with a mutation in the were very similar in size and banding patterns and thus GRIA1), mental retardation X-linked (98 and 102 types), escaped detection by banding methods. Our observations mesomelic dysplasia with a mutation in the AFF3. Several emphasizetheimportanceofCMAnotonlyinthedetection new candidate genes were identified. As a result, 21 of microdeletions and -duplications, but also of large pathogenic variants, 3 probably pathogenic and 12 variants chromosomal imbalances in patients with ID or congenital of unknown significance were found. malformations. Conclusions: The total diagnostic value of the exome K.Cremer:None.M.Kreiß:None.R.C.Betz:None.J. sequencing is 24% (20% for WES; 29% for CES). Many Buchholz: None. E. Mangold: None. H. Lüdicke: None. nonspecificclinicalsignsinIDmakeitdifficulttoestablish J. Maric-Biresev: None. E. Engels: None. H. Hundert- precisediagnosiswithoutmoleculargenetictesting.Inthese mark: None. J. Becker: None. H. Engels: None. cases, exome sequencing is a method of first choice. O. Levchenko: None. E. Dadali: None. L. Bessonova: None. N. Demina: None. G. Rudenskaya: None. G. Matyushchenko: None. T. Markova: None. I.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1391 Anisimova: None. N. Semenova: None. O. Schagina: Nava: None. M. Spentchian: None. D. Heron: None. B. None. O. Ryzhkova: None. R. Zinchenko: None. V. Keren: None. P. Charles: None. Galkina: None. V. Voinova: None. A. Lavrov: None. 
P08 .28A 
P08 .27D Involvement of FMN2 in nonsyndromic autosomal- Whole exome sequencing in a cohort of adults patients dominant intellectual disability with intellectual disability D. T. Babikyan, S. Midyan, A. Hovhannisyan, I. Marey1,2, S. Heide1,2, C. Mignot1,2, S. Whalen1,2, T. Sargsyan A. Afenjar1,2, J. Buratti3, V. Olin3, E. Lejeune3, S. Karagic3, C. Nava3, M. Spentchian1,2, D. Heron1,2, Center of Medical Genetics and Primary Health Care, B. Keren3, P. Charles1,2 Yerevan, Armenia 1APHP, Genetic Department, Medical Genetic UF, We report genetic analysis of a non-consanguineous Armand-Trousseau and Pitié Salpêtrière Hospitals, Paris, Armenian family exhibiting extended history of non- France,2ReferenceCenterforIntellectualdisabilityofRare syndromic intellectual disability (NSID) in four-generation Causes, Paris, France, 3Developmental Genomic UF, pedigree,includingaffectedsixmales(threesibs,fatherand Genetic Department, AP-HP, Pitié-Salpêtrière Hospital, two paternal uncles) and three females (daughter, paternal Paris, France grand-mother and grand-grand-mother) with mild to moderate ID and with normal karyotype. Molecular Intellectual disability (ID) is frequent (about 2% of the karyotypinganalysisofall affected relatives usingIllumina population, i.e. 1.3 million of persons). Etiologies are HumanOmniExpress BeadChip identified only benign numerousandheterogeneous.Wedevelopedsince2005,as CNVsandnoextendedregionofLOH.Assumingapparent part of the Reference Center for ID of Rare Causes, a autosomal dominant inheritance pattern of the clinic specific multidisciplinary consultation (neurologist, geneti- through four generations, all living affected six male and cist and social worker) for adults with ID which main one female relatives were analysed by Whole Exome objectives are diagnosis, genetic counseling, management, Sequencing analysis using Illumina´s SureSelect 62Mb follow-up,phenotypiccharacterization,evolutionaryprofile Enrichment Kit and HiSeq2000 platform. Further variant and natural evolution of different genetic syndromes in calling and annotation by ANNOVAR revealed only one adults.ManyadultswithIDhavenodiagnosisbecausethey heterozygous genetic variation in all affected relatives: a could not benefit from the latest high-throughput sequen- putative exonic 33 bp non-frameshift deletion in FMN2 cing techniques. We focused on adults patients (older than gene (NM_020066:c.2802_2834del) predicting a deletion 15 years) with isolated or syndromic ID without diagnosis. of amino acids 934-945. The heterozygous variant was These patients were from pediatric departments (40%), confirmedbySangersequencinginallaffectedrelativesand adults’ medical departments (30%) (whose neurological wasnotdetectedinanyofthehealthyrelatives(motherand departments20%)orreferredfromtheirgeneralpractitioner sibs).FMN2encodesaproteinoftheforminfamilyofactin or practitioner of their institution (30%). 222 of these cytoskeletonnucleationfactorswhichishighlyexpressedin patients underwent high throughput sequencing in trios the maturing brain. FMN2 as a candidate gene for ID had (patient and 2 parents) consisting in TruSight One gene been speculated in reports of two sporadic cases with panel(T
S1 ,51trios,Illumina*)orwholeexomesequencing interstitial deletions involving FMN2 and suggesting the (171 trios). We established a diagnosis in 21.6% of them mechanismofhaploinsufficiencywhichwascontradictedto with T
S1  and 43% with WES. Whole exome sequencing the further report of homozygous truncating mutations in diagnosis yield is comparable with series published in FMN2 as cause of autosomal-recessive NSID in two literature.Inmostofcaseswefounddenovomutations.We consanguineous families. This is the first report of FMN2 alsofoundcandidategenesneedingvalidationwithongoing intragenic mutation causing autosomal-dominant form gene matching procedures. Identifying genetic causes is of NSID. crucial for relatives’ genetic counseling and to describe D.T. Babikyan: None. S. Midyan: None. A. Hovhan- natural evolution of known syndromes with valuable nisyan: None. T. Sargsyan: None. information on evolutionary profile in adults. I. Marey: None. S. Heide: None. C. Mignot: None. S. 
P08 .30C Whalen: None. A. Afenjar: None. J. Buratti: None. V. Tellingtheuntoldstory:Theeconomicandpsychosocial Olin: None. E. Lejeune: None. S. Karagic: None. C. impacts on families affected by intellectual disability1392 D. Schofield1, O. Tan1, R. Shrestha1, R. Rajkumar1, L.Christie:None.M.Leffler:None.L.Murray:None.T. N. Kasparian2,3, M. Rice1, L. Rynehart1, S. West1, Roscioli: None. M. Field: None. J. Boyle4, L. Christie4, M. Leffler4, L. Murray4, T. Roscioli5,6, M. Field4,7 
P08 .31D The benefits of whole exome sequencing data reanalysis 1GenIMPACT: Centre for Economic Impacts of Genomic in Intellectual disability Medicine, Macquarie Park, Australia, 2Faculty of Medicine, University of New South Wales, Randwick, Z. Fattahi, M. Babanejad, F. Peymani, M. Beheshtian, Australia, 3Heart Centre for Children, the Children's F. Larti, K. Kahrizi, H. Najmabadi Hospital at Westmead, Westmead, Australia, 4Genetics of Learning Disability (GoLD) Service, Newcastle, Australia, GeneticsResearchCentre,UniversityofSocialWelfareand 5NeuroscienceResearchAustralia,UniversityofNewSouth Rehabilitation Sciences, Tehran, Iran, Islamic Republic of Wales, Randwick, Australia, 6Sydney Children’s Hospital, Randwick, Australia, 7Department of Clinical Genetics, Nowadays, whole exome sequencing has become a wide- Royal North Shore Hospital, St Leonards, Australia spreadtoolinstudyingMendeliandisorders.Thediagnostic yieldisassumedaround25-40%andthenegativecasesare Introduction: Data on the financial and psychosocial costs duetoWESlimitations.Besidesthetechnicalissuessuchas incurred by families affected by intellectual disability (ID) low coverage in specific regions or random failure in is scarce, thus limiting the capacity to value the benefits of hybridization reaction, inaccuracies in different data diagnosing and preventing ID through the application of analysisstepsplayasignificantrole.Thesecanberesolved genomictesting.Wereportonthefirstlarge,in-depthstudy by updates in bioinformatics tools, algorithms, databases exploring the economic, psychosocial and potential repro- andliterature,improvingthediagnosticyieldofatleast10- ductive impacts of whole genome sequencing (WGS) 20% in different studies. Recently, we have published the for ID. results of a large cohort of patients presenting intellectual Materials and Methods: A survey instrument was disability in which the diagnostic yield of 54% was developed to assess quality of life, psychosocial impacts, achieved. In present study, 172 negative cases from education, employment, income, wealth, welfare depen- previouscohortwereselectedaimingtoimprovediagnostic dency, living arrangements and family out-of-pocket costs. yield by re-sequencing and/or re-analysis. So far, the Eligible families had WGS. Data on 175 individuals with analysis of 68 patients is accomplished of which, the ID (100 households) has been collected. possible causative variant is detected in 12%. These results Results: Preliminary data showed combined costs to the are ascertained through three main strategies. First, Australian and State Governments, and private households extensive clinical follow up, re-sampling and re- totalled $13.1million per household up to the age of 69. interpretation of previous WES data led to identification Familiesboreasignificantfinancialburden($4.8millionper of one known and two novel candidate genes; ASPM, TTI1 household) mainly due to lost income and out-of-pocket and GPR126. Second; WES-reanalysis applying improved expenses. Families were under enormous psychosocial algorithms and filtering strategies in addition to updates of strainandmostcarersreportedhavingapoorqualityoflife. disease-causing genes revealed two possible candidates; Costs to Governments were $10.7million per household, AKTIP, MAZ, and two known genes; CDK10, FSCN1. with the main costs being for special education, residential Third; re-sequencing revealed another candidate gene; care and welfare. Among the families who have had WGS CCD
C58  possibly by expanding the coverage. In conclu- results returned, 44% have had a diagnosis with a further sion, this project has shown 12% improve in diagnostic 12% having a potential diagnosis. Most families would yield so far, also introduced five possible novel candidate consider using assistive technologies such as prenatal genes and provided a second report for the recently diagnosisandIVFwithpreimplantationgeneticdiagnosisin identified genes; CDK10 and FSCN1. future pregnancies. Z. Fattahi: None. M. Babanejad: None. F. Peymani: Conclusions: Families affected by ID experience a sig- None. M. Beheshtian: None. F. Larti: None. K. Kahrizi: nificant financial and psychosocial burden. This data is None. H. Najmabadi: None. important for benchmarking the potential benefits of WGS in familial ID. 
P08 .32A D. Schofield: None. O. Tan: None. R. Shrestha: None. Mutation in 
C1 orf131, encoding a novel nucleolar R. Rajkumar: None. N. Kasparian: None. M. Rice: protein,causesintellectualdisabilityinalargePakistani None.L.Rynehart:None.S.West:None.J.Boyle:None. familyAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1393 A. I. A. Khayyat1,2,3, S. M. Baig4, U. Abdullah4, 
P08 .33B E. U. Haq4, Z. Ali4, N. A. Malik4, M. Tariq4, B. Budde1, Genetic diagnosis of intellectual disability: results of A. A. Noegel2,5, P. Nürnberg1,5, M. S. Hussain1,2,5 trio-based whole exome sequencing in a cohort of 818 patients 1Cologne center for Genomics, Cologne, Germany, 2Institute of Biochemistry I, Medical Faculty, University of T. Courtin1,2, C. Nava1,2, C. Mignot1, J. Buratti1, Cologne, Cologne, Germany, 3Biochemistry Department, C. Estrade1, S. Karagic1, A. Lafitte1, E. Lejeune1, King Saud University, Riyadh, Saudi Arabia, 4Human C. Mach1, V. Olin1, A. Afenjar3, D. Doummar3, Molecular Genetics Laboratory, Health Biotechnology M. Moutard3, T. Billette de Villemeur3, M. Nougues3, Division, National Institute for Biotechnology and Genetic L.Burglen3,S.Valence3,B.Héron-Longé3,D.Rodriguez- Engineering (NIBGE), PIEAS, Faisalabad, Pakistan, Levi3, S. Whalen3, D. Haye1, S. Heide1, P. Charles1, 5Center for Molecular Medicine Cologne (CMMC), C. Depienne1, I. Marey1, D. Héron1, B. Keren1,4 University of Cologne, Cologne, Germany 1Hôpital Pitié-Salpêtrière, Paris, France, 2Sorbonne Introduction:Intellectualdisability(ID)ischaracterizedby Universités, Paris, France, 3Hôpital Trousseau, Paris, substantial limitations in both intellectual functioning and France, 4Sorbonnes Universités, Paris, France adaptive behavior. 50% of ID cases have genetic basis. It can also be categorized as syndromic intellectual disability Introduction: Intellectual disability (ID) is a clinically and (S-ID) and non-syndromic intellectual disability (NS-ID). genetically heterogeneous condition affecting 1 to 3% of Worldwideprevalenceofthisdisorderisestimatedtorange population worldwide. Recent improvements of new from 1% to 3%. generation sequencing are transforming medical practice. Material and Methods: For genomic analyses, homo- We present the clinical and genetical characteristics of a zygosity mapping was coupled with whole-exome sequen- large cohort of patients suffering from ID and had a trio- cing (WES) whereas immunofluorescence, confocal based whole exome sequencing (WES). microscopy, pulldown assays and mass spectrometry ana- Patients and Methods: 818 patients were recruited lyses were performed for biochemical analyses. through clinical genetic and/or neuro-pediatric consulta- Results: We studied a Pakistani family of NS-ID and tions. ID was assessed based on neuropsychological tests identified linkage regions with a maximum possible LOD when available, DSM-5 classification was used otherwise. score of 2.4 at chromosomes 1, 2, 15 and 21. WES con- Prior to WES, a DNA micro-array, a search for Fragile-X ducted on DNA of two affected members revealed a mis- syndrome and a targeted-gene analysis in case of high sense mutation (NM_152379.3:c.112G>A,p. Asp38Asn) in syndromicsuspicionwereperformed.Ifnegative,trio-based 
C1 orf131, encoding the uncharacterized protein 
C1 orf131, WES was proposed. Molecular results were discussed in as a likely cause of ID. The mutation replaces a highly multidisciplinaryteammeetingsbeforefeed-backtopatient. conservedasparticacidbyasparagineandispredictedtobe Results: The global diagnostic yield was 42% across all pathogenic by Mutation Taster and Polyphen-2. We show patients (338/818 patients). 41 mutations were found in here that 
C1 orf131 is a novel nucleolar component and candidate genes and contributed to their validation as “ID relocates to the chromosomal periphery during mitosis. genes”, rising the potential diagnostic yield to 47% (379/ Mutant primary fibroblasts exhibit reduced and distorted 818patients).Dominantmutationswerepre-eminent(81%) nucleoli, micronuclei and misshapen nuclei. Similar effects andmostofthemweredenovo(95%)affecting224unique are seen upon overexpression of mutant protein or knock- genes. Interestingly, severity of ID had no statistically sig- downbysiRNA.Ourdataalsoshowthat
C1 orf131interacts nificant effect on diagnostic rate (mild ID, 66/180, 37% - with several nucleolar and centrosomal proteins. moderate to profound ID, 108/419, 44%, p-value = Conclusion: We conclude that 
C1 orf131 is a novel gene 0.1997). Epilepsy and family history of ID were not iden- associated with ID and that its protein product plays a tified neither as cofounding factors (p-value = 0.132 and crucial role in maintaining the structural integrity of the 0.516). nucleolus.Itisalsoanessentialcomponentfornormalbrain Conclusion: This study emphasizes the considerable functions. genetic heterogeneity of ID and confirms the efficiency of A.I.A. Khayyat: None. S.M. Baig: None. U. Abdullah: trio-based WES for its exploration and delineation in a None. E.U. Haq: None. Z. Ali: None. N.A. Malik: None. genotype-first approach. M. Tariq: None. B. Budde: None. A.A. Noegel: None. P. T.Courtin:None.C.Nava:None.C.Mignot:None.J. Nürnberg: None. M.S. Hussain: None. Buratti: None. C. Estrade: None. S. Karagic: None. A. Lafitte: None. E. Lejeune: None. C. Mach: None. V. Olin: None. A. Afenjar: None. D. Doummar: None. M.1394 Moutard: None. T. Billette de Villemeur: None. M. triggernonsensemediatedmRNAdecay(NMD)orgenerate Nougues: None. L. Burglen: None. S. Valence: None. B. a truncated version of PHF21A. This confirms that Héron-Longé: None. D. Rodriguez-Levi: None. S. haploinsufficiency of PHF21A causes not only intellectual Whalen: None. D. Haye: None. S. Heide: None. P. disability and craniofacial anomalies, but also epilepsy, Charles: None. C. Depienne: None. I. Marey: None. D. language delay, hypotonia, and neurobehavioral problems. Héron: None. B. Keren: None. We also found that PHF21A is profoundly expressed in humanfetal brain andskeletalmuscle. Thisemphasizesthe 
P08 .34C role of PHF21A in early human development, which is Haploinsufficiency of PHF21A due to frameshift and consistent with developmental delay, autism, ADHD, nonsense mutations causes syndromic autism including epilepsy, and hypotonia observed at an early age in our intellectual disability, craniofacial anomalies, epilepsy, patients. These findings definitely provide proof of the hypotonia, and neurobehavioral problems pathogenicity of this gene in a syndromic form of intellectual disability. Furthermore, our studies suggest H. Kim1, J. A. Rosenfeld2, D. A. Scott2, G. Bénédicte3, additional features, in particular autism, which extend the J. D. Labonne4, J. Brown4, M. McGuire5, S. Mahida6, phenotypic spectrum attributable to PHF21A mutations. S. Naidu6, J. Gutierrez2, G. Lesca7, V. D. Portes7, H.Kim:None.J.A.Rosenfeld:None.D.A.Scott:None. A. Bruel8, A. Sorlin9, F. Xia2, Y. Capri10, E. Muller11, G. Bénédicte: None. J.D. Labonne: None. J. Brown: D. McKnight12, E. Torti12, L. C. Layman4, D. Ryu13, None. M. McGuire: None. S. Mahida: None. S. Naidu: I. Kong14, S. Madan-Khetarpal15, C. Kim16 None. J. Gutierrez: None. G. Lesca: None. V.D. Portes: None. A. Bruel: None. A. Sorlin: None. F. Xia: None. Y. 1Qatar Biomedical Research Institute, Doha, Qatar, Capri: None. E. Muller: None. D. McKnight: None. E. 2Baylor College of Medicine, Houston, TX, United States, Torti: None. L.C. Layman: None. D. Ryu: None. I. 3Nouvel Hôpital Civil, Strasbourg, France, 4Augusta Kong:None.S.Madan-Khetarpal:None.C.Kim:None. University, Augusta, GA, United States, 5Baylor Genetic Laboratories, Houston, TX, United States, 6Kennedy 
P08 .35D Krieger Institute, Baltimore, MD, United States, 7Lyon RNFT2,a novel gene causing intellectual disability; University Hospital, Lyon, France, 8INSERM, Dijon, functional evidence in Drosophila melanogaster French Southern Territories, 9Centre de Génétique, Dijon, France, 10Service de Génétique Clinique, Paris, France, R. Ataei1, M. Haddadi2, K. Kahrizi1, H. Najmabadi1 11StanfordChildren’sHealthatCPMC,SanFrancisco,CA, UnitedStates,12GeneDx,Gaithersburg,MD,UnitedStates, 1University of Social Welfare and Rehabilitation Sciences, 13Northern Illinois University, DeKalb, IL, United States, Tehran, Iran, Islamic Republic of, 2University of Zabol, 14Gyeongsang National University, Jinju, Korea, Republic Zabol, Iran, Islamic Republic of of, 15Children's Hospital of Pittsburgh, Pittsburgh, PA, United States, 16Chungnam National University, Daejeon, Introduction: Intellectual disability (ID) as the most Korea, Republic of prevalent disability in the world and a heterogeneous disease is one of the major unsolved issues in health care. PHF21Aencodesaproteinthatspecificallybindsunmethy- The advent of next generation sequencing (NGS) technol- lated H3K4 as part of a histone demethylase complex that ogy has resulted in an exponential increase in deciphering participates in suppression of neuronal gene expression. It of novel ID-causing genes. Whole exome sequencing had been associated with intellectual disability and (WES) in a part of large cohort study on 404 Iranian craniofacial anomalies, based on its deletion in Potocki- consanguineous families with autosomal recessive intellec- Shaffer syndrome (PSS) interval at 11p11.2 and its tual disability (ARID) led to the identification of a novel disruption in three patients with balanced translocations. likely pathogenic missense variant (cT1150C; p.
C384 R) in However, until now, individuals who carry deleterious RNFT2 gene. This variant is located in highly conserved sequencevariantswithinPHF21Ahavenotbeenidentified. zinc fingerdomainthat may change the protein structure in Moreover, the identity of a novel gene underlying awaytoreducethezinc2+ affinitytoproteinactivesiteand hypotonia or neurobehavioral phenotype at 11p11.2 consequently leading to possible alteration in the DNA remained cryptic. Here, we describe seven individuals bindingsite.Toprovidefunctionalevidencefortheeffectof who carry heterozygous intragenic sequence variants in this gene on cognition, we used transgenic PHF21A: a missense variant, which alters the last Drosophila model. nucleotide of an exon, four frameshift variants, and two Material and Methods: Using Gal4/UAS genetic tool identical nonsense variants. These variants are predicted to RNFT2-ortholog gene (CG13605) in DrosophilaAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1395 melanogasterwasdown-regulatedintheflybrainbyRNAi Medicine, Houston, TX, United States, 17iG
E3  Institute of mechanism. Then the impact of this gene manipulation on Genetics and Genomics of Geneva, Geneva, Switzerland learning ability and short-term memory of the flies were studied using olfactory conditioning assay. We analyzed two consanguineous families with intellectual Results: Remarkable decrease in olfactory memory per- disabilityinwhichhomozygousmissenselikelypathogenic formance indices were observed in the flies underwent variantswereidentifiedintheIQSE
C1  (NM_001134382.3) CG13605 down regulation when compared to control gen- gene. In the first family with two affecteds from Pakistan, otype (P < 0.05). the IQSE
C1  missense segregating variantwas (c.1028C>T: Conclusion: Our finding suggested the possible role for p.(Thr343Met)) while in the second family of three RNFT2 in functionality of Drosophila brain in terms of affecteds from Saudi Arabia, the missense variant was learningandshort-termmemorywhichsupportitsprobable (c.962G>A:p.(Arg321Gln)). Five affected individuals from role in inducing human cognitive impairment. the two families manifested a similar phenotype that R. Ataei: None. M. Haddadi: None. K. Kahrizi: None. includes intellectual disability, developmental delay, short H. Najmabadi: None. stature, aphasia/speech problems, and hypotonia. Affected individuals with the Arg321Gln biallelic variant also have 
P08 .36A early onset epilepsy. The X-linked paralog IQSE
C2  has BiallelicvariantsinIQSE
C1 causeintellectualdisability, previously been linked with intellectual disability and developmental delay and short stature epilepsy.MicewithaconditionalIqsec1deletionincortical neurons exhibited an increased density of dendritic spines M.Ansar1, A. Al-Otaibi2, H.Chung3,4, M.N.Elagabani5, with an immature morphology. The Drosophila ortholog of S. A. Paracha6, R. Scholz7, T. A. Magid2, M. T. Sarwar6, IQSE
C1 isschizo(siz).SizisbroadlyexpressedinCNSand S. F. Shah8, A. A. Qaisar9, P. Makrythanasis1,10, PNS from embryo to adult. RNAi knockdown of siz in E. Falconnet1, E. Ranza1,11,12, F. A. Santoni1,13, neurons does not affect viability, whereas glial specific J.Ahmed6,A.Al-Asmari14,H.Kornau5,7,H.Bellen3,4,15,16, knockdown exhibits severe pupal lethality, suggesting that S. E. Antonarakis1,11,17 siz has a critical role in glia rather than neurons. The identified IQSE
C1  missense variants behave assevere loss- 1Department of Genetic Medicine and Development, of-functionallelesinflygiventhatubiquitousexpressionof University of Geneva, Geneva, Switzerland, 2King Fahad humanIQSE
C1 istoxictotheflysothatwefailedtoobtain Medical City, National Neuroscience Institute, Riyadh, viable flies, whereas expression of the two missense Saudi Arabia, 3Department of Molecular and Human variants consistently produced viable animals. The pheno- Genetics,BaylorCollegeofMedicine,Houston,TX,United typic similarity of the patients in the two families, and the States, 4Jan and Dan Duncan Neurological Research functionalexperimentsinmiceandDrosophilasuggestthat Institute, Texas Children's Hospital, Houston, TX, United IQSE
C1  pathogenic variants cause intellectual disability, States, 5Neuroscience Research Center (NWFZ), Charité - developmental delay and shot stature, in the autosomal Universitätsmedizin Berlin, Berlin, Germany, 6Institute of recessive manner. Basic Medical Sciences, Khyber Medical University, M.Ansar:None.A.Al-Otaibi:None.H.Chung:None. Peshawar, Pakistan, 7Center for Molecular Neurobiology M.N. Elagabani: None. S.A. Paracha: None. R. Scholz: (ZMNH), University of Hamburg, Hamburg, Germany, None.T.A.Magid:None.M.T.Sarwar:None.S.F.Shah: 8Department of Medicine, KMU Institute of Medical None. A.A. Qaisar: None. P. Makrythanasis: None. E. Sciences, Kohat, Pakistan, 9Radiology department, Lady Falconnet:None.E.Ranza:None.F.A.Santoni:None.J. reading Hospital, Peshawar, Pakistan, 10Biomedical Ahmed: None. A. Al-Asmari: None. H. Kornau: None. Research Foundation of the Academy of Athens, Athens, H. Bellen: None. S.E. Antonarakis: None. Greece,11ServiceofGeneticMedicine,UniversityHospitals of Geneva, Geneva, Switzerland, 12current address, 
P08 .37B Medigenome, The Swiss Institute of Genomic Medicine, Deletion of KCNK9, an imprinted gene on 8q24.3 with Geneva, Switzerland, 13Department of Endocrinology maternal expression, is associated with dysmorphic DiabetesandMetabolism,UniversityhospitalofLausanne, features and developmental delays Lausanne, Switzerland, 14King Fahad Medical City, Pediatric Department Medical Genetics division, Riyadh, P. T. Bhola1, T. Young2, D. Stavropoulos2, P. Sabatini3, Saudi Arabia, 15Howard Hughes Medical Institute, M. T. Geraghty4 Houston, TX, United States, 16Department of Neuroscience and Program inDevelopmental Biology, Baylor College of 1Regional Genetics Program, Children’s Hospital of Eastern Ontario, Ontario, Canada, Ottawa, ON, Canada,1396 2LaboratoryMedicine,HospitalforSickChildren,Toronto, France, 6INSERM, UMR-1163, Institut Imagine, Paris, ON,Canada,3LaboratoryMedicine,UniversityofToronto, France Toronto, ON, Canada, 4Metabolics, Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada Mutations in MED12 gene have been described in association with syndromic et non-syndromic X-linked Introduction: KCNK9 imprinting (Birk-Barel) syndrome intellectual disability (XLID). Up to date at least three (MIM 612292) is a rare syndrome characterized by distinct XLID syndromes have been described: FG congenital hypotonia, dysmorphic features, developmental syndrome,Lujan-Frynssyndrome(LS)andOhdosyndrome delay and intellectual disability. It is caused by pathogenic (OSMKB). In the last years, thanks to the massive use of variants in KCNK9, which is an imprinted gene located on next generation sequencing techniques (NGS) it has been 8q24.3 and is normally expressed on the maternally possible to discover at least 13 others MED12 mutations inherited chromosome. To date, the small number of and to expand the phenotype of MED12-related disorders. reported cases of KCNK9 imprinting syndrome have been Here we report three subjects from a large non- attributed to 3 missense variants. There is no known consanguineous family presenting with a mild to severe phenotype associated with a deletion of KCNK9. ID,importantspeechdelay,behaviorproblems,dysmorphic Methods and Results: We describe the case of a 5 year facialfeaturesandhearingloss.NGSallowsustodetectthe oldmalewhopresentedatage3withglobaldevelopmental MED12missensevariantc.3883C>T(p.R1295C)carriedby delay and dysmorphic features including prominent thethreepatients.Thisvarianthasbeenreportedin2016by supraorbital ridges and a prominent nasal root. A chromo- Hu et al in one family from a big cohort of XLID somal microarray revealed a 0.014 Mb deletion on 8q24.3 unresolvedfamilies.Theclinical andphenotypicvariability of uncertain significance, encompassing 1 OMIM gene, between the patients described by the different authors KCNK9. This deletion was maternally inherited. Notably, through the last years is very wide, and it could be the proband’s mother had similar dysmorphic features and explained by the multiple functions of the MED12 protein intellectualdisability.ItwasdeterminedbySNPmicroarray in complex pathways. This clinical report contributes to that the proband’s mother herself had a de novo maternal expanding the phenotype associated with MED12 deletion on 8q24.3. mutations. Conclusions: This is the first report of a clinically E. Rubinato: None. S. Rondeau: None. F. Giuliano: affected mother and child with deletion of the imprinted None. M. Kossorotoff: None. M. Parodi: None. S. region 8q24.3, encompassing the gene KCNK9. Further Gherbi: None. J. Steffan: None. L. Jonard: None. S. studies will contribute to our understanding of the Marlin: None. mechanism and spectrum of KCNK9 associated disorders. P.T. Bhola: None. T. Young: None. D. Stavropoulos: 
P08 .40A None. P. Sabatini: None. M.T. Geraghty: None. Functional delineation of de novo heterozygous intragenic deletion in MED13L 
P08 .39D MED12missensemutationinathree-generationfamily: E. Siavrienė1, V. Mikštienė1,2, Ž. Maldžienė1,2, further evidences for a fourth distinct phenotype G. Petraitytė1, T. Rančelis1,2, A. Utkus1,2, E. Preikšaitienė1,2, V. Kučinskas1 E.Rubinato1,S.Rondeau2,F.Giuliano3,M.Kossorotoff4, M. Parodi5, S. Gherbi1, J. Steffan2, L. Jonard1,2, 1Department of Human and Medical Genetics, Institute of S. Marlin1,6 Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, 2Center for Medical 1Génétique Médicale, Centre de Référence des Surdités Genetics, Vilnius University Hospital Santaros Klinikos, Génétiques, Institut Imagine, Hôpital Necker, AP-HP, Vilnius, Lithuania Paris, France, 2Service de génétique moléculaire, Groupe hospitalierNeckerEnfantsmalades,AP-HP,Paris,France, Introduction: Heterozygous pathogenic variants in 3Service de Génétique Médicale, CHU Nice, Hôpital MED13L (MIM #608771) genecause intellectual disability l'Archet 2, Nice, France, 4Service de Neurologie and distinctive facial features with or without cardiac pédiatrique,CentreNationaldeRéférenceAVCdel’enfant, defects(MIM#616789).Thiscomplexneurodevelopmental Hôpital Necker, AP-HP, Paris, France, disorder is characterized by various phenotypic features 5Otorhinolaryngologie pédiatrique, Centre de Référence includingplagiocephaly, strabismus, clubfoot, poorspeech, des Surdités Génétiques, Hôpital Necker, AP-HP, Paris, anddevelopmentaldelay,whicharepresentinourproband.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1397 Materials and Methods: SNP-CGH followed by func- weight (BW), HC -5.9 SD, sloped forehead, scalp rugae, tional genome analysis was conducted for the proband. In and hyper- and hypopigmented macules (HHPM). At age order to elucidate the pathogenicity of the intragenic 13, he has spastic quadriparesis, partial complex seizures, MED13L gene deletion, proband’s total blood RNA was short stature, and severe intellectual disability without isolated and cDNA was synthesized. Subsequently, a speech. He is fed by gastrostomy tube. His microcephalic quantitativeRT-PCRusingTaqMangeneexpressionassays sister with HHPM, died hours after birth. In Family 2, two designed for MED13L gene was performed. Lastly, microcephalic Iraqi sisters, with consanguineous parents, MED13Lgenewassequencedinpatient'scDNAsampleby have a homozygous ANKL
E2  variant: c.686T>G (p. Sanger method. V229G). They have HC -8-10 SD, scalp rugae, short Results: A de novo 97.88 kb deletion in the cytoband stature (-2-3 SD), and HHPM. Both walk and talk with 12q24.21including3rdand4thexonsofMED13Lgenewas severe neurodevelopmental delay. In Family 3, a Northern detected.Furtherquantitativeexpressionanalysisofseveral European girl with HC -6 SD, without scalp rugae or MED13L exons disclosed the deletion of exons 3-4 but pigmentation, has two ANKL
E2  variants: c.325G>C (p. excluded the deletion of exons 1-2 and 16-17. The borders A109P); c.1421-1G>C. She walks & talks with mild- of the deletion in the coding region were narrowed by moderate neurodevelopmental delay. In Family 4, an Sangersequencing.Thedeletionspanningfromtheexon3rd Indian/Filipino girl has low birth weight (-7.08 SD), to 9th was determined. In silico, the deletion was predicted microcephaly (HC -7.08 SD), HHPM and two ANKL
E2  to result in truncated protein NP_056150:p.(Val104- variants: c.706C>T (p.R236*); c.1606C>T (p.R536C). She Glyfs*5) partly altering Med13_N domain and losing has a closed anterior fontanel and normal neurologic exam medPIWI and Med13_C domains. at2weeks.Allaffectedchildrenhaveseveremicrocephaly, Conclusions: Based on these findings, heterozygous simplified cortical gyri and variable developmental delay. deletionresultsinpartialhaploinsufficiencyoftheMED13L Frontal lobe foreshortening, corpus callosal dysgenesis, geneintheaffectedpatientduetotheprematuretermination scalprugae,andHHPMarecommonbutnotuniversal.The of the protein translation. triad of severe congenital microcephaly, scalp rugae and The work was funded by the Research Council of HHPM suggests this diagnosis. Lithuania (No. S-MIP-17-19/LSS-150000-1179, Ingenes R.D.Clark:None.A.Thomas:None.S.Michels:None. project). L. Mizerick: None. L. Robak: None. G.J. Demmler: E.Siavrienė:None.V.Mikštienė:None.Ž.Maldžienė: None. H.T. Chao: None. G. Mirzaa: None. None. G. Petraitytė: None. T. Rančelis: None. A. Utkus: None. E. Preikšaitienė: None. V. Kučinskas: None. 
P08 .42C Neurochondrin missense variant associated with 
P08 .41B autosomal recessive intellectual disability and epilepsy The clinical phenotype of ANKL
E2 -related microcephaly in 4 families A. Fatima1, J. Schuster1, J. Hoeber1, J. Klar1, L. Laan1, R. Fadoul1, Z. Ali2, M. A. Ali3, C. Castillejo-López1, R. D. Clark1, A. Thomas2,3, S. Michels4, L. Mizerick2,3, S. M. Baig2, N. Dahl1 L.Robak2,3,G.J.Demmler2,3,H.T.Chao2,3,G.Mirzaa5,6 1Department of Immunology, Genetics and Pathology, 1Loma Linda University School of Medicine, Loma Linda, Science for Life Laboratory, Uppsala University, Uppsala, CA, United States, 2Texas Children's Hospital, Houston, Sweden, 2Human Molecular Genetics Laboratory; Health TX, United States, 3Baylor College of Medicine, Houston, Biotechnology Division, National Institute for TX,UnitedStates,4SeattleChildren'sHospital,Seattle,WA, Biotechnology and Genetic Engineering (NIBGE), United States, 5University of Washington School of Fsisalabad, Pakistan, 3Department of Medical Medicine, Seattle, WA, United States, 6Center for Biochemistry and Microbiology, Uppsala Uinversity, Integrative Brain Research, Seattle, WA, United States Uppsala, Sweden Few patients with autosomal recessive ANKL
E2 -related Introduction: The NCDN gene encodes neurochondrin, congenital microcephaly have been described since Yama- predominantlyexpressedinneuraltissueswhereitmediates moto’s report in 2014. We describe four families (6 neural outgrowth, synaptic plasticity and signal transduc- children) with ANKL
E2 -related microcephaly, including tion. Neurochondrin acts as an endogenous modulator of the boy from the original report (Family 1). In Family 1, glutamatereceptormGluR5andinmice,depletionofNcdn two Hispanic siblings have ANKL
E2  variants: c.2344C>T causes epileptic seizures, depressive-like behaviors and (p.Q782X);c.1717C>G(p.
L573 V).Themalehadlowbirth impaired spatial learning.1398 Materialand Methods: We identified a consanguineous Paz, Madrid, Spain, 6CIBERER, Centro de Investigación Pakistanifamily segregatingmild intellectual disability and BiomédicaenReddeEnfermedadesRaras,ISCIII,Madrid, seizures in three children. Whole-exome sequencing was Spain, 7Neurología Pediátrica y Medicina Genética. performed on samples from two affected siblings. Human Instituto Pediátrico de Enfermedades Raras. Hospital Sant neuroblastoma line SH-SY5Y and CRISPR/Cas9 editing Joan de Deu, Barcelona, Spain was used to model loss of NCDN in vitro. Results: We identified a rare homozygous NCDN mis- Introduction: Bainbridge-ropers syndrome (BRPS) is a sense variant (NM_001014841.1:c.1246G>C) in the three neurodevelopmental disorder caused by mutations in affectedfamilymembers.Electroencephalography(EEG)of ASX
L3 . Patients with BRPS show delayed psychomotor two affected siblings revealed epileptic pattern whereas development, intellectual disability, speech alterations, brain MRI was normal. Using CRISPR/Cas9, we then hypotonia, poor growth and dysmorphic features. It is generated NCDN knockout (KO) in SH-SY5Y cells. The categorized as a syndromic cause of Autism spectrum KO cells exhibited significantly reduced neurite outgrowth disorder (ASD). Nowadays, 33 patients with BRPS have as compared to w.t. cells. Neurochondrin modulates the been reported. Our work expands the mutational spectrum activation of mGluR5 of importance for ERK1/2-phos- of the ASX
L3  with the genotype-phenotype characterizing phorylation and we then examined the phosphorylation of 11 new patients. ERK1/2 at position threonine 202. The ERK1/2-phosphor- Material and Methods: In a collaborative initiative we ylation was reduced in NCDN KO cells when compared to have identified 11 patients with neurodevelopmental dis- w.t.SH-SY5Ycells.Conversely,phosphorylationincreased orders and ASD phenotype with loss of function(LoF) when NCDN was overexpressed in both w.t. and KO SH- mutations in the ASX
L3  gene. Exome sequencing was used SY5Y cells. as a diagnostic tool and Sanger sequencing was used for Conclusion: NCDN loss of function in SH-SY5Y cells familial segregation. The mutational spectrum of ASX
L3  revealed impaired neurite outgrowth and reduced mGlu5R was revised in public_data (PubMed, Clinvar, SFARI). dependent ERK1/2-phosphorylation. Our data support a Results: We identified 10 new ASX
L3  LoF variants and role for neurochondrin in neurodevelopment and show that one recurrent mutation (c.3106C>T;p.Arg1036Ter). The a NCDN missense variant is associated with autosomal main clinical characteristics of our patients included recessiveintellectualdisabilityandepilepsy.Thisstudywas moderate-severe intellectual disability with ASD traits and supported by Swedish Research Council (2015-02424) and neuroconductual disorder including aggressively behavior Hjärnfonden (FO2018-0100) to ND. in adolescence. Dysmorphic features highly suggestive of A. Fatima: None. J. Schuster: None. J. Hoeber: None. ASX
L3  were delineated eyebrows and the skeletal pheno- J. Klar: None. L. Laan: None. R. Fadoul: None. Z. Ali: type.Sofar,77differentLoFmutations(48frameshifts,28 None. M.A. Ali: None. C. Castillejo-López: None. S.M. Stop Gain, 1 splicing) have been identified including our Baig: None. N. Dahl: None. present results. There are 3 recurrent mutations and 73 unique variants. 
P08 .43D Conclusions: The inclusion of new patients with BRPS Genotype-Phenotype correlation of 11 new Spanish increases the knowledge of mutational spectrum of ASX
L3  patients with Bainbridge Ropers syndrome and is essential to further delineate the phenotype of this syndrome. The recognition of this syndrome in the context I. Valenzuela1, E. Gabau2, C. Pardo-Domínguez3, of a neurodevelopmental disorder is indispensable for the J. Moreno-Ruiz3, P. Tirado-Requero4, F. Santos- orientation of molecular diagnosis. Simarro5,6, S. García-Miñaur5,6, M. Palomares-Bralo5,6, Grant: FIS_FEDER_PI16/00369; PERIS SLT002/16/ M. Serrano7, A. Cueto1, T. Vendrell1, A. Cordero1, 00174 M. Carcas1, I. Paramonov1, URDCAT consortium, I. Valenzuela: None. E. Gabau: None. C. Pardo- E. Tizzano1, I. Cusco1,6 Domínguez: None. J. Moreno-Ruiz: None. P. Tirado- Requero: None. F. Santos-Simarro: None. S. García- 1Department of Clinical and Molecular Genetics. Hospital Miñaur: None. M. Palomares-Bralo: None. M. Serrano: Vall d’Hebron, Barcelona, Spain, 2Clinical Genetics, None. A. Cueto: None. T. Vendrell: None. A. Cordero: Pediatrics Department, Parc Taulí Hospital Universitari, None. M. Carcas: None. I. Paramonov: None. E. Tiz- Institut d'Investigació i Innovació Parc Taulí., Sabadell, zano: None. I. Cusco: None. Spain, 3Department of Pediatrics. Hospital Costa del Sol, Marbella (Málaga), Spain, 4Neurología Infantil Hospital 
P08 .44A La Paz, Madrid, Spain, 5Instituto de Genética Médica y Neurodevelopmental disorders: a next generation Molecular (INGEMM)-IdiPAZ, Hospital Universitario LaAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1399 M. R. F. Reijnders1, T. Kleefstra2, L. E. L. M. Vissers2, Neurodevelopmental disorders (NDDs) are clinically and H. G. Brunner1,2 genetically extremely heterogeneous. Shared phenotypes areoftencausedbymutationsingenesinvolvedinthesame 1Department of Clinical Genetics, Maastricht University networks, complexes or pathways. Mutations in TCF4, Medical Center, Maastricht, Netherlands, 2Department of MEF2C, UB
E3 A, ZEB2 or ATRX cause overlapping, Human Genetics, Radboud University Medical Center, syndromic forms of severe NDDs with epilepsy, thus Nijmegen, Netherlands suggesting molecular and functional commonalities. TranscriptomeanalysisonRNAfrompatients’peripheral Since 2010 whole exome sequencing (WES) discovered a blood (mutations in either TCF4, MEF2C, ZEB2 or ATRX) large numbers of novel genes and neurodevelopmental revealed common transcriptional targets as pairwise com- disorders(NDDs),denotedhereas‘next-generationNDDs’. parisons of deregulated genes showed significant overlap. Yet, ~40% of NDD patients remain undiagnosed. There- Among these we found enrichment for GO terms such as fore,wepreviouslyestablishedacohortof826patientswith RNA-related and ubiquitin ligase-related processes and unexplained ID, a subtype of NDD, for whom trio-based significant enrichment of known NDD associated genes, WES was performed. ID severity ranged from mild (27%) indicating central roles in neurodevelopment. to severe (27%) and 32.2% of patients had other NDD- Next, we screened for genetic interactions in Drosophila subtypes.WeidentifiedpathogenicvariantsinknownNDD melanogaster by inducing ubiquitous or tissue specific genes in 28.6% ofpatients and386patients (46.7%) hadat knockdown or overexpression of each single gene and in least one de novo mutation in a gene not previously pairwise combinations. We assessed parameters such as associatedwithNDDs.Between2014and2018,wehaveso lethality, wing and eye morphology, neuromuscular junc- far confirmed seven of 586genes as next-generation NDD- tion morphology and bang sensitivity and climbing beha- gene (SON,TLK2,RA
C1 ,RHEB,US
P9 X,RAB11B,WAC). viour. We observed robust genetic interaction between Matchmaking was successful for all but one (RHEB), Ube3aandMef2bymultiplephenotypemodificationsupon resulting in a maximum of 35 additional patients (TLK2) simultaneous dosage manipulation in different tissues and underscoring the need for data-sharing for next- including glia, wing and eye. E.g. single overexpression of generation NDDs. Additionally, mutations in these genes either Ube3a or Mef2 resulted in mild eye phenotypes together only diagnosed ~1% of patients of our initial (rough surface or reduced bristles), respectively, while cohort, illustrating the rarity of next-generation NDDs. Of combinedoverexpressionledtoasevereeyesize reduction note, for US
P9 X, WAC and TLK2, most patients were anddisorganizedommatidiastructure,indicatingsynergistic mildly affected. Further systematic analysis of our cohort interaction. showed that overall a similar percentage of de novo Assessment of genes implicated in clinically overlapping mutations in known NDD genes was present in patients NDDs revealed commonly deregulated target genes and withmildID(27.9%)comparedtomoresevereID(27.2%), genetic interactions between Ube3a and Mef2 in the Dro- indicatingthatWESshouldnotberestrictedtopatientswith sophila model system, suggesting that such perturbed more severe phenotypes. Finally, we observed a challenge interactions contribute to the underlying pathomechanisms to translate the discovered next-generation NDDs to clinic. also in humans. To improve patient care, we propose an organizational J.Straub: None.T.Sauerer:None.A.Fliedner: None. model, in which parents have a key role. L. Distel: None. C. Suchy: None. A.B. Ekici: None. F. M.R.F.Reijnders:None.T.Kleefstra:None.L.E.L.M. Ferrazzi: None. A. Gregor: None. C. Zweier: None. Vissers: None. H.G. Brunner: None. 
P08 .46C 
P08 .45B Exome Sequencing and functional follow up reveal Genetic Interaction screen for severe MAB21
L1  and PP
P1 R21 loss of function causes neurodevelopmental disorders reveals a functional link distinctive syndromal neurodevelopmental phenotypes between Ube3a and Mef2 in Drosophila melanogaster M. Najafi J. Straub, T. Sauerer, A. Fliedner, L. Distel, C. Suchy, A. B. Ekici, F. Ferrazzi, A. Gregor, C. Zweier Radboudumc, Nijmegen, Netherlands Institute of Human Genetics, Friedrich-Alexander- Introduction: Next-generationsequencinghasbeeninstru- Universität Erlangen-Nürnberg, Erlangen, Germany mental in solving the genetic basis of rare inherited diseases, especially neurodevelopmental syndromes. A large number of novel genes has been identified in the last1400 years, however those account for only 50%-70% of all present five new male patients with pathogenic variants in cases. Further, functional workup is essential for precise NONO, with several novel features. phenotype definition and to understand the underlying Methods: All patients were ascertained after routine disease mechanisms. referral to their local Clinical Genetics service. Samples Materials andMethods: Using exome sequencing(ES), fromthreeindividualsunderwentexomesequencingaspart we have analysed a cohort of 100 Iranian individuals of the Wellcome Trust Deciphering Developmental Dis- affected by developmental delay/ intellectual disability. orders study. One patient had whole genome sequencing Results:While49%carriedcausativemutationsingenes performedaspartofthe100,000GenomesProject,andone previouslyassociatedwithneurodevelopmentaldisordersin had service trio exome analysis. human, we identified novel candidate genes in 29%. 22% Results:Fourpatientshadtruncatingpathogenicvariants remained unsolved. Amongst novel genes, we identified inNONO,andonesplicesite.Allwerematernallyinherited. MAB21
L1  loss of function resulting in cerebellar, ocular, All patients had significant developmental delay and facialandgenitalfeatures(COFGsyndrome)andPP
P1 R21 hypotonia. Three required gastrostomy tube placement, loss of function causing hypotonia, neurodevelopmental which has been reported in only two patients previously. delay, facial dysmorphism, eye sight loss, loss of white Twohadrelativemacrocephaly.Noneofthepatientsinour matter and thinning of the corpus callosum as well as series have left ventricular non-compaction. All had hepatosplenomegaly in some cases. We further established abnormal cranial MRI scans. Novel features include peri- that PP
P1 R21 was absent in fibroblasts of an affected ventricular leukomalacia, mild aortic root dilatation, and individual and consistent with the subcellular expression Ebsteinanomaly.Recognizableshareddysmorphicfeatures pattern and the clinical phenotype exhibiting features of include frontal bossing, infra-orbital grooves and long storage diseases, we found patient fibroblasts exhibited a fingers. delay in clearance of transferrin-488 while uptake was Discussion:Ourseriesfurtherexpandsanddelineatesthe normal. This suggests a role of PP
P1 R21 within the endo- phenotypic spectrum associated with variants in NONO. somal sorting process or endosome maturation pathway. This should prove useful to Geneticists, particularly in Conclusions: Our data demonstrates ES is an efficient interpretation of genomic data. diagnostic method for neurodevelopmental phenotypes. In T.M. Yates: None. M. Splitt: None. M. Holder: None. addition, we delineate novel neurodevelopmental syn- A. Kumar: None. C.L. Mercer: None. D.S. dromes and show that bi-allelic PP
P1 R21 loss of function Johnson: None. variants affect the endosomal sorting process or endosome maturation pathway. 
P08 .49B M. Najafi: None. Improved delineation of the clinical spectrum and identification of previously unreported respiratory 
P08 .47D problems in a large participatory cohort study of NONO-relatedsyndromicintellectualdisability:fivenew Koolen-deVriessyndromethroughtheGENIDAproject patients and carrier mothers with novel features F. P. Colin1, D. A. Koolen2, N. Collot1, T. Mazzucotelli1, T. M. Yates1, M. Splitt2, M. Holder3, A. Kumar4, P. Parrend3, J. L. Mandel1 C. L. Mercer5, D. S. Johnson1 1IGBMC, Illkirch-Graffenstaden, France, 2Radboud 1Clinical Genetics Dept, Sheffield Children's NHS University Medical Center, Nijmegen, Netherlands, 3iCube Foundation Trust, Sheffield, United Kingdom, 2Institute of laboratory, Strasbourg, France Genetic Medicine, Newcastle upon Tyne, United Kingdom, 3Guy's and St Thomas' NHS Foundation Trust, London, Introduction:About50recurrentCNVsand800genesare United Kingdom, 4Great Ormond Street Hospital, London, implicated in genetic forms of intellectual disability (ID) United Kingdom, 5University Hospital Southampton NHS with or without autism (ASD). The extreme heterogeneity Foundation Trust, Southampton, United Kingdom of these neurodevelopmental disorders and the rarity of identifiedcasesformanyoftheimplicatedgenesrendersthe Introduction: Pathogenic variants in the X-linked NONO goal of defining the clinical spectrum, comorbidities and gene are associated with intellectual disability, abnormal natural history a daunting task. We reasoned that a corpus callosum, left ventricular non-compaction, slender participatory approach would be a relevant alternative and build, macrocephaly and dysmorphism in males. Only used the Koolen-deVries syndrome (KdvS - 17q21.31del / seven patients have previously been reported. Here, we KANS
L1 mut) for a proof-of-concept.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1401 Methods and Results: We initiated GENIDA, a partici- Lehmann syndrome (BFLS), we performed PHF6 muta- patoryonlinecohortstudyforspecificgeneticcausesofID/ tional analysis that revealed a de novo missense mutation ASD (https://genida.unistra.fr), whereby clinical informa- within the PHD-type 2 domain; X-inactivation analysis tion is entered and updated by the family of the proband showed skewed X-inactivation in blood lymphocytes. The using a structured online questionnaire currently available second patient had severe delayed language development, in 5 languages, with answers from 650 participating intellectual disability (ID), hypermetropia, strabismus, families. The KdVS cohort is the largest, with 179 partici- linear skin hyperpigmentation and increasing obesity: pating families. Results obtained for the frequency of PWS-AS test and array-CGH resulted normal. Whole- behavioral problems, epilepsy or other previously reported exomesequencing(WES),surprisingly,disclosedadenovo comorbidities are consistent with published data. Our missensemutationinPHF6,inthesamefunctionaldomain approach allowed us to refine frequencies of specific man- as our first patient; in this case, X-inactivation analysis ifestations and their perceived severity. Inclusion of pro- showednormalX-inactivationinbloodlymphocytes.BFLS bands from a wide age range generates data on natural is an X-linked recessive disease, characterized by ID, history. A major finding is the identification of recurrent epilepsy, hypogonadism, hypometabolism, obesity and a respiratory problems in 40% of patients, including asthma typical facial gestalt; female carriers usually not show any (30 cases) and pneumonia (17 cases, mostly before 10y) findings or present only mild symptoms. To date, de novo that appear uncorrelated with reported laryngo/tracheoma- aberrations in PHF6 were reported in 13 females with a lacia or immunologic problems. variable phenotype, characterized by ID, characteristic Conclusion: Data comparisons show that parents of facial features, fingers and dental anomalies, only partially patients can adequately answer the questionnaire, and overlapping with BFSL as described in males. Molecular validate our participatory approach. The finding of novel genetics has opened a new path to understand the and relevant comorbidities has now to be translated in complexity of ID, mostly in female patients, where we improved healthcare. would tend to exclude a priori a known as X-linked F.P.Colin:None.D.A.Koolen:None.N.Collot:None. recessive condition. However, in cases with heterogeneous T. Mazzucotelli: None. P. Parrend: None. J.L. ID phenotypes, WES is the instrument to address the exact Mandel: None. diagnosis, as suggested in our second case. A. Pagliazzi: None. R. Artuso: None. G. Traficante: 
P08 .50C None. L. Giunti: None. A. Provenzano: None. G. For- Novel de novo mutations in PHF6: two unrelated zano: None. F. Peluso: None. F. Di Giovanni: None. G. females with Borjeson-Forssman-Lehmann syndrome Contrò: None. E. Bosi: None. A. La Barbera: None. S. Bargiacchi: None. S. Stagi: None. G. Merla: None. S. A. Pagliazzi1, R. Artuso2, G. Traficante2, L. Giunti2, Guarducci: None. M. Pantaleo: None. B. Lucherini: A. Provenzano1, G. Forzano1, F. Peluso1, F. Di None. S. Giglio: None. Giovanni1, G. Contrò1, E. Bosi1, A. La Barbera1, S. Bargiacchi2, S. Stagi3, G. Merla4, S. Guarducci2, 
P08 .51D M. Pantaleo2, B. Lucherini2, S. Giglio5 Elucidation of the phenotypic spectrum and genetic landscape in primary and secondary microcephaly 1Medical Genetics Unit, University of Florence, Florence, Italy, 2Medical Genetics Unit, Meyer Children's University P. Boonsawat1, P. Joset1, K. Steindl1, B. Oneda1, Hospital, Florence, Italy, 3Division of Pediatric L. Gogoll1, S. Azzarello-Burri1, F. Sheth2, C. Datar3, Endocrinology, Meyer University Children's Hospital, I. Verma4, R. Dua Puri4, M. Zollino5, R. Bachmann- University of Florence, Florence, Italy, 4Division of Gagescu1, D. Niedrist1, M. Papik1, J. Figueiro-Silva1, Medical Genetics, Fondazione IRCCS Casa Sollievo della R. Masood1, M. Zweier1, D. Kraemer1, S. Lincoln6, Sofferenza,SanGiovanniRotondo,Italy,5MedicalGenetics L. Rodan6,7, Undiagnosed Diseases Network (UDN), Unit, University of Florence, Meyer Children's University S. Passemard8,9, S. Drunat9, A. Verloes9, A. Horn10, Hospital, Florence, Italy H. Sticht10, R. Steinfeld11, B. Plecko11,12, B. Latal13, O. Jenni13, R. Asadollahi1, A. Rauch1,14,15 We report two unrelated female patients with variable cognitiveimpairmentanddistinctivefacialappearance.The 1Institute of Medical Genetics, Schlieren-Zürich, firstpatientshowedseveredevelopmentaldelay,thincorpus Switzerland,2FRIGE'sInstituteofHumanGenetics,FRIGE callosum (CC), prominent supraorbital ridges with House, Satellite, Ahmedabad, India, 3Sahyadri Medical synophrys, deep set eyes and fleshy earlobes: in order to Genetics and Tissue Engineering Facility, Kothrud, Pune validate our clinical suspicion of Borjeson-Forssman- and Bharati Hospital and Research Center Dhankawadi,1402 Pune,India,4InstituteofMedicalGenetics&Genomics,Sir P.Boonsawat:None.P.Joset:None.K.Steindl:None. Ganga Ram Hospital, Rajinder Nagar, New Delhi, India, B. Oneda: None. L. Gogoll: None. S. Azzarello-Burri: 5Institute of Genomic Medicine, Catholic University, None. F. Sheth: None. C. Datar: None. I. Verma: None. Gemelli Hospital Foundation, Rome, Italy, 6Division of R. Dua Puri: None. M. Zollino: None. R. Bachmann- Genetics and Genomics, Department of Pediatrics, Boston Gagescu: None. D. Niedrist: None. M. Papik: None. J. Children’s Hospital, Boston, MA, United States, Figueiro-Silva: None. R. Masood: None. M. Zweier: 7Department of Neurology, Boston Children’s Hospital, None. D. Kraemer: None. S. Lincoln: None. L. Rodan: Boston, Boston, MA, United States, 8Service de None.S.Passemard:None.S.Drunat:None.A.Verloes: Neuropédiatrie, Hôpital Universitaire Robert Debré, None. A. Horn: None. H. Sticht: None. R. Steinfeld: APHP,Paris,France,9DépartementdeGénétique,Hôpital None. B. Plecko: None. B. Latal: None. O. Jenni: None. Universitaire Robert Debré, APHP, Paris, France, R. Asadollahi: None. A. Rauch: None. 10Division of Bioinformatics, Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, 
P08 .52A Erlangen, Germany, 11Division of Pediatric Neurology, New patient with de novo nonsense PRR12 variant UniversityChildren’sHospitalZurich,Zurich,Switzerland, supports role of this gene in neurodevelopmental 12Department of Pediatrics and Adolescent Medicine, disorder and helps to define phenotypic spectrum DivisionofGeneralPediatrics,MedicalUniversityofGraz, associated with PRR12 haploinsufficiency Graz, Austria, 13Child Development Center, University Children’s Hospital Zurich, Zurich, Switzerland, S. Bendova1, A. Baxova2, M. Hancarova1, D. Prchalova1, 14NeuroscienceCenterZurich,UniversityofZurich,Zurich, V. Stranecky3, Z. Sedlacek1 Switzerland, 15Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland 1Department of Biology and Medical Genetics, Charles University2ndFacultyofMedicineandUniversityHospital Introduction: Microcephaly is a sign of many genetic Motol, Prague, Czech Republic, 2Department of Biology conditionsbuthasbeenrarelysystematicallyevaluated.We and Medical Genetics, Charles University 1st Faculty of therefore comprehensively studied the clinical and genetic Medicine and General University Hospital, Prague, Czech landscape of an unselected cohort of patients with Republic, Prague, Czech Republic, 3Department of microcephaly. Pediatrics and Adolescent Medicine, Diagnostic and Materials and Methods: We performed clinical assess- Research Unit for Rare Diseases, Charles University 1st ment, high-resolution chromosomal microarray analysis, Faculty of Medicine and General University Hospital, exome sequencing and functional studies in 62 patients Prague, Czech Republic, Prague, Czech Republic (58% with primary microcephaly (PM), 27% with second- ary microcephaly (SM), and 15% of unknown onset). The PRR12 gene (19q13.33) encodes a large (2036 Results: We found severity of developmental delay/ residues) proline-rich nuclear protein suspected to partici- intellectual disability correlating with severity of micro- pate in neural development. The protein interacts with cephalyinPM,butnotSM.Wedetectedcausativevariants FMRP and the gene has high constraint to loss-of-function in 48.4% of patients and found divergent inheritance and variation (gnomAD: 0 variants observed / 58 expected). variant pattern for PM (mainly recessive and likely gene- Three de novo loss-of-function PRR12 variants and one disrupting (LGD)) versus SM (all dominant de novo and translocation disrupting the gene have been reported in the evenly LGD or missense). While centrosome-related path- literature in patients showing global developmental delay, ways were solely identified in PM, transcriptional regula- intellectual disability, neuropsychiatric problems, eye and tion was the most frequently affected pathway in both SM vision abnormalities, dysmorphic features, hypotonia, and PM. Unexpectedly, we found causative variants in skeletal abnormalities, sleep problems and anxiety. Three different mitochondria-related genesaccountingfor~5%of other de novo PRR12 variants have been identified in large patients, which emphasizes their role even in syndromic studiesinadditionalpatientsfromwhomnooronlylimited PM. Additionally, we delineated novel candidate genes phenotype information is available. involvedincentrosome-relatedpathway(SPAG5,TED
C1 ), We describe a 3-year-old boy referred for developmental Wnt signaling (VP
S26 A, ZNRF3) and RNA trafficking delay, failure to thrive and congenital hypotonia. His facial (DDX1). features included short forehead, bilateral epicanthal folds, Conclusions: Our findings enable improved evaluation hooded upper eyelids, malar hypoplasia, and borderline and genetic counseling of PM and SM patients and further smallasymmetriclow-setears.Healsoshowedanxietyand elucidate microcephaly pathways. autistictraits,andhadpesplanusandtapereddigits.Exome sequencing revealed a de novo heterozygous PRR12Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1403 nonsense variant NM_020719.2(PRR12):c.3958C>T, p. microcephaly, moderate ID, spastic paraplegia, aggressive (Arg1320*)whichwasabsentfromalldatabases.Thefacial behaviour and convergent strabismus. ES revealed variants phenotype was consistent with previously reported cases, p.(Pro648Ser) and p.(Ile403Thrfs*80) in ALDH18A1. Her except that no significant abnormalities in structure and phenotype corresponded to autosomal recessive spastic function of the eyes were present. paraplegiatype9B(MIM616586).Patients3and4,asister Our findings support the role of PRR12 haploinsuffi- and brother with similar neurological impairment, showed ciency ina rare neurodevelopmental disorder,and show,in hypotonia and moderate ID. ES revealed variants p. accord with several other cases, that the eye phenotype (Ser893Arg) and p.(Leu311Trp) in PIGN, associated with originallydescribedasapartofthetypicalpresentationmay multiplecongenitalanomalies-hypotonia-seizuressyndrome be absent. Additional patients will further specify the phe- type 1 (MIM614080). All three conditions belong to very notype associated with de novo PRR12 variants. rare diseases unlikely to be diagnosed solely based on Supported by 17-29423A and 00064203. clinical evaluation and targeted testing. Careful evaluation S. Bendova: None. A. Baxova: None. M. Hancarova: of variants identified using ES, detailed phenotype re- None. D. Prchalova: None. V. Stranecky: None. Z. evaluation and thorough genotype-phenotype correlation is Sedlacek: None. needed to prevent misinterpretation of findings in such cases. Supported by 17-29423A and 00064203. 
P08 .53B M. Vlckova: None. M. Hancarova: None. J. Haber- Genotypefirstapproachinfourpatientswiththreerare lova:None.L.Rennerova:None.P.Fuchsova:None.M. autosomal recessive neurodevelopmental disorders Paclikova:None.S.Bendova:None.D.Prchalova:None. V. Moslerova: None. M. Kudr: None. V. Stranecky: M. Vlckova1, M. Hancarova1, J. Haberlova2, None. M. Havlovicova: None. Z. Sedlacek: None. L.Rennerova3,P.Fuchsova2,M.Paclikova2,S.Bendova1, D. Prchalova1, V. Moslerova1, M. Kudr2, V. Stranecky4, 
P08 .54C M. Havlovicova1, Z. Sedlacek1 SETD1A Loss of function causes a distinct neurodevelopmental disorder in human and impaired 1Department of Biology and Medical Genetics, Charles memory in Drosophila further highlighting a conserved University2ndFacultyofMedicineandUniversityHospital role of H3K4 methylation in brain function Motol, Prague, Czech Republic, 2Department of Paediatric Neurology,CharlesUniversity2ndFacultyofMedicineand J. Kummeling1, D. Stremmelaar2, N. Raun3, University Hospital Motol, Prague, Czech Republic, M. Reijnders4, C. Man5, M. Schepens5, R. Pfundt2, 3Paediatric Neurology, Usti nad Labem, Czech Republic, J. Kramer3, T. Kleefstra1 4Department of Paediatrics and Adolescent Medicine, Diagnostic and Research Unit for Rare Diseases, Charles 1DepartmentofHumanGeneticsRadboudumcandDonders University 1st Faculty of Medicine and General University Centre of Medical Neuroscience, Nijmegen, Netherlands, Hospital, Prague, Czech Republic 2Department of Human Genetics Radbdoudumc, Nijmegen, Netherlands, 3Department of Biology, Western University, Neurodevelopmentaldisordersareaheterogeneousgroupof London, ON, Canada, 4Department of Clinical Genetics, very rare conditions which make up a significant part of MUMC+,Maastricht,Netherlands,5DepartmentofHuman agendaofmedicalgeneticists.Targeteddiagnosticmethods Genetics Radboudumc, Nijmegen, Netherlands have a limited chance to reveal their aetiology. Global "genotypefirst"approachessuchasexomesequencing(ES) Defects in histone methyltransferases (HMTs) are a major have a better diagnostic yield. However, their results and contributing factor to Neurodevelopmental disorders the genotype-phenotype correlation must be thoroughly (NDDs). Loss-of-function (LoF) variants of SETD1A revised to prevent misdiagnosis due to the lack of (KMT2F), one of the genes involved in histone 3 Lysine experience with rare conditions. We present four patients 4 (H3K4) methylation, have been identified in several withthreesuchconditionsdiagnosedbyES.Inallcasesthe individuals from large schizophrenia cohort studies. Inter- neurological impairment was dominant, and dysmorphic estingly, dominant gene mutations were also identified in andotherfeatureswereunspecificorabsent.Patient1wasa children with developmental delay. To provide further girl with progressive spastic tetraplegia, dysarthria and insight in the somatic and behaviour profile, we further intellectual disability (ID). ES identified variants p. characterized the SETD1A associated Mendelian syndrome (Trp1253*) and p.(Lys849*) in AL
S2 . Phenotype revision bycollectingthemolecularandclinicalfeaturesof15sofar supportedthediagnosisofjuvenileprimarylateralsclerosis unpublished individuals with SETD1A mutations via a (MIM205100). Patient 2 was a girl with short stature, GeneMatcher collaboration. Furthermore, to gain insight1404 into the role of SETD1A in fundamental learning and Señora de la Merced, Tucumán, Argentina, 17Hospital memoryprocesses,westudiedaDrosophilaknockdownof Clínico Universidad de Chile, Santiago de Chile, Chile, the orthologue Set1. 18Clínica Alemana, Santiago de Chile, Chile, The cohort mainly comprised de novo variants that pre- 19Corporación Sanitaria Parc Taulí,, Sabadell, Spain, dict a loss of function with c.4582-2_4582delAG being a 20Hospital Virgen del Rocio, Sevilla, Spain, 21Hospital recurrent mutation resulting in intron retention. The pre- Universitario La Paz. Servicio de Neuropediatría, Madrid, dicted LoF of SETD1A leads to a distinct set of symptoms Spain, 22Q-Genomics Laboratory, Barcelona, Spain, comprising global developmental or intellectual disability, 23UnidaddeGenética,HospitalVirgendelaSalud,Toledo, subtle facial features, behaviour and psychiatric problems. Spain, 24Hospital Son Llàtzer, Palma de mallorca, Spain In the Drosophila Set1 knock down, short- and long-term courtship memory were significantly reduced. Phelan-McDermid syndrome (PMS; OMIM 606232), Whiletheprecisebiologicalpathogenicmechanismshave results either from the loss of genetic material at the distal yet to be clarified, disturbed H3K4 methylation likely region of the long arm of chromosome 22 that including underlies this disorder, underscribing the role of H3K4 SHANK3gene,orbypointmutationsinthisgene.SHANK3 methyltransferases in memory, developmental disability or codes for a structural protein, which plays a central role in neuron function in general. theformationofthepostsynapticterminals,aswellasinthe J.Kummeling:None.D.Stremmelaar:None.N.Raun: maintenanceofsynapticstructures.Sofar,morethan1,200 None.M.Reijnders: None.C.Man:None.M.Schepens: cases have been already reported; a non-specific phenotype None. R. Pfundt: None. J. Kramer: None. T. hasemergedincludingglobaldevelopmentaldelay(>98%), Kleefstra: None. absent to severely delayed speech (>98%), severe neonatal hypotonia (>98%), normal to accelerated growth (95%), 
P08 .55D and minor dysmorphic features, among others. We here Clinical and laboratory management of the largest present the largest cohort of Spanish patients with PMS; cohort of Spanish individuals with Phelan McDermid 181 (mainly from Spain (151) and Latin-America (30 syndrome cases). Patients were characterized by means of deep phenotyping, chromosomal microarrays, and other genetic J. Nevado1,2, M. Palomares1,2, S. García-Miñaúr1,2, approaches (including MLPA, FISH and Karyotype). We M. Mori1,2, F. Santos1,2, E. Vallespín1,2, P. Barrúz1, compareclinical,geneticandfollow-upcharacteristicswith J. A. Tenorio1,2, C. Bel-Fenellós3, E. Guillén-Navarro4,5, previouspublishedseriesofpatientswithPMS.Inaddition, J. Rosell6,7, M. Milá8,9, M. Del Campo10, G. Obregón11, wepresentclinical-moleculardatafromthiscohort;mostof C. Orellana12, H. Pachajoa13, E. Galán14, them, with deletions at 22q13.3 band, including SHANK3 J.C.Cigudosa15,C.Saleme16,S.Castillo17,18,E.Gabau19, anddescribed5newpointmutationsinthisgeneassociated S. Borrego20, P. Tirado21, A. Barcia20, L. Pérez-Jurado22, to PMS. This study set up clinical and laboratory manage- R. Mena1, A. Moresco11, P. García-Murillo23, J. Suela15, ment for the establishment of possible genotype-phenotype Á. Pérez-Granero24, V. López-González4, M. J. Ballesta4, correlations. Based on our data and other previously L. Rodríguez-Revenga8, R. Lleuger1, L. Armengol22, published we propose at first time a complete laboratory C. Peña1, S. Martín1, R. Martín-Arenas1, V. Fernández- management algorithm to verify all the genetic aspects in Montaño1, V. Gómez del Pozo1, B. Fernández1,2, PMS individuals and related, as well as a correct genetic E. Mansilla1,2, I. P. Vallcorba1, Asociación Síndrome counselling. Phelan McDermid-España, P. D. Lapunzina1,2 J. Nevado: None. M. Palomares: None. S. García- Miñaúr: None. M. Mori: None. F. Santos: None. E. 1INGEMM-IdiPaz, Madrid, Spain, 2CIBERER, Madrid, Vallespín: None. P. Barrúz: None. J.A. Tenorio: None. Spain, 3Dpto. Investigación y Psicología en Educación, C. Bel-Fenellós: None. E. Guillén-Navarro: None. J. Fac.deEducación.UCM,Madrid,Spain,4HospitalVirgen Rosell: None. M. Milá: None. M. Del Campo: None. G. de la Arrixaca, Murcia, Spain, 5CIBERER, Murcia, Spain, Obregón: None. C. Orellana: None. H. Pachajoa: None. 6Hospital Son Llàtzer, Palma de Mallorca, Spain, E. Galán: None. J.C. Cigudosa: None. C. Saleme: None. 7CIBERER, Palma de Mallorca, Spain, 8Hospital Clinic, S. Castillo: None.E. Gabau: None. S. Borrego:None. P. Barcelona,Spain,9CIBERER,Barcelona,Spain,10Hospital Tirado: None. A. Barcia: None. L. Pérez-Jurado: None. Vall D´Hebron, Barcelona, Spain, 11Hospìtal Juan P. R. Mena: None. A. Moresco: None. P. García-Murillo: Garrahan, Buenos Aires, Argentina, 12Hospital La Fé, None. J. Suela: None. Á. Pérez-Granero: None. V. Valencia, Spain, 13Universidad Icesi, Cali, Colombia, López-González: None. M.J. Ballesta: None. L. Rodrí- 14Hospital Materno-Infantil Infanta Cristina, Badajoz, guez-Revenga: None. R. Lleuger: None. L. Armengol: Spain,15NIM-Genetics,Madrid,Spain,16MaternityNuestra None. C. Peña: None. S. Martín: None. R. Martín-Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1405 Arenas:None.V.Fernández-Montaño:None.V.Gómez 
P08 .57B delPozo:None.B.Fernández:None.E.Mansilla:None. Identification of compound heterozygous SNX14 I.P. Vallcorba: None. P.D. Lapunzina: None. variants in a Portuguese SCAR20 family by a combination of deep phenotyping, exome sequencing 
P08 .56A and targeted quantitative PCR Functional analysis of a novel c.899+1G>A variant in SL
C9 A6 gene N. Maia1,2, G. Soares3, T. Temudo4, I. Marques1,2, B. Rodrigues1,2, A. M. Fortuna3,2, R. Santos1,2, A. de G. Petraitytė1, E. Siavrienė1, V. Mikštienė1,2, Ž. Brouwer5, P. Jorge1,2 Maldžienė1,2, T. Rančelis1,2, A. Utkus1,2, E. Preikšaitienė1,2, V. Kučinskas1 1Unidade de Genética Molecular, Centro de Genética Médica Jacinto de Magalhães (CGMJM), Centro 1Department of Human and Medical Genetics, Institute of Hospitalar Universitário do Porto (CHUP, EPE), Porto, Biomedical Sciences, Faculty of Medicine, Vilnius Portugal, 2Unidade Multidisciplinar de Investigação University, Vilnius, Lithuania, 2Center for Medical Biomédica (UMIB), Instituto de Ciências Biomédicas Abel Genetics, Vilnius University Hospital Santaros Klinikos, Salazar (ICBAS), Universidade do Porto, Porto, Portugal, Vilnius, Lithuania 3Unidade de Genética Médica, Centro de Genética Médica Jacinto de Magalhães (CGMJM), Centro Hospitalar Introduction:SL
C9 A6(MIM#300231)isacausativegene Universitário do Porto (CHUP, EPE), Porto, Portugal, for Christianson type syndromic mental retardation, also 4Serviço de Neurologia Pediátrica, Centro Hospitalar known as Christianson syndrome, which is inherited in X- Universitário do Porto (CHUP, EPE), Porto, Portugal, linked dominant manner (MRXSCH; MIM# 300243). We 5Department of Human Genetics, Donders Institute for providetheresultsofthefunctionalanalysisofasplicesite Brain, Cognition and Behaviour, Radboud University variantc.899+1G>AintheSL
C9 A6geneidentifiedtothree Nijmegen, Nijmegen, Netherlands affected individuals in one family. Materials and Methods: SC
L9 A6 gene variant Pathogenic variants in the SNX14 gene are implicated in NC_000023.11(NM_001042537.1):c.899+1G>A was pre- AutosomalRecessiveSpinocerebellarAtaxia20(SCAR20), viously detected by whole exome sequencing in two arareconditioncharacterizedbyintellectualdisability,lack affected brothers and their mother. To justify the patho- of speech, ataxia with progressive cerebellar hypoplasia, genicityofthevarianttotalbloodRNAofoneaffectedmale coarse facies and macrocephaly. We describe a Portuguese was isolated, template cDNA was synthesized and family withtwosiblings presentingsimilarclinical features sequencing of SL
C9 A6 gene exons 5-8 was performed by caused by compound heterozygous variants in SNX14. A Sanger method. heterozygousnonsensevariantc.1195C>Tp.(Arg399*)was Results: SL
C9 A6 gene donor splice site variant initiallyidentifiedbyexomesequencing.Duetophenotypic NC_000023.11(NM_001042537.1):c.899+1G>A was similarity with previously published SCAR20 patients, examined by computational algorithms and predicted to further investigation led to the identification of the second affect mRNA splicing. Sanger sequencing of cDNA heterozygous variant c.(612+1_613-1)_(1171+1_1172-1) revealedthatc.899+1G>Aproducesskippingofexon6.In del using targeted quantitative PCR. Reverse transcriptase silico, this leads to a frameshift in cDNA and results in a PCR confirmed the frameshift r.613_1171del p. premature stop codon NP_001036002.1:p.(Val264Alaf- (Val205Argfs*47).Breakpointcharacterizationisunderway sTer3). The truncated protein lacks several transmembrane but preliminary results indicate that the underlying helices and a C-terminal domain. mechanism appears to be Alu-induced non-allelic homo- Conclusions: Our study demonstrates that SL
C9 A6 gene logous recombination. Our results describe the first non- splicesitevariantNC_000023.11(NM_001042537.1):c.899 consanguineous SCAR20 family carrying compound het- +1G>A affects mRNA splicing and leads to a truncated erozygouspathogenicvariantsintheSNX14.Inconclusion, protein product, which is the cause of Christianson syn- this case emphasizes the role of Sorting nexin-14 in drome in affected family members. neurodevelopment and cognitive impairment, and high- The work was funded by the Research Council of lights the value of detailed clinical evaluation and deep Lithuania (No. S-MIP-17-19/LSS-150000-1179, Ingenes phenotyping to disclose the molecular defect underlying a project). highly heterogeneous disease suchasintellectual disability. G.Petraitytė:None.E.Siavrienė:None.V.Mikštienė: Funding:UMIBissupportedbyNationalFundsthroughthe None.Ž.Maldžienė:None.T.Rančelis: None.A.Utkus: FCT-Fundaçãopara aCiênciaeaTecnologia(Portuguese None. E. Preikšaitienė: None. V. Kučinskas: None. national funding agency for science, research and1406 technology)intheframeworksoftheUID/Multi/0215/2016 described (De Rubeis et al., 2014); variant calling was project - Unit for Multidisciplinary Research in Biomedi- performed using a bioinformatics pipeline adapted for dif- cine - UMIB/ICBAS/UP.Nuno Maia received a research ferent patterns of inheritance. grant 2015 DEFI-CHUP, E.P.E. Results: We identified one patient with a de novo likely N. Maia: None. G. Soares: None. T. Temudo: None. I. pathogenic TLK2 variant (p.Asp529Gly) and a family with Marques: None. B. Rodrigues: None. A.M. Fortuna: three siblings who inherited a nonsense variant from an None. R. Santos: None. A. de Brouwer: None. P. affected mother (p.Glu453*). Finally, we report a de novo Jorge: None. 39-kb deletion encompassing the TLK2 and MR
C2  genes. Clinicalphenotypespartiallyoverlappedwithknowncases: 
P08 .58C facial dysmorphisms were present in all patients, while Two de novo and one familiar cases of TLK2-associated intellectual disability and microcephaly were not identified intellectual disability confirm disease variable in the patient with the 39-kb deletion, where the skeletal expressivity anomalies were predominant. Conclusion: Our study describes 6 new cases from 3 L. Pavinato1, E. Giorgio1, V. Antona2, D. Carli3, familieswithTLK2-associateddisease.Ourdatasupportthe K. Ranguin4, C. Colson4, S. De Rubeis5,6,7, T. Pippucci8, recentreportthathaploinsufficiencyofthisgeneisinvolved P. Dimartino9, M. Scaramuzzino1, S. Cardaropoli3, in heterogeneous forms of intellectual disability. A. Ciolfi10, C. Radio10, J. Buxbaum5,6,7, M. Tartaglia10, L.Pavinato:None.E.Giorgio:None.V.Antona:None. A. Brusco1 D. Carli: None. K. Ranguin: None. C. Colson: None. S. De Rubeis: None. T. Pippucci: None. P. Dimartino: 1Department of Medical Sciences, University of Turin, None.M.Scaramuzzino:None.S.Cardaropoli:None.A. Turin,Italy,2DepartmentofSciencesforHealthPromotion Ciolfi: None. C. Radio: None. J. Buxbaum: None. M. and Mother and Child Care "G. D'Alessandro", University Tartaglia: None. A. Brusco: None. of Palermo, Palermo, Italy, 3Department of Pediatrics and Public Health and Pediatric Sciences, University of Turin, 
P08 .59D Turin, Italy, 4Centre de référence Maladies rares et Intellectual disability: Identification of novel genes and Anomalies du développement, Service de génétique, Caen, expansion of genetic and phenotype spectrum by France, 5Seaver Autism Center for Research and multicentercollaboration Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 6Department of Psychiatry, Icahn J. Stephen1, S. Nampoothiri2, J. D. Burke1, K. Steindl3, School of Medicine at Mount Sinai, New York, NY, United N.Balanda4,P.Joset3,A.Shukla5,UndiagnosedDiseases States, 7The Mindich Child Health and Development Network members, T. Ben-Omran6, K. M. Girisha5, Institute, Icahn School of Medicine at Mount Sinai, New R. Ali6, A. Rauch3, J. A. Martinez-Agosto7, York,NY,UnitedStates,8MedicalGeneticsUnit,Polyclinic F. S. Alkuraya8,9, W. A. Gahl1,4,10, M. V. Malicdan1,4,10 Sant'Orsola-Malpighi University Hospital, Bologna, Italy, 9Department of Medical and Surgical Sciences, University 1SectionofHumanBiochemicalGenetics,MedicalGenetics of Bologna, Bologna, Italy, 10Genetics and Rare Diseases Branch, National Human Genome Research Institute, Research Division, Ospedale Pediatrico Bambino Gesù, NationalInstitutesofHealth,Bethesda,MD,United States, Rome, Italy 2Department of Pediatric Genetics, Amrita Institute of Medical Sciences and Research Center, Cochin, India, Introduction:TheTousled-LikeKinase2(TLK2)genehas 3Institute of Medical Genetics, University of Zurich, recently been associate with “Mental Retardation Auto- Schlieren-Zurich 8952, Switzerland and radiz – “Rare somalDominant57”(MIM:618050),aneurodevelopmental Disease Initiative Zurich, Clinical Research Priority disorder characterized by a highly variable phenotype, Program for Rare Diseases University of Zurich”, Zurich, including mild to moderate intellectual disability, beha- Switzerland, 4NIH Undiagnosed Diseases Program, vioural abnormalities, facial dysmorphisms, microcephaly, NHGRI and the Common Fund, National Institutes of epilepsy and skeletal anomalies. The role of TLK2 in brain Health, Bethesda, MD, United States, 5Department of is still unknown. Within the Autism Sequencing Con- Medical Genetics, Kasturba Medical College, Manipal sortium (ASC) project, we identified new patients with Academy of Higher Education, Manipal, India, 6Clinical variants in the TLK2 gene by whole-exome and Metabolic Genetics, Department of Pediatrics, Hamad sequencing (WES). MedicalCorporation,Doha,Qatar,7DepartmentofHuman Methods:DNAsamplesfromtriosweresequencedatthe Genetics, David Geffen School of Medicine, University of BroadInstituteonIlluminaHiSeqsequencersaspreviously California,LosAngeles,CA,UnitedStates,8DepartmentofAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1407 Genetics, King Faisal Specialist Hospital and Research 1DepartmentofMedicalGenetics,LaTimoneHospital,AP- Center,Riyadh,SaudiArabia,9DepartmentofAnatomyand HM, Marseille, France, 2Aix Marseille Univ, INSERM, Cell Biology, College of Medicine, Alfaisal University, MMG, Marseille, France, 3Department of Neuropediatrics, Riyadh, Saudi Arabia, 10Office of the Clinical Director, La Timone Hospital, AP-HM, Marseille, France National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, United States Pathogenicvariantsingenesencodingproteinsbelongingto Trafficking Protein Particle (TRAPP) complex have Intellectual disability (ID), a group of neurodevelopmental recentlybeendescribedinseveralhumandiseasesincluding disorders with a global prevalence approximating 2-3% intellectual disability. with severe ID occurring 0.5-1%, is a frequent reason for We report two siblings with a clinical presentation over- referral to pediatric genetics clinics. ID is genetically and lapping TRAPP
C9 -related disorder (MIM #613192). Preg- phenotypically heterogeneous and can be categorized into nancy and delivery was uneventful. First medical concerns syndromic and non-syndromic forms. Although next appeared before oneyear ofage duetohypotonia andpoor generation sequencing technologies have uncovered more contact. Patients then developed severe intellectual dis- than a thousand underlying genetic causes, many cases ability with neither independent walking nor speech at remain undiagnosed. From our cohort of patients with current age of 11 and 8 yo. They also had stereotypic hand varyingdegreesofID,wegeneticallyevaluated26families movements as well as MRI abnormalities, such as thin whose probands manifested with syndromic intellectual corpuscallosumandcorticalatrophy.Theyhadnoseizures. disability,globaldevelopmentaldelay,andbrainmalforma- Extensive metabolic screening, CGH-array and Intellectual tions. Likely pathogenic variants in known genes were Disability gene panel sequencing were normal. Whole identified in 57% (15/26), novel genetic causes in 20% (5/ exome sequencing revealed that both affected siblings car- 26) and no pathogenic variants were found in 23% (6/26). riedanovelhomozygousvariant(c.367C>T(NM_016209), For three novel genes of unknown function, matchmaking p.(Gln123*),hg19:chr16:88926373C>T)intheTRAPP
C2 L platforms and multi-center collaboration identified an gene. The variant was inherited from heterozygous con- additional 14 families. One novel gene is TMEM94, in sanguineous parents. which bi-allelic truncating variants were identified in 10 This is the first description of a homozygous loss-of- probands from 6 families; all had syndromic ID, speech function variant in the TRAPP
C2 L gene. Only biallelic delay, facial dysmorphisms and congenital heart defects. missense variants in TRAPP
C2 L (*610970) have been We have shown that Tmem94 is essential for neurologic previously reported in three patients with global develop- and cardiovascular development in mice. We also demon- mental delay, microcephaly, dystonia, tetraplegia, rhabdo- strated that, in human cells, TMEM94 is a novel protein myolysis, encephalopathy and epilepsy (Sacher et al. 2018, localized in the centrosome, and may very well have Milevetal.2018).TRAPP
C2 L(TraffickingProteinParticle importantrolesinvolvedincelldivisionandmetabolism.In Complex 2-Like) and TRAPP
C9  proteins belong to the conclusion,theidentificationofnovelIDgenesisfacilitated humanTRAPPIIcomplex,involvedinvesicletraffickingin by matchmaking platforms and collaborative interactions. the secretory pathway by mediating contacts between Efficient analyses using cell and model organisms provide vesicles and target membranes. Our findings suggest that supporting data for diagnosis and understanding of gene loss-of-function variants in these two genes may cause function. similar phenotypes. Additional cases are needed to confirm J. Stephen: None. S. Nampoothiri: None. J.D. Burke: ourfindingsandbetterdelineatetheclinicalspectrumofthis None. K. Steindl: None. N. Balanda: None. P. Joset: TRAPPopathy. None. A. Shukla: None. T. Ben-Omran: None. K.M. M.Abaji:None.C.Ravix:None.F.Riccardi:None.B. Girisha: None. R. Ali: None. A. Rauch: None. J.A. Chabrol: None. L. Villard: None. N. Philip: None. Martinez-Agosto: None. F.S. Alkuraya: None. W.A. Gahl: None. M.V. Malicdan: None. 
P08 .61B ExpandingthephenotypicspectrumofTRIT1mutatins, 
P08 .60A a cause of severe autosomal recessive microcephaly A homozygous loss-of-function variant in the TRAPP
C2 Lgenecausesaneurodevelopmentaldisorder T. Smol1,2, P. Brunelle1, O. Boute-Benejean3,2, overlapping TRAPP
C9 -related disorder J. A. Basseti4, M. Figeac5, L. Faivre6,7, F. Petit3,2, C. Thauvin-Robinet6,7, Q. Thomas6, F. Tran-Mau- M. Abaji1, C. Ravix2, F. Riccardi1,2, B. Chabrol3, Them6,7, S. Manouvrier-Hanu3,2, J. Ghoumid3,2 L. Villard1,2, N. Philip1,21408 1CHU Lille, Institut de Genetique Medicale, Lille, France, J. Courraud1, A. Quartier1, I. Boujelbene1, 2Université de Lille, EA7464 RADEME "Research team on V. Kalscheuer2, J. Mandel1, A. Piton1 rare developmental and metabolic diseases", Lille, France, 3CHU Lille, Clinique de Genetique, Lille, France, 4Weill 1IGBMC, Strasbourg, France, 2Max Planck Institute, Cornell Medicine, Department of Pediatrics, New-York, Berlin, Germany NY, United States, 5Université de Lille, Functional Genomics Platform, Lille, France, 6CHU Dijon, Centre de IntellectualDisability(ID)isaneurodevelopmentaldisorder Génétique, Dijon, France, 7Centre de Référence Maladies characterized by significant genetic contribution and Rares "Anomalies du Développement et Syndromes heterogeneity. While exome sequencing has revolutionized Malformatifs de l'Interrégion Est", Dijon, France theidentificationofnovelIDgenesandpathogenicvariants, a huge challenge that remains is the interpretation of the Introduction: Deciphering genetic basis and identifying vast number of Variants of Unknown Significance (VUS). new candidate genes in autosomal recessive microcephaly Acombinationofgenetic,clinicalandfunctionalarguments require high throughput sequencing strategies and data isessentialforbestinterpretingtheseVUS.Developmentof sharing. We identified compound heterozygous variants in functionalteststocharacterizeVUSeffectsareimportantto TRIT1 gene, encoding a protein involved in i6A37 tRNA make a diagnosis but also to dissect the function of the modification. The purpose of our work was to characterize concerned proteins. We illustrate this question by present- the clinical and molecular spectrum that result from ing functional studies performed to reclassify VUS in three pathogenic TRIT1 variants. Patients and methods: We used ID genes. We first looked at expression and localization of thematchmakingexchangeplatforms,PhenomeCentraland mutant proteins by overexpressing them. For NLGN3, we GeneMatcher to recruit patients with TRIT1 pathogenic used the unfolded protein response (UPR) as a read-out as variants. Clinical and molecular data were assessed and theinitialpathogenicvariantsidentifiedwasshowntocause compared to the four previously published families. endoplasmicreticulumstress.ForDYRK1A,whichrequire Results:Weidentifiedthreenewpatientswithcompound anautophosphorylationtobeactivated,westudytheability heterozygous variants in TRIT1 gene. All variations were of mutant proteins to autophosphorylate themselves. As it inherited from a healthy parent in heterozygous state. was shownthat DYRK1Aand PQB
P1  might regulate gene Taking into account published cases, all patients presented expressionandsplicing,weanalyzedtranscriptomicprofiles moderate to severe ID, seizures and severe microcephaly. in patients’ cells or by loss-of-function of the genes in Cerebral atrophy or dysplasia of corpus callosum could be humanneuronalprecursorstosortoutmolecularsignatures. noted in half of patients. In most of cases, each compound Wehavebeenabletoreclassifytwo-thirdsofVUSintothe state associated one missense and one truncating variation. pathogenic categories and we are currently developing Loss of function variants, considered as pathogenic, pre- novel approaches to characterize the effect of the last third. sentedamean allelecount of75inGnomADdatabase.All The better comprehension of mechanisms involved in but one involved variant were reported many times in het- monogenic forms of ID and the development of functional erozygous state in GnomAD [range 2 - 139]. tests for missense variants will be useful to improve Conclusions: Haplo-insufficiency of TRIT1 causes an diagnosis of patients. emerging clinical syndrome characterized by moderate to J. Courraud: None. A. Quartier: None. I. Boujelbene: severe ID, microcephaly and epileptic encephalopathy. None. V. Kalscheuer: None. J. Mandel: None. A. Allele counts for each known pathogenic variation in Piton: None. GnomAD raise the issue of an underdiagnosed cause of microcephaly and/or rapidly lethal associations. 
P08 .63D T.Smol:None.P.Brunelle:None.O.Boute-Benejean: Pathogenic WDFY3 variants cause neurodevelopmental None. J.A. Basseti: None. M. Figeac: None. L. Faivre: disorders and opposing effects on brain size None. F. Petit: None. C. Thauvin-Robinet: None. Q. Thomas: None. F. Tran-Mau-Them: None. S. Man- D. Le Duc1, C. Giulivi2, S. M. Hiatt3, E. Napoli2, ouvrier-Hanu: None. J. Ghoumid: None. A. Panoutsopoulos2, A. De Crescenzo2, U. Kotzaeridou4, S. Syrbe4, E. Anagnostou5, M. Azage6, R. Bend7, 
P08 .62C A. Begtrup8, N. J. Brown9, B. Büttner1, M. T. Cho8, Functional investigation for Variant of Unknown G. M. Cooper3, J. H. Doering4, C. Dubourg10, significance in intellectual disability genes NLGN3, D. B. Everman7, M. S. Hildebrand9, F. J. Reynoso PQB
P1  and DYRK1A Santos11, B. Kellam12, J. Keller-Ramey8, J. R. Lemke1, S.Liu8,D.Niyazov13,K.Payne14,R.Person8,C.Quélin10, R. E. Schnur8, B. T. Smith7, J. Strober15, S. Walker12,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1409 M. Wallis16, L. Walsh14, S. Yang8, R. Yuen12, A. Ziegler4, human phenotype. Consequently, we propose that in H. Sticht17, M. C. Pride2, V. Martínez-Cerdeño2, humans WDFY3 loss-of-function variants lead to macro- J. Silverman2, S. W. Scherer12, K. S. Zarbalis2, R. Abou cephaly via down-regulation of the Wnt-pathway. Jamra1 Conclusion: We present WDFY3 as a novel gene linked tomildtomoderateNDDandIDandconcludethatvariants 1University of Leipzig Medical Center, Leipzig, Germany, putativelycausinghaploinsufficiencyleadtomacrocephaly, 2University of California at Davis, Davis, CA, United while an opposing pathomechanism due to variants in PH- States, 3HudsonAlpha Institute for Biotechnology, domain of WDFY3 leads to microcephaly. Huntsville, AL, United States, 4University Hospital D. Le Duc: None. C. Giulivi: None. S.M. Hiatt: A. Heidelberg, Heidelberg, Germany, 5University of Toronto, Employment (full or part-time); Modest; HudsonAlpha Toronto, ON, Canada, 6Ochsner Health System and Institute for Biotechnology. E. Napoli: None. A. Panout- University of Queensland, Queensland, Australia, sopoulos:None.A.DeCrescenzo:None.U.Kotzaeridou: 7Greenwood Genetic Center, Greenwood, SC, United None. S. Syrbe: None. E. Anagnostou: None. M. Azage: States, 8GeneDX, Gaithersburg, MD, United States, None.R.Bend:A.Employment(fullorpart-time);Modest; 9University of Melbourne, Melbourne, Australia, Greenwood Genetic Center. A. Begtrup: A. Employment 10University Rennes, Rennes, France, 11Joe DiMaggio (fullorpart-time);Modest;GeneDX.N.J.Brown:None.B. Children’s Hospital, Hollywood, CA, United States, 12The Büttner: None. M.T. Cho: A. Employment (full or part- Hospital for Sick Children, Toronto, ON, Canada, time); Modest; GeneDX. G.M. Cooper: A. Employment 13Ochsner Health System and University of Queensland, (full or part-time); Modest; HudsonAlpha Institute for Queensland, CA, United States, 14Riley Hospital for Biotechnology. J.H. Doering: None. C. Dubourg: None. Children, Indianapolis, IN, United States, 15UCSF Benioff D.B.Everman:A.Employment(fullorpart-time);Modest; Children’s Hospital, San Francisco, CA, United States, Greenwood Genetic Center. M.S. Hildebrand: None. F.J. 16Austin Health Clinical Genetics Service, Heidelberg, Reynoso Santos: None. B. Kellam: None. J. Keller- Australia, 17Friedrich-Alexander-Universität Erlangen- Ramey: A. Employment (full or part-time); Modest; Gen- Nürnberg, Erlangen, Germany eDX. J.R. Lemke: None. S. Liu: A. Employment (full or part-time); Modest; GeneDX. D. Niyazov: None. K. Introduction: The underpinnings of mild to moderate Payne: None. R. Person: A. Employment (full or part- neurodevelopmental delay (NDD) remain elusive often time); Modest; GeneDX. C. Quélin: None. R.E. Schnur: leading to late diagnosis and interventions. A. Employment (full or part-time); Modest; GeneDX. B.T. Materials and Methods: We present data on exome-, Smith: A. Employment (full or part-time); Modest; genome-sequencing, and array analysis of thirteen indivi- Greenwood Genetic Center. J. Strober: None. S. Walker: duals that point to pathogenic, heterozygous, mostly de None. M. Wallis: None. L. Walsh: None. S. Yang: A. novo variants in WDFY3 (significant de novo enrichment Employment (full or part-time); Modest; GeneDX. R. p = 0.0007) as a monogenic cause of mild and non- Yuen: None. A. Ziegler: None. H. Sticht: None. M.C. specific NDD. Pride: None. V. Martínez-Cerdeño: None. J. Silverman: Results: Nine variants were protein-truncating and four None.S.W.Scherer:None.K.S.Zarbalis:None.R.Abou missense. Overlapping symptoms included NDD, intellec- Jamra: None. tualdisability(ID),macrocephaly,andpsychiatricdisorders (ASD/ADHD). One proband presented with an opposing 
P08 .64A phenotype of microcephaly and the only missense-variant Triple diagnosis of Wiedemann-Steiner, Waardenburg locatedinPH-domainofWDFY3.Findingsofthiscaseare and DLG3-related intellectual disability association supported by previously published data demonstrating that found by WES. A case report pathogenic PH-domain variants can lead to microcephaly via canonical Wnt-pathway up-regulation. T. Matis1, V. Michaud1, J. Van-Gils1,2, V. Raclet1, We previously reported that Wdfy3 is required for cere- C. Plaisant1, P. Fergelot1, E. Lasseaux1, B. Arveiler1,2, bral cortical size regulation in mice, by controlling proper A. Trimouille1,2 division of neural progenitors. Here, we show that pro- liferating cortical neural progenitors of human embryonic 1Service de Génétique Médicale, CHU Bordeaux, brains highly express WDFY3, further supporting a role in Bordeaux, France, 2INSERM U1211 – Maladies Rares, regulation of prenatal neurogenesis. We present data on Génétique et Métabolisme (MRGM), Université de Wnt-pathway dysregulation in Wdfy3-haploinsufficient Bordeaux, Bordeaux, France mice, which display macrocephaly and deficits in motor coordination and associative learning, recapitulating the1410 Thank to performance of whole exome sequencing (WES) hencetoestimatethediagnosticyieldofWESandtoselect or whole genome sequencing, it is now possible to identify novel candidate genes for future functional studies. multiple pathogenic variants in patients with rare disease, Materials and Methods: The institutional ethics com- where a single disease has until now been suspected. We mitteeapprovedthisstudy.168patients(104families)with report the simultaneous discovery of three pathogenic neurodevelopmental disorders were enrolled and all eval- variants in KMT2A, PAX3, and DLG3 genes, for a 8-year- uatedbyclinicalgeneticists.ForWES;DNAwasbarcoded old patient. He has a developmental delay, behavioral and enriched using Agilent SureSelect-V6-60 MB and disorders,associateddysmorphicfeatures,suchtelecanthus, sequenced using HiSeq4000 or NovaSeq6000. Raw data blue coloringoftheirisesandcubitalhypertrichosis. Atrio and Variant Calling Files (VCF) processing and annotation based exome sequencing found three deleterious variants: was carried out at the Department of Genetics, SQU. KMT2A: c.9068delA ;p.Gln3023Argfs*3 de novo, PAX3: Results: A database of clinical phenotypes for 104 c.530C>G;p.Ala177GlydenovoandDLG3:c.127delG;p. familieswasestablished.In-housepipelineforfiltrationand Asp43Metfs*22 hemizygous inherited from the mother. prioritization of WES data was standardized and validated. KMT2A mutations are involved in Wiedemann-Steiner Prioritized variants found were as following 1) disease- syndrome, and PAX3 mutations are responsible for causativevariants(definitecause)in21/104families(20%), Waardenburg syndrome. DLG3 mutations are described in 2)possibledisease-causingvariants(VUSs)withsupportive a non-syndromic X-related intellectual disability. This segregationsresultsin28families(27%),and3)variantsin frameshift variant is located on the specific exon 1 of novel genes (new genes not implicated in human disease transcript NM_020730.2 of DLG3 mostly expressed in before) in 19/104 families (18%). While in 36 families brain. Considering the dysmorphic features and intellectual (35%), we detected no abnormality. disabilitypresentedbythispatient,thesethreevariantswere Conclusion: thediagnostic rate achieved inourcohort is therefore imputed as pathogenic and their association 20% when considering pathogenic variants only and up to responsible for his phenotype. Several multiple molecular 47% with VUSs. Nineteen candidate genes that are con- diagnosiswerealreadyfoundbyWES.Yangetal.reported vincing to be causative of neurodevelopmental syndromes dual diagnosis on 4 patients (6%) [1], Posey et al. within 6 identified. Further functional studies to be completed to patients (7%) [2], and Rossi & al. within 4 patients (9.5%) confirm causation. [3]. However none triple diagnosis has been reported in G. Al-Kasbi: None. F. Al-Murshedi: None. N. A- literature. This demonstrates and reminds us of the Hashmi: None. K. Althihli: None. A. Al-Kindi: None. A. importance of analyzing exomes in a rigorous and AlSaegh: None. A. Al-Futaisi: None. W. Al-Mamari: exhaustive manner because it can explain in some cases None. A. Al-Yahyaee: None. M. Al-Nabhani: None. S. (<10%) superimposed traits or blended phenotypes. Al-Rashdi: None. S. Al-Yahyaee: None. A. Al- T.Matis:None.V.Michaud:None.J.Van-Gils:None. Maawali: None. V.Raclet:None.C.Plaisant:None.P.Fergelot:None.E. Lasseaux:None.B.Arveiler:None.A.Trimouille:None. 
P08 .66C VariantsinthetranscriptionalcorepressorBCOR
L1 are 
P08 .65B associated with an X-linked disorder of intellectual Diagnostic Yield and Novel Candidate Genes by Exome disability, dysmorphic features, and behavioral Sequencing in 104 Omani Families abnormalities G. Al-Kasbi, F. Al-Murshedi, N. A-Hashmi, K. Althihli, A. Shukla1, K. M. Girisha1, P. H. Somashekar1, A. Al-Kindi, A. AlSaegh, A. Al-Futaisi, W. Al-Mamari, S. Nampoothiri2, R. McClellan3, H. J. Vernon3,4 A. Al-Yahyaee, M. Al-Nabhani, S. Al-Rashdi, S. Al- Yahyaee, A. Al-Maawali 1Kasturba Medical College and Hospital, Manipal, India, 2Amrita Institute of Medical Sciences & Research Centre, Sultan Qaboos University, Muscat, Oman Kochi, India, 3Kennedy Krieger Institute, Baltimore, MD, United States, 4Johns Hopkins University, Baltimore, MD, Background:Autosomalrecessiveinheritedneurodevelop- United States mental disorders are highly heterogeneous, and many causative genes are still unknown. Whole exome sequen- Introduction: BCOR
L1 , a transcriptional corepressor, is cing (WES) becomes the most efficient test to identify involved in negative gene regulation through associations disease-causing variants in monogenic disorders. Aim: To with several protein complexes including Class II histone promote the identification of disease genes through WES, deacetylases (HDACs). Acquired somatic mutations in BCOR
L1  have been implicated in the pathogenesis ofAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1411 several malignancies, but germline mutations of BCOR
L1  Methods: Cases with deletions involving the 13q33.1- have not been associated with a specific genetic syndrome. q34 cytoband were retrieved using local databases of two However, a hemizygous variant, c.2459A>G [p.(Asn820- largest Israeli centers performing CMA analysis. In addi- Ser)] in BCOR
L1  was reported in 2 brothers with severe tion, literature search in PubMed database and DECIPHER intellectual disability, coarse facial features, and hypotonia database was performed. previously. Results:Localdatabasesearchyieldedeightnewpatients Materials and Methods: Five individuals from 3 pedi- with 13q33.3-q34 microdeletions, three of which had grees with phenotypes including intellectual disability, additional copy number variants. Combined with 15 cases behavioral difficulties, and dysmorphic features were detected by literature search, and additional 23 cases investigated by whole exome sequencing. Our case series reported in DECIPHER database, overall 43 patients with was built via collaborations assisted by GeneMatcher. isolated 13q33.3-q34 microdeletions are described. Devel- Results: Three missense variants c.2345 T>A, c.1487 opmental delay and/or intellectual disability were noted in C>T and c.95C>T were observed in hemizygous state in thevastmajorityofaffected individuals (93.2%),andinall BCOR
L1 . Two of the three BCOR
L1  variants, c.95C>T [p. casesextendingbeyondthe13q34cytoband(n=27).Ofthe (Pro32Leu)] and c.1487C>T [p.(Ser496Phe)] are not 20 deletions involving the 13q34 cytoband only, in three reported in gnomAD and the third variant, c.2345T>A [p. casesdevelopmentaldelayand/orintellectualdisabilitywas (Val782Glu)] is reported in one individual in hemizygous notreported.Interestingly,intwoofthesecases(66.7%)the state. The amino acids, proline at 32nd and serine at 496th deletions did not involve the terminal CHAM
P1  gene, as position are highly conserved with a GERP score of 5.42 opposed to 3/17 (17.6%) of patients with 13q34 deletions and 5.69 respectively. The amino acid, valine at 782th is and neurocognitive disability. Facial dysmorphism and moderately conserved with a GERP score of 2.7. microcephalywerereportedinabouthalfofthecases,while Conclusions: Hemizygous pathogenic variants in convulsions and heart anomalies were noted in one fifth of BCOR
L1  underlie a new X-linked epigenetic syndrome of the patients. None of the 13q33-q34 deletions were inher- variable degrees of intellectual disability, seizures, beha- ited from a reported healthy parent. vioral abnormalities, and dysmorphisms including tall Discussion: 13q33-q34 microdeletions are associated forehead, hypertelorism, downslanting palpebral fissures, withhighriskforneurodevelopmentaldisability.Therarity andlongfingers.Thisnewlydescribedsyndromeshouldbe of this chromosomal aberration necessitates continuous considered in males with the above described features, reporting and collection of available evidence. especially in the setting of an X-linked familial inheritance I.Maya:None.Y.Goldberg:None.A.Peleg:None.R. pattern. Sukenik-Halevy: None. E. Sofrin-Drucker: None. Z. A. Shukla: None. K.M. Girisha: None. P.H. Soma- Appelman:None.S.JosefsbergBen-Yehoshua:None.S. shekar: None. S. Nampoothiri: None. R. McClellan: Ben-Shachar: None. L. Sagi-Dain: None. None. H.J. Vernon: None. 
P09 .002A 
P09 .001D New name? CD59-related immune-mediated The rare 13q33-q34 microdeletions - eight new patients polyneuropathy with/without hemolytic anemia? and review of the literature A. Aydin Gumus, H. Gerik Celebi, D. Gun Bilgic, I. Maya1, Y. Goldberg1, A. Peleg2, R. Sukenik-Halevy1, E. Genis, S. Cam E. Sofrin-Drucker3, Z. Appelman4, S. Josefsberg Ben- Yehoshua4, S. Ben-Shachar5, L. Sagi-Dain2 Manisa Celal Bayar University, Manisa, Turkey 1Rabin Medical Center, Petah Tikva, Israel, 2Carmel Introduction: Hemolytic anemia, CD59-mediated, with or Medical Center, Haifa, Israel, 3Schneider Children's without immune-mediated polyneuropathy is a very rare Medical Center of Israel, Petah Tikva, Israel, 4Kaplan autosomal recessive disease, adding to chronic hemolytic MedicalCenter,Rehovot,Israel,5SouraskyMedicalCenter, anemia, infantile-onset polyneuropathy attacks often trig- Tel Aviv, Israel gered by an acute infection. Here, a previously defined mutation in a few cases in the literature will be discussed. Introduction: Deletions of 13q33-q34 cytoband are rare Methods: The girl’s DNA was analyzed bytru sight one chromosomalaberrations,andliteratureevidencedescribing sequencing.Targetsequenceanalysis wasperformed toher the clinical characteristics is scarce. Our objective was to patient brother and healthy parents. shed light on the phenotype and inheritance pattern of this Results:A14-year-oldgirlappliedtouswith neurologic unique microdeletion. attacks as muscle weakness especially in the right side,1412 decreased vision, painful eye movements after acute infec- resonance imaging was suggestive of delayed myelination, tion started at the age of 4. Her 11-year-old brother had and metabolic workup was non-directive. neurologic attacks that began attheageof15months,with Results: Whole exome sequencing revealed a novel lower extremity muscle weakness, tenderness sleep, homozygous c. 1406G>A (p. Ser469Asn) mutation in the walking-standing up difficulty. During the attacks, MRI ADCY5 gene (OMIM 600293). The variant was not found findings were consistent with ADEM/transverse myelitis; in GnomAD or ExAC browsers, was classified as dama- hematuria and mild anemia with negative direct-indirect ging/disease causing by in-silico prediction programs, and coombs tests was found only once. They benefited from the residue Ser469 was shown to be highly conserved IVIG and steroid treatments. In their physical examination; throughout evolution. Both parents, reported as healthy, ptosis, atrophy, decreased deep tendon reflexes, superficial were found to be heterozygous carriers. sensory loss in the right side of the girl’s body and face; Conclusion:Toourbestknowledge,wepresentasecond decreasedmusclestrength,superficialsensoryloss,absence family with biallelic mutations in ADCY5 gene, associated of deep tendon reflexes in the boy's lower extremities were with a severe neurologic presentation of ADCY5-Related detected. Homozygous pathogenic c.146delA (p. Dyskinesia spectrum. Asp49Valfs * 3) mutation was detected in the girl’s CD59 L. Sagi-Dain: None. L. Shemer: None. G. Larom: gene. The same mutation was found as homozygous in her None. V. Adir: None. J. Haddah-Halloun: None. A. brother, heterozygous in their parents who had a con- Peleg: None. sanguineous marriage. Conclusions: This family presents new data to the lit- 
P09 .005D eraturebecauseofthebeginningage,shapeofneurological Polygenic risk score improves prediction of alcohol- attacks and absence of chronic hemolysis. related morbidities A. Aydin Gumus: None. H. Gerik Celebi: None. D. Gun Bilgic: None. E. Genis: None. S. Cam: None. T. T. J. Kiiskinen1, N. J. Mars1, T. Palviainen1, J. T. Rämö1, P. Ripatti1, J. Koskela1, J. Kaprio1, 
P09 .003B V. Salomaa2, P. Mäkelä2, A. S. Havulinna1,2, A first report of homozygous missense mutation in the S. Ripatti1,3,4, GWAS & Sequencing Consortium of ADCY5 gene related to an autosomal dominant Alcohol and Nicotine use Dyskynesia syndrome 1Institute for Molecular Medicine Finland (FIMM), L. Sagi-Dain, L. Shemer, G. Larom, V. Adir, J. Haddah- HiLIFE,UniversityofHelsinki,Helsinki,Finland,Helsinki, Halloun, A. Peleg Finland, 2National Institute for Health and Welfare, Helsinki,Finland,Helsinki,Finland,3DepartmentofPublic Carmel Medical Center, Haifa, Israel Health, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland, Helsinki, Finland, 4The Broad Background: ADCY5-Related Dyskinesia is a diverse Institute of MIT and Harvard, Cambridge, Massachusetts, group of movement disorders, characterized by dystonia, USA, Cambridge, MA, United States myoclonus or chorea, with variable disability. The disorder is inherited in an autosomal dominant manner; however, Alcohol drinking is a major contributor to global health recently two siblings with generalized dystonia and burden. Affected by genetic factors, genome-wide associa- myoclonus have been reported, associated with compound tion studies (GWAS) have identified multiple loci asso- heterozygous mutations in ADCY5 gene. ciatedwithalcoholconsumption.Toquantifytheprognostic Patient: We describe girl, born to consanguineous par- information of this polygenic burden, we derived a ents(firstcousins)followinganuneventfuldeliveryatterm. polygenic risk score (PRS) for alcohol consumption and At the age of 1 year and 9 months she presented a severe tested its association with alcohol use disorder, alcohol- globaldevelopmentaldelay,andwasunabletospeak,sitor related morbidities and mortality. stand. Her neurologic examination showed markedly Wecreated21majoralcohol-inducedhealtheventsusing increased tonus and episodic dystonic postures in trunk, nationwide hospital discharge, cause-of-death and pre- extremities and face, exacerbated by voluntary movement. scriptiondrugpurchaseregistries. Using thelargest GWAS In addition, spontaneous events of ocular convergence summary statistics on alcohol consumption (GSCAN, spasm and orofacial dystonia were observed. However, n=527,282 non-Finns), we built a genome-wide PRS and during sleep a significant decrease in the tonus was noted, testeditspredictiononalcohol-relatedeventsinprospective with fill range of joint movements. She had recurrent epi- cohorts (total n=39,243). sodes of hyperthermia and hyperhidrosis. MagneticAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1413 Per 1SD increase, the PRS was associated with a 11.2g mtDNAcopynumberis256.5(SD:93.9).Wedidnothave (0.93 drinks) increase in weekly alcohol intake (95% any stage IV patients. CI=9.85-12.58g, p=2.3*10-58) and a 27% increase in Conclusions: Both telomere length and mitochondrial alcohol-induced events (cases=874, HR=1.27,1.19-1.36, copynumberdecreasedwithdiseaseseverity.Nosignificant p=1.7*10-12) while the difference between the risk of the difference between sporadic and familial forms have been lowest and highest PRS-quintiles was 102% (HR=2.02, found. Changes in the telomere length are significant 1.62-2.52, p=5.4x10-10). Controlling for self-reported (p<0.05) and telomere length appears to be a better bio- alcohol-consumption-estimate, socioeconomical status, marker in late stages. Grant: NTP-NFTÖ-17-B-0595 smoking, and GGT, this increase was 17%/SD (1.17, 1.09- B.A.Fekete:None.A.Illes:None.D.Csaban:None.H. 1.25, p=8.9*10-6). For DSM-IV AUD, a similar increase Zeke: None. V. Molnar: None. I.J. Jimoh: None. P. was observed (cases=713, OR=1.20, 1.11-1.31, Balicza: None. Z. Grosz: None. M.J. Molnar: None. p=2.29*10-5). Adding the PRS over age and sex increased the C-index 2% (p=0.017) and self-reported consumption 
P09 .007B andsocioeconomicfactorsincreasedtheC-indexfurtherby Next Generation Exome Sequencing in a Large Sample 13% (p=3.1*10-11) with the C-index for a model including of Alzheimer’s Patients all being 84.9%. In conclusion, increased polygenic risk for alcohol con- D. Grozeva1, S. Saad1, C. Bresner1, A. Frizzati1, sumption was associated with alcohol-related morbidities M. Bareford1, T. Morgan1, R. Raybould1, E. Rees1, alsowhencontrollingforself-reportedalcoholconsumption N. Denning1, A. Meggy1, R. Marshall1, W. Nash1, and other covariates thus showing potential in utilizing C. Davies1, J. Morgan1, B. Hitchings1, G. Leonenko1, geneticinformation for predictionofalcohol-related harms. G. Menzies2, N. Badarinarayan1, V. Escott-Price2, T.T.J. Kiiskinen: None. N.J. Mars: None. T. Palviai- ARCCA Cardiff University, D. Ivanov2, R. Sims1, nen: None. J.T. Rämö: None. P. Ripatti: None. J. Kos- J. Williams1,2 kela: None. J. Kaprio: None. V. Salomaa: None. P. Mäkelä: None. A.S. Havulinna: None. S. Ripatti: None. 1Institute of Psychological Medicine & Clinical Neurosciences, Cardiff University, Cardiff, United 
P09 .006A Kingdom, 2UK Dementia Research Institute at Cardiff, Telomere length and mitochondrial DNA copy number Cardiff University, Cardiff, United Kingdom changes as a biomarker in ALS Introduction: Both early- and late-onset types of Alzhei- B. A. Fekete, A. Illes, D. Csaban, H. Zeke, V. Molnar, mer’s disease (EOAD and LOAD) have a substantial I. J. Jimoh, P. Balicza, Z. Grosz, M. J. Molnar genetic component. Despite the high genetic heritability, a largeproportionoftheriskhasnotbeenexplainedthusfar. Institute of Genomic Medicine and Rare Disorders, A considerable proportion of the missing heritability is Semmelweis University, Budapest, Hungary likely to be accounted for by rare, low frequency and functionalvariants.Hereweapplywholeexomesequencing Introduction:Telomerelengthwaspreviouslyshowntobe (WES) to identify rare genetic variants that influence decreased in several neurodegenerative disorders while disease risk. mitochondrialDNAcopynumberchangeswerereportedto Methods: We are currently sequencing a large cohort of show conflicting results. mtDNA copy numbers and both EOAD (2000 individuals) and LOAD patients (3000) telomerelengtharereportedtobecorrelated.Biggersample and healthy elderly controls (1100). WES is performed sizes, simultaneous measurements and detailed data on using Illumina HiSeq 4000 at a median coverage 40x. The disease severity is lacking. GATKpipelineisutilisedforvariantdiscovery.Thequality Materials and Methods: ALS patients (n=99) were control and statistical analyses are performed within the stagedbasedontheKing’sclinicalstagingsystem(StageI- Hailframework.Wewillperformsingle-variantassociation IV.). mtDNA copy numbers and telomere lengths were analyses as well as gene burden analyses. In addition, we measured with real-time PCR technique. will check if there are rare variants in the genes previously Results: Stage I ALS patients have an average telomere associated with rare forms of dementia. length of 200.6 (kB) (SD: 69.5), mtDNA copy number of Results: We will present our first large scale genomic 300.3 (SD: 90.3), while stage II telomere length is 164.9 analysisresultsbasedontheWESdataforthecohortatthe (SD: 77.9) and mtDNA copy number is 280.7 (SD: 85.9) ESHG2019. and stage III telomer lengths is 114.1 (SD: 40.5) while Conclusions:ToidentifynovelgeneticcausesofAD,we are sequencing a large cohort of both EOAD and LOAD1414 patients. Our analysis will utilise this well powered sample to identify novel low frequency loci in addition to func- Introduction: Apolipoprotein E (APOE) is associated with tional variation that have been potentially missed by cognition, longevity, cardiovascular disease, Alzheimer’s GWAS.Identificationoftheselociwillfurtherelucidatethe disease(AD)andall-causemortality.Homozygosityforthe geneticarchitectureofEOADandLOADandwillimplicate Ɛ4 allele increases AD risk, with homozygotes estimated functionalvariantsformolecularinvestigationandpotential having up to 60-70% lifetime risk (penetrance), with drug targets. average age of onset ~70 years. Some Ɛ4 homozygotes D. Grozeva: None. S. Saad: None. C. Bresner: None. live >75 without AD, suggesting protective factors, yet are A.Frizzati:None.M.Bareford:None.T.Morgan:None. rarely ascertained. We sought to test APOE haplotypes R.Raybould:None.E.Rees:None.N.Denning:None.A. against cognitive function/dementia in a longitudinal study Meggy: None. R. Marshall: None. W. Nash: None. C. and identify Ɛ4 homozygotes aged >75 years without AD. Davies: None. J. Morgan: None. B. Hitchings: None. G. Methods: We sequenced 13,131 healthy elderly partici- Leonenko: None. G. Menzies: None. N. Badarinarayan: pantsintheASPREEstudy.Atbaseline,participantshadno None. V. Escott-Price: None. D. Ivanov: None. R. Sims: history of cardiovascular disease or dementia, and passed a None. J. Williams: None. general cognition screen (Modified Mini-Mental State Examination ≥78), average age 74 years. We administered 
P09 .008C different cognitive tests (general cognition, verbal learning/ Effect ofAPOE on cognitivefunction and dementia ina memory, verbal fluency, processing speed) over five-years. longitudinalcohortof13,131healthyelderlyindividuals Wecollectedclinicaloutcomedataonarangeofendpoints, and associated each APOE haplotype with specific cogni- M. Riaz1, R. Sebra2, A. Huq3,4, J. Ryan1, R. Wolfe1, tive functions and dementia. J. E. Lockery1, S. G. Orchard1, C. M. Reid5, Results: APOE frequencies aligned with other cohorts M. R. Nelson6, J. D. Williamson7, T. T. Chong8, (Ɛ3/Ɛ3=62.3%, Ɛ3/Ɛ4=21.0%, Ɛ2/Ɛ3=12.5%, Ɛ2/ B. Kirpach9, C. Burns9, R. Woods1, E. Store1, Ɛ2=0.6%, Ɛ4/Ɛ4=1.5%). Yet we observed notable differ- R. C. Shah10, A. Murray9, ASPREE Investigator Group, encesincognitivefunction(verballearning/memory),after E. Schadt2, J. McNeil1, P. Lacaze1 controlling for demographic and clinical risk factors. We quantified the effect of each APOE haplotype on dementia 1Department of Epidemiology and Preventive Medicine, riskandage-of-onset.Weidentified200Ɛ4homozygous,of School of Public Health and Preventive Medicine, Monash whomaftermedian4.7yearsfollow-up,only14reachedthe University, Melbourne, Australia., Melbourne, Australia, dementiaendpoint(7%penetrance).Theaverageageofthe 2IcahnInstitute andDept.ofGenetics &GenomicSciences remaining 186 individuals was 78 years, suggesting an at Mount Sinai School of Medicine, New York, NY, United enrichment of unaffected individuals in this study. States, NewYork, NY, United States, 3Department of Conclusion: This uniquely ascertained population pro- Epidemiology and Preventive Medicine, School of Public vides a platform for discovery of protective genetic factors Health and Preventive Medicine, Monash University, M. Riaz: None. R. Sebra: None. A. Huq: None. J. Melbourne, Australia, Melbourne, Australia, 4Department Ryan: None. R. Wolfe: None. J.E. Lockery: None. S.G. of Genetic Medicine, Royal Melbourne Hospital, Orchard:None.C.M.Reid:None.M.R.Nelson:None.J. Melbourne,Australia,Melbourne,Australia,5theSchoolof D. Williamson: None. T.T. Chong: None. B. Kirpach: Public Health, Curtin University, Perth, Australia, None.C.Burns:None.R.Woods:None.E.Store:None. 6Menzies Institute for Medical Research, University of R.C.Shah:None.A.Murray: None.E.Schadt:None.J. Tasmania, Hobart, Hobart, Australia, 7Sticht Center on McNeil: None. P. Lacaze: None. healthy Aging and Alzheimer’s Prevention, Section on Gerontology and Geriatric Medicine, Department of 
P09 .009D Internal Medicine, Wake Forest School of Medicine, Evaluation of a novel variant in CR1 in patients with Winston-Salem, NC,Winston-Salem,NC, United States, 87. Alzheimer's disease Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Victoria, 3800, Australia, Melbourne, J. Szymanski1,2, F. Cardona1,2,3, J. Pérez Tur1,2,3 Australia, 9Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute 1InstitutodeBiomedicinadeValencia,ConsejoSuperiorde Minneapolis, MN, USA, Minneapolis, MN, United States, Investigaciones Científicas, Valencia, Spain, 2Centro de 10Department of Family Medicine and Rush Alzheimer’s Investigación Biomédica en Red sobre Enfermedades Disease Center, 2468 Rush University Medical Center, Neurodegenerativas (CIBERNED), Madrid, Spain, Chicago, IL, USA, Chicago, IL, United States 3InstitutodeInvestigaciónSanitariaLaFe,Valencia,SpainAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1415 5Department of Neurology and Memory Clinics, Hospital Alzheimer's disease (AD) is the most common neurode- Network Antwerp, Antwerp, Belgium, 6Department of generative dementia in the elderly. According to the World Neurology, University Hospital Ghent and University of Alzheimer’sReport2018,50millionpeoplearelivingwith Ghent, Ghent, Belgium dementia and its total estimated cost is US$1 trillion worldwide. This poses a significant burden to the aging Introduction: Genetic studies in early-onset Alzheimer’s population. disease (EOAD) patients suggested an important role for Previous studies have identified genes that increase the premature termination codon (PTC) mutations in ABCA7. risk of the late onset form of the disease (LOAD). Among ABCA7wasinitiallyassociatedwithlate-onset Alzheimer’s them CR1, a gene encoding a receptor in the complement disease (AD) in genome-wide association studies. PTC system. By sequencing of exomes of Spanish family mutations are predicted to lead toloss of functional protein members affected by AD, we identified a novel variant of though active transcript rescue was observed. CR1 gene encoding for a truncated protein caused by a Materials and Methods: Targeted resequencing of the single nucleotide variant (SNV). Allele specific PCR ABCA7 coding region or whole exome sequencing were revealed the presence of this SNV in 3 members of the used to determine the frequency of ABCA7 PTC mutations family, affected by AD but not the unaffected member nor in757EOADpatients(meanonsetage61.2±7.0years)and 192 controls examined nor any public database. These 757 control individuals. Clinicopathological characteristics results together with the implication of the gene in the of mutation carriers were retrospectively reviewed. disease,indicatespossiblepathogenicsignificance. Plasmid Results: We identified 13 different ABCA7 PTC muta- constructs of two most common isoforms and the novel tions in 34 carriers (34/757, 4.49%) and 15 PTC mutations variant of CR1 fused with Flag epitope were used in an incontrols,resultinginanORof2.33(95%CI[1.26-4.31], assay to determine whether the variant mRNA is degraded p=0.006).Carriershadameanonsetageof61.6±5.8(48- bynonsense-mediatedmRNAdecay(NMD).Alsowhether, 70) years. Clinical presentation was predominantly amnes- if translated, the stability of the protein is affected. Pre- tic. A positive first-degree familial history was present in liminary results suggest the novel variant in CR1 is degra- 88.8% (16/18). Neuropathological examination (n=5) dedbyNMDastheinhibitionofthispathwayincreasesthe showed hallmark AD lesions, in 80% (4/5) combined with levels of CR1 mRNA and protein. pronounced cerebral amyloid angiopathy (CAA). Missense Funding acknowledgement: GV/2018//166, CIBERNED mutations were enriched in patients versus controls (OR of (group 209) and SAF2014-49469-R 2.20, 95% CI [1.06-2.85], p = 0.028). J. Szymanski: None. F. Cardona: None. J. Pérez Conclusion: PTC mutations in ABCA7 are relatively Tur: None. frequent in Belgian EOAD patients, particularly in familial EOAD. Clinical and neuropathological data exhibited a classical AD phenotype in combination with CAA and 
P09  highly variable onset ages. Additional information of Neurogenetic and psychiatric disorders mutation frequency and spectrum as well as biological impact is essential before implementation into clinical 
P09 .010A practice, including genetic testing and risk prediction. Genetic and clinicopathological contribution of rare L. Bossaerts: None. E. Hens: None. T. Van den ABCA7 mutations in Belgian early-onset Alzheimer’s Bossche: None. A. De Roeck: None. S. Engelborghs: disease patients None. A. Sieben: None. K. Peeters: None. M. Van den Broeck: None. A. Laureys: None. P. De Deyn: None. K. L. Bossaerts1,2,3, E. Hens1,2,4, T. Van den Bossche1,2,4, Sleegers: None. P. Cras: None. C. Van A. De Roeck1,2,3, S. Engelborghs2,3,5, A. Sieben1,2,6, Broeckhoven: None. K. Peeters1,2, M. Van den Broeck1,2, A. Laureys1,2, P. De Deyn2,3,5, K. Sleegers1,2,3, P. Cras2,4, C. Van 
P09 .012C Broeckhoven1,2,3, Belgian Neurology consortium Anorexia nervosa genome-wide association study identifies eight loci and implicates psychiatric and 1Neurodegenerative Brain Diseases Group, Center for metabolic origins Molecular Neurology, VIB, Antwerp, Belgium, 2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium, C. Hübel1,2, H. J. Watson3,4,5, Z. Yilmaz3, Eating 3Department of Biomedical Sciences, University of Disorders Working Group Psychiatric Genomics Antwerp, Antwerp, Belgium, 4Department of Neurology, Consortium, M.Landén1,6, N.G.Martin7, P. Mortensen8, Antwerp University Hospital, Edegem, Belgium, P. F. Sullivan1,3, G. Breen2,9, C. M. Bulik1,31416 1Karolinska Institutet, Stockholm, Sweden, 2King's College 01GV0624, National Genome Research Net-Plus London, London, United Kingdom, 3University of North 01G
S0820 , 01KU0903); NIAAA (K02AA018755-06, Carolina at Chapel Hill, Chapel Hill, NC, United States, R01AA015416-08); Swiss Anorexia Nervosa Foundation; 4CurtinUniversity,Perth,Australia,5UniversityofWestern MINECO (SAF2013-49108-R); AGAUR (2014 SGR- Australia, Perth, Australia, 6University of Gothenburg, 1138); EC F
P7 /2007-2013 (ESGI 262055, 245009); EU Gothenburg, Sweden, 7QIMR Berghofer Medical Research H2020 (692145, 676550, 654248); Estonian Research Institute, Brisbane, Australia, 8Aarhus University, Aarhus, Council (IUT20-60), European Regional Development Denmark, 9South London and Maudsley National Health Fund (2014-2020.4.01.15-0012); Instituto de Salud Carlos Service Trust, London, United Kingdom III (FIS PI14/290, CIBERobn); MH CZ - DRO (MMCI, 00209805); EC Framework V ‘Factors in Healthy Eating’ Introduction:Anorexianervosa(AN)isaneatingdisorder (INRA/INSERM 4M406D, PHRC ENDANO 2008- characterised by severe weight loss either through caloric A01636-49); iPSYCH; CHOP; NHI/NHGRI eMERGE restriction or heightened energy expenditure or a combina- Network (U01 HG006830); Kurbert Family; EU Marie tion of both. It has one of the highest mortality rates of all Curie Program (MRTN-CT-2006-035988); Ontario Mental psychiatric disorders and psychological and pharmacologi- Health Foundation; Ministry of Health of Ontario AFP cal treatments show only limited effect. Innovation Fund; European Commission Framework 5; Materials and Methods: As an international collabora- MedicalUniversityofVienna;NetherlandsNWO(ZonMW tion between the Anorexia Nervosa Genetics Initiative and VIDI91786327);UniversityofOtagoResearchGrant;NRF the Psychiatric Genomics Consortium, we performed the Korea (2016R1D1A1A09917877); Bergen Research Foun- worldwidelargestgenome-wide associationstudy(GWAS) dation, NFR (NORMENT-SFF); NCNG; Ontario Mental amassing 16,992AN cases and55,525controls. Secondary Health Foundation; IGA MZ ČR (NT 14094-3/2013, AZV analyses included chromosome conformation capture (i.e., 17-28905A, Progres Q27); LifeGene; Ragnar and Torsten Hi-C), linkage disequilibrium score regression, generalised Söderberg Foundation; AFA Insurance; Stockholm County summary data-based Mendelian randomisation (GSMR), Council/Karolinska Institutet Research funds; Lundbeck gene, and gene-set analysis using MAGMA. Foundation; Aarhus University for CIRRAU; Alexander Results: The GWAS identified 8 independent loci and von Humboldt Foundation; Academy of Finland (259764, estimated its common genetic variant heritability to be 11- 28327, 286028, 265240, 263278, 308248, 312073); Nor- 17%, indicating a polygenic trait. Enrichment analyses wegian Institute of Public Health; Research Council of implicate central nervous tissues and cell types in AN. Norway (248778, 223273); The Norwegian Foundation for Additionally,ANshowedpositivegeneticcorrelationswith Health and Rehabilitation; Psychiatry Research Trust obsessive-compulsive disorder (OCD, r = .45), major (284286); Genome Canada; Government of Ontario; g depressive disorder (r = .28), and anxiety (r = .25), Canadian Institutes of Health Research; University of Tor- g g mirroring its clinical comorbidity profile. Surprisingly, onto McLaughlin Centre; Resnick Family Chair in Eating bidirectional GSMR a showed significant bidirectional Disorders; VR (D0886501); DFG (EH 367/5-1, SFB 940, relationship between AN and BMI (β;;;;; AN→BMI = -0.20; HI865/2-1);AustralianNHMRC(310667,324715,480420, OR BMI→AN = 0.96), indicating that genomic variants that 1063061, 1073898, 1058522, AP
P1103623 ); NIH predispose to lower body mass may also increase liability (K01MH109782, K01AA025113, K01MH093750, R01 for AN. Complementing these findings, we also reported MH109528, D0886501, R01 MH092793, K01MH106675, genomic overlap between AN and metabolic traits, such as 2R01DK075787-06A1); Wellcome Trust (WT098051, fasting insulin concentrations (r = -.24) as well as high- WT088827/Z/09) g density lipoprotein concentrations (r = .21). C.Hübel:None.H.J.Watson:None.Z.Yilmaz:None. g Conclusions: Through these findings, we are encoura- M. Landén: D. Speakers Bureau/Honoraria (speakers ging a reconceptualization of AN as both a psychiatric and bureau, symposia, and expert witness); Modest; Lundbeck. metabolic disorder. F.Consultant/AdvisoryBoard;Modest;EPIDResearchOy. Grant numbers: KG Jebsen Stiftelsen (SKGJ‐MED‐ N.G. Martin: None. P. Mortensen: None. P.F. Sullivan: 008); Professional Services Agreement with the Regents of B. Research Grant (principal investigator, collaborator or the University of California; Price Foundation; Health consultant and pending grants as well as grants already Research Society of New Zealand (16/600), NIHR Bio- received); Modest; Lundbeck. D. Speakers Bureau/Honor- medical Research Centre (BRC) and NIHR Dementia Bio- aria (speakers bureau, symposia, and expert witness); medicalResearch Unit (BRU), King’sCollegeLondonand Modest; Roche. F. Consultant/Advisory Board; Modest; South London and Maudsley NHS Foundation Trust; The Lundbeck, Pfizer, Element Genomics. G. Breen: B. Klarman Family Foundation; Veneto Region Grant BIO- Research Grant (principal investigator, collaborator or VEDA (DGR 3984/08); BMBF (01GV0601, ANTOP consultant and pending grants as well as grants alreadyAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1417 received);Modest;EliLilly.D.SpeakersBureau/Honoraria None. I. Terczyńska: None. E. Obersztyn: None. B. (speakers bureau, symposia, and expert witness); Modest; Nowakowska: None. Illumina. F. Consultant/Advisory Board; Modest; Eli Lilly, Otsuka. C.M. Bulik: B. Research Grant (principal investi- 
P09 .014A gator,collaboratororconsultantandpendinggrantsaswell Elucidating the genetic background of childhood-onset asgrantsalreadyreceived);Modest;ShirePharmaceuticals. ataxias F. Consultant/Advisory Board; Modest; Shire. Other; Modest; Pearson and Walker. E. Ignatius1, P. Isohanni1, M. Pohjanpelto2, E. Palin2, V. Brilhante2, S. Ojanen2, A. Suomalainen2, 
P09 .013D T. Lonnqvist1, C. J. Carroll3 The usefulness of array comparative genomic hybridization in detection of copy number variants in 1Helsinki University Central Hospital, Helsinki, Finland, patients with epilepsy 2Helsinki University, Helsinki, Finland, 3St. George's, University of London, London, United Kingdom I. Plaskota, M. Bartnik-Głaska, M. Smyk, K. Sobecka, B. Wiśniowiecka-Kowalnik, J. Bernaciak, E. Szczepanik, Introduction: Despite available genetic testing, a large I. Terczyńska, E. Obersztyn, B. Nowakowska proportion of all documented ataxia cases remain geneti- callyuncharacterized.Childhood-onsetataxiasareclinically Institute of Mother and Child, Warsaw, Poland and genetically heterogeneous, which makes finding the moleculardiagnosischallenging.Theaimofthisstudywas Introduction:Epilepsyisoneofthemostcommondiseases to characterize the genetic background of childhood-onset of the central nervous system affecting about 1% of the ataxias in Finland using WES technology. human population. The causes of epilepsy, because of the Methods: Our cohort includes all pediatric patients with clinical and etiological heterogeneity, often remain ataxia as the primary symptom of disease evaluated in unknown. However, it is well known that genetic factors HelsinkiUniversityCentralHospitalduringtheyears1999- areresponsibleforepilepsyin40-60%cases.Recentstudies 2016. Patients with acute, infection related ataxias, ataxias haveshownthatinadditiontothepointmutations,thecopy that follow brain insult and patients with mild ataxia as a number variants (CNVs) are also important factors in this minorpartofadisorderwereexcluded.42familieslackeda disorder. genetic diagnosis and were investigated using WES. MaterialsandMethods:WeusedarrayCGHmethodin Results:Apathogenicorlikelypathogenicmutationwas agroupof54patientswiththeclinicaldiagnosisofepilepsy found for 17 families (40 %). Known or novel autosomal and neurodevelopmental abnormalities with or without recessive variants were found in known ataxia genes dysmorphic features. Array CGH analysis was performed HIBCH,STUB1,ADCK3,B9D1,CLN5,PTRH2,TP
P1 as using genome-wide microarray with average resolution of well as in the novel ataxia gene SQSTM1, encoding 30 kb (180K, Oxford Gene Technology) with specifically autophagy receptor p62, we reported recently. De novo or designed coverage for over 212 selected genes, known or dominant variants explained approximately a third of candidate to play an important role in the pathogenesis of genetic causes in our cohort, with variants identified in epilepsy. EBF3, ITPR1, NKX2-1 and AT
P1 A3. A de novo variant Results: Chromosomal microarray analysis revealed 20 was identified in MED23, which has not previously been CNVsin17patients(31%).AlloftheidentifiedCNVswere linked to ataxia. submicroscopic in size, ranging from 1.7 kb to 3.84 Mb, Conclusions: WES is an effective way to diagnose and therefore could not have been detected by standard patients with known and novel causes of childhood-onset karyotype analysis. We identified 6 pathogenic or poten- ataxia, and enables early diagnosis, which is critical for tiallypathogenicCNVs(11%)and14CNVswithunknown patients with treatable forms of genetic ataxia and for clinicalsignificance(26%).10CNVs(50%)couldnothave genetic counselling. Furthermore, our findings expand the been detected by our clinical microarray (60K, OGT). genetic spectrum of childhood-onset ataxias and highlight Conclusions: The results of our studies further support novel cellular mechanisms. theroleofsubmicroscopicCNVsintheetiopathogenesisof E.Ignatius:None.P.Isohanni:None.M.Pohjanpelto: epilepsy and demonstrate the usefulness of array CGH in None. E. Palin: None. V. Brilhante: None. S. Ojanen: the genetic diagnosis of this neurodevelopmental disorder. None. A. Suomalainen: None. T. Lonnqvist: None. C.J. I. Plaskota: None. M. Bartnik-Głaska: None. M. Carroll: None. Smyk: None. K. Sobecka: None. B. Wiśniowiecka- Kowalnik: None. J. Bernaciak: None. E. Szczepanik:1418 
P09 .015B 
P09 .016C Ataxia telangiectasia-like disorder in a family deficient Novel intronic and synonymous variants: validation of for MR
E11 A, caused by a MR
E11  variant bioinformatic splicing effect prediction increases the molecular diagnosis rate H. Tajsharghi1, M. Sedghi2, M. Salari3, A. Moslemi4, A. Kariminejad5, M. Davis6, H. Hayley Goullée7, D. Santos1, J. Damásio1,2,3, S. Morais1, C. Pereira1,4, B. Olsson8, N. Laing7 M. Santos1, J. Sequeiros1,3,4, I. Alonso1,3,4 1Health and education, Translational medicine, Skovde, 1UnIGENe, IBMC – Institute for Molecular and Cell Sweden, 21Medical Genetics Laboratory, Alzahra Biology, i3S – Instituto de Investigação e Inovação em University Hospital, Isfahan University of Medical Saúde, Univ. Porto, Porto, Portugal, 2Neurology Sciences,, Isfahan, Iran, Islamic Republic of, 3Department Department, Centro Hospitalar Universitário do Porto, of Neurology, Shahid Beheshti University of Medical Porto, Portugal, 3CGPP – Centro de Genética Preditiva e Science, Tehran, Iran, Islamic Republic of, 4Department of Preventiva, IBMC – Institute for Molecular and Cell Pathology, University of Gothenburg, Sahlgrenska Biology, i3S – Instituto de Investigação e Inovação em University Hospital, gothenburg, Sweden, 5Kariminejad- Saúde, Univ. Porto, Porto, Portugal, 4ICBAS – Instituto de Najmabadi Pathology & Genetics Center, Tehran, Iran, Ciências Biomédicas de Abel Salazar, Univ. Porto, Porto, Islamic Republic of, 6Department of Diagnostic Genomics, Portugal Pathwest,QEIIMedicalCentre,Nedlands,Perth,Australia, 7Centre for Medical Research, The University of Western The correct interpretation of biological consequences of Australia and the Harry Perkins Institute for Medical variantsofunknownsignificance(VUS)onsplicingposesa Research,, Perth, Australia, 8School of Bioscience, major challenge for clinical geneticists in molecular University of Skovde, Skovde, Sweden diagnosis. In silico tools can be used to predict the functional impact of a given VUS; however, software Objective: We report three siblings with the characteristic limitations have not been properly evaluated and final features of ataxia-telangiectasia-like disorder associated confirmation requires further molecular studies. Therefore, with a homozygous MR
E11  synonymous variant causing our aim was to evaluate the functional impact of two novel nonsense-mediatedmRNAdecayandMR
E11 Adeficiency. VUSs(intronicc.1580-18C>GinAT
P8 A2andsynonymous Methods: Clinical assessments, next-generation sequen- c.6819G>T in NIPBL) on splicing, by a minigene assay, cing, transcript and immunohistochemistry analyses were and compare the observed effects with the predictions performed obtained through bioinformatics tools. Minigene constructs Results: The patients presented with poor balance, were generated through PCR amplification, from patient´s developmental delay during the first year of age and suf- DNA, of genomic sequences surrounding the VUS of feredfromintellectualdisabilityfromearlychildhood.They interest, which were cloned into the pCMVdi vector. showed oculomotor apraxia, slurred and explosive speech, Altered splicing was evaluated by PCR and Sanger limb and gait ataxia, exaggerated deep tendon reflex, dys- sequencing of cDNA obtained from HEK293T cells tonic posture and mirror movement in their hands. They expressing the minigene constructs. This strategy showed developed mild cognitive abilities. Brain magnetic reso- thatbothvariantsproducedaberranttranscripts.Thec.1580- nanceimagingintheindexcaserevealedcerebellaratrophy. 18C>G homozygous variant in AT
P8 A2 leads to the Next-generation sequencing revealed a homozygous retention of 17bp of intron 17, by the use of an alternative synonymous variant in MR
E11  (c.657C>T, p.Asn219=) acceptor splice site, resulting in a premature termination that we show affects splicing. A complete absence of codon in the predicted protein sequence. The NIPBL MR
E11  transcripts in the index case suggested nonsense- variant, c.6819G>T, leads to a deletion of 137bp in exon mediated mRNA decay and immunohistochemistry con- 40,throughactivationofanexoniccrypticdonorsplicesite, firmed the absence of a stable protein. also resulting in a premature termination codon. This Conclusions: Despite the critical role of MR
E11 A in allowedustoclearlyclassifytheseVUSasdisease-causing, double-strand break repair and its contribution to the confirming the bioinformatics prediction of their functional Mre11/Rad50/Nbs1 complex, the absence of MR
E11 A is impact. Furthermore, this work denotes the importance of compatible with life. considering intronic and synonymous variants as a way of H. Tajsharghi: None. M. Sedghi: None. M. Salari: increasing the molecular diagnosis rate. None. A. Moslemi: None. A. Kariminejad: None. M. D. Santos: None. J. Damásio: None. S. Morais: None. Davis:None.H.HayleyGoullée:None.B.Olsson:None. C. Pereira: None. M. Santos: None. J. Sequeiros: None. N. Laing: None. I. Alonso: None.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1419 
P09 .017D in childhood and lasts throughout a person's life, character- A novel CDK
L5  mutation in an atypical Rett syndrome ized by challenges with social skills, repetitive behaviors, patient and development an efficient method for speech and non-verbal communication. Large genome detecting CDK
L5  activity rearrangements are being identified in ASD as an under- lying cause for development of this syndrome. These T. Inazu, S. Katayama rearrangements are mostly deletions, but duplications can be found. We present case of twin boys with APBA2 gene Ritsumeikan university, Kusatsu, Shiga, Japan duplication. MaterialsandMethods:Twinboys,age9werereferred Rett syndrome (RTT) is a severe X-linked dominant to genetic counseling and testing with diagnosed ASD inheritance disorder with a wide spectrum of clinical (DSM-IV). DNA was isolated from buccal swabs of the manifestations. Mutations in Methyl CpG binding protein boys, and 3 ml of whole blood from parents. Parents pro- 2 (MEC
P2 ), Cyclin dependent kinase-like 5 (CDK
L5 ) and vided completed questionnaires for tick disorders in chil- Forkhead box G1 (FOXG1) have been associated with dren as well as Coordination Disorder Questionnaire classic and/or variant RTT. This study was conducted to (DCDQ).IdentificationofmutationswasmadewithMLPA identifytheresponsiblegene(s)inatypicalRTTpatient,and (multiplexligase-dependentprobeamplification)technique, to examine the effect of the mutation on protein function. with MLPA kits 
P343  and 
P339  (Mrc-Holland). DNA sequence analysis showed a novel heterozygous Results: All samples were typed successfully. We iden- mutationinCDK
L5 identifiedasc.530A>Gwhichresulted tifiedde novo APBA2 gene duplicationin both twins. This inanaminoacidsubstitutionatposition177,fromtyrosine gene, located on 15q13.1 locus is already associated with to cysteine. We demonstrated in vitro kinase assay using autism features. DCDQ scores are similar in twins with radioisotope (RI) of mutant protein showed impairment of indication of DCD. Assessment of the Questionnaires for its activity. The results suggested the mutant CDK
L5  was tick disorders in children revealed that one sibling is com- responsible for the disease. pletely absent for ticks while other has high score for sec- Next, pathogenic point mutations including Y177C are tion related to vocal and involuntary ticks. mostly observed within the catalytic domain of CDK
L5 , Conclusions: This finding require further investigation therefore loss of catalytic activity may be related todisease andfollowuponspatialandtemporaldifferencesinautism onset. However, this hypothesis has rarely been demon- associated traits in APBA2 gene duplication associated strated. We develop an efficient method for detecting autism. CDK
L5  activity. Appropriately, CDK
L5  underwent autop- N. Lojo-Kadric: None. L. Pojskic: None. hosphorylation following expression in Escherichia coli, with autophosphorylated CDK
L5  detected as a band shift 
P09 .019B by phos-tag SDS-PAGE, without enzyme purification and MLPA analysis as a diagnostic test in patients with RI.Wetriedtoexaminetheeffectof15pathogenicorlikely autism spectrum disorders pathogenic or uncertain significant mutations on their activity,wefoundallvariantsshoweddramaticallyreduced D. Avdjieva-Tzavella1, H. Kathom1, T. Delchev1, catalytic function. Thus, the protocol is useful for examin- S. Bichev2 ing the relationship between disease-causing mutations and their activity. 1Department of Clinical Genetics, University Pediatrics T. Inazu: None. S. Katayama: None. Hospital, Medical University, Sofia, Bulgaria, Sofia, Bulgaria, 2National Genetic Laboratory, University 
P09 .018A Hospital “ Majcin Dom"Medical University, Sofia, AutismmonozygotictwinswithAPBA2geneduplication Bulgaria, Sofia, Bulgaria vary for tick development Introduction: Autism spectrum disorders (ASDs) are a N. Lojo-Kadric, L. Pojskic heterogeneous group of conditions characterized by impaired reciprocal social interaction, lack of communica- Institute for genetic engineering and biotechnology, tion, isolated interests and repetitive or stereotyped Sarajevo, Bosnia and Herzegovina behaviors. Most cases are idiopathic, although there is increasing evidence that ASDs have an important genetic Introduction: Autism, or autism spectrum disorder (ASD) component with aetiological heterogeneity. The aim of our isneurologicalanddevelopmentaldisorderthatbeginsearly study was to evaluate the role of multiplex ligation-1420 dependent probe amplification (MLPA) as a screening test We therefore explored the hypothesis that variants in in patients with autism spectrum disorders. CY
P450  genes, which define the rapid or slow metabolizer Materials and Methods: For this study we used MLPA status of their carriers, may render individuals exposed to 
P245  Microdeletion Syndromes for screening of the most certaintoxicantsmoresusceptibletobraindisruptionduring common microdeletion syndromes and MLPA 
P036  Sub- early development. To identify rare variants in 57 CY
P450  telomeres Mix 1 for screening of subtelomeric deletions/ genes we inspected exome sequence data, from publicly duplicationsin198patientswithautismspectrumdisorders. available ASD datasets, for loss-of-function (LoF) and To confirm alternations discovered with MLPA 
P036  missenseSingleNucleotideVariants(SNVs)predictedtobe Subtelomeres Mix 1 we used MLPA 
P070  Subtelomeres detrimental by in silico tools (MAF<5%), as well as rare Mix 2B. (<1%) Copy Number Variants (CNVs). In 2674 ASD Results: We identified 12 autistic patients with sub- subjects, we found 516 LoF and missense SNVs, targeting microscopic aberrations. There were 2 patients with sub- 54 CY
P450  genes, most frequently in CY
P2 A13, CY
P1 A1, telomeric deletion at the 14q and 2q regions respectively. CY
P2 D6 and CY
P4 B1. Additionally, we identified 135 Two patients had the same deletion at the 1p36.33 region. CNVs targeting 24 CY
P450  genes in 3030 ASD indivi- One patient had a submicroscopic deletion at the 6q region duals.CY
P2 D6wasexclusivelytargetedbyCNVsin13out and duplication at the 13q region simultaneously. Two of 3030 ASD-subjects, while CY
P4 X1 was significantly patients had the submicroscopic deletions at the 4q region. more frequently targetedbyCNVsinASD cases (22/3030; Three duplications were detected at 3p, 9p, and 17p11.2 0.72%) than controls (2/9649; 0.02%). CY
P2 D6 metabo- regions. Two patients were with deletion at the 8p and lizes most psychoactive drugs, while CY
P1 A1 acts on 22q11.21 regions respectively. polycyclic aromatic hydrocarbons (PAHs) and CY
P4 X1 is Conclusions:Thepresentstudyshowsthattheincidence involved in the metabolism of endocrine-disrupting chemi- of a submicroscopic aberrations detected by MLPA in cals (e.g. phthalates and bisphenol A). Early exposure to autisticpatientsisapproximately6%.MLPAisarapidand neurotoxic phthalates, bisphenol A and PAHs has been cost effective method for detection of genomic imbalances previously associated with ASD risk, and here we provide in patients with autism spectrum disorders. evidence for an effect of gene-environmental exposure D. Avdjieva-Tzavella: None. H. Kathom: None. T. interaction mediated by CY
P450  gene variants. Delchev: None. S. Bichev: None. J.X. Santos: None. A.R. Marques: None. H. Marti- niano: None. J. Vilela: None. C. Rasga: None. G. Oli- 
P09 .020C veira: None. A.M. Vicente: None. Rare variants targeting genes that encode for cytochrome
P450 enzymesinAutismSpectrumDisorder 
P09 .021D Autism Spectrum Disorder: gene variants involved in J. X. Santos1,2, A. R. Marques1,2, H. Martiniano2, the nonsense-mediated mRNA decay pathway J. Vilela1,2, C. Rasga1,2, G. Oliveira3,4,5, A. M. Vicente1,2 A. R. Marques1,2, H. Martiniano2,3, J. X. Santos1,2, 1National Health Institute Doutor Ricardo Jorge, Lisbon, J. Vilela1,2, C. Rasga1,2, G. Oliveira4,5, L. Romão6,2, Portugal, 2BioISI - Biosystems & Integrative Sciences A. M. Vicente1,2,7 Institute, Faculty of Sciences, University of Lisbon, Lisbon, Portugal, 3Unidade de Neurodesenvolvimento e Autismo 1Departamento de Promoção da Saúde e Doenças não (UNDA), Serviço do Centro de Desenvolvimento da Transmissíveis, Instituto Nacional de Saúde Doutor Criança, Centro de Investigação e Formação Clínica, Ricardo Jorge, Lisboa, Portugal, 2BioISI - Biosystems & Hospital Pediátrico, Centro Hospitalar e Universitário de Integrative Sciences Institute, Faculdade de Ciências, Coimbra, Coimbra, Portugal, 4Institute for Biomedical Universidade de Lisboa, Lisboa, Portugal, 3Departamento Imaging and Life Sciences, Faculty of Medicine, de Informática, Faculdade de Ciências, Universidade de Universidade de Coimbra, Coimbra, Portugal, 5University Lisboa, Lisboa, Portugal, 4Unidade de Clinic of Pediatrics, Faculty of Medicine, University of Neurodesenvolvimento e Autismo (UNDA), Serviço do Coimbra, Coimbra, Portugal Centro de Desenvolvimento da Criança, Centro de Investigação e Formação Clínica, Hospital Pediátrico, Autism Spectrum Disorder (ASD) heritability estimates of Centro Hospitalar e Universitário de Coimbra, Lisboa, 50-80% support the hypothesis that gene-environment Portugal, 5Institute for Biomedical Imaging and Life interactions play a role in this pathology. ASD risk has Sciences, Faculty of Medicine, Universidade de Coimbra, been associated with early exposure to various xenobiotics Lisboa, Portugal, 6Departamento de Genética Humana, that are cleared in the liver by Cytochrome 
P450  enzymes. InstitutoNacionaldeSaúdeDoutorRicardoJorge,Lisboa,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1421 Portugal, 7Instituto Gulbenkian de Ciência, Oeiras, presence of repetitive and stereotyped behaviour. It is Portugal estimated that the prevalence of ASD is 1-2% in general population with the average male to female ratio 4-5:1. Genetic factors account for 50-80% of the familial risk of Research studies have shown that clinically relevant CNVs Autism Spectrum Disorder (ASD), but most of the genetic (copy number variants) invisible in karyotype analysis are determinants are still unknown and a role for other detected in 7-14% of patients with idiopathic ASD. regulatory mechanisms is likely. The nonsense-mediated We elected to use oligonucleotide microarrays (OGT) decay(NMD)pathwayisessentialtocontrolmRNAquality withaverageresolutionof30kpztoevaluateitsefficacyfor and has an important role in the regulation of the identification and characterization of CNVs in a cohort of transcriptome. Mutations in genes involved in the NMD 275 patients with ASDs. The analyses of the patients’ pathway,suchastheUPF3Bgene,acorecomponentofthis genomes were performed using exon-focused, high- pathway, were previously linked to ASD. In this study we resolution (180k) array design covering relevant 227 explored the potential role of other NMD factors in ASD. genes for autism research. We generated a list of 153 genes involved in the NMD Chromosomal microarray analysis revealed 71 non- pathway using AmiGO, Reactome and a systematic litera- polymorphic CNVs in 63 out of 280 (22.5%) patients with ture review. To identify potentially pathogenic variants in ASD. Pathogenicorlikelypathogenic CNVs weredetected theNMDgenes,weanalyzedwholeexomesequencingdata in24(8.6%)patients,whereasCNVswithunknownclinical (WES)datafrom1338ASDsubjects.Wealsosearchedfor significance were identified in 41 (18.2 %) of cases. All of Copy Number Variants (CNVs) targeting NMD genes in the identified CNVs were submicroscopic in size (between ASD patients (n=3570) and checked their frequency in 15 kb and 3.1 Mb) and therefore could not have been controls (n=9649). detected by standard karyotype analysis. Due to high We identified 43 high impact variants in28 NMDgenes, resolution of the selected microarray, it was possible to including the UPF3B and ACE, two genes previously identify 24 CNVs that could not have been detected using implicated in ASD. Importantly, 11 were novel candidate the clinical microarrays (OGT, 60k). Our study further genes that carry loss-of-function and missense (deleterious confirmedthepotentialofaCGHinelucidatingtheetiology and damaging) variants withafrequency of1 to5% inthis of ASDs, demonstrated by the identification of two novel ASDdataset.Additionally,5NMDgeneswerefoundtobe genes: LRRTM4 and DOCK1 as candidate for ASDs. targeted by CNVs in 12 ASD subjects but none of the B. Wiśniowiecka-Kowalnik: None. I. Plaskota: None. controls. M. Kędzior: None. E. Obersztyn: None. A. Kutkowska- The discovery of 33 NMD genes that are intriguing Kaźmierczak: None. A. Pietrzyk: None. N. Braun- candidates for ASD in large patient genomic datasets sup- Walicka: None. J. Castañeda: None. A. Barczyk: None. ports the involvement of the NMD pathway in ASD A. Sobczyńska-Tomaszewska: None. K. Czerska: None. pathophysiology. B. Nowakowska: None. A.R. Marques: None. H. Martiniano: None. J.X. Santos: None. J. Vilela: None. C. Rasga: None. G. Oli- 
P09 .024C veira: None. L. Romão: None. A.M. Vicente: None. Genetic determinants for social skill training outcomes in autism spectrum disorder 
P09 .022A Application of oligonucleotide array CGH in 280 D. Li1,2, I. Rabkina1,2, S. Stamouli1,2, H. Jiao3, patients with autism spectrum disorder M. Becker1,2, U. Jonsson1,2,4, N. Choque-Olsson1,2,5, S. Bölte1,2, K. Tammimies1,2 B. Wiśniowiecka-Kowalnik1, I. Plaskota1, M. Kędzior1, E. Obersztyn1, A. Kutkowska-Kaźmierczak1, A. Pietrzyk1, 1CenterofNeurodevelopmentalDisorders(KIND),Division N. Braun-Walicka1, J. Castañeda1, A. Barczyk1, of Neuropsychiatry, Department of Women and Children's A. Sobczyńska-Tomaszewska2, K. Czerska2, Health, Karolinska Institutet, Stockholm, Sweden, 2Child B. Nowakowska1 andAdolescentPsychiatry,CenterforPsychiatryResearch, Stockholm County Council, Stockholm, Sweden, 1Institute of Mother and Child, Warsaw, Poland, 3Department of Biosciences and Nutrition, Karolinska 2MEDGEN, Warsaw, Poland Institutet, Huddinge, Stockholm, Sweden, 4Department of Neuroscience, Child and Adolescent Psychiatry, Uppsala AutismSpectrumDisorders(ASD)isaheterogenousgroup University, Uppsala, Sweden, 5Department of Clinical ofneurodevelopmentaldisorderscharacterizedbyproblems Neuroscience, Karolinska Institutet, Stockholm, Sweden in social interaction and communication as well as the1422 Introduction: Social skill group training (SSGT) is one of We identified this subject in a previous study where we themostcommoninterventionsforchildrenandadolescents observed significant changes in the single-channel inositol with autism spectrum disorder(ASD). Individualresponses triphosphate (I
P3 ) receptor kinetics of ASD fibroblasts via to SSGT vary and limited clinical predictors exist for the “optical patch-clamp” and found that this feature could be treatment. visualized with a high-throughput Fluorometric Imaging Material and Methods: Therefore, we performed a Plate Reader (FLIPR) screening assay as a decrease in detailed genetic characterization using genotyping, CNV calcium release from the ER. This release was below the calling and exome sequencing of autistic individuals from lower limit of controls in >75% of ASD subjects, but one of the largest randomized clinical trial for SSGT and uniquelyhighinan18-yearoldautisticfemaleatalevelfar analyzedtheassociationbetweengeneticfactorsandSSGT exceeding the upper limit of controls, nearing levels treatment outcome. Identified rare copy number variations obtained with ionomycin, an ionophore. (CNVs) were prioritized and polygenic risk score (PRS) To assess the molecular basis of this finding, we com- was calculated from ASD, education attainment (EA) and pleted a transcription analysisto compare expression levels attention deficit hyperactivity disorder (ADHD) based on of calcium signaling-related genes in fibroblast-derived different p-value thresholds (Pt < 0.01, 0.05, 0.1, 0.5, 1). RNA from this subject to those of two controls and two Results: Individuals who carried large CNVs (> 500kb) typical autism cases. The subject’s transcriptome showed showed significant worse outcome at 12 weeks post- increasedexpression(>5sd)ofgenesincludingtheAT
P2 A3 treatment (β = 15.4, p = 0.017) and 3-months follow-up calcium pump and purinergic receptors, and extremely low (β = 14.2, p = 0.028). In addition, inferior outcomes were expression (>24sd) of VDA
C2 , a mitochondrial calcium implicated for individuals with higher PRS for ASD (Pt = uptake channel. These findings corroborate suggestions of 0.5: β = 6.5, p = 0.018) and ADHD (Pt 1.0: β = 6.7, p = mitochondrial dysfunction in her clinical biochemical 0.015) at follow-up treatment. Currently, we are analyzing assays and are extended with Seahorse XFp assays. exome sequencing data from the same 205 individuals and R.L. Nguyen: None. P. Flodman: None. M. Smith: then combining different rare and common genetic variant None. J.J. Gargus: None. data carriers together. Conclusion: Autistic individuals with higher genetic 
P09 .026A burden for the disorder, including large rare CNVs and Establishing genotype-phenotype associations for ASD higher load of PRS, have different benefits of SSGT com- pared with individuals with lower genetic risk. Our results A. C. G. Ilhéu, M. Asif, F. M. Couto can aid in personalized intervention modifications for ASD in the future. LASIGE, Lisbon, Portugal D. Li: None. I. Rabkina: None. S. Stamouli: None. H. Jiao: None. M. Becker: None. U. Jonsson: None. N. Genotypic and phenotypic heterogeneity of Autism Spec- Choque-Olsson: None. S. Bölte: Other; Modest; Huber/ trum Disorder (ASD) has hindered the establishment of Hogrefe. K. Tammimies: None. genotype-phenotype associations. Herein, we presented a novel approach that integrates semantic similarity and 
P09 .025B unsupervisedmachinelearningmethodstodissecttheASD Evidence for altered calcium signaling and altered genotypic heterogeneity and to identify phenotypic mani- mitochondrial function in an autism case study festations of ASD genetic variants. This approach was appliedtocopynumbervariants(N=6650),disrupting3998 R. L. Nguyen, P. Flodman, M. Smith, J. J. Gargus genes from 1119 ASD patients. Functional similarities among genes were computed using Resnik semantic University of California, Irvine, Irvine, CA, United States similarity measure. Semantic similarity score, ranging from 0 to 1 represents the functional similarity between two Autism spectrum disorder (ASD) is a group of neurodeve- genes, where 1 represents identical genes while score 0 lopmental disorders characterized by deficits in social reflects functionally dissimilar genes. Agglomerative hier- interaction, communication, and stereotypic behaviors. archical clustering of the computed gene similarity matrix While its etiology is unknown, the large assemblage of identified four different clusters of functionally related risk variants impacting calcium ion channels and signaling genes. Silhouette analysis indicated that clusters were proteins suggest that a functional disruption of this compact and consistent (average Silhouette value=0.31). signaling hub may be involved in ASD pathogenesis. In The genes (N=519)ofcluster 1was morerelevanttoASD this study, we evaluate how such risk variants exert their asthey wereenrichedfor Cell adhesionmolecules (CAMs) deleterious effects in a unique ASD case. (adjusted p-value=0.00001) and Axon guidance (adjustedAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1423 p-value=0.02) pathways, which are known to be strongly differentiating neurons. Transcriptome analysis revealed associated with ASD. Cluster 1 genes were also most dysregulation of genes involved in the synaptic vesicle significantly enriched for Schizophrenia Human Phenotype cycle and single-cell RNA-sequencing indicated an imbal- Ontology (HPO) term, which is a co-occurring condition ance in excitatory-inhibitory neuronal populations. Conse- with ASD. The other three clusters were not enriched for quently, we study synapse morphology and spontaneous ASD related HPO terms. The results indicated that firing rates of excitatory and inhibitory neurons. Moreover, phenotypic-genotypic associations can established for we observed neuron subtype-specific upregulation of WNT ASDbyreducingitsgenotypicheterogeneityi.e.clustering signaling pathway components. of functionally similar genes. However, to associate these Conclusions: We provide strong evidence that CASK clusters with phenotype, further efforts are required to mutations lead to perturbed neurotransmission through enrich HPO resource. (Grant reference: PTDC/CCI-BIO/ dysregulation of synapse vesicle trafficking and differential 28685/2017) distribution of neuronal populations. Our results can guide A.C.G.Ilhéu:None.M.Asif:None.F.M.Couto:None. drugdevelopmentandaidinunderstandingthepathological spectrum of CASK mutations. 
P09 .027B M. Becker: None. F. Mastropasqua: None. J.P. Reis- Resolving effects of CASK mutations in children with ing: None. I. Rabkina: None. L. Ballenberger: None. M. neurodevelopmental disorders Kele: None. C. Willfors: None. E. Herlenius: None. S. Bölte: None. B.M. Anderlid: None. A. Falk: None. K. M. Becker1, F. Mastropasqua1, J. P. Reising2, Tammimies: None. I. Rabkina1, L. Ballenberger1, M. Kele3, C. Willfors1, E. Herlenius2, S. Bölte1, B. M. Anderlid4, A. Falk3, 
P09 .029D K. Tammimies1 Implicating genetic risk variants for circadian rhythm and sleep trait difficulties in individuals with autism 1Center of Neurodevelopmental Disorders (KIND), spectrum disorder Department ofWomen's and Children's Health, Karolinska Institutet, Solna, Sweden, 2Department of Women’s and Z. Schmilovich1,2, R. Tesfaye1,2, G. Huguet3,4, A. Dionne- Children’s Health, Karolinska Institutet, Solna, Sweden, Laporte1, O. Diallo1, B. Chaumette2,5,6, S. Jacquemont3,4, 3Department of Neuroscience, Karolinska Institutet, Solna, M. Elsabbagh1,2, P. A. Dion1,2, G. A. Rouleau1,2 Sweden, 4Department of Molecular Medicine and Surgery, Solna, Sweden 1McGill University, Montreal, QC, Canada, 2Montreal Neurological Institute and Hospital, Montreal, QC, Introduction:MutationsintheCASKgenecausearangeof Canada, 3CHU Sainte-Justine, Montreal, QC, Canada, childhood neurodevelopmental disorders such as micro- 4Université de Montréal, Montreal, QC, Canada, cephalywithpontineandcerebellarhypoplasia(MICPCH), 5Université Paris Descartes; Bio Sorbonne Paris Cité; epilepsy, developmental delay and autism. CASK, located INSERM, Laboratoire de Physiopathologie des Maladies on Xp11.4, plays a role in neuronal differentiation and Psychiatriques, Centre de Psychiatrie et Neurosciences, synapse function. The molecular consequences of CASK UMR894,GDR3557-InstitutdePsychiatrie,Paris,France, mutations have not been studied in human neurons. Our 6Centre Hospitalier Sainte-Anne, Service hospitalo- projectaimstoelucidatethedownstreameffectsofdifferent universitaire, GHU Paris Psychiatrie et Neurosciences, CASK mutations using patient-derived induced pluripotent Paris, France stem cells (iPSCs). Materials and Methods: Skin cells from two patients, Introduction:Autismspectrumdisorder(ASD)isalargely onefemalewithsevereMICPCHandonemalewithautism, hereditary neurodevelopmental disorder characterized by withdifferentCASKmutationswereprogrammedtoiPSCs difficulties in social interaction and communication, and and further differentiated to functional neurons. Bulk and restricted and repetitive behaviour. Sleep is disturbed in up single-cell RNA-sequencing was performed to identify to80%ofaffected youthswithASD.Genesunderlyingthe molecular phenotypes and guide morphological and func- circadian rhythm are proposed to elucidate sleep and other tionalassessmentofneuronalpathologyincomparisonwith timing problems in individuals with ASD. Our first aim control iPSCs. investigates whether copy-number variants(CNVs)encom- Results: A splice-site mutation in the ASD patient passing core circadian clock genes, circadian pathway decreases wild-type CASK mRNA and a tandem duplica- genes, and sleep trait candidate genes, detected from tion of two CASK exons is expressed in the MICPCH previous large genome-wide association studies, are patient. The mutations reduce CASK protein levels in1424 significantly overrepresented in ASD individuals compared type nucleolin; B. mutant nucleolin with the same C- to their unaffected siblings. terminal sequence predicted for the autism proband; C. Material and Methods: We used microarray data from truncation at Gly664. We co-stained with nucleophosmin probandswithASD(n=2926)andtheirunaffectedsiblings antibodies to show co-localization. Real time fluorescent (n=2434) from the Simons Simplex Collection (SSC). recovery after photobleaching (FRAP) was used to study CNVs were called, validated, and subsequently filtered effects on kinetics/binding dynamics. using established pipelines and detection algorithms Results: we have shown that mutant nucleolin mis- (PennCNV, QuantiSNP, SnipPeep). localizes from the nucleolus tothe nucleoplasm.Moreover, Results: Fisher’s exact test reveal that CNVs encom- aconstructwithanonsensemutationatthesameresidue,p. passed in core circadian clock genes, circadian pathway Gly664*, shows a very similar effect on the location of the genes, and sleep trait candidate genes are significantly NCL protein, thus confirming the presence of the nucleolar overrepresented in probands with ASD in comparison to location signal of NCL protein in this region. FRAP shows their unaffected siblings (p=0.003; Odds ratio 1.6; CI95% significant changes in the kinetics and mobility of mutant [1.2 ; 2.3]). NCL protein in the nucleoplasm. Conclusions: These preliminary results are the first to Conclusions: Several other studies have also reported de implicate a broad network of sleep-related genes in the novo mutations in NCL in ASD or neurodevelopmental dis- etiology of ASD. Using whole-exome sequencing (WES) orders.AlteredmislocalizationanddynamicsofmutantNCL data from the SSC, future investigations will evaluate the (p.G664Glufs*70/ p.G664*) may have relevance to the etio- representationofprobands’SNPswithinsleep-relatedgenes pathlogy of NCL-related neurodevelopmental phenotypes. in comparison to their unaffected siblings. Furthermore, T.I. Sheikh: None. N. Vasli: None. M. Ayub: None. R. SNP-set Kernel Association Test (SKAT) using probands’ Sasanfar: None. J.B. Vincent: None. WESandcorrespondingphenotypicsleepobservationswill identify candidate SNPs that associate significantly with 
P09 .031B disturbed sleep traits in individuals with ASD. Screening of ataxia samples reveals potentially Z. Schmilovich: None. R. Tesfaye: None. G. Huguet: pathogenicknownandnovelvariantsinATMandSACS None. A. Dionne-Laporte: None. O. Diallo: None. B. and likely to reveal novel genes and variants associated Chaumette:None.S.Jacquemont:None.M.Elsabbagh: with autosomal recessive ataxia None. P.A. Dion: None. G.A. Rouleau: None. N. Kaya1, M. Al-Muhaizea2, R. Almass1, M. Alsagob1, 
P09 .030A F. BinHumaid1, H. AlDhalaan2, L. AlQuait1, Heterozygous de novo truncating mutation of nucleolin L. Aldosary1,3, A. Alyousef1,3, H. Jaber1,3, in an ASD individual disrupts its nucleolar localization M. M. AlRasheed1,3, M. Aldosary1, D. Colak4 T. I. Sheikh1, N. Vasli2, M. Ayub3, R. Sasanfar4, 1Department of Genetics, King Faisal Specialist Hospital J. B. Vincent1 and Research Centre, Riyadh, Saudi Arabia, 2Department of Neurosciences, King Faisal Specialist Hospital and 1Centre for Addiction and Mental Health, Toronto, ON, Research Centre, Riyadh, Saudi Arabia, 3College of Canada, 2Hospital for Sick Children, Toronto, ON, Pharmacy, King Saud University, Riyadh, Saudi Arabia, Canada, 3Queen’s University,, Kingston, ON, Canada, 4Department of Biostatistics, Epidemiology and Scientific 4University of Massachusetts Memorial Hospital, Computing, King Faisal Specialist Hospital and Research Worcester, MA, United States Centre, Riyadh, Saudi Arabia Introduction: Nucleolin is a major nucleolar protein, Introduction: Autosomal recessive ataxias (ARAs) repre- playing a critical role in multiple processes, including sent a heterogeneous group of rare neurological disorders ribosome assembly and maturation, chromatin decondensa- involving both the central and peripheral nervous system tion, and pre-rRNA transcription. Due to its diverse encountered in various ethnic groups. Here we report functions, nucleolin’s role has been frequently implicated patients from 14 unrelated consanguineous families in pathological processes, including cancer and viral with ARA. infection. Here, we identified a de novo frameshifting indel Materials and Methods: Patients were thoroughly mutation,p.Gly664Glufs*70throughwholeexomesequen- examined by neurologists, radiologist, and evaluated and cing of an autism spectrum disorder trio.. referred to gene testing by medical geneticists. Diagnostic Materials and Methods: We transfected mammalian targeted gene panels as well as whole exome sequencing cells with GFP-tagged constructs encoding either A. wild (WES) coupled with autozygosity mapping wereAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1425 performed. Supplementary or confirmatory Sanger sequen- Introduction: The Spanish Undiagnosed Rare Diseases cing was done together with family segregation analysis. Program (SpainUDP) performs extended genetic analyses Brainmagneticresonanceimaging(MRI)weretakenaspart and deep phenotyping to get a definite diagnosis in rare of radiological exam. syndrome cases. We present the case of a 3-year-old male Results: Among the affected individuals, eight patients with severe generalized hypotonia and muscle weakness were diagnosed with carrying two separate mutations (a together with neurodevelopmental delay. He presents reported deletion and a novel compound heterozygous) in microcephaly and dysmorphic features highlighting micro- ATM.AffectedsfromFamily2,3,and4harboradeletionin retrognathy, low-set ears and hypertelorism. ATM assumingly a founder mutation with an estimated age MaterialsandMethods:Trio-basedexomeanalysiswas of ~879 years. Among the cohort two families were found carried out by using Nextera Truseq Rapid Enrichment kit to carry SACS variants. One was already reported as a and sequenced in NextSeq500 (Illumina). mutation and the other one is novel and likely to be Results: The exome analysis revealed a novel mutation pathogenic. Rest of the families were negative for any consisting on a small de novo 30-bp deletion in exon 9 of known ataxia related genes and variants. AUT
S2  gene (Autism susceptibility candidate 2, Conclusions: Our iterative filtering of WES revealed OMIM:607270),whichallowedthediagnosisofthispatient severalnovelcandidategenesinthesefamilies.Ourstudyis as AUT
S2  Syndrome or Mental Retardation, autosomal likely to discover previously unknown ARA genes. This dominant 26 (OMIM:615834). AUT
S2  gene is involved in study was funded by the grant (No. 14-MED2007-20 to N. the development of neurological disorders. Alterations of K.) from National Plan for Science, Technology and Inno- AUT
S2  gene were described as a result of genomic rear- vation program (NSTIP/KACST). rangements, although large copy number variations and N. Kaya: None. M. Al-Muhaizea: None. R. Almass: intragenic deletions or mutations have also been described None. M. Alsagob: None. F. BinHumaid: None. H. to cause this syndrome. It is noteworthy that the deletion AlDhalaan:None.L.AlQuait:None.L.Aldosary:None. found in this patient included the transcription start site of A. Alyousef: None. H. Jaber: None. M.M. AlRasheed: theshortisoformofthegene,whichplaysanimportantrole None. M. Aldosary: None. D. Colak: None. inbraindevelopment.Thegeneexpressionanalysisshowed that the deletion causes reduction inthe level of expression 
P09 .032C not only of the short isoform but also of the complete Novel mutation causing AUT
S2  síndrome. A de novo transcript of the gene. small deletion affecting the transcription start site of Conclusions: This case helps in establishing the AUT
S2  short isoform genotype-phenotype correlation adding more evidence to theroleofmutationsspecificallyaffectingtheshortisoform B.Martinez-Delgado1,2,E.López1,2,J.Lara3,S.Monzón4, for the development of a severe phenotype. I. Cuesta4, G. Gómez-Mariano1, V. Aquino1, B. Martinez-Delgado: None. E. López: None. J. Lara: C. Rodríguez-Martín1, A. Damián1, I. Gonzalo1, None. S. Monzón: None. I. Cuesta: None. G. Gómez- B. Baladrón1, R. Cazorla3, G. Iglesias3, E. Román3, Mariano:None.V.Aquino:None.C.Rodríguez-Martín: P. Ros3, P. Tutor5, S. Mellor5, C. Jiménez6, None.A.Damián:None.I.Gonzalo:None.B.Baladrón: M.J.Cabrejas7,E.González7,F.J.Alonso1,E.Bermejo- None. R. Cazorla: None. G. Iglesias: None. E. Román: Sánchez1,2, M. Posada1,2 None.P.Ros:None.P.Tutor:None.S.Mellor:None.C. Jiménez: None. M.J. Cabrejas: None. E. González: 1InstitutodeInvestigacióndeEnfermedadesRaras.Instituto None.F.J.Alonso:None.E.Bermejo-Sánchez:None.M. deSaludCarlosIII,Majadahonda,Madrid,Spain,2CIBER Posada: None. de Enfermedades Raras (CIBERER), Madrid, Spain, 3Servicio de Pediatría. Hospital Universitario Puerta de 
P09 .033D Hierro., Majadahonda, Madrid, Spain, 4Bioinformatics Comprehensive genetic analysis of whole genome Unit. Instituto de Salud Carlos III, Majadahonda, Madrid, sequencing data from 108 individuals of 8 Spain, 5Servicio de Medicina Interna, Hospital multigenerational spanish families affected with bipolar Universitario Puerta de Hierro, Majadahonda, Madrid, disorder Spain, 6Servicio de Neurología. Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain, 7Servicio S.B.Fischer1,2,C.K.Y.Ng3,4,M.Fink5,C.S.Reinbold1,2, de Bioquímica Clínica. Hospital Universitario Puerta de A. Maaser6, F. Streit7, S. H. Witt7, J. Guzman-Parra8, Hierro, Majadahonda, Madrid, Spain G. Orozco-Diaz9, G. Auburger10, M. Albus11, M. Borrmann-Hassenbach11, M. J. González8, S. Gil- Flores12,F.J.Cabaleiro-Fabeiro13,F.DelRíoNoriega14,1426 F. Perez-Perez15, J. Haro-González16, F. Rivas17, geneset/pathwayanalysisfortheresultinggenesusingIPA F.Mayoral17,S.Herms1,2,6,M.Rietschel7,M.M.Nöthen6, and ConsensusPathDB. In addition to that we conducted P. Hoffmann1,2,6, A. J. Forstner6,1,18, S. Cichon2,6,19 Polygenic Risk Score analysis in the subset of the 8 families. 1Human Genomics Research Group, Department of In our analysis we focused on rare variants with a minor Biomedicine, University of Basel, Basel, Switzerland, allele frequency below 1% (ExAC database). Our first 2Institute of Medical Genetics and Pathology, University analysisisan“extendedexome”analysisofWGSdata.We Hospital Basel, Basel, Switzerland, 3Institute of Pathology, applied a narrow analysis model to identify overlapping, UniversityHospitalBasel,Basel,Switzerland,4Department rare, co-segregating variants in the affected individuals in of Biomedicine, Hepatology Laboratory, University of one family which are not shared by healthy individuals Basel, Basel, Switzerland, 5Novartis Pharma AG, Basel, withinthesamefamily.Additionallyweappliedananalysis Switzerland, 6Institute of Human Genetics, University of model for incomplete penetrance. In total we identified 3 Bonn, School of Medicine & University Hospital Bonn, proteintruncatingand9missensevariants.PRSanalysesin Bonn, Germany, 7Department of Genetic Epidemiology in the families show very diverse risk profiles for healthy and Psychiatry, Central Institute of Mental Health, University affected individuals. Gene set enrichment analyses mainly Medical Center Mannheim/University of Heidelberg, highlight immunological genes. Mannheim, Germany, 8Department of Mental Health, S.B. Fischer: None. C.K.Y. Ng: None. M. Fink: A. Institute of Biomedicine IBIMA, University Hospital of Employment (full or part-time); Significant; Novartis Malaga, Malaga, Spain, 9Unidad de Gestión Clínica del Pharma AG. C.S. Reinbold: None. A. Maaser: None. F. Dispositivo de Cuidados Críticos y Urgencias del Distrito Streit: None. S.H. Witt: None. J. Guzman-Parra: None. Sanitario Málaga - Coin-Gudalhorceedicine, Malaga, G. Orozco-Diaz: None. G. Auburger: None. M. Albus: Spain, 10Department of Experimental Neurology, Division None.M.Borrmann-Hassenbach: None.M.J.González: of Neurology, Goethe University Hospital, Frankfurt, None.S.Gil-Flores:None.F.J.Cabaleiro-Fabeiro:None. Germany,11IsarAmperKlinikumMünchenOst,kbo,Haar, F. Del Río Noriega: None. F. Perez-Perez: None. J. Germany, 12Department of Mental Health, University Haro-González: None. F. Rivas: None. F. Mayoral: Hospital of Reina Sofia, Cordoba, Spain, 13Department of None. S. Herms: None. M. Rietschel: None. M.M. Mental Health, University Hospital of Jaen, Jaen, Spain, Nöthen:None.P.Hoffmann:None.A.J.Forstner:None. 14Department of Mental Health, University Hospital of S. Cichon: None. Jerez de la Frontera, La Frontera, Spain, 15Department of Mental Health, University Hospital of Puerto Real, 
P09 .036C Department of Mental Health, Cádiz, Spain, 16Department Bi-allelic MYORG variant carriers exhibit primary of Mental Health, Hospital Punta de Europa, Algeciras, brain calcification with a distinct phenotype Spain, 17Department of Psychiatry, Carlos Haya Regional University Hospital, Malaga, Spain, 18Centre for Human L. Grangeon1, D. Wallon1, C. Charbonnier2, O. Quenez2, Genetics, University of Marburg, Marburg, Germany, A.Richard2,S.Rousseau2,C.Budowski1,T.LeBouvier3, 19Institute of Neuroscience and Medicine INM-1, Research C. Anne-Gaëlle4, V. Marie5, M. Aurélie5, R. Emmanuel5, Center Jülich, Jülich, Germany A. Mathieu6, T. Christine6, P. Favrole7, J. Antoine8, L. Defebvre9, X. Ayrignac10, P. Labauge10, J. Pariente11, Bipolar Disorder (BD) is a genetically complex neuropsy- M. Clanet11, D. Maltête12, A. Rovelet-Lecrux2, chiatric disorder with an estimated heritability of approxi- A. Boland13, J. Deleuze13, French PFBC study group, mately 70%. GWAS have shown that common risk factors T. Frebourg2, D. Hannequin1, D. Campion2, G. Nicolas2 substantially contribute to the development of BD and explain 25-38% of the phenotypic variance. Rare variants 1Normandie Univ, UNIROUEN, Inserm U1245 and Rouen with higher penetrance might explain some of the hidden University Hospital, Department of Neurology and CNR- heritability. A research strategy to identify such rare MAJ, Normandy Center for Genomic and Personalized variantsisWholeGenomeSequencing(WGS)ofpromising Medicine, Rouen, France, 2Normandie Univ, UNIROUEN, multigenerationalfamilieswithBD.Inthepresentstudywe Inserm U1245 and Rouen University Hospital, Department conducted WGS of 108 individuals in a set of 8 extended of Genetics and CNR-MAJ, Normandy Center for Genomic multigenerational andmultiply affected families ofSpanish andPersonalizedMedicine,Rouen,France,3Departmentof origin. Neurology, Lille University Hospital, Lille, France, WGS was performed PCR free at 30X. VCFs were cre- 4Department of Neurology, Nantes University Hospital, atedbasedonGATK´sbestpracticeguidelines.Wesetupa Nantes,France,5Départementdeneurologie,HôpitalPitié- WGS analysis workflow based on vcfR. We conducted a Salpêtrière, Assistance Publique - Hôpitaux de Paris,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1427 Faculté de médecine de Sorbonne Université, Inserm radiological phenotype in the interface between PFBC and U1127, CNRS UMR 7225, ICM, F-75013, Sorbonne spino-cerebellar ataxias. Universites, Paris, France, 6Service de Neurologie, L. Grangeon: None. D. Wallon: None. C. Charbon- Hôpitaux Universitaires de Strasbourg, Hôpital de nier: None. O. Quenez: None. A. Richard: None. S. Hautepierre, Strasbourg, France, 7Department of Rousseau: None. C. Budowski: None. T. Le Bouvier: Neurology, Aix Hospital,, Aix en Provence, France, None. C. Anne-Gaëlle: None. V. Marie: None. M. Aur- 8Department of Neurology, Saint-Etienne University élie: None. R. Emmanuel: None. A. Mathieu: None. T. Hospital,SaintEtienne,France,9DepartmentofNeurology Christine: None. P. Favrole: None. J. Antoine: None. L. A, Salengro University Hospital, and EA4559, Lille, Defebvre: None. X. Ayrignac: None. P. Labauge: None. France,10DepartmentofNeurology,MontpellierUniversity J.Pariente:None.M.Clanet:None.D.Maltête:None.A. Hospital, Montpellier, France, 11Toulouse NeuroImaging Rovelet-Lecrux: None. A. Boland: None. J. Deleuze: Center, Toulouse University, Inserm, Toulouse, France, None. T. Frebourg: None. D. Hannequin: None. D. 12DepartmentofNeurology,RouenUniversityHospitaland Campion: None. G. Nicolas: None. University of Rouen, France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and 
P09 .037D Communication, Rouen, France, 13Centre National de Identifying novel KIF1C-cerebellar ataxia variants by Recherche en Génomique Humaine (CNRGH), Institut de exome sequencing and molecular characterization Biologie François Jacob, CEA, Université Paris-Saclay, Evry, France M.Santos1,2,S.Carmona2,3,J.L.Neto2,4,J.Damásio1,5,6, J.Sequeiros1,5,7,C.Barbot5,P.Coutinho5,R.Guerreiro2,3, Introduction:PrimaryFamilialBrainCalcification(PFBC) J. Brás2,3, I. Alonso1,5 is a rare disorder with diverse neuropsychiatric expression. Mutations in four genes cause autosomal dominant PFBC 1UnIGENe, IBMC - Institute for Molecular and Cell (AD-PFBC). Recently, bi-allelic MYORG pathogenic var- Biology, i3S - Instituto de Investigação e Inovação em iants have been reported to cause autosomal Saúde, Univ. Porto, Porto, Portugal, 2Department of recessive PFBC. Neurodegenerative Disease and UK Dementia Research Methods: We screened MYORG by whole exome Institute, University College London, London, United sequencing in 29 unrelated probands negatively screened Kingdom, 3Center for Neurodegenerative Science, Van for the AD-PFBC genes, studied the clinical and radi- AndelResearch Institute, GrandRapids, MI,United States, ologicalfeaturesinbi-allelicpathogenicvariantcarriersand 4Present address: Instituto de Medicina Molecular João compared them to that of 102 AD-PFBC patients. Lobo Antunes, Univ. Lisboa, Lisboa, Portugal, 5CGPP, Results:Weidentified16patientsfrom11familieswitha IBMC - Institute for Molecular and Cell Biology, i3S - bi-allelicrareornovelpredicteddamagingvariant.MYORG Instituto de Investigação e Inovação em Saúde, Univ. patientsexhibitedahighclinicalpenetrance(medianageof Porto, Porto, Portugal, 6Neurology Department, Centro onset of 52 years, range: 21-62) with motor impairment at Hospitalar Universitário do Porto, Porto, Portugal, the forefront. Dysarthria was the presenting sign in 11/16 7ICBAS - Instituto de Ciências Biomédicas Abel Salazar, patients. In contrast to AD-PFBC patients, 80% sympto- Univ. Porto, Porto, Portugal matic patients eventually presented at least 4 of the fol- lowing 5 symptoms: dysarthria, cerebellar syndrome, gait Hereditarycerebellar ataxias areagroup ofneurodegenera- disorder, akinetic-hypertonic syndrome and pyramidal tivedisorderswithahighclinicalandgeneticheterogeneity, signs. In addition, MYORG patients exhibited the most characterized by incoordination of movement and speech, severe pattern of calcifications. Strikingly, 12/15 presented and unsteady gait. Several genes have been identified as brainstem calcifications in addition to extensive calcifica- causative of these diseases; however, several families tions in other brain areas (basal ganglia, cerebellum ± cor- remain without molecular diagnosis. tex). Among them, 8 patients exhibited pontine Inthisstudy,weusedhomozygositymappingandexome calcifications, which were never observed in AD-PDFC. sequencing to study a cohort of Portuguese families with Finally, all patients exhibited cerebellar atrophy as con- autosomal recessive cerebellar ataxia, identified during a firmed by MRI Voxel Based Morphometry. Of note, in systematic population-based survey. These analyses three families, the father carried small pallido-dentate cal- revealed two novel homozygous variants in KIF1C in two cifications, suggesting a putative phenotypic expression in families with spastic ataxia: a frameshift variant some heterozygous carriers. (c.393_396del, p.Ser131Argfs*13) and a splice site variant Conclusions: We confirm MYORG as a novel major (c.1166-2A>G), both segregating with the disease and PFBC causative gene and identify a recognizable clinico- confirmed by Sanger sequencing. Western blot analysis1428 showed that the frameshift variant, located in the motor H. Hu: None. K. Xu: None. D. Liu: None. H. Tang: domain, leads to a truncated protein that lacks most of the None. L. He: None. N. Li: None. KIF1C functional domains. We also demonstrated, using a minigene assay, that the splice variant abolishes the 
P09 .039B acceptorsplicesite,activatinganewone8bpdownstream. TORCH-like encephalopathy due to de novo CO
L4 A1 This change is predicted to cause a frameshift and a pre- mutation mature stop codon, thus leading to a truncated protein (p. Gly389Aspfs*27). A. Gerasimenko1, D. Héron1, T. Billette de Villemeur2, KIF1C encodes amember ofthe kinesin-3 family, which D. Rodriguez2, C. Garel3, E. Tournier-Lasserve4, are microtubule-based motor proteins. Variants in KIF1C F. Chalard3, M. Miné5, T. Coste3, C. Mignot1 have been previously associated with SPG58 and SPAX2, bothautosomal-recessivediseasescombiningspasticityand 1APHP, Department of Genetics, Armand-Trousseau and cerebellar signs. Our study revealed two novel KIF1C Pitié Salpêtrière hospital, Reference Center for Intellectuel variants in two families with a phenotype compatible with disability of Rare Causes, Paris, France, 2APHP, SPAX2. These variants probably cause KIF1C loss-of- Department of pediatric neurology, Armand-Trousseau function, supporting the role of intracellular trafficking in hospital, Paris, France, 3APHP, Department of pediatric the pathogenesis of cerebellar ataxia. radiology, Armand-Trousseau hospital, Paris, France, M.Santos:None.S.Carmona: None.J.L.Neto:None. 4APHP, Department of molecular genetics, Lariboisière- J. Damásio:None. J. Sequeiros: None. C.Barbot: None. Fernand-Widal, Paris, France, 5APHP, Department of P.Coutinho:None.R.Guerreiro:None.J.Brás:None.I. molecular genetics, Lariboisière-Fernand-Widal hospital, Alonso: None. Paris, France 
P09 .038A Cerebrovascular destructive lesions of the brain are well- In-depth genomic investigation reveals a wide spectrum known antenatal manifestations of CO
L4 A1 pathogenic ofdeleteriousvariantsin120casesofidiopathiccerebral variants. These lesions include both limited porencephales palsy and wider lesions such as hydranencephaly and schizence- phaly, sometimes associated with intracranial calcification. H. HU1,2,3, K. XU4, D. LIU5, H. TANG4, L. H
E4 , N. LI1 Nature of the lesions depends on timing and anatomical extension of the vascular insufficiency. 1GuangzhouInstituteofPediatrics,GuangzhouWomenand We report the case of a girl born in Kazakhstan after Children's Medical Center, Guangzhou, China, prenatal suspicion of microcephaly. She received intensive 2Guangzhou Medical University, Guangzhou, China, careafterbirthandshowedinfantilespasmsat3months.At 3Zhengzhou University the third affiliated hospital, our first examination at 9 months, she presented severe Zhengzhou, China, 4Department of Rehabilitation, development delay, tetrapyramidal involvement, marked Guangzhou Women and Children's Medical Center, microcephaly and epilepsy. At 11 years, the girl was pro- Guangzhou, China, 5Co-innovation Center of foundly intellectually disabled and showed stable micro- Neuroregeneration, Key Laboratory of Neuroregeneration cephaly at -7 SD. Initial brain imaging showed widespread of Jiangsu and Ministry of Education, Nantong University, ulegyria, incomplete gyration with major widening of the Nantong, China Sylvian fissure and polymicrogyria, as well as band-like calcifications. This suggested a TORCH infection. Cerebral palsy (CP) is a group of neurodevelopmental Analysis of the OCLN gene, responsible for Pseudo- disordersaffectingmovementandposture,inwhichtherole TORCH syndrome 1, revealed no variation. Cytomegalo- of genetic variation is yet to be fully established. Here we virus fetopathy was suspected since the virus was found in performcomprehensivegenetic analysisonacohortof120 theurine.Finally,targetedsequencingofCO
L4 A1revealed idiopathic CP families by integrating 35X whole-genome the de novo heterozygous p.Gly148Arg variant, typically sequencing, 500X whole-exome sequencing, 5000X mito- altering a Gly-X-Y motive of the collagen triple helix. chondrialgenomesequencing,andhigh-densitycytogenetic CO
L4 A1 mutations should be considered in unproven microarray. We find that up to 40% of idiopathic CP cases TORCH-like encephalopathies combining widespread vas- are attributed to de novo and inherited deleterious variants cularinsufficiencyofthefetal brain,gyrationabnormalities in a spectrum of genes, including novel candidate genes and calcifications. such as TYW1 and GPAM, the dysfunctional copies of A.Gerasimenko:None.D.Héron:None.T.Billettede which are shown to cause abnormal neurodevelopment in Villemeur: None. D. Rodriguez: None. C. Garel: None. organismal models.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1429 E. Tournier-Lasserve: None. F. Chalard: None. M. J. Klar, J. Schuster, M. Sobol, L. Laan, A. Fatima, Miné: None. T. Coste: None. C. Mignot: None. G. Annerén, N. Dahl 
P09 .040C Department of Immunology, Genetics and Pathology, DevelopmentofacellularmodeltostudytheroleofCR1 Uppsala, Sweden in Alzheimer's disease Background: Down syndrome (DS) is a leading genetic F. Cardona1,2, J. Szymanski1,2, J. Pérez-Tur1,2,3 cause of intellectual disability and approximately 95% of patientswithDShaveafulltrisomy21(T21).Thisresultin 1UnitatdeGenèticaMolecular,InstitutodeBiomedicinade aglobaltranscriptionaldysregulationandstudiessuggestan Valencia, CSIC, Valencia, Spain, 2CIBERNED, Madrid, altered distributionofneuronalandglialcellsinDSbrains. Spain, 3Unidad mixta de Neurología y Genética, Instituto Methods: We established induced pluripotent stem cells de Investigación Sanitaria la Fe (IIS La Fe), Valencia, (iPSC) from a patient with full T21 and a healthy control Spain individual. The iPSCs were differentiated into neural cells for 30 days using an undirected protocol. Libraries was Alzheimer's disease (AD) is the most common neurode- prepared using the Chromium Single Cell 3’Reagent Kits generativedementia inthe elderly,affecting between 5 and v2 (10X Genomics), sequenced on a HiSeq 2500 PE (Illu- 10%ofthepopulationover65yearsofage, andincreasing mina) and analyzed using CellRanger V2.0 (10X Geno- its prevalence with age. The ratio of isoforms F and S of mics) and Monocle 2 (Trapnell Lab). CR1 (CD35), determined by the presence of some Results: Cluster analysis from euploid cells shows that haplotypes or variants, has been related to late onset AD. 63% correspond to radial glia, 6% tointermediate neuronal Particularly thesignificant presence ofthe long isoform (S) progenitorcells(nIPC),20%toneuronsand5%tovascular is related to a lower total amount of CR1, which leads to a and leptomeningeal cells (VLMCs). In contrast, the cluster worse elimination of the β-amyloid peptide (Aβ), greater analysis of T21 cells shows that 24% correspond to radial activationofthemicrogliaasaninflammatoryresponse,and glia, 5% nIPCs and only 4% neurons. Importantly, 56% of neuronal death. trisomic cells correspond to VLMCs, making this cluster Inthisworkwehavegeneratedamixedcellularmodelof predominant. neuroinflammation, using as a model the cell lines SH- Conclusion: In our model of T21 neurogenesis we SY5Y (neuron), 1321N1 (astrocyte) and HCM3 (micro- observe a reduced proportion of neuronal cells and an glia). The results shown that these co-cultures are able to increased proportion of glia cell. The formation of the activatetheglialcellswhentreatedwithlipopolysaccharide VLMCpopulationiniPSCneuralcellswithT21appearsto toxin (LPS) or Aβ, increasing the protein markers for each be continuous and with a differentiation trajectory distinct activated cell type. This cellular model also increases the from that of euploid cells consistent with DS brain expression of the genes of the complement complex pro- development. teins (CR1, 
C1 q, 
C3  and 
C4 ) in response to these treat- Grant: This work was supported by the Swedish ments. Preliminary results alsosuggestthat thesilencingof Research Council (VR). CR1 in this model decreases neuronal viability with Aβ, J. Klar: None. J. Schuster: None. M. Sobol: None. L. pointing to the role of this protein in neuronal Laan: None. A. Fatima: None. G. Annerén: None. N. survival in AD. Dahl: None. Thismodelcouldbeausefultooltotesttheeffectofgene orpharmacologicaltherapiestoimprovetheresponsetoAβ 
P09 .042A and neuroinflammation, thus improving neuronal Rare complex chromosome mosaic with two different survival in AD. chromosome-15 derived supernumerary marker Funding acknowledgement: GV/2018//166 and chromosomes in a boy with developmental delay and CIBERNED (group 209) behavioural abnormalities F. Cardona: None. J. Szymanski: None. J. Pérez- Tur: None. U. Heinrich1, M. Cohen1,2, S. Upheber2, I. Rost1 
P09 .041D 1Centre for Human Genetics and Laboratory Medicine, Single cell sequencing of iPSC neural cells from Down Martinsried, Germany, 2kbo Children's Centre, Munich, syndrome patients uncovers perturbed cell Germany differentiation1430 Case report: We report on 5 years old boy with global carriers develop dystonia. The underlying mechanisms of developmental delay, short attention span, lack of coopera- the reduced penetrance remain elusive. Maturing neurons tion, sleep disturbance, and microcephaly. He is the only generatedfrominducedpluripotentstemcells(iPSCs)could child of parents of Nepalese descent. serve as an in-vitro model to unravel penetrance-relevant Materials and Methods: Conventional karyotyping was mechanisms. performed using standard GTG banding technique. FISH Material and Methods: Human dermal fibroblasts were analyseswereperformedonmetaphasespreadsaccordingto reprogrammed using non-integrating Sendai virus and the manufacturer’s specifications. For microarray analysis, iPSCs were cultivated on Matrigel with 
E8  and mTeSR CytoSure Constitutional 180K microarray was used. media. Neural differentiation of 32 iPSC lines into cortical Results: Chromosome analysis revealed four different neurons was achieved using dual SMAD inhibition, two cell lines: cell line I (28 %): normal karyotype; cell line II: neural rosette stages, and a dissociation step. Cortical neu- bisatellited supernumerary marker chromosome (SMC) (50 rons were harvested on day 44 of differentiation for gene %); cell line III: a different SMC (3 %); cell line IV: both expression analysis by quantitative PCR. SMC’s (19 %). The combined use of FISH probes and Results: In the 44-day old neuronal lines, THA
P1  microarray analysis led to the following characterizations: expression was elevated in mutation carriers with p. the bisatellited marker chromosome as monocentric chro- Lys158Asnfs*23 and p.Ser21Cys mutations, but not in p. mosome 15 with no clue for euchromatin; the second Arg13His carriers. A trend of increased THA
P1  expression marker chromosome as a complex ring chromosome 15 in affected compared to unaffected carriers was observed. with a 9,8 Mb duplication 15q11.2q13.3 including the Expression of TOR1A, another dystonia gene that possibly Prader-Willi-/Angelman syndrome critical region, together is regulated by the transcription factor THA
P1 , seemed with a 538 kb gain in band 15q11.2 (Burnside-Butler syn- unaltered. Furthermore, THA
P1  expression was indepen- drome region) presumably in triplicated form. dentofaseeminglypenetrance-linkedpolymorphisminthe Conclusion: We present a patient with a partial pentas- KAT6A promotor, a region that loops to the THA
P1  pro- omy 15q11.2/tetrasomy 15q11.2q13.3 mosaicism. Patients motor as shown by 4C analysis. with the recurrent chromosome 15q11-q13 duplication Conclusion:WeobservedhigherexpressionofTHA
P1 in syndrome are characterized by intellectual disability, sei- some mutation carriers compared to controls depending on zures, and behavioural abnormalities, while patients with a themutation,whichmaybeexplainedbytheautoregulation triplication 15q11-q13 have a more severe neurosycholo- of THA
P1 . Further, the THA
P1  expression level might gical phenotype. Due to the mosaicism the further devel- correlate with the disease status. Future transcriptomic opment of our patient is hardly to predict making genetic profilingwillshedlightondysregulatedsignalingpathways counseling a difficult task. Besides, none of the modern resulting in DYT-THA
P1  dystonia (FOR2488). NGS-based techniques is able to solve this case correctly. H. Baumann: None. M. Trilck-Winkler: None. M. U. Heinrich: None. M. Cohen: None. S. Upheber: Grosse: None. A. Muenchau: None. V. Kostic: None. C. None. I. Rost: None. Klein: None. F. Kaiser: None. P. Seibler: None. K. Lohmann: None. 
P09 .043B Gene expression analysis in cortical neurons 
P09 .044C differentiated from 32 induced pluripotent stem cell Diagnostic yield and clinical relevance of exome trio (iPSC) lines of THA
P1  mutation carriers and controls analysis in patients with epilepsy H. Baumann1, M. Trilck-Winkler1, M. Grosse2, M. Martinez-Garcia, I. Diez, R. Perez-Carro, A. Muenchau1, V. Kostic3, C. Klein1, F. Kaiser2, S. Rosestone, E. Fernandez-Tabanera, C. Rodriguez, P. Seibler1, K. Lohmann1 I. Sanchez-Navarro, R. Sanchez-Alcudia, E. Mata, D. Rodriguez, N. Sanchez-Bolivar, M. Carcajona, 1InstituteofNeurogenetics,UniversityofLuebeck,Luebeck, P. Maietta, S. Alvarez Germany, 2Section of Functional Genetics, Institute of Human Genetics, University of Luebeck, Luebeck, Medical Department, NIMGenetics S.L., Madrid, Spain, Germany, 3Clinic of Neurology, Faculty of Medicine, Madrid, Spain University of Belgrade, Belgrade, Serbia Introduction: Epilepsy is a chronic disorder characterized Introduction: Dystonia is a heterogeneous movement byrecurrentunprovokedseizures.Frequently,thesepatients disorder and can be caused by mutations in THA
P1  have different type of seizure and may have other (DYT-THA
P1 ). However, only ~50% of THA
P1  mutation neurological symptoms. The goal of this study was toAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1431 identify the genetic causes and to establish the diagnostic responsible for 2-11 % of epilepsies. We present cohort of yield of trio analysis on patients with isolated seizures or 193patientswithepilepsy,bothchildrenandadults,divided with syndromic clinical presentations. in two groups - 49 patients with isolated epilepsy and 144 Patients and Methods: A cohort of 81 probands was patients with syndromic epilepsy (i.e. associated with sequenced by Trio whole exome sequencing. The median developmental delay, dysmorphic features etc). ArrayCGH agewas7yearsold.In78%oftheprobands,seizureswere platform SurePrint G3 ISCA 4x180 and 8x60 (Agilent described as part of a more complex phenotype. Genomic Technologies)wereusedfortheexaminations.Wedetected libraries were generated with Ion AmpliSeqTMor SureS- CNVs in 32/193 of patients (16.6 %): 16 deletions (50 %), electXTand sequenced by Ion ProtonTM/ 
S5 TMXL or Nova- 12duplications(38%),onetriplication(3%)andmorethan Seq 6000. The data were processed using an “in house” one CNV were detected in three patients (9 %). 15 CNVs developed pipeline. werepathogenicandexplainingthephenotype,threeCNVs Results: A genetic diagnosis was obtained on 28 out of were probably pathogenic, two were benign and 12 were 81 patients, leading to a diagnostic yield of 35%. Among variants of unknown significance (VOUS). Pathogenic and the identified variants the distribution was, 64% de novo, probably pathogenic CNVs were detected only in syndro- 18% homozygous, and 14% hemizygous, with a large mic patients. In patients with isolated epilepsy only VOUS proportion of missense variants (64%). Diagnostic yield of and benign variants were detected. Origin of variants was 42%, was obtained in the syndromic cases (n=63), identi- determined as maternal (20 %), paternal (13 %), de novo fying variants not previously reported in targeted analysis. (30 %) and was unknown in 37 % of cases. CNVs size In the cases with isolated seizures (n=22), the genetic ranged from 15 kb to 9 Mb. Except of CNVs located in diagnosis was only established in two cases, through the regions associated with known syndromes and epilepsy identification of de novo variants in the genes CO
L4 A3BP "hotspots", we detected new non-recurrent CNVs. Using and TBR1, previously associated to a more complex arrayCGH,weidentifiedCNVsasacauseofepilepsyin18/ phenotype. 144 syndromic patients (12.5 %). CNVs play an important Conclusions: Exome trio sequencing is a cost-effective role in aetiology of epilepsies. Therefore arrayCGH should strategy with a high diagnostic yield in syndromic patients be included into diagnostic algorithm as a first-choice with epilepsy that enables a phenotypic broad-spectrum genetic method in patients with syndromic epilepsy. diagnosis. This approach contributes significantly to the Supported by: 00064203, NF-CZ11-PDP-3-003-2014, 17- identification of new candidate genes. 29423A M. Martinez-Garcia: None. I. Diez: None. R. Perez- H. Zůnová: None. T. Rašpličková: None. D. Novotná: Carro: None. S. Rosestone: None. E. Fernandez-Taba- None. M. Štolfa: None. M. Havlovicová: None. M. nera: None. C. Rodriguez: None. I. Sanchez-Navarro: Malíková:None.P. Tesner:None.J. Drábová:None.K. None. R. Sanchez-Alcudia: None. E. Mata: None. D. Štěrbová: None. P. Kršek: None. J. Zárubová: None. H. Rodriguez: None. N. Sanchez-Bolivar: None. M. Car- Krijtová: None. P. Marušič: None. M. Vlčková: None. cajona: None. P. Maietta: None. S. Alvarez: None. 
P09 .047B 
P09 .045D Howfarcanwego?Wholegenomesequencing,periodic CNVs in patients with epilepsy - Czech experience reanalysis and international collaborations expands our understanding of the causes of developmental and H. Zůnová1, T. Rašpličková1, D. Novotná1, M. Štolfa1, epileptic encephalopathy M. Havlovicová1, M. Malíková1, P. Tesner1, J. Drábová1, K. Štěrbová2, P. Kršek2, J. Zárubová3, H. Krijtová3, E. E. Palmer1,2, R. Sachdev3,2, R. Macintosh3, P. Marušič3, M. Vlčková1 T. Kandula2,3, A. Minoche4, C. Puttick4, V. Gayevskiy4, T. Roscioli3,5, M. Dinger2, L. Hesson6, C. Shoubridge7, 1DBMG, 2nd Faculty of Medicine Charles University and A. Drew4, R. Davis8,9,4, S. Kummerfeld4, M. Cowley10, University Hospital Motol, Prague, Czech Republic, A. Bye2,3, E. Kirk2,3 2Department od Paediactric Neurology, 2nd Faculty of Medicine Charles University and University Hospital 1GeneticsofLearningDisability(GoLD)Service,Waratah, Motol,Prague,CzechRepublic,3DepartmentofNeurology, Australia, 2University of New South Wales, Sydney, 2ndFacultyofMedicineCharlesUniversityandUniversity Australia, 3Sydney Children's Hospital, Sydney, Australia, Hospital Motol, Prague, Czech Republic 4Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, Australia, 5NeuRA, Sydney, Epilepsy is heterogeneous chronic neurological disorder Australia, 6Garvan Institute for Medical Research, Sydney, with prevalence 8/1000. Copy number variants (CNVs) are Australia, 7University of Adelaide, Adelaide, Australia,1432 8Kolling Institute, University of Sydney, Sydney, Australia, 1Montréal Neurological Institute, Montréal, QC, Canada, 9Royal North Shore Hospital, Sydney, Australia, 2McGill University, Montréal, QC, Canada, 3University of 10Children's Cancer Institute, Sydney, Australia Saskatchewan, Saskatoon, SK, Canada, 4Montréal Neurological Institute, Montréal, ON, Canada Introduction:Thereisapressingclinicalneedtodetermine the molecular causes of DEE to guide management and Introduction: The genetic etiology of one of the most genetic counselling. Our trio exome sequencing (ES) study common movement disorders, essential tremor (ET), is not (2016-2017) had a high diagnostic yield (15/30: 50%), yet fully characterized. Currently, studies have focused on demonstrated cost-effectiveness and delineated novel investigating common or rare genetic variants but have yet geneticcausesofDEE;butcouldweimprovethediagnostic to investigate ET transcriptomes. yield further? Methods: To identify relevant pathways and genes, the Materials and Methods: Trio WGS (Illumina HiSeqX transcriptomeoftwocerebellarregions(dentatenucleusand platform)wasappliedto15individualsundiagnosedbyour cortex)derivedfrom16casesand16age-andsex-matched ES study and 16 individuals undiagnosed by massively- controls was interrogated by RNA sequencing. A genome- parallel sequencing panel. In-house platforms Seave, Mity, wide gene association study (GWGAS) was conducted ClinSV,IntromeandROHmerfacilitatedvariantannotation using1,778casesand5,376controlindividuals.Afterward, and filtration and identification of regions of homozygosity pathway enrichment was done using genes shown to be and mitochondrial, non-coding and structural variants. significant after Bonferroni correction (P<2.7E-06) to nar- Collaborations were initiated to clarify pathogenicity of row down transcriptomic pathways. novel variants. Results: We identified several novel dysregulated genes Results: 8 additional diagnoses were made in the 15 including CACNA1A, a calcium voltage-gated channel individualsfromtheESstudy:5weredetectablebyESbut implicated in ataxia and reported to cause tremor in Cac- required collaborative clinical/functional studies to prove na1a-knockout mice. Furthermore, several pathways pathogenicity; 3 (20%) were genomic mechanisms unde- includingaxonguidanceandcalcium channel activity were tectable by ES (complex structural variants). 11 diagnoses significantly enriched. The GWGAS also revealed a sig- were made in the 16 panel-negative individuals (68%): the nificant enrichment across genes associated with calcium majority (n=10) in genes excluded from the panel, 1 was ion-regulated exocytosis of neurotransmitter. Finally, the missed for technical reasons. dentate nucleus and cerebellar cortex appeared to have Conclusions: An ES or WGS approach plus periodic different transcriptomes, supporting the notion of spatially reanalysis and international collaborations can result in a different transcriptomes across the cerebellum. cumulative diagnostic yield of over 75% for DEE. WGS Conclusions: The identification of dysregulated path- canrobustlydetectstructuralvariants;ongoingresearchwill ways in post-mortem cerebellum from patients can increa- assist non-coding variant interpretation. Individuals ses our understanding of the pathogenesis for this undiagnosed after intensive genomic analysis often had understudied condition, which may reveal potential targets normal development prior to seizure onset, and lacked for therapeutic treatment. Calcium-related pathways were congenital anomalies and neurological progression: they shown to be relevant to ET and future studies should may have alternative causes such as somatic mosaicism or investigate the underlying mechanisms of this disruption. polygenic variants. Funding: NHMRC, NSW Health, We thank the participants for providing DNA and the Kinghorn Foundation Canadian Institutes of Health Research (#RN254517- E.E. Palmer: None. R. Sachdev: None. R. Macintosh: 332736). None.T.Kandula:None.A.Minoche: None.C.Puttick: C.Liao:None.F.Sarayloo:None.D.Rochefort:None. None.V.Gayevskiy:None.T.Roscioli:None.M.Dinger: F. Akçimen: None. A.D. Laporte: None. D. Spiegelman: None. L. Hesson: None. C. Shoubridge: None. A. Drew: None. A. Rajput: None. P.A. Dion: None. G.A. None. R. Davis: None. S. Kummerfeld: None. M. Cow- Rouleau: None. ley: None. A. Bye: None. E. Kirk: None. 
P09 .049D 
P09 .048C StudyofTTRfamilialamyloidpolyneuropathyinGreek Multi-omic approaches implicate dysregulated calcium patients pathways in essential tremor C.Kartanou1,M.Breza1,A.Papathoma2,T.Bagratouni2, C. Liao1,2, F. Sarayloo1,2, D. Rochefort1, F. Akçimen1,2, Z. Kontogeorgiou1, A. Georghiou3, P. Koutsou3, A.D.Laporte1,D.Spiegelman1,A.Rajput3,P.A.Dion4,2, K. Christodoulou3, M. Panas1, E. Kastritis2, G. Koutsis1, G. A. Rouleau1,2 G. Karadima1Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1433 1Neurogenetics Unit, 1st Department of Neurology, Significant; Teva Pharmaceuticals, Genesis Pharma. Other; University of Athens Medical School, Eginition Hospital, Significant; Novartis, Genesis Pharma, Sanofi-Genzyme, Athens, Greece, 2Department of Clinical Therapeutics, Teva Pharmaceuticals. G. Karadima: None. Alexandra Hospital National and Kapodistrian, University ofAthens,Athens,Greece,3NeurogeneticsDepartment,The 
P09 .050A Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus InvestigationoftheroleofGRNupstream openreading frames in frontotemporal dementia Introduction: Familial amyloid polyneuropathy (FAP) is a rare, autosomal dominant, neurodegenerative disorder, A. Frydas1,2, E. Wauters1,2, B. Heeman1,2, J. v. d. Zee1,2, usually associated with mutations in the transthyretin gene C. V. Broeckhoven1,2 (TTR). The most common mutation worldwide is p. Val30Met. The present study aims to identify TTR gene 1Neurodegenerative Brain Diseases, Center for Molecular mutations in Greek patients and attempt genotype- Neurology, VIB, Antwerp, Belgium, 2Biomedical Sciences, phenotype correlations. University of Antwerp, Antwerp, Belgium Materials and Methods: We studied 16 Greek indivi- duals belonging to 10 families. These included 8 patients Introduction: Frontotemporal dementia (FTD) is the referred for suspected FAP, 6 asymptomatic relatives of secondmostcommonsubtypeofdementiaregardingpeople patients,and2patientswithanFAPclinicalphenotypethat under 65 years old. It is featured by degeneration of the were,however,originallyreferredforCharcot-Marie-Tooth frontal and temporal lobes of the brain and leads to (CMT) gene testing and selected from a group of 800 sus- behavioral and language impairments. Upstream open pected CMT patients, negative for CMT1A. The molecular reading frames (uORFs) play an important role in control- diagnosis included screening for p.Val30Met with restric- ling protein expression. Variants in these elements have tion fragment length polymorphism analysis (RFLP) and been linked with certain diseases. In this project, we will Sanger sequencing of the entire coding region of the investigate the role of uORFs in granulin (GRN)- TTR gene. associated FTD. Results: The p.Val30Met mutationwas detected in3 out Materials and Methods: Targeted resequencing of of10index-cases(30%).Intheremainingprobands,Sanger uORF-harboring regions of GRN by design of an amplicon sequencing identified the p.Cys10Arg, p.Arg34Gly, p. target amplification assay (Agilent, https://www.agilent. Arg54Thr, p.Ala81Thr, p.Glu89Gln, p.Glu89Lys and p. com) was performed. Screening was done in the Belgian Val94Ala mutations. The p.Val30Met cases had the typical cohort, consisting of 389 patients and 415 control early-onset neuropathic phenotype, without early cardio- individuals. myopathy. The remaining patients had later onset neuro- Results: Investigation of ribosome profiling databases pathyandconcomitantcardiacamyloidosis.Intwoofthese and literature allowed us to identify four uORFs for GRN. patients the presenting symptom was exertional dyspnea. Preliminary screening in the Belgian cohort revealed 2 Conclusions:The p.Val30Metmutationisafrequentbut variants present within a GRN uORF. First variant (2/415 not universal cause of FAP in the Greek population. It controls, 1/389 patients) is within a splice region and its seems to present with the early-onset classic phenotype. presence could promote differential splicing by the spli- Other mutations exhibit more varied phenotypes with later ceosome machinery. The second variant (3/415 controls, 2/ onset. Interestingly, some FAP patients are hidden within 389 patients) leads to a change in the amino acid sequence the large group of “suspected CMT”. of the uORF close to the termination codon, which could C. Kartanou: None. M. Breza: None. A. Papathoma: influence ribosomal occupancy, thus affecting translations None.T.Bagratouni:None.Z.Kontogeorgiou:None.A. of the downstream protein. Georghiou: None. P. Koutsou: None. K. Christodoulou: Conclusions: These variants could act as potential None. M. Panas: None. E. Kastritis: B. Research Grant modifiers, affecting GRN serum levels or age at onset. (principal investigator, collaborator or consultant and Therefore,functionalvalidationofthesevariantscouldlead pendinggrantsaswell asgrantsalreadyreceived); Modest; to the development of biomarkers and provide novel Janssen, Amgen. D. Speakers Bureau/Honoraria (speakers mechanistic insights in FTD. bureau, symposia, and expert witness); Modest; Janssen, A.Frydas:None.E.Wauters:None.B.Heeman:None. Celgene, Genesis, Takeda, Millennium-Takeda, Pharma- J.V.D. Zee: None. C.V. Broeckhoven: None. cyclics. F. Consultant/Advisory Board; Modest; Janssen, Amgen, Takeda, Prothena. G. Koutsis: B. Research Grant 
P09 .051 (principal investigator, collaborator or consultant and bdetection of gene dosage alterations in patients with pending grants as well as grants already received); spinocerebellar disease using an exon-dense snp array1434 B. Quintans1, F. Barros2, I. Quintela3, A. Ordóñez- 
P09 .053D Ugalde4, C. Castro-Fernández1, P. Blanco-Arias2, Autosomal recessive spinocerebellar ataxia with first D. García-Estévez5, I. Sanz6, M. Arias7, M. Sobrido1 homozygous duplication in GRID2 and review of the literature 1NeurogeneticsGroup,InstitutodeInvestigaciónSanitaria, Santiago de Compostela, Spain, 2Fundación Pública A. Ceylan1, E. Acar Arslan2, H. Erdem3, H. Kavus4, Galega de Medicina Xenómica, Santiago de Compostela, M. Arslan5, H. Topaloğlu6 Spain, 3Centro Nacional de Genotipado, Universidade de Santiago de Compostela, Santiago de Compostela, Spain, 1Ankara Yildirim Beyazit University, Ankara Ataturk 4Laboratorio Biomolecular, Hospital José Carrasco Training and Research Hospital, Department of Medical Arteaga IESS, Cuenca, Ecuador, 5Department of Genetics,Ankara,Turkey,2KaradenizTechnicalUniversity, Neurology, Complexo Hospitalario Universitario de Faculty of Medicine, Department of Child Neurology, Ourense, Ourense, Spain, 6Department of Neurology, Trabzon, Turkey, 3Ankara Diskapi Yildirim Beyazit Hospital Nuestra Señora de Sonsoles, Ávila, Spain, Training and Research Hospital, Department of Medical 7Department of Neurology, Complexo Hospitalario Genetics,Ankara,Turkey,4GulhaneTrainingandResearch Universitario de Santiago, Santiago de Compostela, Spain Hospital,DepartmentofMedicalGenetics,Ankara,Turkey, 5Gulhane Training and Research Hospital, Department of AIMS: In spite of NGS many patients remain without a Child Neurology, Ankara, Turkey, 6Hacettepe University, diagnosis. In some cases this might be due to undetected Faculty of Medicine, Department of Child Neurology, pathogenic copy number variants. We evaluated a high- Ankara, Turkey density SNP-array to assess dosage abnormalities in ataxia and spastic paraplegia. Introduction: Autosomal recessive cerebellar ataxias are Methods: 10 patients were genotyped with CytoScan_- characterized by abnormal structure of the cerebellum and XON_array (ThermoFisher). The following deletions had spinalcord.GRID2isinvolvedinataxiathroughbothloss- beenpreviouslydetectedbyMLPA:SPASTexon1(1.52kb, of-functionmutationsandgain-of-functionmutationsdueto N=2), exons 6-7 (0.58kb, N=2) and exons 2-17 (154.4kb, respective deletions and missense variations. Here, we N=1); SPG11 exon29(0.21kb, N=1);ABCD1exons 3-10 report the identification and characterisation of a novel (10.11kb, N=4). We included 94 control samples from the ARCA caused by bi-allelic duplication of GRID2 in two 1000G_IBS collection. Patients with deletion of SPAST siblings. exon1andSPG11exon29weregenotypesinduplicateand Methods: Illuminia® Truesight One clinical exome was triplicate, respectively, to evaluate inter-experiment repro- performed on one of the siblings with MiSeq next‐genera- ducibility. Data analysis was carried out with CHAS® tion sequencing platform. Whereas chromosomal micro- software. array analysis was performed on the entire family by using Results: All assays passed quality check and were con- Affimetrix Optima® chips. Variants were evaluated based sistent between replications. Concordant results from on the phenotype and standard in silico tools. MLPA and array were obtained in 5/10 cases: ABCD1 Results:Nodiseasecausingmutationswerereportedasa exons 3-10, SPAST exons 1, 6-7, and 2-17, the latter result of the clinical exome test.Chromosomal microarray including contiguous genes (SL
C30 A6, NLR
C4 ). In 3 analysis showed a ~121 kb homozygous duplication of patients ABCD1 deletion was partially detected, exons 3-5 GRID2 (chr4:94,447,511-94,569,021), including exon 14, (3.51kb).Thedeletionwasnotdetectedbythearrayin2/10 in two siblings. cases:SPAST exons 6-7,SPG11 exon29,albeitobservable Conclusion: Previously there has been reports of homo- upon visual examination in all 13 assays. There were no zygousdeletionsandmissensemutationsofGRID2,butour gains or losses in control samples. study is the first one to identify a homozygous duplication Conclusions: CytoScan_XON array is useful to identify ofthegene.Thismutation,whichsegregatedintwosiblings genedeletionsinparallel,evenatexonlevel.Falsenegative withautosomalrecessivespinocerebellarataxia,willhelpus ratewas20%(2/10),howeverthesedeletionswerevisually understand the effect of the exon 14 of GRID2 on the observable. Factors influencing the efficiency of the phenotype and the structure of the GluRD2 protein. These approach include the size of the deletion and presence of findings provide us with the conclusion that chromosomal pseudogenes. Funding: ISCIII (P
S09 /01830; PI17/01582) microarrayshouldbethefirststepofthediagnosticprocess B.Quintans:None.F.Barros:None.I.Quintela:None. of autosomal recessive ataxia types. A. Ordóñez-Ugalde: None. C. Castro-Fernández: None. A. Ceylan: None. E. Acar Arslan: None. H. Erdem: P. Blanco-Arias: None. D. García-Estévez: None. I. None. H. Kavus: None. M. Arslan: None. H. Sanz: None. M. Arias: None. M. Sobrido: None. Topaloğlu: None.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1435 
P09 .054A 
P09 .055B Cadherin13interactswithIntegrinBeta-1andIntegrin A rare etiology of epileptic encephalopathy: HECW2 Beta-3 to regulate inhibitory synaptic function in a mutations human neuronal model M. H. Demirbas1, P. Özbudak2, A. Serdaroğlu2, B. Mossink1,2, J. v. Rhijn3,2, M. Selten3,2, K. Linda1,2, M. A. Ergün1, E. F. Perçin1 E. v. Hughte1,2, J. Bak3,2, M. Frega1,2, D. Schubert3,2, N. Nadif Kasri1,2,3 1Medical Genetics Department, Gazi University Hospital, Ankara, Turkey, 2Pediatric Neurology Department, Gazi 1Department of Human Genetics, Radboudumc, Nijmegen, University Hospital, Ankara, Turkey Netherlands, 2Donders Institute for Brain Cognition and Behaviour, Nijmegen, Netherlands, 3Department of Introduction: Heterozygous mutations in the HECW2 Cognitive Neurosciences, Radboudumc, Nijmegen, cause ‘’Neurodevelopmental Disorder with Hypotonia, Netherlands Seizures, and Absent Language; NDHSAL’’ (#617268), which is characterized by severe developmental delay, The brain is a complex neural network that requires a absent speech, epilepsy, hypotonia, dystonia/dyskinesia, preciselytunedinterplayofexcitatoryandinhibitorysignals microcephaly, and structural brain anomalies. Here we inordertofunction.Disruptionsinsynapticconnectivity,in present a novel de novo heterozygous mutation in the particular the balance between excitation (E) and inhibition HECW2 gene in a patient with growth retardation and (I), have been shown to underlie neurodevelopmental epileptic encephalopathy. Material-Methods: A seven-year- disorders (NDDs). However, the mechanisms underlying old boy who referred to our clinic with epileptic this coordination remain elusive. One gene that is encephalopathy had severely delayed psychomotor devel- implicatedNDDsisCadherin13(CDH13).Dysregulations opment, absent speech and feeding difficulty. His height, of CDH13 have been linked to attention-deficit/hyperactiv- weight and head circumference measurements were less ity disorder and comorbid disorders such as autism and than 3rd centile. His motor tonic seizures were reported to schizophrenia.StudiesinmiceshowedthatCdh13localises start at the age of two and to continue daily. Generalized attheinhibitorypresynapse,andwhenknockedoutleadsto epileptic changes were present in his EEG. Progressive increased inhibitory drive onto hippocampal CA1 pyrami- atrophyofcerebrum,cerebellumandbrainstemwasseenin dal neurons. However, the mechanism by which CDH13 the cranial MRI. WES analysis was performed in order to regulates the function of inhibitory synapses in human elucidate theaetiology oftheneurodevelopmental disorder. neurons remains unknown. To understand the function of Results: A novel de novo heterozygous mutation CDH13 in human neurons, we generated both GABAergic c.4484G>A (p.Arg1495Lys) was found in the and Glutamatergic neurons via controlled differentiation of HECW2 gene. Induced Pluripotent Stem Cells (hIPSC). Using RNA Conclusion: To the best of our knowledge, only four interference we reduced CDH13 expression in GABAergic mutations in the HECW2 have been identified in ten neurons.Weinvestigatedneuronalnetworkcommunication patients.Becauseoftherarenessofthereportedcases,here by means of Micro-Electrode Arrays, whereas on a single- we present the patient with a novel HECW2 variant asso- cell level, inhibitory synaptic transmission was assessed ciating with his clinical findings. Similar reports are still using whole-cell patch-clamp recordings. Our data shows needed to clarify genotype-phenotype correlations of that CDH13 knockdown in human GABAergic neurons NDHSAL. increases inhibitory control on glutamatergic neurons M.H. Demirbas: None. P. Özbudak: None. A. Ser- recorded by MEA. Moreover, cell-adhesion assay revealed daroğlu: None. M.A. Ergün: None. E.F. Perçin: None. that ITGβ1 and ITGβ3 play an opposite role in the regulation of inhibitory synaptic strength via interaction 
P09 .056C with CDH13. In summary, these results point towards an Dominant negative heterozygous mutation in Erlin2 important role for CDH13 in inhibitory synapses via preventsdegradationofI
P3 receptorsandisresponsible CDH13-ITGβ1/ITGβ3 interaction, which could be critical for hereditary spastic paraplegia 37 in the maintenance of the E/I balance. B. Mossink: None. J.V. Rhijn: None. M. Selten: None. G. Stevanin1, A. Rastetter1, T. Esteves1, S. Hanein1, K. Linda: None. E.V. Hughte: None. J. Bak: None. M. C. Depienne2, A. Brice2, A. Durr2, F. Darios2 Frega: None. D. Schubert: None. N. Nadif Kasri: None.1436 1Institut du Cerveau et de la Moelle épinière, Inserm, 1Faculty of Medicine, Khartoum, Sudan, 2Institut du CNRS,SU,EPHE,Paris,France,2InstitutduCerveauetde cerveau et de la moelle épinière, Paris, France, 3Ecole la Moelle épinière, Inserm, CNRS, SU, Paris, France pratique des hautes etudes, EPHE, PSL université, Paris, France,4Departmentofneurologyandepileptology,Hertie Introduction: Erlin 2 is an endoplasmic reticulum protein instituteforclinicalbrainresearch,UniversityofTübingen, mediating the degradation of I
P3  receptors. Autosomal Tübingen, Germany, 5Inistitute of endemic diseases, recessive or dominant mutations of Erlin2 have been University ofKhartoum, Khartoum, Sudan,6Departmentof implicatedincomplexmotorneurondiseaseswithcognitive radiology, Dar Al Elaj specialized hospital, Khartoum, impairment,includinghereditaryspasticparaplegiaSPG18. Sudan, 7Alnelain medical center, Khartoum, Sudan, Materials and Methods: We analysed the exome 8Departmentofphysiology,Collegeofmedicine,KingSaud sequencingoffourpatientsofalargefamilywithautosomal University, Ryiadh, Saudi Arabia, 9Department of dominant spastic paraplegia significantly linked to the pediatrics, College of medicine, King Saud University, SPG37 locus, a chromosomal region containing the Erlin2 Ryiadh, Saudi Arabia, 10APHP Pitié-Salpêtrière hospital, gene and overlapping the SPG18 locus. Fibroblasts of an Department of genetics, Paris, France affected patient and of a sex and age-matched control were subjected to an agonist of I
P3  receptors to analyse their Introduction: Hereditary spinocerebellar degeneration degradation by the proteasome. Fibroblasts were also (SCD)encompassesaspectrumofclinicallyandgenetically transfected withsiRNAs targeting the pathological allele to heterogeneous disorders, with phenotypes ranging from observe the reversal of the phenotype. pure spastic paraplegia or pure cerebellar ataxia to more Results: We identified the heterozygous c.194C>T (p. complex forms. Sudan is located in east Africa which is a T65I) missense variant in Erlin2 segregating in the family. region known for the high genetic diversity among its Mutated and wild type alleles were expressed at the same population. The Sudanese population is characterized by level in fibroblasts. Compared to controls, I
P3  receptors high rates of consanguineous marriages (40-49%). degradationwasslowerinmutatedfibroblasts,suggestinga Methodology: We used next generation sequencing tar- degradation process blockage. To test the hypothesis that geted genes panel screening and whole exome sequencing the variant acts as a dominant negative, we specifically to study 25 Sudanese families with SCD. We analyzed the downregulated the p.T65I variant using siRNA. While sequencing data using online and in-house bioinformatic Erlin2 levels remained normal in control lines, a 50% tools. We confirmed the segregation of the identified can- downregulation of the p.T65I allele was observed in the didate variants with the disease phenotype in the studied SPG37 line with reduced degradation capacities of I
P3  families using Sanger sequencing. receptors. Results: We identified 24 culprit variants, 18 of these Conclusion: We report that a heterozygous missense were in 15 genes previously linked to SCD and six were variant of Erlin2 accounts for SPG37 through a dominant located in six new candidate genes never linked to patho- negative effect on the I
P3  receptors degradation in vitro. logical phenotypes in man. Out of the 18 variants in the G. Stevanin: None. A. Rastetter: None. T. Esteves: known SCD genes, 11 variants were novel, one was auto- None. S. Hanein: None. C. Depienne: None. A. Brice: somal dominant, six were compound heterozygous and 11 None. A. Durr: None. F. Darios: None. were homozygous. Three of the variants were possible founder variants: NM_024306.4(FA2H):c.674T>C and 
P09 .057D NM_021222.2(PRUN
E1 ):c.132+2T>C, each in two famil- Hereditary spinocerebellar degeneration in Sudan: ies; NM_138422.3(ADAT3):c.430G>A in one of our identification of variants in known and new genes in a families and was previously identified in families from the large cohort gulf area. Conclusion: We studied 25 Sudanese families with her- A. Yahia Osman Mohamed1,2,3, M. Papin2,3, T. Esteve2,3, editary spinocerebellar degeneration, and we identified the I. Mohammed1, A. Hamed1, M. Elseed1, A. Mutwakil1, causativemutationsin88%ofthesefamilies.The24culprit S. Elsadig1, M. Elzubir1, M. Koko4, J. Schubert4, variants were found in 15 genes previously linked to the R. Abubakr5, F. Abuzar1, S. Emad1, M. Musallam1, phenotype and in six new candidate genes under validation R. Adil1, M. Osama1, E. Osama1, A. Babai5, H. Malik1, through functional studies. Z. Omer1, A. Ahmed1, M. Amin1, A. Khalid1, R. Idris5, A.YahiaOsmanMohamed:None.M.Papin:None.T. S. O. Taha6, H. Mohamed7, E. F. Bushara1, S. Elmalik8, Esteve:None.I.Mohammed:None.A.Hamed:None.M. M.Hamad9,M.A.Salih9,M.I.Elbashir1,M.E.Ibrahim5, Elseed: None. A. Mutwakil: None. S. Elsadig: None. M. H.Lerche4,A.Brice2,10,L.E.O.Elsayed1,A.E.Ahmed1, Elzubir: None. M. Koko: None. J. Schubert: None. R. G. Stevanin2,3,10 Abubakr: None. F. Abuzar: None. S. Emad: None. M.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1437 Musallam: None. R. Adil: None. M. Osama: None. E. commitment. Our study will elucidate the molecular Osama: None. A. Babai: None. H. Malik: None. Z. mechanisms that could underlie the NDDs associated with Omer: None. A. Ahmed: None. M. Amin: None. A. HNRNPU mutations and 1q44 deletions. Khalid: None. R. Idris: None. S.O. Taha: None. H. F.Mastropasqua:None.I.Rabkina:None.M.Becker: Mohamed:None.E.F.Bushara:None.S.Elmalik:None. None.B.Anderlid:None.S.Bölte: None.A.Falk:None. M. Hamad: None. M.A. Salih: None. M.I. Elbashir: K. Tammimies: None. None. M.E. Ibrahim: None. H. Lerche: None. A. Brice: None. L.E.O. Elsayed: None. A.E. Ahmed: None. G. 
P09 .059B Stevanin: None. Heterozygous mutations of HTRA1 and cerebral small vessel diseases, a diagnostic challenge 
P09 .058A Understanding the role of HNRNPU in brain T. Coste1, D. Hervé2, M. Miné1, F. Marchelli1, development and neurodevelopmental disorders E. Tournier-Lasserve1 F.Mastropasqua1,I.Rabkina1,M.Becker1,B.Anderlid2, 1Service de GénétiqueMoléculaire Neurovasculaire,Paris, S. Bölte1, A. Falk3, K. Tammimies1 France, 2Service de Neurologie, Paris, France 1Center of Neurodevelopmental Disorders (KIND), Heterozygous HTRA1 missense mutations have recently Karolinska Institute, Solna, Sweden, 2Department of been involved in an autosomal dominant Cerebral Small Molecular Medicine and Surgery, Karolinska Institute, Vessel Disease (cSVD). Functional in vitro analysis has Solna, Sweden, 3Department of Neuroscience, Karolinska beenperformedforaverylimitednumberofthesevariants, Institutet, Solna, Sweden suggestingaprobabledominantnegativeeffect.Theaimof this study was to investigate the implication of HTRA1 Background: Mutations affecting HNRNPU (Heteroge- heterozygous mutations in cSVD in a large consecutive neous nuclear ribonucleoprotein U) located on chr1q44 series of patients. Samples from 2135 unrelated adult have been described in individuals with various neurode- patients were referred consecutively from 2016 to 2018 in velopmentaldisorders. HNRNPUisoneofthecomponents the neurovascular genetics department of Lariboisière of the spliceosome and shown to regulate the 3D genome hospital for targeted sequencing of known cSVD genes, organization. However, the role of HNRNPU in neuronal including HTRA1. Heterozygous HTRA1 missense variants development has not been characterized. with a prevalence < 1/10 000 in polymorphism databases Material and Methods: Induced pluripotent stem cells and predicted to be pathogenic by at least 2 in silico from controls and individuals with HNRPU mutations will prediction softwares were retained. Among these 2135 be used to investigate its role in neuronal development. patients, 35 patients (1.6%) showed a heterozygous HNRNPUexpressionismeasuredduringtheearlystagesof candidate missense variation. Only 7 of the detected the neuronal differentiation using the neuroepithelial stem variations were previously described (and 5 functionally cell-like(NES)modelfollowedwithdetailedinvestigations tested). 16 of them predicted as being pathogenic have not of the 3D genome organization, transcriptomics including yetbeenreported.Frequenciesofcandidatemissenseinour splicingpatternsandDNA/RNAtargetsofHNRNPUusing series and control samples from GnomAD are significantly high-throughput methods. different (p=6.4E-7,OR:1.8-3.7),confirmingtheinvolve- Results:Wehaveidentifiedamonozygotictwinpairwith ment of HTRA1 in cSVD pathogenesis. Co-segregation of severe ID, autism and epilepsy carrying a ~44.3Kb het- these variants in affected relatives is ongoing. However, erozygous deletion of HNRNPU and COX20. The expres- additional functional screening of these variants, including sionofHNRNPUinNEScellswasconfirmedtobereduced residual htra1 enzyme activity measurement and trimeriza- ~50% due to the deletion as expected. In control cell lines, tion analysis are now required to establish or infirm their the HNRNPU expression was reduced upon neuronal dif- pathogenicity, raising a strong challenge in a diagnosis ferentiation, however similar pattern was not seen in the context. deletion carrier. We are currently investigating the early T. Coste: None. D. Hervé: None. M. Miné: None. F. timepointsofneuronaldifferentiationandhowthemultiple Marchelli: None. E. Tournier-Lasserve: None. rolesofHNRNPUareconnectedtothetypicalandatypical trajectories of the neuronal development using multiple 
P09 .060C omics-methods. Genetic epidemiology analysis of Huntington and Conclusions: Reduction of HNRNPU levels interfere Huntington like disease among Hungarian patients with differentiation at an early phase of neuronal1438 A. Gal, K. Bathori, V. S. Farkas, F. Szabo, A. Suveges, 1Molecular Genetics Unit, Fondazione IRCCS Casa H. Zeke, Z. Grosz, M. J. Molnar Sollievo della Sofferenza, San Giovanni Rotondo, Italy, 2Fondazione Lega Italiana Ricerca Huntington (LIRH) e Institute of Genomic Medicine and Rare Disorders, malattie correlate, Rome, Italy, 3Huntington and Rare Semmelweis Universitiy, Budapest, Hungary, Budapest, Diseases Unit, Fondazione IRCCS Casa Sollievo della Hungary Sofferenza, San Giovanni Rotondo, Italy Introduction:HuntingtonandHuntington-likediseasesare AccuratedeterminationoftheCAGrepeatnumberiscrucial progressive neurodegenerative disorders which are char- inHuntington'sdisease(HD)toeitherconfirmthediagnosis acterized by uncontrolled movements (chorea), emotional in symptomatic patients or to predict the genetic condition problems, and loss of thinking ability. The classical in subjects at risk of HD, including prenatal testing. We Huntington chorea is associated with the abnormal evaluated a novel tripled repeat primed PCR-based trinucleotide (CAG) repeat expansion in the huntingtin technology for estimation of HTT CAG repeats in 46 HD (HTT) gene. In the remaining cases, mutations of the reference DNA samples, including 34 samples carrying 
C9 ORF72 hexanucleotide- (G C ), TBP (TATA box- alleles with full penetrance (> 40 CAGs). Of the samples 4 2 bindingprotein)trinucleotide(CAG/CAA)repeatandprion with full penetrance alleles, 20 harbored alleles larger than protein (PRNP) genes mutations may also cause a 60 CAG repeats, generally seen in subjects with juvenile Huntington-like clinical phenotype. Aims: In this study onset HD < 20 years and in the rarest pediatric variant. the genetic background of chorea-like movement distur- Analyzed samples had been previously tested using either bances were investigated among our Hungarian cohort. flurescentrepeat-flankingPCRortripledrepeatprimedPCR Patients and Methods: In 375 (mean age 45.2 years) method,orboth.Allsamplesshowedfullconcordancewith patients with choreiform movement disorder, the HTT, the previously verified allele sizes. Identical repeat size or 
C9 ORF72, TBP repeats and PRNP mutations were sizing errors within ±1 CAG were obtained for alleles ≤42 analysed. CAGrepeats,whereassizingerrorswithin±3wereobtained Results: The expanded HTT allele (>40 CAG repeat) for alleles > 43 CAG repeats, conforming to established repeatexpansionwerefoundin335cases.Themeanofthe guidelines.Theassaywasabletoaccuratelysize18samples expanded repeat numbers is 44.6. Abnormal 
C9 ORF72 withverylargeallelescomprisedbetween60and100CAG hexanucleotiderepeatsweredetectedin3cases(onepatient repeats, and to detect two exceptionally large alleles with has full mutation (>30 G C repeat) and two others have morethan200CAGrepeats.Thismethodprovidesarapid, 4 2 intermedier-range (24-29 G C repeat) hexanucleotide sensitive and reliable method to accurately genotype the 4 2 repeatexpansions).TheTBPrepeatdiseasewasdetermined HTTCAGrepeatstretch,andextendsthedetectionlimitof in one patient, and in further one case a PRNP octa- large expanded alleles to over 200 CAG repeats, thus nuclteotide in frame deletion was detected. providingacomprehensivemoleculardiagnosticevaluation Discussion: The rate of occurrence of HTT gene abnor- ofallHDsamples,includingthosepediatricformscarrying mal trinucleotide expansion in our investigated cohorts is extremely large, hard to detect, alleles. 90%. The remaining 10% of patients are classified as F. Consoli: None. A. Morella: None. A. Onori: None. Huntington-like clinical phenotypes. In this group, the M. D’Asdia: None. B. D’Alessio: None. A. De Luca: 
C9 ORF72hexanucleotidegenewasdetectedin7.5%,while None. F. Squitieri: None. in the TBP and PRNP mutations were present in 2.5-2.5%. This study was supported by KTIA_13_NAP-A-III/6 to V. 
P09 .062A A-V. grant. Psychological reactions when coping with predictive A.Gal:None.K.Bathori:None.V.S.Farkas:None.F. genetic testing for Huntington’s disease: A qualitative Szabo: None. A. Suveges: None. H. Zeke: None. Z. study Grosz: None. M.J. Molnar: None. C. von der Lippe1, K. H. Tillerås1, S. H. Kjølaas1, 
P09 .061D E. Dramstad2, K. B. Feragen1 A novel repeat-primed PCR assay to detect the full range of trinucleotide CAG repeats in Huntingtin gene 1CentreforRareDisorders,Rikshospitalet,OsloUniversity (HTT) Hospital, Oslo, Norway, 2Dep. of Medical Genetics, Rikshospitalet, Oslo University Hospital, Oslo, Norway F. Consoli1, A. Morella1, A. Onori1, M. D’Asdia1, B. D’Alessio2, A. De Luca1, F. Squitieri3 Introduction: Huntington’s disease (HD) is an autosomal dominant disease characterized by progressive weakeningAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1439 of the cognitive, psychological and motoric systems. HD common congenital disorder (1.1/1000), the genetic aetiol- mayhaveasevereimpactonfamilydynamics,andgrowing ogy of hydrocephalus remains unclear. up with a parent with HD may be challenging. Adult Objectives: 1. Candidate gene analysis of 113 genes in individuals at risk can get predictive genetic testing. 6,077 whole exome sequenced individuals (50 with Materials and Methods: We used an explorative quali- hydrocephalus) tative study design and interviewed 36 persons who cur- 2.Explorethecellularpathwaysinvolvingtheimplicated rently grow up or grew up with a parent with HD, and genes to understand better, how dysfunction of these genes analyzed the interviews using thematic analysis. might lead toorinfluencetheexpression ofhydrocephalus. Results: Participants described several challenges related Materials and Methods: This register-based cohort tothedecisionregardingpredictivetesting.Somewantedto study is a sub-study of the Lundbeck Foundation Initiative enjoy life without knowing. Others lacked motivation for for Integrative Psychiatric Research (iPSYCH) and com- getting an education and limited their involvement in bines data from The National Patient Registry, and The romantic relationships, even though they did not know Danish Neonatal Screening Biobank. Genetic variants whethertheyhadthemutationornot.Participantsdescribed identified in the candidate genes were filtered based on ineffective coping mechanisms and a search for symptoms minor allele frequency (MAF) data. We removed variants before predictive testing, continuing after they had tested with MAF >2 x 10-5 in gnomAD or >5 x 10-3 in controls. positive for the mutation. Others, positive for the mutation, Results: Forty-nine mutations were identified in 31 described a relief of finally having the knowledge, and an genes. Interestingly, along with the known hydrocephalus- increased understanding of affected family members. Par- causing genes (CCD
C88 C, MPDZ) several of the genes ticipants who had tested negative for the mutation were implicated are involved cilia formation and function surprised by ambivalent feelings, and described a need for (CE
P290 , US
P9 X, SNX10, TMEM67) as well as cortico- follow-up after they had received a negative test result. genesis and neuronal adhesion and migration (CELSR2, Conclusion: Predictive testing for HD is a demanding FLNA). process. Individuals who grow up in families affected by Conclusions:Theresultsofthisstudysuggestthatahigh HD, worry about the potential genetic risk for themselves proportion of Danish hydrocephalus patients have an and their siblings. The current study indicates that indivi- underlying genetic predisposition and the genes involved duals may need long-term follow-up from the healthcare affect pathways of importance for Cilia, corticogenesis as system whether they test positive or negative for the well as neuronal adhesion and migration. mutation. T.M. Munch: None. P.L. Hedley: None. C.M. Hagen: C. von der Lippe: None. K.H. Tillerås: None. S.H. None.M.Bækvad-Hansen:None.J.Bybjerg-Grauholm: Kjølaas:None.E.Dramstad:None.K.B.Feragen:None. None. M. Melbye: None. D. Hougaard: None. M. Christiansen: None. 
P09 .063B The genetic background of hydrocephalus - candidate 
P09 .065D gene analysis from +6,000 exomes Evaluation of targeted sequencing as the first-tier genetic test for intellectual disability and autism T. M. Munch1,2, P. L. Hedley1,3, C. M. Hagen1,3, spectrum disorders diagnosis M. Bækvad-Hansen1,3, J. Bybjerg-Grauholm1,3, M. Melbye1, D. Hougaard1,3, M. Christiansen1,3,4 M. Peña-Vilabelda, L. Rausell, M. Lázaro, S. Vidal, M. Molero, L. Cabrera, M. J. García, C. Pérez, P. Cano, 1Statens Serum Institut, Copenhagen, Denmark, E. Férriz, G. Cartagena, M. Bermejo, S. Santamaría, 2Copenhagen University Hospital, Copenhagen, Denmark, C. Ruiz, J. García-Planells, M. García-Hoyos 3The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark, Instituto de Medicina Genómica (IMEGEN), Valencia, 4University of Copenhagen, Copenhagen, Denmark Spain Introduction: Congenital hydrocephalus, a condition Identification of the genetic aetiology of intellectual characterised by relatively excessive intracranialcerebrosp- disability (ID) or autism spectrum disorders (ASDs) inal fluid, is often considered to present neonatally. provides benefits, like specific genetic counselling, more However, in practise, most patients present during infancy accurate prognosis and specialized treatment. The world- withslowlydevelopingsymptoms,orevenlaterinlifewith wide average prevalence of ASDs is 1 in 160 children and subtle or neglected symptoms. Despite being a relatively 1-3% of ID. Due to the genetic heterogeneity of these pathologies different genetic tests are available. Today,1440 chromosomal microarray is the first-tier recommended 
P09 .066A diagnostic test and provides a yield around 10-15% for ID Development of a LYST deficient glutamatergic patients and around 9% for ASDs patients, depending on neuronal model of Chediak-Higashi Syndrome the cohort. Our goal is to evaluate if the diagnostic yield estimated by targeted sequencing in our cohorts of ID or J. Serra-Vinardell1, D. Chauss2, K. Keyvanfar3, ASDs subjects is higher than that obtained by CGH array. W. J. Introne1, M. E. Ward4, W. A. Gahl1,5, M. C. V. We screened 701 in-house selected ID-related genes and Malicdan1,5 189 autism-related genes in a cohort of more than 100 and 60 patients, respectively. Libraries were prepared with 1SectionofHumanBiochemicalGenetics,MedicalGenetics differentcapturekitsandtheIlluminaNextSeq500platform Branch, National Human Genome Research Institute, was used to sequence targeted regions. Bioinformatic NationalInstitutesofHealth,Bethesda,MD,United States, analysis was performed with an in-house pipeline. The 2Section of Immunoregulation, Kidney Diseases Branch, diagnostic yield was 41% in the ID cohort and 20% in the National Institute of Diabetes and Digestive and Kidney ASDs cohort. Variants of uncertain significance were Diseases, National Institutes of Health, Bethesda, MD, identified in 50% of the ID patients and 72% of the autism United States, 3Hematology Branch, National Heart, Lung, patientsandnegativeresultswereobtainedin9%and8%of andBloodInstitute,NationalInstitutesofHealth,Bethesda, the ID and autism individuals, respectively. ID or autism- MD, United States, 4National Institute of Neurological related genes sequencing provide higher diagnostic yields Disorders and Stroke, National Institutes of Health, than CGH array. Furthermore, copy number variants Bethesda,MD,UnitedStates,5NationalInstitutesofHealth evaluation could be performed simultaneously with our Undiagnosed Diseases Program, Common Fund, Office of pipeline. For this reason, we proposed targeted sequencing the Director, National Institutes of Health, Bethesda, MD, as the first-tier genetic test for ID and autism diagnosis. United States M. Peña-Vilabelda: A. Employment (full or part-time); Significant;InstitutodeMedicinaGenómica(IMEGEN).L. Chediak-Higashi Syndrome (CHS) is an autosomal reces- Rausell: A. Employment (full or part-time); Significant; sivedisordercausedbybiallelicmutationsinthelysosomal Instituto de Medicina Genómica (IMEGEN). M. Lázaro: trafficking regulator gene (LYST) that results to impaired A. Employment (full or part-time); Significant; Instituto de functionoflysosomeandlysosome-relatedorganelles.CHS MedicinaGenómica(IMEGEN).S.Vidal:A.Employment ischaracterized byoculocutaneous albinism,predisposition (full or part-time); Significant; Instituto de Medicina Gen- to bleeding, immunodeficiency and progressive neurologi- ómica (IMEGEN). M. Molero: A. Employment (full or cal dysfunction. Bone marrow transplantation has been a part-time); Significant; Instituto de Medicina Genómica symptomatictreatmentfortheimmunedefectsbutdoesnot (IMEGEN). L. Cabrera: A. Employment (full or part- alterthecourseoftherelentlessneurodegeneration.Todate, time); Significant; Instituto de Medicina Genómica (IME- several animal models of CHS have been identified, but GEN). M.J. García: A. Employment (full or part-time); none of them consistently recapitulate the neurological Significant;InstitutodeMedicinaGenómica(IMEGEN).C. phenotype seen in patients. Additionally, the role of LYST Pérez: A. Employment (full or part-time); Significant; in lysosome biology is still is poorly understood and could Instituto de Medicina Genómica (IMEGEN). P. Cano: A. be cell-dependent. For these reasons, we aim to investigate Employment (full or part-time); Significant; Instituto de the function of LYST in a neuronal cell model and to Medicina Genómica (IMEGEN). E. Férriz: A. Employ- identify targets for therapy. We used clustered regularly ment (full or part-time); Significant; Instituto de Medicina interspaced short palindromic repeats (CRISPR) and Genómica(IMEGEN).G.Cartagena:A.Employment(full CRISPR interference technologies to knock-out or knock- or part-time); Significant; Instituto de Medicina Genómica down the expression of endogenous LYST in induced (IMEGEN). M. Bermejo: A. Employment (full or part- pluripotent stem cells (iPSCs), which were genetically time); Significant; Instituto de Medicina Genómica (IME- engineered to facilitate an inducible expression of Neuro- GEN). S. Santamaría: A. Employment (full or part-time); genin 2. With this approach, we have established a Significant;InstitutodeMedicinaGenómica(IMEGEN).C. glutamatergic neuronal CHS model deficient for LYST Ruiz: A. Employment (full or part-time); Significant; expression, to analyze the localization, size and function of Instituto de Medicina Genómica (IMEGEN). J. García- lysosomesinneurons.Usingthistechnique,wewereableto Planells: A. Employment (full or part-time); Significant; generateahomogenouspopulationofneuronalcells,which Instituto de Medicina Genómica (IMEGEN). M. García- are essential for global proteome, transcriptome and Hoyos: A. Employment (full or part-time); Significant; metabolome studies not only of CHS, but also for other Instituto de Medicina Genómica (IMEGEN). Mendelian loss-of-function neurogenetic diseases.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1441 J. Serra-Vinardell: None. D. Chauss: None. K. Key- 
P09 .068C vanfar: None. W.J. Introne: None. M.E. Ward: None. Genome wide association study for late-onset W.A. Gahl: None. M.C.V. Malicdan: None. Alzheimer's disease in Japanese population 
P09 .067B K. Ozaki, R. Mitsumori, S. Niida, D. Shigemizu Gene-phenotype correlation of myoclonic progressive epilepsy type 3 National Center for Geriatrics and Gerontology, Obu, Japan A. Borovikov1, A. Sharkov2, I. Akimova1, S. Michailova3, A. Filatova1, A. Marakhonov4, E. Dadali1, M. Skoblov1 By 2025, the number of people living with dementia in Japan is expected to increase to 7 million. Most common 1Research centre for medical genetics, Moscow, Russian form of dementia is late-onset Alzheimer’s disease Federation, 2Research and Clinical Institute for Pediatrics (LOAD). The pathogenesis of LOAD is result from at the Pirogov Russian National Research Medical interactions among multiple environmental and genetic University, Moscow, Russian Federation, 3Russian factors which consist of considerable hereditary compo- Children's Clinical Hospital, Moscow, Russian Federation, nents. Recent large scale genome wide association studies 4Far East Federal University, Vladivostok, Russian (GWAS) in Caucasian have revealed more than 30 genetic Federation locifor LOADsusceptibility.Incontrast, GWAS for Asian groups including Japanese are relatively modest, and have Progressive myoclonic epilepsies (PME) are a group of poor reproducibility of associations for identified loci in clinically and genetically heterogeneous disorders charac- Caucasianduetopossibledifferenceofgeneticarchitecture terized by myoclonus, seizures, and neurological deteriora- among ethnicity in addition to lack of study power. In this tion. PME type 3 is an autosomal recessive disease and is context, we launched GWAS using an ethnicity specific associatedwithpathogenicvariantsinthegeneKCTD7that SNP array, Japonica. To date, we obtained the genotype encode potassium channel tetramerization domain- data for approximately 7,000 Japanese individuals (includ- containing protein 7. Disruption of the function of this ing2,400LOAD,1,400otherdementiaand3,200controls) genecanleadtoachangeinthepotassiumioncurrentinthe and imputed the data with a Japanese reference panel neurons of the brain. We investigate 9 patients with an (ToMMo 3.5KJ) constructed using whole genome average age of debut of the first attacks between 1 and 2 sequences from 3,500 Japanese. We tentatively conducted yearsoflifeandtrytoestablishgenephenotypecorrelation. a GWAS using the imputed genotype data (~10,000,000 Thefirstsymptomsstartedafteranepisodeoffebrile fever: SNPs) for approximately 2,400 LOAD cases and 3,200 sudden falls without loss of consciousness, and with controls. We combined this GWAS result and the data of episodes of fading. All patients had the drug-resistant another Japanese GWAS reported elsewhere for meta- generalized myoclonic seizures. MRI of the brain, long- analysis (a total of 8,000 individuals), and found GWAS term video EEG monitoring, examination by various significance for the APOE and SOR
L1  loci and a novel clinical specialists were performed for each patient. NGS locus with LOAD. We further identified several new sequencing revealed seven previously undescribed non- candidate susceptible loci for LOAD with suggestive synonymous variants and one previously undescribed significance. We also found convincing associations for dinucleotide frame shift deletion in the last exon. Four severalknownADloci,suchasCLU,PICALMandABCA7 chromosomal microarray analysis were performed for discovered in Caucasian population. patients with large deletions suspected by NGS affecting K. Ozaki: None. R. Mitsumori: None. S. Niida: None. the locus of the KCTD7 gene. Segregation analysis by D. Shigemizu: None. Sanger sequencing were performed for all families and confirmed genotypes. Most of known likely pathogenic or 
P09 .069D pathogenic variants are located in BTB/POZ domain. Leukocyte telomere length in Huntington's Disease. A However, we observed several variants located outside of study in fully penetrant and reduced penetrant alleles thisdomain.Itisnecessarytoconductafunctionalanalysis to confirm the pathogenic effect of the substitutions on the M. Peconi1, D. Scarabino2, E. Mantuano1, M. Frontali1, protein function. M. Morello3, A. Copponi4, R. M. Corbo5, L. Veneziano1 A. Borovikov: None. A. Sharkov: None. I. Akimova: None. S. Michailova: None. A. Filatova: None. A. Mar- 1Institute of Translational Pharmacology. National akhonov: None. E. Dadali: None. M. Skoblov: None. Research Council of Italy, Rome, Italy, 2Institute of Molecular Biology and Pathology. National Research1442 Council of Italy, Rome, Italy, 3Clinical Biochemistry and 1UniversityParisDiderot,Paris,France,2INSERMU1141, Molecular Biology. Dpt of Experimental Medicine and Paris, France, 3University ofKhartoum, Khartoum, Sudan, Surgery. Tor Vergata University, Rome, Italy, 4Clinical 4Hospital Robert Debre, Paris, France Biochemistry. Tor Vergata University, Rome, Italy, 5Dpt of BiologyandBiothechnology.LaSapenzaUniversity,Rome, Background: Leukodystrophies are a group of inherited Italy disorders primarily affecting the white matter of the CNS. There are currently 30 recognized forms of leukodystro- Introduction: Huntington’s Disease (HD), an autosomal phies with distinct clinical, biochemical and radiological dominant neurodegenerative disease, is caused by an characteristics. However, the genetics of these classical expanded CAG repeat in the first exon of HTT gene. The forms of leukodystrophies remain unknown in many parts disease is fully penetrant in individuals with 40 or more of the world especially in Sub-Saharan Africa. CAG repeats, and has reduced penetrance in the range of Methods: In this study, we selected 5 consanguineous 36-39 repeats. Overall the age at onset, usually at midlife, leukodystrophic families from Sudan using clinical and inversely correlates with the number of CAG repeats, and MRI recognition pattern. GenomicDNAwas extractedand severity of symptoms vary widely between individuals. In screened for mutations using NGS panel testing 153 leu- the present study, we investigated the relationship between kodystrophies and leucoencephalopathies causing genes LeukocyteTelomereLength(LTL)anddiseaseprogression. (NextSeq500 Illumina). Methods: LTL(T/Sratio) wasmeasuredinmanifest HD Results: Three novel homozygous variants were dis- patients(HD,n=62)andpre-manifestHDpatients(pre-HD, covered: one (c.380G>C, p.Arg127Pro) in PSAP gene n=38)withfullypenetrant alleles,insubjectswithreduced causing MLD, and two (c.831_838DUPATATCTGT, p. penetrant alleles (rp-HD, n=23), and age-matched controls Ser280Tyrfs*8 and c.971T>G, p.Ile324Ser) in ML
C1  gene (n= 76). inthetwofamilieswith MLC.The segregationpatternwas Results: Mean LTL values of controls, pre-HD and HD consistent with autosomal recessive inheritance. The patients were significantly different (p< 0.0001), in the pathogenicity of these variants was predicted using order: HD (0.58 ± 0.07) <pre-HD (0.78 ± 0.16) <controls bioinformatics tools. (0.92 ± 0.09). Mean LTL values of rp-HD subjects (0.82± Conclusion:Thisisthefirststudytounderliethegenetics 0.16) were significantly lower than controls (p=0.003), but of leukodystrophies in Sudan. Analysis of additional similartopre-HDpatients.Aninverserelationshipbetween families are in progress in order to establish the whole mean LTL and CAG repeat number was found in the pre- spectrum of genetic variations causing inherited leukody- HD (p=0.03). strophies in Sudanese families. Conclusion: In pre-HD patients, LTL shorten gradually M. Amin: None. I. Dorboz: None. I. Mohamed: None. accordingtoadvancingageandCAGnumber,uptothelow A. Hamad: None. M. Elseed: None. A. Yahia: None. A. values observed in HD patients. A similar LTL shortening Babai:None.E.Badi:None.M.Hassan:None.E.Emad: seems to be present in rp-HD, but at more advanced age. None. S. Samaan: None. L. Elsayed: None. A. Ahmed: The possible use of LTL as biomarker of disease progres- None. O. Boespflug-Tanguy: None. sion is discussed. Supportedby:grantEHDN0942toLV;grants2017La 
P09 .071B Sapienza University to RMC Two associated mutations in the glutamyl-prolyl and M. Peconi: None. D. Scarabino: None. E. Mantuano: isoleucyl -tRNA synthetases in patients with a fatal None.M.Frontali:None.M.Morello:None.A.Copponi: leukodystrophy None. R.M. Corbo: None. L. Veneziano: None. I. DORBOZ1, K. Boussaid2, F. Renaldo2, A. Odoul1, 
P09 .070A M. Abuawad1, S. Samaan2, E. Eymard-Pierre3, Novel variants causing inherited leukodystrophies in M. Elmaleh- Bergès2, O. Boespflug-Tanguy2,1 Sudanese families 1INSERM, Paris, France, 2CHU APHP Robert-Debré, M. Amin1, I. Dorboz2, I. Mohamed3, A. Hamad3, Paris, France, 3CHU Clermont-Ferrand, Clermont- M. Elseed3, A. Yahia3, A. Babai3, E. Badi3, M. Hassan3, Ferrand, France E. Emad3, S. Samaan2, L. Elsayed3, A. Ahmed3, O. Boespflug-Tanguy1,2,4 Aminoacyl-tRNAsynthetases(ARSs)havebeenimplicated in leukodystrophies. We report a consanguineous family with two affected children. Both children presented a neurodegenerative disorder with a motor degradation andAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1443 nystagmus after 15 months, spastic quadriplegia after 3y Skövde, Sweden, 9The Queen Silvia Children's Hospital, andepilepsiaafter7yleadingtodeathatrespectively8and Gotenborg, Sweden 10yofage.MRIdemonstrated aprogressiveatrophyofthe spinal cord, the optic nerve, the corpus callosum and the Background: Pathogenic variants in the KIF1A gene have cortex associated with a demyelinating aspect of the been reported in autosomal recessive spastic paraplegia 30, sustentorial periventricular WM. Axonal peripheral neuro- autosomal recessive hereditary sensory neuropathy, and pathywasobservedinbothpatients.Biochemichalanalysis autosomal (de novo) dominant mental retardation type 9. were negative More recently, variants in KIF1A have also been described Homozygosity mapping combined to whole-exome in a few cases with autosomal dominant spastic paraplegia. sequencing revealed two homozygous mutations in two Methods: Clinical exome sequencing data of 315 unre- ARSs.OnemutationinEPRS(c.3344C>T/p.Pro1115Leu)a lated patients with mostly ‘pure’ spastic paraplegia were bifunctional aminoacyl tRNA synthetase that catalyzes the analysed for KIF1A variants. Clinical characteristics of aminoacylation of both glutamic acid and proline tRNA patients with KIF1A variants were analysed, segregation species, recently involved in a hypomyelinating Leukody- analyses were performed, and types of variants were strophy and a second mutation in IAR
S2  encodes a mito- compared. chondrial isoleucyl-tRNA synthetase reported to cause Results: In 21 patients we identified 19 different KIF1A CAGSSSthatischaracterisedbycataracts,growthhormone variants. Patients and affected family members showed a deficiency, sensory neuropathy, sensorineural hearing loss, slowly progressive, mostly pure form of spastic paraplegia, and skeletal dysplasia. Co-segregation analysis confirmed but with a highly variable disease onset (0-57 years). Seg- that the two mutations were inherited from heterozygous regation analyses showed a de novo occurrence in five carrierparents.Insilicoanalysispredictedthesevariationto cases, and a dominant inheritance pattern in eight families. be deleterious. The phenotype of our patients were more The motor domain of KIF1A seems to be the hotspot for severe than the reported patient with the same mutation in pathogenic variants in autosomal dominant spastic para- ERPS gene. Our patients had no cataract or dysplasia or plegia, similar to mental retardation type 9 and recessive growth hormone deficiency reported in IAR
S2  patient. The spastic paraplegia type 30. Unlike these allelic disorders, phenotype may be the result of the mutation of the two however, dominant spastic paraplegia was also caused by genes. Further analysis are required to gain a better under- loss-of-functionvariantsoutsidethisdomaininsixfamilies. standing of the interaction or not of the two ARSs. Three missense variants were identified outside the motor I. Dorboz: None. K. Boussaid: None. F. Renaldo: domain and need further characterization. None. A. Odoul: None. M. Abuawad: None. S. Samaan: Conclusions: KIF1A variants are a frequent cause of None. E. Eymard-Pierre: None. M. Elmaleh- Bergès: autosomal dominant spastic paraplegia in our cohort (5- None. O. Boespflug-Tanguy: None. 7%), with a high de novo rate. The identification of KIF1A loss-of-function variants suggests haploinsufficiency as a 
P09 .072 possible mechanism in autosomal dominant spastic CKIF1A variants are a frequent cause of autosomal paraplegia. dominant hereditary spastic paraplegia E.Kamsteeg:None.M.Pennings:None.M.Schouten: None.R.Meyer:None.J.vanGaalen:None.S.T.deBot: E. Kamsteeg1, M. Pennings1, M. Schouten1, R. Meyer1, None.M.Kriek:None.C.G.J.Saris:None.L.H.vanden J. van Gaalen1, S. T. de Bot2, M. Kriek2, C. G. J. Saris1, Berg: None. M.A. van Es: None. D.M.H. Zuidgeest: L.H.vandenBerg3,M.A.vanEs3,D.M.H.Zuidgeest4, None. M.W. Elting: None. J.M. van de Kamp: None. K. M. W. Elting5, J. M. van de Kamp5, K. Y. van Y. van Spaendonck-Zwarts: None. C. de Die-Smulders: Spaendonck-Zwarts5, C. de Die-Smulders6, None. E.H. Brilstra: None. C.C. Verschuuren: None. B. E. H. Brilstra3, C. C. Verschuuren7, B. B. A. de Vries1, B.A.deVries:None.J.Bruijn:None.K.Sofou:None.B. J. Bruijn8, K. Sofou9, B. P. van de Warrenburg1 P. van de Warrenburg: None. 1Radboud University Medical Centre, Nijmegen, 
P09 .073D Netherlands, 2Leiden University Medical Center, Leiden, Obesity-related genes and the atypical symptoms of Netherlands, 3Utrecht University Medical Centre, Utrecht, major depressive disorder: findings from two large Netherlands, 4Ikazia Hospital, Rotterdam, Netherlands, European epidemiological studies 5Amsterdam University Medical Centre, Amsterdam, Netherlands, 6Maastricht University Medical Centre, G. Pistis1, Y. Milaneschi2, D. I. Boomsma3, E. Castelao1, Maastricht, Netherlands, 7Groningen University Medical M. Gholam-Rezaee1, Z. Kutalik4,5, A. M. Lasserre1, Centre, Groningen, Netherlands, 8Skaraborg Hospital, B. W. J. H. Penninx2, M. Preisig1, C. L. Vandeleur11444 1Department of Psychiatry, University Hospital of 
P09 .074A Lausanne, Lausanne, Switzerland, 2Department of Entire structure ofMEC
P2 cDNA expressed in a patient Psychiatry, Amsterdam UMC, Vrije Universiteit and GGZ withRettsyndromebearingalargedeletionbetweenthe inGeest, Amsterdam, Netherlands, 3Netherlands Twin exon 4 of MEC
P2  and the upstream region of IRAK Register, Dept Biological Psychology, Vrije Universiteit, Amsterdam, Netherlands, 4University Institute for Social K. Yanagi1, M. Minatogawa1, M. Takeshita1, K. Satou1, and Preventive Medicine, Lausanne University Hospital, N. Okamoto2, Y. Matsubara1, T. Kaname1 Lausanne, Switzerland, 5Swiss Institute of Bioinformatics, Lausanne, Switzerland 1National Center for Child Health and Development, Tokyo, Japan, 2Osaka Women’s and Children’s Hospital, Introduction: Disentangling the heterogeneity of depres- Osaka, Japan sion by subtyping according to clinical manifestations has beenshowntobeapertinentapproachtogainmoreinsight Methyl-CpG- binding protein 2 (MEC
P2 ) is a responsible into relationships with obesity. Indeed, previous research gene for Rett syndrome (RTT, OMIM#312750) that is suggeststhatonlytheatypicalMDDsubtype,characterized inherited in an X-linked dominant manner. Pathogenic by five symptoms (increased appetite, hypersomnia, mood variant of MEC
P2  are found in approximately 80% of reactivity, leaden paralysis and interpersonal rejection patients with RTT. Partial and whole-gene deletions are sensitivity), is associated with obesity. We investigated accounting for 7.3% in all variants observed. We encoun- whethertheassociationbetweenatypicalMDDandgenetic tered a patient of RTT with large deletion of MEC
P2 . variants related to obesity is accounted for by the appetite A patient is 7-year-old girl born to non-consanguineous criterion alone or whether the other atypical criteria also parentsat40weekswithbirthweightof2,484,heightof47 contribute to this association. cm and head circumstance of 31.5 cm. Amniotic fluid Materials and Methods: Two studies, CoLaus|PsyCo- karyotyping showed 46,XX. She was clinically suspected Laus (Switzerland) and NESDA|NTR (Netherlands), that RTT based on neurodevelopmental disorder characterized assessed MDD subtypes and symptoms, were meta- by psychomotor regression with the development of dis- analysed to evaluate the associations between atypical tinctive hand stereotypies. However, no pathogenic variant MDD symptoms (386 and 179 participants, respectively) was detected in the MEC
P2  gene by direct-sequencing with the rs9939609 FTO polymorphism and the polygenic and MLPA. risk score (PRS) from 76 loci significantly associated with Whole exome sequencing (WES) was performed. Map- Body Mass Index according to a recent GWAS meta- ping images of WES suggested a heterozygous large dele- analysis. tionbetween theexon4ofMEC
P2 andupstreamregionof Results: Our meta-analysis shows positive associations IRAKinthepatient.Thedeletionwasverifiedbylong-range between the symptom increased appetite and both the FTO PCR and following sequencing. Transcripts of MEC
P2  variant and the PRS (odds ratio (OR)=1.37; 95% con- were confirmed by 3’RACE analysis. The deletion was fidence interval (CI)=1.17-1.62, P=1.33x10-04 and occurred in father’s allele. A novel transcript derived from OR=1.15, 95%CI=1.03-1.29, P=0.014, respectively), a the deleted allele consisted of exon 3 and alternatively negative association between the FTO and the symptom splicedregionsofexon4underGT-ATrule.Codinglength leaden paralysis (OR=0.82, 95%CI=0.72-0.93, P=0.003) was expected 582 bp (194 amino acid). The translated and a negative association between the PRS and the product lacked two AT-hook domains, which are essential symptom rejection sensitivity (OR=0.92, 95%CI=0.85- forDNAbinding.Brainspecificpolyadenylationsignalwas 0.99, P=0.036). found 17 bp upstream of poly A site. This work was sup- Conclusions:Theassociation between increased appetite ported by grants from the AMED. and obesity-related genetic variants drives the association K. Yanagi: None. M. Minatogawa: None. M. Take- betweenthesevariantsandtheatypicalsubtype,suggesting shita: None. K. Satou: None. N. Okamoto: None. Y. that other genes could be involved in the regulation of the Matsubara: None. T. Kaname: None. other atypical symptoms, reflecting the genetic hetero- geneity of MDD. 
P09 .075B G. Pistis: None. Y. Milaneschi: None. D.I. Boomsma: Molecular characterization of Spanish MEC
P2  None. E. Castelao: None. M. Gholam-Rezaee: None. Z. duplication syndrome patients: more IRAK1 than we Kutalik:None.A.M.Lasserre:None.B.W.J.H.Penninx: thought None. M. Preisig: None. C.L. Vandeleur: None.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1445 L. Blasco1, S. Vidal1, A. Pascual-Alonso1, E. Gean2, Results:Wehavenoticedthatintheminimumduplicated M. O'Callaghan2, A. Martínez2, A. Castells3, C. Xiol1, region (MDR) of all our patients there are MEC
P2  and N. Brandi4, P. Pacheco4, V. Català5, M. del Campo6, IRAK1 genes and both are overexpressed. The cohort was E. Guillén7, P. Lapunzina8, E. Lloveras9, D. Ortigoza2, classified according to different chromosomal localizations H. Maortua10, F. Martínez11, A. Mesas12, J. Nevado8, of the MDR: tandem in ChrXq28, ChrXp and ChrY. The M. Obón13, C. Orellana11, A. Plaja14, M. Roselló11, clinical severity seems to be related to the position of the M. Tejada10, F. Santos8, M. Sánchez7, J. Fernández15, duplication, where the insertion in ChrY leads to the most E. Tizzano16, S. Alcántara3, J. Armstrong4 severe phenotype. Conclusions: Due to thefact that IRAK1 ispresent in all 1Sant Joan de Déu research foundation, Barcelona, Spain, the duplications we hypothesize that it must be implicated 2Unidad de Consejo Genético, Hospital Universitario San in the disorder. We encourage the study of the pathways in Juan de Dios, Barcelona, Spain, 3Departament de whichIRAK1participates.Besides,thepointofinsertionof Patologia i Terapèutica Experimental, Campus de the duplication seems to be crucial for the severity of the Bellvitge, Universitat de Barcelona, Barcelona, Spain, patient, as well as the genes involved in each rearrange- 4Servicio de Medicina Genètica i Molecular, Hospital ment. Grants: Miradas que Hablan-Duplicación MEC
P2  UniversitarioSanJuandeDios,Barcelona,Spain,5Unitad parents' association. de genética médica i biologia celular, Universidad L. Blasco: None. S. Vidal: None. A. Pascual-Alonso: Autónoma de Barcelona, Barcelona, Spain, 6Pediatrics, None. E. Gean: None. M. O'Callaghan: None. A. Genetic Epidemiology, Hospital Vall d'Hebrón, Barcelona, Martínez: None. A. Castells: None. C. Xiol: None. N. Spain, 7Unidad de Genética, Hospital Virgen de la Brandi:None.P.Pacheco:None.V.Català:None.M.del Arrixaca, Murcia, Spain, 8Instituto de Genética Médica y Campo:None.E.Guillén:None.P.Lapunzina:None.E. Molecular,InstitutodeInvestigaciónSanitariadelHospital Lloveras: None. D. Ortigoza: None. H. Maortua: None. Universitario La Paz, Madrid, Spain, 9Departamento de F.Martínez:None.A.Mesas:None.J.Nevado:None.M. genètica, LABCO-Iberia, Barcelona, Spain, 10Laboratorio Obón: None. C. Orellana: None. A. Plaja: None. M. de Genética Molecular, Servicio de Genética, Hospital Roselló: None. M. Tejada: None. F. Santos: None. M. Universitario de Cruces, Bilbao, Spain, 11Unidad de Sánchez: None. J. Fernández: None. E. Tizzano: None. genètica, Hospital Universitario y Politécnico La Fe, S. Alcántara: None. J. Armstrong: None. Valencia, Spain, 12Gastroenterologia, Hospital Xanit, Málaga, Spain, 13Area de Genètica clínica i Consell 
P09 .077D Genètic, Laboratoris ICS, Girona, Spain, 14Institut de Population incidence of congenital microcephaly in the Recerca (VHIR), Universitat Autònoma de Barcelona, Czech Republic Hospital Universitari Vall d'Hebron, Barcelona, Spain, 15Hospital Universitario Reina Sofía, Córdoba, Spain, N. Friedova1,2, A. Sipek Jr1,3, V. Gregor3,4, A. Sipek 16AreaGenéticaClínicayMolecular,HospitalUniversitari Sr3,4,5,6, J. Klaschka7,8, M. Maly7,9 Vall d'Hebron, Barcelona, Spain 1InstituteofBiologyandMedicalGenetics,FirstFacultyof Introduction: MEC
P2  duplication syndrome Medicine, Charles University, Prague, Czech Republic, (OMIM#300260) is an X-linked neurodevelopmental dis- 2Department of Internal Medicine, Third Faculty of order characterized by severe to profound intellectual Medicine, Charles University and Thomayer Hospital, disability, early infantile hypotonia, autistic traits, seizures Prague,CzechRepublic,3DepartmentofMedicalGenetics, andrecurrentrespiratoryinfections.Duplicationcouldbede Thomayer Hospital, Prague, Czech Republic, 4Department novoorinheritedfromanasymptomaticcarriermother.We of Medical Genetics, Pronatal Sanatorium, Prague, Czech have molecularly characterized 22 Spanish children with Republic, 5Institute of Medical Genetics, Third Faculty of MEC
P2  duplication syndrome and their carrier mothers. Medicine, Charles University, Prague, Czech Republic, Materials and Methods: Clinical characterization was 6GENNET,Prague,CzechRepublic,7InstituteofComputer doneusingachecklistdesignedfortheproject.Duplications Science of the Czech Academy of Sciences, Prague, Czech were detected by MLPA and/or CGH-array and confirmed Republic, 8Institute of Biophysics and Informatics, First by Real-Time qPCR. Localization of the duplication was Faculty of Medicine, Charles University, Prague, Czech studied by FISH. MEC
P2  expression was checked by RT- Republic, 9National Institute of Public Health, Prague, qPCR in blood cells and skin fibroblast cells when avail- Czech Republic able. We performed XCI assay to affected females and carrier mothers. Introduction: Microcephaly is defined as a congenital anomaly of the central nervous system which is1446 characterized by the decreased head circumference. The exact definition may be slightly different for different Introduction: Microcephaly is a genetically heterogenous countries, in the Czech Republic the microcephaly is condition which may be an isolated trait or in combination defined as the head circumference under the 3rd percentile with other major malformations. The molecular diagnosis for specific age and sex of the particular individual. remains unknown in about 40% cases. Methods: We present a retrospective epidemiological Materials and Methods: Patients with microcephaly study of theincidence ofmicrocephaly(ICD-10 code Q02) with unknown etiology based on preliminary evaluation inthelivebirthsandintheprenatallydiagnosedcasesinthe were enrolled. CMA was done using Affymetrix 750K. Czech Republic (time period 1994-2015). The data were Where no pathogenic CNVs were identified, WES obtained from the National Registry of Congenital was done. Anomalies. During the selected time period the registry Results: Out of total 51 patients, CMA was done in 34 included only the cases of congenital anomalies in children patients. Pathogenic/likely pathogenic CNVs were identi- under 15 years of age. Surveillance program is fiedin6caseswhilecandidategenesinROHwasidentified population based. in 4 cases. WES was done in 32 patients (12 con- Results: There were 2 140 009 livebirths in the Czech sanguineous). Pathogenic/likely pathogenic SNVs were Republic during 1994-2015 time period. The average inci- identified in 14 patients. Biallelic variations were identified dence of microcephaly was 1.07 per 10 000 of livebirths in CIT, ANKL
E2 , OR
C1 , RNASEH2A, ASPM, PEX7, (highest was 1.72 in 2002 and lowest was 0.33 in 1998). CENPF, PCNT, AIM
P2  and RNU4ATAC. Siblings with The anomaly was more common amongst girls - F/M ratio likely pathogenic variation in CENPF had severe short was 1.32/1.0. Only few cases of microcephaly were diag- stature (-3.5SD) and microcephaly (-8SD) without oph- nosed prenatally (average incidence in prenatal diagnostics thalmological abnormalities as reported in cases of 0.12 per 10 000). Stromme syndrome suggesting that CENPF mutation can Discussion:Theoverallincidenceofmicrocephalyinthe result in phenotypes of isolated microcephaly. Previously Czech Republic is low - compared to the data from other reportedheterozygouspathogenicvariationswereidentified population based registries. We believe, that the clinicians in 3 patients (heterozygous in MEC
P2  and TUBA1A and tendtoreportonlyseverecasesofcongenitalmicrocephaly hemizygous deletion in PQB
P1 ). One patient showed with neurological symptoms. double heterozygous likely pathogenic variations in Acknowledgements: The study is supported by the MCPH1 and ASPM inherited from asymptomatic parents Ministry of Health of the Czech Republic, grant nr. AZV indicating the possibility of digenic inheritance. 17-29622A Conclusions: Genomic techniques gave diagnostic yield N. Friedova: None. A. Sipek Jr: B. Research Grant of 39% [20 out of 51]. The study identified 8 novel likely (principal investigator, collaborator or consultant and pathogenic SNVs and 4 likely pathogenic CNVs and pendinggrantsaswell asgrantsalreadyreceived); Modest; expanded the phenotypic spectrum of CENPF. Pathogenic Ministry of Health of the Czech Republic, grant nr. AZV variations in Xlinked genes were identified in2 cases; one 17-29622A. V. Gregor: B. Research Grant (principal withmultipleaffectedfamilymembers.(ICMR:63/8/2010- investigator, collaborator or consultant and pending grants BMS) as well as grants already received); Modest; Ministry of S.Masih:None.M.Amita:None.A.Dwivedi:None.D. Health of the Czech Republic, grant nr. AZV 17-29622A. Saxena: None. K. Mandal: None. S.R. Phadke: None. A. Sipek Sr: B. Research Grant (principal investigator, collaborator or consultant and pending grants as well as 
P09 .079B grants already received); Significant; Ministry of Health of Genomic and phenotypic delineation of congenital the Czech Republic, grant nr. AZV 17-29622A. J. microcephaly Klaschka: None. M. Maly: None. A. M. Alhashem1,2,3, F. Alkuraya1,2, R. Shaheen3 
P09 .078A Application of genomic tools in understanding the 1Prince sultan military and medical city, Riyadh, Saudi etiologies of microcephaly Arabia, 2Alfaisal University, Riyadh, Saudi Arabia, 3King Faisal Specialist Hospital & research Center, Riyadh, S. Masih, M. Amita, A. Dwivedi, D. Saxena, K. Mandal, Saudi Arabia S. R. Phadke Background: Congenital microcephaly (CM) is an impor- SanjayGandhiPostGraduateInstituteofMedicalSciences, tant birth defect with long term neurological sequelae. We Lucknow, IndiaAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1447 aimedtoperformdetailedphenotypicandgenomicanalysis gene panel to investigate the genetic bases of CP and MD of patients with Mendelian forms of CM. with childhood onset. The panel includes 59 genes Methods: Clinical phenotyping, targeted or exome considered disease-causing or related with primitive MD/ sequencing, and autozygome analysis. CPconditions.In9of18subjectstestedsofar,weselected Results:Wedescribe150patients(104families) with56 14neworlow-frequencysinglenucleotidevariants(SNVs) Mendelian forms of CM. Our data show little overlap with in 10 of the 59 selected genes. Five variants in genes thegeneticcausesofpostnatalmicrocephaly.Wealsoshow associatedwithpediatric-onsetMD(ANO3,A
P4 S1
,A P4
E1  that a broad definition of primary microcephaly —as an and VP
S13 D), two (one missense and one intronic) in autosomalrecessiveformofnonsyndromicCMwithsevere GAD1 a gene considered tobe associated to CP, and seven postnatal deceleration of occipitofrontal circumference—is missense variants in candidate CP genes (ITPR1, NAA35, highlysensitivebuthasalimitedspecificity.Inaddition,we MCPH1,PACRG,SCN8A, SPTBN2 andTENM1).Ahomo- expand the overlap between primary microcephaly and zygous truncating mutation, already described in literature, microcephalic primordial dwarfism both clinically (short was found in A
P4 S1
. A few potentially disease-related staturein>52%ofpatientswithprimarymicrocephaly)and variants were detected in genes associated with recessive molecularly (e.g., we report the first instance of CE P135
- phenotypes:anapparentlyhomozygousmissensevariantin relatedmicrocephalicprimordialdwarfism).Weexpandthe MCPH1 suspected tomask a heterozygous genedeletion is allelicandlocusheterogeneityofCMbyreporting37novel currently under characterization. A VP S13
D and a GAD1 likely disease-causing variants in 27 disease genes, con- likely pathogenic variants were detected as compound firming the candidacy of ANKL E2
, YARS, FRMD4A, and heterozygous in association respectively with a samesense THG1L, and proposing the candidacy of BPTF, MA P1
B, and an intronic VUS both predicted as possibly altering CCNH, and PPFIB P1
. splicing mechanisms. Although preliminary these results Conclusion: Our study refines the phenotype of CM, may contribute to the recently highlighted evidence of a expandsitsgeneticsheterogeneity,andinformstheworkup strong genetic base for these rare disorders. of children born with this developmental brain defect. M. Aspromonte: None. R. Polli: None. E. Leonardi: A.M. Alhashem: None. F. Alkuraya: None. R. None. E. Bettella: None. F. Cesca: None. M. Bellini: Shaheen: None. None. M. Nosadini: None. S. Bugin: None. M. Petrella: None. S. Sartori: None. A. Murgia: None.  P09
.080C Targeted gene panel for pediatric Movement Disorders  P09
.081D and Cerebral Palsy The Genetic Basis of paediatric movement disorders: experience from the SYNaPS Study M.Aspromonte1,2,R.Polli1,2,E.Leonardi1,2,E.Bettella1,2, F. Cesca1,2, M. Bellini1,2, M. Nosadini3, S. Bugin4, R. Maroofian, V. Salpietro, H. Houlden M. Petrella5, S. Sartori3, A. Murgia1,2 Molecular Neuroscience Institute of Neurology, london, 1Laboratory Molecular Genetics of Neurodevelopment, United Kingdom Department ofWomen’sand Children’sHealth; University of Padua, Padova, Italy, 2Fondazione Istituto di Ricerca Introduction: Pediatric movement disorders which are Pediatrica (IRP), Città della Speranza, Padova, Italy, usually part of complex neurodevelopmental disorders 3Paediatric Neurology and Neurophysiology Unit, compriseawidegroupofneurologicaldiseaseswithhighly Department of Women's and Children's Health, University variable, often complex clinical presentation. Although of Padua, Padova, Italy, 4UOC Pediatrics San Bortolo causative mutations in >200 genes have been associated Hospital, Vicenza, Italy, 5UOC Pediatrics Angelo Hospital with various movement disorders, many patients remain Mestre, Venice, Italy without a precise genetic diagnosis. The SYNaPS Study, which is IRB/ethics approved and aimed at analysing Childhood Movement Disorders (MD), represent a hetero- unexplained ultra-rare neurological conditions, aim to geneous group of neurological conditions characterized by identifyunderlyinggeneticcausesinpatientswithpediatric abnormal voluntary or involuntary movements also recur- movement disorders by high-throughput genetic ring in Cerebral Palsy (CP), a permanent non progressive investigations. neurodevelopmental condition involving movement and Materials and Methods: As part of SYNaPS study a posturealterations.Althoughtheetiologyisoftenunknown, large cohort of well-phenotyped families recruited from thisspectrumofconditionshasastronggeneticcomponent. multiplepaediatricneurologyclinicsaroundtheworldwith The aim of this study was to design a customized targeted adiverseethnicbackgroundaffectedbydifferentchildhood1448 and early-onset movement disorders were genetically and microRNAs. Clinical data contains motor function score, clinically investigated. exome sequencing was performed muscleelastography(shearwaveelastography(SWE)),and for probands of around 500 families with any forms of whole body muscle computed tomography with ultralow movement disorders. Some of the unsolved individuals level irradiation. As a result, miR206 was significantly weresubjectedtoacombinationofSNP-Arraygenotyping/ overexpressed in FCMD patients compared to normal homozygosity mapping, whole genome sequencing and controls. Correlation coefficient of miR206 with serum long-read sequencing. CKlevel,serumcreatininelevel,andmotorfunctionscores Results:Overall,inthisstudyweresolvedaround50%of were also high. MiR 206 was especially high in FCMD the patients with movement disorders. We also uncovered patients with high muscle contents, suggesting remaining novel disease-causing genes in various families. Re-anno- sparing capacity of muscle regeneration. SWE showed tating/re-analysing the exome data along with more exten- significantly high elasticity in biceps brachii and brachial sive data sharing and also employing homozygosity musclebutnothighinlowerextremitiesinFCMDpatients, mapping in some of the families increased the rate of compared to normal control, because of high content of fat diagnosis. infiltrationduetodisuseoflowerextremities.Inconclusion, Discussion: We made a molecular diagnosis for around serum miR206 and SWE is useful for monitoring muscle half of the families and characterised multiple new genes wasting progression and motor function level of FCMD. and ultra-rare movement disorders. A genetic diagnosis M. Taniguchi-Ikeda: None. R. Harada: None. M. provided either disease-specific treatment or effected man- Nagasaka: None. H. Kurahashi: None. T. Toda: None. agement for some patients with a genetic diagnosis, high- lighting the importance of early and specific diagnosis.  P09
.083B R. Maroofian: None. V. Salpietro: None. H. New genes involved in diseases with neurodegeneration Houlden: None. with brain iron accumulation (NBIA)  P09
.082A D. Martínez-Rubio1, C. Tello1, V. Lupo1, V. Rejas1, Evaluating motor functions and biomarkers for A. Darling2, S. Aguilera3, B. Pérez-Dueñas4, C. Espinos1 Fukuyama muscular dystrophy 1CentrodeInvestigaciónPríncipeFelipe(CIPF),Valencia, M. Taniguchi-Ikeda1, R. Harada2, M. Nagasaka3, Spain, 2Hospital Sant Joan de Déu, Barcelona, Spain, H. Kurahashi4, T. Toda5 3Complejo Universitario de Navarra, Pamplona, Spain, 4Hospital U. Vall d'Hebron, Barcelona, Spain 1DepartmentofClinicalGenetics,FujitaHealthUniversity, Toyoake, Aichi, Japan, 2Department of Rehabilitation, Introduction: Neurodegeneration with brain iron accumu- Kobe University Graduate School of Medicine, Kobe, lation (NBIA) is a heterogeneous group of inherited Japan, 3Department of Pediatrics, Kobe University neurologic disorders characterized by progressive move- Graduate School of Medicine, Kobe, Japan, 4Molecular ment disorders and abnormal accumulation of iron in the Genetics, Fujita Health University, Toyoake,Aichi, Japan, basalganglia.Thereare12genesthatresolve80%ofcases. 5DepartmentofNeurology,TheTokyoUniversityGraduate Our clinical series comprises 134 probands who suffered School of Medicine, Toyoake,Aichi, Japan fromNBIA andothermovementdisorders. Afteranalyzing theNBIAgenes,wehaveachievedthegeneticdiagnosisin Fukuyama muscular dystrophy (FCMD) is an autosomal 54 cases. The aim of the present study is to establish the recessive, severe childhood muscular dystrophy with brain molecular bases in patients without mutation in known anomaly.FCMD ismainlycaused byanancestral insertion NBIA genes. of 3-kb retrotransposal element into the 3’ untranslated MaterialsandMethods:Thirty-eightpatientshavebeen region of the causative gene, fukutin. Recently, we testified studied by a customized gene panel based on SureSelect that pathogenic exon trapping by the transposon cause Technology(Agilent),whichcomprises498genesinvolved splicing abnormality in FCMD. We have testified that inNBIA,ataxia,chorea,dystonia,parkinson,spasticataxia, antisenseoligonucleotidestargetingthissplicingcouldbea and spastic paraplegia. possible therapy in the future. However, there has been no Results: We have achieved a definite diagnosis in 19 biomarkersorfewreportonnaturalhistoryforassessingthe probands. Four of them presented with a neuroimaging disease level of FCMD. To find specific serum biomarkers phenotypesuggestiveofNBIAandcarriednovelmutations and to comprehend natural history of FCMD patients, we in GLB1, FUCA1 and TP P1
, and in one patient born to collected serum and clinical data from patients. We tested consanguineous parents, homozygote mutations were on serum biomarkers by measuring muscle specific identified in two genes, FBOX7 and DLD.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1449 Conclusions: We have solved 50% of cases. Except for ataxia (42%), 12 neuromuscular diseases (25%), 8 spastic FUCA1, these are the first cases described of NBIA with paraplegia(17%),2abnormalmovements(4%)and6others mutations in GLB1, TP P1
, and DLD/FBXO7. According (12%)forwhomthephenotypecouldnotbelabelledunder new cases are reported, the clinical and genetic spectrum a usual neurological syndrome. ES was interpreted in a associated with NBIA are expanding. Funding: Fundació solo-basedstrategy(94%)orintriowithparentalpool(6%). LaMaratódelaTV3,PROMETEO/2018/135,ISCIII-PI15/ Results: ES identified a causal diagnosis in 4/8 indivi- 00187 and ISCIII- P18
/00147, cofund with FEDER funds. dualswithspasticparaplegia(50%),3/6“other”(50%),1/2 D. Martínez-Rubio: None. C. Tello: None. V. Lupo: withabnormalmovements(50%),5/12withneuromuscular None. V. Rejas: None. A. Darling: None. S. Aguilera: diseases (42%), 4/11 with isolated cerebellar ataxia (37%) None. B. Pérez-Dueñas: None. C. Espinos: None. and 2/9 with spinocerebellar ataxia (22%). Overall diag- nostic yield was of 40 %.  P09
.084C Conclusions: With such overall diagnostic yield, this Strong interest of exome sequencing in progressive study reinforces the diagnostic interest of ES in neuroge- neurological diseases netics, in all its fields, as this diagnostic yield ranges from 22% in spinocerebellar ataxia (which is higher than current Q. H. C. Thomas1,2,3, F. Tran Mau-Them2,4, A. Bruel2,4, yield of gene panels) to 50% in spastic paraplegia. It also A. Sorlin1,2,4, A. Fromont5, Y. Béjot3,6, M. Giroud3, includes situations in which clinical displays may be com- B. Daubail3, A. Jacquin-Piques3, M. Hervieu-Begue3, plex and hard to systematize. First-tier implementation T. Moreau5, G. Osseby3, P. Soichot3, S. Nambot2,1, would significantly improve diagnostic yield in P. Callier2,4, A. Denomme-Pichon2,4, L. Faivre2,1, neurogenetics. A. Vitobello2,4, C. Philippe2,4, C. Thauvin-Robinet2,1,4, Q.H.C. Thomas: None. F. Tran Mau-Them: None. A. S. Moutton1,2 Bruel: None. A. Sorlin: None. A. Fromont: None. Y. Béjot: None. M. Giroud: None. B. Daubail: None. A. 1Genetics Center, FHU-TRANSLAD, Dijon Bourgogne Jacquin-Piques: None. M. Hervieu-Begue: None. T. University Hospital, F-21000 Dijon, France, Dijon, Moreau: None. G. Osseby: None. P. Soichot: None. S. France, 2INSERM, LNC UMR1231 team GAD, University Nambot: None. P. Callier: None. A. Denomme-Pichon: of Burgundy and Franche-Comté, F-21000 Dijon, France, None. L. Faivre: None. A. Vitobello: None. C. Philippe: Dijon, France, 3Service de Neurologie, Dijon University None. C. Thauvin-Robinet: None. S. Moutton: None. Hospital, F-21000 Dijon, France, Dijon, France, 4Functional Unity of innovative diagnosis for rare disease,  P09
.085D Dijon Bourgogne University Hospital, F-21000 Dijon, Elevated impact of chromatin regulating genes in the France, Dijon, France, 5Service de Pathologies genetic diagnosis of neurodevelopmental disabilities Inflammatoires du système nerveux central, Neurologie Général, Dijon University Hospital, Dijon, France, 6Dijon I. Diez, M. Martinez-Garcia, R. Sanchez-Alcudia, Stroke Registry, EA7460, Pathophysiology and C.Rodriguez-Solera,R.Perez-Carro,I.Sanchez-Navarro, Epidemiology of Cerebro-Cardiovascular Diseases E. Mata, E. Fernandez-Tabanera, S. Rosenstone, (PE C2
), University Hospital of Dijon, University of D. Rodríguez, G. Benito, N. Sanchez-Bolivar, Burgundy, Dijon, France, Dijon, France M. Carcajona, P. Maietta, S. Alvarez Introduction: Neurogenetics represents a vast, complex, NIMGenetics, Madrid, Spain everchangingdisciplinewhosediagnosiscurrentlyremains challenging, since clinical and/or imaging features fre- Introduction: Exome trio analysis is an effective strategy quently appear very unspecific, especially early in the toidentifypotentialcausalvariantsinraregeneticdisorders evolution (cerebellar ataxia, tremor, dystonia⋯). In mole- withclinicalheterogeneity.Inthisstudy,wefocusedonthe culardiagnosis,currentstrategiesusuallyincludesequential 404 probands with neurodevelopmental disabilities (NDD) investigationsthatmayleadtolong,tedious,expensiveand with causal variants on chromatin-regulating genes to disappointing patients care. Exome sequencing (ES) determine their frequency and their genotypic/phenotypic appearsapromisingapproachforneurogenetics,apartfrom characteristics by trio analysis. when nucleotide motif expansion disorders can be Patients and Methods: A cohort of 259 males and 145 suspected. females, with a median of 7 years old, was studied by trio Materials and Methods: We recruited 48 individuals wholeexomesequencing.LibrariesweregeneratedwithIon without cognitive development impairment, referred to our AmpliSeqTM or SureSelectXT and sequenced with Ion center for suspected neurogenetic disease: 20 cerebellar1450 ProtonTM/ S5
TMXL or NovaSeq 6000. The data were pro- by bioinformatic analysis. Parents and healthy offspring cessed using an in-house pipeline. were assessed for the candidate gene variants. We Results: A genetic diagnosis was established in 129 of delineated a novel neurodevelopmental disorders caused the 404 studied probands, leading to a diagnostic yield of by biallelic PP P1
R21 loss of function variants, and 32%. Among the positive cases, 82 and 47 variants, were identified four previously unreported homozygous truncat- considered as casual or probably casual, respectively. Of ing PP P1
R21 alleles. Pathogenic variants have been that diagnosed patients cohort, 26 probands (20%) had identified in a number of patients presenting broad clinical variants in chromatin-regulating genes (ARID1B, ATRX, phenotypes with autosomal recessive inheritance. By using EHMT1,SATB2,SMARCA2,andKMTfamily).Ofthe26 linkage analysis and exome or genome sequencing, variants identified, 58% were loss of function de novo recessive inactivating mutations in ADPRH L2
 in six variantsassociatedwithanautosomaldominantinheritance. families have been recognized. It has been demonstrated Clinically, these patients shared NDDs phenotypic char- that SL C10
A7 mutations reduce SL C10
A7 protein expres- acteristics (psychomotor delay and/or autism spectrum dis- sionbyinvitrostudies.Wealsodescribedtheparticipation order)withshortstature,dysmorphicfeatures,epilepsyand/ of the AP C2
 and DEAF1 Genes as potential functional or digital malformations. candidates in neurodevelopmental diseases based on Conclusions:Thehaploinsufficiencyassociatedwithloss computational prediction by using several cellular tools. offunctionvariantsinthegenesimplicatedintheregulation Thecurrentfocusofourresearchisonneurodevelopmental of chromatin played a crucial role in neurodevelopment disorders, especially autosomal recessive. To further, disorders. These deleterious variants seemed to be asso- workup with next generation technologies, using several ciated with a common phenotype. A better delineation of cellular tools is essential for precise phenotype definition these clinical manifestations could help to better recognize and to understand the underlying disease mechanisms them in the clinical setting. E. Ghayoor Karimiani: None. I.Diez:None.M.Martinez-Garcia:None.R.Sanchez- Alcudia: None. C. Rodriguez-Solera: None. R. Perez-  P09
.087B Carro:None.I.Sanchez-Navarro:None.E.Mata:None. Neurofibromatosis type 1 mutational spectrum in E. Fernandez-Tabanera: None. S. Rosenstone: None. D. Macedonian patients: A report of seven novel Rodríguez: None. G. Benito: None. N. Sanchez-Bolivar: pathogenic variants None. M. Carcajona: None. P. Maietta: None. S. Alvarez: None. M.Dimishkovska1,V.SabolicAvramovska2,E.Sukarova- Angelovska2, M. Kocova2, D. Plaseska-Karanfilska1  P09
.086A Novel candidate genes in autosomal recessive 1Research Centre for Genetic Engineering and neurodevelopmental disorders: A three year cohort Biotechnology “Georgi D. Efremov”, Skopje, Macedonia, study The Former Yugoslav Republic of, 2University Pediatric Clinic, Medical Faculty, University “Ss Cyril and E. Ghayoor Karimiani Methodius”, Skopje, Macedonia, The Former Yugoslav Republic of Next Generation Genetic Clinic, Mashhad, Iran, Islamic Republic of Introduction: Pathogenic variants in NF1 gene are associated with autosomal dominant Neurofibromatosis In a three-year cohort study, 313 Families with autosomal type 1 (NF1) which is a multi-systemic, neurocutaneous recessive pattern compatible with genetic disorders such as disorder with predisposition to benign or malignant lesions seizures, hypotonia, neurodegenerative disorder, progres- of the skin, nervous system and bone. Here we present the sive brain atrophy, developmental regression have been first genetic study of NF1 in R. Macedonia. conducted. The progression in diagnosis of neurodevelop- MaterialandMethods:Since2014,atotalof33patients mental disorders has undergone considerable in the past suspected for NF1 were referred to our laboratory. The decade. In this cohort study we aim to explain our broad methodology included cDNA sequencing, next-generation research on identification of six novel candidate genes sequencing using Illumina’s TruSight Cancer panel, direct (PP P1
R21, ADPRH L2
, AP C2
, SL C10
A7, AP C2
, DEAF1) DNA sequencing and multiplex ligation probe on the patients with autosomal recessive neurodevelop- amplification. mental disorders. A complete clinical and paraclinical Results: A total of 21 different pathogenic variants were examinationhasbeendonebyexpertspecialistsandclinical detected in 22 unrelated patients. The variants comprised geneticist.ExomeSequencingwasperformedandfollowed nine nonsense, six frameshift, two splicing, two missenseAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1451 mutations, one multi-exon deletion (exons 9-51) and one suspected, but genetic analysis of known NCL genes 1.4MbdeletionincludingtheentireNF1gene.Allvariants yielded negative results. were unique, detected in one patient/family with the Materials and Methods: Whole exome sequencing was exception of 1.4 Mb deletion which was detected in two performedongenomicDNAoftheprobandandbothparents, unrelated patients. Genetic testing of family members was uponwritteninformedconsent.Variantswerealigned,filtered available for 20 patients; the NF1 variation was inherited and prioritized to identify candidate variants. Validation and from an affected parent in 11 (55%), while in nine patients segregationanalysiswereperformedwithSangersequencing. (45%) it has arisen as a de novo event. Seven mutations Results: The proband was found to carry a novel het- were novel: one nonsense (c.5844C>G, p.Tyr1948Ter) and erozygous truncating variant in the IRF2BPL (Interferon sixframeshiftmutationsthatcauseprematureterminationof regulatory factor 2 binding protein-like) gene, arisen de the protein (c.208delA; c.1104_1107delTCAG; novo. Very recently, de novo heterozygous variants in this c.1480_1481delTT; c.2495_2496dupAC; c.4517delC; gene have been reported in 18 patients showing neurode- c.6971delA). Five of the novel mutations were inherited generative phenotypes variably defined as neurodevelop- from an affected parent, while c.2495_2496dupAC and mental disorders with regression, abnormal movements, c.6971delA have occurred de novo. loss of speech and seizures or developmental epileptic Conclusion: Our study presents the NF1 mutational encephalopathies. spectruminR.Macedoniaandexpandstheglobalspectrum Conclusions:Thiscaseexpandsthephenotypicspectrum of NF1 pathogenic variants. of IRF2BPL to include NCL-like phenotypes. M. Dimishkovska: None. V. Sabolic Avramovska: Acknowledgements: This work was funded by the Eur- None. E. Sukarova-Angelovska: None. M. Kocova: opean Research Council (ERC Starting Grant 260888), the None. D. Plaseska-Karanfilska: None. Pierfranco and Luisa Mariani Foundation (PADAPORT project) and the Italian Ministry of Health (Ricerca Fina-  P09
.088C lizzata 2013 NET-2013-02356160, Ricerca Corrente ‘Neu- A novel IRF2BPL truncating variant is responsible for roscienze Sperimentali’ and 5x1000 Anno 2016 to infantile neuronal ceroid lipofuscinosis-like phenotype Fondazione Santa Lucia). M.Ginevrino:None.R.Battini:None.S.Nuovo:None. M. Ginevrino1,2, R. Battini3,4, S. Nuovo5,2, A. Micalizzi6, A. Micalizzi: None. A. Simonati: None. I. Contaldo: A. Simonati7, I. Contaldo8, E. M. Valente1,2 None. E.M. Valente: None. 1Department of Molecular Medicine, University of Pavia,  P09
.089D Pavia, Italy, 2Neurogenetics Unit, IRCCS Fondazione Santa Genetic analysis of early-onset schizophrenia Lucia, Rome, Italy, 3IRCCS Stella Maris Foundation, Pisa, Italy, 4Department of Clinical and Experimental Medicine, D. Krgović1,2, Š. Stangler Herodež1,2, N. Šenica3, University of Pisa, Pisa, Italy, 5DepartmentofMedicine and H. Gregorič Kumperščak3,2, B. Aleksić4, N. Nemec5, Surgery,UniversityofSalerno,Salerno,Italy,6Laboratoryof A. Zagorac1, N. Kokalj Vokač1,2 MedicalGenetics,BambinoGesùChildren'sHospital,Rome, Italy,7DepartmentofNeuroscience,Biomedicine,Movement- 1Laboratory of Medical Genetics, University Medical Neurology (Child Neurology) and Neuropathology, Centre Maribor, Maribor, Slovenia, 2Medical Faculty, Policlinico GB Rossi, University of Verona, Verona, Italy, University of Maribor, Maribor, Slovenia, 3Department of 8Unit of Child Neurology, IRCCS Policlinico Gemelli Paediatrics, University Medical Centre Maribor, Maribor, Foundation, Catholic University, Rome, Italy Slovenia, 4Graduate School of Medicine, Department of Psychiatry, Nagoya University, Nagoya, Japan, Introduction: Neuronal ceroid lipofuscinoses (NCLs) are 5Department of Animal Science, Chair of Genetics, Animal neurodegenerative lysosomal storage disorders character- Biotechnology and Immunology, Biotechnical faculty, ized by the progressive loss of both motor and cognitive University of Ljubljana, Ljubljana, Slovenia skills, myoclonic epilepsy and the presence of lysosomal deposits with characteristic ultrastructural features, due to Introduction: Early onset schizophrenia (EOS) is rare mutationsinthirteendistinctgenes. Here,wereport achild complex psychiatric disorder with polygenic inheritance. presenting a neurological disorder characterized by motor PreliminarydatasuggestthatEOShashighergeneticliability and cognitive regression, spastic-dystonic tetraparesis, tothedisease. Therefore,we preformedgenetictestingusing sporadic myoclonus, typical EEG abnormalities and lyso- both molecular karyotyping (arrayCGH) and next generation somedepositsofgranularosmiophilicmaterialwithtubular sequencing (NGS) for determination of copy number and fingerprint-like structures. A diagnosis of NCL was variations (CNVs) and single nucleotide variants (SNVs),1452 affecting the possible schizophrenia-associated genes in a patients with suspected monogenic disorders using Illumina small group of Slovenian children diagnosed with EOS. NextSeq 500 and in-house analysis software. 3110 samples Material and Methods: Our study included 49 patients. were sequenced using Illumina TruSightOne enrichment In all patients molecular karyotyping was performed, fol- (“clinicalexome”);594samplesbywhole-exomesequencing; lowing the medical exome sequencing (Illumina TruSight 3142samplesusingourcustom2000-genesplatform,focused One capture). Considering the polygenicity of the disorder, on epilepsy and neuromuscular disorders. A definitive wealsoanalysedenrichmentofthelistofgenesharbouring molecular diagnosis could be estimated in 2238 cases possibly deleterious variants in Gene Ontology terms (GO) (32,69%), 1043 (15,24%) having a possible diagnosis with by using GeneMania version 3.4.1 Cytoscape plugin. a need for additional testing. We compare a diagnostic yield Results: In 12% (6/49) of children a clinically significant our epilepsy panel (Table 1) and neuromuscular diseases CNVwasdetected,thatcouldbeassociatedwiththedisorder. panel (Table 2) with results of other published studies. In 14% (6/43) of patients pathogenic SNV were detected, although no clear genotype-phenotype correlations could be Table 1 made.Therefore,usingtheGOterms,weassembledalistof GenomedKodera Trump Møller Butler genes harbouring probably deleterious variants. etal.,2013 etal.,2016etal.,2016etal.,2017 Conclusion:Theaimofthisstudywastoassemblealistof Definitive 27,7% 23% 18,58% 22,67% 18,29% genes harbouring probably pathogenic variants in Slovenian diagnosis patients with EOS by performing the molecular karyotyping Possible 15,48% andNGSmethod.A12%ofpatientsarecarriersofclinically diagnosis significant CNV. NGS analysis and enrichment analysis No 56,82% showedthatgeneontologytermsrelatedtoschizophreniaare diagnosis enriched in genes, selected by our filtering. The over- Genecount 1081 35 46 46 110 represented pathways could be associated with pathology of Numberof 1693 53 323 216 339 schizophrenia in Slovenian population. patients D. Krgović: None. Š. Stangler Herodež: None. N. Šenica: None. H. Gregorič Kumperščak: None. B. Aleksić: None. N. Nemec: None. A. Zagorac: None. N. Table 2 Kokalj Vokač: None. GenomedEvilä Chae Dai etal.,2016 etal.,2015 etal.,2015  P09
.090A Diagnostic yield of ngs-based epilepsy and Definitive 44,67% 15% 48,8% 65% neuromuscular disease panel in russia population diagnosis Possible 12,12% I. V. Kanivets1,2, A. A. Sharkov1,3, S. A. Korostelev4,1, diagnosis D. V. Pyankov1, F. A. Konovalov1, I. F. Komar'kov1, Nodiagnosis 43,21% K. V. Gorgisheli1, O. G. Novoselova1, L. O. Rash1, Genecount 836 180 579 399 V. V. Zakharova1 Numberof 553 61 43 55 patients 1Genomedltd,Moscow,RussianFederation,2Fsbeirussian medical academy continuous professional education, Mutationfrequencyanalysisshowedthatthetop20genes Moscow, Russian Federation, 3Veltischev Research and account for 57,51% and 46,72% definitive diagnosis in Clinical Institute for Pediatrics of the Pirogov RNRMU, epilepsy and neuromuscular disease panel respectively. Moscow, Russia, Moscow, Russian Federation, 4Federal Nevertheless, the use of large panels is justified due to State Autonomous Educational Institution of Higher higher diagnostic yield and cost-effectiveness. Education I.M. Sechenov First Moscow State Medical I.V. Kanivets: None. A.A. Sharkov: None. S.A. Kor- University of the Ministry of Health of the Russian ostelev: None. D.V. Pyankov: None. F.A. Konovalov: Federation (Sechenov University), Moscow, Russian None. I.F. Komar'kov: None. K.V. Gorgisheli: None. O. Federation G. Novoselova: None. L.O. Rash: None. V.V. Zakharova: None. Single nucleotide variants (SNVs) are a common cause of congenital anomalies, developmental delay, epilepsy, neuro-  P09
.091B muscular disorders, cardiovascular and other disorders. In Identification of potential new genes involved in 2014-2019 we are performed 6846 NGS-based tests for autosomal recessive form of Parkinson's diseaseAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1453 C.Tesson,A.Honoré,H.Bertrand,V.Drouet,S.Lesage, Radiology, Institute of Clinical Medicine, University of A. Brice Tartu,Tartu,Estonia,6YaleUniversitySchoolofMedicine, Department of Genetics, New Haven, CT, United States, - INSERM U1127, CNRS UMR 7225, UPMC Université 7Eye Clinic, Tartu University Hospital, Tartu, Estonia, Paris 06 UMR  S1127
, Sorbonne Université Institut du C, 8Broad Institute of MIT and Harvard, Cambridge, MA, Paris, France United States, 9Division of Genetics and Genomics, Department of Medicine, Boston Children`s Hospital, Parkinson disease (PD) affects 1% of the population above Harvard Medical School, Boston, MA, United States 65 years. It is characterized by the triad of symptoms: tremor, rigidity, and bradykinesia. To date the identified PEHO syndrome (MIM 260565) is characterized by genes associated with early-onset (EO, >40 years) auto- progressive encephalopathy with edema, hypsarrhythmia, somal recessive (AR) PD only explain 45%, other genes and optic atrophy, first described in 14 Finnish patients. A remaintobediscovered. The aim oftheworkistoidentify homozygous missense substitution c.92C>T (p.Ser31Leu) new genes involved in AR EO PD, using consanguineous in ZNHIT3 was identified as the primary cause of PEHO PD families and applying genotyping on DNA microarrays syndrome in Finland. and NGS technologies. Case report: The index patient was hospitalised at 1m Using a series of 99 families with confirmed con- duetomuscularhypotoniaandlethargy.BrainMRIshowed sanguinity, we looked for homozygous loss of function or mildlydilatedlateralventricles,aporencephaliccystonthe missensemutationspredicteddeleteriousinregionoflossof left,hypoplasticoccipitallobesandabsenceofmyelininthe homozygosity.Thenwefirstfocusedonvariantsharedbyat cerebellarwhitematter.At10m,generalizedseizuresstarted least two families. We identified mutations in PSMF1 an (myoclonus and infantile spasms). EEG showed hypsar- interactor of FBXO7. In one family, only this variant rhythmia. The child was blind at 17m; she had pale and remains, moreover both mutations code for amino acid smalldisks,andtemporaldiskpallor.At8y,shehassevere highly conserved upon evolution. microcephaly (-4SD), no active movements, severe spasti- Most of the candidate’s genes are private genes high- city, and scoliosis. Her face is edematous with an opened lightinggeneticheterogeneityofPD.Therefore,inasecond mouth appearance. Brain MRI showed severe cerebral, time we hypothesized that some candidate’s genes can be cerebellar and brainstem atrophy, thin and short corpus involved in a common pathway. Using ClusterProfiler we callosumandalmostabsentperiventricularwhitematter.To performedGOtermenrichmentanalyses,thenwewereable identify the underlying etiology of this phenotype, trio to grouped together some genes and were able to see an exome was performed and negative, after which trio gen- statistical enrichment in autophagy pathway. ome sequencing was performed. We identified a strong candidate gene for AR-PD: Result:Twohighqualityheterozygousmissensevariants PSMF1.Furtherfunctionaldataareneededtostrengthenthe inZNHIT3genewereidentified:thec.92C>Tp.(Ser31Leu) role of this gene in PD, possibly affecting the proteasome variant(NM_004773.3),whichwaspreviouslydescribedin activity and α-synucleine aggregation. We will also con- Finnish patients and the novel variant c.41G>T p.(Cys14- tinue to investigate pathway analyses in order to identify Phe).Thereareeightheterozygotesandnohomozygotesfor candidates for PD in our families. thelattervariantingnomADdatabaseandmultiplein-silico C. Tesson: None. A. Honoré: None. H. Bertrand: pathogenicity predicting algorithms indicated a damaging None.V.Drouet:None.S.Lesage:None.A.Brice:None. effect. Conclusion:WereportedthefirstpatientoutsideFinland  P09
.093D with confirmed ZNHIT3 variants causing PEHO syndrome. PEHO syndrome caused by compound heterozygote Funding: Estonian Research Council grants PUT355, variants in ZNHIT3 gene PRG471, and PUTJD827. K. Muru: None. E. Õiglane-Shlik: None. P. Ilves: K. Muru1,2, E. Õiglane-Shlik3, P. Ilves4,5, S. Pajusalu1,2,6, None. S. Pajusalu: None. I. Kuus: None. M.H. Wojcik: I. Kuus7, M. H. Wojcik8,9, T. Reimand1,2, K. Õunap1,2,8 None. T. Reimand: None. K. Õunap: None. 1Department of Clinical Genetics, United Laboratories,  P09
.094A Tartu University Hospital, Tartu, Estonia, 2Department of Exome-based bottom-up approach of molecular ClinicalGenetics,InstituteofClinicalMedicine,University diagnostics in a clinically ambiguous family with a of Tartu, Tartu, Estonia, 3Children`s Clinic, Tartu polystigmatized patient revealed ultra-rare NEDD4L University Hospital, Tartu, Estonia, 4Radiology Clinic of associated periventricular nodular heterotopia Tartu University Hospital, Tartu, Estonia, 5Department1454 M.Pecimonova1,2,D.Smolak1,2,J.Budis1,3,4,M.Lichvar1,  P09
.095B J. Turna2,3,4, J. Radvanszky1,4,5, T. Szemes1,2,4 Pitt-Hopkins syndrome caused by a pathogenic splicing variant 1Geneton Ltd., Bratislava, Slovakia, 2Department of Molecular Biology, Faculty of Natural Sciences, Comenius P. Sparber1, A. Filatova1, I. Anisimova1, A. Chuhrova1, University, Bratislava, Slovakia, 3Slovak Centre of M. Skoblov1,2 Scientific and Technical Information, Bratislava, Slovakia, 4Comenius University Science Park, Bratislava, Slovakia, 1Research center of medical genetics, Moscow, Russian 5Institute for Clinical and Translational Research, Federation, 2School of Biomedicine, Far Eastern Federal Biomedical Research Center, Slovak Academy of Sciences, University, Vladivostok, Russian Federation Bratislava, Slovakia Introduction: Pitt-Hopkins syndrome is a rare inherited Introduction: Periventricular nodular heterotopia-7 neurologicalcondition,associatedwithheterozygouspatho- (PVNH7) is an ultra-rare neurodegenerative disorder genic variant in the TCF4 gene or with deletion of the affecting proper neuronal migration during neurogenesis. 18q21.2 chromosome region, in which the TCF4 gene is Only seven patients carrying pathogenic variants in the located.Inthepresentstudy wereport anovel clinicalcase NEDD4L gene, associated with PVNH7, were reported so of a 7-year-old patient with global development delay and far. We report a polystigmatized 2-year-old boy having multiply minor dysmorphic features. significant symptomatologic overlap with PVNH7, how- Materials and Methods: Whole exome sequencing was ever, showing also symptoms falling outside performed on Ion  S5
 next-generation sequencing system. PVNH7 symptomatology. His brother presents with some TheidentifiedvariantwasconfirmedbySangersequencing. of the proband´s symptoms, specifically those falling RT-PCR analysis was performed using total RNA isolated outside PVNH7 symptomatology. from patient fibroblasts. HEK293 cells were transfected Materials and Methods: The boy, his brother and their with minigene plasmid vector containing the variant of parentsweresubjectedtowhole-exomesequencing.Variant interest. Splicing alterations were validated using RT-PCR prioritization was performed using an inheritance-pattern with further Sanger sequencing. and phenotype-driven top-down approach, or by a bottom- Results: Whole exome sequencing revealed a previously up approach, beginning with the identified known patho- undescribed heterozygous variant in the intron 11 of the genic variants in the proband’s data. TCF4 gene - NM_001083962: c.922+5G>C. Segregation Results:Becauseofuncertaintiesinsymptomatologyand analysis showed that the variant is de novo. Functional inheritance pattern, the top-down approach was hard to analysis using two independent approaches: RT-PCR ana- apply. The bottom-up approach, however, identified a lysis of total RNA extracted from patient fibroblast and a known pathogenic variant, NM_001144967.2(NEDD4L): splicing minigene assay, showed that c.922+5G>C variant c.2677G>A:p.Glu893Lys, in the proband’s genome, disrupt the donor splicing site of the intron 11 leading to a absenting in any other analyzed family member. This de completeskippingofexon11,resultinginaframeshiftand novo variant explained symptoms overlapping those repor- premature stop codon formation p.(Ser264GlnFsTer83). tedforPVNH7,suchasdelayedpsychomotordevelopment Conclusion: Therefore, after performing functional ana- and intellectual disability, absenting speech and walking, lysisweclassifythec.922+5G>Cvariantaspathogenicand hypotonia, strabismus, cleft palate, microretrognathia, and disease causing in our patient. 2-3 toe syndactyly. Symptoms shared with the brother, on P. Sparber: None. A. Filatova: None. I. Anisimova: theotherhand,werenotexplainedbythisvariant.Theseare None. A. Chuhrova: None. M. Skoblov: None. most probably not extended phenotypes of PVNH7, rather an independent clinical entity.  P09
.096C Conclusion: Our case highlights: 1) the usefulness of a Expanding the phenotypic spectrum associated to bottom-up approach of causative variant identification PMPCA mutations during differential diagnostics of patients/families having unclear/overlapping phenotypes; 2) the importance of V. Serpieri1, R. Battini2,3, S. Nuovo4,5, M. Ginevrino1,4, reporting yet undescribed symptoms of known disorders, F. Tinelli2, E. Valente1,4 found in single patients/families, with special care. M. Pecimonova: None. D. Smolak: None. J. Budis: 1Dept. of Molecular Medicine, University of Pavia, Pavia, None. M. Lichvar: None. J. Turna: None. J. Rad- Italy, 2IRCCS Stella Maris Foundation, Pisa, Italy, 3Dept. vanszky: None. T. Szemes: None. of Clinical and Experimental Medicine, University of Pisa, PIsa, Italy, 4Neurogenetics Unit, IRCCS Fondazione SantaAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1455 Lucia, Rome, Italy, 5Dept. of Medicine and Surgery, 1ClinicalinstituteofMedicalGenetics,Ljubljana,Slovenia, University of Salerno, Salerno, Italy 2University of Udine, Udine, Italy Introduction: Biallelic missense mutations in the PMPCA The pontocerebellar hypoplasias (PCH) represent a hetero- gene, encoding mitochondrial processing peptidase alpha- geneous group of conditions characterized by structural subunit,wereinitiallyidentified in19individualsfrom five abnormalitiesofcentralnervoussystem,typicallyinvolving familieswithearlyonset,non-progressivecerebellarataxia, cerebellum and ventral pons. In the present study, we developmental delay and intellectual disability. Brain MRI propose a novel association between biallelic variants in showed non-progressive cerebellar atrophy; muscle biopsy ATOH1 and PCH with severe neurodevelopmental dis- wasnormal,althoughmitochondrialcomplexesactivitywas order. We report a family with two children affected with mildly decreased insome cases. Subsequently, twocousins pontocerebellar dysplasia, severe motor and speech delay were reported with amore severe phenotypeofprogressive and sensorineural hearing loss. Using exome sequencing, mitochondrial encephalopathy, including profound devel- we identified a homozygous rare missense variant in opmentaldelay,ptosis,ophthalmoplegia,weakness,respira- ATOH1 in both affected probands. ATOH1 encodes atonal toryinsufficiency,blindnessandlacticacidemia.BrainMRI bHLHtranscriptionfactor1,acoreneurogenictranscription showed progressive cerebral-cerebellar atrophy, with a factorthatregulatescelldifferentiationincerebellum,drives lactate peak at spectroscopy. Muscle biopsy demonstrated development of inner ear hair cells and is essential in enlarged, structurally abnormal mitochondria. Finally, a 7- developmentofneurosensorysystems.DisruptionofAtoh1 year-oldboywasrecentlyreportedwithpsychomotordelay, in mouse models was previously shown to result in severe spastic-ataxic gait and regression. He had elevated blood cerebellar hypoplasia and hearing loss. The identified lactate and abnormal muscle biopsy with mitochondrial variant (NM_005172.1:c.481C>G, p.Arg161Gly) substi- damage. Besides cerebellar atrophy, brain MRI showed tutes a highly conserved residue in the DNA binding bilateral symmetric hyperintensity in the striatum (Leigh- domain of Atoh1. It is absent from control populations of like features). the gnomAD project and our in-house database of 3000 Case Report: We report a 12-year-old girl carrying two exomes. We performed molecular modelling, which novel, likely pathogenic PMPCA missense variants, who predicted that this change can affect DNA binding affinity presented a complex, non-progressive early-onset pheno- of Atoh1 through distortion of its contacts to DNA and type of spastic ataxia with superimposed generalized through remodelling of the helical part of HLH domain. In hyperkinetic movements, intellectual disability, micro- conclusion, we report a novel potential genetic cause of cephaly and epilepsy. Several brain MRIs showed non- developmental brain anomalies, due to mutations in progressive cerebellar atrophy and bilateral symmetric T2- ATOH1. Although the evidence is currently too limited to hyperintensity and hypotrophy of both caudate and puta- conclusively establish its causality, this report may present men, resembling striatal necrosis. Blood lactate and MRI basis for further studies on the role of ATOH1 in human spectroscopy were normal. disease. Conclusions: This case further expands the clinical T. Višnjar: None. K. Writzl: None. G. Bergant: None. spectrum associated with PMPCA mutations to include a O.Maloku:None.F.Fogolari:None.A.Maver:None.B. complex encephalopathy without obvious mitochondrial Peterlin: None. involvement. The association of non-progressive cerebellar atrophywithbilateralstriatalhyperintensitymayrepresenta  P09
.098A “red flag” for this genetic condition. The effect of APOE in Alzheimer’s disease is age Acknowledgements:MarianiFoundation,ItalianMinistry dependent; demonstrated in the UK Biobank data of Health V. Serpieri: None. R. Battini: None. S. Nuovo: None. E. A. Baker1, M. Bracher-Smith2, G. Menzies1, M. Ginevrino: None. F. Tinelli: None. E. Valente: None. J. Williams1,2, V. Escott-Price1,2  P09
.097D 1UK Dementia Research Institute at Cardiff University, Novel association of biallelic ATOH1 variants with Cardiff, United Kingdom, 2Medical Research Council pontocerebellar hypoplasia, developmental delay and Centre for Neuropsychiatric Genetics and Genomics, hearing loss Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, United T. Višnjar1, K. Writzl1, G. Bergant1, O. Maloku2, Kingdom F. Fogolari2, A. Maver1, B. Peterlin11456 Alzheimer’s disease (AD) is a devastating neurodegenera- Philadelphia, PA, United States, 7Universidade Federal do tive condition with significant genetic heritability. The ABC, Santo André, Brazil apolipoprotein E (APOE) gene is the strongest genetic risk factor for AD. The risk of APOE in AD varies with age. DNA methylation plays a role in the regulation of gene This age-related genetic heterogeneity has been shown in expressioninresponsetoenvironmentalfactors.Aprevious theAlzheimer’sDiseaseGeneticsConsortiumdata;thereis longitudinal study of our group found 66 genes differen- little genetic correlation between two age groups (60-79 tially expressed in the blood of youths who presented an yearsvs.80+years)andtheheritabilityexplainedbySNPs increase of dimensional psychopathology after a 3-year on chromosome-19 was larger at younger ages. follow-up.Thesegeneswereexclusivelyfoundinthegroup WeaimtofurtherdemonstratethatAPOEimpactstherisk with the emergence of psychopathology and were not of AD in younger subjects, whereas older subjects are differentially expressed in the longitudinal control groups. influenced by the polygenic effect of variants outside the Here, we aimed to identify whether the gene expression of APOE region. these 65 genes were influenced by changes in DNA TheUKBiobankdataisalarge(N=443,019)prospective methylationinthebloodofthesameindividuals.Moreover, cohort of individuals containing genetic data for 7,654,308 for those markers associated with gene expression, we imputedSNPs.IndividualsinBiobankarerelativelyyoung, verified whether DNA methylation was influenced by with only 92 AD cases. Polygenic risk score (PRS) is a adversities experienced by the youths during the 3-year method to combine the effect of genetic variants. We follow-up. Then, we compared gene expression and DNA computed the PRS for individuals in Biobank, using sum- methylation data in peripheral blood samples (n=44) mary statistics from the largest AD GWAS to weight obtainedfrom22youthsbeforeandafterdevelopingsevere the score. psychopathology. Life adversities variables were generated ADPRSshowsanassociationwith AD,butthiseffect is by using a latent modelling approach with a bifactor removed when the PRS excludes chromosome-19. When structure. We identified 11 differentially expressed genes consideringfamilyproxiesofAD;siblingproxiesshowthe regulatedbyDNAmethylation.Amongthese11genes,the same pattern, however, parental proxies remain associated methylation of LMF2 and ET S1
 was influenced by factors withPRSevenaftertheremovalofchromosome-19.Thisis describing adversities related to interpersonal, context similarly shown in biological pathways; beta-amyloid reg- change, school, health/loss and unpredictable events. Also, ulation, protein-lipid complex and APP regulation. This is these influences persisted when modelling a general also demonstrated using age-stratified analyses which dis- adversity factor. LMF2 methylation has been associated play a stronger association with AD and higher mean PRS with Alzheimer's disease and ET S1
 is a transcriptional in AD cases in the older cohort. factor involved in downstream biological pathways. These E.A. Baker: None. M. Bracher-Smith: None. G. results provide further evidence that life adversities and the Menzies: None. J. Williams: None. V. Escott- emergence of psychopathology are functionally linked by Price: None. changes in DNA methylation and, consequently, in gene expression.  P09
.099B L.M. Spíndola: None. D. Micali: None. M.L. Santoro: DNA methylation as link between life adversities and None. J. Schafer: None. P.M. Pan: None. V.K. Ota: emergence of psychopathology None. G. Xavier: None. C.M. Carvalho: None. F. Talarico: None. R. Pellegrino: None. E. Brietzke: None. L. M. Spíndola1, D. Micali1, M. L. Santoro1, J. Schafer2, R. Grassi-Oliveira: None. J.J. Mari: None. A. Gadelha: P. M. Pan1, V. K. Ota1, G. Xavier1, C. M. Carvalho1, None. E.C. Miguel: None. L.A. Rohde: None. R.A. F. Talarico1, R. Pellegrino3, E. Brietzke1, R. Grassi- Bressan: None.D.R.Mazzoti:None.J.R.Sato:None.G. Oliveira4, J. J. Mari1, A. Gadelha1, E. C. Miguel5, A. Salum: None. H. Hakonarson: None. S.I. L. A. Rohde2, R. A. Bressan1, D.R. Mazzoti6, J. R. Sato7, Belangero: None. G. A. Salum2, H. Hakonarson3, S. I. Belangero1  P09
.100C 1Universidade Federal de São Paulo, Sao Paulo, Brazil, No individual prediction of clinical outcome of ultra- 2UniversidadeFederaldoRioGrandedoSul,PortoAlegre, high-risk individuals by the polygenic risk scores Brazil, 3The Children's Hospital of Philadelphia, Philadelphia, PA, United States, 4Pontifícia Universidade Q. He1, O. Kebir2,3, G. Houle1, P. A. Dion1, Católica do Rio Grande do Sul, Porto Alegre, Brazil, G. A. Rouleau1, M. Krebs2,4, B. Chaumette1,2,4 5Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 6University of Pennsylvania,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1457 1Montreal Neurological Institute, Montreal, QC, Canada, F.Sarayloo,A.Dionne-Laporte,H.Catoire,D.Rochefort, 2Université Paris Descartes; Bio Sorbonne Paris Cité; P. Dion, G. Rouleau INSERM, Laboratoire de Physiopathologie des Maladies Psychiatriques, Centre de Psychiatrie et Neurosciences, McGill University, Montreal, QC, Canada UMR894,GDR3557-InstitutdePsychiatrie,Paris,France, 3Centre Hospitalier Sainte-Anne, Service d’Addictologie « Restless legs syndrome (RLS) is a common complex Moreau de Tours », GHU Paris Psychiatrie et disorder for which different genes and environmental Neurosciences, Paris, France, 4Centre Hospitalier Sainte- elements are considered risk factors. Such a mixed nature Anne, Service hospitalo-universitaire, GHU Paris makes itchallengingtocharacterizethedefective pathways Psychiatrie et Neurosciences, Paris, France associated with the condition. Here we conducted a genome-widetranscriptome(RNA-Seq)studyandobserved Introduction: The identification of clinical ultra-high-risk how the gene reported to present the most significant state for psychosis (UHR) is now allowed in clinical association with RLS, MEI S1
, acts as a regulator over the practice by assessing attenuated symptoms. Prediction of expression of additional genes. Interestingly these addi- the emergence of psychosis and dimensional clinical tional genes appear to entail some of the pathogenic outcomes is important for early intervention. The results pathways known to be linked to RLS. Our data revealed of recent large-scale genome-wide association studies HMOX1, TFR2 and VDR, three genes encoding products (GWAS) expanded our knowledge of the genetic factors with RLS relevant functions, to be regulated by MEI S1
 in and suggested a polygenic model of inheritance of human cells where the expression of MEI S1
 was either psychiatric disorders. We aimed to test if the individual increased or prevented. These manipulations of MEI S1
 in polygenicrisk scores(PRS)couldpredictfor conversionto cellsrevealedmineralabsorptiontobeanenrichedpathway psychosis and dimensional outcomes and if the converters inregardtoMEI S1
regulatoryroleasatranscriptionfactor. to psychosis have polygenic risk for psychiatric disorders. The same enrichment is observed in postmortem brain Materials and Methods: In the French cohort ICAAR, regions(thalamusandpons)obtainedfromasubsetofRLS we collected longitudinal data of 104 individuals with at- patients presenting changes in MEI S1
 expression. The risk mental state enrolled in a 1-year follow-up study. expression of genes encoding metallothioneins (MTs) was Clinical assessments included CAARMS, PANSS, observed to be affected across the different RNA-Seq MADRS, YMRS, SOFAS and CGI. The conversion to datasets. MTs are highly relevant to RLS as they bind psychosis was characterized using the CAARMS-defined intracellularmetalsandinteractwithferritinswhichmanage psychosis onset threshold. We genotyped more than iron levels. Overall, our study suggests that in a subset of 500,000commonvariantsandcomputedfourdifferentPRS patients, the contribution of MEI S1
 to RLS is associated to based on the data of four GWAS from the Psychiatric its transcriptional regulation of other genes more directly Genomics Consortium. involved in cellular pathways relevant to RLS. Results: The PRS from currently available GWAS were F. Sarayloo: None. A. Dionne-Laporte: None. H. poor predictors of the conversion to psychosis, and there Catoire: None. D. Rochefort: None. P. Dion: None. G. was no significant difference between converters and non- Rouleau: None. converters. The PRS were not correlated with any pheno- typicscaleatthebaselinemeasurement(M0)andatthelast  P09
.102A measurement (after 6 months or 12 months). AlterationsinGABAA1ReceptorinRettsyndrome:the Conclusion: The PRS cannot be used in clinical practice necessity of early GABAergic modulation as a to predict the individual risk of conversion to psychosis. therapeutic strategy Further studies are needed to examine the correlation between genetic variance and clinical outcomes in psy- A.Oyarzabal1,2,3,C.Xiol-Viñas2,4,A.Castells5,C.Grau1,2, chiatric disorders. M.O'Callaghan2,3,6,G.Fernández5,A.Pascual-Alonso2,4, Q. He: None. O. Kebir: None. G. Houle: None. P.A. S.Alcántara7,M.Pineda2,J.Armstrong2,5,X.Altafaj8,À. Dion: None. G.A. Rouleau: None. M. Krebs: None. B. García-Cazorla1,2,3 Chaumette: None. 1Synaptic Metabolism Lab, Neurology Department,  P09
.101D Hospital Sant Joan de Déu, Barcelona, Spain, 2Institut Mineralabsorption is an enriched pathwayin the brain Pediàtric de Recerca, Hospital Sant Joan de Déu, regions of restless legs syndrome patients with lower Barcelona, Spain, 3CIBERER (Biomedical Network MEI S1
 expression Research Center for Rare Diseases), Instituto de Salud Carlos III, Madrid, Spain, 4Sant Joan de Déu research1458 foundation, Barcelona, Spain, 5Genetics Department, L. Li1, A. Knickle2, J. Dooley1,2, K. Harrison1,2, Hospital Sant Joan de Déu, Barcelona, Spain, 6Neurology L. Penney1,2 Department,HospitalSantJoandeDéu,Barcelona,Spain, 7Neural Development Lab, Departament de Patologia i 1Dalhousie University, Halifax, NS, Canada, 2IWK Health Terapèutica Experimental, Institut de Neurociències, Centre, Halifax, NS, Canada Universidat de Barcelona, IDIBELL, Barcelona, Spain, 8Bellvitge Biomedical Research Institute, Neonatal Lethal Rigidity and Multifocal Seizure Syndrome Neuropharmacology and Pain Unit, University of (RMFSL)isarareautosomalrecessiveconditioncharacter- Barcelona, Barcelona, Spain izedbyintractableseizures,hypertonia,autonomicinstabil- ity and early death. Mutations in BRAT1 (Breast Cancer 1- Introduction: Rett syndrome (RTT; OMIM#312750) is a associated ataxia telangiectasia mutated activation-1) have severe neurological disorder which mainly affects young been associated with severe RMFSL as well as related females and is usually caused by mutations in the gene phenotypes of varying clinical severity. We report on a MEC P2
. However, not much is known about which femalebaby who presentedwithmild dysmorphic features, pathways can be disrupted in RTT downstream MeC P2
 striking hypertonicity, seizures with a burst suppression dysfunction. Nevertheless, recent studies demonstrate the pattern on EEG and apneic spells shortly after birth who possible implication of a disturbance in inhibitory circuits, died at 2 months of age. Chromosomal microarray analysis especially of the GABAergic inhibitory neurons, in RTT using a combined non-polymorphic /SNP probe based pathophysiology. platform (Affymetrix CytoScan HD) did not identify any Methods: This work analyses changes in expression of copy number variations but several stretches of absence of the most common subunits of GABA(A) ionotropic recep- heterozygosity(AOH)wereidentifiedincludingaregionon tors in different models of RTT (in vitro cell culture and chromosome 7p22.3p22.1. As BRAT1 is contained within in vivo mouse model) by shRNA knock-down, qRT-PCR, this region and the clinical phenotype was suggestive of western blot and immunocytochemistry, as well as in post- RMFSL, BRAT1 sequencing was performed. A homozy- mortembrainsamplesofRTTpatientsbyRNAseq,withthe gous, previously unreported pathogenic mutation aimoffindingasuitabletherapeutictargetfortreatingRTT. (c.1013dupC) was identified, confirming the diagnosis of Results: We observed a direct relationship between RFMSL. To our knowledge, this is the seventh report of MeC P2
 and GABA (A) receptor subunit a1 (Gabra1) RFMSL due to a homozygous BRAT1 mutation in the expression in cell lines and primary cultured neurons. Pro- literature, and the first one reported in a family of French Mecp2+/- tein analyses of female and control mice at dif- Acadian background from Atlantic Canada. This case ferent developmental stages confirmed our previous demonstrates the utility of SNP-based microarrays which findings and pointed towards the importance of the devel- can detect regions of AOH and help narrow the differential opmental status in this relationship, highlighting synaptic diagnosis and approach to subsequent diagnostic protein expression changes in presymptomatic stages of investigations. RTT. RNAseq results in brain samples of RTT patients L. Li: None. A. Knickle: None. J. Dooley: None. K. confirmed the importance of the time frame when studying Harrison: None. L. Penney: None. RTT unbalanced neurotransmission. Conclusions: Our results strongly support Gabra1 as a  P09
.104C noveltherapeutictargetfortreatingRTT.Proteinexpression Changes in expression levels of some microRNAs in the changes in presymptomatic stages of RTT highlight the ratfrontallobeatdifferenttimesofhealingperiodafter importance of early therapeutic strategies targeting neuro- experimental subarachnoid hemorrhage transmission. Grants: Mi Princesa Rett and FIS (PI15/ 01159, PI16/00851 and PI15/01082 ISCIII and FEDER). F. B. Ergen1, D. Turgut Cosan2,1, T. Kandemir3, A.Oyarzabal:None.C.Xiol-Viñas:None.A.Castells: F. Mutlu4, T. E. Cosan3,1 None. C. Grau: None. M. O'Callaghan: None. G. Fer- nández: None. A. Pascual-Alonso: None. S. Alcántara: 1Department of Interdisciplinary Neuroscience, Health None.M.Pineda:None.J.Armstrong:None.X.Altafaj: Science Institute, Eskişehir Osmangazi University, None. À. García-Cazorla: None. Eskisehir, Turkey, 2Department ofMedicalBiology, Health Science Institute, Eskişehir Osmangazi University,  P09
.103B Eskisehir,Turkey,3DepartmentofNeurosurgery,Facultyof Absence of Heterozygosity Flags BRAT1 and Leads to Medicine, Eskişehir Osmangazi University, Eskisehir, theDiagnosisofNeonatalLethalRigidityandMultifocal Turkey, 4Department of Biostatistics, Health Science Seizure Syndrome Institute,EskişehirOsmangaziUniversity,Eskisehir,TurkeyAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1459 the NO P56
 gene causing RNA gain of function is Introduction: The expression of certain miRNAs, such as responsible for the disease. Normal size alleles vary from miR-132, miR-134 and miR-138, which are thought to be 3 to 14 repeats, pathogenic alleles have more than 650 associated with synaptic plasticity and neurological func- repeats, and intermediate alleles are of uncertain tions,canaffectthedensityandvolumeofdendriticspines. significance. In this study, it was aimed to observe how the levels of Materials and Methods: Our cohort consisted of different miRNAs in the frontal lobes of experimental 98 selected index patients. 92 patients came from an ataxia subarachnoidhemorrhage(SAH)inducedratswerechanged cohort (n=600), negative for the most common SCAs in different time intervals (SCA1, SCA2, SCA3, SCA6, SCA7), with pedigree and Materials and Methods: Adult female Sprague-Dawley phenotype consistent with SCA36 and 6 came from a sus- rats(n=21)aredividedinto3groups:control-group(n=7), pected Kennedy’s disease cohort (n=200), negative for the 7th day post-SAH-group (n=7) and 14th day post-SAH- CAG trinucleotide repeat in AR and pedigree consistent group (n=7). Experimental-SAH was induced in SAH- with SCA36. The number of GGCCTG hexanucleotide groups. The levels of miR-132, miR-134 and miR-138 in repeats was determined with conventional PCR for the the frontal lobes were determined by qPCR and statistical smaller alleles andRP-PCR for thelargeralleles. Fragment differences were calculated using one-way ANOVA test. length analysis was performed and positive controls were Results: A statistically significant increase in expression used in every run. levels of miR-132,miR-134 and miR-138 was observed on Results:NopathologicrepeatexpansionsinNO P56
were day7 post-SAH (p<0,001). On the 14th day, it was deter- detected in our cohort. mined that the level of miRNAs which were increased Conclusion:SupplementarytoourpreviousstudyofAD earlier, decreased to the control values (p>0.05). spinocerebellar ataxias in the Greek population, we Conclusions: Expressions of microRNAs are elevated screened a less common gene causing inherited ataxia. In during 1-7 days post-SAH, and decreased again in the line with SCA3, SCA36 seems to be a very rare finding in interval of 7-14 days. These results show that miR-132, the Greek population. miR-134 and miR-138 levels were affected during the first D.Katsimpouris:None.C.Kartanou:None.M.Breza: week of recovery post-SAH. This increase in microRNA None. M. Panas: None. G. Koutsis: B. Research Grant levels,whichhavedifferenteffectsonsynapticconnections, (principal investigator, collaborator or consultant and intheshort-termafterSAHmayplayaroleintheinaccurate pending grants as well as grants already received); Sig- arrangement of synaptic structures and in the emergence of nificant; Teva Pharmaceuticals, Genesis Pharma. Other; neurological dysfunctions. Further studies needed to sup- Significant; Novartis, Genesis Pharma, Sanofi-Genzyme, port our data. Teva Pharmaceuticals, Merck. G. Karadima: None. This study was supported by ESOGÜ Scientific Research ProjectCommitteewithprojectsupportnumber:201611003.  P09
.106A F.B. Ergen: None. D. Turgut Cosan: None. T. Kan- Rare genetic variants in SHANK1 and SHANK2 genes demir: None. F. Mutlu: None. T.E. Cosan: None. found in Bulgarian patients with schizophrenia and bipolar disorder  P09
.105D Screeningforspinocerebellar ataxiatype36(SCA36) in R. Bozhilova1, I. Popov1, M. Penchev2, G. dzhebir1, the Greek population O. Beltcheva1, V. Stoyanova2, G. Kirov3, V. Milanova2, R. Kaneva1 D. Katsimpouris, C. Kartanou, M. Breza, M. Panas, G. Koutsis, G. Karadima 1Molecular Medicine Center, Medical University - Sofia, Sofia, Bulgaria, 2Clinic of Psychiatry, Alexandrovska Neurogenetics Unit, 1st Department of Neurology, University Hospital, Medical University – Sofia, Sofia, University of Athens Medical School, Eginition Hospital, Bulgaria, 3Cardiff University, Cardiff, United Kingdom ATHENS, Greece Genes associated in postsynaptic plasticity have been Introduction:Spinocerebellarataxiatype36(SCA36)isan shown to contribute to schizophrenia (SCZ) and bipolar autosomal dominant (AD) disorder, characterized by late- affective disorder (BAD), so is reasonable to hypothesize onset cerebellar ataxia (5th and 6th decade of life), thattheetiologyofpsychiatricdiseasesislinkedtosynapse dysarthria, sensorineural hearing loss and lower motor structure,transmissionandpostsynapticdensity.Shanksare neuron involvement, particularly tongue atrophy. A adapter proteins in the postsynaptic density that intercon- GGCCTG hexanucleotide repeat expansion in intron1 of nect receptors of the postsynaptic membrane.The members1460 of SHANK gene family are candidate genes for psychiatric characterized by repeated episodes of hemiplegia. Genes disorders. associated with AHC are known and guided our genetic A total of 300 individuals with BAD, 151 with SCZ, exploration of these two patients using the targeted 15SAD diagnosed based on DSMIV, 85 healthy controls sequencing of the AT P1
A3 gene. Then, we replicated our and 40 healthy relatives were recruited. The samples were findings in a database of whole exome sequencing of 17 sequenced on the IonPROTON. The sequencing panel independent COS cases. In the cases with comorbid AHC, comprised of 187 genes, including SHANK1 and SHANK2 two distinct pathogenic de novo variants were identified in genes.Only samples with coverage of at least 95% were theAT P1
A3gene.Inthereplicationcohort,weidentifieda included in the analyses.SIFT&PolyPhen2 were used to thirdcasewithapossiblydamagingmissensevariantinthe identify pathogenic variants. The identified rare variants same exon of AT P1
A3. Three other cases with predicted within SHANK1 and SHANK2 genes were validated by pathogenic missense variants in the FXYD gene family Sanger sequencing and tested in group of 100 patients and (FXYD1,FXYD6,andFXYD6-FXYD2readthrough)were 100 controls. found. AT P1
A3 encodes the α-subunit of a neuron-specific Altogether 17 rare variants in SHANK1 and SHANK2, ATP-dependent transmembrane sodium-potassium pump. presentinaffectedonlywerefound.Amongthe16missense Thefunctionofthispumpismodulatedbyproteinsencoded variants, 12 were potentially damaging. One splice variant by the FXYD genes. Our report is the first to identify was detected. Two of the missense variants in SHANK2, variants in the same pathway for COS. It illustrates the rs117843717 and rs150857128, were found both in schi- interestofexploringmedicalcomorbiditiesandstratifyinga zophrenia and BAD patients. In the mutation burden ana- complex condition according to the age of onset for the lysis, SHANK1 was one of the genes with more variants identification of deleterious missense variants. Whereas than expected in the BAD patients compared to controls. AT P1
A3isareplicatedgeneinrareneuropediatricdiseases, SHANK1 and SHANK2 mutations have been previously we extended the phenotype to a pure psychiatric presenta- implicated in neuropsychiatric disorders. Recent functional tion. Our study highlights the interest of DNA sequencing analysis of SHANK2 mutations found in schizophrenia in psychiatry and opens the way to develop genetic patients support their causative role. The current data adds counseling in COS. totheevidencethatpostsynapticplasticityisinvolvedinthe B. Chaumette: None. V. Ferrafiat: None. A. Ambala- pathogenesis of psychiatric disorder. The work was sup- vanan:None.A.Goldenberg:None.A.Dionne-Laporte: ported by projects DUNK01-2/2009 and D-131/2018MU- None.D.Spiegelman:None.P.Dion:None.P.Gerardin: Sofia None. C. Laurent: None. D. Cohen: None. J. Rapoport: R. Bozhilova: None. I. Popov: None. M. Penchev: None. G. Rouleau: None. None. G. dzhebir: None. O. Beltcheva: None. V. Stoya- nova: None. G. Kirov: None. V. Milanova: None. R.  P09
.108C Kaneva: None. Transcriptome analysis of post-mortem brain tissue reveals up-regulation of immune response genes in a  P09
.107B subset of schizophrenia patients IdentificationofNewGenesAssociatedwithChildhood- Onset Schizophrenia, AT P1
A3 and the FXYD Gene M. Etemadikhah1, E. Lindholm Carlström1, Family J. Halvardson1, A. Niazi1, S. Enroth1, A. Stockmeier Craig2, G. Rajkowska2, B. Nilsson1, L. Feuk1 B. Chaumette1,2, V. Ferrafiat3, A. Ambalavanan1, A. Goldenberg3, A. Dionne-Laporte1, D. Spiegelman1, 1Department of Immunology, Genetics and Pathology, P. Dion1, P. Gerardin3, C. Laurent4, D. Cohen4, Science for Life Laboratory Uppsala, Uppsala University, J. Rapoport5, G. Rouleau1 Uppsala, Sweden, 2Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 1McGill University, Montreal, QC, Canada, 2INSERM Jackson, MS, United States U1266, Paris, France, 3CHU, Rouen, France, 4Hôpital Pitié Salpêtrière, Paris, France, 5NIMH, Bethesda, MD, Introduction: Schizophrenia is a genetically complex United States neuropsychiatric disorder. While the heritability of schizo- phrenia is around 80%, the precise underlying molecular Childhood-onset schizophrenia (COS) is a rare and severe mechanisms and pathways are still unclear. To investigate form of schizophrenia starting before age of 13. We pathways associated with schizophrenia, we performed identifiedtwounrelatedcasesdiagnosedwithbothCOSand gene expression study and we are now following up by alternating hemiplegia of childhood (AHC), a rare disease measurement of protein expression.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1461 Materials and Methods: Whole transcriptome poly-A Denmark, 3Department of Neurology and Epileptology, selected paired-end RNA sequencing was performed on Hertie Institute for Clinical Brain Research, University of post-mortem brain tissue samples from 68 schizophrenia Tuebingen,, Tuebingen, Germany, 4Department of Child patients and 44 matched controls. Differential RNA Neurology, Charles University, 2nd Faculty of Medicine expression was detected between cases and controls. The and University Hospital Motol, P, rague, Czech Republic, results were validated with RT-qPCR. Expression analysis 5Department of Pediatrics, Copenhagen University for >100 proteins is currently under way using proximity Hospital,Copenhagen,Denmark,6PediatricNeurologyand extension assay. Muscular Diseases Unit, Department of Neurosciences, Results:Significantdifferentialexpressionwasfoundfor Rehabilitation, Ophthalmology, Genetics, Maternal and 71 genes in cases compared to unaffected controls. Gene Child Health, University of Genoa, Genova, Italy, ontology of differentially expressed genes revealed an up- 7Department of Paediatrics, Divison of Paediatric regulationofmultiplegenesinimmuneresponseamongthe Neurology, Ghent University Hospital, Gent, Belgium, patients as the most significant category. Several genes of 8Academic Center for Epileptology, Heeze, Netherlands, complement system, including  C1
R,  C1
S,  C7
, FCN3 and 9Department of Genetics, University Medical Center SERPING1 were also in the category. The increased com- Utrecht, Utrecht, Netherlands, 10Department of Neurology, plement expression was stronger in a subgroup of patients Leiden University Medical Centre, Leiden, Netherlands, whichmightbeduetodifferencesindiseaseetiologywithin 11Department of Clinical Genetics, Leiden University patients. Specific proteins were also associated with dif- Medical Centre, Leiden, Netherlands, 12: Department of ferential expression in this subgroup of patients. Weighted Neuropediatrics, Universitätsklinikum Schleswig Holstein gene co-expression network analysis highlighted networks Campus Kiel, Kiel, Germany, 13Pediatric Neurology Unit, associated with synaptic transmission and activation of Department of Pediatrics, Lausanne University Hospital, immune response. Lausanne, Switzerland, 14Department of Neurology, Conclusions: Our results implicate upregulation of the HospitalItalianodeBuenosAires,BuenoAires,Argentina, complement cascade as a crucial pathway associated with 15Institute of Human Genetics, University of Leipzig schizophrenia pathology. Hospitals and Clinics, Leipzig, Germany, 16Center for This work was supported by grants from the European Pediatric Neurology, Cleveland Clinic, Cleveland, OH, Research Council ERC Starting Grant Agreement n. United States, 17Department of Neurology, Aarhus 282330 and the Swedish Medical Research Council to University Hospital, Aarhus, Denmark, 18Department of Lars Feuk. Neuropediatrics, Klinikum Weiden, Weiden, Germany, M. Etemadikhah: None. E. Lindholm Carlström: 19Department of Neuroscience and Neurorehabilitation, None. J. Halvardson: None. A. Niazi: None. S. Enroth: Ospedale Pediatrico Bambino Gesù, Rome, Italy, 20: None.A.Stockmeier Craig: None.G.Rajkowska:None. Department of Neuroscience and Neurorehabilitation, B. Nilsson: None. L. Feuk: None. Ospedale Pediatrico Bambino Gesù, Rome, Italy, 21Department of Medical Genetics, Institute of Mother and  P09
.109D Child,Warsaw,Poland,22PediatricNeurologyUnit,Vittore SCN8A-related epilepsies: phenotypic overview and Buzzi Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, correlation with antiepileptic treatment 23Department of Medical Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, K.M.Johannesen1,2,Y.Liu3,C.Tronhjem1,K.Stêrbová4, 24Child Neurology and Clinical Neurophysiology Unit, C.Høi-Hansen5,P.Striano6,H.Verhelst7,J.Verhoeven8, Department of Women's and Children's Health, University R. Oegema9, A. Harder10,11, M. Pendziwiat12, S. Lebon13, Hospital of Padua, Padua, Italy, 25Department of M. Vaccarezza14, C. Heine15, J. Lemke15, N. Le16, Pediatrics, Østfold Hospital, Graalum, Norway, J. Christensen17, A. Berger18, M. Trivisano19, 26Department of Clinical Genetics, Academic Medical N. Specchio20, D. Hoffman-Zacharska21, Center at the University of Amsterdam, Amsterdam, M. Mastrangelo22, E. Brilstra23, M. Vecchi24, A. Vallø25, Netherlands, 27Unit of Medical Genetics, Necker Enfants- M.Motazacker26,P.Lakeman26,M.Nizon27,C.Betzler28, Malades Hospital, Paris, France, 28Clinic for S. Masnada29, P. Vegiotti30, C. Marini31, R. Guerrini31, Neuropediatrics and Neurorehabilitation, Epilepsy Center G. Rubboli1, G. Lesca32, E. Gardella1, H. Lerche33, for Children and Adolescents, Schön Klinik, Vogtareuth, R. S. Møller1 Germany, 29Department of Brain and Behavioural Sciences,UniversityofPavia,Pavia,Italy,30Departmentof 1Department of Epilepsy Genetics and Personalized Child Neurology, V. Buzzi Children's Hospital, University Treatment, Dianalund, Denmark, 2Institute for Regional of Milan, Milan, Italy, 31Pediatric Neurology, HealthServices,UniversityofSouthernDenmarkj,Odense, Neurogenetics and Neurobiology Unit and Laboratories,1462 Meyer Children's Hospital, University of Florence, Vegiotti: None. C. Marini: None. R. Guerrini: None. G. Florence, Italy, 32Service de génétique clinique, Centre de Rubboli: None. G. Lesca: None. E. Gardella: None. H. Référence Anomalies du Développement et Syndromes Lerche: None. R.S. Møller: None. Malformatifs Centre Est- HCL, Lyon, France, 33Department of Neurology and Epileptology, Hertie  P09
.110A Institute for Clinical Brain Research, University of Severe neurodevelopmental disorder with intractable Tuebingen, Tuebingen, Germany seizures due to a novel SL C1
A4 homozygous mutation Introduction: SCN8A is well-known gene being the L. Sedlackova1, K. Sterbova2, M. Vlckova3, monogenic cause of SCN8A-related developmental and P. Lassuthova1, P. Seeman1 epileptic encephalopathy, as well as self-limiting epilepsies and epilepsies with an intermediate phenotype, with mild 1DNA laboratory, Department of Pediatric Neurology, 2nd intellectual disability and treatable seizures. Reports so far, Faculty of Medicine, Charles University in Prague and suggest that sodium channel blockers (SCBs) have a University Hospital Motol, Prague, Czech Republic, positive effect on seizure in SCN8A-related epilepsy. In 2Department of Pediatric Neurology, 2nd Faculty of this overview, we sought to describe the complete Medicine, Charles University in Prague and University phenotypic spectrum, provide novel data on functional Hospital Motol, Prague, Czech Republic, 3Department of studies, as well as evaluate treatment response in the Biology and Medical Genetics, 2nd Faculty of Medicine, patients suffering from epilepsy. Charles University in Prague and University Hospital Methods: Clinical information on cognitive status, epi- Motol, Prague, Czech Republic lepsy onset, epilepsy type and treatment response was col- lected via standardized spreadsheets. Clinicians and Introduction:BiallelicmutationsintheSL C1
A4genehave geneticists worldwide participated in the study. Previously been identified as a very rare cause of neurodevelopmental published cases were included via a PubMed search. All disorders with or without epilepsy and almost exclusively patients signed informed consent, and the study was described in the Ashkenazi-Jewish population. That is why approved by the local ethical committee. the SL C1
A4 gene is not routinely included in the genetic Results: In total, we investigated 36 previously unpub- diagnostic panels for neurological diseases or epilepsy. lished patients, and 246 patients in total. We found five Patients and Methods: Here we present a 5-year-old Czech distinct clinical subgroups; BFNIS, intermediate epilepsy, boywithmicrocephaly,severepsychomotorretardationand DEE, severe DEE (non-ambulant, no speech, cortical intractable seizures who remained unsolved using clinical blindness) and patients without epilepsy. The DEE sub- experience and standard diagnostic methods including groups comprise 74% of the total cohort. SCBs were the examination by an epilepsy targeted gene panel. Whole- most efficient anti-epileptic drug.Several recurrentvariants exomesequencing(WES)wasfinallyusedtoobtaingenetic were found. Some of these variants showed a persistent diagnosis. phenotype and others not. The underlying reasons for this Results:Anovelmutation,p.Arg457Gln(c.1370G>A)of remain unexplained. the SL C1
A4 gene, was detected in homozygous state by Conclusion: The phenotypic range of SCN8A is wide WESinthepatient,andafterwardsbySangersequencingin ranging from self-limiting epilepsies to severe DEEs, and heterozygous state in both parents confirming the biallelic also including patients without epilepsy. Phenotypic varia- originofthemutation.ThisvariantisnotreportedinExAC/ bility within the same genetic variants are common, so gnomAD databases in homozygous state, in heterozygous geneticcounsellingmustbedonecarefully.SCBsshouldbe state in a very low frequency (0.002%), it affects a highly first-line treatment in SCN8A-related epilepsy. conserved aminoacid predicted to be deleterious. Mutation K.M. Johannesen: None. Y. Liu: None. C. Tronhjem: in the same codon but different aminoacid exchange was None. K. Stêrbová: None. C. Høi-Hansen: None. P. previously described in a patient with very similar pheno- Striano: None. H. Verhelst: None. J. Verhoeven: None. type, however, without epilepsy. Our patient suffers from R. Oegema: None. A. Harder: None. M. Pendziwiat: microcephaly, global developmental delay, axial hypotonia None. S. Lebon: None. M. Vaccarezza: None. C. Heine: with acral spasticity, brain and corpus callosum atrophy, None. J. Lemke: None. N. Le: None. J. Christensen: impaired visual function and drug-resistant epilepsy. None. A. Berger: None. M. Trivisano: None. N. Spec- Conclusion: Our data suggest that the SL C1
A4 gene chio: None. D. Hoffman-Zacharska: None. M. Mas- should be considered in the diagnosis of patients with trangelo: None. E. Brilstra: None. M. Vecchi: None. A. severe early onset neurodevelopmental impairment with Vallø: None. M. Motazacker: None. P. Lakeman: None. epilepsy and encourages SL C1
A4 gene variants’ analysis M.Nizon:None.C.Betzler:None.S.Masnada:None.P.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1463 via targeted gene panel or WES. Supported by: NV19-08- the gene’s implication in complex neuropsychiatric dis- 00194 orders should be re-evaluated. L.Sedlackova:None.K.Sterbova:None.M.Vlckova: M.A.Khan:None.J.Blatterer:None.M.Z.Ali:None. None. P. Lassuthova: None. P. Seeman: None. L. Baufeld: None. E. Petek: None. K. Wagner: None. J. Ramadani-Muja:None.R.Malli: None.M.Muzammal:  P09
.111B None. C. Windpassinger: None. Molecular genetic and cellular characterization of a missense mutation in SLITRK1 associated with non-  P09
.112C syndromic autosomal recessive intellectual disability Somatic mutation that affects transcription factor binding upstream of CD55 in the temporal cortex of a M. A. Khan1, J. Blatterer2, M. Z. Ali1, L. Baufeld2, late-onset Alzheimer disease patient E. Petek2, K. Wagner2, J. Ramadani-Muja3, R. Malli3, M. Muzammal1, C. Windpassinger2 H. T. Helgadottir1, P. Lundin2, E. Wallén Arzt1, A. Lindström3, C. Graff3, M. Eriksson1 1Gomal Centre of Biochemistry and Biotechnology, Gomal University, D.I.Khan, Pakistan, 2Diagnostic & Research 1Department of Biosciences and Nutrition, Center for Institute of Human Genetics, Medical University of Graz, Innovative Medicine, Karolinska Institutet, Huddinge, Graz, Austria, 3Gottfried Schatz Research Center, Division Sweden, 2Science for Life Laboratory, Stockholm, Sweden, ofMolecularBiologyandBiochemistry,MedicalUniversity 3Department of Neurobiology, Care Sciences and Society, of Graz, Graz, Austria Center for Alzheimer Research, Division for Neurogeriatrics, Solna, Sweden Introduction:Intellectualdisabilityisaphenotypicallyand genetically heterogeneous neurodevelopmental disorder Alzheimer’s disease (AD) is the most common neurode- with an estimated prevalence of 1 % in the general generative disease worldwide. Familial cases suggest population. So far sixty-nine gene loci have been reported genetic components, however monogenetic causes are few to be involved in autosomal recessive non-syndromic and the vast majority of incidences have unknown cause. intellectual disability (NS-ARID). Sequencingeffortshavefocusedongermlinemutations,but Materials and Methods: A novel disease locus was improved technology has opened up for studies on somatic identified using homozygosity by descent (HBD) mapping mutations in affected brain tissue samples. Here we use coupled with whole exome sequencing in a large con- ultra-deep sequencing on brain and blood from early and sanguineous Pakistani family. On the cellular level, the late onset AD patients, and non-AD individuals (n=16). In impact of the novel mutation on protein expression was total 2.86 Megabases of genomic regions, previously characterized in subcellular colocalization experiments. associated with AD was targeted, included 28 genes and Results: Herein this study, HBD mapping identified a upstream and downstream regulatory regions. Tailored single shared homozygous region on chromosome 13 downstream bioinformatics filtering identified 11 somatic between markers rs9531043 to rs7318889. The subsequent single nucleotide variants in the temporal cortex in AD exome sequence analysis identified a novel SLITRK1 gene patientsandnoneinthecontrols.Onevariantwasvalidated mutation, which segregated with the disease phenotype. tobepresentat0.4%allelefrequencyintemporalcortexof SLITRK1 is an adhesion molecule located in the post- alate-onsetADpatient.Thisvariantwaspredictedtoaffect synaptic membrane of excitatory synapses. Cellular assays transcription factor binding sites upstream of the CD55 showed that the identified novel mutation results in loss of gene, contributing to AD pathogenesis by affecting the protein function by trapping mutated SLITRK1 intracellu- complement system. Our results suggest that future studies larly in the endoplasmic reticulum and thus preventing targetinglargerportionsofthegenomeforsomaticmutation surface transport and ligand-binding. Additionally, several analysisareimportanttoobtainan increased understanding reportedmutationsshowingdecreasedsurfaceexpressionof for the molecular basis of both early and late onset AD. SLITRK1 were selected for colocalization analysis. We H.T. Helgadottir: None. P. Lundin: None. E. Wallén proof that all variants are transported into the plasma Arzt: None. A. Lindström: None. C. Graff: None. M. membrane with the exception of SLITRK1 harboring the Eriksson: None. novel mutation. Conclusions: SLITRK1 has previously been associated  P09
.113D with a variety of neuropsychiatric disorders. However, our Ddhd1knockout mouse as a model for familial spastic findings suggest a possible, to date unreported, association paraplegia ofSLITRK1inNS-ARID.Thus,inthelightofourfindings,1464 T. Morikawa1, S. Miura2,3, H. Ohishi4, K. Kosaka1, M. Takahashi: None. M. Nakao: None. Y. Izumi: None. T. Shimojo1, A. Nagano1, R. Fujioka5, K. Moriyama6, T. Bamba: None. H. Sasaki: None. H. Shibata: None. M. Unoki4, M. Takahashi7, M. Nakao7, Y. Izumi7, T. Bamba7, H. Sasaki4, H. Shibata1  P09
.114A Blood-based gene expression analysis in children with 1Division of Genomics, Medical Institute of bioregulation, specific language impairment Kyushu University, Fukuoka, Japan, 2Division of Respirology, Neurology and Rheumatology, Department of I. Y. Hristo1, I. G. Sotkova-Ivanova1, T. Vachev2, Medicine, Kurume University, Fukuoka, Japan, N. Popov3, I. Ivanov1, I. Pacheva1, R. Yordanova1, 3Department of Geriatric Medicine and Neurology, Ehime V. Stoyanova1 University Graduate School of Medicine, Toon, Japan, 4Division of Epigenomics and Development Medical 1Medical University Plovdiv, Departament of Pediatrics Institute of Bioregulation, Kyushu University, Fukuoka, and Medical Genetics, Plovdiv, Bulgaria, 2University of Japan, 5Department of Food and Nutrition, Beppu Plovdiv, Department of Plant Physiology and Molecular University Junior College, Beppu, Japan, 6Department of Biology, Plovdiv, Bulgaria, 3State Phsychiatry Hospital Nutritional Sciences, Nakamra Gakuen University, Pazardzhik, Psychiatric ward for active treatment, Fukuoka, Japan, 7Division of Metabolomics, Medical Pazardzhik, Bulgaria Institute of bioregulation, Kyushu University, Fukuoka, Japan Introduction: Comparative gene expression profiling dis- covers differentially expressed genes associated with Wehavepreviouslyidentifiedahomozygous4-bpdeletion, various diseases, including neurodevelopment disorders. in exon2 in DDHD1as the responsible variant for spastic Specific language impairment (SLI) is defined as an paraplegiatype28(SPG28)(Miuraetal2016).Thevariant unexpected and persistent impairment in language ability is expected to cause a premature termination resulting in a despiteadequatesocialenvironmentandintelligenceandin functionally null allele. DDHD1encodes phospholipase A the absence of any explanatory medical conditions. This 1 (PA-PLA ),anenzymecatalyzingphosphatidylinositol(PI) condition is highly heritable and affects around 7% of pre- 1 to lysophosphatidylinositol (LPI). Towards the clarification school children. of the pathogenic mechanism of SPG28, we established Materials and Methods: The study aimed to examine Ddhd1knockout(KO)micecarryinga1-bpdeletioninexon gene expression profiling in the peripheral blood of 60 2 in Ddhd1, resulting in a frameshift and premature individuals divided into two groups: children with SLI and termination at the very similar position with the patient. age- and gender-matched healthy controls. A genome-wide Since we observed no obvious abnormalities in their sequencing of copy DNA molecules was conducted in the locomotion, we measured foot-base-angle (FBA) which is pooled probes of the two groups investigating the quanti- an established character to evaluate SPG phenotypes. We tative expression of the genes and Kyoto Encyclopedia of observed a significant decrease of FBA in the homozygous Genes and Genomes (KEGG) pathway-based analysis was KOs, as a partial replication of SPG phenotypes. By RNA used to further understand genes’ biological functions. sequencing, we identified 22 genes showing significantly Results:Asaresultoftheconductedexpressionanalysis, changed expressions in cerebrum of the homozygous KOs. 60 differentially expressed genes and 7 KEGG signaling The 22 genes are characterized by a GO term, ”positive pathways with statistical significant change were identified. regulationofGTPaseactivity”andaKEGGpathway,”NF- The KEGG names of these pathways were: "Hepatitis C", kappa B signaling pathway”. By lipidome analyses using "Herpes simplex infection", "Leukocyte transendothelial supercriticalfluidchromatographymassspectrometry(SFC/ migration", "Primary immunodeficiency", "Calcium sig- MS) we observed significant increase of PI and significant naling pathway" and "Tight junction". decrease of LPI in cerebrum of the homozygous KOs. LPI Conclusions: Clear and significant abnormalities exist in isknowntobetheagonistforaGproteincoupledreceptor, thegeneexpressioninperipheralbloodsamplesofchildren Ca2+ GPR55 triggering mobilization of intracellular . Our withSLIcomparedtohealthycontrols.Wesuggestthatnot currentdatasuggestthemechanismofSPGthatthereduced only cellular signaling but immune mechanisms may also LPI level in cerebrum triggers abnormal reduction of be involved in the pathogenesis of SLI. intracellularCa2+ ,resultinginneuralapoptosisbyabnormal I.Y. Hristo: None. I.G. Sotkova-Ivanova: None. T. NF-kappa B signaling. Vachev: None. N. Popov: None. I. Ivanov: None. I. T.Morikawa:None.S.Miura:None.H.Ohishi:None. Pacheva: None. R. Yordanova: None. V. K. Kosaka: None. T. Shimojo: None. A. Nagano: None. Stoyanova: None. R.Fujioka:None.K.Moriyama:None.M.Unoki:None.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1465  P09
.115B  P09
.116C Overview of molecular diagnostic testing of Identificationof geneticfactorsthat modify age atonset spinocerebellar ataxias in Estonia of spinocerebellar ataxia type 3 T. Kahre1,2, Ü. Murumets1, H. Roomere1, S. Sarv2, F. Akcimen1, S. Martins2, C. V. Bourassa3, C. Liao1, K. Gross-Paju3, K. Õunap1,2,4, S. Pajusalu1,2,5 M.Lima4,I.Lopes-Cendes5,L.B.Jardim6,J.Sequeiros7, P. A. Dion3, G. A. Rouleau1 1Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia, 2Department of 1Department of Human Genetics, McGill University; ClinicalGenetics,InstituteofClinicalMedicine,University Montreal Neurological Institute, Montreal, QC, Canada, of Tartu, Tartu, Estonia, 3Neurology Clinic, West Tallinn 2Institute of Molecular Pathology and Immunology of the Central Hospital, Tallinn, Estonia, 4Broad Institute of MIT University of Porto, Porto, Portugal, 3Montreal and Harvard,, Cambridge, MA, United States, 5Yale Neurological Institute, McGill University, Montreal, QC, University School of Medicine, Department of Genetics, Canada, 4Faculdade de Ciências e Tecnologia, New Haven, CT, United States Universidade dos Açores, Ponta Delgada, Ponta Delgada, Portugal, 5Faculty of Medical Sciences, Department of Spinocerebellar ataxias (SCAs) are a heterogeneous group Medical Genetics, (UNICAMP), Campinas, Brazil, of neurodegenerative disorders. Due to extensive clinical 6Medical Genetics Service, Hospital de Clínicas de Porto overlap among different forms of hereditary ataxia Alegre (HCPA), Porto Alegre, Brazil, 7Institute for (>35 subtypes known), genetic testing is required to MolecularandCellBiology,UniversidadedoPorto,Porto, establish a diagnosis. The most common causes of SCAs Portugal are expansions of trinucleotide CAG repeats within genes ATXN1, ATXN2, ATXN3, ATXN7 and CACNA1A. Next- Introduction: There is a strong correlation between CAG generationsequencing(NGS)assayshaveabledtodelineate repeat size of ATXN3 and the age at onset (AAO) of other types of hereditary ataxias caused by other variant spinocerebellar ataxia type-3 (SCA3). However, AAO types. The aim of this study was to clarify which types of variability is not entirely explained by the length of the SCAs are most prevalent in Estonia and to compare the repeat, suggesting the existence of additional modifying diagnostic yield of trinucleotide repeat assay and factors. (NGS) panel. Materials and Methods: To examine the residual Patientsandmethods:TheSCArepeatexpansionassay variability in AAO, a genome-wide association study wasperformedin317EstonianpatientsreferredtotheTartu (GWAS)wasconductedacrossacohortof700SCA3cases University Hospital during the years 2000-2018. All indi- fromNorthAmerica,BrazilandPortugal.Thefirstphaseof viduals were tested for triplet expansions in ATXN1, the study established the CAG repeat size in cases as it ATXN2, ATXN3, CACNA1A genes with PCR based frag- assessed the proportion of AAO variability that could be ment analysis, and since 2012 ATXN7 was added to the accounted to the repeat size. In the second phase, a linear standard panel. Since 2016, 72 patients were studied using regression analysis tested for genomic factors affecting the NGS based panel (Illumina TruSight One) with ataxia residual AAO. subpanel (151 genes included). Results: The inverse relationship between CAG repeat Results: In 35 (11.0%) patients, repeat extension (34 size and AAO was confirmed (ρ=0.62). No loci reached SCA2cases,1SCA1case)wasdetected.FromNGS-based genome-wide significance but eight suggestive loci paneltesting,7(9.7%)diagnosticfindingswerereportedin (p<1×10-5). We also observed 80 loci with a p<1×10-4; 6 different genes (PRKCG, TGM6, ITPR1, SACS, 2x some of which revealed associations with genes causing ANO10, and XPA). other forms of ataxia. The later would be good candidates Conclusion:ThemostprevalentformofSCAsinEstonia for the AAO of SCA3. is SCA2. Triplet repeat expansion assay and NGS panel Conclusions: This is the first GWAS to focus on the sequencing showed similar diagnostic yields, but it is more identificationofvariantsthatcouldrevealmodifiersofAAO cost-efficienttostartwithrepeat expansionassay.Funding: in SCA3. We confirmed the known inverse correlation Estonian Research Council grants PRG471, and between CAG repeat size and AAO as we provided evi- PUTJD827. denceforothermodifyingfactors.Areplicationstudyusing T. Kahre: None. Ü. Murumets: None. H. Roomere: a well-powered independent cohort is now required to None. S. Sarv: None. K. Gross-Paju: None. K. Õunap: confirm our results. None. S. Pajusalu: None.1466 Acknowledgement:F.A.issupportedbyaHealthyBrains similarinage (mean age atbaseline 35.7±7.8),quantitative andHealthyLives(HBHL)scholarshipandtheDepartment cerebellar functional score (CCFS), cognitive evaluation of Human Genetics of McGill University. (MMS, BREF and Stroop) and DOP at the baseline. Inter- F. Akcimen: None. S. Martins: None. C.V. Bourassa: estingly,SARAscoreatbaselinewasbelowfivebuthigher None. C. Liao: None. M. Lima: None. I. Lopes-Cendes: incarriers(1.47±0.85vs0.78±0.72,p<0.05).Atfollow-up, None.L.B.Jardim:None.J.Sequeiros:None.P.A.Dion: DOPincreasedfrom2.2±1.7to2.2±3.8innon-carriers and None. G.A. Rouleau: None. from 3.5±3.6 to 8.2±8.2 in carriers (p<0.05). For the con- verterswithSARA>5,meanDOPreached12.5±8.2whileit  P09
.117D remained at 3.3±5.3 in non-converters (p=<0.01). There Distance between oculomotor patterns in premanifest was a positive correlation between DOP and CCFS spinocerebellar ataxias reflects disease onset (p=0.01) and SARA (p=0.001). No changes in cognitive assessments were found at follow-up. G.Coarelli1,2,S.Rivaud-Pechoux1,S.Sayah1,P.Pouget1, Conclusions: DOP and CCFS reflect disease conversion C. Cazeneuve2,M.Monin1,2,M.Anheim3,4, B.Gaymard5, andareindependentfromtheraterthusmorereliableinpre- T. Klockgether6,7, S. Tezenas du Montcel8, A. Durr1,2 symptomatic carriers. Grant references: NCT01037777, Institut National de la 1ICM (Brain and Spine Institute), Paris, France, Santé Et de la Recherche Médicale. 2Department of Genetics, Pitié-Salpêtrière Charles-Foix G. Coarelli: None. S. Rivaud-Pechoux: None. S. University Hospital, Assistance Publique – Hôpitaux de Sayah: None. P. Pouget: None. C. Cazeneuve: None. M. Paris (AP-HP), Sorbonne Université, Paris, France, Monin: None. M. Anheim: None. B. Gaymard:None. T. 3Department of Neurology, Hôpital de Hautepierre, Klockgether: None. S. Tezenas du Montcel: None. A. Strasbourg, France, 4Institut de Génétique et de Biologie Durr: None. Moléculaire etCellulaire(IGBMC),INSERM-U964/CNRS- UMR7104; Fédération de Médecine Translationnelle de  P09
.118A Strasbourg (FMTS), Université de Strasbourg, Strasbourg, Novel glycine receptor variants identified in startle France, 5Department of Neurophysiology, AP-HP, disease patients Assistance Publique – Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France, 6Department of G. Aboheimed1,2,3, M. ALRasheed2, M. Salih4, Neurology, University of Bonn, Bonn, Germany, 7German M. AlOwain5, M. Alsagob1, R. Almass1, L. AlQuait1, Center for Neurodegenerative Diseases (DZNE), Bonn, R. Harvey6,7, H. AlDhallaan8, O. Dabbagh5, A. Ruiz3, Germany,8INSERMU1136,SorbonneUniversités,Institut N. Kaya1 Pierre Louis d’Epidémiologie et de Santé Publique, AssistancePublique–HôpitauxdeParisAP-HP,Hôpitaux 1Department of Genetics, KFSHRC, Riyadh, Saudi Arabia, Universitaires Pitié-Salpêtrière – Charles Foix, Paris, 2College of Pharmacy, Clinical Pharmacy Department, France Riyadh, Saudi Arabia, 3UCL School of Pharmacy, Department of Pharmacology, London,W C1
N 1AX, United Introduction: Knowledge about premanifest stage of Kingdom, 4Division of Pediatric Neurology, Department of spinocerebellar ataxias (SCAs) will guide therapeutic Pediatrics, College of Medicine,, Riyadh, Saudi Arabia, preventive interventions. The aim of this work was to 5DepartmentofMedicalGenetics,KFSHRC,Riyadh,Saudi follow oculomotor and cognitive changes over time in Arabia,6SchoolofHealthandSportSciences,Universityof unaffected premanifest SCAs carriers. the Sunshine Coast, Sippy Downs, QLD, Australia, MaterialsandMethods:AspartoftheRISCAstudy,we 7Sunshine Coast Health Institute, Birtiny,QLD, Australia, assessed preclinical SCA1-2-3 carriers and non-carriers at 8Department of Neurosciences, KFSHRC, Riyadh, Saudi baseline and at 72 months follow-up. Distance between Arabia OculomotorPatterns(DOP)weredeterminedbycombining values of standard deviation from the norm of prosaccades Startle disease, also known as hyperekplexia, is a rare latency, velocity and gain for leftward and rightward pro- inherited neurological disorder that affects newborn chil- saccade, antisaccade latencies and square-wave jerks dren. The predominant genetic causes are mutations in the (pathologicalif>4)andcorrelatedwithcognitiveoutcomes. genesGLRA1 and GLRB, encoding glycine receptor alpha Quantitative motor battery and volumetric MRI were and beta subunits, respectively, and SL C6
A5 encoding the performed. glycine transporter GlyT2. The disease has hallmark Results: There were 16 carriers (3 SCA1 carriers, 4 characteristics of noise- or touch-induced non-epileptic SCA2 carriers, 9 SCA3 carriers) and 16 non-carriers, seizures resulting in muscle stiffness and apnea. However,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1467 cases are often misdiagnosed as spastic quadriplegia or Results: All injected eggs showed high frequency of epilepsy. Our study focuses on likely disease causative modifications at the stub1 locus at 48 hours post injection. mutations in startle disease patients in the Kingdom of F1 heterozygous carriers with a 7 nucleotide-deletions at Saudi Arabia. Sanger sequencing, homozygosity mapping, position 10800 in the stub1 gene were produced from the and targeted next-generationsequencing were conductedin founder fish, and further used to obtain homozygous off- fifteenpatients.Functionalanalysisofselectedvariantswas spring. Immunohistochemistry studies provided initial evi- performedusing whole-cellrecordings andconfocalmicro- dences regarding localization of CHIP protein in Purkinje scopy in acutely transfected N2A cells. We identified one cells in the cerebellum of WT fish. novel (p.A455P) and two (p.Q195X and p. M177R) Conclusions: We here described the use of CRISPR/ recurrent variants in the GLRB. We also identified one Cas9 system to induce modifications of the stub1 gene in novel frameshift mutation in the SL C6
A5(p.I692fs) and zebrafishandcontributetoestablishinganewanimalmodel threerecurrentvariantsinGLRA1(p.G342S,p.R252H,and for studying STUB1-related ataxia diseases. Future work p.R218Q). Cells transfected with mutant GLRB showed a will focus on phenotypic and behavior analysis of homo- reduction in glycine-evoked currents compared to those of zygous mutant zebrafish lines. wild type. Tagging of glycine receptor subunits further This study has received funding from Helse Vest (grant revealed disrupted membrane localisation of the mutated 911810) and the University of Bergen. proteins. Our results uncover novel mutations in glycine Y. Pakdaman: None. E. Austad: None. E. Denker: receptorgenesthatarepotentiallylinkedtotheaetiologyof None. S. Johansson: None. I. Aukrust: None. P.M. startle disease Knappskog: None. S. Ellingsen: None. G.Aboheimed:None.M.ALRasheed:None.M.Salih: None.M.AlOwain:None.M.Alsagob:None.R.Almass:  P09
.120C None. L. AlQuait: None. R. Harvey: None. H. AlDhal- Proposal for a new subcategory in the classification of laan: None. O. Dabbagh: None. A. Ruiz: None. N. the Copy Number Variants as Factor of susceptibility Kaya: None. N.Baena1,E.Gabau2,N.Capdevila2,A.Ruiz1,L.Capel1,  P09
.119B C. Aguilera1, S. Ourani2, N. Spataro1, M. Guitart1 Characterization ofSTUB1in zebrafish - development of a new knock-out model to study neurodegeneration 1Genetics Laboratory, UDIAT-Centre Diagnòstic. Parc Taulí Hospital Universitari. Institut d’Investigació i Y.Pakdaman1,2,3,E.Austad3,E.Denker3,S.Johansson1,2, Innovació Parc Taulí I3PT. Universitat Autònoma de I. Aukrust1,2, P. M. Knappskog1,2, S. Ellingsen3 Barcelona, Sabadell, Barcelona, Spain, 2Paediatric Unit. Parc Taulí Hospital Universitari. Institut d’Investigació i 1Department of Clinical Science, University of Bergen, Innovació Parc Taulí I3PT. Universitat Autònoma de Bergen, Norway, 2Department of Medical Genetics, Barcelona, Sabadell, Barcelona, Spain Haukeland University Hospital, Bergen, Norway, 3Department of Biological Sciences, University of Bergen, Introduction: The interpretation of variants of uncertain Bergen, Norway significance (VOUS) remains a challenge for geneticists since the criteria used and the continuous updating of the Introduction: Autosomal Recessive Spinocerebellar databases may change their classification. We reviewed the Ataxia-16 (SCAR16) is caused by deficiencies in the postnatal recurrent CNV in neurodevelopmental disorders STUB1 gene encoding the ubiquitin  E3
 ligase and co- withlackofagreementintheinterpretationacrossdatabases chaperone CHIP. There is limited knowledge regarding the and labelled as VOUS, probably pathogenic or probably pathogenicroleofmutantCHIPinvivo.Thisstudyaimsto benignwiththeaimofreclassifyingthemasasusceptibility establish a zebrafish model for SCAR16 by CRISPR/Cas9- factor. mediatedmutagenesisofthezebrafishorthologueofhuman Materials and Methods: A CGH array (8x60K ISCA, STUB1. Agilent Technologies) was performed on 2,858 patients Material and Methods: Single guide RNAs targeting with neurodevelopmental disorders. We define a suscept- a 20 nucleotide-sequence in stub1 gene were injected ibility factor as a CNV with reduced penetrance, variable together with Cas9 proteins into wild type zebrafish clinical expressivity and complex to associate with a spe- embryos atone-cell stage. Offspring fish were analyzed for cific phenotype. transmitted germline mutations. The expression of CHIP Results: A total of 69 (2.4%) patients with a CNV clas- protein was also examined in WT fish brain using sified as a susceptibility factor have been identified. immunohistochemistry. Dup3p26.2 (CNTN4 / CNTN6) in 7 cases, del15q11.21468 (NIPA1)in22cases,dup15q13.3(CHNRNA7-OTUD7A)in Patient 1 molecular testing (via Whole Exome Sequen- 17 cases, dup16p13.11 (ND E1
, NTAN1) in 5 cases, cing): De Novo, SYNGA P1
 p.Q1106X dup16p13.3 (RBFOX1) in 3 cases and dupXp22.33 Patient2EEG:Rhythmicposteriornotcheddeltaslowing (SHOX1) in 16 cases. A second CNV was detected in 11 increasedwitheyeclosure,generalizedandleftcentralfocal cases and was classified mostly as VOUS. The variable epileptiform activity clinicalexpressionobservedineachofthesevariantsagrees Patient 2 molecular testing (via Whole Exome Sequen- with what is described in the literature. cing): De Novo, SYNGA P1
 p.R967X Conclusions: A new subcategory of susceptibility factor Conclusions: Given the degree of clinical and EEG is proposed for these CNVs classified in the VOUS group. findingoverlap,SYNGA P1
syndromeshouldbeconsidered Its clinical significance is subject to the penetrance and in patients with an Angelman-like phenotype. expression in each individual. Given the wide hetero- A.K.Petersen:None.A.Golden:None.K.Magnussen: geneity, the clinical geneticist must decide if the CNV is None. L. Durham: None. responsible for the phenotype and determine if the family segregation study is necessary.  P09
.122A N.Baena:None.E.Gabau:None.N.Capdevila:None. Familial Adult Myoclonic Epilepsy linked to A. Ruiz: None. L. Capel: None. C. Aguilera: None. S. chromosome 5p15 (FAM E3
) is caused by an intronic Ourani: None. N. Spataro: None. M. Guitart: None. ATTTT/ATTTC expansion in MARCH6  P09
.121D R.T.Florian1,F.Kraft2,S.Klebe3,E.Magnin4,A.F.Van Expandingthe“Angelman-like”spectrum:patientswith Rootselaar5, S. Kaya1, J. Buratti6, E. Leitao1, SYNGA P1
-related disorders show EEG findings most S. Giesselmann2, I. Kurth2, N. Tschernoster7, often attributed to Angelman syndrome J. Altmueller7, A. Lamiral4, L. Thivard8,9, FAME consortium, E. Leguern6, P. Labauge10, P. S. Reif11, A. K. Petersen1, A. Golden2, K. Magnussen1, L. Durham1 F. Rosenow11,12, K. M. Klein11,12, M. Bennett13,14, M. Bahlo13,14, J. Gecz15,16, M. A. Corbett15, M. A. J. 1Divison of Genetics and Metabolism, Department of Tijssen17, A. M. J. M. van den Maagdenberg18, Development and Rehabilitation, Randall Children’s C. DEPIENN E1
 Hospital, Portland, OR, United States, 2Department of Pediatric Neurology, Randall Children’s Hospital, 1Institüt für Humangenetik, Essen, Germany, 2Institüt für Portland, OR, United States Humangenetik, Aachen, Germany, 3Department of Neurology, UK Essen, Essen, Germany, 4Department of Introduction: The group of Angelman-like neurodevelop- Neurology, CHU Jean Minjoz, Besançon, France, mental syndromes continues to expand. In patients with 5Departments of Neurology and Clinical Neurophysiology, characteristic behaviors, developmental delays, speech Amsterdam UMC, University of Amsterdam, Amsterdam impairment and seizures, specific EEG patterns have been Neuroscience, Amsterdam, Netherlands, 6Département de proposed as having relative specificity for Angelman. Here Génétique, AP-HP, Hôpital Pitié-Salpêtrière, Paris, we report on two patients with Angelman-associated France, 7Cologne Center for Genomics (CCG), Cologne, phenotypes and EEG findings who were ultimately Germany, 8Département de Neurologie, AP-HP, Hôpital diagnosed with SYNGA P1
 syndrome. Pitié-Salpêtrière, Paris, France, 9Sorbonne Université, Materials and Methods: Patient 1 is a female with Faculté de Médecine; CNRS UMR 7225, UMR S 1127, infantile onset oropharyngeal dysphagia, hypotonia, global InstitutduCerveauetdelaMoelleépinière,Paris,France, developmental delays, and early childhood epilepsy. EEG 10MS Unit. Montpellier Universitary Hospital, Montpellier, findings appeared to suggest Angelman syndrome, how- France, 11Department of Neurology, Epilepsy Center ever, targeted testing was negative. Further molecular test- Frankfurt Rhine-Main, Frankfurt, Germany, 12Department ing confirmed a pathogenic variant in SYNGA P1
. ofNeurology,Epilepsy CenterHessen, Philipps University, Patient 2 is a male with similar history of oropharyngeal Margburg, Germany, 13Department of Medical Biology, dysphagia, hypotonia, global developmental delays, and University of Melbourne, Melbourne, Australia, childhood onset epilepsy in addition to tremors and ataxia. 14Population Health and Immunity Division, The Walter EEG findings showed patterns suggestive of Angelman, and Eliza Hall Institute of Medical Research, Melbourne, with a final diagnosis of SYNGA P1
 syndrome. Australia, 15University of Adelaide, Adelaide, Australia, Results:Patient1EEG:rhythmicposteriordeltaslowing 16School of Biological Sciences, School of Medicine, with embedded spikes, generalized epileptiform activity Robinson Research Institute, and South Australian Health and Medical Research Institute, Adelaide, Australia,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1469 17University Medical Centre Groningen, University of Department of Paediatrics, The University of Hong Kong, Groningen, Groningen, Netherlands, 18Department of Hong Kong, Hong Kong Neurology and Department of Human Genetics, Leiden, Netherlands An autosomal dominant type of spinocerebellar ataxia (SCA), SCA35, has been associated with pathogenic Introduction:FamilialAdultMyoclonicEpilepsy(FAME) mutations in the gene TGM6. In a Chinese exome isanautosomaldominantdisordercharacterizedbycortical sequencingcohort with 116indexesand135asymptomatic or myoclonic tremor occurring in association with general- parents, we identified 8 families with reported TGM6 ized seizures typically beginning in adulthood. Despite the variants sharing no features of SCA35. Considering this early identification of multiple loci on chromosomes 8, 2 finding, we reviewed the public database gnomAD, these and 5, the genetic basis of this condition has remained reported pathogenic variants are significantly more com- elusive for 20 years. Recently, intronic expansions of monly found in theEast Asians than inother ethnicgroups ATTTT/ATTTC pentanucleotide repeats in SAMD12 on (P<0.0001). Bioinformatics analysis of gene constraint chromosome 8 have been identified as a major cause of showed that both missense and loss-of-function variants in FAME in Asia. TGM6arelikelytobetoleratedwithnoregionalconstraint. Methods and Results: In this study, we used genome Byperforminginflationanalysistoempiricallyevaluatethe sequencing (Illumina, short-read technology) and repeat- pathogenicity of TGM6, it is found that there is an over- primedPCRtoidentifyanewexpandedsiteinMARCH6on representation of reported pathogenic variants in the chromosome 5p15 in four European families. Further ana- population. The cumulative frequency of reported patho- lysis of single DNA molecules using long-read nanopore genic TGM6 variants is at least 111-fold inflated over the sequencing and, in parallel, molecular combing combined combined prevalence of all autosomal dominant SCAs withfluorescentstainingoftheATTTCrepeatsandflanking (<5.6 per 100,000), indicating a high chance of misdiag- regions,revealedthattheexpansionsrangeonaveragefrom nosisorverylowpenetrance.Misclassificationofbenignor 4 to 13 kb. However, we observed a high variability in lowpenetrantvariantsaspathogenicisasignificantproblem expansion length and structure, compatible with the exis- that often results in genetic misdiagnosis and premature tence of different expansion configurations in the blood ending of diagnostic odyssey. This highlights the necessity cells of the same individual. Moreover, the largest expan- of evaluating variant pathogenicity with sequencing of sions were associated with complex microrearrangements genomesfromdiversepopulations,bothfromasymptomatic occurring at the expanded site in up to 20% of the cells. controls and phenotypically different patients, in order to Conclusion: This study provides further evidence that ensure accurate classification of variants. FAME is homogeneously caused by intronic ATTTT/ H. Chung: None. J. Fung: None. M. Tsang: None. M. ATTTC expansions in distinct genes and shows that Yu: None. expansions exhibit a high somatic instability that can ulti- mately result in genomic rearrangements.  P09
.124C R.T.Florian:None.F.Kraft:None.S.Klebe:None.E. Autosomal recessive tubulinopathy-like disorder caused Magnin: None. A.F. Van Rootselaar: None. S. Kaya: by loss of function of the tubulin-modifying enzyme None.J.Buratti:None.E.Leitao:None.S.Giesselmann: Tubulin Tyrosine Ligase None. I. Kurth: None. N. Tschernoster: None. J. Alt- mueller: None. A. Lamiral: None. L. Thivard: None. E. R. De Mori1, M. Magiera2, S. Tardivo1, P. Accorsi3, Leguern: None. P. Labauge: None. P.S. Reif: None. F. M. Ginevrino1,4, S. Bodakuntla2, S. Nuovo1,5, Rosenow: None. K.M. Klein: None. M. Bennett: None. L. Giordano3, E. Lorefice6, R. Liserre7, L. Pinelli7, M.Bahlo:None.J.Gecz:None.M.A.Corbett:None.M. T. Biagini8, A. Micalizzi9, A. Casella4, T. Mazza8, A.J. Tijssen: None. A.M.J.M. van den Maagdenberg: M. O. Steinmetz10, C. Janke2, E. Valente1,4 None. C. Depienne: C. Other Research Support (supplies, equipment, receipt of drugs or other in-kind support); 1NeurogeneticUnit,IRCCSFondazioneSantaLucia,Rome, Modest; Genomic Vision. Italy, 2Institut Curie, Dept. "Genotoxic stress and Cancer", Orsay Cedex, France, 3UOC Neuroradiologia, UOS  P09
.123B Neuroradiologia Pediatrica, Spedali Civili, Brescia, Italy, AsignificantinflationinTGM6geneticriskcastsdoubtin 4Detp. of Molecular Medicine, University of Pavia, Pavia, its causation in spinocerebellar ataxia type 35 Italy,5DeptofMedicineandSurgery,UniversityofSalerno, Salerno, Italy, 6Dept. Of Molecular Medicine, Sapienza H. Chung, J. Fung, M. Tsang, M. Yu University of Rome, Rome, Italy, 7UOC Neuroradiologia, Spedali Civili, Brescia, Italy, 8IRCCS Casa Sollievo della1470 Sofferenza, Laboratory of Bioinformatics, San Giovanni S. Smolders1,2, S. Philtjens1,2, D. Crosiers1,2,3, S. Van Rotondo, Italy, 9Laboratory of Medical Genetics, Bambino Mossevelde1,2,3,4, B. Heeman1,2, A. Sieben1,2,5, P. Pals2,3, Gesù Children's Hospital, Rome, Italy, 10Laboratory of S. Engelborghs2,4, P. De Deyn2,4, P. Cras2,3, C. Van Biomolecular Rese rach, Division of Biology and Broeckhoven1,2, BELNEU Consortium Chemistry, Paul Scherrer Institut, Villigen, Switzerland 1VIB Center for Molecular Neurology, University of Introduction: Tubulin Tyrosine Ligase (TTL) is a Antwerp, Antwerp, Belgium, 2Institute Born-Bunge, ubiquitous enzyme that catalyzes the convertion of University of Antwerp, Antwerp, Belgium, 3Department of detyrosinated to tyrosinated α-tubulin, a process that Neurology,AntwerpUniversityHospital,Edegem,Belgium, regulatesmultiple essential microtubulefunctions.Deletion 4Memory Clinic, Department of Neurology, Hospital of TTL in mice causes perinatal death due to a strong Network Antwerp Middelheim and Hoge Beuken, Antwerp, accumulationofdetyrosinatedα-tubulininthebrain,which Belgium, 5Department of Neurology, University Hospital leads to massive aberrations in brain development. More- Ghent and University of Ghent, Ghent, Belgium over, TTL has recently been demonstrated to be crucial for post-injury axon regeneration. Introduction: Lewy body disease (LBD) and Parkinson Materials and Methods: We describe two sisters from Disease (PD) share clinical and pathological features. healthy consanguineous parents, presenting with global VP S13
C was identified as a risk factor for PD in GWAS, developmental delay, intellectual disability, cerebellar and premature termination codon (PTC) mutations in ataxia, hypotonia and microcephaly. Brain MRI findings VP S13
C were associated with recessive PD. We identified was suggestive of a tubulinopathy, showing dysmorphic inwholegenomesequencingdataofarecessiveearly-onset basal ganglia, commissural agenesis or hypoplasia, dys- age LBD family (AAO: 41-42 years) compound hetero- plasia of the cerebellar vermis and brainstem. After zygous VP S13
C missense mutations reducing VP S13
C excluding mutations in tubulin genes, whole exome protein expression. sequencing analysis was performed. Materials and Methods: Targeted resequencing of cod- Results: Both siblings shared the homozygous missense ing VP S13
C in 230 LBD patients (AAO: 70.8±9.7 years), variant c.1013G>A (Cys338Thr) in the TTL gene 612 PD patients (AAO: 60.5±11.1 years) and 663 control (NM_153712.4). The variant was predicted as pathogenic individuals (AAI: 72.0±9.4 years). Protein analysis was by all prediction software and was absent from population performed in lymphoblast cells and brain lysates of LBD databases. Molecular dynamics simulation demonstrated compound heterozygous VP S13
C mutations carriers. that the mutant protein is more flexible than wild type, Results: We identified 4 LBD carries of compound het- whichcouldleadtoimpairedinteractionwithα-tubulin,and erozygous missense mutations in VP S13
C. Two mutant thus, impaired enzymatic function. Indeed, enzymatic alleles decreased protein expression by near 90% in lym- activity assays showed that mutant TTL protein is inactive, phoblast cells. VP S13
C reduction was also observed in while patient fibroblasts show significantly higher levels of autopsy brain of two LBD carriers. In the PD cohort, we detyrosinated α-tubulin compared to healthy controls. identified 7 patients compound heterozygous (splice site/ Conclusion: We report the first recessively inherited missense or missense/missense) and 1 patient homozygous tubulinopathy-like disorder, caused by biallelic loss of (missense) for VP S13
C mutations. In control individuals, functionmutationsintheTTLgene.Funding:ERCStarting we observed 6 carriers of compound heterozygous muta- Grant 260888; Ricerca Finalizzata NET-2013-02356160 tions of which 3 shared the same variants suggesting cis R. De Mori: None. M. Magiera: None. S. Tardivo: configuration. Trans/cis position of the heterozygous None. P. Accorsi: None. M. Ginevrino: None. S. Boda- VP S13
C alleles are being determined by long-read kuntla: None. S. Nuovo: None. L. Giordano: None. E. sequencing on VP S13
C cDNA. Lorefice: None. R. Liserre: None. L. Pinelli: None. T. Conclusion:Ourgeneticandexpressiondatasuggestthat Biagini: None. A. Micalizzi: None. A. Casella: None. T. alsoVP S13
CmissensemutationscontributetoriskforLBD Mazza:None.M.O.Steinmetz:None.C.Janke:None.E. orPDbyloss-of-functionmechanism.Additionalfunctional Valente: None. studieswillbeneeded tounderstandthecontributionofthe different mutated VP S13
C alleles to LBD and PD.  P09
.125D S. Smolders: None. S. Philtjens: None. D. Crosiers: Reduced VP S13
C protein expression caused by None. S. Van Mossevelde: None. B. Heeman: None. A. recessivemissenseandsplicesitemutationsisassociated Sieben: None. P. Pals: None. S. Engelborghs: None. P. with Lewy body disease and Parkinson disease De Deyn: None. P. Cras: None. C. Van Broeckhoven: None.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1471  P09
.126A methods. Furthermore, 7 pathogenic intronic variants were Comprehensiverarevariantanalysisofindividualswith identified, as well as 3 likely pathogenic variants in the neurodevelopmental disorders by whole-genome mitochondrial genome. This study demonstrates the value sequencing ofusingWGStoinvestigatethegeneticcausesofNDDasa single pass investigation. It also corroborates previous A. Sanchis-Juan1, C. Armirola1, K. Megy1, K. Low1, reports that reanalysis of data allows more patients to C. E. French2, D. Grozeva3, E. Dewhurst1, J. Stephens1, receive genetic diagnoses. WGS provides comprehensive K. Stirrups1, M. Erwood1, C. Penkett1, O. Shamardina1, andunbiasedcoveragefacilitatingidentificationofalltypes G. Ambegaonkar4, M. Chitre3, D. Josifova5, M. Kurian6, ofvariantsthroughoutthehumannuclearandmitochondrial A. Parker7, J. Rankin8, E. Reid9, E. Wakeling10, genome. Importantly, this includes variants that would not E. Wassmer11, G. Woods3, NIHR Bioresource, have been identified using the more commonly used whole W. H. Ouwehand1, F. Raymond3, K. J. Carss1 exome sequence approach. A. Sanchis-Juan: None. C. Armirola: None. K. Megy: 1Department of Haematology, University of Cambridge, None. K. Low: None. C.E. French: None. D. Grozeva: Cambridge, United Kingdom, 2Department of Paediatrics, None. E. Dewhurst: None. J. Stephens: None. K. Stir- University of Cambridge, Cambridge, United Kingdom, rups: None. M. Erwood: None. C. Penkett: None. O. 3DepartmentofMedicalGenetics,UniversityofCambridge, Shamardina: None. G. Ambegaonkar: None. M. Chitre: Cambridge, United Kingdom, 4Child Development Centre, None. D. Josifova: None. M. Kurian: None. A. Parker: Addenbrookes Hospital, Cambridge, United Kingdom, None. J. Rankin: None. E. Reid: None. E. Wakeling: 5Guy'sandStThomas'Hospital,Guy'sandStThomas'NHS None. E. Wassmer: None. G. Woods: None. W.H. Foundation Trust, London, United Kingdom, 6Department Ouwehand:None.F.Raymond:None.K.J.Carss:None. of Neurology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom,  P09
.127B 7Addenbrookes Hospital, Cambridge University Hospitals Denovo,heterozygousmissensevariantsinYWHAGasa NHS Foundation Trust, Cambridge, United Kingdom, novel cause of developmental and epileptic 8Royal Devon and Exeter NHS Foundation Trust, Exeter, encephalopathy United Kingdom, 9Department of Clinical Genetics, Addenbrookes Hospital, Cambridge, United Kingdom, F. Kanani1, H. Titheradge2, N. Cooper2, F. Elmslie3, 10North West Thames Regional Genetics Service, London M.Lees4,J.Juusola5,L.Pisani6,C.Mignot7,S.Valence8, North West Healthcare NHS Trust, Harrow, United B. Keren9, I. Guella10, DDD Study, Kingdom, 11Birmingham Children's Hospital, Birmingham M. Balasubramanian1,11 Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom 1Sheffield Clinical Genetics Service, Sheffield Children’s NHS Foundation Trust, Sheffield, UK, Sheffield, United Despitethesignificantprogressinunravellingtheoriginsof Kingdom, 2Birmingham Women’s and Children’s NHS neurodevelopmental disorders (NDDs), up to 50% of Foundation Trust, Birmingham, United Kingdom, 3South affected individuals remain without a genetic diagnosis. West Thames Regional Genetics Service, St George's Here we demonstrate the power of using whole-genome Hospital, London, United Kingdom, 4North East Regional sequencing(WGS)toidentifypathogenicvariantsinNDDs, Genetics Service, Great Ormond Street Hospital, London, inoneofthelargeststudiestodate.WGSwasperformedon United Kingdom, 5Clinical Genomics and Research 691individuals(488affectedand201unaffectedrelatives). Programs, GeneDx, Gaithersburg, MD, United States, Initially, pathogenic variants were identified in 31% 6HumanGeneticsandGenomics,NorthwellHealthSystem, individuals, and 21% had a variant of uncertain signifi- New York, NY, United States, 7Assistance Publique – cance. Reanalysis of the data two years later increased the HôpitauxdeParis,ServicedeGénétiqueMédicale,Groupe yieldto36%and23%respectively.Ofallreportedvariants, Hospitalier Pitié Slapêtrière, Paris, France, 8APHP, 90% were SNVs/indels in coding regions of NDD- Service de Neuropédiatrie, Hôpital Armand Trousseau, associatedgenes. However,WGS providedpowertodetect Paris, France, 9Département de génétique, hôpital Pitié- three additional categories of variants: structural, intronic Salpêtrière, Assistance publique, Hôpitaux de Paris, Paris, and mitochondrial variants. Structural variants (SVs) France, 10Centre for Applied Neurogenetics, Djavad comprised 25 deletions, 6 duplications, 2 inversions, one MowafaghianCentreforBrainHealth,UniversityofBritish partial uniparental isodisomy and one complex SV. Columbia, Vancouver, BC, Canada, 11Academic Unit of Nanopore long-read WGS was used to resolve the genetic Child Health, University of Sheffield, Sheffield, United architecture of SVs that could not be resolved by other Kingdom1472 1Department of Molecular Genetics, Institute of Pathology, Introduction: Developmental and Epileptic encephalopa- Faculty of Medicine, University of Ljubljana, Ljubljana, thies (DEE) describe heterogeneous epilepsy syndromes, Slovenia,2InstituteofClinicalNeurophysiology,Divisionof characterised by early-onset, refractory seizures and devel- Neurology, University Medical Centre Ljubljana, opmental delay (DD). With increased access to whole Ljubljana, Slovenia, 3Department of Neurology, Faculty of exome sequencing (WES), new candidate genes are being Medicine, University of Ljubljana, Ljubljana, Slovenia, identified. YWHAG (*605356) on Chr 7q11.23 encodes for 4Institute of Biochemistry, Faculty of Medicine, University YWHAG, from the 14-3-3 protein family, playing impor- of Ljubljana, Ljubljana, Slovenia tant roles in signal transduction and cellular proliferation. YWHAG is highly expressed in brain, skeletal and heart Introduction:ManymicroRNAs(miRNAs)areaberrantly muscle. Mouse models suggest alterations in Ywhag level expressedinALSpatientsasaresultofinterruptedmiRNA cause delayed neuronal migration and interstitial deletions biogenesis and processing or due to other changes that at Chr 7q11.23 result in infantile seizures and cardiomyo- affect miRNA expression levels, including DNA methyla- pathy, suggesting haploinsufficiency as an explanation. tion. Several studies showed global methylation changes in Materials and Methods: We present 12 patients with ALS patients that could lead to altered expression levels. YWHAG de novo missense variants. We describe a syn- However, none of them focused on the influence of dromal phenotype, report novel and a recurrent p.Arg132- promoter methylation on miRNA expression. CysYWHAGvariantandcomparedevelopmentaltrajectory Materials and Methods: We identified methylated and treatment strategies in this cohort. Patients 1-9 had regions in the genome of ALS patients through MeDIP WES via Deciphering Developmental Disorders Study. sequencing (methylated DNA immunoprecipitation and Patients10-12wereidentifiedviaGenematcherandAnnEX sequencing of precipitated DNA fragments). databases. De novo variants from exome data were vali- Results: Sequenced fragments were mapped to a total of dated using Sanger sequencing. 1321 miRNA promoters. Based on the methylation differ- Results: 12/12 patients in the cohort have de novo, het- ences between samples we selected 358 ofthem for further erozygous missense variants in YWHAG including 4/12 assessment. Using KEGG analysis it turned out that miR- patients with a recurrent c.394C >T, p.Arg132Cys variant. NAs with altered methylation status in promoter region Characteristic features included: early-onset seizures, pre- target numerous genes including those involved in ErbB dominantly generalised tonic-clonic and absence type with signalling pathway (p= 1*10-8), Hippo signalling pathway good response to standard anti-epileptic medications; DD; (p=2*10-8), prion diseases (p=9*10-6), long-term depres- IntellectualDisability(ID)andarecognisablefacialgestalt. sion (p=9*10-6), endocytosis (p=2*10-5), adherens junc- Conclusions: Our findings support the hypothesis that tions (p=3*10-5), and axon guidance (p=4*10-5). YWHAG loss-of-function causes a neurological phenotype. Conclusions: Promoter methylation of miRNA genes Although the exact mechanism of YWHAG is not fully couldbeanimportantfactorfortheiraberrantexpressionin known, it is likely that YWHAG haploinsufficiency in ALS. Since miRNA target genes are involved in diverse developing cerebral cortex leads to abnormal neuronal biochemicalpathwaysandprocesses,aberrantexpressionof migration resulting in DEE. miRNAs may contribute to ALS pathology. However, fur- F. Kanani: None. H. Titheradge: None. N. Cooper: ther validation studies are needed to confirm this. None.F.Elmslie:None.M.Lees:None.J.Juusola:None. Acknowledgements: This work was supported by Slove- L. Pisani: None. C. Mignot: None. S. Valence: None. B. nianResearch Agency(ARRS)underPhDthesisgrantsfor Keren: None. I. Guella: None. M. young researchers Ana Dolinar and Katarina Vrabec, and Balasubramanian: None. under research program  P3
-0054. Authors thank all the patients and healthy controls for their participation in the study.  P10
 A.Dolinar:None.K.Vrabec:None.B.Koritnik:None. Neuromuscular disorders D. Glavač: None. M. Ravnik-Glavač: None.  P10
.01D  P10
.02A Analysis of miRNA promoter methylation profiles in Comprehensive genetic analysis in a cohort of 107 ALS patients Hungarian patients with amyotrophic lateral sclerosis A. Dolinar1, K. Vrabec1, B. Koritnik2,3, D. Glavač1, K. Tripolszki1, P. Gampawar2, H. Schmidt2, Z. F. Nagy1, M. Ravnik-Glavač1,4 P. Klivenyi3, J. I. Engelhardt3, M. Szell1Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1473 1University of Szeged, Department of Medical Genetics, 1Department of Neurology, Hannover, Germany, 2Institute Szeged, Hungary, 2Research Unit for Genetic of Diagnostic and Interventional Neuroradiology, Epidemiology, Gottfried Schatz Research Center, Hannover, Germany MolecularBiologyandBiochemistry,MedicalUniversityof Graz, Graz,Austria,3Department ofNeurology, University Introduction: The neuromuscular disorder SMA is the of Szeged, Szeged, Hungary most frequent genetic cause of death in children. Due to lower motor neuron loss caused by homozygous deletions Introduction:Amyotrophiclateralsclerosis(ALS)isafatal in the survival of motor neuron (SMN) 1 gene patients neurodegenerative disease characterized by the degenera- suffer from progressive muscular atrophy and paralysis. tion of upper and lower motor neurons. The frequency of Whereas SMA 1 and 2 patients never walk independently, mutationsinALSpatientshasbeenextensivelyinvestigated SMA 3 patients present with a milder phenotype and later in populations of various ethnic origins. Patients and onset mainly attributable to higher copy numbers of the methods: All investigated ALS patients (n=107) were of only partially functional SMN2 gene. In 2017 the Hungarian origin. Repeat sizing of  C9
orf72 and ATXN2 intrathecally administered antisense oligonucleotide (ASO) genes andtargetednext generationsequencing(NGS)were Nusinersenhasbeenapprovedasfirsttreatmentforalltypes used to comprehensively assess genetic variation in 35 of SMA by the EU, based on results from phase 3 trials in major ALS genes. The cohort was previously screened for pediatric patients. Nusinersen alters the splicing of SMN2 SOD1 and TARDBP genes, with negative results. Variants pre-mRNA in order to increase production of full-length from whole-exome sequencing data of other studies (200 SMNprotein.Longtermevaluationoftreatmenteffectsand individuals of Hungarian or Austrian origin) were used as impactofSMN2carrierstatus inadultSMApatientsunder in-house control database. ASO therapy is urgently needed. Results: Pathogenic repeat expansions in the  C9
orf72 Materials and Methods: In our center, 24 patients aged gene were detected in 10 patients (9.3%); intermediate 18-65yearshavebeentreatedwithintrathecalloadingdoses polyQlengths(27-33)intheATXN2genewereidentifiedin of Nusinersen at day 1, 14, 28 and 63, followed by main- 9 (8.4%) patients. Using panel sequencing, 31 rare, poten- tenance doses every 4 months so far. Treatment efficacy tially pathogenic variants were detected in 16 genes. was assessed by monitoring of muscular functions and According to the NGS results, the most frequently mutated patient reported outcome measures in correlation to the geneswereNEK1(5.6%),NEFH,SQSTM1(3.7%),KIF5A, SMN2 carrier status. SPG11 (2.8%), AL S2
, CCNF, FUS, MATR3, TBK1 and Results:Intrathecaladministrationeitherbyconventional UBQLN2 (1.9%). Furthermore, potentially pathogenic var- orcomputedtomography(CT)-guidedlumbarpuncturewas iants were found in ERBB4, FIG4, GRN and SIGMAR1 well tolerated. No patient has developed communicating genes in single patients. hydrocephalus. First objective and subjective results indi- Conclusion: Combining targeted NGS and repeat sizing, cate a benefit in motor function in dependence of disease potentially causative variants were detected in 41% of severityandSMAtypewhichcorrelates totheSMN2copy patientsincludingpatientswithvariantsconsideredtobeof number. uncertain significance (VUS). Our findings highlight the A. Osmanovic: None. G. Ranxha: None. M. Kumpe: necessity for large-scale multi-center studies on ALS None. K. Kollewe: None. L. Müschen: None. O. Abu- patients to better understand the underlying genetic causes. Fares:None.F.Götz:None.O.Schreiber-Katz:None.S. Funding: Hungarian Brain Research Program (Grant No. Petri: B. Research Grant (principal investigator, colla- 2017-1.2.1-NKP-2017-00002). borator or consultant and pending grants as well as grants K.Tripolszki:None.P.Gampawar:None.H.Schmidt: already received); Modest; Biogen, Cytokinetics Inc, None. Z.F. Nagy: None. P. Klivenyi: None. J.I. Engel- GlaxoSminthKline GmbH,, Orion Pharma. D. Speakers hardt: None. M. Szell: None. Bureau/Honoraria (speakers bureau, symposia, and expert witness); Modest; Desitin Arzneimittel GmbH, TEVA,  P10
.03B Novartis, Biogen. Bringing genetics into clinical practice: antisense oligonucleotide (ASO) therapy in 5q-associated spinal  P10
.04C muscular atrophy (SMA) A de novo mutation of the stress granules-associated CAPRIN1causesanovelprogressiveneurodegenerative A. Osmanovic1, G. Ranxha1, M. Kumpe1, K. Kollewe1, disorder L. Müschen1, O. Abu-Fares2, F. Götz2, O. Schreiber- Katz1, S. Petri1 A. Delle Vedove1,2,3, M. Storbeck1,2,3, M. Eckenweiler4, S. Hosseinibarkooie1,2,3, N. Mendoza Ferreira1,2,3,1474 R. Heller1, I. Hölker1,2,3, O. Magnusson5, F. Körber6,  P10
.05D M. Kye1,2, J. Kirschner4, B. Wirth1,2,3 Neuropathy related genes as possible modifiers of PM P22
 related neuropathies 1Institute of Human Genetics, Cologne, Germany, 2Center for Molecular Medicine Cologne, Cologne, Germany, B.W.vanPaassen1,F.vanRuissen2,A.J.vanderKooi2, 3Institute for Genetics, Cologne, Germany, 4Clinic for M. de Visser2, C. Verhamme2, F. Baas3 Neuropediatrics and Muscular Disorders, Freiburg, Germany, 5deCODE genetics, Reykjavik, Iceland, 6Institute 1Erasmus Medical Center, Rotterdam, Netherlands, 2, of Diagnostic and Interventional Radiology, Cologne, Amsterdam University Medical Center, location Academic Germany Medical Center, Amsterdam, Netherlands, 3Leiden University Medical Center, Leiden, Netherlands Introduction: Motor neuron disorders (MNDs) are neuro- logical diseases whose diagnosis is still challenging due to Charcot-Marie-Tooth disease type 1A (CMT1A) and their highly overlapping phenotypes and genetic hereditary neuropathy with liability to pressure palsies heterogeneity. (HNPP) are autosomal dominantly inherited peripheral Materials and Methods: An eight year-old girl born neuropathies caused by copy number variation of the fromanon-consanguineouscouple,presentedaprogressive PM P22
 gene. Considerable phenotypic variation is known motor-sensory axonal polyneuropathy and subsequently for both disorders, suggesting modifiers. developed cerebellar ataxia, dysphagia and cognitive We undertook a search for genetic modifiers of PM P22
 decline. She underwent SMN1 deletion testing, NMD-gene related neuropathies by selecting the extremes of the spec- panel analysis and a trio WES. trum of CMT1A and HNPP patients, based on disability Results: WES led to the identification of a de novo assessed by the Overall Neuropathy Limitation Scale c.1535C>T variant (p.Pro512Leu) in the CAPRIN1 (Cell (ONLS).TheONLSdataof287patients(184CMT1Aand CycleAssociatedProtein1)gene.Thisvariantisnotpresent 103 HNPP patients) showed a Gaussian distribution for in1000GandgnomAD.CAPRIN1hasreducedtoleranceto both disorders. The median score for CMT1A patients was missense (Z = 1.79) and is intolerant to nonsense variants 4 and for HNPP patients 3. Twenty-one mild CMT1A (pLI=1.0).CAPRIN1isabundantintheadultbrain,where (ONLS<2),26severeCMT1A(ONLS>5),25mildHNPP itregulatesthetransportandtranslationofmRNAsofgenes (ONLS <2) and 25 severe HNPP patients (ONLS >4) were involvedinsynapticplasticity.Moreover,itcontainsanLC/ clinically evaluated to further characterize disease severity. ID domain and it is a component of stress granules. A next generation sequencing gene panel containing 147 Mutations in proteins containing LC/ID domains (TD P43
, genes related to neuropathies and hereditary motor syn- TIA1, hnRNPA1/2) cause MNDs and increase the like- dromes was tested in this selection of patients. lihood of protein aggregates formation. Several in silico Missense, frameshift, nonsense and intronic mutations tools predict that the p. P512
L mutation to increase the possibly affecting splicing were selected. No significant aggregation propensity. Indeed, experiments in difference was found in the mean number of variants HEK293T cells show that CAPRIN1 P512
L forms bulky (mutation burden) per patient between the mild and severe aggregates as compared to CAPRIN1WT. Moreover, an groups. Further selection of variants with an allele fre- insoluble protein extraction assay demonstrates that quency of ≤4% in a control population was done. A sig- CAPRIN1WT elutes in the RIPA-soluble fraction while nificant difference between the mild and the severe HNPP CAPRIN1 P512
L in the urea-soluble one. group was found. In several patients double trouble was Conclusions: Our results suggest that CAPRIN1 P512
L is found (another likely pathogenic mutation in a neuropathy prone to aggregation. As CAPRIN1 deficiency is linked to related gene). Replication of these resultsin a largercohort autism-spectrum disorders (ASD) in human and mice, we are needed. propose CAPRIN1 P512
L as a novel gain-of-function NMD B.W. van Paassen: None. F. van Ruissen: None. A.J. candidate gene. vanderKooi:None.M.deVisser:None.C.Verhamme: A. Delle Vedove: None. M. Storbeck: None. M. Eck- None. F. Baas: None. enweiler: None. S. Hosseinibarkooie: None. N. Mendoza Ferreira: None. R. Heller: None. I. Hölker: None. O.  P10
.06A Magnusson: None. F. Körber: None. M. Kye: None. J. A novel ddPCR method for the copy number variation Kirschner: None. B. Wirth: None. analysis of the segmental duplication regions in nebulin and titinAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1475 L. J. Sagath1, V. Lehtokari1, C. Wallgren-Pettersson1, surveyed 10 pairs of DMD participants and their parents K. B. Pelin2, K. J. Kiiski1 withinthisclinicaltrialviaaniPadsurveyformandthrough interviews regarding their understanding of the trial, 1Folkhälsan Research Center, Helsinki, Finland, 2Faculty expectations, anxieties, and reasons for participating in the of Biological and Environmental Sciences, University of trial.Approximatelyhalfoftheparticipantsactivelydecided Helsinki, Helsinki, Finland to participate of their own volition, and none considered quittingthetrial.Thisindicatesthatparticipantsparticipated Introduction: The giant genes nebulin (NEB) and titin more positively in this clinical trial than previously (TTN) both harbour large expressed segmental duplication expected. However, some potential concerns were also (SD) regions. Mutations in NEB cause nemaline myopathy revealed, with one being that the desire to please those (NM), and mutations in TTN cause myopathies and around them might be more important to the DMD cardiomyopathy. Using custom, targeted Comparative participants than the effects of the drug. Another issue is Genomic Hybridization arrays for NM and other neuro- the possibility of biased information originating from the muscular disorders, we have shown that copy number studysubjects’parents;whilesevenoutof10oftheparents variations (CNVs) in the NEB SD are potentially patho- toldtheirchildrenthatthestudydrugmightwork,onlyfour genic. We have also shown that the TTN SD harbours oftheseparentsalsoexplainedthatitmightnotwork.Only recurrent and potentially pathogenic CNVs. For validation, two study participants received an explanation concerning we have established custom Digital Droplet PCR (ddPCR) thedrug’ssideeffectsfromtheirparents.Thisresultimplies assays targeting the SD regions of NEB and TTN. that caution should be taken when family expectations are Materials and Methods: We created custom assays for high, and there is a possibility that subjects will be given exons 4 and 8 of the NEB SD, and exon-intron regions 1-2 biased information from their parents. This work was and 7-8 of the TTN SD. The ddPCR method was validated supportedgrantfromthe[IntramuralResearchGrant(26-6) using 70 controls previously run on our CGH-arrays. for Neurological and Psychiatric Disorders of National Results:WeshowthatCNVsintheTTNSDarerecurrent Center of Neurology and Psychiatry] andappearin25%ofbothhealthyandaffectedindividuals. R. Shimizu: None. M. Ohata: None. H. Tachimori: The ddPCR method is sensitive, and reliably detects CNV None.E.Kimura:None.Y.Harada:None.E.Takeshita: in both NEB and TTN SDs. None. A. Tamaura: None. S. Takeda: None. H. Conclusions: Our ddPCR assay for the SD regions of Komaki: None. NEB and TTN allows for rapid, specific and inexpensive assessmentofCNVswithintheseregions.Currently,weare  P10
.08C investigating the potential pathogenicity of TTN SD Genomic profiling of adult onset isolated focal dystonia region CNVs. in a group of Romanian patients Funding: This study is supported by Muscular Dystrophy UK R. Cocos1, I. Popescu-Olaru2,3, O. Băjenaru4,5, L.J. Sagath: None. V. Lehtokari: None. C. Wallgren- L. Cozma4,3, L. Dumitrescu4,3, R. Tănăsescu4,3,6, Pettersson: None. K.B. Pelin: None. K.J. Kiiski: None. F. Raicu1,7, B. Popescu4,3,8  P10
.07B 1University of Medicine and Pharmacy - Department of Expectations and anxieties of Duchenne muscular Medical Genetics, Bucharest, Romania, 2University of dystrophypatientsandtheirfamiliesduringthefirst-in- Medicine and Pharmacy -Department of Clinical human clinical trial of NS-065/NCNP-01 Neurosciences, Bucharest, Romania, 3Colentina Clinical Hospital - Department of Neurology, Bucharest, Romania, R. Shimizu, M. Ohata, H. Tachimori, E. Kimura, 4University of Medicine and Pharmacy - Department of Y. Harada, E. Takeshita, A. Tamaura, S. Takeda, ClinicalNeurosciences,Bucharest,Romania,5“AnaAslan” H. Komaki National Institute of Geriatrics and Gerontology, Bucharest,Romania,6UniversityofNottingham-Academic National Center Hospital, Tokyo, Japan Clinical Neurology, Division of Clinical Neuroscience, Nottingham, United Kingdom, 7Institute of Anthropology Duchenne muscular dystrophy (DMD) is a recessive X- Romanian Academy, Bucharest, Romania, 8“Victor Babeş linked genetic disease caused by a mutation in the National Institute of Pathology - Laboratory of dystrophin gene. The new drug NS-065/NCNP-01 utilizing Ultrastructural Pathology, Bucharest, Romania exon-skipping therapy targeting specific deletions has been usedinafirst-in-humantrialforthetreatmentofDMD.We1476 Introduction: We proposed to identify the relevant genomic profiles of adult-onset isolated focal dystonia by Single-cellanalyseshavebecomeincreasinglyimportantfor gaining insights into the interplay of potential causative uncovering cellular dynamics during health and disease. disease-associated genetic variants at the genomic level. Not only have they began to unravel a greater level of Isolatedfocaldystoniaisthethirdmostcommonmovement cellular heterogeneity than previously could have been disorderafterParkinson’sdiseaseandessential tremor. The appreciated, it also enables the identification of sporadic etiology is genetic in some cases, but over 75% are cellular aberrations involved in disease etiology and idiopathic. development. Materials and Methods: In the first stage of our study, One prime example of disease-associated cellular het- we analyzed onto the Ion Torrent PGM platform a well- erogeneity is found in facioscapulohumeral muscular dys- described homogenous group of 120 Romanian dystonia trophy (FSHD), which is characterized by sporadic de- cases using our own designed Targeted Sequencing repression of the cleavage-stage transcription factor DUX4 AmpliSeq panel of 30 genes previously found to be asso- in ~1:200 myonuclei. Yet, with the sporadic nature of ciated with dystonia (DYT) and other movement disorders. DUX4 de-repression limiting the resolution of bulk RNA- All samples had 97.85% average of target regions with seq analyses, essential insights in the cascade of events coverage by at least 30 folds. Data were analyzed using a leadingtoapoptosisandseveremusclewastingobservedin bioinformatics in house pipeline based on GATK, Picard patients are currently limited. and Annovar software for reading alignments, variant call- We used single-cell RNA-sequencing combined with ing, filtering and annotation. pseudotime trajectory modeling to generate a detailed Results:Moleculargeneticscreeningidentifiedmutations FSHDcellularprogressionmodel.Weshowthatourmodel in 46/120 (38%) of the clinically diagnosed adult-onset detectsFSHD-associatedcellularprogressioninapprox.1% isolated focal dystonia subjects. All identified mutations ofallcells,andfaithfullyreflectsboth theburst-likeDUX4 were previously reported to be associated with DYTs. expression as well as the downstream activation of various Conclusions:Thesubsequentanalysisofnegative-known pathwayspreviouslyimplicatedinFSHD.Inaddition,using DYTs patients for the genes in the customized panel using our model we were now able to identify new expression the Whole Exome Sequencing could offer the opportunity signatures that are likely related to both direct and indirect to assess extensively the genomic profiles of adult-onset effects of DUX4. idiopathic isolated focal dystonia and could result in iden- Our data therefore highlights the potential for single-cell tification of new genes and variants causing-disease. This transcriptomics in studying disease etiology in genetic dis- workwassupportedbytheCNCS-UEFISCDIgrantPN-III- eases,evenwhenhallmarkedbyhighcellularheterogeneity  P4
-ID-PCE-2016-0696. asinFSHD,andshowsthatpseudotimetrajectorieslikeour R.Cocos:None.I.Popescu-Olaru:None.O.Băjenaru: FSHDpseudotimemodelmaycontainvaluableinformation None. L. Cozma: None. L. Dumitrescu: None. R. for further unraveling the role of cellular heterogeneity in Tănăsescu: None. F. Raicu: None. B. Popescu: None. disease etiology and progression. A. van den Heuvel: None. A. Mahfouz: None. S.L.  P10
.09D Kloet:None.J.Balog:None.B.G.M.VanEngelen:None. Cellular heterogeneity in FSHD R. Tawil: None. S.J. Tapscott: None. S.M. van der Maarel: None. A.vandenHeuvel1,A.Mahfouz2,3,S.L.Kloet1,J.Balog1, B. G. M. Van Engelen4, R. Tawil5, S. J. Tapscott6,  P10
.10A S. M. van der Maarel1 Functional analysis of an intronic variant of uncertain significance c.911-13A>G in the FKTN gene 1Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands, 2Leiden V. Freire1, A. Filatova1, I. Akimova1, M. Bulakh1, Computational Biology Center, Leiden University Medical M. Skoblov1,2 Center, Leiden, Netherlands, 3Bioinformatics Lab, Delft University of Technology, Delft, Netherlands, 4Department 1Research Centre for Medical Genetics, Moscow, Russian of Neurology, Donders Institute for Brain Cognition and Federation, 2School of Biomedicine, Far Eastern Federal Behaviour, Radboud University Medical Center, Nijmegen, University, Vladivostok, Russian Federation Netherlands, 5Department of Neurology, University of Rochester, Rochester, NY, United States, 6Division of Introduction: Next generation sequencing methods allow HumanBiology,FredHutchinsonCancerResearchCenter, the identification of previously ignored deep intronic Seattle, WA, United States variants, but it is still difficult to determine theirAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1477 pathogenicity. In a patient with congenital muscular makesdiagnosticofFSHDcomplicatedforbasicdiagnostic dystrophy and cardiomyopathy, two heterozygous variants laboratories. in the FKTN gene were identified: previously described Materials and Methods: Blood-derived DNA was iso- pathogenic variant NM_001079802.1(FKTN_v001): lated from 55 FSHD patients and its relatives. For the c.509C>A p.(Ala170Glu) and a previously undescribed molecular-genetic diagnostic, we used three methods: intronic variant of uncertain significance NG_008754.1 Southern blotting, molecular combing and a newly devel- (FKTN_v001): c.911-13A>G, inherited from the mother. oped PCR based method. Materials and Methods: In order to study the effect of Results: Totally 55 individuals were analyzed by the c.911-13A>G on FKTN splicing and confirm its patho- Southern blotting, among them 12 parents/children, genicity,weperformedRT-PCRoftotalRNAisolatedfrom 28 sporadic cases. Six patients with difficult interpretation peripheralbloodmononuclearcellsandfibroblastsobtained of the Southern blotting results were further analyzed by fromtheproband,hismotherandhealthydonors,aswellas molecular combing. For all cases we determined the D4Z4 using a FKTN minigene expression system in a HEK293T repeat size and haplotype. The PCR based diagnostic was cell model line. applied to 7 FSHD patients with one 4qA repeat below 10 Results: When studying the obtained mRNA structure, units and to 8 healthy relatives with normal-sized D4Z4 three FKTN isoforms were identified: two normal (present repeats.ThePCRresultswereconcordantwiththeSouthern incontrolsamplesofhealthydonors)andoneaberrantwith blottingin57.1%forthepatientsandin88%forthehealthy exon 9 skipping. The minigene expression analysis con- relatives. We suggest that the discordant results were firmed this data. The short isoform canbe explained bythe obtained due to high background of amplification or to destruction of the intron 8 acceptor splice-site. Thus, the DNA quality issues. work showed that the presence of a deep intronic variant Conclusions: The Southern blot and the molecular c.911-13A>G in the FKTN gene leads to the loss of 133 combing results are highly correlated. The PCR-based nucleotides, with an open reading frame shifting and a 145 method shows potential to diagnose FSHD; however needs amino acid shortening (p.W301Rfs*13) of the protein. further optimization. Improvement of the PCR-based Conclusions: Functional analysis of intron variants method may simplify FSHD diagnostic for basic diag- allowstoestablishthepathogenicityofvariantsofuncertain nostic laboratories. clinical significance and confirm the diagnosis in patients. Acknowledgments: We are grateful to Genomic Vision Inthisstudy,thepathogenicityofthec.911-13A>Gvariant Company for the ability to test DNA samples. in the FKTN gene was demonstrated. M.Y. Skoblov: None. N.V. Zernov: None. A.A. Gus- V.Freire:None.A.Filatova:None.I.Akimova:None. kova:None.P.J.vanderVliet:None.G.E.Rudenskaya: M. Bulakh: None. M. Skoblov: None. None. I.A. Sharkova: None. I.A. Akimova: None. R.J. Lemmers: None. N.A. Semenova: None. N.A. Demina:  P10
.12C None. V.A. Galkina: None. T.V. Markova: None. O.E. Methods of the DNA diagnostics for Zinovyeva: None. E.L. Dadali: None. facioscapulohumeral muscular dystrophy (FSHD)  P10
.13D M. Y. Skoblov1, N. V. Zernov1, A. A. Guskova1, P. J. van Genetic analysis of autosomal dominant motor and der Vliet2, G. E. Rudenskaya1, I. A. Sharkova1, sensory neuropathy with proximal dominancy in the I. A. Akimova1, R. J. Lemmers2, N. A. Semenova1, lower extremities, urinary disturbance, and paroxysmal N. A. Demina1, V. A. Galkina1, T. V. Markova1, dry cough O. E. Zinovyeva3, E. L. Dadali1 S. MIURA1,2, K. Kosaka3, R. Fujioka4, S. Mori1, 1Research Center for Medical Genetics, Moscow, Russian H. Shibata5 Federation, 2Department of Human Genetics, Leiden UniversityMedicalCenter,Leiden,Netherlands,3Sechenov 1Division of Respirology, Neurology and Rheumatology, First Moscow State Medical University, Moscow, Russian Department of Medicine, Kurume University School of Federation Medicine, Kurume, Japan, 2Department of Geriatric Medicine and Neurology, Ehime University Graduate Introduction:In95%FSHDcausedbyapartialcontraction School of Medicine, Toon, Japan, 3Division of Human oftheD4Z4arrayupto10-1repeatsata4qAhaplotypeof Molecular Genetics, Medical Institute of Bioregulation, chromosome 4q35. The size of D4Z4 repeats and its high Kyushu University, Fukuoka, Japan, 4Department of Food similarity with the D4Z4 locus on chromosome 10q26 and Nutrition, Beppu University Junior College, Beppu,1478 Japan, 5Division of Genomics, Medical Institute of characterized by progressive spasticity and weakness in Bioregulation, Kyushu University, Fukuoka, Japan lower limbs. The mode of inheritance in HSP can be autosomal-dominant, autosomal-recessive, X-linked, or We have reported a clinically new type of autosomal mitochondrial. There is significant genetic heterogeneity dominant disorders of motor and sensory neuropathy inHSP,withatleast65genesand80lociidentifiedthusfar. (Miura et al. J Neurol Sci 2008). The cardinal clinical Whole exome sequencing (WES) has been used for gene features of the disease were slow progression, muscular discoveryinHSPsince2011,resultinginamarkedincrease weakness with dominancy in the proximal portion of the in the rate of novel disease-causing genes being identified. lower limbs and in the distal portion of the upper limbs, Despite the use of WES, genetic analysis has failed in sensory involvement with dominancy in the lower limbs finding of causative genes in ~45%-60% in the autosomal (gloveandstockingtype),areflexia,fineposturalandaction dominant-HSP(AD-HSP)and~71%-80%intheautosomal tremors, painful muscle cramps, elevated serum creatine recessive-HSP (AR-HSP) groups, indicating that, the kinaselevels,urinarydisfunction,andrecurrentparoxysmal majority of HSP-genes especially AR-HSPs have remained dry cough. Sural nerve biopsy showed moderate, chronic, unknown. mainly axonal neuropathy. To identify the causative Materials and Methods: In order to identification of nucleotide variant for the disease, we studied the Japanese novel HSP-disease causing genes, we investigated the pedigree with the disease of 19 family members including causes of AR-HSP in 12 unrelated Iranian families ninepatientsinfivegenerations.Bythelinkageanalysis,we using WES. mapped the disease locus to 1p13.3-q23 (maximum Results:Thisapproachledustoidentifythemutationsin logarithm-of-oddsscore=2.24).Thewhole-exomesequen- seven known disease-causing genes including SPG7 (two cing upon five patients and one healthy relative from the cases), CAPN1, CY P7
B1, ENTPD1, GJ C2
, ERLIN2, and pedigree revealed 2,526 patient-specific single nucleotide SPG11 (two cases) and three novel candidate HSP genes. variants(SNVs).Bythefilteringprocessesusingthepublic Functionalanalysestoevaluateofthebiologicalimplication SNP databases, our linkage analysis, validation by Sanger of the novel genes are ongoing. sequencing, confirming cosegregation, genotyping 520 Conclusions: Here, we could find nine variations in healthy Japanese individuals, and functional predictions, seven known HSP-causing genes in 12 cases (75%) and weidentifiedoneSNVlocated inIQGA P3
whichisknown three novel HSP-genes in the remaining ones using WES tobeassociatedwithneuriteoutgrowth.Immunohistochem- method. Identification of novel genes and novel molecular istryshowincreasedexpressionofIQGA P3
inlymphocytes pathways will greatly enhance our understanding of the andsuralnervesofapatientcomparedtothoseofacontrol. cellular pathways that are critical for axonal health and our We conclude that IQGA P3
 is a causative gene for the knowledge about pathogenesis of the disease. disease. This is the first record of a disease caused by an M.Rahimi Bidgoli:None.A.Alavi:None.M.Rohani: IQGA P3
 variant. None. L. Javan Parast: None. M. Pashaei: None. F. S. Miura: None. K. Kosaka: None. R. Fujioka: None. Fatehi: None. S. Nafissi: None. K. Kahrizi: None. H. S. Mori: None. H. Shibata: None. Najmabadi: None.  P10
.14A  P10
.15B Genetics heterogeneity and novel genes in autosomal Clinical background of hyper creatine kinase in girls recessive Hereditary Spastic Paraplegia (AR-HSP) without a family history of genetic muscular disease M. Rahimi Bidgoli1, A. Alavi1, M. Rohani2, L. Javan T. Lee1, S. Tokunaga1, C. Mure1, M. Misaki1, Parast1, M. Pashaei1, F. Fatehi3, S. Nafissi3, K. Kahrizi1, H. Shimomura1, I. Nishino2, K. Ito3, Y. Takeshima1 H. Najmabadi1 1Department of Pediatrics, Hyogo College of Medicine, 1Geneticsresearchcenter,UniversityofSocialWelfareand Nishinomiya, Japan, 2National Center of Neurology and Rehabilitation Sciences, Tehran, Iran, Islamic Republic of, Psychiatry, Tokyo, Japan, 3Department of Pathology and 2Department of Neurology, Iran University of Medical Applied Neurobiology, Kyoto Prefectural University of Sciences, Hazrat Rasool Hospital, Tehran, Iran, Islamic Medicine Graduate School of Medical Science, Kyoto, Republic of, 3Department of Neurology, Tehran University Japan of Medical Sciences, Tehran, Iran, Islamic Republic of Persistent elevated plasma creatine kinase (CK) raises the Introduction: Hereditary spastic paraplegia (HSPs) is a suspicion of various conditions such as genetic muscular group of inherited neurodegenerative disorders disease, inflammatory muscular disease, metabolicAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1479 myopathy, or hypothyroidism. In girls, carrier status of Felipe (CIPF), Valencia, Spain, 6Northcott Neuroscience Duchenne/Beckermusculardystrophy(DMD/BMD)should Laboratory, ANZAC Research Institute, Concord NSW, be taken into consideration so that the diagnostic process Australia, 7Sydney Medical School, University of Sydney, mightincludebothtechnicalandethicalaspects.Therefore, Sydney, Australia, 8The R&D Unit, Stiftelsen Stockholms no diagnostic system has been established and the clinical Sjukhem, Stockholm, Sweden, 9Division of background is still unclear. This study aimed to investigate Neurodegeneration, Department of Neurobiology, Care theclinicalbackgroundofhyper-creatine-kinase-emiagirls. Sciences and Society, Karolinska Institutet, Stockholm, Fifteen girls, who were referred to our hospital between Sweden, 10Department of Pediatric Neurology, DNA April 2014 and August 2018 with persistent elevated Laboratory,2ndFacultyofMedicine,CharlesUniversityin plasma CK without a family history of muscular disease, Prague and University Hospital Motol, Prague, Czech were included. Age and Value of CK at the first visit were Republic, 11Neuropediatrics Department, Hospital 0-12 years old and 740-21,944 IU/L. Eight cases exhibited Universitario La Paz, Madrid, Spain, 12Department of clinical symptoms (symptomatic group), while seven cases Neurology, Hospital Universitari i Politècnic La Fe, and showed no symptoms (asymptomatic group). Genetic CIBER of Rare Diseases (CIBERER), Valencia, Spain, muscular disease was diagnosed using muscle biopsy or 13Department of Medicine, University of Valencia, geneticanalysis.Inthesymptomaticgroup,diagnoseswere Valencia, Spain, 14Molecular Medicine Laboratory, DMD/BMD carrier (3 cases), Fukuyama congenital mus- Concord Hospital, Concord NSW, Australia, 15INCLIVA & cular dystrophy (1 case), sarcoglycanopathy (1 case), IIS-La Fe Rare Diseases Joint Units, Centro de dermatomyositis (1 case), and undiagnosed (2 cases). One Investigación Príncipe Felipe (CIPF), Valencia, Spain girlpresentingwithmarkedelevatedCKanddevelopmental delay was diagnosed with balanced translocation with the Introduction:MutationsinMOR C2
leadtoanaxonalform breakpointlocatedwithintheDMDgeneandskewingofX- of Charcot-Marie-Tooth neuropathy (CMT2Z). To date, chromosome inactivation. Diagnoses in the asymptomatic thirty-one families have been reported, showing that this group were DMD/BMD carrier (3 cases), calpainopathy gene is frequently involved in CMT. However, the (1case), and undiagnosed (3cases). Both groups included phenotypic consequences of MOR C2
 in patients and its patients affected by muscular disease and DMD/BMD role in neuronal biology remain to be clarified. carriers, suggesting that both conditions should be con- Materials and Methods: A gene capture panel was sidered regardless of presence of symptoms. Building a performed to screen undiagnosed patients with CMT. To diagnostic system is necessary based on the clinical determine the effect of the most common MOR C2
 muta- background shown in this study. tions in a neural context, p. S87
L and p.R252W, we used a T. Lee: None. S. Tokunaga: None. C. Mure: None. M. virus-based system in vitro to overexpress MOR C2
 in Misaki: None. H. Shimomura: None. I. Nishino: None. sensoryneurons.ATPaseactivityofMOR C2
wasmeasured K. Ito: None. Y. Takeshima: None. bycolorimetricassay.Apatients-derivedfibroblastsandrat sensory neurons overexpressing clinical mutations were  P10
.16C investigatedbybothtranscriptomicsandproteomicsstudies Expanding the molecular characterization of the to gain an insight into the pathogenic mechanisms CMT2Z disease associated gene MOR C2
 of MOR C2
. Results:Here,we report the MOR C2
 mutations detected P. Sancho1, L. Bartesaghi2,3, O. Moissec2,3, F. García- in our clinical series, including a review of the reported García4,L.Ramírez-Jiménez5,A.Siddell6,7,E.Åkesson8,9, literature.Moreover,we show that the overexpression ofp. E. Hedlund2, P. Laššuthová10, S. Pascual-Pascual11,  S87
L mutantinsensory neurons inducedsignificant axonal T. Sevilla12,13, M. Kennerson6,7,14, V. Lupo1,5,15, phenotype.Inaddition,weobservedthatp. S87
Lmutanthas R. Chrast2,3, C. Espinós1,5,15 an impaired ATPase activity. The data analysis of tran- scriptomic and proteomic approach in sensory neurons and 1Unit of Genetics and Genomics of Neuromuscular and patients’ fibroblasts indicate complex changes affecting Neurodegenerative Disorders, Centro de Investigación transcripts involved in neuronal and axonal functions. Príncipe Felipe (CIPF), Valencia, Spain, 2Department of Conclusions: Our data expand the spectrum of clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, mutationsinMOR C2
andprovideanimportantinsightinto 3Department of Clinical Neuroscience, Karolinska the pathophysiological role of MOR C2
 in the nervous Institutet, Stockholm, Sweden, 4Unit of Bioinformatics and system. Funds: AFM-Téléthon, ISCIII (Grant PI15/00187) Biostatistics, Centro de Investigación Príncipe Felipe co-funded with FEDER funds, Prometeo Program from the (CIPF), Valencia, Spain, 5Department of Genomics and Generalitat Valenciana and Fundación Ramón Areces. Translational Genetics, Centro de Investigación Príncipe1480 P. Sancho: None. L. Bartesaghi: None. O. Moissec:  P10
.18A None. F. García-García: None. L. Ramírez-Jiménez: IdentificationofCAPN3genenovelvariationsinIranian None. A. Siddell: None. E. Åkesson: None. E. Hedlund: LGMD patients None.P.Laššuthová:None.S.Pascual-Pascual:None.T. Sevilla: None. M. Kennerson: None. V. Lupo: None. R. M. Fadaee1, Z. Fattahi1,2, R. Vazehan1, F. Ahangari1, Chrast: None. C. Espinós: None. A.Abolhassani1,Z.Kalhor1,S.Dehdahsi1,E.Parsimehr1, M. Faraji Zonooz1, M. Beheshtian1,2, A. Kariminejad1,  P10
.17D H. Najmabadi1,2 Molecular analysis of sarcoglycanopathies in Russian LGMD patients 1Kariminejad-Najmabadi Pathology and Genetics Center, Tehran, Iran, Islamic Republic of, 2Genetics Research M. V. Bulakh, O. P. Ryzhkova, A. V. Polyakov Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran, Islamic Republic of Federal State Budgetary Institution «Research Centre for Medical Genetics», Moscow, Russian Federation Introduction: Limb Girdle Muscular Dystrophy type2A (LGMD2A), caused by mutations in CAPN3 gene, is the Introduction: Sarcoglycanopathies (SGCs, LGMD2C-F) most common LGMD form worldwide (30-40% of all areasubgroupofautosomal-recessivelimb-girdlemuscular LGMD2 cases). LGMD2A is an autosomal recessive dystrophies (LGMD), caused by mutations in four sarco- disorderhighlightedbyweaknessofthepelvicandshoulder glycan genes (SGCG, SGCA, SGCB, SGCD). These forms girdle muscles. Recently, CAPN3 heterozygous mutations are characterized by childhood onset and rapidly progres- have been known to cause dominant LGMD type4 sive course with loss of ability to walk during a second (LGMDD4). decade of progression. In general, SGCs could hardly be Materials and Methods: We investigated a large cohort distinguished from Duchenne/Becker myopathy and other of 192 Iranian patients with different grades of muscular pseudohypertrophic LGMDs due to quite similar clinical dystrophy who referred to Kariminejad-Najmabadi Pathol- symptoms. ogy and Genetics Center during 2012-2018 by exome and Materials and Methods: Targeted massive parallel targeted next-generation sequencing. sequencing was performed in 290 Russian patients with Results: Twenty nine LGMD2A cases were identified, progressive muscle weakness using a custom gene panel carrying 22 different CAPN3 gene variants. Approximately covering four sarcoglycan genes. 15% of participants possessed variations in CAPN3 gene; Results: Genetic analysis revealed homozygous and including 10 missense, 5 frameshift, 1 inframe, 2 nonsense compound-heterozygous mutations in 16 patients in 3 of and 4 splice site changes; in which 9 variants were novel 4 sarcoglycan genes. The SGCA mutations have been compromises p.Gly127Glu, p.Ile266_Asp267del, p. detected in 13 cases (4,5%); the SGCB and SGCG muta- Ser265Pro, p.Gly221Cys, p.Ser432*, p.Tyr507Cys, p. tions have been found in 2 (0,7%) and 1 (0,3%) cases Gln545Serfs*50, c.1115+1dup and c.1353A>G at splice respectively. Mutation spectrum of SGCA gene was repre- donor site. Moreover, 4 variants occurred multiple times in sented by 12 different mutations, 4 of them are recurrent. the cohort (p.Ile266_Asp267del, p.Ser432*, p.Arg748Gln Previously we also identified 4 patients with SGCA muta- and c.1115+1dup). In 3 patients, the second causative tionsinaDuchenne/Beckermyopathycohort.Astheresult, variant has not been found which suggests diagnosing of twopathogenicSGCAvariantsc.229C>T(p.Arg77Cys)and LGMDD4. c.271G>A (p.Gly91Ser) were defined as the most common Conclusions:Basedonfindings,itseemsthatprevalence SGCA mutations in Russian patients accounting 29,4% and of LGMD2A is high in Iranian LGMD patients and some 26,5% of all mutant alleles respectively. mutations are more frequent. Besides, most of the variants Conclusions: This study revealed that LGMD2D is the have been occurred in Domain III and the catalytic domain mostcommonformofSGCs inRussianLGMD cohort.To (domain II) of the calpain3 protein involved in Ca2 sum up, SGCs account 5,5% of all LGMDs in total that +-induced activation of the protein. Defects in these makethemthethirdLGMDsubgroupfollowingLGMD2A domains lead to impair its autolytic activity. Therefore, and LGMD2I. However, in contrast to other European designing drugs to target this part of the Calpain3 protein populations, SGCs are very uncommon in Russia. might help to improve the quality of life in patients. M.V. Bulakh: None. O.P. Ryzhkova: None. A.V. M.Fadaee:None.Z.Fattahi:None.R.Vazehan:None. Polyakov: None. F. Ahangari: None. A. Abolhassani: None. Z. Kalhor: None.S.Dehdahsi:None.E.Parsimehr:None.M.FarajiAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1481 Zonooz: None. M. Beheshtian: None. A. Kariminejad: Foundation [2013-14290]); NIH K99/R00 Pathway to None. H. Najmabadi: None. IndependenceAward;CancerPreventionResearchInstitute of Texas Recruitment Award.  P10
.19B L.Nazaryan-Petersen:None.I.RodriguesdeOliveira: Multigenic involvement of the semaphorin-plexin None. M.M. Mehrjouy: None. J.M. Medina Mendez: pathway in Moebius syndrome by a germline None.M.Bak:None.M.Bugge:None.V.M.Kalscheuer: chromothriptic rearrangement None. I. Bache: None. D.C. Hancks: None. N. Tommerup: None. L. Nazaryan-Petersen1, I. Rodrigues de Oliveira1,2, M. M. Mehrjouy1, J. M. Medina Mendez1, M. Bak1,3,  P10
.20C M.Bugge1,V.M.Kalscheuer4,I.Bache1,3,D.C.Hancks5, Inactivation of KLH L24
 results in myopathy and N. Tommerup1 cardiomyopathy 1Department of Cellular and Molecular Medicine, Faculty C. Hedberg-Oldfors1, A. Abramsson1, D. Osborn2, ofHealthScience,UniversityofCopenhagen,Copenhagen, O. Danielsson3, A. Fazlinezhad4, Y. Nilipour5, Denmark, 2Faculty of Pharmacy, University of Lisbon, L. Hübbert6, I. Nennesmo7, K. Visuttijai1, J. Bharj2, Lisbon, Portugal, 3Department of Clinical Genetics, E. Petropoulou2, A. Shoreim2, B. Vona8, N. Ahangari9, Copenhagen University Hospital, Rigshospitalet, M. Dávila López1, M. Doosti10, R. Kumar Banote1, Copenhagen, Denmark, 4Group Development and Disease, R. Maroofian2, M. Edling1, M. Taherpour4, Max Planck Institute for Molecular Genetics, Berlin, H. Zetterberg1, E. Ghayoor Karimiani4, A. Oldfors1, Germany, 5Department of Immunology, The University of Y. Jamshidi2 Texas Southwestern Medical Center, Dallas, TX, United States 1University of Gothenburg, Gothenburg, Sweden, 2St George’s University of London, London, United Kingdom, Moebius syndrome (MBS) is a congenital disorder 3Linköping University, Linköping, Sweden, 4Imam Reza primarily caused by unilateral or bilateral paralysis of the International University, Mashhad, Iran, Islamic Republic facial and abducens nerves. Both genetic defects and of, 5Shahid Beheshti University of Medical Sciences, environmental toxic factors leading to abnormal brainstem Tehran, Iran, Islamic Republic of, 6Linkoping University, developmentareproposedtobeinvolvedintheaetiologyof Linköping, Sweden, 7Karolinska University Hospital, MBS. Recently, mutations in PLXND1 and REV3L were Stockholm, Sweden, 8Julius Maximilians University confirmed to cause MBS.Here,we appliednext generation Würzburg, Würzburg, Germany, 9Mashhad University of mate-pair sequencing to map the breakpoints of a complex Medical Sciences, Mashhad, Iran, Islamic Republic of, chromosomalrearrangement(CCR)46,XY,t(7;8;11;13)ina 10Next Generation Genetic Polyclinic, Mashhad, Iran, previously reported patient with MBS, and confirmed 39 Islamic Republic of out of 41 breakpoint-junctions by Sanger sequencing. Molecular mapping revealed 41 clustered breakpoints, Introduction: Hypertrophic cardiomyopathy (HCM) is the involving chromosomes 7, 8, 11 and 13, resulting in heavy most common inherited cardiovascular disorder, yet the intra- and interchromosomal rearrangements with typical genetic cause remains unknown in up to 50% of the hallmarks of chromothripsis. Among 12 truncated protein- individuals who lack sarcomere gene mutations. We report coding genes, SEMA3A and SEMA3D are attractive anovelgeneticcauseofacardiomyopathymimickingHCM candidates for the MBS features, as they encode class in two consanguineous families with a high incidence of 3 semaphorins, where SEMA3A is known to bind to the suddencardiacarrest.Theageatonsetinthepatientswasin MBS-associated PLXND1. Intriguingly, the CCR also adolescence or in young adulthood. truncated PIK3CG, which in silico interacts with a protein Material and Methods: Investigations included clinical encoded by the other known MBS-gene REV3L, and with examination, endomyocardial and skeletal muscle biopsy the SEMA3A/PLXND1 complex via the vascular endothe- and genetic analyses by exome sequencing and homo- lial growth factor FLT1. In conclusion, the simultaneous zygosity mapping. Functional studies were performed in truncation of several interactors of the known MBS-genes zebrafish by expression analysis and genetic down- by a single CCR suggests that the multiple breakpoints in regulation using antisense morpholino oligomers. germline chromothripsis may predispose to complex multi- Results: Endomyocardial biopsy and skeletal muscle genic disorders. Grants: Danish Council for Independent biopsy of individuals from both families demonstrated Research[4183-00482B];UniversityofCopenhagenExcel- characteristic alterations including muscle fibers with a lence Programme for Interdisciplinary Research; Lundbeck “cogwheel” appearance, and desmin accumulation.1482 Homozygositymappingandexome sequencingidentified a TP-PCR method (Radvansky et al.) in which amplification homozygous missense mutation in KLH L24
, c.917G>A, p. products are anchored at the 3’end of a CTG repeat Arg306His in one family and a nonsense mutation, expansionratherthanthe5’end.Theeffectofthisredesign c.1048G>T, p.Glu350* in the second family. KLH L24
 is that it may prevent the failure in detecting expansion- encodes a conserved protein, which is highly expressed in positive patients carrying repeat interruptions. striated muscle. Studies in zebrafish revealed expression of Results: TP-PCR reverse primer combinations showed the homolog gene klhl24a in the heart and downregulation expansion above 50 repeats at the 3'end of the CTG repeat by antisense morpholino oligomers resulted in cardiac sequence. dysfunction. Conclusions:Thankstothecombinationofboth:forward Conclusions: We have identified a novel form of cardi- andreverseTP-PCRprimersthereisasimpleandeffective omyopathy that mimics HCM with recessive inheritance method of identifying the presence or absence of expanded and onset in adolescence or young adulthood. Genetic, CTGrepeatallelesintheDMPKgene.Itseemsnecessaryto morphological and functional studies demonstrated that use forward and reverse TP-PCR primers, due to the pos- inactivation of KLH L24
 is associated with the disease. sibilityofoccurrenceofinterruptionsobservedatbothends Several individuals had died of sudden cardiac arrest indi- of the CTG repeat sequence. cating that lethal arrhythmias may be a common A. Bialek-Proscinska: None. J. Muszynski: None. M. complication. Jopek:None.M.Przyborska:None.K.Lacna:None.M. C. Hedberg-Oldfors: None. A. Abramsson: None. D. Piechota: None. M. Krawczynski: None. Osborn: None. O. Danielsson: None. A. Fazlinezhad: None. Y. Nilipour: None. L. Hübbert: None. I. Nen-  P10
.22A nesmo: None. K. Visuttijai: None. J. Bharj: None. E. Validation of a fast, robust, inexpensive, two-tiered Petropoulou: None. A. Shoreim: None. B. Vona: None. neonatal ncreening test algorithm on dried blood spots N. Ahangari: None. M. Dávila López: None. M. Doosti: for spinal muscular atrophy None.R.KumarBanote:None.R.Maroofian:None.M. Edling: None. M. Taherpour: None. H. Zetterberg: A. Strunk1, A. Abbes1, A. R. Stuitje2, C. Hettinga2, None. E. Ghayoor Karimiani: None. A. Oldfors: None. E. Sepers2, R. Snetselaar2, J. Schouten2, F. Asselman3, Y. Jamshidi: None. I. Cuppen3, H. Lemmink4, W. L. van der Pol3, H. Engel1  P10
.21D 1Department of Clinical Chemistry and Neonatal InterruptionsintheCTGrepeatsequenceintheDMPK Screening, Isala Hospital, Zwolle, Netherlands, 2MRC- gene in a 40-year-old patient with myotonic dystrophy Holland, Amsterdam, Netherlands, 3Department of type I Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands, A. Bialek-Proscinska1, J. Muszynski1, M. Jopek1, 4Department of Genetics, University Medical Center M. Przyborska1, K. Lacna1, M. Piechota1, Groningen, Groningen, Netherlands M. Krawczynski1,2 Spinal Muscular Atrophy (SMA) is one of the leading 1Centre for Medical Genetics GENESIS, Poznan, Poland, genetic causes of infant mortality with an incidence of 2Department of Medical Genetics, Poznan University of 1:10,000. Recently introduced antisense oligonucleotide Medical Sciences, Poland, Poznan, Poland treatment improves outcome, in particular when applied presymptomatically.Thegeneticcause ofSMA isin>95% Introduction: Myotonic dystrophy type 1 is an autosomal of cases a homozygous deletion of the survival motor dominant neuromuscular disorder that is caused by the neuron (SMN1)1 gene,which makes low costdetection of expansionofaCTGtripletsintheDMPKgene.Wewantto SMAcasesaspartofnewbornscreeningprogramsfeasible. present that using a standard TP-PCR method it is possible WedevelopedandvalidatedanewSALSAM C002
melting to skip expansion of CTG triplets due to interruptions curve assay that meets Dutch legal requirements of not present in the CTG repeat sequences. detectingasymptomaticcarriersandthatdetectstheabsence Materials and Methods: Patient- female (40 years old) of the SMN1 exon 7 DNA sequence using crude extracts symptomsofdystrophiaappearedattheageof30:problems from dried blood spot (DBS) newborn screening cards. withwalking,balancedisordersandweaknessinthelimbs. Melting curve analysis shows specific peaks of both the A test for dynamic mutation in the DMPK gene was per- SMN1 and the disease modifying SMN2 homolog, and in formed.StandardTP-PCRmethoddidn'tshowexpansionof case of insufficient amounts of sample DNA, a warning CTG repeat sequence. We used a bidirectionally labeled peak. We retrieved 47 DBS samples from children withAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1483 genetically confirmed SMA (identified by using the Dutch total, 6novel and 8known pathogenic variants in12genes SMAdatabase)afterconsentfromparentsand375controls were identified. Autosomal recessive axonal neuropathy fromthenationalarchiveoftheDutchNationalInstitutefor with neuromyotonia was the most prevalent type in our Public Health and the Environment (RIVM). The assay cohort (4 patients). Additionally, autosomal recessive correctly identified all anonymized SMA and control inheritance was confirmed in patients harbouring GDA P1
 samples (i.e. sensitivity and specificity of 100%), without and FIG4 variants. Our targeted gene panel allowed us to the detection of carriers, on 3 most commonly used PCR perform a very rapid and cost-effective screening of genes platforms with melting curve analysis. Concordance with associated with CMT. We expanded a spectrum of the second-tier ‘golden standard’  P021
 SMA MLPA test genotypes of CMT and clinical phenotypes of known was 100%. Using the new  P021
-B1 version, crude extracts CMT related genes. This diagnostic rate was achieved by fromDBScardscouldalsobeusedtodeterminetheSMN2 performing accurate neurologic examination prior to copy number of SMA patients with high accuracy. enrolment patients in the study and interpreting the A. Strunk: C. Other Research Support (supplies, equip- NGS data. ment, receipt of drugs or other in-kind support); Modest; B. Burnyte: None. K. Grigalioniene: None. A. Mor- MRC-Holland. A. Abbes: C. Other Research Support kuniene:None.L. Ambrozaityte: None.A.Utkus: None. (supplies, equipment, receipt of drugs or other in-kind support); Modest; MRC-Holland. A.R. Stuitje: A.  P10
.25D Employment(fullorpart-time); Significant;MRC-Holland. Identification and characterization of disease-causing C. Hettinga: A. Employment (full or part-time); Sig- genes in non-5q-SMA by next-generation sequencing nificant;MRC-Holland.E.Sepers:A.Employment(fullor technology: Lessons learned from NeurOmics study part-time); Significant; MRC-Holland. R. Snetselaar: A. Employment(fullorpart-time); Significant;MRC-Holland. M. Karakaya1, M. Storbeck1, E. Strathmann1, A. Delle J. Schouten: E. Ownership Interest (stock, stock options, Vedove1, I. Hoelker1, J. Altmueller2, S. Motameny2, patent or other intellectual property); Significant; MRC- S. Alawbathani2, H. Thiele2, I. Polat3, G. Wunderlich4, Holland. F. Asselman: None. I. Cuppen: None. H. Lem- D. Ardicli5, H. Topaloglu5, J. Kirschner6, B. Schrank7, mink:None.W.L.vanderPol:None.H.Engel:C.Other R. Maroofian8, O. Magnusson9, U. Yis3, P. Nuernberg2, Research Support (supplies, equipment, receipt of drugs or R. Heller1,10, B. Wirth1 other in-kind support); Modest; MRC-Holland. 1Institute of Human Genetics, Center for Molecular  P10
.23B Medicine Cologne, Institute of Genetics, and Center for ImprovingmoleculardiagnosisofCharcot-Marie-Tooth Rare Diseases Cologne, Cologne, Germany, 2Cologne disease by targeted next-generation sequencing in a Center for Genomics, Cologne, Germany, 3Dokuz Eylul cohort of Lithuanian patients University, Department of Pediatric Neurology, Izmir, Turkey, 4University Hospital Cologne, Department of B. Burnyte, K. Grigalioniene, A. Morkuniene, Neurology, Cologne, Germany, 5Hacettepe University, L. Ambrozaityte, A. Utkus Department of Pediatric Neurology, Ankara, Turkey, 6Department of Neuropediatrics and Muscle Disorders, Institute of Biomedical Sciences, Faculty of Medicine, Faculty of Medicine, Medical Center, University of Vilnius University, Vilnius, Lithuania Freiburg, Freiburg, Germany, 7DKD Helios Kliniken, Department of Neurology, Wiesbaden, Germany, 8Genetics Charcot-Marie-Tooth disease (CMT) is the most common andMolecularCellSciencesResearchCentre,St.George's hereditary neuropathy with over 100 causative genes UniversityofLondon,London,United Kingdom,9deCODE identified to date. Next generation sequencing (NGS) Genetics/Amgen, Inc., Reykjavik, Iceland, 10GHSNZ approaches represent a powerful tool to identify genetic Northern Hub, ADHB, Auckland City Hospital, Auckland, variantsinCMTincontrasttoclassictimeconsuminggene New Zealand bygeneapproach.However,approximately50%ofpatients remainundiagnosedafteruseofNGStools.Theaimofthis Introduction: Spinal muscular atrophy (SMA) without study was to identify the molecular diagnosis in a group of deletions/mutations in SMN1(non-5q-SMA) is genetically patients with CMT using targeted NGS. 38 patients very heterogeneous. Due to strongly overlapping pheno- presenting with hereditary neuropathies were tested by types of neuromuscular disorders, the differential diagnosis targeted NGS for 150 nuclear genes associated with CMT of non-5q-SMAs is challenging. and related neuropathies. In 15 of the 38 patients, we Materials and Methods: For the last 23 years, we have identified the definite molecular diagnosis (39.47%). In performedSMN1deletionanalysisto3,535individualswith1484 suspected SMA. In 1,715 (48.5%) of these individuals, no includes agenesis of corpus callosum, severe congenital SMN1 deletion/mutation was detected. Review of the clin- truncal hypotonia, severe scoliosis, short stature, delay in ical data with respect to a possible motor neuron disorder bone age, ataxic gait / jerky walking, triangular face with led to 114 patients who were available and consented to narrow maxilla affecting speech, congenital clasped thumb participate. These 114 patients were analysed by two dif- and congenital clubfoot (female patient), lateral deviation ferent gene panels. Of these, 24 unresolved patients and 49 deformityof foot bilaterallyand upper and lower extremity new patients were analysed by WES or/and WGS. spasticity. Phenotype-driven WES analysis did not identify Results: Gene panel provided a diagnosis in 39% (44/ any known pathogenic or novel predicted damaging 114)oftheprobands.Theneuromusculardiseasepanelwith variants in known genes. Genotype-driven WES analysis 479 genes outperformed the lower motor neuron disease for known pathogenic mutations and novel variants panel with 62 genes with a 44% to 13% diagnostic yield, predicted as damaging in MIM genes, identified two novel respectively. WES/WGS revealed the disease-causing PIEZO2 exon 27 splice site mutations (c.4093-1G>C and mutation in 38% (28/73) of these patients. Within the c.4189+1G>A, both predicted damaging). Recessive NeurOmics project, we published five novel disease- PIEZO2 pathogenic mutations cause Distal Arthrogryposis causing genes (BICD2, CH P1
, PIEZO2, VAM P1
, with Impaired Proprioception & Touch (DAIPT) with ADPRH L2
) and introduced three novel genes (PRUN E1
, clinical presentation that overlaps that of the patients under MCM3AP, AGTPB P1
) with recently published overlapping investigation. Mutation-to-disease co-segregation in the phenotypes. nuclear family by Sanger sequencing, showed the variants Discussion:NGSisapowerfulmethodfordiagnosticand in “trans” configuration as both parents were carriers of a gene identification purposes in non-5q-SMA, and illustrate different mutation and the affected siblings compound the wide spectrum of neuromuscular disorders that initially heterozygotes. Phenotype-driven WES analysis failed to present as motor neuron disease. Gene panels with larger identify the offending gene most likely due to clinical generepresentationperformbestinclinical conditionswith heterogeneity. Agenesis of corpus callosum has not been heterogenic genetic background. For phenotypes that are associated with DAIPT. Impaired proprioception was not not fulfilling the core clinical criteria for motor neuron properly diagnosed, and arthrogryposis was erroneously disorders, a more comprehensive WES or WGS methods referred as “spasticity”. Genotype-driven WES analysis is should be used. an invaluable tool that should be utilized rather than M. Karakaya: None. M. Storbeck: None. E. Strath- phenotype-driving analysis to accommodate for clinical mann:None.A.DelleVedove:None.I.Hoelker:None.J. heterogeneity and variability in clinical presentation. Altmueller: None. S. Motameny: None. S. Alawbathani: E. Darmani: A. Employment (full or part-time); Sig- None. H. Thiele: None. I. Polat: None. G. Wunderlich: nificant; ANALYSI IATRIKI SA. K. Kydonopoulou: A. None. D. Ardicli: None. H. Topaloglu: None. J. Kirsch- Employment (full or part-time); Significant; ANALYSI ner: None. B. Schrank: None. R. Maroofian: None. O. IATRIKI SA. E. Papadopoulou: A. Employment (full or Magnusson:None.U.Yis:None.P.Nuernberg:None.R. part-time);Significant;ANALYSIIATRIKISA.S.Gerou: Heller: None. B. Wirth: None. A. Employment (full or part-time); Significant; ANALYSI IATRIKI SA. M. Kambouris: None.  P10
.26A Genotype-driven WES analysis identifies novel  P10
.27B compound heterozygous splice-site mutations Distinguishing Highly Similar SMN1/2 Genes and inPIEZO2causing a unique variant of distal Identifying Novel SMN Transcripts by Targeted arthrogryposis with impaired proprioception & touch Capture of PacBio Single-molecule Long-read Sequencing E. Darmani1, K. Kydonopoulou1, E. Papadopoulou1, S. Gerou1, M. Kambouris2 M. Dai, Y. Xu, X. Ji 1Analysi Iatriki S.A, Thessaloniki, Greece, 2Division of Department of Genetic Counseling, Xinhua Hospital, Genetics, Department of Pathology & Laboratory School of Medicine, Shanghai Jiao Tong University, Medicine, Sidra Medicine, Doha, Qatar shanghai, China Afamilywithtwosiblings(20-yearoldmale&18-yearold Introduction:Spinalmuscularatrophy(SMA)isautosomal female)affected byanundiagnosed Neuromusculardisease recessively inherited disease with a high carrier frequency was analyzed by WES of a single affected individual to caused by biallelic mutations in SMN1 gene. As high identifytheoffendinggenedefect.Theclinicalpresentation homology between SMN1 and SMN2, it would be difficultAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1485 to distinguish the mutations in SMN1 from SMN2. PacBio group of patients with a clinical suspect of FSHD, by single molecule real time (SMRT) sequencing techniques molecular analysis of SMCHD1 sequence. can aids the identification of transcript variants due to the Materials and Methods: 58 patients with a clinical longer read lengths suspectofFSHDwereenrolledandwereanalyzedbyNGS Materials and Methods: Twenty-one study subjects methodology and direct sequencing. The detected variants were selected from the diagnostic laboratory. Multiplex wereinvestigatedbybioinformaticstoolsinordertopredict PCR with four pairs of specific-primers to enrich SMN their impact on the protein and evaluate the potential transcripts. Enriched products sequenced by long-read pathogenic effect on FSHD. sequencing approach using SMRT. An 20bp anchor Results: Molecular analysis of SMCHD1 sequence sequences were used to distinguish SMN1 and SMN2. revealed the presence of exonic, intronic and 3’UTR var- Marked with SMN1/SMN2 reads utilized GATK for varia- iants. Among them, five novel variants (c.183_184insGT; tion calling. c.1131+2delTAAG; c.2130insC; c.3469G>T; Results:Forthemajorityofsubjectsinthisstudy,SMN1 c.5150_5151delAA) were predicted to be pathogenic for transcripts full-length SMN mRNA (FL-SMN) and SMN2 FSHD, causing a substantial alteration of protein structure transcripts lacking exon 7 mRNA (SMNΔ7) as reported. and function. In addition, four variants (c.7394A>C; Nine in ten subjects with subtle mutation are detected by c.7597G>A; c.*1397A>G; c.*1889G>C) in 3’UTR were long-readsequencing.DetectedmutationofM0areexisting predicted to affect the binding of different miRNAs. in SMNΔ7, all the other detected mutation are existing in Conclusions:MolecularanalysisofSMCHD1allowedto FL-SMN. There are ten novel transcripts detected. Six of detectnovelpotentialpathogenicvariantsinpatientswitha ten are successfully amplified by PCR. clinical suspect of FSHD. In particular, those variants may Conclusions: We have developed a novel method to modify the structure and function of SMCHD1 protein, distinguish highly similar SMN1 and SMN2 genes and leadingtherebytothedisruptionofitsphysiologicalactivity identify affected mutationsinSMN1orSMN2bylong-read and, ultimately, contributing to FSHD etiopathogenesis. SMRT sequencing. Meanwhile, the method can compre- Moreover,the3’UTRvariantsunveiledapossibleimpactof hensively illustrate SMN transcripts existed. miRNA-dependent regulation on FSHD-related pathways. M. Dai: None. Y. Xu: None. X. Ji: None. V.Caputo:None.R.Galota:None.G.Campoli:None. S. Chimienti: None. S. Zampatti: None. L. Colantoni:  P10
.28C None.C.Strafella:None.G.Minozzi:None.R.Cascella: Facioscapulohumeral Muscular Dystrophy (FSHD): None. E. Ricci: None. L. Politano: None. E. insights into the genetic characterization of SMCHD1 Giardina: None. V. Caputo1, R. Galota2, G. Campoli2, S. Chimienti2,  P10
.29D S. Zampatti2, L. Colantoni2, C. Strafella1, G. Minozzi3, Screening multiple populations reveals large differences R. Cascella2,4, E. Ricci5, L. Politano6, E. Giardina1,2 intheprevalenceofatruncatedSMNgenelackingexon 7 and 8 1Department of Biomedicine and Prevention, “Tor Vergata” University, Rome, Italy, 2Molecular Genetics R. Vijzelaar, R. Snetselaar, M. Clausen, A. Mason, Laboratory UILDM, Santa Lucia Foundation, Rome, Italy, M. Rinsma, M. Zegers, N. Molleman, R. Boschloo, 3Department of Veterinary Medicine, University of Milan, R. Yilmaz, R. Kuilboer, S. Sulchan, J. Schouten Milan, Italy,4DepartmentofBiomedicalSciences,Catholic University Our Lady of Good Counsel, Tirana, Albania, MRC-Holland, Amsterdam, Netherlands 5Institute of Neurology, Catholic University of the Sacred Heart,Rome,Italy,6DepartmentofExperimentalMedicine, Introduction:Spinalmuscularatrophy(SMA)isoneofthe Cardiomyology and Medical Genetics, University of most frequent genetic disorders in Caucasians, with an Campania Luigi Vanvitelli, Naples, Italy incidence of approximately 1:10.000 in newborns. SMA is an autosomal recessive disorder with a population depen- Introduction: SMCHD1 (18p11.32) is a gene coding for a dent carrier frequency ranging from 1:35 in Caucasians to chromatinremodellerinvolvedintheepigeneticsilencingof 1:91 in African Americans. In the majority of populations, different targets, including genes located in D4Z4 locus most individuals have two copies of both SMN1 and the (4q35).SMCHD1lossoffunctionmutationscanhamperits almost identical SMN2 gene. Previous studies have function, leading to the aberrant expression of D4Z4 genes identified the presence of SMN1 or SMN2 gene copies associated with FSHD. This study aimed to characterize a lackingthelasttwoexons,exons7and8,in8%and23%of healthy Swedish and Spanish individuals respectively. No1486 information on the presence of these truncated gene copies SPAST, encoding Spastin, are the most frequent cause of in other populations has been reported. HSP.Recently,throughtheanalysisof842SPASTmutated Methods: A new version of the SALSA MLPA  P021
 patients,weshowedthatmutationnatureaccountsforsome SMA probemix was tested on 1255 samples from the 1000 of the age at onset variability and that sex influences the genomes / HapMap projects from 15 different populations. disorder penetrance. To identify additional age at onset TheprobemixcoversallSMN1andSMN2exonsbyatleast modifiers, a GWAS analysiswas performed on 134 SPAST one probe and contains four SMN1 or SMN2 specific truncating mutations carriers. probes. Materials and Methods: Patients were genotyped using Results:Largedifferencesinthefrequencyofatruncated Illumina InfiniumOmni2.5Exome-8 kit. Single variant test SMN gene were observed between all the different popu- wasperformedusingalogisticmixedmodelforbinarytraits lations tested, ranging from 0 to 20%. Frequencies in the available with GMMAT R package, adjusted for sex and different populations were as follows: 8-20% in European patients’ relatedness. Patients with very discordant age at populations, 7-11% in American populations, and 0-1% in onset were compared (≤15 years versus ≥45 years). both the Asian and African populations. Results: A group of SNPs in linkage disequilibrium Conclusion:Theimproved P021
MLPAProbemixmakes (r2>0.8)reachedap-valuesuggestiveforassociation(topp- the identification of truncated SMN genes straightforward. value = 10e-6). The 7 suggestive SNPs are located on ThesetruncatedSMNgenesarefoundfrequentlyinseveral chromosome 19, in the 3’UTR region of SAR S2
 gene and populations while they are relatively non-existent in other are described as eQTLs of this gene in the GTEx database. populations with their clinical significance still unknown. Among the genotyped patients, a significantly lower age at R. Vijzelaar: A. Employment (full or part-time); Sig- onset (p<0.0001, Mann-Whitney test) was associated with nificant; MRC-Holland. R. Snetselaar: A. Employment the minor allele at all SNPs, as well as a tendency to a (fullorpart-time);Significant;MRC-Holland.M.Clausen: decreased disorder severity. A. Employment (full or part-time); Significant; MRC- Conclusions: Pathogenic mutations affecting SAR S2
, Holland. A. Mason: A. Employment (full or part-time); encoding a mitochondrial seryl-tRNA synthetase, have Significant; MRC-Holland. M. Rinsma: A. Employment alreadybeenlinkedtoprogressivespasticparaparesisonset, (full or part-time); Significant; MRC-Holland. M. Zegers: suggesting it as a good candidate. iPSCs-derived neurons A. Employment (full or part-time); Significant; MRC- and Drosophila model are being used to further confirm its Holland.N.Molleman:A.Employment(fullorpart-time); role as SPAST-HSP age of onset modifier. Significant; MRC-Holland. R. Boschloo: A. Employment L.Parodi:None.F.Lejeune:None.M.Barbier:None. (full or part-time); Significant; MRC-Holland. R. Yilmaz: A. Brice: None. G. Stevanin: None. A. Durr: None. A. Employment (full or part-time); Significant; MRC- Holland. R. Kuilboer: A. Employment (full or part-time);  P10
.31B Significant; MRC-Holland. S. Sulchan: A. Employment Development of motor function in late vs early (fullorpart-time);Significant;MRC-Holland.J.Schouten: treatment with nusinersen for SMA type 1 and 2 E. Ownership Interest (stock, stock options, patent or other patients intellectual property); Significant; MRC-Holland. I.Henriksson1,L.Alberg2,A.Kroksmark2,L.Wahlgren2,  P10
.30A M. Tulinius2 SAR S2
 modifies spastic paraplegia type 4 age at onset 1Department of Clinical Pathology and Genetics, L. Parodi1, F. Lejeune1, M. Barbier1, A. Brice1, Sahlgrenska University Hospital, Gothenburg, Sweden, G. Stevanin1,2, A. Durr1 2Department of Pediatrics, Gothenburg University, Queen Silvia Children’s Hospital, Gothenburg, Sweden 1Institut du Cerveau et de la Moelle épinière (ICM), INSERM, CNRS, Assistance Publique-Hôpitaux de Paris Introduction: Spinal muscular atrophy (SMA) is an (AP-HP), Sorbonne Université, Pitié-Salpêtrère University autosomal recessive neuromuscular disorder caused by Hospital,Paris,France,2EcolePratiquedesHautesEtudes mutations in the SMN1-gene (5q 12.2-13.3) generating (EPHE), Paris Sciences et Lettres (PSL) Research atrophy of anterior horn cells in the spinal cord and University, Neurogenetics Group, Paris, France brainstem leading to muscle weakness. The antisense oligonucleotide nusinersen was recently approved in Introduction: Hereditary Spastic Paraplegias (HSPs) are Sweden for treatment of SMA in the public health care rare neurological disorders caused by the progressive distal system.Inthisstudywecomparethedevelopmentinmotor degeneration of the corticospinal tracts. Mutations in function in patients who received treatment within threeAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1487 months of symptom onset for SMA type 1, and within additional factors such as DNA methylation is also twelve months for SMA type 2, to the patients receiving examined. Previous studies have demonstrated correlation treatment later in the course of disease. between methylation profiles of several genes and SMA Materials and Methods: All patients diagnosed with severity. Current study is devoted to investigation of SMAtype1or2treatedwithnusinersenforatleasttwelve methylation level of genes in SMA patients’ derived cells months at the Department of Pediatrics, Queen Silvia onsequentialstagesofdifferentiationofinducedpluripotent Children's Hospital, Gothenburg, Sweden are included in stem cells (iPS) into motor neurons. The level of the study. The motor function is assessed by standardized methylation of SMN2 gene as well as genes playing role motorfunctionscales;CHOP-INTEND/HFMSE,developed in neural cells (OLIG2, IS L1
, SL C23
A2, DYN C1
H1) and and validated for SMA patients. pluripotency-regulating genes (Oct4, SAL L4
) has been Results: Data regarding age of onset, age at start of determined by means of methylation-sensitive high-resolu- treatment, genetic constitution and development of motor tionmelting.Significantdifferenceshavebeenfoundinthe function will be presented. methylationleveloftheregulatoryregionsofOCT4,SAL L4
 Conclusion: Previous studies have indicated that treat- and SMN genes between patients with SMA type I, type II ment efficacy for motor function is greater in patients andahealthyindividual.Adecreaseinmethylationlevelof receiving treatment close to onset of symptoms or even in the promoter region of OLIG2 gene in SMA type I presymptomatic patientscomparedtopatients receivingthe compared to SMA type II, as well as of 41 exons of the treatment later in the course of disease. This highlights the DYN C1
H1 gene in SMA type I compared to a healthy importance of early diagnosis and raises the question of individual was also found. The results observed in this inclusion of SMA in newborn screening programmes. study may elucidate new pathways involved in SMA I.Henriksson:None.L.Alberg:None.A.Kroksmark: progression and may contribute to better understanding of None. L. Wahlgren: None. M. Tulinius: None. the particularities of disease pathogenesis. This work is supported by Russian Foundation for Basic Research grant  P10
.32C 18-315-00258 mol_a. Methylation level of genes on various stages of M.A. Maretina: B. Research Grant (principal investi- differentiation of induced pluripotent stem cells, gator,collaboratororconsultantandpendinggrantsaswell generated from patients with spinal muscular atrophy, asgrantsalreadyreceived);Modest;RussianFoundationfor into motoneurons Basic Research. N.A. Tsyganova: B. Research Grant (principal investigator, collaborator or consultant and M. A. Maretina1, N. A. Tsyganova2, S. V. Shtykalova2, pendinggrantsaswell asgrantsalreadyreceived); Modest; A.A.Egorova1,K.R.Valetdinova3,4,5,6,S.M.Zakian3,4,5,6, Russian Foundation for Basic Research. S.V. Shtykalova: V. S. Baranov1,2, A. V. Kiselev1 B. Research Grant (principal investigator, collaborator or consultant and pending grants as well as grants already 1The Research Institute of Obstetrics, Gynecology and received);Modest;RussianFoundation for Basic Research. Reproductology named after D.O. Ott, Saint-Petersburg, A.A. Egorova: None. K.R. Valetdinova: None. S.M. Russian Federation, 2Saint-Petersburg State University, Zakian: None. V.S. Baranov: None. A.V. Kiselev: None. Saint-Petersburg, Russian Federation, 3Federal Research Center Institute of Cytology and Genetics, the Siberian  P10
.33D Branch of the Russian Academy of Sciences, Novosibirsk, Mutation Spectrum of the Survival of Motor Neuron 1 Russian Federation, 4Institute of Chemical Biology and in Iranian Population FundamentalMedicine,theSiberianBranchoftheRussian Academy of Sciences, Novosibirsk, Russian Federation, M. Taheri, A. Sayad 5StateResearchInstituteofCirculationPathology,Ministry of Healthcare of the Russian Federation, Novosibirsk, Shahid Beheshti University of Medical Sciences, Tehran, Russian Federation, 6National Research University Iran, Islamic Republic of Novosibirsk State University, Novosibirsk, Russian Federation Spinal muscular atrophy (SMA) is a lethal disorder characterized by loss of motor neurons, muscle weakness, Spinal muscular atrophy (SMA) is a severe neuromuscular hypotonia and muscle atrophy. SMA is highly heteroge- disorder caused by mutations in the SMN1 gene. SMA is neous with various genes with different heritable patterns subdivided into four clinical groups based on age of onset causing the disease. In the typical form, patients have andachievedmotormilestones.SMN2genecopynumberis defective SMN1 genes. To date, tens of genes have been a key modifier of the disease, though involvement of identified for Atypical SMA. In this study, 144 families1488 suspected for SMA were included. Patients were first numbers and evaluated the clinical performance by ana- examined for typical SMA by MLPA and assessment of lyzing 89 patient samples. STR markers for SMN1. Next, patients who did not have Results: Both methods showed 100% sensitivity and mutations in the SMN1 gene were examined using STR specificity to detect SMN1 copy numbers0-2or higher and markers for the DNAJB2, IGHMB P2
, SIGMAR1 and SMN2 copy numbers 0-3 or higher. In clinical samples, the PLEKHG5 genes. Subsequently, autozygosity mapping obtained SMN1 and SMN2 copy numbers showed 100% followed by sequencing were performed for cases with concordance between the methods. Additionally, we homozygoushaplotypes.Finally,WholeExomesequencing applied the bioinformatic analysis to 2196 de-identified (WES)wasdonefortheremainingcaseswhodidnotshow patient samples not referred for the indication of SMA. associationwithanyofthestudiedgenes.Thepathogenicity HeterozygousSMN1deletionswereobservedin2.6%ofthe of the newly identified mutations was examined using samples,whichagreeswithpreviouslyreportedfrequencies. various softwares and ACMG guideline.SMN1 deletions/ Conclusions: We established an accurate and high- mutationswereidentifiedin134families.Oftheremaining throughput approach to test for SMN1 and SMN2 copy 10 families, three families showed mutations in DNAJB2, numbers enabling diagnostics of SMA and application of SIGMAR1 and PLEKHG5 genes. In six families tested by novel therapeutic strategies. WES, four families had pathogenic variants in TNNT1, H. Junnila: A. Employment (full or part-time); Sig- TPM3 and TTN genes respectively. MLPA and assessment nificant; Blueprint Genetics. M. Valori: A. Employment of STR markers can be helpful in both typical and atypical (full or part-time); Significant; Blueprint Genetics. A. SMA cases. Moreover, linkage analysis and WES are Korppoo: A. Employment (full or part-time); Significant; suggested as effective strategies for identification of Blueprint Genetics. L. Koskinen: A. Employment (full or mutations in patients with atypical SMA. part-time);Significant;BlueprintGenetics.E.Salminen:A. M. Taheri: None. A. Sayad: None. Employment (full or part-time); Significant; Blueprint Genetics. K. Gall: A. Employment (full or part-time);  P10
.34A Significant; Blueprint Genetics. T. Alastalo: A. Employ- Accurately resolving copy number variation in highly ment (full or part-time); Significant; Blueprint Genetics. E. homologous SMN1 and SMN2 genes using next- Ownership Interest (stock, stock options, patent or other generation sequencing and rhPCR intellectual property); Significant; Blueprint Genetics. S. Myllykangas: A. Employment (full or part-time); Sig- H. Junnila, M. Valori, A. Korppoo, L. Koskinen, nificant; Blueprint Genetics. E. Ownership Interest (stock, E. Salminen, K. Gall, T. Alastalo, S. Myllykangas, stock options, patent or other intellectual property); Sig- J. Koskenvuo, P. Salmenperä, J. Sistonen nificant; Blueprint Genetics. J. Koskenvuo: A. Employ- ment (full or part-time); Significant; Blueprint Genetics. E. Blueprint Genetics, Helsinki, Finland Ownership Interest (stock, stock options, patent or other intellectual property); Significant; Blueprint Genetics. P. Introduction: Spinal muscular atrophy (SMA) is a Salmenperä: A. Employment (full or part-time); Sig- neuromusculardisordercharacterizedbyprogressivedegen- nificant; Blueprint Genetics. E. Ownership Interest (stock, eration of spinal cord motor neurons. In most cases, the stock options, patent or other intellectual property); Sig- diseaseiscaused bythe homozygousabsence ofthe SMN1 nificant; Blueprint Genetics. J. Sistonen: A. Employment gene. Copy number of the highly homologous SMN2 gene (full or part-time); Significant; Blueprint Genetics. canalsomodifythediseaseseverity.Toaddresstheclinical importance of accurate SMN1 and SMN2 copy number  P10
.35B analysis, we developed a custom bioinformatic analysis Accuratesingle-tube quantificationofSMN1 andSMN2 basedonnext-generationsequencing(NGS)datacombined copy numbers using a rapid and streamlined PCR/CE with a novel RNase H2-dependent PCR (rhPCR) for assay evaluated at two different laboratories confirmation analysis. Materials and Methods: The bioinformatic method uti- M. E. Oliveira1, S. Filipovic-Sadic2, S. Gokul2, lizes sequence reads at four loci differing between the J. Janovsky2, J. Milligan2, G. J. Latham2, R. Santos1 genes. The rhPCR assays target two of the loci with RNA- modified primers that require activation by RNase H2 1Molecular Genetics Unit, Centro Genética Médica Dr. enzyme improving assay specificity and sensitivity com- Jacinto Magalhães, Centro Hospitalar Porto, Porto, paredtostandardmethods.Wevalidatedthemethodsusing Portugal, 2Asuragen, Inc., Austin, TX, United States 27 reference samples with known SMN1/SMN2 copyAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1489 Introduction: Spinal Muscular Atrophy (SMA) is an 3Institute for Biomedical Technologies, National Research autosomal recessive neuromuscular disease and a leading Council (CNR-ITB), Segrate (MI), Italy, 4Institute for geneticcauseofinfantmortality.SMAiscommonlycaused Biomedical Technologies, National Research Council by homozygous exon 7 deletions in the survival motor (CNR-ITB),, Segrate (MI), Italy, 5ALS Center AOU neuron 1 gene (SMN1). The severity of SMA is modulated MaggioredellaCarità,NOvara,Italy,6UPO,Vercelli,Italy bythecopynumberoftheparalogousSMN2gene.Here,we report the two-site evaluation of a single-tube assay that The  C9
ORF72 gene repeat expansion is the most frequent quantifies SMN1 and SMN2 copy number. cause of ALS. Long repeats alleles in ATXN-1, ATXN-2, Materials and Methods: A prototype SMN1/2 single- and NIPA1 genes are associated to ALS susceptibility. tube PCR was developed from AmplideX® PCR/CE SMN1 Tandem Repeat Polymorphisms (TRPs) are good candi- reagents (Asuragen). Amplicons generated from whole dates for missing hereditability in ALS (40%), although blood genomic DNA were resolved by capillary electro- theywereneversystematicallyanalyzedastheyrepresenta phoresis (CE) on a 3130 Genetic Analyzer (Thermo Fisher remarkable challenge to NGS. The aim of this study is to Scientific). Gene copy numbers were calculated from peak perform a systematic analysis of TRPs in ALS by area ratios that were normalized to a plate calibrator and combining NGS and novel bioinformatics tools. We binned as 0, 1, 2, 3, or ≥4 copies. Two laboratories (one in performed our analysis from whole genome sequencing Portugal and one in the US) evaluated 60 residual clinical data (WGS) of 70 ALS cases. TRPs were evaluated by samples with reference genotypes. means of a software developed within our consortium to Results: Normalized SMN1 and SMN2 copy numbers detect tandem repeat expansion. Validation of expanded demonstrated operator-to-operator and site-to-site agree- lociwasconductedbyRepeatprimerPCRWeidentifiedan ment (R2>0.98). Binned copy-number calls for SMN1 ALS patient with a CGG expansion in 5’UTR of spanned0to≥4copiesandwereconcordantwithreference FRA10A C1
 gene. To explore the possible role of this results for both laboratories. SMN2 copy numbers ranged CGG expansion in ALS we screened a cohort of 337 ALS from0to≥4copiesandwereconcordantfor59/60(98.3%) and 285 controls and we found 3 expanded patients (0.9%) samples. and no control. We failed to replicated this result in a Conclusions: A simple, high-throughput SMN1/2 PCR/ secondcohortof426ALSpatientsand733controls(1ALS CE assay was successfully evaluated using 60 samples, (0.2%) and 5 controls (0.7%)) Overall, we observed the including 15 SMA and 13 carrier samples. This method CGG expansion in 4/763 (0.5%) ALS patients and 5/1018 offers a simple workflow and fast turnaround time (< 4hrs controls (0.5%). FRA10A C1
 gene expression was not from sample-to-answer) with potential as an accurate and silenced by the expansion. The software we developed can reliable alternative to existing methods. detect repeat expansions from WGS data, although M.E. Oliveira: None. S. Filipovic-Sadic: A. Employ- FRA10A C1
 CGG expansion seems not to be involved in ment (full or part-time); Significant; Asuragen, Inc. S. ALSpathogenesis.Converselytowhatpreviouslyreported, Gokul: A. Employment (full or part-time); Significant; large CGG expansion at this locus do not decrease gene Asuragen, Inc. J. Janovsky: A. Employment (full or part- expression time); Significant; Asuragen, Inc. J. Milligan: A. L. Corrado: None. L. Genovese: None. E. Mangano: Employment (full or part-time); Significant; Asuragen, Inc. None. R. Croce: None. A. Di Pierro: None. F. Geraci: G.J. Latham: A. Employment (full or part-time); Sig- None. R. Bordoni: None. R. D'Aurizio: None. N. Bar- nificant; Asuragen, Inc.. R. Santos: None. izzone:None.F.DeMarchi:None.L.Mazzini:None.G. DeBellis:None.G.Manzini:None.M.Severgnini:None.  P10
.36C M. Pellegrini: None. S. D'Alfonso: None. Analysis of DNA tandem repeats in ALS from Whole Genome Sequencing: Role of FRA10Ac1 gene repeat  P10
.37D expansion in ALS Clinicaldiagnosisofspinocerebellarataxias(SCAs)and hereditary spastic paraplegia (HSPs) in Portugal using L.Corrado1,L.Genovese2,E.Mangano3,R.Croce1,A.Di exome sequencing Pierro1, F. Geraci2, R. Bordoni4, R. D'Aurizio2, N. Barizzone1, F. De Marchi5, L. Mazzini5, G. De Bellis3, S. Sousa1,2, P. Silva1,2, A. Brandão1,2, A. Lopes1,2, G. Manzini2,6, M. Severgnini3, M. Pellegrini2, P. Arinto1,2, R. Bastos1,2, S. Morais1,2, S. Barbosa1,2, S. D'Alfonso1 J. Sequeiros1,2,3, I. Alonso1,2 1University of Eastern Piedmont UPO, NOvara, Italy, 1CGPP-IBMC, Universidade do Porto, Porto, Portugal, 2InstituteofInformaticsandTelematicsofCNR,Pisa,Italy, 2i3S - Instituto de Investigação e Inovação em Saúde,1490 UniversidadedoPorto,Porto,Portugal,3ICBAS-Instituto Switzerland, 3Institut de Génétique et de Biologie de Ciências Biomédicas Abel Salazar, Universidade do Moléculaire et Cellulaire, Illkirch, France Porto, Porto, Portugal Rearrangements of the proximal 16p11.2 B P4
-B P5
 region SCAs andHSPs arerare genetic neurological diseases with are associated with mirroring anthropometric traits and a prevalence of 12.9/100,000 in Portugal. Clinical symp- neurodevelopmental disorders. To assess the molecular tomsoftendistinguishSCAsfromHSPs;however,complex impact of 16p11.2 dosage and investigate possible sex formscombinetheseandotherneurologicalsymptoms,ina interaction(s), we profiled the transcriptomes of brain wide phenotypic diversity (age-at-onset, severity and cortices of wild-type, 16p11.2 deletion and 16p11.2 progression rate). In this study, we provide an estimate of duplicationmaleand female mouse models across embryo- the diagnostic yield of SCAs and HSPs at our laboratory. nic ( E11
.5), newborn ( P0
) and adult ( P77
) stages. Whereas Weperformedwhole-exomesequencing(WES)andapplied we corroborate previous results by identifying expression virtual gene panels on 333 patients with SCAs and HSPs, changes of transcripts associated with primary cilium and andanalysedSNVs,usinganinhousepipeline,andCNVs, metabolism, we also uncovered significant perturbation of usingGoldenHelix’sVarSeqsoftware.Wetested161SCA immune-related genes that encode proteins influencing patients using a WES-based virtual panel (145 genes), neuronal development and synaptic function (P=6.44E- 16p11.2Del/+ where we achieved a molecular diagnosis for 17 patients 05) in mice. This signal is already present in (18 previously described and 13 novel disease-causing embryos and newborns, and becomes especially exacer- variants); in another 72 patients, we reported a VUS, bated in adult females with 6203 differentially expressed according to the ACMG classification. In 172 patients with genes compared to 146 in males, suggesting that hormonal HSP (118 genes in the virtual panel), we established a changes could be involved. This massive transcriptome molecular diagnosis in 27 cases (35 described and 8 novel modification could be a compensation mechanism of 16p11.2Del/+ disease-causingvariants),whilein50probandswereported females,consistentwiththemilderphenotypes a VUS. We obtained a diagnostic yield of 10.6% for SCAs of human female deletion carriers. Unfortunately, the vast and 15.7% for HSPs; VUS reported represented 44.7% of majorityof16p11.2animalmodelshavenotbeenstudiedin SCA and 29.1% of HSP cases. In undiagnosed patients, a sex-specific manner. We also assessed the transcriptome of16p11.2Dup/+ familystudies,correlationwithphenotype,CNVanalysisin mice,andinagreementwiththehypothesis addition to flexible virtual gene panels (e.g., including that aneuploidy of the genes of the rearranged interval is newly discovered genes or using a large neurological moredetrimentalthantheiroverexpression,wefound,atall disordermultigenepanel)mayincreasethediagnosticyield, developmental stages, greater transcriptional alterations in 16p11.2Del/+ ratherthan16p11.2Dup/+ in order to provide a better disease management and mice.Ourdatareveal improve genetic counselling for affected patients and their time- and sex-specific transcriptional changes in the brain 16p11.2Del/+ families. cortex of mice, and shed light on possible S. Sousa: None. P. Silva: None. A. Brandão: None. A. intimate connections between the immune and nervous Lopes: None. P. Arinto: None. R. Bastos: None. S. systems and its influence on neurologic manifestations in Morais: None. S. Barbosa: None. J. Sequeiros: None. I. carriers of 16p11.2 rearrangements. Alonso: None. P. De Nittis: None. G. Giannuzzi: None. E. Porcu: None. L. Dib: None. J. Chrast: None. Y. Herault: None. F.Schütz:None.C.Attanasio:None.A.Reymond:None.  P11
 Multiple malformation/anomalies syndromes  P11
.02B Duplication 17q24.3q25.1, inserted on 17p13,  P11
.01A encompassing SOX9: the impact on the phenotype Sex-specific transcriptome analysis highlights immune andneuronaldysfunctioninthedevelopingbraincortex E.Matoso1,2,3,P.Louro4,5,6,A.Estevinho1,S.I.Ferreira7, of 16p11.2 deletion mouse models P. Paiva7, J. B. Melo7,3,8, A. Mirante9, U. S. Melo10,11, S. Mundlos10,11, S. B. Sousa2,4, L. Ramos4,6, J. Saraiva4,2, P. De Nittis1, G. Giannuzzi1, E. Porcu1,2, L. Dib2, I. M. Carreira7,8,3 J. Chrast1, Y. Herault3, F. Schütz2, C. Attanasio1, A. Reymond1 1LaboratóriodeCitogenética,ServiçodeGenéticaMédica, Hospital Pediátrico, Centro Hospitalar e Universitário de 1Center for Integrative Genomics, Lausanne, Switzerland, Coimbra, Coimbra, Portugal, 2Faculdade de Medicina da 2Swiss Institute of Bioinformatics (SIB), Lausanne, UniversidadedeCoimbra,Coimbra,Portugal,3CIMAGO–Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1491 Centro de Investigação em Meio Ambiente, Genética e imbalance, providing a better interpretation and correlation Oncobiologia, Coimbra, Portugal, 4Serviço de Genética to the phenotype. Médica, Hospital Pediátrico, Centro Hospitalar e E.Matoso:None.P.Louro:None.A.Estevinho:None. Universitário de Coimbra, Coimbra, Portugal, 5Clínica de S.I.Ferreira:None.P.Paiva: None.J.B.Melo: None.A. RiscoFamiliar,InstitutoPortuguêsdeOncologiadeLisboa Mirante:None.U.S.Melo:None.S.Mundlos:None.S.B. Francisco Gentil, Lisboa, Portugal, 6Faculty of Health Sousa: None. L. Ramos: None. J. Saraiva: None. I.M. Sciences, Universidade da Beira Interior, Covilhã, Carreira: None. Portugal, 7Laboratório de Citogenética e Genómica, Faculdade de Medicina da Universidade de Coimbra,  P11
.03C Coimbra, Portugal, 8CNC.IBILI Consortium, Universidade Understanding microcephaly/macrocephaly de Coimbra, Coimbra, Portugal, 9Unidade de mechanisms in the new 19p13.3 microduplication/ Endocrinologia, Hospital Pediátrico, Centro Hospitalar e microdeletion syndrome Universitário de Coimbra, Coimbra, Portugal, 10Max Planck Institute for Molecular Genetics, RG Development G. Jouret1, M. Egloff2, O. Tassy3, F. Giuliano4, & Disease, Berlin, Germany, 11Institute for Medical and H. Karmous-Benailly4, C. Coutton5, V. Satre5, Human Genetics, Charité Universitätsmedizin Berlin, F.Devillard5,K.Dieterich5,G.Vieville5,P.Kuentz6,C.Le Berlin, Germany Caignec7,P.Callier8,V.Marquet9,C.Laroche-Raynaud9, E. Bieth10, C. Rooryck-Thambo11, P. Pennamen11, Intrachromosomal insertions are uncommon rearrange- C. Angélini11, J. Lévy12, A. Philippe-Recasens2, ments. The cytogenetic recognition of these structurally S.Lyonnet2,G.Baujat2,M.Rio2,F.Cartault13,S.Berg13, rearrangedchromosomescanbedifficulttoascertain.Inlast S. Sophie14, A. Gouronc14, A. SCHALK1, C. Jacquin1, years the application of array-CGH in the investigation of E. Gouy1, E. Landais1, M. Spodenkiewicz1, C. Poirsier1, patients with intellectual disability and congenital malfor- M. Doco-Fenzy1 mations increased substantially the detection of cryptic chromosomal imbalances. However, the rearrangement 1Reims University Hospital, Reims, France, 2Necker underlying the imbalance could be missed, when we only University Hospital, Paris, France, 3IGBMC, Strasbourg, perform molecular techniques. France,4NiceUniversityHospital,Nice,France,5Grenoble We report a 10 year-old girl presenting intellectual dis- University Hospital, Grenoble, France, 6Besançon ability,attentiondeficithyperactivitydisorder,shortstature, University Hospital, Besançon, France, 7Nantes University prenatal microcephaly, aplasia cutis congenita, bulbous Hospital, Nantes, France, 8Dijon University Hospital, bifid nose, bilateral congenital trigger thumb, shortening of Dijon, France, 9Limoges University Hospital, Limoges, the fourth metacarpal of the right hand, pectus excavatum, France, 10Toulouse University Hospital, Toulouse, France, long first toe, and mild hypertrichosis. 11Bordeaux University Hospital, Bordeaux, France, High resolution cytogenetic analysis revealed a cryptic 12Robert-Debré University Hospital, Paris, France, 13La alteration: 46,XX,add(17)(p13.1). To characterize the Réunion University Hospital, Saint Denis, France, imbalance 180K oligonucleotide array-CGH was per- 14Strasbourg University Hospital, Strasbourg, France formed, revealing a 2.4 Mb duplication: arr[hg19] 17q24.3q25.1(68,620,187-71,083,594)x3 encompassing 10 Introduction: A small but growing body of scientific genes. Molecular cytogenetics showed an intrachromoso- literatureisemergingaboutclinicalfindingsinpatientswith mal insertion on 17p. Parents were not available to study. 19p13.3 rearrangements. Most reported individuals have The most relevant gene involved in the imbalance is SOX9 deletions, and only eleven patients with clinical findings (MIM*608160) and encodes a transcription factor essential attributed to 19p13.3 duplications have been reported. for both sex and skeletal development. Duplications of Interestingly, 19p13.3 microdeletions are described in noncoding elements 5-prime of SOX9 were associated with patients with syndromic intellectual disability and macro- abnormal digit and nail development. Investigations are cephaly, and 19p13.3 microduplications in patients with being addressed, by chromosome conformation capture syndromic intellectual disability and microcephaly. More- (HiC) in patient cell lines in combination with whole- over,patientswith19p13.3microduplicationsharecommon genomesequencing,inordertodoabetterinterpretationof developmental features, suggesting the existence of a new the pathogenic mechanisms underlying the chromosomal microduplication syndrome. rearrangement. Methods: To characterize these new syndromes, we This report emphasis the contribution of high resolution formed a French collaborative study, and included 37 new cytogenetics, molecular cytogenetics and array-CGH to a patients with 19p13.3 rearrangements. We performed phe- better understanding of the rearrangement involved in the notype and genotype analysis, including genotype-1492 phenotype correlations by critical region delineation. We Background: 22q11.2DS is the most frequent CNV, screened this critical region with experimental findings in affecting ~1/1000 fetuses and ~1/2000–4000 children, murine model by using the data-mining software Manteia, resulting in recognizable but variable findings across to purpose candidate genes never associated with human multiple organ systems. Patients with atypical features phenotype before. shouldpromptconsiderationofcoexistingdiagnosesdueto Results: We report the largest cohort of patients with the possibility of additional genome‐wide mutations/CNVs 19p13.3rearrangements,anddescribeanew377Kbcritical whichmaybeinherited,aswellas,mutations/CNVsonthe region associated with syndromic intellectual disability and other chromosome 22q11.2alleleresultinginan autosomal micro/macrocephaly. 19p13.3 rearrangements are asso- recessivecondition.Bothoccurrencescompoundsymptoms ciated with specific recurrent clinical findings: mild to impacting management and genetic counseling. moderate intellectual disability, pre and post-natal growth Methods: Records on 1422 patients with laboratory delay, micro or macrocephaly, osteoarticular anomalies confirmed 22q11.2DS followed at Children's Hospital of including precocious osteoporosis in children, congenital Philadelphia were reviewed to identify a dual diagnosis, severe hip dysplasia and scoliosis, congenital heart defect, including a subset with atypical features, e.g. craniosynos- genitourinary findings and immunodeficiency. Breakpoint tosis, whose samples underwent NGS of theintact 22q11.2 analysis and supporting murine model allowed us to pur- allele in Leuven/Warsaw. pose candidate genes associated with micro/macrocephaly. Results: 24 patients had a coexisting diagnosis (1.7% of Conclusions:19p13.3rearrangementsareassociatedwith ourcohort)including8patientswithconditionsunrelatedto specific clinical findings, including intellectual disability 22q11.2DS (SCID, Trisomy 8 mosaic, CHD7 mutation, andmicro/macrocephaly.Wedelineategenotype-phenotype cystic fibrosis, maternally inherited 17q12 deletion, G6PD correlations and purposedcandidate genes never associated deficiency,vonWillebranddisease,1q21.1deletion)and16 with human phenotype before. patients with 22q11.2DS and a CNV/mutation on the G. Jouret: None. M. Egloff: None. O. Tassy: None. F. remaining allele resulting in an autosomal recessive condi- Giuliano: None. H. Karmous-Benailly: None. C. Cout- tion.Thelatter groupincludedmutations/CNVsinG P1
BB, ton: None. V. Satre: None. F. Devillard: None. K. Diet- CD C45
 (4), LZTR1 (2), SNA P29
 (4), and TANGO2 (5) erich: None. G. Vieville: None. P. Kuentz: None. C. Le explaining their atypical features, unfortunately including Caignec: None. P. Callier: None. V. Marquet: None. C. sudden death in a 5-year-old child with post mortem iden- Laroche-Raynaud: None. E. Bieth: None. C. Rooryck- tification of TANGO2 Related Disease. Thambo: None. P. Pennamen: None. C. Angélini: None. Conclusions: These findings support considering addi- J. Lévy: None. A. Philippe-Recasens: None. S. Lyonnet: tional laboratory testing in this population to ensure None.G.Baujat:None.M.Rio:None.F.Cartault:None. appropriate personalized care, as formulating medical S. Berg: None. S. Sophie: None. A. Gouronc: None. A. management decisions hinges on establishing the correct Schalk: None. C. Jacquin: None. E. Gouy: None. E. diagnoses in their entirety, especially given that these Landais: None. M. Spodenkiewicz: None. C. Poirsier: findings are medically actionable, potentially altering long‐ None. M. Doco-Fenzy: None. term outcome and recurrence risk counseling. D.M.McDonald-McGinn:None.M.Unolt:None.T.B.  P11
.04D Crowley:None.D.E.McGinn:None.J.Cohen:None.A. 22q11.2 Deletion syndrome and coexisting conditions - Bailey: None. M. Lambert: None. B. Emanuel: None. E. an important prognostic, management, and genetic Zackai: None. B. Nowakowska: None. J. Vermeesch: counseling consideration None. D. M. McDonald-McGinn1,2, M. Unolt3, T. B. Crowley1,  P11
.05A D. E. McGinn1, J. Cohen1, A. Bailey1, M. Lambert1,2, SNVsandCNVsinfluencingphenotypevariabilityinthe B. Emanuel1,2, E. Zackai1,2, B. Nowakowska4, patients with 22q11.2 Deletion Syndrome detected from J. Vermeesch5 whole exome sequencing data 1TheChildren'sHospitalofPhiladelphia,Philadelphia,PA, K. Ziemkiewicz1, M. Smyk1, T. Gambin1, M. Geremek1, United States, 2Perelman School of Medicine at the A. Kutkowska-Kaźmierczak1, D. M. McDonald-McGinn2, University of Pennsylvania, Philadelphia, PA, United T. B. Crowley2, M. Piotrowicz3, D. Gieruszczak-Białek4, States, 3Ospedale Bambino Gesu and Sapienza University, B. A. Nowakowska1 Rome, Italy, 4Institute of Mother and Child, Warsaw, Poland, 5KU Leuven, Philadelphia, Belgium 1Institute of Mother and Child, Warsaw, Poland, 2Human Genetics, The Children's Hospital of Philadelphia,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1493 Philadelphia, PA, United States, 3Department of Genetics, Background: The 47,XYY syndrome is common as being Polish Mother’s Memorial Hospital Research Institute, diagnosedamong18per100,000newbornmales.However, Łódź,Poland,4DepartmentofMedicalGenetics,Children’s knowledge of the long-term health outcomes of this Memorial Health Institute, Warsaw, Poland condition is sparse. Aim:Todescribemorbidityinanational47,XYYcohort The 22q11.2DS has an estimated frequency of 1 in 3000 using complete registry data on hospital admissions and live births. There is still very poor understanding of how prescribed medication. heterozygous microdeletion of approximately 50 genes can Setting: A uniform public health care system. lead to such diverse expressivity of the clinical features in Participants: A total of 251 males with 47,XYY patients carrying the same deletions. Two aspects seem to (n=205),46,XY/47,XYY(n=28)orcompatiblekaryotypes haveanimpactonphenotypevariability;coexistenceofthe (n=18) diagnosed during 1965-2014 and a randomly second condition and modifiers of typical clinical features. selected age-matched control cohort of 25,100 males from In this project we focused on three of the potential the general population. mechanismsunderlyingthefirstaspect:pathogenicvariants Results: Hospital admission owing to any diagnosis was within the remaining 22q11.2 region, SNVs in genes significantly increased among 47,XYY compared to con- outside of the deletion and additional CNVs. trols(HR=1.8,CI:1.6-2.4).Amongatotalof18diagnostic For 85 22q11DS carriers deep phenotype was performed groups the risk of admission was increased in all but three based on the form with over 230 clinical features. Subse- groups. The highest HRs were observed for congenital quently for all patients whole exome sequencing (WES) malformations (HR=6.1, CI: 4.8-7.6); psychiatric diseases wascarriedout.Datawasanalysedusingstandardprotocol, (HR=5.7, CI: 4.5-7.1); endocrine and metabolic disorders additionally two algorithms were implemented to identify (HR=3.2, CI: 2.4-4.4); neurologic diseases (HR=3.0, CI: CNVs in genome (CoNIFER and HMZdelfinder). 2.2-4.0);andurogenitalsystemdisorders(HR=3.0,CI:2.4- WES analysis revealed: 9 pathogenic SNVs and 54 3.7). Overall, 47,XYY had an increased risk of receiving potentially pathogenic variants in known disease related medicinal prescriptions compared to controls (HR=1.3, genes correlating with patients’ phenotypes. Moreover we CI:1.1-1.5), and it was significantly increased in 11 out of found 149 rare variants of unknown significance, including 14 medicinal groups. The highest HRs were observed for 2 in 22q11.2 region. All variants were classified as dele- medication related to the blood (HR=2.5, CI:1.8-3.5); the terious by at least 3 of 4 applied function prediction scores nervous system (HR=2.2, CI:1.9-2.7); as well as for uro- and located in genes with increased expression in brain, genital system disorders and sex hormones (HR=2.7, CI: nervous system, immune system or heart. CoNIFER algo- 2.0-3.7). rithm identified 12 rare CNVs and HMZdelfinder 14 Conclusions: The 47,XYY syndrome is associated with deletions. an increased morbidity as interpreted from data of hospital Conclusions: The, second hit” – pathogenic/potentially admissionsandmedicinalprescriptions.Whetherthesedata pathogenic SNV or CNV may act as a phenotype modifier, extendtotheapproximately80%of47,XYYsufferingfrom changes patient’s prognosis and should be considered in non-diagnosis remains unknown. genetic counselling. A. Berglund: None. M. Viuff: None. K. Stochholm: Financed by NSC, OPUS NCN2015/17/B/NZ5/ None. C. Gravholt: None. 01357 to BN. K. Ziemkiewicz: None. M. Smyk: None. T. Gambin:  P11
.08D None. M. Geremek: None. A. Kutkowska-Kaźmierczak: Characterization of a CRISPR-Cas9 cellular model to None. D.M. McDonald-McGinn: None. T.B. Crowley: Alström syndrome None. M. Piotrowicz: None. D. Gieruszczak-Białek: None. B.A. Nowakowska: None. B. Bea-Mascato, E. Neira-Goyanes, D. Valverde  P11
.06B University of Vigo, Vigo, Spain Morbidity is increased in 47,XYY syndrome: a nationwide registry study Alström syndrome is a rare disease with a prevalence of 1/ 1,000,000 per inhabitant. ALM S1
 gene has been implicated A. Berglund, M. Viuff, K. Stochholm, C. Gravholt in this disease, with more than 290 causal mutations, mostly ofthemlocatedinexons8,10and16.Themajorityofthese Aarhus University Hospital, Aarhus, Denmark mutations leads to a change of the reading frame that concludesinaprematurestopcodon,resultinginatruncated protein. The modelling of this disease through KO models1494 becomes in this context an interesting tool to understand the analysisconfirmedthemultipleaetiopatologyoftheclinical cellular processes that take place in this disease. We have picture identifying mutations in different causative genes. generatedaKnock-out(KO)modelinHeLacellline.Weuse The likely pathogenetic missense mutations in CAPN10, the CRISPR/Cas9 method with dual system with Homology SL C2
A2 and GCKR explained only diabetes mellitus non- Direct Repair (HDR). After isolation of homozygous clones, insulin dependent. The kidney anomaly correlated to we validated ALM S1
 expression by qPCR and Sanger CHD1L mutation, candidate gene for congenital anomalies sequencing of the recombinant amplicon comprised between of the kidney and urinary tract (CAKUT). An essential in- Exon 1 and 3. Then we evaluate mitochondrial activity, depth study of WES identified a new ANKRD11 mutation, proliferation and apoptosis resistance. We obtained a total responsible of KBG syndrome. This is a rare autosomal inhibition in the expression of the ALM S1
 gene. We are dominant condition characterized by short stature, neurolo- performing the characterization but we expected apoptosis gical involvement, skeletal anomalies and macrodontia. resistance, cell cycle elongation and inhibition of mitochon- ANKRD11 encodes for a member of family of Ankyrin drial activity like other authors report in analysis of patient´s repeat domain-containing cofactors that are inhibitors of fibroblasts. The generation of cellular models using CRIPR/ ligand-dependent transcriptional activation. Moreover, it is Cas9fortheAlströmsyndromeisconsideredasasimpleand known as a tumor protein p53-interacting protein. easytoimplementtoolthatwouldbroadentheknowledgeof ANKRD11 enhances T P53
-dependent transcriptional acti- the molecular basis of this disease. vation promoting its tumor-suppressive effects. Retrospec- B. Bea-Mascato: None. E. Neira-Goyanes: None. D. tively analysis of literature (about hundred cases) Valverde: None. highlightedthepresenceofonlytwocaseswithmalignancy, testicular rhabdoid tumor and acute myeloid leukemia.  P11
.09A Although we cannot exclude that tumor observed in KBG Beyondthefirstclinicaldiagnosis:anewinterestingcase patients developed coincidentally, the role of ANKRD11 of KBG syndrome and our new case suggest a general cancer surveillance. R. Artuso: None. F. Peluso: None. E. Bosi: None. V. R.Artuso1,F.Peluso2,E. Bosi2,V.Palazzo1,S.Landini2, Palazzo:None.S.Landini:None.D.Formicola:None.D. D. Formicola3, D. Vergani2, L. Tiberi2, L. Giunti1, Vergani: None. L. Tiberi: None. L. Giunti: None. C. C. Cosentino4, L. Pala4, C. Rotella4, S. Giglio1,5 Cosentino: None. L. Pala: None. C. Rotella: None. S. Giglio: None. 1Medical Genetic Unit, Meyer's Children University Hospital, Firenze, Italy, 2Medical Genetics Unit,  P11
.10B Department of Clinical and Experimental Biomedical Fruits of Genomic Match-making: De Novo Variants in Sciences 'Mario Serio', University of Florence, Florence, PRR12 are Associated with a Spectrum of Eye and Italy., Firenze, Italy, 3Department of Science’s Health, Neurodevelopmental Anomalies Medical Genetics Unit, Meyer Children’s University Hospital,Florence,Italy,Firenze,Italy,4DiabetologyUnit, T. B. Balci1, L. Wang2, S. Lalani3, S. Heide4, B. Keren4, Department of Clinical and Experimental Biomedical C. Mignot4, G. Morley5, J. Walia6, P. Wheeler7, Sciences "Mario Serio", University of Florence, Careggi J. Lemons8, D. Rodriguez Buritica8, E. Riberi9, University Hospital, Florence, Italy., Firenze, Italy, E. Biamino9, K. Schatz10, M. Gunay-Aygun10, 5Medical Genetics Unit, Department of Clinical and A. Wiesener11, C. Zweier11, I. Wentzensen12, V. M. Siu1, ExperimentalBiomedicalSciences'MarioSerio',University W. Bi3 of Florence, Florence, Italy., Florence, Italy 1Western University, Schulich School of Medicine and A 48 years old man acceded in emergency unit for Dentistry, London, ON, Canada, 2Baylor Genetics addominal pain and vomit. He presented polyuria, poly- Laboratories, Houston, TX, United States, 3Baylor College dipsia for 2 months and important weight loss. Hematic of Medicine, Houston, TX, United States, 4GH Pitie- exam showed high glycemia, high value of HB1Ac and Salpetriere, Paris, France, 5Mercyhealth Hospital, negative specific insulin autoantibodies suspecting diabetic Rockford, IL,United States,6Queen's University, Kingston, ketoacidosis.Theinsulintreatmentimprovedsymptomsand ON, Canada, 7Arnold Palmer Hospital for Children, glicemia. The genetic evaluation revealed a more complex Orlando, FL, United States, 8University of Texas Health phenotype included hyposomia, growth delay, mild intel- SciencesCenter,Houston,TX,UnitedStates,9Universityof lectual disability, monosomy of left kidney, fusion of Turin, Turin, Italy, 10Johns Hopkins University School of cervical vertebrates, brachydactyly, Arnold-Chiari syn- Medicine, Baltimore, MD, United States, 11Friedrich drome and chronic lymphocytic leucemia. The WES Alexander Universitat Erlangen-Nurnberg, Erlangen,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1495 Germany, 12GeneDx Clinical Genetics Laboratories, 1Genetics and Rare Diseases Research Division, Ospedale Gaithersburg, MD, United States Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 2Multifactorial Disease and Complex Phenotype Research Rare disease research has made great strides in the last Area, Ospedale Pediatrico Bambino Gesù,, Rome, Italy, decade; first with unbiased genome-wide sequencing 3Radiologia e Bioimaging, Ospedale Pediatrico Bambino methods, then with global data-sharing efforts. Genomic Gesù,Rome,Italy,4DipartimentodiEmatologia,Oncologia match-makinghasacceleratedthepathfromcandidategene eMedicina Molecolare,Istituto SuperiorediSanità,Rome, identification to establishing causality. Using exome Italy, Rome, Italy, 5Division of Genetics, Department of sequencing, we identified a de novo frameshift variant in Pediatrics, All Institute of Medical Sciences,, New Delhi, thePRR12 geneina 2-year-old girlwith anophthalmiaand India,6CentroNacionaldeGenéticaMédica,BuenosAires, developmental delay. PRR12 is highly expressed in the Argentina,7DepartmentofClinicalandMolecularGenetics brain and the visual system. It has a high missense andRareDiseaseUnit,UniversityHospitalValld´Hebron, constraint score (Z=3.37) and no loss of function variants Barcelona, Spain, 8Ambulantes Gesundheitszentrum listed in Gnomad (pLI=1.00). De novo truncating variants Humangenetik, Charité Universitätsmedizin Berlin, Berlin, in PRR12 were recently reported in three individuals with Germany, 9Center for Rare Diseases, Department of developmental delay and iris abnormalities. Through Pediatrics, Polo Salute Donna e Bambino, Fondazione GeneMatcher, we were connected to 11 additional patients Policlinico Universitario A. Gemelli, Catholic University, from around the globe, bringing the total number of Rome, Italy, 10Institute of Human Genetics, Friedrich- individuals with de novo variants in PRR12 to 15. There Alexander-Universität (FAU) Erlangen-Nürnberg, werenorecurrentvariants;allbutone,weretruncating;and Erlangen, Germany, 11Institut für Klinische Genetik, nonewerelistedinGnomad.Avarietyofeyeabnormalities Technische Universität Dresden, Dresden, Germany, were observed in 10/15 individuals; including myopia, 12Center for Intractable Diseases, Saitama Medical stellate iris, coloboma, Rieger’s anomaly, microphthalmia, University Hospital, Moroyama-cho, Irima-gun, Saitama, cryptophthalmos and anophthalmia. Developmental delay Japan was noted in 13/15 and microcephaly in 5/15. The overlapping clinical findings, especially the ophthalmolo- Ayme-Gripp syndrome (AYGRPS) is the eponym of a gical features, support an association between haploinsuffi- recognizable condition caused by a restricted spectrum of ciency of PRR12 and a distinct neurodevelopmental dominantly acting missense mutations affecting the basic disorder.Featuresarevariableandfunctionaldataisneeded leucine zipper (bZIP)-containing transcription factor, MAF. to confirm pathogenicity. We plan to use zebrafish and Major clinical features include congenital cataracts, sensor- mouse models to replicate the eye and growth phenotypes ineuralhearingloss,intellectualdisability,seizures,reduced andfurtherinvestigatethepathogenicityofdifferentPRR12 growth, and a distinctive flat facial appearance. Skeletal variants. This cohort once again demonstrates the utility of abnormalities have also been noted in affected individuals; global data sharing efforts in rare disease research. even thought, these features have not been assessed T.B. Balci: None. L. Wang: None. S. Lalani: None. S. systematically due to the small number of subjects. Heide: None. B. Keren: None. C. Mignot: None. G. AYGRPS-causing MAF mutations cluster in the GSK3 Morley: None. J. Walia: None. P. Wheeler: None. J. phosphorylationmotifwithintheN-terminaltransactivation Lemons: None. D. Rodriguez Buritica: None. E. Riberi: domainoftheprotein,andimpairproperphosphorylationof None. E. Biamino: None. K. Schatz: None. M. Gunay- MAF, perturbing its activation and stability. Here, we Aygun: None. A. Wiesener: None. C. Zweier: None. I. characterize clinically and molecularly four additional Wentzensen: A. Employment (full or part-time); Sig- patients. Expanding the series, we provide a more accurate nificant; GeneDx. V.M. Siu: None. W. Bi: None. delineation of the clinical phenotype, particularly focusing on the skeletal features characterizing this disorder. Beside  P11
.11C midfacial hypoplasia and joints limitations, we report that Skeletal defects and defective osteoclast and osteoblast delayed bone age, radio-ulnar synostosis, carpal/tarsal and function in Aymé-Gripp syndrome long bone defects, and hip dysplasia variably occur in affected subjects. Consistent with this findings, by func- M. NICETA1, A. Del Fattore2, D. Barbuti3, M. Rossi2, tional characterization of mutations using informative cell E. Stellacci4, N. Gupta5, C. Ruggiero6, E. Tizzano7, models, we provide first data documenting defective L.Graul-Neumann8,C.Leoni9,C.Zweier10,P.Fernandez osteoblast and osteoclast differentiation and function. Alvarez7, A. Tzschach11, M. Valenzuela7, S. Barresi1, M. Niceta: None. A. Del Fattore: None. D. Barbuti: B. Dallapiccola1, G. Zampino9, M. Tartaglia1, None. M. Rossi: None. E. Stellacci: None. N. Gupta: G. Nishimura12 None. C. Ruggiero: None. E. Tizzano: None. L. Graul-1496 Neumann: None. C. Leoni: None. C. Zweier: None. P. that its sequence of 2435 bp contains hallmarks of LIN E1
 Fernandez Alvarez: None. A. Tzschach: None. M. mediated retrotransposition with a 5’ truncation compared Valenzuela: None. S. Barresi: None. B. Dallapiccola: tothecanonicalSVA-Fsequence.Weconfirmedourinitial None. G. Zampino: None. M. Tartaglia: None. G. finding (Redin et al, 2012) that MEI is occurring in BBS. Nishimura: None. Wedescribe4newfamilieswiththesameSVA-Finsertion in BB S1
. Thus this insertion is now described in 5 families  P11
.12D sincetheinitialcasereportedbyTavaresetal(2018).Such A not so rare insertion of a retrotransposon (SVA-F) in findings highlight the importance of using dedicated one of the major Bardet-Biedl gene (BB S1
) bioinformatics pipelines to identify all types of variations. Our PhD student is supported by a FRM grant C. Delvallée1, S. Nicaise1, C. Stoetzel1, V. Geoffroy1, (ECO20170637509). B. Keren2,3, C. Depienne2,3, J. Klar4, N. Dahl4, C.Delvallée:None.S.Nicaise:None.C.Stoetzel:None. J. Deleuze5, A. Piton6, J. Mandel6, J. Muller1,7, V. Geoffroy: None. B. Keren: None. C. Depienne: None. H. Dollfus1,8 J.Klar:None.N.Dahl:None.J.Deleuze:None.A.Piton: None. J. Mandel: None. J. Muller: None. H. 1Laboratoire de Génétique Médicale, Institut de génétique Dollfus: None. médicale d’Alsace, INSERM U1112, Fédération de Médecine Translationnelle de Strasbourg (FMTS),  P11
.14B Université de Strasbourg, Strasbourg, France, 2AP-HP, Adult phenotype of Beckwith-Wiedemann syndrome Hôpital de la Pitié-Salpêtrière, Département de Génétique, F-75013, Paris, France, 3Sorbonne Universités, UPMC D. Carli1, A. Gazzin1, C. Molinatto1, F. Sirchia2, UnivParis06,Inserm,CNRS,UM75,U1127,UMR7225, S. Cardaropoli1, A. Mussa1, G. B. Ferrero1 ICM,F-75013,Paris,France,4DepartmentofImmunology, Genetics and Pathology, Science for Life Laboratory, 1DepartmentofPublicHealthandPediatrics,Universityof UppsalaUniversity,Uppsala,Sweden,5CentreNationalde Torino, Torino, Italy, 2Institute for Maternal Child Health Recherche en Génomique Humaine (CNRGH), Institut de IRCCS “Burlo Garofolo”, Trieste, Italy biologie François Jacob, CEA, 91000, Evry, France, 6Institut de Génétique et de Biologie Moléculaire et Background: Beckwith-Wiedemann syndrome (BWS) Cellulaire,CNRSUMR7104,INSERMU964,Universitéde phenotype usually mitigatewith age and data on adulthood Strasbourg, Illkirch, France, 7Laboratoires de Diagnostic arescanty.Ourstudyaimsatreportingphenotypeevolution Génétique, Hôpitaux Universitaires de Strasbourg, and health issues in adulthood. Strasbourg,France,8Centrederéférencepourlesmaladies Methods: 31 patients (14 males), aged 18-58 years rares ophtalmologiques CARGO, Hôpitaux Universitaires (median 28.45) with BWS were enrolled. de Strasbourg, Strasbourg, France Results:14patientshadI C2
-hypomethylation,5paternal UPD11, two I C1
-hypermethylation, one 11p15.5 micro- Bardet Biedl syndrome is a ciliopathy with typical features duplication, 5 negative molecular tests and 4 were not tes- including retinitis pigmentosa, polydactyly, cognitive ted. Final tall stature was present in 38%. Three patients impairmentandrenalfailure.Mutationsin22genesaccount developednephroblastoma(2,3and10years,respectively); for80%ofthecases.BB S1
representsthehighestfractionof one hepatoblastoma (22 years); one acute lymphoblastic patientswithpathogenicvariationsincludingfor17%ofall leukemia (21 years); one adrenal adenoma and testicular BBSpatientsthec.1169T>G,p.M390Rvariant.Amongthe Sertoli cell tumour (22 and 24 years, respectively); and unsolved cases in our cohort, several patients were three benign tumours (hepatic haemangioma, uterine heterozygous carriers of this specific recurrent mutation myomaandmammaryfibroepithelioma).SurgeryforBWS- suggesting a second allele in BB S1
. Targeted exome related features was required in 84%. Despite surgical sequencing and mobile element insertion (MEI) detection correctionseveralpatientspresentedmorbidityandsequelae (Mobster)wasappliedto200BBSsamples.Wholegenome ofBWSpediatric issues: pronunciation/swallow difficulties sequencing,denovoassemblyandSNParrayanalysiswere (n=8) due to macroglossia, painful scoliosis (n=4) con- performedtocharacterizethegenomiceventsidentified.We sistent with lateralized overgrowth, recurrent urolithiasis identified a few large exons deletions in BB S1
 gene. (n=4), azoospermia (n=3) likely consequent to cryptorch- Interestingly, 4 families carried the c.1169T>G variation in idism, severe intellectual disability (n=2) likely related to transofahominid-specificretrotransposoninsertion(SVA- neonatal asphyxia and diabetes mellitus (n=1) due to sub- F) in exon 13 of BB S1
. We characterized this insertion in total pancreatectomy for intractable hyperinsulinism. Three thegeneralpopulation(>400samplesscreened),determinedAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1497 patients(2males)hadhealthychildren(twophysiologically unrecognized by clinicians,though highlyrelevanttoreach conceived and one through ART). the accurate diagnosis. Conclusions: adult health conditions in BWS are mostly V.Ivashchenko:None.S.Julia:None.A.Lebre:None. consequent to pediatric issues, underlying the preventive O. Patat: None. role of follow-up strategies in childhood. Malignancy rate observed in early adulthood in this small cohort matches  P11
.16D thatobservedinthefirstdecadeoflife,cumulativelyraising Novel patient with Contiguous ABCD1/ DX S1375
E tumor rate in BWS to 20% during the observation period. (BCA P31
) Deletion Syndrome (CADDS) and review of Further studies are warranted in this direction. the literature D. Carli: None. A. Gazzin: None. C. Molinatto: None. F.Sirchia:None.S.Cardaropoli:None.A.Mussa:None. S. Whalen1, A. Gomart2, C. Mignot3, T. Billette De G.B. Ferrero: None. Villemeur4, A. Gerasimenko3, D. Heron5, J. Siffroi6, P. Gobalakichenane2, M. Lachtar2, D. Mitanchez2,  P11
.15C S. Chantot-Bastaraud6 Branchio-Oculo-Facial Syndrome: a case report on an atypical case with broad intra-familial variability 1APHP, UF de génétique clinique, Hôpital Armand Trousseau,Centrederéférencemaladiesrares«Anomalies V. Ivashchenko1, S. Julia1, A. Lebre2, O. Patat1 du développement et syndromes malformatifs », Paris, France, 2APHP, Service de néonatologie, Hôpital Armand 1CHU Toulouse Purpan, TOULOUSE, France, 2CHU Trousseau, Paris, France, 3APHP, UF de génétique Reims, Reims, France clinique, Hôpital Armand Trousseau, Paris, France, 4AP- HP,Servicedeneuropédiatrie,HôpitalArmandTrousseau, Introduction: Branchio-oculo-facial syndrome (BOFS) is Sorbonne Université, Inserm U1141, Paris, France, an autosomal-dominant inherited disorder, related to 5APHP, Département de génétique, Groupe Hospitalier mutations in TFA P2
A. This gene encodes for the A P2
-α Pitié Salpêtrière, Centre de référence maladies rares « protein, which plays a major role in human craniofacial Déficiencesintellectuellesdecausesrares»,Paris,France, development. While cardinal features of this syndrome 6APHP, Département de Génétique, UF de Génétique commonly involve branchial skin defects, oculo-facial Chromosomique, Hôpital Armand Trousseau, Paris, abnormalities, and hearing loss, a broad phenotypic France variabilitycanhamperthediagnosisinsomeatypicalcases. Case Presentation: We report two siblings and their The contiguous ABCD1/DX S1375
E (BCA P31
) deletion mother, with a familial history of Pierre Robin sequence syndrome (CADDS) was first reported in 2002. Up to date without cleft palate, coloboma, pseudo-cleft aspect of the thereareonly6reportedpatients.Thesepatientspresenteda upper lip, nasolacrimal duct stenosis and hearing loss, with similar phenotype with marked neonatal hypotonia, severe a broad intra-familial variability. Focusing on the severe growth failure, failure to thrive, profound developmental syndromic Pierre Robin sequence and ear dysplasia in one delayandliverdysfunctionleadingtoearlydeathinthefirst affected child, a gene panel of mandibulofacial dysostosis year.Wepresenta7thpatientwithCADDS,a2monthsold (EFTUD2,POLR1A,POLR1C,POLR1D,andTCOF1)was boy who presented severe antenatal and postnatal growth performed without identifying any mutation. A CGH array retardation, failure to thrive, irritability, mild hypotonia, showed a 22q11.21 microduplication in one of the affected transient liver dysfunction with cholestasis and elevated children, assessed as insufficient to explain the poly- liverenzymes.Healsohadexocrineandpossibleendocrine malformative familial phenotype. After a second clinical pancreatic deficiency which has not yet been described. evaluation, a diagnosis of branchio-oculo-facial syndrome Chromosomal microarray showed a 60kb Xq28 including was suggested based on the association of “pseudo-cleft” thefirstthreeexonsoftheBCA P31
gene,theentireABCD1 defects of the upper lip, coloboma, and nasolacrimal duct geneandpartofthePLXNB3gene.ABCD1loss-of-function stenosis. Specific Sanger sequencing of TFA P2
A in the mutations lead to X linked-Adrenoleucodystrophy, a index case revealed a predicted pathogenic c.532+2T>C neurodegenerative condition with broad clinical variability. variant (NM_003220.2) in a heterozygous state, supporting No cases have been described under the age of 2.7 years. the diagnosis of BOFS. And no liver involvement has been described. BCA P31
 Conclusion: This case report highlights the broad varia- loss-of-functionmutationshavebeenidentifiedin7patients bility of BOFS phenotypic spectrum. However, it empha- from 3 families, all boys with severe developmental delay, sizes some distinctive clinical features, which can be dystonia, deafness, central hypomyelination, growth retar- dation. No apparent chronic liver dysfunction was1498 described.Fourofthepatientsdiedinthefirstyearsoflife, (TNFalpha), which was reduced the eye-size. Then, the either suddenly or during a febrile episode. The phenotype eiger effect was suppressed by the mutant MA P3
K7, sug- of CADDS patients seems distinctive from those with gesting that the variant showed dominant negative effect. isolated ABCD1 or BCA P31
 loss-of-function. Different We concluded that the patient was caused by the missense hypotheses have been made to explain the severe liver denovovariantofMA P3
K7andCSCFwascausedbyloss- phenotype of the deletion, however further studies are of-function of MA P3
K7. needed to conclude. T. Kaname: None. K. Saito: None. K. Yanagi: None. S.Whalen:None.A.Gomart:None.C.Mignot:None. M. Takeshita: None. N. Kobayashi: None. T. Tohma: T. Billette De Villemeur: None. A. Gerasimenko: None. None. I. Inoue: None. Y. Matsubara: None. D. Heron: None. J. Siffroi: None. P. Gobalakichenane: None. M. Lachtar: None. D. Mitanchez: None. S.  P11
.20D Chantot-Bastaraud: None. Deleterious mutations in one third of non-syndromic discontinuous cleft lip and palate patients  P11
.17A A novel missense variant of MA P3
K7 causes B. Demeer1,2,3, N. Revencu2,4, R. Helaers2, C. Gbaguidi5, cardiospondylocarpofacial syndrome by dominant S. Dakpe5,3, G. François6, B. Devauchelle5,3, B. Bayet7, negative effect M. Vikkula2 T. Kaname1, K. Saito2, K. Yanagi1, M. Takeshita1, 1Center for Human Genetics, CLAD nord de France, CHU N. Kobayashi1, T. Tohma3, I. Inoue4, Y. Matsubara5 Amiens-Picardie, amiens, France, 2Human Molecular Genetics, de Duve Institute, Université catholique de 1Dept Genome Medicine, NationalCenter for Child Health Louvain, Brussels, Belgium, 3EA CHIMERE, Université and Development, Tokyo, Japan, 2Invertebrate Genetics Picardie Jules Verne, Amiens, France, 4Center for Human Laboratory,NationalInstituteofGenetics,Mishima,Japan, Genetics, Cliniques universitaires Saint-Luc, University of 3Wanpaku Clinic, Okinawa, Japan, 4Div Human Genetics, Louvain, Brussels, Belgium, 5Department of Maxillofacial National Institute of Genetics, Mishima, Japan, 5National Surgery and Stomatology, centre de compétence fentes et Center for Child Health and Development, Tokyo, Japan malformations faciales (MAFACE), CHU Amiens-Picardie, amiens, France, 6Department of Pediatrics, Cliniques Cardiospondylocarpofacial syndrome (CSCF) is character- universitaires Saint-Luc, University of Louvain, Brussels, ized by growth retardation, dysmorphic facial features, Belgium,7CentreLabiopalatin,DivisionofPlasticSurgery, brachydactyly, vertebral synostosis, cardiac septal defects, Cliniques universitaires Saint Luc, Brussels, Belgium and deafness. Here we report a patient with growth retardation, dys- Cleft of the lip and/or palate (CLP) are among the most morphic facial appearance, vertebral abnormalities and common birth defects, with an approximate incidence of 1/ congenitalheartdefectassociatedwithapathogenicvariant 700 live births and with a wide variability of expression in MA P3
K7 identified by whole exome sequencing (WES) dependingonethnicity,genderandclefttype.Whencleftof and animals model analyses. The patient was a four-year- the palate is associated with a cleft of the lip with old boy. The boy was born at 39 weeks of gestation with preservation of the primary palate, it defines an atypical apgarindexof3(1min)and6(5min).Afterbirth,theboy phenotype called discontinuous cleft. Although this pheno- wassoonadministratedourhospitalduetoseverecyanosis. type may represent 5% of clefts of the lip and/or palate At4year-of-age,thepatientshowedshortstature(-5S.D.), (CLP), it is rarely specifically referred to and its developmental delay, dysmorphic facial features with pathophysiology is unknown. To date only few WES macrocephalus, long face, frontal bossing, epicanthal fold studies, mostly applied to familial cases, have been and mid-face hypoplasia, coarctation of aorta and atrial performed to search for rare coding variants in non- septaldefect,scoliosis,vertebralsynostosis,andjointlaxity. syndromicCLPindividuals.Onestudyidentifiedmutations Written informed consent was obtained from his parents. in genes mutated in syndromic forms of CLP in 10%. We WES analysis was performed and detected variants were conducted Whole Exome sequencing (WES) on 8 non- confirmed using Sanger sequencing. A novel heterozygous syndromic discontinuous CLP individuals whether familial missense variant, c,574 A>G (p. S192
G), in the MA P3
K7 or not in order to identify genes and mutations that could gene was found in the patient. The variant was de novo. underlie this phenotype. We discovered loss-of-function We confirmed the effect of the variant using transgenic mutationsin3outofthe8individualsin3genespreviously Drosophila. The MA P3
K7 gene with the variant was implicated in CLP, representing almost 40% of this cohort. introduced into Drosophila overexpressed eiger Whole exome sequencing of clinically well-definedAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1499 subgroupsofCLP,suchasdiscontinuouscleft,isarelevant  P11
.22B approach to study CLP etiopathogenesis. Non-syndromic Adding evidence to the role of NEUROG1 in congenital discontinuous cleft lip and palate seems to have a strong cranialdysinnervationdisorders(CCDDs):acasereport genetic basis. B. Demeer: None. N. Revencu: None. R. Helaers: J. Dupont1, J. Alves1, A. Taylor Tavares2, P. Janeiro3, None. C. Gbaguidi: None. S. Dakpe: None. G. François: A. Sousa1 None. B. Devauchelle: None. B. Bayet: None. M. Vikkula: None. 1ServiçodeGenética,DepartamentodePediatria,Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa  P11
.21A Norte, Centro Académico de Medicina de Lisboa, Lisbon, A new cloverleaf skull syndrome in a pair of twins Portugal, 2East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Foundation Trust, O. Caluseriu, D. Wang, A. E. Reichert, R. Bhargava, Cambridge, United Kingdom, 3Centro de Referência de F. D. Jacob, T. Laut, C. Young, V. Jain, T. Stryker, Doenças Hereditárias do Metabolismo, Unidade de S. Chandra Doenças Metabólicas, Serviço de Pediatria, Centro Hospitalar Universitário Lisboa Norte, Centro Académico University of Alberta, Edmonton, AB, Canada de Medicina de Lisboa, Lisbon, Portugal Cloverleaf skull (Kleeblattschaedel, OMIM 148800) is a Introduction: CCDDs are a heterogeneous group of rare congenital anomaly resulting from complex craniosy- neurodevelopmental phenotypes caused by a primary nostosis. The condition shows clinical and etiologic disturbance of innervation due to deficient, absent, or heterogeneity. The cause of isolated cloverleafskull is misguided cranial nerves. Several phenotypes still await unknown, and this feature is a component of at least 15 etiological elucidation. monogenic disorders which account for majority of all NEUROG1 encodes Ngn1 which is a basic helix-loop- cloverleaf skull syndromes (JM Graham & PA Sanchez- helix transcription factor essential for the formation of the Lara, 2016). A diamniotic, dichorionic pregnancy was trigeminal, vestibule-cochlear and accessory nerves. So far assessed starting at 20 weeks gestation for skull and it hasn’t been associated with a phenotype in OMIM. possiblebrainanomaliesbyultrasoundandMRI.Aninitial Nonetheless, in 2013 Schroder et al (PMID: 23419067) suspicion of encephaloceles in both fetuses was raised reported a patient with mild developmental delay (DD), followed by that of craniosynostosis. Genetic testing was bilateral profound sensorineural deafness due to absent postponed for the postnatal time. The 24-year-old G2 P1
A1 bilateralVIIInerves,andsevereoromotordysfunction,who mother experienced PPROM at 28 weeks gestation and had a homozygous deletion including NEUROG1. delivery took place by C/S at 32w2d gestation. Both Case description: We describe a 10 year- old boy with newborns, a boy and a girl shared the same phenotype hypotonia, mild DD, bilateral profound sensorineural including typical craniofacial dysostosis associated with hearingloss,andkeratoconjunctivitisduetolackofcorneal cloverleaf skull, and bilateral parietal encephaloceles, reflexandincompleteeyeclosure.Onphysicalexamination micromelia, no skeletal anomalies, and unilateral kidney hehadalongexpressionlessface,righteyeleucocoria,and dysplasia in one fetus. Extensive genetic testing including severe oromotor dysfunction.EMGshowedaxonal sensory targeted sequencing (FGFR1, 2, and 3, TWIST1), cranio- polyneuropathy of the lower limbs. Brain-MRI revealed synostosis panel, exome sequencing (WES) and chromoso- bilateral agenesis/severe hypoplasia of the VIII nerve with malmicroarray(CMA)didnotrevealaclearetiology.WES marked atresia of the internal auditory canals and cochlear and CMA showed a 2.4 Mb VUS deletion at chromosome labyrinth malformation. Trio-exome identified a homo- 18p11.32, seen in gnomAD, shared between the two zygousvariantinNEUROG1(NM_006161.2:c.202G>T,p. affected newborns and the father who has a history of an Glu68*).Thisvariantisclassifiedasuncertainaccordingto unclear seizure disorder, mild developmental delay and no ACMG guidelines, but is considered pathogenic applying craniosynostosis. We are raising the possibility of a new the ClinGen SVI Bayesian classification framework (pos- geneticsyndromewithcloverleafskullofunknownetiology terior probability 0.997). that requires further investigations to inform appropriate Conclusions: The resemblance between our case and counseling for this young family. Schroder’s is remarkable. This case adds support to estab- O. Caluseriu: None. D. Wang: None. A.E. Reichert: lishing NEUROG1 as a new gene for CCDDs associated None. R. Bhargava: None. F.D. Jacob: None. T. Laut: withaverydistinctivephenotype,andcontributestoabetter None.C.Young:None.V.Jain:None.T.Stryker:None. understanding and classification of these disorders. S. Chandra: None.1500 J. Dupont: None. J. Alves: None. A. Taylor Tavares: analysis shows overlapping genes are highly expressed in None. P. Janeiro: None. A. Sousa: None. neurons and astrocytes. Conclusions: We have identified significant overlap of  P11
.23C pathogenic and VUS CNVs between NDD and CHD sam- Genomic overlap between neurodevelopmental ples. This study also shows evidence of specific cell types disorders and congenital heart defects that might contribute to the etiology of NDD and CHD. S. Safizadeh Shabestari: None. S. Sopariwala: None. S.SafizadehShabestari1,S.Sopariwala2,A.Ali1,N.K.Al A.Ali:None.N.K.AlJezawi:None.G.Begum:None.B. Jezawi1, G. Begum1, B. Berdiev1, S. W. Scherer3,4,5, Berdiev: None. S.W. Scherer: None. A. Alsheikh-Ali: A. Alsheikh-Ali1, A. AlBanna6, A. Tayoun6, M. Speevak7, None.A.AlBanna:None.A.Tayoun:None.M.Speevak: D. J. Stavropoulos3,8,7, M. Uddin1,3 None. D.J. Stavropoulos: None. M. Uddin: None. 1MohammedBinRashidUniversityofMedicineandHealth  P11
.24D Sciences, Dubai, United Arab Emirates, 2University of 49 novel recessive candidate genes for intellectual Guelph, Toronto, ON, Canada, 3The Centre for Applied disability and visual impairment in 350 consanguineous Genomics, The Hospital for Sick Children, Toronto, ON, families Canada, 4Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada, 5McLaughlin Centre, S. E. Antonarakis1,2,3, S. A. Paracha4, S. Imtiaz5, University of Toronto, Toronto, ON, Canada, 6Al Jalila A. Nazir4, Y. M. Waryah6, P. Makrythanasis1,7, Specialty Children’s Hospital, Dubai, United Arab S. Qureshi4, J. Khan4, E. Falconnet1, M. Guipponi2, Emirates, 7Department of Laboratory Medicine and C. Borel1, M. A. Ansari5, E. Frengen8, E. Ranza1,2,9, Pathobiology, University of Toronto, Toronto, ON, F. A. Santoni1,10, I. Shah4, K. Gul5,11, J. Ahmed4, Canada, 8Genome Diagnostics, Paediatric Laboratory M. T. Sarwar4, A. M. Waryah6, M. Ansar1 Medicine, The Hospital for Sick Children, Toronto, ON, Canada 1Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland, 2Service of Introduction: The phenotypic overlap between neurode- GeneticMedicine,UniversityHospitalsofGeneva,Geneva, velopmental disorders (NDD) and congenital heart disease Switzerland, 3iG E3
 Institute of Genetics and Genomics of (CHD) is well documented and in this study, we Geneva, Geneva, Switzerland, 4Institute of Basic Medical investigated the genomic overlaps in large clinical cohorts. Sciences, Khyber Medical University, Peshawar, Pakistan, Materials and Methods: We analyzed whole genome 5Department of Genetics, University of Karachi, Karachi, clinical microarray data from10,797NDD and3,174 CHD Pakistan, 6Molecular Biology and Genetics Department, casesfromOntariotoanalyzelargecopynumbervariations Medical Research Center, Liaquat University of Medical (CNVs). Clinical cytogeneticists identified a consensus set and Health Sciences, Jamshoro, Pakistan, 7Biomedical of variants(pathogenic, variant of uncertain significance Research Foundation of the Academy of Athens, Athens, (VUS)) based on established guidelines. We have con- Greece, 8Department of Medical Genetics, Oslo University ducted pathway enrichment and brain single cell tran- Hospital and University of Oslo, Oslo, Norway, 9current criptomeanalysistoidentifycelltypesforpleiotropicgenes address, Medigenome, The Swiss Institute of Genomic that are impacted in both NDD and CHD cases. Medicine, Geneva, Switzerland, 10Department of Results: We have identified 186 de novo CNVs from Endocrinology Diabetes and Metabolism, University NDD and CHD cases. Our analysis on clinically relevant Hospital of Lausanne, Lausanne, Switzerland, CNVrevealed573and181pathogenicvariantsinNDDand 11Department of Bio Sciences, Faculty of Life Sciences, CHD, respectively. Similarly, we have identified 4753 and Muhammad Ali Jinnah University, Karachi, Pakistan 1361 variants of uncertain significance in NDD and CHD, respectively. Genes with at least one exon impacted by Consanguinity, practiced in a substantial fraction of human pathogenic(OR=6.41) and VUS(OR=6.68) deletions populations, reveals numerous rare recessive phenotypes showssignificant(P<0.001)overlapsbetweentheNDDand because of the extensive regions of homozygosity by CHD cases. Similar significant overlap was also observed decent. In Pakistan, the frequency of consanguineous for duplications. “activation of gtpase activity” pathway marriages approaches 70%. To bridge the gap between showed significance (P<0.001) for the overlapping genes. the 1800 known and the estimated >9000 recessive gene- For example, CLSTN1 gene was found to be impacted by phenotypes, we have initiated a Swiss-Pakistani project to pathogenic variants for both NDD and CHD. Single cell identify novel recessive candidate genes for two pheno- types: Intellectual Disability (ID) and Visual ImpairmentAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1501 (VI). We have collected samples from 1265 individuals of coding elements. Therefore, in a cohort of cases with 197 ID, and 1809 individual of 236 VI families of first suspected genetic diseases who underwent chromosomal cousin marriages with at least two affecteds. Exome microarray analysis, we searched for CNV interposed sequence of one affected and genotyping of the whole between relevant disease genes and their corresponding family (parents, all affected and unaffected siblings) has enhancers. beencompletedin166IDand184VIfamiliestodate.The Methods: Out of a dataset of 1,176 CNV from 682 likely causative gene/variant in known genes was found in patients, we selected CNVs that were: (1) smaller than 1 64% of the VI and 32% in the ID families. Thus, there are Mb, (2) devoid of disease genes, and (3) mapped between more unknown “recessive genes” for ID. In 18% of the VI disease genes and their enhancers. Then, we manually familieswehaveidentified25novelcandidategenes,andin analyzed these gene-CNV-enhancers groups for con- 27%oftheID families24such candidates (to bepresented cordance between involved genes and corresponding phe- in the conference). International genematching identified notypes. Finally, we predicted effect of CNV on chromatin additional families in 20% of the candidate genes. Careful folding by the strings-and-binders method. evaluation of the phenotypes is mandatory to assess the Results:235CNV(34%)mappedbetweenadiseasegene possibility of two or more causative genes in certain and one of its enhancers and 26 gene-phenotype relation- families, and to minimize false negative results. Interna- shipswereconsistentaftermanualevaluation.Amongthese tional databases from consanguineous individuals are cases,thebestCNVcandidatewasa50kbdenovodeletion needed to facilitate the assignment of pathogenicity to encompassing a region between sonic hedgehog gene homozygous variants. (SHH) and two of its enhancers, in a patient with limb S.E. Antonarakis: None. S.A. Paracha: None. S. abnormalities, aortic malformation, cardiac arrythmia, and Imtiaz: None. A. Nazir: None. Y.M. Waryah: None. P. facial dysmorphisms. Makrythanasis:None.S.Qureshi:None.J.Khan:None. Conclusion: Systematic analysis of potential positional E.Falconnet:None.M.Guipponi:None.C.Borel:None. effect of CNV has potential for identifying the genetic M.A. Ansari: None. E. Frengen: None. E. Ranza: None. defectsinundiagnosedcasesandinouranalysisitdetected F.A. Santoni: None. I. Shah: None. K. Gul: None. J. a CNV affecting contacts of SHH, an important transcrip- Ahmed:None.M.T.Sarwar:None.A.M.Waryah:None. tion factor involved in development, with its enhancers. M. Ansar: None. M.Pinelli:None.P.Pignataro:None.S.Bianco:None. R. Genesio: None. G. Cappuccio: None. A. Chiariello:  P11
.25A None.M.Nicodemi:None.L.Nitsch:None.N.Brunetti- A CNV positional effect analysis implicates enhancer- Pierri: None. mediated SHH dysregulation in a patient with multiple congenital anomalies and malformations  P11
.28D Downsyndrome-iPSCneurogenesisconnectsdifferential M. Pinelli1,2, P. Pignataro3, S. Bianco4, R. Genesio3, methylation to dysregulated gene expression G.Cappuccio1,2,A.Chiariello4,M.Nicodemi4,L.Nitsch3, N. Brunetti-Pierri1,2 L. Laan1, J. Klar1, M. Sobol1, J. Hoeber1, M. Zakaria1, G. Annerén1, A. Falk2, J. Schuster1, N. Dahl1 1TIGEM,Pozzuoli,Italy,2DipartimentodiScienzeMediche Traslazionali, Università degli Studi di Napoli “Federico 1Department of Immunology, Genetics and Pathology, II”, Naples, Italy, 3Dipartimento di Medicina Molecolare e Science for Life Laboratory, Uppsala University, Uppsala, Biotecnologie mediche, Università degli Studi di Napoli Sweden, 2Department of Neurosceince, Karolinska “Federico II”, Naples, Italy, 4Dipartimento di Fisica, Institutet, Stockholm, Sweden Università di Napoli Federico II, and INFN Napoli Complesso Universitario di Monte Sant'Angelo, Naples, Introduction: Down syndrome is caused by trisomy 21 Italy (T21) in humans and affects approximately one in 700 live births. Despite major efforts the molecular mechanisms Introduction: Despite application of genome-wide diag- leading to the morphological and functional brain abnorm- nostics, such as chromosomal microarrays and whole alities associated with T21 remain largely unknown. exome sequencing,a significantproportion of patients with MaterialandMethods:Toclarifytheroleofdifferential suspected genetic disease continue to lack a definitive methylation on transcriptional dysregulation and neurode- diagnosis. The underlying genetic defects in a subgroup of velopment in T21, we established an induced pluripotent these cases may be altered expression of disease genes due stem cell (iPSC) derived neural cell model showing a to copy-number variants (CNV) involving regulatory non- transctiptional profile comparable to early-mid gestational1502 period. The DNA methylation pattern was analysed using States, 8Department of Pediatrics, Icahn School of IlluminaHumanMethylation450kBeadChipandparalleled Medicine at Mount Sinai. Department of Genetics and by RNA sequencing. Genomics, Icahn School of Medicine at Mount Sinai, New Results: We assessed the genome wide methylation pat- York, NY, United States tern in T21 and euploid iPSC neural derivatives and iden- tified 500 differentially methylated positions (DMPs). Introduction:DPH1variantshavebeenassociatedwithan Approximately half of DMPs (281 of 500) could be anno- ultra-rare and severe neurodevelopmental disorder mainly tated to a total of 202 genes. Gene Ontology (GO) analysis characterized by variable developmental delay, short of these 202 genesrevealed enrichment of neurotransmitter stature, dysmorphic features, and sparse hair. transporters (GO:0006836). Integrated analysis of methy- Material and methods: WES was applied to two trios lation and transcriptome data sets revealed altered expres- with undiagnosed patients. A survey of all the clinical sion in 77 out of the 202 genes in T21 lines. Furthermore, featuresof17DPH1syndromepatientsfrom7familieswas the most profound methylation changes (>9DMPs/gene) performed. The DPH1 enzyme activity of wild-type and of associated with differential expression was observed for a 7 disease-causing mutants was assessed through the diph- cluster of genes (ZNF69 and ZNF700) on chromosome 19 theria toxinADP-ribosylationassay. Ahomology model of encodingzinkfingertranscriptionfactors.TheseZNFgenes the human DPH1-DPH2 heterodimer was built, and mole- have yet unknown functions and are highly expressed cular dynamics simulations were performed to study the during normal embryonic brain development. effect of these variants on the catalytic sites, as well as on Conclusion: Our results suggest that differential methy- the interactions between subunits of the heterodimer. lation contributes to transcriptional dysregulation in T21 Results: Two DPH1 novel variants were identified in 2 neural cells derived from iPSCs. Our study further high- independent families, enriching the clinical delineation of lights a set of ZNF transcription factor genes showing DPH1 syndrome. The enzyme assay demonstrated com- profound differential methylation in T21 neurogenesis. promised functionality for 5 mutations (p.Leu234Pro; p. L. Laan: None. J. Klar: None. M. Sobol: None. J. Ala411Argfs*91; p.Leu164Pro; p.Leu125Pro; p.Tyr112- Hoeber:None.M.Zakaria:None.G.Annerén:None.A. Cys). According to the structural model, p.Leu125Pro may Falk: None. J. Schuster: None. N. Dahl: None. affect dimerization while p.Tyr112Cys, p.Leu164Pro, p. Leu234Pro and p.Pro382Ser may interfere the binding of  P11
.29A the iron-sulphur cluster necessary for catalysis. DPH1 syndrome. Clinical review and structural and Conclusions: The overall good correlation observed functional analyses of seven disease-causing variants between DPH1 protein activity, structural prediction and identified so far clinical features indicate that these biochemical and struc- tural tests may be useful tools for assessing the pathogeni- L. Castilla-Vallmanya1, R. Urreizti1, K. Mayer2, cityofDPH1variantsandforhelpingtopredicttheclinical G. Evrony3, E. Said4, N. Cody5, G. Plasencia6, B. Gelb7, severity of future DPH1 cases. D. Grinberg1, U. Brinkmann2, B. Webb8, S. Balcells1 Funding: Associació Síndrome Opitz C, Spain; Spanish MINECO (SAF2016-75948-R, FECYT-PRECIPITA); Cata- 1Department of Genetics, Microbiology and Statistics, lan Government (2014SGR932); CIBERER (U720); the Faculty of Biology, University of Barcelona, IBUB, IRSJD, MindichInstitute(MCHDI)attheIcahnSchoolofMedicine- CIBERER,Barcelona,Spain,2RochePharmaResearchand Mount Sinai, NY; Genetic Disease Foundation, NY. Early Develpoment. Large Molecule Research, Roche L. Castilla-Vallmanya: None. R. Urreizti: None. K. Innovation Center, Munich, Penzberg, Germany, Mayer:A.Employment(fullorpart-time);Modest;Roche. 3Department of Pediatrics, Icahn School of Medicine at G. Evrony: None. E. Said: None. N. Cody: A. Employ- Mount Sinai, New York, NY, United States, 4Section of ment (full or part-time); Modest; Sema4, a Mount Sinai Medical Genetics, Mater dei Hospital. Department of venture. G. Plasencia: A. Employment (full or part-time); anatomy and Cell Biology, University of Malta, Msida, Modest; Lead Molecular Desgin, S.L. B. Gelb: None. D. Malta, 5Department of Genetics and Genomic Sciences, Grinberg: None. U. Brinkmann: A. Employment (full or Icahn School of Medicine at Mount Sinai., New York, NY, part-time); Modest; Roche. B. Webb: None. S. UnitedStates,6LeadMolecularDesign,S.L,SantCugatdel Balcells: None. Vallès, Spain, 7Department of Pediatrics, Icahn School of Medicine at Mount Sinai. Department of Genetics and  P11
.30B Genomics, Icahn School of Medicine at Mount Sinai. Pontocerebellar hypoplasia with Mindich Child Health and Development Institute, Icahn rhombencephalosynapsis and microlissencephaly School of Medicine at Mount Sinai, New York, NY, United expands the spectrum of PCH type 1BAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1503 M. Vezain1, F. Marguet2, M. Bucourt3, P. Letard3, M. Vezain: None. F. Marguet: None. M. Bucourt: A. Delahaye4, T. Frébourg5, A. Laquerrière2, P. Saugier- None.P.Letard:None.A.Delahaye:None.T.Frébourg: Veber5 None. A. Laquerrière: None. P. Saugier-Veber: None. 1Normandie Univ, UNIROUEN, Inserm U1245, F 76000,  P11
.31C NormandyCenterforGenomicandPersonalizedMedicine, MRneuroimagingandEEGfindingsin62patientswith Rouen, France, 2Normandie Univ, UNIROUEN, INSERM Fetal alcohol spectrum disorders U1245 and Rouen University Hospital, Department of Pathology, F76000, Normandy Center for Genomic and S. Boronat1, E. Vázquez2, Á. Sánchez-Montañez2, Personalized Medicine, Rouen, France, 3Paris University M. Vicente2, M. del Campo3 Hospital,JeanVerdierHospital, Department ofPathology, F93141, Bondy, France, 4Paris University Hospital, Jean 1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, Verdier Hospital,Department ofGenetics, F93141,Bondy, 2Hospital de la Vall d´Hebron, Barcelona, Spain, 3Rady France,5NormandieUniv,UNIROUEN,InsermU1245and Children´s Hospital, San Diego, CA, United States Rouen University Hospital, Department of Genetics, F 76000, Normandy Center for Genomic and Personalized Introduction:Thefetalalcoholspectrumdisorders(FASD) Medicine, Rouen, France span a group of neurodevelopmental disorders related to maternal alcohol intake during pregnancy. Studies correlat- Rhombencephalosynapsis (RES) is a rare cerebellar mal- ing EEG and neuroimaging with specific FASD categories formation, developing during embryogenesis, defined by are lacking. complete or partial vermis agenesis with fusion of the Materialandmethods:Classificationof62patientsinto cerebellar hemispheres. It occurs either alone or in 3 FASD categories, including fetal alcohol syndrome association with other cerebral and/or extracerebral anoma- (FAS), partial FAS (pFAS) and alcohol related neurodeve- lies. Its association with microlissencephaly is exceedingly lopmental disorders (ARND). Prospective studies of MR rare and to date, only a heterozygous de novo missense imaging and EEG. variant in ADGR L2
, a gene encoding Adhesion G-Protein- Results:Neuroimaging:Themostfrequentfindingswere Coupled Receptor  L2
, has been identified. Here, we report corpus callosum abnormalities (42%) and cerebellar vermis two siblings of Roma origin presenting with severe growth hypoplasia (24%). Additional findings were vascular retardation, fetal akinesia, microlissencephaly and small anomalies, gliosis, prominent perivascular spaces, occipito- cerebellumwithvermianagenesis.Neuropathologyshowed cervical junction and cervical vertebral anomalies, pituitary extreme paucity in pontine transverse fibres, rudimentary hypoplasia,arachnoidcysts,andcavumseptumpellucidum. olivary nuclei, RES and vanishing motoneurons in both Only16%hadnormalneuroimaging.EEG(includingsleep foetuses. Comparative foetus-parent exome sequencing recording in 43%) showed anomalies in 23%, including revealed in both foetuses a homozygous variant in exon 1 slowing of background activity and interictal epileptiform of the EXOS C3
 gene encoding a core component of the discharges, focal and/or generalized, and 3 of them had RNA exosome, c.92G>C;p.(Gly31Ala). EXOS C3
 variants epilepsy. In one patient, seizures were first detected during account for 40% to 75% of patients affected by ponto- the EEG recording and one case had an encephalopathy cerebellar hypoplasia with spinal muscular atrophy with electrical status epilepticus during slow sleep (ESES). (PCH1B). The c.92G>C variant is a founder mutation in Focal interictal discharges in our patients did not imply the the Roma population and has been reported in severe presence of underlying visible focal brain lesions in the PCH1B. PCH1B is characterized by a broad phenotypic neuroimaging studies, such as cortical dysplasia or poly- spectrum, ranging from mild phenotypes with spasticity, microgyria. However, they had nonspecific brain MR mildtomoderateintellectualdisability,distallypronounced abnormalities, including corpus callosum hypoplasia, ver- muscular atrophy, and cerebellar atrophy, to severe mishypoplasiaorcavumseptumpellucidum.Thelatterwas phenotypes with profound global developmental delay, significantlymorefrequentinthegroupwithEEGabnormal progressive microcephaly, and atrophy of the cerebellar findings (p < 0.01). hemispheres. The typical dragonfly pattern of the cerebel- Conclusion: Patients with FASD exhibit frequent and lumobservedinPCH1Bpatientswithflattenedhemispheres diverse neuroimaging and EEG findings. and relative prominence of vermis differs markedly from S. Boronat: None. E. Vázquez: None. Á. Sánchez- RES. This novel foetal presentation expands the spectrum Montañez: None. M. Vicente: None. M. del of PCH1B and highlights the diversity of RES aetiologies. Campo: None.1504  P11
.32D Conclusions:Wereportthatdenovomissensemutations Gating-affecting mutations in KCNK4 cause a in KCNK4 cause a recognizable syndrome for which we recognizable neurodevelopmental syndrome propose the acronym FHEIG (facial dysmorphism, hyper- trichosis, epilepsy, intellectual disability/developmental F. C. Radio1, P. Calligari2, V. Caputo3, M. L. Dentici1, delay, and gingival overgrowth). Overall, our findings N. Falah4, F. High5, F. Pantaleoni1, S. Barresi1, illustrate the pleiotropic effect of dysregulated KCNK4 A. Ciolfi1, S. Pizzi1, A. Bruselles6, R. Person7, function and provide support to the hypothesis of a gating S.Richards7,M.T.Cho8,D.J.ClapsSepulveda1,S.Pro1, mechanism based on the lateral fenestrations of K2P R. Battini9, G. Zampino10, M. C. Digilio1, channels. G. Bocchinfuso2, B. Dallapiccola1, L. Stella2, F.C. Radio: None. P. Calligari: None. V. Caputo: C. K. Bauer11, M. Tartaglia1 None. M.L. Dentici: None. N. Falah: None. F. High: None. F. Pantaleoni: None. S. Barresi: None. A. Ciolfi: 1Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, None. S. Pizzi: None. A. Bruselles: None. R. Person: 2University of Rome Tor Vergata, Rome, Italy, 3Sapienza None. S. Richards: None. M.T. Cho: None. D.J. Claps University of Rome, Rome, Italy, 4Nemours Children’s Sepulveda: None. S. Pro: None. R. Battini: None. G. Hospital, Orlando, FL, United States, 5Mass General Zampino: None. M.C. Digilio: None. G. Bocchinfuso: Hospital for Children, Massachusetts General Hospital, None. B. Dallapiccola: None. L. Stella: None. C.K. Boston, MA, United States, 6Istituto Superiore di Sanità, Bauer: None. M. Tartaglia: None. Rome, Italy, 7GeneDX, Gaithersburg, MD, United States, 8GeneDX, Gaithersburg, Italy, 9Stella Maris, IRCCS,  P11
.33A Calambrone, Italy, 10Fondazione Policlinico Universitario De novo mutation of CSNK2B encoding beta subunit of A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, casein kinase 2 causes Filippi syndrome Rome, Italy, 11University Medical Center Hamburg- Eppendorf, Hamburg, Germany M. Asif1,2,3, E. Kaygusuz1,2,3,4, F. Brancati5,6, C. Nienberg7, A. Nickelsen8, J. Jose7, J. Hochscherf9, Introduction: Aberrant activation or inhibition of potas- K. Niefind9, A. A. Noegel2, P. Nürnberg1,10, sium (K+) currents across the plasma membrane of cells M. S. Hussain1,2,3 hasbeencausallylinkedtoalteredvariousfunctionsinboth excitable and non-excitable cells. KCNK4 belongs to the 1Cologne Center for Genomics (CCG), University of mechano-gated ion channels of the TRAAK/TREK sub- Cologne, Cologne, Germany, 2Institute of Biochemistry I, familyoftwopore-domain(K2P)K+channels.WhileK2P Medical Faculty, University of Cologne, Cologne, channels are well-known to contribute to the resting Germany, 3Center for Molecular Medicine Cologne membrane potential/cellular excitability, their involvement (CMMC), University of Cologne, Cologne, Germany, in pathophysiological processes remains largely 4Institute of Human Genetics, University Medical Center uncharacterized. Göttingen, Göttingen, Germany, 5Medical Genetics, Materials and Methods: In the frame of the Undiag- Department of Life, Health and Environmental Science, nosedPatientsProgramattheOspedalePediatricoBambino University of L’Aquila, L’Aquila, Italy, 6Istituto Gesù, Rome, the exomes of two unrelated subjects with a Dermopatico dell’Immacolata (IDI) IRCCS, Rome, Italy, molecularly unexplained, clinically superimposable pheno- 7Institute of Pharmaceutical and Medicinal Chemistry, type were scanned to identify the underlying molecular Westphalian Wilhelms-University, Münster, Germany, cause. Patch-clamp analyses, co-expression experiments 87Institute of Pharmaceutical and Medicinal Chemistry, and molecular dynamics simulations were used to func- Westphalian Wilhelms-University, Münster, Germany, tionally characterized the genomic findings. 9Department of Chemistry, Institute of Biochemistry, Results: Two variants in KCNK4 were identified as the University of Cologne, Cologne, Germany, 103Center for only shared events in these two patients and a third was Molecular Medicine Cologne (CMMC), University of found by using GeneMatcher. Patch-clamp analyses docu- Cologne, Cologne, Germany mented an impressive gain-of-function of the identified KCNK4 channel mutants. Co-expression experiments pro- Introduction: Filippi syndrome (FS) is a rare genetic vided evidence of the dominant behavior of the disease- condition characterized by short stature, microcephaly, causing mutations. Remarkably, molecular dynamics intellectual disability, syndactyly and distinctive facial simulations consistently indicated that mutations seal the features. A total of 33 patients from 25 families are lateral intramembrane fenestration proposed to negatively documented worldwide. Previously, we reported the first control K+ flow. gene (CKA P2
L) involved in FS. Here, we ascertain aAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1505 mutation in CSNK2B as a likely cause of FS. CSNK2B using TALENs, where expression of the long isoform of encodes CK2β – thebeta subunitof casein kinase 2, which FLNA was specifically blocked. plays pivotal role in diverse cellular processes. Results: FLNA expression was detected in the muscular Material and Methods: To identify the causal variant, layer of the small intestine from early embryonic stages. trio whole-exome sequencing was performed. To further Moreover,FLNAmutationsassociatedwithCSBS,blocked exploretheconsequencesofthemutation,pulldownassays, expression of the long isoform of FLNA, but did not affect microscale thermophoresis (MST), immunofluorescence the binding of FLNA to actin filaments. These mutations andRNA-seqtranscriptomeprofilingoflymphoblastoidcell also impaired contractility of human intestinal smooth lines (LCLs) were conducted. muscle cells in vitro. Finally, FLNA mutant fish were phe- Results: A pathogenic de novo mutation (CSNK2B: notypicallyindistinguishablefromwild-typefish,exceptfor c.94G>C; p.Asp32His) was identified in an Italian patient a significant reduction in gut length (10%), and diminished diagnosedwith FS. The mutationcaused anup-regulation of intestinal motility. CSNK2B expression at transcript and protein level, which Conclusion: Our results bring new insights into CSBS resulted in impaired cross talk between α and β subunits of pathogenesis, by showing that the intestinal defects asso- CK2. The effects of mutation were also observed in two ciated with this disease, are likely caused by impaired crucial pathways; canonical Wnt signaling (CWS) and DNA smoothmusclecontraction, as a consequence ofthe loss of damageresponse(DDR).InCWS,animpairedinteractionof expression of the long isoform of FLNA. DV L3
 with mutant CK2β and up-regulation as well as mis- M.M.Alves:None.D.Halim:None.Y.Zhao:None.S. localizationofβ-catenininmutantLCLswasfound.InDDR, Overkleeft:None.H.vanderLinde:None.A.S.Brooks: γH2AXwassubstantiallyincreasedinmutantLCLs.Finally, None. A.J. Burns: A. Employment (full or part-time); RNA-seq data confirmed differential expression of proteins Modest; Takeda Pharmaceuticals. R.M.W. Hofstra: None. involved in the aforementioned pathways. Conclusion: Our findings suggest that CSNK2B is a  P11
.35C novel candidate gene for Fillippi syndrome and the muta- Intragenic de novo frame shift deletion of two exon tion found in our patient causes the disorder by dysregu- confirms a role for FND C3
B in human craniofacial lating CWS and DDR. development and possibly neuro-psychiatric M.Asif:None.E.Kaygusuz:None.F.Brancati:None. development C.Nienberg:None.A.Nickelsen:None.J.Jose:None.J. Hochscherf:None.K.Niefind:None.A.A.Noegel:None. I. K. Ystrøm1, R. Chistensen1, E. M. Vestergaard1, P. Nürnberg: None. M.S. Hussain: None. M. Sommerlund1, L. Graversen1, M. F. Boxill2, U. B. Jensen1  P11
.34B Intestinal elongation and motility require the long 1Aarhus University Hospital, Aarhus N, Denmark, isoform of FLNA 2Regional Hospital Midt, Viborg, Denmark M.M.Alves,D.Halim,Y.Zhao,S.Overkleeft,H.vander Background: De novo 3q26.31 microdeletions has been Linde, A. S. Brooks, A. J. Burns, R. M. W. Hofstra reported in four cases with dysmorphic facial features. The overlapping deleted region was shown to only contain the Erasmus University Medical Center, Rotterdam, FND C3
B gene. The product of this gene, the fibronectin Netherlands domain III-containing protein 3B (also known as factor for adipocyte differentiation-104 (FAD104)) has been identi- Introduction: Filamin A (FLNA) encodes a cytoskeletal fied in mouse models as a positive regulator of adipocytes protein that regulates cell shape by cross-linking actin differentiation butalso asa negativeregulator of osteoblast filaments. Mutations in FLNA have been associated with a differentiation. Cranial changes have also been described wide spectrum of disorders, and more recently with an for FND C3
B knock-out mice. X–linked form of Congenital Short Bowel Syndrome Methods: Agilent 180K oligo array CGH analysis and (CSBS). These mutations are located between two methio- clinical evaluation including a neurodevelopmental nines present at the N-terminal of the protein, and seem to evaluation. only block expression of the long isoform of FLNA. Results: We report the first case of a de novo intragenic MaterialandMethods:TounderstandtheroleofFLNA microdeletion involving two exons of the FND C3
B gene in intestinal development, expression studies at different resultinginanframeshiftdeletion.Thepatientisaboywith human embryonic stages, and several in vitro studies were subtle dysmorphic facial features and behavioral problems performed. A transgenic zebrafish line was also generated1506 within the autism spectrum. The boy is 9 years old and we in the intron four. Considering only the pathogenic muta- present the developmental evaluation at different ages. tions,PTPN11mutationrateinourcohortwasaround16%. Conclusion: CNVs have contributed much to our Conclusions: Since the first diagnosis of PTPN11 understanding of disease development and the underlying mutations in a Moroccan Noonan family, considerable mechanism. However, the role of individual genes in dis- efforts have been made to improve the genetic services easedevelopmentcanbedifficulttointerpretincaseswhere offered to patients. Although several challenges are still the deletion includes more genes or expands beyond the retarding the progress of NS genetic diagnosis in Morocco, boundaries of a single gene. Such deletions may include the NGS technologies that have recently been installed crucial elements that affects the 3 dimensional structure of seems to provide a promising future. the genome and therefore affects the function of several I. El Bouchikhi: None. I. Samri: None. F. Moufid: genes in the region. This is the first case with an intragenic None. L. Bouguenouch: None. K. Belhassan: None. M. exondeletioninFND C3
Bsupportingaroleforthisgenein Iraqui Houssaini: None. S. Atmani: None. K. both craniofacial development and neuro-psychiatric Ouldim: None. development. I.K. Ystrøm: None. R. Chistensen: None. E.M. Ves-  P11
.37A tergaard: None. M. Sommerlund: None. L. Graversen: Does my expertise still make a difference? A single- None. M.F. Boxill: None. U.B. Jensen: None. clinician’s experience of genomic sequencing in 120 pediatric patients  P11
.36D Genetic screening of Noonan syndrome in central north F. B. Bengur1, E. Kar1, K. Yararbas2, Y. Alanay3 of Morocco: achievements, challenges & perspectives 1Acibadem Mehmet Ali Aydinlar University School of I.ElBouchikhi1,I.Samri1,F.Moufid1,L.Bouguenouch1, Medicine, Istanbul, Turkey, 2Acibadem Mehmet Ali K. Belhassan1, M. Iraqui Houssaini2, S. Atmani3, Aydinlar University School of Medicine, Department of K. Ouldim1 MedicalGenetics,Istanbul,Turkey, 3AcibademMehmetAli Aydinlar University School of Medicine, Department of 1MedicalGeneticsandOncogeneticsLaboratory,HassanII Pediatrics, Pediatric Genetics Unit, Istanbul, Turkey University Hospital, Fez, Morocco, 2Faculty of Sciences & techniques, Sidi Mohamed ben Abdellah University, Fez, Introduction: Genomic sequencing (WES/WGS) provides Morocco, 3Medico-Surgical Unit of Cardio-Pediatrics diagnosis in 40% of unsolved cases in the pediatric Department, Hassan II University Hospital, Fez, Morocco population. Current clinical approach mandates integration ofphenotypicdatawithvariantanalysis.Thisstudyaimsto Introduction:Noonansyndromeisanautosomaldominant assess the diagnostic yield of NGS ordered by a single disorder with an incidence of 1/1000 - 2500 live births. clinician to a single laboratory. WhiletheveryfirstgenetictestinMoroccowascarriedout Materials and Methods: Data from 120 patients were in the nineties, the first genetic diagnosis of Noonan retrospectively analyzed. Time interval was September syndrome (NS) was performed seven years ago. Thus, the 2015-January 2019. Tests were performed at Centogene, aim of this presentation is to expose results of molecular Germany. All patients were re-evaluated after test results. screening of Noonan syndrome in the central north of Variants of unknown significance (VUS) were specifically Morocco, and discuss its challenges and perspectives. re-analyzed with evolving clinical story, current literature Material and methods: Thirty-one patients were and results ofother investigations.Diagnoses confirmed by recruited in the medical genetics laboratory from different NGS (ACMG Class 1 or 2 variants) were coined as “sug- regions of central North of Morocco. After obtaining gestedmoleculardiagnosis”.Thoseestablishedafterclinical informed consents, genomic DNAs were extracted from re-analysis were considered “robust clinical diagnosis”. leucocytes. Then, all samples were screened for PTPN11 Results: Median age was 4.7 (0.1-15.1) years. M/F ratio mutations using PCR and direct sequencing. The obtained was 1.14. Time passed since first symptom until a robust sequences were analyzed using NCBI bioinformatics tools. diagnosiswas2.8(0.1-14.3)years.Blendedphenotypewas Results: We have detected five pathogenic missense presentin8%.Table1summarizesthedata.Diagnosticrate mutations, one synonymous mutation and three novel of trio-based WES was significantly higher than proband- intronic duplications. All variants were heterozygous. The only WGS, where both increased after clinical re- pathogenic mutations were clustered on exons three and evaluation. Suggested molecular diagnosis was sig- eight, while most of thenon-codingvariants were localised nificantly higher in trio-based testing. Consanguinity,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1507 Numberofindexpatients Suggestedmolecular Robustgenetic Difference Nodiagnosis(%) diagnosis diagnosis betweenmolecular androbust diagnosis Positive(%) pvalue Positive(%) pvalue Percentage pvalue Testtype 0.008 0.779 0.054 Proband-onlyWES 13 7(54%) 10(77%) 23% 3(23%) Trio-basedWES 59 27(46%) 42(71%) 25% 17(29%) Proband-onlyWGS 41 10(24%) 28(68%) 44% 13(32%) Trio-basedWGS 7 6(86%) 6(86%) 0% 1(14%) Testtype(proband-onlyvstrio- 0.041 0.776 0.055 based) Proband-only 54 17(32%) 38(70%) 39% 16(30%) Trio-based 66 33(50%) 48(73%) 23% 18(27%) Consanguinity 0.647 0.717 0.891 No 89 36(40%) 63(71%) 30% 26(29%) Yes 31 14(45%) 23(74%) 29% 8(26%) Affectedsiblings 0.508 0.856 0.593 No 100 43(43%) 72(72%) 29% 28(28%) Yes 20 7(35%) 14(70%) 35% 6(30%) Dysmorphicfeatures 0.666 0.861 0.524 No 58 23(40%) 42(72%) 33% 16(28%) Yes 62 27(44%) 86(72%) 27% 18(28%) affected siblings and dysmorphic features did not have an (HSA), Centro Hospitalar Universitário do Porto (CHUP), effect on diagnostic rate. Porto, Portugal, 5Serviço de Genética, Centro Hospitalar Conclusions:Ourresultsemphasizetheadditionalimpact Trás-os-Montes e Alto Douro (CHTMAD, EPE), Vila Real, ofclinical expertise. Anexperiencedclinicianfamiliar with Portugal, 6Department of Human Genetics, Donders rare disease diagnoses is essential to determine whether a Institute for Brain, Cognition and Behaviour, Radboud variant is causative, contributory or unrelated. University Nijmegen, Nijmegen, Netherlands F.B.Bengur:None.E.Kar:None.K.Yararbas:None. Y. Alanay: None. Thisstudyaimedtoidentifytheunderlingmoleculardefect in a family with two male adults showing a similar  P11
.38B phenotype consisting of distinct facial features, intellectual Flow-cytometric analysis confirms the GPI biosynthesis disability with a complete lack of speech, hypotonia, in deficitinafamilywithanatypicalphenotypeassociated combination with abnormal muscle, skin, urinary, and with a PIGA variant dentalfindings.Exome sequencing(ES)wascarriedouton oneofthepatients.Functionalvalidationwasperformedby N. Maia1,2, P. Jorge1,2, M. L. Queirós3,4,2, M. Martins5, flow cytometry determining surface expression of GPI I. Marques1,2, R. Santos1,2, A. de Brouwer6, M. Lima3,4,2 (identifiedbyFLAER)andGPIanchoredproteins(GPI-AP) in white and red blood cells. ES identified a hemizygous 1Unidade de Genética Molecular, Centro de Genética variant in PIGA gene: NM_002641.3: c.232A>G; p. Médica Jacinto de Magalhães (CGMJM), Centro (Lys78Glu). Sanger sequencing confirmed the presence of Hospitalar Universitário do Porto (CHUP, EPE), Porto, the variant in both brothers and established that the mother Portugal, 2Unidade Multidisciplinar de Investigação is a carrier. Flow cytometry results showed that, despite Biomédica (UMIB), Instituto de Ciências Biomédicas Abel normal peripheral blood counts, patient granulocytes/ Salazar (ICBAS), Universidade do Porto, Porto, Portugal, neutrophils and monocytes were partially deficient in cell 3Serviço de Hematologia Clínica, Hospital de Santo surface GPI and at least some GPI-AP (e.g. CD16 in António (HSA), Centro Hospitalar Universitário do Porto neutrophils and CD14 in monocytes), supporting the (CHUP), Porto, Portugal, 4Laboratório de Citometria, pathogenicity of the PIGA variant. In contrast, red blood ServiçodeHematologiaClínica,HospitaldeSantoAntónio cells had normal levels of GPI-AP (CD55 and CD59). The1508 p.(Lys78Glu) missense mutation results in a partial bp pseudo-exon corresponding to a non-coding region deficiency of GPI and GPI-AP affecting the myeloid, but located at the beginning of the long arm of chromosome X nottheerythroidcells.Notably,theaminoacidsubstitution (Xq11.1).Thepseudo-exonwasflankedbyacanonicalAG describedhereinleadstodiminishedexpressionofCD14on on its 5’side and contained two putative polyadenylation monocytes as well, representing the first monocyte defect signals on its 3’side. Cytogenetic Microarray Analysis described in a germline PIGA case. Funding: UMIB is showed the presence of a 3.8 Mb gain of the Xq11.1q12 supported by National Funds through the FCT - Fundação chromosomal region. PCR amplification of junction frag- paraaCiênciaeaTecnologiaintheframeworksoftheUID/ ments and FISH analysis confirmed that the Xq11.1q12 Multi/0215/2016 project. Grants: NM, DEFI-CHUP, EPE duplicated region was inserted in F8 intron 25. PhD 2015 and PJ, research grant 145/2015. Conclusion: Exceptionally, this structural variant char- N. Maia: None. P. Jorge: None. M.L. Queirós: None. acterization was conducted from cDNA analysis. To our M. Martins: None. I. Marques: None. R. Santos: None. knowledge, this is the first case of chromosomal rearran- A. de Brouwer: None. M. Lima: None. gement revealed through nanopore sequencing without previous cytogenetic study. This study highlights the use-  P11
.39C fulness of single molecule long-read sequencing technolo- Severe haemophilia A caused by an unbalanced gies for molecular diagnosis of genetic disorders especially chromosomal rearrangement identified using nanopore when structural variants are suspected. sequencing N. Chatron: None. C. Schluth-Bolard: None. M. Fré- tigny: None. A. Labalme: None. G. Vilchez: None. S. N. Chatron1,2, C. Schluth-Bolard1,2, M. Frétigny3, Castet: None. C. Négrier: None. D. Sanlaville: None. C. A. Labalme1, G. Vilchez4, S. Castet5, C. Négrier3,6, Vinciguerra: None. Y. Jourdy: None. D. Sanlaville1,2, C. Vinciguerra3,6, Y. Jourdy3,6  P11
.40D 1Servicedegénétique,CentredeBiologieetPathologieEst, Modelling Hirschsprung disease with human induced Hospices Civils deLyon,Lyon,France, 2EquipeGENDEV, pluripotent stem cells: a preliminary study CRNL, INSERM U1028, CNRS UMR5282, UCB L1
, Lyon, France, 3Service d’hématologie Biologique, Centre de A.Zada1,K.C.MacKenzie1,E.Brosens1,B.M.deGraaf1, Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, T. van Gestel1, T. Wai1, P. Sloots2, R. M. H. Wijnen2, France, 4Cellule bioinformatique de la plateforme de M. M. Alves1, R. M. W. Hofstra1 séquençage NGS du CHU de Lyon, Groupement Hospitalier Est, Lyon, France, 5Service de traitement des 1DepartmentofClinicalGenetics,ErasmusMedicalCenter, hémophiles, Hôpital Universitaire de Bordeaux, Bordeaux, Rotterdam,Netherlands,2DepartmentofPediatricSurgery, France, 6EA 4609 Hémostase et cancer, Université Claude Erasmus Medical Center, Rotterdam, Netherlands Bernard Lyon 1, Lyon, France Introduction:Hirschsprungdisease(HSCR)isacongenital Background: No F8 genetic abnormality was detected in neuropathy characterized by the lack of the enteric nervous about 2% of severe haemophilia A patients using conven- system in the distal part of the colon. Mutations in more tional genetic approaches. In these patients, deep intronic than20geneshavebeenidentified.Onesinglegoodinvitro variation or F8 disrupting genomic rearrangement could be model to determine the functional consequences of the causal. different mutated genes is lacking. In this study we tested Objective: to characterize a Xq28 rearrangement dis- whether induced pluripotent stem cells (iPSCs) could serve rupting F8 in a genetically unresolved severe haemophilia as such a model. A patient. Material and Methods: Functional assays of the EDN3, MaterialsandMethods:alargepanelofcomprehensive EDNRB, and ZEB2 variants identified, were performed by molecular techniques including long-range PCR, RNA overexpressing the corresponding variant in HEK293 cells. analysis, nanopore sequencing and cytogenetic analysis qRT-PCR and Western Blot were performed to investigate were used. the effect of these mutations on protein expression. In Results: Long-range PCR performed throughout F8 parallel, five iPSC lines obtained from fibroblasts derived identified a non-amplifiable region in intron 25 indicating fromfourHSCRpatientscarryingthemutationstested,and the presence of a chromosomal rearrangement. F8 mRNA one individual control were differentiated into Enteric analysis including 3’Rapid Amplification of cDNA Ends NeuralCrestCells(ENCCs)accordingapreviousdescribed and nanopore sequencing showed the presence of a F8 protocol.ENCCsdifferentiationwasevaluatedusingFACS fusiontranscriptinwhichF8exon26wasreplacedbya742 and immunostaining.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1509 Results: The EDN3 mutant showed lower expression in Results: The patient carried a 2.3 Mb chromosomal comparison to the wild type, while the variants in EDNRB deletion at9q31.2thatexcludesPALM2/AKA P2
. Targeted and ZEB2 had the opposite effect. iPSC-derived ENCCs sequencing revealed no other causative mutations or novel were positive for the neuronal marker HNK1. However, rare variants in this proband. In our patient set, no likely patient derived iPSCs yield lower percentage of ENCCs causative mutations were found. than controls. Conclusions: We report a patient with a deletion at Conclusions: The mutations identified in RET, GFRA1, 9q31.2 yet intact PALM2 and AKA P2
 genes. The roles of EDN3,EDNRBandZEB2showedsignificantdifferenceson PALM2andAKA P2
inKallmannsyndromerequirefurther proteinexpression,andseemtoimpairiPSCsdifferentiation investigations. into ENCCs. However, further studies are needed to fully Grants: by the Academy of Finland, Foundation for characterize the effect of these mutations on the iPSC- Pediatric Research, Sigrid-Juselius Foundation, Novo Nor- derived ENCCs to show whether indeed iPSCs are the disk Foundation, Emil Aaltonen Foundation, University of perfect model system for HSCR. Helsinki,HelsinkiUniversityCentralHospital,Päivikkiand A. Zada: None. K.C. MacKenzie: None. E. Brosens: Sakari Sohlberg foundation None. B.M. de Graaf: None. T. van Gestel: None. T. A. Iivonen: None. K. Vaaralahti: None. V. Sidoroff: Wai: None. P. Sloots: None. R.M.H. Wijnen: None. M. None. T. Raivio: None. M. Alves: None. R.M.W. Hofstra: None.  P11
.42B  P11
.41A Overgrowth disorders with intellectual disability due to ScreeningforPALM2andAKA P2
mutationsinasetof mutations in chromatin regulatory genes congenital hypogonadotropic hypogonadism patients: a case with a chromosomal deletion at 9q31, PALM2 and P. Lapunzina1, J. A. Tenorio1, P. Arias1, I. Dapía1, AKA P2
 chromosomal region G. Gordo1, P. Alarcón2, S. García-Miñaur1, F. Santos- Simarro1, V. Martínez-Glez1, M. Palomares1, M. Solís1, A. Iivonen1, K. Vaaralahti1, V. Sidoroff2, T. Raivio1,3 S. Ramos1, The SOGRI consortium, V. L. Ruíz-Pérez3, J. Nevado1 1Institute of Biomedicine/Physiology, Stem Cells and Metabolism Research Program, Helsinki, Finland, 2North 1Medical and Molecular Genetics Institute (INGEMM), Karelia Central Hospital, Joensuu, Finland, 3New Madrid, Spain, 2Hospital Clínico Universidad de Chile, Children’s Hospital, Pediatric Research Center, Helsinki Santiago,Chile,34-InstitutodeInvestigacionesBiomédicas University Central Hospital, Helsinki, Finland de Madrid (CSIC-UAM), Madrid, Spain Introduction: The genetic cause of congenital hypogona- Introduction: Overgrowth disorders (OGS) encompass an dotropic hypogonadism (cHH) remains unidentified in half heterogeneous group on conditions in which the main of the patients. PALM2 encodes paralemmin-2, a para- features is an increase of weight, height and head lemmin family plasma membrane protein, and AKA P2
 circumference or a combination of all, above +2SD for encodes an A-kinase anchor protein. PALM2 and AKA P2
 age, sex and ethnicity. Most OGS has additional features are adjacent on chromosome 9 and can form fusion associated such as intellectual disability. Thus, the aim of transcripts. PALM2 has been implicated in cHH, since a this project was to perform a molecular screening of OGS deleterious PALM2 mutation has been found in one cHH withIDandtounderstandtheunderlyingphysiopathogenic patient. A chromosomal translocation causing monoallelic associated mechanisms. expression of AKA P2
 has been found in another patient Material and Methods: Patients were selected retro- withKallmannsyndrome(cHHandanosmia/hyposmia)and spectively from the Spanish Overgrowth registry database bone anomalies. (SOGRI). Molecular analysis included Sanger sequencing, Materials and Methods: Targeted sequencing of MLPAandacustomNGSpanelof211genes(Overgrowth ANO S1
, CHD7, FGF8, FGFR1, GNRHR, KIS S1
R, v2.3). Variantsannotationandprioritizationwas performed PROK2, PROKR2 and TACR3 and subsequent whole- with a custom in-house bioinformatic script. genomelinked-readsequencingwasperformedonapatient Results:AsubgroupofpatientswithOGS+IDcausedby with cHH, anosmia, learning difficulties and motoric pro- mutations in chromatin regulation genes was observed: (5) blems. We Sanger-sequenced the coding regions and exon- BRWD3 (X-linked mental retardation), (6)DNMT3A (Tat- intron boundaries of PALM2 and AKA P2
 in 22 Finnish ton-Brown-Rahmansyndrome),(2)SETD2(Luscan-Lumish cHH patients who have no mutations in currently known syndrome),(3)EZH2(Weaversyndrome),(99)NSD1(Sotos cHH genes. syndrome).1510 Conclusions: There is a high relationship between interpretation of the variants were made according to patients who present some overgrowth disorders with ACMG guidelines. intellectual disability, with alterations in chromatin reg- Results: Four different pathogenic variants have been ulatory genes. These genes encode enzymes that possess found in five patients. Three of the four variants were histonemethyltransferaseactivity,andtherefore,arecritical classified as pathogenic and the missense variant as likely during the processes of human development. A correct pathogenic.AllvariantswerelocatedwithintheWD40and molecular and clinical characterization is essential to carry Bromodomain of the protein, and all was not previously out an adequate advice in patients with overgrowth that reported in the 14 patients with MRX93 already published. associate other clinical characteristics that overlap with Conclusions: MRX93 syndrome (XLID due to BRWD3 several entities. mutations) is a relatively new and uncommon condition Grants: FEDER-ISCIII Grant FIS PI15/01481 Unrest- mainly characterized by ID, overgrowth and facial dys- ricted Sotos syndrome spanish association funds morphism. We report five patients with novel variants in P. Lapunzina: None. J.A. Tenorio: None. P. Arias: BRWD3 and review all the published cases so far. MRX93 None. I. Dapía: None. G. Gordo: None. P. Alarcón: diagnosis should be suspected in male patients with these None. S. García-Miñaur: None. F. Santos-Simarro: featuresandgenetictestingishighlyrecommendedinorder None.V.Martínez-Glez:None.M.Palomares: None.M. to confirm the diagnosis. Solís: None. S. Ramos: None. V.L. Ruíz-Pérez: None. J. Grants: FEDER-ISCIII Grant FIS PI15/01481 Nevado: None. P.Arias:None.J.A.Tenorio:None.P.Alarcón:None. F. Ramos: None. J. Campistol: None. S. Climent: None.  P11
.43C S.García-Miñaur:None.I.Dapía:None.A.Hernández: MRX93 syndrome (BRWD3 gene): five new patients None.J.Nevado:None.M.Solís:None.V.L.Ruíz-Pérez: with novel mutations None. P. Lapunzina: None. P. Arias1, J. A. Tenorio1, P. Alarcón2, F. Ramos3,  P11
.44D J. Campistol4, S. Climent5, S. García-Miñaur1, I. Dapía1, Interstitial 2q24.2q24.3 microdeletion: description of A. Hernández1, J. Nevado1, M. Solís1, V. L. Ruíz-Pérez6, two new cases and delineation of the critical minimal The SOGRI consortium, P. Lapunzina1 region. A new emerging syndrome? 1Medical and Molecular Genetics Institute (INGEMM), E. Tassano, L. Pisciotta, S. Uccella, T. Giacomini, Madrid, Spain, 2Hospital Clínico Universidad de Chile, M.Mancardi,M.Divizia,M.Lerone,A.Puliti,G.Gimelli, Santiago, Chile, 3University Hospital “Lozano Blesa”, D. Coviello, P. Ronchetto University of Zaragoza School of Medicine, Zaragoza, Spain, 4Hospital Sant Joan de Deu, Barcelona, Spain, Istituto Giannina Gaslini, Genova, Italy 5Hospital General de Ontinyent, Valencia, Spain, 6Instituto de Investigaciones Biomédicas de Madrid (CSIC-UAM), Interstitialdeletionsin2q24.2q24.3arerareeventsreported Madrid, Spain in literature and in publicly available databases associated mainlywithdevelopmentaldelayandintellectualdisability. Introduction: Overgrowth syndromes (OGS) comprise a Thebreakpointofthesedeletionsvaries,extendingfrom7.5 heterogeneousgroupofdisorderswhosemaincharacteristic Mb to 2.3 Mb. Although some clinical features seem to be is that either the weight, height, or head circumference are recurrent, these deletions are associated with a clinically above the 97th centile or 2-3 standard deviations (SD) heterogeneous phenotype. This is probably due to the above the mean for age and sex. Additional features are differentdeletionsizeandgenecontent,togeneticvariation usually associated with OGS. Genetic analysis in patients in the remaining allele and to the influence of the genetic with overlapping clinical features is essential, in order to background of the rest of the genoma. Here we report on distinguish between two or more similar conditions, and to two patients with similar clinical phenotype and interstitial provide appropriate genetic counseling. 2q24.2q24.3 deletions of different size overlapping a 1.7 Material and Methods: Patients were selected from the Mb region. In particular, patient 1 was characterized by “Spanish Overgrowth Registry” (SOGRI). All patients or hypotonia, growth retardation, and psychomotor develop- tutors gave informed consent. Two targeted custom gene mentalandlanguagedelay,dysmorphismsandhearingloss panels were designed (183genes, OGLYVAS V1.0) and with a de novo 3,7 Mb 2q24.2q24.3 deletion. Patient 2 (212genes, Overgrowth v2.3) respectively. After the filter- presentedwithhypotonia,psychomotorandlanguagedelay, ingoftherelevantvariantsandvalidation,classificationand stereotypesmovementsandepilepsywithadenovo2,9Mb 2q24.2q24.3 deletion. We identified the smallest region ofAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1511 overlap encompassing eight genes and our attention was Introduction:Interstitialinvertedduplication8passociated particularly drawn to SL C4
A10, DP P4
, KCNH7. All these with a distal deletion of the short arm of chromosome 8 three genes are associated to neurological features. (invdupdel[8p]) is a complex and rare chromosomal SL C4
A10 is highly expressed in the cerebral cortex and rearrangement. Intellectual disability (ID) is constant, and hippocampus, where it regulates the neuronal intracellular anomaliesofthecorpuscallosum(ACC)arepresentin80% pH. Abnormal levels of DP P4
 were seen in patients with of (invdupdel[8p]) patients. Almost all reported patients neuropsychiatricdisorders.KCNH7encodesavoltagegated carry the same 8pter deletion, but the size and proximal potassium channels and is widely expressed in human breakpoint of the duplication are variable. Previous studies centralnervoussystem.Inconclusion,haploinsufficiencyof suggested a correlation between the size of the duplication these genes may be a good candidate for the main clinical andtheseverityofID.Moreover,Sajanetal.(2013)defined features of this emerging syndrome. a minimal duplicated critical region of 10.7 Mb associated E.Tassano:None.L.Pisciotta:None.S.Uccella:None. with ACC. However, no gene of ACC has yet been clearly T. Giacomini: None. M. Mancardi: None. M. Divizia: identified in this region. In order to refine genotype- None. M. Lerone: None. A. Puliti: None. G. Gimelli: phenotype correlation in this complex rearrangement, we None. D. Coviello: None. P. Ronchetto: None. report clinical and chromosomal data from 29 new patients with invdupdel[8p].  P11
.45A PatientsandMethod:3fetusand26patients(meanage: Inversion-duplication-deletion of chromosome 8p: 9.7 years) were included. CGH/SNP array were performed genotype-phenotype correlation and determination of a for all of them. new minimal duplicated region involved in ACC in 29 Results:Alllivingpatients(n=26/26)haddevelopmental patients delay and ID (n= 5/22 mild and n=17/22 moderate to severe). 16/22 patients had ACC (4 complete agenesis, 7 R. Vibert1, B. Keren2,3, S. Chantot-Bastaraud4, partial agenesis, and 5 dysplasia), associated with other C. Mignot1,3, N. Chatron5, M. Portnoï4, M. Nouguès6, cerebral abnormalities in 11 patients. Mean size of the M. Moutard6, A. Faudet1,3, S. Whalen1, D. Haye1, deletion was 6.9 Mb and duplication was 19.2 Mb. Dis- C. Pebrel-Richard7, C. Missirian8, C. Vincent-Delorme9, cussion - Conclusion: As expected, the severity of ID is O. Boute9, J. Andrieux10, F. Devillard11, C. Coutton11, correlatedwiththesizeoftheduplication.Ourstudyrefines S. Taviaux12, M. Perez13, C. Colson14, D. Sanlaville5, theminimalduplicatedcriticalregionforACCtoa1.7Mb- J. Siffroi4, D. Héron1,3, S. Heide1,3 long region spanning one gene only, which is a new can- didate gene for ACC. 1APHP, Department of Genetics, Armand-Trousseau and R. Vibert: None. B. Keren: None. S. Chantot-Bastar- Pitié Salpêtrière Hospitals, Paris, France, 2APHP, Service aud: None. C. Mignot: None. N. Chatron: None. M. of Developmental Genetics, Department of Genetics, Pitié- Portnoï: None. M. Nouguès: None. M. Moutard: None. Salpêtrière Hospital, Paris, France, 3Reference Center for A. Faudet: None. S. Whalen: None. D. Haye: None. C. Intellectual disability of Rare Causes, Paris, France, Pebrel-Richard: None. C. Missirian: None. C. Vincent- 4APHP, Department of Cytogenetics, Armand Trousseau Delorme: None. O. Boute: None. J. Andrieux: None. F. Hospital, Paris, France, 5Service of Genetic, Hospices Devillard: None. C. Coutton: None. S. Taviaux: None. Civils of Lyon, Bron, France, 6APHP, Service of pediatric M.Perez:None.C.Colson:None.D.Sanlaville:None.J. neurology, Armand Trousseau Hospital, Paris, France, Siffroi: None. D. Héron: None. S. Heide: None. 7Service of Cytogenetic, Clermont-Ferrand’s University Hospital, Clermont-Ferrand, France, 8APHM, Laboratory  P11
.46B of Genetic, Timone enfants’ Hospital, Marseille, France, KMT2A mutations (Wiedemann-Steiner Syndrome): a 9Service of Clinical Genetic, Jeanne de Flandre Hospital, new phenotype of corpus callosum agenesis without Lille, France, 10Institute of Medical Genetics, Jeanne de intellectual disability Flandre Hospital, Lille, France, 11Service of Genetic, Grenoble’s University Hospital, Grenoble, France, E. Marchionni1, S. Heide1, C. Depienne2, A. Rastetter2, 12Laboratory of Genetic, Department of medical genetics, C. Nava2, J. Buratti1, M. Spentchian1, M. L. Moutard3, Arnaud de Villeneuve Hospital, Montpellier, France, C. Mignot1, B. Keren1, S. Valence3, D. Héron1 13Department of Medical Genetics, Arnaud de Villeneuve Hospital, Montpellier, France, 14Service of Clinical 1APHP, Département de Génétique, GH Pitié-Salpêtrière, Genetic, Caen’s University Hospital, Caen, France CRMR Déficiences Intellectuelles de Causes Rares, Paris, France, 2ICM, UPMC Inserm UMR  S975
/CNRS UMR1512 7225,Paris,France,3APHP,HôpitalTrousseau,Servicede 1Centre de Génétique et Centre de référence « Anomalies Neurologie Pédiatrique, Paris, France du Développement et Syndromes Malformatifs », Hôpital d’Enfants, Centre Hospitalier Universitaire de Dijon, Introduction: KMT2A mutations are responsible for Dijon, France, 2Laboratoire de Génétique chromosomique Wiedemann-Steiner Syndrome (WDSTS), a rare autosomal etmoléculaire,UFInnovationendiagnosticgénomiquedes dominant disorder characterized by dysmorphic features, maladies rares, Centre Hospitalier Universitaire de Dijon, hypertrichosis,shortstature,andintellectualdisability(ID). Dijon, France, 3UMR-Inserm 1231 GAD team, Génétique Corpus callosum anomalies have been described in 16% of desAnomaliesdudéveloppement,UniversitédeBourgogne patients.Wereporthere2unrelatedpatientswithadenovo Franche-Comté, Dijon, France, 4Institute of Cancer and KMT2A heterozygous variant presenting with isolated GenomicSciences,UniversityofBirmingham,Birmingham, prenatal agenesis of the corpus callosum (ACC), and a United Kingdom, 5West Midlands Regional Genetics normal psychomotor development. Patients: Patient 1: Service and Birmingham Health Partners, Birmingham partial ACC was diagnosed prenatally. At 4 years and Women’sandChildren’sHospitalsNHSFoundationTrust, 6monthsofage,hehadnormalpsychomotordevelopment, Birmingham, United Kingdom, 6Service de génétique whereas attention and praxic disorders were observed, médicale - Hôpitaux Universitaires de Strasbourg - Institut especially in fine motor skills. The WPPSI-III at 4 years ½ de Génétique Médicale d'Alsace, Strasbourg, France, showedaheterogenousprofile.Inaddition,hehadpostnatal 7Department of Medical Genetics, Oslo University weight growth retardation (-2SD) and dysmorphic features. Hospital, Oslo, Norway, 8Department of Medical Genetics, Patient 2: ACC was diagnosed prenatally. At the age of 8 Telemark Hospital Trust, Skien, Norway, 9West Midlands years, he had normal neurodevelopment. WPPSI-IV Regional Genetics Laboratory, Birmingham Women’s and performed at 5 years was in a normal range, with a Children’s NHS Foundation Trust, Birmingham, United heterogenous profile. Mild dysmorphic features were Kingdom,10Inserm–UBUMR1231GAD«Génétiquedes observed. Anomalies du Développement », FHU-TRANSLAD, Dijon, Methods: Trio-based Whole Exome Sequencing (WES) France, 11Unité Fonctionnelle d’Innovation diagnostique was performed in the 2 male patients and their non- des maladies rares, FHU-TRANSLAD, CHU Dijon consanguineous and unaffected parents. Bourgogne, Dijon, France, 12Service de Dermatologie, Results: Patient 1: WES analysis detected a novel de CHU de Dijon, Université de Bourgogne, Dijon, France novo heterozygous missense variant in KMT2A (c.4256G>A; p.Gly1419Asp), predicted as probably Introduction: Kosaki overgrowth syndrome (KOGS), first damaging by all prediction tools. Patient 2: WES analysis described in 2015, is a rare overgrowth disorder caused by detected a de novo heterozygous truncating variant in de novo pathogenic variants in the PDGFRB gene. Only 5 KMT2A (c.1539del; p.Ile515Phefs*52). paediatric cases have been reported in the literature. Conclusions: These two observations expand the Material and Methods: We present 3 cases of KOGS WDSTS phenotypic spectrum, since ID may be absent. living in Europe including the first adult patient, gathered Thus, this syndrome might be considered in cases of iso- through a collaboration within the ERN ITHACA network. lated corpus callosum anomalies, associated with normal Results:TheFrenchpatient,aged55,hasinthepastbeen development. reported as a typical case of Sphritzen-Goldberg syndrome E. Marchionni: None. S. Heide: None. C. Depienne: (Stoll, Clin Dysmorphol 2012). Analysis of SKI was None. A. Rastetter: None. C. Nava: None. J. Buratti: negative, and WES identified the recurrent PDGFRB None. M. Spentchian: None. M.L. Moutard: None. C. c.1751C>Gvariant.The Englishpatient,aged6,diagnosed Mignot: None. B. Keren: None. S. Valence: None. D. by NGS panel for syndromic overgrowth (de novo Héron: None. PDGFRB c.1751C>G variant), had tall stature, craniosy- nostosis, facial features, progressive contractures and  P11
.47C developmental delay. The Norwegian patient, aged 9, Expansion of the phenotype of Kosaki overgrowth diagnosedbyWES(denovoPDGFRBc.1696T>Cvariant) syndrome, and description of the long-term outcome in had tall stature, severe scoliosis, facial features and devel- the oldest case opmental delay. Long-term outcome in the oldest patient revealed an evolving phenotype with persistent tall stature B. Chalot1,2,3, A. Foster4,5, E. Schaeffer6, C. Rustad7, despite severe scoliosis not accessible to surgery (188 cm), K.Tveten8,T.Cole5,C.Thauvin-Robinet1,2,3,J.Woodley9, extremely fragile skin with diffuse erythrosis, dystrophic A. Bruel10,11, R. Keelagher9, C. Philippe10,11, scars due to multiple injuries, nail dystrophy, progressive T. Antoniadi9, P. Vabres12, D. Lim5, L. Faivre1,2,3 camptodactyly, early osteoporosis, basilar artery aneurysm complicated by a stroke, and severe ocular impairment dueAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1513 to complicated surgeries for pterygions. The patient had 12Département de Génétique Médicale, Maladies rares et normal intelligence, with no cognitive decline nor cerebral Médecine Personnalisée, CHRU de Montpellier, calcifications. Montpellier, France, 13Unité de Génétique Médicale et Conclusion: Genotype-first approach is a powerful Cytogénétique,CHUdeNîmes,Nîmes,France,14Servicede approach to reach the diagnosis of ultra-rare syndromes. Dermatologie, CHU de Nice, Nice, France, 15Département Indeed, the clinical diagnosis was not raised before NGS, deGénétiqueMédicale, CHUdeNice -Hôpital del'Archet due to the lack of knowledge of this entity. II, Nice, France, 16Pôle Enfants, CHU de la Réunion - B. Chalot: None. A. Foster: None. E. Schaeffer: None. Hôpital Félix Guyon, Saint Denis, France, 17Centre C. Rustad: None. K. Tveten: None. T. Cole: None. C. d'Activité Génétique Clinique et Oncogénétique, Centre Thauvin-Robinet: None. J. Woodley: None. A. Bruel: Hospitalier Universitaire d'Amiens, Amiens, France, None. R. Keelagher: None. C. Philippe: None. T. Anto- 18ServicedeDermatologie,CHUdeNancy,Nancy,France, niadi: None. P. Vabres: None. D. Lim: None. L. 19Centre d'Investigation Clinique INSERM 1432, Centre Faivre: None. Hospitalier Universitaire de Dijon, Dijon, France, 20Genetics Department, Hospices Civils de Lyon and  P11
.49A GENDEV team, Lyon Neuroscience Research Centre, Further delineation of the phenotypic spectrum of INSERM U1028, CNRS UMR 5292, Claude Bernard Lyon MCAP in a French cohort of 31 patients 1 University, Lyon, France, 21Service de Dermatologie, CHU de Dijon, Dijon, France A. Garde1,2, L. Guibaud3, A. Goldenberg4, F. Petit5, R. Dard6, J. Mazereeuw-Hautier7, D. Lacombe8, Introduction:MCAPsyndrome(megalencephaly-capillary F. Morice-Picard8, A. Toutain9, S. Arpin9, O. Boccara10, malformation syndrome) is a genetic disorder that results R. Touraine11, P. Blanchet12, C. Coubes12, M. Willems12, from somatic, mosaic, gain of function mutations of the L. Pinson12, P. Khau Van Kien13, C. Chiaverini14, PI3KCA gene, and belongs to the spectrum of PIK3CA- F. Giuliano15, J. Alessandri16, M. Mathieu-Dramart17, related overgrowth spectrum (PROS). A. Bursztejn18, E. Gautier1, M. Yousfi1, M. Luu19, Material and Methods: Based on a national collabora- M. Bardou19, A. Sorlin1,2, C. Philippe2, P. Edery20, tion, we described the clinical features of 31 patients with M. Rossi20, V. Carmignac2, C. Thauvin-Robinet1,2, MCAP syndrome carrying mosaic PIK3CA pathogenic P. Vabres21,2, L. Faivre1,2 variants.Theobjectiveofthisstudywastobetterdefinethe clinical features of patients with MCAP syndrome in con- 1Centre de Référence Anomalies du Développement et nection with imaging features, to improve diagnosis and Syndromes Malformatifs, FHU TRANSLAD - CHU de management. Dijon, Dijon, France, 2Inserm UMR1231 GAD, Génétique Results:Themosaicratewasbetween0%and20%inthe des Anomalies du Développement, Université de blood, between 1% and 47% in the skin, and between 4% Bourgogne,Dijon,France,3Serviced'ImageriePédiatrique and 34% in the saliva. Macrocephaly had been observed in et Foetale, Hôpital Femme Mère Enfant, Lyon and Claude 21/28patients(75%)atbirth,andin26/28patients(93%)at Bernard University, Lyon, France, 4Service de Génétique, time of the diagnosis. Hemihypertrophy was noticed in 22 CHU de Rouen et Inserm U1079, Université de Rouen, patients (71%). Intellectual disability was present in 15 Centre Normand de Génomique Médicale et Médecine patients (50%), ranging from mild to severe, 4 patients had Personnalisée, Rouen, France, 5Service de Génétique learning disabilities (12%). Six patients suffered from sei- Clinique, CHU Lille, Lille, France, 6Département de zures(20%).Cerebralmalformationswerereportedin23/26 Génétique, Cytogénétique et Biologie de la Reproduction, patients: ventriculomegaly (65%), megalencephaly (53%), CHI Poissy St Germain-en-Laye, St Germain-en-Laye, cerebellar tonsilla ectopia (35%), polymicrogyria (15%). France, 7Centre de Référence des Maladies Rares de la Correlations between neurogognitive development and Peau, CHU de Toulouse, Toulouse, France, 8INSERM cerebral malformations were made. All patients had cuta- U1211, Université de Bordeaux, Service de Génétique neous vascular malformation: angioma (53%), cutis mar- Médicale, CHU de Bordeaux, Bordeaux, France, 9Service morata (29%), capillary malformations (26%). Internal de Génétique Clinique, CHRU de Tours, Tours, France, vascular anomalies are reported on 5 patients (16%). Limb 10Department of Dermatology and Reference Center for and distal anomalies were also observed. Genodermatoses and Rare Skin Diseases (MAGEC), Conclusion: This study confirms the large clinical het- Université Paris Descartes-Sorbonne Paris Cité, Institut erogeneity in MCAP, in particular in the neurocognitive Imagine, Hôpital Universitaire Necker-Enfants Malades, development. This point is of importance for determining Paris, France, 11Service de Génétique Clinique, CHU de the outcome measures for future therapeutic trials. Saint-Etienne, Saint-Priest-en-Jarez, France,1514 A. Garde: None. L. Guibaud: None. A. Goldenberg: additional seven who have not been reported in the litera- None. F. Petit: None. R. Dard: None. J. Mazereeuw- ture to identify genotype-phenotype correlations. Hautier: None. D. Lacombe: None. F. Morice-Picard: Improved understanding of the hallmark features, None. A. Toutain: None. S. Arpin: None. O. Boccara: includingthoseleadingtomorbidityandmortality,inMIC- None.R.Touraine:None.P.Blanchet:None.C.Coubes: CAP syndrome will facilitate early diagnosis, inform man- None.M.Willems:None.L.Pinson:None.P.KhauVan agement strategies and provide prognostic information. Kien: None. C. Chiaverini: None. F. Giuliano: None. J. J.L. Zambonin: None. G. Mirzaa: None. M. Alessandri: None. M. Mathieu-Dramart: None. A. Carter: None. Bursztejn:None.E.Gautier:None.M.Yousfi:None.M. Luu: None. M. Bardou: None. A. Sorlin: None. C. Phi-  P11
.51C lippe: None. P. Edery: None. M. Rossi: None. V. Car- DominantnegativeeffectofACTG2mutationsinfluence mignac: None. C. Thauvin-Robinet: None. P. Vabres: TGF-beta signaling in MMIHS None. L. Faivre: None. Y. Zhao1,2, J. Burger1,3, Y. Gao2, R. M. W. Hofstra1,4,  P11
.50B M. M. Alves1 InvestigatingtheClinicalFeaturesLeadingtoMorbidity and Mortality in Microcephaly-Capillary Malformation 1Department of Clinical Genetics, Erasmus University Syndrome Medical Center, Rotterdam, Netherlands, 2Department of Pediatric Surgery, The Second Affiliated Hospital of Xi׳an J. L. Zambonin1, G. Mirzaa2, M. Carter1 JiaotongUniversity,Xi׳an,Shaanxi,China,3Departmentof Molecular Genetics, Oncode Institute, Erasmus University 1Children's Hospital of Eastern Ontrio, Ottawa, ON, Medical Center, Rotterdam, Netherlands, 4Birth Defects Canada,2SeattleChildren'sResearchInstitute,Seattle,WA, Research Centre, UCL Institute of Child Health, London, United States United Kingdom Microcephaly-capillary malformation syndrome (MIC- Introduction: Megacystis microcolon intestinal hypoper- CAP) is a rare neurocutaneous disorder characterized by istalsis syndrome (MMIHS) is a rare inherited disorder congenital microcephaly, multiple capillary malformations, characterized by bladder hypocontractility, and intestinal hypoplastic distal phalanges, infantile-onset intractable obstruction.Mutationsinfivegeneshavebeenidentifiedas seizures, profound neurologic impairment and abnormal its cause, but the majority of cases are caused by de novo neuroimaging findings including a diffusely simplified heterozygous mutations in the γ-smooth muscle actin gene cortical gyral pattern with increased extra-axial space. It is (ACTG2). ACTG2 encodes for an actin isoform specifically causedbybiallelicpathogenicvariantsintheSTAMBPgene expressed in the intestinal and urogenital tracts. Previous and has been reported in only 14 individuals worldwide, to studies by us and others, have shown that mutated ACTG2 date.Giventherarity,thefullphenotypicspectrumremains disrupt actin polymerization and result in reduced cellular poorly understood with limited natural history and prog- contractility. However, the mechanisms underlying these nosisinformation,aswellasguidelines onoptimalmedical effects are still unknown. management. Additionally, there is one reported individual Materials and Methods: Wild-type and mutant ACTG2 with a mild phenotype suggesting variable severity, with proteinsfusedtoaGFPandmCherrytagrespectively,were insufficient data to define genotype-phenotype correlations. stably expressed in U2OS cells and human intestinal Here we present a case series of patients with MIC-CAP smooth muscle cells. Transfected cells were analyzed by obtainedthroughaprospectivewell-designedonlinesurvey immunofluorescence, actin polymerization and cellular oftheirprimarycaregiversandphysicians.Inthisstudy,we contractilityassays.InParallel,fibroblastsderivedfromtwo describethemostfrequentlyreportedfeatures,management MMIHS patients carrying ACTG2 mutations, and three and impact on disease course. We specifically focused on controls have been used for trans-differentiation assays. hallmark features leading to morbidity and decreased life- Immunofluorescence, qRT-PCR, and a TGF-beta reporter span including seizures, neurologic impairment and assay were performed, to investigate the effect of ACTG2 respiratory insufficiency. We report the various therapies mutations on cellular differentiation. usedbyaffectedindividualsandperceivedbenefitsofthese Results: Actin polymerization, and cellular contractility therapies including anti-epileptics medications. Addition- were significantly impaired when the mutant ACTG2 pro- ally, we describe the spectrum of severity of other major tein is expressed, alone or in combination with the wild- features in previously reported individuals, including an type. Furthermore, TGF-beta is up-regulated in fibroblasts derived from MMIHS patients when compared to controls.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1515 Conclusion:ACTG2mutationsleadtoadysregulationof D.Lehalle7,S.Nambot7,N.Jean-Marçais7,N.Houcinat7, the TGF-beta pathway, and reduce cellular contractility by S. Moutton1,7, N. Marle8, L. Lambert9, P. Jonveaux10, exerting a dominant negative effect in MMIHS. B. Foliguet11, J. Mazutti11, D. Gaillard12, E. Alanio12, Y. Zhao: None. J. Burger: None. Y. Gao: None. R.M. C. Poirisier13, A. Lebre14, M. Aubert-Lenoir15, F. Arbez- W. Hofstra: None. M.M. Alves: None. Gindre16, S. Odent17, C. Quelin17,18, P. Loget18, M. Fradin17, M. Willems19, N. Bigi20, M. Perez20,  P11
.52D S. Blesson21, C. Francannet22, A. Beaufrere23, 22q11.2 deletion as a genetic model for multimorbidity S. Patrier24, A. Guerrot25, A. Goldenberg25, N. Laurent26, in young adults C. Philippe1,2, F. Tran Mau-Them1,27, J. Thevenon1,7, L. Faivre1,7, C. Thauvin1,7, A. Vitobello1,7 A. S. Bassett, S. L. Malecki 1Inserm –UBUMR 1231GAD «GénétiquedesAnomalies University of Toronto, Toronto, ON, Canada du Développement », FHU-TRANSLAD, Dijon, France, 2Unité Fonctionnelle d’Innovation diagnostique des Background: Multimorbidity is increasing in younger maladies rares, FHU-TRANSLAD, CHU Dijon, Dijon, adults but is understudied in the general population. France, 3Service de Génétique Médicale, CHU de 22q11.2 deletion syndrome (22q11.2DS) could act as a Strasbourg, Hôpital de Hautepierre, Strasbourg, France, genetic model of multimorbidity in young to middle-aged 4Service de Fœtopathologie, CHU de Strasbourg, Hôpital adults. de Hautepierre, Strasbourg, France, 5Laboratoire de Methods: Using Anatomic Therapeutic Classification cytogénétique constitutionnelle et prénatale, CHU de (ATC) and setting 5 or more concurrent prescription med- Strasbourg, Strasbourg, France, 6Département Médecine icationsasaproxyformultimorbidity,wecompareddataon translationnelle et neurogénétique, Institut de génétique et 264 adults with 22q11.2DS (median age 27.8, range 17.3- de biologie moléculaire et cellulaire, Strasbourg, France, 68.3 years) to that for a community-based general popula- 7Centre de Référence « Anomalies du Développement et tion sample in Canada (n=25,287). We used logistic syndromes malformatifs », Centre de Génétique, FHU- regressiontoexaminepossiblepredictorsofmultimorbidity TRANSLAD, CHU Dijon Bourgogne, Dijon, France, in 22q11.2DS. 8Laboratoire de génétique chromosomique et moléculaire, Results: Multimorbidity in 22q11.2DS in the 25-44 year CHU de Dijon, Dijon,France, 9UFde génétique médicale, agegroup(34.7%)wassignificantlymoreprevalentthanin Maternité régionale, CHU de Nancy, Nancy, France, the general population, both for the same age group (2.9%, 10Laboratoire de génétique médicale, CHU de Nancy, prevalenceratio,PR=11.9)andcomparedtothoseaged45- Nancy, France, 11Laboratoire de Biologie de la 64 years (16.4%, PR=2.1). Neuropsychiatric and endocri- Reproduction et du Développement Maternité de Nancy, nological ATC medication classes predominated. Within Nancy, France, 12Service de foetopathologie, CHU de 22q11.2DS, older age and psychotic illness, but not sex, Reims, Reims, France, 13Laboratoire de cytogénétique, major congenital heart disease or intellectual disability, CHU de Reims, Reims, France, 14Service de Génétique et were significant predictors of multimorbidity. Biologie de la Reproduction, CHU de Reims, Reims, Conclusion: The results indicate that adults with France, 15Service d’imagerie médicale, CHU de Besançon, 22q11.2DS have a significant burden of illness with levels Besançon, France, 16Service de fœtopathologie, CHU de of multimorbidity comparable to those of the general Besançon, Besançon, France, 17Service de génétique population several decades older. In younger adults with clinique, CHU de Rennes, Rennes, France, 18Service de multimorbidity, certain disease patterns may also help fœtopathologie,CHUdeRennes,Rennes,France, 19Equipe identify genetic disorders in “big data”. Maladies Génétiques de l'Enfant et de l'Adulte, CHU de A.S. Bassett: None. S.L. Malecki: None. Montpellier, Montpellier, France, 20. Service de fœtopathologie, CHU de Montpellier, Montpellier, France,  P11
.53A 21Service de Génétique, Centre Hospitalo-Universitaire Transversal cohort analysis with data aggregation of Tours, Tour, France, 22Service de génétique médicale, singleton exome sequencing significantly increases the CHU de Clermont-Ferrand, Clermont-Ferrand, France, diagnosticyieldforthediagnosisoffetuseswithmultiple 23Service de fœtopathologie, CHU de Clermont-Ferrand, congenital abnormalities Clermont-Ferrand, France, 24Service de fœtopathologie, CHU de Rouen, Rouen, France, 25Service de génétique A. Bruel1,2, M. Lefebvre1, N. Bourgon1, Y. Duffourd1, clinique, CHU de Rouen, Rouen, France, 26Service de M. Assoum1, P. Kuentz1, E. Schaefer3, S. El Chehadeh3, fœtopathologie, CHU de Dijon, Dijon, France, 27Unité M. Antal4, V. Kremer5, F. Girard-Lemaire5, J. Mandel6, Fonctionnelle d’Innovation diagnostique des maladies1516 rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon,  P11
.54B France New recurrent 2q12.2q12.3 microdeletion involving ST6GA L2
 gene in a boy with neurological phenotype Exome sequencing (ES) harbors a diagnostic yield in fetuses with multiple congenital abnormalities (MCA) E. Tassano, T. Giacomini, S. Uccella, M. Celle, (25%) higher than any other diagnostic tool in fetal M. Malacarne, G. Gimelli, D. Coviello, P. Ronchetto pathology but lower than in live birth individuals with malformations (30-35%). Most fetuses remaining undiag- Istituto Giannina Gaslini, Genova, Italy nosed deprive couples of obtaining precise genetic counseling and molecular diagnosis in future pregnancies. Recurrent microdeletion and microduplication syndromes This limited yield is explained by fetal wide phenotypic are among the most common causes of human neurodeve- variability and difficulties to define precise phenotypes. lopmental and psychiatric disorders. These reciprocal Here,weaimedtoassessthecontributionofEStodiagnose genomicdisordersoftenresultfromnon-allelichomologous MCA fetuses and also identify new genes. We performed recombination (NAHR) between near-identical segmental singleton ES in 95 MCA fetuses undiagnosed after current duplications.Copynumberchangesmediatedbysegmental investigations. Fetal DNA quantity/quality permitted ES in duplications may be either pathogenic or may exist as only 95/151 fetuses. The strategy combined usual indivi- benign variants in the human population. dual ES analysis and an original cohort analysis based on However, almost all pathogenic CNVs are characterized bioinformatics scores and variant databases independently by a range of phenotypic outcomes (variable expressivity) of fetal phenotype. We selected variants on the following and by unaffected family members who carry the same criteria: truncating with a significant probability of loss-of- CNV (incomplete penetrance). Here we report a boy with function intolerance (pLI=0.9-1), reported in denovo-db mild intellectual disability, speech delay, and hypotonia database,reported(likely)pathogenicinClinVARdatabase, presenting a 1.56 Mb interstitial deletion at 2q12.2-12.3 or with probably recessive mode of inheritance. Usual inherited from his healthy father. The microdeletion individual ES identified pathogenic or likely pathogenic includes three OMIM genes, of which ST6GA L2
, in our variants in 21/95 fetuses (22%). The cohort analysis opinion, is the most interesting. This gene encodes a beta- identified not only these 21 variants but also additional galactoside alpha-2,6-sialyltransferase expressed in brain pathogenic or likely pathogenic variants in 3/95 fetuses and its transcription could be potentially activated for spe- (4%), increasing the diagnostic yield from 22% to 25%. 9 cific neuronal functions. In the literature four cases have candidate genes were suspected in 8/95 fetuses (8%) been reported with microdeletions/microduplications com- remaining to be replicated. In conclusion, this original prising ST6GA L2
 gene and associated with neurological strategyincreasedthediagnosticyieldinafetalcohortwith diseases. In DECIPHER database seventeen individuals atypical or non-described phenotype and could so be have been identified with deletions similar to that of our applied to other heterogeneous cohorts with developmental case and neurological disease as intellectual disability, abnormalities. delayed speech, autism. Ten patients inherited the deletion A. Bruel: None. M. Lefebvre: None. N. Bourgon: from an apparently unaffected parent. It is interesting to None.Y.Duffourd:None.M.Assoum:None.P.Kuentz: note that all these microdeletions are very similar in None. E. Schaefer: None. S. El Chehadeh: None. M. extension and are possibly mediated by NAHR. Antal: None. V. Kremer: None. F. Girard-Lemaire: Inconclusion,wedescribeanewrecurrentmicrodeletion None. J. Mandel: None. D. Lehalle: None. S. Nambot: 2q12.2-12.3containingtheST6GA L2
gene,whichmaybea None. N. Jean-Marçais: None. N. Houcinat: None. S. significant and independent risk factor for neurological Moutton: None. N. Marle: None. L. Lambert: None. P. diseases acting in association with other factors to modify Jonveaux:None.B.Foliguet:None.J.Mazutti:None.D. neurological phenotypes. Gaillard: None. E. Alanio: None. C. Poirisier: None. A. E. Tassano: None. T. Giacomini: None. S. Uccella: Lebre: None. M. Aubert-Lenoir: None. F. Arbez- None. M. Celle: None. M. Malacarne: None. G. Gimelli: Gindre: None. S. Odent: None. C. Quelin: None. P. None. D. Coviello: None. P. Ronchetto: None. Loget: None. M. Fradin: None. M. Willems: None. N. Bigi: None. M. Perez: None. S. Blesson: None. C. Fran-  P11
.55C cannet: None. A. Beaufrere: None. S. Patrier: None. A. Expanding the LZTR1-RASopathy association: Three Guerrot:None.A.Goldenberg:None.N.Laurent:None. new cases of Noonan Syndrome with LZTR1 mutations C. Philippe: None. F. Tran Mau-Them: None. J. The- venon: None. L. Faivre: None. C. Thauvin: None. A. P. Fernández Alvarez1, I. Valenzuela Palafoll1, F. López Vitobello: None. Grondona1, M. Masas Castro1, L. Iranzo Nuez1,Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1517 I. Paramonov1, L. Blasco Perez1, E. García-Arumi1,2, D. Lehalle13, S. M. Amudhavalli14, E. Repnikova15, E. Tizzano1,2 C. Saunders15, I. Thiffault15, I. Thiffault15, I. Saadi16, D. Li17, H. Hakonarson17, Y. Vial1, E. Zackai9, 1Department of Clinical and Molecular Genetics. Hospital P. Callier13, S. Drunat1, E. E. Bhoj9 Universitari Vall d'Hebron, Barcelona, Spain, 2Biomedical Network Research Centre on RareDiseases (CIBERER), 1Department ofGenetics,APHP-Robert DEBREUniversity Instituto de Salud Carlos III, Madrid, Spain Hospital, Sorbonne Paris-Cité University, and INSERM UMR 1141, PARIS, France, 2Department of Genetics, Sincethefirstpublicationin2014,LZTR1missensegainof PARIS, France, 3Bretonneau University Hospital, Tours, function variants have been associated with Noonan France, 4Department of Biochemistry and Genetics, and Syndrome (NS) in both dominant and recessive pattern, UMR CNRS 6015 INSERM 1083, University Hospital, withthedominantvariantsclusteringonthedifferentKelch Angers, France, 5Department of Genetics, Aalborg motifsoftheprotein.Herewepresent3newindexcasesof University Hospital,, aalborg, Denmark, 6Department of Noonan syndrome with variants in LZTR1. Two of them Pathology, Aalborg University Hospital, Aalborg, have novel unreported variants. Case1. A12 year oldboy, Denmark, 7Department of GynObs, Aalborg University with prenatal polyhydramnios, unilateral ptosis, relative Hospital, Aalborg, Denmark, 8Dr Ersin Arslan Research macrocephaly, short stature (p10), cryptorchidism and and Training Hospital, Department Of Medical Genetics, pulmonaryvalve stenosis. He also presented mild language Gaziantep, Turkey, 9Department of Genetics, Children´s delay. Genetic testing identified a heterozygous missense Hospital of Philadelphia, Philadelphia, PA, United States, variant c.848G>A p.(Arg283Gln) located on the Kelch4 10Genetics Department, Research Unit-Genetics motif previously reported in another NS individual (Umeki Department, Institute of Ophthalmology, Conde de et al. 2018). Case 2. A 42 year old man with dysmorphic Valenciana, Mexico City, Mexico, 11Genetics Department, features of NS, short stature (p3), cryptorchidism, bicuspid Research Unit-Genetics Department, Institute of aortic valve and visual loss. Genetic testing identified a Ophthalmology, Conde de Valenciana, Mexico City, heterozygousmissensenewvariantc.289C>T(.(Arg97Trp) Mexico, 12Clinical Genetics Department, Coimbra in the Kelch1 motif. The same variant was detected in his Paediatric Hospital, Coimbra, Portugal, 13Children 69 year old mother who shared dysmorphic features and University Hospital, Dijon, France, 14Division of Clinical short stature. Case 3. A 22 year old woman with neonatal Genetics, Children’s Mercy Hospital, University of diagnosis of hypertrophic cardiomyopathy in context of Missouri Kansas City, School of Medicine, Kansas City, multiple angiomas. She also presented short stature (p3), MO, United States, 15Center for Pediatric Genomic pectus carinatum, scoliosis and dysmoprhic facial features Medicine, Department of Pathology and Laboratory resembling Noonan syndrome. She is heterozygous for the Medicine, Children’s Mercy Hospital, Kansas City, MO, new variant c.905C>T p.(Ala302Glu) located on the Kelch United States, 16Department of Anatomy and Cell Biology, 5 motif. These 3 new cases in patients with clinical University of Kansas Medical Center, Kansas City, MO, diagnosis of NS and variants in LZTR1 further help to United States, 17Center for Applied Genomics, Children´s delineate the phenotype of NS patients, expanding the Hospital of Philadelphia, Philadelphia, PA, United States LZTR1-RASopathy association P. Fernández Alvarez: None. I. Valenzuela Palafoll: The SPEC C1
L protein plays a role in adherens junctions None. F. López Grondona: None. M. Masas Castro: involved in cell adhesion, actin cytoskeleton organization, None. L. Iranzo Nuez: None. I. Paramonov: None. L. microtubulestabilization,spindleorganizationandcytokin- Blasco Perez: None. E. García-Arumi: None. E. esis.It modulates PI3K-AKTsignalingandcontrols cranial Tizzano: None. neural crest cell delamination during facial morphogenesis. SPEC C1
L causative variants were first identified in  P11
.56D individuals with oblique facial clefts. Recently, causative Phenotypic spectrum associated with SPEC C1
L variants in SPEC C1
L were reported in a pedigree reported pathogenic variants: new families and critical review of in 1988 as atypical Opitz GBBB syndrome. Six families the nosology of Teebi, Opitz GBBB, and Baraitser- with SPEC C1
L variants have been reported thus far. We Winter syndromes report here eight further pedigrees with SPEC C1
L variants, includingathree-generationfamily,andafurtherindividual A. VERLOE S1
, D. Haye2, A. Toutain3, D. Bonneau4, of a previously published family. We discuss the nosology I. Kibæk Nielsen5, I. Bay Lund6, P. Bogaard7, of Teebi and GBBB, and the syndromes related to S. Leenskjold7, K. Karaer8, K. T. Wild9, K. L. Grand9, SPEC C1
L variants. Although the phenotype of individuals M.C.Astiazaran10,L.A.Gonzalez-Nieto11,A.Carvalho12, with SPEC C1
L mutations shows overlap with Opitz1518 syndrome in its craniofacial anomalies, the canonical receiving a positive, weighted score (e.g., the cerebriform laryngeal malformations and male genital anomalies are connective tissue nevus) and each atypical manifestation not observed. Instead, individuals with SPECC L1
 variants receiving a negative, weighted score (e.g., congenital, non- have branchial fistulae, omphalocele, diaphragmatic her- CNSovergrowth).ThepresenceofanAKT1mosaicvariant nias, and uterus didelphis. We also point to the clinical wasassignedahighpositivescore.Wepilotedthesecriteria overlap of SPEC C1
L syndrome with mild Baraitser-Winter on the NIH mosaic overgrowth cohort and adjusted and craniofrontofacialsyndrome:theysharesimilardysmorphic adapted them to achieve agreement on appropriate thresh- features (wide, short nose with a large tip, cleft lip and olds. We suggest that this semi-quantitative, integrated palate, blepharoptosis, retrognathia, and craniosynostosis), clinical-molecular diagnostic approach is generalizable to although intellectual disability, neuronal migration defect, othermosaicdisorders,withitsmostimportantcontribution andmuscularproblemsremainlargelyspecifictoBaraitser- beingtheformalrecognitionthatpatientswithlowervariant Winter syndrome. In conclusion, we suggest that patients burdenshavearelated,butdistinctandmilderdisorderthat with pathogenic variants in SPEC C1
L should not be mustbedifferentiatedfromtheclassicformofthedisorder. described as “dominant (or type 2) Opitz GBBB syn- J.C. Sapp: None. A. Buser: None. J. Burton-Akright: drome”, and instead should be referred to as “SPEC C1
L None. L.G. Biesecker: C. Other Research Support (sup- syndrome” as both disorders show distinctive, non over- plies,equipment,receiptofdrugsorotherin-kindsupport); lapping developmental anomalies beyond facial Modest; ArQule, Inc.. F. Consultant/Advisory Board; communalities. Modest; Illumina, Inc.. Other; Modest; Royalties: A.Verloes:None.D.Haye:None.A.Toutain:None.D. Genentech, Inc.. Bonneau: None. I. Kibæk Nielsen: None. I. Bay Lund: None. P. Bogaard: None. S. Leenskjold: None. K. Kar-  P11
.58B aer: None. K.T. Wild: None. K.L. Grand: None. M.C. Multiple anomalies in an adult case with pentasomy X Astiazaran: None. L.A. Gonzalez-Nieto: None. A. Car- valho:None.D.Lehalle:None.S.M.Amudhavalli:None. D.L.Stoicanescu1,M.L.Cevei2,C.R.Gug1,A.Simedrea1 E. Repnikova: None. C. Saunders: None. I. Thiffault: None.I.Thiffault:None.I.Saadi:None.D.Li:None.H. 1University of Medicine and Pharmacy, Timisoara, Hakonarson: None. Y. Vial: None. E. Zackai: None. P. Romania, 2University of Oradea, Faculty of Medicine& Callier: None. S. Drunat: None. E.E. Bhoj: None. Pharmacy, Oradea, Romania  P11
.57A PentasomyXisaveryrarechromosomaldisorder,theexact Integrated clinical-molecular diagnostic criteria for prevalence is not known. Even rarer are descriptions of mosaic overgrowth syndromes adult cases. We present a 20 years old girl hospitalized for functionalrehabilitation.Shewasbornfromhealthy,young, J. C. Sapp, A. Buser, J. Burton-Akright, L. G. Biesecker unrelated parents. Mother reported severe nausea and vomiting during early pregnancy, birth at term, pelvic NHGRI, Bethesda, MD, United States presentation, Apgar 10. Medical history revealed multiple corrective orthopedic surgeries such as osteotomies and Establishing robust clinical diagnostic criteria for mosaic elongations/tendon transpositions for the skeletal abnorm- disorders is difficult because of variation in the number of alities, operated and recidivate varus equin, bilateral genu mutant cells amongst patients. Using Proteus syndrome as valgum operated and relapsed, atrial septal defect without an example, a patient with a high level of mutant cells is indicationforsurgery,moderatementalretardation,primary easy to diagnose, but one with few mutant cells may be nocturnal enuresis, mixt astigmatism. She was diagnosed impossibletorecognize. Also,sometumorshavetheAKT1 with cerebral palsy, spastic diparesis, periventricular c.49G>A p.( E17
K) variant, and this is not Proteus leukomalacia. Clinical and functional evaluation revealed syndrome. Also, some aspects of the phenotype are not normalheight,174cm,overweight,microcephaly,hyperte- unique to Proteus syndrome. We therefore recognize that lorism, epicantus, bilateral corneal leukoma, divergent proper diagnosis must integrate both clinical and molecular strabismus, low-set ears and mandibular prognathism. She aspects. To address this, we have developed an integrated, had many bone and joint anomalies such as clinodactily, clinical-molecular diagnostic system that defines a robust rightvarusequin,bilateralgenuvalgumwithmarkedlatero- threshold for Proteus syndrome stricto sensu and a broader lateral and antero-posterior instability, congenital right hip category of what we term ‘AKT1-related overgrowth dislocation with femoral head necrosis, congenital left hip spectrum’. Each Proteus syndrome manifestation is subluxation, shortening of the right lower limb by 2 cm, assigned a weighted score with associated manifestations right radialhead subluxation with functional impairmentofAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1519 therightelbow,hyperextension oftheleftelbow,moderate osteolysisandotherPROSspectrumsyndromes,supporting motor deficit and muscular hypotonia in both lower limbs, the inclusion of GLA within this spectrum. This research dorso-lumbar sinistro-convex scoliosis, dorsal kyphosis, was supported by the project IP-17 from the call “Todos lumbar lordosis, generalized ligamentous laxity. She was SomosRaros”,andCo-financedbyISCIII,FEDERFUNDS able to walk independently with right knee marked FIS PI17/00519. deviation in valgus, typical cerebral palsy gait. Our patient V. Martinez-Glez: None. G. Gordo: None. L. Rodri- was a rare case, an adult with atypical height, multiple guez-Laguna:None.J.Tenorio:None.N.Agra:None.P. musculoskeletal congenital defects associated with eye and Arias: None. F. Santos: None. S. Garcia-Minaur: None. heart anomalies. E. Vallespín: None. R. Martín-Arenas: None. A. del D.L. Stoicanescu: None. M.L. Cevei: None. C.R. Gug: Pozo: None. M. Feito: None. J.C. Lopez-Gutierrez: None. A. Simedrea: None. None. P. Lapunzina: None.  P11
.59C  P11
.60D First case of osteolysis in a patient with clinical and Mosaic activating PIK3CA mutations during early molecular diagnosis of CLOVES syndrome embryonic development cause ectopic muscle development and upper limb overgrowth V. Martinez-Glez1, G. Gordo1, L. Rodriguez-Laguna1, J. Tenorio1, N. Agra1, P. Arias1, F. Santos1, S. Garcia- F. Taylan1, S. Frisk1,2, I. Blaszczyk3, I. Nennesmo4, Minaur1, E. Vallespín1, R. Martín-Arenas1, A. del Pozo1, G. Annerén5, E. Stattin5, V. Zachariadis1,6, M. Feito2, J. C. Lopez-Gutierrez3, P. Lapunzina1 A. Lindstrand1,2, B. Tesi1,2, T. Laurell7, A. Nordgren1,2 1INGEMM-CIBERER-IdiPaz-Hospital Universitario La 1Department of Molecular Medicine and Surgery, Center Paz,Madrid,Spain,2DepartmentofDermatology,Hospital for Molecular Medicine, Karolinska Institutet, Stockholm, Universitario La Paz, Madrid, Spain, 3Vascular Anomalies Sweden, 2Department of Clinical Genetics, Karolinska Center, Plastic Surgery, Hospital Universitario La Paz, University Laboratory, Karolinska University Hospital, Madrid, Spain Stockholm, Sweden, 3Department of Surgical and Perioperative Sciences, Hand and Plastic Surgery, Umeå The PIK3CA Related Overgrowth Spectrum (PROS) University Hospital, Umeå, Sweden, 4Department of includes a large number of pathologies showing clinical Pathology, Karolinska University Laboratory, Karolinska overlapduetosharingthesamecausinggene(PIK3CA)and University Hospital, Stockholm, Sweden, 5Science for Life genetic mechanism (somatic mosaicism). The clinical Laboratory, Department of Immunology, Genetics and manifestations in PROS depend on the time and place Pathology, Uppsala University, Uppsala, Sweden, 6Present during the embryonic development in which the mutation address: Department of Cell and Molecular Biology, occurred. One of the most recognizable syndromes within Karolinska Institute, Stockholm, Sweden, 7Department of the PROS spectrum is CLOVES (Congenital Lipomatous Hand Surgery, Södersjukhuset, Stockholm, Sweden Overgrowth, Vascular malformations, Epidermal nevi, Scoliosis/Skeletal/Spinal anomalies), which presents a Activating somatic mutations in the phosphatidylinositol- larger clinical severity associated with a wide distribution 4,5-bisphospate 3-kinase, catalytic subunit alpha (PIK3CA) ofaffectedtissuesduetotheappearanceofearlymutations. gene cause PIK3CA-Related Overgrowth Spectrum Recently, we have described that Generalized Lymphatic (PROS). The timing and location of the PIK3CA mutations Anomaly(GLA)mayalsobecausedbysomatic,activating can explain the phenotypic heterogeneity within PROS. mutationsinPIK3CA.AnintriguingclinicalfeatureinGLA Here, we present a 4-year-old male individual ( P1
) and an is the presence of osteolysis associated with hyperplastic 18-year-oldfemaleindividual( P2
)withaPROSphenotype lymphaticsinbone.Itisnotknownwhybonelossoccursin withisolatedmuscleovergrowthofupperlimbsandectopic GLA but has not been described in isolated lymphatic muscles. P1
hadfourectopicmusclesandunilateralisolated malformations or in the rest of the PROS syndromes with muscle overgrowth and  P2
 had 13 ectopic muscles and morepleiotropicclinicalfeatures.Wepresentapatientwith bilateral symmetric isolated muscle overgrowth of upper a clinical diagnosis of CLOVES, in whom there is also a limbs.SequencinganddigitalPCRonDNAextractedfrom vertebral lytic lesion accompanied by a venous/lymphatic biopsies from hypertrophic ectopic muscles identified component. The patient shows the variant PIK3CA: mosaic PIK3CA mutations p.His1047Arg (VAF 18%) and c.241G>A;p.Glu81Lys, detected in a mosaic of 8.53% in p.Glu542Lys(VAF 26%) in P1
 and  P2
, respectively.Since the affected tissue and absent in blood and saliva samples.  P2
 has bilateral findings, the mutation might have occurred This is the first description of phenotypic overlap between before day 15 after fertilization in a cell of the primitive1520 streak in the middle of the embryo. The mutation in  P1
 observedin15patients(14.9%).Significantlyoldermothers mighthaveoccurredafterday21post-fertilizationsincehis (mean age= 31.9 years vs 28.2 years) were found in the muscular overgrowth is unilateral. Observation of super- mUPD, ID group compared with the deletion subtype. numerarymusclesinlocationsintheupperextremitywhere Conclusions: The mean age at diagnosis was late. there should not be muscles implies that the cells with Increase IGF-1 and decrease obesity rate after GH treat- PIK3CA mutations might have differentiated into muscles ment. The risk of mUPD may also increase with maternal instead of tendons or fascia. Our findings highlight that the age or this suggests that ethnic differences be relevant timing of PIK3CA mutagenesis during embryonic develop- for PWS. menthasanimpactonthephenotypeandPI3Khasarolein L.T.An:None.N.T.H.Dinh:None.L.T.Le:None.M. pluripotency and cell fate in early human development. T.P.Nguyen:None.T.M.Ngo:None.N.D.Ngo:None.A. Grants: The Swedish Childhood Cancer Foundation, the N. Do: None. D.C. Vu: None. H.T. Le: None. H.T. Swedish Cancer Society, the Swedish Research Council, Phan: None. KarolinskaInstitutet,BerthvonKantzow’sfoundation,The Hållsten Research Foundation  P11
.62B F.Taylan:None.S.Frisk:None.I.Blaszczyk:None.I. A lower BMI and growth hormone use results in Nennesmo: None. G. Annerén: None. E. Stattin: None. decreased mortality in Prader-Willi syndrome V. Zachariadis: None. A. Lindstrand: None. B. Tesi: None. T. Laurell: None. A. Nordgren: None. J.N.Proffit1,2,K.Osann1,B.MacManus3,M.G.Butler4, V. E. Kimonis1, J. Heinemann3, D. Stevenson5,  P11
.61A J. A. Gold6,7,8 Clinicalandgeneticfeaturesofprader-willisyndromein vietnam 1University California Irvine, Orange, CA, United States, 2Perinatal Genetics Clinic, Stanford Medical Center, L. T. An1, N. T. H. Dinh1, L. T. Le1, M. T. P. Nguyen1, Stanford, CA, United States, 3Prader-Willi Syndrome T. M. Ngo1, N. D. Ngo1, A. N. Do1, D. C. Vu1, H. T. Le1, Association(USA),Sarasota,FL,UnitedStates,4University H. T. Phan2 ofKansasMedical Center, KansasCity, KS, United States, 5StanfordUniversity,Stanford,CA,UnitedStates,6Dept.of 1Vietnam National Children's Hospital, Hanoi, Viet Nam, Pediatrics, Division of Genetics and Genomics University 2Hanoi medical university, Hanoi, Viet Nam California Irvine, Orange, CA, United States, 7Dept. of ClinicalGeneticsandGenomics,AddenbrookesCambridge Introduction: Prader-Willi syndrome (PWS) is a complex UniversityNHSTrust,Cambridge,UnitedKingdom,8Loma genetic disorder that results from the lack of paternally Linda University Childrens Hospital, Loma Linda, CA, expressedinthechromosome15q11-q13region.Thisstudy United States wasperformed todelineatetheclinical andgeneticfeatures of children with PWS. Early mortality has been reported in PWS. Recent studies Methods: The clinical signs were studied. Karyotype, have shown an increase in survival estimates in the last 20 fluorescence in situ hybridization, methylation- specific years. The hypothesis is that it is due to preventative polymerase chain reaction and subsequent methylation- measures to avoid morbid obesity. The PWS Association specific multiplex ligation- dependent probe amplification (PWSA) USA created a long standing bereavement and were used to describe characteristics of genetic classes of research program to investigate causes of death and collect PWS.Datawerecollectedon101patientswithamolecular data in living individuals with PWS. A familial-response diagnosisofPWSatVietnamNationalChildren’sHospital. questionnaires from the PWSA (USA), tested the hypoth- Results: The mean age at diagnosis was 30.2 months. esis that body mass index (BMI), age of diagnosis, clinical Most patients who showed the characteristics of facial symptoms, and growth hormone treatment differ among dysmorphism. 92.1% had neonatal hypotonia and feeding deceased and living individuals with PWS. Data were difficulties,61.4%oftheneonateswerehospitalized,11.8% available on a total of 2,029 individuals with PWS (114 had obesity, 79.6% showed developmental delays and deceased and 1,915 living) from the USA. Categorical and cryptorchidism was 84%. Among 101 patients, 51 patients continuous variables were compared using chi-square and had been treated with growth hormon (GH) and GH treat- two-group t-tests, respectively. For categorical variables, ment resulted in an increase of insulin-like growth factor 1 theeffectofagewaslimitedbystratifyingforage(<20yv. (IGF-1) and a decrease in obesity. Deletion subtype was ≥20y) and birth year (<1994 v. ≥ 1994) and testing with a present in 86 patients (85.1%), 4 patients had a transloca- Mantel-Haenszeltest.Forcontinuousvariables,theeffectof tion,onecaseisanuniquePWSdeletions.mUPD,IDwere age was limited by adjusting for age as a continuousAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1521 variable in logistic regression. Average age at death was inhibitors. Interestingly, CCND2, a major cell cycle reg- 31.6 years. Deceased individualshad lower rates of growth ulatory protein was down-expressed upon functional inhi- hormoneuse(p<0.001)andhigherratesofincreasedweight bition of HSF1. comparedtolivingindividuals.BMIinlivinganddeceased Conclusion:OurresultsidentifyHSF1asanewpotential individuals with PWS were 28.6 (SD=11.9) and 51.7 therapeutic target in PROS. (SD=21.7), respectively (p<0.001). This study highlights L. Duplomb: None. R. Da Costa: None. M. Chevarin: thebenefitsof growth hormone, externalcontrolof weight, None.S.Hadj-Rabia:None.S.Lecler-Mercier:None.C. early diagnosis, and the need for a low threshold for Thauvin-Robinet: None. C. Garrido: None. L. Faivre: bringing affected individuals to medical attention. None. P. Vabres: None. G. Jego: None. J.N. Proffit: None. K. Osann: None. B. MacManus: None. M.G. Butler: None. V.E. Kimonis: None. J. Hei-  P11
.64D nemann: None. D. Stevenson: None. J.A. Gold: None. PUF60 splicing variant in a boy with coloboma, short stature and subtle facial features  P11
.63C Neutralization of heat shock transcription factor 1 in S. MIZUNO1, M. Izawa2, S. Miyatake3, M. Inaba1, cells from segmental overgrowth syndrome patients K. Kato1, Y. Muramatsu1, H. Taniai1, N. Matsumoto3 blocks abnormal proliferation 1Department of Clinical Genetics, Aichi Developmental L. Duplomb1, R. Da Costa1, M. Chevarin1, S. Hadj- Disability Center Hospital, Kasugai, Aichi, Japan, 2Aichi Rabia2, S. Lecler-Mercier3, C. Thauvin-Robinet1, Children’s Health and Medical Center, Obu, Aichi, Japan, C. Garrido1, L. Faivre1, P. Vabres1, G. Jego1 3Department of Human Genetics, Yokohama City UniversityGraduateSchoolofMedicine,Yokohama,Japan 1INSERM 1231, University of Burgundy, Dijon, France, 2Department of Dermatology, Necker-Enfants Malades Recent studies have clarified that microdeletion involving Hospital, Paris, France, 3Department of Pathology, PUF60 [Poly(U) Binding Splicing Factor 60] and de novo Necker-Enfants Malades Hospital, Paris, France variantsinPUF60causemultiplecongenitalanomaliesand intellectual disability. We report a boy with a PUF60 PIK3CA-Related Overgrowth Syndromes (PROS) are variant and coloboma, congenital heart disease, and short caused by mosaicism mutations in the PIK3CA gene. The stature. He was born uneventfully to healthy unrelated useofspecificinhibitors totarget PI3KormTORinPROS parents, with around average birth weight and height. He was recently found to lead to disease regression. However, underwent surgical ligation at 7 months for symptomatic the downstream effectors of the PI3K/mTOR pathways patentductusarteriosus.Hehadrecurrentfebrileseizuresin specifically involved in the pathogenicity of PROS remain infancy. He walked by 17 months and spoke his first word unknown. Heat shock transcription factor 1 (HSF1) is the by 15 months. His facial features include a square face, majorstress-responsivetranscriptionfactor.Recentfindings webbedneck,broadnasalbridge,longeyelashes,darkthick indicate that AKT phosphorylates and activates HSF1 eyebrows, flat philtrum, thin upper vermilion and dental independently of heat-shock in breast cancer cells. We crowding. His square face and large teeth were similar to aimed to investigate the role of HSF1 in PROS. KBG syndrome. He had a right choroidal coloboma We found elevated phosphorylation and activation of (corrected visual acuity 0.06), short stature (Z-score -2.5) HSF1 in cells from PROS patients, which are directly cor- and borderline head circumference. He goes to junior high related to the presence of activated form of AKT. In line school without special needs. Whole exome sequencing of with its function as a transcription factor, active HSF1 theboyandhisparentsidentifiedadenovonovelvariantin localized in the nucleus of cells from PROS but not in PUF60 [NM_078480, c.297+1G>A]. RT-PCR analysis of control donors. Inhibition of PI3K or mTOR activity lymphoblastoid cells from the patient and a control strongly reduced HSF1 activation in patient cells. Messen- identified an abnormal splicing event involving intron ger RNA expression of 47 genes that are known to be 4 sequences in the patient but not in the control. The regulated by HSF1 were repeatedly down-expressed upon abnormal splicing product underwent nonsense mediated PI3Kinhibition.WealsoobservedthattargetingHSF1with mRNA decay. specific inhibitors reduced the proliferation of mutant cells Conclusion: This case of a PUF60 pathogenic variant in as efficiently as PI3K or mTOR inhibitors. The increased aboywithcoloboma,congenitalheartdisease,shortstature, numberofcellsenteringtheSphaseofthecellcycle,which subtle facial features, and normal intellectual development ischaracteristicofPROS,wascompletelybluntedbyHSF1 suggests that PUF60 variants should be considered in1522 syndromic phenotypes with coloboma with or without reports of PXDN mutations have been associated with intellectual disability. autosomal recessive ASMD in patients with similar phe- S.Mizuno:None.M.Izawa:None.S.Miyatake:None. notypes. It is currently unknown whether the proband’s M. Inaba: None. K. Kato: None. Y. Muramatsu: None. non-ocularphenotypesarelinkedtoPXDN;therefore,more H. Taniai: None. N. Matsumoto: None. similarcasesareneededtoreachacorrelation.Theseresults highlight the strength of WES as a diagnostic tool and the  P11
.65A diversity of phenotypes caused by PXDN mutations. Novel homozygous nonsense PXDN mutation detected E. Kritioti: None. N. Nicolaou: None. A. Alexandrou: by whole exome sequencing causing anterior segment None. A. Syrimis: None. I. Papaevripidou: None. A. dysgenesis Theodosiou: None. V. Christophidou-Anastasiadou: None. C. Sismani: None. G.A. Tanteles: None. E. Kritioti1,2,3, N. Nicolaou2, A. Alexandrou1, A. Syrimis2,3, I. Papaevripidou1, A. Theodosiou1,  P11
.66B V. Christophidou-Anastasiadou2,4, C. Sismani1,3, Aclinicalutilitystudyofdiagnosinggeneticdisordersin G. A. Tanteles2 newborns admitted to the Neonatal Intensive Care Unit 1Cytogenetics and Genomics Department, The Cyprus A. C. Deden1,2, L. E. L. M. Vissers3, R. A. C. M. Olde Institute of Neurology and Genetics, Nicosia, Cyprus, Keizer4, G. W. J. Frederix4, RADICON-NL, 2Clinical Genetics Clinic, The Cyprus Institute of P. Andriessen5, K. A. Bergman6, R. A. van Lingen7, Neurology and Genetics, Nicosia, Cyprus, 3The Cyprus L. S. de Vries8, K. D. Lichtenbelt9, W. S. Kerstjens- School of Molecular Medicine, The Cyprus Institute of Frederikse2, I. P. C. Krapels10, J. S. Klein Wassink- Neurology and Genetics, Nicosia, Cyprus, 4Clinical Ruiter2, K. Neveling1, M. Nelen1, S. Castelein1, M. del Genetics Clinic, Archbishop Makarios III Medical Centre, Rosario1, S. van den Heuvel1, C. Gilissen1, E. Kamsteeg1, Nicosia, Cyprus R. Pfundt1, T. Rinne1, H. G. Yntema1, R. J. Sinke2, W. P. de Boode11, W. A. G. Zelst-Stams12 Anterior segment dysgeneses (ASMD - MIM #269400) encompass a spectrum of anterior chamber ocular develop- 1Department of Human Genetics, Radboud University mental defects affecting the cornea, iris, and lens and are Medical Center, Nijmegen, Netherlands, 2Department of generally associated with a significant risk for glaucoma. Genetics,UniversityMedicalCentreGroningen,University Clinical features include iris hypoplasia, corneal opacity, of Groningen, Groningen, Netherlands, 3Department of posterior embryotoxon, corectopia, polycoria, an abnormal Human Genetics, Donders Institute for Brain, Cognition, iridocorneal angle, ectopia lentis, and anterior synechiae and Behaviour, Radboud University Medical Center, between the iris and posterior corneal surface. Nijmegen, Netherlands, 4Julius Center for Health Sciences We report on a Greek-Cypriot male born to parents who and Primary Care, University Medical Center Utrecht, were distantly related. He presented with bilateral iris Utrecht University, Utrecht, Netherlands, 5Department of defects, extensive anterior synechiae, posterior embry- Neonatology, Máxima Medical Center, Veldhoven, otoxon, nystagmus, glaucoma and cataracts. Other non- Netherlands, 6Department of Neonatology, Beatrix ocular abnormalities included bilateral hydronephrosis, Children'sHospital,UniversityMedicalCenterGroningen, vesicoureteric obstruction, bilateral megaureter and bipolar Groningen, Netherlands, 7Department of Neonatology, disorder. Princess Amalia Department of Pediatrics, Isala, Zwolle, Negative investigations included array-CGH, MLPA for Netherlands, 8Department of Neonatology, Wilhelmina PAX6 deletions and Sanger sequencing of PAX6, FOX C1
 Children's Hospital, Utrecht University, Utrecht, and PITX2. Trio-based WES was subsequently performed Netherlands, 9Department of Medical Genetics, University on the Illumina NextSeq500 platform using the TruSeq Medical Center Utrecht, Utrecht, Netherlands, DNAexomelibrarykit.Bioinformaticsanalysiswascarried 10Department of Clinical Genetics, Maastricht University out using an in-house pipeline according to the Genome Medical Center, Maastricht, Netherlands, 11Department of Analysis Toolkit Best Practices. Neonatology, Radboud University Medical Center, Homozygosity for a novel nonsense PXDN p.(Gly700*) Radboud Institute for Health Sciences, Amalia Children’s variant was identified in the index case. The variant was Hospital, Nijmegen, Netherlands, 12Department of Human confirmed by Sanger sequencing as was parental carrier Genetics, Radboud University Medical Center, Radboud status. Institute for Health Sciences, Nijmegen, Netherlands In conclusion, a novel, homozygous PXDN variant was identified with a strong phenotypic correlation. OtherAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1523 Rapid whole exome sequencing (rWES) is feasible, but 1DepartmentofPediatricNeurology,MedicalUniversityof awaitsembedding inroutine clinical care inmosthospitals. Silesia,, Katowice, Poland, 2Clinical Genetics Services, We hypothesized that routine rWES will profoundly VCUHealth,Richmond,VA,UnitedStates,3Departmentof increase genetic diagnoses for critically ill newborns, MedicalGenetics,MedicalUniversityofWarsaw,,Warsaw, leading to improved patient care. Therefore we performed Poland, 4Postgraduate School of Molecular Medicine, aclinical utility study assessingthevalue ofgenetic testing Medical University of Warsaw, Warsaw, Poland, in routine neonatal clinical practice. In a multi-centre 5Department of Genetics, Wroclaw Medical University, prospective study set-up, 60 critically ill newborns with a Wroclaw, Poland, 6Department of Diagnostic Imaging, presumed genetic disorder received rWES, parallel to MedicalUniversityofSilesia,,Katowice,Poland,7Pediatric routinegenetictesting.Toobtaininsightintotheprevalence Department of Radiology, VCU Health, Richmond, VA, of genetic testing in the first 30 days of life, historical data United States from all 1423 patients admitted to the NICU in the Radboudumc (October 2013 to October 2015) served as a Schilbach-Rott/Blepharofacioskeletal Syndrome (SR/ control period.Prospectively, a conclusive molecular diag- BRSS) (OMIM #164220) is an autosomal dominant nosis was obtained in 19 of 60 patients (31.7%), with a condition characterized by blepharophimosis, cleft palate, median time-to-diagnosis of 14 days (IQR 11-21). In dysmorphic facies, and hypospadias in males. In many comparison, genetic testing was performed in 149 patients patients hypotelorism and mild skeletal anomalies in the (10.5%) in the control period, leading to a conclusive handsorfeethavebeenreported.NocausativegeneofSR/ molecular diagnosis within 30 days of life in 13 of them BRSS has been found to date. We present the clinical (8.7%). The median time-to-diagnosis was 14 days (IQR characteristicsoftwoboyswithseveredevelopmentaldelay 12-15). Importantly, from our control period, we noticed and dysmorphic features suggestive of SR/BRSS. In both, that in a further 136 patients (9.6%) genetic test reports blepharophimosis, cleft orhigh-arched palate,hypospadias, outlasted the first 30 days of life, but increased the scoliosis, and arachnodactyly with clinodactyly were diagnostic yield to 32.2%. This suggests that more NICU observed.Additionallymicrocephaly,archedeyebrow,high patients may benefit from rWES than currently tested. Our narrownasalbridge,longhangingcolumella,micrognathia, datashowthattheintroductionofrWESforallcriticallyill hypoplastic earlobes, hypermobile joints have been noted. newborns with a presumed genetic disorder increases The same novel de novo mutation, HNRNPH1 c.616C>T diagnostic yield earlier in life than conventional (p.Arg206Trp), was found in both patients using whole diagnostic tests. exome sequencing. To date, mutations in the highly A.C. Deden: None. L.E.L.M. Vissers: None. R.A.C.M. conserved autosomal HNRNPH1 gene have not been Olde Keizer: None. G.W.J. Frederix: None. P. Andries- associated with human disease. HNRNPH1 belongs to the sen:None.K.A.Bergman:None.R.A.vanLingen:None. group of nuclear ribonucleoproteins involved in regulation L.S. de Vries: None. K.D. Lichtenbelt: None. W.S. ofpre-mRNAssplicing.Interestingly,theidenticalrecurrent Kerstjens-Frederikse: None. I.P.C. Krapels: None. J.S. mutation affecting the small domain encoding nuclear Klein Wassink-Ruiter: None. K. Neveling: None. M. localizationsignalinthehighlyparalogousHNRNPH2gene Nelen: None. S. Castelein: None. M. del Rosario: None. has been previously associated with X-linked, syndromic, S. van den Heuvel: None. C. Gilissen: None. E. Kam- Bain type mental retardation [MRXSB, OMIM #300986]. steeg: None. R. Pfundt: None. T. Rinne: None. H.G. MRXSBhasbeenidentifiedinfemaleswithdevelopmental Yntema: None. R.J. Sinke: None. W.P. de Boode: None. delay, intellectual disability, autism, hypotonia, and sei- W.A.G. Zelst-Stams: None. zures. Only in single cases hypotelorism, small palpebral fissures, or elongated fingers were observed. Although  P11
.67C defective function of HNRNPH2 and HNRNPH1 proteins Is Schilbach-Rott/Blepharofacioskeletal Syndrome havesimilarclinical consequences inregardstointellectual caused by a mutation in HNRNPH1? - a report on a 2 disability, mutations in HNRNPH1 gene may represent a cases distinct syndromeperhapsrelated oridentical toSchilbach- Rott/Blepharofacioskeletal Syndrome. Grant Numbers: J. Pilch1, S. L. Reichert2, A. A. Koppolu3,4, A. Walczak3, KNW-1-036/K/7/K; 2013/11/B/NZ7/04944; V. A. Murcia Pienkowski3,4, A. Biernacka3,4, R. Li2, J. Pilch: None. S.L. Reichert: None. A.A. Koppolu: P. Skiba5, J. Machnik-Broncel6, R. L. Lewandowski2, None. A. Walczak: None. V.A. Murcia Pienkowski: P. Gasperowicz3, J. Kosińska3, M. Rydzanicz3, None. A. Biernacka: None. R. Li: None. P. Skiba: None. G. Vorona7, E. Emich-Widera1, R. Płoski3 J.Machnik-Broncel:None.R.L.Lewandowski:None.P. Gasperowicz: None. J. Kosińska: None. M. Rydzanicz:1524 None. G. Vorona: None. E. Emich-Widera: None. R. D. Halperin: None. R. Kadir: None. Y. Perez: None. Płoski: None. M.Drabkin:None.Y.Yogev:None.O.Wormser:None. E.Berman:None.E.Eremenko:None.B.Rotblat:None.  P11
.68D Z.Shorer:None.L.Gradstein:None.I.Shelef:None.R. SE C31
A mutation affects ER homeostasis, causing Birk: None. U. Abdu: None. H. Flusser: None. O.S. neurological syndrome Birk: None. D. Halperin1, R. Kadir1, Y. Perez1, M. Drabkin1,  P11
.70B Y. Yogev1, O. Wormser1, E. Berman1, E. Eremenko1, SMCHD1 mutation spectrum for facioscapulohumeral B.Rotblat1,Z.Shorer2,L.Gradstein2,I.Shelef2,R.Birk3, musculardystrophytype2(FSHD2)andBosmaarhinia U. Abdu1, H. Flusser2, O. S. Birk1,2 microphthalmia syndrome (BAMS) reveals disease- specific localization of variants in the ATPase domain 1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Soroka University Medical Center, Beer-Sheva, Israel, R. J. L. F. Lemmers1, N. van der Stoep1, P. J. van der 3Ariel University, Ariel, Israel Vliet1, S. A. Moore2, A. Topf3, K. Johnson3, D. San Leon Granado1, T. Evangelista3, V. Straub3, C. Scotton4, Introduction: Consanguineous kindred presented with an A. Ferlini4, N. Voermans5, B. van Engelen5, S. Sacconi6, autosomal recessive syndrome of intra-uterine growth R. Tawil7, M. Lamers1, S. M. van der Maarel1 retardation, marked developmental delay, spastic quadri- plegia with profound contractures, pseudobulbar palsy, 1Leiden University Medical Center, Leiden, Netherlands, epilepsy, dysmorphism, neurosensory deafness and optic 2University of Iowa, Iowa city, IA, United States, nerve atrophy with no eye fixation. Affected individuals 3University of Newcastle, Newcastle, United Kingdom, died by the age of four. Brain MRI demonstrated 4UniversityofFerrara,Ferrara,Italy,5RadboudUniversity microcephaly, semilobar holoprosencephally and agenesis Medical Center, Nijmegen, Netherlands, 6Nice University of corpus callosum. We aimed at elucidating the molecular Hospital, Nice, France, 7University of Rochester Medical basis of this disease. Center, Rochester, NY, United States Methods: Genome-wide linkage analysis combined with whole exome sequencing were performed to identify Introduction:VariantsinthechromatinmodifierStructural disease-causing variants. Functional consequences were Maintenance Of Chromosomes Flexible Hinge Domain- investigated in fruit flies null mutant for the Drosophila ContainingProtein1(SMCHD1)havebeenassociatedwith SE C31
A orthologue. SE C31
A knockout SH-SY5Y and the myopathy FSHD2 and with the unrelated nasal HEK293T cell-lines were generated using CRISPR/Cas9 developmental syndrome BAMS. FSHD2 is a digenic and studied through qRT-PCR, immunoblotting and viabi- hereditary disease with heterozygous variants anywhere in lity assays. SMCHD1causing toxic derepression of DUX4, a gene that Results:Throughgeneticstudies,weidentifiedadisease- is embedded in the D4Z4 repeat on chromosome 4 variant associatedhomozygousnonsensemutationinSE C31
A.We 4A. BAMS also requires missense variants in SMCHD1, demonstrate that SE C31
A is ubiquitously expressed, and but specifically in the ATPase domain. Irrespective of the that the mutation triggers nonsense mediated decay of its phenotypic outcome, both FSHD2 and BAMS associated transcript, comprising a practical null mutation. Similar to SMCHD1variantsresultinquantifiablehypomethylationof the human disease phenotype, knockdown SE C31
A flies the D4Z4 locus. We identified numerous new pathogenic had defective brains and early lethality. Moreover, in line FSHD2variantsandnon-pathogenicvariantsandcompared with SE C31
A encoding one of the two coating layers these to BAMS associated variants. M&M: Genetic and comprising the COP-II complex, trafficking newly synthe- methylation studies of D4Z4 and SMCHD1 in 91 new sizedproteinsfromtheendoplasmicreticulumtotheGolgi, FSHD2 families. Examination of the position and mutation CRISPR/Cas9-mediated SE C31
A null mutant cells demon- type for SMCHD1 variants in 180 (89 from previous strated reduced viability through upregulation of ER-stress publications) FSHD2 families, 41 BAMS patients and 57 pathways. control individuals. Generation of a 3D model for the Conclusions: We demonstrate that a severe neurological SMCHD1 ATPase-domain in which we modeled all syndrome is caused by a null mutation in SE C31
A, redu- missense variants in FSHD2 and BAMS. cing cell viability through enhanced ER-stress response, in Results:TheFSHD2mutationspectrumshowsmissense, line with SE C31
A’s role in the COP-II complex. Funding: nonsense, indels and splice site variants covering the entire LegacyHeritageBio-MedicalProgramoftheIsraelScience SMCHD1 locus, but missense variants are specifically Foundation (grants no. 1814/13 and 1798/16) enriched in the ATPase domain. Non-pathogenic missenseAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1525 variants were almost absent from the ATPase domain. Methods: We performed whole exome sequencing in a FSHD2andBAMSvariantsoccupydifferentsitesinthe3D patient exhibiting a syndromic developmental delay and in model of the ATPase domain. her unaffected parents and report the phenotypic features. Conclusions:ThelocalizationwithintheATPase-domain Results:Ourpatientwasborntoconsanguineousparents mightunderliethephenotypicoutcomeofmissensevariants at 28 weeks of gestation. During pregnancy follow-up, left in the ATPase-domain of SMCHD1. Funded by NIH and cleft lip and alveolus, polyhydramnios and intrauterine Prinses Beatrix Spierfonds. growth restriction were noticed. Postnatal examination R.J.L.F.Lemmers:None.N.vanderStoep:None.P.J. revealed prominent forehead, hypertelorism, ears abnorm- van der Vliet: None. S.A. Moore: None. A. Topf: None. alities, cataracts, kyphosis, renal hypoplasia, as well as K. Johnson: None. D. San Leon Granado: None. T. complexventricularseptaldefectsandaorticbicuspidvalve Evangelista: None. V. Straub: None. C. Scotton: None. on cardiac ultrasound and thin corpus callosum and dilated A. Ferlini: None. N. Voermans: None. B. van Engelen: ventricles on brain MRI at the age of 12 months. She pre- None. S. Sacconi: None. R. Tawil: None. M. Lamers: sented early and severe feeding difficulties, severe growth None. S.M. van der Maarel: None. restriction,globaldevelopmentaldelay,andmultiplesevere infections requiring hospitalizations. She carried a novel  P11
.71C c.1177C>T, p.(Gln393*) (NM_019108) SMG9 homo- SMG9 deficiency syndrome: confirmation and further zygous variant while her unaffected parents were both phenotypic characterization heterozygous. Conclusions:Weconfirmthatbi-allelictruncatingSMG9 F.Lecoquierre1,A.Bonnevalle1,A.Guerrot1,A.Chadie2, variants cause a severe brain and heart malformation syn- C.Gayet3,C.DumantForest3,M.RenauxPetel4,J.Leca4, drome including ventricular septal defects, brain abnorm- T. Hazelzet3, M. Brasseur-Daudruy5, F. Louillet3, alities, facial dysmorphic features, and severe growth and M. Muraine6, S. Coutant1, O. Quenez1, A. Boland7, developmentaldelay(4/4)withorwithoutophthalmological J. Deleuze7, T. Frebourg1, A. Goldenberg1, P. Saugier- abnormalities (3/4), severe feeding difficulties (2/3), and Veber1, G. Nicolas1 life-threatening infections (2/4). F. Lecoquierre: None. A. Bonnevalle: None. A. Guer- 1Normandie Univ, UNIROUEN, Inserm U1245 and Rouen rot:None.A.Chadie:None.C.Gayet:None.C.Dumant UniversityHospital,DepartmentofGeneticsandReference Forest: None. M. Renaux Petel: None. J. Leca: None. T. Center for Developmental Disorders, F 76000, Normandy Hazelzet: None. M. Brasseur-Daudruy: None. F. Louil- Center for Genomic and Personalized Medicine, Rouen, let: None. M. Muraine: None. S. Coutant: None. O. France, 2Department of Neonatal Pediatrics and Intensive Quenez: None. A. Boland: None. J. Deleuze: None. T. Care -Neuropediatrics, Rouen University Hospital, Rouen, Frebourg: None. A. Goldenberg: None. P. Saugier- France, 3Department of Pediatrics, Rouen University Veber: None. G. Nicolas: None. Hospital, 76000, Rouen, France, 4Department of Pediatric Surgery,RouenUniversityHospital,76000,Rouen,France,  P11
.72D 5Department of Radiology, Rouen University Hospital, The complete loss of function of the SMS gene is 76000, Rouen, France, 6Department of Ophthalmology, responsible for an antenatal onset and a lethal form of Rouen University Hospital, 76000, Rouen, France, 7Centre Snyder-Robinson Syndrome National de Recherche en Génomique Humaine (CNRGH), InstitutdeBiologieFrançoisJacob,CEA,UniversitéParis- L. Larcher1,2, J. Norris3, S. Whalen1,4, E. Lejeune1,2, Saclay, Evry, France J. Buratti1,2, C. Mignot1,2,4, C. Garel1,4, C. Schwartz3, B. Keren1,2 Introduction: SMG9 deficiency syndrome is a rare autosomal recessive condition originally described in three 1AssistancePubliquedesHôpitauxdeParis,Paris,France, patients from two families with homozygous truncating 2Hôpital Pitié Salpêtrière, Paris, France, 3Greenwood SMG9 variants. Affected individuals presented with a Genetic Center, Greenwood, SC, United States, 4Hôpital severe syndromic developmental disorder, and a mouse Armand Trousseau, Paris, France model revealed the embryonic lethality of bi-allelic Smg9 deficiency, in a context of major brain, eye and cardiovas- Introduction: Snyder-Robinson syndrome (SRS) is an X- cular malformations. To our knowledge, no additional linkedsyndromicintellectualdisabilityconditionwithpost- patient has been described since this report. natal expression caused by variants in the Spermine Synthase gene (SMS). The syndrome is characterized by facial dysmorphism, thin habitus, hypotonia and a1526 nonspecific movement disorder. Until now, only missense columella, resembling KS patients. ArrayCGH identified a variants with a functionally characterized partial loss of 40.76-Mb pathogenic duplication at 1p13.3q21.2 pericen- function(LoF)havebeendescribed.Herewereportthefirst tromeric region and a 4.69-Mb duplication of unclear complete LoF variant in a male patient with a congenital clinical significance at 10q22.2q22.3, both with profiles formofSRS.PatientandMethods:Thepatienthadmultiple suggesting mosaicism. Subsequent karyotype and FISH malformationswithantenatalonsetanddiedat4monthsof analyses revealed a supernumerary ring chromosome in age after staying in the intensive care unit. His phenotype 40% of the cells that co-hybridizes with probes for both included IUGR, cysts of the vermis, facial dysmorphism, chromosome 1 and 10 duplicated regions. hypotonia with no eye contact, complex cardiac, gut and Discussion: sSMC derived from chromosome 1 can kidney malformations. His DNA and that of his parents present a variable phenotype, ranging from normality to were sent to our genetics laboratory to perform whole- severeintellectualdisability.However,theregion1p12to exome-sequencing.Functionalstudieshavebeenperformed 1q12 appears to be non-dosage dependant and the size of tovalidateavariantfoundbyWES:westernblotanalysisto the sSMC seems to correlate with the severity of quantitatively determine the protein level of SMS and the phenotype. The resemblance with KS was interest- UPLC - MS/MS to qualitatively determine the enzyme ingly reported 20 years ago in a patient presenting an activity. interstitial duplication of the short arm of chromosome 1, Results: Genomic analysis revealed a de novo hemi- in a locus with significant overlap with ours. In conclu- zygous frameshift in SMS, c.906_909delAATG; p. sion, we illustrate a distinctive phenotype of a rare chro- M303Kfs3, classified as pathogenic according to the mosome abnormality, while emphasizing the importance ACMG criteria. Functional in vitro assays showed a com- of resorting to complementary classical cytogenetic plete absence of functional SMS protein. studies. Conclusion:Takentogether,ourfindingsconfirmthatthe R.Silveira-Santos:None.J.Dupont:None.J.R.Alves: mechanism of pathogenicity in SRS is a LoF in SMS and None. A. Sousa: None. A.B. Sousa: None. thatcompleteLoFleadstoafarmoreseverephenotypethan partial LoF due to missense variants.  P11
.74B L. Larcher: None. J. Norris: None. S. Whalen: None. Tetrasomy 21 pter→q21.3 due to an extra +dic(21;21) E.Lejeune:None.J.Buratti:None.C.Mignot:None.C. in a severe psychomotor retarded female without Down Garel: None. C. Schwartz: None. B. Keren: None. syndrome phenotype  P11
.73A T. Takano1,2, K. Nakabayashi3, H. Ota2, Y. Arai2, Rare case of a complex small supernumerary r(1;10) H. Kamura3, K. Hata3 chromosome mosaicism associated with a Kabuki-like phenotype 1Tokyo Kasei University, Tokyo, Japan, 2Tokyo Metropolitan Tobu Medical Center for Children with R. Silveira-Santos, J. Dupont, J. R. Alves, A. Sousa, Developmental Disabilities, Tokyo, Japan, 3National A. B. Sousa Research Institute for Child Health and Development, Tokyo, Japan Serviço de Genética Médica, Departamento de Pediatria, Hospital de Santa Maria, CHULN, CAML, Lisboa, Introduction: Complete or partial tetrasomy 21 without Portugal mosaicismhasbeenreportedinonlyrarecases.Wereporta Japanese female patient with tetrasomy 21 due to an extra Introduction: Complex small supernumerary marker chromosome derived from chromosome 21. chromosomes (sSMC) originate from more than one Materials and Methods: Chromosome, fluorescence chromosomeandcancausevariablephenotypes.Wereport in situ hybridization (FISH) and whole genomesequencing the first case of mosaic ring-shaped sSMC derived from (WGS) analyses for the patient, and SNP array-based gen- chromosomes 1 and 10 in a child with dysmorphisms otyping for the trio were carried out. reminiscent of Kabuki Syndrome (KS). KS is a genetically Results: The patient had severe psychomotor retardation heterogeneous autosomal dominant condition characterized withoutDownsyndrome(DS)phenotype;sheshowedshort byintellectualdisability(ID),multiplecongenitalanomalies stature, microcephaly, round face and some dysmorphic and a recognizable facial gestalt. Case presentation: The 3- features. At eight years old, she could not speak any year-old girl showed moderate ID, aggressive behaviour meaningful words nor walk. The developmental quotients anddysmorphisms,includinghypertelorism,longpalpebral scorewasbelow20.Thechromosomeanalysesdetectedan fissures, eyebrows with sparse lateral third, and short extradicentricchromosome21,andrevealedherkaryotypeAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1527 tobe47,XX,+dic(21;21).FISHresultswereconsistentwith of Michigan, Ann Arbor, MI, United States, 14Columbia the karyotype. Allelic ratios of heterozygous SNPs indi- Univ., New York, NY, United States, 15Ann & Robert H. catedthematernaloriginoftheextrachromosome21.Copy Lurie Children’s Hospital of Chicago, Chicago, IL, United number and structural variant analyses using WGS data States, 16Univ. de Bourgogne-Franche Comté, Dijon, indicated that the distal breakpoint of the dicentric chro- France, 17CHU Lyon, Lyon, France, 18Univ. Medical mosome 21 is located within 21q21, and that the extra Center, Groningen, Netherlands, 19Saint Louis Univ. Sch. chromosome 21 doesn’t simply consist of inverted dupli- of Medicine, Saint Louis, MO, United States, 20Virginia cations of pter→q21.3region but contain multiple partial Commonwealth Univ., Richmond, VA, United States, deletions, duplications, and inversions within it. 21Univ. of British Columbia, Vancouver, BC, Canada, Conclusions: The patient’ lack of DS phenotype turned 22Humangenetik, Charité Campus Virchow, Berlin, out to be due to the normal copy number of DS critical Germany, 23Inst. of Human Genetics, FAU Erlangen- region (21q22.2-22.3). We will present the genomic orga- Nürnberg, Erlangen, Germany, 24Inst. of Human Genetics, nization of the tetrasomic region being further assessed by Univ. Medical Center Hamburg-Eppendorf, Hamburg, FISH and WGS data, and discuss possible molecular Germany, 25Driscoll Children’s Hospital, Corpus Christi, mechanisms that lead to the complex genomic rearrange- TX, United States, 26State Univ. of Bahia, Bahia, Brazil, ments in the patient. 27Univ. of Arkansas for Medical Sciences, Lowell, AR, T. Takano: None. K. Nakabayashi: None. H. Ota: United States, 28Mercy Kids Genetics, Saint Louis, MO, None.Y.Arai: None.H.Kamura:None.K.Hata:None. United States, 29Massachusetts General Hospital, Boston, MA, United States, 30Seattle Children's Hospital, Seattle,  P11
.75C WA, United States, 31London Health Sciences Centre, Delineating the clinical spectrum due to heterozygous London, ON, Canada, 32Center for Medical Genetics, Keio TRAF7 missense mutations: A series of 38 cases Univ. Sch. of Medicine, Tokyo, Japan, 33Emory Univ. Sch. of Medicine, Atlanta, GA, United States, 34Duke Univ., J. Amiel1,2,3, K. Mishra4, L. Castilla5, K. K. Selmer6, Durham, NC, United States, 35VCGS, Murdoch Children's T.Barak4,S.Yang7,B.Blanco-Sánchez1,2,M.Reijnders8, Research Inst., Univ. of Melbourne, Melbourne, Australia, G. Houge9, H. Cox10, H. Kingston11, J. Clayton-Smith12, 36Univ. of California, San Francisco, CA, United States, J. W. Innis13, W. Chung14, V. Sanders15, A. Vitobello16, 37Univ. of Miami, Coral Gables, FL, United States C. Thauvin16, G. Lesca17, M. Kerstjens-Frederikse18, K.Christensen19,R.Gannaway20,A.Lehman21,L.Graul- TRAF7 belongs to the Tumor necrosis factor receptor- Neumann22, C. Zweier23, D. Lessel24, B. Lozic24, associatedfactor(TRAF) family,involvedinabroad range R. Peretz25, J. Meira26, B. Schaefer27, E. M. Beaver28, ofbiologicalfunctions andrecentlyidentifiedbyWESin7 L. C. Briere29, D. L. Earl30, V. M. Siu31, K. Kosaki32, patients associating developmental delay, congenital mal- M. Gambello33, D. Karlowicz34, T. Y. Tan35, S. White35, formations and dysmorphic features with de novo missense A. Slavotinek36, D. Barbouth37, V. Pingault1,2,3, mutations. A.Munnich2,3,S.Balcells5,V.Cormier-Daire2,3,M.Cho7, Wegatheredaseriesof38patients(afamilywith3cases D. Grinberg5, S. Lyonnet1,2,3, M. Gunel4, R. Urreizti5, and 35 sporadic cases) by WES, direct sequencing and C. T. Gordon1,2 GeneMatcherwithheterozygousmissensemutationswithin the WD40 repeats, 8 being recurrent. Facial features are 1INSERM UMR 1163, Inst. Imagine, Paris, France, 2Paris distinctiveandwillbedescribed.Manyareshort(12)witha Descartes-Sorbonne Paris Cité Univ., Paris, France, shortneck(20),pectuscarinatum(14)andanomaliesofthe 3HôpitalNecker,AP-HP,Paris,France,4Dept.ofGenetics, extremitieswithcamptodactyly(8),ulnaorradialdeviation Yale Sch. of Medicine, New Haven, CT, United States, of fingers (10) and overriding toes (9). Ribs and vertebrae 5Dept. de Genètica, Facultad de Biologia, Univ. de anomaliesareeachdescribedin5and16cases.Conductive Barcelona, Barcelona, Spain, 6Dept. Of Research and and/or sensorineural hearing loss is frequent (20). Con- Development, Neuroclinic, Oslo Univ. Hospital, Oslo, genital cardiac defects are also frequent with persistent Norway, 7GeneDx, Gaithersburg, MD, United States, ductus arteriosus(21) andatrial septaldefects(9) being the 8RadboudUMC,Nijmegen,Netherlands,9HaukelandUniv. most frequent. Worth noting are kidney abnormalities (10), Hospital, Bergen, Norway, 10Birmingham Women’s and genitaliaanomalies(4),umbilicaland/oringuinalhernia(8), Children’s NHS Foundation Trust, Birmingham, United dental anomalies (9), sparse hair (5) and lymphedema of Kingdom, 11Manchester Centre for Genomic Medicine, lowerlimbs(3).Mostpatientspresentedfeedingdifficulties Manchester, United Kingdom, 12Manchester Univ. NHS andmotor delay withindependent walking between 18and FoundationTrust,Manchester,UnitedKingdom,13Dept.of 24 months of age. They developed mild to moderate Human Genetics, Pediatrics and Internal Medicine, Univ.1528 intellectual deficiency with speech delay, frequent nasal speech and usually preserved social interactions. TRAPP C11
 is a component of the TRAPP complex A different repertoire of somatic missense mutations involved in intracellular vesicle trafficking. TRAPP C11
 withintheWD40domainsofTRAF7hasbeenidentifiedin mutations were reported in only 20 patients with various meningioma. The clustering of germline and somatic mis- phenotypes from limb-girdle muscular dystrophy (LGMD) sense mutations suggests a gain of function or a dominant phenotype to congenital disorder of glycosylation (CDG), negative effect. characterized by frequent proximal muscle weakness with J.Amiel:None.K.Mishra:None.L.Castilla:None.K. elevated creatine kinase (CK), associated with global K. Selmer: None. T. Barak: None. S. Yang: None. B. developmental delay, and movement disorders. Using trio Blanco-Sánchez: None. M. Reijnders: None. G. Houge: whole exome sequencing (WES), we identified two new None. H. Cox: None. H. Kingston: None. J. Clayton- patients with intellectual disability (ID) carrying biallelic Smith: None. J.W. Innis: None. W. Chung: None. V. variantsinTRAPP C11
.Patient1:Pregnancywasmarkedby Sanders: None. A. Vitobello: None. C. Thauvin: None. agenesisofcorpuscallosum(ACC)andintrauterinegrowth G. Lesca: None. M. Kerstjens-Frederikse: None. K. retardation (IUGR). At 4 years old, he presented neurode- Christensen: None. R. Gannaway: None. A. Lehman: velopemental delay, progressive microcephaly (-4SD) and None. L. Graul-Neumann: None. C. Zweier: None. D. small stature (-2.5SD). Immune screening showed hypo- Lessel:None.B.Lozic:None.R.Peretz:None.J.Meira: gammaglobulinemia, causing multiple infections. CK level None. B. Schaefer: None. E.M. Beaver: None. L.C. was normal. Postnatal brain MRI showed global cerebral Briere: None. D.L. Earl: None. V.M. Siu: None. K. atrophy and thin corpus callosum. He carried compound Kosaki:None.M.Gambello:None.D.Karlowicz:None. heterozygoussplicingvariantsc.965+5G>T/c.1287+5G>A T.Y.Tan:None.S.White:None.A.Slavotinek:None.D. in TRAPP C11
 inherited from both parents. Patient 2: Barbouth: None. V. Pingault: None. A. Munnich: None. Pregnancy was marked by IUGR. He had epilepsy with S. Balcells: None. V. Cormier-Daire: None. M. Cho: onset at 5 months of age. At 30 months old, he presented None. D. Grinberg: None. S. Lyonnet: None. M. Gunel: with hypotonia, neurodevelopemental delay, and progres- None. R. Urreizti: None. C.T. Gordon: None. sive microcephaly (-5SD). He had mildly elevated CK without myopathy. Brain MRI showed thin corpus  P11
.76D callosum. He carried homozygous variants c.1287+5>A Biallelic variants in TRAPP C11
 cause syndromic in TRAPP C11
, both inherited from his father, due to intellectual disability uniparental isodisomy (UPD) of chromosome 4. We confirm the extended phenotype related to TRAPP C11
 A. Lunati1, S. Heide1,2, S. Vuillaumier3, G. Leverger4, variants, including syndromic ID. Hypogammaglobuline- I. Desguerre5, M. Moutard6, M. Spentchian1, mia was not reported as related to this gene so far. N. Hadouiri7, V. Darmency8, Q. Thomas7, Moreover, this report demonstrates the importance to F. Lecoquierre7, A. Vitobello7, C. Philippe7, L. Faivre9, explore UPD in case of homozygous variants inherited C. Thauvin-Robinet7,9, D. Heron1,2 from a single parent. A. Lunati: None. S. Heide: None. S. Vuillaumier: 1APHP, Département de Génétique, Groupe Hospitalier None. G. Leverger: None. I. Desguerre: None. M. Pitié Salpêtrière et GHUEP Hôpital Armand-Trousseau, Moutard: None. M. Spentchian: None. N. Hadouiri: Paris, France, 2Centre de Référence Déficiences None. V. Darmency: None. Q. Thomas: None. F. Leco- Intellectuelles de Causes Rares, Paris, France, 3APHP, quierre:None.A.Vitobello:None.C.Philippe:None.L. Service de Biochimie et génétique, Hôpital Bichat-Claude Faivre: None. C. Thauvin-Robinet: None. D. Bernard, Paris, France, 4APHP, Service hématologie- Heron: None. oncologie-pédiatrique, Hôpital Armand-Trousseau, Paris, France, 5APHP,Département de Neurologie, Hôpital  P11
.77A NeckerEnfantsMalades,Paris,France,6APHP,Servicede First mutation in TSHZ1 in a family with Rasmussen Neuropédiatrie,HôpitalArmand-Trousseau,Paris,France, syndrome 7Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon B. Hanker, J. Eckhold, I. Hüning, Y. Hellenbroich, Bourgogne,Dijon,France,8Servicedeneurophysiologieet F. Kaiser pédiatrie, CHU de Dijon, Dijon, France, 9Centre de Référencemaladiesrares«AnomaliesduDéveloppementet Institut für Humangenetik, Lübeck, Germany syndromes malformatifs », Centre de Génétique, FHU- TRANSLAD, CHU Dijon Bourgogne, Dijon, FranceAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1529 In 1979, Rasmussen reported of a family with congenital disease and recurrent sinus and ear infections, a constella- bilateral vertical talus, bilateral external auditory canal tion of symptoms strongly reminiscent of ciliopathies. atresia and increased interocular distance. After Rasmussen Consistent with this phenotype, we show that the mutation syndromewasmentionedin2002forthefirsttime,Feenstra which affects Pro358 have a dramatic effect on ciliation. et al. reported of families with deletion or mutations in MaterialandMethods:Ciliafromnasalbrushingofthe TSHZ1 causing congenital aural atresia (CAA), in 2011. index cases were analyzed by TEM. The dynamics of MT Here, we describe for the first time a family with vertical growth and ciliation were analyzed in cultured cells over- talus (VT) and mutation only affecting TSHZ1. expressing FLAG-tagged wild-type or mutant TUBB4B. We report on a family with an eleven year old boy, who Results: Cilia from nasal brushing of the index case was born at term after uneventful pregnancy. The boy had revealed ultrastructural abnormalities with rare axonemes CAA andVT.He hadmild intellectual disabilityandfacial and disorganized basal bodies. Inspection of the β-tubulin features including epicanthus, hypertelorism and broad atomic structure revealed that the Pro358 residue is located nasal root. The mother of non-consanguineous parents had in a binding domain necessary for the dynamics of micro- learning difficulties as well as CAA and VT. The grand- tubules.Functionalanalysisinculturedcellsoverexpressing father had CAA like several members of the family of the FLAG-tagged wild-type or mutant TUBB4B showed that mother, too. In addition, the daughter of one cousin had the mutant TUBB4B have a drastic impact on microtubule CAA and VT. growthwithnolatticeaswellasonciliogenesiswithabsent In suspicion of Rasmussen syndrome a targeted sequen- cilia in the vast majority of cells. cinganalysisofTSHZ1identifiedaheterozygousframeshift Conclusion: This study shows that TUBB4B mutations mutation c.718delA;p.Arg240Glyfs*10 in the index patient can cause a sensorineural disease or a multisystemic cilio- and his mother resulting in a premature stop of translation. pathy, depending on the localization of the alteration. Systematic review of the literature showed that affected S. Mechaussier: None. J. Rozet: None. M. Descartes: persons of two families with mutations in TSHZ1 show None. I. Perrault: None. CAA but VT has not been described in these patients. Therefore,weshowforthefirsttimethecombinationofVT  P11
.79C and CAA due to mutation in TSHZ1. Further delineation of O2HE syndrome due to Therefore, our findings support the hypothesis that het- UN C45
Abiallelicvariantsandlaunchingoftheinitiative erozygousmutationsinTSHZ1causeRasmussensyndrome adopt a gene for UN C45
A with incomplete penetrance and variable clinical expressivity. C. Racine1,2, J. Baptista3,4, L. Hawkes5, C. Thauvin- B. Hanker: None. J. Eckhold: None. I. Hüning: None. Robinet1,2, A. Vitobello2, P. Callier2, Y. Duffourd2, Y. Hellenbroich: None. F. Kaiser: None. C. Philippe2, B. De Vries6, A. Verloes7, J. Hugot8, D. Bremond-Gignac9, F. Huet10, C. Bensignor10,  P11
.78B R. Maudinas10, A. Fabre11, C. Esteve11, S. Ellard3,4, Mutations in TUBB4B can cause a cliopathy A. Rodrigues12, E. Blair5, L. Faivre1,2 S. Mechaussier1, J. Rozet1, M. Descartes2, I. Perrault1 1Genetics Center, FHU TRANSLAD, Dijon Bourgogne University Hospital, Dijon, France, 2INSERM, LNC 1INSERM UMR_1163 - Imagine Institute, Paris, France, UMR1231 team GAD, University of Burgundy and 2University of Alabama at Birmingham, Birmingham, AL, Franche-Comté, Dijon, France, 3Department of Molecular United States Genetics, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom, 4University of Exeter College of Introduction: Recently, we reported heterozygous muta- Medicine and Health, Exeter, United Kingdom, 5Oxford tionsaffectingArg391intheβ-tubulin4Bisotype-encoding Centre forGenomicMedicine, OxfordUniversity Hospitals gene (TUBB4B) dampening the dynamics of growing NHS Foundation Trust, Oxford, United Kingdom, microtubules (MT) in a distinctive neurosensorineural 6DepartmentofHumanGenetics,RadboudMedicalCenter, disorder (early-onset and severe retinal dystrophy and Nijmegen, Netherlands, 7Genetics department, Robert sensorineural hearing loss). Despite abnormal MT Debré Hospital, APHP, Paris, France, 8Pediatric dynamics, patient fibroblasts and cells overexpressing the Gastroenterology and Nutrition department, Robert Debré mutant proteins displayed apparently normal ciliation and Hospital, APHP, Paris, France, 9Pediatric Ophthalmology trafficking. Here, we report the identification of a novel department, Robert Debré Hospital, APHP, Paris, France, TUBB4B mutation in a sporadic case displaying blindness, 10Pediatric department, Dijon Bourgogne University sensorineural hearing loss, short stature, chronic kidney Hospital, Dijon, France, 11Aix Marseille Univ, INSERM,1530 MMG, Marseille, France, 12Oxford Children's Hospital, S.Maitz4,V.Leuzzi5,G.Parenti1,3,M.Scala6,M.Donati7, Oxford University Hospitals NHS Foundation Trust, R. Guerrini7, C. Pantaleoni8, S. D'Arrigo8, M. Zollino9, Oxford, United Kingdom V.Capra6,A.Selicorni10,N.Brunetti-Pierri1,3,S.Banfi1,2, TUDP, V. Nigro1,2, G. Casari1,11 Introduction:Only4patientswithUN C45
A-related osteo- oto-hepato-entericsyndrome(O2HE)havebeenreportedin 1Telethon Institute of Genetics and Medicine, Pozzuoli, 2018, and no further replication has been published. The Naples, Italy, Pozzuoli, Italy, 2Department of Precision four core clinical features include congenital diarrhea, Medicine, University of Campania – “Luigi Vanvitelli”, cholestasis, bone fragility, deafness, associated to learning Naples, Italy, 3Department of Translational Medicine, disability. Section of Pediatrics, Federico II University, Naples, Italy, Material and Methods: We report two novel cases of 4San Gerardo Hospital, Monza, Italy, 5Department of O2HE diagnosed by trio WES, enlarging the clinical Human Neuroscience, SapienzaUniversityofRome, Rome, spectrum by the presence of malformations. Italy, 6Neurosurgery service, Giannina Gaslini Institute, Results: In patient 1 (20 years), severe congenital diar- Genoa, Italy, 7Meyer Children Hospital, Florence, Italy, rhea due to microvilli atrophy was diagnosed at week 1, 8Neurological Institute Besta, Milan, Italy, 9Cattolica requiring long-term hospitalization with exclusive enteral University, Rome, Italy, 10Department of Pediatrics. ASST- nutrition. Diarrhea became intermittent until age 10 and Lariana. Sant'Anna Hospital, Como, Italy, 11Vita-Salute then stopped. Chronic pruritus caused by congenital cho- San Raffaele University and Neurogenomics Unit, Division lestasis was diagnosed in childhood. He was blind due to of Genetics and Cell Biology, San Raffaele Scientific right anophthalmia, Peters anomaly with left pyramidal Institute, Milan, Italy cataract, had severe sensorineural deafness, severe intel- lectual disability with behavioral disorder, had 2 fractures We present the experience of the first 30 months of the after minimal injury. Trio WES revealed a paternally Telethon Undiagnosed Diseases Program (TUDP), a pilot inherited UN C45
A c.1407delinsGCA variant and a mater- program devoted to unsolvable pediatric patients with nally inherited c.2467G>C variant; and a de novo PBRM1 complex syndromes. Pediatric patients with genetic com- VUS (c.1301G>A). In patient 2 (3 weeks), cleft palate and plex disorders who went undiagnosed through array-CGH, severe diarrhea was diagnosed at day 1, with flattening of biochemical and specific genetic tests, are discussed and brush border, requiring total parenteral nutrition. No cho- prioritized in clinical plenary meetings. Patients may be lestasis was diagnosed, and testing of the audition is plan- recruitedalsobywebformathttp://www.telethon.it/cosa-fa ned. Rapid trio exome revealed a maternally inherited cciamo/malattie-senza-diagnosi. Human Phenotype Ontol- c.721C>T;p.(Arg241*) UN C45
A variant and paternally ogyisusedforphenotypedescription.Selectedpatientsand inherited c.2182G>A variant. parents (mostly as trios or quartet) are studied by high Conclusion: Further cases will be needed in order to coverage(150x)WES.FromJune2016toDecember2018, better describe the phenotypic spectrum of UN C45
A, and twelve national pediatric centers have presented 503 particularly the level of the neurocognitive phenotype, and undiagnosed families. Fifty-two have been considered the associated congenital malformation spectrum. There- low-priority since outside inclusion criteria (i.e. severity, fore, we decided to adopt this gene, to compile the clinical pediatric age, complexity). Of the 451 enrolled families, consequences of novel variants. 196 have completed the entire diagnostic NGS workflow C.Racine: None. J.Baptista:None.L. Hawkes: None. andfinalresulthasbeenprovided.In71families(36%)we C. Thauvin-Robinet: None. A. Vitobello: None. P. Cal- detected causative variants in known genes, mostly lier: None. Y. Duffourd: None. C. Philippe: None. B. De extending the phenotype appearance. Forty-six (65%) are Vries: None. A. Verloes: None. J. Hugot: None. D. Bre- de novo mutations, while 16 are autosomal recessive, 8 X- mond-Gignac:None.F.Huet:None.C.Bensignor:None. linked and one autosomal dominant with variable expres- R.Maudinas:None.A.Fabre:None.C.Esteve:None.S. sion. In 67 trios (34%), we identified a strong candidate Ellard: None. A. Rodrigues: None. E. Blair: None. L. gene, while the pathogenic role of specific genetic variants Faivre: None. is under investigation. In 58 trios (30%) no putative causative or candidate variant was identified. A fraction of  P11
.80D families shares different mutations in the same genes, such The first 30 months of experience of the Telethon as DDXD3 and ASX L3
 (in three families) and EEF1A2, Undiagnosed Diseases Programs GRIN1, IRF2BPL, RAR S2
 and SMAD4 (in two families). SelectedWES-negativecases arebeingstudiedbyWGSor A. Torella1,2, M. Pinelli1,3, R. Castello1, F. Musacchia1, bylinkedreadWESusing10xtechnology.TelethonGrant: M. Mutarelli1, G. Cappuccio1,3, D. Carrella1, G. Vitiello3, GS P15001
Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1531 A. Torella: None. M. Pinelli: None. R. Castello: None. geneticdata,weproposeVP S26
Casanoveldiseasegenein F.Musacchia:None.M.Mutarelli:None.G.Cappuccio: humans.ConsistentwithwidespreadexpressionofVP S26
C None. D. Carrella: None. G. Vitiello: None. S. Maitz: andwiththefundamentalbiologicalfunctionoftheencoded None. V. Leuzzi: None. G. Parenti: None. M. Scala: protein, its bi-allelic inactivation causes a wide range of None. M. Donati: None. R. Guerrini: None. C. Panta- symptoms involving multiple organs. leoni: None. S. D'Arrigo: None. M. Zollino: None. V. C.Beetz: A.Employment (fullorpart-time); Significant; Capra: None. A. Selicorni: None. N. Brunetti-Pierri: Centogene AG. A. Kdissa: A. Employment (full or part- None. S. Banfi: None. V. Nigro: None. G. Casari: None. time); Significant; Centogene AG. V. Karageorgou: A. Employment(fullorpart-time);Significant;CentogeneAG.  P11
.81A N. Ameziane: A. Employment (full or part-time); Sig- A homozygous VP S26
C nonsense variant is associated nificant;CentogeneAG.P.Bauer:A.Employment(fullor with a novel syndromic phenotype part-time);Significant;CentogeneAG.J.Suleiman:None. V.R. Sutton: None. A.W. El-Hattab: None. C. Beetz1, A. Kdissa1, V. Karageorgou1, N. Ameziane1, P. Bauer1, J. Suleiman2,3, V. R. Sutton4, A. W. El-  P11
.82B Hattab5,6,7 Diagnostic microdeletion/microduplication detection by exome sequencing enabling copy number variation 1Centogene AG, Rostock, Germany, 2Tawam Hospital, Al analysis Ain, United Arab Emirates, 3United Arab Emirates University, Al Ain, United Arab Emirates, 4Baylor College G. Christopoulou1, A. Oikonomaki1, S. Samara1, of Medicine, Houston, TX, United States, 5KidsHeart L.Florentin2,F.Sachinidi2,S.Vitas3,P.Constantoulakis1 Medical Center, Abu Dhabi, United Arab Emirates, 6KidsHeart Medical Center, Dubai, United Arab Emirates, 1Genotypos Science Labs, Athens, Greece, 2AlfaLab, 7KidsHeart Medical Center, Al Ain, United Arab Emirates Athens, Greece, 3DNA Analysis, Athens, Greece Introduction: Novel fully penetrant monogenic disorders Introduction: We present two cases where copy number are presumably very rare. Initial non-availability of variation (CNV) analysis by exome sequencing revealed a unrelated patients is therefore likely. To still enable the microdeletionandamicroduplication,respectively,explain- molecular classification of such cases, several types of ing the under-investigation phenotypes. information need to be considered. MaterialsandMethods:A31y.o.pregnantwomanwith Materials and Methods: Two reportedly related indivi- mild symptoms of Waardenburg Syndrome (WS) and a 35 duals with a distinct syndromic phenotype were investi- y.o.womanwithabsenceoftheuterusweretested.Clinical gated. Following negative chromosomal microarray and exome sequencing was performed using Sophia Genetics’ exome sequencing in the proband, patients were subjected Clinical Exome Solution v2, which includes 4,493 genes. to whole genome sequencing. The variants from the duo Following preparations according to the manufacturer’s were analysed in a comparative manner, and used to esti- protocol, DNA libraries were sequenced on an Illumina mate the degree of relatedness. NextSeq-500 genetic analyzer. Data processing, variant Results: The major clinical findings in both patients calling and CNV analysis were conducted by SOPHiA overlapped; they included neurodevelopmental deficit, DDM® bioinformatics pipelines. skeletalabnormalitiesanddistinctivefacialfeatures.Variant Results: The analyses revealed a PAX3 gene deletion, filtering demonstrated a single unique shared homozygous confirming WS in the first patient and a duplication, high impact variant, c.178G>T (p.Glu60*), in VP S26
C. includingatleastSCARF2,SERPIND1,SNA P29
andCRKL Variation databases do not list individuals with bi-allelic genes, consistent with Mayer-Rokitanski-Kuster-Hauser truncating variants in this gene, which codes for a protein syndrome, in the second patient. Both CNVs were ascer- involved in membrane protein recycling. Detailed geneal- tained and their exact size determined (≈725kb and ogy analysis suggested close relationship for the patients’ ≈1.05Mb respectively) by arrCGH. fathers, but very distant relationship for the mothers. An Discussion: Until recently, exome sequencing rose the overall low degree of relatedness of the two patients, as diagnostic yield of genomic investigations by revealing confirmedbycomparativeanalysisofthegenomes,implies SNV/INDEL disease-causing variants. The design and a low likelihood for the genotype-phenotype association to analysis pipelines of the exome sequencing we implement be a chance observation. empowers CNV detection as well. We believe that in the Conclusion: Based on the genealogical information, near future, technology and bioinformatics advancements clinical findings, and comprehensive consideration of the may permit CNV analysis as effectively as with well-1532 established approaches thus, facilitating more efficient mutation in NBAS in a critically sick newborn with a genetic diagnosis and healthcare management. complex immunologic phenotype G. Christopoulou: None. A. Oikonomaki: None. S. Samara:None.L.Florentin:None.F.Sachinidi:None.S. G. M. A. Forzano1, G. Mancano2, A. La Barbera1, Vitas: None. P. Constantoulakis: None. A. Pagliazzi1, F. Peluso1, F. Di Giovanni1, G. Contrò1, R. Artuso2, A. Provenzano1, S. Ricci3, M. Moroni4,  P11
.83C P. Fiorini4, D. Serranti5, S. Giglio6 Exploring WAGR syndrome: genotype-phenotype associations in the 11p13 region 1Medical Genetics Unit, University of Florence, Florence, Italy, 2Medical Genetics Unit, Meyer Children's University G. Buglyó, S. Biró, K. Szakszon, J. Mátyus, G. Méhes, Hospital, Florence, Italy, 3Immunology Unit, Meyer G. Vargha, É. Oláh, B. Nagy Children's University Hospital, Florence, Italy, 4Neonatal Intensive Care Unit, Meyer Children's University Hospital, University of Debrecen, Debrecen, Hungary Florence, Italy, 5Hepatology Unit, Meyer Children's University Hospital, Florence, Italy, 6Medical Genetics Introduction: WAGR syndrome (Wilms’ tumor, aniridia, Unit, University of Florence, Meyer Children's University genitourinary malformations and impaired mental develop- Hospital, Florence, Italy ment) is associated with deletions of chromosomal region 11p13. Recently, some evidence accumulated on micro- Wereportanewbornwithamultisystemicdiseaseseverely deletionswithin11p13withvaryingclinicalmanifestations. affectingimmuneandgastrointestinalsystemsandskin.He We report two such cases, and tentatively outline possible was admitted to Neonatal Intensive Care Unit because of genotype-phenotype associations in the region. growth failure, recurrent infections with sepsis and Patients and Methods: Our first case featured normal dehydration, hypogammaglobulinemia, absence of B lym- intellectual ability, pseudohermaphroditism, acute lympho- phocytes, reduced NK cells, ichthyosis, hepatosplenome- blastic leukemia, Wilms tumor, glomerulonephritis and galyandfacialdysmorphism(proptosis,thinlips,looseskin cerebellar angioblastoma. The second patient had complex and reduced subcutaneous fat). At a first glance, clinical genitourinary malformations, global developmental delay presentation made us think about a syndromic immuno- and mental deficit. RT-PCR was used to detect gene copy dysregulation; we performed whole exome sequencing numbers in the 11p13 region in both cases. FISH and a (WES) which identified a biallelic variant in NBAS. dPCR-based analysis were performed in case 2. Neuroblastoma amplified sequence (NBAS) gene encodes Results: In patient 1, a heterozygous deletion was found a protein highly expressed in connective tissue, eye, brain affecting the whole WT1 gene but neither one of the and spinal cord, and it is involved in nonsense-mediated flankinggenes.Inpatient2,amicrodeletionwasseeninthe mRNA decay. Mutations in NBAS cause disregulation of 11p13 region affecting only WT1 and EIF3M. In this case, genes involved in instruction of inflammatory response. we also detected a deletion at 22q13. Biallelic mutations in this gene have been associated with Conclusions: While WAGR syndrome is generally con- phenotypic spectrum that ranges from isolated acute liver sideredasasingleclinicalentitycausedbyarelativelylarge failure in infancy to a multisystemic condition including deletion,theseeminglyhighfrequencyofmicrodeletionsin short stature, optic nerve atrophy and Pelger-Huet (PH) the area (as seen in our cases and various anecdotal reports anomaly of granulocytes (SOPH). Moreover, biallelic intheliterature)suggeststhatitmayrepresentaspectrumof variants were reported recently in two unrelated patients clinical features, the observed phenotype depending on with characteristic facial appearance, PH anomaly and which genes happen to be deleted. WT1 seems to be severe hypogammaglobulinemia with frequent infections. responsible for genitourinary tumors and malformations, Clinical exome sequencing uncovers monogenic disorders whileincasesfeaturingaPAX6orBDNFdeletion,wemay in a significant number of infants in NICU when suspected observeaniridiaorobesity,respectively.GenesPRRG4and to have genetic disorders, significantly influencing the SL C1
A2arelikelycandidatesforcausingintellectualdeficit medicalcare.Performingexomesequencingasfirst-linetest when deleted. canachieved overthree times diagnosis rate, with less than G.Buglyó:None.S.Biró:None.K.Szakszon:None.J. one-third of the cost, compared with traditional tiered Mátyus: None. G. Méhes: None. G. Vargha: None. É. testing strategy of single gene or gene panels. Oláh: None. B. Nagy: None. G.M.A. Forzano: None. G. Mancano: None. A. La Barbera: None. A. Pagliazzi: None. F. Peluso: None. F.  P11
.84D Di Giovanni: None. G. Contrò: None. R. Artuso: None. Whole exome sequencing reveals a homozygousAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1533 A.Provenzano: None.S.Ricci:None.M.Moroni:None.  P11
.86B P. Fiorini: None. D. Serranti: None. S. Giglio: None. Whole exome sequencing reveals novel mutations in a cohort of undiagnosed patients with multiple  P11
.85A malformation syndromes Family trio analysis in rare syndromes - Clinical experience and outcome E. Kritioti1,2,3, N. Nicolaou2, A. Alexandrou1, I. Papaevripidou1, A. Theodosiou1, V. Christophidou- K. Lagerstedt-Robinson, B. Anderlid, A. Nordgren, Anastasiadou2,4, G. A. Tanteles2, C. Sismani1,3 G. Grigelioniene, M. Kvarnung, P. Gustavsson, E. Tham, D. Nilsson, M. Johansson Soller, M. Nordenskjöld, 1Cytogenetics and Genomics Department, The Cyprus A. Lindstrand, H. Malmgren Institute of Neurology and Genetics, Nicosia, Cyprus, 2Clinical Genetics Clinic, The Cyprus Institute of Department of Molecular Medicine and Surgery, Neurology and Genetics, Nicosia, Cyprus, 3The Cyprus Karolinska Institutet and Department of Clinical Genetics, School of Molecular Medicine, The Cyprus Institute of Karolinska Univ Hospital, Stockholm, Sweden Neurology and Genetics, Nicosia, Cyprus, 4Clinical Genetics Clinic, Archbishop Makarios III Medical Centre, Whole exome (WES) or whole genome (WGS) sequencing Nicosia, Cyprus intriosisbecomingacommonmoleculardiagnostictoolfor analysis of rare genetic disorders. Multiple malformation syndromes (MMS) represent a At Clinical Genetics, Karolinska University Hospital, heterogeneous group of genetic disorders associated with clinical trio analysis has increased tenfold from 2012 - developmental anomalies in two or more systems. Using 2018. In total, trio analysis has been finalized for 503 wholeexomesequencing(WES)ourongoingstudyaimsto patients with undiagnosed, suspected rare genetic condi- molecularly characterise a cohort of undiagnosed Cypriot tions.Datawasanalyzedforsequencevariantsinthecoding MMS patients. Recruitment criteria included: normal part or splice regions of the OMIM genes that were con- karyotype and array-CGH analyses and negative results sistent with Mendelian inheritance. In general CGH-array forfragile-Xsyndromeandtargetedgenetesting.Thestudy and FRAXA analyses had been performed on the patients also aims to develop an in-house population-specific allele prior to trio analysis. frequency database. Of the 503 cases, the molecular diagnosis rate was 33%. Family-based WES was performed in 21 families (67 De novo heterozygote sequence variants were the most individuals) comprising 26 MMS patients, using Illumina’s prevalent causes of genetic disorder, 55%. Sequence var- TruSeq DNA exome library preparation kit and the Next- iants consistent with autosomal recessive inheritance were Seq500. Bioinformatics analysis was carried out using an detected in 32% and X-linked recessive inheritance in 8% in-house pipeline according to the Genome Analysis of the cases. In eight cases, an autosomal dominant inher- Toolkit Best Practices. Possible pathogenic mutations were itedsequencevariantwasidentified-explainedbyaknown confirmed by Sanger sequencing followed by segregation dominant trait or variable expressivity. Most patients were analysis. referredregardingintellectualdisabilityand/orasyndromic NGSanalysisrevealed11potentiallypathogenicvariants, phenotype. The different detected genetic diagnoses are including 9 novel and 2 known variants, achieving an rare,andformostcasesthegeneticoutcomecouldnothave overall detection rate of 42% (11/26 patients). Flagged been predicted. variants were found in PCNT, SPR, PXDN, CO L27
A1, In conclusion, trio analysis in families with an unknown UB E3
A, KAT6A, KDM6A, POMGNT1 and PIEZO2, caus- rare disorder has proven to be a valuable tool to obtain a ingmicrocephalicosteodysplasticprimordialdwarfismtype genetic diagnosis. The identification of the genetic aberra- II, sepiapterin reductase deficiency, anterior segment dys- tion in these patients is crucial for estimation of recurrence genesis of the eye, Steel syndrome, Angelman syndrome, risk. Itisalso apre-requisitefor carriertesting, prenatal- or intellectual disability, Kabuki syndrome-2, muscle-eye- preimplantation diagnostics. brain disease and distal arthrogryposis, respectively. K. Lagerstedt-Robinson: None. B. Anderlid: None. A. Inconclusion, thisstudy hasidentified9novel mutations Nordgren:None.G.Grigelioniene:None.M.Kvarnung: inknowngenesandhasexpandedthephenotypicspectrum None. P. Gustavsson: None. E. Tham: None. D. Nilsson: associatedwiththesegenes.Thisstudyalsoreportsthefirst None. M. Johansson Soller: None. M. Nordenskjöld: CO L27
A1 mutation in the Caucasian population. The None. A. Lindstrand: None. H. Malmgren: None. detection rate of 42% indicates that WES is a reliable and cost-effective tool for identifying the molecular basis of MMS. Further functional studies are ongoing.1534 E. Kritioti: None. N. Nicolaou: None. A. Alexandrou: D. Ayyildiz Emecen: None. E. Isık: None. M. Kose: None. I. Papaevripidou: None. A. Theodosiou: None. V. None. T. Atik: None. F. Ozkinay: None. Christophidou-Anastasiadou: None. G.A. Tanteles: None. C. Sismani: None.  P11
.88D BAZ1B is a candidate gene responsible for  P11
.87C hypothyroidism in Williams syndrome The utility of reverse phenotyping using whole-exome sequencing in an undiagnosed infant with neurological L. Allegri1, F. Baldan1, C. Mio1, M. De Felice2, symptoms E. Amendola2, A. Franzoni3, D. Fabbro3, G. Damante1 D. Ayyildiz Emecen, E. Isık, M. KOSE, T. Atik, 1University of Udine, Udine, Italy, 2University of Naples F. Ozkinay Federico II, Naples, Italy, 3Academic Hospital “Azienda Sanitaria Universitaria Integrata di Udine”, Udine, Italy Subdivision of Pediatric Genetics, Department of Pediatrics, Faculty of Medicine, Ege University, Izmir, Williams syndrome (WS) is a rare neurodevelopmental Turkey disorder affecting 1/7500 live births resulting from a hemizygous deletion of 28 genes on chromosome Aim: Whole-exome sequencing (WES) is being used 7q11.23. This condition is characterized by mild to increasingly to diagnose rare complex diseases. The moderateintellectualdisabilityorlearningproblems,unique purpose of this study is to determine the contribution of personality characteristics, distinctive facial features, and reverse phenotyping in diagnosing diseases with blended heart and cardiovascular problems. Moreover, WS subjects phenotypes. frequently suffer ofseveral endocrine abnormalities includ- Method: A 22-month-old girl was referred to our clinic ing hypothyroidism, idiopathic hypercalcemia, early pub- with developmental delay, hypotonia, convulsion and erty, impaired glucose tolerance. Full hypothyroidism vomiting.Shewasthefirstchildofconsanguineousparents. occurs in about 10% of WS subjects; however, subclinical On physical examination she had growth retardation, hypothyroidism occurs in about 30% of patients. Several hypotonia and dysmorphic facial features. Her laboratory data indicate that the hypothyroidism is due to thyroid tests were normal. A brain MRI revealed a white matter morphologydefects:thyroidhypoplasiahasbeenfoundina hypomyelination. largefractionofWSpatientssufferingoffullorsubclinical Result: A specific diagnosis could not be established via hypothyroidism. Several genes involved in thyroid dysgen- clinical features and laboratory tests, however WES esis have been identified; however, none of them is in the revealed homozygous mutations in three different genes. 7q11.23 region. Thus, the hypothyroidism molecular bases The variant c.3412_3418del (p.Val1138Metfs*25) in in WS are not known. By a microarray approach we CNTNA P1
 gene has been classified as likely pathogenic, analyzed the expression levels of 7q11.23 region genes in c.1090G>A (p.Val364Met) variant in DPYS gene classified embryomiceandselectedthoseexpressedalsointhyroidor as a variant of uncertain significance (VOUS), and involved in its development. Among them, BAZ1B, a c.2480G>A (p.Arg827Gln), in AT P7
B gene classified as a member of bromodomain protein family, appeared particu- VOUS in accordance with ACMG 2015 criteria. The par- larlyrelevant.Silencing,byRNAinterference,BAZ1Bina entswerefoundtobeheterozygousforthesamemutations. normalthyroidcellline(Nthy-ori-3.1)andintwoanaplastic Disscussion: Following WES results, clinical compat- thyroid cancer derived cell line (SW1736 and 8505C), we ibility was investigated. Developmental delay and hypo- observedasignificantcellviabilityreduction(about50%in myelination in the patient were suggestive of Congenital both cell lines), demonstrating the importance of BAZ1B Hypomiyelinating Neuropathy caused by CNTNA P1
 muta- for thyroid cell proliferation. These results demonstrate the tions. Persistent vomiting is a symptom of Dihy- relevance of BAZ1B loss in thyroid cells proliferation, dropriminidase deficiency caused by DPYS mutations. A suggesting a correlation between its deletion and thyroid decreasedlevelofceruloplasmininthepatientisconsidered hypoplasia in WS. as the first sign of Wilson's disease caused by AT P7
B L. Allegri: None. F. Baldan: None. C. Mio: None. M. mutations. DeFelice:None.E.Amendola:None.A.Franzoni:None. Conclusion: Reverse phenotyping using WES shortens D. Fabbro: None. G. Damante: None. the diagnostic process, identifies the additional diseases in patients with blended phenotypes and improves the quality  P11
.89A of genetic counseling. A new phenotype associated to an unreported ZFPM2 variant: call for additional casesAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1535 A. JUVEN1,2, C. Thauvin-Robinet2, A. Garde1, A. Bruel2, subtypes in the absence of recurrent chromosomal J. Thevenon3, A. Vitobello2, F. Tran-Mau Them1, aberrations S. Falcon-Eicher4, C. Philippe2, L. Faivre1, A. S. Denommé-Pichon1,2 T. Nasedkina1, L. Ghukasyan1, G. Krasnov1, L. Baidun2, S. Ibragimova3 1Centre de génétique de Dijon, Dijon, France, 2Equipe Génétique des Anomalies du Développement (GAD), 1Engelhardt Institute of Molecular Biology Russian UMR1231 Inserm/uB, Dijon, France, 3Unité de génétique Academy of Sciences, Moscow, Russian Federation, clinique, CHU de Grenoble, Grenoble, France, 4Centre 2Russian Children's Clinical Hospital, Moscow, Russian HospitalierUniversitairedeDijon,Hôpitald'enfant,Dijon, Federation, 3Scientific Research Institute of Hematology France and Blood Transfusion, Tashkent, Uzbekistan Introduction: ZFPM2 is a gene coding for a zinc finger Introduction: Recurrent cytogenetic aberrations leading to protein. It is a transcription factor involved in lung, the formation of fusion genes are found in more than 40% diaphragm and cardiac development regulating the GATA of pediatric acute myeloid leukemia (AML), while in familyproteins.Threedistinctphenotypicentitiesrelatedto approximately 20% of the patients their blast cells display ZFPM2havebeendescribed:disordersofsexdevelopment, cytogenetically normal karyotype (NK-AML). The aim of non-syndromic diaphragmatic hernia and congenital the work was to investigate mutational profile of AML cardiopathies. patientswithoutknownchromosomaltranslocationsregard- Material and Methods: We report on a patient present- ing to immunophenotype data and clinical features. ing with major facial features associated with a poly- PatientsandMethods:The34patientsfromUzbekistan malformative syndrome and a novel truncating ZFPM2 with AML without known recurrent chromosomal aberra- variant. tions were investigated (18 boys and 16 girls, mean age Results: This 31-year-old patient presented at birth with 10.6years).Thecodingregionsof26genesinvolvedinthe diaphragmatic anterior eventration, pulmonary stenosis and pathogenesis of AML were captured with SeqCap EZ right ventricular hypertrophy. He also had growth defi- Target Enrichment System (NimbleGen, Roche) and ciency, micropenis, cryptorchidism and a shawl scrotum. sequenced using Illumina’s MiniSeq platform. The muta- He had a coarse face, hypertelorism, anteverted nares, a tions were verified using Sanger sequencing. long philtrum, macrostomia, gingival hyperplasia and teeth Results:Mostpatients(20from34)hadoneormorenon- agenesis. He was in a school for special needs, but intel- synonymous mutations. One patient with M4 variant had lectual deficiency was ruled out. He developed a dilatation biallelic CEBPA mutation, two patients had previously oftheascendingaortainadulthood.Multipleinvestigations undescribed ETV6 mutations. Also, known somatic muta- were normal. Exome sequencing revealed a frameshift tions were revealed in the following genes: NPM1 (8.8%), insertion in ZFPM2 (c.621delA; p.Ala208Leufs*5), not JAK2(5.9%),IDH1(5.9%),NRAS(8.8%).Inaddition,rare inherited from the father (mother not available). germline variants with minor allele frequency less than 1% Conclusion:Thepatientpresentsapeculiarassociationof were found in CUX1, FLT3, TET2, PTPN11 and NU P98
 malformations that belong to the ZFPM2 spectrum, but genes, that may indicate their role in genetic susceptibility usually in a non-syndromic context. Such observations are to pediatric leukemia. needed in order to be able to describe a novel ZFPM2 Conclusion: The data may contribute to understanding associated phenotype. themechanismsofleukemogenesisinpediatricAMLinthe A.Juven:None.C.Thauvin-Robinet:None.A.Garde: absenceofknownfusiongenes.Theworkwassupportedby None. A. Bruel: None. J. Thevenon: None. A. Vitobello: the Russian Science Foundation (grant # 18−15-00398). None. F. Tran-Mau Them: None. S. Falcon-Eicher: T. Nasedkina: None. L. Ghukasyan: None. G. Kras- None. C. Philippe: None. L. Faivre: None. A.S. nov: None. L. Baidun: None. S. Ibragimova: None. Denommé-Pichon: None.  P12
.002C Integrative analysis of miRNA and mRNA paired  P12
 expression profiling of androgen-dependent and Cancer genetics -independent prostate cancer cells treated with anticancer imidazoacridinone C-1311  P12
.001B Mutationalprofilingofpediatricacutemyeloidleukemia M. Niemira1, A. Bielska1, M. Kwasniewski2, A. Kretowski1,3, A. Skwarska41536 1ClinicalResearchCentre,MedicalUniversityofBialystok, 1Institute of Biomedical Research of Salamanca (IBSAL), Bialystok, Poland, 2Centre of Bioinformatics and Data Salamanca, Spain, 2Molecular Medicine Unit, Department Analysis, Medical University of Bialystok, Bialystok, of Medicine, University of Salamanca, Salamanca, Spain, Poland, 3Department of Endocrinology, Diabetology and 3Institute of Molecular and Cellular Biology of Cancer Internal Medicine, Medical University of Bialystok, (IBMCC), University-CIC, Salamanca, Spain Bialystok, Poland, 4Department of Oncology, University of Oxford, Oxford, United Kingdom Introduction: Breast and prostate cancers depend on steroid hormones (oestrogens, androgens) to stimulate their Introduction: Prostate cancer remains one of the most growth. This makes hormonal pathways prime targets to common cancer in the male population. Imidazoacridinone treat these kinds of cancer. Counter-intuitively, it has been C-1311(Symadex™)isanewinhibitoroftopoisomeraseII shown that the androgen receptor (AR) is expressed in and receptor tyrosine kinase FLT3 that has been tested in approximately 80% of breast cancer patients and over 30% phase II studies against metastatic breast cancer. Here, we of triple-negative breast cancer patients. Thus, we aim to assessed the effect of C-1311 on the miRNA and mRNA study the effects of androgen receptor-inhibitor enzaluta- integrated profiles of prostate cancer cells with different mide on breast cell lines expression of androgen receptor (AR). Material and methods: HCC-1937, HCC-1569, MCF- Materials and Methods: Prostate cancer cells were 7, Hs578T, HB L100
, BT-549, MDA-MB231, AU-565, exposed to C-1311 for 24h. The miRNA and mRNA MDA-MB-415, BT-474 (breast cancer cell lines) and expression profiles (adj. p < 0.05 and log fold change > 1) VCAP (androgen receptor-positive prostate cancer cell weregeneratedfromtotalRNA usingnCounterNanostring lineusedasapositivecontrol),wereusedtoextractRNA platformandRNA-sequsingIlluminaHiSeq4000platform, and proteins. Expression of AR and variant 7 (AR-V7) respectively. MiRNA-mRNA expression pairing and path- was confirmed by RT-PCR, droplet digital PCR and ways analysis was performed using Ingenuity Pathway simple western analyses. MTT viability assays with Analysis software. enzalutamide (50, 75 μM) were performed. Results: Paired genomic analysis identified a total of 33 Results: The PCR and simple western results are shown miRNA-mRNA pairs in LNCaP (AR+) and 65 miRNA- in the table below. MTT assays show growth inhibition at mRNApairsinDU-145(AR-)cells.SelectedmiRNAsand enzalutamide concentrations of over 50uM in BT-474, mRNAs associated with tumor formation and progression, MDA-MB-231, Hs578T, MCF-7 and MDA-MB-415. cell cycle or apoptosis (includingmiR-542, miR-138, miR- 590, miR-125, miR-34, BIR C5
, CDKN1A, CD C25
A, CellLines ERPR HER2 T P53
 ARAR- Simple MTT KNT C1
) were validated by qPCR. Paired miRNA-mRNA V7 WesternAR response profiles revealed activation of diverse signaling pathways depending on AR status. In LNCaP (AR+) cells major HCC- − − − − − − − NA 1937 changeswerefoundforgenesinvolvedincellcyclecontrol, HCC- − − + −M + − − NA p53 signaling and DNA damage response, whereas path- 1569 ways enriched for DU-145 (AR-) cells were involved in MCF-7 + + − +/−WT+ − + + cancer-related inflammation and cellular metabolism. Hs-578T − − − +M + + + + Conclusions: Our study identified C-1311 induced HBL-100 − − − ++ + + − NA miRNAcandidateswhichmaybeeffectivetargetsforfuture BT-549 − − − ++M + + + NA prostate cancer therapy. Founded by the National Science MDA- − − − ++M + − + + Centre, Grant No 2013/09/D/NZ7/04185. MB-231 M.Niemira:None.A.Bielska:None.M.Kwasniewski: AU-565 − − + +WT − − + NA None. A. Kretowski: None. A. Skwarska: None. MDA- + − − + + + + + MB-415  P12
.003D BT-474 + + + + + + + + Study of androgen-receptor pathway in breast cancer cell lines: a new potential target Conclusions: Androgen inhibitors could be a potential M. Ovejero-Sánchez1,2,3, P. Vázquez-Cárdenas1,2,3, therapeutic target for androgen receptor-positive breast M. Martínez-Soto2, S. Vallejo-Fuente2,3, C. Gutiérrez- cancers. Cerrajero1,2,3, J. Perez-Losada1,3, R. González- This Project was funded by PI16/01920. Sarmiento1,2,3 M. Ovejero-Sánchez: None. P. Vázquez-Cárdenas: None.M.Martínez-Soto:None.S.Vallejo-Fuente:None.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1537 C. Gutiérrez-Cerrajero: None. J. Perez-Losada: None.  P12
.005B R. González-Sarmiento: None. An ALK inhibitor, AZD3463 improves the anticancer effects of rapamycin in breast cancer cells  P12
.004A Mosaic APC mutations in patients with mild polyposis N. P. Ozates Ay, F. Sogutlu, C. Gunduz, C. Biray Avci phenotypes Ege University, Izmir, Turkey D. Terlouw1, M. Suerink1, C. Tops1, A. Langers2, F. J. Hes3, S. ten Broeke4, L. Dams1, T. van Wezel5, Introduction: Breast cancer is the most common type of H. Morreau5, M. Nielsen1 neoplasia in women and rapamycin analogues are frequently used in current treatment protocols. The 1Department of Clinical Genetics, LUMC, Leiden, limitations of the use of rapamycin in therapy include Netherlands, 2Department of Gastroenterology, LUMC, the activation of the PI3K signaling pathway by other Leiden, Netherlands, 3Medical Genetics, UZ Brussel, signaling pathways and reactivation via feedback regula- Brussel, Belgium, 4Department of Clinical Genetics, tion. AZD3463 is an anticancer agent used as a potential UMCG, Groningen, Netherlands, 5Department of ALK/IGF1R inhibitor and it has been determined that Pathology, LUMC, Leiden, Netherlands ALKinhibitorsinducePI3K/AKT/mTOR-mediatedapop- tosis and autophagy. In this study we investigated the Introduction: Mosaic mutations in the APC gene have invitroeffectoftherapamycin-AZD3463combinationon been identified as a common cause (25%) for polyposis in breast cancer by providing lateral inhibition of PI3K patientswith>20adenomasandnogermlinemutation.The signaling pathway. frequency remains unknown in patients with milder MaterialMethods:Cytotoxic,apoptotic,autophagicand phenotypes. cytostatic effects ofrapamycin,AZD3463andcombination Materials and Methods: The APC gene was sequenced onMCF7celllinewereassessedbytheWST1,AnnexinV in DNA isolated from 4 adenomas in a cohort of polyposis and JC-1, Tb/GFP TR-FRET L C3
B Expression, Cycletest patients (n=120) using Next Generation Sequencing. assays in a dose‐and time‐dependent manner. Expression Patients were considered mosaic if an identical mutation level alterations of PI3K/Akt/mTOR pathway related genes wasidentifiedinalllesions.Detectionrateswerecompared in treated MCF7 cells were evaluated by quantitative Real- between subgroups according to the number of adenomas. time PCR (qRT-PCR), compared to control cells. Clinical characteristics were compared between those with Result: The effects of AZD, rapamycin and combination and those without a mosaic mutation. on cell viability, apoptosis, autophagy, cell cycle and gene Results: The mosaicism detection rate was 18% in the expression levels in MCF7 cell line are summarized in the wholecohort(22/120),0%inpatientswith<10adenomas table. (0/18), 9% in those with 10-20 adenomas (3/34) and 12% in patients over age 70 (2/17). Some patients were found AZD3463 Rapamycin Combination Comment to have an identical variant in only a subset of adenomas (n=21) and were called hybrid cases. Mean age of diag- IC 50Values 7 (76 25 nn dM 1 (70 2.0 nd3 )nM A RaZ pD a- -0.3nM A was sy on be srg eris vt eic de inffe thc et ) nosis was comparable in hybrid and non-mosaic cases 28.85nM combination. (72nd) (both62years)andlowerinpuremosaiccases(50years). AnnexinV (+)3.6 (+)1.2 (+)7.4 Itwasdetermined Number of adenomas was also comparable between Assay(Fold thatapoptosis hybrid and non-mosaic cases (n=22 versus n=18) and changerelativeto increasedin acontrol) combination higher in mosaic cases (n=38) accordingto separate Conclusions: Our results indicate that mosaic APC applications. mutations also play a role in patients with less than 20 JC-1Assay(% (+)0.04 (+)5.5 (+)48.2 Combination adenomas and/or older age at presentation. Further expan- changeof application mitochondrial increased sion of the cohort is needed to validate our results and to membrane mitochondrial elucidate the cause and clinical significance of hybrid potential) membrane potential. mosaic mutation patterns. Dutch Cancer Society CellCycleAssay G/G (+) G/G-(+) G/G-(+)2 Rapamycin, 0 1 0 1 0 1 project 11292 (Foldchangeof 2.4S- 2.8S-1.12 S-1.2G 2/M- AZD3463,and checkpoint 1.05G/ G/M- (-)1.8 combinationhave D. Terlouw: None. M. Suerink: None. C. Tops: None. arrest) M-(-)2 2.7 (-)2 4.7 beenfoundto A. Langers: None. F.J. Hes: None. S. ten Broeke: None. effectivelyinduce G0/G1arrest. L.Dams:None.T.vanWezel:None.H.Morreau:None. M. Nielsen: None.1538 Autophagy (+)3.84 (+)3.31 (+)4.17 Combination TPDSdiagnostic.GiventhevariablePPVupontumortypes, Assay(Fold applicationinterms changeof ofautophagic only results of the 28 families with at least BA P1
 IHC for autophagosome effectsismore two independent tumors are presented in the table below: accumulation) effectivethan individualdoses. GeneExpression WASL(-) WASL(-) WASL(-) Itwasdetermined Analysis(PI3K/ 5,7 4,5RHOA 12,5RHOA thatthe Numberoftumors Numberof Numberof BA P1
genetictest AKT/mTOR RHOA (-)0,9FOS (-)4,2FOS combination withBA P1
loss testedtumors families results pathway (+)5,4 (+)2,0 (-)4.2 applicationwas relatedgenes) FOS(+) moreeffectivethan 1 2to7 7 6wildtype 0,19 theothergroups. 1class3 variant(VUS) 2 2 9 8class5variants Conclusion: In this study, we suggest that the combina- (deleterious) tion of rapamycin-AZD3463 can increase the efficacy of 1wildtype treatment by overcoming factors limiting the use of rapa- Morethan2 3to21 12 9class5variants mycininthetreatmentbysimultaneousinhibitionofALK/ (deleterious) 3class3 IGF1R pathway. variants(VUS) N.P. Ozates Ay: None. F. Sogutlu: None. C. Gunduz: None. C. Biray Avci: None. Inconclusion,weproposethatthepresenceoftwolesions  P12
.006C with BA P1
 expression loss in a family (same or different BA P1
 loss of protein expression: an analysis for BA P1
 patients) be considered as a Pathogenic Moderate criterion germline Variants of Unknown Signification (VUS) to classify BA P1
 variants under ACMG criteria. interpretation O. Cabaret: None.C. Caillot: None.T. Fenouil: None. N.Soufir:None.B.Bressac-dePaillerets:None.A.dela O. Cabaret1, C. Caillot2, T. Fenouil3, N. Soufir4, Fouchardière: None. B. Bressac - de Paillerets1,5, A. de la Fouchardière2  P12
.007D 1DépartementdeBiologieetPathologieMédicales,Gustave Insights in genetic mechanisms of aggressiveness of Roussy, Villejuif, France, 2Département de Biopathologie, Basal Cell Carcinoma Centre Léon Bérard, Lyon, France, 3Laboratoire d'AnatomiePathologiqueEst,GroupementHospitalierEst- S. I. Nikolaev1, A. Yurchenko1, L. Flatz2, M. Ighil3, Hospices Civils de Lyon, Lyon, France, 4Inserm U976, N. Basset-Seguin3 Université Paris 7, Paris, France, 5Inserm U1186, Université Paris-Saclay, Villejuif, France 1Gustave Roussy, Villejuif, France, 2Kantonsspital St. Gallen, Department of Dermatology, St. Gallen, The BRCA1‐associated protein‐1 (BA P1
) tumor- Switzerland, 3Saint Louis Hospital, Paris, France predisposition syndrome (BA P1
-TPDS) is a hereditary cancer syndrome with increased risk to develop a variety Vismodegibisasmoinhibitorapprovedforthetreatmentof of cancers including four core tumors types, uveal and advanced basal cell carcinoma (BCC) with activated cutaneous melanomas, mesotheliomas and renal clear cell Hedgehog pathway. Most patients show clinical benefit carcinomas (Walpole et al. 2017). Worldwide, 40 different from the drug but a small subset shows intrinsic resistance missensevariantswereidentified,butonly9wereclassified (IR) and progresses on treatment. We report for the first as likely pathogenic upon modified ACMG criteria (higher time molecular mechanisms of IR in 4 aggressive BCC weight for phenotypical evidence for rare tumors). BA P1
 cases. Using whole exome sequencing, analysis of copy genebeingatumorsuppressor,geneticinactivationleadsto number aberrations and transcriptional profiling we were lossofnuclearexpressionbyimmunohistochemistry(IHC). able touncover themajordeterminants ofIR inthestudied Thefrequencyofinactivationbytwosomaticgeneticevents samples. Our results show that these BCCs harbor either varies upon tumor types; therefore, the specificity of BA P1
 molecular signature earlier reported in BCCs with acquired loss of staining to indicate a germline BA P1
 mutation resistance to vismodegib, such as p.W535L SMO mutation (positive predictive value, PPV) varies also. and amplification of GLI2; or bear molecular signature Inthepresentstudy,weperformed217BA P1
IHC(145of compatible with squamous cell carcinoma evolution (muta- them in cutaneous melanocytic tumors) in 118 members of tionsandfocalcopynumberalterationsofMYC,LGR4and 102 families, analyzed in parallel for BA P1
 germline muta- TCF7 L1
). In line with the detected driver events at DNA tions to address the interest of BA P1
 IHC to the BA P1
- level upregulation of target genes of either Hh or WNTAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1539 pathway was confirmed with RNA sequencing. Addition- arr (11q14.1q14.2(81417643-86071005), 17q25.1q25.3 ally we report that all the BCC IR cases overexpress (73593574-77382564))x2hmz. No chromosomal abbera- TRAG3, SNORA42 and microRNA711, markers of poor tions were found only in two pTa samples. Genomic prognosisandresistancetotreatmentwhichwerepreviously imbalances – losses were mostly found for arr 6p21.32 identified in other types of cancer. (32453988-32538289)x0 and arr 9p21.3(20351075- S.I. Nikolaev: None. A. Yurchenko: None. L. Flatz: 22755025)x0. CNVs gains were identified in almost all None. M. Ighil: None. N. Basset-Seguin: None. chromosomes, but the most frequent were in chromosome (9)(q21.11q21.13), (9)(q31.2q31.3), (20)(q11.21q13.33)  P12
.008A and (20)(p13p11.1) mainly in pT1 and pT2 tumours. Molecular signature for improvement of clinical UnexpectedlyinpT3andpT4tumoursamplesonlygainsin prognosis accuracy in superficial bladder carcinoma chromosomes:1p, 11q, 17p and 17q were detected. Acknowledgements: Contract DM13/4, 2017 NSF, -60/ O. S. Antonova1, B. S. Mladenov2, S. Rangelov3, 03.05.2018, Bulgaria, MANU-BAS. B. B. Rukova1, Z. A. Hammoudeh1, D. V. Nesheva1, O.S. Antonova: None. B.S. Mladenov: None. S. Ran- D. Serbezov1, R. G. Staneva1,4, M. B. Ganev1, gelov: None. B.B. Rukova: None. Z.A. Hammoudeh: S. Karachanak-Yankova1,5, V. G. Spasova1, None. D.V. Nesheva: None. D. Serbezov: None. R.G. S. P. Hadjidekova1,4, L. Balabanski1,6, R. Vazharova6,7, Staneva: None. M.B. Ganev: None. S. Karachanak- C. Slavov3, D. Toncheva1,6 Yankova:None.V.G.Spasova:None.S.P.Hadjidekova: None. L. Balabanski: None. R. Vazharova: None. C. 1Department of Medical Genetics, Medical University- Slavov: None. D. Toncheva: None. Sofia,Sofia,Bulgaria,2DepartmentofUrology,UMBALSM "N. I. Pirogov", Sofia, Bulgaria, 3Department of Urology,  P12
.009B University Hospital "Tsaritsa Yoanna", Sofia, Bulgaria, Cytogenetic abnormalities in B-precursor acute 4Women’s Health Hospital “Nadhezda”, Sofia, Bulgaria, lymphoblastic leukemia from a tertiary care centre in 5Department of Genetics, Faculty of Biology, Sofia India University“St.KlimentOhridski”,Sofia,Bulgaria,6GARH “Malinov”, Sofia, Bulgaria, 7Department of Biology, D. Shetty1, H. Jain1, V. Mistri1, H. Jain2, B. Bagal2, Medical Genetics and Microbiology, Faculty of Medicine, A. Bonda3, S. Punatar3, A. Gokarn3, L. Nayak3, Sofia University, Sofia, Bulgaria M. Prasad2, G. Narula2, M. Sengar2, N. Khattry3, S. Banavali2, P. Tembhare4, P. Subramanian4 Background: The aim of our study is to identify the correlation between molecular changes in uroepithelial 1Department of Cancer Cytogenetics, Advanced Centre for tumors and tumor stage, grade and progression, as well as Treatment, Research & Education in Cancer (ACTREC), to evaluate potential prognostic markers. Navi Mumbai, India, 2Department of Medical Oncology, Materials and Methods:Tumour samples from 65 Bul- Tata Memorial Hospital, Parel, Mumbai, India, garianpatients,stagedpTa,pT1,pT2,pT2a,pT2b,pT3and 3Department of Medical Oncology, Advanced Centre for pT4 were collected. Four genes (A P1
S1 , FIGF, HDA
C11 , Treatment, Research & Education in Cancer (ACTREC), CDK9)thatshowedsignificantdifferencebetweeninvasive Navi Mumbai, India, 4Department of Hemato-pathology, and non-invasive bladder carcinoma in a previous pool Advanced Centre for Treatment, Research & Education in analyseswereselectedforindividualvalidationbyRT-PCR Cancer (ACTREC), Navi Mumbai, India analysis (Qiagen). CNVs of 30 uroepithelial neoplastic samples (CytoChip Oligo aCGH, 4x44K and Infinium Introduction: B-precursor acute lymphoblastic leukemia OncoArray-500K BeadChip, Illumina) were performed. (BCP-ALL) is a neoplastic disease characterized by clonal Data was analyzed by BluefuseMulti software and expansion of leukemic cells and cytogenetics is an Karyostudio. important diagnostic parameter in its classification. Results and discussion: The gene expression analysis Material and Methods: Retrospective study was carried revealed4-12foldchangedifferenceintheexpressionlevel outin2270patients(Adult-759;Pediatric-1511)diagnosed between pT2 and pTa and pT1 tumors. The highest up- as BCP-ALL (January 2016 to December 2018). Fluores- regulation was shown for A
P1 S1
 gene, involved in protein cence In Situ Hybridization (FISH) was performed using traffickingbyclathrin-coatedvesicles.FiveLOHvariantsin commercial probes for LSI BCR/AB L1
; MLL; ETV6/ two pT2 samples were determined: arr 6p12.1p11.1 RUNX1; TCF3/PBX1 and centromeric probes for chromo- (55721511-58767335)x2hmz, arr (7q21.3(94372640- somes 4, 10 and 17 for ploidy status. A pilot study was 97676259), 7q22.1q22.2(99552168-104336782))x2hmz, conductedforPh-likeALL(FISHwasperformedforAB L1
,1540 AB L2
, PDGFRβ, CSF1R and CRLF2 rearrangements) on genetic testing of a large panel of breast cancer susceptibility 219 cases (June 2018 to December 2018). genes by MPS on a blood sample. The c.4688G>A, p. Results: Cytogenetic abnormality was detected in 51% (Trp1563*)BRCA2mutationwasdetectedin23%ofsequence cases (1162/2270) [Adult: 60% (454/759); Pediatric: 47% reads (>500X depth coverage) suggesting mosaic condition. (708/1511)]. Incidence of t(9;22); BCR-AB L1
, t(1;19); Mosaicratewasconfirmedinothertissuesasbladdercellsand TCF3-PBX1andMLLtranslocationswas31%,4%and3% salivary sample. Higher rate was found in capillary bulb. The in adult B-ALL while 6%, 7% and 3% in pediatric B-ALL analysis of the non-cancerous breast tissue is in progress. respectively. Translocation (12; 21): ETV6/RUNX1 was Finally, this case suggests that, although rare, this event found in 13% pediatric cases. Trisomy 4, 10, 17 were should be taken into account in the evaluation of high-risk detected either as a sole or in combination with each other families and it is probably underestimate. Two reasons in31%(462/1511)pediatriccasesand22%(165/759)adult should increase the number of cases reported: large cases. Chromosomal counting revealed hyperdiploidy and screeningperformedbyhighlyaccurateMPSandenhanced hypodiploidy in 25% and 5% pediatric cases; 12% and 6% BRCA testing (outside of the fulfilled high-risk selection in adult cases which was correlated with flow cytometry criteria) because of targeted therapies. DNA index. Of 219, 4 cases (1.8%) showed rearrangement V. Cusin: None. N. Basset: None. E. Guillerm: None. in CRLF2 (1 Pediatric case with Down syndrome) and M. Eyries: None. T. Lisner: None. R. Nicolle: None. G. CSF1R (Adult-1; Pediatric-2). Follow-up studies were L'Helgoualc'h: None. F. Coulet: None. performed. Conclusions: Various cytogenetic subtypes have sig-  P12
.011D nificant impact on risk stratification and hence remain The BRCA1 intronic c.5407-25T>A variant: effect on strong independent indicators of disease outcome. splicing and association with breast and ovarian cancer D. Shetty: None. H. Jain: None. V. Mistri: None. H. Jain:None.B.Bagal:None.A.Bonda:None.S.Punatar: H. Høberg-Vetti1,2,3, E. Ognedal1,2, A. Buisson4, None. A. Gokarn: None. L. Nayak: None. M. Prasad: T. Vamre5, S. Ariansen5, G. Houge2,3, T. Fiskerstrand2,3, None. G. Narula: None. M. Sengar: None. N. Khattry: B. I. Haukanes2, C. Bjorvatn1,3,6, P. M. Knappskog2,3 None. S. Banavali: None. P. Tembhare: None. P. Subramanian: None. 1Western Norway Familial Cancer Center, Haukeland University Hospital, Bergen, Norway, 2Department of  P12
.010C Medical Genetics, Haukeland University Hospital, Bergen, Constitutional mosaicism of BRCA2 gene mutation Norway, 3Department of Clinical Science, University of detected by massive parallel sequencing in a case of Bergen, Bergen, Norway, 4Hospices Civils de Lyon, Lyon, early onset breast cancer France, 5Department of Medical Genetics, Oslo University Hospital, Oslo, Norway, 6Department of Research and V. Cusin1,2, N. Basset1, E. Guillerm1, M. Eyries1, Development, Haukeland University Hospital, Bergen, T. Lisner1, R. Nicolle1, G. L'Helgoualc'h2, F. Coulet1 Norway 1Département de Génétique, Paris, France, 2Hôpital Privé Introduction: The increasing genetic testing for hereditary d'Antony, Antony, France breastandovariancancerleadstodetectionofraresequence variantsofunknownclinicalsignificanceintheBRCA1and Pathogenic variants in BRCA1 and BRCA2 genes are BRCA2 genes. Correct interpretation of these variants is responsible for over 50% of genetic susceptibility to breast challenging, butimportantfor correct clinical management. andovariancancer.Nowadays,thescreeningofthosegenesis Theaimofthisstudywastodeterminethepathogenicityof commonly performed with expanded panel genes using the intronic BRCA1 c.5407-25T>A variant found in massive parallel sequencing (MPS). This technology is more Norwegian and French families. sensitive and improves the capacity for detection of mosaic Results:TheBRCA1c.5407-25T>Avariantwasdetected events. Very few cases of de novo mutations have been in 17 families with suspected hereditary breast and ovarian described in BRCA genes with only one constitutional cancer (meanManchester score 16.1).Thisisa rare variant mosaicism of BRCA1 mutation demonstrated by Friedman with a reported frequency of 0.00001579 in non-Finnish and coll. Here, we report the first case of constitutional EuropeanpopulationinthegnomADdatabase.Itwasfound mosaicism of BRCA2 mutation in a 46 years old woman in 1/370 anonymous Norwegian blood donors and 0/784 referredtogeneticcounsellingforbifocallobularbreastcancer. patientsincludedinanin-housediagnosticexomedatabase. Two sisters developed breast cancer at 74 and 58 years old. NGS-based RNA sequencing of BRCA1 in blood revealed Anycancerwasn’tdiagnosedinuppergeneration.Weperform that thevariantleads toskippingofexon22andframeshiftAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1541 predicting the truncated BRCA1 protein p.(Gly1803Glnf- glycosylase genes as modifiers of cancer susceptibility for sTer11). This exon skipping was confirmed by PCR and BRCA1/2 mutation carriers. Grants: J.M.B. is supported by Sanger sequencing of the BRCA1 mRNA booth in blood, grant FPU15/01978 from the Spanish Ministry of Educa- breast and in ovarian tissue. However, sequencing of two tion, Culture and Sport. c.5407-25T>A carriers heterozygous for a transcribed SNP J.M. Baquero: None. C. Benítez-Buelga: None. V. (c.4837A>G), showed that a low amount of correctly Fernández:None.M.Urioste:None.J.García-Giménez: spliced transcript including exon 22 is generated from the None. A. Osorio: None. J. Benítez: None. c.5407-25T>A allele. Western blot analysis of transiently expressedBRCA1proteinsinHeLacellsshowedareduced  P12
.013B amount of the mutant p.Gly1803GlnfsTer11 compared to Impact of germline BRCA mutation identification on wild-type protein. subsequent breast cancer stage, therapy and survival - Conclusion: Our results indicate that BRCA1 c.5407- implications for routine screening 25T>A is a likely pathogenicsplice variant associated with hereditary breast and ovarian cancer. S. Lieberman1, T. Hadar2, P. Mor1, G. Amit2,3, H.Høberg-Vetti:None.E.Ognedal:None.A.Buisson: E. Tahover4, O. Rosengarten4, M. Carmon2, O. Olsha2, None. T. Vamre: None. S. Ariansen: None. G. Houge: R. Abu-Dalo2, R. Michaelson-Cohen1,3, E. Golomb5, None. T. Fiskerstrand: None. B.I. Haukanes: None. C. R. Rabinovitch6, E. Levy-Lahad1,3 Bjorvatn: None. P.M. Knappskog: None. 1Medical Genetics Institute, Shaare Zedek Medical Center,  P12
.012A Jerusalem, Israel, 2Breast Surgery Unit, General Surgery Functional studies of SNPs in glycosylase genes as Department, Shaare Zedek Medical Center, Jerusalem, modifiersofcancerriskinBRCA1andBRCA2mutation Israel, 3Faculty of Medicine, Hebrew University, carriers Jerusalem, Israel, 4Oncology Department, Shaare Zedek MedicalCenter,Jerusalem,Israel,5PathologyDepartment; J. M. Baquero1, C. Benítez-Buelga2, V. Fernández1, Shaare Zedek Medical Center, Jerusalem, Israel, M. Urioste1,3, J. García-Giménez4,3, A. Osorio1,3, Jerusalem, Israel, 6Department of Radiation Oncology; J. Benítez1,3 University of Colorado Comprehensive Cancer Center, Aurora, CO, United States 1SpanishNationalCancerResearchCentre,Madrid,Spain, 2KarolinskaInstitutet,Solna,Sweden,3SpanishNetworkon Background: Screening healthy Ashkenazi Jews for Rare Diseases, Madrid, Spain, 4Universitat de Valencia, germline BRCA1/BRCA2 mutations (gBRCA) is not stan- Valencia, Spain dard policy, despite high (2.5%) carrier rates. Most carriers are identified only after breast cancer diagnosis. Introduction: In a previous association study, we found Aim: to determine if pre-symptomatic knowledge of three SNPs in different DNA glycosylase genes (OGG1, carrier status affects breast cancer stage and management. NEI L2
,andUNG)thatmodifybreastorovariancancerrisk Methods: Record review of gBRCA carriers (excluding in BRCA1 and BRCA2 mutation carriers. women with risk-reduction mastectomy), diagnosed with Materials and Methods: We have used a series of 300 breast cancer between 1/2005-4/2016. We compared out- familial breast and ovarian cancer patients to try to gain comes between carriers whose gBRCA was identified pre- molecularinsightsintohowthesevariantsexerttheircancer breast cancer (PRE-C-D) vs. post-breast cancer (POST-C- risk modifier effect. In this series, we have measured gly- D) diagnosis. cosylase expression and activity and different genome Results: 105 women with breast cancer had gBRCA: 42 instabilityandoxidativestresshallmarkstoexploretherole (40%) PRE-C-D and 63 (60%) POST-C-D. Mean age at of these SNPs. diagnosis (50.4y) and BRCA1:BRCA2 distribution Results:ThestudiedSNPsareassociatedwithexpression (64%:36%) were similar in both groups. PRE-C-D carriers changes in their respective glycosylases. We have also were significantly more likely to have suggestive family found associations of the SNPs with DNA damage levels, history (93% vs. 63%), prior breast cancer screening (78% telomere length or oxidative stress levels, specifically for vs 64%) and diagnosis by imaging (78% vs 25%) rather the group of mutations carriers where the different SNPs than clinical symptoms (19% vs 73%) (p<0.001, all com- respectively exert their cancer risk modifier effect. parisons). PRE-C-D carriers had lower stage at diagnosis Conclusions:Ourfindingshelptoexplaintheassociation (p<0.001), with no differences in tumor grade, hormonal of these SNPs with cancer risk in BRCA1/2 mutation car- receptororHer2status.PRE-C-Dcarrierswerelesslikelyto riers, highlighting the importance of genetic changes in receive chemotherapy (34% vs. 94%), and more likely to1542 elect bilateral mastectomies (66% vs 17%) (p≤.001 all two women were heterozygote for pathogenic mutation in comparisons). In multivariate analysis, PRE-C-D gBRCA the RAD51C and RAD51D genes, respectively. identification predicted for early stage (0-I) breast cancer Conclusion: The overall occurrence of possibly patho- diagnosis (OR=18.4, p<0.001). Initial analysis indicates genic mutations in breast cancer susceptibility genes, better overall survival (HR=0.16, p=0.087) excluding the ones detected in the highly penetrant BRCA1 Conclusions: Presymptomatic identification of gBRCA and BRCA2 genes, is 4.8%. Thus, these genes seem to status is significantly associated with earlier stage breast enable the identification of more clinical cases which may cancer diagnosis, less extensive treatment, and possibly be benefited by closer monitoring. improvement in overall survival. This supports routine M. Chatzidaki: None. Y.L. Loukas: None. G. Thodi: gBRCAtestingintheAshkenaziJewishpopulation.Funded A. Employment (full or part-time); Modest; Neoscreen by the BCRF LTD. O. Triantafilli: A. Employment (full or part-time); S. Lieberman: None. T. Hadar: None. P. Mor: None. Modest;NeoscreenLTD.C.A.Sarri:A.Employment(full G. Amit: None. E. Tahover: None. O. Rosengarten: or part-time); Modest; Neoscreen LTD. E. Molou: A. None.M.Carmon:None.O.Olsha: None.R.Abu-Dalo: Employment (full or part-time); Modest; Neoscreen LTD. None.R.Michaelson-Cohen:None.E.Golomb:None.R. Y. Dotsikas: None. Rabinovitch: None. E. Levy-Lahad: None.  P12
.015D  P12
.014C Detection of variants of pathogenic and uncertain Estimation of mutation frequency in new breast cancer significance in an Irish population using multi-gene susceptibility genes in a Greek patients’ cohort panels for breast cancer risk M.Chatzidaki1,Y.L.Loukas1,G.Thodi2,O.Triantafilli2, U. M. McVeigh1, T. P. McVeigh2, N. Miller1, C. A. Sarri2, E. Molou2, Y. Dotsikas1 D. W. Morris3, M. J. Kerin1 1Department of Pharmacy, National and Kapodistrian 1Discipline of Surgery, Lambe Institute for Translational University of Athens, Greece, Athens, Greece, 2Neoscreen Research, NUI, Galway, Ireland, 2Cancer Genetics Unit, LTD, Athens, Greece TheRoyalMarsdenNHSFoundationTrust,London,United Kingdom, 3Discipline of Biochemistry, NUI, Galway, Introduction: Many other than BRCA1 and BRCA2 genes Ireland havebeenimplicatedinbreastcancerpredispositionduring thelastdecadeenablingtheidentificationofmorewomenat Breast cancer (BC) is the second most common cancer higher risk for breast cancer compared to the general worldwide. Twin studies estimate that >30% BCs are the population and develop surveillance protocols tailored to result of hereditary factors. While hugely informative, their needs in the near future. pathogenicvariantsinBRCA1andBRCA2explainonly16- Purpose: The purpose of the current study was to esti- 22% of hereditary BCs. Several high- and moderate-risk mate the prevalence of pathogenic mutations in the “new” genes, and >100 single nucleotide polymorphism (SNPs) breast cancer susceptibility genes in a Greek patients’ have been identified which explain 33% of hereditary BCs. cohort. Approximately 50% of the hereditary risk of BC is Patients and Methods: 104 women who developed unknown. Next-generation sequencing (NGS) is a cost- breast cancer under theage of55 years oldwith orwithout effective method of investigating numerous genes in one family history and women free of cancer but with two or assay. There are an abundance of clinical multi-gene panel more affected first degree relatives constitute our patients’ tests aimed at assessing the inherited risk of BC ± ovarian cohort. DNA was extracted with Nucleospin tissue kit and cancer. This study aimed to investigate germline variants libraries were prepared using the TruSight® Cancer genes included on breast ± ovarian cancer risk panels in an Sequencing Panel, which includes 40 breast cancer sus- Irish population. DNA from 90 BCs and 77 controls were ceptibilitygenes,followingthemanufacturer’sinstructions. sequenced for variants in 83 genes from clinical breast ± Massive parallel sequencing was conducted on Miseq ovarian cancer risk panels. Variant calling was performed platform (Illumina). following GATK best practices, and prioritised as loss-of- Results: Two cases carrying missense mutations of function(LOF) and missense variants; further grading was unknownclinicalsignificance wereidentifiedinMLH1and performed using five in silico prediction tools. Excluding PALB2 genes, respectively. One case harbors the CHEK2 common/benign variants, 56 variants were identified in 37 c.1100delC mutation, which confers three- to five-fold genes.36.5%and39.2%ofcasesandcontrolscarried≥one increased risk compared to the general population, while variant. Nine variants were classified as pathogenic/likelyAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1543 pathogenic; three occurred in ATM, BRCA1, and CHEK2. showed100% ofHER2+, 100% ofPR- andthesame 50% Eight novel variants were identified, including a frameshift of ER+ and ER- (p=0.006, p=0.018, p=0.04). variant in NF1. Six variants were identified in the Lynch Conclusion:Outofeightgeneticvariantsanalysedinour syndrome genes MLH1, MSH2, MSH6, and PM S1
. These study, four were identified to associate with BC, namely results highlight the need for caution when considering the within genes FGFR2, MA P3
K1, LS P1
 and CAS P8
. use of multi-gene testing in the clinic given the challenges Z. Dankova: None. K. Zelinová: None. M. Jagelková: of accurately predicting variant pathogenicity. None. M. Grendár: None. P. Kasajová: None. M. Kal- U.M.McVeigh:None.T.P.McVeigh:None.N.Miller: man: None. Z. Lasabová: None. P. Žúbor: None. None. D.W. Morris: None. M.J. Kerin: None.  P12
.018C  P12
.017B Analysis of a CHEK2 variant in a family with an ATM Geneticmodelsofbreastcancerbasedoneightcommon mutation and multiple breast cancer cases genetic variants M.Barzily-Rokni1,R.Michaelson-Cohen1,S.Lieberman1, Z. Dankova1, K. Zelinová1, M. Jagelková1, M. Grendár2, S. Casadei2, O. Weiss1, O. Freireich1, S. Zuckerman1, P. Kasajová3, M. Kalman4, Z. Lasabová1, P. Žúbor3 M. Sebbagh1, M. C. King2, R. Beeri1, E. Levy-Lahad1,3 1BiomedicalCenterMartin-DivisionofOncology,Martin, 1Medical Genetics Institute, Shaare Zedek Medical Center, Slovakia, 2Biomedical Center Martin - Bioinformatic Unit, Hebrew University, Jerusalem, Israel, 2Departments of Martin, Slovakia, 3Clinic of Gynaecology and Obstetrics, Medicine and Genome Sciences, University of Washington, Martin University Hospital, Martin, Slovakia, 4Department Seattle, WA, United States, 3Faculty of Medicine, Hebrew of Pathology,Martin University Hospital,Martin,Slovakia University, Jeruslaem, Israel Introduction: This study analyses eight SNPs of low We present analysis of a CHEK2 variant found in a family penetrant genes to detect possible importance in breast of Moroccan Jewish origin with multiple breast cancer cancer (BC) risk. cases.Of11sisters,5werediagnosedwithbreastcancerin Materials and Methods: The study consists of 317 their 60’s; one had both papillary thyroid cancer (age 67) women: 171 with breast cancer (57.06±11.60 years) and and pancreatic cancer (age 76). Their mother had breast 146 without previous history of any malignancy (50.24 cancer (age 70). Panel testing in four sisters revealed two ±10.69 years). Major breast cancer histological type was germlinevariants:aknownpathogenicmutationinATM-p. DIC(76.0%),followedbyLIC(7.8%).Wegenotypedeight Q1970X; and a variant in CHEK2 classified as being of genetic variants (rs4415084 FGF10, rs2981582 FGFR2, uncertain significance - c.592+3A>T. (rs587782849, gno- rs889312 MA P3
K1, rs3817198 LS P1
, rs3803662 TOX3/ mAD allele frequency= 0.000032). This variant has been TNR C9
, rs2293554 CAS P8
, rs13387042 and rs13281615 reported once to alter CHEK2 splicing (Kraus C et al, Int J CAS C21
) by High Resolution Melting method and vali- Cancer, 2017). 8 sisters were tested. Of the 5 with breast dated by Sanger sequencing. cancer,3(ages60-66)carriedofbothvariantsandtwo(ages Results: General, dominant and multiplicative genetic 61,67)carriedonlytheCHEK2variant.Thesisteraffected models confirmed significant association with BC in the with thyroid and pancreatic cancer carried only the ATM case of FGFR2 (C/T) and MA P3
K1 (A/C´) polymorphisms mutation, as did 2 unaffected sisters (ages 53, 67). CHEK2 (in all cases p≤0.03). Odd ratios for general model: c.592+3A>T was found in 2/234 (0.8%) Sephardi breast CT=1.771, TT=1.953, AC´=1.760, C´C´=2.894. Odd cancer patients (also of Moroccan origin), and was also ratios for dominant model: CT+TT=1.822 and AC´+ observedinanunaffectedwomanofBalkanorigin(age36). C´C´=1.868andoddratiosofmultiplicativegeneticmodels cDNA analysis revealed two alternate transcripts, one T=1.517 (95%CI=1.083-2.131), C´=1.676 (p≤0.04). lacking exon 4, and one lacking exons 4-5 (both out-of- Logistic regression of interaction revealed the lowest OR frame, confirming the previous report). Semi-quantitative forthecombinationoforiginalhomozygotegenotypes(AA PCRindicated50%reductionofthewild-typetranscript.In +CC+TT) of MA P3
K1, FGFR2 and LS P1
 genotypes summary, CHEK2 c.592+3 A>T is a rare splicing variant, (OR=0.024, 95%CI 0.001-0.306, p=0.011), indicating which should be reclassified as mild pathogenic. In this lower risk for those without risk alleles. family, the presence of two pathogenic variants in The risk allele genotype (CC) of LS P1
 (T/C) gene poly- moderate-risk breast cancer genes may explain the high morphism showed solely ER-positivity (100%), hetero- load of late-onset breast cancer. zygotes with one risk allele (TC) were also mostly ER+ M.Barzily-Rokni:None.R.Michaelson-Cohen:None. (90.6%). The risk genotype (GG) of CAS P8
 polymorphism S. Lieberman: None. S. Casadei: None. O. Weiss: None.1544 O. Freireich: None. S. Zuckerman: None. M. Sebbagh: biomarkers in order to achieve efficient TRAIL targeted None. M.C. King: None. R. Beeri: None. E. Levy- therapy. Lahad: None. E. Roupou: None. M. Michelli: None. I. Chatzian- dreou: None. N.V. Michalopoulos: None. P. Kar-  P12
.019D athanasis: None. A.A. Saetta: None. Deregulation of TRAIL apoptotic pathway mRNA expression in breast tumours  P12
.020A Identification of significant network markers for breast E. Roupou1, M. Michelli1, I. Chatziandreou1, cancer in Middle Eastern women using integrated N. V. Michalopoulos2, P. Karathanasis3, A. A. Saetta1 transcriptomic and network analysis 11st Department of Pathology, School of Medicine, O. Al-Harazi1,2, I. H. Kaya1,3, A. El Allali2, N. Kaya4, National and Kapodistrian University of Athens, Ath, D. Colak1 Athens, Greece, 2Department of Surgery Attikon Hospital, SchoolofMedicine,UniversityofAthensN.K.U.A.,Athens, 1Department of Biostatistics, Epidemiology and Scientific Greece, Athens, Greece, 31st Department of Propaedeutic Computing, King Faisal Specialist Hospital and Research Surgery Hippokrateion Hospital, School of Medicine, Centre, Riyadh, Saudi Arabia, 2College of Computer and University of Athens N.K.U.A., Athens, Greece, Athens, Information Sciences, Computer Science Department, King Greece Saud University, Riyadh, Saudi Arabia, 3College of Medicine, Alfaisal University, Riyadh, Saudi Arabia, Introduction: TRAIL apoptotic pathway constitutes a 4Department of Genetics, King Faisal Specialist Hospital promising therapeutic target for cancer patients, due to and Research Centre, Riyadh, Saudi Arabia high selectivity and low toxicity of TRAIL agents when administered in monotherapy/combination therapies. The Introduction: Breast cancer is a major health problem in aim of our study was to search for possible predictive the world and it is the most common cause of cancer death biomarkers for patient stratification to ensure maximum among women. The integration of gene expression profiles treatment efficacy of TRAIL targeted therapy. and protein-protein interaction (PPI) network provides a Materials and Methods: 88 breast cancer tissues were better understanding of the molecular architecture of examined for relative mRNA expression of TRAIL and its diseases. Recently, many researchers have invested efforts receptors (DR4, DR5, DcR1, DcR2), using RT-PCR/ΔΔCt for identifying subnetwork biomarkers for cancer. It has method.ForstatisticalanalysisSPSSv22packagewasused. been shown that these subnetwork biomarkers are more Deathreceptor(DR4,DR5)proteinlevelswereanalyzedby robust and reliable than single biomarker genes that are Western blot in a subset of cases. selected based on the gene expression data only. Results: Elevated mRNA levels were observed in 11%, Materials and Methods: We performed an integrated 19.3%, 23.9%, 11.6% and 12% of the cases for TRAIL, network analysis of gene expression data with the PPI to DR4, DR5, DcR1 and DcR2 genes respectively. Reduced identify significant subnetwork biomarkers. In addition, we mRNA levels were detected in 64.6%, 38.6%, 31.8%, used the k-nearest neighbor (KNN) algorithm to define the 45.3%and42.2%ofthecasesforTRAIL,DR4,DR5,DcR1, classifier.Wevalidatedtheclassificationperformanceonan and DcR2 genes respectively. TRAIL expression was cor- independent gene expression dataset of breast cancer sam- related with molecular subtype (p=0,011), DR4 with N ples. Moreover, we performed survival analyses using dif- category(p=0,029)andtumorgrade(p=0,015),DcR1with ferent transcriptomic datasets that consisted of over tumor grade (p=0,001) and ER/PR expression (p=0,051). 3,000 samples. All receptors correlated with the prognostic stage (DR4 Results: We have identified four subnetwork biomarkers p=0,005, DR5 p=0,029, DcR1 and DcR2 p=0,006). The that significantly distinguished breast cancer patients from receptors’ mRNA levels presented linear correlations and healthy controls. The identified classifier achieved 97% the strongest was found between DR4/DR5 (R=0,634, predictive accuracy between tumor and normal samples. p<0,001). Moreover, the survival analysis demonstrated that high Conclusions: A significant deregulation of TRAIL expressionofourbiomarkersisassociatedwithpoordisease pathway components mRNA expression in breast cancer outcome. was observed in the present study. Multiple simultaneous Conclusions: Our results suggest that the network ana- expression patterns of TRAIL receptors emerged, under- lysis coupled with genomic data may provide a robust scoring the importance of patient selection using predictive methodologytoidentifykeybiologicalprogramsassociated withbreastcancerprogressionandinvasionandmayleadtoAbstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1545 improved diagnosis, prognosis and therapeutic options. None. S. Rowley: None. L. Devereux: None. A. Lee: Funding:ThisstudyisfundedbyKFSHRCResearchGrant None. N. Grewal: None. P. James: None. (2110006 to DC). O. Al-Harazi: None. I.H. Kaya: None. A. El Allali:  P12
.022C None. N. Kaya: None. D. Colak: None. Genomic mapping of Crete via BRCA1 and BRCA2 mutation analysis  P12
.021B Integration of tumour sequencing and case-control P. Apostolou1, F. Fostira1, C. Kourousis2, A. Vagena1, analyses is a powerful tool for identification of cancer A. Delimitsou1, M. Papamentzelopoulou1, predisposition genes V. Georgoulias3, D. Mavroudis3, K. Kalpakis3, N. Androulakis4, I. Drositis4, D. Yannoukakos1, I. Campbell, N. Li, B. Lim, S. McInerny, M. Zethoven, E. Saloustros5, I. Konstantopoulou1 D. Cheasley, S. Rowley, L. Devereux, A. Lee, N. Grewal, P. James 1Molecular Diagnostics Laboratory, NCSR Demokritos, Athens, Greece, 2General Clinic "IASO", Chania, Crete, Peter MacCallum Cancer Centre, Melbourne, Australia Greece, 3Department of Medical Oncology, University Hospital of Heraklion, Heraklion-Crete, Greece, 4General Background: The genetic causes of a large proportion of Hospital of Heraklion "Venizelio-Pananio", Heraklion- breast cancer families is unknown and while our targeted Crete, Greece, 5Department of Oncology, University sequencing of over 12,000 index cases and controls has Hospital of Larissa, Larissa, Greece identified numerous strong candidates, individually muta- tions in these genes are rare. Our work highlights the fact Introduction: Germline BRCA1/2 loss-of-function variants that in isolation, case-control studies will remain substan- arelinkedtoincreasedbreastandovariancancerrisk.Upto tiallyunderpoweredtoestablishaclearrolefornovelbreast date, more than 5000distinct BRCA1/2pathogenic variants cancer predisposition genes and orthogonal validation have been reported, while their frequency and distribution approaches will be required. Genomic analysis of tumours varies between populations and ethnicities. In the Greek from carriers of germline variants in candidate genes can population, founder effects have been described, mainly provide powerful additional evidence for involvement of a involving BRCA1 loss-of-function variants. However, gene in cancer predisposition through identification of certain geographical regions were underrepresented in “second hit” somatic inactivation events and characteristic previous studies. We therefore aimed to define and “mutational signatures”. molecularly characterize the BRCA1/2 mutational spectrum Results: We applied this approach to assess the role of in Crete, the largest Greek island with unique demographic RAD51C in breast cancer predisposition. Full exon and cultural characteristics. sequencingofRAD51Cinacase/controlanalysis identified MaterialsandMethods:PatientsofCretandescent,with a significant excess of loss of function variants in cases breast or/and ovarian cancer fulfilling NCCN guidelines compared with controls (0.36% versus 0.04%; OR=8.67, were selected for genetic testing by NGS or Sanger 95% CI =1.89 to 80.52, P=9.87x10-04). In addition, the sequencing, followed by MLPA. Haplotype analysis was association was highly significant among cases with ER subsequently performed to investigate potential founder negative (P=1.57x10-05) or triple-negative cancer effects of recurrent alleles. (P=7.33x10-06), but not in ER positive cases. Tumour Results: In total 291 patients (273 females, 18 males) sequencingfromcarriersconfirmedbi-allelicinactivationin were included. Forty-eight patients (16.5%) carried 21 dif- all the triple-negative cases and this was associated with ferent pathogenic variants in BRCA1 (45.8%; 22/48) and high levels of large-scale genomic alterations and a muta- BRCA2 (54.2%; 26/48). The deleterious variants c.6842- tional signature 3, both indicative of homologous recom- 2675_7008-5558del and c.7806-2A>T in BRCA2 and bination repair deficiency. c.5492delinBRCA1wererecurrentandconstituted50%of Conclusions: This study provides compelling evidence all identified pathogenic variants. Haplotype analysis con- that germline loss of function variants in RAD51C are firmedafoundereffectforallthreevariantswithaparticular associated with triple-negative breast cancer and demon- origin for each of them. Subsequent analyses indicate that strates the substantial power of tumour sequencing to theseareCretanfounders,sincetheyhavenotbeendetected advance the discover new cancer genes. in patients originating from other regions of Greece. I. Campbell: None. N. Li: None. B. Lim: None. S. Conclusions: The BRCA1/2 mutational spectrum of the McInerny: None. M. Zethoven: None. D. Cheasley: Cretan population shows particular geographical distribu- tion, influenced by strong founder effects. These findings1546 may facilitate a population-based genetic screening for  P12
.024A identification of unaffected mutation carriers and primary Exome sequencing identified potential causative cancer prevention. candidate genes for serrated polyposis syndrome P. Apostolou: None. F. Fostira: None. C. Kourousis: None. A. Vagena: None. A. Delimitsou: None. M. S. Peters1, C. Trueck1, C. Perne1,2, R. Adam1,3, Papamentzelopoulou: None. V. Georgoulias: None. D. J. Altmueller4,5, H. Thiele4, I. Spier1,2, S. Aretz1,2 Mavroudis: None. K. Kalpakis: None. N. Androulakis: None. I. Drositis: None. D. Yannoukakos: None. E. Sal- 1Institute of Human Genetics, University of Bonn, Bonn, oustros: None. I. Konstantopoulou: None. Germany, 2Center for Hereditary Tumor Syndromes, University of Bonn, Bonn, Germany, 3Center for  P12
.023D Experimental and Molecular Medicine, Academic Medical Putative non-coding regulatory driver discovery using Center Amsterdam, Amsterdam, Netherlands, 4Cologne unmatched tumor-normal samples Center for Genomics, University of Cologne, Cologne, Germany, 5Institute of Human Genetics, University of N. M. R. Lykoskoufis, H. Ongen, E. T. Dermitzakis Cologne, Cologne, Germany UniversityofGeneva,MedicalSchool,Geneva,Switzerland Serrated polyposis syndrome (SPS) is a poorly defined colorectal cancer predisposition syndrome characterized by We had previously developed a methodology using allele multiple and/or large serrated lesions throughout the colon. specific expression (ASE) as a proxy to discovering Genes Todate,onlyfewmolecularsignatureshavebeendescribed withAllelicDysregulation(GADs)impactedbynon-coding and the etiology of the syndrome has not been identified in somatic mutations, which requires matched healthy-tumour the vast majority of patients. samples. Here, we describe a methodology to discover To uncover causative variants, the exomes of 49 SPS GADs using unmatched samples to compare tumor and patients have been sequenced (Illumina HiSeq) using leu- reference RNAseq ASE (e,g. GTEx). Somatic mutations kocyte DNA. For data analysis, the GATK- and the under selectionfor tumorigenesis andfalling innon-coding Varbank2-software were used. The germline variants were regulatoryregionsofagenetendtoaffecttranscriptioninan filtered for rare (biallelic: MAF≤1%, monoallelic: ≤0.1% allelic fashion that is observed as altered allelic imbalance according to gnomAD and an in-house-database) loss of between normal and tumor samples. Moreover, we also function (LoF) variants. The pLi-score and reactome path- expect this gene to have altered gene expression for way analysis were used for further prioritization. selection to occur. Hence, to detect non-coding regulatory Biallelic LoF variants were found in 3 genes none of drivers in tumorigenesis, discriminating genes under which being recurrently mutated. All in all, 548 genes selectionorunderaneQTLeffect,wedevisedthreecriteria harbored heterozygous LoF variants. 25 genes were recur- to discover true driver genes. To test our method, we used rentlymutated.31/551geneswereextremelyLoFintolerant colorectal cancer data from the SYSCOL project treating indicated by pLi-score ≥ 0.9. 10/551 genes are involved in tumor and healthy samples as unmatched. We discov- DNA repair, 12 in cell cycle checkpoint control, and one ered702 genes passing all filtering criteria. Of them, 197 geneinprogrammedcelldeath.Mostinterestingly,different overlapped with the 373 GADs previously discovered with variantsintwopatientswerefoundinonegenefunctioning matchedsamples.Next,weusedSYSCOLtumorandGTEx inthecanonicalwntsignallingpathway,asdoesRNF43,in samples as control from colon sigmoid and colon which pathogenic variants have been shown to be causal transverse, discovering 612 and 689 GADs, respectively. for SPS. Ofthese,480genesoverlappedamong allthreeunmatched Exome sequencing identifies potentially causative germ- analyses passing all criteria with 152 overlapping with the line variants underlying the susceptibility to SPS. The cur- previously discovered GADs indicating that our methodol- rent work-up consists of screening of additional SPS ogy can detect regulatory drivers. Many of these have patientsfor the most interesting genes, and the inclusion of alreadybeenimplicatedinvariouscancers.Currentworkis missense variants as well as CNVs. Additionally, a rare validating our approach using prostate adenocarcinoma variant analysis and burden tests will be conducted. samples and other cancers and exploring the understudied S. Peters: None. C. Trueck: None. C. Perne: None. R. non-coding regulatory drivers. Adam: None. J. Altmueller: None. H. Thiele: None. I. N.M.R. Lykoskoufis: None. H. Ongen: None. E.T. Spier: None. S. Aretz: None. Dermitzakis: None.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1547  P12
.025B E. Jarhelle1, H. F. R. Stensland1, G. Å. M. Hansen1, The prognostic landscape of alternative transcript S. Skarsfjord1, C. Jonsrud1, M. Ingebrigtsen1, isoforms across human cancers N. Strømsvik1, M. Van Ghelue1,2 K. M. Vincent1, S. D. Findlay2, L. Postovit3 1University Hospital of North Norway, Tromsø, Norway, 2The Arctic University of Norway, Tromsø, Norway 1University of Ottawa, Ottawa, ON, Canada, 2Massachusetts Institute of Technology, Cambridge, MA, Introduction: Patients with hereditary breast and ovarian United States, 3University of Alberta, Edmonton, AB, cancer (HBOC) are diagnostically tested for pathogenic Canada variants (PVs) in BRCA1 and BRCA2. However, in most HBOC families no PVs are detected. Currently, several Introduction: Through alternative start site usage and additional genes were shown to be involved in increasing alternative splicing, individual genes commonly produce the cancer risk in HBOC patients. Accordingly, we multiple mRNA isoforms that can code for proteins with investigatedaNorwegianHBOCcohortinordertoidentify similar, distinct, or even opposing functions. Most cancer genetic risk factors for cancer in these patients. expression studies evaluate expression at a gene-level, not Material and Methods: Hundred and one HBOC accounting for the impact of multiple transcript isoforms patientsnegative for pathogenic variants inBRCA1/BRCA2 arising from the same genetic locus. were screened for PVs in 94 genes using next-generation Materials and Methods: Herein, we used clinical and sequencing. We used Illumina TruSight rapid capture RNA-sequencingdatafrom5642tumoursfrom14different technologytopreparetheIlluminaTruSightCancertargeted cancers from The Cancer Genome Atlas to investigate sequencing libraries, which were sequenced using an Illu- associations between gene expression, atboth the gene and mina MiSeq System. The sequencing data were analyzed isoform levels, and patient outcomes using Cox regression using Illumina MiSeq Reporter, and detected variants were models. In addition, we used SNP and methylation data to annotated and filtered in Cartagenia Bench Lab NGS soft- analyzehowcoordinatedgeneticandepigeneticeventsmay ware using different criteria. The detected variants were regulate these alternative isoform decisions through appli- scrutinized for their pathogenicity using Alamut Visual cation of the sQTLseekeR algorithm and a methylation (Interactive Biosoftware). correlation analysis. Results: Nine different deleterious germline PV/likely Results:Wehavefoundthatmanygeneshavealternative pathogenic variants were identified in seven genes in 12 isoforms that associate with survival in opposite directions, patients: three in ATM, and one in CHEK2, ERC C5
, unveiling a new molecular level with strong associations FANCM, RAD51C, T P53
 and WRN. Six of the 12 patients with patient outcomes. Isoform-level data, when compared were carriers of a variant of uncertain significance (VUSs) to gene-level data, revealed an additional 6605 genes with in other genes. Several different VUSs were identified isoforms significantly associated with survival in the 14 requiring further characterization. different cancers studied (|meta Z score| Q<0.001). Addi- Conclusion: In order to improve the clinical follow-up, tionally, we have identified potential genetic (SNP) and more knowledge is needed regarding the diversity of epigenetic (methylation) mechanisms for these alternative genetic risk factors possibly involved in cancer develop- isoform decisions. ment. Currently, for carriers of PV/LPV in many of these Conclusions: We have shown that approaching gene genes, there are no clinical management programs in expression as an isoform-level phenomenon provides a Norway. moresensitiveapproachtoidentifyingsignaturesassociated E. Jarhelle: None. H.F.R. Stensland: None. G.Å.M. withpatientoutcomes.Moreover,thegeneticandepigenetic Hansen: None. S. Skarsfjord: None. C. Jonsrud: None. regulationoftheseeventsrevealsspecificmolecularbiology M. Ingebrigtsen: None. N. Strømsvik: None. M. Van that may contribute to individual differences in disease Ghelue: None. outcome, and should be further explored. K.M. Vincent: None. S.D. Findlay: None. L.  P12
.027D Postovit: None. Molecular characterization of tumour DNA from patients with non-small cell lung cancer  P12
.026C Identifyingsequencevariantscontributingtohereditary S. Kyriakou1, A. Eliades1, C. Loizides1, K. Tsangaras1, breast/ovarian cancer in patients with no identified A. Achilleos1, E. Kypri1, I. Drejeriene2,3, BRCA1 or BRCA2 variants J. Kasnauskiene2, M. Ioannides1, G. Koumbaris1, P. C. Patsalis11548 1NIPD Genetics, Nicosia, Cyprus, 2Klaipeda University referral of patients with advanced cancer to Cancer Hospital, Klaipeda, Lithuania, 3Vilnius University, Vilnius, Genetics Services Lithuania C. Moss, S. Ward, E. Cojocaru, W. Xu, J. Hanwell, Introduction: Cancer is often characterized as an evolu- M. van Zyl, L. O'Leary, J. de Bono, U. Banerji, S. Kaye, tionary process driven by sequential acquisition of somatic A. Minchom, A. George, J. Lopez, T. McVeigh mutationsandclonalselection.Therefore,genomicanalysis of cancer cells has greatly enhanced our ability to identify The Royal Marsden Hospital, London, United Kingdom genetic alterations associated with various cancer types. Taking this in mind, cancer diagnosis and treatment is Molecular aberrations in cancer may represent therapeutic undergoing a fundamental shift from a histopathologically targets, and, if arising from the germline, impact further defined tumour treated with chemotherapy towards mole- cancer risk management in patients and their blood cular characterisation of the tumour and use of targeted relatives. Annually, 600-700 patients are referred for therapies. The challenge of clinical centres is to meet the consideration of experimental drug trials in the Drug needs for molecular testing using reliable methods and Development Unit (DDU) in our institution. A proportion processestoensurethepatientreceivesaccurateresultsina of patients may merit germline genetic testing because of timely manner. This study is focusing on the identification suspicious personal/family history or findings of tumour- of actionable mutations in non-small cell lung cancer based testing. We aimed to assess the impact of different (NSCLC)patientsthatcouldinformtheclinicianinregards multi-disciplinary interventions on family history taking in to diagnosis, prognosis and therapy decision. and referral rates from DDU to Cancer Genetics Materials and Methods: Formalin-fixed, paraffin- Unit (CGU). embedded (FFPE) tumour DNA from 57 patients diag- Methods: nosed with NSCLC were subjected to NIPD Genetics pro- Over 42 months, three interventions were undertaken at prietary targeted capture enrichment technology followed different intervals; byNGS.Sequencingdatawerevalidatedbyanindependent laboratory using Ion Torrent platform and Ampliseq colon 1. Embedding a genetics provider in DDU review clinic and lung cancer panel from Thermofisher. 2. “Traffic light” system flagging cancers with heritable Results: The most frequent mutations were identified in component T P53
 (46.81%), KRAS (14.89%), EGFR (10.64%) and 3. Virtual multi-disciplinary meeting (MDM). PIK3CA(10.64%).ResultswerevalidatedwithIonTorrent- NGS for 26 patients for which there was adequate DNA Comparativeanalysesbetweenintervalswereundertaken, material from the same tissue sections with a 97.3% con- including referral rates to CGU, investigations and patient cordance between the two methods. outcomes. Family history-taking in a sample of 20 patients Conclusion: These results highlight the clinical utility of managed in each interval was assessed by retrospective our assay as a companion diagnostics tool that can inform chart review. cancer diagnosis, prognosis and guide therapy. Results: Frequency of family history taking, and referral S. Kyriakou: None. A.Eliades: A. Employment (full or to CGU, increased with each intervention, particularly, the part-time); Significant; NIPD Genetics. C. Loizides: A. virtual MDM (40%-v- 85%). Referral rates increased over Employment(fullorpart-time);Significant;NIPDGenetics. thestudyperiod,from0.1referral/week(5/year,0.36%total K. Tsangaras: A. Employment (full or part-time); Sig- referrals) to 1.2/week (projected 63/year (3.81%). Forty- nificant;NIPDGenetics.A.Achilleos:A.Employment(full four (52%) patients referred required germline testing, in or part-time); Significant; NIPD Genetics. E. Kypri: A. three of whom variants were identified. Non-attendance Employment(fullorpart-time);Significant;NIPDGenetics. rates were low (6, 7%). I. Drejeriene: None. J. Kasnauskiene: None. M. Ioan- Conclusion: Patients in the DDU are unique, with long nides:A.Employment(fullorpart-time);Significant;NIPD cancer histories and short estimated life expectancy. Mul- Genetics. G. Koumbaris: A. Employment (full or part- tidisciplinary working between CGU and DDU facilitates time); Significant; NIPD Genetics. P.C. Patsalis: A. germline testing of those patients that may otherwise miss Employment(fullorpart-time);Significant;NIPDGenetics. the opportunity. C.Moss:None.S.Ward:None.E.Cojocaru:None.W.  P12
.028A Xu: None. J. Hanwell: None. M. van Zyl: None. L. Interventions in a Specialist Drug Development Unit to O'Leary: None. J. de Bono: None. U. Banerji: None. S. improve family history documentation and onward Kaye: None. A. Minchom: None. A. George: None. J. Lopez: None. T. McVeigh: None.Abstractsfromthe52ndEuropeanSocietyofHumanGenetics(ESHG)... 1549  P12
.029B 1Department of Human Genetics, Faculty of Medicine, Alterations of DNA Damage Response Pathway in University of Debrecen, Debrecen, Hungary, 2Institute of Lithuanian Patients with Castration-Resistant Prostate Obstetrics and Gynaecology, Faculty of Medicine, Cancer University of Debrecen, Debrecen, Hungary R.Sabaliauskaite1,I.Trockaja1,A.Sestokaite1,2,A.Ulys1, CD24 is a small molecular weight cell-surface protein and F. Jankevicius1,3, S. Jarmalaite1,2 an independent marker for poor prognosis in the different type of cancers. Determination of CD24 expression in 1National Cancer Institute, Vilnius, Lithuania, 2Institute of plasma, exosomes and ovarian tissue samples of serous Biosciences, Life Sciences Center, Vilniu University, ovarian cancer patients was our aim. Vilnius,Lithuania,3FacultyofMedicine,VilniusUniversity, Ovariantissueandbloodsamplesfrom21casesofserous Vilnius, Lithuania ovarian cancer and eight healthy controls were collected. After RNA isolation, the cDNA was synthesized, and then Introduction:Prostatecancer(PCa)isaheterogeneousand quantitativereal-timePCRwasperformedusingbeta-globin dynamic disease, which usually progresses to castration as a housekeeping gene for the normalization of the data. resistant PCa (CRPC) - the highly lethal form. Recent data Protein-protein and miRNA network analysis were per- suggest that CRPC may carry the germline or sporadic formed using Biogrid and miRTargetLink databases. mutationsin DNA damage response(DDR) pathway genes Significant difference in the expression of CD24 in and this cancer is commonly identified in families with a ovarian tissue between controls and patients (0.1595 high predisposition to the breast and ovarian cancer. Next ±0.3213 vs. 44.97±68.06 p=0.0068) was observed, while generation sequencing based-studies can uncover the CD24 expression was detected in exosomes in 38.1% of complex genomic landscape of CRPC and identify novel patients, mainly with FIGO III, and in plasma 9.5% of targets for efficient anticancer therapies. The aim of our cases. Correlation in the expression of CD24 and FIGO study was the assessment of DDR pathway alterations in stages was determined between controls and patients. Our Lithuanian cohort of CRPC cases using qPCR and NGS network analysis shows LYN, SELP, FGR, and NPM1 targeted gene panel. proteins are interacting with CD24. Materials and Methods: DNA was extracted from leu- Our research work demonstrated higher expression of kocytesof143CRPCpatientsthatenrolledthestudyduring CD24 in ovarian cancer patients’ tissue samples, and there 2016-2018. Dominant germline gene mutations in periph- was an association with FIGO classification. However, eral blood leukocytes were analyzed by custom made CD24 expression was detected only in some cell-free TaqMan assays and by NGS using custom made panel. plasma and exosome samples. Results: DNA mutation in at least one of the five DDR B. Soltesz: None. J. Lukács: None. E. Szilágyi: None. genes was detected in 23 of 143 (16%) CRPC cases: in É.Márton:None.M.SzilágyiBónizs:None.A.Penyige: BRCA1, BRCA2, CHEK2, NBN and ATM were detected 2 None. R. Póka: None. B. Nagy: None. (1,4%), 3 (2,1%), 12 (8,4%), 1 (0,7%) and 5 (3,5%), respectively. The most predominant mutation of the DDR  P12
.031D pathway was the CHEK2 c.470T>C mutation. CDH1 pathogenic variants in patients who do not fulfill Conclusions: Germline or sporadic mutations of DDR testing criteria are not necessarily incidental findings pathway genes were detected in 16% of CRPC cases showing significant involvement of this molecular pathway K. Strojnik1, M. Krajc1, M. Banjac1, V. Stegel2, P. Skerl2, in progression of PCa to the most aggressive form of the V. Setrajcic Dragos2, G. Klancar2, S. Novakovic2, disease.Inthefuture,specifictreatmentregimensshouldbe A. Blatnik1 considered for this subgroup of CRPC cases. R. Sabaliauskaite: None. I. Trockaja: None. A. Sesto- 1Cancer Genetic Clinic, Institute of Oncology, Ljubljana, kaite: None. A. Ulys: None. F. Jankevicius: None. S. Slovenia, 2Department of Molecular Diagnostics, Institute Jarmalaite: None. of Oncology, Ljubljana, Slovenia  P12
